PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MILLER, AF; ORMEJOHNSON, WH				MILLER, AF; ORMEJOHNSON, WH			THE DEPENDENCE ON IRON AVAILABILITY OF ALLOCATION OF IRON TO NITROGENASE COMPONENTS IN KLEBSIELLA-PNEUMONIAE AND ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR; AZOTOBACTER-VINELANDII; GENE-PRODUCT; FIXATION GENES; MOFE PROTEIN; FE-PROTEIN; NUCLEOTIDE-SEQUENCE; FOREIGN HOSTS; BIOSYNTHESIS; PURIFICATION	Nitrogenase contains approximately 38 iron ions/complete unit. Therefore, we sought to identify steps and genes involved in nitrogenase production that are responsive to iron availability. We have characterized nitrogenase production in Klebsiella pneumoniae grown in a range of different iron concentrations. We find significant accumulation (50-75%) and normal synthesis rates of the structural polypeptides, even under conditions in which the observed nitrogenase activities are only 14-28% of those observed in iron-sufficient conditions. Thus, maturation instead of synthesis of the structural polypeptides is primarily responsible for the iron dependence of nitrogenase activity. We have also used a binary plasmid system in Escherichia coli to investigate the contributions of various nitrogen fixation (nif) genes to the iron dependence of nitrogenase production. At least one of the nif genes DKTYENXUSVW can modulate synthesis of the structural polypeptide NIF H in response to iron availability. We speculate that an iron-deficient complex of the product(s) of at least one of these genes may repress structural polypeptide synthesis in iron-depleted K. pneumoniae. Such a system would compensate for the inactivity of NIF L in iron-depleted cultures and ensure balanced production of the structural polypeptides of nitrogenase in accordance with the iron available for their maturation.	MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)			Miller, Anne-Frances/M-7703-2017					ARNOLD W, 1988, J MOL BIOL, V203, P715, DOI 10.1016/0022-2836(88)90205-7; AUSTIN S, 1990, EUR J BIOCHEM, V187, P353, DOI 10.1111/j.1432-1033.1990.tb15312.x; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BERMAN J, 1985, J BIOL CHEM, V260, P5240; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; CARNAHAN JE, 1958, J BACTERIOL, V75, P121, DOI 10.1128/JB.75.2.121-124.1958; CARTER P, 1971, ANAL BIOCHEM, V40, P450, DOI 10.1016/0003-2697(71)90405-2; COLLINS JJ, 1986, J BACTERIOL, V168, P173, DOI 10.1128/jb.168.1.173-178.1986; DIXON RA, 1972, NATURE, V237, P102, DOI 10.1038/237102a0; Eady R. R., 1980, Methods for evaluating biological nitrogen fixation., P213; ESPOSITO RG, 1956, P SOC EXP BIOL MED, V93, P564; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; GEORGIADIS MM, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P111; GILL PR, 1991, PLANT SOIL, V130, P211, DOI 10.1007/BF00011875; GOSINK MM, 1990, J BACTERIOL, V172, P1441, DOI 10.1128/jb.172.3.1441-1447.1990; GUERINOT ML, 1991, PLANT SOIL, V130, P199, DOI 10.1007/BF00011874; HARRIS GS, 1990, J BIOL CHEM, V265, P15909; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HENDERSON N, 1989, MOL GEN GENET, V216, P484, DOI 10.1007/BF00334394; HOLLAND D, 1987, J BIOL CHEM, V262, P8814; HOOVER T R, 1988, Biofactors, V1, P199; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; HOOVER TR, 1987, NATURE, V329, P855, DOI 10.1038/329855a0; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; HOWARD KS, 1986, J BIOL CHEM, V261, P772; JOERGER RD, 1991, J BACTERIOL, V173, P4440, DOI 10.1128/JB.173.14.4440-4446.1991; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KUO CF, 1988, ANAL BIOCHEM, V170, P183, DOI 10.1016/0003-2697(88)90106-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMLEY PV, 1986, THESIS MIT CAMBRIDGE; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNEIL T, 1978, J BACTERIOL, V136, P253, DOI 10.1128/JB.136.1.253-266.1978; MAHASNEH IA, 1991, MICROBIOS, V65, P31; MARTIN JH, 1988, NATURE, V331, P341, DOI 10.1038/331341a0; MCLEAN PA, 1987, J BIOL CHEM, V262, P12900; MORENOVIVIAN C, 1989, MOL GEN GENET, V216, P353, DOI 10.1007/BF00334376; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NEILANDS JB, 1989, METAL IONS BACTERIA, P141; NELSON MJ, 1983, P NATL ACAD SCI-BIOL, V80, P147, DOI 10.1073/pnas.80.1.147; OHARA GW, 1988, NEW PHYTOL, V108, P51, DOI 10.1111/j.1469-8137.1988.tb00203.x; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; PAERL HW, 1990, ADV MICROB ECOL, V11, P305; PAUL W, 1989, EUR J BIOCHEM, V178, P675, DOI 10.1111/j.1432-1033.1989.tb14497.x; PAUSTIAN TD, 1989, P NATL ACAD SCI USA, V86, P6082, DOI 10.1073/pnas.86.16.6082; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; POSTLE K, 1990, J BACTERIOL, V172, P2287, DOI 10.1128/jb.172.5.2287-2293.1990; ROBERTS GP, 1978, J BACTERIOL, V136, P267, DOI 10.1128/JB.136.1.267-279.1978; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; SANDMANN G, 1990, PHOTOSYNTH RES, V26, P119, DOI 10.1007/BF00047083; SHAH VK, 1983, J BIOL CHEM, V258, P2064; STIEFEL EI, 1988, METAL CLUSTERS PROTE, P372; STJOHN RT, 1975, J BACTERIOL, V121, P759, DOI 10.1128/JB.121.3.759-765.1975; TANG CX, 1990, NEW PHYTOL, V114, P173, DOI 10.1111/j.1469-8137.1990.tb00388.x; UGALDE RA, 1985, J BACTERIOL, V164, P1081, DOI 10.1128/JB.164.3.1081-1087.1985; WAHL RC, 1987, J BIOL CHEM, V262, P10489; WHITE TC, 1990, NITROGEN FIXATION AC, P174; YAKUNIN AF, 1990, MICROBIOLOGY+, V59, P524; ZUMFT WG, 1974, EUR J BIOCHEM, V46, P525, DOI 10.1111/j.1432-1033.1974.tb03646.x	61	6	7	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9398	9408						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577767				2022-12-27	WOS:A1992HR85400105
J	SCHALKWIJK, C; PFEILSCHIFTER, J; MARKI, F; VANDENBOSCH, H				SCHALKWIJK, C; PFEILSCHIFTER, J; MARKI, F; VANDENBOSCH, H			INTERLEUKIN-1-BETA-INDUCED AND FORSKOLIN-INDUCED SYNTHESIS AND SECRETION OF GROUP-II PHOSPHOLIPASE-A(2) AND PROSTAGLANDIN-E(2) IN RAT MESANGIAL CELLS IS PREVENTED BY TRANSFORMING GROWTH-FACTOR-BETA-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA SYNTHESIS; FACTOR-BETA; SIGNAL TRANSDUCTION; PURIFICATION; RELEASE; CHONDROCYTES; STIMULATION; EXPRESSION; INHIBITOR	Interleukin-1-beta and forskolin induce prostaglandin E2 release as well as 14-kDa group II phospholipase A2 gene expression and secretion of the enzyme from rat glomerular mesangial cells. We now report that pretreatment of mesangial cells with transforming growth factor-beta-2 prior to stimulation with interleukin-1-beta or forskolin inhibits the induced release of prostaglandin E2. At the same time the secretion of group II phospholipase A2, measured both as enzyme activity with sn-2-labeled phosphatidylethanolamine as substrate and as enzyme protein in immunoblot experiments, is dose-dependently inhibited by pretreatment of the cells with transforming growth factor-beta-2. Analyses of enzyme activity and enzyme protein levels in the cells indicated that this is not due to inhibition of enzyme secretion with a concomitant increase in cellular levels of the enzyme. Rather, pretreatment of the cells with transforming growth factor-beta-2 largely prevented both the interleukin-1-beta- and the forskolin-induced synthesis of phospholipase A2. This is the first report indicating an inhibition of group II phospholipase A2 gene expression by transforming growth factor-beta-2. In line with those results, transforming growth factor-beta-2 did not induce the synthesis and secretion of group II phospholipase A2. However, under conditions where the interleukin-1-beta-induced expression of group II phospholipase A2 is fully suppressed by transforming growth factor-beta-2, the growth factor itself stimulated prostaglandin E2 synthesis by a mechanism apparently not involving group II phospholipase A2. The immunochemical identification of the inducible and secretable phospholipase A2 from rat mesangial cells as a group II enzyme was confirmed by purification and N-terminal amino acid sequence determination.	CTR BIOMEMBRANES & LIPID ENZYMOL,PADUALAAN 8,3584 CH UTRECHT,NETHERLANDS; CIBA GEIGY AG,DIV PHARMACEUT,RES DEPT,CH-4002 BASEL,SWITZERLAND	Novartis								AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL IK, 1990, BIOCHIM BIOPHYS ACTA, V1051, P310, DOI 10.1016/0167-4889(90)90140-9; COYNE DW, 1990, BIOCHEM BIOPH RES CO, V173, P718, DOI 10.1016/S0006-291X(05)80094-4; CROWL RM, 1991, J BIOL CHEM, V266, P2647; DEJONG JGN, 1987, EUR J BIOCHEM, V164, P129; DIAZ A, 1989, J BIOL CHEM, V264, P11554; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1989, CRIT REV IMMUNOL, V9, P1; DUBOIS CM, 1990, J EXP MED, V172, P737, DOI 10.1084/jem.172.3.737; GODFREY RW, 1987, BIOCHEM BIOPH RES CO, V142, P235, DOI 10.1016/0006-291X(87)90476-1; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; HAWKINS NJ, 1990, PATHOLOGY, V22, P24, DOI 10.3109/00313029009061422; HAYAKAWA M, 1988, J BIOCHEM-TOKYO, V104, P767, DOI 10.1093/oxfordjournals.jbchem.a122547; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYONSGIORDANO B, 1989, BIOCHEM BIOPH RES CO, V164, P488, DOI 10.1016/0006-291X(89)91746-4; MACKAY K, 1989, J CLIN INVEST, V83, P1160, DOI 10.1172/JCI113996; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; MUHL H, 1991, FEBS LETT, V291, P249, DOI 10.1016/0014-5793(91)81295-J; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; ONO T, 1988, J BIOL CHEM, V263, P5732; PFEILSCHIFTER J, 1989, BIOCHEM BIOPH RES CO, V159, P385, DOI 10.1016/0006-291X(89)90003-X; PFEILSCHIFTER J, 1990, BIOCHEM BIOPH RES CO, V169, P585, DOI 10.1016/0006-291X(90)90371-S; PFEILSCHIFTER J, 1990, BIOCHEM J, V270, P269, DOI 10.1042/bj2700269; PFEILSCHIFTER J, 1989, BIOCHEM SOC T, V17, P916, DOI 10.1042/bst0170916; PFEILSCHIFTER J, 1984, BIOCHEM J, V223, P855, DOI 10.1042/bj2230855; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; RAZ A, 1988, J BIOL CHEM, V263, P3022; ROBERTS AB, 1983, BIOCHEMISTRY-US, V22, P5692, DOI 10.1021/bi00294a002; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V174, P268, DOI 10.1016/0006-291X(91)90515-9; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V180, P46, DOI 10.1016/S0006-291X(05)81252-5; SUFFYS P, 1988, FEBS LETT, V232, P24, DOI 10.1016/0014-5793(88)80379-X; TOJO H, 1988, BIOCHEM BIOPH RES CO, V151, P1188, DOI 10.1016/S0006-291X(88)80491-1; TOJO H, 1988, J BIOL CHEM, V263, P5724; TOPLEY N, 1989, J IMMUNOL, V143, P1989; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENBOSCH H, 1979, AGENTS ACTIONS, V9, P382; VANDENBOSCH H, 1974, BIOCHIM BIOPHYS ACTA, V348, P197, DOI 10.1016/0005-2760(74)90231-8; VILCEK J, 1991, J BIOL CHEM, V266, P7313	46	84	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8846	8851						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577722				2022-12-27	WOS:A1992HR85400025
J	GUENET, C; LEPAGE, P; HARRIS, BA				GUENET, C; LEPAGE, P; HARRIS, BA			ISOLATION OF THE LEUCINE AMINOPEPTIDASE GENE FROM AEROMONAS-PROTEOLYTICA - EVIDENCE FOR AN ENZYME PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; PROTEIN SECRETION; ZINC ENZYMES; PEPN GENE; DNA; CLEAVAGE; CDNA	The leucine aminopeptidase of Aeromonas proteolytica (EC 3.4.11.10) is a monomeric metalloenzyme having the capacity to bind two Zn2+ atoms in the active site. Structural information of this relatively small aminopeptidase that could illuminate the catalytic mechanism of the metal ions is lacking; hence, we have obtained sequences from the purified enzyme, cloned the corresponding gene, and expressed the recombinant protein in Escherichia coli. The deduced primary amino acid sequence of this secreted protease suggests a potential signal peptide at the NH2 terminus. Expression of the recombinant and native proteins in E. coli and in extracts of culture media of A. proteolytica indicates that the aminopeptidase is secreted as an active and thermosensitive 43-kDa protein that is rapidly transformed to thermostable forms of 30 and 32 kDa. Comparison of the deduced amino acid sequence of the A. proteolytica leucine aminopeptidase with other Zn2+-binding metalloenzymes failed to show homologies to the consensus binding sequence His-Glu-X-X-His for the metal ion.	MARION MERRELL DOW RES INST,16 RUE ANKARA,F-67009 STRASBOURG,FRANCE									BAYLISS ME, 1986, BIOCHEMISTRY-US, V25, P8113, DOI 10.1021/bi00372a047; BURLEY SK, 1990, P NATL ACAD SCI USA, V87, P6878, DOI 10.1073/pnas.87.17.6878; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DEANE SM, 1989, GENE, V76, P281, DOI 10.1016/0378-1119(89)90168-6; DELEPELAIRE P, 1990, J BIOL CHEM, V265, P17118; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FILLOUX A, 1990, EMBO J, V9, P4323, DOI 10.1002/j.1460-2075.1990.tb07881.x; FOGLINO M, 1986, GENE, V49, P303, DOI 10.1016/0378-1119(86)90366-5; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARLOW FU, 1988, ANTIBODIES LABORATOR; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKINEN KK, 1982, J BIOL CHEM, V257, P1765; MAKINEN KK, 1982, J BIOL CHEM, V128, P257; MCCAMAN MT, 1986, GENE, V48, P145, DOI 10.1016/0378-1119(86)90360-4; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; NAKAHAMA K, 1986, NUCLEIC ACIDS RES, V14, P5843, DOI 10.1093/nar/14.14.5843; OLIVER D, 1985, ANNU REV MICROBIOL, V39, P615; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; Prescott J M, 1976, Methods Enzymol, V45, P530; PRESCOTT JM, 1966, ARCH BIOCHEM BIOPHYS, V117, P328, DOI 10.1016/0003-9861(66)90420-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALK C, 1992, ARCH BIOCHEM BIOPHYS, V293, P6953; SILHAVY TJ, 1983, MICROBIOL REV, V47, P313, DOI 10.1128/MMBR.47.3.313-344.1983; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VONHEIJNE G, 1984, EMBO J, V3, P2315, DOI 10.1002/j.1460-2075.1984.tb02132.x; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WATT VM, 1989, J BIOL CHEM, V264, P5480	29	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8390	8395						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569090				2022-12-27	WOS:A1992HQ18500068
J	ZEBALA, JA; CHOI, J; BARANY, F				ZEBALA, JA; CHOI, J; BARANY, F			CHARACTERIZATION OF STEADY-STATE, SINGLE-TURNOVER, AND BINDING-KINETICS OF THE TAQI RESTRICTION ENDONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECO RI ENDONUCLEASE; SUBSTRATE RECOGNITION; CATALYTIC PROPERTIES; THERMUS-AQUATICUS; CLEAVAGE CENTER; DNA-SEQUENCES; MINOR-GROOVE; BGL-II; OLIGONUCLEOTIDES; SPECIFICITY	The TaqI restriction endonuclease recognizes and cleaves the duplex DNA sequence T down CGA. Steady state kinetic analysis with a small oligodeoxyribonucleotide substrate showed that the enzyme obeyed Michaelis-Menten kinetics (K(m) = 53 nM, k(cat) = 1.3 min-1 at 50-degrees-C and K(m) = 0.5 nM, k(cat) = 2.9 min-1 at 60-degrees-C). At 0-degrees-C, the enzyme was completely inactive, while at 15-degrees-C, turnover produced nicked substrate as the major product in excess of enzyme indicating dissociation between nicking events. Above 37-degrees-C, both strands in the duplex were cleaved prior to dissociation. In contrast to the tight, temperature-dependent binding of substrate, binding of the Mg2+ cofactor was weak (K(d) = 2.5 mM) and the same at either 50-degrees-C or 60-degrees-C. Single-turnover experiments using oligonucleotide substrate showed that hydrolysis of duplex DNA occurred via two independent nicking events, each with a first order rate constant (k(st)) of 5.8 min-1 at 60-degrees-C and 3.5 min-1 at 50-degrees-C. The pH dependence of K(m) (pK(a) = 9) and k(st( (pK(a) = 7) suggests Lys/Arg and His, respectively, as possible amino acids influencing these constants. Moreover, although k(st) increased significantly with pH, k(cat) did not, indicating that at least two steps can be rate-controlling in the reaction pathway. Binding of protein to canonical DNA in the presence of Mg2+ at 0-degrees-C or in the absence of Mg2+ at 50-degrees-C was weak (K(d) = 2.5-mu-M or 5,000-fold weaker than the optimal measured K(m)) and equal to the binding of noncanonical DNA as judged by retention on nitrocellulose. Similar results were seen in gel retardation assays. These results suggest that both Mg2+ and high temperature are required to attain the correct protein conformation to form the tight complex seen in the steady state analysis. In the accompanying paper (Zebala, J. A., Choi, J., Trainor, G. L., and Barany, F. (1992) J. Biol. Chem. 267, 8106-8116), we report how these kinetic constants are altered using substrate analogues and propose a model of functional groups involved in TaqI endonuclease recognition.	CORNELL UNIV,MED CTR,COLL MED,HEARST MICROBIOL RES CTR,DEPT MICROBIOL,BOX 62,NEW YORK,NY 10021	Cornell University					NIGMS NIH HHS [GM-41337-03] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKEN CR, 1991, J BIOL CHEM, V266, P19063; AIKEN ILL, 1991, J BIOL CHEM, V266, P19070; BARANY F, 1988, GENE, V63, P167; BARANY F, 1988, GENE AMST, V63, P149; BARANY F, 1992, IN PRESS GENE AMST; BODNAR JW, 1983, J BIOL CHEM, V258, P5206; BRENNAN CA, 1986, J BIOL CHEM, V261, P7270; COSSTICK R, 1990, NUCLEIC ACIDS RES, V18, P4771; DWYERHALLQUIST P, 1982, BIOCHEMISTRY-US, V21, P4693, DOI 10.1021/bi00262a027; Fersht A., 1985, ENZYME STRUCTURE MEC; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GHOSH SS, 1990, NUCLEIC ACIDS RES, V18, P5063, DOI 10.1093/nar/18.17.5063; HALFORD SE, 1988, BIOCHEMISTRY-US, V27, P1771, DOI 10.1021/bi00405a058; HALFORD SE, 1980, BIOCHEM J, V191, P593, DOI 10.1042/bj1910593; HALFORD SE, 1983, BIOCHEM J, V211, P405, DOI 10.1042/bj2110405; HEITMAN J, 1990, PROTEINS, V7, P185, DOI 10.1002/prot.340070207; HEITMAN J, 1990, EMBO J, V9, P3369, DOI 10.1002/j.1460-2075.1990.tb07538.x; JENJACOBSON L, 1983, J BIOL CHEM, V258, P4638; KADDURAHDAOUK R, 1985, J BIOL CHEM, V260, P5345; KIM R, 1984, NUCLEIC ACIDS RES, V12, P7285, DOI 10.1093/nar/12.19.7285; KING K, 1989, J BIOL CHEM, V264, P11807; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LU AL, 1981, J BIOL CHEM, V256, P3200; MAYER A, 1992, THESIS CORNELL U; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MCCLELLAND M, 1981, NUCLEIC ACIDS RES, V9, P6795, DOI 10.1093/nar/9.24.6795; MCLAUGHLIN LW, 1987, BIOCHEMISTRY-US, V26, P7238, DOI 10.1021/bi00397a007; MODRICH P, 1976, J BIOL CHEM, V251, P5866; NEEDELS MC, 1989, P NATL ACAD SCI USA, V86, P3579, DOI 10.1073/pnas.86.10.3579; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9902, DOI 10.1021/bi00494a021; ONO A, 1987, NUCLEIC ACIDS RES, V15, P3059, DOI 10.1093/nar/15.7.3059; ONO A, 1987, NUCLEIC ACIDS RES, V15, P219, DOI 10.1093/nar/15.1.219; ONO A, 1984, NUCLEIC ACIDS RES, V12, P8939, DOI 10.1093/nar/12.23.8939; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SATO S, 1977, P NATL ACAD SCI USA, V74, P542, DOI 10.1073/pnas.74.2.542; Segel IH, 1976, BIOCH CALCULATIONS; SLATKO BE, 1987, NUCLEIC ACIDS RES, V15, P9781, DOI 10.1093/nar/15.23.9781; STEPHENSON FH, 1989, GENE, V85, P1, DOI 10.1016/0378-1119(89)90458-7; SZYBALSKI W, 1991, GENE, V100, P13, DOI 10.1016/0378-1119(91)90345-C; TABOR S, 1989, J BIOL CHEM, V264, P6447; TAYLOR JD, 1989, BIOCHEMISTRY-US, V28, P6198, DOI 10.1021/bi00441a011; TAYLOR JD, 1991, BIOCHEMISTRY-US, V30, P8743, DOI 10.1021/bi00100a005; Terry B J, 1987, Gene Amplif Anal, V5, P103; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816; YANOFSKY SD, 1987, PROTEINS, V2, P273, DOI 10.1002/prot.340020403; ZEBALA JA, 1992, J BIOL CHEM, V267, P8106; 1987, USER B APPLIED BIOSY, P50	49	65	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8097	8105						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569066				2022-12-27	WOS:A1992HQ18500023
J	CONRICODE, KM; BREWER, KA; EXTON, JH				CONRICODE, KM; BREWER, KA; EXTON, JH			ACTIVATION OF PHOSPHOLIPASE-D BY PROTEIN-KINASE-C - EVIDENCE FOR A PHOSPHORYLATION-INDEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHORBOL ESTERS; RAT-BRAIN; PHOSPHATIDYLCHOLINE HYDROLYSIS; HL-60 GRANULOCYTES; PHOSPHATIDIC-ACID; CALCIUM IONOPHORE; SMOOTH-MUSCLE; D PATHWAY; PHOSPHATIDYLETHANOL; ACCUMULATION	The role of protein kinase C (PKC) in the regulation of phosphatidylcholine-hydrolyzing phospholipase D (PLD) was investigated. In membranes from Chinese hamster lung fibroblasts that had been incubated with [C-14]choline to label endogenous phosphatidylcholine, phorbol 12-myristate 13-acetate (PMA) failed to stimulate production of [C-14]choline. However, stimulation was observed if fibroblast cytosolic fraction or PKC partially purified from this fraction was added. When incubated with membranes in the presence of PMA, pure PKC from rat brain stimulated [C-14]choline production in a concentration-dependent manner, with a maximal 2-3-fold effect. PMA similarly stimulated [C-14]phosphatidylpropanol formation from propanol using membranes from [C-14]myristic acid-prelabeled cells, confirming the activation of PLD. None of the effects described required exogenous ATP. To probe the role of phosphorylation in the PKC effect, we included high concentrations of apyrase in the assay. This ATPase had no effect on the ability of PKC to activate PLD, but under exactly the same conditions, it eliminated autophosphorylation of PKC. The results provide conclusive evidence for the involvement of PKC in the activation of PLD and suggest that ATP-dependent phosphorylation is not required.	VANDERBILT UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040919] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32DK07061] Funding Source: Medline; NIGMS NIH HHS [GM40919] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGWU DE, 1989, J BIOL CHEM, V264, P1405; ANTHES JC, 1989, BIOCHEM BIOPH RES CO, V163, P657, DOI 10.1016/0006-291X(89)92187-6; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; CABOT MC, 1989, FEBS LETT, V245, P85, DOI 10.1016/0014-5793(89)80197-8; CAO YZ, 1990, BIOCHEM BIOPH RES CO, V171, P955, DOI 10.1016/0006-291X(90)90777-K; CONRICODE KM, 1991, BIOCHIM BIOPHYS ACTA, V1095, P161, DOI 10.1016/0167-4889(91)90079-D; EXTON JH, 1990, J BIOL CHEM, V265, P1; GUSTAVSSON L, 1990, J NEUROCHEM, V54, P737, DOI 10.1111/j.1471-4159.1990.tb02313.x; HUANG CF, 1990, J BIOL CHEM, V265, P14858; HUANG R, 1991, J BIOL CHEM, V266, P1652; KIKKAWA U, 1987, FEBS LETT, V217, P227, DOI 10.1016/0014-5793(87)80668-3; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; Kitano T, 1986, Methods Enzymol, V124, P349; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PAI JK, 1991, CELL REGUL, V2, P897, DOI 10.1091/mbc.2.11.897; PUTNEY JW, 1980, NATURE, V284, P345, DOI 10.1038/284345a0; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; SANDMANN J, 1991, J NEUROCHEM, V56, P1312, DOI 10.1111/j.1471-4159.1991.tb11427.x; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; TETTENBORN CS, 1988, BIOCHEM BIOPH RES CO, V155, P249, DOI 10.1016/S0006-291X(88)81076-3; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693; WELSH CJ, 1990, LIPIDS, V25, P675, DOI 10.1007/BF02544033; WOLF M, 1986, J BIOL CHEM, V261, P3327; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; YAMADA K, 1991, BIOCHEM BIOPH RES CO, V175, P159, DOI 10.1016/S0006-291X(05)81214-8; YAVIN E, 1976, J BIOL CHEM, V251, P1392	36	243	245	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7199	7202						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559964				2022-12-27	WOS:A1992HN48500002
J	BATINIC, D; ROBEY, FA				BATINIC, D; ROBEY, FA			THE V3 REGION OF THE ENVELOPE GLYCOPROTEIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 BINDS SULFATED POLYSACCHARIDES AND CD4-DERIVED SYNTHETIC PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRALIZING MONOCLONAL-ANTIBODY; DEXTRAN SULFATE; HIV-1 GP120; SYNCYTIUM FORMATION; VIRION BINDING; CD4 MOLECULE; PROTEIN; CELLS; SITE; SEQUENCE	Gp120 is the envelope glycoprotein found on the surface of human immunodeficiency virus type 1 (HIV-1), and it binds to human cell surface CD4 receptors to initiate the HIV-1 infection process. It is now well-established that synthetic peptides from the V3 region on gp120 elicit antibodies that block HIV-1 infection and HIV-1-mediated cell fusion. Here we show that synthetic peptides derived from similar V3 regions of several isolates of HIV-1 bind [H-3]heparin, and we also demonstrate that [H-3]heparin binds to recombinant gp120 IIIB. The binding could be blocked by unlabeled heparin, dextran sulfate, and by a highly anionic benzylated synthetic peptide derived from human CD4 (amino acids 81-92). The nonbenzylated peptides from the same region were considerably less active. Unlabeled heparin, dextran sulfate, and the CD4-derived peptides were able to compete with the binding of soluble gp120 to immobilized antibodies against fragments of the V3 from isolate IIIB, but they had no effect on the binding of gp120 to anti-peptide antibodies targeted against another unrelated region of gp120. Biotin conjugated to the benzylated CD4-peptide bound to gp120 and was blocked from this binding by anti-V3 antibodies. These results indicate that the three materials that have been demonstrated by others to block HIV-1 infection in vitro, sulfated polysaccharides, certain CD4-derived synthetic peptides, and anti-V3 antibodies, may be acting through a common mechanism that includes binding to the V3 region of gp120 on HIV-1.			BATINIC, D (corresponding author), NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892, USA.							ARDMAN B, 1990, J ACQ IMMUN DEF SYND, V3, P206; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742; BAGASRA O, 1988, J INFECT DIS, V158, P1084, DOI 10.1093/infdis/158.5.1084; CALLAHAN LN, 1991, J VIROL, V65, P1543, DOI 10.1128/JVI.65.3.1543-1550.1991; CAMERINI D, 1990, CELL, V60, P747, DOI 10.1016/0092-8674(90)90089-W; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEANGELIS PL, 1987, J BIOL CHEM, V262, P13946; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HAYASHI Y, 1989, ARCH VIROL, V105, P129, DOI 10.1007/BF01311123; IVANOFF LA, 1991, AIDS RES HUM RETROV, V7, P595, DOI 10.1089/aid.1991.7.595; JAMESON BA, 1988, SCIENCE, V240, P1335, DOI 10.1126/science.2453925; KALYANARAMAN VS, 1990, J IMMUNOL, V145, P4072; KINNEYTHOMAS E, 1988, AIDS, V2, P25; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LIFSON JD, 1988, SCIENCE, V241, P712, DOI 10.1126/science.2969619; LIFSON JD, 1991, AIDS RES HUM RETROV, V7, P521, DOI 10.1089/aid.1991.7.521; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LITTMAN DR, 1988, CELL, V55, P541, DOI 10.1016/0092-8674(88)90211-5; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; MCKEATING JA, 1989, AIDS, V3, pS35, DOI 10.1097/00002030-198901001-00005; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MITSUYA H, 1988, SCIENCE, V240, P646, DOI 10.1126/science.2452480; MIZUKAMI T, 1988, P NATL ACAD SCI USA, V85, P9273, DOI 10.1073/pnas.85.23.9273; MYERS G, HUMAN RETROVIRUSES A; MYERS G, 1990, HUMAN RETROVIRUSES A; NARA PL, 1989, P NATL ACAD SCI USA, V86, P7139, DOI 10.1073/pnas.86.18.7139; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PARISH CR, 1990, J IMMUNOL, V145, P1188; ROBEY FA, 1989, ANAL BIOCHEM, V177, P373, DOI 10.1016/0003-2697(89)90068-7; RUOSLAHTI E, 1980, BIOCHIM BIOPHYS ACTA, V631, P350, DOI 10.1016/0304-4165(80)90308-6; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319; SCHOLS D, 1990, VIROLOGY, V175, P556, DOI 10.1016/0042-6822(90)90440-3; SCHOLS D, 1989, J ACQ IMMUN DEF SYND, V2, P10; SHAPIRANAHOR O, 1990, CELL IMMUNOL, V128, P101, DOI 10.1016/0008-8749(90)90010-O; SKINNER MA, 1988, AIDS RES HUM RETROV, V4, P187, DOI 10.1089/aid.1988.4.187; TRUNEH A, 1991, J BIOL CHEM, V266, P5942; UENO R, 1987, LANCET, V1, P1379	46	140	144	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6664	6671						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551875				2022-12-27	WOS:A1992HM05300034
J	KHAN, R; GIEDROC, DP				KHAN, R; GIEDROC, DP			RECOMBINANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 NUCLEOCAPSID (NC(P7)) PROTEIN UNWINDS TRANSFER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; AVIAN-MYELOBLASTOSIS VIRUS; STRANDED NUCLEIC-ACIDS; PRIMER TRANSFER-RNA; CYS-HIS BOX; COOPERATIVE BINDING; COMPLEX PROTEIN-A1; ANNEALING ACTIVITY; SYNTHESIS INVITRO; DIMER FORMATION	The nucleocapsid protein (NC) of all animal retroviruses, encoded by the gag gene, is the major structural protein of the core ribonucleoprotein complex, bound to genomic RNA in mature virions. NC is also thought to play one or more accessory roles in reverse transcription. Mature NC (p7NC) from human immunodeficiency virus type 1 (HIV-1) is a 71-amino acid, basic protein which contains two Cys3His Zn(II) retroviral-type zinc finger domains. Herein, we describe the subcloning and expression of HIV-1 NC, denoted NC71, from an inducible phage T7 RNA polymerase promoter in Escherichia coli. Purified NC71 can be reversibly reconstituted with 2 g.at Zn(II) determined by atomic absorption. Ultraviolet circulation dichroism spectroscopy has been used to characterize the complexes between highly purified NC71 and the RNA homopolynucleotide poly(A) and E. coli tRNA(mixed). On poly(A), Zn2 NC71 is characterized by an apparent site size n = 15 +/- 3 nucleotides and high affinity (K(app) = 3 x 10(7) M-1) and moderately cooperative (omega almost-equal-to 170 +/- 25) binding. A mixture of E. coli tRNA species (tRNA(mixed)) was used to probe the conformational changes induced in tRNA upon binding of HIV-1 NC71. Two structural forms of tRNA(mixed), which differ in their degree of tertiary structure, were assayed for their susceptibility to denaturation by NC71. Five molar monomer equivalents of NC71 are required to denature the "inactive" tRNA in the absence of Mg2+. A Zn(II)-free, oxidized form of NC71 was also shown to unwind inactive tRNA with the same efficiency and stoichiometry. The detailed spectral changes which occur on NC-induced denaturation closely mimic temperature-induced denaturation of inactive tRNA(mixed). The prototype helix-destabilizing protein, T4 gene 32 protein, is unable to unwind this form of tRNA under the same conditions. The stoichiometry of unwinding of inactive tRNA by NC71 is consistent with the site size determined with poly(A). An "active" form of tRNA(mixed), prepared by thermal denaturation and refolding of the inactive form with Mg2+, proved less susceptible to both temperature and NC71-induced unwinding. The mechanistic implications of these findings on the reported biochemical activities of RNA:RNA annealing and replication primer tRNA positioning by NC are discussed.	TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station			Giedroc, David/A-8608-2018	Giedroc, David/0000-0002-2342-1620	NIGMS NIH HHS [GM42569] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042569, R01GM042569] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERG JM, 1989, MET IONS BIOL SYST, V25, P235; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; CHEN MJ, 1980, P NATL ACAD SCI-BIOL, V77, P1296, DOI 10.1073/pnas.77.3.1296; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; CORNILLE F, 1990, INT J PEPT PROT RES, V36, P551; DICKSON C, 1985, RNA TUMOR VIRUSES, V1, P513; DUPRAZ P, 1990, J VIROL, V64, P4978, DOI 10.1128/JVI.64.10.4978-4987.1990; FITZGERALD DW, 1991, BIOCHEMISTRY-US, V30, P5195, DOI 10.1021/bi00235a012; FU XD, 1988, J BIOL CHEM, V263, P2140; GIEDROC DP, 1991, BIOCHEMISTRY-US, V31, P765; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990; GREEN LM, 1989, P NATL ACAD SCI USA, V86, P4047, DOI 10.1073/pnas.86.11.4047; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; HENDERSON LE, 1988, UCLA S MOL CELL BIOL, V71, P135; JENSEN DE, 1976, J BIOL CHEM, V251, P7215; JENTOFT JE, 1988, P NATL ACAD SCI USA, V85, P7094, DOI 10.1073/pnas.85.19.7094; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KARPEL RL, 1982, BIOCHEMISTRY-US, V21, P2102, DOI 10.1021/bi00538a019; KARPEL RL, 1980, BIOCHEMISTRY-US, V19, P4674, DOI 10.1021/bi00561a021; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; LUBAN J, 1991, J VIROL, V65, P3203, DOI 10.1128/JVI.65.6.3203-3212.1991; MANIATIS T, 1982, MOLC LONING LABORATO; MANN R, 1985, J VIROL, V54, P401, DOI 10.1128/JVI.54.2.401-407.1985; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MERIC C, 1986, J VIROL, V60, P450; MERIC C, 1989, J VIROL, V63, P1558; MERIC C, 1988, J VIROL, V62, P3328; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MORRICAL SW, 1990, J BIOL CHEM, V265, P15096; NISSENMEYER J, 1980, J MOL BIOL, V142, P19, DOI 10.1016/0022-2836(80)90203-X; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ROBERTS WJ, 1989, BIOCHEMISTRY-US, V28, P10043, DOI 10.1021/bi00452a024; ROBILLARD GT, 1977, BIOCHEMISTRY-US, V16, P5261, DOI 10.1021/bi00643a016; SECNIK J, 1990, BIOCHEMISTRY-US, V29, P7991, DOI 10.1021/bi00486a030; SOUTH TL, 1990, BIOCHEMISTRY-US, V29, P7786, DOI 10.1021/bi00486a002; SOUTH TL, 1989, J AM CHEM SOC, V111, P395, DOI 10.1021/ja00183a074; STEWART L, 1990, J VIROL, V64, P5076, DOI 10.1128/JVI.64.10.5076-5092.1990; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRITCH RJ, 1991, J VIROL, V65, P922, DOI 10.1128/JVI.65.2.922-930.1991; WILLICK G, 1973, BIOCHEMISTRY-US, V12, P899, DOI 10.1021/bi00729a017	51	163	166	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6689	6695						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551877				2022-12-27	WOS:A1992HM05300037
J	MANZELLA, JM; BLACKSHEAR, PJ				MANZELLA, JM; BLACKSHEAR, PJ			SPECIFIC PROTEIN-BINDING TO A CONSERVED REGION OF THE ORNITHINE DECARBOXYLASE MESSENGER-RNA 5'-UNTRANSLATED REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; HIGH-LEVEL; CELL-LINE; POLYAMINES; TRANSLATION; GENE; EXPRESSION; INHIBITION; SYNTHETASE; INVITRO	An RNA gel retardation assay was used to identify one or more cellular protein(s) (ornithine decarboxylase mRNA 5'-UTR binding protein (ODCBP) that bind specifically to a conserved region of the 5'-untranslated region (5'-UTR) of rat ornithine decarboxylase (ODC) mRNA. Ultraviolet light cross-linking demonstrated that this protein has an apparent M(r) = 58,000 in mammalian cells. Treatment with the oxidizing agent diamide prevented binding of the ODCBP to ODC mRNA; addition of beta-mercaptoethanol reversed this inhibition and permitted mRNA.ODCBP complex formation. Cytoplasmic extracts from a variety of animal cells and tissues demonstrated similar binding activities; however, there was marked tissue-specific expression of the protein in the rat, with brain, heart, lung, and testis containing large amounts, and kidney, spleen, and skeletal muscle expressing negligible amounts. Binding was completely prevented by several mutations within a highly conserved heptanucleotide region (CCAU/ACUC) that was within 61 bases of the initiation codon in ODC mRNAs from mammals, Xenopus, and Caenorhabditis elegans; mutations 5' and 3' of the conserved heptanucleotide domain had no effect on binding activity. Binding was not affected by manipulation of cellular polyamine levels or by treatment of cells with agents that stimulate ODC biosynthesis. Thus, we have identified a widely distributed cellular protein that binds to a conserved domain within the 5'-UTR of ODC mRNA from many animal species; functional consequences of this binding remain to be determined.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,BOX 3897,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV ENDOCRINOL METAB & GENET,DURHAM,NC 27710	Duke University; Duke University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				BASSEZ T, 1990, DEVELOPMENT, V110, P955; BLACKSHEAR PJ, 1989, MOL ENDOCRINOL, V3, P68, DOI 10.1210/mend-3-1-68; BRABANT M, 1988, P NATL ACAD SCI USA, V85, P2200, DOI 10.1073/pnas.85.7.2200; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GRENS A, 1990, J BIOL CHEM, V265, P11810; GRENS A, 1990, NUCLEIC ACIDS RES, V17, P10497; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HOLTTA E, 1986, J BIOL CHEM, V261, P9502; JANNE J, 1978, BIOCHIM BIOPHYS ACTA, V473, P7549; KAHANA C, 1985, J BIOL CHEM, V260, P5390; KAMEJI T, 1987, J BIOL CHEM, V262, P2427; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; KOONTZ SW, 1979, J BIOL CHEM, V254, P12277; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Maniatis T., 1982, MOL CLONING; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; MOSHIER JA, 1990, J BIOL CHEM, V265, P4884; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAJITA L, 1990, P NATL ACAD SCI USA, V87, P5846, DOI 10.1073/pnas.87.15.5846; PARKIN NT, 1989, ONCOGENE, V4, P815; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, J BIOL CHEM, V263, P11008; PERSSON L, 1982, BIOCHEM BIOPH RES CO, V104, P1196, DOI 10.1016/0006-291X(82)91377-8; PERSSON L, 1988, J BIOL CHEM, V263, P3528; RAINA A, 1976, FEBS LETT, V67, P252, DOI 10.1016/0014-5793(76)80540-6; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; ROMANIUK PJ, 1985, BIOCHEMISTRY-US, V24, P4239, DOI 10.1021/bi00336a064; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STARZYK RM, 1982, NATURE, V298, P136, DOI 10.1038/298136a0; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; VANSTEEG H, 1988, NUCLEIC ACIDS RES, V16, P8173, DOI 10.1093/nar/16.16.8173; WEN L, 1989, J BIOL CHEM, V264, P9016; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; Wood W.B., 1988, NEMATODE CAENORHABDI, P1091; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	37	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7077	7082						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551914				2022-12-27	WOS:A1992HM05300095
J	BUTLER, MH; DOUVILLE, K; MURNANE, AA; KRAMARCY, NR; COHEN, JB; SEALOCK, R; FROEHNER, SC				BUTLER, MH; DOUVILLE, K; MURNANE, AA; KRAMARCY, NR; COHEN, JB; SEALOCK, R; FROEHNER, SC			ASSOCIATION OF THE M(R)-58,000 POSTSYNAPTIC PROTEIN OF ELECTRIC TISSUE WITH TORPEDO DYSTROPHIN AND THE M(R)-87,000 POSTSYNAPTIC PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; RECEPTOR-RICH MEMBRANES; ACETYLCHOLINE-RECEPTOR; SKELETAL-MUSCLE; 58K PROTEIN; DEFICIENCY; JUNCTION; CHANNELS; MYOTUBES; CLUSTERS	Dystrophin was purified by immunoaffinity chromatography from detergent-solubilized Torpedo electric organ postsynaptic membranes using monoclonal antibodies. A major doublet of proteins at M(r) 58,000 and minor proteins at M(r) 87,000, M(r) 45,000, and M(r) 30,000 reproducibly copurified with dystrophin. The M(r) 58,000 and M(r) 87,000 proteins were identical to previously described peripheral membrane proteins (M(r) 58,000 protein and 87,000 protein) whose muscle homologs are associated with the sarcolemma (Froehner, S. C., Murnane, A. A., Tobler, M., Peng, H. B., and Sealock, R. (1987) J. Cell Biol. 104, 1633-1646; Carr, C., Fischbach, G. D., and Cohen, J. B. (1989) J. Cell Biol. 109, 1753-1764). The copurification of dystrophin and M(r) 58,000 protein was shown to be specific, since dystrophin was also captured with a monoclonal antibody against the M(r) 58,000 protein but not by several control antibodies. The M(r) 87,000 protein was a major component (along with the M(r) 68,000 protein) in material purified on anti-58,000 columns, suggesting that the M(r) 58,000 protein forms a distinct complex with the M(r) 87,000 protein, as well as with dystrophin. Immunofluorescence staining of skeletal and cardiac muscle from the dystrophin-minus mdx mouse with the anti-58,000 antibody was confined to the sarcolemma as in normal muscle but was much reduced in intensity, even though immunoblotting demonstrated that the contents of M(r) 58,000 protein in normal and mdx muscle were comparable. Thus, the M(r) 58,000 protein appears to associate inefficiently with the sarcolemmal membrane in the absence of dystrophin. This deficiency may contribute to the membrane abnormalities that lead to muscle necrosis in dystrophic muscle.	UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599; DARTMOUTH COLL,DEPT BIOCHEM,HANOVER,NH 03755; WASHINGTON UNIV,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	University of North Carolina; University of North Carolina Chapel Hill; Dartmouth College; Washington University (WUSTL)					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029343, R01NS015293, R01NS014871] Funding Source: NIH RePORTER; NINDS NIH HHS [NS14871, NS15293, NS29343] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; BLOCH RJ, 1983, J CELL BIOL, V97, P217, DOI 10.1083/jcb.97.1.217; BONILLA E, 1988, CELL, V54, P447, DOI 10.1016/0092-8674(88)90065-7; BULLFIELD G, 1984, P NATL ACAD SCI USA, V81, P1189; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; CHANG HW, 1989, J BIOL CHEM, V264, P20831; CHEN Q, 1990, J CELL BIOL, V110, P2061, DOI 10.1083/jcb.110.6.2061; ENGEL AG, 1986, DUCHENNE DYSTROPHY M; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FARDEAU M, 1990, CR ACAD SCI III-VIE, V311, P197; FONG P, 1990, SCIENCE, V250, P673, DOI 10.1126/science.2173137; FOX GO, 1979, J COMP NEUROL, V179, P677; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; FROEHNER SC, 1983, J BIOL CHEM, V258, P7112; HOFFMAN EP, 1989, NEURON, V2, P1019, DOI 10.1016/0896-6273(89)90226-2; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; JASMIN BJ, 1990, P NATL ACAD SCI USA, V87, P3938, DOI 10.1073/pnas.87.10.3938; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KRAMARCY NR, 1990, FEBS LETT, V274, P171, DOI 10.1016/0014-5793(90)81356-S; LAROCHELLE WJ, 1987, J BIOL CHEM, V262, P8190; MANDEL JL, 1989, NATURE, V339, P584, DOI 10.1038/339584a0; PENG HB, 1985, J CELL BIOL, V100, P1698, DOI 10.1083/jcb.100.5.1698; PORTER S, 1983, J BIOL CHEM, V258, P34; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; WOODRUFF ML, 1987, J CELL BIOL, V104, P939, DOI 10.1083/jcb.104.4.939; YEADON JE, 1991, J CELL BIOL, V115, P1069, DOI 10.1083/jcb.115.4.1069	31	85	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6213	6218						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556129				2022-12-27	WOS:A1992HK31800075
J	JOZIASSE, DH; SHAPER, NL; KIM, DY; VANDENEIJNDEN, DH; SHAPER, JH				JOZIASSE, DH; SHAPER, NL; KIM, DY; VANDENEIJNDEN, DH; SHAPER, JH			MURINE ALPHA-1,3-GALACTOSYLTRANSFERASE - A SINGLE GENE LOCUS SPECIFIES 4 ISOFORMS OF THE ENZYME BY ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; TISSUE-SPECIFIC EXPRESSION; DETERMINES EXPRESSION; RETINOIC ACID; UDP-GALACTOSE; MESSENGER-RNA; CDNA; DNA; BETA-1,4-GALACTOSYLTRANSFERASE; IDENTIFICATION	We have reported the characterization of a cDNA (clone 31A) encoding bovine alpha-1,3-galactosyltransferase (alpha-1,3-GT) (Joziasse, D. H., Shaper, J. H., Van den Eijnden, D. H., Van Tunen, A. J., and Shaper, N. L. (1989) J. Biol. Chem. 264, 14290-14297). With the goal of isolating a full-length cDNA encoding murine alpha-1,3-GT we screened a cDNA library with clone 31A and isolated a 3.4-kilobase (kb) alpha-1,3-GT clone (4A). The murine coding sequence is 78% similar to that of the bovine alpha-1,3-GT cDNA, but the "stem" region (defined as the region that links the single transmembrane domain to the catalytic domain) of the murine alpha-1,3-GT encoded by clone 4A, is 31 amino acids shorter than the corresponding region of the bovine alpha-1,3-GT. To screen for heterogeneity in the murine alpha-1,3-GT transcripts, we carried out a polymerase chain reaction (PCR) analysis on mouse C127 cDNA. Four distinct transcripts were detected, which predict four isoforms of the alpha-1,3-GT polypeptide that differ only in the length of their stem region. To determine how the four different transcripts are generated from a single gene, we have established the genomic organization for murine alpha-1,3-GT. The full-length mRNA spans at least 35 kb of genomic DNA and is distributed over nine exons that range in size from 36 base pairs (bp) to approximately 2600 bp. The protein coding region is distributed over six exons, and the 5'-untranslated sequence is distributed over three exons. Comparison of the genomic DNA sequence with that of the four different mRNAs indicates that these transcripts are produced by alternative splicing of the murine pre-mRNA according to a cassette model. A tissue survey using RNA-PCR revealed the presence of four different alpha-1,3-GT transcripts in all mouse tissues and cell lines examined to date, with the notable exception of male germ cells. Additionally, although alpha-1,3-GT levels increased upon thioglycollate-induced activation of mouse peritoneal macrophages, the ratio of the alpha-1,3-GT isoforms was essentially unchanged. Similar results were obtained upon retinoic acid-induced differentiation of murine F9 teratocarcinoma cells. Lastly, a similar PCR analysis of bovine cDNA produced only a single DNA fragment, corresponding to bovine cDNA clone 31A.	JOHNS HOPKINS UNIV, SCH MED, CTR ONCOL, CELL STRUCT & FUNCT LAB, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	JOZIASSE, DH (corresponding author), FREE UNIV AMSTERDAM, DEPT MED CHEM, VANDERBOECHORSTSTR 7, 1081 BT AMSTERDAM, NETHERLANDS.				NATIONAL CANCER INSTITUTE [R01CA045799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038310] Funding Source: NIH RePORTER; NCI NIH HHS [CA45799] Funding Source: Medline; NIGMS NIH HHS [GM38310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER RT, 1988, NUCLEIC ACIDS RES, V16, P1198, DOI 10.1093/nar/16.3.1198; BEELEN RHJ, 1983, CELL IMMUNOL, V82, P246, DOI 10.1016/0008-8749(83)90159-4; BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUMMINGS RD, 1988, J BIOL CHEM, V263, P511; GALILI U, 1988, J BIOL CHEM, V263, P17755; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; HULL E, 1991, BIOCHEM BIOPH RES CO, V176, P608, DOI 10.1016/S0006-291X(05)80227-X; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; JOZIASSE DH, 1990, EUR J BIOCHEM, V191, P75, DOI 10.1111/j.1432-1033.1990.tb19095.x; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; JOZIASSE DH, 1991, SOMAT CELL MOLEC GEN, V17, P201, DOI 10.1007/BF01232977; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LETTS PJ, 1974, BIOCHIM BIOPHYS ACTA, V343, P192, DOI 10.1016/0304-4165(74)90251-7; LOWE JB, 1991, J BIOL CHEM, V266, P17467; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SHAPER NL, 1992, IN PRESS GENOMICS; SHEARES BT, 1987, J IMMUNOL, V139, P3748; SPIRO RG, 1984, J BIOL CHEM, V259, P9858; STEFFENS DL, 1989, BIOTECHNIQUES, V7, P674; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WASSARMAN PM, 1987, ANNU REV CELL BIOL, V3, P109, DOI 10.1146/annurev.cellbio.3.1.109; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1991, GLYCOCONJUGATE J, V8, P146; WIJFFELS JFAM, 1991, LYMPHATIC TISSUES AND IN VIVO IMMUNE RESPONSES, P815; YADAV S, 1990, J BIOL CHEM, V265, P14163; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0	45	101	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5534	5541						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544928				2022-12-27	WOS:A1992HH74700081
J	MORAVEC, CS; BOND, M				MORAVEC, CS; BOND, M			EFFECT OF INOTROPIC STIMULATION ON MITOCHONDRIAL CALCIUM IN CARDIAC-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT-HEART; ELECTRON-PROBE MICROANALYSIS; FREE CA-2+ CONCENTRATION; PYRUVATE-DEHYDROGENASE; INTRAMITOCHONDRIAL CA-2+; SARCOPLASMIC-RETICULUM; SUBCELLULAR CALCIUM; OXYGEN-CONSUMPTION; FORCE DEVELOPMENT; RUTHENIUM RED	Ca2+-dependent activation of citric acid cycle enzymes has been demonstrated in isolated cardiac mitochondria. These observations led to the hypothesis that Ca2+ is the signal coupling myofibrillar energy use to mitochondrial energy production in vivo. To test this hypothesis we have measured mitochondrial Ca2+ content during increased energy demand, using electron probe microanalysis. Mitochondrial Ca2+ was measured in hamster papillary muscles rapidly frozen at the peak rate of tension rise under control conditions and after stimulation with the beta-adrenergic agonist isoproterenol (10(-6) M). A third group of muscles was frozen after incubation in low (46.5 mM) Na+ solution to Ca2+ load the cells. Pyruvate dehydrogenase activity was measured in each of the muscles. Isoproterenol caused a 39% increase in force and a 43% increase in pyruvate dehydrogenase activity but no change in mitochondrial Ca2+ (0.46 +/- 0.19 (S.E.) mmol of Ca2+/kg, dry weight) compared with control (0.54 +/- 0.12). In contrast, low Na+ increased pyruvate dehydrogenase activity by 56% and also elevated mitochondrial Ca2+ to 1.28 +/- 0.31 (p < 0.02). These results demonstrate that mitochondrial Ca2+ is not elevated after inotropic stimulation of cardiac muscle by beta-adrenergic agonists although pyruvate dehydrogenase activity is increased. We conclude that Ca2+ uptake by mitochondria is not a requirement for activation of mitochondrial respiration after increased energy demand.	CLEVELAND CLIN FDN,RES INST,DEPT HEART & HYPERTENS RES,FF1,9500 EUCLID AVE,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041883, P50HL033713] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33713, HL41883] Funding Source: Medline; PHS HHS [R05582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN DG, 1983, J PHYSIOL-LONDON, V345, P391, DOI 10.1113/jphysiol.1983.sp014984; BERS DM, 1990, AM J PHYSIOL, V258, pC944, DOI 10.1152/ajpcell.1990.258.5.C944; BOND M, 1989, CIRC RES, V64, P1001, DOI 10.1161/01.RES.64.5.1001; BOND M, 1987, J BIOL CHEM, V262, P15630; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNGER R, 1984, AM J PHYSIOL, V247, pC45, DOI 10.1152/ajpcell.1984.247.1.C45; CALLEWAERT G, 1988, P NATL ACAD SCI USA, V85, P2009, DOI 10.1073/pnas.85.6.2009; CHAMBERLAIN BK, 1984, J BIOL CHEM, V259, P7547; CHANCE B, 1955, J BIOL CHEM, V217, P409; CHAPMAN RA, 1986, J PHYSIOL-LONDON, V373, P163, DOI 10.1113/jphysiol.1986.sp016040; CROMPTON M, 1983, BIOCHEM J, V216, P333, DOI 10.1042/bj2160333; CROMPTON M, 1976, EUR J BIOCHEM, V69, P429, DOI 10.1111/j.1432-1033.1976.tb10927.x; DAVIS MH, 1987, BIOCHEM BIOPH RES CO, V149, P40, DOI 10.1016/0006-291X(87)91602-0; DENTON RM, 1972, BIOCHEM J, V128, P161, DOI 10.1042/bj1280161; ENDOH M, 1988, CIRC RES, V62, P247, DOI 10.1161/01.RES.62.2.247; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FROM AHL, 1986, FEBS LETT, V206, P257, DOI 10.1016/0014-5793(86)80992-9; GIESEN J, 1980, J MOL CELL CARDIOL, V12, P891, DOI 10.1016/0022-2828(80)90058-9; GUPTA MP, 1988, AM J PHYSIOL, V255, pH1413, DOI 10.1152/ajpheart.1988.255.6.H1413; HANSFORD RG, 1987, BIOCHEM J, V241, P145, DOI 10.1042/bj2410145; HANSFORD RG, 1990, BIOCHIM BIOPHYS ACTA, V1018, P282, DOI 10.1016/0005-2728(90)90268-9; HANSFORD RG, 1982, J BIOENERG BIOMEMBR, V14, P361, DOI 10.1007/BF00743064; HANSFORD RG, 1985, REV PHYSIOL BIOCH P, V102, P1, DOI 10.1007/BFb0034084; HASSINEN IE, 1986, BIOCHIM BIOPHYS ACTA, V853, P135, DOI 10.1016/0304-4173(86)90008-X; HIRAOKA T, 1980, J BIOL CHEM, V255, P7604; HOERTER JA, 1986, CIRC RES, V58, P539, DOI 10.1161/01.RES.58.4.539; KATZ LA, 1989, AM J PHYSIOL, V256, pH265, DOI 10.1152/ajpheart.1989.256.1.H265; KITAZAWA T, 1983, ULTRAMICROSCOPY, V11, P251, DOI 10.1016/0304-3991(83)90005-0; KOBAYASHI K, 1979, CIRC RES, V44, P166, DOI 10.1161/01.RES.44.2.166; LEFURGEY A, 1988, ULTRAMICROSCOPY, V24, P185, DOI 10.1016/0304-3991(88)90311-7; LUKACS GL, 1988, FEBS LETT, V229, P219, DOI 10.1016/0014-5793(88)80831-7; LYNCH RM, 1989, AM J PHYSIOL, V257, pC736, DOI 10.1152/ajpcell.1989.257.4.C736; MCCORMACK JG, 1984, BIOCHEM J, V218, P235, DOI 10.1042/bj2180235; MCCORMACK JG, 1983, BIOCHEM J, V214, P581, DOI 10.1042/bj2140581; MCCORMACK JG, 1981, BIOCHEM J, V194, P639, DOI 10.1042/bj1940639; MCCORMACK JG, 1989, BIOCHIM BIOPHYS ACTA, V973, P420, DOI 10.1016/S0005-2728(89)80384-6; MCMILLIN JB, 1988, MOL CELL BIOCHEM, V81, P121; MORAVEC CS, 1990, CIRCULATION, V82, P1973, DOI 10.1161/01.CIR.82.6.1973; MORAVEC CS, 1991, AM J PHYSIOL, V260, pH989, DOI 10.1152/ajpheart.1991.260.3.H989; MORENOSANCHEZ R, 1988, BIOCHEM J, V256, P403, DOI 10.1042/bj2560403; OROURKE B, 1990, AM J PHYSIOL, V259, pH230, DOI 10.1152/ajpheart.1990.259.1.H230; PAN BS, 1987, J BIOL CHEM, V262, P7839; PETERSON JN, 1991, AM J PHYSIOL, V260, pH1013, DOI 10.1152/ajpheart.1991.260.3.H1013; RANDLE PJ, 1979, HDB PHYSL          2, V1, P805; REERS M, 1989, BIOCHEM J, V257, P131, DOI 10.1042/bj2570131; ROBERTSON SP, 1982, J BIOL CHEM, V257, P1743; SCARPA A, 1973, J GEN PHYSIOL, V62, P756, DOI 10.1085/jgp.62.6.756; SHEU SS, 1982, J GEN PHYSIOL, V80, P325, DOI 10.1085/jgp.80.3.325; SHUMAN H, 1976, ULTRAMICROSCOPY, V1, P317, DOI 10.1016/0304-3991(76)90049-8; SPURGEON HA, 1990, AM J PHYSIOL, V258, pH574, DOI 10.1152/ajpheart.1990.258.2.H574; UNITT JF, 1989, BIOCHEM J, V262, P293, DOI 10.1042/bj2620293; WAN B, 1989, J BIOL CHEM, V264, P13430; WENDTGALLITELLI MF, 1991, J PHYSIOL-LONDON, V435, P349, DOI 10.1113/jphysiol.1991.sp018514; WIKMANCOFFELT J, 1983, AM J PHYSIOL, V245, pH354, DOI 10.1152/ajpheart.1983.245.2.H354; WOLSKA BM, 1991, J MOL CELL CARDIOL, V23, P217, DOI 10.1016/0022-2828(91)90108-X; YUE DT, 1987, AM J PHYSIOL, V252, pH760, DOI 10.1152/ajpheart.1987.252.4.H760; [No title captured]	57	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5310	5316						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544913				2022-12-27	WOS:A1992HH74700049
J	PRENDERGAST, JA; HELGASON, CD; BLEACKLEY, RC				PRENDERGAST, JA; HELGASON, CD; BLEACKLEY, RC			QUANTITATIVE POLYMERASE CHAIN-REACTION ANALYSIS OF CYTOTOXIC-CELL PROTEINASE GENE TRANSCRIPTS IN T-CELLS - PATTERN OF EXPRESSION IS DEPENDENT ON THE NATURE OF THE STIMULUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; SERINE PROTEASE GENES; ANTIGEN RECEPTOR; MESSENGER-RNA; 2 GENES; CLONING; IDENTIFICATION; MECHANISMS; ACTIVATION; GRANULES	A quantitative polymerase chain reaction assay was developed that allowed us to monitor transcript levels corresponding to individual members of the cytotoxic cell proteinase (CCP) gene family during T cell activation. Selective expression was observed and shown to depend upon the mode of T cell antigen receptor stimulation. Mitogen or allogeneic stimulation of cells resulted in the appearance of transcripts corresponding to all the genes measured, whereas alpha-CD3 antibody produced a response restricted to just two family members. This differential gene activation represents a heterogeneity in cytotoxic T lymphocytes that has not been recognized previously. It may indicate that the T cell branch of the immune system can distinguish between different forms of stimulation and respond by synthesizing a specific set of effector and ancillary molecules that is most appropriate for lysis of cells bearing that type of antigen. Only CCP1 transcripts correlated with cytotoxicity for all modes of stimulation. The patterns for the others are suggestive of distinct and ancillary, rather than direct effector, roles in the lytic mechanism.	UNIV ALBERTA,DEPT BIOCHEM,MED SCI BLDG,EDMONTON T6G 2H7,ALBERTA,CANADA	University of Alberta								BERKE G, 1987, ANN INST PASTEUR IMM, V138, P304, DOI 10.1016/S0769-2625(87)80084-3; BLEACKLEY RC, 1988, IMMUNOL REV, V103, P5, DOI 10.1111/j.1600-065X.1988.tb00746.x; BRUNET JF, 1987, J IMMUNOL, V138, P4102; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROSBY JL, 1990, GENOMICS, V6, P252, DOI 10.1016/0888-7543(90)90564-B; EBNET K, 1991, INT IMMUNOL, V3, P9, DOI 10.1093/intimm/3.1.9; FREGEAU CJ, 1991, SOMAT CELL MOLEC GEN, V17, P239, DOI 10.1007/BF01232820; GARCIASANZ JA, 1990, J IMMUNOL, V145, P3111; GERSHENFELD HK, 1988, P NATL ACAD SCI USA, V85, P1184, DOI 10.1073/pnas.85.4.1184; HADDAD P, 1990, INT IMMUNOL, V3, P57; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; JENNE D, 1988, P NATL ACAD SCI USA, V85, P4814, DOI 10.1073/pnas.85.13.4814; JOAG S, 1989, J CELL BIOCHEM, V39, P239, DOI 10.1002/jcb.240390304; KANELLOPOULOS JM, 1985, EUR J IMMUNOL, V15, P479, DOI 10.1002/eji.1830150512; KWON BS, 1988, J EXP MED, V168, P1839, DOI 10.1084/jem.168.5.1839; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIN CC, 1990, CYTOGENET CELL GENET, V53, P169, DOI 10.1159/000132921; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; LOBE CG, 1988, BIOCHEMISTRY-US, V27, P6941, DOI 10.1021/bi00418a040; LOBE CG, 1986, P NATL ACAD SCI USA, V83, P1448, DOI 10.1073/pnas.83.5.1448; MASSON D, 1986, EMBO J, V5, P1595, DOI 10.1002/j.1460-2075.1986.tb04401.x; MEIER M, 1990, BIOCHEMISTRY-US, V29, P4042, DOI 10.1021/bi00469a003; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUELLER C, 1988, J EXP MED, V167, P1124, DOI 10.1084/jem.167.3.1124; NAGLERANDERSON C, 1988, IMMUNOL REV, V103, P111, DOI 10.1111/j.1600-065X.1988.tb00753.x; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; OSTERGAARD HL, 1989, J IMMUNOL, V143, P2120; PRENDERGAST JA, 1991, J MOL BIOL, V220, P867, DOI 10.1016/0022-2836(91)90359-E; REDMOND MJ, 1987, J IMMUNOL, V139, P3184; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SCHMID J, 1987, J IMMUNOL, V139, P250; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P2641, DOI 10.1021/bi00408a001; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WEISS A, 1987, J IMMUNOL, V138, P2169; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; YOUNG JDE, 1986, P NATL ACAD SCI USA, V83, P5668, DOI 10.1073/pnas.83.15.5668	37	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5090	5095						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544892				2022-12-27	WOS:A1992HH74700016
J	HASNAIN, S; HIRAMA, T; TAM, A; MORT, JS				HASNAIN, S; HIRAMA, T; TAM, A; MORT, JS			CHARACTERIZATION OF RECOMBINANT RAT CATHEPSIN-B AND NONGLYCOSYLATED MUTANTS EXPRESSED IN YEAST - NEW INSIGHTS INTO THE PH-DEPENDENCE OF CATHEPSIN-B-CATALYZED HYDROLYZES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PAPAIN; SPLEEN; BIOSYNTHESIS; PURIFICATION; MACROPHAGES; HEPATOCYTES; SEQUENCE; ENZYME; SITE	The cysteine proteinase rat cathepsin B was expressed in yeast in an active form and was found to be heterogeneously glycosylated at the consensus sequence for N-linked oligosaccharide substitution. Purified enzyme fractions containing the highest levels of glycosylation were shown to have reduced activity. A glycosylation minus mutant constructed by site-directed mutagenesis (by changing the Ser to Ala in the consensus sequence) was still secreted by the yeast and was shown to be functionally identical with purified rat liver cathepsin B. Recombinant cathepsin B was used to further characterize the pH dependence of cathepsin B-catalyzed hydrolyses using 7-amido-4-methylcoumarin (AMC) and p-nitroaniline (pNA) substrates with arginine as the P1, and either arginine or phenylalanine as the P2 residue. The AMC and pNA groups give insights into the leaving group binding site (P') of cathepsin B. These studies show for the first time that at least seven dissociable groups are involved in substrate binding and hydrolysis in cathepsin B activity. Two of these groups, with pK(a) values of 6.9 and 7.7 in the recombinant enzyme, are in the leaving group binding site and are most likely His110 and His111. The same groups in rat liver cathepsin B have higher pK(a) values than in recombinant cathepsin B, but have identical function in the two enzymes. Two other groups are probably the active site Cys29 and His199 with pK(a) values of 3.6 and 8.6, respectively. A group with a pK(a) of 5.1 interacts with substrates containing Arg at P2, and the group is most likely Glu245. The remaining two groups, one with a pK(a) of about 4.9 and the other about 5.3, are most likely carboxyl residues possibly interacting with Arg at P1 in the substrate. The possible candidates on the basis of the x-ray structure are Asp22, Asp69, Glu171, and Glu122, all found within a 13 angstrom radius from the active site thiol of Cys29.	SHRINERS HOSP CRIPPLED CHILDREN, JOINT DIS LAB, MONTREAL H3G 1A6, QUEBEC, CANADA; MCGILL UNIV, DEPT SURG, MONTREAL H3G 1A6, QUEBEC, CANADA	McGill University; McGill University	HASNAIN, S (corresponding author), NATL RES COUNCIL CANADA, INST BIOL SCI, PROT STRUCT & DESIGN SECT, OTTAWA K1A 0R6, ONTARIO, CANADA.							ALBERTY RA, 1954, BIOCHIM BIOPHYS ACTA, V13, P347, DOI 10.1016/0006-3002(54)90340-6; BAJKOWSKI AS, 1983, J BIOL CHEM, V258, P1645; BAJKOWSKI AS, 1983, J BIOL CHEM, V258, P1650; BARRETT AJ, 1973, BIOCHEM J, V131, P809, DOI 10.1042/bj1310809; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; CHAN MM, 1988, FEBS LETT, V239, P219, DOI 10.1016/0014-5793(88)80920-7; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; COHEN LW, 1990, GENE, V88, P263, DOI 10.1016/0378-1119(90)90041-O; ERNST JF, 1986, DNA-J MOLEC CELL BIO, V5, P483, DOI 10.1089/dna.1.1986.5.483; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; GOPALAN P, 1987, CAN J PHYSIOL PHARM, V65, P124, DOI 10.1139/y87-025; HARA K, 1988, FEBS LETT, V231, P229, DOI 10.1016/0014-5793(88)80737-3; KATUNUMA N, 1987, REV PHYSIOL BIOCH P, V108, P1, DOI 10.1007/BFb0034070; KHOURI HE, 1991, BIOCHEM J, V275, P751, DOI 10.1042/bj2750751; KOMINAMI E, 1988, FEBS LETT, V231, P225, DOI 10.1016/0014-5793(88)80736-1; LAH TT, 1989, CLIN EXP METASTAS, V7, P461, DOI 10.1007/BF01753666; LEE X, 1990, J BIOL CHEM, V265, P5950; LEWIS SD, 1976, BIOCHEMISTRY-US, V15, P5009, DOI 10.1021/bi00668a010; LEWIS SD, 1981, BIOCHEMISTRY-US, V20, P48, DOI 10.1021/bi00504a009; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; MORT JS, 1988, BIOL CHEM H-S, V369, P163; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V262, P159, DOI 10.1016/0003-9861(88)90178-6; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V263, P107, DOI 10.1016/0003-9861(88)90618-2; POHL J, 1987, ANAL BIOCHEM, V165, P96, DOI 10.1016/0003-2697(87)90205-3; POLGAR L, 1987, J BIOL CHEM, V262, P14448; RICH DH, 1986, BIOCHEM J, V235, P731, DOI 10.1042/bj2350731; RITONJA A, 1985, FEBS LETT, V181, P169, DOI 10.1016/0014-5793(85)81136-4; SEGUNDO BS, 1985, P NATL ACAD SCI USA, V82, P2320, DOI 10.1073/pnas.82.8.2320; Sloane B F, 1990, Semin Cancer Biol, V1, P137; SLOANE BF, 1990, CANCER METAST REV, V9, P333, DOI 10.1007/BF00049523; SMITH SM, 1989, J BIOL CHEM, V264, P20487; TAKAHASHI T, 1984, J BIOL CHEM, V259, P6059; VANNOORDEN CJF, 1988, J RHEUMATOL, V15, P1525; VERNET T, 1989, GENE, V77, P229, DOI 10.1016/0378-1119(89)90071-1; WILLENBROCK F, 1985, BIOCHEM J, V227, P521, DOI 10.1042/bj2270521	36	89	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4713	4721						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537854				2022-12-27	WOS:A1992HF64200066
J	KENNEDY, TA; LIEBLER, DC				KENNEDY, TA; LIEBLER, DC			PEROXYL RADICAL SCAVENGING BY BETA-CAROTENE IN LIPID BILAYERS - EFFECT OF OXYGEN PARTIAL-PRESSURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; ALPHA-TOCOPHEROL; CANCER; RISK; CANTHAXANTHIN; PEROXIDATION; ANTIOXIDANT; INHIBITION; TRANSFORMATION; CELLS	The effect of the partial pressure of oxygen (pO2) on the antioxidant reactions of all-trans-beta, beta-carotene (BC) was investigated in a soybean phosphatidylcholine liposome system. Peroxyl radicals generated by thermolysis of azo-bis(2,4-dimethylvaleronitrile) at 37-degrees-C initiated lipid peroxidation. BC inhibited lipid peroxidation, which was monitored by conjugated diene formation, by up to 70% versus control at 160 and 15 torr O2. In contrast, at 760 torr O2 the maximum inhibition was approximately 40% versus control and inhibition was less reproducible. Peroxyl radicals oxidized BC to 5,6-epoxy-beta,beta-carotene and several unidentified polar products. The rates of both product formation and BC consumption were significantly higher at 160 torr than at 15 torr O2. However, at 160 and 760 torr O2, the rates of product formation and BC depletion were similar. In liposomes without azo-bis(2,4-dimethylvaleronitrile), BC depletion at 160 torr was only 64% that at 760 torr O2. These results suggest that both radical trapping and autoxidation reactions consume BC and that the latter are accelerated by high pO2. Autoxidation consumes BC without scavenging peroxyl radicals and may attenuate BC antioxidant activity, especially at high pO2. The similarity in its antioxidant effects at 15 and 160 torr O2 suggests that BC could provide antioxidant protection to any tissue within the normal physiologic range of pO2.	UNIV ARIZONA,COLL PHARM,DEPT PHARMACOL & TOXICOL,TUCSON,AZ 85721	University of Arizona				Liebler, Daniel/0000-0002-7873-3031	NIEHS NIH HHS [ES 07091-11] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALAM B S, 1987, Nutrition and Cancer, V9, P93; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BARCLAY LRC, 1981, J AM CHEM SOC, V103, P6478, DOI 10.1021/ja00411a036; BENDICH A, 1988, NUTR CANCER, V11, P207, DOI 10.1080/01635588809513989; BUDZIKIE.H, 1970, MONATSH CHEM, V101, P579, DOI 10.1007/BF00910247; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; Deamer DW, 1983, LIPOSOMES, P27; HEYWOOD R, 1985, TOXICOLOGY, V36, P91, DOI 10.1016/0300-483X(85)90043-5; HIRAYAMA T, 1985, INT S PRINCESS TAKAM, V16, P41; KENNEDY TA, 1991, CHEM RES TOXICOL, V4, P290, DOI 10.1021/tx00021a005; KRINSKY NI, 1982, J NATL CANCER I, V69, P205; KRINSKY NI, 1989, FREE RADICAL BIO MED, V7, P617, DOI 10.1016/0891-5849(89)90143-3; KUNERT KJ, 1983, LIPIDS, V18, P271, DOI 10.1007/BF02534701; LIEBLER DC, 1991, CHEM RES TOXICOL, V4, P89, DOI 10.1021/tx00019a012; MATHEWSROTH MM, 1988, TOXICOL LETT, V41, P185, DOI 10.1016/0378-4274(88)90053-7; MATHEWSROTH MM, 1982, ONCOLOGY, V39, P33, DOI 10.1159/000225601; MENKES MS, 1986, NEW ENGL J MED, V315, P1250, DOI 10.1056/NEJM198611133152003; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P491; MOORE MM, 1989, ARCH BIOCHEM BIOPHYS, V270, P419, DOI 10.1016/0003-9861(89)90524-9; NOMURA AMY, 1985, CANCER RES, V45, P2369; PAGANINIHILL A, 1987, JNCI-J NATL CANCER I, V79, P443; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; PRYOR WA, 1984, METHOD ENZYMOL, V105, P293; PRYOR WA, 1988, J AM CHEM SOC, V110, P2224, DOI 10.1021/ja00215a036; PUNG A, 1988, CARCINOGENESIS, V9, P1533, DOI 10.1093/carcin/9.9.1533; SAMOKYSZYN VM, 1990, FREE RADICAL BIO MED, V8, P491, DOI 10.1016/0891-5849(90)90063-O; SHKLAR G, 1988, EUR J CANCER CLIN ON, V24, P839, DOI 10.1016/0277-5379(88)90192-7; SOM S, 1984, CARCINOGENESIS, V5, P937, DOI 10.1093/carcin/5.7.937; STICH HF, 1988, INT J CANCER, V42, P195, DOI 10.1002/ijc.2910420209; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; TEMPLE NJ, 1987, J NATL CANCER I, V78, P1211; TSUKIDA K, 1958, ARCH BIOCHEM BIOPHYS, V74, P408, DOI 10.1016/0003-9861(58)90011-0; VANDEVEN M, 1984, BIOCHEM BIOPH RES CO, V120, P1060, DOI 10.1016/S0006-291X(84)80214-4; VILE GF, 1988, FEBS LETT, V238, P353, DOI 10.1016/0014-5793(88)80511-8; WALD NJ, 1988, BRIT J CANCER, V57, P428, DOI 10.1038/bjc.1988.97; YAMAMOTO HY, 1978, BIOCHIM BIOPHYS ACTA, V507, P119, DOI 10.1016/0005-2736(78)90379-6; ZIEGLER RG, 1991, AM J CLIN NUTR, V53, pS251, DOI 10.1093/ajcn/53.1.251S	37	197	201	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4658	4663						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537849				2022-12-27	WOS:A1992HF64200059
J	VANDERJAGT, DL; ROBINSON, B; TAYLOR, KK; HUNSAKER, LA				VANDERJAGT, DL; ROBINSON, B; TAYLOR, KK; HUNSAKER, LA			REDUCTION OF TRIOSES BY NADPH-DEPENDENT ALDO-KETO REDUCTASES - ALDOSE REDUCTASE, METHYLGLYOXAL, AND DIABETIC COMPLICATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE-CONDUCTION VELOCITY; RED-BLOOD-CELLS; POLYOL PATHWAY; ACETONE METABOLISM; MYOINOSITOL DEPLETION; HUMAN-PLACENTA; ORAL SORBINIL; ASCORBIC-ACID; HUMAN-TISSUES; PREVENTION	The substrate specificities of human aldose reductase and aldehyde reductase toward trioses, triose phosphates, and related three-carbon aldehydes and ketones were evaluated. Both enzymes are able to catalyze the NADPH-dependent reduction of all of the substrates used. Aldose reductase shows more discrimination among substrates than does aldehyde reductase and is generally the more efficient catalyst. The best substrate for aldose reductase is methylglyoxal (k(cat) = 142 min-1, k(cat)/K(m) = 1.8 x 10(7) M-1 min-1), a toxic 2-oxo-aldehyde that is produced nonenzymatically from triose phosphates and enzymatically from acetone/acetol metabolism. D- and L-glyceraldehyde and D- and L-lactaldehyde are also good substrates for aldose reductase. The aldose reductase-catalyzed reduction of methylglyoxal produces 95% acetol, 5% D-lactaldehyde. Further reduction of acetol produces only L-1,2-propanediol. Acetol and propanediol are two products that accumulate in uncontrolled diabetes. Both acetol and methylglyoxal were compared with glucose for their abilities to produce covalent modification of albumin. All three of these carbonyl compounds reacted with albumin to produce modified proteins with new absorption and emission bands that are spectrally similar. Both methylglyoxal and acetol are much more reactive than glucose. A new integrative model of diabetic complications is proposed that combines the aldose reductase/polyol pathway theory and the nonenzymatic glycation theory except that emphasis is placed both on methylglyoxal/acetol metabolism and on glucose metabolism.			VANDERJAGT, DL (corresponding author), UNIV NEW MEXICO, SCH MED, DEPT BIOCHEM, ALBUQUERQUE, NM 87131 USA.				PHS HHS [A130675] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEYERMEARS A, 1984, DIABETES, V33, P604, DOI 10.2337/diabetes.33.6.604; BEYERMEARS A, 1986, PHARMACOLOGY, V32, P52, DOI 10.1159/000138152; BROWNLEE M, 1989, COMPLICATIONS DIABET, P9; BROWNLEE M, 1987, DIABETIC COMPLICATIO, P94; CARPER D, 1987, FEBS LETT, V220, P209, DOI 10.1016/0014-5793(87)80905-5; CASAZZA JP, 1985, ANAL BIOCHEM, V148, P344, DOI 10.1016/0003-2697(85)90238-6; CASAZZA JP, 1984, J BIOL CHEM, V259, P231; CHEN MS, 1983, DIABETES, V32, P1078, DOI 10.2337/diabetes.32.11.1078; CLEMENTS RS, 1985, AM J MED, V79, P2, DOI 10.1016/0002-9343(85)90503-0; COHEN MP, 1985, DIABETES, V34, P1071, DOI 10.2337/diabetes.34.11.1071; COOPER RA, 1984, ANNU REV MICROBIOL, V38, P49, DOI 10.1146/annurev.mi.38.100184.000405; COOPER RA, 1970, FEBS LETT, V11, P273, DOI 10.1016/0014-5793(70)80546-4; ELLIOTT WH, 1959, NATURE, V183, P1051, DOI 10.1038/1831051a0; GABBAY KH, 1975, ANNU REV MED, V26, P521, DOI 10.1146/annurev.me.26.020175.002513; GONZALEZ AM, 1986, DIABETES, V35, P1200, DOI 10.2337/diabetes.35.11.1200; GONZALEZ RG, 1984, DIABETES, V33, P196, DOI 10.2337/diabetes.33.2.196; GREENE DA, 1987, J CLIN INVEST, V79, P1479, DOI 10.1172/JCI112977; GREENE DA, 1986, DIABETES, V35, P1106, DOI 10.2337/diabetes.35.10.1106; GREENE DA, 1987, DIABETIC COMPLICATIO, P66; GRIMSHAW CE, 1989, ANAL BIOCHEM, V176, P66, DOI 10.1016/0003-2697(89)90273-X; HUNT JV, 1990, FEBS LETT, V269, P258, DOI 10.1016/0014-5793(90)81168-N; JAIN SK, 1990, METABOLISM, V39, P971, DOI 10.1016/0026-0495(90)90310-9; KADOR PF, 1985, AM J MED, V79, P8, DOI 10.1016/0002-9343(85)90504-2; KEMPER C, 1986, P SOC EXP BIOL MED, V182, P505; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; KOOP DR, 1985, J BIOL CHEM, V260, P3607; LAMBERT JB, 1985, J AM CHEM SOC, V107, P7978, DOI 10.1021/ja00312a030; MAYER JH, 1983, DIABETOLOGIA, V25, P433, DOI 10.1007/BF00282524; MILLER KW, 1984, ARCH BIOCHEM BIOPHYS, V229, P483, DOI 10.1016/0003-9861(84)90179-6; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; MOREL DW, 1989, J LIPID RES, V30, P1827; MURATA K, 1989, CAN J MICROBIOL, V35, P423, DOI 10.1139/m89-065; MURATA K, 1986, EUR J BIOCHEM, V157, P297, DOI 10.1111/j.1432-1033.1986.tb09668.x; OHMORI S, 1989, ENZYMOLOGY MOL BIOL, V2, P397; OWEN OE, 1982, DIABETES, V31, P242, DOI 10.2337/diabetes.31.3.242; PENNINCKX MJ, 1983, J BIOL CHEM, V258, P6030; PFEIFER MA, 1985, AM J MED, V79, P18, DOI 10.1016/0002-9343(85)90506-6; PONGOR S, 1984, P NATL ACAD SCI-BIOL, V81, P2684, DOI 10.1073/pnas.81.9.2684; RAY S, 1981, J BIOL CHEM, V256, P6230; REICHARD GA, 1986, DIABETES, V35, P668, DOI 10.2337/diabetes.35.6.668; REICHARD GA, 1979, J CLIN INVEST, V63, P619, DOI 10.1172/JCI109344; ROBISON WG, 1986, DRUGS, V32, P19, DOI 10.2165/00003495-198600322-00006; ROBISON WG, 1986, DIABETES, V35, P295, DOI 10.2337/diabetes.35.3.295; RUTSTEIN DD, 1983, LANCET, V2, P534; SIMARDDUQUESNE N, 1985, P SOC EXP BIOL MED, V178, P599; SKUTCHES CL, 1990, DIABETES, V39, P450, DOI 10.2337/diabetes.39.4.450; THORNALLEY PJ, 1988, BIOCHEM J, V254, P751, DOI 10.1042/bj2540751; UNAKAR N, 1989, INVEST OPHTH VIS SCI, V30, P1623; Vander Jagt D. L., 1989, GLUTATHIONE CHEM B A, P598; VANDERJAGT DL, 1990, J BIOL CHEM, V265, P20982; VANDERJAGT DL, 1990, J BIOL CHEM, V265, P10912; VANDERJAGT DL, 1988, BIOCHEM PHARMACOL, V37, P1051, DOI 10.1016/0006-2952(88)90509-6; WERMUTH B, 1985, ENZYMOLOGY CARBONYL, V2, P209; WILLIAMS WF, 1986, SCIENCE, V233, P233; WIRTH HP, 1985, FEBS LETT, V187, P280, DOI 10.1016/0014-5793(85)81259-X; WOHAIEB SA, 1987, CAN J PHYSIOL PHARM, V65, P2191, DOI 10.1139/y87-346; WOLFF SP, 1984, EXPERIENTIA, V40, P244, DOI 10.1007/BF01947562; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; YUE DK, 1989, DIABETES, V38, P257, DOI 10.2337/diabetes.38.2.257	59	259	265	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4364	4369						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537826				2022-12-27	WOS:A1992HF64200019
J	BROWNING, KS; WEBSTER, C; ROBERTS, JKM; RAVEL, JM				BROWNING, KS; WEBSTER, C; ROBERTS, JKM; RAVEL, JM			IDENTIFICATION OF AN ISOZYME FORM OF PROTEIN-SYNTHESIS INITIATION-FACTOR 4F IN PLANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; MESSENGER-RNA TRANSLATION; WHEAT-GERM; SACCHAROMYCES-CEREVISIAE; ELONGATION-FACTORS; PURIFICATION; RECOGNITION; YEAST; CELLS	We showed previously that wheat germ extracts contain two forms of protein synthesis initiation factor 4F that have very similar functional properties (Browning, K. S., Lax, S. R., and Ravel, J. M. (1987) J. Biol. Chem. 262, 11228-11232). One form, designated eIF-4F, is a complex containing two subunits, p220 and p26. The other form, designated eIF-(iso)4F, is a complex containing two subunits, p82 and p28, which are antigenically distinct from the subunits of eIF-4F. Both the p26 subunit of eIF-4F and the p28 subunit of eIF-(iso)4F are m7G cap-binding proteins. In this investigation, affinity-purified antibodies to the p220 and p26 subunits of wheat germ eIF-4F and to the p82 and p28 subunits of wheat germ eIF-(iso)4F were used to determine if isozyme forms of eIF-4F are present in maize and cauliflower. Extracts from wheat germ, maize root tips, and cauliflower inflorescences were partially purified by adsorption on m7GTP-Sepharose and elution with m7GTP (MGS eluate). Analysis by sodium dodecyl sulfate gel electrophoresis and immunoblotting with antibodies to the subunits of the wheat germ factors showed that the MGS eluate from maize contains polypeptides that react with antibodies to the p82 and p28 subunits of wheat eIF-(iso)4F, as well as polypeptides that react with antibodies to the p220 and p26 subunits of wheat eIF-4F. The MGS eluate from cauliflower also contains polypeptides that reacted with antibodies to the subunits of wheat eIF-(iso)4F. These results indicate that both maize and cauliflower contain the isozyme form of eIF-4F. In addition, it was found that the factors in the MGS eluate from maize support polypeptide synthesis in a system from wheat deficient in eIF-4F and eIF-(iso)4F, whereas the factors in the MGS eluate from cauliflower support polypeptide synthesis only to a small extent.	UNIV TEXAS,CLAYTON FDN BIOCHEM INST,AUSTIN,TX 78712; UNIV CALIF IRVINE,DEPT BIOCHEM,IRVINE,CA 92717	University of Texas System; University of Texas Austin; University of California System; University of California Irvine					NIGMS NIH HHS [GM 18775] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018775] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; ABRAMSON RD, 1988, J BIOL CHEM, V263, P5462; ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; BLUM S, 1989, P NATL ACAD SCI USA, V86, P6043, DOI 10.1073/pnas.86.16.6043; BROWNING KS, 1989, J BIOL CHEM, V264, P8491; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; BROWNING KS, 1987, J BIOL CHEM, V262, P538; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P1624, DOI 10.1021/bi00220a026; EDERY I, 1983, J BIOL CHEM, V258, P1398; ETCHISON D, 1987, MOL CELL BIOCHEM, V76, P15; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JARAMILLO M, 1990, BIOCHIM BIOPHYS ACTA, V1050, P134, DOI 10.1016/0167-4781(90)90154-T; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; LAX SR, 1986, METHOD ENZYMOL, V118, P109; LAX SR, 1986, J BIOL CHEM, V261, P5632; MAROTO FG, 1989, MOL CELL BIOL, V9, P2181, DOI 10.1128/MCB.9.5.2181; Merrick W C, 1979, Methods Enzymol, V60, P101, DOI 10.1016/S0076-6879(79)60010-1; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; SEAL SN, 1986, ARCH BIOCHEM BIOPHYS, V246, P710, DOI 10.1016/0003-9861(86)90327-9; SONENBERG N, 1979, P NATL ACAD SCI USA, V76, P4345, DOI 10.1073/pnas.76.9.4345; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; TAHARA SM, 1981, J BIOL CHEM, V256, P7691; WEBSTER C, 1991, J BIOL CHEM, V266, P23341	29	90	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10096	10100						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577779				2022-12-27	WOS:A1992HT96500097
J	BURKE, CJ; SANYAL, G; BRUNER, MW; RYAN, JA; LAFEMINA, RL; ROBBINS, HL; ZEFT, AS; MIDDAUGH, CR; CORDINGLEY, MG				BURKE, CJ; SANYAL, G; BRUNER, MW; RYAN, JA; LAFEMINA, RL; ROBBINS, HL; ZEFT, AS; MIDDAUGH, CR; CORDINGLEY, MG			STRUCTURAL IMPLICATIONS OF SPECTROSCOPIC CHARACTERIZATION OF A PUTATIVE ZINC FINGER PEPTIDE FROM HIV-1 INTEGRASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; PROTEIN; PREDICTION; DOMAIN; POL; RECOGNITION; MUTAGENESIS; SELECTION	The N-terminal domain of human immunodeficiency virus (HIV-1) integrase (IN) contains the sequence motif His-Xaa3-His-Xaa23-Cys-Xaa2-Cys, which is strongly conserved in all retroviral and retrotransposon IN proteins. This structural motif constitutes a putative zinc finger in which a metal ion may be coordinately bound by the His and Cys residues. A recombinant peptide, IN(1-55), composed of the N-terminal 55 amino acids of HIV-1 IN was expressed in Escherichia coli and purified. Utilizing a combination of techniques including UV-visible absorption, circular dichroism, Fourier transform infrared, and fluorescence spectroscopies, we have demonstrated that metal ions (Zn2+, Co2+, and Cd2+) are bound with equimolar stoichiometry by IN(1-55). The liganded peptide assumes a highly ordered structure with increased alpha-helical content and exhibits remarkable, thermal stability. UV-visible difference spectra of the peptide-Co2+ complexes directly implicate thiols in metal coordination, and Co2+ d-d transitions in the visible range indicate that Co2+ is tetrahedrally coordinated. Mutant peptides containing conservative substitutions of one of the conserved His or either of the Cys residues displayed no significant Zn2+-induced conformational changes as monitored by CD and fluorescence spectra. We conclude that the N terminus of HIV-1 IN contains a metal-binding domain whose structure is stabilized by tetrahedral coordination of metal by histidines 12 and 16 and cysteines 40 and 43. A preliminary structural model for this zinc finger is presented.	MERCK SHARP & DOHME LTD,DEPT PHARMACEUT RES,W POINT,PA 19486; MERCK SHARP & DOHME LTD,DEPT VIRUS & CELL BIOL,W POINT,PA 19486	Merck & Company; Merck & Company								BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; Bertini I, 1984, Adv Inorg Biochem, V6, P71; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COPELAND RA, 1991, ARCH BIOCHEM BIOPHYS, V289, P53, DOI 10.1016/0003-9861(91)90441-K; Cotton F.A., 1980, ADV INORG CHEM, P768; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; DEVEREUX J, 1989, GCG SEQUENCE ANAL SO; DONEHOWER LA, 1984, P NATL ACAD SCI-BIOL, V81, P6461, DOI 10.1073/pnas.81.20.6461; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FUJIWRA T, 1987, CELL, V54, P497; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREEN LM, 1989, P NATL ACAD SCI USA, V86, P4047, DOI 10.1073/pnas.86.11.4047; HIPPENMEYER PJ, 1984, VIROLOGY, V137, P358, DOI 10.1016/0042-6822(84)90228-9; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; Kaptein R, 1991, CURR OPIN STRUC BIOL, V1, P63, DOI 10.1016/0959-440X(91)90013-J; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LEFEMINA RL, 1991, J VIROL, V65, P5624; LIN TH, 1989, PROTEINS, V5, P156, DOI 10.1002/prot.340050210; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MILLER WT, 1991, BIOCHEMISTRY-US, V30, P6970, DOI 10.1021/bi00242a023; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHWARTZBERG P, 1984, CELL, V37, P1043, DOI 10.1016/0092-8674(84)90439-2; SOUTH TL, 1990, BIOCHEM PHARMACOL, V40, P123, DOI 10.1016/0006-2952(90)90187-P; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P9808, DOI 10.1021/bi00494a008	34	155	157	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9639	9644						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577801				2022-12-27	WOS:A1992HT96500031
J	TSUNEOKA, M; MEKADA, E				TSUNEOKA, M; MEKADA, E			DEGRADATION OF A NUCLEAR-LOCALIZED PROTEIN IN MAMMALIAN COS CELLS, USING ESCHERICHIA-COLI BETA-GALACTOSIDASE AS A MODEL PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC ONCOGENE; GENE-PRODUCT; EXPRESSION; YEAST; PHOSPHORYLATION; SEQUENCE; SIGNAL; CYCLE	To investigate the mechanism of degradation of proteins localized in the nucleus, we constructed genes encoding modified Escherichia coli beta-galactosidases and expressed them in mammalian COS cells. When the beta-galactosidase with a nuclear localization signal from SV 40 T antigen was expressed in COS cells, the beta-galactosidase polypeptide was localized in the nuclei and was stable for at least 4 h. When 16 amino acid residues were deleted from the C-terminal end, the beta-galactosidase polypeptide was also observed in the nuclei but it was degraded rapidly, with a half-life of 1.6 h. When the nuclear localizing signal was replaced with a mutant sequence, which lacks nuclear targeting activity, the beta-galactosidase polypeptides were present throughout the cells rather than in the nuclei. The beta-galactosidase polypeptide with the complete C terminus was stable and the cytoplasmic truncated polypeptide was degraded at the same rate as the nuclear C terminus truncated polypeptide. The beta-galactosidase polypeptides with the complete C terminus were present as a tetramer as reported previously and had beta-galactosidase activity, but the C terminus truncated polypeptides were present as monomer and had no enzyme activity, indicating that C terminus truncated beta-galactosidase is malfolded. Together, the results suggest that a nuclear-localized malfolded protein is degraded as rapidly as a cytoplasmic malfolded protein.			TSUNEOKA, M (corresponding author), KURUME UNIV,INST LIFE SCI,2432-3 AIKAWA,KURUME,FUKUOKA 830,JAPAN.			Mekada, Eisuke/0000-0001-8858-4781				BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BEGUM N, 1990, J BIOL CHEM, V265, P11936; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FOWLER AV, 1966, SCIENCE, V154, P1027, DOI 10.1126/science.154.3752.1027; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KATZNELSON R, 1985, EUR J BIOCHEM, V146, P437, DOI 10.1111/j.1432-1033.1985.tb08670.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MCKNIGHT JL, 1981, J BIOL CHEM, V256, P9652; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RECHSTEINER M, 1987, TRENDS BIOCHEM SCI, V12, P390; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SIMON R, 1990, MOL CELL BIOL, V10, P5609, DOI 10.1128/MCB.10.11.5609; SLAVICEK JM, 1988, EMBO J, V7, P3171, DOI 10.1002/j.1460-2075.1988.tb03184.x; TANAKA K, 1989, J CELL PHYSIOL, V139, P34, DOI 10.1002/jcp.1041390107; WANG S S, 1987, Journal of Biological Chemistry, V262, P6357	31	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9107	9111						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577746				2022-12-27	WOS:A1992HR85400063
J	WU, L; VERTINO, A; KOUDELKA, GB				WU, L; VERTINO, A; KOUDELKA, GB			NONCONTACTED BASES AFFECT THE AFFINITY OF SYNTHETIC P22-OPERATORS FOR P22-REPRESSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SPECIFICITY; LAC REPRESSOR; ALPHA-HELIX; DNA; OPERATOR; RESOLUTION	The affinity of synthetic P22 operators for P22 repressor varies with the base sequence at the operator's center. At 100 mm KCl, the affinity of these operators for P22 repressor varies over a 10-fold range. Dimethylsulfate protection experiments indicate that the central bases of the P22 operator are not contacted by the repressor. The K(D) for the complex of P22 repressor with an operator bearing central T-A bases (9T) increases less than 2-fold between 50 and 200 mm KCl, whereas the K(D) for the complex of repressor with an operator bearing central C-G bases (9C) increases 10-fold in the same salt range. The DNase I cleavage patterns of both bound and unbound P22 operators also vary with central base sequence. The DNase I pattern of the repressor-9C operator complex changes markedly with salt concentration, whereas that of the 9T operator-repressor complex does not. These changes in nuclease digestion pattern thereby mirror the salt-dependent changes in the P22 operator's affinity for repressor. P22 repressor protects the central base pair of the 9T operator from cleavage by the intercalative cleavage reagent Cu(I)-phenanthroline, while repressor does not protect the central bases of the 9C operator. Together these data indicate that central base pairs affect P22 operator strength by altering the structure of the unbound operator and the repressor-operator complex.	SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Koudelka, Gerald B./AAI-3738-2020	Koudelka, Gerald B./0000-0001-6280-0837	NIGMS NIH HHS [GM42138] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042138, R01GM042138] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON JE, 1987, NATURE, V326, P888; BARKLEY MD, 1979, J CHEM PHYS, V70, P2991, DOI 10.1063/1.437838; CARLSON P, 1992, NATURE, V355, P89; CHEN CH, 1990, ANN REV BIOCH, V59, P7; DEANDA J, 1983, J BIOL CHEM, V258, P536; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P4783, DOI 10.1021/bi00641a004; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LOMONOSSOFF GP, 1981, J MOL BIOL, V149, P745, DOI 10.1016/0022-2836(81)90356-9; Maniatis T., 1982, MOL CLONING; MESSING J, 1983, METHOD ENZYMOL, V101, P29; POTEETE AR, 1980, J MOL BIOL, V137, P81, DOI 10.1016/0022-2836(80)90158-8; POTEETE AR, 1982, J MOL BIOL, V157, P21, DOI 10.1016/0022-2836(82)90511-3; Ptashne M., 1986, A GENETIC SWITCH; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SAUER RT, 1982, NATURE, V298, P447, DOI 10.1038/298447a0; SENN H, 1987, EUR BIOPHYS J BIOPHY, V14, P301, DOI 10.1007/BF00254895; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P8050, DOI 10.1021/bi00348a032; VEAL JM, 1991, BIOCHEMISTRY-US, V30, P1132, DOI 10.1021/bi00218a035; WHARTON RP, 1986, TRENDS BIOCHEM SCI, V11, P71, DOI 10.1016/0968-0004(86)90268-9; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0; WHARTON RP, 1984, CELL, V38, P361, DOI 10.1016/0092-8674(84)90491-4	29	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9134	9139						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577749				2022-12-27	WOS:A1992HR85400067
J	YADA, T; ARAI, M; SUZUKI, S; KIMATA, K				YADA, T; ARAI, M; SUZUKI, S; KIMATA, K			OCCURRENCE OF COLLAGEN AND PROTEOGLYCAN FORMS OF TYPE-IX COLLAGEN IN CHICK-EMBRYO CARTILAGE - PRODUCTION AND CHARACTERIZATION OF A COLLAGEN FORM-SPECIFIC ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE CHAIN(S); HUMAN-MELANOMA CELLS; MONOCLONAL-ANTIBODY; II COLLAGEN; POLYPEPTIDE; PROTEINS; CONTAINS; FIBRILS; DOMAIN; GLYCOSAMINOGLYCANS	Type IX collagen from chick embryonic cartilage is a proteoglycan bearing a single chondroitin sulfate chain covalently linked to the alpha-2(IX) polypeptide chain. We have isolated type IX collagen metabolically labeled with [H-3]proline using an antibody to type IX collagen and have found that the molecule is synthesized in two forms, a collagen form (COLIX) and a proteoglycan form (PGIX). In cultured chondrocytes, the two forms of type IX collagen showed a different ability to be deposited in the matrix. We have suggested the possibility that both forms may arise from an alternative substitution of a chondroitin sulfate chain to the NC3 domain of the alpha-2(IX) chain. Based on the reported amino acid sequence at the NC3 domain of alpha-2(IX), we have synthesized undecapeptides containing the sequence around the glycosaminoglycan attachment site of the alpha-2(IX) chain. Antibody against the peptide, which was raised in rabbit, only recognized COLIX and made it possible to distinguish COLIX from PGIX. Evidence shows that this could be due to a difference in antigenicity of the NC3 domain of the alpha-2(IX) chain between COLIX and PGIX caused by the substitution of a chondroitin sulfate chain to the serine residue in this domain. Therefore, this antibody may be useful as a probe for studies on the functions of glycosaminoglycan substitution in type IX collagen.	AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN; SEIKAGAKU CORP,TOKYO RES INST,HIGASHIYAMATO 189,JAPAN	Aichi Medical University; Seikagaku Corporation								AYAD S, 1989, BIOCHEM J, V262, P753, DOI 10.1042/bj2620753; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BOURIN MC, 1986, P NATL ACAD SCI USA, V83, P5924, DOI 10.1073/pnas.83.16.5924; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; BRUCKNER P, 1988, J BIOL CHEM, V263, P16911; BUMOL TF, 1984, J BIOL CHEM, V259, P2733; BUMOL TF, 1982, P NATL ACAD SCI-BIOL, V79, P1245, DOI 10.1073/pnas.79.4.1245; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; DUANCE VC, 1984, BIOCHEM J, V221, P885, DOI 10.1042/bj2210885; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FITCH JM, 1988, DEV BIOL, V128, P396, DOI 10.1016/0012-1606(88)90301-6; FITCH JM, 1989, DEVELOPMENT, V105, P85; Gordon MK, 1990, CURR OPIN CELL BIOL, V2, P833, DOI 10.1016/0955-0674(90)90080-X; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HARPER JR, 1986, J BIOL CHEM, V261, P3600; HUBER S, 1986, J BIOL CHEM, V261, P5965; HUBER S, 1988, J BIOL CHEM, V263, P752; IRWIN MH, 1986, J BIOL CHEM, V261, P6281; JALKANEN S, 1988, J IMMUNOL, V141, P1615; KATO Y, 1978, J BIOL CHEM, V253, P2784; KIMATA K, 1978, BIOCHEM BIOPH RES CO, V85, P1431, DOI 10.1016/0006-291X(78)91163-4; KONOMI H, 1986, J BIOL CHEM, V261, P6742; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; LOHMANDER LS, 1979, J BIOL CHEM, V254, P551; MANN DM, 1990, J BIOL CHEM, V265, P5317; MCCORMICK D, 1987, P NATL ACAD SCI USA, V84, P4044, DOI 10.1073/pnas.84.12.4044; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; NORO A, 1983, J BIOL CHEM, V258, P9323; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; RENNARD SI, 1981, ARCH BIOCHEM BIOPHYS, V207, P399, DOI 10.1016/0003-9861(81)90047-3; RODEN L, 1985, FED PROC, V44, P373; SHIMOKOMAKI M, 1990, ANN NY ACAD SCI, V580, P1, DOI 10.1111/j.1749-6632.1990.tb17912.x; TAKAGAKI K, 1990, J BIOL CHEM, V265, P854; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VASIOS G, 1988, J BIOL CHEM, V263, P2324; VAUGHAN L, 1985, J BIOL CHEM, V260, P4758; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; YADA T, 1990, J BIOL CHEM, V265, P6992; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YASUMOTO S, 1980, DEV GROWTH DIFFER, V22, P445	43	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9391	9397						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577766				2022-12-27	WOS:A1992HR85400104
J	ZEBALA, JA; CHOI, J; TRAINOR, GL; BARANY, F				ZEBALA, JA; CHOI, J; TRAINOR, GL; BARANY, F			DNA RECOGNITION OF BASE ANALOG AND CHEMICALLY MODIFIED SUBSTRATES BY THE TAQI RESTRICTION ENDONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECO-RI ENDONUCLEASE; REPRESSOR OPERATOR COMPLEX; FUNCTIONAL-GROUP CHANGES; ENDODEOXYRIBONUCLEASE ECORI; CRYSTAL-STRUCTURE; CLEAVAGE CENTER; BGL-II; SEQUENCE; SPECIFICITY; NUCLEOTIDES	It has been proposed that protein-DNA recognition is mediated via specific hydrogen bond, hydrophobic, and/or electrostatic interactions between the protein and DNA surfaces. We have attempted to map and quantitate the energies of these interactions for the TaqI endonuclease by constructing substrates substituted with base or phosphate analogues that either remove or sterically obstruct particular functional groups in the canonical TCGA sequence. The DNA backbone was also modified using a chemical approach (phosphate ethylation) which identified several phosphates in the recognition sequence essential for cleavage. The base analogues, N6-methyl-A, N7-deaza-A, N7-deaza-G, inosine, N4-methyl-C, 5-methyl-C, uracil, 5-bromo-U, and the phosphate analogues, alpha-thio-A, alpha-thio-G, alpha-thio-T, alpha-thio-A, were substituted for their corresponding unmodified counterpart in one strand of the TCGA duplex. The effects of these analogues were monitored by measuring the steady state (K(m), k(cat)) and single-turnover (k(st)) kinetic constants. Only the N6-methyl-A-substituted DNA, which mimics in vivo methylation, was unreactive while the remaining analogue substitutions exhibited Michaelis-Menten kinetics. In general, the K(m) was either unchanged or lowered by the analogue substitutions. In contrast, many of the analogues severely reduced k(cat), suggesting the modified functional groups served mainly to destabilize the transition state. Single-turnover measurements paralleled the k(cat) results, pointing to the N7 and N6 of A, the N7 of G, and one of the nonbridging oxygens 3' to T as putative contacts made in achieving the transition state. Substrates with double substitutions displayed simple additivity of DELTA-DELTA-G" implying that these changes behaved independently. The unmodified strand in 10 out of 12 hemisubstituted substrates had a normal k(st) value suggesting that a particular cleavage center is controlled predominantly by recognition of determinants on the same strand as the scissile bond. These results are discussed in relation to base analogue work from the EcoRI, RsrI, and EcoRV restriction endonucleases.	CORNELL UNIV,MED CTR,COLL MED,HEARST MICROBIOL RES CTR,DEPT MICROBIOL,BOX 62,NEW YORK,NY 10021; DUPONT CO,DEPT CENT RES & DEV,EXPTL STN,WILMINGTON,DE 19880	Cornell University; DuPont					NIGMS NIH HHS [GM-41337-03] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; AIKEN CR, 1991, J BIOL CHEM, V266, P19063; AIKEN CR, 1991, J BIOL CHEM, V266, P19070; AIKEN R, 1991, METHOD ENZYMOL, V208, P433; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BARANY F, 1988, GENE, V63, P167; BARANY F, 1988, GENE AMST, V63, P149; BARANY F, 1992, IN PRESS GENE AMST; BODNAR JW, 1983, J BIOL CHEM, V258, P5206; BRENNAN CA, 1986, J BIOL CHEM, V261, P7270; CALLADINE CR, 1986, J MOL BIOL, V192, P907, DOI 10.1016/0022-2836(86)90036-7; DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0; Fersht A., 1985, ENZYME STRUCTURE MEC; FREY PA, 1985, SCIENCE, V228, P541, DOI 10.1126/science.2984773; GHOSH SS, 1990, NUCLEIC ACIDS RES, V18, P5063, DOI 10.1093/nar/18.17.5063; GLUSHKA J, 1989, BIOCHEM BIOPH RES CO, V164, P88, DOI 10.1016/0006-291X(89)91686-0; GUO LH, 1982, NUCLEIC ACIDS RES, V10, P2065, DOI 10.1093/nar/10.6.2065; HALFORD SE, 1980, BIOCHEM J, V191, P593, DOI 10.1042/bj1910593; HEITMAN J, 1990, PROTEINS, V7, P185, DOI 10.1002/prot.340070207; HEITMAN J, 1990, EMBO J, V9, P3369, DOI 10.1002/j.1460-2075.1990.tb07538.x; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KEZDY FJ, 1962, BIOCHEMISTRY-US, V1, P1097, DOI 10.1021/bi00912a021; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KING K, 1989, J BIOL CHEM, V264, P11807; KLUG A, 1979, J MOL BIOL, V131, P669, DOI 10.1016/0022-2836(79)90196-7; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LOMONOSSOFF GP, 1981, J MOL BIOL, V149, P745, DOI 10.1016/0022-2836(81)90356-9; LU AL, 1981, J BIOL CHEM, V256, P3200; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZZARELLI J, 1989, BIOCHEMISTRY-US, V28, P4616, DOI 10.1021/bi00437a016; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MCLAUGHLIN LW, 1987, BIOCHEMISTRY-US, V26, P7238, DOI 10.1021/bi00397a007; MODRICH P, 1976, J BIOL CHEM, V251, P5866; NEEDELS MC, 1989, P NATL ACAD SCI USA, V86, P3579, DOI 10.1073/pnas.86.10.3579; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9891, DOI 10.1021/bi00494a020; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9902, DOI 10.1021/bi00494a021; ONO A, 1987, NUCLEIC ACIDS RES, V15, P3059, DOI 10.1093/nar/15.7.3059; ONO A, 1987, NUCLEIC ACIDS RES, V15, P219, DOI 10.1093/nar/15.1.219; ONO A, 1984, NUCLEIC ACIDS RES, V12, P8939, DOI 10.1093/nar/12.23.8939; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PATEL DJ, 1987, ANNU REV BIOPHYS BIO, V16, P423; Rosenberg J M, 1987, Gene Amplif Anal, V5, P119; SATO S, 1977, P NATL ACAD SCI USA, V74, P542, DOI 10.1073/pnas.74.2.542; SEELA F, 1987, BIOCHEMISTRY-US, V26, P2232, DOI 10.1021/bi00382a024; SEELA F, 1986, NUCLEIC ACIDS RES, V14, P2319, DOI 10.1093/nar/14.5.2319; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; Segel IH, 1976, BIOCH CALCULATIONS; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TABOR S, 1989, J BIOL CHEM, V264, P6447; TAYLOR JD, 1991, BIOCHEMISTRY-US, V30, P8743, DOI 10.1021/bi00100a005; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; VONHIPPEL PH, 1986, P NATL ACAD SCI USA, V83, P1608; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WILSON GG, 1991, NUCLEIC ACIDS RES, V19, P2539, DOI 10.1093/nar/19.10.2539; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816; YANOFSKY SD, 1987, PROTEINS, V2, P273, DOI 10.1002/prot.340020403; YARUS M, 1969, ANNU REV BIOCHEM, V38, P841, DOI 10.1146/annurev.bi.38.070169.004205; ZEBALA JA, 1992, J BIOL CHEM, V267, P8097; 1987, USER B APPLIED BIOSY, P50	61	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8106	8116						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569067				2022-12-27	WOS:A1992HQ18500024
J	QIAN, XH; INMAN, RB; COX, MM				QIAN, XH; INMAN, RB; COX, MM			REACTIONS BETWEEN HALF-FLP AND FULL-FLP RECOMBINATION TARGET SITES - A MODEL SYSTEM FOR ANALYZING EARLY STEPS IN FLP PROTEIN-MEDIATED SITE-SPECIFIC RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST 2-MU PLASMID; BACTERIOPHAGE-LAMBDA; SACCHAROMYCES-CEREVISIAE; HOLLIDAY STRUCTURES; COPY NUMBER; DNA; HOMOLOGY; PRODUCTS; DIRECTIONALITY; AMPLIFICATION	The FLP recombination target (FRT) can be cut in half so that only one FLP protein binding site is present (a "half site"). FLP protein binds the half sites and joins them into dimeric, asymmetric head-to-head complexes held together chiefly by strong noncovalent interactions. These complexes react with full (normal) FRT sites to generate a variety of products. Analysis of these DNA species reveals that the reaction follows a well-defined reaction pathway that generally parallels the normal reaction pathway. The system is useful in analyzing early steps in recombination, since the identity of the products in a given recombination event unambiguously pinpoints the order in which the cleavage and strand exchange reactions occur. Two conclusions are derived from the present study: (i) Formation of the dimeric head-to-head complex of half sites is a prerequisite to further steps in recombination. (ii) The identity of the base pairs at positions 6 and -6 within the FRT site has a subtle effect in directing the first strand exchange event in the reaction to predominantly one of two possible cleavage sites. In addition, results are presented that suggest that a DNA-DNA pairing intermediate involving only two base pairs of the core sequence is formed prior to the first cleavage and strand exchange. DNA-DNA interactions may therefore not be limited to the isomerization step that follows the first strand exchange.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM-14711, GM-32335] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM032335, R01GM032335, R01GM014711] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN A, 1991, MOL CELL BIOL, V11, P4497, DOI 10.1128/MCB.11.9.4497; ANDREWS BJ, 1985, CELL, V40, P795, DOI 10.1016/0092-8674(85)90339-3; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCKNER RC, 1986, J BIOL CHEM, V261, P1798; Cox M. M., 1989, MOBILE DNA, P661; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DEMASSY B, 1989, EMBO J, V8, P1591, DOI 10.1002/j.1460-2075.1989.tb03543.x; FUNNELL BE, 1979, J MOL BIOL, V131, P331, DOI 10.1016/0022-2836(79)90079-2; FUTCHER AB, 1986, J THEOR BIOL, V119, P197, DOI 10.1016/S0022-5193(86)80074-1; GATES CA, 1987, UCLA S MOL CELL BIOL, V69, P197; GRIFFITH JD, 1985, P NATL ACAD SCI USA, V82, P3124, DOI 10.1073/pnas.82.10.3124; HOESS R, 1987, P NATL ACAD SCI USA, V84, P6840, DOI 10.1073/pnas.84.19.6840; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; JAYARAM M, 1988, P NATL ACAD SCI USA, V85, P7902, DOI 10.1073/pnas.85.21.7902; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; KITTS PA, 1988, NUCLEIC ACIDS RES, V16, P6839, DOI 10.1093/nar/16.14.6839; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; Maniatis T., 1982, MOL CLONING; MEYERLEON L, 1987, NUCLEIC ACIDS RES, V15, P6469, DOI 10.1093/nar/15.16.6469; MEYERLEON L, 1990, MOL CELL BIOL, V10, P235, DOI 10.1128/MCB.10.1.235; MEYERLEON L, 1988, MOL CELL BIOL, V8, P3784, DOI 10.1128/MCB.8.9.3784; MURRAY JAH, 1987, EMBO J, V6, P4205, DOI 10.1002/j.1460-2075.1987.tb02768.x; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; NASH HA, 1983, J MOL BIOL, V170, P19, DOI 10.1016/S0022-2836(83)80225-3; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; NUNESDUBY SE, 1989, CELL, V59, P197, DOI 10.1016/0092-8674(89)90881-7; QIAN XH, 1990, J BIOL CHEM, V265, P2779; REYNOLDS AE, 1987, MOL CELL BIOL, V7, P3566, DOI 10.1128/MCB.7.10.3566; RICKET E, 1988, CELL, V52, P9; SADOWSKI P, 1986, J BACTERIOL, V165, P341, DOI 10.1128/jb.165.2.341-347.1986; SENECOFF JF, 1986, J BIOL CHEM, V261, P7380; SENECOFF JF, 1988, J MOL BIOL, V201, P405, DOI 10.1016/0022-2836(88)90147-7; TRASK DK, 1984, EMBO J, V3, P671, DOI 10.1002/j.1460-2075.1984.tb01865.x; UMLAUF SW, 1988, EMBO J, V7, P1845, DOI 10.1002/j.1460-2075.1988.tb03017.x; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; VOLKERT FC, 1986, CELL, V46, P541, DOI 10.1016/0092-8674(86)90879-2; WEISBERG RA, 1983, J MOL BIOL, V170, P319, DOI 10.1016/S0022-2836(83)80151-X	39	22	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7794	7805						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560013				2022-12-27	WOS:A1992HN48500084
J	SCHIEBEL, E; WICKNER, W				SCHIEBEL, E; WICKNER, W			PREPROTEIN TRANSLOCATION CREATES A HALIDE ANION PERMEABILITY IN THE ESCHERICHIA-COLI PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROCHEMICAL PROTON GRADIENT; M13 COAT PROTEIN; PRECURSOR PROTEINS; TRIGGER FACTOR; SECB PROTEIN; VESICLES; PROOMPA; BINDING; OMPA; RECOGNITION	The electrochemical potential drives the translocation of the precursor form of outer membrane protein A (proOmpA) and other proteins across the plasma membrane of Escherichia coli. We have measured the electrical potential, DELTA-psi, across inverted membrane vesicles during proOmpA translocation. DELTA-psi, generated by the electron transport chain, is substantially dissipated by proOmpA translocation. DELTA-psi dissipation requires SecA, ATP, and proOmpA. proOmpA which, due to the covalent addition of a folded protein to a cysteinyl side chain, is arrested during its translocation, can nevertheless cause the loss of DELTA-psi. Thus the movement of charged amino acyl residues is not dissipating the potential. This translocation-specific reduction in DELTA-psi is only seen in the presence of halide anions, although halide anions are not needed for proOmpA translocation per se. We therefore propose that translocation intermediates directly increase the membrane permeability to halide anions.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								APELL HJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P480, DOI 10.1016/0005-2736(87)90055-1; BAKKER EP, 1984, EMBO J, V3, P895, DOI 10.1002/j.1460-2075.1984.tb01902.x; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; CORONADO R, 1982, NATURE, V298, P849, DOI 10.1038/298849a0; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DANIELS CJ, 1981, P NATL ACAD SCI-BIOL, V78, P5396, DOI 10.1073/pnas.78.9.5396; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; ITO K, 1980, J BIOL CHEM, V255, P2123; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LECKER SH, 1990, EMBO J, V9, P2309, DOI 10.1002/j.1460-2075.1990.tb07402.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; RAMOS S, 1977, BIOCHEMISTRY-US, V16, P848, DOI 10.1021/bi00624a006; REENSTRA WW, 1980, BIOCHEMISTRY-US, V19, P1, DOI 10.1021/bi00542a001; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WHITE MM, 1979, J BIOL CHEM, V254, P161; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; ZIMMERMANN R, 1982, J BIOL CHEM, V257, P6529; ZIMMERMANN R, 1983, J BIOL CHEM, V258, P3920	31	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7505	7510						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559988				2022-12-27	WOS:A1992HN48500046
J	WEDEMAYER, GJ; KIDD, DG; WEMMER, DE; GLAZER, AN				WEDEMAYER, GJ; KIDD, DG; WEMMER, DE; GLAZER, AN			PHYCOBILINS OF CRYPTOPHYCEAN ALGAE - OCCURRENCE OF DIHYDROBILIVERDIN AND MESOBILIVERDIN IN CRYPTOMONAD BILIPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIN ATTACHMENT SITES; CHROOMONAS SP CRYPTOPHYCEAE; SP-NOV CRYPTOPHYCEAE; AMINO-ACID-SEQUENCE; ALPHA-SUBUNIT; PICOSECOND FLUORESCENCE; INVITRO ATTACHMENT; B-PHYCOERYTHRIN; ENERGY-TRANSFER; BETA-SUBUNIT	Structures of the open-chain tetrapyrrole (bilin) prosthetic groups of the cryptophycean biliproteins phycocyanin 645 (Cr-PC 645; from strain UW374), phycoerythrin 566 (Cr-PE 566; from strain Bermani) and phycoerythrin 545 (Cr-PE 545; from Proteomonas sulcata Hill & Wetherbee) were examined by absorption, H-1 NMR spectroscopy, and mass spectrometry. These biliproteins carry the following covalently attached bilins: Cr-PC 645 (alpha-subunit) has one mesobiliverdin, (beta-subunit), two phycocyanobilins and a doubly linked 15,16-dihydrobiliverdin; Cr-PC 566 (alpha), bilin 584, (beta), phycoerythrobilin and two bilin 584 chromophores (Wedemayer, G. J., Wemmer, D. E., and Glazer, A. N. (1991) J. Biol. Chem. 266, 4731-4741); Cr-PE 545 (alpha) has one 15,16-dihydrobiliverdin and (beta), only phycoerythrobilins. This is the first report of naturally occurring biliproteins carrying either 15,16-dihydrobiliverdin or mesobiliverdin chromophores. Native cryptomonad phycobiliproteins have been classified on the basis of the position of their long wavelength absorption maxima. However, comparison of the bilins of Cr-PE 566 from strain Bermani with those of Cr-PE 566 of strain CBD shows that the two proteins carry different bilins on the alpha-subunit. Consequently, the identity of the bilin prosthetic groups on cryptophycean phycobiliproteins cannot be unambiguously inferred from simple inspection of the visible absorption spectra.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV BIOCHEM & MOLEC BIOL,STANLEY DONNER ASU,BERKELEY,CA 94720; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DEPT PLANT BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV CHEM BIODYNAM,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028994] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28994] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MB, 1959, NATURE, V184, P1047, DOI 10.1038/1841047a0; ARCIERO DM, 1988, J BIOL CHEM, V263, P18343; ARCIERO DM, 1988, J BIOL CHEM, V263, P18358; ARCIERO DM, 1988, J BIOL CHEM, V263, P18350; BEALE SI, 1991, J BIOL CHEM, V266, P22341; BISHOP JE, 1986, J BIOL CHEM, V261, P6790; BISHOP JE, 1987, J AM CHEM SOC, V109, P875, DOI 10.1021/ja00237a039; BROOKS C, 1973, ARCH MIKROBIOL, V88, P193, DOI 10.1007/BF00421845; GLAZER AN, 1977, FEMS MICROBIOL LETT, V1, P113, DOI 10.1111/j.1574-6968.1977.tb00593.x; GLAZER AN, 1975, ARCH MICROBIOL, V104, P29, DOI 10.1007/BF00447296; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GLAZER AN, 1971, ARCH MIKROBIOL, V80, P1, DOI 10.1007/BF00410574; GUARDFRIAR D, 1986, PHOTOCHEM PHOTOBIOL, V43, P81, DOI 10.1111/j.1751-1097.1986.tb05594.x; GUARDFRIAR D, 1985, BIOPHYS J, V47, P787, DOI 10.1016/S0006-3495(85)83982-5; GUARDFRIAR D, 1989, BIOCHIM BIOPHYS ACTA, V973, P118, DOI 10.1016/S0005-2728(89)80411-6; HANZLIK CA, 1985, J LUMIN, V34, P99, DOI 10.1016/0022-2313(85)90099-7; HAXO FT, 1959, NATURE, V184, P1051, DOI 10.1038/1841051a0; HILL DRA, 1989, PHYCOLOGIA, V28, P455, DOI 10.2216/i0031-8884-28-4-455.1; HILL DRA, 1986, PHYCOLOGIA, V25, P521, DOI 10.2216/i0031-8884-25-4-521.1; HILLER RG, 1987, BIOCHIM BIOPHYS ACTA, V923, P98, DOI 10.1016/0304-4165(87)90131-0; HOLZWARTH AR, 1983, BIOCHIM BIOPHYS ACTA, V724, P388, DOI 10.1016/0005-2728(83)90098-1; HU H, 1980, KEXUE TONGBAO, V25, P852; JENKINS J, 1990, FEBS LETT, V273, P191, DOI 10.1016/0014-5793(90)81082-Y; Jordan B. R., 1986, Oxford Surveys of Plant Molecular and Cell Biology, V3, P315; JUNG J, 1980, BIOCHEMISTRY-US, V19, P24, DOI 10.1021/bi00542a005; KELLER MD, 1987, J PHYCOL, V23, P633; KLAVENESS D, 1981, J PROTOZOOL, V28, P83, DOI 10.1111/j.1550-7408.1981.tb02809.x; KLOTZ AV, 1986, J BIOL CHEM, V261, P6797; KLOTZ AV, 1984, J BIOL CHEM, V260, P4856; KUFER W, 1989, PHYSIOL PLANTARUM, V75, P389, DOI 10.1111/j.1399-3054.1989.tb04643.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGARIAS JC, 1988, J BIOL CHEM, V263, P12977; LAGARIAS JC, 1980, J AM CHEM SOC, V102, P4821, DOI 10.1021/ja00534a042; LICHTLE C, 1987, BIOCHIM BIOPHYS ACTA, V894, P76, DOI 10.1016/0005-2728(87)90214-3; LUNDELL DJ, 1984, J BIOL CHEM, V259, P5472; MACCOLL R, 1983, ARCH MICROBIOL, V135, P194, DOI 10.1007/BF00414479; MACCOLL R, 1979, BIOCHEM BIOPH RES CO, V90, P849, DOI 10.1016/0006-291X(79)91905-3; MACCOLL R, 1990, BIOCHEMISTRY-US, V29, P430, DOI 10.1021/bi00454a018; MACCOLL R, 1983, BIOCHEMISTRY-US, V22, P5568, DOI 10.1021/bi00293a018; MACCOLL R, 1983, J BIOL CHEM, V258, P4327; MACCOLL R, 1976, ARCH BIOCHEM BIOPHYS, V177, P265, DOI 10.1016/0003-9861(76)90436-7; MACCOLL R, 1973, J BIOL CHEM, V248, P7080; MALAK H, 1991, BIOCHIM BIOPHYS ACTA, V1059, P165, DOI 10.1016/S0005-2728(05)80201-4; MARTIN CD, 1987, BIOCHIM BIOPHYS ACTA, V923, P88, DOI 10.1016/0304-4165(87)90130-9; MEYER SR, 1984, S AFR J BOT, V3, P306, DOI 10.1016/S0022-4618(16)30019-5; MORSCHEL E, 1975, ARCH MICROBIOL, V105, P153, DOI 10.1007/BF00447130; MORSCHEL E, 1977, ARCH MICROBIOL, V113, P83, DOI 10.1007/BF00428585; Moss G P, 1988, Eur J Biochem, V178, P277, DOI 10.1111/j.1432-1033.1988.tb14453.x; NAGY JO, 1985, J BIOL CHEM, V260, P4864; OHEOCHA C, 1959, NATURE, V184, P1049, DOI 10.1038/1841049a0; OHEOCHA C, 1964, Proc R Ir Acad B, V63, P191; ONG LJ, 1991, J BIOL CHEM, V266, P9515; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOENLEBER RW, 1984, J BIOL CHEM, V259, P5481; SCHOENLEBER RW, 1984, J BIOL CHEM, V259, P5485; SIDLER W, 1985, BIOL CHEM H-S, V366, P233, DOI 10.1515/bchm3.1985.366.1.233; SIDLER W, 1990, BIOL CHEM H-S, V371, P537, DOI 10.1515/bchm3.1990.371.2.537; SIDLER W, 1986, EXPERIENTIA, V42, P658; SIDLER WA, 1987, PROGR PHOTOSYNTHESIS, V2, P153; SIEBZEHNRUBL S, 1989, PHOTOCHEM PHOTOBIOL, V49, P753, DOI 10.1111/j.1751-1097.1989.tb05573.x; STEIN JR, 1958, AM J BOT, V45, P664, DOI 10.2307/2439502; STEWART DE, 1984, LIMNOL OCEANOGR, V29, P392, DOI 10.4319/lo.1984.29.2.0392; SWANSON RV, 1990, ANAL BIOCHEM, V188, P295, DOI 10.1016/0003-2697(90)90609-D; WEDEMAYER GJ, 1991, J BIOL CHEM, V266, P4731; WILBANKS SM, 1989, J BIOL CHEM, V260, P17860; Zhang X., 1983, P431	66	47	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7315	7331						17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559975				2022-12-27	WOS:A1992HN48500021
J	BHATTACHARYA, S; RIDGE, KD; KNOX, BE; KHORANA, HG				BHATTACHARYA, S; RIDGE, KD; KNOX, BE; KHORANA, HG			LIGHT-STABLE RHODOPSIN .1. A RHODOPSIN ANALOG RECONSTITUTED WITH A NONISOMERIZABLE 11-CIS RETINAL DERIVATIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE RHODOPSIN; DEPENDENT PHOSPHORYLATION; PROTEINS; GENE; BACTERIORHODOPSIN; CHROMOPHORE; SEQUENCE; CASCADE; VISION	With the aim of preparing a light-stable rhodopsin-like pigment, an analog, II, of 11-cis retinal was synthesized in which isomerization of the C-11-C-12 cis-double bond is blocked by a cyclohexene ring built around the C-10 to C-13-methyl. The analog II formed a rhodopsin-like pigment (rhodopsin-II) with opsin expressed in COS-1 cells and with opsin from rod outer segments. The rate of rhodopsin-II formation from II and opsin was approximately 10 times slower than that of rhodopsin from 11-cis retinal and opsin. After solubilization in dodecyl maltoside and immunoaffinity purification, rhodopsin-II displayed an absorbance ratio (A280 nm/A512 nm) of 1.6, virtually identical with that of rhodopsin. Acid denaturation of rhodopsin-II formed a chromophore with lambda(max), 452 nm, characteristic of protonated retinyl Schiff base. The ground state properties of rhodopsin-II were similar to those of rhodopsin in extinction coefficient (41,200 M-1 cm-1) and opsin-shift (2600 cm-1). Rhodopsin-II was stable to hydroxylamine in the dark, while light-dependent bleaching by hydroxylamine was slowed by approximately 2 orders of magnitude relative to rhodopsin. Illumination of rhodopsin-II for 10 s caused approximately 3 nm blue-shift and 3% loss of visible absorbance. Prolonged illumination caused a maximal blue-shift up to approximately 20 nm and approximately 40% loss of visible absorbance. An apparent photochemical steady state was reached after 12 min of illumination. Subsequent acid denaturation indicated that the retinyl Schiff base linkage was intact. A red-shift (approximately 12 nm) in lambda(max) and a 45% recovery of visible absorbance was observed after returning the 12-min illuminated pigment to darkness. Rhodopsin-II showed marginal light-dependent transducin activation and phosphorylation by rhodopsin kinase.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Bhattacharya, Santanu/N-6531-2019; BHATTACHARYA, SANTANU/E-9739-2010; Bhattacharya, Santanu/GRS-4780-2022	Bhattacharya, Santanu/0000-0001-9040-8971; BHATTACHARYA, SANTANU/0000-0001-9040-8971; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028289, R01GM028289] Funding Source: NIH RePORTER; NEI NIH HHS [E53-EY0629] Funding Source: Medline; NIAID NIH HHS [AI 11479] Funding Source: Medline; NIGMS NIH HHS [GM 28289] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA H, 1980, J AM CHEM SOC, V102, P6370, DOI 10.1021/ja00540a047; [Anonymous], 1982, EUR J BIOCHEM, V129, P1; ARNABOLDI M, 1979, J AM CHEM SOC, V101, P7082, DOI 10.1021/ja00517a059; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6757; DEGRIP WJ, 1990, EUR J BIOCHEM, V191, P211; DEMIN VV, 1987, RETINAL PROTEINS, P519; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FUKADA Y, 1984, BIOCHEMISTRY-US, V23, P5826, DOI 10.1021/bi00319a023; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; HARGRAVE PA, 1983, BIOPHYS STRUCT MECH, V9, P235, DOI 10.1007/BF00535659; HArgrave PA, 1982, PROGR RET RES, V1, P1; HUBBARD R, 1958, P NATL ACAD SCI USA, V44, P130, DOI 10.1073/pnas.44.2.130; ITO M, 1982, CHEM PHARM BULL, V30, P1913; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KATRE NV, 1981, P NATL ACAD SCI-BIOL, V78, P4068, DOI 10.1073/pnas.78.7.4068; KITO Y, 1968, NATURE, V218, P955, DOI 10.1038/218955a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU RSH, 1984, J AM CHEM SOC, V106, P8298, DOI 10.1021/ja00338a051; MICHEL H, 1982, EMBO J, V1, P1267, DOI 10.1002/j.1460-2075.1982.tb00023.x; NAKAYAMA TA, 1990, J BIOL CHEM, V265, P15762; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OVCHINNIKOV YA, 1982, BIOORG KHIM+, V8, P1011; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RIDGE KD, 1992, J BIOL CHEM, V267, P6770; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P5460, DOI 10.1021/bi00367a017; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; VANDERSTEEN R, 1989, RECL TRAV CHIM PAY B, V108, P20; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	37	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6763	6769						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551885				2022-12-27	WOS:A1992HM05300047
J	HOLLAND, LJ; SUKSANG, C; WALL, AA; ROBERTS, LR; MOSER, DR; BHATTACHARYA, A				HOLLAND, LJ; SUKSANG, C; WALL, AA; ROBERTS, LR; MOSER, DR; BHATTACHARYA, A			A MAJOR ESTROGEN-REGULATED PROTEIN SECRETED FROM THE LIVER OF XENOPUS-LAEVIS IS A MEMBER OF THE SERPIN SUPERFAMILY - NUCLEOTIDE-SEQUENCE OF CDNA AND HORMONAL INDUCTION OF MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; AMINO-ACID-SEQUENCE; REACTIVE CENTER REGIONS; ANTI-THROMBIN-III; GENE FAMILY; HUMAN ALPHA-1-ANTICHYMOTRYPSIN; BINDING GLOBULIN; THYROID-HORMONE; SERUM-ALBUMIN; HOMOLOGY	Estrogen treatment of Xenopus frogs causes four mRNAs to become highly abundant in the liver. Three of these mRNAs have been previously identified as coding for vitellogenin, ferritin, and serum retinol binding protein. We show here that the fourth abundant liver messenger RNA comprises about 1500 nucleotides and codes for a 45-kDa secreted protein, designated Ep45. A clone complementary to Ep45 mRNA was isolated, and its identity was confirmed by hybridization selection of mRNA that translated in vitro into the Ep45 precursor. Nucleotide sequence analysis of the nearly full length cDNA revealed a total length of 1454 base pairs consisting of: 36 nucleotides of the 5' noncoding region, 1308 base pairs encoding an open reading frame of 436 amino acids, and 110 nucleotides of the 3' untranslated region. Ep45 mRNA may originate from as many as four closely spaced transcription start sites, which are 15 to 21 bases upstream of the first nucleotide of the cDNA clone. The Xenopus laevis genome appears to contain a single Ep45 gene. The deduced amino acid sequence indicates that Ep45 has features typical of a secreted protein, including a signal peptide of 16 amino acids and three potential sites for N-linked glycosylation, and is related to the serine protease inhibitors, a large family of proteins with very diverse physiological functions. Ep45 mRNA was absent in the liver of normal male frogs and increased at least 100-fold in response to estradiol-17-beta. Thus, both Ep45 and vitellogenin mRNAs are switched from undetectable to very high levels, a pattern of expression not found for any other mRNAs in Xenopus liver.	UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, CTR DIABET & ENDOCRINOL RES CTR, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa	HOLLAND, LJ (corresponding author), UNIV MISSOURI, SCH MED, DEPT PHYSIOL, COLUMBIA, MO 65212 USA.			Roberts, Lewis/0000-0001-7885-8574; Moser, David/0000-0003-4102-5266	NHLBI NIH HHS [R01-HL39095] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTS B, 1983, MOL BIOL CELL, P345; BAKER HJ, 1977, J BIOL CHEM, V252, P8428; BELTZ GA, 1983, METHOD ENZYMOL, V100, P266; BHATTACHARYA A, 1990, MOL CELL ENDOCRINOL, V72, P213, DOI 10.1016/0303-7207(90)90145-X; BHATTACHARYA A, 1991, MOL CELL ENDOCRINOL, V75, P111, DOI 10.1016/0303-7207(91)90225-H; BHATTACHARYA A, 1991, MOL ENDOCRINOL, V5, P587, DOI 10.1210/mend-5-4-587; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; Blobel G, 1979, Symp Soc Exp Biol, V33, P9; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; BOSWELL DR, 1988, BIOESSAYS, V8, P83, DOI 10.1002/bies.950080209; BOURSNELL MEG, 1988, J GEN VIROL, V69, P2995, DOI 10.1099/0022-1317-69-12-2995; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CHANDRA T, 1983, BIOCHEMISTRY-US, V22, P5055, DOI 10.1021/bi00291a001; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; Clemens M J, 1974, Prog Biophys Mol Biol, V28, P69, DOI 10.1016/0079-6107(74)90017-0; CORTHESY B, 1988, SCIENCE, V239, P1137, DOI 10.1126/science.2830672; DOOLITTLE RF, 1983, SCIENCE, V222, P417, DOI 10.1126/science.6604942; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FLINK IL, 1986, P NATL ACAD SCI USA, V83, P7708, DOI 10.1073/pnas.83.20.7708; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HAMMOND GL, 1987, P NATL ACAD SCI USA, V84, P5153, DOI 10.1073/pnas.84.15.5153; HEJGAARD J, 1985, FEBS LETT, V180, P89, DOI 10.1016/0014-5793(85)80238-6; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HILL RE, 1984, NATURE, V311, P175, DOI 10.1038/311175a0; HOLLAND LJ, 1983, NUCLEIC ACIDS RES, V11, P3283, DOI 10.1093/nar/11.10.3283; HOLLAND LJ, 1984, MOL CELL BIOL, V4, P2543, DOI 10.1128/MCB.4.11.2543; HOLLAND LJ, 1991, MOL CELL ENDOCRINOL, V30, P1965; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; ING NH, 1989, J BIOL CHEM, V264, P3372; KISO U, 1988, FEBS LETT, V230, P51, DOI 10.1016/0014-5793(88)80640-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNAPULI SP, 1987, ARCH BIOCHEM BIOPHYS, V254, P642, DOI 10.1016/0003-9861(87)90148-2; LEWIS JA, 1976, MOL CELL ENDOCRINOL, V4, P311, DOI 10.1016/0303-7207(76)90048-4; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; MALATHY PV, 1990, MOL ENDOCRINOL, V4, P428, DOI 10.1210/mend-4-3-428; Marshall R D, 1974, Biochem Soc Symp, P17; MAY FEB, 1982, J BIOL CHEM, V257, P3919; MCREYNOLDS L, 1978, NATURE, V273, P723, DOI 10.1038/273723a0; MORII M, 1983, J BIOL CHEM, V258, P2749; MOSKAITIS JE, 1989, MOL ENDOCRINOL, V3, P464, DOI 10.1210/mend-3-3-464; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; OKA T, 1969, J CELL BIOL, V43, P123, DOI 10.1083/jcb.43.1.123; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RYFFEL GU, 1977, CELL, V11, P213, DOI 10.1016/0092-8674(77)90332-4; SCHUBIGER JL, 1986, NUCLEIC ACIDS RES, V14, P8723, DOI 10.1093/nar/14.22.8723; SOMMER J, 1987, BIOCHEMISTRY-US, V26, P6407, DOI 10.1021/bi00394a016; SPOLSKI RJ, 1985, DEV BIOL, V108, P332, DOI 10.1016/0012-1606(85)90037-5; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; SUZUKI K, 1987, J BIOL CHEM, V262, P611; SUZUKI Y, 1991, J BIOL CHEM, V266, P928; TECCE MF, 1986, BIOCHEMISTRY-US, V25, P5831, DOI 10.1021/bi00367a073; UPTON C, 1986, MOL CELL BIOL, V6, P265, DOI 10.1128/MCB.6.1.265; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wallace R A, 1985, Dev Biol (N Y 1985), V1, P127; WANGH LJ, 1979, DEV BIOL, V70, P479, DOI 10.1016/0012-1606(79)90040-X; YE RD, 1987, J BIOL CHEM, V262, P3718; YOON JB, 1987, J BIOL CHEM, V262, P4284	63	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7053	7059						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551912				2022-12-27	WOS:A1992HM05300091
J	HURTA, RAR; WRIGHT, JA				HURTA, RAR; WRIGHT, JA			ALTERATIONS IN THE ACTIVITY AND REGULATION OF MAMMALIAN RIBONUCLEOTIDE REDUCTASE BY CHLORAMBUCIL, A DNA DAMAGING AGENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED POSTTRANSCRIPTIONAL MODULATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; PROTEIN KINASE-C; CELL-LINE; HYDROXYUREA RESISTANCE; MOLECULAR MECHANISMS; CULTURED-CELLS; MOUSE; HAMSTER; EXPRESSION	Ribonucleotide reductase provides the four deoxyribonucleotides required for the synthesis of DNA. In this study, we examined the hypothesis that alterations in the regulation of ribonucleotide reductase activity may be necessary to provide the deoxyribonucleotides required for DNA repair, following exposure of mammalian cells to DNA damaging agents such as the antitumor agent chlorambucil. We observed a marked transient increase in ribonucleotide reductase activity within 2 h of exposing BALB/c 3T3 mouse cells to DNA damaging concentrations of chlorambucil. Northern blot analysis showed that elevations in activity were accompanied by transient increases in the mRNA levels of both genes (R1 and R2) that code for ribonucleotide reductase. Western blot analysis indicated that only the protein for the limiting component for enzyme activity, R2, was significantly elevated in chlorambucil treated cultures. The chlorambucil effects upon activity and regulation of ribonucleotide reductase occurred without any detectable changes in the rate of DNA synthesis, as would be expected if the elevation in enzyme activity is required for DNA repair. The chlorambucil-induced elevations in R1 and R2 message levels were blocked by treatment of cells with actinomycin D or the tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate, indicating the importance of the reductase transcriptional process in responding to the action of chlorambucil and providing evidence for the involvement of a protein kinase C pathway in the regulation of mammalian ribonucleotide reductase. In addition to the chlorambucil-induced elevations in enzyme activity, message, and protein levels, the drug was also shown to be an inhibitor of ribonucleotide reductase activity in cell-free preparations. Separation of ribonucleotide components on an affinity column followed by selective exposure of the protein components to chlorambucil showed that both R1 and R2 proteins were targets for chlorambucil, in keeping with the known alkylating abilities of the drug. These observations provide the first direct demonstration of a link between the regulation of mammalian ribonucleotide reductase and the process of DNA repair and contribute to our understanding of the mode of action of a class of drugs represented by chlorambucil, in which chemotherapeutic activity has been attributed to DNA damaging effects.	UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG R3E 0V9,MANITOBA,CANADA; UNIV MANITOBA,DEPT BIOCHEM & MOLEC BIOL,WINNIPEG R3E 0V9,MANITOBA,CANADA	University of Manitoba; University of Manitoba								BANK BB, 1989, CANCER RES, V49, P554; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CARLSON J, 1984, P NATL ACAD SCI-BIOL, V81, P4294, DOI 10.1073/pnas.81.14.4294; CHOY BK, 1988, CANCER RES, V48, P2029; CHOY BK, 1989, BIOCHEM BIOPH RES CO, V162, P1417, DOI 10.1016/0006-291X(89)90832-2; EDWARDS DR, 1985, MOL CELL BIOL, V5, P3280, DOI 10.1128/MCB.5.11.3280; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P4932, DOI 10.1128/MCB.9.11.4932; ENDRESEN L, 1983, CANCER RES, V43, P2918; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HURTA RAR, 1990, BIOCHIM BIOPHYS ACTA, V1087, P165, DOI 10.1016/0167-4781(90)90201-C; HURTA RAR, 1991, J BIOL CHEM, V266, P24097; JIANG BZ, 1989, CANCER RES, V49, P5514; JOHNSTON JB, 1990, J NATL CANCER I, V82, P776, DOI 10.1093/jnci/82.9.776; LEWIS WH, 1978, J CELL PHYSIOL, V94, P287, DOI 10.1002/jcp.1040940306; MCCLARTY GA, 1988, BIOCHEMISTRY-US, V27, P7524, DOI 10.1021/bi00419a052; MCCLARTY GA, 1987, BIOCHEMISTRY-US, V26, P8004, DOI 10.1021/bi00398a068; MCCLARTY GA, 1990, J BIOL CHEM, V265, P7539; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PHILLIPS DR, 1986, BIOCHEMISTRY-US, V25, P7355, DOI 10.1021/bi00371a017; ROBSON CN, 1986, CANCER RES, V46, P6290; RUBIN EH, 1986, CANCER RES, V46, P6165; STEEPER JR, 1970, ANAL BIOCHEM, V34, P123, DOI 10.1016/0003-2697(70)90092-8; THELANDER L, 1980, J BIOL CHEM, V255, P7426; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLMAN B, 1980, J BIOL CHEM, V255, P8308; ULLMAN B, 1989, DRUG RESISTANCE MAMM, V1, P69; WEBER G, 1983, CANCER RES, V43, P3466; WEINBERG G, 1981, P NATL ACAD SCI-BIOL, V78, P2447, DOI 10.1073/pnas.78.4.2447; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; WRIGHT JA, 1987, SOMAT CELL MOLEC GEN, V13, P155, DOI 10.1007/BF01534695; WRIGHT JA, 1989, DRUG RESISTANCE MAMM, V1, P15; WRIGHT JA, 1989, INT ENCY PHARM THERA, V128, P89; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	33	75	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7066	7071						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551913				2022-12-27	WOS:A1992HM05300093
J	SRINIVAS, SK; SRINIVAS, RV; ANANTHARAMAIAH, GM; SEGREST, JP; COMPANS, RW				SRINIVAS, SK; SRINIVAS, RV; ANANTHARAMAIAH, GM; SEGREST, JP; COMPANS, RW			MEMBRANE INTERACTIONS OF SYNTHETIC PEPTIDES CORRESPONDING TO AMPHIPATHIC HELICAL SEGMENTS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE PROTEIN; OLIGOMERIC STRUCTURE; HTLV-III; SYNCYTIUM FORMATION; HUMAN RETROVIRUS; AIDS RETROVIRUS; FUSION PEPTIDE; ANALOGS; HIV; CYTOPATHOGENICITY	The human and simian immunodeficiency virus envelope glycoproteins, which mediate virus-induced cell fusion, contain two putative amphipathic helical segments with large helical hydrophobic moments near their carboxyl-terminal ends. In an attempt to elucidate the biological role of these amphipathic helical segments, we have synthesized peptides corresponding to residues 768-788 and 826-854 of HIV-1/WMJ-22 gp160. Circular dichroism studies of the peptides showed that the alpha helicity of the peptides increased with the addition of dimyristoyl phosphatidylcholine (DMPC) indicating that the peptides form lipid-associating amphipathic helixes. The peptides solubilized turbid suspensions of DMPC vesicles, and electron microscopy of peptide-DMPC mixtures revealed the formation of discoidal complexes, suggesting that the peptides bind to and perturb lipid bilayers. The peptides were found to lyse lipid vesicles and caused carboxyfluorescein leakage from dye-entrapped egg phosphatidylcholine liposomes. The peptides also lysed human erythrocytes and were found to be toxic to cell cultures. At subtoxic concentrations, the peptides effectively inhibited the fusion of CD4+ cells infected with recombinant vaccinia virus expressing human immunodeficiency virus (HIV)-1 envelope proteins. Based on these results, and reported studies on the mutational analysis of HIV envelope proteins, we suggest that the amphipathic helical segments near the carboxyl terminus of HIV envelope proteins may play a role in lysis of HIV-infected cells and also may modulate the extent of cell fusion observed during HIV infection of CD4+ cells.	UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, ATHEROSCLEROSIS RES UNIT, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham			Compans, Richard W/I-4087-2013	Compans, Richard W/0000-0003-2360-335X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028928, U01AI025784] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 28928, AI 25784] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; ANANTHARAMAIAH GM, 1986, METHOD ENZYMOL, V128, P627; ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; EISENBERG D, 1990, BIOPOLYMERS, V29, P171, DOI 10.1002/bip.360290122; FISHER AG, 1986, SCIENCE, V233, P655, DOI 10.1126/science.3014663; FUJI G, 1988, 2ND PROT SOC S, pS265; GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5; GARRY RF, 1989, AIDS, V3, P683, DOI 10.1097/00002030-198911000-00001; GELDERBLOM HR, 1985, LANCET, V2, P1016; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAFFAR OK, 1988, J CELL BIOL, V107, P1677, DOI 10.1083/jcb.107.5.1677; HAFFAR OK, 1991, VIROLOGY, V180, P439, DOI 10.1016/0042-6822(91)90054-F; HASELTINE WA, 1991, FASEB J, V5, P2349, DOI 10.1096/fasebj.5.10.1829694; JAYNES J M, 1989, Peptide Research, V2, P157; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KODAMA T, 1989, J VIROL, V63, P4709, DOI 10.1128/JVI.63.11.4709-4714.1989; KONG LI, 1988, SCIENCE, V240, P1525, DOI 10.1126/science.3375832; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; KOWALSKI M, 1991, J VIROL, V65, P281, DOI 10.1128/JVI.65.1.281-291.1991; LEE SJ, 1989, AIDS RES HUM RETROV, V5, P441, DOI 10.1089/aid.1989.5.441; LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463; LUCY JA, 1986, FEBS LETT, V199, P1, DOI 10.1016/0014-5793(86)81213-3; LYNN WS, 1988, VIROLOGY, V163, P43, DOI 10.1016/0042-6822(88)90232-2; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MILLER MA, 1991, AIDS RES HUM RETROV, V7, P511, DOI 10.1089/aid.1991.7.511; OWENS RJ, 1990, J CLIN INVEST, V86, P1142, DOI 10.1172/JCI114819; OWENS RJ, 1989, J VIROL, V63, P978, DOI 10.1128/JVI.63.2.978-982.1989; OZEL M, 1988, ARCH VIROL, V100, P255, DOI 10.1007/BF01487688; PASTERNAK CA, 1973, J MEMBRANE BIOL, V14, P293, DOI 10.1007/BF01868082; PINTER A, 1989, J VIROL, V63, P2674, DOI 10.1128/JVI.63.6.2674-2679.1989; SAKAI K, 1988, J VIROL, V62, P4078, DOI 10.1128/JVI.62.11.4078-4085.1988; SCHAWALLER M, 1989, VIROLOGY, V172, P367, DOI 10.1016/0042-6822(89)90142-6; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1991, IN PRESS MOL CONFORM; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SRINIVAS RV, 1990, VIROLOGY, V176, P48, DOI 10.1016/0042-6822(90)90229-K; SRINIVAS RV, 1991, J CELL BIOCHEM, V45, P224, DOI 10.1002/jcb.240450214; SRINIVAS RV, 1992, ADV MEMBRANE FLUIDIT, V6, P187; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; STEVENSON M, 1990, J VIROL, V64, P3792, DOI 10.1128/JVI.64.8.3792-3803.1990; TERWILLIGER E, 1986, J VIROL, V60, P754, DOI 10.1128/JVI.60.2.754-760.1986; VENABLE RM, 1989, AIDS RES HUM RETROV, V5, P7, DOI 10.1089/aid.1989.5.7; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223	49	101	105	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7121	7127						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551918				2022-12-27	WOS:A1992HM05300102
J	CHATTERJEE, D; HUNTER, SW; MCNEIL, M; BRENNAN, PJ				CHATTERJEE, D; HUNTER, SW; MCNEIL, M; BRENNAN, PJ			LIPOARABINOMANNAN - MULTIGLYCOSYLATED FORM OF THE MYCOBACTERIAL MANNOSYLPHOSPHATIDYLINOSITOLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TUBERCULOSIS; LIPOPOLYSACCHARIDE; MACROPHAGES; METHYLATION; LIPOMANNAN; SMEGMATIS; LEPRAE; GAMMA	The lipopolysaccharides of mycobacteria, lipoarabinomannan (LAM) and lipomannan (LM), of key importance in host-pathogen interaction, were recently shown to contain a phosphatidylinositol "anchoring domain." We now have established that LAM and LM are based on the phosphatidylinositol mannosides, the characteristic glycophospholipids of mycobacteria. Digestion of the arabinose-free LM with an endo-alpha-1 --> 6-mannosidase yielded evidence for the presence of the 1-(sn-glycerol-3-phospho)-D-MYO-inositol-2,6-bis-alpha-D-mannopyranoside unit, indistinguishable from that derived from phosphatidylinositol dimannoside. This same inositol substitution pattern was shown to be present in LAM by methylation analysis before and after dephosphorylation. Positions C-2 and C-6 of the inositol unit of LAM are occupied by mannosyl residues and C-1 by a phosphoryl group. Partial acid hydrolysis of per-O-methylated LAM and comparison by gas chromatography-mass spectrometry of the resulting derivatized oligosaccharides with like products from phosphatidylinositol hexamannoside demonstrated that the C-6 of inositol is the point of attachment of the mannan core of LAM, which consists of an alpha-1 --> 6-linked backbone with considerable alpha-1 --> 2 side chains. Thus, a structural and presumably biosynthetic relationship is established between some of the membranous mannosylphosphatidylinositols described some 25 years ago and the newly emerging, biologically active lipopolysaccharides of mycobacteria.	COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523	Colorado State University			McNeil, Michael/G-3325-2019		NIAID NIH HHS [N01 AI-05074, AI 18357] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018357, R22AI018357, N01AI005074, R01AI018357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson R. J, 1939, PROG CHEM ORG NAT PR, V3, P145; BALLOU CE, 1963, J BIOL CHEM, V238, P69; BALLOU CE, 1964, BIOCHEMISTRY-US, V3, P682, DOI 10.1021/bi00893a014; BARNES PF, 1990, J IMMUNOL, V145, P149; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; BRENNAN PJ, 1990, MICROBIAL DETERMINANTS OF VIRULENCE AND HOST RESPONSE, P55; CAMPHAUSEN RT, 1987, J BACTERIOL, V169, P5473, DOI 10.1128/jb.169.12.5473-5480.1987; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; DAFFE M, 1990, J BIOL CHEM, V265, P6734; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GAYLORD H, 1987, INFECT IMMUN, V55, P2860, DOI 10.1128/IAI.55.11.2860-2863.1987; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; JOHANSSON C, 1990, CARBOHYD RES, V207, P177, DOI 10.1016/0008-6215(90)84047-X; LEE YC, 1964, J BIOL CHEM, V239, P1316; LEE YC, 1965, BIOCHEMISTRY-US, V4, P1395, DOI 10.1021/bi00883a026; MAITRA SK, 1976, BIOCHEM BIOPH RES CO, V73, P1101, DOI 10.1016/0006-291X(76)90236-9; MOLLOY A, 1990, P NATL ACAD SCI USA, V87, P973, DOI 10.1073/pnas.87.3.973; MORENO C, 1989, CLIN EXP IMMUNOL, V76, P240; NAKAJIMA T, 1976, J BIOL CHEM, V251, P174; PREHM P, 1980, CARBOHYD RES, V78, P372, DOI 10.1016/0008-6215(80)90018-X; SIBLEY LD, 1990, CLIN EXP IMMUNOL, V80, P141; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; SUTCLIFFE IC, 1989, FEMS MICROBIOL LETT, V59, P249, DOI 10.1111/j.1574-6968.1989.tb03119.x; WEBER PL, 1979, CARBOHYD RES, V74, P259, DOI 10.1016/S0008-6215(00)84781-3; WICKEN AJ, 1980, BIOCHIM BIOPHYS ACTA, V604, P1, DOI 10.1016/0304-4157(80)90002-7	28	175	179	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6228	6233						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556131				2022-12-27	WOS:A1992HK31800077
J	GREIS, KD; TURCO, SJ; THOMAS, JR; MCCONVILLE, MJ; HOMANS, SW; FERGUSON, MAJ				GREIS, KD; TURCO, SJ; THOMAS, JR; MCCONVILLE, MJ; HOMANS, SW; FERGUSON, MAJ			PURIFICATION AND CHARACTERIZATION OF AN EXTRACELLULAR PHOSPHOGLYCAN FROM LEISHMANIA-DONOVANI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C ACTIVITY; EXCRETED FACTOR; ACID-PHOSPHATASE; LIPOPHOSPHOGLYCAN; PROMASTIGOTES; PROTEIN; GLYCOCONJUGATE; INHIBITION; SURVIVAL; TROPICA	An extracellular phosphoglycan (exPG), present in the culture medium of the promastigote form of Leishmania donovani, was purified and structurally characterized. The purification scheme included ethanol precipitation of the culture medium, anion exchange chromatography, hydrophobic chromatography on phenyl-Sepharose, and preparative polyacrylamide gel electrophoresis. Structural analysis by H-1-H-1 NMR, methylation linkage analysis, and glycosidase digestion revealed that the exPG consisted of the following structure: (CAP) --> [PO4-6Galp-beta-1-4Manp-alpha-1]10-11-PO4-6Galp-beta-1-4Man. The cap was found to be one of several small, neutral oligosaccharides, the most abundant of which was the trisaccharide Galp-beta-1-4(Manp-alpha-1-2)Man. The results indicated structural analogy to the cellular-derived lipophosphoglycan (LPG) from L. donovani. The important exceptions are a lack of the lipid anchor, the entire phosphosaccharide core, and several of the repeating disaccharide units. Although the function of exPG is presently unknown, it may play a protective role for the promastigote in the insect vector or during infection of a mammalian host.	UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Kentucky; University of Dundee			Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714; Greis, Kenneth/0000-0002-5316-3351	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020941, R37AI020941] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20941] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; BRAATZ JA, 1974, J BIOL CHEM, V249, P2536; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DAVIES CR, 1990, PARASITOLOGY, V101, P337, DOI 10.1017/S0031182000060522; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EILAM Y, 1985, EXP PARASITOL, V59, P161, DOI 10.1016/0014-4894(85)90068-2; ELON J, 1990, PARASITE IMMUNOL, V12, P285, DOI 10.1111/j.1365-3024.1990.tb00955.x; ELON J, 1979, EXP PARASITOL, V47, P254, DOI 10.1016/0014-4894(79)90078-X; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; GLASER TA, 1991, MOL BIOCHEM PARASIT, V45, P337, DOI 10.1016/0166-6851(91)90102-C; HANDMAN E, 1985, EMBO J, V4, P329, DOI 10.1002/j.1460-2075.1985.tb03633.x; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; ILG T, 1991, J CELL SCI, V99, P175; JAFFE CL, 1990, MOL BIOCHEM PARASIT, V41, P233, DOI 10.1016/0166-6851(90)90186-P; JAFFE CL, 1989, EXP PARASITOL, V70, P12; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; KING DL, 1987, MOL BIOCHEM PARASIT, V24, P47, DOI 10.1016/0166-6851(87)90114-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; MCNEELY TB, 1989, BIOCHEM J, V259, P601, DOI 10.1042/bj2590601; MCNEELY TB, 1987, BIOCHEM BIOPH RES CO, V148, P653, DOI 10.1016/0006-291X(87)90926-0; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; SACKS DL, 1989, EXP PARASITOL, V69, P100, DOI 10.1016/0014-4894(89)90176-8; SLUTZKY GM, 1979, INFECT IMMUN, V26, P916, DOI 10.1128/IAI.26.3.916-924.1979; TAKASAKI S, 1974, J BIOCHEM-TOKYO, V76, P783; TALAMASROHANA P, 1990, J IMMUNOL, V144, P4817; TURCO SJ, 1990, EXP PARASITOL, V70, P241, DOI 10.1016/0014-4894(90)90105-L; TURCO SJ, 1991, MOL BIOCHEM PARASIT, V45, P91, DOI 10.1016/0166-6851(91)90030-A; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2	35	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5876	5881						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556103				2022-12-27	WOS:A1992HK31800027
J	MCDONOUGH, VM; STUKEY, JE; MARTIN, CE				MCDONOUGH, VM; STUKEY, JE; MARTIN, CE			SPECIFICITY OF UNSATURATED FATTY ACID-REGULATED EXPRESSION OF THE SACCHAROMYCES-CEREVISIAE OLE1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUTRITIONAL REGULATION; DESATURASE; BINDING; INITIATION; ELEMENT; RNA	The Saccharomyces cerevisiae OLE1 gene encodes the DELTA-9 fatty acid desaturase, an enzyme which forms the monounsaturated palmitoleic (16:1) and oleic (18:1) fatty acids from palmitoyl (16:0) or stearoyl (18:0) CoA. Previous studies demonstrated that OLE1 mRNA levels and desaturase enzyme activity are repressed when either 16:1 DELTA-9 and 18:1 DELTA-9 are added to the growth medium (1). The polyunsaturate, linoleic acid (18:2, DELTA-9,12), which is not a product of the enzyme, is also a strong repressor. The specificity of the OLE1 transcriptional regulatory sensor was examined by testing the response of OLE1 promoter-lacZ fusion reporter genes to fatty acids that differ in chain length, degree of unsaturation and double bond positions. Monounsaturated and polyunsaturated fatty acids that contain a DELTA-9 double bond are strong repressors of reporter gene activity and native OLE1 mRNA levels. Monounsaturated fatty acids containing double bonds in the DELTA-10, DELTA-11, or DELTA-5 positions showed no repression of reporter enzyme levels although they were rapidly incorporated into membrane lipids and some supported growth of an OLE1 gene disrupted strain. Although 17:1 DELTA-10 does not repress OLE1 transcription, lipid analysis showed that it replaces almost all of the endogenous 16:1 DELTA-9 and 18:1 DELTA-9 in cellular lipids and OLE1 mRNA levels are strongly repressed. This suggests that additional systems regulate desaturase activity by post-transcriptional mechanisms that differ from the transcriptional sensor in their responses to specific fatty acids.	RUTGERS STATE UNIV,NELSON BIOL LAB,BUR BIOL RES,BUSCH CAMPUS,POB 1059,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick								Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenner R., 1989, R FACTORS INFLUENCIN, VVolume 1989, P45; BROWSE J, 1986, PLANT PHYSIOL, V81, P859, DOI 10.1104/pp.81.3.859; CLARKE SD, 1989, FASEB J, V3, P2480, DOI 10.1096/fasebj.3.13.2680704; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; GODOWSKI PJ, 1989, BIOCHEM PHARMACOL, V38, P3135, DOI 10.1016/0006-2952(89)90605-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; KATES M, 1972, TECHNIQUES LIPIDOLOG, P127; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; Maniatis T, 1982, MOL CLONING LABORATO; MARTIN CE, 1981, BIOCHIM BIOPHYS ACTA, V665, P399, DOI 10.1016/0005-2760(81)90252-6; MORRISON WR, 1964, J LIPID RES, V5, P600; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; NEMECZ G, 1991, J BIOL CHEM, V266, P17180; NUNN WD, 1986, MICROBIOL REV, V50, P179, DOI 10.1128/MMBR.50.2.179-192.1986; STORCH J, 1991, J BIOL CHEM, V266, P13473; STRITTMATTER P, 1988, J BIOL CHEM, V263, P2532; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; THIEDE MA, 1985, J BIOL CHEM, V260, P4459	25	124	136	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5931	5936						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556107				2022-12-27	WOS:A1992HK31800036
J	PROBST, JC; HAUSER, F; JOBA, W; HOFFMANN, W				PROBST, JC; HAUSER, F; JOBA, W; HOFFMANN, W			THE POLYMORPHIC INTEGUMENTARY MUCIN-B.1 FROM XENOPUS-LAEVIS CONTAINS THE SHORT CONSENSUS REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; C4B-BINDING PROTEIN; MOLECULAR-CLONING; CANDIDA-ALBICANS; SKIN; GENES; PEPTIDES; EXPRESSION; CDNAS; FROG	The frog integumentary mucin B.1 (FIM-B.1), discovered by molecular cloning, contains a cysteine-rich C-terminal domain which is homologous with von Willebrand factor. With the help of the polymerase chain reaction, we now characterize a contiguous region 5' to the von Willebrand factor domain containing the short consensus repeat typical of many proteins from the complement system. Multiple transcripts have been cloned, which originate from a single animal and differ by a variable number of tandem repeats (rep-33 sequences). These different transcripts probably originate solely from two genes and are generated presumably by alternative splicing of an huge array of functional cassettes. This model is supported by analysis of genomic FIM-B.1 sequences from Xenopus laevis. Here, rep-33 sequences are arranged in an interrupted array of individual units. Additionally, results of Southern analysis revealed genetic polymorphism between different animals which is predicted to be within the tandem repeats. A first investigation of the predicted mucins with the help of a specific antibody against a synthetic peptide determined the molecular mass of FIM-B.1 to > 200 kDa. Here again, genetic polymorphism between different animals is detected.	MAX PLANCK INST PSYCHIAT, NEUROCHEM ABT, W-8033 MARTINSRIED, GERMANY	Max Planck Society			Hoffmann, Werner/AAY-9182-2020; Hauser, Frank/M-2952-2014	Hauser, Frank/0000-0001-5563-2345; Hoffmann, Werner/0000-0003-0031-9540				AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339; BERKOWITZ BA, 1990, BIOCHEM PHARMACOL, V39, P625, DOI 10.1016/0006-2952(90)90138-B; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; BOACKLE RJ, 1991, CRIT REV ORAL BIOL M, V2, P355, DOI 10.1177/10454411910020030401; BOLS NC, 1986, J CELL BIOL, V102, P492, DOI 10.1083/jcb.102.2.492; BORK P, 1991, FEBS LETT, V286, P47, DOI 10.1016/0014-5793(91)80937-X; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEKKER J, 1990, J BIOL CHEM, V265, P18116; DOOLITTLE RF, 1986, URFS ORFS, P87; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; EDWARDS JE, 1986, J IMMUNOL, V137, P3577; ELS WJ, 1990, HISTOL HISTOPATHOL, V5, P343; ENGELMANN TW, 1872, PFLUGERS ARCH PHYSL, V5, P498; FEARON DT, 1990, CURR TOP MICROBIOL, V153, P83; FLUCHER BE, 1986, J CELL BIOL, V103, P2299, DOI 10.1083/jcb.103.6.2299; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUM JR, 1989, J BIOL CHEM, V264, P6480; HAUSER F, 1991, J BIOL CHEM, V266, P21306; HAUSER F, 1990, EXP CELL RES, V189, P157, DOI 10.1016/0014-4827(90)90230-8; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; HESSING M, 1991, BIOCHEM J, V277, P581, DOI 10.1042/bj2770581; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; HOFFMANN W, 1983, EMBO J, V2, P111, DOI 10.1002/j.1460-2075.1983.tb01390.x; HOFFMANN W, 1988, J BIOL CHEM, V263, P7686; HOFFMANN W, 1988, FEBS LETT, V237, P178, DOI 10.1016/0014-5793(88)80196-0; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; JANATOVA J, 1989, BIOCHEMISTRY-US, V28, P4754, DOI 10.1021/bi00437a036; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KONIGSTORFER A, 1989, J BIOL CHEM, V264, P13689; LANCASTER CA, 1990, BIOCHEM BIOPH RES CO, V173, P1019, DOI 10.1016/S0006-291X(05)80888-5; LILLYWHITE HB, 1971, Z VERGL PHYSIOL, V73, P84, DOI 10.1007/BF00297703; LINEHAN L, 1988, INFECT IMMUN, V56, P1981, DOI 10.1128/IAI.56.8.1981-1986.1988; LOZIER J, 1984, P NATL ACAD SCI-BIOL, V81, P3640, DOI 10.1073/pnas.81.12.3640; MACK DR, 1991, INFECT IMMUN, V59, P1015, DOI 10.1128/IAI.59.3.1015-1023.1991; Maniatis T., 1982, MOL CLONING; MIRELMAN D, 1975, NATURE, V256, P414, DOI 10.1038/256414a0; MOLE JE, 1984, J BIOL CHEM, V259, P3407; Neutra M., 1987, PHYSL GASTROINTESTIN, P975; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERKINS SJ, 1988, BIOCHEMISTRY-US, V27, P4004, DOI 10.1021/bi00411a017; POST TW, 1991, J EXP MED, V174, P93, DOI 10.1084/jem.174.1.93; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6; SAXENA A, 1990, INFECT IMMUN, V58, P309, DOI 10.1128/IAI.58.2.309-314.1990; SHULDINER AR, 1989, J BIOL CHEM, V264, P9428; SORAVIA E, 1988, FEBS LETT, V228, P337, DOI 10.1016/0014-5793(88)80027-9; SORIMACHI H, 1988, J BIOL CHEM, V263, P17678; SPANNHOF L, 1953, WISS Z HUMBOLDT U MN, V3, P295; SPICER AP, 1991, J BIOL CHEM, V266, P15099; STEELE RE, 1985, NUCLEIC ACIDS RES, V13, P1747, DOI 10.1093/nar/13.5.1747; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; THIEBAUD CH, 1977, CHROMOSOMA, V59, P253, DOI 10.1007/BF00292781; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WAHLI W, 1979, CELL, V16, P535, DOI 10.1016/0092-8674(79)90028-X; Ziemer A, 1990, Dermatol Monatsschr, V176, P169	60	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6310	6316						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556137				2022-12-27	WOS:A1992HK31800089
J	SEOL, WG; SHATKIN, AJ				SEOL, WG; SHATKIN, AJ			ESCHERICHIA-COLI ALPHA-KETOGLUTARATE PERMEASE IS A CONSTITUTIVELY EXPRESSED PROTON SYMPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-VESICLES; DNA-SEQUENCE; GALACTOSE TRANSPORT; ACTIVE-TRANSPORT; LAC PERMEASE; PROTEINS; IDENTIFICATION; RECONSTITUTION; ARABINOSE; GRADIENT	Escherichia coli kgtP which maps at 56.5 min codes for alpha-ketoglutarate permease (KgtP). This protein, expressed from the cloned gene using the T7 polymerase system and [S-35]methionine labeling, fractionated with cell membranes. Right-side-out (RSO) membrane vesicles prepared from a kgtP negative mutant strain did not transport alpha-ketoglutarate, but RSO vesicles from the same strain expressing KgtP from a transforming plasmid transported alpha-ketoglutarate effectively as measured by uptake of the C-14-labeled substrate. E. coli JC7623 strain grown in M9 minimal medium with glucose, glycerol, or alpha-ketoglutarate as carbon source contained a 1.3-kilobase RNA which hybridized to nick-translated kgtP probe. In addition, strain MC1061 cultures grown under these same conditions were all capable of transporting alpha-ketoglutarate, demonstrating that KgtP is constitutively expressed. The K(m) and V(max) of KgtP assayed in strain MC 1061 vesicles were 13-46-mu-M and 8 nmol/min/mg protein, respectively. Uncouplers that permeabilized the membrane to protons inhibited alpha-ketoglutarate transport into energized vesicles, and the addition of alpha-ketoglutarate to vesicle suspensions under non-energized conditions resulted in an increase in pH. These results indicate that KgtP is an alpha-ketoglutarate-proton symporter.			SEOL, WG (corresponding author), CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854, USA.							CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; DAVIS EO, 1987, J BIOL CHEM, V262, P13928; Henderson PJF, 1991, CURR OPIN STRUC BIOL, V1, P590, DOI 10.1016/S0959-440X(05)80082-X; HENDERSON PJF, 1990, PHILOS T ROY SOC B, V326, P391, DOI 10.1098/rstb.1990.0020; HENDERSON PJF, 1986, METHOD ENZYMOL, V125, P387; HORNE P, 1983, BIOCHEM J, V210, P699, DOI 10.1042/bj2100699; ISHIGURO N, 1988, GENE, V68, P181; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACPHERSON AJS, 1983, J BIOL CHEM, V258, P4390; MACPHERSON AJS, 1981, BIOCHEM J, V196, P269, DOI 10.1042/bj1960269; Magasanik B., 1987, ESCHERICHIA COLI SAL, V2, P1318; MAIDEN MCJ, 1988, J BIOL CHEM, V263, P8003; Maloney P. C., 1987, ESCHERICHIA COLI SAL, V1, P222; Maniatis T, 1989, DECONTAMINATION DILU; RAMOS S, 1976, P NATL ACAD SCI USA, V73, P1892, DOI 10.1073/pnas.73.6.1892; RAMOS S, 1977, BIOCHEMISTRY-US, V16, P854, DOI 10.1021/bi00624a007; SEOL W, 1990, J BACTERIOL, V172, P4745, DOI 10.1128/jb.172.9.4745.1990; SEOL W, 1991, P NATL ACAD SCI USA, V88, P3802, DOI 10.1073/pnas.88.9.3802; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VANDERREST ME, 1990, EUR J BIOCHEM, V189, P401; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1	24	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6409	6413						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556144				2022-12-27	WOS:A1992HK31800102
J	STONE, N; REINBERG, D				STONE, N; REINBERG, D			PROTEIN-KINASES FROM ASPERGILLUS-NIDULANS THAT PHOSPHORYLATE THE CARBOXYL-TERMINAL DOMAIN OF THE LARGEST SUBUNIT OF RNA POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION; REPEAT DOMAIN; INVIVO; PHOSPHOTYROSINE; INVITRO; P34CDC2	Three serine kinases which phosphorylate the CTD of RNA polymerase II have been identified in Aspergillus nidulans. The kinases (KI, KII, KIII) were identified using a synthetic peptide containing four copies of the CTD consensus heptamer repeat, and differ in chromatographic behavior, and apparent molecular mass (KI approximately 60kDa; KII approximately 82kDa; KIII approximately 43 kDa). KIII utilized, in addition to peptide, histone Hl as substrate, whereas casein was not phosphorylated by any of the three kinases. The kinases appear to be unrelated to the p34cdc2 kinase, as judged by Western blot analysis and the position of serine phosphorylation of the synthetic CTD peptide. KI was highly purified and renaturation experiments have shown that it consists of a single polypeptide of 57 kDa. KI also phosphorylated RNA polymerase II associated in a preinitiation complex.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,675 HOES LN,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center				Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037110] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37110] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHO KWY, 1985, J BIOL CHEM, V260, P5204; CHRISTMANN JL, 1981, J BIOL CHEM, V256, P1798; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, IN PRESS METHODS ENZ; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; HA I, 1991, IN PRESS NATURE; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; KIM WY, 1988, J BIOL CHEM, V263, P18880; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LU H, 1991, IN PRESS P NATL ACAD; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORRIS NR, 1975, GENET RES, V26, P237, DOI 10.1017/S0016672300016049; NEUFELD E, 1989, ANAL BIOCHEM, V177, P138, DOI 10.1016/0003-2697(89)90028-6; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SULLIVAN S, 1991, IN PRESS ANAL BIOCH; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHANG J, 1991, J BIOL CHEM, V266, P2290; ZHANG J, 1991, J BIOL CHEM, V266, P2297	36	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6353	6360						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556138				2022-12-27	WOS:A1992HK31800094
J	BRITSCH, L; RUHNAUBRICH, B; FORKMANN, G				BRITSCH, L; RUHNAUBRICH, B; FORKMANN, G			MOLECULAR-CLONING, SEQUENCE-ANALYSIS, AND INVITRO EXPRESSION OF FLAVANONE 3-BETA-HYDROXYLASE FROM PETUNIA-HYBRIDA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N SYNTHETASE GENE; SYNTHASE MULTIGENE FAMILY; EUKARYOTIC MESSENGER-RNA; CHALCONE SYNTHASE; STREPTOMYCES-CLAVULIGERUS; DIFFERENTIAL EXPRESSION; PROLYL 4-HYDROXYLASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; ISOMERASE GENES	A cDNA encoding flavanone 3-beta-hydroxylase was isolated from petals of Petunia hybrida. The open reading frame of the nearly full length cDNA coded for a 369-amino acid polypeptide with a calculated M(r) of 41,466. The function of this nucleotide sequence was verified by comparison with amino acid sequence of the amino terminus and tryptic peptides from purified plant enzyme, by Northern blotting with RNA from wild type and mutant plants, and by prokaryotic expression yielding an enzymatically active hydroxylase. Computer-aided sequence analysis revealed high similarity (73.5%) to flavanone 3-beta-hydroxylase from barley. Genomic Southern blot analysis showed the presence of only one gene for flavanone 3-beta-hydroxylase in P. hybrida.	UNIV TUBINGEN, LEHRSTUHL ALLGEMEINE GENET, INST BIOL, W-7400 TUBINGEN 1, GERMANY; MAX PLANCK INST ZUCHTUNGSFORSCH, W-5000 COLOGNE 30, GERMANY	Eberhard Karls University of Tubingen; Max Planck Society	BRITSCH, L (corresponding author), UNIV FREIBURG, LEHRSTUHL BIOCHEM PFLANZEN, INST BIOL 2, SCHANZLESTR 1, W-7800 FREIBURG, GERMANY.							BASSUK JA, 1989, P NATL ACAD SCI USA, V86, P7382, DOI 10.1073/pnas.86.19.7382; BELD M, 1989, PLANT MOL BIOL, V13, P491, DOI 10.1007/BF00027309; BLYDEN ER, 1991, PLANT MOL BIOL, V16, P167, DOI 10.1007/BF00017927; BOUZAYEN M, 1991, PLANTA, V184, P244, DOI [10.1007/BF01102424, 10.1007/BF00197953]; BRITSCH L, 1990, ARCH BIOCHEM BIOPHYS, V276, P348, DOI 10.1016/0003-9861(90)90731-D; BRITSCH L, 1986, EUR J BIOCHEM, V156, P569, DOI 10.1111/j.1432-1033.1986.tb09616.x; BRITSCH L, 1981, Z NATURFORSCH C, V36, P742; CARR LG, 1986, GENE, V48, P257, DOI 10.1016/0378-1119(86)90084-3; DOUGLAS C, 1987, EMBO J, V6, P1189, DOI 10.1002/j.1460-2075.1987.tb02353.x; FORKMANN G, 1991, PLANT BREEDING, V106, P1, DOI 10.1111/j.1439-0523.1991.tb00474.x; FORKMANN G, 1984, PLANTA, V161, P261, DOI 10.1007/BF00982923; FORKMANN G, 1981, Z NATURFORSCH C, V36, P411; FORKMANN G, 1980, Z NATURFORSCH C, V35, P691; FROEMEL S, 1985, THEOR APPL GENET, V70, P561, DOI 10.1007/BF00305991; GERATS AGM, 1982, PLANTA, V155, P364, DOI 10.1007/BF00429466; HAMILTON AJ, 1990, NATURE, V346, P284, DOI 10.1038/346284a0; HANAUSKEABEL HM, 1982, J THEOR BIOL, V94, P421, DOI 10.1016/0022-5193(82)90320-4; HARKER CL, 1990, PLANT CELL, V2, P185, DOI 10.1105/tpc.2.3.185; HEIDECKER G, 1986, ANNU REV PLANT PHYS, V37, P439, DOI 10.1146/annurev.arplant.37.1.439; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HOLDSWORTH MJ, 1987, NUCLEIC ACIDS RES, V15, P731, DOI 10.1093/nar/15.2.731; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P9627, DOI 10.1093/nar/15.23.9627; KOES RE, 1987, PLANT MOL BIOL, V10, P159, DOI 10.1007/BF00016153; KOVACEVIC S, 1989, J BACTERIOL, V171, P754, DOI 10.1128/jb.171.2.754-760.1989; LAND H, 1981, NUCLEIC ACIDS RES, V9, P2251, DOI 10.1093/nar/9.10.2251; LANZ T, 1990, PLANTA, V181, P169, DOI 10.1007/BF02411534; LAPEYRE B, 1985, GENE, V37, P215, DOI 10.1016/0378-1119(85)90275-6; LESKIW BK, 1988, GENE, V62, P187, DOI 10.1016/0378-1119(88)90557-4; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MARTIN C, 1991, PLANT J, V1, P37, DOI 10.1111/j.1365-313X.1991.00037.x; MATSUDA J, 1991, J BIOL CHEM, V266, P9460; MCGARVEY DJ, 1990, PLANT MOL BIOL, V15, P165, DOI 10.1007/BF00017736; MELDGAARD M, 1991, IN PRESS THEOR APPL; MENSSEN A, 1990, EMBO J, V9, P3051, DOI 10.1002/j.1460-2075.1990.tb07501.x; MEYER P, 1987, NATURE, V330, P677, DOI 10.1038/330677a0; MOL JNM, 1988, PLANT MOL BIOL REP, V6, P274; MURRAY NE, 1983, LAMBDA, V2, P395; MYLLYLA R, 1991, J BIOL CHEM, V266, P2805; NAKAMURA K, 1982, EMBO J, V1, P771, DOI 10.1002/j.1460-2075.1982.tb01244.x; NIESBACHKLOSGEN U, 1987, J MOL EVOL, V26, P213, DOI 10.1007/BF02099854; ONEILL SD, 1990, MOL GEN GENET, V224, P279, DOI 10.1007/BF00271562; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAMON D, 1987, GENE, V57, P171, DOI 10.1016/0378-1119(87)90120-X; Sambrook J, 1989, MOL CLONING LABORATO; SAMSON SM, 1985, NATURE, V318, P191, DOI 10.1038/318191a0; SAMSON SM, 1987, BIO-TECHNOL, V5, P1207, DOI 10.1038/nbt1187-1207; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STOREY RD, 1986, PHYTOCHEMISTRY, V25, P2701; SUN YJ, 1991, PLANT PHYSIOL, V95, P570, DOI 10.1104/pp.95.2.570; VANTUNEN AJ, 1988, EMBO J, V7, P1257, DOI 10.1002/j.1460-2075.1988.tb02939.x; VERVERIDIS P, 1991, PHYTOCHEMISTRY, V30, P725, DOI 10.1016/0031-9422(91)85241-Q; WINGENDER R, 1989, MOL GEN GENET, V218, P315, DOI 10.1007/BF00331284; WU FS, 1984, ANAL BIOCHEM, V139, P100, DOI 10.1016/0003-2697(84)90394-4; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2	56	110	138	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5380	5387						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544919				2022-12-27	WOS:A1992HH74700059
J	CICHOWSKI, K; MCCORMICK, F; BRUGGE, JS				CICHOWSKI, K; MCCORMICK, F; BRUGGE, JS			P21RASGAP ASSOCIATION WITH FYN, LYN, AND YES IN THROMBIN-ACTIVATED PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AVIAN-SARCOMA VIRUSES; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; TRANSFORMING PROTEINS; RECOGNIZE; GAP	Activation of platelets by thrombin and other physiological agonists leads to a dramatic increase in tyrosine phosphorylation of multiple cellular proteins (Ferrell, J. E., and Martin, G. S. (1988) Mol. Cell. Biol. 8, 3606-3610; Golden, A., and Brugge, J. S. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 901-905; Nakamura, S., and Yamamura, H. (1989) J. Biol. Chem. 264, 7089-7091). To date, none of the tyrosine kinases that are involved in platelet activation, nor the substrates that are phosphorylated in response to agonists, have been identified. A "kinase trapping" strategy, designed to take advantage of the stability of known tyrosine kinase-substrate interactions, was employed to address both issues. p21(ras)GAP antibodies were used to examine the phosphorylated state of GAP in agonist-treated platelets and to isolate potential GAP-kinase complexes. We show that GAP and two proteins of 59 and 68 kDa are phosphorylated on tyrosine after thrombin stimulation and that three Src-related protein tyrosine kinases, Fyn, Lyn and Yes, are associated with GAP in complexes, detectable only after agonist stimulation. The thrombin-dependent detection of these kinases in GAP immunoprecipitates suggests that thrombin may either induce the formation of these complexes or activate kinases that are associated with GAP prior to, or following, agonist stimulation. This approach of "trapping" kinases bound to their substrates will be useful in identifying non-receptor tyrosine kinases involved in signaling pathways. Furthermore, although GAP phosphorylation has been previously implicated in growth factor signaling pathways, this is the first example of its involvement downstream from a G-protein-coupled receptor.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT MICROBIOL,CLIN RES BLDG,RM 405,PHILADELPHIA,PA 19104; CETUS CORP,EMERYVILLE,CA 94608	Howard Hughes Medical Institute; University of Pennsylvania					NATIONAL CANCER INSTITUTE [R01CA047572] Funding Source: NIH RePORTER; NCI NIH HHS [CA47572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HORAK ID, 1990, ONCOGENE, V5, P597; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P939; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAPETINA EG, 1990, FEBS LETT, V268, P400, DOI 10.1016/0014-5793(90)81293-W; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZHAO YH, 1990, ONCOGENE, V5, P1629	22	105	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5025	5028						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544885				2022-12-27	WOS:A1992HH74700003
J	MAUNE, JF; KLEE, CB; BECKINGHAM, K				MAUNE, JF; KLEE, CB; BECKINGHAM, K			CA2+ BINDING AND CONFORMATIONAL CHANGE IN 2 SERIES OF POINT MUTATIONS TO THE INDIVIDUAL CA2+-BINDING SITES OF CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN CALMODULIN; CALCIUM-BINDING; TROPONIN-C; TRYPTIC FRAGMENTS; PROTEIN ACTIVATOR; ESCHERICHIA-COLI; EXPRESSION; H-1-NMR; GENE; PHOSPHODIESTERASE	Two series of site-directed mutations to the individual Ca2+-binding sites of Drosophila melanogaster calmodulin have been generated and studied. In each mutant, a conserved glutamic acid residue at position 12 in all of the Ca2+-binding loops has been mutated in one site. In one series the residue is changed to glutamine; in the second series the change is to lysine. The Ca2+-binding properties of these mutants and the wild-type protein under pseudo-physiological conditions are presented. In addition, Ca2+-induced changes to the environment of the single tyrosine residue (Tyr-138) have been studied for some of the mutants. Ca2+ binding to the wild-type protein is best modeled as two pairs of sites with a higher affinity pair that shows strong cooperativity. For all but one of these eight mutant proteins, only three Ca2+-binding events can be detected. In three of the amino-terminal mutants, the three residual sites are (i) a pair of relatively high affinity sites and (ii) a weakened low affinity site. For all four carboxyl-terminal mutations, the residual sites are three relatively low affinity sites. In general, mutations to sites 2 and 4 prove more deleterious than mutations to sites 1 and 3. The Ca2+-induced conformational changes in the vicinity of Tyr-138 are relatively undisturbed by mutations of site 1. However, the changes to Tyr-138 in the carboxyl-terminal site mutants indicate that upon disruption of the cooperative binding at the high affinity sites, conformational change in the carboxyl terminus occurs in two phases. It appears that binding of Ca2+ to either carboxyl-terminal site can elicit the first phase of the response but the second phase is almost abolished when site 4 is the mutated site. The final conformations of site 3 and 4 mutants are thus significantly different.	RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA; NCI, BIOCHEM LAB, BETHESDA, MD 20205 USA	Rice University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NIGMS NIH HHS [GM37214] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037214] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; BURGER D, 1984, BIOCHEMISTRY-US, V23, P1966, DOI 10.1021/bi00304a013; Cohen P., 1988, MOL ASPECTS CELL REG, V5; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3692, DOI 10.1021/bi00557a009; DALGARNO DC, 1984, EUR J BIOCHEM, V138, P281, DOI 10.1111/j.1432-1033.1984.tb07913.x; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FLETCHER JE, 1970, BIOCHEMISTRY-US, V9, P4580, DOI 10.1021/bi00825a018; FORSEN S, 1986, CALCIUM CELL FUNCTIO, V6, P113; GARIEPY J, 1983, FEBS LETT, V160, P1, DOI 10.1016/0014-5793(83)80924-7; GOLD L, 1981, ANNU REV MICROBIOL, V35, P365, DOI 10.1146/annurev.mi.35.100181.002053; HAIECH J, 1991, J BIOL CHEM, V266, P3427; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HILL AV, 1910, J PHYSIOL-LONDON, V40, pP4; IIDA S, 1986, J BIOCHEM-TOKYO, V99, P1765, DOI 10.1093/oxfordjournals.jbchem.a135654; IKURA M, 1985, BIOCHEMISTRY-US, V24, P4264, DOI 10.1021/bi00337a002; KILHOFFER MC, 1988, J BIOL CHEM, V263, P17023; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; KRETSINGER RH, 1976, ANNU REV BIOCHEM, V45, P239, DOI 10.1146/annurev.bi.45.070176.001323; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSE S, 1991, J BIOL CHEM, V266, P8050; LUAN Y, 1987, J BIOCHEM-TOKYO, V102, P1531, DOI 10.1093/oxfordjournals.jbchem.a122201; Maniatis T., 1982, MOL CLONING; MAUNE J F, 1988, Journal of Cell Biology, V107, p287A; MAUNE JF, 1991, THESIS RICE U HOUSTO; MINOWA O, 1984, J BIOCHEM-TOKYO, V96, P1175, DOI 10.1093/oxfordjournals.jbchem.a134935; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; OGAWA Y, 1984, J BIOCHEM-TOKYO, V95, P19, DOI 10.1093/oxfordjournals.jbchem.a134584; PUNDAK S, 1984, BIOCHEMISTRY-US, V23, P1549, DOI 10.1021/bi00302a032; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; REID RE, 1987, BIOCHEMISTRY-US, V26, P6070, DOI 10.1021/bi00393a019; RICHMAN PG, 1978, BIOCHEMISTRY-US, V17, P3001, DOI 10.1021/bi00608a010; RICHMAN PG, 1979, J BIOL CHEM, V254, P5372; RUSSELL DR, 1982, GENE, V20, P231, DOI 10.1016/0378-1119(82)90042-7; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; SHATZMAN AR, 1986, ANN NY ACAD SCI, V478, P233, DOI 10.1111/j.1749-6632.1986.tb15534.x; SHAW GS, 1990, SCIENCE, V249, P280, DOI 10.1126/science.2374927; SMITH VL, 1987, J MOL BIOL, V196, P471, DOI 10.1016/0022-2836(87)90025-8; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TAYLOR DA, 1991, J BIOL CHEM, V266, P21375; TONEGUZZO F, 1988, BIOTECHNIQUES, V6, P460; VERMERSCH PS, 1986, GENE, V41, P289, DOI 10.1016/0378-1119(86)90109-5; WANG CLA, 1982, EUR J BIOCHEM, V124, P7, DOI 10.1111/j.1432-1033.1982.tb05900.x; WNUK W, 1984, J BIOL CHEM, V259, P9017; YAMANAKA MK, 1987, NUCLEIC ACIDS RES, V15, P3335, DOI 10.1093/nar/15.8.3335; YAZAWA M, 1990, J BIOCHEM-TOKYO, V107, P287, DOI 10.1093/oxfordjournals.jbchem.a123040; YAZAWA M, 1978, J BIOCHEM-TOKYO, V84, P1253, DOI 10.1093/oxfordjournals.jbchem.a132243; YAZAWA M, 1987, J BIOL CHEM, V262, P10951; YOSHIDA M, 1983, J BIOCHEM-TOKYO, V94, P1925, DOI 10.1093/oxfordjournals.jbchem.a134546	55	208	208	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5286	5295						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544911				2022-12-27	WOS:A1992HH74700046
J	MILLER, BT; COLLINS, TJ; NAGLE, GT; KUROSKY, A				MILLER, BT; COLLINS, TJ; NAGLE, GT; KUROSKY, A			THE OCCURRENCE OF O-ACYLATION DURING BIOTINYLATION OF GONADOTROPIN-RELEASING-HORMONE AND ANALOGS - EVIDENCE FOR A REACTIVE SERINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL ENERGY ANALYSIS; NATIVE DECAPEPTIDE; MASS-SPECTROMETRY; RECEPTOR; MOLECULE; PITUITARY; BINDING; CELLS; LH	Gonadotropin-releasing hormone (GnRH) and two of its analogs ([D-Lys6]GnRH and des-Gly10-[D-Trp6]GnRH) were reacted with sulfonated N-hydroxysuccinimide esters of biotin that have been reported to react specifically with primary amino groups. Fractionation by reversed-phase high performance liquid chromatography demonstrated the occurrence of multiple biotinylated derivatives for each reacted peptide. These results were unexpected since GnRH and des-Gly10-[D-Trp6]GnRH contained no reactive amino groups and [D-Lys6]GnRH had only one. Reaction of the biotinylated derivatives with hydroxylamine indicated that significant O-biotinylation had occurred. Mass spectrometric analyses established the stoichiometry of biotinylation and confirmed that substantial O-biotinylation of residue Ser4, and to a minor extent Tyr5, of GnRH and the two analogs had occurred. In contrast, the biotinylation of selected peptides unrelated to GnRH under identical reaction conditions indicated no significant evidence of O-acylation of seryl residues. Strikingly, biotinylation of GnRH under denaturing conditions largely abolished O-acylation, indicating that the observed O-biotinylation was dependent on peptide conformation. All the O-biotinylated derivatives displayed significantly reduced bioactivity. Taken together, these results give strong evidence that the Ser4 hydroxyl of GnRH has a significantly elevated intrinsic reactivity, which raises new questions concerning its putative role in the conformation and mode of action of the hormone. These results also demonstrate for the first time that the N-hydroxysuccinimide-biotin esters are capable of significant O-acylation and may be generally useful reagents for detecting highly reactive hydroxyamino acid residues.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77550 USA; UNIV TEXAS, MED BRANCH, DEPT ANAT & NEUROSCI, GALVESTON, TX 77550 USA; UNIV TEXAS, MED BRANCH, INST MARINE BIOMED, GALVESTON, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston					NCRR NIH HHS [RR 00317] Funding Source: Medline; NINDS NIH HHS [NS 29261] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029261] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABA Y, 1971, J BIOL CHEM, V246, P7581; BALLS AK, 1952, ADV ENZYMOL REL S BI, V13, P321; BARBER M, 1981, J CHEM SOC CHEM COMM, P325, DOI 10.1039/c39810000325; Bayer E A, 1980, Methods Biochem Anal, V26, P1; BERNARDI L, 1966, EXPERIENTIA, V22, P29, DOI 10.1007/BF01897751; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BRUNING JL, 1977, COMPUTATIONAL HDB ST, P112; BULLESBACH EE, 1990, INT J PEPT PROT RES, V35, P416; DONZEL B, 1977, BIOCHEMISTRY-US, V16, P2611, DOI 10.1021/bi00631a006; Fink G., 1988, P1349; FREIDINGER RM, 1980, SCIENCE, V210, P656, DOI 10.1126/science.7001627; FRESHNEY RI, 1983, CULTURE ANIMAL CELLS, P207; GEIGER R, 1972, BIOCHEM BIOPH RES CO, V49, P1467, DOI 10.1016/0006-291X(72)90504-9; GOUNARIS AD, 1967, J BIOL CHEM, V242, P2739; HOCHHAUS G, 1988, J BIOL CHEM, V263, P92; HOFMANN K, 1985, ANN NY ACAD SCI, V447, P359, DOI 10.1111/j.1749-6632.1985.tb18451.x; KARTEN MJ, 1986, ENDOCR REV, V7, P44, DOI 10.1210/edrv-7-1-44; KNOCK SL, 1991, J BIOL CHEM, V266, P24413; MATSUO H, 1971, BIOCHEM BIOPH RES CO, V43, P1334, DOI 10.1016/S0006-291X(71)80019-0; MOMANY FA, 1976, J AM CHEM SOC, V98, P2990, DOI 10.1021/ja00426a052; MOMANY FA, 1976, J AM CHEM SOC, V98, P2996, DOI 10.1021/ja00426a053; Moss RL, 1989, NEURAL CONTROL REPRO, P485; NEWMAN W, 1989, J BIOL CHEM, V264, P16359; PARKENING TA, 1982, J ENDOCRINOL, V95, P417, DOI 10.1677/joe.0.0950417; REICHELT KL, 1987, BIOCHEM BIOPH RES CO, V146, P1493, DOI 10.1016/0006-291X(87)90818-7; SATO K, 1987, ANAL CHEM, V59, P1652, DOI 10.1021/ac00140a016; SCHAFFER NK, 1953, J BIOL CHEM, V202, P67; SHERWOOD N, 1987, TRENDS NEUROSCI, V10, P129, DOI 10.1016/0166-2236(87)90058-0; SMITH JS, 1991, ANAL BIOCHEM, V197, P247, DOI 10.1016/0003-2697(91)90384-6; TIBOLT RE, 1985, ENDOCRINOLOGY, V117, P396, DOI 10.1210/endo-117-1-396; WESTLUND KN, 1984, PEPTIDES, V5, P627, DOI 10.1016/0196-9781(84)90094-9; WILCHEK M, 1990, METHOD ENZYMOL, V184, P5; WILCHEK M, 1988, ANAL BIOCHEM, V171, P1, DOI 10.1016/0003-2697(88)90120-0; YANAIHARA N, 1973, BIOCHEM BIOPH RES CO, V52, P64, DOI 10.1016/0006-291X(73)90954-6; YEM AW, 1989, J BIOL CHEM, V264, P17691	36	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5060	5069						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544890				2022-12-27	WOS:A1992HH74700012
J	PORTER, DJT; CHESTNUT, WG; MERRILL, BM; SPECTOR, T				PORTER, DJT; CHESTNUT, WG; MERRILL, BM; SPECTOR, T			MECHANISM-BASED INACTIVATION OF DIHYDROPYRIMIDINE DEHYDROGENASE BY 5-ETHYNYLURACIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA 5-FLUOROURACIL LEVELS; ANTITUMOR-ACTIVITY; ACID OXIDASE; RAT-LIVER; PIG-LIVER; BROMOVINYLDEOXYURIDINE; MICE; ADENOCARCINOMA-755; PURIFICATION; DEGRADATION	Uracil analogues with appropriate substituents at the 5-position inactivated dihydropyrimidine dehydrogenase (DHPDHase). The efficiency of these inactivators was highly dependent on the size of the 5-substituent. For example, 5-ethynyluracil inactivated DHPDHase with an efficiency (k(inact)/K(i)) that was 500-fold greater than that for 5-propynyluracil. 5-Ethynyluracil inactivated DHPDHase by initially forming a reversible complex with a K(i) of 1.6 +/- 0.2-mu-M. This initial complex yielded inactivated enzyme with a rate constant of 20 +/- 2 min-1 (k(inact)). Thymine competitively decreased the apparent rate constant for inactivation of DHPDHase by 5-ethynyluracil. The absorbance spectrum of 5-ethynyluracil-inactivated DHPDHase was different from that of reduced enzyme. These optical changes were correlated with the loss of enzymatic activity. 5-Ethynyluracil inactivated DHPDHase with a stoichiometry of 0.9 mol of inactivator per mol of active site. Enzyme inactivated with [2-C-14]5-ethynyluracil retained all of the radiolabel after denaturation in 8 M urea, but lost radiolabel under acidic conditions. These results suggested that inactivation was due to covalent modification of an amino acid residue and not due to modification of a noncovalently bound prosthetic group. A radiolabeled peptide was isolated from a tryptic digest of the enzyme inactivated with [2-C-14]5-ethynyluracil. The sequence of this peptide was Lys-Ala-Glu-Ala-Ser-Gly-Ala-Y-Ala-Leu-Glu-Leu-Asn-Leu-Ser-X-Pro-His-Gly-Met-Gly-Glu-Arg, where X and Y were unidentified amino acids. Since the radiolabel was lost from the peptide during the first cycle on the amino acid sequenator, the position of the radiolabeled amino acid was not determined. The amino acid residue designated by X was identified as a cysteine from previous work with DHPDHase inactivated with 5-iodouracil. In contrast to 5-ethynyluracil, 5-cyanouracil was a reversible inactivator of the enzyme. 5-Cyanouracil-inactivated enzyme slowly regained activity (t1/2 = 1.8 min) after dilution into the standard assay. DHPDHases isolated from rat, mouse, and human liver had similar sensitivities to inactivation by 5-alkynyluracils.	WELLCOME RES LABS,DIV ORGAN CHEM,RES TRIANGLE PK,NC 27709	Wellcome Research Laboratories	PORTER, DJT (corresponding author), WELLCOME RES LABS,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709, USA.							ALSTON TA, 1981, PHARMACOL THERAPEUT, V12, P1, DOI 10.1016/0163-7258(81)90074-7; ALSTON TA, 1980, BIOCHEM BIOPH RES CO, V95, P299; BARR PJ, 1983, BIOCHEMISTRY-US, V22, P1697; BENEFRAIM S, 1986, BRIT J CANCER, V54, P847, DOI 10.1038/bjc.1986.250; Bevington P.R., 1969, DATA REDUCTION ERROR; BRANDSMA L, 1967, CHEM ETHER LINKAGE, P566; COOPER GM, 1970, CANCER RES, V30, P2937; CROMARTIE TH, 1975, BIOCHEMISTRY-US, V14, P3482, DOI 10.1021/bi00686a030; DESGRANGES C, 1986, CANCER RES, V45, P1094; ENDO K, 1970, J BIOL CHEM, V245, P4293; FENDRICH G, 1982, BIOCHEMISTRY-US, V21, P6685, DOI 10.1021/bi00269a011; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; IIGO M, 1989, BIOCHEM PHARMACOL, V38, P1885; IIGO M, 1988, BIOCHEM PHARMACOL, V37, P1609; KITZ R, 1962, J BIOL CHEM, V237, P3245; KRENITSKY TA, 1981, BIOCHEMISTRY-US, V20, P3615, DOI 10.1021/bi00515a048; MARCOTTE P, 1978, BIOCHEMISTRY-US, V17, P2864, DOI 10.1021/bi00607a026; MAYCOCK A, 1976, ACCOUNTS CHEM RES, V9, P313; MAYCOCK AL, 1976, BIOCHEMISTRY-US, V15, P114, DOI 10.1021/bi00646a018; NAGUIB FNM, 1989, BIOCHEM PHARMACOL, V38, P1471, DOI 10.1016/0006-2952(89)90187-1; PENNING TM, 1981, J BIOL CHEM, V256, P6851; PODSCHUN B, 1989, EUR J BIOCHEM, V185, P219, DOI 10.1111/j.1432-1033.1989.tb15105.x; PODSCHUN B, 1990, J BIOL CHEM, V265, P12966; SHIOTANI T, 1981, J BIOL CHEM, V256, P219; TATSUMI K, 1987, JPN J CANCER RES, V78, P748; WALSH C, 1982, TETRAHEDRON, V38, P871, DOI 10.1016/0040-4020(82)85068-0; WASTERNACK C, 1980, PHARMACOL THERAPEUT, V8, P629, DOI 10.1016/0163-7258(80)90079-0	27	124	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5236	5242						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544906				2022-12-27	WOS:A1992HH74700039
J	LEBEAU, MC; MASSOL, N; HERRICK, J; FABER, LE; RENOIR, JM; RADANYI, C; BAULIEU, EE				LEBEAU, MC; MASSOL, N; HERRICK, J; FABER, LE; RENOIR, JM; RADANYI, C; BAULIEU, EE			P59, AN HSP 90-BINDING PROTEIN - CLONING AND SEQUENCING OF ITS CDNA AND PREPARATION OF A PEPTIDE-DIRECTED POLYCLONAL ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEAT-SHOCK PROTEIN; PROGESTERONE-RECEPTOR; 59-KILODALTON PROTEIN; MONOCLONAL-ANTIBODY; STEROID-RECEPTORS; 70-KILODALTON; COMPONENT	The primary sequence of the rabbit liver cDNA coding for protein p59 has been determined. The protein binds to the 90-kDa heat shock protein (hsp 90) and is associated with it, including when hsp 90 participates in hetero-oligomeric complexes of untransformed mammalian steroid receptors that sediment at 8-10 S. The cloned cDNA codes for an open reading frame of 458 amino acids defining a yet unknown protein. However, 55% amino acid homology to peptidyl-prolyl isomerase is found between amino acids 41 and 137, suggesting rotamase activity for p59, which speculatively may apply to bound hsp 90 and thus be implied in the intracellular trafficking of hetero-oligomeric forms of steroid hormone receptors. A polyclonal antibody derived from the COOH-terminal peptide 441-458 demonstrates a good affinity for rabbit, rat, and human "p59" protein. It interacts with at least one epitope, available in 8-10 S untransformed steroid receptor complexes and different from that recognized by the monoclonal antibody KN382/EC-1.			LEBEAU, MC (corresponding author), HOP BICETRE,INSERM,U33,F-94275 LE KREMLIN BICETR,FRANCE.		RADANYI, Christine/A-8921-2008					Baulieu E E, 1971, Recent Prog Horm Res, V27, P351; BAULIEU EE, 1986, STEROID THYROID HORM, P301; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; DOUGHERTY JJ, 1984, J BIOL CHEM, V259, P8004; GASC JM, 1990, EXP CELL RES, V186, P362, DOI 10.1016/0014-4827(90)90317-4; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOUSLEY PR, 1985, J BIOL CHEM, V260, P3810; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; MATTS RL, 1991, FED AM SOC EXP BIOL; NAKAO K, 1985, CAN J BIOCHEM CELL B, V63, P33, DOI 10.1139/o85-005; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; RENOIR JM, 1990, J BIOL CHEM, V265, P14402; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SHERMAN MR, 1984, ANNU REV PHYSIOL, V46, P83; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; VENNER TJ, 1990, NUCLEIC ACIDS RES, V18, P5309, DOI 10.1093/nar/18.17.5309	20	194	198	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4281	4284						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537818				2022-12-27	WOS:A1992HF64200002
J	SCHILLINGBARTETZKO, S; BARTETZKO, A; NIERHAUS, KH				SCHILLINGBARTETZKO, S; BARTETZKO, A; NIERHAUS, KH			KINETIC AND THERMODYNAMIC PARAMETERS FOR TRANSFER-RNA BINDING TO THE RIBOSOME AND FOR THE TRANSLOCATION REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; ALLOSTERIC 3-SITE MODEL; ELONGATION CYCLE; MESSENGER-RNA; E SITE; POLYAMINES	Kinetic analyses of tRNA binding to the ribosome and of the translocation reaction showed the following results. 1) The activation energy for the P site binding of AcPhe-tRNA to poly(U)-programmed ribosomes is relatively high (E(a) = 72 kJ mol-1; 15 mM Mg2+). If only the P site is occupied with deacylated tRNA(Phe), then the E site can be filled more easily with tRNA(Phe) (no activation energy measurable) than the A site with AcPhe-tRNA (E(a) = 47 kJ mol-1; 15 mM Mg2+). 2) A ribosome with blocked P and E sites represents a standard state of the elongation cycle, in contrast to a ribosome with only a filled P site. The two states differ in that AcPhe-tRNA binding to the A site of a ribosome with prefilled P and E sites requires much higher activation energy (87 versus 47 kJ mol-1). The latter reaction simulates the allosteric transition from the post- to the pretranslocational state, whereby the tRNA(Phe) is released from the E site upon occupation of the A site (Rheinberger, H.-J., and Nierhaus, K. H. (1986) J. Biol. Chem. 261, 9133-9139). The reversed transition from the pre- to the posttranslocational state (translocation reaction) requires about the same activation energy (90 kJ mol-1). 3) Both elongation factors EF-Tu and EF-G drastically reduce the respective activation energies. 4) The rate of the A site occupation is slower than the rate of translocation in the presence of the respective elongation factors. The data suggest that the A site occupation rather than, as generally assumed, the translocation reaction is the rate-limiting step of the elongation cycle.	MAX PLANCK INST MOLEC GENET, WITTMANN ABT, IHNESTR 73, W-1000 BERLIN 33, GERMANY	Max Planck Society								ABDURASHIDOVA GG, 1986, EUR J BIOCHEM, V159, P103, DOI 10.1111/j.1432-1033.1986.tb09838.x; ADAM NK, 1977, PHYSICS CHEM SURFACE; ATKINS PW, 1988, PHYSIKALISCHE CHEM, P115; BARTETZKO A, 1988, METHOD ENZYMOL, V164, P650; BERGEMANN K, 1983, J BIOL CHEM, V258, P5105; BILGIN N, 1988, BIOCHIMIE, V70, P611, DOI 10.1016/0300-9084(88)90244-1; GAST FU, 1987, J BIOL CHEM, V262, P11920; GEIGENMULLER U, 1986, EUR J BIOCHEM, V161, P715, DOI 10.1111/j.1432-1033.1986.tb10498.x; GNIRKE A, 1989, BIOCHEM INT, V18, P551; GNIRKE A, 1989, J BIOL CHEM, V264, P7291; GRAIFER DM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P146, DOI 10.1016/0167-4781(80)90002-0; HAUSNER TP, 1988, J BIOL CHEM, V263, P13103; KAMEKURA M, 1987, FEMS MICROBIOL LETT, V43, P301; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOORE WJ, 1966, PHYSICAL CHEM, P273; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; RHEINBERGER HJ, 1987, J BIOMOL STRUCT DYN, V5, P435, DOI 10.1080/07391102.1987.10506403; RHEINBERGER HJ, 1988, METHOD ENZYMOL, V164, P658; RHEINBERGER HJ, 1986, J BIOL CHEM, V261, P9133; RHEINBERGER HJ, 1983, P NATL ACAD SCI-BIOL, V80, P4213, DOI 10.1073/pnas.80.14.4213; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; RHEINBERGER HJ, 1986, J BIOL CHEM, V261, P9140; ROBERTSON JM, 1986, J MOL BIOL, V189, P653, DOI 10.1016/0022-2836(86)90495-X; SCHILLINGBARTET.S, 1990, J BIOL CHEM, V267, P4693; SIEBER G, 1978, BIOCHEMISTRY-US, V17, P3505, DOI 10.1021/bi00610a013; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TRAUB P, 1969, J MOL BIOL, V40, P391, DOI 10.1016/0022-2836(69)90161-2	28	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4703	4712						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537853				2022-12-27	WOS:A1992HF64200065
J	SHERIFF, S; BALASUBRAMANIAM, A				SHERIFF, S; BALASUBRAMANIAM, A			INHIBITORY AND STIMULATORY EFFECTS OF NEUROPEPTIDE-Y(17-36) ON RAT CARDIAC ADENYLATE-CYCLASE ACTIVITY - STRUCTURE-FUNCTION STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Y NPY; VENTRICULAR MEMBRANES; RABBIT HEART; GUINEA-PIG; G-PROTEINS; ACTIVATION; HEPATOCYTES; PEPTIDES; GLUCAGON; NEURONS	Neuropeptide Y (NPY) inhibits cardiac adenylate cyclase activity by interacting with specific receptors coupled to a pertussis toxin-sensitive G protein. Structure-activity studies revealed that only C-terminal fragments can exhibit an NPY-like inhibitory effect on I-125-NPY binding and adenylate cyclase activity of rat cardiac ventricular membranes. Although NPY(17-36) inhibited I-125-NPY binding with high potency, it produced a biphasic effect on basal (GTP, 10 and 100-mu-M or guanosine 5'-gamma-O-(thio)triphosphate (GTP-gamma-S), 10-mu-M) adenylate cyclase activity. Low concentrations (< 1 nM) of NPY(17-36) inhibited the adenylate cyclase activity whereas high concentrations (> 1 nM) reversed this action. GTP-gamma-S (100-mu-M) reversed the biphasic effect of NPY(17-36). NPY(17-36) exhibited only a stimulatory effect in the membranes from pertussis toxin-treated rats and an inhibitory effect with membranes from cholera toxin-treated rats. Low concentrations (< 1 nM) of NPY(17-36) inhibited isoproterenol-stimulated adenylate cyclase activity whereas high doses (> 1 nM) reversed this activity. The cardiac NPY receptor antagonist, NPY(18-36) (1-mu-M), completely blocked the biphasic effect of NPY(17-36) on isoproterenol-stimulated activity. The inhibitory dose-response curve of NPY on isoproterenol-stimulated adenylate cyclase activity was shifted parallel to the right by NPY(17-36) (1-mu-M), suggesting that it is an antagonist of NPY at high concentrations. N-alpha-acetylated and C-terminally deamidated analogs of NPY(17-36) had no effect on the adenylate cyclase activity. [im-DNP-His26] NPY exhibited a more pronounced biphasic effect whereas N-alpha-myristoyl-NPY(17-36) elicited only a stimulatory effect. These investigations suggest that: 1) the inhibitory and stimulatory effects of NPY(17-36) are mediated by high affinity NPY receptors coupled to a pertussis toxin-sensitive G protein and a distinct population of low affinity receptors coupled to a cholera toxin-sensitive G protein, respectively; and 2) the stimulatory effect of NPY(17-36) is dissociable.	UNIV CINCINNATI, MED CTR, DEPT SURG, DIV GASTROINTESTINAL HORMONES, CINCINNATI, OH 45267 USA	University of Cincinnati					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038601] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38601] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JM, 1983, REGUL PEPTIDES, V6, P247, DOI 10.1016/0167-0115(83)90143-X; ALLEN JM, 1986, NEUROCHEM INT, V8, P1, DOI 10.1016/0197-0186(86)90093-8; BALASUBRAMANIAM A, 1990, PEPTIDES, V11, P1151, DOI 10.1016/0196-9781(90)90145-U; BALASUBRAMANIAM A, 1990, J BIOL CHEM, V265, P14724; BALASUBRAMANIAM A, 1987, INT J PEPT PROT RES, V29, P78; BALASUBRAMANIAM A, 1990, PEPTIDES, V11, P545, DOI 10.1016/0196-9781(90)90057-C; BALASUBRAMANIAM A, 1988, REGUL PEPTIDES, V21, P289, DOI 10.1016/0167-0115(88)90012-2; BALASUBRAMANIAM A, 1990, ANN NY ACAD SCI, V611, P355; CHRISTOPHE J, 1984, PEPTIDES, V5, P341, DOI 10.1016/0196-9781(84)90232-8; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GRADY T, 1987, J BIOL CHEM, V262, P15514; HASSALL CJS, 1984, NEUROSCI LETT, V52, P111, DOI 10.1016/0304-3940(84)90359-8; KANTOR H S, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1317, DOI 10.1073/pnas.71.4.1317; KASSIS S, 1987, J BIOL CHEM, V262, P3429; LOTERSZTAJN S, 1990, J BIOL CHEM, V265, P9876; LUNDBERG JM, 1983, NEUROSCI LETT, V42, P167, DOI 10.1016/0304-3940(83)90401-9; LUNDBERG JM, 1984, ACTA PHYSIOL SCAND, V121, P325, DOI 10.1111/j.1748-1716.1984.tb07463.x; MAGNALDO I, 1988, BIOCHEM J, V253, P711, DOI 10.1042/bj2530711; MAISEL AS, 1989, AM J MED, V86, P43, DOI 10.1016/0002-9343(89)90228-3; MAREK KL, 1990, ANN NY ACAD SCI, V611, P463; MCLEAN LR, 1990, BIOCHIM BIOPHYS ACTA, V1024, P1, DOI 10.1016/0005-2736(90)90201-X; MILLAR BC, 1988, N-S ARCH PHARMACOL, V338, P426; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; RIGEL DF, 1989, AM J PHYSIOL, V257, pH1082, DOI 10.1152/ajpheart.1989.257.4.H1082; RIOUX F, 1986, PEPTIDES, V7, P27, DOI 10.1016/0196-9781(86)90056-2; WAHLESTEDT C, 1990, ANN NY ACAD SCI, V611, P7; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P317; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0; WESTFALL TC, 1990, ANN NY ACAD SCI, V611, P145; WHARTON J, 1990, ANN NY ACAD SCI, V611, P133	30	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4680	4685						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537851				2022-12-27	WOS:A1992HF64200062
J	TAN, JA; MARSCHKE, KB; HO, KC; PERRY, ST; WILSON, EM; FRENCH, FS				TAN, JA; MARSCHKE, KB; HO, KC; PERRY, ST; WILSON, EM; FRENCH, FS			RESPONSE ELEMENTS OF THE ANDROGEN-REGULATED C3 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; PROSTATIC BINDING-PROTEIN; RAT VENTRAL PROSTATE; LONG TERMINAL REPEAT; TYROSINE AMINOTRANSFERASE GENE; MESSENGER RIBONUCLEIC-ACID; GROWTH-HORMONE GENE; GLUCOCORTICOID RECEPTOR; DNA-BINDING; STEROID-HORMONES	Intron and 5'-flanking regions of the androgen-regulated C3 subunit gene contain potential cis-acting transcription control sequences including several 15-base pair (bp) partial palindromes resembling response elements for glucocorticoid (GRE) and progesterone (PRE) receptors. Specific DNA binding of the androgen receptor (AR) and androgen-dependent activation of transcription indicate that some of these GRE/PRE-like sequences are capable of functioning as androgen response elements (ARE). A 0.3-kilobase pair (kbp) 5'-flanking fragment including the promoter region contains one such sequence (element A) and a 0.5-kbp region of the first intron contains two sequences (elements B and C). Androgen-dependent enhancement of transcription was assayed by cotransfection of CV1 cells with a rat AR expression vector, pCMVrAR, and C3 genomic fragments or synthetic elements cloned into the reporter vector ptkCAT. Enhancement of chloramphenicol acetyltransferase activity with the 0.5-kbp first intron fragment was 16 +/- 4-fold, while with the 0.3-kbp 5'-flanking fragment no response was detected and element C alone was greater than B or A. Binding of AR in the mobility shift assay correlated with androgen-dependent enhancement of chloramphenicol acetyltransferase activity. The intensity of transcriptional enhancement with the 0.5-kbp intron fragment suggested that other regulatory sequences within this intron region potentiated the ARE activities of elements B and C. ARE activity of the strongest C3 gene response element (C) was similar to that of a potent GRE (element M) of the mouse mammary tumor virus gene.	UNIV N CAROLINA, REPROD BIOL LABS, CB 7500, MACNIDER BLDG, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT BIOCHEM BIOPHYS, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NICHD NIH HHS [HD04466, P30-HD18968] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD004466, P30HD018968, R01HD004466] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLISON J, 1989, MOL CELL BIOL, V9, P2254, DOI 10.1128/MCB.9.5.2254; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEATO M, 1987, J STEROID BIOCHEM, V27, P9, DOI 10.1016/0022-4731(87)90288-3; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOSSYNS D, 1986, J STEROID BIOCHEM, V24, P661, DOI 10.1016/0022-4731(86)90840-X; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BUSK H, 1987, NATURE, V327, P638, DOI 10.1038/327638a0; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; Coffey D S, 1987, Prog Clin Biol Res, V239, P1; COLLINS S, 1988, FEBS LETT, V233, P173, DOI 10.1016/0014-5793(88)81378-4; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; DARBRE P, 1986, MOL CELL BIOL, V6, P2847, DOI 10.1128/MCB.6.8.2847; DAVIES P, 1988, BIOCHEM SOC T, V16, P695, DOI 10.1042/bst0160695; DENISON SH, 1989, ENDOCRINOLOGY, V124, P1091, DOI 10.1210/endo-124-2-1091; DEVOS P, 1991, J BIOL CHEM, V266, P3439; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOVINDAN MV, 1990, MOL ENDOCRINOL, V4, P417, DOI 10.1210/mend-4-3-417; GRANGE T, 1989, NUCLEIC ACIDS RES, V17, P8695, DOI 10.1093/nar/17.21.8695; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HARRIS SE, 1988, CELLULAR FACTORS DEV, P53; HO KC, 1991, ENDOCRINOLOGY S, V128, P317; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HURST HC, 1983, EMBO J, V2, P769, DOI 10.1002/j.1460-2075.1983.tb01498.x; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LORENI F, 1988, MOL CELL BIOL, V8, P2350, DOI 10.1128/MCB.8.6.2350; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; LUND SD, 1991, MOL CELL BIOL, V11, P5426, DOI 10.1128/MCB.11.11.5426; MATUSIK RJS, 1990, MOL CELLULAR BIOL PR, P299; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOORE DD, 1985, P NATL ACAD SCI USA, V82, P699, DOI 10.1073/pnas.82.3.699; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PAGE MJ, 1982, MOL CELL ENDOCRINOL, V27, P343, DOI 10.1016/0303-7207(82)90099-5; PARKER M, 1985, REGULATION ANDROGEN, P175; PARKER MG, 1983, J BIOL CHEM, V258, P12; PARKER MG, 1980, J BIOL CHEM, V255, P6996; PARKER MG, 1988, J STEROID BIOCHEM, V30, P47, DOI 10.1016/0022-4731(88)90075-1; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PEETERS B, 1983, EUR J BIOCHEM, V132, P669; PEETERS B, 1982, EUR J BIOCHEM, V123, P55, DOI 10.1111/j.1432-1033.1982.tb06497.x; PEETERS BL, 1980, J BIOL CHEM, V255, P7017; PERRY ST, 1984, REGULATION ANDROGEN, P167; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P1399, DOI 10.1210/mend-4-9-1399; QUARMBY VE, 1987, MOL ENDOCRINOL, V1, P865, DOI 10.1210/mend-1-12-865; RINGOLD GM, 1977, P NATL ACAD SCI USA, V74, P2879, DOI 10.1073/pnas.74.7.2879; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; RUSHMERE NK, 1987, MOL CELL ENDOCRINOL, V51, P259, DOI 10.1016/0303-7207(87)90036-0; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SLATER EP, 1985, MOL CELL BIOL, V5, P2984, DOI 10.1128/MCB.5.11.2984; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; Thompson T C, 1987, Prog Clin Biol Res, V239, P239; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VANDIJCK P, 1989, MOL CELL ENDOCRINOL, V64, P195, DOI 10.1016/0303-7207(89)90146-9; VISKOCHIL DH, 1983, J BIOL CHEM, V258, P8861; VONDERAHE D, 1985, NATURE, V313, P706, DOI 10.1038/313706a0; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WHITE R, 1983, J BIOL CHEM, V258, P8943; Wilson E M, 1987, Prog Clin Biol Res, V239, P205; Wilson E M, 1981, Prog Clin Biol Res, V75A, P351; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YARBROUGH WG, 1990, J BIOL CHEM, V265, P8893; YOUNG CYF, 1990, MOL ENDOCRINOL, V4, P1841, DOI 10.1210/mend-4-12-1841; ZHANG YL, 1990, MOL ENDOCRINOL, V4, P1219, DOI 10.1210/mend-4-8-1219; ZHANG YL, 1985, MOL CELL ENDOCRINOL, V43, P151, DOI 10.1016/0303-7207(85)90078-4; ZHANG YL, 1988, J ENDOCRINOL, V117, P361, DOI 10.1677/joe.0.1170361	88	114	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4456	4466						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537831				2022-12-27	WOS:A1992HF64200030
J	LI, HH; MERCHANT, S				LI, HH; MERCHANT, S			2 METAL-DEPENDENT STEPS IN THE BIOSYNTHESIS OF SCENEDESMUS-OBLIQUUS PLASTOCYANIN - DIFFERENTIAL MESSENGER-RNA ACCUMULATION AND HOLOPROTEIN FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASTIDIC CYTOCHROME-C; RECIPROCAL FORMATION; COMPLEMENTARY-DNA; CRYSTAL-STRUCTURE; GREEN-ALGA; COPPER; APOPLASTOCYANIN; CHLAMYDOMONAS; PROTEINS; CHLOROPLASTS	The accumulation of the interchangeable electron transfer catalysts plastocyanin and cytochrome c6 (cyt c6) in Scenedesmus obliquus is reciprocally regulated by the amount of copper ions in the medium. In copper-deficient cells, plastocyanin levels are severely reduced, whereas cyt c6 levels are high. Western blot analysis indicates that neither pre-apoplastocyanin nor apoplastocyanin accumulate to significant extents in copper-deficient Scenedesmus cells, and time course studies indicate that upon provision of copper salts to copper-deficient cells, the accumulation of plastocyanin to the levels maintained in copper-sufficient cells takes about 12-24 h. By 1) Northern hybridization analysis of Scenedesmus obliquus mRNA and 2) in vitro translation of polyadenylylated mRNA followed by immunoprecipitation of a 19.2-kilodalton precursor to plastocyanin, we demonstrate that the regulation of plastocyanin synthesis by copper must occur primarily at the level of mRNA accumulation. These results suggest that copper-dependent stimulation of holoplastocyanin accumulation requires de novo synthesis of the pre-apoprotein and contradict the conclusion of Bohner, H., Bohme, H., and Boger, P. (1981) FEBS Lett. 131, 386-388 that high levels of apoplastocyanin and a precursor to plastocyanin accumulate in copper-deficient Scenedesmus cells. We note also that although metal ions other than copper (e.g. silver) insert into Scenedesmus obliquus plastocyanin in vitro, synthesis of holoplastocyanin in vivo is specific for copper versus silver or mercury as it is in Chlamydomonas reinhardtii. Finally, the very different electrophoretic mobility and immunoreactivity of apoplastocyanin compared with holoplastocyanin suggests rather significant differences in structure between the copper-protein and the metal-free protein.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,405 HILGARD AVE,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles								BISHOP N, 1971, METHOD ENZYMOL, V53, P53; BOHNER H, 1981, BIOCHIM BIOPHYS ACTA, V636, P65, DOI 10.1016/0005-2728(81)90076-1; BOHNER H, 1978, FEBS LETT, V85, P337, DOI 10.1016/0014-5793(78)80486-4; BOHNER H, 1980, BIOCHIM BIOPHYS ACTA, V592, P103, DOI 10.1016/0005-2728(80)90117-6; BOHNER H, 1981, FEBS LETT, V131, P386, DOI 10.1016/0014-5793(81)80410-3; BOULTER D, 1977, INT REV BIOCHEM, V13, P3; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; BRUTSCH S, 1984, INORG CHIM A-BIOINOR, V92, P147, DOI 10.1016/S0020-1693(00)80012-2; CHAZIN WJ, 1988, J MOL BIOL, V202, P623, DOI 10.1016/0022-2836(88)90291-4; COLLYER CA, 1990, J MOL BIOL, V211, P617, DOI 10.1016/0022-2836(90)90269-R; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DAVIS DJ, 1980, PLANT PHYSIOL, V65, P697, DOI 10.1104/pp.65.4.697; GARRETT TPJ, 1984, J BIOL CHEM, V259, P2822; GUSS JM, 1983, J MOL BIOL, V169, P521; HARRIS EH, 1989, CHLAMDYDOMONAS SOUCE; HIBINO T, 1991, BIOCHIM BIOPHYS ACTA, V1058, P107, DOI 10.1016/S0005-2728(05)80226-9; HILL KL, 1991, J BIOL CHEM, V266, P15060; HO KK, 1984, BIOCHIM BIOPHYS ACTA, V766, P310, DOI 10.1016/0005-2728(84)90246-9; HOWE G, 1992, PLANT PHYSIOL, V98, P127, DOI 10.1104/pp.98.1.127; KATOH S, 1964, J BIOCHEM-TOKYO, V55, P378, DOI 10.1093/oxfordjournals.jbchem.a127898; LAUDENBACH DE, 1990, PLANT CELL, V2, P913, DOI 10.1105/tpc.2.9.913; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; Maniatis T., 1982, MOL CLONING; MATHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1, DOI 10.1016/0079-6107(85)90004-5; MCMILLIN DR, 1974, P NATL ACAD SCI USA, V71, P4760, DOI 10.1073/pnas.71.12.4760; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MERCHANT S, 1990, J BIOL CHEM, V265, P12372; MERCHANT S, 1987, J BIOL CHEM, V262, P9062; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; MOORE JM, 1988, SCIENCE, V240, P314, DOI 10.1126/science.3353725; SANDMANN G, 1980, PLANTA, V147, P330, DOI 10.1007/BF00379841; SANDMANN G, 1983, ARCH MICROBIOL, V134, P23, DOI 10.1007/BF00429401; SATO M, 1991, J BIOL CHEM, V266, P5128; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; SCHMIDT RJ, 1984, J CELL BIOL, V98, P2011, DOI 10.1083/jcb.98.6.2011; SYKES AG, 1985, CHEM SOC REV, V14, P283, DOI 10.1039/cs9851400283; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; VANDERPLAS J, 1989, MOL MICROBIOL, V3, P275; WEEKS DP, 1986, ANAL BIOCHEM, V152, P376, DOI 10.1016/0003-2697(86)90423-9; WILDNER GF, 1974, ARCH BIOCHEM BIOPHYS, V164, P136, DOI 10.1016/0003-9861(74)90015-0; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x	42	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9368	9375						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577764				2022-12-27	WOS:A1992HR85400101
J	ORLOWSKI, J; KANDASAMY, RA; SHULL, GE				ORLOWSKI, J; KANDASAMY, RA; SHULL, GE			MOLECULAR-CLONING OF PUTATIVE MEMBERS OF THE NA/H EXCHANGER GENE FAMILY - CDNA CLONING, DEDUCED AMINO-ACID-SEQUENCE, AND MESSENGER-RNA TISSUE EXPRESSION OF THE RAT NA/H EXCHANGER NHE-1 AND 2 STRUCTURALLY RELATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; NA+-H+ EXCHANGER; INTRACELLULAR PH REGULATION; SODIUM-HYDROGEN; GROWTH-FACTORS; CA-2+ PUMP; ANTIPORTER; BRAIN; IDENTIFICATION; ACTIVATION	Biochemical and pharmacological data support the existence of multiple forms of the Na/H exchanger (NHE). Two isoforms, termed NHE-1 and NHE-2, have recently been isolated from rabbit ileal villus epithelial cells (Tse, C. M., Ma, A. I., Yang, V. W., Watson, A. J. M., Levine, S., Montrose, M. H., Potter, J., Sardet, C., Pouyssegur, J., and Donowitz, M. (1 99 1) EMBO J. 10, 1957-1967; Tse, C. M., Watson, A. J. M., Ma, A. I., Pouyssegur, J., and Donowitz, M. (1991) Gastroenterology 100, A258). To identify additional molecular forms of the exchanger, rat brain, heart, kidney, stomach, and spleen cDNA libraries were screened for their presence using an NHE-1 cDNA probe under low stringency hybridization conditions. cDNAs encoding rat NHE-1 and two structurally related proteins, designated NHE-3 and NHE-4, have been isolated. Based on the deduced amino acid sequences, NHE-1, -3, and -4 are similar in size, having relative molecular masses of 91,506, 92,997, and 81,427, respectively. Overall, the proteins exhibit approximately 40% amino acid identity to each other and have similar hydropathy profiles, suggesting that they have the same transmembrane organization. The predicted N-terminal transmembrane regions of the three proteins, which span between 453 and 503 amino acids, exhibit the highest degree of identity (45-49%). In contrast, the C-terminal cytoplasmic regions, which span between 247 and 378 amino acids, exhibit very low amino acid identity (24-31%). Tissue distribution studies reveal that the NHE-1 mRNA is present at varying levels in all tissues examined, whereas NHE-3 and NHE-4 mRNAs exhibit a more limited distribution. NHE-3 mRNA is expressed at high levels in colon and small intestine, with significant levels also present in kidney and stomach. NHE-4 mRNA is most abundant in stomach, followed by intermediate levels in small intestine and colon and lesser amounts in kidney, brain, uterus, and skeletal muscle. These data suggest that the molecular basis for, the functional diversity of the Na/H exchanger in mammals is based, at least in part, on expression of multiple members of a gene family.	UNIV CINCINNATI,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati	ORLOWSKI, J (corresponding author), MCGILL UNIV,DEPT PHYSIOL,MCINTYRE MED SCI BLDG,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA.				NHLBI NIH HHS [HL41496] Funding Source: Medline; NIDDK NIH HHS [DK39626] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039626] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BOGART RB, 1989, P NATL ACAD SCI USA, V86, P8170; BORON WF, 1986, ANNU REV PHYSIOL, V48, P377; BURK SE, 1989, J BIOL CHEM, V264, P18561; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FRIEDRICH T, 1986, J MEMBRANE BIOL, V94, P253, DOI 10.1007/BF01869721; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREEB J, 1989, J BIOL CHEM, V264, P18569; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1985, P NATL ACAD SCI USA, V82, P1429, DOI 10.1073/pnas.82.5.1429; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRINSTEIN S, 1985, J CELL BIOL, V101, P269, DOI 10.1083/jcb.101.1.269; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HAGGERTY JG, 1988, P NATL ACAD SCI USA, V85, P6797, DOI 10.1073/pnas.85.18.6797; HUOT SJ, 1989, J BIOL CHEM, V264, P683; IKEDA U, 1988, J MOL CELL CARDIOL, V20, P493, DOI 10.1016/S0022-2828(88)80076-2; KNICKELBEIN RG, 1988, J CLIN INVEST, V82, P2158, DOI 10.1172/JCI113838; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAPF R, 1991, J CLIN INVEST, V88, P783, DOI 10.1172/JCI115377; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KULANTHAIVEL P, 1990, J BIOL CHEM, V265, P1249; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; PERIYASAMY SM, 1990, J BIOL CHEM, V265, P6035; PREISIG PA, 1987, J CLIN INVEST, V80, P970, DOI 10.1172/JCI113190; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAJENDRAN VM, 1990, J BIOL CHEM, V265, P8408; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; RAMASWAMY K, 1989, BIOCHIM BIOPHYS ACTA, V981, P193, DOI 10.1016/0005-2736(89)90028-X; ROSS W, 1990, J BIOL CHEM, V265, P5341; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TSE C M, 1991, Gastroenterology, V100, pA258; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; WATSON AJM, 1991, AM J PHYSIOL, V261, pG229, DOI 10.1152/ajpgi.1991.261.2.G229; WEINMAN EJ, 1987, AM J PHYSIOL, V252, pF19, DOI 10.1152/ajprenal.1987.252.1.F19; WEINMAN EJ, 1986, J MEMBRANE BIOL, V93, P133, DOI 10.1007/BF01870805; WERNKE G R, 1989, Biophysical Journal, V55, p390A; WU JSR, 1989, BIOCHEMISTRY-US, V28, P2980, DOI 10.1021/bi00433a036; YUSUFI ANK, 1988, J BIOL CHEM, V263, P13683	54	632	643	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9331	9339						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577762				2022-12-27	WOS:A1992HR85400096
J	CHEVALLIER, S; GOELTZ, P; THIBAULT, P; BANVILLE, D; GAGNON, J				CHEVALLIER, S; GOELTZ, P; THIBAULT, P; BANVILLE, D; GAGNON, J			CHARACTERIZATION OF A PROLYL ENDOPEPTIDASE FROM FLAVOBACTERIUM-MENINGOSEPTICUM - COMPLETE SEQUENCE AND LOCALIZATION OF THE ACTIVE-SITE SERINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-SPECIFIC ENDOPEPTIDASE; PURIFICATION; PROTEINS; PEPTIDE	A prolyl endopeptidase was purified from Flavobacterium meningosepticum. It was digested with trypsin. Two oligonucleotides, based on tryptic peptide sequences and used in PCR experiments, amplified a 300-base pair (bp) fragment. A 2.4-kilobase EcoRI fragment that hybridized to the 300-bp probe was cloned in lambda-ZAP and sequenced from both strands. It contains a reading frame of 2115 bp, encoding the complete protein sequence of 705 amino acids. Ion-spray mass spectrometry experiments demonstrated the presence of an NH2-terminal signal peptide: the periplasmic mature protease is 685 residues in length for a molecular mass of 76784 Da. The prolyl endopeptidase showed no general sequence homology with known protein sequences except with that of porcine brain prolyl endopeptidase. In order to identify the active-site serine, the prolyl endopeptidase was labeled with [H-3]diisopropyl fluorophosphate. One labeled peptide was purified and sequenced. The active-site serine was located in position 536 within the sequence GRSNGG. This sequence is different from the active-site sequence of the trypsin (GDSGGP) and subtilisin (GTSMAS) families.	CEN, CEA, 85X, F-38041 GRENOBLE, FRANCE; CEN, DSV DBMS, CNRS, URA 1333, F-38041 GRENOBLE, FRANCE; NATL RES COUNCIL CANADA, ATLANTIC REG LAB, INST MARINE BIOSCI, HALIFAX B3H 3Z1, NS, CANADA; NATL RES COUNCIL CANADA, INST BIOTECHNOL RES, MONTREAL H4P 2R2, QUEBEC, CANADA	CEA; Centre National de la Recherche Scientifique (CNRS); International Business Machines (IBM); National Research Council Canada; National Research Council Canada			Gagnon, Jean/C-3136-2008	Gagnon, Jean/0000-0002-0177-824X; Thibault, Pierre/0000-0001-5993-0331				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BRANDTS JF, 1986, METHOD ENZYMOL, V131, P117; Cohen J.A., 1967, METHODS ENZYMOLOGY, P686; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DOOLITTLE RF, 1986, URFS ORFS, P55; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GASCUEL O, 1986, J MOL EVOL, V24, P130, DOI 10.1007/BF02099961; Gros E., 1967, METHOD ENZYMOL, V11, P238; JOHNSON DMA, 1980, BIOCHEM J, V187, P863, DOI 10.1042/bj1870863; KALWANT S, 1991, BIOCHEM J, V276, P237, DOI 10.1042/bj2760237; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN LN, 1983, BIOCHEMISTRY-US, V22, P4480, DOI 10.1021/bi00288a020; MANIATIS T, 1982, MOL CLONING LABORATO, P92; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MORIYAMA A, 1988, J BIOCHEM, V104, P112, DOI 10.1093/oxfordjournals.jbchem.a122404; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PLEASANCE S, 1991, RAPID COMMUN MASS SP, V5, P307, DOI 10.1002/rcm.1290050612; RAMACHANDRAN GN, 1976, J MOL BIOL, V107, P85, DOI 10.1016/S0022-2836(76)80019-8; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SARGES R, 1965, J AM CHEM SOC, V87, P2011, DOI 10.1021/ja01087a027; SATTAR AKMA, 1990, J BIOCHEM, V107, P256, DOI 10.1093/oxfordjournals.jbchem.a123035; STONE SR, 1991, BIOCHEM J, V276, P837, DOI 10.1042/bj2760837; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WALTER R, 1976, BIOCHIM BIOPHYS ACTA, V422, P138, DOI 10.1016/0005-2744(76)90015-2; WALTER R, 1971, SCIENCE, V173, P828, DOI 10.1126/science.173.3999.827; WU HC, 1986, PROTEIN COMPARTMENTA, P33; YOSHIMOTO T, 1978, AGR BIOL CHEM TOKYO, V42, P2417, DOI 10.1080/00021369.1978.10863376; YOSHIMOTO T, 1980, J BIOL CHEM, V255, P4786; YOSHIMOTO T, 1988, J BIOCHEM, V104, P622, DOI 10.1093/oxfordjournals.jbchem.a122522	33	54	57	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8192	8199						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569074				2022-12-27	WOS:A1992HQ18500037
J	HEINECKE, JW; SHAPIRO, BM				HEINECKE, JW; SHAPIRO, BM			THE RESPIRATORY BURST OXIDASE OF FERTILIZATION - A PHYSIOLOGICAL TARGET FOR REGULATION BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SEA-URCHIN EGGS; TREATED MOUSE EGGS; INTRACELLULAR PH; INOSITOL 1,4,5-TRISPHOSPHATE; OVOPEROXIDASE ACTIVITY; BINDING-PROTEIN; CROSS-LINKING; ACTIVATION; CALCIUM; IONOPHORE		UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								BABIOR BM, 1987, TRENDS BIOCHEM SCI, V12, P241, DOI 10.1016/0968-0004(87)90118-6; BAGGIOLINI M, 1990, TRENDS BIOCHEM SCI, V15, P69, DOI 10.1016/0968-0004(90)90179-F; BATTAGLIA DE, 1988, J CELL BIOL, V107, P2447, DOI 10.1083/jcb.107.6.2447; CHENG HC, 1986, J BIOL CHEM, V261, P989; DERBES M, 1847, ANN SCI NAT ZOOL, V8, P80; DIETS T, 1984, J BIOL CHEM, V259, P13525; DIETS T, 1985, J BIOL CHEM, V260, P7882; DIETS T, 1986, J BIOL CHEM, V261, P12159; EPEL D, 1981, CELL, V23, P543, DOI 10.1016/0092-8674(81)90150-1; EPEL D, 1964, BIOCHEM BIOPH RES CO, V17, P69, DOI 10.1016/0006-291X(64)90302-X; FOERDER CA, 1977, P NATL ACAD SCI USA, V74, P4214, DOI 10.1073/pnas.74.10.4214; FOERDER CA, 1978, P NATL ACAD SCI USA, V75, P3183, DOI 10.1073/pnas.75.7.3183; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GULYAS BJ, 1980, GAMETE RES, V3, P267, DOI 10.1002/mrd.1120030309; HALL HG, 1978, CELL, V15, P343, DOI 10.1016/0092-8674(78)90003-X; HEINECKE JW, 1989, P NATL ACAD SCI USA, V86, P1259, DOI 10.1073/pnas.86.4.1259; HEINECKE JW, 1990, J BIOL CHEM, V265, P9241; HEINECKE JW, 1990, DEV BIOL, V142, P216, DOI 10.1016/0012-1606(90)90165-F; HEINECKE JW, 1990, J BIOL CHEM, V265, P7717; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOLLER TP, 1988, J AM CHEM SOC, V110, P4837, DOI 10.1021/ja00222a057; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; JAFFE LA, 1976, NATURE, V261, P68, DOI 10.1038/261068a0; JOHNSON CH, 1981, J CELL BIOL, V89, P284, DOI 10.1083/jcb.89.2.284; JOHNSON JD, 1976, NATURE, V262, P661, DOI 10.1038/262661a0; KAY E, 1982, CELL, V29, P867, DOI 10.1016/0092-8674(82)90448-2; KLEBANOFF SJ, 1979, J EXP MED, V149, P938, DOI 10.1084/jem.149.4.938; LAU AF, 1986, EXP CELL RES, V166, P23, DOI 10.1016/0014-4827(86)90505-7; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; MOPPER K, 1990, SCIENCE, V250, P661, DOI 10.1126/science.250.4981.661; MORI T, 1980, J BIOL CHEM, V255, P8378; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PALUMBO A, 1982, TETRAHEDRON LETT, V23, P3207, DOI 10.1016/S0040-4039(00)88597-4; PETASNE RG, 1987, NATURE, V325, P516, DOI 10.1038/325516a0; ROTHSCHILD L, 1959, FERTILIZATION, P91; SCHACHTELE C, 1988, BIOCHEM BIOPH RES CO, V151, P542, DOI 10.1016/0006-291X(88)90628-6; SCHMELL ED, 1980, GAMETE RES, V3, P279, DOI 10.1002/mrd.1120030310; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SELMANREIMER S, 1991, J BIOL CHEM, V266, P182; SHAPIRO BM, 1991, SCIENCE, V252, P533, DOI 10.1126/science.1850548; SHAPIRO BM, 1981, ANNU REV BIOCHEM, V50, P815, DOI 10.1146/annurev.bi.50.070181.004123; SHEN SS, 1986, J CELL PHYSIOL, V127, P330, DOI 10.1002/jcp.1041270222; SHEN SS, 1979, NATURE, V282, P87, DOI 10.1038/282087a0; SHEN SS, 1978, NATURE, V272, P253, DOI 10.1038/272253a0; STEINHAR.RA, 1974, P NATL ACAD SCI USA, V71, P1915, DOI 10.1073/pnas.71.5.1915; SWANN K, 1985, NATURE, V314, P274, DOI 10.1038/314274a0; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TURNER E, 1987, BIOCHEMISTRY-US, V26, P4028, DOI 10.1021/bi00387a043; TURNER E, 1988, SCIENCE, V252, P393; TURNER PR, 1984, NATURE, V310, P414, DOI 10.1038/310414a0; TURNER PR, 1986, J CELL BIOL, V102, P70, DOI 10.1083/jcb.102.1.70; VACQUIER VD, 1975, DEV BIOL, V43, P62, DOI 10.1016/0012-1606(75)90131-1; VACQUIER VD, 1972, NATURE, V237, P34, DOI 10.1038/237034a0; VERNON M, 1977, CELL, V10, P321; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; Warburg O, 1908, H-S Z PHYSIOL CHEM, V57, P1, DOI 10.1515/bchm2.1908.57.1-2.1; WASSARMAN PM, 1987, ANNU REV CELL BIOL, V3, P109, DOI 10.1146/annurev.cellbio.3.1.109; WEIDMAN PJ, 1985, J CELL BIOL, V100, P938, DOI 10.1083/jcb.100.3.938; Weiss B, 1980, Ann N Y Acad Sci, V356, P319, DOI 10.1111/j.1749-6632.1980.tb29621.x; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; WINKLER MM, 1978, NATURE, V273, P536, DOI 10.1038/273536a0	62	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					7959	7962						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569052				2022-12-27	WOS:A1992HQ18500001
J	KAWAMURA, S; SAITOU, N; UEDA, S				KAWAMURA, S; SAITOU, N; UEDA, S			CONCERTED EVOLUTION OF THE PRIMATE IMMUNOGLOBULIN ALPHA-GENE THROUGH GENE CONVERSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL GLOBIN GENES; NUCLEOTIDE-SEQUENCES; DISTANCE; GORILLA; REGION; HUMANS; RATES; TREE	We determined four nucleotide sequences of the hominoid immunoglobulin-alpha (C-alpha) genes (chimpanzee C-alpha-2, gorilla C-alpha-2, and gibbon C-alpha-1 and C-alpha-2-genes), which made possible the examination of gene conversions in all hominoid C-alpha-genes. The following three methods were used to detect gene conversions: 1) phenetic tree construction; 2) detection of a DNA segment with extremely low variability between duplicated C-alpha genes; and 3) a site by site search of shared nucleotide changes between duplicated C-alpha genes. Results obtained from method 1 indicated a concerted evolution of the duplicated C-alpha genes in the human, chimpanzee, gorilla, and gibbon lineages, while results obtained from method 2 suggested gene conversions in the human, gorilla, and gibbon C-alpha genes. With method 3 we identified clusters of shared nucleotide changes between duplicated C-alpha genes in human, chimpanzee, gorilla, and gibbon lineages, and in their hypothetical ancestors. In the present study converted regions were identified over the entire C-alpha gene region excluding a few sites in the coding region which have escaped from gene conversion. This indicates that gene conversion is a general phenomenon in evolution, that can be clearly observed in non-functional regions.	UNIV TOKYO,FAC SCI,DEPT ANTHROPOL,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								Arnheim N., 1983, P38; BALTIMORE D, 1981, CELL, V24, P592, DOI 10.1016/0092-8674(81)90082-9; FITCH DHA, 1990, J BIOL CHEM, V265, P781; FITCH WM, 1977, AM NAT, V111, P223, DOI 10.1086/283157; FLANAGAN JG, 1984, CELL, V36, P681, DOI 10.1016/0092-8674(84)90348-9; HONJO T, 1989, IMMUNOGLOBULIN GENES; HOOD L, 1975, ANNU REV GENET, V9, P305, DOI 10.1146/annurev.ge.09.120175.001513; JUKES T H, 1969, P21; KAWAMURA S, 1989, NUCLEIC ACIDS RES, V17, P6732, DOI 10.1093/nar/17.16.6732; KAWAMURA S, 1991, MOL BIOL EVOL, V8, P743; KAWAMURA S, 1990, J MOL BIOL, V215, P201, DOI 10.1016/S0022-2836(05)80336-5; KIMURA M, 1972, J MOL EVOL, V2, P87, DOI 10.1007/BF01653945; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KOOP BF, 1989, J BIOL CHEM, V264, P68; KORNFELD SJ, 1981, REV INFECT DIS, V3, P521; NEI M, 1985, MOL BIOL EVOL, V2, P66; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SARICH VM, 1967, P NATL ACAD SCI USA, V58, P142, DOI 10.1073/pnas.58.1.142; SLIGHTOM JL, 1987, J BIOL CHEM, V262, P7472; SLIGHTOM JL, 1988, J BIOL CHEM, V263, P12427; Sokal RR, 1963, PRINCIPLES NUMERICAL; STEPHENS JC, 1985, MOL BIOL EVOL, V2, P539; TAJIMA F, 1984, MOL BIOL EVOL, V1, P269; UEDA S, 1985, P NATL ACAD SCI USA, V82, P3712, DOI 10.1073/pnas.82.11.3712; UEDA S, 1988, J MOL EVOL, V27, P77, DOI 10.1007/BF02099732; WU CI, 1985, P NATL ACAD SCI USA, V82, P1741, DOI 10.1073/pnas.82.6.1741; WYSOCKI LJ, 1989, ANNU REV BIOCHEM, V58, P509	28	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7359	7367						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559979				2022-12-27	WOS:A1992HN48500025
J	KWON, OS; PARK, J; CHURCHICH, JE				KWON, OS; PARK, J; CHURCHICH, JE			BRAIN 4-AMINOBUTYRATE AMINOTRANSFERASE - ISOLATION AND SEQUENCE OF A CDNA-ENCODING THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note								4-Aminobutyrate aminotransferase is a key enzyme of the 4-aminobutyric acid shunt. It is responsible for the conversion of the neurotransmitter 4-aminobutyrate to succinic semialdehyde. By using oligonucleotide probes based on partial amino acid sequence data for the pig brain enzyme, several overlapping cDNA clones of 2.0-2.2 kilobases in length have been isolated. The largest cDNA clone was selected for sequence analysis. The amino acid sequence predicted from the cDNA sequence shows that the precursor of 4-aminobutyrate aminotransferase consists of the mature enzyme of 473 amino acid residues and an amino-terminal segment of 27 amino acids attributed to the signal peptide. The cofactor pyridoxal-5-P is bound to lysine residue 330 of the deduced amino acid sequence of the mature enzyme.			KWON, OS (corresponding author), UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37916, USA.							ANDRE B, 1990, NUCLEIC ACIDS RES, V18, P3049, DOI 10.1093/nar/18.10.3049; BEELER T, 1978, EUR J BIOCHEM, V85, P365, DOI 10.1111/j.1432-1033.1978.tb12248.x; BLOCHTARDY M, 1971, J NEUROCHEM, V18, P1779, DOI 10.1111/j.1471-4159.1971.tb03755.x; BUZENET AM, 1978, BIOCHIM BIOPHYS ACTA, V522, P400, DOI 10.1016/0005-2744(78)90073-6; CHOI SY, 1986, EUR J BIOCHEM, V161, P289, DOI 10.1111/j.1432-1033.1986.tb10445.x; CHURCHICH JE, 1981, J BIOL CHEM, V256, P1101; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HOUSLEYMARKOVIC Z, 1990, J MOL BIOL, V214, P821; KIM DS, 1984, CHEM BIOL ASPECTS VI, P161; KIM YT, 1989, EUR J BIOCHEM, V181, P397, DOI 10.1111/j.1432-1033.1989.tb14738.x; LIPPERT B, 1977, EUR J BIOCHEM, V74, P441, DOI 10.1111/j.1432-1033.1977.tb11410.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463	13	40	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7215	7216						2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559966				2022-12-27	WOS:A1992HN48500006
J	ROZAKISADCOCK, M; KELLY, PA				ROZAKISADCOCK, M; KELLY, PA			IDENTIFICATION OF LIGAND-BINDING DETERMINANTS OF THE PROLACTIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MURINE INTERLEUKIN-2 RECEPTOR; EXPRESSION CLONING; MOLECULAR-CLONING; GROWTH-HORMONE; ALPHA-CHAIN; BETA-CHAIN; SECONDARY-STRUCTURE; IL-2 RECEPTOR; GENE FAMILY	The prolactin (PRL) receptor, a lactogen- and primate somatogen-binding protein, is a member of an expanding superfamily (cytokine/growth hormone (GH)/PRL) of single membrane-spanning receptors. Two features commonly shared among this group of proteins are the presence of two pairs of cysteines, generally found in the N-terminal region of the extracellular domain, and a WSxWS (WS) motif, frequently located proximal to the transmembrane domain. We have recently shown the 4 cysteines to be critical to the maintenance of the structural and functional integrity of the PRL-receptor. In the present study, we prepared a set of eight chimeric rat PRL/human GH receptors and several alanine mutants, to assess the importance of the Cys-rich domain (residues 12-68) in confering specificity to PRL binding. The role of the WS motif in high affinity binding was also investigated. Binding of I-125-labeled ovine PRL or human GH to membrane preparations from COS-7 cells transiently expressing the mutant receptors have defined a region within the first disulfide loop (residues Arg13, Asp16, Glu18) and the set of lactogen-specific sequences between the two pairs of cysteines as key determinants of PRL-binding specificity, which converge to form a patch on a two-dimensional model of the PRL receptor. We also demonstrate that, although PRL- and GH-specific determinants overlap in certain areas, they are not identical. Finally, substitution of the WS motif with alanine residues precludes high affinity binding to ovine PRL and human GH and suggests that this structural element may provide a target site for the interaction of an accessory protein necessary for the formation of a high-affinity receptor complex.	UNIV PARIS 05, INSERM, U344, 156 RUE DE VAUGIRARD, F-75730 PARIS 15, FRANCE; MCGILL UNIV, ROYAL VICTORIA HOSP, MOLEC ENDOCRINOL LAB, MONTREAL H3A 1A1, QUEBEC, CANADA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; McGill University; Royal Victoria Hospital			Kelly, Paul/A-7951-2008					AMSELEM S, 1989, NEW ENGL J MED, V321, P989, DOI 10.1056/NEJM198910123211501; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; EDIDIN M, 1988, J IMMUNOL, V141, P1206; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1991, CELL, V66, P9, DOI 10.1016/0092-8674(91)90131-H; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERRMANN T, 1987, IMMUNOBIOLOGY, V175, P145, DOI 10.1016/S0171-2985(87)80024-4; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NAKAMURA Y, 1989, P NATL ACAD SCI USA, V86, P1318, DOI 10.1073/pnas.86.4.1318; NISBET IT, 1985, GENE ANAL TECH, V2, P23, DOI 10.1016/0735-0651(85)90001-9; NOVOTNY J, 1984, NUCLEIC ACIDS RES, V12, P243, DOI 10.1093/nar/12.1Part1.243; POSTELVINAY MC, 1991, P NATL ACAD SCI USA, V88, P6687, DOI 10.1073/pnas.88.15.6687; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAGOVI H, 1987, J IMMUNOL, V139, P1918; SHARON M, 1990, P NATL ACAD SCI USA, V87, P4869, DOI 10.1073/pnas.87.12.4869; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SZOLLOSI J, 1987, P NATL ACAD SCI USA, V84, P7246, DOI 10.1073/pnas.84.20.7246; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZHANG R, 1990, BIOCHEM BIOPH RES CO, V168, P415, DOI 10.1016/0006-291X(90)92337-Y	43	63	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7428	7433						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559983				2022-12-27	WOS:A1992HN48500035
J	NIINO, YS; OHNO, S; SUZUKI, K				NIINO, YS; OHNO, S; SUZUKI, K			POSITIVE AND NEGATIVE REGULATION OF THE TRANSCRIPTION OF THE HUMAN PROTEIN-KINASE-C BETA-GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; IMMUNOCYTOCHEMICAL LOCALIZATION; RAT-BRAIN; EXPRESSION; DNA; HETEROGENEITY; SEQUENCE; ISOZYMES	To analyze the mechanism of the cell type-specific expression of protein kinase C-beta (PKC-beta), we isolated the 5'-portion of the human gene for PKC-beta and identified multiple positive and negative regulatory sequences that regulate its transcription. S1 nuclease mapping as well as primer extension analysis of the 5'-end of the PKC-beta mRNA identified a putative transcriptional initiation site (position +1) 484 base pairs (bp) upstream of the first ATG codon. The 5'-upstream sequence contains a CCAAT sequence at position -110, but no TATA box. The transcriptional activities of various 5'-deletion mutants of the PKC-beta gene upstream region, fused to the chloramphenicol acetyltransferase structural gene, were examined in terms of chloramphenicol acetyltransferase expression after transfection into three kinds of rodent cell lines: P19 and GH4C1, which are positive for the expression of PKC-beta mRNA; and 3Y1, which is negative. Mutants containing a 5'-flanking sequence longer than 1.9 kilobases (kb) showed chloramphenicol acetyltransferase activities of the same order as the expression of the endogenous gene. This indicates that this region contains sequences regulating the cell-type specificity of PKC-beta gene expression and that the specificity is determined at least partially at the level of transcription. The 1.9-kb sequence contains at least three positive elements: P1 (-56 to -234 bp), P2 (-234 to -411 bp), and PN (-1.4 to -1.9 kb). PN is active only in P19 cells, P1 in GH4C1 and P19 cells, and P2 in all three cell lines. In addition to these positive elements, there are negative elements: N1 (-411 to -674 bp), which is active in all three cell lines; and PN, which is active only in GH4C1 cells. These results suggest the presence of multiple trans-acting factors that act on these positive and negative cis-acting elements and regulate the cell type-specific expression of the PKC-beta gene.	TOKYO METROPOLITAN INST MED SCI, DEPT MOLEC BIOL, BUNKYO KU, TOKYO 113, JAPAN	Tokyo Metropolitan Institute of Medical Science			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269				CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; HATA A, 1989, J BIOL CHEM, V264, P6404; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; HOSODA K, 1989, P NATL ACAD SCI USA, V86, P1393, DOI 10.1073/pnas.86.4.1393; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KILEY S, 1990, J BIOL CHEM, V265, P15704; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KUBO K, 1987, NUCLEIC ACIDS RES, V15, P7179, DOI 10.1093/nar/15.17.7179; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; OSADA S, 1990, J BIOL CHEM, V265, P22434; SAITO N, 1989, P NATL ACAD SCI USA, V86, P3409, DOI 10.1073/pnas.86.9.3409; WADA H, 1989, BIOCHEM BIOPH RES CO, V165, P533, DOI 10.1016/0006-291X(89)91102-9; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; YAMANISHI DT, 1991, CARCINOGENESIS, V12, P105, DOI 10.1093/carcin/12.1.105; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868	28	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6158	6163						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556124				2022-12-27	WOS:A1992HK31800067
J	PARKER, KC; CARRENO, BM; SESTAK, L; UTZ, U; BIDDISON, WE; COLIGAN, JE				PARKER, KC; CARRENO, BM; SESTAK, L; UTZ, U; BIDDISON, WE; COLIGAN, JE			PEPTIDE BINDING TO HLA-A2 AND HLA-B27 ISOLATED FROM ESCHERICHIA-COLI - RECONSTITUTION OF HLA-A2 AND HLA-B27 HEAVY-CHAIN BETA-2-MICROGLOBULIN COMPLEXES REQUIRES SPECIFIC PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; TOXIC LYMPHOCYTES-T; HISTOCOMPATIBILITY ANTIGENS; MONOCLONAL-ANTIBODY; IMMUNOGENIC PEPTIDES; CELL RECOGNITION; MHC RESTRICTION; VIRAL PEPTIDES; PROTEINS; ASSOCIATION	The specificity of peptide binding by human leukocyte antigen (HLA) class I molecules was investigated in a cell-free direct-binding assay. Peptides were assessed for binding to HLA-A2 and HLA-B27 by measuring the formation of heterotrimeric HLA complexes that consisted of iodinated beta-2-microglobulin, HLA heavy chain fragments isolated from the Escherichia coli cytoplasm, and peptide. In this system, no detectable HLA heavy chain-beta-2-microglobulin complexes were formed unless appropriate peptides were intentionally added to the reconstitution solution. Analysis with monoclonal antibodies demonstrated that these heterotrimeric complexes were correctly folded. Five nonhomologous peptides, known to form complexes with HLA-A2 or HLA-B27 from T-cell functional studies, were tested for their capacity to bind to HLA-A2 and HLA-B27 using the reconstitution assay. Four of the peptides bound to the appropriate class I molecule only. One peptide and some (but not all) substitution analogs of it bound to both HLA-A2 and HLA-B27. The effect of peptide length on binding to HLA-B27 was studied, and it was found that the optimal length was 9 or 10 amino acid residues; however, one peptide that bound to HLA-B27 was 15 amino acids long. All peptides that bound to HLA-B27 in the direct-binding assay also competed with antigenic peptides for binding to HLA-B27 on the surface of intact cells, as determined by a standard cytotoxic T-lymphocyte functional assay. Thus, we conclude that HLA-A2 and HLA-B27 bind distinct but partially overlapping sets of peptides and that, at least in vitro, the assembly of HLA heavy chain-beta-2-microglobulin complexes requires specific peptides.	NINCDS,NEUROIMMUNOL BRANCH,MOLEC IMMUNOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	PARKER, KC (corresponding author), NIAID,BIOL RESOURCES BRANCH,BETHESDA,MD 20892, USA.		Sestak, Ivana/H-7305-2014	Sestak, Ivana/0000-0001-6999-2851; Parker, Kenneth/0000-0002-6282-2478				BEDNAREK MA, 1991, J IMMUNOL METHODS, V139, P41, DOI 10.1016/0022-1759(91)90349-K; BENJAMIN RJ, 1991, NATURE, V351, P74, DOI 10.1038/351074a0; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER HC, 1989, IMMUNOLOGY, V66, P163; BODMER HC, 1989, NATURE, V337, P653, DOI 10.1038/337653a0; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BRODSKY FM, 1982, J IMMUNOL, V128, P129; BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; CARRENO BM, 1990, P NATL ACAD SCI USA, V87, P3420, DOI 10.1073/pnas.87.9.3420; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHOPPIN J, 1990, J EXP MED, V172, P889, DOI 10.1084/jem.172.3.889; CHOPPIN J, 1991, J IMMUNOL, V147, P569; CHOPPIN J, 1991, J IMMUNOL, V147, P575; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; DUFFAUD GD, 1987, METHOD ENZYMOL, V153, P492; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; ENNIS PD, 1990, P NATL ACAD SCI USA, V87, P2833, DOI 10.1073/pnas.87.7.2833; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAL RB, 1991, J INFECT DIS, V163, P41, DOI 10.1093/infdis/163.1.41; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUESCHER IF, 1991, NATURE, V351, P72, DOI 10.1038/351072a0; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; ORR HT, 1979, BIOCHEMISTRY-US, V18, P5711, DOI 10.1021/bi00592a030; PALA P, 1988, J IMMUNOL, V141, P2289; PARHAM P, 1981, HUM IMMUNOL, V3, P277, DOI 10.1016/0198-8859(81)90065-3; PARHAM P, 1978, NATURE, V276, P397, DOI 10.1038/276397a0; PARKER KC, 1983, BIOCHEMISTRY-US, V22, P1145, DOI 10.1021/bi00274a024; PARKER KC, 1992, IN PRESS MOL IMMUNOL; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; REDDEHASE MJ, 1991, EUR J IMMUNOL, V21, P1697, DOI 10.1002/eji.1830210717; REYES VE, 1991, MOL IMMUNOL, V28, P341, DOI 10.1016/0161-5890(91)90146-B; ROBBINS PA, 1989, J IMMUNOL, V143, P4098; ROCK KL, 1990, P NATL ACAD SCI USA, V87, P7517, DOI 10.1073/pnas.87.19.7517; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P301, DOI 10.1073/pnas.88.1.301; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SHIMOJO N, 1989, J IMMUNOL, V143, P2939; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANBLEEK GM, 1990, NATURE, V348, P213; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002	62	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5451	5459						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544922				2022-12-27	WOS:A1992HH74700069
J	DAHL, NK; REED, KL; DAUNAIS, MA; FAUST, JR; LISCUM, L				DAHL, NK; REED, KL; DAUNAIS, MA; FAUST, JR; LISCUM, L			ISOLATION AND CHARACTERIZATION OF CHINESE-HAMSTER OVARY CELLS DEFECTIVE IN THE INTRACELLULAR METABOLISM OF LOW-DENSITY LIPOPROTEIN-DERIVED CHOLESTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIEMANN-PICK DISEASE; RECEPTOR-MEDIATED ENDOCYTOSIS; TRANSFER PROTEIN; AMPHOTERICIN-B; CULTURED FIBROBLASTS; C FIBROBLASTS; TRANSPORT; BIOSYNTHESIS; SUPPRESSION; SELECTION	We have isolated clones of an established cell line which express defects in intracellular cholesterol metabolism. Chinese hamster ovary cells were mutagenized, and clones unable to mobilize low density lipoprotein (LDL)-derived cholesterol to the plasma membrane were selected. Biochemical analysis of two mutant clones revealed a phenotype characteristic of the lysosomal storage disease, Niemann-Pick type C. The mutant cell lines were found to be defective in the regulatory responses elicited by LDL-derived cholesterol. LDL-mediated stimulation of cholesterol esterification was grossly defective, and LDL suppression of 3-hydroxy-3-methylglutaryl-CoA reductase was impaired. However, the mutants modulated these activities normally in response to 25-hydroxycholesterol or mevalonate. The LDL-specific defects were predicated by the inability of these mutants to mobilize LDL-derived cholesterol from lysosomes. Cell fractionation studies showed that LDL-derived, unesterified cholesterol accumulated in the lysosomes of mutant cells to significantly higher levels than normal, commensurate with defective movement of cholesterol to other cellular membranes. Characterization of cell lines defective in intracellular cholesterol transport will facilitate identification of the gene(s) required for intracellular cholesterol movement and regulation.	TUFTS UNIV,SCH MED,DEPT PHYSIOL,136 HARRISON AVE,BOSTON,MA 02111	Tufts University			Dahl, Neera/AAI-7380-2021; Dahl, Neera/AAV-4856-2021		NIDDK NIH HHS [DK 07542] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007542] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITKEN JF, 1990, J BIOL CHEM, V265, P4711; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; CHANG TY, 1982, BIOCHEMISTRY-US, V21, P5316, DOI 10.1021/bi00264a030; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; DEKRUIJFF B, 1990, BIOSCIENCE REP, V10, P127; FAUST J, 1987, J BIOL CHEM, V262, P1996; FAUST JR, 1977, J BIOL CHEM, V252, P4861; FINK JK, 1989, NEUROLOGY, V39, P1040, DOI 10.1212/WNL.39.8.1040; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HIDAKA K, 1978, CELL, V14, P415, DOI 10.1016/0092-8674(78)90126-5; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KINSKY SC, 1970, ANNU REV PHARMACOLOG, V10, P119, DOI 10.1146/annurev.pa.10.040170.001003; KRIEGER M, 1983, ANAL BIOCHEM, V135, P383, DOI 10.1016/0003-2697(83)90700-5; KRIEGER M, 1983, P NATL ACAD SCI-BIOL, V80, P5607, DOI 10.1073/pnas.80.18.5607; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NORMAN AW, 1972, J BIOL CHEM, V247, P1918; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; REYLAND ME, 1991, P NATL ACAD SCI USA, V88, P2375, DOI 10.1073/pnas.88.6.2375; RODRIGUEZLAFRASSE C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P123, DOI 10.1016/0005-2760(90)90284-5; SAITO Y, 1977, P NATL ACAD SCI USA, V74, P3730, DOI 10.1073/pnas.74.9.3730; SIMINOVITCH L, 1985, MOL CELL GENETICS, P869; SPENCE MW, 1989, METABOLIC BASIS INHE, P1655; TRZASKOS JM, 1983, BIOCHIM BIOPHYS ACTA, V751, P52, DOI 10.1016/0005-2760(83)90256-4; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463	33	87	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4889	4896						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537866				2022-12-27	WOS:A1992HF64200089
J	WEDRYCHOWSKI, A; HENZEL, W; HUSTON, L; PASLIDIS, N; ELLERSON, D; MCRAE, M; SEONG, D; HOWARD, OMZ; DEISSEROTH, A				WEDRYCHOWSKI, A; HENZEL, W; HUSTON, L; PASLIDIS, N; ELLERSON, D; MCRAE, M; SEONG, D; HOWARD, OMZ; DEISSEROTH, A			IDENTIFICATION OF PROTEINS BINDING TO INTERFERON-INDUCIBLE TRANSCRIPTIONAL ENHANCERS IN HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOGENOUS LEUKEMIA PATIENTS; NUCLEAR PROTEINS; REGULATORY ELEMENTS; SYNTHETASE GENE; ALPHA; KU; PROMOTER; ISGF3; EXPRESSION; ACTIVATOR	The binding of nuclear proteins of hematopoietic cells to transcriptional enhancers of interferon-inducible genes has been studied before and after exposure to alpha-interferon. Mobility shift assays show that a complex formed with interferon-inducible transcriptional enhancers before interferon induction contains a 73- and 84-kDa protein. Amino acid sequencing of the oligoaffinity column purified 73- and 84-kDa proteins showed that they belonged to a family of DNA-binding proteins which have been previously identified to exhibit binding in a sequence nonspecific manner to the ends of fragmented DNA or the origin of replication of adenovirus Type 2 DNA and sequence-specific binding to the distal regions of the U1 small nuclear RNA promoter, the promoter of the transferrin receptor gene, and the transcriptional regulatory regions of HLA genes. Following exposure to alpha-interferon, more slowly migrating complexes appeared which contained a 48-kDa protein, a 95-kDa protein, and a 105-kDa protein which bound to the 9-27 transcriptional enhancer in a sequence-specific manner.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT HEMATOL,BOX 24,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; GENENTECH INC,SAN FRANCISCO,CA 94080	University of Texas System; UTMD Anderson Cancer Center; Roche Holding; Genentech			Howard, O M Zack/B-6117-2012	Howard, O M Zack/0000-0002-0505-7052; Henzel, William/0000-0003-2940-3797	NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA49639-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEDERMAN P, 1990, Journal of Interferon Research, V10, pS33; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; HOWARD OMZ, 1990, BLOOD, V76, P1117; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MANIATIS T, 1990, J INTERFERON RES S1, V10, pS32; MAY G, 1991, J BIOL CHEM, V266, P3052; MCMAHON M, 1986, J VIROL, V57, P362, DOI 10.1128/JVI.57.1.362-366.1986; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; REEVES WH, 1989, J BIOL CHEM, V264, P5047; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SEONG D, 1991, BRIT J HAEMATOL, V78, P359, DOI 10.1111/j.1365-2141.1991.tb04449.x; SEONG DC, 1990, J CLIN INVEST, V86, P1664, DOI 10.1172/JCI114889; SHIRAYOSHI Y, 1988, P NATL ACAD SCI USA, V85, P5884, DOI 10.1073/pnas.85.16.5884; STRIFE A, 1990, CHRONIC MYELOGENOUS, P1; WEDRYCHOWSKI A, 1990, J BIOL CHEM, V265, P21433; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YANEVA M, 1989, J BIOL CHEM, V264, P13407	27	4	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4533	4540						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537839				2022-12-27	WOS:A1992HF64200041
J	KAN, CC; KOLESNICK, RN				KAN, CC; KOLESNICK, RN			A SYNTHETIC CERAMIDE ANALOG, D-THREO-1-PHENYL-2-DECANOYLAMINO-3-MORPHOLINO-1-PROPANOL, SELECTIVELY INHIBITS ADHERENCE DURING MACROPHAGE DIFFERENTIATION OF HUMAN LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCYTIC DIFFERENTIATION; LINE HL-60; MELANOMA-CELLS; PROTO-ONCOGENE; EXPRESSION; GLYCOLIPIDS; GANGLIOSIDES; FIBRONECTIN; RECOGNITION; CARCINOMA	Prior studies have demonstrated that sphingomyelin synthesis is involved in adherence during macrophage differentiation of HL-60 cells (Dressler, K. A., Kan, C.-C., and Kolesnick, R. N. (1991) J. Biol Chem 266, 11522-11527). The present studies show that glycosphingolipid synthesis is also involved. Initial studies demonstrated that the potent phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) stimulates a 6- and 12-fold increase in the levels of sialosyllactosylceramide (G(M3)) and glucosylceramide (GlcCer), respectively, during development of an adherent macrophage population. In contrast, the level of lactosylceramide (LacCer) decreased to 20% of unstimulated controls. These effects were specific to adherent macrophages as nonadherent cells had minimal alteration in the glycosphingolipid profile. D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), a competitive inhibitor of UDP-glucose:ceramide glucosyltransferase (EC 2.4.1.80), selectively blocked adherence during macrophage differentiation. PDMP markedly reduced basal levels of GlcCer, LacCer, and G(M3) and prevented TPA-stimulated effects. PDMP (0.03-10-mu-M) reduced adherence after TPA from 30 to 6% of the total population. PDMP did not block other aspects of phorbol ester-induced macrophage differentiation including growth inhibition, expression of mRNA transcripts for the proto-oncogenes c-fos and c-myc, development of the specific enzyme markers alpha-naphthyl acetate esterase and acid phosphatase, and the gross morphologic changes associated with macrophage differentiation. PDMP appeared to have no short term or prolonged toxic effect on HL-60 cells. These studies show that PDMP selectively blocked adherence of HL-60 cells during phorbol ester-induced macrophage differentiation and suggest that this compound may be useful in the description of the biologic roles of glycosphingolipids.	CORNELL UNIV,MED CTR,COLL MED,SLOAN KETTERING INST,PROGRAM MOLEC PHARMACOL & THERAPEUT,NEW YORK,NY 10021	Cornell University; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [R01-CA-42385] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042385] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACKBURN CC, 1986, J BIOL CHEM, V261, P2873; DRESSLER KA, 1991, J BIOL CHEM, V266, P11522; EGGENS I, 1989, J BIOL CHEM, V264, P9476; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HUANG RTC, 1978, NATURE, V276, P624, DOI 10.1038/276624a0; INOKUCHI J, 1990, CANCER RES, V50, P6731; INOKUCHI JI, 1989, J CELL PHYSIOL, V141, P573, DOI 10.1002/jcp.1041410316; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; MacNeal WJ, 1922, JAMA-J AM MED ASSOC, V78, P1122, DOI 10.1001/JAMA.1922.26410680001011; MILLER LJ, 1986, J IMMUNOL, V137, P2891; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MOMOI T, 1983, J NATL CANCER I, V70, P229; MUELLER J, 1975, EUR J IMMUNOL, V5, P270, DOI 10.1002/eji.1830050411; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; NOJIRI H, 1984, BLOOD, V64, P534; OKADA Y, 1988, FEBS LETT, V235, P25, DOI 10.1016/0014-5793(88)81227-4; PERKINS RM, 1982, EXP CELL RES, V141, P231, DOI 10.1016/0014-4827(82)90211-7; Radin N S, 1981, Methods Enzymol, V72, P673; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SAITO M, 1985, BIOCHEM BIOPH RES CO, V132, P223, DOI 10.1016/0006-291X(85)91011-3; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SCHNYDER J, 1978, J EXP MED, V148, P435, DOI 10.1084/jem.148.2.435; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; SINGER MS, 1990, J CELL BIOL, V111, P1225; VUNNAM RR, 1980, CHEM PHYS LIPIDS, V26, P265; YAM LT, 1971, AM J CLIN PATHOL, V21, P1; YAMADA KM, 1981, J CELL PHYSIOL, V109, P343, DOI 10.1002/jcp.1041090218	29	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9663	9667						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577803				2022-12-27	WOS:A1992HT96500034
J	NGUYEN, TD; WOLFE, MS; HEINTZ, GG; WHITCOMB, DC; TAYLOR, IL				NGUYEN, TD; WOLFE, MS; HEINTZ, GG; WHITCOMB, DC; TAYLOR, IL			HIGH-AFFINITY BINDING-PROTEINS FOR PANCREATIC-POLYPEPTIDE ON RAT-LIVER MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-YY; RECEPTORS; CELLS; HORMONE; CHICKEN	We report here the identification on rat liver plasma membranes and microsomes of proteins that bind pancreatic polypeptide (PP) with high affinity and specificity (plasma membranes: K(D) = 4.6 nm, B(max) = 3.28 pmol/mg protein; microsomes: K(D) = 3.45 nm, B(max) = 18.7 pmol/mg protein). These binding proteins appeared coupled to a G-protein, since 0.1 mm guanosine 5'-O-(3-thiotriphosphate) decreased the affinity by half. When I-125-labeled PP-binding protein complexes covalently cross-linked with disuccinimido suberate were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, two radioactive bands with M(r) values of 52,000 and 38,000 were demonstrated. Both bands were inhibited by unlabeled PP with an IC50 of approximately 5 nM (but not by neuropeptide Y or peptide YY). After the cross-linked complexes were solubilized from liver microsomes with 0.2% Triton X-100 and gel-filtered, they did not interact with the lectins wheat germ agglutinin, Ulex europaeus agglutinin, Ricinus communis agglutinin, and soy bean agglutinin. That these binding proteins may not be glycosylated was further supported by the failure of either peptide N-glycosidase F and endo-beta-N-acetylglucosaminidase F to alter the size of the PP-binding protein complexes on gel electrophoresis. These PP-binding proteins may serve as receptors and mediate a hepatic effect of PP.	DUKE UNIV,MED CTR,DIV GASTROENTEROL,DURHAM,NC 27710	Duke University	NGUYEN, TD (corresponding author), VET ADM MED CTR,EG-018,508 FULTON ST,DURHAM,NC 27705, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040506, R01DK044072] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40506, DK 44072] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMO ML, 1983, ENDOCRINOLOGY, V113, P508, DOI 10.1210/endo-113-2-508; ADRIAN TE, 1982, AM J PHYSIOL, V243, pG204, DOI 10.1152/ajpgi.1982.243.3.G204; AMARCOSTESEC A, 1974, J CELL BIOL, V61, P201, DOI 10.1083/jcb.61.1.201; BEGLINGER C, 1984, AM J PHYSIOL, V246, pG286, DOI 10.1152/ajpgi.1984.246.3.G286; BONNEVIENIELSEN V, 1982, P NATL ACAD SCI-BIOL, V79, P2167, DOI 10.1073/pnas.79.7.2167; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; GETTYS TW, 1991, PANCREAS, V6, P46, DOI 10.1097/00006676-199101000-00007; GILBERT WR, 1986, ENDOCRINOLOGY, V118, P2495, DOI 10.1210/endo-118-6-2495; GILBERT WR, 1988, P NATL ACAD SCI USA, V85, P4745, DOI 10.1073/pnas.85.13.4745; INUI A, 1990, ENDOCRINOLOGY, V127, P934, DOI 10.1210/endo-127-2-934; KIMMEL JR, 1968, ENDOCRINOLOGY, V83, P1323, DOI 10.1210/endo-83-6-1323; KIMMEL JR, 1981, ENDOCRINOLOGY, V109, P1693, DOI 10.1210/endo-109-5-1693; KIMMEL JR, 1975, J BIOL CHEM, V250, P9369; Lin T M, 1974, Gastroenterology, V67, P737; NATA K, 1990, BIOCHEM BIOPH RES CO, V171, P330, DOI 10.1016/0006-291X(90)91397-B; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; NGUYEN TD, 1986, BIOCHEMISTRY-US, V25, P361, DOI 10.1021/bi00350a013; NGUYEN TD, 1987, J MEMBRANE BIOL, V98, P197, DOI 10.1007/BF01871183; OSWALD B, 1987, J LIPID RES, V28, P798; SCHWARTZ SS, 1980, ENDOCRINOLOGY, V106, P1178, DOI 10.1210/endo-106-4-1178; SCHWARTZ TW, 1987, FEBS LETT, V225, P209, DOI 10.1016/0014-5793(87)81159-6; SUN YS, 1986, AM J SURG, V151, P130, DOI 10.1016/0002-9610(86)90023-1; WHITCOMB DC, 1990, AM J PHYSIOL, V259, pG687, DOI 10.1152/ajpgi.1990.259.4.G687	23	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9416	9421						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577769				2022-12-27	WOS:A1992HR85400107
J	REIZER, J; SUTRINA, SL; WU, LF; DEUTSCHER, J; REDDY, P; SAIER, MH				REIZER, J; SUTRINA, SL; WU, LF; DEUTSCHER, J; REDDY, P; SAIER, MH			FUNCTIONAL INTERACTIONS BETWEEN PROTEINS OF THE PHOSPHOENOLPYRUVATE-SUGAR PHOSPHOTRANSFERASE SYSTEMS OF BACILLUS-SUBTILIS AND ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; PHOSPHO-CARRIER PROTEIN; SALMONELLA-TYPHIMURIUM; INDUCER EXCLUSION; ENZYME-I; STAPHYLOCOCCUS-AUREUS; NUCLEOTIDE-SEQUENCE; LACTOSE TRANSPORT; CRR GENES; IIIGLC	Proteins of the phosphoenolpyruvate:sugar phosphotransferase system (PTS) of Bacillus subtilis were overexpressed, purified to near homogeneity, and characterized. The proteins isolated include Enzyme I, HPr, the glucose-specific IIA domain of the glucose-specific Enzyme II (IIA(glc)), and the mannitol-specific IIA protein, IIA(mtl). Site specific mutant proteins of IIA(glc) and HPr were also overexpressed and purified, and their properties were compared with those of the wild type proteins. These proteins and their phosphorylated derivatives were characterized with respect to their immunological cross-reactivities employing the Western blot technique and in terms of their migratory behavior during sodium dodecyl sulfate-gel electrophoresis, nondenaturing gel electrophoresis, and isoelectric focusing. The interactions between homologous and heterologous Enzymes I and HPrs, between homologous and heterologous HPrs and the IIA(glc) proteins, and between homologous and heterologous IIAg(glc) proteins and IIBC(scr) of B. subtilis as well as IICB(glc) of Escherichia coli were defined and compared kinetically. The mutant HPrs and IIA(glc) proteins were also characterized kinetically as PTS phosphocarrier proteins and/or as inhibitors of the phosphotransferase reactions of the PTS. These studies revealed that complexation of IIA(glc) with the mutant form of HPr in which serine 46 was replaced by aspartate (S46D) did not increase the rate of phosphoryl transfer from phospho Enzyme I to S46D HPr more than when IIA(mtl) was complexed to S46D HPr. These findings do not support a role for HPr(Ser-P) in the preferential utilization of one PTS carbohydrate relative to another. Functional analyses in E. coli established that IIA(glc) of B. subtilis can replace IIA(glc) of E. coli with respect both to sugar transport and to regulation of non-PTS permeases, catabolic enzymes, and adenylate cyclase. Site-specific mutations in histidyl residues 68 and 83 (H68A and H83A) inactivated IIA(glc) of B. subtilis with respect to phosphoryl transfer and its various regulatory roles.	NATL INST STANDARDS & TECHNOL,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850	National Institute of Standards & Technology (NIST) - USA	REIZER, J (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014176, R01AI021702] Funding Source: NIH RePORTER; NIAID NIH HHS [5R01 AI 21702, 2R01 AI 14176] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; DEAN DA, 1990, J BIOL CHEM, V265, P21005; DEREUSE H, 1988, J BACTERIOL, V170, P3827, DOI 10.1128/jb.170.9.3827-3837.1988; DEREUSE H, 1985, GENE, V35, P199; DEUTSCHER J, 1984, BIOCHEMISTRY-US, V23, P4455, DOI 10.1021/bi00314a033; DEUTSCHER J, 1982, BIOCHEMISTRY-US, V21, P4867, DOI 10.1021/bi00263a006; DORSCHUG M, 1984, EUR J BIOCHEM, V144, P113, DOI 10.1111/j.1432-1033.1984.tb08438.x; FAIRBROTHER WJ, 1991, BIOCHEMISTRY-US, V30, P6896, DOI 10.1021/bi00242a013; GONZYTREBOUL G, 1987, J BACTERIOL, V169, P2287, DOI 10.1128/jb.169.5.2287-2290.1987; GONZYTREBOUL G, 1989, MOL MICROBIOL, V3, P103, DOI 10.1111/j.1365-2958.1989.tb00109.x; GRENIER FC, 1986, J CELL BIOCHEM, V31, P97, DOI 10.1002/jcb.240310203; HENGSTENBERG W, 1969, J BACTERIOL, V99, P383, DOI 10.1128/JB.99.2.383-388.1969; KAPADIA G, 1991, J MOL BIOL, V221, P1079; KUKURUZINSKA MA, 1984, J BIOL CHEM, V259, P1679; KUKURUZINSKA MA, 1982, J BIOL CHEM, V257, P4470; KUNDIG W, 1971, J BIOL CHEM, V246, P1393; LECOO D, 1990, GENETIC TRANSFORMATION AND EXPRESSION, P447; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; LONDON J, 1983, J BACTERIOL, V156, P611, DOI 10.1128/JB.156.2.611-619.1983; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEADOW ND, 1986, J BIOL CHEM, V261, P3504; MISKO TP, 1987, J BIOL CHEM, V262, P16261; MITCHELL WJ, 1987, J BIOL CHEM, V262, P16254; NELSON SO, 1986, EUR J BIOCHEM, V154, P337, DOI 10.1111/j.1432-1033.1986.tb09402.x; NOEL D, 1979, BIOCHEMISTRY-US, V18, P4159, DOI 10.1021/bi00586a017; PELTON JG, 1991, P NATL ACAD SCI USA, V88, P3479, DOI 10.1073/pnas.88.8.3479; PEREGO M, 1989, J BACTERIOL, V171, P6187, DOI 10.1128/jb.171.11.6187-6196.1989; PRESPER KA, 1989, P NATL ACAD SCI USA, V86, P4052, DOI 10.1073/pnas.86.11.4052; REIZER J, 1989, BIOCHIMIE, V71, P989, DOI 10.1016/0300-9084(89)90102-8; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1988, P NATL ACAD SCI USA, V85, P2041, DOI 10.1073/pnas.85.7.2041; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; REIZER J, 1988, CRC CR REV MICROBIOL, V15, P297, DOI 10.3109/10408418809104461; REIZER J, 1984, J BACTERIOL, V159, P243, DOI 10.1128/JB.159.1.243-250.1984; REIZER J, 1987, SUGAR TRANSPORT META, P333; REIZER J, 1989, FEMS MICROBIOL REV, V63, P149; ROMANO AH, 1990, J BACTERIOL, V172, P6741, DOI 10.1128/jb.172.12.6741-6748.1990; SAFFEN DW, 1987, J BIOL CHEM, V262, P16241; SAIER MH, 1990, RES MICROBIOL, V141, P1033, DOI 10.1016/0923-2508(90)90077-4; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SAIER MH, 1976, J BIOL CHEM, V251, P6606; SAIER MH, 1975, J BIOL CHEM, V250, P7078; SAIER MH, 1985, MECHANISMS REGULATIO; Sambrook J, 1989, MOL CLONING LABORATO; SIMONI RD, 1973, J BIOL CHEM, V248, P932; STEINMETZ M, 1990, GENETICS BIOTECHNOLO, V3, P303; SUTRINA SL, 1990, J BIOL CHEM, V265, P18581; VOGLER AP, 1988, MOL GEN GENET, V213, P175, DOI 10.1007/BF00333417; WAYGOOD EB, 1980, CAN J BIOCHEM CELL B, V58, P40, DOI 10.1139/o80-006; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4514, DOI 10.1073/pnas.84.13.4514	53	112	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9158	9169						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577753				2022-12-27	WOS:A1992HR85400071
J	HABUKA, N; MIYANO, M; KATAOKA, J; TSUGE, H; NOMA, M				HABUKA, N; MIYANO, M; KATAOKA, J; TSUGE, H; NOMA, M			SPECIFICITIES OF RNA N-GLYCOSIDASE ACTIVITY OF MIRABILIS ANTIVIRAL PROTEIN VARIANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN-A CHAIN; ENZYMATIC INACTIVATION; GLUTAMIC ACID-177; ESCHERICHIA-COLI; CELLS; REPLICATION; EXPRESSION; INHIBITION; RIBOSOMES	Mirabilis antiviral protein (MAP), a ribosome-inactivating protein, inactivates both eukaryotic and prokaryotic ribosomes by means of site-specific RNA N-glycosidase activity. In order to identify the site of this activity, some amino acid residues of MAP, conserved in homologous ribosome-inactivating proteins, were altered to other amino acids by replacing DNA fragments of the total synthetic gene of MAP. When the in vitro protein synthesis of rabbit reticulocyte was treated with MAP variants secreted into culture media of Escherichia coli transformants, the inhibitory effect of R26L and R48L (R26L designates MAP variant with Arg-26 changed to Leu) was found to be similar to that of native MAP. Both purified Y72F and Y118F had the same effect as native MAP, and E168D had a slightly weaker effect. In contrast, on the protein synthesis of E. coli, Y118F had one-tenth the effect of native MAP, and Y72F and E 168D approximately one-hundredth the effect. These three variant proteins also exhibited reduced RNA N-glycosidase activity on substrate E. coli ribosomes. These results suggest that Tyr-72 and Glu-168 are involved in RNA N-glycosidase activity. When the R171K gene was expressed in E. coli, an N-glycosidic bond of the 23 S rRNA of the host ribosome was found to be cleaved, although no product of the gene could be detected. This suggests that MAP variants can maintain their N-glycosidase activity when the conserved Glu-168 and Arg-171 are changed to similarly charged residues.			HABUKA, N (corresponding author), JAPAN TOBACCO INC,LIFE SCI RES LAB,6-2 UMEGAOKA,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN.		Tsuge, Hideaki/ABF-6424-2021; Miyano, Masashi/R-2785-2016	Miyano, Masashi/0000-0003-2253-6175; Tsuge, Hideaki/0000-0003-0166-9163				BARBIERI L, 1982, CANCER SURV, V1, P489; Endo Y, 1988, IMMUNOTOXINS, P75; FRANKEL A, 1990, MOL CELL BIOL, V10, P6257, DOI 10.1128/MCB.10.12.6257; HABUKA N, 1990, J BIOL CHEM, V265, P10988; HABUKA N, 1991, J MOL BIOL, V221, P737, DOI 10.1016/0022-2836(91)80168-T; HABUKA N, 1989, J BIOL CHEM, V264, P6629; HOVDE CJ, 1988, P NATL ACAD SCI USA, V85, P2568, DOI 10.1073/pnas.85.8.2568; IKEDA T, 1987, PLANT CELL REP, V6, P216, DOI 10.1007/BF00268483; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; MAY MJ, 1989, EMBO J, V8, P301, DOI 10.1002/j.1460-2075.1989.tb03377.x; MCGRATH MS, 1989, P NATL ACAD SCI USA, V86, P2844, DOI 10.1073/pnas.86.8.2844; MONFORT W, 1987, J BIOL CHEM, V262, P5398; Olsnes S., 1982, MOL ACTION TOXINS VI, P51; SCHLOSSMAN D, 1989, MOL CELL BIOL, V9, P5012, DOI 10.1128/MCB.9.11.5012; SUGIO S, 1988, J BIOCHEM-TOKYO, V103, P354, DOI 10.1093/oxfordjournals.jbchem.a122274; ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0	16	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7758	7760						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560009				2022-12-27	WOS:A1992HN48500079
J	BHATTACHARYA, S; MARTI, T; OTTO, H; HEYN, MP; KHORANA, HG				BHATTACHARYA, S; MARTI, T; OTTO, H; HEYN, MP; KHORANA, HG			A BACTERIORHODOPSIN ANALOG RECONSTITUTED WITH A NONISOMERIZABLE 13-TRANS RETINAL DERIVATIVE DISPLAYS LIGHT INSENSITIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON TRANSLOCATION; ESCHERICHIA-COLI; BACTERIO-OPSIN; ISOMERIZATION; RENATURATION; RESOLUTION; DETERGENTS; PHOTOCYCLE; MEMBRANE; PROTEINS	With the aim of preparing a light-insensitive bacteriorhodopsin-like pigment, bacterio-opsin expressed in Escherichia coli was treated in phospholipid-detergent micelles with the retinal analog II, in which the C-13-C-14 trans-double bond cannot isomerize due to inclusion in a cyclopentene ring. The formation of a complex with a fine structure (lambda(max), 439 nm) was first observed. This partially converted over a period of 12 days to a bacteriorhodopsin-like chromophore (ebR-II) with lambda(max), 555 nm. An incidental behavior has been observed previously upon reconstitution of bleached purple membrane with the analog II. Purification by gel filtration gave pure ebR-II with lambda(max), 558 similar to that of light-adapted bacterio-opsin reconstituted with all-trans retinal (ebR-I). Spectrophotometric titration of ebR-II as a function of pH showed that the purple to blue transition of bacteriorhodopsin at acidic pH was altered, and the apparent pK(a) of Schiff base deprotonation at alkaline pH was lowered by 2.4 units, relative to that of ebR-I. ebR-II showed no light-dark adaptation, no proton pumping, and no intermediates characteristic of the bacteriorhodopsin photocycle. In addition, the rates of reaction with hydroxylamine in the dark and in the light were similar. These results show, as expected, that isomerization of the C-13-C-14 double bond is required for bacteriorhodopsin function and that prevention of this isomerization confers light insensitivity.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA; FREE UNIV BERLIN, BIOPHYS GRP, W-1000 BERLIN 33, GERMANY	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Free University of Berlin			Bhattacharya, Santanu/N-6531-2019; BHATTACHARYA, SANTANU/E-9739-2010; Bhattacharya, Santanu/GRS-4780-2022	Bhattacharya, Santanu/0000-0001-9040-8971; BHATTACHARYA, SANTANU/0000-0001-9040-8971; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028289, R01GM028289] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11479] Funding Source: Medline; NIGMS NIH HHS [GM 28289] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBECK A, 1986, J AM CHEM SOC, V108, P4614, DOI 10.1021/ja00275a056; BALOGHNAIR V, 1990, CHEM BIOL SYNTHETIC, P147; BAYLEY H, 1981, J BIOL CHEM, V256, P3797; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BRAIMAN MS, 1987, J BIOL CHEM, V262, P9271; CHANG CH, 1985, BIOPHYS J, V47, P509, DOI 10.1016/S0006-3495(85)83944-8; FANG JM, 1983, J AM CHEM SOC, V105, P5162, DOI 10.1021/ja00353a068; FISCHER U, 1979, BIOPHYS J, V28, P211, DOI 10.1016/S0006-3495(79)85172-3; FLITSCH SL, 1989, BIOCHEMISTRY-US, V28, P7800, DOI 10.1021/bi00445a041; HUANG KS, 1982, J BIOL CHEM, V257, P13616; HUANG KS, 1980, P NATL ACAD SCI-BIOL, V77, P323, DOI 10.1073/pnas.77.1.323; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; LONDON E, 1982, J BIOL CHEM, V257, P7003; MARTI T, 1991, J BIOL CHEM, V266, P6919; MARTI T, 1991, J BIOL CHEM, V266, P18674; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; MOWERY PC, 1979, BIOCHEMISTRY-US, V18, P4100, DOI 10.1021/bi00586a007; NASSAL M, 1987, J BIOL CHEM, V262, P9264; OK H, 1988, TETRAHEDRON LETT, V29, P2275, DOI 10.1016/S0040-4039(00)86036-0; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; RIDGE KD, 1992, J BIOL CHEM, V267, P6770; SCHERRER P, 1989, BIOCHEMISTRY-US, V28, P829, DOI 10.1021/bi00428a063; SCHRECKENBACH T, 1977, EUR J BIOCHEM, V76, P499, DOI 10.1111/j.1432-1033.1977.tb11620.x; SCHRECKENBACH T, 1978, BIOCHEMISTRY-US, V17, P5353, DOI 10.1021/bi00618a005; STOECKENIUS W, 1982, ANNU REV BIOCHEM, V51, P587, DOI 10.1146/annurev.bi.51.070182.003103; SUBRAMANIAM S, 1991, P NATL ACAD SCI USA, V88, P2583, DOI 10.1073/pnas.88.6.2583; TOWNER P, 1981, EUR J BIOCHEM, V117, P353, DOI 10.1111/j.1432-1033.1981.tb06345.x; VANAKEN T, 1986, METHOD ENZYMOL, V125, P27; YAN B, 1990, BIOPHYS J, V57, P807, DOI 10.1016/S0006-3495(90)82600-X	30	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6757	6762						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551884				2022-12-27	WOS:A1992HM05300046
J	MARIDONNEAUPARINI, I; DEGUNZBURG, J				MARIDONNEAUPARINI, I; DEGUNZBURG, J			ASSOCIATION OF RAP1 AND RAP2 PROTEINS WITH THE SPECIFIC GRANULES OF HUMAN NEUTROPHILS - TRANSLOCATION TO THE PLASMA-MEMBRANE DURING CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; RAS-RELATED PROTEIN; ALKALINE-PHOSPHATASE; IDENTIFICATION; SECRETION; PURIFICATION; MACROPHAGES; ANTIBODIES; PLATELETS; RECEPTORS	Activation of human neutrophils involves the degranulation of specific-and azurophil granules. This process is GTP-dependent and the presence of small GTP-binding proteins (SGBPs) has been detected in the two granule populations. At present, none of these SGBPs has been definitely identified. In order to characterize some of these proteins and obtain further insights as to their potential role in degranulation processes, we have used specific antibodies directed against the ras-related rap1 and rap2 proteins. By immunoblot analysis, we observed that rap2p is predominantly located in specific granules, whereas rap1p is detected both in specific granules and a fraction enriched in plasma membranes. Neither rap1p nor rap2p was found in the cytosol or in azurophil granules. Similarly, by indirect immunofluorescence, we observed that cytoplasmic granules were stained with anti-rap1p antibodies and anti-rap2p antibodies, and the plasma membrane was labeled with both antibodies but more distinctly with anti-rap1p than with anti-rap2p antibodies. rap1p and rap2p are tightly bound to the membrane of specific granules since they cannot be extracted by high salt or alkaline buffers. In addition, treatment of intact specific granules with pronase induced the degradation of rap proteins suggesting that they are exposed to the cytoplasmic face of the granules. Degranulation of neutrophils consists of the translocation and subsequent fusion of granules with the plasma membrane. Activation of this process induced the accumulation of rap proteins in the plasma membrane as observed by subcellular fractionation and indirect immunofluorescence experiments; this was not associated with the appearance of a soluble form of these proteins, showing that they remain membrane-bound during this process. The identification and subcellular localization of rap1p and rap2p at the surface of specific granules and the observation that they translocate to the plasma membrane upon cell stimulation without appearance of soluble forms constitute an important step toward the understanding of their physiological functions in human neutrophils.	FAC MED LARIBOISIERE,INSERM,U248,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	MARIDONNEAUPARINI, I (corresponding author), INST COCHIN GENET MOLEC,INSERM,U332,22 RUE MECHAIN,F-75014 PARIS,FRANCE.		Maridonneau-Parini, Isabelle/F-1985-2011	Maridonneau-Parini, Isabelle/0000-0003-0189-0976				Bainton D.F., 1988, INFLAMMATION BASIC P, P265; BAINTON DF, 1987, J EXP MED, V166, P1641, DOI 10.1084/jem.166.6.1641; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BERANGER F, 1991, ONCOGENE, V6, P1835; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BORREGAARD N, 1990, J CLIN INVEST, V85, P408, DOI 10.1172/JCI114453; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRITTINGER G, 1968, J CELL BIOL, V37, P394, DOI 10.1083/jcb.37.2.394; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CANONICO PG, 1978, J RETICULOENDOTH SOC, V24, P115; DECHATELET LR, 1970, BIOCHEM MED METAB B, V4, P61, DOI 10.1016/0006-2944(70)90103-1; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; DEXTER D, 1990, J IMMUNOL, V145, P1845; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HATA Y, 1991, J BIOL CHEM, V266, P6571; HEIPLE JM, 1986, J EXP MED, V164, P826, DOI 10.1084/jem.164.3.826; HENSON PM, 1988, INFLAMMATION BASIC P, P363; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; JIMENEZ B, 1991, INT J CANCER, V49, P471, DOI 10.1002/ijc.2910490327; JOINER KA, 1989, J CELL BIOL, V109, P2771, DOI 10.1083/jcb.109.6.2771; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KRAUSE KH, 1987, J CLIN INVEST, V80, P107, DOI 10.1172/JCI113035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LEROSEY I, 1991, BIOCHEM BIOPH RES CO, V175, P430, DOI 10.1016/0006-291X(91)91582-W; LOEROSEY I, 1991, J BIOL CHEM, V266, P4315; MARIDONNEAUPARINI I, 1989, J CLIN INVEST, V83, P1936, DOI 10.1172/JCI114101; MARIDONNEAUPARINI I, 1986, J IMMUNOL, V137, P2925; MARIDONNEAUPARINI I, 1991, J CLIN INVEST, V87, P901, DOI 10.1172/JCI115096; METCALF JA, 1986, LABORATORY MANUAL NE; NAGATA K, 1989, J BIOL CHEM, V264, P17000; OHMSTEDE CA, 1990, P NATL ACAD SCI USA, V87, P6527, DOI 10.1073/pnas.87.17.6527; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; SINGER II, 1989, J CELL BIOL, V109, P3169, DOI 10.1083/jcb.109.6.3169; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WINEGAR DA, 1991, J BIOL CHEM, V266, P4381; WRIGHT DG, 1977, AM J PATHOL, V87, P273; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	53	109	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6396	6402						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556142				2022-12-27	WOS:A1992HK31800100
J	PRENTKI, M; VISCHER, S; GLENNON, MC; REGAZZI, R; DEENEY, JT; CORKEY, BE				PRENTKI, M; VISCHER, S; GLENNON, MC; REGAZZI, R; DEENEY, JT; CORKEY, BE			MALONYL-COA AND LONG-CHAIN ACYL-COA ESTERS AS METABOLIC COUPLING FACTORS IN NUTRIENT-INDUCED INSULIN-SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FATTY-ACID OXIDATION; ISOLATED PANCREATIC-ISLETS; COENZYME-A; TRANSPORT VESICLES; ARACHIDONIC-ACID; GOLGI CISTERNAE; BETA-CELLS; FREE CA-2+; GLUCOSE	Several approaches were used to test the hypothesis proposing a role for acyl-CoA esters in nutrient-induced insulin release (Prentki, M., and Matschinsky, F. M. (1987) Physiol. Rev. 67, 1185-1248; Corkey, B. E., Glennon, M. C., Chen, K. S., Deeney, J. T., Matschinsky, F. M., and Prentki, M. (1989) J. Biol. Chem. 264, 21608-21612). Exogenous saturated long chain fatty acids markedly potentiated glucose-induced insulin release and elevated long chain acyl-CoA esters in the clonal beta-cell line (HIT). The secretory action depended on the fatty acid chain length, occurred in the range 3-20-mu-M (free concentration of palmitate), and was reversible and inhibitable by the neuromodulator somatostatin. 2-Bromopalmitate, an inhibitor of carnitine palmitoyl transferase I, suppressed the oxidation of endogenous fatty acids and promoted release of insulin. Only the nutrients or the combination of nutrients that caused secretion elevated malonyl-CoA. The short-chain acyl-CoA profile of HIT cells stimulated by various nutrients was determined in the presence of the nonstimulatory fuel glutamine. Glucose and leucine each provoked similar changes in acyl-CoA compounds. Both secretagogues elevated malonyl-CoA 3-6-fold, whereas succinyl-CoA, free CoASH, acetyl-CoA, and the free CoASH to acetyl-CoA ratio remained unaltered. Furthermore, only when inhibition of fatty acid oxidation was associated with a rise in malonyl-CoA did the total (mitochondrial plus cytoplasmic) content of long chain acyl-CoA esters correlate inversely with insulin release promoted by various nutrients. The results are consistent with the concept that fuel stimuli cause a rise in malonyl-CoA which by inhibiting fatty acid oxidation increase cytosolic long chain acyl-CoA esters. These data provide further support for a model in which malonyl-CoA and long chain acyl-CoAs esters serve as metabolic coupling factors when pancreatic beta-cells are stimulated with glucose and other nutrient secretagogues.	BOSTON UNIV, SCH MED, DIV DIABET & METAB, BOSTON, MA 02118 USA	Boston University	PRENTKI, M (corresponding author), UNIV GENEVA, CTR MED UNIV, DIV BIOCHIM CLIN, CH-1211 GENEVA 4, SWITZERLAND.		Vischer, Solange/ABE-2163-2021; Corkey, Barbara/E-7712-2015	Vischer, Solange/0000-0002-7087-1974; Corkey, Barbara/0000-0002-5467-1630; Deeney, Jude/0000-0003-0988-9419	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035914, R56DK035914, R01DK035914] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1990, P NATL ACAD SCI USA, V87, P7334, DOI 10.1073/pnas.87.18.7334; ARKHAMMAR P, 1989, BIOCHEM J, V264, P207, DOI 10.1042/bj2640207; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BERNE C, 1975, BIOCHEM J, V152, P667, DOI 10.1042/bj1520667; BERNE C, 1975, BIOCHEM J, V152, P661, DOI 10.1042/bj1520661; BRONFMAN M, 1988, BIOCHEM BIOPH RES CO, V152, P987, DOI 10.1016/S0006-291X(88)80381-4; COOK GA, 1987, J BIOL CHEM, V262, P4968; CORKEY BE, 1988, METHOD ENZYMOL, V166, P55; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; CORKEY BE, 1988, J BIOL CHEM, V263, P4254; DUNLOP ME, 1985, BIOCHEM BIOPH RES CO, V132, P467, DOI 10.1016/0006-291X(85)91157-X; EASOM RA, 1990, J BIOL CHEM, V265, P14938; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; FARESE RV, 1986, ENDOCRINOLOGY, V118, P1498, DOI 10.1210/endo-118-4-1498; GANESAN S, 1990, P NATL ACAD SCI USA, V87, P9893, DOI 10.1073/pnas.87.24.9893; GARLAND PB, 1964, BIOCHEM J, V93, P665, DOI 10.1042/bj0930665; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GOBERNA R, 1974, HORM METAB RES, V6, P256, DOI 10.1055/s-0028-1093862; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HILL RS, 1985, DIABETES, V34, P115, DOI 10.2337/diabetes.34.2.115; HUTTON JC, 1980, ENDOCRINOLOGY, V106, P203, DOI 10.1210/endo-106-1-203; IDELLWENGER JA, 1978, J BIOL CHEM, V253, P4310; KIM KH, 1983, CURR TOP CELL REGUL, V22, P143; LIANG Y, 1991, DIABETES, V40, P327, DOI 10.2337/diabetes.40.3.327; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MALAISSE WJ, 1968, J LAB CLIN MED, V72, P438; MALAISSE WJ, 1983, ARCH BIOCHEM BIOPHYS, V224, P102, DOI 10.1016/0003-9861(83)90193-5; MALAISSE WJ, 1984, EXPERIENTIA, V40, P1035, DOI 10.1007/BF01971449; MCGARRY JD, 1979, J BIOL CHEM, V254, P8163; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; METZ SA, 1988, DIABETES, V37, P3, DOI 10.2337/diabetes.37.1.3; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; REGAZZI R, 1990, J BIOL CHEM, V265, P15003; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; SANTERRE RF, 1981, P NATL ACAD SCI USA, V78, P115; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; SENER A, 1981, P NATL ACAD SCI-BIOL, V78, P5460, DOI 10.1073/pnas.78.9.5460; SHRAGO E, 1986, CLIN ASPECTS HUMAN C, P28; SPECTOR AA, 1971, BIOCHEMISTRY-US, V10, P3229; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5; VARA E, 1986, ENDOCRINOLOGY, V119, P404, DOI 10.1210/endo-119-1-404; VARA E, 1988, DIABETOLOGIA, V31, P687, DOI 10.1007/BF00278753; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4; WOLF BA, 1989, BIOCHEMISTRY-US, V28, P4291, DOI 10.1021/bi00436a026; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914	56	393	398	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5802	5810						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556096				2022-12-27	WOS:A1992HK31800016
J	BARTLEY, GE; VIITANEN, PV; BACOT, KO; SCOLNIK, PA				BARTLEY, GE; VIITANEN, PV; BACOT, KO; SCOLNIK, PA			A TOMATO GENE EXPRESSED DURING FRUIT RIPENING ENCODES AN ENZYME OF THE CAROTENOID BIOSYNTHESIS PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RHODOBACTER-CAPSULATUS; CDNA CLONES; PROTEIN; CHLOROPLASTS; PHYTOENE; SEQUENCE; PRODUCTS; PLASTIDS; CLUSTER	In the initial stages of carotenoid biosynthesis in plants the enzyme phytoene synthase converts two molecules of geranylgeranyl diphosphate into phytoene, the first carotenoid of the pathway. We show here that a tomato (Lycopersicon esculentum) cDNA for a gene (Psy1) expressed during fruit ripening directs the in vitro synthesis of a 47-kDa protein which, upon import into isolated chloroplasts, is processed to a mature 42-kDa form. The imported protein is largely associated with membranes, but it can be easily solubilized by dilution or by treatment at high pH. A plasmid construct containing prokaryotic promoter and ribosome-binding sequences fused to the Psy1 cDNA complements the carotenoidless phenotype of a Rhodobacter capsulatus crtB mutant. We conclude that Psy1 encodes phytoene synthase and that this enzyme is a peripheral plastid membrane protein.	DUPONT CO,CENT RES & DEV,DUPONT EXPTL STN,POB 80402,WILMINGTON,DE 19880	DuPont								ARMSTRONG GA, 1990, J BIOL CHEM, V265, P8329; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ARMSTRONG GA, 1990, P NATL ACAD SCI USA, V87, P9975, DOI 10.1073/pnas.87.24.9975; BARTLEY GE, 1991, P NATL ACAD SCI USA, V88, P6532, DOI 10.1073/pnas.88.15.6532; BARTLEY GE, 1990, J BIOL CHEM, V265, P16020; BARTLEY GE, 1991, CELL CULTURE SOMAT B, V7, P331; BIRD CR, 1991, BIO-TECHNOL, V9, P635, DOI 10.1038/nbt0791-635; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CLINE K, 1985, J BIOL CHEM, V260, P3691; DOGBO O, 1988, P NATL ACAD SCI USA, V85, P7054, DOI 10.1073/pnas.85.19.7054; GIULIANO G, 1988, MOL GEN GENET, V213, P78, DOI 10.1007/BF00333401; KINZER SM, 1990, THEOR APPL GENET, V79, P489, DOI 10.1007/BF00226158; KLEINIG H, 1989, ANNU REV PLANT PHYS, V40, P39, DOI 10.1146/annurev.pp.40.060189.000351; LUTKEBRINKHAUS F, 1982, PLANTA, V156, P176, DOI 10.1007/BF00395433; LUTKEBRINKHAUS F, 1987, PLANTA, V170, P121, DOI 10.1007/BF00392388; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; MISHKIND ML, 1988, PHOTOSYNTH RES, V19, P153, DOI 10.1007/BF00114573; RAY J, 1987, NUCLEIC ACIDS RES, V15, P10587, DOI 10.1093/nar/15.24.10587; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT GW, 1981, J CELL BIOL, V91, P468, DOI 10.1083/jcb.91.2.468; SLATER A, 1985, PLANT MOL BIOL, V5, P137, DOI 10.1007/BF00015677; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; ZILSER J, 1990, THESIS U BRIT COLUMB	24	105	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5036	5039						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544888				2022-12-27	WOS:A1992HH74700006
J	HARTELSCHENK, S; AGRE, P				HARTELSCHENK, S; AGRE, P			MAMMALIAN RED-CELL MEMBRANE RH POLYPEPTIDES ARE SELECTIVELY PALMITOYLATED SUBUNITS OF A MACROMOLECULAR COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; FATTY ACYLATION; RHO(D) ANTIGEN; PROTEINS; IDENTIFICATION; ACID; ERYTHROCYTES; COMPONENTS; SPECTRIN; CLONING	Incubation of [H-3]palmitic acid, ATP, and CoA with inside-out membrane vesicles prepared from human or other mammalian red cells resulted in nearly exclusive H-3-palmitoylation of the M(r) = 32,000 Rh polypeptides. [H-3]Palmitic, [H-3]myristic, and [H-3]oleic acids were comparably esterified onto Rh polypeptides in inside-out membrane vesicles in the presence of ATP and CoA, although [H-3]palmitic acid was preferentially incorporated by intact human red cells. Experiments using sulfhydryl reagents or tryptic digestions suggested that multiple sulfhydryl groups on the Rh polypeptides located near the cytoplasmic leaflet of the lipid bilayer were H-3-palmitoylated; the exofacial sulfhydryl group essential for Rh antigenic reactivity was not H-3-palmitoylated. Transfer of fatty acid from [C-14]palmitoyl-CoA to sites on the Rh polypeptides occurred even after previous incubation of inside-out membrane vesicles at 95-degrees-C or after solubilization of inside-out membrane vesicles in Triton X-100. Hydrodynamic analyses of Triton X-100-solubilized membranes surprisingly demonstrated that H-3-palmitoylated Rh polypeptides behaved as a protein of apparent M(r) = 170,000. These in vitro studies suggest that palmitoylation of Rh polypeptides occurs within a macromolecular complex by a highly selective but possibly nonenzymatic mechanism.	JOHNS HOPKINS UNIV, SCH MED, DEPT ANAT, BALTIMORE, MD 21205 USA	Johns Hopkins University	HARTELSCHENK, S (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MED & CELL BIOL, BALTIMORE, MD 21205 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA009012] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33991] Funding Source: Medline; NIAAA NIH HHS [AA09012] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AGRE P, 1991, BLOOD, V78, P551, DOI 10.1182/blood.V78.3.551.bloodjournal783551; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; BUTKOFER P, 1990, J BIOL CHEM, V265, P160; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; DAVIS J, 1982, J BIOL CHEM, V257, P5816; DEVETTEN MP, 1988, J BIOL CHEM, V263, P18193; EPSTEIN WW, 1990, P NATL ACAD SCI USA, V87, P7352, DOI 10.1073/pnas.87.19.7352; Gahmberg C G, 1988, Subcell Biochem, V12, P95; GAHMBERG CG, 1982, FEBS LETT, V140, P93, DOI 10.1016/0014-5793(82)80528-0; GREEN FA, 1983, MOL IMMUNOL, V20, P769, DOI 10.1016/0161-5890(83)90055-X; GREEN FA, 1967, IMMUNOCHEMISTRY, V4, P247, DOI 10.1016/0019-2791(67)90186-3; HRESKO RC, 1990, J BIOL CHEM, V265, P21075; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEMAIRE M, 1989, ANAL BIOCHEM, V177, P50, DOI 10.1016/0003-2697(89)90012-2; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MOLLER JV, 1988, METHOD ENZYMOL, V157, P261; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; OKUBO K, 1991, J BIOL CHEM, V266, P16420; SABOORI AM, 1989, J CLIN INVEST, V83, P187, DOI 10.1172/JCI113857; SADLER JE, 1979, J BIOL CHEM, V254, P4443; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1678; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SMITH MH, 1970, HDB BIOCH, pC3; SMITH RPP, 1973, J MEMBRANE BIOL, V12, P177, DOI 10.1007/BF01869998; STAUFENBIEL M, 1988, J BIOL CHEM, V263, P13615; Steck T L, 1974, Methods Enzymol, V31, P172; Steele J C Jr, 1978, Methods Enzymol, V48, P11; SUYAMA K, 1990, BLOOD, V75, P255; SUYAMA K, 1992, IN PRESS BLOOD, V79; Tanford C, 1961, PHYS CHEM MACROMOLEC, P364; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441	40	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5569	5574						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544931				2022-12-27	WOS:A1992HH74700085
J	URATANI, Y				URATANI, Y			IMMUNOAFFINITY PURIFICATION AND RECONSTITUTION OF SODIUM-COUPLED BRANCHED-CHAIN AMINO-ACID CARRIER OF PSEUDOMONAS-AERUGINOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-SPECIFIC ANTIBODY; ESCHERICHIA-COLI; DEPENDENT TRANSPORT; CARBOXYL TERMINUS; LACTOSE CARRIER; PROLINE CARRIER; PROTEIN; SOLUBILIZATION; MEMBRANE; SYSTEM	The gene product of braB encoding the Na+(Li+)-coupled carrier protein for L-leucine, L-isoleucine, and L-valine (LIV-II carrier) of Pseudomonas aeruginosa PML strain was identified and overexpressed using a T7 RNA polymerase/promoter plasmid system. The gene product was pulse-labeled with [S-35]methionine as a protein of an apparent M(r) of 34,000 on a sodium dodecyl sulfate-polyacrylamide gel. Cell membranes overproducing the LIV-II carrier were solubilized with n-dodecyl beta-D-maltopyranoside. The carrier protein was purified from the detergent extract by two purification steps: (i) immunoaffinity column chromatography using purified polyclonal antibody directed against synthetic 13-mer peptide corresponding to the carboxyl terminus region of the carrier and (ii) subsequent DEAE-cellulose column chromatography. The detergent was replaced by n-octyl beta-D-glucopyranoside prior to the first elution and phospholipid was present during purification. Proteoliposomes reconstituted with the purified LIV-II carrier exhibited Na+ or Li+ concentration gradient-driven transport of leucine, isoleucine, and valine. These results show that the LIV-II carrier was purified to be in a functional form.			URATANI, Y (corresponding author), MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN.							BOTFIELD MC, 1989, J BIOL CHEM, V264, P11649; HANADA K, 1988, BIOCHIM BIOPHYS ACTA, V939, P282, DOI 10.1016/0005-2736(88)90072-7; HANADA K, 1988, J BIOL CHEM, V263, P7181; HARLOW E, 1988, ANTIBODIES LABORATOR; HOSHINO T, 1979, J BACTERIOL, V139, P705, DOI 10.1128/JB.139.3.705-712.1979; HOSHINO T, 1979, J BACTERIOL, V137, P73, DOI 10.1128/JB.137.1.73-81.1979; HOSHINO T, 1991, J BACTERIOL, V173, P1855, DOI 10.1128/jb.173.6.1855-1861.1991; HOSHINO T, 1990, MOL GEN GENET, V220, P461, DOI 10.1007/BF00391754; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KOMEIJI Y, 1989, FEBS LETT, V256, P135, DOI 10.1016/0014-5793(89)81733-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORBER B, 1990, BIOCHIM BIOPHYS ACTA, V1023, P254, DOI 10.1016/0005-2736(90)90421-J; Maniatis T., 1982, MOL CLONING; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; NEWMAN MJ, 1980, J BIOL CHEM, V255, P583; OHSAWA K, 1983, ANAL BIOCHEM, V135, P409, DOI 10.1016/0003-2697(83)90703-0; PAGE MGP, 1988, J BIOL CHEM, V263, P15897; ROEPE PD, 1990, BIOCHEMISTRY-US, V29, P2572, DOI 10.1021/bi00462a020; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SECKLER R, 1983, J BIOL CHEM, V258, P817; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; URATANI Y, 1985, J BIOL CHEM, V260, P23; URATANI Y, 1989, J MEMBRANE BIOL, V107, P57, DOI 10.1007/BF01871083; URATANI Y, 1989, J BIOL CHEM, V264, P18944; VANAKEN T, 1986, METHOD ENZYMOL, V125, P27; VANREGENMORTAL MHV, 1988, SYNTHETIC POLYPEPTID, P108; WRIGHT JK, 1984, EUR J BIOCHEM, V138, P497, DOI 10.1111/j.1432-1033.1984.tb07944.x; YAMATO I, 1975, J BIOCHEM, V77, P705, DOI 10.1093/oxfordjournals.jbchem.a130774; YAMATO Y, 1980, J BACTERIOL, V144, P36	31	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5177	5183						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544899				2022-12-27	WOS:A1992HH74700029
J	WALLIS, CJ; WENEGIEME, EF; BABITCH, JA				WALLIS, CJ; WENEGIEME, EF; BABITCH, JA			CHARACTERIZATION OF CALCIUM-BINDING TO BRAIN SPECTRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE-MEMBRANE PROTEINS; CALPAIN-MEDIATED DEGRADATION; ENTORHINAL CORTEX PRODUCE; ALPHA-SPECTRIN; GEL-ELECTROPHORESIS; SECRETORY-CELLS; DENTATE GYRUS; FODRIN; CALMODULIN; IDENTIFICATION	Brain spectrin alpha and beta-chains bind Ca-45(2+), as shown by the calcium overlay method. Flow dialysis measurements revealed eight high affinity binding sites/tetramer that comprise two binding components (determined by nonlinear regression analysis). The first component has one or two sites (k(d) = 2-30 x 10(-8) M), depending on the ionic strength of the binding buffer, with the remaining high affinity sites in the second component (k(d) = 1-3 x 10(-6) M). In addition, there is a variable, low affinity binding component (n = 100-400, k(d) = 1-2 x 10(-4) M). Magnesium inhibits calcium binding to the low affinity sites with a K(I) = 1.21 mM. Proteolytic fragments from trypsin or chymotrypsin digests of brain spectrin bind Ca-45(2+) if they include alpha-domain IV, alpha-domain III, or the amino-terminal half of the beta-chain (but more than 25 kDa from the amino-terminal). These data suggest that calcium ions bind with high affinity to the putative EF-hands in alpha-domain IV and to one site in the amino-terminal half of the beta-chain that is associated with alpha-domain IV in the native dimer. This localization is consistent with a direct calcium modulation of the spectrin-actin-protein 4.1 interaction. In addition, there appears to be one high affinity site near the hypersensitive region of alpha-brain spectrin. All four proposed binding sites occur near probable calmodulin-binding or calcium-dependent protease cleavage sites.	TEXAS CHRISTIAN UNIV, DEPT CHEM, FT WORTH, TX 76129 USA	Texas Christian University					NINDS NIH HHS [NS-26518] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026518] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUNIS D, 1988, J EXP BIOL, V139, P253; BAUDRY M, 1981, SCIENCE, V212, P937, DOI 10.1126/science.7015504; BENNETT V, 1986, METHOD ENZYMOL, V134, P55; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BURRIDGE K, 1982, J CELL BIOL, V95, P478, DOI 10.1083/jcb.95.2.478; CARLIN RK, 1983, J CELL BIOL, V96, P443, DOI 10.1083/jcb.96.2.443; CHENEY R, 1986, METHOD ENZYMOL, V134, P42; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; COX JA, 1988, BIOCHEM J, V249, P621, DOI 10.1042/bj2490621; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DAVISON MD, 1989, INT J BIOL MACROMOL, V11, P81, DOI 10.1016/0141-8130(89)90047-0; DISTASI AMM, 1991, NEURON, V6, P445, DOI 10.1016/0896-6273(91)90252-U; DUBREUIL RR, 1991, J BIOL CHEM, V266, P7189; FELDMANN K, 1978, ANAL BIOCHEM, V88, P225, DOI 10.1016/0003-2697(78)90414-1; GLENNEY JR, 1984, EUR J BIOCHEM, V144, P529, DOI 10.1111/j.1432-1033.1984.tb08498.x; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; GULTEKIN H, 1988, ANAL BIOCHEM, V172, P320, DOI 10.1016/0003-2697(88)90451-4; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; HARRIS AS, 1988, J NEUROSCI, V8, P2640; HU RJ, 1991, J BIOL CHEM, V266, P18200; IVY G, 1988, BRAIN RES, V459, P233, DOI 10.1016/0006-8993(88)90639-7; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; KLOTZ IM, 1971, BIOCHEMISTRY-US, V10, P3065, DOI 10.1021/bi00792a013; KOENIG E, 1985, J NEUROSCI, V5, P705; KONG CF, 1988, BIOCHIM BIOPHYS ACTA, V952, P13, DOI 10.1016/0167-4838(88)90096-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1983, SCIENCE, V222, P931, DOI 10.1126/science.6356364; LEE JK, 1988, CELL, V55, P807, DOI 10.1016/0092-8674(88)90136-5; LEVINE J, 1983, P NATL ACAD SCI-BIOL, V80, P191, DOI 10.1073/pnas.80.1.191; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCHESI VT, 1985, ANNU REV CELL BIOL, V1, P531, DOI 10.1146/annurev.cellbio.1.1.531; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MENDEL CM, 1985, BIOCHEM J, V228, P269, DOI 10.1042/bj2280269; MORROW JS, 1983, METHOD ENZYMOL, V96, P298; PERRIN D, 1987, NATURE, V326, P498, DOI 10.1038/326498a0; PERRIN D, 1985, NATURE, V315, P589, DOI 10.1038/315589a0; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEUBERT P, 1988, BRAIN RES, V459, P226, DOI 10.1016/0006-8993(88)90638-5; SIMAN R, 1985, NATURE, V313, P225, DOI 10.1038/313225a0; SIMAN R, 1987, SYNAPTIC FUNCTION, P519; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STEINER JP, 1988, J BIOL CHEM, V263, P14417; STEINER JP, 1989, J BIOL CHEM, V264, P2783; TANAKA T, 1991, J BIOL CHEM, V266, P1134; TSUKITA S, 1983, J CELL BIOL, V97, P574, DOI 10.1083/jcb.97.2.574; TYLER JM, 1980, J BIOL CHEM, V255, P7034; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WILLARD M, 1977, J CELL BIOL, V75, P1, DOI 10.1083/jcb.75.1.1	51	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4333	4337						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537825				2022-12-27	WOS:A1992HF64200014
J	GUAN, KL; DESCHENES, RJ; DIXON, JE				GUAN, KL; DESCHENES, RJ; DIXON, JE			ISOLATION AND CHARACTERIZATION OF A 2ND PROTEIN TYROSINE PHOSPHATASE GENE, PTP2, FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; FISSION YEAST; RECEPTOR; CLONING; EXPRESSION; SEQUENCE; KINASE; FAMILY; CDNA; TRANSFORMATION	A putative protein tyrosine phosphatase (PTPase) gene, PTP2, was cloned from Saccharomyces cerevisiae. The complete yeast PTP2 gene encodes a 750-amino acid residue protein with a predicted mass of 86 kDa. The conserved PTPase domain wag localized in the C-terminal half of the protein. Amino acid sequence alignment of the yeast PTPase domain with other phosphatases indicated approximately 20-25% sequence identity with the mammalian PTPase and a similar degree of identity with the PTPase encoded by the yeast PTP1 gene. The PTP2 gene is closely linked to the yeast RET1 and STE4 genes and is localized on the right arm of chromosome 15. Gene disruption experiments demonstrated that neither PTP2 alone nor P2P2 in combination with PTP1 was essential for growth under the conditions tested. The ability of PTP2 to complement the cdc25-22 mutant of Schizosaccharomyces pombe was also examined, and unlike the human T-cell PTPase, which was able to complement the cdc25-22 mutant, the S. cerevisiae PTP2 was unable to complement the cdc25-22 mutant of S. pombe.	UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, MED SCI I BLDG, ROOM 0606, ANN ARBOR, MI 48109 USA; WALTHER CANC INST, INDIANAPOLIS, IN 46208 USA; UNIV IOWA, DEPT BIOCHEM, IOWA CITY, IA 52242 USA	University of Michigan System; University of Michigan; Walther Cancer Institute; University of Iowa			Guan, Kun-Liang/ADK-7088-2022; Deschenes, Robert J/E-4926-2010	Deschenes, Robert J/0000-0001-8325-4257	NATIONAL CANCER INSTITUTE [R01CA050211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018024, R37DK018024] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50211] Funding Source: Medline; NIDDK NIH HHS [NIDDKD 18024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BENSON S A, 1984, Biotechniques, V2, P126; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUAN K, 1991, J BIOL CHEM, V266, P12964; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAMES P, 1991, J BIOL CHEM, V266, P5616; JAMES P, 1991, CELL CYCLE, P79; JIRIK FR, 1990, FEBS LETT, V273, P239, DOI 10.1016/0014-5793(90)81094-5; KABACK DB, 1984, GENETICS, V108, P67; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Maniatis T., 1982, MOL CLONING; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MICHIELS T, 1988, MICROB PATHOGENESIS, V5, P449, DOI 10.1016/0882-4010(88)90006-X; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NEIGEBORN L, 1991, GENE DEV, V5, P533, DOI 10.1101/gad.5.4.533; OHAGI S, 1990, NUCLEIC ACIDS RES, V18, P7159, DOI 10.1093/nar/18.23.7159; OTA IM, 1991, YEAST CELL BIOL, P241; OTTILIE S, 1991, P NATL ACAD SCI USA, V88, P3455, DOI 10.1073/pnas.88.8.3455; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POT DA, 1991, J BIOL CHEM, V266, P19688; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1989, MOL BIOL FISSION YEA, P3244; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SAGA Y, 1986, P NATL ACAD SCI USA, V83, P6940, DOI 10.1073/pnas.83.18.6940; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Sherman F., 1974, METHODS YEAST GENETI; SHERO JH, 1991, GENE DEV, V5, P549, DOI 10.1101/gad.5.4.549; SIKORSKI RS, 1989, GENETICS, V122, P19; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; THOMAS ML, 1985, CELL, V41, P83, DOI 10.1016/0092-8674(85)90063-7; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WOODFORDTHOMAS TA, 1992, IN PRESS J CELL BIOL; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	63	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10024	10030						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577774				2022-12-27	WOS:A1992HT96500087
J	OZAKI, K; II, M; ITOH, N; KAWASAKI, T				OZAKI, K; II, M; ITOH, N; KAWASAKI, T			EXPRESSION OF A FUNCTIONAL ASIALOGLYCOPROTEIN RECEPTOR THROUGH TRANSFECTION OF A CLONED CDNA THAT ENCODES A MACROPHAGE LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PERITONEAL-MACROPHAGES; HUMAN HEPATOMA-CELLS; N-ACETYLGALACTOSAMINE; BINDING PROTEINS; RABBIT LIVER; GALACTOSE; HEPATOCYTES; OLIGOSACCHARIDES; IDENTIFICATION; TRANSFORMATION	The Gal/GalNAc-specific lectin on rat peritoneal macrophages (macrophage asialoglycoprotein binding protein, M-ASGP-BP) is structurally similar to rat hepatic asialoglycoprotein-binding protein (ASGP-BP) or rat hepatic lectin (RHL) and is highly homologous with the major component of RHL, RHL-1 (Ii, M, Kurata, H., Itoh, N., Yamashina, I., and Kawasaki, T. (1990) J. Biol. Chem. 265, 11295-11298). We found in this study that transfection with a cDNA clone that encodes a single polypeptide, M-ASGP-BP, was sufficient for the expression of an endocytic receptor for asialoorosomucoid (ASOR) on the COS-1 cell surface. The K(uptake) value for ASOR for the transfected cells was 12.5 nm, which is similar to that for peritoneal macrophages (23 nM), and the number of ASOR bound on the cell surface was 1-8 x 10(5)/cell, this value being hundreds of times larger than that for peritoneal macrophages. I-125-ASOR bound on the surfaces of the transfected cells was rapidly internalized on incubation at 37-degrees-C, and after 90 min of incubation, most of the radioactivity was recovered in acid-soluble degraded products from the medium. These results confirmed that the cDNA cloned in our previous study does in fact encode M-ASGP-BP and also that the single polypeptide chain can form a homooligomeric receptor (probably a hexamer or octamer) exhibiting high affinity for ASOR. The latter property was distinct from that of the hepatic ASGP-BP in that simultaneous transfection of two cloned cDNAs that encode RHL- 1 and RHL- 2/3 was required to produce an active ASOR receptor (McPhaul, M., and Berg, P. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 8863-8867). This M-ASGP-BP expression system may serve as a simple model with which to investigate the molecular mechanisms underlying carbohydrate-mediated endocytosis.	KYOTO UNIV, FAC PHARMACEUT SCI, DEPT BIOL CHEM, SAKYO KU, KYOTO 606, JAPAN	Kyoto University								ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BAENZIGER JU, 1980, CELL, V22, P611, DOI 10.1016/0092-8674(80)90371-2; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BISCHOFF J, 1987, J BIOL CHEM, V262, P11825; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; BREITFELD PP, 1984, J BIOL CHEM, V259, P414; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; FUKUNAGA R, 1984, P NATL ACAD SCI-BIOL, V81, P5086, DOI 10.1073/pnas.81.16.5086; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HARFORD J, 1983, J BIOL CHEM, V258, P3191; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HONG WJ, 1988, HEPATOLOGY, V8, P553, DOI 10.1002/hep.1840080320; II M, 1988, J BIOCHEM-TOKYO, V104, P587; II M, 1990, J BIOL CHEM, V265, P11295; II M, 1988, BIOCHEM BIOPH RES CO, V155, P720; KAWASAKI T, 1978, BIOCHEM BIOPH RES CO, V81, P1018, DOI 10.1016/0006-291X(78)91452-3; KAWASAKI T, 1986, CARBOHYD RES, V151, P197, DOI 10.1016/S0008-6215(00)90340-9; KAWASAKI T, 1976, J BIOL CHEM, V251, P1296; KAWASAKI T, 1990, 15TH P INT CARB S YO; KELM S, 1988, BIOL CHEM H-S, V369, P693, DOI 10.1515/bchm3.1988.369.2.693; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE RT, 1982, BIOCHEMISTRY-US, V21, P1045, DOI 10.1021/bi00534a034; LEE YC, 1983, J BIOL CHEM, V258, P199; MACKETT M, 1985, DNA CLONING, V2, P209; MCPHAUL M, 1986, P NATL ACAD SCI USA, V83, P8863, DOI 10.1073/pnas.83.23.8863; OHARE K, 1981, P NATL ACAD SCI-BIOL, V78, P1527, DOI 10.1073/pnas.78.3.1527; RICE KG, 1990, J BIOL CHEM, V265, P18429; SAWYER JT, 1988, J BIOL CHEM, V263, P10534; Schauer R., 1988, SIALIC ACIDS REGULAT, P5; SCHWARTZ AL, 1980, J BIOL CHEM, V255, P9033; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; WONG TC, 1987, CARBOHYD RES, V170, P27, DOI 10.1016/0008-6215(87)85003-6	40	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9229	9235						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577757				2022-12-27	WOS:A1992HR85400080
J	TERLECKY, SR; CHIANG, HL; OLSON, TS; DICE, JF				TERLECKY, SR; CHIANG, HL; OLSON, TS; DICE, JF			PROTEIN AND PEPTIDE BINDING AND STIMULATION OF INVITRO LYSOSOMAL PROTEOLYSIS BY THE 73-KDA HEAT-SHOCK COGNATE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROINJECTED RIBONUCLEASE-A; MAMMALIAN STRESS PROTEINS; SACCHAROMYCES-CEREVISIAE; HSP70-LIKE PROTEIN; UNCOATING PROTEIN; SERUM WITHDRAWAL; GENE FAMILY; HUMAN-CELLS; EXPRESSION; MEMBER	Lysosomal degradation of intracellular proteins during serum withdrawal is stimulated by a member of the 70-kDa heat shock protein (hsp70) family (Chiang, H.-L., Terlecky, S. R., Plant, C. P., and Dice, J. F. (1989) Science 246, 382-385). This hsp70, isolated by affinity chromatography with RNase S-peptide-Sepharose, is referred to as the 73-kDa peptide recognition protein (prp73). We now report that prp73 binds to several proteins and peptides whose degradative rates are increased during serum withdrawal. prp73 also binds to the pentapeptide, KFERQ, and more weakly to most modified RNase S-peptide derivatives with a single amino acid substitution within the KFERQ sequence. Taken together, these results suggest that prp73 binds to a variety of proteins at peptide regions biochemically related to KFERQ. Three lines of evidence indicate that prp73 is the heat shock cognate protein of 73 kDa (hsc73): (a) among five hsp70s tested, hsc73 binds to RNase S-peptide most avidly, (b) both prp73 and hsc73 also bind to RNase A and aspartate aminotransferase but not to ovalbumin, lysozyme, or ubiquitin, and (c) both prp73 and hsc73 promote uptake and degradation of [H-3] RNase S-peptide by lysosomes in vitro, while three other hsp70s are without activity in this assay.			TERLECKY, SR (corresponding author), TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG006116, R01AG006116] Funding Source: NIH RePORTER; NIA NIH HHS [AG06116] Funding Source: Medline; NIDDK NIH HHS [DK07542] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVARES K, 1990, P NATL ACAD SCI USA, V87, P5293, DOI 10.1073/pnas.87.14.5293; BACKER JM, 1983, P NATL ACAD SCI-BIOL, V80, P2166, DOI 10.1073/pnas.80.8.2166; BACKER JM, 1986, P NATL ACAD SCI USA, V83, P5830, DOI 10.1073/pnas.83.16.5830; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CAIRO G, 1989, HEPATOLOGY, V9, P740, DOI 10.1002/hep.1840090514; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1987, P NATL ACAD SCI USA, V84, P4156, DOI 10.1073/pnas.84.12.4156; DANA RC, 1990, ENDOCRINOLOGY, V126, P672, DOI 10.1210/endo-126-1-672; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DICE JF, 1989, BIOCHEM SOC SYMP, V55, P45; DICE JF, 1986, J BIOL CHEM, V261, P6853; ELLWOOD MS, 1984, MOL CELL BIOL, V4, P1454, DOI 10.1128/MCB.4.8.1454; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAO BC, 1991, J BIOL CHEM, V266, P19565; GIEBEL LB, 1988, DEV BIOL, V125, P200, DOI 10.1016/0012-1606(88)90073-5; GOFF SA, 1987, DNA-J MOLEC CELL BIO, V6, P381, DOI 10.1089/dna.1987.6.381; GREEN LAD, 1989, J BIOL CHEM, V264, P15210; GUIDON PT, 1986, J CELL PHYSIOL, V128, P239, DOI 10.1002/jcp.1041280215; HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206; HIGHTOWER LE, 1981, J CELL PHYSIOL, V108, P261, DOI 10.1002/jcp.1041080216; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEUNG TKC, 1990, BIOCHEM J, V267, P125, DOI 10.1042/bj2670125; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOWE DG, 1986, J BIOL CHEM, V261, P2102; LOWE DG, 1984, P NATL ACAD SCI-BIOL, V81, P2317, DOI 10.1073/pnas.81.8.2317; MAEKAWA M, 1989, BIOL REPROD, V40, P843, DOI 10.1095/biolreprod40.4.843; MARGULIS BA, 1991, J BIOL CHEM, V266, P9295; MCELLIGOTT MA, 1985, J BIOL CHEM, V260, P1986; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MIZZEN LA, 1989, J BIOL CHEM, V264, P20664; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAPOLITANO EW, 1987, J BIOL CHEM, V262, P1493; NEFF NT, 1981, J CELL BIOL, V91, P184, DOI 10.1083/jcb.91.1.184; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PARDUE M, 1989, STRESS IND PROTEINS; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; SADIS S, 1990, CURRENT RES PROTEIN, P339; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCHREIER AA, 1977, BIOCHEMISTRY-US, V16, P4203, DOI 10.1021/bi00638a012; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SHERWOOD LM, 1965, J BIOL CHEM, V240, P3799; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; ULLMANN A, 1984, GENE, V29, P27, DOI 10.1016/0378-1119(84)90162-8; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; VANBUSKIRK A, 1989, J EXP MED, V170, P1799, DOI 10.1084/jem.170.6.1799; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WING SS, 1991, BIOCHEM J, V275, P165, DOI 10.1042/bj2750165; ZAKERI ZF, 1988, MOL CELL BIOL, V8, P2925, DOI 10.1128/MCB.8.7.2925	67	172	177	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9202	9209						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577755				2022-12-27	WOS:A1992HR85400076
J	WETTENHALL, REH; ERIKSON, E; MALLER, JL				WETTENHALL, REH; ERIKSON, E; MALLER, JL			ORDERED MULTISITE PHOSPHORYLATION OF XENOPUS RIBOSOMAL PROTEIN-S6 BY S6 KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; RAT-LIVER; SUBSTRATE-SPECIFICITY; PEPTIDE ANALOG; INSULIN; PURIFICATION; SUBUNITS; INITIATION; GROWTH; SERUM	Phosphorylated ribosomal proteins were isolated from Xenopus 40 S ribosomal subunits by reversed-phase high performance liquid chromatography (HPLC) to enable direct analysis of the phosphorylation sites in ribosomal protein S6. Xenopus S6 closely resembled mammalian S6 with respect to the following properties: (i) reversed-phase HPLC elution behavior, (ii) amino-terminal sequence (96% identity in the first 37 residues), and (iii) an identical sequence within the region of its phosphorylation sites. Whereas S6 was the only ribosomal protein phosphorylated in vitro by Xenopus S6 kinase II, ribosomes phosphorylated in vivo were found to be associated with an additional phosphoprotein having an amino-terminal sequence identical to that of the ubiquitin carboxyl-terminal extension protein CEP 80. S6 kinase II phosphorylated at least four sites (serines 1-3 and 5) in the sequence Arg-Arg-Leu-Ser(1)-Ser(2)-Leu-Arg-Ala-Ser(3)-Thr-Ser(4)-Lys-Ser(5)-, which correspond to the residues known to be phosphorylated in the carboxyl-terminal region of mammalian S6. The in vivo S6 phosphorylation sites in maturing Xenopus oocytes were shown to be located within the same cluster of serine residues, although individual sites were not identified. Kinetic analysis of S6 kinase II-catalyzed phosphorylation events indicated a simple sequential mechanism of multisite phosphorylation initiating at either serine 2 (preferred) or serine 1, with the rates of phosphorylation of individual sites occurring in the order serine 2 > serine 1 > serine 3 > serine 5.	LA TROBE UNIV, CTR PROT & ENZYME TECHNOL, BUNDOORA, VIC 3083, AUSTRALIA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, HOWARD HUGHES MED INST, DENVER, CO 80262 USA	La Trobe University; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	WETTENHALL, REH (corresponding author), UNIV MELBOURNE, DEPT BIOCHEM, PARKVILLE, VIC 3052, AUSTRALIA.				NIDDK NIH HHS [DK28353] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBERSOLD R, 1990, ANAL BIOCHEM, V187, P56, DOI 10.1016/0003-2697(90)90417-8; ANDRES JL, 1989, J BIOL CHEM, V264, P151; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BRANDON SD, 1991, J BIOL CHEM, V266, P380; CHAN YL, 1988, J BIOL CHEM, V263, P2891; DELGRANDE RW, 1982, EUR J BIOCHEM, V123, P421; DUNCAN R, 1982, EUR J BIOCHEM, V123, P535; ECKOLS TK, 1983, EUR J BIOCHEM, V134, P249, DOI 10.1111/j.1432-1033.1983.tb07558.x; ERIKSON E, 1988, SEC MESS PHOSPHOPROT, V12, P135; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1991, J BIOL CHEM, V266, P5249; ERIKSON E, 1991, METHOD ENZYMOL, V200, P252; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GABRIELLI B, 1984, FEBS LETT, V175, P219, DOI 10.1016/0014-5793(84)80740-1; GORDON J, 1982, CURR TOP CELL REGUL, V21, P89; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HEINZE H, 1988, J BIOL CHEM, V263, P4139; HOUSE C, 1987, J BIOL CHEM, V262, P772; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KRIEG J, 1988, J BIOL CHEM, V263, P11473; KRUSE C, 1985, P NATL ACAD SCI USA, V82, P7515, DOI 10.1073/pnas.82.22.7515; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LEPEUCH CJ, 1983, P NATL ACAD SCI-BIOL, V80, P6858; LUBBEN TH, 1983, J BIOL CHEM, V258, P3992; MARTINPEREZ J, 1983, P NATL ACAD SCI-BIOL, V80, P926, DOI 10.1073/pnas.80.4.926; MONIA BP, 1989, J BIOL CHEM, V264, P4093; NICK HP, 1985, ANAL BIOCHEM, V148, P93, DOI 10.1016/0003-2697(85)90632-3; NIELSEN PJ, 1982, P NATL ACAD SCI-BIOL, V79, P2937, DOI 10.1073/pnas.79.9.2937; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5995; PADEL U, 1985, EUR J BIOCHEM, V151, P1, DOI 10.1111/j.1432-1033.1985.tb09061.x; PARKER PJ, 1985, EUR J BIOCHEM, V148, P579, DOI 10.1111/j.1432-1033.1985.tb08879.x; PELECH SL, 1987, J BIOL CHEM, V262, P11598; PELECH SL, 1986, P NATL ACAD SCI USA, V83, P5968, DOI 10.1073/pnas.83.16.5968; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; SAKANOUE Y, 1987, EUR J BIOCHEM, V168, P669, DOI 10.1111/j.1432-1033.1987.tb13468.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0; WETTENHALL R E H, 1991, Peptide Research, V4, P158; WETTENHALL REH, 1986, J BIOL CHEM, V261, P2444; WETTENHALL REH, 1982, FEBS LETT, V148, P207, DOI 10.1016/0014-5793(82)80809-0; WETTENHALL REH, 1984, J BIOL CHEM, V259, P2084; WETTENHALL REH, 1988, BIOCHEMISTRY-US, V27, P170, DOI 10.1021/bi00401a026; WETTENHALL REH, 1982, FEBS LETT, V140, P263, DOI 10.1016/0014-5793(82)80910-1; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443	48	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9021	9027						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577739				2022-12-27	WOS:A1992HR85400050
J	GHILDYAL, N; MCNEIL, HP; GURISH, MF; AUSTEN, KF; STEVENS, RL				GHILDYAL, N; MCNEIL, HP; GURISH, MF; AUSTEN, KF; STEVENS, RL			TRANSCRIPTIONAL REGULATION OF THE MUCOSAL MAST CELL-SPECIFIC PROTEASE GENE, MMCP-2, BY INTERLEUKIN-10 AND INTERLEUKIN-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONNECTIVE-TISSUE-TYPE; DEFICIENT W/WV MICE; MOLECULAR-CLONING; GROWTH-FACTOR; CARBOXYPEPTIDASE-A; SURFACE EXPRESSION; KINASE RECEPTOR; P-CELL; MOUSE; DIFFERENTIATION	Although transcription of mast cell (MC) secretory granule neutral protease genes has been shown to distinguish MC subclasses in mucosal and serosal environments, the specific cytokines that regulate the expression of these genes have not been determined. To examine cytokine-mediated gene regulation, bone marrow-derived MC (BMMC) differentiated in vitro were obtained by culturing mouse bone marrow progenitor cells in the presence of WEHI-3 cell-conditioned medium, concanavalin A-stimulated splenocyte-conditioned medium (BMMC(C)), or recombinant (r) interleukin (IL)-3 (BMMC(IL-3)). All three populations of BMMC expressed the serosal MC-specific transcripts that encode mouse MC serine protease (MMCP)-5, MMCP-6, and MC carboxypeptidase A. However, only BMMC(C) contained MMCP-2 mRNA, a late expressed gene selectively transcribed by intestinal mucosal MC that proliferate during helminthic infestation in response to the T cell-derived cytokines IL-3, IL-4, and IL-10. When BMMC(IL-3) were exposed to rIL-10 in the presence of either rIL-3 or rIL-4, they expressed MMCP-2 mRNA. Not only was the transcription of the MMCP-2 gene in BMMC dependent on continuous exposure of the cells to rIL-10, but the level of MMCP-2 mRNA in these cells could be down-regulated by rIL-3. These studies comparing the effects of two cytokines on the transcriptional regulation of secretory granule protease genes in MC demonstrate that rIL-10 induces BMMC(IL-3) to express the mucosal MC protease MMCP-2, that rIL-3 attenuates the rIL-10-induced expression of this gene, and that transcription of the MMCP-2 gene is reversed in the absence of rIL-10.	HARVARD UNIV,SCH MED,DEPT MED,SEELEY G MUDD BLDG,RM 617,250 LONGWOOD AVE,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital				McNeil, Hugh Patrick/0000-0003-4336-2960	NIAID NIH HHS [AI-23483, AI-22531, AI-23401] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI023401, R01AI022531, R01AI023483, R37AI022531] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVRAHAM S, 1989, P NATL ACAD SCI USA, V86, P3763, DOI 10.1073/pnas.86.10.3763; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUBUSKE L, 1984, J IMMUNOL, V133, P1535; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P303, DOI 10.1111/apm.1966.66.3.303; GURISH MF, 1991, J IMMUNOL, V146, P1527; GURISH MF, 1992, IN PRESS J EXP MED; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; IHLE JN, 1983, J IMMUNOL, V131, P282; ISHIZAKA T, 1976, J IMMUNOL, V116, P747; KAMADA MM, 1989, J IMMUNOL, V142, P609; KANAKURA Y, 1988, BLOOD, V72, P877; KATZ HR, 1988, J IMMUNOL, V140, P3090; KITAMURA Y, 1978, BLOOD, V52, P447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1988, J CLIN INVEST, V81, P431, DOI 10.1172/JCI113337; LEVISCHAFFER F, 1987, J IMMUNOL, V139, P3431; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; MADDEN KB, 1991, J IMMUNOL, V147, P1387; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MCBRIDE P, 1988, J ALLERGY CLIN IMMUN, V82, P638, DOI 10.1016/0091-6749(88)90977-3; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NAGAO K, 1981, SCIENCE, V212, P333, DOI 10.1126/science.7209531; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; OTSU K, 1987, J EXP MED, V165, P615, DOI 10.1084/jem.165.3.615; RA C, 1989, J BIOL CHEM, V264, P15323; RAZIN E, 1981, P NATL ACAD SCI-BIOL, V78, P2559, DOI 10.1073/pnas.78.4.2559; RAZIN E, 1984, J IMMUNOL, V132, P1479; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1988, J BIOL CHEM, V263, P12783; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SCHRADER JW, 1981, P NATL ACAD SCI-BIOL, V78, P323, DOI 10.1073/pnas.78.1.323; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; SONODA S, 1986, J IMMUNOL, V137, P1319; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; TERTIAN G, 1981, J IMMUNOL, V127, P788; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; Trong H Le, 1989, BIOCHEMISTRY-US, V28, P391, DOI 10.1021/BI00427A054; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	49	91	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8473	8477						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569097				2022-12-27	WOS:A1992HQ18500080
J	MATTINGLY, RR; WASILENKO, WJ; WOODRING, PJ; GARRISON, JC				MATTINGLY, RR; WASILENKO, WJ; WOODRING, PJ; GARRISON, JC			SELECTIVE AMPLIFICATION OF ENDOTHELIN-STIMULATED INOSITOL 1,4,5-TRISPHOSPHATE AND CALCIUM SIGNALING BY V-SRC TRANSFORMATION OF RAT-1 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; PHOSPHATIDYLINOSITOL TURNOVER; PHOSPHOINOSITIDE HYDROLYSIS; CELL-PROLIFERATION; PERTUSSIS TOXIN; GROWTH-FACTOR; G-PROTEINS; 3T3 CELLS; DIACYLGLYCEROL; METABOLISM	The effects of the expression of the protein tyrosine kinase pp60v-src on endothelin- and thrombin-stimulated inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) production and calcium responses were investigated in Rat-1 fibroblasts. The ability of endothelin-1 to induce the accumulation of these second messengers was dramatically amplified by v-src transformation, with 6- and 3-fold enhancements of the peak Ins(1,4,5)P3 and peak calcium responses, respectively. In contrast, thrombin-dependent responses were slightly reduced following v-src transformation, demonstrating that the augmentation of endothelin-stimulated signal transduction is a selective effect. The magnitude of the stimulated accumulation of Ins(1,4,5)P3 presumably depends upon both the functional activation of phospholipase C to produce Ins(1,4,5)P3, and the activity of the enzymes that metabolize Ins(1,4,5)P3. Although the metabolism of Ins(1,4,5)P3 was strikingly altered by expression of pp60v-src, with a bias towards the production of higher inositol polyphosphates that is consistent with an activated Ins(1,4,5)P3 3-kinase, this change could not account for the marked increase in endothelin-stimulated signaling induced by v-src transformation. This suggests that an effect of pp60v-src is expressed at the level of the plasma membrane, through an interaction with one or more components in the receptor/guanine nucleotide binding protein (G protein)/phospholipase C system that transduces the endothelin signal into Ins(1,4,5)P3 production. Preparation of membranes from normal and v-src-transformed cells showed that, while there was no change in the number of high-affinity endothelin binding sites, the release of Ins(1,4,5)P3 in response to guanine nucleotides and endothelin-1 was significantly increased following v-src transformation. In contrast, the Ins(1,4,5)P3 responses to thrombin and high Ca2+ concentrations were unaffected by transformation. Thus the selective interactions within the G protein system that couples the endothelin receptor to phospholipase C are potential sites at which the v-src transformation process may act to amplify endothelin-dependent Ins(1,4,5)P3 production.	UNIV VIRGINIA, SCH MED, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, CTR CANC RES, CHARLOTTESVILLE, VA 22908 USA; EASTERN VIRGINIA MED SCH, DEPT MICROBIOL & IMMUNOL, NORFOLK, VA 23510 USA	University of Virginia; University of Virginia; Eastern Virginia Medical School					NATIONAL CANCER INSTITUTE [R29CA053085, P01CA040042] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40042, R29 CA-53085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER PH, 1991, MOL PHARMACOL, V39, P579; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CALDWELL P C, 1970, P10; CAMPANILE CP, 1982, J BIOL CHEM, V257, P4951; CHIARUGI V, 1987, ONCOGENE, V2, P37; DIRINGER H, 1977, CANCER RES, V37, P2979; FOWLER CJ, 1990, BIOCHEM J, V271, P735, DOI 10.1042/bj2710735; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GRAY GM, 1989, ONCOGENE, V4, P1213; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAN JW, 1990, ONCOGENE, V5, P467; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; LAPETINA EG, 1986, BIOCHIM BIOPHYS ACTA, V884, P219, DOI 10.1016/0304-4165(86)90166-2; LOVENBERG W, 1990, NEUROCHEM RES, V15, P407, DOI 10.1007/BF00969926; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MACARA IG, 1989, PHYSIOL REV, V69, P797, DOI 10.1152/physrev.1989.69.3.797; MACNULTY EE, 1990, BIOCHEM J, V272, P761, DOI 10.1042/bj2720761; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARIN P, 1991, J NEUROCHEM, V56, P1270, DOI 10.1111/j.1471-4159.1991.tb11421.x; MARTIN TFJ, 1991, PHARMACOL THERAPEUT, V49, P329, DOI 10.1016/0163-7258(91)90062-Q; MARTINS TJ, 1989, J CELL BIOL, V108, P683, DOI 10.1083/jcb.108.2.683; MATTINGLY RR, 1991, J BIOL CHEM, V266, P15144; MITSUHASHI T, 1989, J CLIN INVEST, V84, P635, DOI 10.1172/JCI114209; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SHICHIRI M, 1991, J CLIN INVEST, V87, P1867, DOI 10.1172/JCI115210; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; TAYLOR CW, 1990, BIOCHEM J, V272, P1; THOMAS CP, 1991, AM J PHYSIOL, V260, pF347, DOI 10.1152/ajprenal.1991.260.3.F347; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WASILENKO WJ, 1987, J CELL PHYSIOL, V131, P450, DOI 10.1002/jcp.1041310318; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WHITMAN M, 1989, BIOCHIM BIOPHYS ACTA, V948, P327, DOI 10.1016/0304-419X(89)90005-X; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WYKE JA, 1987, BIOCHIM BIOPHYS ACTA, V907, P47, DOI 10.1016/0304-419X(87)90018-7	46	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7470	7477						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559985				2022-12-27	WOS:A1992HN48500041
J	YANG, XJ; MILES, EW				YANG, XJ; MILES, EW			THREONINE-183 AND ADJACENT FLEXIBLE LOOP RESIDUES IN THE TRYPTOPHAN SYNTHASE-ALPHA SUBUNIT HAVE CRITICAL ROLES IN MODULATING THE ENZYMATIC-ACTIVITIES OF THE BETA-SUBUNIT IN THE ALPHA-2-BETA-2 COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET VISIBLE SPECTROSCOPY; SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; L-SERINE; TRIOSEPHOSPHATE ISOMERASE; GUANIDINE-HYDROCHLORIDE; 3-DIMENSIONAL STRUCTURE; MULTIENZYME COMPLEX; MECHANISM	This study investigates the catalytic and allosteric roles of a flexible loop in the tryptophan synthase alpha-2-beta-2-complex. This loop connects helix 6 and strand 6 in the alpha-subunit, an 8-fold alpha/beta-barrel polypeptide. We have engineered three mutations in this disordered loop: a deletion of residues 185-187 and the replacement of threonine 183 by serine (T183S) or by alanine (T183A). Position 183 is a site of an inactivating mutation identified by Yanofsky's group (Yanofsky, C., Drapeau, G. R., Guest, J. R., and Carlton, B. C. (1967) Proc. Natl. Acad. Sci. U.S.A. 57,296-298). The three engineered alpha-subunits form stable, stoichiometric alpha-2-beta-2-complexes with the beta-subunit which bind alpha and beta-subunit ligands. Although changing threonine 183 to serine has little effect on the enzymatic properties, changing threonine 183 to alanine or deleting residues 185-187 results in a 50-fold reduction in the intrinsic activity of the alpha-subunit alone and in the alpha-site activity of the alpha-2-beta-2-complex. The latter two mutations profoundly alter the way in which the alpha-subunit modulates the spectral properties and the activities of the wild-type beta-subunit. These mutations also eliminate the effects of alpha-subunit ligands on the beta-subunit. Although the beta-subunit ligand, L-serine, greatly stabilizes the wild-type alpha-2-beta-2 complex to dissociation and to proteolysis, L-serine stabilizes the T183A alpha-2-beta-2-complex weakly or not at all. Our findings suggest that the hydroxyl residue at position 183 and the adjacent residues in the alpha-subunit loop play critical roles in the reciprocal communication between the alpha and beta-subunits in the alpha-2-beta-2-complex. The results also help to explain how the wild-type alpha-subunit or ammonium ion modulates the activities of the beta-subunit.	NIDDKD, BIOCHEM PHARMACOL LAB, BLDG 8, RM 2A09, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								AHMED SA, 1991, J BIOL CHEM, V266, P21548; AHMED SA, 1988, BIOCHEM BIOPH RES CO, V151, P672, DOI 10.1016/S0006-291X(88)80333-4; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BEASTY AM, 1985, BIOCHEMISTRY-US, V24, P3547, DOI 10.1021/bi00335a024; BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; BRZOVIC PS, 1991, 8TH P INT C VIT B6 C, P277; CRAWFORD IP, 1987, PROTEINS, V2, P118, DOI 10.1002/prot.340020206; CRAWFORD IP, 1989, BIOCHIMIE, V71, P521, DOI 10.1016/0300-9084(89)90183-1; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; CREIGHTON TE, 1966, J BIOL CHEM, V241, P980; CRISANTI MM, 1981, BIOCHEMISTRY-US, V20, P2700, DOI 10.1021/bi00512a052; DREWE WF, 1986, BIOCHEMISTRY-US, V25, P2494, DOI 10.1021/bi00357a032; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 1987, INDIAN J BIOCHEM BIO, V24, P44; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; DUNN MF, 1991, 8TH P INT C VIT B6 C, P257; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; GOLDBERG ME, 1967, BIOCHEMISTRY-US, V6, P2113, DOI 10.1021/bi00859a032; HADERO A, 1986, MOL BIOL EVOL, V3, P191; HATANAKA M, 1962, ARCH BIOCHEM BIOPHYS, V97, P596, DOI 10.1016/0003-9861(62)90129-7; HEILMANN HD, 1978, BIOCHIM BIOPHYS ACTA, V522, P614, DOI 10.1016/0005-2744(78)90092-X; HIGGINS W, 1979, BIOCHEMISTRY-US, V18, P4827, DOI 10.1021/bi00589a010; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HURLE MR, 1987, PROTEINS, V2, P54, DOI 10.1002/prot.340020107; HYDE CC, 1990, BIO-TECHNOL, V8, P27, DOI 10.1038/nbt0190-27; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KAYASTHA AM, 1991, J BIOL CHEM, V266, P7618; KAYASTHA AM, 1991, ANAL BIOCHEM, V193, P200, DOI 10.1016/0003-2697(91)90009-I; KIRSCHNER K, 1975, EUR J BIOCHEM, V60, P513, DOI 10.1111/j.1432-1033.1975.tb21030.x; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1991, BIOCHEMISTRY-US, V30, P479, DOI 10.1021/bi00216a025; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; MATTHEWS CR, 1981, BIOCHEMISTRY-US, V20, P784, DOI 10.1021/bi00507a021; MATTHEWS CR, 1983, BIOCHEMISTRY-US, V22, P1445, DOI 10.1021/bi00275a019; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1988, J BIOL CHEM, V263, P8611; MILES EW, 1982, BIOCHEMISTRY-US, V21, P2586, DOI 10.1021/bi00540a002; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1978, J BIOL CHEM, V253, P6266; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1982, J BIOL CHEM, V257, P4203; MILES EW, 1991, J BIOL CHEM, V266, P10715; MILES EW, 1991, CONFORMATIONS FORCES, P115; MILES EW, 1991, 15TH INT C BIOCH JER, P12; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; PRIESTLE JP, 1987, P NATL ACAD SCI USA, V84, P5690, DOI 10.1073/pnas.84.16.5690; ROY M, 1988, BIOCHEMISTRY-US, V27, P6698, DOI 10.1021/bi00418a009; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SHIRVANEE L, 1990, J BIOL CHEM, V265, P6624; STACKHOUSE TM, 1988, BIOCHEMISTRY-US, V27, P824, DOI 10.1021/bi00402a050; TWEEDY NB, 1990, BIOCHEMISTRY-US, V29, P1539, DOI 10.1021/bi00458a027; WEISCHET WO, 1976, EUR J BIOCHEM, V65, P375, DOI 10.1111/j.1432-1033.1976.tb10351.x; WIERENGA RK, 1991, PROTEINS, V10, P33, DOI 10.1002/prot.340100105; WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; YANG XJ, 1992, FASEB J, V6, pA458; YANOFSKY C, 1966, COLD SPRING HARB SYM, V31, P151, DOI 10.1101/SQB.1966.031.01.023; YANOFSKY C, 1967, P NATL ACAD SCI USA, V57, P296, DOI 10.1073/pnas.57.2.296; Yanofsky C., 1972, ENZYMES, P1, DOI [10.1016/s1874-6047(08)60445-x, DOI 10.1016/S1874-6047(08)60445-X]; YORK SS, 1972, BIOCHEMISTRY-US, V11, P2733, DOI 10.1021/bi00764a029; YUTANI K, 1979, J BIOCHEM-TOKYO, V85, P915, DOI 10.1093/oxfordjournals.jbchem.a132423; YUTANI K, 1980, J MOL BIOL, V144, P455, DOI 10.1016/0022-2836(80)90331-9	72	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7520	7528						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559990				2022-12-27	WOS:A1992HN48500048
J	YUAN, Q; JIANG, WM; LEUNG, E; HOLLANDER, D; WATSON, JD; KRISSANSEN, GW				YUAN, Q; JIANG, WM; LEUNG, E; HOLLANDER, D; WATSON, JD; KRISSANSEN, GW			MOLECULAR-CLONING OF THE MOUSE INTEGRIN BETA-7 SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; COMPLEMENT RECEPTOR TYPE-3; HUMAN INSULIN-RECEPTOR; CYSTEINE-RICH REPEATS; FIBRONECTIN RECEPTOR; INTESTINAL LYMPHOCYTES; VONWILLEBRAND-FACTOR; CYTOPLASMIC DOMAIN; CHAIN REVEALS; ALPHA-SUBUNIT	The complete analysis of a cDNA clone encoding the mouse integrin beta-7 subunit that was isolated from a lambda-gt10 cDNA library prepared from interleukin-4-activated mouse spleen B cells is reported. The 805-amino acid sequence deduced from the cDNA revealed a signal peptide, a 704-amino acid extracellular domain with eight N-glycosylation sites, a transmembrane domain, and a 61-amino acid intracellular domain. Several structural features were conserved with other integrin beta-chains including the four cysteine-rich epidermal growth factor-like repeat sequences in the extracellular domain. Comparative analysis of the mouse and human beta-7 subunits revealed 87% sequence identity with conservation of three potential intracellular tyrosine phosphorylation sites. The cDNA hybridized to two mRNA transcripts of 3 and 2 kilobases (kb) in size. The 3-kb transcript, which is considered the productive form, was found in T and B leukemic cell lines, a macrophage line, and a mastocytoma cell line. Surprisingly, the smaller 2-kb transcript, which seems unlikely to encode a complete beta-7 protein, was found expressed in epithelial cells cultured from mouse skin. The integrin beta-7 subunit displays sequence identity with the beta-subunit of the M290 antigen found expressed almost exclusively on intraepithelial lymphocytes in the small intestine suggesting that beta-7 may play an adhesive role in intraepithelial lymphocytes immuno-surveillance of the gut mucosa. The cellular distribution of beta-7 transcripts is more extensive than the T-lineage-restricted distribution of the M290 antigen, indicating that beta-7 may be the common beta-subunit for more than one receptor or that translation of beta-7 transcripts varies in different cell types.	UNIV AUCKLAND, SCH MED, DEPT MOLEC MED, AUCKLAND, NEW ZEALAND; UNIV CALIF IRVINE, DEPT MED, IRVINE, CA 92717 USA	University of Auckland; University of California System; University of California Irvine			Leung, Euphemia/D-2642-2009	Leung, Euphemia/0000-0002-6932-3188				ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; Ausubel FM, 1988, MOL REPROD DEV; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DESIMONE DW, 1988, J BIOL CHEM, V263, P5333; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOLERS VM, 1989, J EXP MED, V169, P1589, DOI 10.1084/jem.169.5.1589; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KILSHAW PJ, 1990, EUR J IMMUNOL, V20, P2201, DOI 10.1002/eji.1830201008; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; MARCELO CL, 1978, J CELL BIOL, V79, P356, DOI 10.1083/jcb.79.2.356; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SCHIEFERDECKER HL, 1990, J IMMUNOL, V144, P2541; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; YUAN Q, 1990, INT IMMUNOL, V2, P1097, DOI 10.1093/intimm/2.11.1097; YUAN Q, 1991, BIOCHEM BIOPH RES CO, V176, P1443, DOI 10.1016/0006-291X(91)90448-G; YUAN Q, 1991, IN PRESS INT IMMUNOL; ZEGER DL, 1990, IMMUNOGENETICS, V31, P191	32	41	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7352	7358						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559978				2022-12-27	WOS:A1992HN48500024
J	HARPEL, MR; HARTMAN, FC				HARPEL, MR; HARTMAN, FC			ENHANCED CO2/O2 SPECIFICITY OF A SITE-DIRECTED MUTANT OF RIBULOSE-BISPHOSPHATE CARBOXYLASE OXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; RIBULOSEBISPHOSPHATE CARBOXYLASE; RHODOSPIRILLUM-RUBRUM; 1,5-BISPHOSPHATE CARBOXYLASE; SPECIES VARIATION; RESOLUTION; MECHANISM; IONS	The CO2/O2 specificity factor of ribulose-bisphosphate carboxylase/oxygenase partially determines the efficiency of photosynthetic carbon assimilation. Heretofore, engineered alterations of the enzyme have only decreased the selectivity for CO2 utilization. We show that alanyl replacement of active-site Ser-368 of the Rhodospirillum rubrum carboxylase enhances the carboxylation selectivity approximately 1.6-fold over the wild-type level. This enhancement reflects a greater relative decline in oxygenase efficiency than in carboxylase efficiency. In contrast to wild-type enzyme, the carboxylase activity of the Ser-368 mutant protein is not perceptibly inhibited by O2, perhaps indicative of a change in rate-limiting steps in the overall reaction pathway.			HARPEL, MR (corresponding author), OAK RIDGE NATL LAB,DIV BIOL,PROT ENGN PROGRAM,OAK RIDGE,TN 37831, USA.							ABELL LM, 1991, BIOCHEMISTRY-US, V30, P7883, DOI 10.1021/bi00246a002; AHRWEILER PM, 1991, BIOCHEMISTRY-US, V30, P7801, DOI 10.1021/bi00245a020; Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; CHEN ZX, 1991, PLANTA, V183, P597, DOI 10.1007/BF00194282; CHEN ZX, 1991, BIOCHEMISTRY-US, V30, P8846, DOI 10.1021/bi00100a017; CHEN ZX, 1989, J BIOL CHEM, V264, P3051; CHRISTELLER JT, 1979, BIOCHEM J, V183, P747, DOI 10.1042/bj1830747; EDSALL JT, 1985, BIOPHYSICAL CHEM, P558; FRANCONE OL, 1991, BIOCHEMISTRY-US, V30, P10074, DOI 10.1021/bi00106a002; HARPEL MR, 1991, J BIOL CHEM, V266, P24734; Hartman F. C., 1989, J BIOL CHEM, V246, P11784; JAWOROWSKI A, 1984, J BIOL CHEM, V259, P6783; JORDAN DB, 1983, ARCH BIOCHEM BIOPHYS, V227, P425, DOI 10.1016/0003-9861(83)90472-1; JORDAN DB, 1981, NATURE, V291, P513, DOI 10.1038/291513a0; JORDAN DB, 1981, PLANT PHYSIOL, V67, P237, DOI 10.1104/pp.67.2.237; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KRECKL W, 1989, J BIOL CHEM, V264, P10982; KUEHN GD, 1978, BIOCHEM J, V175, P909, DOI 10.1042/bj1750909; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; LORIMER GH, 1976, BIOCHEMISTRY-US, V15, P529, DOI 10.1021/bi00648a012; LUNDQVIST T, 1991, BIOCHEMISTRY-US, V30, P904, DOI 10.1021/bi00218a004; LUNDQVIST T, 1988, J BIOL CHEM, V263, P3643; NIYOGI SK, 1986, J BIOL CHEM, V261, P87; PIERCE J, 1986, BIOCHEMISTRY-US, V25, P1636, DOI 10.1021/bi00355a029; PIERCE J, 1986, J BIOL CHEM, V261, P248; ROBISON PD, 1979, BIOCHEMISTRY-US, V18, P4453, DOI 10.1021/bi00588a001; SCHLOSS JV, 1990, ENZYMATIC MODEL CARB, P321; SCHNEIDER G, 1990, J MOL BIOL, V211, P989, DOI 10.1016/0022-2836(90)90088-4; SMITH HB, 1990, J BIOL CHEM, V265, P1243; VANDYK DE, 1986, BIOCHEMISTRY-US, V25, P5145, DOI 10.1021/bi00366a024	30	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6475	6478						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551863				2022-12-27	WOS:A1992HM05300007
J	LANGUINO, LR; RUOSLAHTI, E				LANGUINO, LR; RUOSLAHTI, E			AN ALTERNATIVE FORM OF THE INTEGRIN BETA-1-SUBUNIT WITH A VARIANT CYTOPLASMIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN RECEPTOR; HUMAN-PLATELETS; CELLS; PROTEINS; SUBUNIT; FAMILY	We have identified an alternatively spliced form of the human beta(1) integrin subunit, beta(1s). The beta(1s) mRNA is expressed in human platelets, HEL and K562 erythroleukemia cell lines, and THP1 monocytic and HL60 promyelocytic cell lines. It is undetectable in peripheral blood lymphocytes and cultured umbilical vein endothelial cells at early passages. The beta(1s) cDNA encodes a new cytoplasmic domain distinct from the previously reported alternative cytoplasmic domain of the beta(1) subunit. The sequence reveals the presence of an insert of 116 nucleotides which produces a frame shift in the previously reported 3' end of the beta(1) integrin subunit and codes for a unique 48-amino acid COOH-terminal sequence. An antiserum prepared against a synthetic peptide generated from the deduced sequence of the beta(1s) cytoplasmic domain immunoprecipitated an HEL cell surface molecule that comigrated with the usual beta(1) subunit in sodium dodecyl sulfate electrophoresis. The immunoprecipitation indicated that beta(1s) constitutes a minor portion of total beta(1) subunit in these cells. This variant beta(1) cytoplasmic tail may modulate integrin affinity and may provide additional modes for the transduction of extracellular signals and modulation of cytoskeletal organization by beta(1) integrins.	LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute				Languino, Lucia/0000-0001-9011-7031	NATIONAL CANCER INSTITUTE [P30CA030199, R35CA042507] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026838] Funding Source: NIH RePORTER; NCI NIH HHS [CA42507, CA30199] Funding Source: Medline; NHLBI NIH HHS [HL26838] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BRAY PF, 1990, J BIOL CHEM, V265, P9587; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LANZA F, 1990, J BIOL CHEM, V265, P18098; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; PLOW EF, 1986, BIOCH PLATELETS, P226; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; TAPLEY P, 1989, ONCOGENE, V4, P325; VANKUPPEVELT THM, 1989, P NATL ACAD SCI USA, V264, P13369	22	112	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7116	7120						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551917				2022-12-27	WOS:A1992HM05300101
J	THOMAS, JR; MCCONVILLE, MJ; THOMASOATES, JE; HOMANS, SW; FERGUSON, MAJ; GORIN, PAJ; GREIS, KD; TURCO, SJ				THOMAS, JR; MCCONVILLE, MJ; THOMASOATES, JE; HOMANS, SW; FERGUSON, MAJ; GORIN, PAJ; GREIS, KD; TURCO, SJ			REFINED STRUCTURE OF THE LIPOPHOSPHOGLYCAN OF LEISHMANIA-DONOVANI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HARTMANN-HAHN SPECTROSCOPY; MAJOR PROMASTIGOTES; H-1-NMR SPECTRA; GLYCOLIPIDS; GALACTOFURANOSE; ASSIGNMENT; MOIETY; FAMILY	The primary structure of the major surface glycoconjugate of Leishmania donovani parasites, a lipophosphoglycan, has been further characterized. The repeating PO4-6Galp-beta-1-4Man disaccharide units, which are a salient feature of the molecule, are shown to terminate with one of several neutral structures, the most abundant of which is the branched trisaccharide Galp-beta-1-4(Manp-alpha-1-2)Man. The phosphosaccharide core of lipophosphoglycan, which links the disaccharide repeats to a lipid anchor, contains 2 phosphate residues. One of the core phosphates has previously been localized on O-6 of the galactosyl residue distal to the lipid anchor; the second phosphate is now shown to be on O-6 of the mannosyl residue distal to the anchor and to bear an alpha-linked glucopyranosyl residue. Also, the anomeric configuration of the unusual 3-substituted Galf residue in the phosphosaccharide core is established as beta. The complete structure of the core is thus PO4-6Galp-alpha-1-6Galp-alpha-1-3Galf-beta-1-3[Glcp-alpha-1-PO4-6]Manp-alpha-1-3Manp-alpha-1-4GlcN-alpha-1-. This further clarification of the structure of lipophosphoglycan may prove beneficial in determining the structure-function relationships of this highly unusual glycoconjugate.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND; UNIV FED PARANA,DEPT BIOQUIM,BR-81504 CURITIBA,PARANA,BRAZIL; UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Dundee; Universidade Federal do Parana; University of Kentucky			Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714; Greis, Kenneth/0000-0002-5316-3351	NIAID NIH HHS [AI204941] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DAVIES CR, 1990, PARASITOLOGY, V101, P337, DOI 10.1017/S0031182000060522; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DEJONGH DC, 1969, J AM CHEM SOC, V91, P1728, DOI 10.1021/ja01035a022; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HANDMAN E, 1985, EMBO J, V4, P329, DOI 10.1002/j.1460-2075.1985.tb03633.x; HOMANS SW, 1987, P NATL ACAD SCI USA, V84, P1202, DOI 10.1073/pnas.84.5.1202; ILG T, 1992, J BIOL CHEM, V267, P6834; INAGAKI F, 1987, FEBS LETT, V212, P91, DOI 10.1016/0014-5793(87)81563-6; INAGAKI F, 1987, FEBS LETT, V219, P445; Lonngren J., 1974, ADV CARBOHYD CHEM BI, V29, P41; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; MCNEELY TB, 1989, BIOCHEM J, V259, P601, DOI 10.1042/bj2590601; NEUHAUS D, 1984, J MAGN RESON, V57, P164, DOI 10.1016/0022-2364(84)90250-6; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PUENTES SM, 1988, J EXP MED, V167, P887, DOI 10.1084/jem.167.3.887; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SACKS DL, 1989, EXP PARASITOL, V69, P100, DOI 10.1016/0014-4894(89)90176-8; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; SWEET DP, 1975, CARBOHYD RES, V40, P217, DOI 10.1016/S0008-6215(00)82604-X; TALAMASROHANA P, 1990, J IMMUNOL, V144, P4817; TSUI DS, 1986, CARBOHYD RES, V156, P1, DOI 10.1016/S0008-6215(00)90094-6; TURCO SJ, 1990, EXP PARASITOL, V70, P241, DOI 10.1016/0014-4894(90)90105-L; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042; TURCO SJ, 1989, J BIOL CHEM, V264, P6711	29	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6829	6833						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551889				2022-12-27	WOS:A1992HM05300057
J	SKALHEGG, BS; LANDMARK, B; FOSS, KB; LOHMANN, SM; HANSSON, V; LEA, T; JAHNSEN, T				SKALHEGG, BS; LANDMARK, B; FOSS, KB; LOHMANN, SM; HANSSON, V; LEA, T; JAHNSEN, T			IDENTIFICATION, PURIFICATION, AND CHARACTERIZATION OF SUBUNITS OF CAMP-DEPENDENT PROTEIN-KINASE IN HUMAN TESTIS - REVERSE MOBILITIES OF HUMAN RII-ALPHA AND RII-BETA ON SODIUM DODECYL SULFATE-POLYACRYLAMIDE GEL-ELECTROPHORESIS COMPARED WITH RAT AND BOVINE RIIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; I REGULATORY SUBUNIT; FOLLICLE-STIMULATING HORMONE; OVARIAN GRANULOSA-CELLS; MOLECULAR-CLONING; CDNA STRUCTURE; MESSENGER-RNA; CATALYTIC SUBUNIT; EXPRESSION; TISSUES	We have previously identified and characterized regulatory (R) subunits of cyclic AMP-dependent protein kinase, particularly the RII subunits in rat tissues (Jahnsen, T., Lohmann, S. M., Walter, U., Hedin, L., and Richards, J. S. (1985) J. Biol. Chem. 260, 15980-15987; Jahnsen, T., Hedin, L., Lohmann, S. M., Walter, U., and Richards, J. S. (1986) J. Biol. Chem. 261, 6637-6639; Jahnsen, T., Hedin, L., Kidd, V. J., Beattie, W. G., Lohmann, S. M., Walter, U., Durica, J., Schulz, T. Z., Schiltz, E., Browner, M., Lawrence, C. B., Goldman, D., Ratoosh, S. L., and Richards, J. S. (1986) J. Biol. Chem. 261,12352-12361). These studies showed that rat RII(alpha) and RII(beta), had apparent molecular masses of 54 and 52 kDa, respectively. The aim of the present study was to purify and characterize cAMP-dependent protein kinase R subunits in human testis and to examine which of the subunits (mRNAs and proteins) are present in this tissue. Our results show that human testis contains mRNAs for five out of the seven known subunits of cAMP-dependent protein kinase. We observed strong expression of mRNAs for RI(alpha) (1.5 and 3.2 kilobases (kb)), RII(alpha) (2.2, 2.4, and 7.0 kb), and RII(beta) (3.3 kb). We also demonstrated mRNAs for two of the three catalytic subunits, C(alpha) (2.7 kb) and C(gamma) (1.7 kb). Purification of R subunits by DEAE-cellulose and cAMP affinity chromatography revealed three distinct forms with apparent molecular masses of 49, 51, and 53 kDa, respectively. Characterization of these R subunits by their 8-azido-cAMP photoaffinity labeling and immunoreactivity, as well as by a phosphorylation-dependent mobility shift on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), indicated subunit sizes of RII(beta) (53 kDa) > RII(alpha) dephosphoform (51 kDa) > RI(alpha) (49 kDa). This conclusion was verified by the analysis of RII subunits produced by in vitro transcription/translation of full-length cDNAs for both human RII(alpha) and RII(beta) in wheat germ lysates. The in vitro translated products were the same size as the purified human testis subunits, and only the smallest RII subunit (RII(alpha)) revealed a distinct mobility shift on SDS-PAGE after phosphorylation/dephosphorylation. This study supports the conclusion that the mobilities of human RII subunits (RII(alpha), RII(beta)) on SDS-PAGE are reversed in contrast with those of other species such as rat and bovine. This has to be taken into consideration when examining R subunits in other human tissues by methods such as photoaffinity labeling which cannot distinguish subtype identities.	UNIV OSLO,INST MED BIOCHEM,N-0317 OSLO 3,NORWAY; NATL HOSP NORWAY,INST IMMUNOL & RHEUMATOL,N-0027 OSLO 1,NORWAY	University of Oslo; University of Oslo; National Hospital Norway	SKALHEGG, BS (corresponding author), NATL HOSP NORWAY,INST PATHOL,N-0027 OSLO 1,NORWAY.		Landmark, Brynjar/AAK-2165-2020; Skålhegg, Bjørn Steen/AAZ-2976-2021	Skålhegg, Bjørn Steen/0000-0002-3481-8084				BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BEEBE SJ, 1986, ENZYMES, V17, P43; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMSON HN, 1984, CRC CR REV BIOCH MOL, V15, P93, DOI 10.3109/10409238409102298; Carlson G M, 1979, Adv Enzymol Relat Areas Mol Biol, V50, P41; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1975, J BIOL CHEM, V250, P218; DORRINGTON JH, 1975, MOL CELL ENDOCRINOL, V3, P57, DOI 10.1016/0303-7207(75)90031-3; EKANGER R, 1985, J BIOL CHEM, V260, P3393; FROYSA A, 1988, MOL CELL ENDOCRINOL, P65; GLASS DB, 1980, ANNU REV PHARMACOL, V20, P363, DOI 10.1146/annurev.pa.20.040180.002051; HEMMINGS BA, 1986, FEBS LETT, V209, P219, DOI 10.1016/0014-5793(86)81114-0; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; JAHNSEN T, 1986, J BIOL CHEM, V261, P6637; JAHNSEN T, 1985, J BIOL CHEM, V260, P5980; KUO JF, 1969, P NATL ACAD SCI USA, V64, P1349, DOI 10.1073/pnas.64.4.1349; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; MANIATIS T, 1982, MOL CLONING LABORATO, P447; MASSA JS, 1990, MOL REPROD DEV, V26, P129, DOI 10.1002/mrd.1080260206; MEANS AR, 1976, BIOL REPROD, V14, P54, DOI 10.1095/biolreprod14.1.54; NILSEN DA, 1986, NUCLEIC ACIDS RES, V14, P5963; NIMMO HG, 1977, ADV CYCLIC NUCLEOTID, V48, P923; OYEN O, 1990, BIOL REPROD, V43, P46, DOI 10.1095/biolreprod43.1.46; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; ROBINSONSTEINER AM, 1984, J BIOL CHEM, V259, P596; SANDBERG M, 1988, BIOCHEM BIOPH RES CO, V154, P705, DOI 10.1016/0006-291X(88)90197-0; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; SOLBERG R, 1991, BIOCHEM BIOPH RES CO, V176, P166, DOI 10.1016/0006-291X(91)90904-L; SPURILL WA, 1983, P NATL ACAD SCI USA, V80, P993; STEIN JC, 1985, J BIOL CHEM, V260, P991; STEINBERGER A, 1978, BIOL REPROD, V19, P566, DOI 10.1095/biolreprod19.3.566; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4200, DOI 10.1021/bi00313a029; TASH JS, 1986, J CELL BIOL, V103, P649, DOI 10.1083/jcb.103.2.649; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TORTORA G, 1990, P NATL ACAD SCI USA, V87, P705, DOI 10.1073/pnas.87.2.705; UHLER MD, 1986, J BIOL CHEM, V261, P5360; WALTER U, 1983, METHOD ENZYMOL, V99, P154	42	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5374	5379						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544918				2022-12-27	WOS:A1992HH74700058
J	HASHIMOTO, M; SHODA, A; INOUE, S; YAMADA, R; KONDO, T; SAKURAI, T; UENO, N; MURAMATSU, M				HASHIMOTO, M; SHODA, A; INOUE, S; YAMADA, R; KONDO, T; SAKURAI, T; UENO, N; MURAMATSU, M			FUNCTIONAL REGULATION OF OSTEOBLASTIC CELLS BY THE INTERACTION OF ACTIVIN-A WITH FOLLISTATIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH-FACTOR; ERYTHROID-DIFFERENTIATION FACTOR; INHIBITS PROLIFERATION; RAT FOLLISTATIN; BONE-FORMATION; FACTOR-BETA; PROTEIN; EXPRESSION; CHAIN; IDENTIFICATION	A high number of I-125-activin-A binding sites (an apparent K(d) of 260 pM and 5,600 sites/cell) were observed on MC3T3-E1 cells, a well characterized osteoblastic cell line. Activin-A has a mitogenic effect on these cells, with the greatest influence being observed on cells in an undifferentiated state, as well as a suppressive effect on the alkaline phosphatase activity. Northern and ligand blotting analyses revealed that these osteoblastic cells produce follistatin, which was down-regulated by retinoic acid treatment. Because follistatin is an activin-A-binding protein, we suggest that activin-A modulates the function of osteoblastic cells by being regulated by follistatin during differentiation.	UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT ANAT,BUNKYO KU,TOKYO 113,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; University of Tokyo; University of Tsukuba				Ueno, Naoto/0000-0002-8375-2317				ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; CHENU C, 1988, P NATL ACAD SCI USA, V85, P5683, DOI 10.1073/pnas.85.15.5683; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; GRAY TK, 1987, P NATL ACAD SCI USA, V84, P6267, DOI 10.1073/pnas.84.17.6267; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; KAISER M, 1990, ENDOCRINOLOGY, V126, P2768, DOI 10.1210/endo-126-5-2768; KOGAWA K, 1991, ENDOCRINOLOGY, V128, P1434, DOI 10.1210/endo-128-3-1434; KOJIMA I, 1989, BIOCHEM BIOPH RES CO, V159, P1107, DOI 10.1016/0006-291X(89)92223-7; KONDO S, 1989, BIOCHEM BIOPH RES CO, V161, P1267, DOI 10.1016/0006-291X(89)91379-X; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MICHEL U, 1990, BIOCHEM BIOPH RES CO, V173, P401, DOI 10.1016/S0006-291X(05)81072-1; MURATA M, 1988, P NATL ACAD SCI USA, V85, P2434, DOI 10.1073/pnas.85.8.2434; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; NAKAYAMA Y, 1990, FEBS LETT, V261, P93, DOI 10.1016/0014-5793(90)80644-X; NODA M, 1986, BIOCHEM BIOPH RES CO, V140, P56, DOI 10.1016/0006-291X(86)91057-0; ROBEY PG, 1987, J CELL BIOL, V105, P457, DOI 10.1083/jcb.105.1.457; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SEYDIN SM, 1987, J BIOL CHEM, V262, P1946; SEYDINN SM, 1986, J BIOL CHEM, V261, P5693; SHIMASAKI S, 1989, MOL ENDOCRINOL, V3, P651, DOI 10.1210/mend-3-4-651; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; SUGINO H, 1988, J BIOL CHEM, V263, P15249; TASHIRO K, 1991, BIOCHEM BIOPH RES CO, V174, P1022, DOI 10.1016/0006-291X(91)91521-D; UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282; UENO N, 1990, Progress in Growth Factor Research, V2, P113, DOI 10.1016/0955-2235(90)90027-H; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; VANDENEIJNDENVA.AJ, 1990, NATURE, V345, P729; VFANDENEIJNDENV.AJ, 1991, MECH DEV, V33, P157; VUKICEVIC S, 1990, BIOCHEM BIOPH RES CO, V166, P750, DOI 10.1016/0006-291X(90)90873-L; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	39	103	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4999	5004						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537876				2022-12-27	WOS:A1992HF64200105
J	WEISINGER, G; DECRISTOFARO, JD; LAGAMMA, EF				WEISINGER, G; DECRISTOFARO, JD; LAGAMMA, EF			TISSUE-SPECIFIC AND TREATMENT-SPECIFIC USAGE OF MULTIPLE PREPROENKEPHALIN TRANSCRIPTIONAL START SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; MESSENGER-RNA; PROENKEPHALIN GENE; RAT; EXPRESSION; MECHANISMS; PEPTIDES; ELEMENTS	The significance of the 5' heterogeneity of the transmitter gene ppEnk was evaluated by comparing start site usage (E1-E4) between 12 tissues from untreated rats, using primer extension analysis. In the basal state, we found that E3- and E4-initiated transcripts accounted for 80% of the total striatal RNA present compared with a preferential usage of the E2 start site in all other tissues. To determine whether this selective expression could be modified by biologically relevant pathways, rats were made hypoglycemic. After insulin shock, only E3 + E4-initiated transcripts increased (16-fold at 1 day) in the adrenal medulla but were unaffected in the striatum. As the effects of insulin shock on the adrenal medulla are mediated by cholinergic pathways and the striatum also receives cholinergic inputs, we also compared the effects of cholinergic drug treatments on start site usage in these two tissues. Rats were treated with cholinergic agonists (nicotine + oxotremorine) which induced adrenomedullary E2 and E3 + E4 transcripts (5- and 80-fold, respectively). This effect peaked at 2 days. In contrast, in the same animals, striatal ppEnk RNA (E3 + E4) increased only 10-15-fold after drug treatment. Hence it appears that biologically relevant whole animal stimuli (insulin shock or cholinergic agents) activate biochemical pathways, which affect start site usage in a tissue-specific fashion. Selective RNA start site usage suggests a biological significance, which may be important in the widespread tissue expression of this gene.	SUNY STONY BROOK,DEPT NEUROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	WEISINGER, G (corresponding author), SUNY STONY BROOK,DEPT PEDIAT,HSC-T11,STONY BROOK,NY 11794, USA.			LaGamma, Edmund/0000-0001-9720-1949				BLACK IB, 1987, SCIENCE, V236, P1263, DOI 10.1126/science.2884727; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECRISTOFARO JD, 1990, NEUROSCIENCE, V35, P203, DOI 10.1016/0306-4522(90)90135-Q; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GARRETT JE, 1989, MOL CELL BIOL, V9, P4381, DOI 10.1128/MCB.9.10.4381; JEANNOTTE L, 1987, MOL ENDOCRINOL, V1, P749, DOI 10.1210/mend-1-10-749; JULIUS MA, 1988, ONCOGENE, V2, P469; KANAMATSU T, 1986, P NATL ACAD SCI USA, V83, P9245, DOI 10.1073/pnas.83.23.9245; KAPITO RR, 1987, P NATL ACAD SCI USA, V84, P7149; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; KINGSTON RE, 1988, CURRENT PROTOCOLS MO; LAGAMMA CF, 1992, IN PRESS MOL BRAIN R; LAGAMMA CF, 1991, MOL CELL NEUROSCI, V2, P517; LAGAMMA EF, 1989, MOL BIOL STRESS, P143; LAGAMMA EF, 1988, INT J DEV NEUROSCI, V7, P499; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MOCCHETTI I, 1985, MOL PHARMACOL, V28, P86; MORRIS BJ, 1988, MOL BRAIN RES, V4, P15, DOI 10.1016/0169-328X(88)90013-7; NODA M, 1982, NATURE, V297, P431, DOI 10.1038/297431a0; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; ROSEN H, 1984, J BIOL CHEM, V259, P4309; Sharp P A, 1980, Methods Enzymol, V65, P750; SPRUCE BA, 1990, EMBO J, V9, P1787, DOI 10.1002/j.1460-2075.1990.tb08303.x; SUTCLIFFE JG, 1988, ANNU REV NEUROSCI, V11, P157, DOI 10.1146/annurev.ne.11.030188.001105; TERAO M, 1983, EMBO J, V2, P2223, DOI 10.1002/j.1460-2075.1983.tb01727.x; WEISINGER G, 1988, ONCOGENE, V3, P635; WEISINGER G, 1990, J BIOL CHEM, V265, P17389; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x; YOSHIKAWA K, 1984, J BIOL CHEM, V259, P4301; ZAR JH, 1974, BIOSTAT ANAL, P101	34	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4508	4512						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537835				2022-12-27	WOS:A1992HF64200037
J	POOLMAN, B; MODDERMAN, R; REIZER, J				POOLMAN, B; MODDERMAN, R; REIZER, J			LACTOSE TRANSPORT-SYSTEM OF STREPTOCOCCUS-THERMOPHILUS - THE ROLE OF HISTIDINE-RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; DEPENDENT PROTON TRANSPORT; SITE-DIRECTED MUTANTS; ESCHERICHIA-COLI; LAC PERMEASE; NUCLEOTIDE-SEQUENCES; BACILLUS-SUBTILIS; MELIBIOSE CARRIER; ENHANCED RECOGNITION; PHOSPHOENOLPYRUVATE	The lactose transport protein (LacS) of Streptococcus thermophilus is a chimeric protein consisting of an amino-terminal carrier domain and a carboxyl-terminal phosphoenolpyruvate:sugar phosphotransferase system (PTS) IIA protein domain. The histidine residues of LacS were changed individually into glutamine or arginine residues. Of the 11 histidine residues present in LacS, only the His-376 substitution in the carrier domain significantly affected sugar transport. The region around His-376 was found to exhibit sequence similarity to the region around His-322 of the lactose transport protein (LacY) of Escherichia coli, which has been implicated in sugar binding and in coupling of sugar and H+ transport. The H376Q mutation resulted in a reduced rate of uptake and altered affinity for lactose (beta-galactoside), melibiose (alpha-galactoside), and the lactose analog methyl-beta-D-thiogalactopyranoside. Similarly, the extent of accumulation of the galactosides by cells expressing LacS(H376Q) was highly reduced in comparison to cells bearing the wild-type protein. Nonequilibrium exchange of lactose and methyl-beta-D-thiogalactopyranoside by the H376Q mutant was approximately 2-fold reduced in comparison to the activity of the wild-type transport protein. The data indicate that His-376 is involved in sugar recognition and is important, but not essential, for the cotransport of protons and galactosides. The carboxyl-terminal domain of LacS contains 2 histidine residues (His-537 and His-552) that are conserved in seven homologous IIA protein(s) (domains) of PTSs. P-enolpyruvate-dependent phosphorylation of wild-type LacS, but not of the mutant H552Q, was demonstrated using purified Enzyme I and HPr, the general energy coupling proteins of the PTS, and inside-out membrane vesicles isolated from E. coli in which the lactose transport gene was expressed. The His-537 and His-552 mutations did not affect transport activity when the corresponding genes were expressed in E. coli.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	POOLMAN, B (corresponding author), UNIV GRONINGEN,DEPT MICROBIOL,KERKLAAN 30,9751 NN HAREN,NETHERLANDS.		Poolman, Bert/D-1882-2012					ASLANIDIS C, 1989, J BACTERIOL, V171, P6753, DOI 10.1128/jb.171.12.6753-6763.1989; BASSILANA M, 1987, J BIOL CHEM, V262, P16865; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CARRASCO N, 1989, BIOCHEMISTRY-US, V28, P2533, DOI 10.1021/bi00432a028; CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; COLLINS JC, 1989, J BIOL CHEM, V264, P14698; DORSCHUG M, 1984, EUR J BIOCHEM, V144, P113, DOI 10.1111/j.1432-1033.1984.tb08438.x; FRANCO PJ, 1989, J BIOL CHEM, V264, P15988; FRANCO PJ, 1991, J BIOL CHEM, V266, P6693; GONZYTREBOUL G, 1989, MOL MICROBIOL, V3, P103, DOI 10.1111/j.1365-2958.1989.tb00109.x; KING SC, 1989, J BIOL CHEM, V264, P7390; KING SC, 1990, J BIOL CHEM, V265, P3153; KING SC, 1989, BIOCHIM BIOPHYS ACTA, V982, P253, DOI 10.1016/0005-2736(89)90062-X; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JA, 1989, BIOCHEMISTRY-US, V28, P2540, DOI 10.1021/bi00432a029; LIAU DI, 1991, BIOCHEMISTRY-US, V30, P9583; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MCMORROW I, 1988, BIOCHIM BIOPHYS ACTA, V945, P315, DOI 10.1016/0005-2736(88)90494-4; MENICK DR, 1987, BIOCHEMISTRY-US, V26, P6638, DOI 10.1021/bi00395a012; NELSON SO, 1986, EUR J BIOCHEM, V154, P337, DOI 10.1111/j.1432-1033.1986.tb09402.x; NELSON SO, 1983, EMBO J, V3, P1587; NIEFIND K, 1991, J MOL BIOL, V219, P481, DOI 10.1016/0022-2836(91)90188-C; POOLMAN B, 1989, J BACTERIOL, V171, P244, DOI 10.1128/jb.171.1.244-253.1989; POOLMAN B, 1990, J BACTERIOL, V172, P4037, DOI 10.1128/jb.172.7.4037-4047.1990; POOLMAN B, 1983, EUR J BIOCHEM, V135, P41, DOI 10.1111/j.1432-1033.1983.tb07615.x; POOLMAN B, 1990, MOL MICROBIOL, V4, P1629, DOI 10.1111/j.1365-2958.1990.tb00539.x; POURCHER T, 1990, PHILOS T ROY SOC B, V326, P411, DOI 10.1098/rstb.1990.0021; POURCHER T, 1990, P NATL ACAD SCI USA, V87, P468, DOI 10.1073/pnas.87.1.468; PUTTNER IB, 1986, BIOCHEMISTRY-US, V25, P4483; PUTTNER IB, 1989, BIOCHEMISTRY-US, V28, P2525, DOI 10.1021/bi00432a027; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; ROGERS MJ, 1988, GENE, V62, P197; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR HK, 1988, P NATL ACAD SCI USA, V85, P5463, DOI 10.1073/pnas.85.15.5463; SATO Y, 1989, J BACTERIOL, V171, P263, DOI 10.1128/jb.171.1.263-271.1989; SCHNETZ K, 1987, J BACTERIOL, V169, P2579, DOI 10.1128/jb.169.6.2579-2590.1987; SUTRINA SL, 1990, J BIOL CHEM, V265, P18581; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; VOGLER AP, 1988, MOL MICROBIOL, V2, P719, DOI 10.1111/j.1365-2958.1988.tb00082.x; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAZYU H, 1984, J BIOL CHEM, V259, P4320	49	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9150	9157						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577752				2022-12-27	WOS:A1992HR85400070
J	ZEROVNIK, E; JERALA, R; KROONZITKO, L; PAIN, RH; TURK, V				ZEROVNIK, E; JERALA, R; KROONZITKO, L; PAIN, RH; TURK, V			INTERMEDIATES IN DENATURATION OF A SMALL GLOBULAR PROTEIN, RECOMBINANT HUMAN STEFIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC-ANHYDRASE-B; RAY CRYSTAL-STRUCTURE; MOLTEN-GLOBULE; ALPHA-LACTALBUMIN; FOLDING INTERMEDIATE; CONFORMATIONAL TRANSITIONS; EQUILIBRIUM DENATURATION; CHICKEN CYSTATIN; GROWTH-HORMONE; STATE	Guanidinium HCl (GdmHCl), pH, and heat denaturation of the recombinant human stefin B, a low molecular weight protein inhibitor of cysteine proteinases, has been followed by circular dichroism. From the noncoincidence of the transitions in the near and far UV, the existence of stable intermediate states possessing few persistent tertiary interactions but most of the native-like secondary structure, was inferred. These intermediate states exist at equilibrium under various conditions, namely, state G at 1.7 M GdmHCl (pH 8, 25-degrees-C), state A at pH 4 (0.6 M GdmHCl, 25-degrees-C) and state T above 68-degrees-C. By size exclusion chromatography, their apparent compactness was determined. The intermediate states A, T, and G were compact and are therefore classified as "molten globule" states.	UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT BIOCHEM & GENET, Newcastle Upon Tyne NE2 4HH, ENGLAND	Newcastle University - UK	ZEROVNIK, E (corresponding author), EDVARD KARDELJ UNIV, INST J STEFAN, DEPT BIOCHEM, JAMOVA 39, YU-61000 LJUBLJANA, SLOVENIA.		Zerovnik, Eva/AAB-6498-2022; Jerala, Roman/H-9850-2015	Jerala, Roman/0000-0002-6337-5251				BARRETT AJ, 1986, BIOCHEM J, V236, P312, DOI 10.1042/bj2360312; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BRAZHNIKOV EV, 1985, BIOPOLYMERS, V24, P1899, DOI 10.1002/bip.360241005; BREMS DN, 1985, BIOCHEMISTRY-US, V24, P7662, DOI 10.1021/bi00347a025; BREMS DN, 1990, J BIOL CHEM, V265, P5504; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; DAVIS LC, 1983, J CHROMATOGR SCI, V21, P214, DOI 10.1093/chromsci/21.5.214; DOLGIKH DA, 1984, FEBS LETT, V165, P88, DOI 10.1016/0014-5793(84)80020-4; ENDO S, 1983, ANAL BIOCHEM, V131, P108, DOI 10.1016/0003-2697(83)90141-0; GOLDBERG ME, 1990, FEBS LETT, V263, P51, DOI 10.1016/0014-5793(90)80703-L; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; JAGANNADHAM MV, 1985, FEBS LETT, V188, P326, DOI 10.1016/0014-5793(85)80396-3; JERALA R, 1988, FEBS LETT, V239, P41, DOI 10.1016/0014-5793(88)80541-6; JERALA R, 1990, BIOL CHEM H-S, V371, P157; KRIVACIC JR, 1971, ANAL CHEM, V43, P1508, DOI 10.1021/ac60305a031; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Lenarcic B., 1986, CYSTEINE PROTEINASES, P473; MATTHEWS CR, 1981, BIOCHEMISTRY-US, V20, P784, DOI 10.1021/bi00507a021; MITCHINSON C, 1985, J MOL BIOL, V184, P331, DOI 10.1016/0022-2836(85)90384-5; NOZAKA M, 1978, BIOCHEMISTRY-US, V17, P3753, DOI 10.1021/bi00611a013; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; PFEIL W, 1987, BIOCHIM BIOPHYS ACTA, V911, P114, DOI 10.1016/0167-4838(87)90277-9; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RITONJA A, 1985, BIOCHEM BIOPH RES CO, V131, P1187, DOI 10.1016/0006-291X(85)90216-5; ROBSON B, 1976, BIOCHEM J, V155, P331, DOI 10.1042/bj1550331; SAITO Y, 1983, BIOPOLYMERS, V22, P2123, DOI 10.1002/bip.360220910; SHALONGO W, 1989, BIOCHEMISTRY-US, V28, P4820, DOI 10.1021/bi00437a045; SHALONGO W, 1987, BIOCHEMISTRY-US, V26, P3135, DOI 10.1021/bi00385a029; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; WEDLER FC, 1991, BIOCHIM BIOPHYS ACTA, V1076, P161, DOI 10.1016/0167-4838(91)90235-R; WONG KP, 1973, J BIOL CHEM, V248, P8518; ZEROVNIK E, 1990, BIOL CHEM H-S, V371, P151; ZEROVNIK E, 1991, BIOCHIM BIOPHYS ACTA, V1078, P313, DOI 10.1016/0167-4838(91)90149-T	40	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9041	9046						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577741				2022-12-27	WOS:A1992HR85400053
J	FOURNIER, PA; PETROF, EO; GUDERLEY, H				FOURNIER, PA; PETROF, EO; GUDERLEY, H			THE GLUCOSIDIC PATHWAYS AND GLUCOSE-PRODUCTION BY FROG-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; RABBIT MUSCLE; METABOLISM; GLYCOGEN; LACTATE	Resting muscle is generally perceived as a glucose-utilizing organ; however, we show that resting well-oxygenated frog muscle recovering from strenuous exercise can release significant amounts of glucose. The metabolic pathway responsible for this process does not involve glucose-6-phosphatase because this enzyme is undetectable in frog muscle. The participation of amylo-1,6-glucosidase in the production of glucose is also ruled out since neither marked net phosphorolytic breakdown of glycogen nor considerable cycling between glycogen and glucose 6-phosphate occur. The glucosidic pathways of glycogen breakdown are the likely source of glucose as they are the only metabolic avenues with sufficient capacity to account for the rate at which glucose is released from post-exercised muscle. This rate of glucose production is high enough to be of physiological importance. Our results clearly indicate that to measure lactate glycogenesis in muscle, the simultaneous hydrolysis of muscle glycogen by the glucosidic pathways must be taken into account to prevent marked underestimation of the rate of glycogen synthesis. The glucosidic pathways seem the predominant avenues of glycogen breakdown in post-exercised resting frog muscle and are active enough to account for the rate of glycogen breakdown in resting muscle, suggesting that these rather than the phosphorolytic pathways are the chief routes of glycogen breakdown in resting muscle.			FOURNIER, PA (corresponding author), UNIV LAVAL, DEPT BIOL, Ste Foy G1K 7P4, QUEBEC, CANADA.			Fournier, Paul/0000-0002-9963-9685				BENDALL JR, 1970, BIOCHEM J, V118, P887, DOI 10.1042/bj1180887; BERGER M, 1975, BIOCHEM J, V146, P231, DOI 10.1042/bj1460231; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BROWN BI, 1970, BIOCHEMISTRY-US, V9, P1423, DOI 10.1021/bi00808a017; BROWN BI, 1965, BIOCHIM BIOPHYS ACTA, V110, P124, DOI 10.1016/S0926-6593(65)80101-1; BROWN DH, 1978, J BIOL CHEM, V253, P5005; CHALLISS RAJ, 1987, EUR J BIOCHEM, V163, P205, DOI 10.1111/j.1432-1033.1987.tb10756.x; CONNETT RJ, 1979, AM J PHYSIOL, V237, pC231, DOI 10.1152/ajpcell.1979.237.5.C231; FARRAR ES, 1979, GEN COMP ENDOCR, V39, P372, DOI 10.1016/0016-6480(79)90134-5; FOURNIER PA, 1992, IN PRESS AM J PHYSL; Geddes R., 1985, POLYSACCHARIDES, V3, P283; HERS HG, 1973, LYSOSOMES STORAGE DI, P197; HERS HG, 1968, CARBOHYD METABOL, V1, P151; HOLLOSZY JO, 1965, J BIOL CHEM, V240, P3493; HOWELL RR, 1983, METABOLIC BASIS INHE, P141; HUTCHISON VH, 1975, J COMP PHYSIOL, V99, P287, DOI 10.1007/BF00710369; KUSHMERICK MJ, 1976, J PHYSIOL-LONDON, V254, P693, DOI 10.1113/jphysiol.1976.sp011253; MANNERS DJ, 1957, ADV CARBOHYD CHEM, V12, P261; NARAHARA HT, 1960, J BIOL CHEM, V235, P3370; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; OZAND P, 1962, J BIOL CHEM, V237, P3037; PALMER TN, 1971, BIOCHEM J, V124, P701, DOI 10.1042/bj1240701; SMITH EE, 1968, CARBOHYD METABOL, V1, P89; URETA T, 1982, COMP BIOCHEM PHYS B, V71, P549, DOI 10.1016/0305-0491(82)90461-8; WAHREN J, 1970, SCAND J CLIN LAB INV, V25, P129, DOI 10.3109/00365517009049194; WHALEN WJ, 1963, J CELL COMPAR PHYSL, V61, P293, DOI 10.1002/jcp.1030610310	26	9	9	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8234	8237						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569076				2022-12-27	WOS:A1992HQ18500043
J	MCPHERSON, MJ; OGEL, ZB; STEVENS, C; YADAV, KDS; KEEN, JN; KNOWLES, PF				MCPHERSON, MJ; OGEL, ZB; STEVENS, C; YADAV, KDS; KEEN, JN; KNOWLES, PF			GALACTOSE-OXIDASE OF DACTYLIUM-DENDROIDES - GENE CLONING AND SEQUENCE-ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; DNA	The gaoA gene, encoding the secreted copper-containing enzyme galactose oxidase, has been isolated from the Deuteromycete fungus Dactylium dendroides. Degenerate oligonucleotide primers were designed from amino acid sequence data for use in the polymerase chain reaction. A 1.4-kilobase DNA fragment amplified from genomic DNA was used to screen a genomic library constructed in ZAP. A strongly hybridizing clone was rescued as a pBluescript derivative, pGAO9, by in vivo excision. The sequence of 3466 nucleotides of pGAO9 insert DNA was determined by progressively designing sequencing primers. The translation product of the single long open reading frame matches the available galactose oxidase peptide sequence data, which represents 42% of the residues in the protein. The mature enzyme has 639 residues, which have been assigned to a 1.7-angstrom electron density map (Ito, N., Phillips, S. E. V., Stevens, C., Ogel, Z. B., McPherson, M. J., Keen, J. N., Yadav, K. D. S., and Knowles, P. F. (1991) Nature 350, 87-90). The gene lacks introns and encodes an mRNA of approximately 2.5 kilobases with three transcription initiation start points at least 324 nucleotides upstream of the translation start site. Multiple ATG codons are present between the transcription initiation region and the start of the mature protein; two in-frame ATGs could encode the initiating Met residue to give proteins with 89 or 41 residue N-terminal leader peptides. The shorter potential leader has N-terminal features characteristic of a secretion signal sequence and may also contain a pro-sequence processed by an enzyme specific for a monobasic (arginine) cleavage site, as proposed for other fungal genes. The codon bias of gaoA is characteristic of other filamentous fungal genes. No significant homologies exist between galactose oxidase and other protein sequences available in data bases.			MCPHERSON, MJ (corresponding author), UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.			McPherson, Michael/0000-0002-0719-6427				AKRIGG D, 1992, IN PRESS COMPUT APPL; AZEVEDO MD, 1990, J GEN MICROBIOL, V136, P2569; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BLEASBY AJ, 1990, PROTEIN ENG, V3, P153, DOI 10.1093/protein/3.3.153; BUSSINK HJD, 1991, CURR GENET, V19, P467, DOI 10.1007/BF00312738; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GREENE J, 1989, CURRENT PROTOCOLS MO; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HOOPES BC, 1981, NUCLEIC ACIDS RES, V9, P5493, DOI 10.1093/nar/9.20.5493; HUIET L, 1986, P NATL ACAD SCI USA, V83, P3381, DOI 10.1073/pnas.83.10.3381; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOSMAN DJ, 1974, ARCH BIOCHEM BIOPHYS, V165, P456, DOI 10.1016/0003-9861(74)90271-9; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MARKUS Z, 1965, APPL MICROBIOL, V13, P686, DOI 10.1128/AEM.13.5.686-693.1965; McPherson M.J., 1991, PCR PRACTICAL APPROA, P171; MENDONCA MH, 1987, ARCH BIOCHEM BIOPHYS, V252, P507, DOI 10.1016/0003-9861(87)90058-0; MENDONCA MH, 1989, ARCH BIOCHEM BIOPHYS, V275, P130, DOI 10.1016/0003-9861(89)90357-3; MENDONCA MH, 1988, ARCH BIOCHEM BIOPHYS, V266, P427, DOI 10.1016/0003-9861(88)90274-3; Sambrook J, 1989, MOL CLONING LABORATO; SHYAMALA V, 1989, GENE, V84, P1, DOI 10.1016/0378-1119(89)90132-7; TRESSEL PS, 1982, METHOD ENZYMOL, V89, P163; VANDERMEER RA, 1989, J BIOL CHEM, V264, P7792; VONHEIJNE G, 1984, EMBO J, V3, P2315, DOI 10.1002/j.1460-2075.1984.tb02132.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHITTAKER MM, 1989, J BIOL CHEM, V264, P7104; ZHANG YZ, 1991, GENE, V97, P191, DOI 10.1016/0378-1119(91)90051-C	30	62	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8146	8152						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569070				2022-12-27	WOS:A1992HQ18500030
J	VANNUFFEL, P; DIGIAMBATTISTA, M; MORGAN, EA; COCITO, C				VANNUFFEL, P; DIGIAMBATTISTA, M; MORGAN, EA; COCITO, C			IDENTIFICATION OF A SINGLE BASE CHANGE IN RIBOSOMAL-RNA LEADING TO ERYTHROMYCIN RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BINDING-SITE; MUTATIONS; GENE; YEAST; DNA; CHLORAMPHENICOL; SYNERGIMYCINS; ANTIBIOTICS; COMPONENTS	The molecular basis of a mutation conferring an erythromycin-resistance phenotype was explored, as an approach to the role of 23 S rRNA in the peptidyltransferase activity of 50 S ribosomal subunits. Mutagenization of an Escherichia coli strain, which carried the multicopy plasmid pLC7-21 containing the rrnH operon, led to the production of an erythromycin-resistant strain. Plasmid pBFL1 isolated from this mutant was able to transform the sensitive RecA- strain EM4 and to induce a "dissociated" type of antibiotic resistance. Two ribosome populations occurred in EM4/pBFL1: normal particles coded for by the seven rrn chromosomal genes and mutated particles containing rRNA of plasmid origin. The latter particles displayed in vitro lower affinity and susceptibility to erythromycin than wild type particles. The mutation within plasmid pBFL1 was mapped by a multiple primer extension technique. Three synthetic primers were used to sequence the central loop in domain V of 23 S rRNA, leading to identification of a C to U transition at position 2611. This base change was proved to be responsible for the erythromycin-resistance phenotype by the plasmid-plasmid marker rescue technique. A molecular explanation for the rrn mutations leading, respectively, to undissociated and to dissociated types of resistance to the MLS(b) (macrolide-lincosamide-synergimycin B) group of antibiotics is proposed. These results and some literature data support the notion that rRNA bases involved in antibiotic resistance play a conformational role in the ribosomal binding sites for the MLS(b) antibiotics.	CATHOLIC UNIV LOUVAIN, SCH MED,INST CELL PATHOL,MICROBIOL & GENET UNIT, AVE HIPPOCRATE 75, B-1200 BRUSSELS, BELGIUM; ROSWELL PK MEM INST, DEPT EXPTL BIOL, BUFFALO, NY 14260 USA	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Roswell Park Cancer Institute								AREVALO MA, 1988, J BIOL CHEM, V263, P58; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHINALI G, 1988, BIOCHIM BIOPHYS ACTA, V951, P42, DOI 10.1016/0167-4781(88)90023-1; CHINALI G, 1973, EUR J BIOCHEM, V32, P463, DOI 10.1111/j.1432-1033.1973.tb02629.x; DAVIS RW, 1980, ADV MOL BACTERIAL GE; DIGIAMBATTISTA M, 1987, J BIOL CHEM, V262, P8591; DIGIAMBATTISTA M, 1990, BIOCHEMISTRY-US, V29, P9203, DOI 10.1021/bi00491a014; DIGIAMBATTISTA M, 1989, J ANTIMICROB CHEMOTH, V24, P485; DIGIAMBATTISTIA M, 1988, J ANTIMICROB CHEMOTH, V18, P307; DOUTHWAITE S, 1985, P NATL ACAD SCI USA, V82, P8330, DOI 10.1073/pnas.82.24.8330; DUJON B, 1980, CELL, V20, P185, DOI 10.1016/0092-8674(80)90246-9; ETTAYEBI M, 1985, J BACTERIOL, V162, P551, DOI 10.1128/JB.162.2.551-557.1985; GALE EF, 1981, MOL BASIS ANTIBIOTIC, P468; GUTELL RR, 1988, NUCLEIC ACIDS RES, V16, pR175, DOI 10.1093/nar/16.suppl.r175; KENERLEY ME, 1977, J BACTERIOL, V132, P931, DOI 10.1128/JB.132.3.931-949.1977; LAI CJ, 1971, P NATL ACAD SCI USA, V68, P856, DOI 10.1073/pnas.68.4.856; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ SA, 1971, J BIOL CHEM, V246, P6318; SIGMUND CD, 1982, P NATL ACAD SCI-BIOL, V79, P5602, DOI 10.1073/pnas.79.18.5602; SIGMUND CD, 1988, METHOD ENZYMOL, V164, P673; SIGMUND CD, 1984, NUCLEIC ACIDS RES, V12, P4653, DOI 10.1093/nar/12.11.4653; SKINNER RH, 1982, J GEN MICROBIOL, V128, P2411; SOR F, 1984, NUCLEIC ACIDS RES, V12, P8313, DOI 10.1093/nar/12.22.8313; SOR F, 1982, NUCLEIC ACIDS RES, V10, P6571, DOI 10.1093/nar/10.21.6571; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TEJEDOR F, 1986, BIOCHEMISTRY-US, V25, P7725, DOI 10.1021/bi00371a066; VESTER B, 1987, BIOCHIMIE, V69, P891, DOI 10.1016/0300-9084(87)90217-3; WEISBLUM B, 1979, J BACTERIOL, V137, P635, DOI 10.1128/JB.137.1.635-643.1979; ZASSENHAUS HP, 1982, ANAL BIOCHEM, V125, P125, DOI 10.1016/0003-2697(82)90392-X	31	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8377	8382						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569089				2022-12-27	WOS:A1992HQ18500066
J	WU, YN; YANG, YC; WAGNER, PD				WU, YN; YANG, YC; WAGNER, PD			MODIFICATION OF CHROMAFFIN CELLS WITH PERTUSSIS TOXIN OR N-ETHYLMALEIMIDE LOWERS CYTOSKELETAL F-ACTIN AND ENHANCES CA2+-DEPENDENT SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADRENAL-MEDULLARY CELLS; CATECHOLAMINE SECRETION; HUMAN-NEUTROPHILS; PHORBOL ESTER; RELEASE; EXOCYTOSIS; CALCIUM; STAUROSPORINE; FILAMENTS	In an attempt to identify proteins involved in the secretory response, bovine chromaffin cells were modified with N-ethylmaleimide (NEM). NEM concentrations less than 30-mu-M enhanced norepinephrine secretion evoked by nicotine or by K+ depolarization and increased Ca2+-dependent secretion from digitonin-permeabilized cells. Higher concentrations of NEM inhibited secretion. The protein modified by NEM which was responsible for the enhancement of secretory activity appeared to rapidly diffuse out of the digitonin-permeabilized cells. When proteins which diffuse from control digitonin-permeabilized cells were incubated with pertussis toxin and [P-32]NAD, several proteins were ADP-ribosylated. However, when proteins from cells preincubated with 30-mu-M NEM were incubated with pertussis toxin and [P-32]NAD, these GTP-binding proteins (G-proteins) were not ADP-ribosylated, which suggests that they were modified in the cell by NEM. Stimulation of norepinephrine secretion by NEM was not additive with that caused by pertussis toxin. Modification of chromaffin cells with pertussis toxin or with 30-mu-M NEM caused a 40-50% decrease in the amount of cytoskeletal F-actin. This decrease in cytoskeletal F-actin may account for the increase in secretory activity.	NCI,BIOCHEM LAB,BLDG 37,RM 4C24,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; ASANO T, 1986, MOL PHARMACOL, V29, P244; BADER MF, 1986, J BIOL CHEM, V261, P5777; BAKER PF, 1981, PHILOS T R SOC B, V296, P83, DOI 10.1098/rstb.1981.0174; BENGTSSON T, 1986, EUR J CELL BIOL, V42, P338; BENGTSSON T, 1990, P NATL ACAD SCI USA, V87, P2921, DOI 10.1073/pnas.87.8.2921; BILKSTAD I, 1978, CELL, V15, P935; BOCKOCH GM, 1984, J BIOL CHEM, V259, P3560; BROCKLEHURST KW, 1988, FEBS LETT, V234, P439, DOI 10.1016/0014-5793(88)80133-9; BURGOYNE RD, 1989, CELL SIGNAL, V1, P323, DOI 10.1016/0898-6568(89)90051-X; CHANG J, 1987, BIOCHEM PHARMACOL, V36, P2429, DOI 10.1016/0006-2952(87)90512-0; CHEEK TR, 1986, FEBS LETT, V207, P110, DOI 10.1016/0014-5793(86)80022-9; CHENG HC, 1986, J BIOL CHEM, V261, P989; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DUNN LA, 1983, J BIOL CHEM, V258, P4989; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERRIS R M, 1970, Biochemical Pharmacology, V19, P505, DOI 10.1016/0006-2952(70)90207-8; FLOWER RJ, 1976, BIOCHEM PHARMACOL, V25, P285, DOI 10.1016/0006-2952(76)90216-1; FRYE RA, 1985, J NEUROCHEM, V44, P265, DOI 10.1111/j.1471-4159.1985.tb07140.x; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GREENBERG A, 1982, CELL TISSUE RES, V226, P655; HERTTING G, 1988, CELL MOL NEUROBIOL, V8, P105, DOI 10.1007/BF00712916; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; LELKES PI, 1986, FEBS LETT, V208, P357, DOI 10.1016/0014-5793(86)81049-3; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; OSULLIVAN AJ, 1989, BIOSCIENCE REP, V9, P243, DOI 10.1007/BF01116001; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SARAFIAN T, 1987, J BIOL CHEM, V262, P16671; SASAKAWA N, 1988, BIOCHEM PHARMACOL, V37, P2485; SCHAFER T, 1987, J NEUROCHEM, V49, P1697, DOI 10.1111/j.1471-4159.1987.tb02427.x; SHEFCYK J, 1985, BIOCHEM BIOPH RES CO, V126, P1174, DOI 10.1016/0006-291X(85)90309-2; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; SONTAG JM, 1991, BIOCHEM J, V274, P339, DOI 10.1042/bj2740339; TACHIKAWA E, 1989, J NEUROCHEM, V53, P19, DOI 10.1111/j.1471-4159.1989.tb07290.x; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TANAKA T, 1987, BIOCHEM BIOPH RES CO, V144, P907, DOI 10.1016/S0006-291X(87)80050-5; TERBUSH DR, 1990, J BIOL CHEM, V265, P21179; TERBUSH DR, 1986, J BIOL CHEM, V261, P7099; TRIFARO JM, 1984, CAN J PHYSIOL PHARM, V62, P493, DOI 10.1139/y84-079; UI M, 1990, ADP RIBOSYLATING TOX, P45; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; WILSON SP, 1983, J BIOL CHEM, V258, P4994; WILSON SP, 1990, J BIOL CHEM, V265, P648; WINSLOW JW, 1987, J BIOL CHEM, V262, P4501; WU YN, 1991, BIOCHIM BIOPHYS ACTA, V1092, P384, DOI 10.1016/S0167-4889(97)90016-1; WU YN, 1991, FEBS LETT, V282, P197, DOI 10.1016/0014-5793(91)80476-J	46	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8396	8403						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569091				2022-12-27	WOS:A1992HQ18500069
J	DEVADAS, B; LU, TB; KATOH, A; KISHORE, NS; WADE, AC; MEHTA, PP; RUDNICK, DA; BRYANT, ML; ADAMS, SP; LI, Q; GOKEL, GW; GORDON, JI				DEVADAS, B; LU, TB; KATOH, A; KISHORE, NS; WADE, AC; MEHTA, PP; RUDNICK, DA; BRYANT, ML; ADAMS, SP; LI, Q; GOKEL, GW; GORDON, JI			SUBSTRATE-SPECIFICITY OF SACCHAROMYCES-CEREVISIAE MYRISTOYL-COA-PROTEIN N-MYRISTOYLTRANSFERASE - ANALYSIS OF FATTY-ACID ANALOGS CONTAINING CARBONYL GROUPS, NITROGEN HETEROATOMS, AND NITROGEN-HETEROCYCLES IN AN INVITRO ENZYME ASSAY AND SUBSEQUENT IDENTIFICATION OF INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS-I REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; ALPHA-ACETYLTRANSFERASE; METHIONINE AMINOPEPTIDASE; MEMBRANE ASSOCIATION; TERMINAL SEQUENCE; ESCHERICHIA-COLI; PLASMA-MEMBRANE; YEAST-CELLS; MYRISTYLATION; ACYLATION	Covalent attachment of myristic acid (C14:0) to the amino-terminal glycine residue of a variety of eukaryotic cellular and viral proteins can have a profound influence on their biological properties. The enzyme that catalyzes this modification, myristoyl-CoA-protein N-myristoyltransferase (NMT), has been identified as a potential target for antiviral and antifungal therapy. Its reaction mechanism is ordered Bi Bi with myristoyl-CoA binding occurring before binding of peptide and CoA release preceding release of myristoylpeptide. Perturbations in the binding of its acyl-CoA substrate would therefore be expected to have an important influence on catalysis. We have synthesized 56 analogs of myristic acid (C14:0) to further characterize the acyl-CoA binding site of Saccharomyces cerevisiae NMT. The activity of fatty acid analogs was assessed using a coupled in vitro assay system that employed the reportedly nonspecific Pseudomonas acyl-CoA synthetase, purified S. cerevisiae NMT, and octapeptide substrates derived from residues 2-9 of the catalytic subunit of cyclic AMP-dependent protein kinase and the Pr55gag polyprotein precursor of human immunodeficieney virus I (HIV-I). Analysis of ketocarbonyl-, ester-, and amide-containing myristic acid analogs (the latter in two isomeric arrangements, the acylamino acid (-CO-NH-) and the amide (-NH-CO)) indicated that the enzyme's binding site is able to accommodate a dipolar protrusion from C4 through C13. This includes the region of the acyl chain occurring near C5-C6 (numbered from carboxyl) that appears to be bound in a bent conformation of 140-150-degrees. The activities of NMT's acyl-CoA substrates decrease with increasing polarity. This relationship was particularly apparent from an analysis of a series of analogs in which the hydrocarbon chain was terminated by (i) an azido group or (ii) one of three nitrogen heterocycles (imidazole, triazole, and tetrazole) alkylated at either nitrogen or carbon. This inverse relationship between polarity and activity was confirmed after comparison of the activities of the closely related ester- or amide-containing tetradecanoyl-CoA derivatives. Members from all of the analog series were surveyed to determine whether they could inhibit replication of human immunodeficiency virus I (HIV-I), a retrovirus that depends upon N-myristoylation of its Pr55gag for propagation. 12-Azidododecanoic acid was the most active analog tested, producing a 60-90% inhibition of viral production in both acutely and chronically infected T-lymphocyte cell lines at a concentration of 10-50-mu-M without associated cellular toxicity.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103,660 S EUCLID AVE,ST LOUIS,MO 63110; MONSANTO CO,ST LOUIS,MO 63198; UNIV MIAMI,DEPT CHEM,CORAL GABLES,FL 33124	Washington University (WUSTL); Monsanto; University of Miami					NIAID NIH HHS [AI-27179, AI-30188] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, U01AI030188] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; AMES DE, 1950, J CHEM SOC, P174, DOI 10.1039/jr9500000174; ARAGOZZINI F, 1972, TETRAHEDRON, V28, P5493, DOI 10.1016/S0040-4020(01)93872-4; AWAYA J, 1975, BIOCHIM BIOPHYS ACTA, V409, P267, DOI 10.1016/0005-2760(75)90022-3; BARTRA M, 1988, J CHEM SOC CHEM COMM, P270, DOI 10.1039/c39880000270; BLUMER KJ, 1991, ANNU REV PHYSIOL, V53, P37; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BRYANT ML, 1991, P NATL ACAD SCI USA, V88, P2055, DOI 10.1073/pnas.88.6.2055; BRYANT ML, 1989, P NATL ACAD SCI USA, V86, P8655, DOI 10.1073/pnas.86.22.8655; CHANG YH, 1990, J BIOL CHEM, V265, P19892; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CYERT MS, 1991, YEAST CELL BIOL, P224; DASILVA AM, 1990, J CELL BIOL, V111, P401, DOI 10.1083/jcb.111.2.401; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; FABRICHNYI BP, 1958, ZH OBSHCH KHIM+, V28, P2520; GENSLER WJ, 1979, TETRAHEDRON, V35, P2595, DOI 10.1016/0040-4020(79)88026-6; GOKEL GW, 1992, IN PRESS ISRAEL J CH, V33; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GREENE JL, 1969, IND ENG CHEM PROD RD, V8, P171, DOI 10.1021/i360030a015; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HEUCKEROTH RO, 1990, J LIPID RES, V31, P1121; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; HIBBS AR, 1986, BIOCHIM BIOPHYS ACTA, V862, P445, DOI 10.1016/0005-2736(86)90249-X; JACOBS E, 1989, GENE, V79, P71, DOI 10.1016/0378-1119(89)90093-0; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JAMES G, 1989, J BIOL CHEM, V264, P20928; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P8511, DOI 10.1073/pnas.87.21.8511; KAISER R, 1978, HELV CHIM ACTA, V61, P2671, DOI 10.1002/hlca.19780610736; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAWASAKI T, 1950, J PHARM SOC JAPAN, V70, P485; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; LEE FJS, 1990, J BIOL CHEM, V265, P3603; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; LEE FJS, 1989, FEBS LETT, V256, P139, DOI 10.1016/0014-5793(89)81734-X; LEE FJS, 1988, J BIOL CHEM, V263, P14948; LEE FJS, 1989, J BIOL CHEM, V264, P12339; LEE FJS, 1990, J BIOL CHEM, V265, P11576; LINDER ME, 1991, J BIOL CHEM, V266, P4654; Lycan WH, 1929, J AM CHEM SOC, V51, P625, DOI 10.1021/ja01377a042; MAKITA A, 1986, J ANTIBIOT, V39, P1257, DOI 10.7164/antibiotics.39.1257; MARC D, 1989, EMBO J, V8, P2661, DOI 10.1002/j.1460-2075.1989.tb08406.x; MITA MA, 1950, J AM CHEM SOC, V72, P1231; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NARIA MA, 1989, NATURE, V337, P615; OLSON EN, 1988, PROG LIPID RES, V27, P177, DOI 10.1016/0163-7827(88)90012-4; ORME TW, 1972, EUR J BIOCHEM, V24, P407, DOI 10.1111/j.1432-1033.1972.tb19700.x; PAPA D, 1949, J ORG CHEM, V14, P723, DOI 10.1021/jo01157a002; PATTISON FLM, 1956, J AM CHEM SOC, V78, P2255, DOI 10.1021/ja01591a062; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RAPOPORT H, 1953, J AM CHEM SOC, V75, P5290, DOI 10.1021/ja01117a043; RAPOPORT L, 1947, J AM CHEM SOC, V69, P471, DOI 10.1021/ja01194a601; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RHEE SS, 1987, J VIROL, V61, P1045, DOI 10.1128/JVI.61.4.1045-1053.1987; Robinson GM, 1930, J CHEM SOC, P745, DOI 10.1039/jr9300000745; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; SHIMIZU S, 1980, ANAL BIOCHEM, V107, P193, DOI 10.1016/0003-2697(80)90511-4; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; STORK G, 1963, J AM CHEM SOC, V85, P207, DOI 10.1021/ja00885a021; TANIHIRO Y, 1978, PROSTAGLANDINS, V16, P529; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; TSUCHIDA E, 1989, CHEM LETT, V10, P1727; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; 1979, BEILSTEIN EIV, V3, P1675	80	69	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7224	7239						16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559967				2022-12-27	WOS:A1992HN48500009
J	KHAN, Z; AITKEN, A; GARCIA, JD; SMYTH, DG				KHAN, Z; AITKEN, A; GARCIA, JD; SMYTH, DG			ISOLATION AND IDENTIFICATION OF 2 NEUTRAL THYROTROPIN RELEASING HORMONE-LIKE PEPTIDES, PYROGLUTAMYLPHENYLALANINEPROLINE AMIDE AND PYROGLUTAMYLGLUTAMINEPROLINE AMIDE, FROM HUMAN SEMINAL FLUID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS PEPTIDE; PRECURSOR	Two tripeptide amides with stuctures similar to thyrotropin releasing hormone were isolated from human seminal fluid and their amino acid sequences determined. The peptides were purified by gel exclusion from Sephadex G50 and were detected by radioimmunoassay with thyrotropin releasing hormone antibody; in addition, N-terminally extended forms were demonstrated by radioimmunoassay after trypsin digestion. Further purification of the tripeptides was by chromatography on SP-Sephadex C25 and by high performance liquid chromatography on C18 Microbondapak using an HCl/acetonitrile gradient. After exclusion from mini-columns of SP-Sephadex C25 and DEAE-Sephadex A25, two neutral peptides were obtained in homogeneous form by high performance liquid chromatography with an HCl/methanol gradient. Amino acid analysis gave the following compositions: Glu, 0.74, Phe, 1.0, Pro, 1.0; and Glu, 1.72, Pro, 1.0. Both peptides possessed a blocked N terminus, but after opening the pyroglutamyl ring the sequences Glu-Phe-Pro and Glu-Glx-Pro were demonstrated. The chromatographic properties of the endogenous peptides were identical to the properties of the corresponding synthetic peptides. The structure of pGlu-Phe-Pro (where p- indicates pyro-) amide was confirmed by fast atom bombardment mass spectrometry. The presence in human semen of three structurally related peptides, pGlu-Phe-Pro amide, pGlu-Gln-Pro amide, and the previously reported pGlu-Glu-Pro amide (Cockle, S. M., Aitken, A., Beg, F., and Smyth, D. G. (1989) J. Biol. Chem. 264, 7788-7791), suggests that this series of peptides may have evolved to fulfil complementary biological roles.	NATL INST MED RES,THE RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research								AITKEN A, 1989, PROTEIN SEQUENCING P, P43; BILEK R, 1992, J ENDOCRINOL, V132, P177, DOI 10.1677/joe.0.1320177; BILEK R, 1991, J LABELLED COMPD RAD, V10, P1099; COCKLE SM, 1989, J BIOL CHEM, V264, P7788; COCKLE SM, 1989, FEBS LETT, V252, P13; DELRIOGARCIA J, 1990, J ENDOCRINOL, V127, P445, DOI 10.1677/joe.0.1270445; FRASER HM, 1982, ENDOCRINOLOGY, V111, P1964, DOI 10.1210/endo-111-6-1964; GEISOW MJ, 1989, PROTEIN SEQUENCING P, P85; LECHAN RM, 1986, SCIENCE, V231, P159, DOI 10.1126/science.3079917; PEKARY AE, 1985, J ANDROL, V6, P379; PEKARY AE, 1980, BIOCHEM BIOPH RES CO, V95, P993, DOI 10.1016/0006-291X(80)91571-5; PEKARY AE, 1983, J ANDROL, V4, P339; RICHTER K, 1984, EMBO J, V3, P617, DOI 10.1002/j.1460-2075.1984.tb01857.x; RUI H, 1987, J ENDOCRINOL, V114, P329, DOI 10.1677/joe.0.1140329; SMYTH DG, 1978, BIOCHEM J, V175, P261, DOI 10.1042/bj1750261; STARK GR, 1963, J BIOL CHEM, V238, P214	16	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7464	7469						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559984				2022-12-27	WOS:A1992HN48500040
J	ZELEZNIKLE, NJ; ITOHLINDSTROM, Y; CLARKE, JB; MOORE, TL; TING, JPY				ZELEZNIKLE, NJ; ITOHLINDSTROM, Y; CLARKE, JB; MOORE, TL; TING, JPY			THE B-CELL-SPECIFIC NUCLEAR FACTOR OTF-2 POSITIVELY REGULATES TRANSCRIPTION OF THE HUMAN CLASS-II TRANSPLANTATION GENE, DRA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN PROMOTER; OCTAMER DNA MOTIF; RNA POLYMERASE-II; HISTONE H2B GENE; IMMUNOGLOBULIN GENES; CONSERVED SEQUENCE; ALPHA GENE; STIMULATES TRANSCRIPTION; BINDING PROTEINS; PURIFICATION	The promoter of the major histocompatibility class II gene DRA contains an octamer element (ATTTGCAT) that is required for efficient DRA expression in B cells. Several DNA-binding proteins are known to bind this sequence. The best characterized are the B cell-specific OTF-2 and the ubiquitous OTF-1. This report directly demonstrates that OTF-2 but not OTF-1 regulates the DRA gene. In vitro transcription analysis using protein fractions enriched for the octamer-binding protein OTF-2 demonstrate a positive functional role for OTF-2 in DRA gene transcription. In contrast, OTF-1-enriched protein fractions did not affect DRA gene transcription although it functionally enhanced the transcription of another gene. Recombinant OTF-2 protein produced by in vitro transcription/translation could also enhance DRA gene transcription in vitro. In vivo transient transfection studies utilizing an OTF-2 expression vector resulted in similar findings: that OTF-2 protein enhanced DRA gene transcription, and that this effect requires an intact octamer element. Together these results constitute the first direct evidence of a positive role for the lymphoid-specific octamer-binding factor in DRA gene transcription.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CB 7295, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA 48185, 5F32 CA08857] Funding Source: Medline; NIAID NIH HHS [AI 29564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048185, F32CA008857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029564, R56AI029564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHEN ZZ, 1987, J IMMUNOL, V138, P2345; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COGSWELL JP, 1991, CRIT REV IMMUNOL, V11, P87; CRESSWELL P, 1990, NATURE, V343, P593, DOI 10.1038/343593a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUS M, 1987, EMBO J, V6, P1685, DOI 10.1002/j.1460-2075.1987.tb02418.x; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GAUR LK, 1991, IN PRESS IMMUNOGENET; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GRABB DW, 1987, ANAL BIOCHEM, V163, P88; HUH NE, 1991, NUCLEIC ACIDS RES, V19, P93, DOI 10.1093/nar/19.1.93; HUME CR, 1990, TISSUE ANTIGENS, V36, P108; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; King P. V., 1986, FOCUS, V8, P1; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; MARRACK P, 1988, IMMUNOL TODAY, V9, P308, DOI 10.1016/0167-5699(88)91324-2; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; ONEILL EA, 1988, J BIOL CHEM, V263, P931; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; PONCE E, 1909, BIOCHEMISTRY-US, V30, P2961; ROSALES R, 1987, EMBO J, V6, P3015, DOI 10.1002/j.1460-2075.1987.tb02607.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SHERMAN PA, 1989, P NATL ACAD SCI USA, V86, P6739, DOI 10.1073/pnas.86.17.6739; SHERMAN PA, 1989, MOL CELL BIOL, V9, P50, DOI 10.1128/MCB.9.1.50; SHERMAN PA, 1987, P NATL ACAD SCI USA, V84, P4254, DOI 10.1073/pnas.84.12.4254; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SIVE HL, 1986, MOL CELL BIOL, V6, P3329, DOI 10.1128/MCB.6.10.3329; SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YOZA BK, 1990, MOL CELL BIOL, V10, P2145, DOI 10.1128/MCB.10.5.2145; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873	51	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7677	7682						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560002				2022-12-27	WOS:A1992HN48500068
J	WIESENBERGER, G; WALDHERR, M; SCHWEYEN, RJ				WIESENBERGER, G; WALDHERR, M; SCHWEYEN, RJ			THE NUCLEAR GENE MRS2 IS ESSENTIAL FOR THE EXCISION OF GROUP-II INTRONS FROM YEAST MITOCHONDRIAL TRANSCRIPTS INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; CYTOCHROME-OXIDASE; INTERVENING SEQUENCE; CATALYTIC INTRONS; SPLICE DEFECT; S-CEREVISIAE; SUBUNIT-I; PROTEIN	RNA splicing defects in mitochondrial intron mutants can be suppressed by a high dosage of several proteins encoded by nuclear genes. In this study we report on the isolation, nucleotide sequence, and possible functions of the nuclear MRS2 gene. When present on high copy number plasmids, the MRS2 gene acts as a suppressor of various mitochondrial intron mutations, suggesting that the MRS2 protein functions as a splicing factor. This notion is supported by the observations that disruption of the single chromosomal copy of the MRS2 gene causes (i) a pet- phenotype and (ii) a block in mitochondrial RNA splicing of all four mitochondrial group II introns, some of which are efficiently self-splicing in vitro. In contrast, the five group I introns monitored here are excised from pre-mRNA in a MRS2-disrupted background although at reduced rates. So far the MRS2 gene product is unique in that it is essential for splicing of all four group II introns, but relatively unimportant for splicing of group I introns. In strains devoid of any mitochondrial introns the MRS2 gene disruption still causes a pet- phenotype and cytochrome deficiency, although the standard pattern of mitochondrial translation products is produced. Therefore, apart from RNA splicing, the absence of the MRS2 protein may disturb the assembly of mitochondrial membrane complexes.	UNIV VIENNA,INST MIKROBIOL & GENET,A-1090 VIENNA,AUSTRIA	University of Vienna				Wiesenberger, Gerlinde/0000-0002-3788-7974				AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BELFORT M, 1991, CELL, V64, P9, DOI 10.1016/0092-8674(91)90201-9; BENASHER E, 1989, MOL GEN GENET, V215, P517; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BOUSQUET I, 1990, CURR GENET, V18, P117, DOI 10.1007/BF00312599; CARIGNANI G, 1983, CELL, V35, P733, DOI 10.1016/0092-8674(83)90106-X; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CECH TR, 1989, GENE AMST, V82, P191; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GRIVELL LA, 1989, EUR J BIOCHEM, V182, P477, DOI 10.1111/j.1432-1033.1989.tb14854.x; HAID A, 1979, EUR J BIOCHEM, V94, P451, DOI 10.1111/j.1432-1033.1979.tb12913.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P635; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; KOLL H, 1987, CURR GENET, V12, P503; KREIKE J, 1987, EMBO J, V6, P2123, DOI 10.1002/j.1460-2075.1987.tb02479.x; LABOUESSE M, 1984, EUR J BIOCHEM, V144, P85, DOI 10.1111/j.1432-1033.1984.tb08434.x; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LAZOWSKA J, 1989, J MOL BIOL, V205, P275, DOI 10.1016/0022-2836(89)90341-0; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; LISOWSKY T, 1990, MOL GEN GENET, V220, P186; Maniatis T., 1982, MOL CLONING; MCGRAW P, 1983, J BIOL CHEM, V258, P9459; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; NEEDLEMAN RB, 1975, ANAL BIOCHEM, V64, P545, DOI 10.1016/0003-2697(75)90466-2; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHMELZER C, 1981, J BIOL CHEM, V256, P7610; SCHMELZER C, 1983, EMBO J, V2, P2047, DOI 10.1002/j.1460-2075.1983.tb01698.x; SCHMELZER C, 1986, CELL, V46, P557, DOI 10.1016/0092-8674(86)90881-0; SCHMIDT C, 1987, MOL GEN GENET, V210, P145, DOI 10.1007/BF00337771; SERAPHIN B, 1988, EMBO J, V7, P1455, DOI 10.1002/j.1460-2075.1988.tb02963.x; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; SERAPHIN B, 1987, P NATL ACAD SCI USA, V84, P6810, DOI 10.1073/pnas.84.19.6810; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; VALENCIK ML, 1989, EMBO J, V8, P3899, DOI 10.1002/j.1460-2075.1989.tb08569.x; VANDERKOOI G, 1972, ANN NY ACAD SCI, V195, P135, DOI 10.1111/j.1749-6632.1972.tb54792.x; VANDERVEEN R, 1986, EMBO J, V6, P1079; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WEISENBERGER G, 1990, J MOL BIOL, V217, P23; WEISSBRUMMER B, 1982, CELL, V29, P527, DOI 10.1016/0092-8674(82)90169-6; WINSTON F, 1983, METHOD ENZYMOL, V101, P122	51	88	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6963	6969						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551905				2022-12-27	WOS:A1992HM05300078
J	BOWMAN, BF; PETERSON, JA; STULL, JT				BOWMAN, BF; PETERSON, JA; STULL, JT			PRE-STEADY-STATE KINETICS OF THE ACTIVATION OF RABBIT SKELETAL-MUSCLE MYOSIN LIGHT CHAIN KINASE BY CA2+/CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; DEPENDENT PROTEIN-KINASE; CROSS-BRIDGE KINETICS; SMOOTH-MUSCLE; SPINACH CALMODULIN; PHOSPHORYLATION; PEPTIDE; CA-2+; PHOSPHODIESTERASE; QUANTITATION	Myosin light chain kinase is activated by Ca2+/calmodulin. Insights into the kinetic mechanism of this activation by Ca2+/calmodulin have now been obtained using extrinsically labeled fluorescent calmodulin, a fluorescent peptide substrate, and a stopped-flow spectrophotofluorimeter. We employed spinach calmodulin labeled with the sulfhydryl-selective probe, 2-(4-maleimidoanilino) naphthalene-6-sulfonic acid, to measure changes in the fluorescence intensity of the 2-(4-maleimidoanilino) naphthalene-6-sulfonic acid-calmodulin upon binding to rabbit skeletal muscle myosin light chain kinase. The fluorescent peptide substrate KKRAARAC(sulfobenzo-furazan)SNVFS-amide was used to measure kinase activity. Our results showed that the binding interaction could be modeled as a two-step process: a bimolecular reaction with an association rate of 4.6 x 10(7) M-1 s-1 followed by an isomerization with a rate of 2.2 s-1. Phosphorylation of the peptide during stopped-flow experiments could be modeled by a two-step process with a catalytic association rate of 6.5 x 10(6) M-1 s-1 and a turnover rate of 10-20 s-1. Our results also indicated that kinase activity occurred too rapidly for the slower isomerization rate of 2.2 s-1 to be linked specifically to the activation process.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26093, HL06296] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON JM, 1983, METHOD ENZYMOL, V102, P9; ANDREWS JL, 1982, ARCH BIOCHEM BIOPHYS, V214, P386, DOI 10.1016/0003-9861(82)90043-1; BOWMAN BF, 1990, BIOPHYS J, V57, P152; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAU V, 1982, CALMODULIN INTRACELL, P199; FRIEDENWALD JS, 1968, S MECHANISM ENZYME A, P168; GREENSPAN D, 1974, DISCRETE NUMERICAL M, P12; HAIECH J, 1991, J BIOL CHEM, V266, P3427; HARDIE G, 1988, NATURE, V335, P592, DOI 10.1038/335592a0; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HEIDORN DB, 1989, BIOCHEMISTRY-US, V28, P6757, DOI 10.1021/bi00442a032; HERRING BP, 1990, J BIOL CHEM, V265, P1724; JOHNSON JD, 1981, J BIOL CHEM, V256, P2194; KAMM KE, 1986, SCIENCE, V232, P80, DOI 10.1126/science.3754063; KELLER CH, 1982, BIOCHEMISTRY-US, V21, P156, DOI 10.1021/bi00530a027; KENNELLY PJ, 1987, J BIOL CHEM, V262, P11958; KENNELLY PJ, 1991, FEBS LETT, V286, P217, DOI 10.1016/0014-5793(91)80977-B; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; KLEVIT RE, 1983, METHOD ENZYMOL, V102, P82; KLEVIT RE, 1985, BIOCHEMISTRY-US, V24, P8152, DOI 10.1021/bi00348a047; MAYR GW, 1983, BIOCHEMISTRY-US, V22, P4316, DOI 10.1021/bi00287a024; MCILROY BK, 1991, ANAL BIOCHEM, V195, P148, DOI 10.1016/0003-2697(91)90310-P; MICHNOFF CH, 1986, J BIOL CHEM, V261, P8320; MILLS JS, 1988, BIOCHEMISTRY-US, V27, P991, DOI 10.1021/bi00403a023; NUNNALLY MH, 1985, J BIOL CHEM, V260, P1020; OLWIN BB, 1984, J BIOL CHEM, V259, P949; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; SEEHOLZER SH, 1989, BIOCHEMISTRY-US, V28, P4011, DOI 10.1021/bi00435a057; SEGAL IH, 1975, ENZYME KINETICS BEHA, P25; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P165, DOI 10.1085/jgp.91.2.165; Stewart JM, 1984, SOLID PHASE PEPTIDE; STULL JT, 1985, ENZYMES, V23, P123; SUKO J, 1986, EUR J BIOCHEM, V159, P425, DOI 10.1111/j.1432-1033.1986.tb09904.x; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P414, DOI 10.1073/pnas.87.1.414; TODA H, 1985, J BIOCHEM-TOKYO, V98, P833, DOI 10.1093/oxfordjournals.jbchem.a135342; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; WATTERSON DM, 1980, BIOCHEMISTRY-US, V19, P5762, DOI 10.1021/bi00566a015; WRIGHT DE, 1981, P NATL ACAD SCI-BIOL, V78, P6048, DOI 10.1073/pnas.78.10.6048; YAGI S, 1988, P NATL ACAD SCI USA, V85, P4109, DOI 10.1073/pnas.85.11.4109; YUAN SX, 1988, EUR J BIOCHEM, V175, P119, DOI 10.1111/j.1432-1033.1988.tb14173.x; ZOT HG, 1990, J BIOL CHEM, V265, P14796; [No title captured]; 1976, OPERATION MAINTENANC	44	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5346	5354						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544916				2022-12-27	WOS:A1992HH74700054
J	BRUNING, A; KARRENBAUER, A; SCHNABEL, E; WIELAND, FT				BRUNING, A; KARRENBAUER, A; SCHNABEL, E; WIELAND, FT			BREFELDIN-A-INDUCED INCREASE OF SPHINGOMYELIN SYNTHESIS - ASSAY FOR THE ACTION OF THE ANTIBIOTIC IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-G PROTEIN; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; GOLGI-APPARATUS; TRANSPORT; PATHWAY; CIS; ER	Brefeldin A leads to an increase of sphingomyelin in Chinese hamster ovary cells. The antibiotic is known to cause a dramatic morphological change of the endomembrane system in various mammalian cells resulting in a redistribution of Golgi resident proteins to the endoplasmic reticulum (Lippincott-Schwartz, J., Donaldson, J. G., Schweizer, A., Berger, E. G., Hauri, H. P., Yuan, L. C., and Klausner, R. D. (1990) Cell 60, 821-836). A strict correlation was found between the brefeldin A-induced increase of sphingomyelin and the biochemical criteria that apply for this morphological change. From our data we conclude that the increase in sphingomyelin caused by brefeldin A reflects translocation of the enzyme sphingomyelin synthase from the Golgi apparatus to the endoplasmic reticulum. Using a radioactively labeled truncated ceramide this increase in sphingomyelin synthesis is easily detectable, and thus this method can serve as a convenient biochemical assay for the action of brefeldin A in mammalian cells.	UNIV HEIDELBERG, INST BIOCHEM 1, NEUENHEIMER FELD 328, W-6900 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg								ARMSTRONG J, 1990, NATURE, V344, P383, DOI 10.1038/344383a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HELMS JB, 1990, J BIOL CHEM, V265, P20027; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; ORCI L, 1991, CELL, V64, P1183; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; STOFFEL W, 1980, H-S Z PHYSIOL CHEM, V361, P755, DOI 10.1515/bchm2.1980.361.1.755; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; URBANI L, 1990, J BIOL CHEM, V265, P1919; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VANCE JE, 1991, J BIOL CHEM, V266, P8241	25	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5052	5055						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544889				2022-12-27	WOS:A1992HH74700010
J	TAKAKURA, H; TSUNASAWA, S; MIYAGI, M; WARNER, JR				TAKAKURA, H; TSUNASAWA, S; MIYAGI, M; WARNER, JR			NH2-TERMINAL ACETYLATION OF RIBOSOMAL-PROTEINS OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; CYTOPLASMIC RIBOSOMES; TERMINAL ACETYLATION; XENOPUS-LAEVIS; AMINO-ACIDS; YEAST; GENES; ACETYLTRANSFERASE; IDENTIFICATION; NOMENCLATURES	Using a mutant of Saccharomyces cerevisiae defective in the NAT1 gene, that encodes one of the NH2-terminal acetyltransferases, we have identified 14 ribosomal proteins whose electrophoretic mobility at pH 5.0 suggests they carry an additional charge, presumably due to the lack of NH2-terminal acetylation. At least 30 other ribosomal proteins from the mutant are electrophoretically normal. Attempted NH2-terminal analysis of most of the presumed acetylated proteins from wild type cells indicated that all were blocked. NH2-terminal analysis of the same proteins from the nat1 mutant strain yielded unique sequences. Each one carries an NH2-terminal serine. We conclude that these are normally acetylated due to the presence of the NAT1 gene product. It seems surprising that cells whose ribosomes have been altered to this degree grow rather well and synthesize the same spectrum of proteins as do wild type cells (Mullen, J. R., Kayne, P. S., Moerschell, R. P., Tsunasawa, S. Gribskov, M., Sherman, F., and Sternglanz, R. (1989) EMBO J. 8, 2067-2075). Finally, this analysis has provided the first sequence information available for several of the acetylated ribosomal proteins and for one non-acetylated ribosomal protein, which is clearly the product of the MFT1 gene (Garrett, J. M., Singh, K. K., Vonder Haar, R. A., and Emr. S. D. (1991) Mol. Gen. Gen. 225, 483-491).	ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10465; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Yeshiva University; Albert Einstein College of Medicine; Osaka University					NCI NIH HHS [CA13330] Funding Source: Medline; NIGMS NIH HHS [GM25532] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025532] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLROBYN JA, 1990, MOL CELL BIOL, V10, P6544, DOI 10.1128/MCB.10.12.6544; AREVALO SG, 1990, NUCLEIC ACIDS RES, V18, P1447, DOI 10.1093/nar/18.6.1447; BROWN SJ, 1990, GENE, V91, P293, DOI 10.1016/0378-1119(90)90103-X; CHAN YL, 1990, FEBS LETT, V262, P253, DOI 10.1016/0014-5793(90)80203-U; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; FRIED HM, 1981, J BIOL CHEM, V256, P176; GARRETT JM, 1991, MOL GEN GENET, V225, P483, DOI 10.1007/BF00261691; GORENSTEIN C, 1976, P NATL ACAD SCI USA, V73, P1547, DOI 10.1073/pnas.73.5.1547; KLEIN H, 1990, NUCLEIC ACIDS RES, V18, P3997, DOI 10.1093/nar/18.13.3997; LARKIN JC, 1987, MOL CELL BIOL, V7, P1764, DOI 10.1128/MCB.7.5.1764; LEE FJS, 1990, J BIOL CHEM, V265, P3603; LEER RJ, 1984, NUCLEIC ACIDS RES, V12, P6685, DOI 10.1093/nar/12.17.6685; MICHEL S, 1983, MOL GEN GENET, V191, P251, DOI 10.1007/BF00334822; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; OTAKA E, 1981, MOL GEN GENET, V181, P176, DOI 10.1007/BF00268424; OTAKA E, 1982, BIOCHEMISTRY-US, V21, P4545, DOI 10.1021/bi00262a005; OTAKA E, 1983, MOL GEN GENET, V191, P519, DOI 10.1007/BF00425772; OTAKA E, 1984, MOL GEN GENET, V195, P544, DOI 10.1007/BF00341461; PERSSON B, 1985, EUR J BIOCHEM, V152, P523, DOI 10.1111/j.1432-1033.1985.tb09227.x; PRESUTTI C, 1988, J BIOL CHEM, V263, P6188; RAUE HA, 1986, STRUCTURE FUNCTION G, P699; SCHUBART UK, 1977, J BIOL CHEM, V252, P92; SCHULTZ LD, 1983, J BACTERIOL, V155, P8, DOI 10.1128/JB.155.1.8-14.1983; TANAKA T, 1985, J BIOL CHEM, V260, P6329; TEEM JL, 1984, NUCLEIC ACIDS RES, V12, P8295, DOI 10.1093/nar/12.22.8295; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TSUNASAWA S, 1984, METHOD ENZYMOL, V106, P165; TSUNASAWA S, 1985, J BIOCHEM-TOKYO, V97, P701, DOI 10.1093/oxfordjournals.jbchem.a135108; TSUNASAWA S, 1990, Journal of Protein Chemistry, V9, P265; Warner J R, 1978, Methods Cell Biol, V20, P45, DOI 10.1016/S0091-679X(08)62008-7; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WARNER JR, 1982, MOL BIOL YEAST SACCH, P529; WELLNER D, 1990, P NATL ACAD SCI USA, V87, P1947, DOI 10.1073/pnas.87.5.1947; ZINKER S, 1976, J BIOL CHEM, V251, P1799	35	43	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5442	5445						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544921				2022-12-27	WOS:A1992HH74700067
J	TAKEI, Y; KUROSU, H; TAKAHASHI, K; KATADA, T				TAKEI, Y; KUROSU, H; TAKAHASHI, K; KATADA, T			A GTP-BINDING PROTEIN IN RAT-LIVER NUCLEI SERVING AS THE SPECIFIC SUBSTRATE OF PERTUSSIS TOXIN-CATALYZED ADP-RIBOSYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; LEUKEMIC HL-60 CELLS; ALPHA-SUBUNITS; BOVINE BRAIN; MATRIX; DIFFERENTIATION; ORGANIZATION; HEPATOCYTES; MEMBRANES; CYCLASE	The ADP-ribosyl moiety of NAD was transferred to a 40-kDa protein when rat liver nuclei were incubated with pertussis toxin. The 40-kDa substrate in the nuclei displayed unique properties as follows, some of which were apparently distinct from those observed with the toxin-substrate GTP-binding protein (G(i)) in the liver plasma membranes. 1) The nuclear 40-kDa protein was recognized with antibodies reacting with the alpha-subunits (alpha(i)-1 and alpha(i)-2) of G(i), but not with anti-G(o)-alpha-subunit antibody. 2) The nuclear protein had a higher mobility than alpha-subunit of the plasma membrane-bound G(i) upon electrophoresis with a urea/sodium dodecyl sulfate-containing polyacrylamide gel. 3) The nuclear protein was not extracted from the nuclei with 1% Triton X-100, whereas G(i) was easily solubilized from the plasma membranes. 4) There was a beta-gamma-subunit-like activity in the nuclei, which was assayed by an ability to support pertussis toxin-catalyzed ADP-ribosylation of a purified alpha-subunit of G(i). Moreover, a 36-kDa protein in the nuclei was recognized with antibody raised against purified beta-subunits of G(i). 5) Pertussis toxin-induced ADP-ribosylation of the nuclear protein was selectively inhibited by the addition of a nonhydrolyzable GTP analogue, and its inhibitory action was competitively blocked by the simultaneous addition of GDP or its analogues, as had been observed with plasma membrane-bound G(i). It thus appeared that a novel form of alpha-beta-gamma-trimeric GTP-binding protein serving as the substrate of pertussis toxin was present in rat liver nuclei. In order to examine a possible role of the nuclear GTP-binding protein, rats were injected with carbon tetrachloride, a necrosis inducer of hepatocytes. There was a marked increase in the nuclear substrate activity from 3-6 days after the injection, without a significant change in the activity of G(i) in the plasma membranes. The time course of the increase corresponded with a recovering stage from the hepatocyte necrosis. These results suggested that the nuclear GTP-binding protein found in the present study might be involved at some stages in the hepatocyte growth.	TOKYO INST TECHNOL,DEPT LIFE SCI,YOKOHAMA,KANAGAWA 227,JAPAN	Tokyo Institute of Technology								BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; Bergmeyer, 1974, METHOD ENZYMAT AN, V2, P727, DOI 10.1016/B978-0-12-091302-2.50042-6; BODNAR JW, 1988, J THEOR BIOL, V132, P479, DOI 10.1016/S0022-5193(88)80086-9; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURGOYNE LA, 1970, BIOCHEM BIOPH RES CO, V39, P254, DOI 10.1016/0006-291X(70)90786-2; CAREY DJ, 1980, J BIOL CHEM, V255, P4348; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; FUJINAGA Y, 1989, FEBS LETT, V245, P117, DOI 10.1016/0014-5793(89)80203-0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HOSHINO S, 1990, FEBS LETT, V276, P227, DOI 10.1016/0014-5793(90)80548-W; IIRI T, 1989, J BIOL CHEM, V264, P21394; KATADA T, 1986, J BIOL CHEM, V261, P8182; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; KNOX WE, 1975, METHODS ENZYMOL A, V17, P415; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NAKAMURA T, 1983, BIOCHIM BIOPHYS ACTA, V678, P91; NODA C, 1984, J BIOCHEM-TOKYO, V95, P37, DOI 10.1093/oxfordjournals.jbchem.a134600; OINUMA M, 1987, J BIOL CHEM, V262, P8347; RAZIN SV, 1987, BIOESSAYS, V6, P19, DOI 10.1002/bies.950060106; RIBEIRONETO FAP, 1989, P NATL ACAD SCI USA, V86, P2577, DOI 10.1073/pnas.86.8.2577; RUBINS JB, 1990, P NATL ACAD SCI USA, V87, P7080, DOI 10.1073/pnas.87.18.7080; SEYDEL U, 1991, J BIOL CHEM, V266, P7602; SHIBASAKI H, 1991, FEBS LETT, V285, P268, DOI 10.1016/0014-5793(91)80814-J; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TAKEDA S, 1989, FEBS LETT, V244, P469, DOI 10.1016/0014-5793(89)80585-X; TOHKIN M, 1989, FEBS LETT, V255, P187, DOI 10.1016/0014-5793(89)81088-9; VERHEIJEN R, 1988, J CELL SCI, V90, P11; WEST RE, 1985, J BIOL CHEM, V260, P4428	32	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5085	5089						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544891				2022-12-27	WOS:A1992HH74700015
J	SAMPATH, D; VARKI, A; FREEZE, HH				SAMPATH, D; VARKI, A; FREEZE, HH			THE SPECTRUM OF INCOMPLETE N-LINKED OLIGOSACCHARIDES SYNTHESIZED BY ENDOTHELIAL-CELLS IN THE PRESENCE OF BREFELDIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; TRANS-GOLGI NETWORK; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; LYSOSOMAL-ENZYMES; RECOGNITION MARKER; DICTYOSTELIUM-DISCOIDEUM; AFFINITY-CHROMATOGRAPHY; MOLECULAR DISSECTION; PARTIAL-PURIFICATION	Previous studies in many cell lines have shown that Brefeldin A (BFA) inhibits the forward movement of newly synthesized glycoconjugates by fusing the cis-, medial-, and trans-Golgi compartments with the rough endoplasmic reticulum. Studies on the oligosaccharide processing of individual glycoproteins have yielded confusing and incomplete results regarding the location of the block. Assuming that all glycoproteins with N-linked oligosaccharides follow the same endoplasmic reticulum to the Golgi pathway, a more complete picture on the location and nature of the block can be determined by analyzing N-linked oligosaccharides synthesized in the presence of BFA. In bovine pulmonary artery endothelial cells, BFA (0.1-mu-g/ml) reversibly inhibits the secretion of > 95% of TranS-35 and [H-3]Man-labeled glycoproteins without affecting protein synthesis or N-linked glycosylation. In addition, BFA inhibits the synthesis and secretion of (SO4)-S-35-labeled oligosaccharides. Initial oligosaccharide trimming is uninhibited, but further processing is affected since the majority (65%) of the chains terminate only in beta-GlcNAc residues. Concomitantly, the proportion of [H-3]Man-labeled N-linked anionic oligosaccharides is reduced from 60 to 20%, and the great majority of the charge is due to one sialic acid. The rate-limiting step for sialylation appears to be the branch selective addition of beta-Gal residues. The remaining charge is due to sulfate esters (0.6%) which normally account for > 10% of the anionic substituents. BFA also reduces the amount of phosphorylated chains by 80% and greatly diminishes further phosphodiester processing since the majority of these oligosaccharides (60%) contain a Man-6-PO4 residue in an acid-sensitive diester linkage. The addition of all polylactosamine chains, outer-branch fucose and terminal alpha-Gal residues are completely inhibited by BFA. Secretion, fucosylation, and sialylation are completely restored when BFA is removed, but the other modification steps are only partially restored. Our results indicate that addition of sulfate esters, terminal alpha-Gal residues, polylactosamine chains, outer-branch fucose residues, some initial phosphorylation, and most phosphodiester processing may occur beyond a compartment where some beta-Gal and sialic acid residues can be added. Essentially, all of the effects on oligosaccharide processing are partially or completely reversible.	LA JOLLA CANC RES FDN, GLYCOBIOL CHEM PROGRAM, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of California System; University of California San Diego				Freeze, Hudson/0000-0001-6316-0501	NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA38701] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSSHART H, 1991, J CELL PHYSIOL, V147, P149, DOI 10.1002/jcp.1041470119; BROWN WJ, 1987, P NATL ACAD SCI USA, V84, P9001, DOI 10.1073/pnas.84.24.9001; BYRD JC, 1985, J BIOL CHEM, V260, P7474; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHEN SY, 1991, J VIROL, V65, P1427, DOI 10.1128/JVI.65.3.1427-1439.1991; CUMMINGS RD, 1989, METHOD CELL BIOL, V32, P141; DEUTSCHER SL, 1983, P NATL ACAD SCI-BIOL, V80, P3938, DOI 10.1073/pnas.80.13.3938; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FARQUHAR MG, 1991, INTRACELLULAR TRAFFI; FREEZE HH, 1989, J BIOL CHEM, V264, P5653; FREEZE HH, 1983, J BIOL CHEM, V258, P4874; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA MN, 1987, J BIOL CHEM, V262, P7195; GEUZE HJ, 1991, J ELECTRON MICR TECH, V17, P24, DOI 10.1002/jemt.1060170105; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; HUDSON TH, 1991, J BIOL CHEM, V266, P18586; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; ISIDORO C, 1990, EUR J BIOCHEM, V191, P591, DOI 10.1111/j.1432-1033.1990.tb19162.x; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KAKIUCHI T, 1991, J IMMUNOL, V147, P3289; KEAN EL, 1974, J BIOL CHEM, V249, P7813; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRESSE H, 1981, J BIOL CHEM, V256, P2926; LAZZARINO DA, 1989, J BIOL CHEM, V264, P5015; LAZZARINO DA, 1988, J BIOL CHEM, V263, P10118; LI E, 1978, J BIOL CHEM, V253, P7762; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LITTLE LE, 1986, J BIOL CHEM, V261, P733; MARSHALL RD, 1972, GLYCOPROTEINS THEIR; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUELLER OT, 1983, J CLIN INVEST, V72, P1016, DOI 10.1172/JCI111025; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; ORCI L, 1991, CELL, V64, P1183; PAQUET MR, 1984, J BIOL CHEM, V259, P4716; PAVELKA M, 1991, J ELECTRON MICR TECH, V17, P35, DOI 10.1002/jemt.1060170106; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PERKEL VS, 1989, P SOC EXP BIOL MED, V190, P286; POHLMANN R, 1982, J BIOL CHEM, V257, P5323; RADONS J, 1990, BIOL CHEM H-S, V371, P567, DOI 10.1515/bchm3.1990.371.2.567; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; ROUX L, 1988, J BIOL CHEM, V263, P8879; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; Schachter H, 1986, Adv Exp Med Biol, V205, P53; SHITE S, 1990, EUR J BIOCHEM, V191, P491, DOI 10.1111/j.1432-1033.1990.tb19148.x; SHITE S, 1990, J BIOL CHEM, V265, P17385; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; STROUS GJ, 1991, BIOL CELL, V71, P25, DOI 10.1016/0248-4900(91)90048-R; STULTS NL, 1989, J BIOL CHEM, V264, P19956; TAKAMI N, 1990, EUR J BIOCHEM, V194, P805, DOI 10.1111/j.1432-1033.1990.tb19473.x; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; ULMER JB, 1991, J BIOL CHEM, V266, P9173; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1983, J BIOL CHEM, V258, P2808; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WANG WC, 1988, ANAL BIOCHEM, V175, P390, DOI 10.1016/0003-2697(88)90562-3; WHEALY ME, 1991, J VIROL, V65, P1066, DOI 10.1128/JVI.65.3.1066-1081.1991; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z	82	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4440	4455						16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537830				2022-12-27	WOS:A1992HF64200029
J	AHMAD, SS; RAWALASHEIKH, R; CHEUNG, WF; STAFFORD, DW; WALSH, PN				AHMAD, SS; RAWALASHEIKH, R; CHEUNG, WF; STAFFORD, DW; WALSH, PN			THE ROLE OF THE 1ST GROWTH-FACTOR DOMAIN OF HUMAN FACTOR-IXA IN BINDING TO PLATELETS AND IN FACTOR-X ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY CALCIUM-BINDING; COAGULATION; EXPRESSION; SITE	We have recently shown that thrombin-stimulated human platelets have specific, saturable receptors for factor IXa, occupancy of which promotes factor X activation (Ahmad, S. S., Rawala-Sheikh, R., and Walsh, P. N. (1989) J. Biol. Chem. 264, 3244-3251, 20012-20016; Rawala-Sheikh, R., Ahmad, S. S., and Walsh, P. N. (1990) Biochemistry 29, 2606-2611). To study the structural requirements for factor IXa binding to platelets, we have carried out equilibrium binding studies with human factor IXa after replacing the first epidermal growth factor (EGF) domain by the corresponding polypeptide region of factor X (Lin, S.-W., Smith, K. J., Welsch, D., and Stafford, D. W. (1990) J. Biol. Chem. 265, 144-150). The chimeric protein, factor IX(Xegf1), as well as the wild-type, factor IX(wt), produced in embryo kidney cells, and factor IX isolated from human plasma were radiolabeled with I-125 and activated with factor XIa. Direct binding studies with thrombin-activated platelets showed normal stoichiometry and affinity of binding of factor IXa(Xegf1) (566 sites/platelet, K(d) = 0.69 nM) and factor IXa(wt) (590 sites/platelet, K(d) = 0.61 nM) in the presence of factor VIIIa (5 units/ml) and factor X (1.5-mu-M) compared to factor IXa(N) (558 sites/platelet, K(d) = 0.67 nM). The concentration of factor IXa(N), factor IXa(wt), and factor IXa(Xegf1) required for half-maximal rates of factor Xa formation were 0.63, 0.7, and 0.83 nM, indicating that the K(d)app for binding of factor IXa(Xegf1) to the factor X activating complex on activated platelets is normal. These studies suggest either that the EGF-1 domain of factor IXa is not involved in factor IXa binding to platelets or that the EGF-1 domain from factor X when inserted into factor IXa, suffices to promote normal factor IXa binding.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,THROMBOSIS RES CTR,3400 N BROAD ST,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT MED,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL46213, HL36579, HL45486] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL045486, R01HL046213, P01HL036579] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1989, J BIOL CHEM, V264, P20012; AHMAD SS, 1989, J BIOL CHEM, V264, P3244; AHMAD SS, 1990, J BIOL CHEM, V265, P20907; AHMAD SS, 1989, J CLIN INVEST, V84, P824, DOI 10.1172/JCI114242; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; ASTERMARK J, 1991, J BIOL CHEM, V266, P2438; CHEUNG WF, 1991, J BIOL CHEM, V266, P8797; CRAIK CS, 1983, SCIENCE, V220, P1125, DOI 10.1126/science.6344214; DAYHOFF MD, 1976, ATLAS PROTEIN SEQUEN, V5, P195; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; Fersht A., 1985, ENZYME STRUCTURE MEC; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GREEN PM, 1989, EMBO J, V8, P1067, DOI 10.1002/j.1460-2075.1989.tb03474.x; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HEDNER U, 1987, HEMOSTASIS THROMBOSI, P87; HUANG LH, 1991, BIOCHEMISTRY-US, V30, P7402, DOI 10.1021/bi00244a006; HUBER P, 1990, CIRCULATION, V82, P356; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SW, 1990, J BIOL CHEM, V265, P144; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; MIYATA T, 1991, THROMB HAEMOSTASIS, V65, P817; MONROE DM, 1988, ANAL BIOCHEM, V172, P427, DOI 10.1016/0003-2697(88)90465-4; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OLSSON G, 1979, VITAMIN K METABOLISM, P8; PERSSON E, 1989, J BIOL CHEM, V264, P16897; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; RAWALASHEIKH R, 1992, BLOOD, V79, P398; ROGERS J, 1985, NATURE, V315, P458, DOI 10.1038/315458a0; RYAN J, 1989, J BIOL CHEM, V264, P20283; THOMPSON AR, 1986, BLOOD, V67, P565	31	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8571	8576						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569103				2022-12-27	WOS:A1992HQ18500092
J	ZORBAS, H; REIN, T; KRAUSE, A; HOFFMANN, K; WINNACKER, EL				ZORBAS, H; REIN, T; KRAUSE, A; HOFFMANN, K; WINNACKER, EL			NUCLEAR FACTOR-I (NF-I) BINDS TO AN NF I-TYPE SITE BUT NOT TO THE CCAAT SITE IN THE HUMAN ALPHA-GLOBIN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS DNA-REPLICATION; TRANSCRIPTION FACTORS; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; EUKARYOTIC TRANSCRIPTION; COLLAGEN PROMOTER; RECOGNITION SITE; ALBUMIN GENE; PROTEIN; SEQUENCE; POLYMERASE	Methylation interference and missing contact analyses demonstrate that nuclear factor I (NF I) recognizes an NF I-like site (5'-GGG(N)6GCCAG-3') within the alpha-globin promoter rather than the adjacent CCAAT box. Consistent with this, mutations within the CCAAT box do not alter significantly the affinity and specificity of the interaction whereas elimination of the 5'-GGG-3' half-site of the recognition sequence reduces the DNA binding strength of NF I by 2 orders of magnitude down to the range of unspecific interaction. On the other hand, the mutated alpha-globin promoter sequence that is no longer bound by NF I, although it retains an intact CCAAT box, interacts specifically with a protein component from nuclear extracts of HeLa cells. From these results we conclude that NF I is not the factor that interacts with the CCAAT box and that the second half of the canonical 5'-TGG(N)6GCCAA-3' NF I binding site cannot be regarded as identical with the CCAAT promoter element, as suggested previously.	UNIV MUNICH,INST BIOCHEM,KARLSTR 23,W-8000 MUNICH 2,GERMANY	University of Munich				Rein, Theo/0000-0003-2850-4289				APRHYS CMJ, 1989, J VIROL, V63, P2798, DOI 10.1128/JVI.63.6.2798-2812.1989; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BOSHER J, 1990, New Biologist, V2, P1083; BRADSHAW MS, 1988, J BIOL CHEM, V263, P8485; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHEN M, 1990, J BIOL CHEM, V265, P18634; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CLEAT PH, 1989, EMBO J, V8, P1841, DOI 10.1002/j.1460-2075.1989.tb03579.x; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GIL G, 1988, J BIOL CHEM, V263, P19009; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GRONOSTAJSKI RM, 1984, P NATL ACAD SCI-BIOL, V81, P4013, DOI 10.1073/pnas.81.13.4013; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; HAY RT, 1985, EMBO J, V4, P421, DOI 10.1002/j.1460-2075.1985.tb03645.x; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; HENNIGHAUSEN L, 1985, NATURE, V314, P289, DOI 10.1038/314289a0; HENNIGHAUSEN L, 1986, EMBO J, V5, P1367, DOI 10.1002/j.1460-2075.1986.tb04368.x; HOSS A, 1990, J VIROL, V64, P6291; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; JOSEESTANYOL M, 1988, J BIOL CHEM, V263, P10865; KAMATA N, 1991, MOL CELL BIOL, V11, P765, DOI 10.1128/MCB.11.2.765; KIM CG, 1990, J BIOL CHEM, V265, P13362; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MUL YM, 1990, J VIROL, V64, P5510, DOI 10.1128/JVI.64.11.5510-5518.1990; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; RISTINIEMI J, 1989, J BIOL CHEM, V264, P2164; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STUIVER MH, 1990, J VIROL, V65, P379; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; VANDERVLIET PC, 1988, CANCER CELL, V6, P61; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YUAN R, 1981, ANNU REV BIOCHEM, V50, P285, DOI 10.1146/annurev.bi.50.070181.001441; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873; ZORBAS H, 1989, NUCLEIC ACIDS RES, V17, P7735, DOI 10.1093/nar/17.19.7735	59	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8478	8484						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569098				2022-12-27	WOS:A1992HQ18500081
J	BRUNING, A; ISHIKAWA, T; KNEUSEL, RE; MATERN, U; LOTTSPEICH, F; WIELAND, FT				BRUNING, A; ISHIKAWA, T; KNEUSEL, RE; MATERN, U; LOTTSPEICH, F; WIELAND, FT			BREFELDIN-A BINDS TO GLUTATHIONE-S-TRANSFERASE AND IS SECRETED AS GLUTATHIONE AND CYSTEINE CONJUGATES BY CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; GOLGI PROTEINS; IDENTIFICATION; PEROXIDATION; COMPONENTS; RESOLUTION; TRANSPORT; MECHANISM; ANTIGENS	Radioactively labeled brefeldin A was used to probe for proteins that interact with this metabolite. The most prominent protein labeled after in vivo incubation of Chinese hamster ovary cells with [H-3]brefeldin A turned out to have an apparent molecular mass of 26 kDa. Radioactive peptides derived from the [H-3]brefeldin A-labeled protein showed sequence identity with glutathione S-transferases, and immunoblotting after two-dimensional gel electrophoresis confirmed this result. In addition, Chinese hamster ovary cells convert the antibiotic to its glutathionyl and cysteinyl derivatives and secrete them rapidly into the medium. From these findings we conclude that detoxification of the antibiotic in mammalian cells occurs via the glutathion S-transferase system. This may explain the often observed reversibility of brefeldin A's action on the steady state of organelles in mammalian cells.	UNIV HEIDELBERG, INST BIOCHEM 1, NEUENHEIMER FELD 328, W-6900 HEIDELBERG, GERMANY; GERMAN CANC RES CTR, TUMORBIOCHEM ABT, W-6900 HEIDELBERG 1, GERMANY; UNIV FREIBURG, INST BIOL 2, W-7800 FREIBURG, GERMANY; MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; Max Planck Society								ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9; BACIKOVA V, 1964, NATURWISSENSCHAFTEN, V51, P445; BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X; BETINA V, 1962, FOLIA BIOL-PRAGUE, V7, P353, DOI 10.1007/BF02928123; BRUNING A, 1992, IN PRESS J BIOL CHEM, V267; DANIELSON UH, 1987, BIOCHEM J, V247, P707, DOI 10.1042/bj2470707; DEBLAS AL, 1983, ANAL BIOCHEM, V133, P214, DOI 10.1016/0003-2697(83)90245-2; DETHMERS JK, 1981, P NATL ACAD SCI-BIOL, V78, P7492, DOI 10.1073/pnas.78.12.7492; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; ESTERBAUER H, 1986, BIOCHIM BIOPHYS ACTA, V876, P154, DOI 10.1016/0005-2760(86)90329-2; ESTERBAUER H, 1975, Z NATURFORSCH C, V30, P466; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; HARRI E, 1963, HELV CHIM ACTA, V46, P1235, DOI 10.1002/hlca.19630460419; HAYASHI T, 1982, AGR BIOL CHEM TOKYO, V46, P2241, DOI 10.1080/00021369.1982.10865421; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; ISHIKAWA T, 1990, TRENDS BIOCHEM SCI, V15, P219, DOI 10.1016/0968-0004(90)90032-7; ISHIKAWA T, 1986, J BIOL CHEM, V261, P1576; KNEUSEL RE, 1990, FEBS LETT, V275, P107, DOI 10.1016/0014-5793(90)81450-3; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1981, Methods Enzymol, V77, P231; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORCI L, 1991, CELL, V64, P1183; RANDERATH K, 1970, ANAL BIOCHEM, V34, P188, DOI 10.1016/0003-2697(70)90100-4; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHITE S, 1990, J BIOL CHEM, V265, P17385; Sies H, 1988, GLUTATHIONE CONJUGAT; SINGLETON VL, 1958, NATURE, V181, P1072, DOI 10.1038/1811072a0; STEVENS JL, 1989, COENZYMES COFACTOR B, V3, P45; TAKATSUKI A, 1969, J ANTIBIOT, V22, P442, DOI 10.7164/antibiotics.22.442; TAMURA G, 1968, J ANTIBIOT, V21, P160, DOI 10.7164/antibiotics.21.160; TIETJEN KG, 1985, PHYSIOL PLANT PATHOL, V26, P241, DOI 10.1016/0048-4059(85)90024-4; TIETJEN KG, 1983, EUR J BIOCHEM, V131, P401, DOI 10.1111/j.1432-1033.1983.tb07277.x; TOWNSEND AJ, 1989, J BIOL CHEM, V264, P21582; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; VANCE JE, 1991, J BIOL CHEM, V266, P8241; WATTENBERG BW, 1986, J BIOL CHEM, V261, P2208; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838	45	26	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7726	7732						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560007				2022-12-27	WOS:A1992HN48500075
J	SCHEPER, GC; VOORMA, HO; THOMAS, AAM				SCHEPER, GC; VOORMA, HO; THOMAS, AAM			EUKARYOTIC INITIATION FACTOR-4E AND FACTOR-4F STIMULATE 5' CAP-DEPENDENT AS WELL AS INTERNAL INITIATION OF PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED HELA-CELLS; ENCEPHALOMYOCARDITIS VIRUS-RNA; GLOBIN MESSENGER-RNA; MOUTH-DISEASE VIRUS; BINDING-PROTEIN; POLIOVIRUS RNA; FACTOR-III; TRANSLATION INITIATION; NONTRANSLATED REGION; NONCODING REGION	Two mechanisms of initiation of protein synthesis are known. The 5' cap-dependent model requires the activity of cap-binding eukaryotic initiation factors (eIF)1-4E and -4F, inducing unwinding of mRNA secondary structures. The internal initiation model is 5' cap-independent and requires a ribosomal entry site formed by higher order structures of the mRNA. It has been proposed that this mechanism does not need eIF-4E and eIF-4F. We prepared bicistronic transcripts on which both mechanisms of initiation occur, allowing the determination of the initiation factor dependence of these two mechanisms simultaneously. The unwinding factors eIF-4A, eIF-4B, and eIF-4F were found to be necessary for 5' cap-dependent initiation as well as for internal initiation. Surprisingly, efficient translation of both cistrons on the bicistronic mRNA required eIF-4E. A model is presented in which assembly of eIF-4E into a functional eIF-4F complex is a prerequisite for both types of initiation.			SCHEPER, GC (corresponding author), UNIV UTRECHT, DEPT MOLEC CELL BIOL, PADUALAAN 8, 3584 CH UTRECHT, NETHERLANDS.		Scheper, Gert C/D-7001-2014					ALTMANN M, 1990, GENE, V91, P127, DOI 10.1016/0378-1119(90)90173-O; ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; BELSHAM GJ, 1990, J VIROL, V64, P5389, DOI 10.1128/JVI.64.11.5389-5395.1990; BUCKLEY B, 1987, J BIOL CHEM, V262, P13599; CHU LY, 1980, BIOCHEMISTRY-US, V19, P184, DOI 10.1021/bi00542a028; CONROY SC, 1990, ARCH BIOCHEM BIOPHYS, V282, P363, DOI 10.1016/0003-9861(90)90130-Q; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; Donahue TF, 1990, CURR OPIN CELL BIOL, V2, P1087, DOI 10.1016/0955-0674(90)90160-G; EDERY I, 1984, BIOCHEMISTRY-US, V23, P2456, DOI 10.1021/bi00306a021; ETCHISON D, 1990, J BIOL CHEM, V265, P7492; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; FALVEY AK, 1970, J MOL BIOL, V53, P1, DOI 10.1016/0022-2836(70)90042-2; FILIPOWICZ W, 1976, P NATL ACAD SCI USA, V73, P1559, DOI 10.1073/pnas.73.5.1559; FLETCHER L, 1990, J BIOL CHEM, V265, P19582; GOSS DJ, 1990, BIOCHEMISTRY-US, V29, P5008, DOI 10.1021/bi00473a002; HANSEN J, 1982, J VIROL, V42, P200, DOI 10.1128/JVI.42.1.200-207.1982; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KOZAK M, 1983, MICROBIOL REV, V47, P1; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAWRENCE C, 1974, J VIROL, V14, P598, DOI 10.1128/JVI.14.3.598-610.1974; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LE SY, 1990, J MOL BIOL, V216, P729, DOI 10.1016/0022-2836(90)90395-3; LEE KAW, 1985, J VIROL, V54, P515, DOI 10.1128/JVI.54.2.515-524.1985; LLOYD RE, 1988, VIROLOGY, V123, P60; Maniatis T., 1982, MOL CLONING; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; OUDSHOORN P, 1990, BIOCHIM BIOPHYS ACTA, V1050, P124, DOI 10.1016/0167-4781(90)90152-R; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PELLETIER J, 1988, J VIROL, V62, P4486, DOI 10.1128/JVI.62.12.4486-4492.1988; PELLETIER J, 1989, J VIROL, V63, P441, DOI 10.1128/JVI.63.1.441-444.1989; PILIPENKO EV, 1989, NUCLEIC ACIDS RES, V17, P5701, DOI 10.1093/nar/17.14.5701; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROSEN H, 1982, J BIOL CHEM, V257, P946; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHEPER GC, 1991, BIOCHIM BIOPHYS ACTA, V1089, P220, DOI 10.1016/0167-4781(91)90011-A; SONENBERG N, 1991, TRENDS GENET, V7, P105, DOI 10.1016/0168-9525(91)90440-2; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; TAHARA SM, 1981, J BIOL CHEM, V256, P7691; THOMAS A, 1979, EUR J BIOCHEM, V98, P329, DOI 10.1111/j.1432-1033.1979.tb13192.x; THOMAS AAM, 1991, J VIROL, V65, P2953, DOI 10.1128/JVI.65.6.2953-2959.1991; VANHEUGTEN HAA, 1991, J BIOL CHEM, V266, P7279; VANSTEEG H, 1991, BIOCHEM J, V274, P521, DOI 10.1042/bj2740521; Voorma H O, 1979, Methods Enzymol, V60, P124, DOI 10.1016/S0076-6879(79)60012-5; WYCKOFF EE, 1990, P NATL ACAD SCI USA, V87, P9529, DOI 10.1073/pnas.87.24.9529	50	60	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7269	7274						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559971				2022-12-27	WOS:A1992HN48500015
J	DUBIN, A; TRAVIS, J; ENGHILD, JJ; POTEMPA, J				DUBIN, A; TRAVIS, J; ENGHILD, JJ; POTEMPA, J			EQUINE LEUKOCYTE ELASTASE INHIBITOR - PRIMARY STRUCTURE AND IDENTIFICATION AS A THYMOSIN-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; AMINO-ACID-SEQUENCE; ANTI-THROMBIN-III; SIGNAL SEQUENCE; OVALBUMIN GENE; ALPHA-1-PROTEINASE INHIBITOR; SERPIN SUPERFAMILY; CHICKEN OVALBUMIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI	The primary structure of an elastase inhibitor located in the cytoplasm of leukocytes obtained from the equine species has been determined. By sequence comparison, the protein was found to be a member of the serpin family with strong identity to plasminogen activator inhibitor-2. In contrast to other serpins this protein contained no carbohydrate and had a blocked amino terminus. Preliminary evidence indicates that the inhibitor has the additional feature of being a thymosin beta(4)-binding protein, since this polypeptide was always located in purified preparations of the protein. This suggests a physiological role for cytoplasmic elastase inhibitors in the thymosin beta(4)-regulated rearrangement of the cytoskeleton of leukocytes.	UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; JAGIELLONIAN UNIV,INST MOLEC BIOL,PL-31120 KRAKOW,POLAND; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	University System of Georgia; University of Georgia; Jagiellonian University; Duke University				Enghild, Jan Johannes/0000-0001-9292-9172				ANTALIS TM, 1988, P NATL ACAD SCI USA, V85, P985, DOI 10.1073/pnas.85.4.985; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BARBEYMOREL C, 1991, PEDIATR RES, V29, P133, DOI 10.1203/00006450-199102000-00005; BAUMANN U, 1991, J MOL BIOL, V218, P295; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BOCK SC, 1982, NUCLEIC ACIDS RES, V10, P8113, DOI 10.1093/nar/10.24.8113; BOLLEN A, 1983, DNA-J MOLEC CELL BIO, V2, P255, DOI 10.1089/dna.1983.2.255; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CARRELL R, 1985, TIBS, P20; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CHAPMAN HA, 1982, CELL, V28, P653, DOI 10.1016/0092-8674(82)90220-3; DIXON HBF, 1968, BIOCHEM J, V109, P312, DOI 10.1042/bj1090312; DUBIN A, 1977, EUR J BIOCHEM, V73, P429, DOI 10.1111/j.1432-1033.1977.tb11334.x; ERICKSONVIITANEN S, 1983, ARCH BIOCHEM BIOPHYS, V221, P570, DOI 10.1016/0003-9861(83)90177-7; GEIGER R, 1988, J CLIN CHEM CLIN BIO, V26, P605; GOLDER JP, 1983, EUR J BIOCHEM, V136, P517, DOI 10.1111/j.1432-1033.1983.tb07771.x; GOODALL GJ, 1983, ARCH BIOCHEM BIOPHYS, V221, P598, DOI 10.1016/0003-9861(83)90182-0; HANNAPPEL E, 1987, J CHROMATOGR, V397, P279, DOI 10.1016/S0021-9673(01)85010-X; HEILIG R, 1982, NUCLEIC ACIDS RES, V10, P4363, DOI 10.1093/nar/10.14.4363; HEJGAARD J, 1985, FEBS LETT, V180, P89, DOI 10.1016/0014-5793(85)80238-6; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; HINTZ P, 1987, BIOL CHEM H-S, V368, P1333, DOI 10.1515/bchm3.1987.368.2.1333; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; JOHNSON D, 1977, BIOCHEM J, V163, P639, DOI 10.1042/bj1630639; JOHNSON GP, 1986, ANAL CHEM, V58, P1084; JONES BN, 1986, METHODS PROTEIN MICR, P337; JUNGER W, 1988, BIOL CHEM H-S, V369, P63; KANOST MR, 1989, J BIOL CHEM, V264, P965; KOPITAR M, 1975, EUR J BIOCHEM, V56, P571, DOI 10.1111/j.1432-1033.1975.tb02264.x; KORZUS E, 1992, IN PRESS BIOMED BIOC, V50; KRUITHOF EKO, 1986, J BIOL CHEM, V261, P1207; KURDOWSKA A, 1990, J BIOL CHEM, V265, P21023; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LINGAPPA VR, 1979, NATURE, V281, P117, DOI 10.1038/281117a0; LOBERMANN H, 1984, J MOL BIOL, V177, P531; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; LOW TLK, 1985, METHOD ENZYMOL, V116, P248; MAHONEY WC, 1981, BIOCHEMISTRY-US, V20, P443, DOI 10.1021/bi00505a033; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MEEK RL, 1982, J BIOL CHEM, V257, P2245; MIMURO J, 1989, J BIOL CHEM, V264, P936; MOLNARPERL I, 1989, ANAL BIOCHEM, V177, P16, DOI 10.1016/0003-2697(89)90005-5; NARITA K, 1958, BIOCHIM BIOPHYS ACTA, V28, P184, DOI 10.1016/0006-3002(58)90445-1; PALMITER RD, 1978, P NATL ACAD SCI USA, V75, P94, DOI 10.1073/pnas.75.1.94; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; POTEMPA J, 1991, J BIOL CHEM, V266, P21482; POTEMPA J, 1988, J BIOL CHEM, V263, P7364; POTEMPA J, 1986, J BIOL CHEM, V261, P14330; POTEMPA J, 1990, SERINE PROTEASES THE, P163; PRESS EM, 1966, BIOCHEM J, V99, P356, DOI 10.1042/bj0990356; REMOLDODONNELL E, 1983, J BIOL CHEM, V258, P3251; REMOLDODONNELL E, 1985, J EXP MED, V162, P2142, DOI 10.1084/jem.162.6.2142; REMOLDODONNELL E, 1989, J EXP MED, V169, P1071, DOI 10.1084/jem.169.3.1071; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SASAKI T, 1986, J BIOCHEM-TOKYO, V99, P1699, DOI 10.1093/oxfordjournals.jbchem.a135645; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; SHAFER D, 1991, J BIOL CHEM, V266, P4029; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; TABE L, 1984, J MOL BIOL, V180, P645, DOI 10.1016/0022-2836(84)90031-7; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P73, DOI 10.1073/pnas.82.1.73; TAKEUCHI KH, 1989, J BIOL CHEM, V264, P7431; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TREFZ G, 1987, BIOL CHEM H-S, V368, P1343, DOI 10.1515/bchm3.1987.368.2.1343; WAXDAL MJ, 1968, BIOCHEMISTRY-US, V7, P1959, DOI 10.1021/bi00845a046; WEBB AC, 1987, J EXP MED, V166, P77, DOI 10.1084/jem.166.1.77; WELLNER D, 1990, P NATL ACAD SCI USA, V87, P1947, DOI 10.1073/pnas.87.5.1947; WOO SLC, 1981, BIOCHEMISTRY-US, V20, P6437, DOI 10.1021/bi00525a024; WRIGHT HT, 1990, J MOL BIOL, V213, P513; YE RD, 1988, J BIOL CHEM, V263, P4869; YE RD, 1987, J BIOL CHEM, V262, P3718; YE RD, 1989, J BIOL CHEM, V264, P5495	78	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6576	6583						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551869				2022-12-27	WOS:A1992HM05300022
J	WEITMAN, D; ETLINGER, JD				WEITMAN, D; ETLINGER, JD			A MONOCLONAL-ANTIBODY THAT DISTINGUISHES LATENT AND ACTIVE FORMS OF THE PROTEASOME (MULTICATALYTIC PROTEINASE COMPLEX)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEOLYSIS; MOLECULAR-WEIGHT PROTEASE; RETICULOCYTE EXTRACTS; SOLUBLE EXTRACTS; RAT-LIVER; UBIQUITIN; PURIFICATION; MACROPAIN; IDENTIFICATION; SPECIFICITY	Monoclonal antibodies (mAbs) were generated to proteasome purified from human erythrocytes. Five of six proteasome-specific mAbs reacted with three subunits in the molecular mass range of 25-28 kDa, indicating a common epitope. The other mAb (AP5C10) exhibited a more restricted reactivity, recognizing a 32-kDa subunit of the proteasome purified in its latent state. However, when the proteasome is isolated in its active state, AP5C10 reacts with a 28-kDa subunit, evidence for processing of the proteasome subunits during purification. Purified proteasome preparations which exhibited partial latency have both AP5C10 reactive subunits. Although the 32-kDa subunit appears required for latency, loss of this component and generation of the 28-kDa component are not obligatory for activation. The 32- and 28-kDa subunits can each be further resolved into three components by isoelectric focusing. The apparent loss of 4 kDa during the conversion of the 32- to 28-kDa subunit is accompanied by a shift to a more bassic pI for each polypeptide. Western blots of the early steps of proteasome purification reveal an AP5C10-reactive protein at 41 kDa. This protein was separated from proteasomes by sizing chromatography and may represent a pool of precursor subunits. Since the 32-kDa subunit appears necessary for latency, it is speculated to play a regulatory role in ATP-dependent proteolytic activity.	NEW YORK MED COLL,DEPT CELL BIOL & ANAT,VALHALLA,NY 10595; SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,BROOKLYN,NY 11203	New York Medical College; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					NHLBI NIH HHS [R01 HL38478] Funding Source: Medline; NIAMS NIH HHS [AR37145] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038478] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037145] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAHLMANN B, 1985, BIOCHEM J, V228, P161, DOI 10.1042/bj2280161; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FALKENBURG PE, 1989, J BIOL CHEM, V264, P6660; GANOTH D, 1988, J BIOL CHEM, V263, P12412; HAASS C, 1989, EMBO J, V8, P2373, DOI 10.1002/j.1460-2075.1989.tb08366.x; HAASS C, 1989, EXP CELL RES, V180, P243, DOI 10.1016/0014-4827(89)90228-0; HOUGH R, 1986, J BIOL CHEM, V261, P2400; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI XC, 1991, BIOCHEMISTRY-US, V30, P9709, DOI 10.1021/bi00104a020; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MCGUIRE MJ, 1988, BIOCHIM BIOPHYS ACTA, V967, P195, DOI 10.1016/0304-4165(88)90009-8; MCGUIRE MJ, 1989, BIOCHEM BIOPH RES CO, V160, P911, DOI 10.1016/0006-291X(89)92521-7; MURAKAMI K, 1986, P NATL ACAD SCI USA, V83, P7588, DOI 10.1073/pnas.83.20.7588; MYKLES DL, 1991, ARCH BIOCHEM BIOPHYS, V288, P543, DOI 10.1016/0003-9861(91)90233-9; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; RICE RH, 1971, J BIOL CHEM, V246, P831; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; SPEISER S, 1983, P NATL ACAD SCI-BIOL, V80, P3577, DOI 10.1073/pnas.80.12.3577; TANAKA K, 1988, FEBS LETT, V236, P159, DOI 10.1016/0014-5793(88)80306-5; TANAKA K, 1990, CELL STRUCT FUNCT, V15, P127, DOI 10.1247/csf.15.127; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TANAKA K, 1990, BIOCHEMISTRY-US, V29, P3777, DOI 10.1021/bi00467a026; WAXMAN L, 1987, J BIOL CHEM, V262, P2451; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x	28	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6977	6982						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551907				2022-12-27	WOS:A1992HM05300080
J	BENZEEV, O; DOOLITTLE, MH; DAVIS, RC; ELOVSON, J; SCHOTZ, MC				BENZEEV, O; DOOLITTLE, MH; DAVIS, RC; ELOVSON, J; SCHOTZ, MC			MATURATION OF LIPOPROTEIN-LIPASE - EXPRESSION OF FULL CATALYTIC ACTIVITY REQUIRES GLUCOSE TRIMMING BUT NOT TRANSLOCATION TO THE CIS-GOLGI COMPARTMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR CHAINS; N-LINKED GLYCOSYLATION; ENDOPLASMIC-RETICULUM; BREFELDIN-A; INTRACELLULAR-TRANSPORT; SECRETORY PROTEINS; DENSITY LIPOPROTEIN; SURFACE EXPRESSION; MEMBRANE-PROTEINS; RAT HEPATOCYTES	The relationship between maturation of lipoprotein lipase (LPL) and its translocation from the endoplasmic reticulum (ER) to the Golgi complex was determined by measuring lipolytic activity under conditions preventing transport of the enzyme from the ER to the Golgi compartment. In the presence of brefeldin A, a reagent that inhibits movement of proteins from the ER and causes the disassembly of the Golgi complex, pro-5 Chinese hamster ovary cells accumulated catalytically active LPL, while secretion of the enzyme was effectively blocked. LPL retained intracellularly by brefeldin A treatment possessed oligosaccharide chains that were processed to the complex form by the Golgi enzymes redistributed into the ER. At 16-degrees-C, a condition disrupting protein transport to the cis-Golgi, the retained enzyme again remained catalytically active although the oligosaccharides remained in the high mannose form. Lastly, attachment of the specific ER retention signal KDEL (Lys-Asp-Glu-Leu) to the carboxyl terminus of LPL also resulted in intracellularly retained enzyme that was fully active. The importance of oligosaccharide processing for attainment of LPL catalytic activity in vitro was also determined. LPL was active and secreted when trimming of the mannose residues was inhibited by deoxymannojirimycin and when addition of complex sugars was blocked using Chinese hamster ovary mutants (lec1 and lec2), indicating that these processing events are not necessary for the expression of a functional enzyme. However, blocking glucose removal by glucosidase inhibitors (castanospermine and N-methyl-deoxynojirimycin) resulted in a significant reduction in LPL specific activity and secretion. Thus, glucose trimming of LPL oligosaccharides is essential for enzyme activation; however, further oligosaccharide processing or translocation of the enzyme to the cis-Golgi is not required for full expression of lipolytic activity in vitro.	VET ADM WADSWORTH MED CTR,BLDG 113,RM 312,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28481] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AILHAUD G, 1990, CLIN BIOCHEM, V23, P343, DOI 10.1016/0009-9120(90)90034-R; AILHAUD G, 1986, ENZYMES LIPID METABO, P485; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE B, 1984, EMBO J, V3, P551, DOI 10.1002/j.1460-2075.1984.tb01845.x; CHAJEKSHAUL T, 1985, BIOCHIM BIOPHYS ACTA, V837, P123, DOI 10.1016/0005-2760(85)90235-8; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CISAR LA, 1989, J BIOL CHEM, V264, P1767; CRYER A, 1981, INT J BIOCHEM, V13, P525, DOI 10.1016/0020-711X(81)90177-4; DAVIS RC, 1990, J BIOL CHEM, V265, P17960; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; DOOLITTLE MH, 1991, ANAL BIOCHEM, V195, P364, DOI 10.1016/0003-2697(91)90342-Q; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; EDWARDS EH, 1989, BIOCHEMISTRY-US, V28, P7679, DOI 10.1021/bi00445a024; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRIES E, 1986, BIOCHEM J, V237, P33, DOI 10.1042/bj2370033; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GARFINKEL AS, 1983, J LIPID RES, V24, P775; GARFINKEL AS, 1987, PLASMA LIPOPROTEINS, P335; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOERS JWF, 1987, ANAL BIOCHEM, V166, P27, DOI 10.1016/0003-2697(87)90541-0; HOOGEWERF AJ, 1991, J BIOL CHEM, V266, P1048; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KELLY RB, 1990, NATURE, V345, P480, DOI 10.1038/345480a0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; MASUNO H, 1990, J BIOL CHEM, V265, P1628; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MORRE DJ, 1989, BIOL CELL, V67, P51, DOI 10.1111/j.1768-322X.1989.tb03009.x; MURASE T, 1981, ATHEROSCLEROSIS, V39, P293, DOI 10.1016/0021-9150(81)90015-0; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; OLIVECRONA T, 1987, J BIOL CHEM, V262, P10748; ORCI L, 1991, CELL, V64, P1183; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PATERNITI JR, 1983, SCIENCE, V221, P167, DOI 10.1126/science.6857276; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PEYRIERAS N, 1983, EMBO J, V2, P823, DOI 10.1002/j.1460-2075.1983.tb01509.x; PRADINESFIGUERES A, 1990, J LIPID RES, V31, P1467; ROJAS C, 1990, BIOCHEM J, V271, P11, DOI 10.1042/bj2710011; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SATO R, 1990, J BIOL CHEM, V265, P11880; SCHLESINGER S, 1984, J BIOL CHEM, V259, P7597; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SEMB H, 1989, J BIOL CHEM, V264, P4195; SEMB H, 1987, BIOCHIM BIOPHYS ACTA, V921, P104, DOI 10.1016/0005-2760(87)90176-7; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; VANNIER C, 1989, J BIOL CHEM, V264, P13206; VANNIER C, 1985, J BIOL CHEM, V260, P4424; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VERHOEVEN AJM, 1990, J LIPID RES, V31, P1883; WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907	63	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6219	6227						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556130				2022-12-27	WOS:A1992HK31800076
J	HIGASHIYAMA, S; LAU, K; BESNER, GE; ABRAHAM, JA; KLAGSBRUN, M				HIGASHIYAMA, S; LAU, K; BESNER, GE; ABRAHAM, JA; KLAGSBRUN, M			STRUCTURE OF HEPARIN-BINDING EGF-LIKE GROWTH-FACTOR - MULTIPLE FORMS, PRIMARY STRUCTURE, AND GLYCOSYLATION OF THE MATURE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; FACTOR-ALPHA; FACTOR GENE; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; AFFINITY; VIRUS; SEQUENCE; ENCODES; CODONS	Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a newly described member of the epidermal growth factor (EGF) family that is mitogenic for BALB/c 3T3 cells, inhibits the binding of I-125-EGF to its receptor, and triggers autophosphorylation of the EGF receptor. HB-EGF was purified from the conditioned medium of U-937 cells using cation exchange, copper affinity, heparin affinity, and two rounds of C4 reversed phase liquid chromatography. The elution profile of the first round of C4 column chromatography contained four growth factor activity peaks with similar specific biological activities. N-terminal and tryptic fragment microsequencing demonstrated that these peaks contained different structural forms of the HB-EGF protein. Some of the differences in the various forms of HB-EGF were found to be due to N-terminal heterogeneity. Microsequencing of tryptic fragments indicated that the mature HB-EGF polypeptide can contain at least 86 of the 208 amino acids predicted by nucleotide sequence to be the HB-EGF precursor molecule. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis indicated that the various forms of HB-EGF have apparent molecular masses of 19-23 kDa. Further analysis of the most predominant form of HB-EGF found in U-937 cell conditioned medium indicated that it has a pI of 7.2-7.8 and is O-glycosylated.	CHILDRENS HOSP MED CTR,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; CALIF BIOTECHNOL INC,MT VIEW,CA 94043	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	HIGASHIYAMA, S (corresponding author), CHILDRENS HOSP MED CTR,DEPT SURG RES,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [P01CA045548, R37CA037392, R01CA037392] Funding Source: NIH RePORTER; NCI NIH HHS [CA45548, CA37392] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; CHANG W, 1987, MOL CELL BIOL, V7, P535, DOI 10.1128/MCB.7.1.535; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; ENGLER DA, 1988, J BIOL CHEM, V263, P12384; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; FAGERSTAM LG, 1983, J CHROMATOGR, V266, P523, DOI 10.1016/S0021-9673(01)90923-9; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KLAGSBRUN M, 1987, P NATL ACAD SCI USA, V84, P1839, DOI 10.1073/pnas.84.7.1839; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LAZAR E, 1988, MOL CELL BIOL, V8, P1247, DOI 10.1128/MCB.8.3.1247; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RAY P, 1988, BIOCHEMISTRY-US, V27, P7289, DOI 10.1021/bi00419a017; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; UENO N, 1986, BIOCHEM BIOPH RES CO, V138, P580, DOI 10.1016/S0006-291X(86)80536-8; UPTON C, 1987, J VIROL, V61, P1271, DOI 10.1128/JVI.61.4.1271-1275.1987; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	31	335	344	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6205	6212						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556128				2022-12-27	WOS:A1992HK31800074
J	MANGELS, LA; GNEGY, ME				MANGELS, LA; GNEGY, ME			CARBACHOL STIMULATES BINDING OF A PHOTOREACTIVE CALMODULIN DERIVATIVE TO CALMODULIN-BINDING PROTEINS IN INTACT SK-N-SH HUMAN NEUROBLASTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; MUSCARINIC CHOLINERGIC RECEPTORS; LIGHT CHAIN KINASE; ADENYLATE-CYCLASE; CALCIUM-BINDING; PHOSPHODIESTERASE ACTIVITY; NUCLEAR MATRIX; SMOOTH-MUSCLE; BOVINE BRAIN; CALCINEURIN	Calmodulin (CaM) mediates the Ca2+-dependent activation of many enzyme systems in accordance with its cellular localization. We have described previously a muscarinic receptor-mediated translocation of CaM from membranes into the cytosol of SK-N-SH human neuroblastoma cells. To explore the potential targets (CaM-binding proteins, CaMBP) for CaM upon translocation, a photoreactive CaM derivative was introduced into living SK-N-SH cells using a scrape-loading technique. Scrape-loading incorporated rhodamine isothiocyanate-labeled CaM with an efficiency of 38%. CaM-diazopyruvamide (CaM-DAP), a Ca2+-dependent and CaM-specific probe, was also introduced into the cells. The muscarinic agonist carbachol stimulated a translocation of CaM from membranes into cytosol in CaM-DAP-loaded SK-N-SH cells. Upon photochemical cross-linking, cross-linked adducts of CaM-CaMBP were detected by immunoblotting with anti-CaM antibody. Carbachol stimulated increased photoaffinity labeling of three proteins with relative adduct molecular masses of 70, 120, and 180 kDa. The time course of labeling for the 70- and 120-kDa adducts showed maximal increases by 15-30 min. The 180-kDa adduct displayed a slower time course of maximal labeling, with increases maintained for 2-4 h. Subtracting the molecular mass of CaM, carbachol stimulated binding to CaMBPs of 55, 105, and 163 kDa. Predominant cellular CaMBP were identified using a biotinylated CaM overlay procedure. Western blot analysis indicated the expression of specific CaM-dependent enzymes such as calcineurin, phosphodiesterase, the beta-isoform (rat brain) of CaM kinase II, and Ca2+-ATPase. Numerous cytoskeletal CaMBP were expressed such as microtubule-associated protein-2, spectrin, tubulin, caldesmon, adducin, and neuromodulin. Of the CaMBP expressed, phosphodiesterase, calcineurin, caldesmon, and adducin cross-linked with CaM-DAP in the loaded SK-N-SH cells. Carbachol stimulated the time-dependent CaM-DAP labeling of calcineurin and adducin. This study demonstrates the novel- incorporation of a photoreactive CaM derivative into living cells, as well as muscarinic receptor-activated CaM-DAP interaction with several cellular CaMBP. We postulate that carbachol-stimulated CaM translocation in SK-N-SH cells may affect the activity of CaM-dependent enzymes and may alter aspects of cytoskeletal function.	UNIV MICHIGAN, SCH MED, DEPT PHARMACOL, 7427 MED SCI 1, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NIMH NIH HHS [MH36044, MH09954] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH036044, F31MH009954] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; BARAM D, 1983, J NEUROCHEM, V40, P55, DOI 10.1111/j.1471-4159.1983.tb12652.x; BARON BM, 1989, J NEUROCHEM, V53, P602, DOI 10.1111/j.1471-4159.1989.tb07376.x; BAUMGOLD J, 1988, BIOCHEM BIOPH RES CO, V154, P1137, DOI 10.1016/0006-291X(88)90259-8; BENNETT V, 1988, J BIOL CHEM, V263, P5860; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; BROSTROM CO, 1975, P NATL ACAD SCI USA, V72, P64, DOI 10.1073/pnas.72.1.64; CARLIN RK, 1983, J CELL BIOL, V96, P443, DOI 10.1083/jcb.96.2.443; CHEUNG WY, 1970, BIOCHEM BIOPH RES CO, V38, P533, DOI 10.1016/0006-291X(70)90747-3; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; CIMLER BM, 1985, J BIOL CHEM, V260, P784; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; CONN PM, 1981, NATURE, V292, P264, DOI 10.1038/292264a0; DEBOLAND AR, 1988, CALCIFIED TISSUE INT, V43, P370, DOI 10.1007/BF02553281; DEDMAN JR, 1977, J BIOL CHEM, V252, P8415; FISHER SK, 1989, MOL PHARMACOL, V35, P195; FISHER SK, 1987, MOL PHARMACOL, V32, P81; GLENNEY JR, 1983, METHOD ENZYMOL, V102, P204; GNEGY ME, 1976, P NATL ACAD SCI USA, V73, P3887, DOI 10.1073/pnas.73.11.3887; GONZALES RC, 1975, J CELL PHYSL, V118, P257; GRAF E, 1982, BIOCHEMISTRY-US, V21, P4511, DOI 10.1021/bi00261a049; HARRISON JK, 1989, BIOCHEMISTRY-US, V28, P6023, DOI 10.1021/bi00440a045; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YC, 1984, J BIOL CHEM, V259, P1226; LIU Y, 1989, J BIOL CHEM, V264, P12800; MANGELS L A, 1990, FASEB Journal, V4, pA621; MANGELS LA, 1991, FASEB J, V5, pA1233; MANGELS LA, 1992, IN PRESS MOL BRAIN R; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; POPOV N, 1989, EUR J PHARM-MOLEC PH, V172, P205, DOI 10.1016/0922-4106(89)90050-3; PUJOL MJ, 1989, J BIOL CHEM, V264, P18863; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SCHULMAN H, 1978, NATURE, V271, P478, DOI 10.1038/271478a0; SIMMEN RCM, 1984, J CELL BIOL, V99, P588, DOI 10.1083/jcb.99.2.588; SOBUE K, 1985, P NATL ACAD SCI USA, V82, P5025, DOI 10.1073/pnas.82.15.5025; STOCLET JC, 1987, PROG NEUROBIOL, V29, P321, DOI 10.1016/0301-0082(87)90018-9; SWEET SC, 1991, J IMMUNOL METHODS, V136, P31, DOI 10.1016/0022-1759(91)90246-C; TAKASU N, 1988, J ENDOCRINOL, V117, P109, DOI 10.1677/joe.0.1170109; TANNER LI, 1986, MOL PHARMACOL, V29, P455; TEO TS, 1973, J BIOL CHEM, V248, P5950; WALSH MP, 1980, J BIOL CHEM, V255, P335; WASEEM A, 1988, EUR J BIOCHEM, V178, P563, DOI 10.1111/j.1432-1033.1988.tb14483.x; YANG SD, 1982, BIOCHEM BIOPH RES CO, V106, P1419, DOI 10.1016/0006-291X(82)91272-4	47	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5847	5854						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556101				2022-12-27	WOS:A1992HK31800023
J	MCGARVEY, DJ; CHRISTOFFERSEN, RE				MCGARVEY, DJ; CHRISTOFFERSEN, RE			CHARACTERIZATION AND KINETIC-PARAMETERS OF ETHYLENE-FORMING ENZYME FROM AVOCADO FRUIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID; ISOLATED VACUOLES; BIOSYNTHESIS; CONVERSION; INHIBITION; STEREOCHEMISTRY; OXYGEN; STEREOISOMERS; 1-BUTENE; INVIVO	Biosynthesis of the phytohormone ethylene in higher plants proceeds via the following pathway: S-adenosylmethionine --> 1-aminocyclopropane-1-carboxylic acid (ACC) --> ethylene. Ethylene-forming enzyme (EFE), the enzyme responsible for the oxidation of ACC to ethylene, has been only partially characterized in vitro. We have obtained authentic EFE activity in vitro from extracts of avocado fruit (Persea americana Mill. cv Hass). Ammonium sulfate fractionation revealed the presence of two EFE activities, which we designate as EFE1 and EFE2. EFE1 activity utilizes ACC and O2 as substrates and requires Fe(II) and ascorbate as cofactors. The enzyme has a relatively low K(m) (32-mu-M) for ACC, discriminates diastereomers of 1-amino-2-ethylcyclopropane-1-carboxylic acid, and is inhibited competitively by 2-aminoisobutyric acid, thus confirming its identity with authentic EFE. Activity is retained in a 100,000 x g supernatant and has a pH optimum of 7.5-8.0, suggesting a cytosolic localization.	UNIV CALIF SANTA BARBARA,DEPT BIOL SCI,DIV MOLEC & CELLULAR BIOL,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara			Christoffersen, Rolf E/K-2785-2013					ADLINGTON RM, 1983, J CHEM SOC CHEM COMM, P290, DOI 10.1039/c39830000290; ANDERSON JD, 1979, PLANT PHYSIOL, V63, P931, DOI 10.1104/pp.63.5.931; APELBAUM A, 1981, PLANT PHYSIOL, V67, P80, DOI 10.1104/pp.67.1.80; APELBAUM A, 1981, PLANT PHYSIOL, V67, P74, DOI 10.1104/pp.67.1.74; BALDWIN JE, 1988, NAT PROD REP, V5, P129, DOI 10.1039/np9880500129; BALDWIN JE, 1985, J CHEM SOC CHEM COMM, P206, DOI 10.1039/c39850000206; BOUZAYEN M, 1991, PLANTA, V184, P244, DOI [10.1007/BF01102424, 10.1007/BF00197953]; BRITSCH L, 1986, EUR J BIOCHEM, V156, P569, DOI 10.1111/j.1432-1033.1986.tb09616.x; CORNISHBOWDEN A, 1976, PRINCIPLES ENZYME KI; ENGLARD S, 1986, ANNU REV NUTR, V6, P365, DOI 10.1146/annurev.nu.06.070186.002053; GUY M, 1990, PHYSIOL PLANTARUM, V79, P526; GUY M, 1984, PLANTA, V160, P281, DOI 10.1007/BF00402867; HAMILTON AJ, 1991, P NATL ACAD SCI USA, V88, P7434, DOI 10.1073/pnas.88.16.7434; HAMILTON AJ, 1990, NATURE, V346, P284, DOI 10.1038/346284a0; HOFFMAN NE, 1982, PLANT PHYSIOL, V70, P195, DOI 10.1104/pp.70.1.195; INGRAHAM LL, 1985, BIOCH DIOXYGEN; JOHN P, 1985, J PLANT PHYSIOL, V121, P397, DOI 10.1016/S0176-1617(85)80076-6; KAO CH, 1982, PLANTA, V155, P261, DOI 10.1007/BF00392725; KENDE H, 1989, PLANT PHYSIOL, V91, P1, DOI 10.1104/pp.91.1.1; LURSSEN K, 1979, Z PFLANZENPHYSIOL, V92, P285; MAYNE RG, 1986, PLANTA, V167, P159, DOI 10.1007/BF00391410; MCGARVEY DJ, 1990, PLANT MOL BIOL, V15, P165, DOI 10.1007/BF00017736; MCGARVEY DJ, 1992, IN PRESS PLANT PHYSL; McKeon T. A., 1987, Plant hormones and their role in plant growth and development., P94; MCKEON TA, 1984, PLANTA, V160, P84, DOI 10.1007/BF00392470; MITCHELL T, 1988, NEW PHYTOL, V109, P313, DOI 10.1111/j.1469-8137.1988.tb04200.x; PEISER GD, 1984, P NATL ACAD SCI-BIOL, V81, P3059, DOI 10.1073/pnas.81.10.3059; PERCIVAL FW, 1991, PLANT CELL REP, V10, P512, DOI 10.1007/BF00234584; PIRRUNG MC, 1983, J AM CHEM SOC, V105, P7207, DOI 10.1021/ja00362a052; PORTER AJR, 1986, J PLANT PHYSIOL, V125, P207, DOI 10.1016/S0176-1617(86)80143-2; SATOH S, 1980, PLANT CELL PHYSIOL, V21, P939; SPANU P, 1991, EMBO J, V10, P2007, DOI 10.1002/j.1460-2075.1991.tb07730.x; STARRETT DA, 1991, PLANT PHYSIOL, V95, P921, DOI 10.1104/pp.95.3.921; TUCKER ML, 1985, PLANT CELL ENVIRON, V8, P117, DOI 10.1111/j.1365-3040.1985.tb01218.x; VENIS MA, 1984, PLANTA, V162, P85, DOI 10.1007/BF00397425; VERVERIDIS P, 1991, PHYTOCHEMISTRY, V30, P725, DOI 10.1016/0031-9422(91)85241-Q; WHITE RL, 1982, BIOCHEM J, V203, P791, DOI 10.1042/bj2030791; YIP WK, 1988, PLANT PHYSIOL, V88, P553, DOI 10.1104/pp.88.3.553; YU YB, 1980, PLANT PHYSIOL, V66, P286, DOI 10.1104/pp.66.2.286; YU YB, 1979, PLANT PHYSIOL, V64, P1074, DOI 10.1104/pp.64.6.1074	40	105	115	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5964	5967						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556109				2022-12-27	WOS:A1992HK31800041
J	BOWYER, JR; PACKER, JCL; MCCORMACK, BA; WHITELEGGE, JP; ROBINSON, C; TAYLOR, MA				BOWYER, JR; PACKER, JCL; MCCORMACK, BA; WHITELEGGE, JP; ROBINSON, C; TAYLOR, MA			CARBOXYL-TERMINAL PROCESSING OF THE D1 PROTEIN AND PHOTOACTIVATION OF WATER-SPLITTING IN PHOTOSYSTEM-II - PARTIAL-PURIFICATION AND CHARACTERIZATION OF THE PROCESSING ENZYME FROM SCENEDESMUS-OBLIQUUS AND PISUM-SATIVUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST MEMBRANE POLYPEPTIDE; OXYGEN-EVOLVING COMPLEX; LOW-FLUORESCENT MUTANTS; MANGANESE-BINDING SITE; OXIDIZING SIDE; CHLAMYDOMONAS-REINHARDTII; SPINACH-CHLOROPLASTS; THYLAKOID MEMBRANE; PRECURSOR PROTEIN; PEA-CHLOROPLASTS	The D1 polypeptide of photosystem II (PSII) is synthesized as a precursor that is processed by cleavage at the carboxyl terminus during assembly of the active PSII complex. A mutant of the green alga Scenedesmus obliquus, LF-1, inactive in water-splitting, lacks the D1 processing activity but assembles otherwise normal PSII complexes containing the precursor D1 molecule. We have isolated and partially purified a soluble protease from sonicated thylakoids of both wild-type S. obliquus and Pisum sativum which will process the precursor Dl molecule in PSII-enriched membranes from the LF-1 mutant to the mature size. After processing (but not before), photoactivation of these PSII membranes in the presence of manganese restores water-splitting to levels seen after photoactivation of PSII membranes from dark-grown, wild-type, cells. The protease is unable to process D1 in intact thylakoids from the LF-1 mutant but processes D1 if present during sonication of the thylakoids, indicating that processing of the carboxyl-terminal extension of D1 occurs in the lumen of the thylakoid. The processing protease from both S. obliquus and P. sativum is a single subunit enzyme of native molecular mass 33-35 kDa. Processing rate is optimal at pH 6.5. Processing in vitro is evident within 5 min and is markedly inhibited by millimolar concentrations of divalent cations (Cu, Zn > Mn > Ca, Mg) but not by any known inhibitors of the major classes of proteases. The protease is inactive against the precursors of other thylakoidal proteins and is thus distinct from the thylakoidal amino-terminal processing enzyme involved in the removal of transit peptides from cytoplasmically-synthesised proteins imported into the thylakoid lumen.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick	BOWYER, JR (corresponding author), UNIV LONDON,ROYAL HOLLOWAY & BEDFORD NEW COLL,DEPT BIOCHEM,EGHAM HILL,EGHAM TW20 0EX,SURREY,ENGLAND.							ABAD MS, 1989, PLANT PHYSIOL, V90, P117, DOI 10.1104/pp.90.1.117; ADIR N, 1990, J BIOL CHEM, V265, P12563; ANDERSSON B, 1985, BIOCHIM BIOPHYS ACTA, V809, P288, DOI 10.1016/0005-2728(85)90073-8; ARMSTRONG JM, 1964, BIOCHIM BIOPHYS ACTA, V86, P194; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BARBER J, 1987, TRENDS BIOCHEM SCI, V12, P123, DOI 10.1016/0968-0004(87)90058-2; BISHOP NI, 1971, METHODS ENZYMOLOGY A, V23, P372; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALLAHAN FE, 1986, PLANT PHYSIOL, V82, P261, DOI 10.1104/pp.82.1.261; CHENIAE GM, 1973, PHOTOCHEM PHOTOBIOL, V17, P441, DOI 10.1111/j.1751-1097.1973.tb06378.x; CURTIS SE, 1984, PLANT MOL BIOL, V3, P249, DOI 10.1007/BF00029661; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; DINER BA, 1988, J BIOL CHEM, V263, P8972; ELDERFIELD PD, 1991, THESIS U WARWICK UK; ERICKSON JM, 1984, EMBO J, V3, P2753, DOI 10.1002/j.1460-2075.1984.tb02206.x; FUJITA S, 1989, FEBS LETT, V255, P1, DOI 10.1016/0014-5793(89)81049-X; Gray J.C., 1982, METHODS CHLOROPLAST, P1093; GUENTHER JE, 1990, PHOTOSYNTH RES, V24, P35, DOI 10.1007/BF00032642; GUENTHER JE, 1990, PHOTOSYNTH RES, V23, P105, DOI 10.1007/BF00030070; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HANSSON O, 1990, PHOTOSYNTH RES, V23, P131, DOI 10.1007/BF00035006; HERRIN D, 1985, FEBS LETT, V184, P90, DOI 10.1016/0014-5793(85)80660-8; HOFFMANFALK H, 1982, J BIOL CHEM, V257, P4583; HURT E, 1981, EUR J BIOCHEM, V117, P591; INAGAKI N, 1989, FEBS LETT, V246, P218, DOI 10.1016/0014-5793(89)80286-8; INAGAKI N, 1990, CURRENT RES PHOTOSYN, V3, P763; JAMES HE, 1989, J BIOL CHEM, V264, P19573; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; KELLER M, 1984, FEBS LETT, V175, P173, DOI 10.1016/0014-5793(84)80593-1; KIRWIN PM, 1987, J BIOL CHEM, V262, P16386; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; KLIMOV VV, 1990, PHOTOSYNTH RES, V23, P59, DOI 10.1007/BF00030063; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARDER JB, 1989, PLANT CELL ENVIRON, V12, P595, DOI 10.1111/j.1365-3040.1989.tb01228.x; MARDER JB, 1984, J BIOL CHEM, V259, P3900; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; MEADOWS JW, 1989, FEBS LETT, V253, P244, DOI 10.1016/0014-5793(89)80968-8; MELIS A, 1991, BIOCHIM BIOPHYS ACTA, V1058, P87, DOI 10.1016/S0005-2728(05)80225-7; METZ J, 1980, BIOCHEM BIOPH RES CO, V94, P560, DOI 10.1016/0006-291X(80)91268-1; METZ JG, 1985, FEBS LETT, V185, P191, DOI 10.1016/0014-5793(85)80768-7; METZ JG, 1980, FEBS LETT, V114, P61, DOI 10.1016/0014-5793(80)80861-1; METZ JG, 1986, FEBS LETT, V205, P269, DOI 10.1016/0014-5793(86)80911-5; METZ JG, 1984, PLANT PHYSIOL, V76, P829, DOI 10.1104/pp.76.3.829; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MILLER AF, 1990, BIOCHEMISTRY-US, V29, P1385, DOI 10.1021/bi00458a007; MINAMI EI, 1984, ARCH BIOCHEM BIOPHYS, V235, P562, DOI 10.1016/0003-9861(84)90230-3; MIYAO M, 1991, BIOCHIM BIOPHYS ACTA, V1056, P47, DOI 10.1016/S0005-2728(05)80071-4; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; NIXON PJ, 1991, PLANT CELL, V3, P383, DOI 10.1105/tpc.3.4.383; OISHI KK, 1984, MOL CELL BIOL, V4, P2556, DOI 10.1128/MCB.4.11.2556; OSIWACZ HD, 1987, NUCLEIC ACIDS RES, V15, P10585; PFISTER K, 1981, P NATL ACAD SCI-BIOL, V78, P981, DOI 10.1073/pnas.78.2.981; PORTIS AR, 1976, J BIOL CHEM, V251, P1610; PRESTON C, 1989, PHOTOSYNTH RES, V22, P101, DOI 10.1007/BF00114770; REISFELD A, 1982, EUR J BIOCHEM, V124, P125, DOI 10.1111/j.1432-1033.1982.tb05914.x; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; ROCHAIX JD, 1988, TRENDS BIOCHEM SCI, V13, P56, DOI 10.1016/0968-0004(88)90029-1; RUTHERFORD AW, 1988, BIOCHIM BIOPHYS ACTA, V932, P171, DOI 10.1016/0005-2728(88)90152-1; SAYRE RT, 1986, CELL, V47, P601, DOI 10.1016/0092-8674(86)90624-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHREIER PH, 1985, EMBO J, V4, P25, DOI 10.1002/j.1460-2075.1985.tb02312.x; SEIBERT M, 1989, BIOCHIM BIOPHYS ACTA, V974, P185, DOI 10.1016/S0005-2728(89)80371-8; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1985, NATURE, V317, P456, DOI 10.1038/317456a0; SPEILMAN A, 1983, NUCLEIC ACIDS RES, V11, P7157; SVENSSON B, 1990, EMBO J, V9, P2051, DOI 10.1002/j.1460-2075.1990.tb07372.x; TAKAHASHI M, 1988, FEBS LETT, V240, P6, DOI 10.1016/0014-5793(88)80330-2; TAKAHASHI Y, 1990, PLANT CELL PHYSIOL, V31, P273; TAMURA N, 1987, BIOCHIM BIOPHYS ACTA, V890, P179, DOI 10.1016/0005-2728(87)90019-3; TAYLOR MA, 1988, FEBS LETT, V237, P229, DOI 10.1016/0014-5793(88)80207-2; TAYLOR MA, 1988, FEBS LETT, V235, P109, DOI 10.1016/0014-5793(88)81243-2; TODD CM, 1990, THESIS U LONDON; TREBST A, 1986, Z NATURFORSCH C, V41, P240; TYAGI A, 1987, MOL GEN GENET, V207, P288, DOI 10.1007/BF00331591; WOLBER PK, 1984, Z NATURFORSCH C, V33, P425; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZURAWSKI G, 1982, P NATL ACAD SCI-BIOL, V79, P6260, DOI 10.1073/pnas.79.20.6260	79	64	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5424	5433						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544920				2022-12-27	WOS:A1992HH74700065
J	SMITH, GK; DUCH, DS; EDELSTEIN, MP; BIGHAM, EC				SMITH, GK; DUCH, DS; EDELSTEIN, MP; BIGHAM, EC			NEW INHIBITORS OF SEPIAPTERIN REDUCTASE - LACK OF AN EFFECT OF INTRACELLULAR TETRAHYDROBIOPTERIN DEPLETION UPON INVITRO PROLIFERATION OF 2 HUMAN CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENOVO BIOSYNTHESIS; BIOPTERIN; CATECHOLAMINE; PURIFICATION; BRAIN; ACID	N-Acetylserotonin (compound 1) and N-acetyldopamine (compound 7) inhibit bovine adrenal medullary sepiapterin reductase in a manner competitive with the pterin substrate and have K(i) values of 0.12 and 0.4-mu-M, respectively. Molecular modeling suggests that the phenyl rings of the two compounds bind in the pyrimidine pocket of the enzyme with the 3-hydroxyl of dopamine or the 5-hydroxyl of serotonin aligned at the pyrimidine 4-position. Further, the acetyl moieties of the two inhibitors appear to mimic the substrate side chain. Consistent with this analysis, N-acetyl-m-tyramine (compound 13) is also an excellent competitive inhibitor (K(i) = 0.13-mu-M), whereas N-acetyltryptamine (compound 2), N-acetyl-p-tyramine (compound 14) and N-acetylphenylethylamine (compound 15) all bind poorly. Interestingly, restricted-rotation analogs of N-acetyldopamine and N-acetyl-m-tyramine are noncompetitive inhibitors of the enzyme. Modification of N-acetyldopamine to N-chloroacetyldopamine (compound 10) or of N-acetylserotonin to the N-chloroacetyl (5) or N-methoxyacetyl (compound 6) analogs results in greatly increased competitive affinity, with K(i) = 0.014-mu-M for the dopamine analog and 0.006 and 0.008-mu-M, respectively, for the serotonin analogs. In MOLT-4 T-cell leukemia and MCF-7 breast adenocarcinoma in culture, 0.1 mM N-methoxyacetylserotonin depleted tetrahydrobiopterin by greater-than-or-equal-to 97 and > 50%, respectively, with no effect upon cell growth. In both cell lines, the GTP cyclohydrolase inhibitor, 2,4-diamino-6-hydroxypyrimidine at 1-5 mM also depleted tetrahydrobiopterin greater-than-or-equal-to 97%. In this case, however, modest growth inhibition did occur. Since the growth inhibition could not be reversed upon tetrahydrobiopterin repletion, inhibition was due to other effects of the inhibitor rather than to tetrahydrobiopterin depletion. The results show that there is no effect on cell growth when at least 97% of the tetrahydrobiopterin in these cell lines is depleted. Since the sepiapterin reductase inhibitor depleted tetrahydrobiopterin with fewer nonspecific effects than the cyclohydrolase inhibitor, it will be useful for determining metabolic effects of tetrahydrobiopterin depletion.	WELLCOME RES LABS,DIV ORGAN CHEM,RES TRIANGLE PK,NC 27709	Wellcome Research Laboratories	SMITH, GK (corresponding author), WELLCOME RES LABS,DIV CELL BIOL,RES TRIANGLE PK,NC 27709, USA.							AYLING JE, 1982, OXYGENASES OXYGEN ME, P267; BENKOVIC SJ, 1980, ANNU REV BIOCHEM, V49, P227, DOI 10.1146/annurev.bi.49.070180.001303; BRAUTIGAM M, 1984, J NEUROCHEM, V42, P390, DOI 10.1111/j.1471-4159.1984.tb02690.x; BRETSCHNEIDER H, 1948, MONATSH CHEM, V78, P71, DOI 10.1007/BF00942490; BROWN G M, 1986, P125; CACCHI S, 1982, J ORG CHEM, V47, P2995, DOI 10.1021/jo00136a036; CURTIUS H-C, 1986, P141; ELORRIAGA C, 1976, AN QUIM-INT, V72, P1018; FOSTER BC, 1989, XENOBIOTICA, V19, P531, DOI 10.3109/00498258909042292; Groen A, 1982, METABOLIC COMPARTMEN, P9; HARRIES CD, 1891, BER DTSCH CHEM GES, V24, P3180; HIRABAYASHI S, 1987, Patent No. 62141553; KATOH S, 1982, BIOCHEM BIOPH RES CO, V105, P75, DOI 10.1016/S0006-291X(82)80012-0; KAUFMAN S, 1967, ANNU REV BIOCHEM, V36, P171, DOI 10.1146/annurev.bi.36.070167.001131; Kaufman S., 1974, MOL MECH OXYGEN ACTI, P285; KERLER F, 1990, EXP CELL RES, V189, P151, DOI 10.1016/0014-4827(90)90229-4; MILSTIEN S, 1989, J BIOL CHEM, V264, P8066; MILSTIEN S, 1986, P169; NAIR MG, 1989, J MED CHEM, V32, P1277, DOI 10.1021/jm00126a022; NARUTO S, 1973, CHEM PHARM BULL, V21, P629, DOI 10.1248/cpb.21.629; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NICHOL CA, 1984, BIOCH CLIN ASPECTS P, V3, P61; OTTENHEIJM HCJ, 1975, SYNTHESIS-STUTTGART, P163; PRATESI P, 1959, J CHEM SOC, P4062, DOI 10.1039/jr9590004062; SCHENKER F, 1971, J HETEROCYCLIC CHEM, V8, P665; Segel I.H., 1975, ENZYME KINETICS BEHA, P161; SMISSMAN EE, 1976, J MED CHEM, V19, P127, DOI 10.1021/jm00223a022; SMITH G K, 1986, P151; SMITH GK, 1985, J BIOL CHEM, V260, P5221; SMITH GK, 1986, J BIOL CHEM, V261, P2725; SMITH GK, 1987, ARCH BIOCHEM BIOPHYS, V255, P254, DOI 10.1016/0003-9861(87)90392-4; Spath E, 1930, BER DTSCH CHEM GES, V63, P120, DOI 10.1002/cber.19300630117; STEINERSTAUCH P, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P238; STILL WC, 1989, MACROMODEL V2 5; SUEOKA T, 1985, BIOCHIM BIOPHYS ACTA, V843, P193, DOI 10.1016/0304-4165(85)90139-4; TAKIKAWA SI, 1986, EUR J BIOCHEM, V161, P295, DOI 10.1111/j.1432-1033.1986.tb10446.x; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5864, DOI 10.1073/pnas.86.15.5864; TIETZ A, 1964, J BIOL CHEM, V239, P4081; WOOLF JH, 1983, J CHROMATOGR, V274, P398, DOI 10.1016/S0378-4347(00)84451-5	39	35	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5599	5607						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544933				2022-12-27	WOS:A1992HH74700089
J	DATTA, B; WEINER, AM				DATTA, B; WEINER, AM			CROSS-LINKING OF U2 SNRNA USING NITROGEN-MUSTARD - EVIDENCE FOR HIGHER-ORDER STRUCTURE .1.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; 3' SPLICE SITE; ESCHERICHIA-COLI; MAMMALIAN U2; INTRA-RNA; PROTEIN; BINDING; PARTICLES; RECOGNIZES	Nuclear mRNA precursors are spliced by a large macromolecular complex called the spliceosome which contains, in most eucaryotes, five small nuclear RNAs (snRNAs) each in the form of a small ribonucleoprotein particle (the U1, U2, U5, and U4/U6 snRNPs). Although secondary structures have been derived for all five spliceosomal snRNAs based on phylogenetic, biochemical, and genetic data, little tertiary structure information is available. Here we use the general cross-linking reagent nitrogen mustard [bis-(2-chloroethyl) methylamine] to detect tertiary interactions within U2 snRNA. After the cross-linking of deproteinized HeLa nuclear extract, two intramolecularly cross-linked U2 species with anomalous electrophoretic mobility can be detected (X-U2#1 and X-U2#2). The 3' and 5' boundaries of each cross-link were determined by rapid enzymatic RNA sequencing of end-labeled RNA. X-U2#1 is cross-linked between the region U41-U55 and G105 or G106, X-U2#2 between U53 and G97 or G98. We then tested the ability of the two cross-linked species to bind snRNP proteins in vitro (in nuclear extract or S100) and in vivo (in Xenopus oocytes). X-U2#2 reconstituted efficiently both in vitro and in vivo but X-U2#1 did not, as judged by immunoprecipitation with antibodies specific for Sm- and U2-specific proteins. Since the cross-link in X-U2#2 involves the Sm binding site but does not block snRNP assembly, our data strongly suggest that the Sm binding site lies on the surface of the native snRNP.			DATTA, B (corresponding author), YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031073] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31073] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; ATMADJA J, 1986, NUCLEIC ACIDS RES, V14, P659, DOI 10.1093/nar/14.2.659; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BRIMACOMBE R, 1988, METHOD ENZYMOL, V164, P287; CALVET JP, 1987, J MOL BIOL, V197, P543, DOI 10.1016/0022-2836(87)90563-8; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; DATTA B, 1992, J BIOL CHEM, V267, P4503; DEROBERTIS EM, 1982, NATURE, V295, P572, DOI 10.1038/295572a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; DORING T, 1991, NUCLEIC ACIDS RES, V19, P3517, DOI 10.1093/nar/19.13.3517; ENGLAND TE, 1978, NATURE, V275, P560, DOI 10.1038/275560a0; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; HAMM J, 1989, CELL, V59, P159, DOI 10.1016/0092-8674(89)90878-7; HARTMUTH K, 1988, MOL CELL BIOL, V8, P2011, DOI 10.1128/MCB.8.5.2011; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JONES MH, 1990, EMBO J, V9, P2555, DOI 10.1002/j.1460-2075.1990.tb07436.x; KELLER EB, 1985, NUCLEIC ACIDS RES, V13, P4971, DOI 10.1093/nar/13.13.4971; LUHRMANN R, 1988, STRUCTURE FUNCTION M, P71; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MIDGLEY CA, 1985, EMBO J, V4, P2695, DOI 10.1002/j.1460-2075.1985.tb03989.x; MIMORI T, 1984, J BIOL CHEM, V259, P560; NELSON KK, 1989, GENE DEV, V3, P1562, DOI 10.1101/gad.3.10.1562; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PIKIELNY CW, 1989, GENE DEV, V3, P479, DOI 10.1101/gad.3.4.479; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105; RINKE J, 1985, J MOL BIOL, V185, P721, DOI 10.1016/0022-2836(85)90057-9; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SHUSTER EO, 1990, NATURE, V345, P270, DOI 10.1038/345270a0; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZHANG P, 1989, BIOCHEMISTRY-US, V28, P4607, DOI 10.1021/bi00437a015; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	41	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4497	4502						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537834				2022-12-27	WOS:A1992HF64200035
J	JACKSON, DG; BUCKLEY, J; BELL, JI				JACKSON, DG; BUCKLEY, J; BELL, JI			MULTIPLE VARIANTS OF THE HUMAN LYMPHOCYTE HOMING RECEPTOR CD44 GENERATED BY INSERTIONS AT A SINGLE SITE IN THE EXTRACELLULAR DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE GLYCOPROTEIN; LEUKOCYTE-COMMON ANTIGEN; MONOCLONAL-ANTIBODIES; HIGH ENDOTHELIUM; PROTEOGLYCAN CORE; MOLECULAR-CLONING; LINK PROTEINS; CDNA; RECOGNITION; SEQUENCE	The human CD44 cell-surface glycoprotein participates in a wide variety of cell-cell interactions including lymphocyte homing and tumor metastasis. The CD44 antigen is known to display extensive size heterogeneity when compared between different tissue sources although the structural basis for this variation is not yet clear. Recently, two further isotypes in addition to the basic hemopoietic form of the CD44 antigen have been cloned and sequenced and these have been found to contain all or part of a 200-400-base pair insert within the extracellular domain, suggesting that the characteristic heterogeneity in the molecule may be generated by a mechanism of alternative splicing. We have obtained further evidence for alternative splicing, and we report here the cloning and sequencing of six different CD44 sequence variants from a variety of cell lines using a combination of expression cloning and the polymerase chain reaction. Comparison of these variants indicates that each is probably assembled by the insertion of five different exon units in tandem into a discrete site within the membrane proximal region of the extracellular domain. One of the variants contains an exon that shares extensive amino acid sequence homology with a recently described rat CD44 variant that mediates tumor metastasis. Another variant contains a new exon that encodes a tandem repeat of the consensus sequence SG for covalent modification with chondroitin sulfate and is expressed predominantly on mammary tumors. We suggest that a mechanism of alternative exon splicing generates much of the observed structural heterogeneity of CD44 and that the particular set of CD44 variants expressed in a single cell may represent a precise postal code directing the final destination of migrating cells and metastatic tumors.			JACKSON, DG (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND.			, david/0000-0002-4133-9364	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARCLAY AN, 1987, EMBO J, V6, P1259, DOI 10.1002/j.1460-2075.1987.tb02362.x; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALCHAU R, 1980, EUR J IMMUNOL, V10, P745, DOI 10.1002/eji.1830101004; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P4654, DOI 10.1073/pnas.86.12.4654; GOLDSTEIN LA, 1990, IMMUNOGENETICS, V32, P389; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUET S, 1989, J IMMUNOL, V143, P798; IDZERDA RL, 1989, P NATL ACAD SCI USA, V86, P4659, DOI 10.1073/pnas.86.12.4659; JACKSON DG, 1990, J IMMUNOL, V144, P2811; JALKANEN S, 1988, J IMMUNOL, V141, P1615; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; KANSAS GS, 1989, J IMMUNOL, V142, P3050; Maniatis T., 1982, MOL CLONING; MCMICHAEL AJ, 1989, LEUCOCYTE TYPING, V4; MCMICHAEL AJ, 1987, LEUCOCYTE TYPING, V3, P31; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; OMARY MB, 1988, IMMUNOGENETICS, V27, P460, DOI 10.1007/BF00364434; PAGANI F, 1991, J CELL BIOL, V113, P1223, DOI 10.1083/jcb.113.5.1223; PALS ST, 1989, J IMMUNOL, V143, P851; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; REBER S, 1990, INT J CANCER, V46, P919, DOI 10.1002/ijc.2910460528; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; TELEN MJ, 1983, J CLIN INVEST, V71, P1878, DOI 10.1172/JCI110943; UNDERHILL CB, 1987, J BIOL CHEM, V262, P13142; WOLFFE EJ, 1990, J BIOL CHEM, V265, P341	40	250	258	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4732	4739						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537855				2022-12-27	WOS:A1992HF64200068
J	LAWSON, JH; BUTENAS, S; MANN, KG				LAWSON, JH; BUTENAS, S; MANN, KG			THE EVALUATION OF COMPLEX-DEPENDENT ALTERATIONS IN HUMAN FACTOR-VIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VII; HUMAN-TISSUE FACTOR; FACTOR-X; BLOOD-COAGULATION; EXTRINSIC PATHWAY; FACTOR-IX; PHOSPHOLIPID-VESICLES; PROTEIN-C; ACTIVATION; PURIFICATION	Factor VIIa is a plasma glycoprotein which, when bound to the integral membrane glycoprotein tissue factor, forms an enzymatic complex that is essential for normal hemostasis. We have developed a fluorescent substrate (6-(Mes-D-Leu-Gly-Arg)amino-1-naphthalenediethylsulfamide) which can be used to directly measure the enzymatic activity of factor VIIa in the presence and absence of tissue factor and phospholipid. The sensitivity of this substrate allows for detection of factor VIIa at concentrations below 10(-9) M. The kinetics of substrate hydrolysis by factor VIIa were evaluated and it was observed that the binding of factor VIIa to tissue factor increases the catalytic efficiency (k(cat)/K(m)) of factor VIIa substrate hydrolysis > 100-fold. The increase in enzymatic efficiency of factor VIIa, when complexed to tissue factor, is mediated primarily by an increase in k(cat). These data suggest that tissue factor induces an alteration in the catalytic site of factor VIIa, which allows for more efficient hydrolysis of the small fluorescent substrate. Measurements conducted using various phospholipids and detergents demonstrated that the increase in catalytic efficiency of factor VIIa, when complexed to tissue factor, is independent of the supporting surface. The differential rate of substrate hydrolysis when factor VIIa is complexed to tissue factor was used to estimate the binding of factor VIIa to tissue factor. From these data an apparent dissociation constant for factor VIIa binding to tissue factor was calculated to be between 1.1 and 2.1 nM with a binding stoichiometry of 1.04:1 (factor VIIa:tissue factor). When the reactivity of this small fluorescent substrate toward single-chain factor VII was investigated, both in the presence and absence of tissue factor, no substrate hydrolysis was observed.	UNIV VERMONT,DEPT BIOCHEM,HLTH SCI COMPLEX,BURLINGTON,VT 05405; INST BIOCHEM,VILNIUS 232600,LITHUANIA,USSR	University of Vermont					NHLBI NIH HHS [T32 HL07594, R01 HL4697] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007594] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; BARLOW GH, 1984, BIOCHEMISTRY-US, V23, P2384, DOI 10.1021/bi00306a010; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; CHARGAFF E, 1948, J BIOL CHEM, V173, P253; CLAEYS H, 1973, Thrombosis Research, V3, P515, DOI 10.1016/0049-3848(73)90113-8; FORMAN SD, 1986, P NATL ACAD SCI USA, V83, P4675, DOI 10.1073/pnas.83.13.4675; Fujikawa K, 1976, Methods Enzymol, V45, P89; HALEY PE, 1989, J BIOL CHEM, V264, P16303; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; JENNY R, 1986, PREP BIOCHEM, V11, P397; KAM CM, 1990, THROMB HAEMOSTASIS, V64, P133; KISIEL W, 1981, METHOD ENZYMOL, V80, P320; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KRISHNASWAMY S, 1990, CIRCULATION, V82, P133; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KRISHNASWAMY S, 1991, THROMB HAEMOSTASIS, V6, P750; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; Lundblad R L, 1976, Methods Enzymol, V45, P156; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MANN KG, 1981, METHOD ENZYMOL, V80, P286; NEMERSON Y, 1988, BLOOD, V71, P1; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; PEDERSEN AH, 1991, THROMB HAEMOSTASIS, V5, P528; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO LVM, 1986, BLOOD, V68, P685; RIJKEN DC, 1981, J BIOL CHEM, V256, P7035; RUF W, 1991, J BIOL CHEM, V266, P2158; SAKAI T, 1989, J BIOL CHEM, V264, P9980; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; White W.F., 1970, METHOD ENZYMOL, V19, P665; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536; ZUR M, 1982, J BIOL CHEM, V257, P5623; ZUR M, 1978, J BIOL CHEM, V253, P2203; ZUR M, 1980, J BIOL CHEM, V255, P5703	41	118	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4834	4843						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537862				2022-12-27	WOS:A1992HF64200082
J	DESNOYERS, L; MANJUNATH, P				DESNOYERS, L; MANJUNATH, P			MAJOR PROTEINS OF BOVINE SEMINAL PLASMA EXHIBIT NOVEL INTERACTIONS WITH PHOSPHOLIPID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; MANNOSE 6-PHOSPHATE RECEPTOR; PLATELET-ACTIVATING-FACTOR; LIPID TRANSFER PROTEINS; APOLIPOPROTEIN-A-I; HUMAN FACTOR-VIII; BINDING-PROTEINS; POLYACRYLAMIDE GELS; SPERM CAPACITATION; GENOMIC STRUCTURE	A group of similar proteins, namely BSP-A1, BSP-A2, BSP-A3, and BSP-30-kDa (collectively called BSP proteins), are the major proteins found in bovine seminal fluid. These proteins are secretory products of seminal vesicles, and they bind to spermatozoa upon ejaculation, suggesting that there are binding sites for these proteins on the spermatozoa. It was of interest to characterize these binding sites on spermatozoa which may help in the elucidation of the biological function of BSP proteins. The binding sites on spermatozoa are resistant to protease or acid treatment and are heat-stable but extractable with organic solvents. The solvent-extractable material, when coated on plastic microtitration wells, binds radiolabeled BSP proteins thus indicating the lipid nature of the BSP binding sites on spermatozoa. We investigated the specificity of interaction of BSP proteins with lipids using liposomes of phospholipids, solid-phase, and thin-layer chromatography-overlay techniques. Results showed that BSP-A1, -A2, and -A3 proteins bound specifically to those phospholipids which contain the phosphorylcholine group. In contrast, BSP-30-kDa protein preferentially bound to phospholipids containing the phosphorylcholine moiety but also interacted with phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, and cardiolipin. Furthermore, of those lipids that were extracted from spermatozoa, only phospholipids which contain the phosphorylcholine moiety bound radiolabeled BSP proteins. These data suggest that the BSP protein binding sites on spermatozoa are phospholipids. We propose that this specific interaction plays an important role in the membrane modification of spermatozoa that occurs during capacitation and/or acrosome reaction.	HOP MAISON NEUVE ROSEMONT, CTR RECH, ENDOCRINE LAB, 5415 BLVD ASSOMPT, MONTREAL H1T 2M4, QUEBEC, CANADA; UNIV MONTREAL, DEPT MED, MONTREAL H3C 3J7, QUEBEC, CANADA	Universite de Montreal; Universite de Montreal								BAKER ME, 1985, BIOCHEM BIOPH RES CO, V130, P1010, DOI 10.1016/0006-291X(85)91715-2; BELLESISLES M, 1986, BIOCHEM J, V240, P863, DOI 10.1042/bj2400863; BLOOM JW, 1989, THROMB RES, V54, P261, DOI 10.1016/0049-3848(89)90084-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; BURK RR, 1983, METHOD ENZYMOL, V91, P247; BURNS AL, 1989, P NATL ACAD SCI USA, V86, P3798, DOI 10.1073/pnas.86.10.3798; CHANDONNET L, 1990, MOL REPROD DEV, V26, P313, DOI 10.1002/mrd.1080260404; CLEGG ED, 1973, J REPROD FERTIL, V34, P379, DOI 10.1530/jrf.0.0340379; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DUCKCHONG CG, 1979, LIPIDS, V14, P492, DOI 10.1007/BF02533467; ESCH FS, 1983, BIOCHEM BIOPH RES CO, V113, P861, DOI 10.1016/0006-291X(83)91078-1; FOLCH J, 1957, J BIOL CHEM, V226, P497; GEISOW MJ, 1987, BIOSCIENCE REP, V7, P289, DOI 10.1007/BF01121450; GEISOW MJ, 1986, FEBS LETT, V203, P99, DOI 10.1016/0014-5793(86)81445-4; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GO KJ, 1983, ADV LIPID RES, V20, P317; HAWGOOD S, 1989, AM J PHYSIOL, V257, pL13, DOI 10.1152/ajplung.1989.257.2.L13; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; JI I, 1981, BIOL REPROD, V24, P617, DOI 10.1095/biolreprod24.3.617; JOHNSTON PA, 1990, BIOCHEM SOC T, V18, P1097, DOI 10.1042/bst0181097; KEMME M, 1988, DNA-J MOLEC CELL BIO, V7, P595, DOI 10.1089/dna.1988.7.595; KUZAN FB, 1990, PROSTAGLANDINS, V39, P61, DOI 10.1016/0090-6980(90)90095-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLAIS J, 1985, GAMETE RES, V12, P183, DOI 10.1002/mrd.1120120209; LICHTENHELD MG, 1988, NATURE, V335, P448, DOI 10.1038/335448a0; LIU TY, 1987, J PROTEIN CHEM, V6, P263; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MANJUNATH P, 1987, BIOSCIENCE REP, V7, P231, DOI 10.1007/BF01124794; MANJUNATH P, 1982, J BIOL CHEM, V257, P7109; MANJUNATH P, 1989, J BIOL CHEM, V264, P16853; MANJUNATH P, 1987, BIOCHEM J, V241, P685, DOI 10.1042/bj2410685; Manjunath P, 1984, GONADAL PROTEINS PEP, P49; Manjunath P, 1988, MOL BIOL BRAIN ENDOC, P259; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MILLER DJ, 1990, MOL REPROD DEV, V26, P184, DOI 10.1002/mrd.1080260213; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NAGPURKAR A, 1983, J BIOL CHEM, V258, P518; OHNISHI S, 1974, BIOCHEMISTRY-US, V13, P881, DOI 10.1021/bi00702a008; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; PARKS JE, 1990, BIOL REPROD, V43, P806, DOI 10.1095/biolreprod43.5.806; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PFAFFLE M, 1988, EMBO J, V7, P2335, DOI 10.1002/j.1460-2075.1988.tb03077.x; PURSEL VG, 1967, J REPROD FERTIL, V14, P203, DOI 10.1530/jrf.0.0140203; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; SEIDAH NG, 1987, BIOCHEM J, V243, P195, DOI 10.1042/bj2430195; SIDHU KS, 1989, INT REV CYTOL, V118, P231; SPIEGEL S, 1985, SCIENCE, V230, P1285, DOI 10.1126/science.2999979; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USUI T, 1963, J BIOCHEM-TOKYO, V54, P283, DOI 10.1093/oxfordjournals.jbchem.a127785; VAHOUNY GV, 1987, ADV LIPID RES, V22, P83; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WAGNER H, 1961, BIOCHEM Z, V334, P175; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; WIRTZ KWA, 1982, LIPID PROTEIN INTERA, P151; Yanagimachi R., 1988, P135; ZILVERSMIT DB, 1983, METHOD ENZYMOL, V98, P565	62	247	249	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10149	10155						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577785				2022-12-27	WOS:A1992HT96500105
J	KILLEEN, M; COULOMBE, B; GREENBLATT, J				KILLEEN, M; COULOMBE, B; GREENBLATT, J			RECOMBINANT TBP, TRANSCRIPTION FACTOR-IIB, AND RAP30 ARE SUFFICIENT FOR PROMOTER RECOGNITION BY MAMMALIAN RNA POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INITIATION-FACTOR; BINDING-PROTEIN; PURIFICATION; SPECIFICITY; REQUIREMENT; COMPLEXES; ELEMENT; REGION	Initiation of transcription by RNA polymerase II is a complex, multistep process which requires several accessory factors in addition to the polymerase itself. A critical event in transcription initiation is the specific association of RNA polymerase II with promoter DNA. In this report we show that three eukaryotic polypeptides, produced in Escherichia coli and purified to near homogeneity, constitute a minimal set of general transcription factors both necessary and sufficient for specific and stable promoter binding by RNA polymerase II. These polypeptides are the yeast TATA box binding protein TBP, the human general initiation factor TFIIB, and human RAP30, the small subunit of RAP30/74 (or transcription factor IIF). Formation of the polymerase-containing complex required only the TATA box, and not the initiator element (Inr), of the adenovirus major late promoter which was used in these experiments.	BANTING & BEST DEPT MED RES,112 COLL ST,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto; University of Toronto			Killeen, Marie/C-1131-2012	Killeen, Marie/0000-0001-9404-4845				AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, P1222; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; COULOMBE B, IN PRESS GENE EXPRES, V2; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MERMELSTEIN FH, 1989, BIOCHIM BIOPHYS ACTA, V1009, P1, DOI 10.1016/0167-4781(89)90071-7; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PETERSON MG, 1991, NATURE, V354, P369; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAFER B, 1991, J BIOL CHEM, V266, P10989; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495	37	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9463	9466						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577790				2022-12-27	WOS:A1992HT96500004
J	CAMPO, ML; KINNALLY, KW; TEDESCHI, H				CAMPO, ML; KINNALLY, KW; TEDESCHI, H			THE EFFECT OF ANTIMYCIN-A ON MOUSE-LIVER INNER MITOCHONDRIAL-MEMBRANE CHANNEL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR LIPID BILAYERS; GATING KINETICS; MITOPLASTS	In a patch-clamp study, we found antimycin A in low (1-2) mu-M concentrations decreased the open probability of the multiple conductance channel activity and the approximately 110 picosiemens channel of the inner mitochondrial membrane (for a review of mitochondrial channels see Kinnally, K. W., Antonenko, Yu. N., and Zorov, D. B. (1992) J. Bioenerg. Biomembr. 24, 99-110). Higher antimycin A concentrations (e.g. 10-mu-M) facilitated multiple conductance channel opening. These effects were reversible, and the binding site(s) are probably distinct from those responsible for the inhibition of the electron transport chain, since the latter are virtually irreversible. A model with two closed and two open states is presented for the approximately 110-picosiemens activity.	SUNY ALBANY,DEPT BIOL SCI,1400 WASHINGTON AVE,ALBANY,NY 12222; UNIV EXTREMADURA,DEPT BIOQUIM & BIOL MOLEC & GENET,E-10071 CACERES,SPAIN	State University of New York (SUNY) System; State University of New York (SUNY) Albany; Universidad de Extremadura			Campo, Maria Luisa/L-5211-2014					ANTONENKO YN, 1991, FEBS LETT, V285, P89, DOI 10.1016/0014-5793(91)80731-H; ANTONENKO YN, 1991, J MEMBRANE BIOL, V124, P151, DOI 10.1007/BF01870459; BOWMAN CL, 1983, BIOCHIM BIOPHYS ACTA, V731, P261, DOI 10.1016/0005-2736(83)90017-2; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; COSTA G, 1991, BIOCHEM BIOPH RES CO, V175, P305, DOI 10.1016/S0006-291X(05)81235-5; CRIADO M, 1987, FEBS LETT, V224, P172, DOI 10.1016/0014-5793(87)80442-8; DECKER GL, 1977, J ULTRA MOL STRUCT R, V59, P44, DOI 10.1016/S0022-5320(77)80027-0; HARTSHORNE R, 1986, ION CHANNEL RECONSTI, P337; HOLDEN MJ, 1988, FEBS LETT, V241, P105, DOI 10.1016/0014-5793(88)81040-8; HUANG LYM, 1982, P NATL ACAD SCI-BIOL, V79, P2082, DOI 10.1073/pnas.79.6.2082; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; KINNALLY KW, 1992, J BIOENERG BIOMEMBR, V24, P99, DOI 10.1007/BF00769536; KINNALLY KW, 1991, BIOCHEM BIOPH RES CO, V176, P1183, DOI 10.1016/0006-291X(91)90410-9; KLITSCH T, 1991, J MEMBRANE BIOL, V122, P69, DOI 10.1007/BF01872740; MOCZYDLOWSKI E, 1983, J GEN PHYSIOL, V82, P511, DOI 10.1085/jgp.82.4.511; MOCZYDLOWSKI E, 1984, J GEN PHYSIOL, V84, P665, DOI 10.1085/jgp.84.5.665; Moczydlowski E., 1986, ION CHANNEL RECONSTI, P75; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; VANKEULEN MA, 1985, BIOCHIM BIOPHYS ACTA, V808, P32, DOI 10.1016/0005-2728(85)90024-6; ZOROV DB, 1992, J BIOENERG BIOMEMBR, V24, P119, DOI 10.1007/BF00769538	24	86	87	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8123	8127						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569069				2022-12-27	WOS:A1992HQ18500026
J	BOMMAKANTI, RK; BOKOCH, GM; TOLLEY, JO; SCHREIBER, RE; SIEMSEN, DW; KLOTZ, KN; JESAITIS, AJ				BOMMAKANTI, RK; BOKOCH, GM; TOLLEY, JO; SCHREIBER, RE; SIEMSEN, DW; KLOTZ, KN; JESAITIS, AJ			RECONSTITUTION OF A PHYSICAL COMPLEX BETWEEN THE N-FORMYL CHEMOTACTIC PEPTIDE RECEPTOR AND G-PROTEIN - INHIBITION BY PERTUSSIS TOXIN-CATALYZED ADP RIBOSYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; NUCLEOTIDE REGULATORY PROTEIN; GTP-BINDING-PROTEINS; ISLET-ACTIVATING PROTEIN; HL-60 CELLS; PLASMA-MEMBRANE; CHEMOATTRACTANT RECEPTOR; ALPHA-SUBUNIT; PHOSPHOLIPID-VESICLES; GUANINE-NUCLEOTIDES	Photoaffinity-labeled N-formyl chemotactic peptide receptors from human neutrophils solubilized in octyl glucoside exhibit two forms upon sucrose density gradient sedimentation, with apparent sedimentation coefficients of approximately 4 and 7 S. The 7 S form can be converted to the 4 S form by guanosine 5'-O-(3-thiotriphosphate) (GTP-gamma-S) with an EC50 of approximately 20 nM, suggesting that the 7 S form may represent a physical complex of the receptor with endogenous G protein (Jesaitis, A. J., Tolley, J. O., Bokoch, G. M., and Allen, R. A. (1989) J. Cell Biol. 109, 2783-2790). To probe the nature of the 7 S form, we reconstituted the 7 S form from the 4 S form by adding purified G protein. The 4 S form, obtained by solubilizing GTP-gamma-S-treated neutrophil plasma membranes, was incubated with purified (> 95%) G(i) protein from bovine brain (containing both G(i-alpha-1) and G(i-alpha-2)) or with neutrophil G protein (G(n)), and formation of the 7 S complex was analyzed on sucrose density gradients. The EC50 of 7 S complex formation induced by the two G proteins was 70 +/- 25 and 170 +/- 40 nM for G(n) and G(i), respectively. No complexation was measurable when bovine transducin (G(t)) was used up to 30 times the EC50 for G(n). The EC50 for Gi was the same for receptors, obtained from formyl peptide-stimulated or unstimulated cells. The addition of 10-mu-M GTP-gamma-S to the reconstituted 7 S complex caused a complete reversion of the receptor to the 4 S form, and anti-G(i) peptide antisera immunosedimented the 7 S form. ADP-ribosylation of G(i) prevented formation of the 7 S form even at 20 times the concentration of unribosylated G(i) normally used to attain 50% conversion to the 7 S form. These observations suggest that the 7 S species is a physical complex containing N-formyl chemotactic peptide receptor and G protein.	MONTANA STATE UNIV, DEPT CHEM & BIOCHEM, BOZEMAN, MT 59717 USA; Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Montana State University System; Montana State University Bozeman; Scripps Research Institute				Jesaitis, Algirdas/0000-0001-9001-5617; Klotz, Karl-Norbert/0000-0003-3553-3205	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI22735] Funding Source: Medline; NIGMS NIH HHS [R01-GM39434] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RA, 1986, BIOCHIM BIOPHYS ACTA, V882, P271, DOI 10.1016/0304-4165(86)90248-5; ALLEN RA, 1989, BIOCHIM BIOPHYS ACTA, V991, P123, DOI 10.1016/0304-4165(89)90037-8; ALLEN RA, 1988, HEMATOL ONCOL CLIN N, V2, P33; ALLEN RA, 1986, J BIOL CHEM, V261, P1854; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOKOCH GM, 1988, J BIOL CHEM, V263, P16744; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BOKOCH GM, 1990, CURR TOP MEMBR TRANS, V35, P65; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; CLARKE S, 1975, J BIOL CHEM, V250, P5459; CUPO JF, 1989, BIOCHIM BIOPHYS ACTA, V982, P31, DOI 10.1016/0005-2736(89)90170-3; DIDSBURY JR, 1987, FEBS LETT, V211, P160, DOI 10.1016/0014-5793(87)81428-X; GIERSCHIK P, 1987, FEBS LETT, V224, P219, DOI 10.1016/0014-5793(87)80451-9; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GIERSCHIK P, 1989, EUR J BIOCHEM, V183, P97, DOI 10.1111/j.1432-1033.1989.tb14901.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; Hallet M. B., 1989, NEUTROPHIL CELLULAR, P1; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HYSLOP PA, 1984, FEBS LETT, V166, P165, DOI 10.1016/0014-5793(84)80065-4; IIRI T, 1989, J BIOL CHEM, V264, P21394; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; JESAITIS AJ, 1989, J CELL BIOL, V109, P2783, DOI 10.1083/jcb.109.6.2783; KATADA T, 1984, J BIOL CHEM, V259, P3568; KIKUCHI A, 1986, J BIOL CHEM, V261, P1558; KLOTZ K-N, 1991, Journal of Cell Biology, V115, p352A; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; KUROSE H, 1986, J BIOL CHEM, V261, P6423; LOHSE MJ, 1986, MOL PHARMACOL, V30, P403; MALECH HL, 1985, J BIOL CHEM, V260, P2509; MATESIC DF, 1991, MOL PHARMACOL, V40, P347; MUMBY SM, 1987, J BIOL CHEM, V263, P2020; MURPHY PM, 1987, FEBS LETT, V221, P81, DOI 10.1016/0014-5793(87)80356-3; NIEDEL J, 1980, J BIOL CHEM, V255, P7063; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, BIOCHIM BIOPHYS ACTA, V932, P71, DOI 10.1016/0005-2728(88)90140-5; POLAKIS PG, 1988, J BIOL CHEM, V263, P4969; Price CA, 1982, CENTRIFUGATION DENSI, DOI [10.1016/C2013-0-11329-3, DOI 10.1016/C2013-0-11329-3]; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; SCHMITT M, 1983, J BIOL CHEM, V258, P649; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SKLAR LA, 1987, J BIOL CHEM, V262, P135; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; STRYER L, 1983, METHOD ENZYMOL, V96, P617; SUNYER T, 1989, MOL ENDOCRINOL, V3, P1115, DOI 10.1210/mend-3-7-1115; UHING RJ, 1987, J BIOL CHEM, V262, P15575; WATANABE T, 1990, J BIOL CHEM, V265, P21237; WATANABE T, 1991, BIOCHIM BIOPHYS ACTA, V1074, P398, DOI 10.1016/0304-4165(91)90091-T; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WILLIAMS LT, 1977, P NATL ACAD SCI USA, V74, P1204, DOI 10.1073/pnas.74.3.1204; WILLIAMSON K, 1988, BIOCHEMISTRY-US, V27, P5371, DOI 10.1021/bi00414a062	54	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7576	7581						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559994				2022-12-27	WOS:A1992HN48500055
J	ISAYA, G; KALOUSEK, F; ROSENBERG, LE				ISAYA, G; KALOUSEK, F; ROSENBERG, LE			AMINO-TERMINAL OCTAPEPTIDES FUNCTION AS RECOGNITION SIGNALS FOR THE MITOCHONDRIAL INTERMEDIATE PEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MITOCHONDRIA; ORNITHINE TRANSCARBAMYLASE; PROCESSING PEPTIDASE; TARGETING PEPTIDES; PROTEIN IMPORT; LEADER PEPTIDE; PRECURSOR; CLEAVAGE; PEP	We have shown previously that cleavage of a number of precursors by the mitochondrial processing peptidase (MPP) requires an intermediate octapeptide (FXXSXXXX) between the MPP cleavage site and the mature protein amino terminus. We show now that these octapeptides, present at the amino termini of the intermediates, direct recognition of these substrates by the mitochondrial intermediate peptidase (MIP), leading to formation of mature proteins. Synthetic peptides, corresponding to the intermediate octapeptides of human ornithine transcarbamylase (OTC) and of Neurospora cytochrome c reductase Fe/S subunit (Fe/S), inhibit the processing activity of purified rat liver MIP in vitro, without affecting MPP activity; this indicates that the octapeptides can be recognized by MIP independent of the presence of the corresponding mature proteins and interact with a site that is crucial for MIP activity. MIP activity is not inhibited by a peptide lacking the amino-terminal hydrophobic residue, while substitution of such a residue by a polar amino acid causes a 10-fold reduction in the efficiency of MIP inhibition. To analyze the requirements for removal of the octapeptide from the intermediate proteins by MIP, artificial intermediates were synthesized and subjected to in vitro processing by purified MIP. The octapeptide can be cleaved by MIP only when the amino-terminal hydrophobic residue is also the amino terminus of the intermediate. Further, when the OTC octapeptide is joined to the mature amino terminus of another twice-cleaved precursor (pFe/S; rat malate dehydrogenase, pMDH), the chimeric intermediate is cleaved by MIP to the corresponding mature-sized protein. When the OTC octapeptide is joined to the mature amino terminus of a once-cleaved precursor (yeast F1-beta-ATPase, pF1-beta), however, this intermediate is not cleaved by MIP; rather, it is processed by MPP to mature-sized F1-beta. Therefore, amino-terminal octapeptides can be cleaved by MIP only within the structural context of twice-cleaved precursors.			ISAYA, G (corresponding author), YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009527] Funding Source: NIH RePORTER; NIDDK NIH HHS [DKO9527] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEDWELL DM, 1989, MOL CELL BIOL, V9, P1014, DOI 10.1128/MCB.9.3.1014; CHU TW, 1987, J BIOL CHEM, V262, P12806; FU W, 1990, J BIOL CHEM, V265, P16541; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HORWICH AL, 1984, SCIENCE, V224, P1068, DOI 10.1126/science.6372096; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; ROSENBERG LE, 1986, ANN NY ACAD SCI, V488, P99; SZTUL ES, 1988, J BIOL CHEM, V263, P12085; SZTUL ES, 1987, J CELL BIOL, V105, P2631, DOI 10.1083/jcb.105.6.2631; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG M, 1991, J BIOL CHEM, V266, P6416	23	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7904	7910						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560019				2022-12-27	WOS:A1992HN48500098
J	GILKES, NR; JERVIS, E; HENRISSAT, B; TEKANT, B; MILLER, RC; WARREN, RAJ; KILBURN, DG				GILKES, NR; JERVIS, E; HENRISSAT, B; TEKANT, B; MILLER, RC; WARREN, RAJ; KILBURN, DG			THE ADSORPTION OF A BACTERIAL CELLULASE AND ITS 2 ISOLATED DOMAINS TO CRYSTALLINE CELLULOSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; BINDING DOMAINS; TRICHODERMA-REESEI; FIMI CELLULASES; CELLOBIOHYDROLASES; PROTEOLYSIS; PROTEIN; LATTICE	CenA is a bacterial cellulase (beta-1,4-glucanase) comprised of a globular catalytic domain joined to an extended cellulose-binding domain (CBD) by a short linker peptide. The adsorption of CenA and its two isolated domains to crystalline cellulose was analyzed. CenA and CBD.PT(CenA) (the CBD plus linker) adsorbed rapidly to cellulose at 30-degrees-C, and no net desorption of protein was observed during the following 16.7 h. There was no detectable adsorption of the catalytic domain. Scatchard plots of adsorption data for CenA and for CBD.PT(CenA) were nonlinear (concave upward). The adsorption of CenA and CBD.PT(CenA) exceeded 7 and 8-mu-mol/g cellulose, respectively, but saturation was not attained at the highest total protein concentrations employed. A new model for adsorption was developed to describe the interaction of a large ligand (protein) with a lattice of overlapping potential binding sites (cellobiose residues). A relative equilibrium association constant (K(r)) of 40.5 and 45.3 liter.g cellulose-1 was estimated for CenA and CBD.PT(CenA), respectively, according to this model. A similar K(r) value (33.3 liter.g-1) was also obtained for Cex, a Cellulomonas fimi enzyme which contains a related CBD but which hydrolyzes both beta-1,4-xylosidic and beta-1,4-glucosidic bonds. It was estimated that the CBD occupies approximately 39 cellobiose residues on the cellulose surface.	UNIV BRITISH COLUMBIA, DEPT CHEM ENGN, VANCOUVER V6T 1Z3, BC, CANADA; CNRS, CTR RECH MACROMOLEC VEGETALES, F-38041 GRENOBLE, FRANCE	University of British Columbia; Centre National de la Recherche Scientifique (CNRS)	GILKES, NR (corresponding author), UNIV BRITISH COLUMBIA, DEPT MICROBIOL, VANCOUVER V6T 1Z3, BC, CANADA.		Henrissat, Bernard/J-2475-2012	Henrissat, Bernard/0000-0002-3434-8588				ABUJA PM, 1988, BIOCHEM BIOPH RES CO, V156, P180, DOI 10.1016/S0006-291X(88)80821-0; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P380; CHANZY H, 1984, FEBS LETT, V172, P193, DOI 10.1016/0014-5793(84)81124-2; DURRANT AJ, 1991, BIOCHEM J, V273, P289, DOI 10.1042/bj2730289; EPPSTEIN L, 1989, BIO-TECHNOL, V7, P1178; GARDNER KH, 1974, BIOPOLYMERS, V13, P1975, DOI 10.1002/bip.1974.360131005; GILKES NR, 1989, J BIOL CHEM, V264, P17802; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; GILKES NR, 1984, J BIOL CHEM, V259, P455; GILKES NR, 1991, EUR J BIOCHEM, V202, P367, DOI 10.1111/j.1432-1033.1991.tb16384.x; GILKES NR, 1988, J BIOL CHEM, V263, P10401; GIORDA R, 1990, BIOCHEMISTRY-US, V29, P7264, DOI 10.1021/bi00483a015; GREENWOOD JM, 1989, FEBS LETT, V244, P127, DOI 10.1016/0014-5793(89)81177-9; GUO Z, 1988, FEMS MICROBIOL LETT, V49, P279; HENRISSAT B, 1988, FEBS LETT, V231, P177, DOI 10.1016/0014-5793(88)80726-9; Henrissat B., 1986, CELLULOSE STRUCTURE, P337; Hestrin S., 1963, METHODS CARBOHYDRATE, V3, P4; JAURIS S, 1990, MOL GEN GENET, V223, P258, DOI 10.1007/BF00265062; KLOTZ IM, 1989, PROTEIN FUNCTION PRA, P25; KUGA S, 1987, J ELECTRON MICR TECH, V6, P349, DOI 10.1002/jemt.1060060405; KULSHRESHTHA AK, 1973, J POLYM SCI POL PHYS, V11, P487, DOI 10.1002/pol.1973.180110307; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LANGSFORD ML, 1987, FEBS LETT, V225, P163, DOI 10.1016/0014-5793(87)81150-X; LEE SB, 1982, BIOTECHNOL BIOENG, V24, P2137, DOI 10.1002/bit.260241003; MARSHALL K, 1975, DRUG DEV COMMUN, V1, P51; MCGAVIN M, 1989, J BACTERIOL, V171, P3310, DOI 10.1128/jb.171.6.3310-3315.1989; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MEINKE A, 1991, J BACTERIOL, V173, P308, DOI 10.1128/jb.173.1.308-314.1991; Meyer KH, 1937, HELV CHIM ACTA, V20, P232, DOI 10.1002/hlca.19370200134; ONG E, 1989, BIO-TECHNOL, V7, P604, DOI 10.1038/nbt0689-604; ONG E, 1989, TRENDS BIOTECHNOL, V7, P239, DOI 10.1016/0167-7799(89)90014-0; ONG E, 1991, ENZYME MICROB TECH, V13, P59, DOI 10.1016/0141-0229(91)90189-H; OOSHIMA H, 1983, BIOTECHNOL BIOENG, V25, P3103, DOI 10.1002/bit.260251223; PILZ I, 1990, BIOCHEM J, V271, P277, DOI 10.1042/bj2710277; PY B, 1991, PROTEIN ENG, V4, P325, DOI 10.1093/protein/4.3.325; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SHEN H, 1991, J BIOL CHEM, V266, P11335; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STAHLBERG J, 1991, BIO-TECHNOL, V9, P286, DOI 10.1038/nbt0391-286; SVENSSON B, 1989, BIOCHEM J, V264, P309, DOI 10.1042/bj2640309; TOMME P, 1988, EUR J BIOCHEM, V170, P575, DOI 10.1111/j.1432-1033.1988.tb13736.x; TOMME P, 1990, BIOTECHNOL LETT, V12, P525, DOI 10.1007/BF01086347; WARREN R A J, 1986, Proteins Structure Function and Genetics, V1, P335, DOI 10.1002/prot.340010407; WHITE AR, 1981, P NATL ACAD SCI-BIOL, V78, P1047, DOI 10.1073/pnas.78.2.1047; WONG WKR, 1986, GENE, V44, P315	46	224	233	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6743	6749						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551882				2022-12-27	WOS:A1992HM05300044
J	PREDKI, PF; SARKAR, B				PREDKI, PF; SARKAR, B			EFFECT OF REPLACEMENT OF ZINC FINGER ZINC ON ESTROGEN-RECEPTOR DNA INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTOR; BINDING DOMAIN; RESPONSIVE ELEMENT; AMINO-ACIDS; METAL; PROTEIN	Exposure of bovine estrogen receptor to the metal chelators EDTA and 1,10-phenanthroline results in a loss of nonspecific DNA binding, presumably because of the removal of "zinc finger" zinc. Nonspecific DNA binding, as measured by a DNA-cellulose binding assay, can be restored by dialysis of the aporeceptor against buffer containing zinc, cadmium, and cobalt but not with buffer containing copper or nickel. More detailed studies were carried out using a bacterially expressed polypeptide encompassing the DNA binding domain of the human estrogen receptor. Apopolypeptide fails to bind DNA specifically, as measured by mobility shift assay using a consensus estrogen response element hexamer containing oligonucleotide, but DNA binding was restored by dialysis of the apopolypeptide against buffer containing zinc, cadmium, and cobalt but not with buffer containing copper or nickel. Dissociation constants of zinc- and cadmium-reconstituted polypeptide for the estrogen response element hexamer (66 and 48 nM, respectively) are virtually indistinguishable from native polypeptide (K(d) = 48 nM) whereas cobalt-reconstituted polypeptide has a lower affinity (K(d) = 720 nM). However, native, zinc-, cadmium-, and cobalt-reconstituted polypeptides gave identical results in a methylation interference assay. Competition experiments with zinc and copper or nickel suggest that copper and nickel are able to bind to zinc finger residues but do so nonproductively. The relative affinities copper > cadmium > zinc > cobalt > nickel for the polypeptide were determined by a zinc blot competition assay. The ability of cadmium and cobalt to substitute for zinc in the zinc fingers demonstrates a structural "flexibility" in the DNA binding domain as each of these metals has slightly different ionic radii. On the other hand, subtle differences in DNA binding affinity and/or specificity could exist, which may not be detectable here. Also, the ability of metals to substitute for zinc in the DNA binding domain suggests that metal substitution in these zinc fingers in vivo may be of relevance to the toxicity and/or carcinogenicity of some of these metals.	HOSP SICK CHILDREN,DEPT BIOCHEM RES,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								Baldwin A.S.J., 1989, CURRENT PROTOCOLS MO; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FISHMAN JH, 1988, BIOCHEM BIOPH RES CO, V152, P783, DOI 10.1016/S0006-291X(88)80106-2; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HUTCHENS TW, 1989, J BIOL CHEM, V264, P17206; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU C, 1990, BIOCHEM INT, V21, P191; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MAKOWSKI GS, 1991, BIOL TRACE ELEM RES, V29, P93, DOI 10.1007/BF03032687; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; SABBAH M, 1987, J BIOL CHEM, V262, P8631; Sambrook J.E., 1989, MOL CLONING LAB MANU, V2nd ed., P182, DOI [10.1016/0003-2697(90)90595-Z, DOI 10.1016/0003-2697(90)90595-Z]; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SIMONS SS, 1990, J BIOL CHEM, V265, P1938; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUNDERMAN FW, 1988, ANN CLIN LAB SCI, V18, P267; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; ZILLIACUS J, 1991, J BIOL CHEM, V266, P3101	25	181	184	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5842	5846						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556100				2022-12-27	WOS:A1992HK31800022
J	GREINER, RA; JACOBSKRAHNEN, D; MUTZEL, R; MALCHOW, D; WURSTER, B				GREINER, RA; JACOBSKRAHNEN, D; MUTZEL, R; MALCHOW, D; WURSTER, B			A 138-KDA GLYCOPROTEIN FROM DICTYOSTELIUM MEMBRANES WITH FOLATE DEAMINASE AND FOLATE BINDING-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; FOLIC-ACID; AMP SIGNALS; DISCOIDEUM; CELLS; CHEMOTAXIS; PROTEINS; OSCILLATIONS; RECEPTOR; SITES	A 138-kDa glycoprotein comprising folate deaminase activity was purified to apparent homogeneity from membranes of Dictyostelium discoideum. Deaminase activity could be effectively inhibited by p-chloromercuriphenylsulfonate. This treatment protected folate from deamination and thus allowed investigation of folate binding to deaminase fractions. Two types of folate binding sites, differing in affinity and specificity, were detected on the folate deaminase glycoprotein. One type displays high affinity and binds folate stronger than N10-methylfolate. This binding site appears to be identical with the catalytic site of folate deaminase. The other type of binding site shows lower affinity but prefers N10-methylfolate relative to folate. A similar preference for N10-methylfolate was observed in chemotaxis tests pointing to the possibility that the second type of binding site is involved in chemotactic perception of folate compounds. Folate perception and deamination could thus be performed by activities residing on the same polypeptide.			GREINER, RA (corresponding author), UNIV CONSTANCE, FAK BIOL, W-7750 CONSTANCE, GERMANY.							BONNER JT, 1969, DEV BIOL, V20, P72, DOI 10.1016/0012-1606(69)90005-0; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; COSULICH DB, 1948, J AM CHEM SOC, V70, P1922, DOI 10.1021/ja01185a081; DAS OP, 1983, BIOCHIM BIOPHYS ACTA, V736, P45; DEVREOTES PN, 1979, J CELL BIOL, V80, P300, DOI 10.1083/jcb.80.2.300; DEWIT RJW, 1985, BIOCHIM BIOPHYS ACTA, V814, P214, DOI 10.1016/0005-2736(85)90439-0; DEWIT RJW, 1982, FEBS LETT, V150, P445, DOI 10.1016/0014-5793(82)80786-2; DEWIT RJW, 1985, BIOCHIM BIOPHYS ACTA, V814, P199, DOI 10.1016/0005-2736(85)90438-9; GERISCH G, 1982, ANNU REV PHYSIOL, V44, P535, DOI 10.1146/annurev.ph.44.030182.002535; GERISCH G, 1975, BIOCHEM BIOPH RES CO, V65, P364, DOI 10.1016/S0006-291X(75)80102-1; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; KAKEBEEKE PIJ, 1980, J BACTERIOL, V143, P307, DOI 10.1128/JB.143.1.307-312.1980; KESBEKE F, 1990, J CELL SCI, V96, P669; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KONIJN TM, 1967, P NATL ACAD SCI USA, V58, P1152, DOI 10.1073/pnas.58.3.1152; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATO JM, 1977, FEBS LETT, V79, P331, DOI 10.1016/0014-5793(77)80814-4; MATO JM, 1977, P NATL ACAD SCI USA, V74, P2348, DOI 10.1073/pnas.74.6.2348; NANDINIKISHORE SG, 1981, P NATL ACAD SCI-BIOL, V78, P7299, DOI 10.1073/pnas.78.12.7299; ORLOW SJ, 1981, J BIOL CHEM, V256, P7620; PAN P, 1972, NATURE-NEW BIOL, V237, P181, DOI 10.1038/newbio237181a0; PAN P, 1975, J BACTERIOL, V122, P185, DOI 10.1128/JB.122.1.185-191.1975; REMBOLD H, 1969, BIOCHIM BIOPHYS ACTA, V184, P589, DOI 10.1016/0304-4165(69)90273-6; ROBERTSO.A, 1972, SCIENCE, V175, P333, DOI 10.1126/science.175.4019.333; ROOS W, 1975, FEBS LETT, V53, P139, DOI 10.1016/0014-5793(75)80005-6; SALTER DN, 1972, FEBS LETT, V20, P302, DOI 10.1016/0014-5793(72)80092-9; SEEGER DR, 1949, J AM CHEM SOC, V71, P1753, DOI 10.1021/ja01173a061; SHAFFER BM, 1975, NATURE, V255, P549, DOI 10.1038/255549a0; SHAFFER BM, 1956, J EXP BIOL, V33, P645; TILLINGHAST HS, 1984, FEBS LETT, V176, P325, DOI 10.1016/0014-5793(84)81189-8; TOMCHIK KJ, 1981, SCIENCE, V212, P443, DOI 10.1126/science.6259734; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WURSTER B, 1977, FEBS LETT, V76, P141, DOI 10.1016/0014-5793(77)80139-7; WURSTER B, 1981, J BACTERIOL, V148, P183, DOI 10.1128/JB.148.1.183-192.1981; WURSTER B, 1980, EUR J BIOCHEM, V109, P613, DOI 10.1111/j.1432-1033.1980.tb04834.x; WURSTER B, 1983, FEMS MICROBIOL LETT, V18, P139	37	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5096	5101						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544893				2022-12-27	WOS:A1992HH74700017
J	KIEFFER, LJ; THALHAMMER, T; HANDSCHUMACHER, RE				KIEFFER, LJ; THALHAMMER, T; HANDSCHUMACHER, RE			ISOLATION AND CHARACTERIZATION OF A 40-KDA CYCLOPHILIN-RELATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASE; CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CYCLOSPORIN-A; IMMUNOSUPPRESSANT FK506; T-CELLS; DISTINCT; GENE; IMMUNOPHILIN; EXPRESSION	Major and minor isoforms of cyclophilin (CyP-18), a 17.8-kDa protein with peptidyl-prolyl cis-trans isomerase activity, comprise the primary intracellular binding proteins for cyclosporin A. Additional CyP-like proteins with approximate molecular masses of 22 (CyP-22) and 40 kDa (CyP-40) have been recovered from the soluble fraction of calf brain along with CyP-18 by adsorption onto a cyclosporin A affinity column and elution with cyclosporin A. Based on a limited number of peptide sequences from CyP-22, it appears that we have isolated from tissue CyPB, a protein whose sequence was deduced previously from cloned cDNA. The 40-kDa protein was separated from CyP-18 and CyP-22 on a molecular sieving column. Isoelectric focusing of CyP-40 yielded two bands at pl 5.3 and 5.5, in contrast to the basic pl values of CyP-18. Some tryptic peptides from CyP-40 were found to be highly homologous but not identical to bovine CyP-18; others were not significantly homologous to CyP-18 or any other protein in the data base. Unlike the major and minor isoforms of Cyp-18, monospecific polyclonal anti-CyP-18 antibodies did not cross-react with CyP-22 and CyP-40. Likewise, anti-CyP-40 serum minimally cross-reacts with CyP-18 and CyP-22. Cyp-40 possesses peptidyl-prolyl cis-trans isomerase activity which is less sensitive to inhibition by cyclosporin A (IC50 = 300 nM) than is CyP-18 (IC50 = 20 nM).	YALE UNIV,SCH MED,NEW HAVEN,CT 06510	Yale University					NCI NIH HHS [5 T32 CA09085-16] Funding Source: Medline; NIGMS NIH HHS [GM-40660-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM040660] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BICKEL M, 1987, P NATL ACAD SCI USA, V84, P3274, DOI 10.1073/pnas.84.10.3274; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CARONI P, 1991, J BIOL CHEM, V266, P10739; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; ELLIOTT JF, 1984, SCIENCE, V226, P1439, DOI 10.1126/science.6334364; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FOXWELL BMJ, 1988, TRANSPLANTATION, V46, pS35; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GAUTAM A, 1987, HEPATOLOGY, V7, P216, DOI 10.1002/hep.1840070203; HAENDLER B, 1990, EUR J BIOCHEM, V190, P477, DOI 10.1111/j.1432-1033.1990.tb15598.x; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HEROLD KC, 1986, J IMMUNOL, V136, P1315; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; PALASZYNSKI EW, 1991, CLIN BIOCHEM, V24, P63, DOI 10.1016/0009-9120(91)90252-A; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SPIK G, 1991, J BIOL CHEM, V266, P10735; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029	34	111	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5503	5507						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544925				2022-12-27	WOS:A1992HH74700077
J	LEVERY, SB; WEISS, JB; SALYAN, MEK; ROBERTS, CE; HAKOMORI, S; MAGNANI, JL; STRAND, M				LEVERY, SB; WEISS, JB; SALYAN, MEK; ROBERTS, CE; HAKOMORI, S; MAGNANI, JL; STRAND, M			CHARACTERIZATION OF A SERIES OF NOVEL FUCOSE-CONTAINING GLYCOSPHINGOLIPID IMMUNOGENS FROM EGGS OF SCHISTOSOMA-MANSONI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBARDMENT MASS-SPECTROMETRY; FRESH-WATER BIVALVE; ASPARAGINE-LINKED OLIGOSACCHARIDES; PROTECTIVE MONOCLONAL-ANTIBODIES; ADENOCARCINOMA COLO-205 CELLS; GAS-LIQUID CHROMATOGRAPHY; CERCARIAL GLYCOCALYX; CERAMIDE OCTASACCHARIDE; STRUCTURAL ELUCIDATION; CARBOHYDRATE EPITOPES	Lipid extracts of eggs, worms, and cercariae of the parasitic trematode Schistosoma mansoni have been shown to contain a large number of highly immunogenic glycolipids (Weiss, J. B., Magnani, J. L., and Strand, M. (1986) J. Immunol. 136, 4275-4282). Three fractions of schistosome egg glycolipids were selected on the basis of their reactivity with an anti-schistosome monoclonal antibody (128C3/3), which recognizes a developmentally regulated carbohydrate epitope present on both glycolipid and glycoprotein antigens from S. mansoni. These fractions were purified by silica gel chromatography and preparative high performance thin layer chromatography and characterized by monosaccharide, fatty acid, and linkage analysis with gas chromatography-mass spectrometry, as well as by positive and negative ion fast atom bombardment-mass spectrometry. The immunogens were shown to be glycosphingolipids having homologous structures based on a highly novel extension of glucosylceramide. Monosaccharide inhibition studies indicated that the epitope recognized by 128C3/3 resides in an outer region of the immunogens consisting of Fuc2GlcNAc (where Fuc is fucose) repeating units. The largest antigen characterized may have the following structure, based on the evidence presented in this paper. [GRAPHICS] The evidence indicated the existence of a series of glycan structures created by deletions of one or more Fuc1 --> 3 side chains from the above structure.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA; BIOCARB INC, GAITHERSBURG, MD 20879 USA	Johns Hopkins University	LEVERY, SB (corresponding author), BIOMEMBRANE INST, 201 ELLIOTT AVE W, SEATTLE, WA 98119 USA.							ALI PO, 1988, J IMMUNOL, V140, P3273; ARITA M, 1984, J BIOCHEM-TOKYO, V95, P971, DOI 10.1093/oxfordjournals.jbchem.a134724; ARITA M, 1983, J BIOCHEM-TOKYO, V94, P249, DOI 10.1093/oxfordjournals.jbchem.a134336; BICKLE QD, 1986, PARASITE IMMUNOL, V8, P95, DOI 10.1111/j.1365-3024.1986.tb00836.x; BJORNDAL H, 1970, ANGEW CHEM INT EDIT, V9, P610, DOI 10.1002/anie.197006101; BOUT D, 1980, PARASITOLOGY, V80, P247, DOI 10.1017/S003118200000072X; BREMER EG, 1984, J BIOL CHEM, V259, P4773; CAPRON A, 1987, SCIENCE, V238, P1065, DOI 10.1126/science.3317823; CARTER CE, 1979, J IMMUNOL, V122, P2204; CAULFIELD JP, 1988, EXP PARASITOL, V65, P10, DOI 10.1016/0014-4894(88)90102-6; CAULFIELD JP, 1987, J PARASITOL, V73, P514, DOI 10.2307/3282129; DALTON JP, 1987, EXP PARASITOL, V63, P215, DOI 10.1016/0014-4894(87)90164-0; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; DISSOUS C, 1986, NATURE, V323, P443, DOI 10.1038/323443a0; EGGE H, 1987, MASS SPECTROM REV, V6, P331, DOI 10.1002/mas.1280060302; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FUJII I, 1985, J CHEM SOC CHEM COMM, P405, DOI 10.1039/c39850000405; GREGOIRE RJ, 1987, J IMMUNOL, V139, P3792; HAKOMORI S, 1983, JNCI-J NATL CANCER I, V71, P231; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HAMBURGER J, 1982, J IMMUNOL, V128, P1864; HARN DA, 1984, J EXP MED, V159, P1371, DOI 10.1084/jem.159.5.1371; HARN DA, 1987, J IMMUNOL, V138, P1571; HOCKLEY D J, 1973, International Journal for Parasitology, V3, P13, DOI 10.1016/0020-7519(73)90004-0; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P633, DOI 10.1016/0003-9861(89)90479-7; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P14, DOI 10.1016/0003-9861(89)90410-4; HORI T, 1983, J BIOL CHEM, V258, P2239; HORI T, 1981, J BIOL CHEM, V256, P979; ISOBE R, 1987, TRAC-TREND ANAL CHEM, V6, P78, DOI 10.1016/0165-9936(87)87037-1; ITASAKA O, 1979, J BIOCHEM-TOKYO, V85, P1469, DOI 10.1093/oxfordjournals.jbchem.a132475; ITASAKA O, 1983, BIOCHIM BIOPHYS ACTA, V750, P440, DOI 10.1016/0005-2760(83)90183-2; Jansson P-E., 1976, CHEM COMMUN U STOCKH, V8, P1; KO AI, 1990, P NATL ACAD SCI USA, V87, P4159, DOI 10.1073/pnas.87.11.4159; KOSTER B, 1989, AM SOC TROP MED HYG, V115, P141; LAINE RA, 1981, ANAL BIOCHEM, V116, P383, DOI 10.1016/0003-2697(81)90376-6; LEMIEUX RU, 1982, IUPAC FRONTIERS CHEM, P3; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; LUSTIGMAN S, 1985, J IMMUNOL, V134, P1961; MAGNANI JL, 1987, METHOD ENZYMOL, V138, P195; MCNEIL M, 1977, CARBOHYD RES, V56, P239, DOI 10.1016/S0008-6215(00)83346-7; NANDURI J, 1991, J BIOL CHEM, V266, P1341; NORDEN AP, 1984, EXP PARASITOL, V58, P333, DOI 10.1016/0014-4894(84)90050-X; NYAME K, 1988, MOL BIOCHEM PARASIT, V28, P265, DOI 10.1016/0166-6851(88)90011-4; NYAME K, 1989, J BIOL CHEM, V264, P3235; NYAME K, 1988, J PARASITOL, V74, P562, DOI 10.2307/3282171; OBERLIN UP, 1977, AM J TROP MED HYG, V26, P1178, DOI 10.4269/ajtmh.1977.26.1178; OMERALI P, 1986, J IMMUNOL, V137, P3601; RIVERAMARRERO CA, 1990, MOL BIOCHEM PARASIT, V43, P59, DOI 10.1016/0166-6851(90)90130-E; ROBERTS CE, 1990, 38TH P ASMS C MASS S, P1373; SAMUELSON JC, 1986, INFECT IMMUN, V51, P181, DOI 10.1128/IAI.51.1.181-186.1986; SAMUELSON JC, 1985, J CELL BIOL, V100, P1423, DOI 10.1083/jcb.100.5.1423; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P21, DOI 10.1515/bchm2.1973.354.1.21; STRAND M, 1982, EXP PARASITOL, V54, P145, DOI 10.1016/0014-4894(82)90121-7; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; TAI T, 1975, J BIOCHEM-TOKYO, V78, P679, DOI 10.1093/oxfordjournals.jbchem.a130955; WEISS JB, 1986, J IMMUNOL, V136, P4275; WEISS JB, 1985, J IMMUNOL, V135, P1421; YANG HJ, 1971, J BIOL CHEM, V246, P1192	59	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5542	5551						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544929				2022-12-27	WOS:A1992HH74700082
J	MULDER, KM; MORRIS, SL				MULDER, KM; MORRIS, SL			ACTIVATION OF P21RAS BY TRANSFORMING GROWTH-FACTOR-BETA IN EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COLON-CARCINOMA-CELLS; C-MYC; STIMULATION; INHIBITION; PROTEIN; PROLIFERATION; FACTOR-BETA-1; TRANSCRIPTION; FIBROBLASTS; SUPPRESSION	The transforming growth factor-beta (TGF-beta) family members are ubiquitously expressed and control a variety of cellular processes by interacting with at least two types of high affinity cell surface receptors. However, the primary signal transduction mechanism of the receptors is unknown. The ras-encoded 21-kDa GTP binding proteins have recently been shown to mediate the effects of other polypeptide growth factors. Here we show that both TGF-beta-1 and TGF-beta-2 (5 ng/ml) result in a rapid (within 6 or 12 min, respectively) stimulation of GTP bound to p21ras in TGF-beta-sensitive intestinal epithelial cells. Further, the CCL64 epithelial cell line, extremely sensitive to growth inhibition by TGF-beta, displayed a concentration-dependent increase in GTP bound to p21ras by TGF-beta-1 and a rapid activation of p21ras by TGF-beta-2. The results provide the first direct evidence for rapid activation of a receptor coupling component for TGF-beta in epithelial cells.	BAYLOR COLL MED,DEPT PHARMACOL,HOUSTON,TX 77030	Baylor College of Medicine	MULDER, KM (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT PHARMACOL,POB 850,HERSHEY,PA 17033, USA.				NCI NIH HHS [CA51452] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051452, R01CA051452] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOERNER P, 1985, P NATL ACAD SCI USA, V82, P1350, DOI 10.1073/pnas.82.5.1350; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHAMBARD JC, 1988, J CELL PHYSIOL, V135, P101, DOI 10.1002/jcp.1041350114; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FANGER BO, 1986, BIOCHEMISTRY-US, V25, P3083, DOI 10.1021/bi00359a003; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GRUPPUSO PA, 1991, J BIOL CHEM, V266, P3444; HOWE PH, 1990, J CELL PHYSIOL, V142, P39, DOI 10.1002/jcp.1041420106; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; INMAN WH, 1985, P NATL ACAD SCI USA, V82, P1346, DOI 10.1073/pnas.82.5.1346; KRAMER J, 1991, EMBO J, V10, P1083; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIKE B, 1986, J BIOL CHEM, V261, P3426; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MULDER KM, 1990, J CELL PHYSIOL, V145, P501, DOI 10.1002/jcp.1041450316; MULDER KM, 1990, CANCER RES, V50, P7581; MULDER KM, 1988, BIOCHEM BIOPH RES CO, V150, P711, DOI 10.1016/0006-291X(88)90449-4; MULDOON LL, 1988, J BIOL CHEM, V263, P18834; MURTHY US, 1988, BIOCHEM BIOPH RES CO, V152, P1228, DOI 10.1016/S0006-291X(88)80416-9; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PIEZ KA, 1990, ANN NY ACAD SCI, V593, P1; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1988, FEBS LETT, V236, P185, DOI 10.1016/0014-5793(88)80311-9; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039	30	193	201	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5029	5031						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544886				2022-12-27	WOS:A1992HH74700004
J	CHAUVAUX, S; BEGUIN, P; AUBERT, JP				CHAUVAUX, S; BEGUIN, P; AUBERT, JP			SITE-DIRECTED MUTAGENESIS OF ESSENTIAL CARBOXYLIC RESIDUES IN CLOSTRIDIUM-THERMOCELLUM ENDOGLUCANASE CELD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOPHYLLUM-COMMUNE; NUCLEOTIDE-SEQUENCE; TRICHODERMA-REESEI; ESCHERICHIA-COLI; CELLOBIOHYDROLASE-I; CELLULASE; GENE; IDENTIFICATION; CRYSTALLIZATION; PROTEINS	12 carboxyl residues of the Clostridium thermocellum endoglucanase CelD were mutated to alanine. The specific activity of five of the mutated proteins was 1% or less that of wild type. The Ca2+ binding isotherms of these five were similar to those of wild type CelD, consistent with the fact that none of the mutated residues is observed to be directly involved in Ca2+ binding in the three-dimensional structure of the protein (Juy, M., Anit, A. G., Alzuri, P. M., Poljak, R. J., Claeyssens, M., Beguin, P., and Aubert, J.-P., manuscript in preparation) and suggesting that the mutations did not result in gross alterations of the tertiary structure. Analysis of the physico-chemical and enzymatic properties of the five purified mutated proteins and consideration of their position in the three-dimensional structure suggest that carboxyl groups identified may play roles as a general acid catalyst and a source of negative charge in stabilizing a carbonium ion intermediate. Among mutated residues, Glu-555 appears as the most likely candidate for participating in the catalytic mechanism of endoglucanase CelD.	INST PASTEUR,DEPT BIOTECHNOL,CNRS,URA 1300,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	CHAUVAUX, S (corresponding author), INST PASTEUR,UNITE PHYSIOL CELLULAIRE,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.			Beguin, Pierre/0000-0002-5372-6281				BAIRD SD, 1990, BIOCHEM BIOPH RES CO, V169, P1035, DOI 10.1016/0006-291X(90)91998-8; BERGER E, 1990, MOL GEN GENET, V223, P310, DOI 10.1007/BF00265068; CHAUVAUX S, 1990, BIOCHEM J, V265, P261, DOI 10.1042/bj2650261; CLARKE AJ, 1986, BIOCHIM BIOPHYS ACTA, V870, P401, DOI 10.1016/0167-4838(86)90247-5; CLARKE AJ, 1985, EUR J BIOCHEM, V149, P233, DOI 10.1111/j.1432-1033.1985.tb08917.x; CLARKE AJ, 1987, BIOCHIM BIOPHYS ACTA, V912, P424, DOI 10.1016/0167-4838(87)90048-3; COUTINHO JB, 1991, MOL MICROBIOL, V5, P1221, DOI 10.1111/j.1365-2958.1991.tb01896.x; Gibson T., 1984, THESIS U CAMBRIDGE C; GIORDA R, 1990, BIOCHEMISTRY-US, V29, P7264, DOI 10.1021/bi00483a015; GREPINET O, 1988, J BACTERIOL, V170, P4576, DOI 10.1128/jb.170.10.4576-4581.1988; HALL J, 1988, MOL GEN GENET, V213, P112, DOI 10.1007/BF00333406; HENRISSAT B, 1989, GENE, V81, P83, DOI 10.1016/0378-1119(89)90339-9; JAURIS S, 1990, MOL GEN GENET, V223, P258, DOI 10.1007/BF00265062; JOLIFF G, 1986, J MOL BIOL, V189, P249, DOI 10.1016/0022-2836(86)90396-7; JOLIFF G, 1986, NUCLEIC ACIDS RES, V14, P8605, DOI 10.1093/nar/14.21.8605; JOLIFF G, 1986, BIO-TECHNOL, V4, P896, DOI 10.1038/nbt1086-896; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMED R, 1988, FEMS S, V43, P101; Maniatis T., 1982, MOL CLONING; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MEINKE A, 1991, J BACTERIOL, V173, P308, DOI 10.1128/jb.173.1.308-314.1991; MITSUISHI Y, 1990, FEBS LETT, V275, P135, DOI 10.1016/0014-5793(90)81457-Y; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SIERKS MR, 1990, PROTEIN ENG, V3, P193, DOI 10.1093/protein/3.3.193; TEERI TT, 1990, TRICHODERMA REESEI CELLULASES : BIOCHEMISTRY, GENETICS, PHYSIOLOGY AND APPLICATION, P156; TOKATLIDIS K, 1991, FEBS LETT, V282, P205, DOI 10.1016/0014-5793(91)80478-L; TOMME P, 1989, FEBS LETT, V243, P239, DOI 10.1016/0014-5793(89)80136-X; TOMME P, 1991, J BIOL CHEM, V266, P10313; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCKER ML, 1987, PLANT MOL BIOL, V9, P197, DOI 10.1007/BF00166456	31	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4472	4478						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537833				2022-12-27	WOS:A1992HF64200032
J	RICHARDSON, RM; PTASIENSKI, J; HOSEY, MM				RICHARDSON, RM; PTASIENSKI, J; HOSEY, MM			FUNCTIONAL-EFFECTS OF PROTEIN KINASE-C-MEDIATED PHOSPHORYLATION OF CHICK HEART MUSCARINIC CHOLINERGIC RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; AGONIST-INDUCED PHOSPHORYLATION; GTP-BINDING PROTEINS; ACETYLCHOLINE-RECEPTOR; PHOSPHOINOSITIDE HYDROLYSIS; BETA-2-ADRENERGIC RECEPTOR; RECONSTITUTION SYSTEM; GUANINE-NUCLEOTIDES; HIGH-AFFINITY; EXPRESSION	Muscarinic cholinergic receptors (mAChR) purified from chick heart were phosphorylated by protein kinase C (PKC) and reconstituted with the purified GTP-binding regulatory protein G(o). The effects of PKC phosphorylation on the interaction of mAChR with G(o) were assessed by monitoring for agonist-stimulated guanosine-5'-O-(3-thiotriphosphate) (GTP-gamma-S) binding to G(o), agonist-stimulated GTPase activity of G(o), and the capability of G(o) to induce high affinity agonist binding to mAChR. Both the receptor-stimulated GTP-gamma-S binding and GTPase activity of G(o) were markedly diminished as a result of PKC-mediated phosphorylation of the mAChR, whereas the ability of G(o) to induce high affinity agonist binding to the receptors was unaffected. When mAChR were first reconstituted with G(o) and then subjected to phosphorylation with PKC, a complete inhibition of the phosphorylation of mAChR by PKC was observed. The inhibitory effect of G(o) on mAChR phosphorylation was concentration-dependent and was prevented by the presence of GTP-gamma-S in the reaction mixtures. Taken together, these results indicate that the phosphorylation of mAChR by PKC modulates receptor/G-protein interactions and that the ability of the receptors to act as substrates for PKC may be regulated by receptor/G-protein interactions.	NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031601] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007140] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31601] Funding Source: Medline; NINDS NIH HHS [5T32-NS07140-80] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; BROWN JH, 1984, J BIOL CHEM, V259, P3777; BURGOYNE RD, 1983, J NEUROCHEM, V40, P324, DOI 10.1111/j.1471-4159.1983.tb11286.x; BURGOYNE RD, 1981, FEBS LETT, V127, P144, DOI 10.1016/0014-5793(81)80361-4; BURGOYNE RD, 1980, FEBS LETT, V122, P288, DOI 10.1016/0014-5793(80)80458-3; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; ELFAKAHANY EE, 1988, FASEB J, V2, P2575, DOI 10.1096/fasebj.2.10.2838363; FEIGENBAUM P, 1985, J PHARMACOL EXP THER, V233, P134; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; GEORGE WJ, 1970, P NATL ACAD SCI USA, V66, P398, DOI 10.1073/pnas.66.2.398; GILES W, 1976, J PHYSIOL-LONDON, V261, P103, DOI 10.1113/jphysiol.1976.sp011550; HAGA K, 1990, J NEUROCHEM, V54, P1639, DOI 10.1111/j.1471-4159.1990.tb01216.x; HAGA K, 1989, MOL PHARMACOL, V35, P286; HAGA K, 1989, BIOMED RES-TOKYO, V10, P293, DOI 10.2220/biomedres.10.293; HAGA K, 1986, J BIOL CHEM, V261, P133; HAGA K, 1983, J BIOL CHEM, V258, P3575; HO AKS, 1985, BIOCHEM BIOPH RES CO, V133, P1193, DOI 10.1016/0006-291X(85)91263-X; JACOBS KH, 1979, N-S ARCH PHARMACOL, V310, P113; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KEENAN AK, 1987, FEBS LETT, V217, P287, DOI 10.1016/0014-5793(87)80680-4; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, MOL PHARMACOL, V35, P553; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAI WS, 1987, J PHARMACOL EXP THER, V241, P366; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LILES WC, 1986, J BIOL CHEM, V261, P5307; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MURAD F, 1962, J BIOL CHEM, V237, P1233; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; RICHARDSON MR, 1992, MOL PHARMACOL, V40, P908; RICHARDSON RM, 1990, BIOCHEMISTRY-US, V29, P8555, DOI 10.1021/bi00489a008; ROSENBAUM LC, 1987, BIOCHEMISTRY-US, V26, P8183, DOI 10.1021/bi00399a024; SERRA M, 1986, BIOCHEM BIOPH RES CO, V140, P160, DOI 10.1016/0006-291X(86)91071-5; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TIETJE KM, 1991, J BIOL CHEM, V266, P17382; TIETJE KM, 1990, J BIOL CHEM, V265, P2828; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	53	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10127	10132						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577782				2022-12-27	WOS:A1992HT96500102
J	GUPTA, D; RAO, NVSAVP; PURI, KD; MATTA, KL; SUROLIA, A				GUPTA, D; RAO, NVSAVP; PURI, KD; MATTA, KL; SUROLIA, A			THERMODYNAMIC AND KINETIC-STUDIES ON THE MECHANISM OF BINDING OF METHYLUMBELLIFERYL GLYCOSIDES TO JACALIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTOCARPUS-INTEGRIFOLIA AGGLUTININ; BEAN PSOPHOCARPUS-TETRAGONOLOBUS; ALPHA-D-MANNOPYRANOSIDE; DIMERIC CONCANAVALIN-A; SACCHARIDE BINDING; LIGAND-BINDING; LECTIN; JACKFRUIT; REVEALS	The binding of Artocarpus integrifolia lectin (jacalin) to 4-methylumbelliferyl (Meumb)-glycosides, Gal-alpha-Meumb, Gal-beta-Meumb, GalNAc-alpha-Meumb, GalNAc-beta-Meumb, and Gal-beta-3GalNAc-beta-Meumb was examined by extrinsic fluorescence quenching titration and stopped flow spectrofluorimetry. The binding was characterized by 100% quenching of fluorescence of Meumb-glycosides. Their association constants range from 2.0 x 10(4) to 1.58 x 10(6) M-1 at 15-degrees-C. Entropic contribution is the major stabilizing force for avid binding of Meumb-glycosides indicating the existence of a hydrophobic site that is complementary to their methylumbelliferyl group. The second order association rate constants for interaction of these sugars with lectin at 15-degrees-C vary from 8.8 x 10(5) to 3.24 x 10(6) M-1 s-1, at pH 7.2. The first order dissociation rate constants range from 2.30 to 43.0 s-1 at 15-degrees-C. Despite the differences in their association rate constants, the overall values of association constants for these saccharides are determined by their dissociation rate constants. The second order rate constant for the association of Meumb-glycosides follows a pattern consistent with the magnitude of the activation energies involved therein. Activation parameters for association of all ligands illustrate that the origin of the barrier between binding of jacalin to Meumb-glycosides is entropic, and the enthalpic contribution is small. A correlation between these parameters and the structure of the ligands on the association rates underscores the importance of steric factors in determining protein saccharide recognitions.	ROSEWELL PK MEM INST,NEW YORK,NY 10018		GUPTA, D (corresponding author), INDIAN INST SCI,MOLEC BIOPHYS UNIT,BANGALORE 560012,KARNATAKA,INDIA.		SUROLIA, AVADESHA/C-5442-2009					ACHARYA S, 1990, J BIOL CHEM, V265, P11586; APPUKUTTAN PS, 1977, INDIAN J BIOCHEM BIO, V14, P382; BANERJEE R, 1991, IN PRESS J MOL BIOL; BESSLER W, 1974, ARCH BIOCHEM BIOPHYS, V165, P444, DOI 10.1016/0003-9861(74)90184-2; BUNNMORENO MM, 1981, J IMMUNOL, V127, P427; CHIPMAN DM, 1967, J BIOL CHEM, V242, P4388; CLEGG RM, 1977, BIOCHEMISTRY-US, V16, P167, DOI 10.1021/bi00621a002; CRAMER F, 1967, J AM CHEM SOC, V89, P14, DOI 10.1021/ja00977a003; DEBOECK H, 1983, EUR J BIOCHEM, V131, P453; FARINA RD, 1980, BIOCHIM BIOPHYS ACTA, V631, P428, DOI 10.1016/0304-4165(80)90019-7; FLOWERS HM, 1965, J ORG CHEM, V30, P2041, DOI 10.1021/jo01017a078; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KHAN MI, 1986, J BIOL CHEM, V261, P3013; KONDOH H, 1986, J IMMUNOL METHODS, V88, P171; LEWIS SD, 1976, ARCH BIOCHEM BIOPHYS, V172, P689, DOI 10.1016/0003-9861(76)90125-9; LOONTIENS FG, 1977, BIOCHEMISTRY-US, V16, P159, DOI 10.1021/bi00621a001; MAHANTA SK, 1990, BIOCHEM J, V265, P831, DOI 10.1042/bj2650831; NEUBERGER A, 1971, CARBOHYD RES, V17, P81; PAYNE NR, 1990, INFECT IMMUN, V58, P3663, DOI 10.1128/IAI.58.11.3663-3670.1990; ROQUEBARREIRA MC, 1985, J IMMUNOL, V134, P1740; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; SASTRY MVK, 1988, J BIOL CHEM, V263, P14826; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SWAMY MJ, 1986, BIOCHEM J, V234, P515, DOI 10.1042/bj2340515	24	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8909	8918						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577729				2022-12-27	WOS:A1992HR85400034
J	MATSUI, T; TITANI, K; MIZUOCHI, T				MATSUI, T; TITANI, K; MIZUOCHI, T			STRUCTURES OF THE ASPARAGINE-LINKED OLIGOSACCHARIDE CHAINS OF HUMAN VONWILLEBRAND-FACTOR - OCCURRENCE OF BLOOD GROUP-A, GROUP-B, AND GROUP-H(O) STRUCTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON WILLEBRAND FACTOR; HUMAN FACTOR-VIII; COMPLEX-TYPE OLIGOSACCHARIDES; HUMAN CHORIONIC-GONADOTROPIN; SUGAR CHAINS; CARBOHYDRATE MOIETY; ASPERGILLUS-SAITOI; ALPHA-MANNOSIDASE; IMMUNOGLOBULIN-G; BINDING DOMAIN	The asparagine-linked oligosaccharide chains of human von Willebrand factor (vWF) purified from pooled plasma were quantitatively liberated from the polypeptide moiety by hydrazinolysis. After N-acetylation, these were fractionated by paper electrophoresis and sequential chromatography on lectin-affinity columns of concanavalin A, Phaseolus vulgaris erythrophyto-hemagglutinin, Datura stramonium agglutinin, Ricinus communis agglutinin 120, and Ulex europaeus agglutinin I and on a Bio-Gel P-4 column. Their structures were investigated by sequential exoglycosidase digestion in conjunction with methylation analysis. The glycoprotein was shown to be unique in its great diversity of oligosaccharide structures. Another note-worthy finding which had not been reported previously was the occurrence of asparagine-linked oligosaccharide chains with blood group A, B, and H(O) structures. In the present study, this glycoprotein was shown to contain mono- (0.4% of the total oligosaccharides), bi- (78.2%), tri- (12.3%), and tetraantennary (2.3%) complex type oligosaccharides in addition to a series of high mannose type oligosaccharides, Man6-9GleNAC2 (0.8%). Biantennary complex type oligosaccharide chains were those with (8.2%) and without (70.0%) a bisecting GlcNAc residue and approximately 13.2%, 2.2%, and 0.4% of these contained blood group H(O), A, and B structures, respectively. The tri- and tetraantennary complex type chains were those with and without N-acetyllactosamine repeats, and about 13.0% of the triantennary chains without the N-acetyllactosamine repeat contained the blood group H(O) structure. Occurrence of these asparagine-linked oligosaccharides with blood group A and B structures suggest that the repeated use of factor VIII/vWF pooled concentrate for the treatment of hemophiliacs could result in the production of antibodies against vWF with a different blood group from that of the patient, and this development may be pathogenic.	FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,DIV BIOMED POLYMER SCI,TOYOAKE,AICHI 47011,JAPAN	Fujita Health University								AMANO J, 1986, J BIOCHEM-TOKYO, V99, P1645, DOI 10.1093/oxfordjournals.jbchem.a135639; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; CAEKEBEKEPEERLINCK KMJ, 1989, BRIT J HAEMATOL, V73, P217, DOI 10.1111/j.1365-2141.1989.tb00255.x; CHOPEK MW, 1986, BIOCHEMISTRY-US, V25, P3146, DOI 10.1021/bi00359a012; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; DEBEIRE P, 1983, FEBS LETT, V151, P22, DOI 10.1016/0014-5793(83)80334-2; DEMARCO L, 1981, J CLIN INVEST, V68, P321, DOI 10.1172/JCI110259; ENDO Y, 1979, J BIOCHEM-TOKYO, V85, P669; FEDERICI AB, 1988, BLOOD, V71, P947; FEDERICI AB, 1984, J CLIN INVEST, V74, P2049, DOI 10.1172/JCI111628; FINNE J, 1989, J BIOL CHEM, V264, P5720; FOSTER PA, 1987, J BIOL CHEM, V262, P8443; FUJIMURA Y, 1987, J BIOL CHEM, V262, P1734; GILL JC, 1987, BLOOD, V69, P1691; GIRMA JP, 1987, BLOOD, V70, P605; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GOUDEMAND J, 1985, THROMB HAEMOSTASIS, V53, P390; GRALNICK HR, 1976, SCIENCE, V192, P56, DOI 10.1126/science.1083071; HINDSGAUL O, 1985, CAN J CHEM, V63, P2653, DOI 10.1139/v85-440; HORMIA M, 1983, CELL BIOL INT REP, V7, P467, DOI 10.1016/0309-1651(83)90136-4; ICHISHIMA E, 1981, BIOCHIM BIOPHYS ACTA, V658, P45, DOI 10.1016/0005-2744(81)90248-5; KESSLER CM, 1990, THROMB RES, V57, P59, DOI 10.1016/0049-3848(90)90195-I; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MATSUI T, 1991, BIOCHEM BIOPH RES CO, V178, P1253, DOI 10.1016/0006-291X(91)91028-B; MIZUOCHI T, 1982, J IMMUNOL, V129, P2016; MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519; MIZUOCHI T, 1987, ARCH BIOCHEM BIOPHYS, V257, P387, DOI 10.1016/0003-9861(87)90581-9; MIZUOCHI T, 1983, J BIOL CHEM, V258, P4126; Mizuochi T, 1988, Biomed Chromatogr, V2, P260; MIZUOCHI T, 1992, IN PRESS METHODS MOL; NARASIMHAN S, 1986, CARBOHYD RES, V149, P65, DOI 10.1016/S0008-6215(00)90370-7; OGATA S, 1975, J BIOCHEM, V78, P687, DOI 10.1093/oxfordjournals.jbchem.a130956; ORDONEZ NG, 1984, ARCH PATHOL LAB MED, V108, P129; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; RENWICK AGC, 1987, J BIOCHEM-TOKYO, V101, P1209, DOI 10.1093/oxfordjournals.jbchem.a121985; SAMOR B, 1989, GLYCOCONJUGATE J, V6, P263, DOI 10.1007/BF01047846; SAMOR B, 1986, EUR J BIOCHEM, V158, P295, DOI 10.1111/j.1432-1033.1986.tb09750.x; SANO M, 1989, SEIKAGAKU, V61, P1109; SODETZ JM, 1979, J BIOL CHEM, V254, P754; SODETZ JM, 1978, J BIOL CHEM, V253, P7202; TAKAGI J, 1989, J BIOL CHEM, V264, P6017; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; TITANI K, 1988, TRENDS BIOCHEM SCI, V13, P94, DOI 10.1016/0968-0004(88)90048-5; WAGNER DD, 1986, J CELL BIOL, V102, P1320, DOI 10.1083/jcb.102.4.1320; WALKER RA, 1985, J PATHOL, V146, P123, DOI 10.1002/path.1711460207; YAMASHITA K, 1980, J BIOL CHEM, V255, P5635; YAMASHITA K, 1980, BIOCHEM BIOPH RES CO, V96, P1335, DOI 10.1016/0006-291X(80)90097-2; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; YAMASHITA K, 1981, BIOCHEM BIOPH RES CO, V100, P226, DOI 10.1016/S0006-291X(81)80086-1; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753	52	153	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8723	8731						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577715				2022-12-27	WOS:A1992HR85400006
J	ZUPAN, LA; STEFFENS, DL; BERRY, CA; LANDT, M; GROSS, RW				ZUPAN, LA; STEFFENS, DL; BERRY, CA; LANDT, M; GROSS, RW			CLONING AND EXPRESSION OF A HUMAN 14-3-3 PROTEIN MEDIATING PHOSPHOLIPOLYSIS - IDENTIFICATION OF AN ARACHIDONOYL-ENZYME INTERMEDIATE DURING CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROSTAGLANDIN ENDOPEROXIDES; PANCREATIC PHOSPHOLIPASE-A2; HUMAN-PLATELETS; MECHANISM; PURIFICATION; ACTIVATOR; ACID	The major phospholipase A2 activity in sheep platelets is mediated by at least three chromatographically resolvable isoforms of a 30-kDa dimeric polypeptide which are responsive to physiologic increments in calcium ion and possess a dramatic substrate selectivity (Loeb, L. A., and Gross, R. W. (1986) J. Biol. Chem. 261, 10467-10470). Herein, we describe the cloning and expression of the human equivalent of one such isoform and demonstrate that it catalyzes the cleavage of the sn-2 fatty acid of choline and ethanolamine glycerophospholipids through the formation of a stable acyl-enzyme intermediate. Transesterification of the sn-2 acyl group of phosphatidylcholine to the recombinant 30-kDa polypeptide is over 50-fold selective for arachidonic acid, is augmented by calcium ion, and results in the formation of an arachidonoyl-thioester intermediate. Homology analysis demonstrated that the polypeptide mediating this transesterification is one member of a family of proteins collectively designated as 14-3-3 proteins. These results demonstrate that at least one intracellular mammalian phospholipase A2 employs a catalytic strategy distinct from that utilized by extracellular phospholipases A2 (i.e. formation of an acyl-enzyme intermediate by nucleophilic attack versus activation of a water molecule) and that arachidonic acid in endogenous phospholipid storage depots can, in principle, be sequentially transferred through an acyl-enzyme intermediate without the prior obligatory release of free arachidonic acid.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV BIOORGAN CHEM & MOLEC PHARMACOL,660 S EUCLID,BOX 8020,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035864] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35864] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAENZIGER NL, 1977, BIOCHEM BIOPH RES CO, V78, P294, DOI 10.1016/0006-291X(77)91253-0; BORGEAT P, 1976, J BIOL CHEM, V251, P7816; BRUCK C, 1982, J IMMUNOL METHODS, V53, P313, DOI 10.1016/0022-1759(82)90178-8; BUNTING S, 1976, PROSTAG OTH LIPID M, V12, P897, DOI 10.1016/0090-6980(76)90125-8; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; GREEN K, 1971, EUR J BIOCHEM, V22, P391, DOI 10.1111/j.1432-1033.1971.tb01556.x; GROSS RW, 1983, J BIOL CHEM, V258, P5165; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; JAUHIAINEN M, 1986, J BIOL CHEM, V261, P7032; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; LOEB LA, 1986, J BIOL CHEM, V261, P10470; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; NIETO ML, 1991, J BIOL CHEM, V266, P18699; ROLLINS TE, 1980, J BIOL CHEM, V255, P4872; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SMITH JB, 1970, BRIT J PHARMACOL, V40, pP545; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VERHEIJ HM, 1980, BIOCHEMISTRY-US, V19, P743, DOI 10.1021/bi00545a021; WILSON DB, 1982, J BIOL CHEM, V257, P3510; YE RD, 1987, J BIOL CHEM, V262, P3718; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZUPAN LA, 1991, FEBS LETT, V384, P27	27	133	135	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8707	8710						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577711				2022-12-27	WOS:A1992HR85400002
J	VALTORTA, F; BENFENATI, F; GREENGARD, P				VALTORTA, F; BENFENATI, F; GREENGARD, P			STRUCTURE AND FUNCTION OF THE SYNAPSINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DEPENDENT PROTEIN-KINASE; TERMINAL-SPECIFIC PHOSPHOPROTEIN; SMALL SYNAPTIC VESICLES; SQUID GIANT SYNAPSE; NEUROTRANSMITTER RELEASE; NERVE-TERMINALS; MAMMALIAN BRAIN; NEUROMUSCULAR-JUNCTION; PHOSPHORYLATION SITES; MEMBRANE FRACTIONS		UNIV MODENA,SCH MED,INST HUMAN PHYSIOL,I-41100 MODENA,ITALY; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021	Universita di Modena e Reggio Emilia; Rockefeller University	VALTORTA, F (corresponding author), UNIV MILAN,S RAFFAELE SCI INST,CNR,CTR CYTOPHARMACOL,BRUNO CECCARELLI CTR,I-20129 MILAN,ITALY.		Flavia, Valtorta/F-3450-2012	Flavia, Valtorta/0000-0001-9556-4746	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039327, R01MH039327] Funding Source: NIH RePORTER; NIMH NIH HHS [MH39327] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P7713, DOI 10.1073/pnas.81.24.7713; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BAHLER M, 1990, BIOESSAYS, V12, P259, DOI 10.1002/bies.950120603; BAINES AJ, 1986, NATURE, V319, P145, DOI 10.1038/319145a0; BAINES AJ, 1985, NATURE, V315, P410, DOI 10.1038/315410a0; BENENATI F, 1990, J BIOL CHEM, V265, P12584; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BENFENATI F, 1989, J CELL BIOL, V108, P1851, DOI 10.1083/jcb.108.5.1851; BENFENATI F, 1991, P NATL ACAD SCI USA, V88, P575, DOI 10.1073/pnas.88.2.575; BENFENATI F, 1992, NEURON, V8, P377, DOI 10.1016/0896-6273(92)90303-U; BENFENATI F, 1991, Society for Neuroscience Abstracts, V17, P1157; BERNSTEIN BW, 1989, NEURON, V3, P257, DOI 10.1016/0896-6273(89)90039-1; BROWNING MD, 1987, J NEUROSCI, V7, P847; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CHUN JJM, 1988, NEURON, V1, P297; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; FESCE R, 1990, PROG NEUROBIOL, V35, P85, DOI 10.1016/0301-0082(90)90019-D; FESCE R, 1992, IN PRESS J BIOL CHEM, V267; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; FONT B, 1989, BIOCHEM J, V264, P893, DOI 10.1042/bj2640893; FORN J, 1978, P NATL ACAD SCI USA, V75, P5195, DOI 10.1073/pnas.75.10.5195; GOELZ SE, 1981, P NATL ACAD SCI-BIOL, V78, P2130, DOI 10.1073/pnas.78.4.2130; HACKETT JT, 1990, J NEUROPHYSIOL, V63, P701, DOI 10.1152/jn.1990.63.4.701; HALL FL, 1990, J BIOL CHEM, V265, P6944; HAN HQ, 1991, NATURE, V349, P697, DOI 10.1038/349697a0; HARADA A, 1990, CELL STRUCT FUNCT, V15, P329, DOI 10.1247/csf.15.329; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; HO MF, 1991, J BIOL CHEM, V266, P5600; HUANG CK, 1982, J BIOL CHEM, V257, P6524; HUGANIR RL, 1983, P NATL ACAD SCI-BIOL, V80, P1130, DOI 10.1073/pnas.80.4.1130; HUTTNER WB, 1981, J BIOL CHEM, V256, P1482; HUTTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402, DOI 10.1073/pnas.76.10.5402; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JOHNSON EM, 1972, J BIOL CHEM, V247, P5650; KENNEDY MB, 1983, J NEUROSCI, V3, P818; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; LEVITT P, 1984, J NEUROSCI, V4, P2553; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; LOHMANN SM, 1978, P NATL ACAD SCI USA, V75, P4037, DOI 10.1073/pnas.75.8.4037; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; LUTHI T, 1991, J NEUROCHEM, V56, P1493; MANDELL JW, 1990, NEURON, V5, P19, DOI 10.1016/0896-6273(90)90030-J; MASON CA, 1986, NEUROSCIENCE, V19, P1319, DOI 10.1016/0306-4522(86)90146-6; MCCAFFERY CA, 1986, EMBO J, V5, P3167, DOI 10.1002/j.1460-2075.1986.tb04625.x; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAVONE F, 1984, SCIENCE, V226, P1209, DOI 10.1126/science.6438799; Nestler E. J., 1984, PROTEIN PHOSPHORYLAT; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; NICHOLS RA, 1992, J NEUROCHEM, V58, P783, DOI 10.1111/j.1471-4159.1992.tb09788.x; PETRUCCI TC, 1988, J CELL BIOCHEM, V36, P25, DOI 10.1002/jcb.240360104; PETRUCCI TC, 1991, BIOCHEMISTRY-US, V30, P413, DOI 10.1021/bi00216a016; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; ROMANO C, 1987, J NEUROSCI, V7, P1300; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCARFONE E, 1991, J NEUROSCI, V11, P1173; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SCHULMAN H, 1978, NATURE, V271, P478, DOI 10.1038/271478a0; SEVERIN SE, 1989, FEBS LETT, V258, P223, DOI 10.1016/0014-5793(89)81658-8; SIHRA TS, 1989, P NATL ACAD SCI USA, V86, P8108, DOI 10.1073/pnas.86.20.8108; SIKORSKI AF, 1991, J CELL BIOL, V114, P313, DOI 10.1083/jcb.114.2.313; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; SUDHOF TC, 1990, J BIOL CHEM, V265, P7843; THIEL G, 1991, P NATL ACAD SCI USA, V88, P3431, DOI 10.1073/pnas.88.8.3431; THIEL G, 1990, J BIOL CHEM, V265, P16527; TORRITARELLI F, 1990, J CELL BIOL, V110, P449, DOI 10.1083/jcb.110.2.449; UEDA T, 1973, J BIOL CHEM, V248, P8295; UEDA T, 1977, J BIOL CHEM, V252, P5155; VALTORTA F, 1990, NEUROSCIENCE, V35, P477, DOI 10.1016/0306-4522(90)90323-V; VALTORTA F, 1988, NEUROSCIENCE, V24, P593, DOI 10.1016/0306-4522(88)90353-3; VALTORTA F, 1992, IN PRESS J BIOL CHEM, V267; VOLKNANDT W, 1987, J NEUROCHEM, V49, P342, DOI 10.1111/j.1471-4159.1987.tb02871.x; WANG JKT, 1988, J NEUROSCI, V8, P281	79	157	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7195	7198						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559963				2022-12-27	WOS:A1992HN48500001
J	CHATTERJEE, S; GHOSH, N; KHURANA, S				CHATTERJEE, S; GHOSH, N; KHURANA, S			PURIFICATION OF URIDINE DIPHOSPHATE-GALACTOSE-GLUCOSYL CERAMIDE, BETA-1-4 GALACTOSYLTRANSFERASE FROM HUMAN KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL TUBULAR CELLS; BIOSYNTHESIS; GLYCOLIPIDS; CDNA	A galactosyltransferase that transfers galactose from UDP-galactose to glucosylceramide was purified 440-fold to apparent homogeneity from normal human kidney "buffy coat" preparation employing detergent extraction, ultrafiltration, and Sepharose Q column chromatography. On reducing and nonreducing gels, the enzyme resolved into two bands with apparent molecular weights on the order of 60,000 and 58,000, respectively. The activity of the enzyme was also associated with these two bands following separation on polyacrylamide gels. Analytical isoelectric focusing revealed that the pI of this enzyme is approximately 4.55. Product characterization and substrate specificity studies employing chromatography, enzymatic digestion with various glycosidases, and use of a variety of glycosphingolipid substrates revealed that the major product synthesized by this enzyme was Cer1-1-beta-Glc4-1Gal, and Cer1-1-beta-Glc was the preferred substrate. Digestion of the 60- and 58-kDa proteins with Staphylococcus aureus (V-8) protease revealed at least six peptides having identical electrophoretic migration. This finding suggests that the two proteins may be related to each other. Western immunoblot assays revealed that the antibody against UDP-galactose:GlcCer, beta-1-4 galactosyltransferase (GalT-2) but not galactosyltransferase UDP-Gal:N-acetyl-D-glucosaminyl-glycopeptide 4-beta-D-galactosyltransferase (EC 2.4.1.38) (B-GT) immunoprecipitated (recognized) the kidney GalT-2. In contrast, antibody against B-GT did not immunoprecipitate GalT-2. Thus our data indicate that GalT-2 and B-GT are two distinct enzymes. The availability of the enzyme GalT-2 and corresponding antibody will allow functional studies in the near future.			CHATTERJEE, S (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031722] Funding Source: NIH RePORTER; NIDDK NIH HHS [R0-1-DK-31722] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASU M, 1987, METHOD ENZYMOL, V138, P575; BASU S, 1988, BIOCHIMIE, V70, P1551, DOI 10.1016/0300-9084(88)90291-X; BASU S, 1968, J BIOL CHEM, V243, P5802; BASU S, 1990, INDIAN J BIOCHEM BIO, V27, P386; BULL CA, 1990, P AM SOC CELL BIOL, P73; CHATTERJEE S, 1988, J BIOL CHEM, V263, P13017; CHATTERJEE S, 1987, BIOCHIM BIOPHYS ACTA, V923, P136, DOI 10.1016/0304-4165(87)90136-X; CHATTERJEE S, 1990, INDIAN J BIOCHEM BIO, V27, P375; CLAUSEN H, 1990, J BIOL CHEM, V265, P1139; DESNICK RJ, 1983, METABOLIC BASIS INHE, P906; HAKOMORI SI, 1983, HDB LIPID RES SPHING, V3, P329; HILDEBRAND J, 1969, J BIOL CHEM, V244, P5170; Hill R L, 1968, Brookhaven Symp Biol, V21, P139; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MELKERSONWATSON LJ, 1991, J BIOL CHEM, V266, P4448; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHUR BD, 1988, J BIOL CHEM, V263, P17706; SOUMI WD, 1965, J LIPID RES, V6, P211; TAKI T, 1982, J BIOCHEM-TOKYO, V91, P665, DOI 10.1093/oxfordjournals.jbchem.a133739; TANIGUCHI N, 1982, J BIOL CHEM, V257, P631; TRINCHERA M, 1991, BIOCHEMISTRY-US, V30, P2719, DOI 10.1021/bi00224a021; YAMATO K, 1982, J BIOCHEM-TOKYO, V92, P1123, DOI 10.1093/oxfordjournals.jbchem.a134028; ZIELENSKI J, 1982, EUR J BIOCHEM, V125, P323, DOI 10.1111/j.1432-1033.1982.tb06686.x	25	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7148	7153						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551920				2022-12-27	WOS:A1992HM05300106
J	KUBISESKI, TJ; HYNDMAN, DJ; MORJANA, NA; FLYNN, TG				KUBISESKI, TJ; HYNDMAN, DJ; MORJANA, NA; FLYNN, TG			STUDIES ON PIG MUSCLE ALDOSE REDUCTASE - KINETIC MECHANISM AND EVIDENCE FOR A SLOW CONFORMATIONAL CHANGE UPON COENZYME BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ALCOHOL-DEHYDROGENASE; ALDEHYDE REDUCTASE; INHIBITORS; PURIFICATION	Steady state kinetic analysis at pH 7.0 of the reduction of DL-glyceraldehyde by pig muscle aldose reductase showed that the enzyme follows a sequential ordered mechanism with NADPH binding first. However, the "off constant" for NADP+ in the forward direction was 1 order of magnitude less than the k(cat). Analysis of this anomaly by pre-steady state kinetics using stopped-flow fluorescence spectroscopy showed that this could be accounted for by isomerization of the enzyme-NADP+ complex and that the rate of isomerization is the rate-limiting step. The rate constant for this step was of the same order of magnitude as the k(cat) for the forward reaction. Fluorescence emission spectra of free and NADP(H)-bound enzyme suggested a conformational change upon binding of coenzyme. In the reverse direction (oxidation of glycerol) pre-steady state and steady state kinetic analyses were consistent with the rate-limiting step occurring before isomerization of the enzyme-NADPH complex. We conclude, therefore, that during the kinetic mechanism of the reduction of aldehydes by aldose reductase, a slow (kinetically detectable) conformational change in the enzyme occurs upon coenzyme binding. Since NADPH and NADP+ bind to the enzyme very tightly, this has implications for the targeting and binding of drugs that are aldose reductase inhibitors.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada				Kubiseski, Terrance/0000-0001-9388-8608				BHATNAGAR A, 1988, ARCH BIOCHEM BIOPHYS, V261, P264, DOI 10.1016/0003-9861(88)90341-4; BOGHOSIAN RA, 1981, INT J BIOCHEM, V13, P909, DOI 10.1016/0020-711X(81)90017-3; CARPER D, 1987, FEBS LETT, V220, P209, DOI 10.1016/0014-5793(87)80905-5; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CONRAD SM, 1982, BIOCHIM BIOPHYS ACTA, V708, P358; CROMLISH JA, 1983, J BIOL CHEM, V258, P3416; DAVIDSON WS, 1979, BIOCHEM J, V177, P595, DOI 10.1042/bj1770595; DELCORSO A, 1990, ARCH BIOCHEM BIOPHYS, V283, P512, DOI 10.1016/0003-9861(90)90675-O; DUNN SMJ, 1978, BIOCHEMISTRY-US, V17, P2356, DOI 10.1021/bi00605a016; DWORSCHACK R, 1975, BIOCHEMISTRY-US, V14, P200, DOI 10.1021/bi00673a002; EKLUND H, 1987, PYRIDINE NUCLEOTIDE, P51; ELKABBANI O, 1991, J MOL BIOL, V218, P695, DOI 10.1016/0022-2836(91)90257-7; FERSHT A, 1985, ENZYME STRUCTURE MEC, P121; FLYNN TG, 1986, METABOLISM, V35, P105, DOI 10.1016/0026-0495(86)90197-6; GARLAND WJ, 1977, ARCH BIOCHEM BIOPHYS, V182, P614, DOI 10.1016/0003-9861(77)90542-2; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9936, DOI 10.1021/bi00494a026; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9947, DOI 10.1021/bi00494a027; KADOR PF, 1985, ANNU REV PHARMACOL, V25, P691, DOI 10.1146/annurev.pa.25.040185.003355; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MORJANA NA, 1989, J BIOL CHEM, V264, P2906; NISHIMURA C, 1990, J BIOL CHEM, V265, P9788; PETERSON MJ, 1979, METABOLISM, V28, P456, DOI 10.1016/0026-0495(79)90056-8; PETRASH JM, 1989, CURR EYE RES, V8, P1021, DOI 10.3109/02713688908997394; ROBISON WG, 1983, SCIENCE, V221, P1177, DOI 10.1126/science.6612330; RONDEAU JM, 1987, J MOL BIOL, V195, P945, DOI 10.1016/0022-2836(87)90498-0; RYLE CM, 1985, BIOCHEM J, V227, P621, DOI 10.1042/bj2270621; SCHADE SZ, 1990, J BIOL CHEM, V265, P3628; Segel I. H., 1975, ENZYME KINETICS, P560; STRIBLING D, 1985, METABOLISM, V34, P336, DOI 10.1016/0026-0495(85)90223-9; STRIBLING D, 1990, EXP EYE RES, V50, P621, DOI 10.1016/0014-4835(90)90103-2; Turner A J, 1982, Prog Clin Biol Res, V114, P401; VISSER AJW, 1987, PYRIDINE NUCLEOTIDE, P163; WARD WHJ, 1990, BIOCHEM PHARMACOL, V39, P337, DOI 10.1016/0006-2952(90)90033-H; WOLFE JK, 1977, J BIOL CHEM, V252, P433	35	104	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6510	6517						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551865				2022-12-27	WOS:A1992HM05300013
J	MCKENNA, E; HARDY, D; KABACK, HR				MCKENNA, E; HARDY, D; KABACK, HR			EVIDENCE THAT THE FINAL TURN OF THE LAST TRANSMEMBRANE HELIX IN THE LACTOSE PERMEASE IS REQUIRED FOR FOLDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LAC CARRIER PROTEIN; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; MEMBRANE-VESICLES; CYTOPLASMIC SIDE; COOH TERMINUS; PROTEOLIPOSOMES; EXPRESSION; TRANSPORT; STABILITY	Although truncation of the hydrophilic C-terminal tail of the lactose (lac) permease of Escherichia coli (residues 401-417) has no significant effect on membrane insertion, stability, or transport activity, sequential substitution of stop codons for amino acid codons 398-401 leads to a progressive increase in transport activity and in the lifetime of the permease in the membrane (McKenna, E., Hardy, D., Pastore, J. C., and Kaback, H. R. (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 2969-2973). Thus, either the last turn of putative helix XII or the region immediately distal to helix XII is important for proper folding, and hence, activity and resistance to proteolysis. In an effort to determine whether this 3-4-amino acid sequence comprises the final turn of the last transmembrane helix of the permease or the beginning of the hydrophilic C-terminal tail, we deleted residues 401-417 and replaced amino acid residues 397-400 with either 4 Leu residues ("helix making") or Gly-Pro-Gly-Pro ("helix breaking"). Permease with 4 Leu residues at positions 397-400 is fully functional with respect to transport and completely stable, as judged by [S-35]methionine labeling experiments. In marked contrast, permease with Gly-Pro-Gly-Pro at the same positions exhibits minimal activity and is unstable. The results imply that the amino acid sequence ...Val397Phe398Thr399 Leu400... in lac permease may comprise the last turn of transmembrane helix XII, rather than the beginning of the C-terminal tail.	UNIV CALIF LOS ANGELES, DEPT PHYSIOL, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1984, BIOCHEMISTRY-US, V23, P3681, DOI 10.1021/bi00311a017; CARRASCO N, 1982, P NATL ACAD SCI-BIOL, V79, P6894, DOI 10.1073/pnas.79.22.6894; CARRASCO N, 1984, P NATL ACAD SCI-BIOL, V81, P4672, DOI 10.1073/pnas.81.15.4672; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DANHO W, 1985, PEPT STRUCT FUNCT P, V9, P59; FOSTER DL, 1983, J BIOL CHEM, V258, P31; GOLDKORN T, 1983, P NATL ACAD SCI-BIOL, V80, P3322, DOI 10.1073/pnas.80.11.3322; HERZLINGER D, 1984, BIOCHEMISTRY-US, V23, P3688, DOI 10.1021/bi00311a018; HERZLINGER D, 1985, BIOCHEMISTRY-US, V24, P221, DOI 10.1021/bi00322a032; KABACK HR, 1989, HARVEY LECT, V83, P77; KABACK HR, 1983, J MEMBRANE BIOL, V76, P95; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKENNA E, 1991, P NATL ACAD SCI USA, V88, P2969, DOI 10.1073/pnas.88.8.2969; PAGE MGP, 1988, J BIOL CHEM, V263, P15906; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; ROEPE PD, 1989, P NATL ACAD SCI USA, V86, P3992, DOI 10.1073/pnas.86.11.3992; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SECKLER R, 1986, BIOCHEMISTRY-US, V25, P2403, DOI 10.1021/bi00357a016; SECKLER R, 1984, EUR J BIOCHEM, V142, P269, DOI 10.1111/j.1432-1033.1984.tb08281.x; SECKLER R, 1983, J BIOL CHEM, V258, P817; STOCHAJ U, 1986, EUR J BIOCHEM, V158, P423, DOI 10.1111/j.1432-1033.1986.tb09770.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; VANIWAARDEN PR, 1991, J BIOL CHEM, V30, P9595; VOGEL H, 1985, EMBO J, V4, P3625, DOI 10.1002/j.1460-2075.1985.tb04126.x	30	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6471	6474						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551862				2022-12-27	WOS:A1992HM05300006
J	WALSH, MJ; TSAO, KL; LELEIKO, NS				WALSH, MJ; TSAO, KL; LELEIKO, NS			CHARACTERIZATION OF DNA-PROTEIN INTERACTIONS WITHIN A DISTAL REGULATORY ELEMENT UPSTREAM OF A MAMMALIAN HOUSEKEEPING GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE GENE; SERUM RESPONSE ELEMENT; CELL-CYCLE; C-FOS; TRANSCRIPTION FACTOR; BINDING PROTEINS; COORDINATE REGULATION; ADENOSINE-DEAMINASE; MOUSE FIBROBLASTS; TOPOISOMERASE-II	We have characterized a DNA-protein interaction within a sequence element distal from the site of transcription initiation within the mouse housekeeping gene (HPRT) promoter region. This interaction occurs within a 35-base pair regulatory element which confers cell type-specific gene transcription, designated as the HPRT cis-acting regulatory element (HCRE). Competition analysis by gel mobility shift electrophoresis indicates that this DNA-protein interaction is novel and not related to many transcription factors previously reported. Cell cycle synchronization experiments and gel mobility shift assays have demonstrated that within the HCRE a specific DNA-protein complex responds to G1 activation of the cell cycle. Experiments to purify specific DNA-binding proteins that interact with the HCRE has resulted in the purification of one sequence-specific DNA-binding protein of approximately 66 kDa. To determine the putative DNA-binding sequence, footprinting analysis has mapped the protection from DNase I hydrolysis which confers a core sequence of GTCTGGGT using both affinity purified protein and crude nuclear extract. This DNA motif represents a novel protein-binding sequence. Interestingly, data base searches have identified the same or homologous sequences of this DNA motif in additional genes, potentially related to cellular growth and proliferation. This consensus was most notable within a region 5' upstream of the ornithine decarboxylase gene. The unique cell type-specific regulation of the HPRT gene in the intestinal mucosa is not completely understood at this time but because of the relationship of ornithine decarboxylase expression to cell proliferation and more specifically, to mucosal cell renewal in the intestine, the function of DNA-protein interactions within the consensus sequence may prove analogous. This may account for the cell type-specific and cell-cycle responsive gene regulation previously demonstrated with HPRT. Identification of one sequence-specific DNA-binding protein within the HCRE suggest that this protein contributes to the trans-activation of specific genes during the immediate-early response of the cell cycle.			WALSH, MJ (corresponding author), CUNY MT SINAI SCH MED, DEPT PEDIAT, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.		LeLeiko, Neal/GRJ-6855-2022	leleiko, neal/0000-0001-7699-1400				ABRAHAMSEN MS, 1990, MOL CELL BIOL, V10, P5525, DOI 10.1128/MCB.10.10.5525; ARTISHEVSKY A, 1987, NATURE, V328, P823, DOI 10.1038/328823a0; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISENBERG LM, 1989, NUCLEIC ACIDS RES, V17, P2359, DOI 10.1093/nar/17.6.2359; EVANS RK, 1987, BIOCHEMISTRY-US, V26, P269, DOI 10.1021/bi00375a037; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; HAUFT SM, 1989, J BIOL CHEM, V264, P8419; HEBY O, 1981, DIFFERENTIATION, V19, P1, DOI 10.1111/j.1432-0436.1981.tb01123.x; HUMPHREY RM, 1970, INT J RADIAT BIOL RE, V18, P61, DOI 10.1080/09553007014550821; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LI Y, 1991, MOL CELL BIOL, V11, P1023, DOI 10.1128/MCB.11.2.1023; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LLOYD D, 1987, BIOCHEM J, V242, P313, DOI 10.1042/bj2420313; LUK GD, 1980, SCIENCE, V210, P195, DOI 10.1126/science.6774420; LUK GD, 1987, ADV ENZYME REGUL, V26, P91, DOI 10.1016/0065-2571(87)90007-0; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MANIATIS T, 1989, MOL CLONING, V2; Maxam A M, 1980, Methods Enzymol, V65, P499; MORACQ JC, 1989, GENE DEV, V3, P760; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NAGARAJAN M, 1989, EXP CELL RES, V181, P289, DOI 10.1016/0014-4827(89)90203-6; PARFETT CLJ, 1985, MOL CELL BIOL, V5, P3289, DOI 10.1128/MCB.5.11.3289; PAULI U, 1989, J CELL PHYSIOL, V139, P320, DOI 10.1002/jcp.1041390214; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; REID LH, 1990, P NATL ACAD SCI USA, V87, P4299, DOI 10.1073/pnas.87.11.4299; RINCONLIMAS DE, 1991, MOL CELL BIOL, V11, P4157, DOI 10.1128/MCB.11.8.4157; ROUX E, 1989, GENE DEV, V3, P1613, DOI 10.1101/gad.3.10.1613; RUBIN DC, 1989, P NATL ACAD SCI USA, V86, P1278, DOI 10.1073/pnas.86.4.1278; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHOTER H, 1987, NUCLEIC ACIDS RES, V15, P10145; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; SPITZNER JR, 1990, NUCLEIC ACIDS RES, V18, P1, DOI 10.1093/nar/18.1.1; STEEN AM, 1990, EXP CELL RES, V186, P236, DOI 10.1016/0014-4827(90)90301-P; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; VANWIJNEN AJ, 1991, P NATL ACAD SCI USA, V88, P2573, DOI 10.1073/pnas.88.6.2573; WALSH MJ, 1990, MOL CELL BIOL, V10, P4356, DOI 10.1128/MCB.10.8.4356; WRIGHT N, 1984, BIOL EPITHELIAL CELL, V2, P689	59	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7026	7035						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551910				2022-12-27	WOS:A1992HM05300087
J	ANDRES, JL; DEFALCIS, D; NODA, M; MASSAGUE, J				ANDRES, JL; DEFALCIS, D; NODA, M; MASSAGUE, J			BINDING OF 2 GROWTH-FACTOR FAMILIES TO SEPARATE DOMAINS OF THE PROTEOGLYCAN BETAGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; GLYCOSAMINOGLYCAN CHAINS; MEMBRANE PROTEOGLYCAN; RECEPTOR; CLONING; CHONDROCYTES; EXPRESSION; MATRIX; FGF	Cell surface proteoglycans help present some polypeptide growth factors such as basic fibroblast growth factor (bFGF) to their receptors and may act as reservoirs for others such as transforming growth factor-beta (TGF-beta). Betaglycan, a cell surface heparan sulfate/chondroitin sulfate proteoglycan that binds TGF-beta via its core protein, is shown here to bind bFGF via its heparan sulfate chains. We investigated the potential for regulation of betaglycan by its ligands in osteoblasts, a system in which bFGF and TGF-beta have complementary effects. We report here that the apparent molecular mass of betaglycan from an osteoblast-enriched primary culture of fetal rat calvaria is decreased in response to bFGF, as detected by an increased electrophoretic migration of betaglycan. The betaglycan forms expressed in bFGF-treated osteoblasts have a reduced content of heparan sulfate GAGs, without detectable changes in the content of chondroitin sulfate GAGs or the size of the core protein. bFGF did not affect the overall population of cell-surface-associated proteins identified by sulfate labeling, which contained primarily heparan sulfate, and had only small effects on the major secreted proteoglycans, which were, by contrast, chondroitin sulfate proteoglycans. The effect of bFGF on betaglycan is therefore a selective one. These results suggest that cells can interact with members of the TGF-beta and FGF families through separate domains of the same membrane proteoglycan, and can selectively regulate the bFGF-binding carbohydrate chains of this proteoglycan in response to bFGF.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MERCK SHARP & DOHME LTD,DEPT BONE BIOL,W POINT,PA 19486	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Merck & Company	ANDRES, JL (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.			Massague, Joan/0000-0001-9324-8408	NATIONAL CANCER INSTITUTE [R37CA034610, R01CA034610] Funding Source: NIH RePORTER; NCI NIH HHS [CA34610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES JL, 1991, J BIOL CHEM, V266, P23282; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIRAKI Y, 1985, BIOCHIM BIOPHYS ACTA, V845, P445, DOI 10.1016/0167-4889(85)90210-1; KATO Y, 1990, J BIOL CHEM, V265, P5903; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MAKOWER AM, 1988, EXP CELL RES, V179, P498, DOI 10.1016/0014-4827(88)90287-X; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; NADRES J, 1989, J CELL BIOL, V119, P3137; NODA M, 1987, J CELL BIOL, V105, P1671, DOI 10.1083/jcb.105.4.1671; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBEY PG, 1987, J CELL BIOL, V105, P457, DOI 10.1083/jcb.105.1.457; Ruiz i Altaba A, 1989, Nature, V341, P33; SACHS BL, 1982, J CELL PHYSIOL, V112, P51, DOI 10.1002/jcp.1041120109; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	30	125	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5927	5930						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556106				2022-12-27	WOS:A1992HK31800035
J	LAM, WL; DOOLITTLE, WF				LAM, WL; DOOLITTLE, WF			MEVINOLIN-RESISTANT MUTATIONS IDENTIFY A PROMOTER AND THE GENE FOR A EUKARYOTE-LIKE 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE IN THE ARCHAEBACTERIUM HALOFERAX-VOLCANII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; MULTIPLE SEQUENCE ALIGNMENT; HALOBACTERIUM-VOLCANII; CATALYTIC SITE; IMPROVED TOOLS; TATA BOX; DNA; BIOSYNTHESIS; BACTERIA; YEAST	Both eukaryotes and archaebacteria use 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase to synthesize mevalonate, which eukaryotes employ in the production of sterols and archaebacteria need for the isoprenoid side chains of their unique and characteristic lipids. The drug mevinolin inhibits HMG-CoA reductase in eukaryotes and in the halophilic archaebacteria, and we have used a spontaneous mutation to mevinolin resistance in the construction of a selectable shuttle vector for Haloferax volcanii. Sequence analysis shows that this resistance determinant encodes an HMG-CoA reductase very like its eukaryotic homologs, but sharing with the one sequenced eubacterial HMG-CoA reductase (that of Pseudomonas mevalonii) few residues other than those common to all HMG-CoA reductases. Characterization of several spontaneous mevinolin-resistant mutants reveals that they are of two sorts: amplifications of the HMG-CoA reductase gene with varying amounts of flanking sequence, and point mutants upstream of the HMG-CoA reductase coding region. We compared sequence and expression of a mutant gene of the latter class to those of the wild-type gene. The point mutation found affects the TATA box-like "distal promoter element," results (like gene amplification) in resistance through the synthesis of excess gene product, and provides the first true genetic definition of an archaebacterial promoter.	DALHOUSIE UNIV,DEPT BIOCHEM,HALIFAX B3H 4H7,NS,CANADA	Dalhousie University	LAM, WL (corresponding author), DALHOUSIE UNIV,CANADIAN INST ADV RES,HALIFAX B3H 4H7,NS,CANADA.			Doolittle, W. Ford/0000-0002-4675-8832				AUER J, 1989, CAN J MICROBIOL, V35, P200, DOI 10.1139/m89-031; BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; BEACH MJ, 1989, J BACTERIOL, V171, P2994, DOI 10.1128/jb.171.6.2994-3001.1989; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CABRERA JA, 1986, J BIOL CHEM, V261, P3578; CHARLEBOIS RL, 1991, J MOL BIOL, V222, P509, DOI 10.1016/0022-2836(91)90493-P; CHARLEBOIS RL, 1987, P NATL ACAD SCI USA, V84, P8530, DOI 10.1073/pnas.84.23.8530; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DEROSA M, 1986, MICROBIOL REV, V50, P70, DOI 10.1128/MMBR.50.1.70-80.1986; DUGAN RE, 1986, BIOCHEM BIOPH RES CO, V141, P278, DOI 10.1016/S0006-291X(86)80365-5; GELIEBTER J, 1987, FOCUS, V9, P5; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GREENE JJ, 1988, CURRENT PROTOCOLS MO; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; LAM WL, 1989, P NATL ACAD SCI USA, V86, P5478, DOI 10.1073/pnas.86.14.5478; LAM WL, 1990, P NATL ACAD SCI USA, V87, P6614, DOI 10.1073/pnas.87.17.6614; LEARNED RM, 1989, P NATL ACAD SCI USA, V86, P2779, DOI 10.1073/pnas.86.8.2779; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; REITER WD, 1990, P NATL ACAD SCI USA, V87, P9509, DOI 10.1073/pnas.87.24.9509; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.ge.19.120185.002035; ROITELMAN J, 1989, J LIPID RES, V30, P97; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMM M, 1988, NUCLEIC ACIDS RES, V16, P151, DOI 10.1093/nar/16.1.151; WANG YL, 1990, J BIOL CHEM, V265, P21634; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; ZHOU D, 1991, BIOCHEM J, V273, P627, DOI 10.1042/bj2730627; ZILLIG W, 1988, EUR J BIOCHEM, V173, P473, DOI 10.1111/j.1432-1033.1988.tb14023.x	32	79	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5829	5834						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556098				2022-12-27	WOS:A1992HK31800020
J	MOSCOW, JA; MORROW, CS; HE, R; MULLENBACH, GT; COWAN, KH				MOSCOW, JA; MORROW, CS; HE, R; MULLENBACH, GT; COWAN, KH			STRUCTURE AND FUNCTION OF THE 5'-FLANKING SEQUENCE OF THE HUMAN CYTOSOLIC SELENIUM-DEPENDENT GLUTATHIONE-PEROXIDASE GENE (HGPX1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CDNA SEQUENCE; S-TRANSFERASE-PI; MESSENGER-RNA; BREAST-CANCER; BUTHIONINE SULFOXIMINE; NUCLEOTIDE-SEQUENCE; RAT-LIVER; TRANSCRIPTIONAL REGULATION; MULTIDRUG RESISTANCE; CELL-LINE	Human selenium-dependent glutathione peroxidase (hGPx1) (EC 1.11.1.9) is thought to be involved in many critical cellular functions as a result of its role in glutathione-mediated reduction of toxic peroxides, and it is implicated as a mechanism of resistance against oxygen free radicals. Previous studies have demonstrated that the gene encoding hGPx1 (hgpx1) is more highly expressed in multidrug-resistant AdrR MCF-7 human breast cancer cells than in the parental WT MCF-7 cell line. In order to further study the transcriptional regulation of hgpx1, we have cloned the genomic hgpx1 gene and determined its nucleotide sequence. The 2550-base pair (bp) 5'-flanking sequence of hgpx1 contained the terminal 511 bp of the 3' end of a previously reported rhoH12 cDNA (Yeramian, P., Chardin, P., Madaule, P., and Tavitian, A. (1987) Nucleic Acids Res. 15, 1989), a ras-related oncogene. Further downstream from rhoH12, but before the start of transcription of hgpx1, RNase protection analysis revealed a transcribed sequence of at least 270 bp which we have called mid. RNA transcripts homologous to both rhoH12 (1.8 and 1.5 kilobase pairs (kb)) and mid (1.8 kb) are also more highly expressed in AdrR MCF-7 cells than in WT MCF-7 cells. We screened an AdrR MCF-7 cDNA library with the mid sequence and isolated a partial cDNA clone which contains both mid and rhoH12 sequences and is colinear with the genomic sequence which extends from 10 bp 3' to the rhoH12 stop codon to 810 bp 5' to the start of transcription of hgpx1. The start of transcription of hgpx1 in AdrR MCF-7 cells was determined by primer extension analysis. The promoter and 2 kb of the 5'-flanking sequence of hgpx1 was fused to the bacterial chloramphenicol acetyltransferase gene (hGPx1-CAT1). Analysis of deletion constructs of hGPx1-CAT1 revealed three possible cis-acting regulatory regions. The transcriptional regulation of hgpx1 was examined using the hGPx1-CAT hybrid genes and nuclear run-on studies. We found no evidence that increased mRNA transcript formation could account for different levels of hgpx1 RNA either in different breast cancer cell lines or in response to selenium.	NCI,PEDIAT BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MOSCOW, JA (corresponding author), NCI,MED BRANCH,BLDG 10,RM 12N226,BETHESDA,MD 20892, USA.							AKASAKA M, 1990, NUCLEIC ACIDS RES, V18, P4619, DOI 10.1093/nar/18.15.4619; Ausubel FM., 1988, CURRENT PROTOCOLS MO; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AYKAC G, 1985, TOXICOLOGY, V36, P71, DOI 10.1016/0300-483X(85)90008-3; CANNIZZARO LA, 1990, GENOMICS, V6, P197, DOI 10.1016/0888-7543(90)90557-B; CAPEL ID, 1983, RES COMMUN CHEM PATH, V40, P367; CHADA S, 1990, GENOMICS, V6, P268, DOI 10.1016/0888-7543(90)90566-D; CHADA S, 1989, BLOOD, V74, P2535; CHAMBERS I, 1988, OXYRADICALS MOL BIOL, P289; CHU FF, 1990, NUCLEIC ACIDS RES, V18, P1531, DOI 10.1093/nar/18.6.1531; DUSRE L, 1989, CANCER RES, V49, P511; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; Flohe L., 1989, GLUTATHIONE CHEM BIO, P644; FRANK L, 1984, PEDIATR RES, V18, P240, DOI 10.1203/00006450-198403000-00004; GERDIN E, 1985, PEDIATR RES, V19, P687, DOI 10.1203/00006450-198507000-00010; HIETANEN E, 1985, TOXICOLOGY, V34, P103, DOI 10.1016/0300-483X(85)90160-X; HOWIE AF, 1989, BRIT J CANCER, V60, P834, DOI 10.1038/bjc.1989.375; IGARISHI T, 1985, J BIOCHEM-TOKYO, V9, P117; ISHIDA K, 1987, NUCLEIC ACIDS RES, V15, P10051, DOI 10.1093/nar/15.23.10051; JACKSON RM, 1984, AM REV RESPIR DIS, V129, P425; KRAMER RA, 1988, SCIENCE, V241, P694, DOI 10.1126/science.3399900; LI NQ, 1990, J BIOL CHEM, V265, P108; LOUIE KG, 1985, CANCER RES, V45, P2110; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACDONALD CM, 1973, FEBS LETT, V35, P227, DOI 10.1016/0014-5793(73)80291-1; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MAIORINO M, 1991, J BIOL CHEM, V266, P7728; MANNIRONI C, 1989, NUCLEIC ACIDS RES, V17, P9113, DOI 10.1093/nar/17.22.9113; MCBRIDE O W, 1988, Biofactors, V1, P285; MITCHELL JB, 1983, RADIAT RES, V96, P422, DOI 10.2307/3576226; MORANDI C, 1982, J MOL BIOL, V156, P583, DOI 10.1016/0022-2836(82)90268-6; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; MOSCOW JA, 1988, P NATL ACAD SCI USA, V85, P6518, DOI 10.1073/pnas.85.17.6518; MULLENBACH GT, 1987, NUCLEIC ACIDS RES, V15, P5484, DOI 10.1093/nar/15.13.5484; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; OSHAUGHNESSY J, 1991, MOL F ONCOLOGY, P319; PINTO RE, 1969, BIOCHEM J, V115, P449, DOI 10.1042/bj1150449; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; RIETJENS IMCM, 1985, TOXICOLOGY, V37, P205, DOI 10.1016/0300-483X(85)90083-6; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; SAEDI MS, 1988, BIOCHEM BIOPH RES CO, V153, P855, DOI 10.1016/S0006-291X(88)81174-4; SAMBROOK J, 1989, MOL CLONING LABORATO, P432; SCHRAMM H, 1985, BIOCHEM PHARMACOL, V34, P3735, DOI 10.1016/0006-2952(85)90239-4; SUKENAGA Y, 1987, NUCLEIC ACIDS RES, V15, P7178, DOI 10.1093/nar/15.17.7178; TAKAHASHI K, 1990, J BIOCHEM-TOKYO, V108, P145, DOI 10.1093/oxfordjournals.jbchem.a123172; TAKAHASHI K, 1986, J CLIN INVEST, V77, P1402, DOI 10.1172/JCI112449; TOWNSEND AJ, 1991, CANCER COMMUN, V3, P265, DOI 10.3727/095535491820873119; TOYODA H, 1989, BIOCHIM BIOPHYS ACTA, V1008, P301, DOI 10.1016/0167-4781(89)90020-1; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VICKERS PJ, 1988, MOL ENDOCRINOL, V2, P886, DOI 10.1210/mend-2-10-886; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; YOSHIMURA S, 1988, BIOCHEM BIOPH RES CO, V154, P1024, DOI 10.1016/0006-291X(88)90242-2	52	65	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5949	5958						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556108				2022-12-27	WOS:A1992HK31800039
J	MUGURUMA, M; MATSUMURA, S; FUKAZAWA, T				MUGURUMA, M; MATSUMURA, S; FUKAZAWA, T			AUGMENTATION OF ALPHA-ACTININ-INDUCED GELATION OF ACTIN BY TALIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; PROTEINS; MYOSIN	Interactions among the three major constituents of focal adhesions, talin, actin, and alpha-actinin, were studied. No evidence was obtained for the direct interaction between talin and alpha-actinin. Both talin and alpha-actinin increased the rate and extent of polymerization of actin, and their effects were additive. Whereas talin alone exhibited very little actin-gelating activity, it potentiated markedly the gelation in the presence of alpha-actinin and lowered the concentration of alpha-actinin necessary for the gel formation. Its gelation-potentiating activity on prepolymerized actin was much smaller than observed on G-actin. Treatment of talin with a cross-linking reagent, 1-ethyl-3[3-(dimethylamino)propyl] carbodiimide or dimethyl suberimidate, resulted in the formation of its oligomeric polypeptides. The complexes of talin and G-actin were also demonstrated with the cross-linking reagents and fluorescence-labeled actin. These results indicate that talin is able to cross-link some limited regions of actin filaments.	SAGA MED SCH,DEPT BIOCHEM,SAGA 849,JAPAN	Saga University	MUGURUMA, M (corresponding author), KYUSHU UNIV,FAC AGR,DEPT ANIM SCI,FUKUOKA 812,JAPAN.							BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HOZUMI T, 1983, BIOCHEMISTRY-US, V22, P799, DOI 10.1021/bi00273a014; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P416; MEYER RK, 1990, J CELL BIOL, V110, P2013, DOI 10.1083/jcb.110.6.2013; MOLONY L, 1987, J BIOL CHEM, V262, P7790; MUGURUMA M, 1990, BIOCHEM BIOPH RES CO, V171, P1217, DOI 10.1016/0006-291X(90)90815-5; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866	17	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5621	5624						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544936				2022-12-27	WOS:A1992HH74700092
J	PANYUTIN, IG; WELLS, RD				PANYUTIN, IG; WELLS, RD			NODULE DNA IN THE (GA)37(CT)37 INSERT IN SUPERHELICAL PLASMIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOPURINE-HOMOPYRIMIDINE SEQUENCES; INTRAMOLECULAR TRIPLEX FORMATION; B-Z JUNCTIONS; HANDED Z-DNA; H-DNA; SUPERCOILED PLASMIDS; SITE; VIRUS; TRANSITION; STABILITY	Di- or trivalent metal ions stabilize a supercoil-dependent transition in pGA37, which contains the (GA)37.(CT)37 insert, at neutral and basic pH. The structure formed is different from the well known protonated triplexes (H-DNA) adopted at low pH by polypurine.polypyrimidine (Pur.Pyr) inserts in plasmids. DNA samples must be preincubated in the presence of multivalent ions at 50-degrees-C for the new transition to occur. At neutral pH in the presence of Co hexamine, both strands of the insert have modification maxima situated at one-third of the distance from both ends. We propose the formation of a new structure called nodule DNA which consists of both Pyr.Pur.Pyr and Pur.Pur.Pyr triplexes and does not contain continuous single-stranded regions. At basic pH (> 8.5) in the presence of magnesium ions, the modification pattern corresponds to Pur.Pur.Pyr triplex formation in the whole insert. At neutral pH in the presence of magnesium, both nodule DNA and the Pur.Pur.Pyr triplex can be formed in the insert. We also observed a magnesium-dependent transition at neutral pH in the other Pur.Pyr insert containing plasmids. These data demonstrate that Pur.Pyr sequences can adopt several non-B conformations at close to in vivo conditions.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294; TEXAS A&M UNIV SYST,INST BIOSCI & TECHNOL,HOUSTON,TX 77030	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030822] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30822] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNUES J, 1989, EMBO J, V8, P2087, DOI 10.1002/j.1460-2075.1989.tb03617.x; BERNUES J, 1990, NUCLEIC ACIDS RES, V18, P4067, DOI 10.1093/nar/18.14.4067; BIANCHI A, 1990, J BIOL CHEM, V265, P21789; BROITMAN SL, 1987, P NATL ACAD SCI USA, V84, P5120, DOI 10.1073/pnas.84.15.5120; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; EVANS T, 1986, J BIOL CHEM, V261, P4771; GALAZKA G, 1986, J BIOL CHEM, V261, P7093; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P3781; HERR W, 1985, P NATL ACAD SCI USA, V82, P8009, DOI 10.1073/pnas.82.23.8009; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWI Y, 1989, NUCLEIC ACIDS RES, V17, P4493, DOI 10.1093/nar/17.12.4493; KOHWISHIGEMATSU T, 1991, NUCLEIC ACIDS RES, V19, P4267, DOI 10.1093/nar/19.15.4267; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; LYAMICHEV VI, 1985, J BIOMOL STRUCT DYN, V3, P327, DOI 10.1080/07391102.1985.10508420; Maniatis T., 1982, MOL CLONING; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MOCARSKI ES, 1981, P NATL ACAD SCI-BIOL, V78, P7047, DOI 10.1073/pnas.78.11.7047; PALECEK E, 1987, J BIOMOL STRUCT DYN, V5, P297, DOI 10.1080/07391102.1987.10506395; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PANYUTIN IG, 1989, NUCLEIC ACIDS RES, V17, P8257, DOI 10.1093/nar/17.20.8257; PANYUTIN IG, 1991, J BIOMOL STRUCT DYN, V8, P967, DOI 10.1080/07391102.1991.10507860; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; SHIMIZU M, 1990, BIOCHEMISTRY-US, V29, P4704, DOI 10.1021/bi00471a027; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; VLCEK C, 1990, VIROLOGY, V179, P365, DOI 10.1016/0042-6822(90)90304-A; WEINREB A, 1990, J BIOL CHEM, V265, P1352; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WOHLRAB F, 1987, J BIOL CHEM, V262, P6407; ZACHARIAS W, 1988, P NATL ACAD SCI USA, V85, P7069, DOI 10.1073/pnas.85.19.7069	38	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5495	5501						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544923				2022-12-27	WOS:A1992HH74700075
J	MAHLBERG, FH; ROTHBLAT, GH				MAHLBERG, FH; ROTHBLAT, GH			CELLULAR CHOLESTEROL EFFLUX - ROLE OF CELL-MEMBRANE KINETIC POOLS AND INTERACTION WITH APOLIPOPROTEIN-A-I, APOLIPOPROTEIN-AII, AND APOLIPOPROTEIN-CS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEIN; PLASMA-MEMBRANE; ADIPOSE-CELLS; EXCHANGE; FIBROBLASTS; METABOLISM; TRANSPORT; PROTEIN; FLUX; ESTERIFICATION	Efflux of [C-14]cholesterol from various cells was monitored in the presence of discoidal complexes of egg phosphatidylcholine and purified apolipoproteins, containing either apoAI, AII, or Cs. Particles containing apoAI were more efficient acceptors than those containing apoAII or Cs when the donor cells were J774 macrophages. No differences were observed when the same acceptor preparations were exposed to Fu5AH rat hepatoma or rabbit aortic smooth muscle cells. The differential efficiency of apolipoproteins in stimulating cholesterol removal from J774 cells was maintained in a plasma membrane-enriched fraction isolated from the same cells. Nonlinear regression analysis of kinetic data obtained from J774 cells exposed to apoAI complexes indicated that cholesterol efflux was best fitted to a curve describing the release from two kinetic compartments. Approximately 10% of cholesterol was transferred from a rapidly exchangeable pool with a t1/2 ranging between 1.5 and 3 h, and the remaining fraction was released from a slower pool with a t1/2 of about 20 h. Modulation of cholesterol efflux from J774 cells by either varying the concentration or the apolipoprotein composition of the acceptors influenced the size of the pools and the t1/2 of the slow pool. Kinetics of cholesterol efflux from membranes isolated from J774 cells also best fit a two-compartment model and modification of the apolipoprotein composition of the acceptor induced a pattern of changes in pool size and half-time similar to that described for whole cells. In the three cell lines studied, we consistently resolved a slow pool with a half-time ranging between 15 and 20 h. In smooth muscle cells only the slow pool was evident, whereas in Fu5AH a very large fast pool was also resolved. In contrast to J774 cells, apolipoprotein composition of the acceptor did not influence the pools in these two cell lines. These results led us to propose a new model regarding the influence of multiple kinetic pools of cholesterol on the regulation of cholesterol desorption from the cell membrane.	MED COLL PENN,DEPT PHYSIOL & BIOCHEM,PHILADELPHIA,PA 19129	Drexel University					NHLBI NIH HHS [HL 22633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIS PJG, 1972, SUBCELLULAR COMPONEN, P1; BAMBERGER M, 1983, J LIPID RES, V24, P869; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BELLINI F, 1984, BIOCHIM BIOPHYS ACTA, V777, P209, DOI 10.1016/0005-2736(84)90422-X; BIELICKI JK, 1991, BIOCHIM BIOPHYS ACTA, V1084, P7; BITTMAN R, 1989, BIOL CHOLESTEROL, P173; BLOJ B, 1982, J BIOL CHEM, V257, P7608; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BRUNETTE DM, 1971, J MEMBRANE BIOL, V5, P215, DOI 10.1007/BF01870550; CHACKO GK, 1988, J LIPID RES, V29, P319; CLEJAN S, 1984, J BIOL CHEM, V259, P441; DELAMATRE J, 1986, BIOCHIM BIOPHYS ACTA, V875, P419, DOI 10.1016/0005-2760(86)90061-5; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; HARA H, 1991, J BIOL CHEM, V266, P3080; JEFFERSON JR, 1991, J BIOL CHEM, V266, P5486; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1986, METHOD ENZYMOL, V128, P553; LETIZIA JY, 1991, BIOCHEMISTRY-US, V30, P866, DOI 10.1021/bi00217a041; MAHLBERG FH, 1991, J BIOL CHEM, V266, P19930; MAHLBERG FH, 1990, BIOCHIM BIOPHYS ACTA, V1045, P291, DOI 10.1016/0005-2760(90)90133-I; MAHLBERG FH, 1990, ATHEROSCLEROSIS, V84, P95, DOI 10.1016/0021-9150(90)90078-W; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MINOR LK, 1989, J LIPID RES, V30, P189; MINOR LK, 1991, EXP MOL PATHOL, V540, P159; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; NEMECZ G, 1988, BIOCHEMISTRY-US, V27, P7740, DOI 10.1021/bi00420a024; NEMECZ G, 1988, BIOCHIM BIOPHYS ACTA, V943, P511, DOI 10.1016/0005-2736(88)90384-7; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PICARDO M, 1986, ARTERIOSCLEROSIS, V6, P434, DOI 10.1161/01.ATV.6.4.434; REICHL D, 1989, ARTERIOSCLEROSIS, V9, P785, DOI 10.1161/01.ATV.9.6.785; Rothblat G H, 1986, Methods Enzymol, V129, P628; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; ROTHBLAT GH, 1978, J LIPID RES, V19, P350; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; VANHEUSDEN GPH, 1989, J LIPID RES, V30, P1357; WERB Z, 1972, J EXP MED, V135, P21, DOI 10.1084/jem.135.1.21	45	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4541	4550						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537840				2022-12-27	WOS:A1992HF64200042
J	MCMILLAN, DR; FAUST, C				MCMILLAN, DR; FAUST, C			THE EXPRESSION AND CHARACTERIZATION OF RAT IGE PRODUCED BY CONSTRUCTION OF THE EPSILON-HEAVY CHAIN GENE FROM EXON MODULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; IMMUNOGLOBULIN-E; MAST-CELLS; MONOCLONAL-ANTIBODIES; MAMMALIAN-CELLS; MESSENGER-RNAS; BINDING-SITE; MURINE IGE; INHIBITION; SEQUENCE	A system of exon "modules" was produced from the functionally rearranged epsilon-heavy gene isolated from the rat IgE-secreting immunocytoma IR162. The five individual exons, encoding the variable and constant region domains, were isolated and subcloned into the multiple cloning site of a pair of plasmid vectors with opposed orientation multiple cloning sites. The use of opposed orientation multiple cloning sites and the flanking restriction enzyme sites contained therein allows for the modular manipulation of the gene. These exon modules were initially used to reconstruct the epsilon-heavy chain gene into the native configuration to demonstrate the efficacy of the modular system for synthesis of IgE. Upon transfection into the rat myeloma cell line Y3, the reconstructed gene produced a polypeptide that associated with the endogenous light chain polypeptide and was secreted from the cell as tetrameric IgE. All physical and functional characterizations indicate that the IgE molecule produced is indistinguishable from native IR162 IgE. This modular system of exons will facilitate the manipulation of IgE structure through the systematic assembly of different epsilon-heavy chain mutant constructions. The resulting novel IgE proteins will be very useful to study the molecular nature of the interaction of IgE with its Fc receptor.			MCMILLAN, DR (corresponding author), TEXAS TECH UNIV,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,3601 4TH ST,LUBBOCK,TX 79430, USA.				NIAID NIH HHS [AI-23456] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023456] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAIRD B, 1989, INT ARCH ALLER A IMM, V88, P23, DOI 10.1159/000234742; BANIYASH M, 1986, J IMMUNOL, V136, P588; BANIYASH M, 1988, MOL IMMUNOL, V25, P705, DOI 10.1016/0161-5890(88)90106-X; BAZIN H, 1974, IMMUNOLOGY, V26, P713; BURT DS, 1987, MOL IMMUNOL, V24, P379, DOI 10.1016/0161-5890(87)90180-5; BURT DS, 1987, EUR J IMMUNOL, V17, P437, DOI 10.1002/eji.1830170323; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COLEMAN JW, 1985, EUR J IMMUNOL, V15, P966, DOI 10.1002/eji.1830150920; FAUST CH, 1979, BIOCHEMISTRY-US, V18, P1106, DOI 10.1021/bi00573a027; FAUST CH, 1981, J BIOL CHEM, V256, P2262; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GALFRE G, 1979, NATURE, V277, P131, DOI 10.1038/277131a0; GOUGH JA, 1983, J MOL BIOL, V166, P1, DOI 10.1016/S0022-2836(83)80047-3; GOULD HJ, 1987, INT ARCH ALLER A IMM, V82, P392, DOI 10.1159/000234235; HELLMAN L, 1982, NUCLEIC ACIDS RES, V10, P6041, DOI 10.1093/nar/10.19.6041; HELM B, 1989, P NATL ACAD SCI USA, V86, P9465, DOI 10.1073/pnas.86.23.9465; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; HENIKOFF S, 1984, GENE, V28, P352; HICKMAN S, 1977, J BIOL CHEM, V252, P4402; IKEYAMA S, 1987, MOL IMMUNOL, V24, P231; ISHIZAKA T, 1975, PROG ALLERGY, V19, P60, DOI 10.1159/000313384; KULCZYCKI A, 1974, J EXP MED, V139, P600, DOI 10.1084/jem.139.3.600; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laskey R A, 1980, Methods Enzymol, V65, P363; Maniatis T., 1982, MOL CLONING; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; PEREZMONTFORT R, 1982, MOL IMMUNOL, V19, P113; ROBERTSON MW, 1988, MOL IMMUNOL, V25, P103, DOI 10.1016/0161-5890(88)90057-0; ROUSSEAUXPREVOST R, 1987, MOL IMMUNOL, V24, P187, DOI 10.1016/0161-5890(87)90091-5; SCHWARZBAUM S, 1989, EUR J IMMUNOL, V19, P1015, DOI 10.1002/eji.1830190610; SOLNICK D, 1987, MOL CELL BIOL, V7, P3194, DOI 10.1128/MCB.7.9.3194; SOOD AK, 1986, J IMMUNOL METHODS, V95, P227, DOI 10.1016/0022-1759(86)90410-2; STEEN ML, 1984, J MOL BIOL, V177, P19, DOI 10.1016/0022-2836(84)90055-X; TIAN SS, 1987, MOL CELL BIOL, V7, P2614, DOI 10.1128/MCB.7.7.2614; WEETALL M, 1990, J IMMUNOL, V145, P3849; WIERINGA B, 1984, CELL, V37, P915, DOI 10.1016/0092-8674(84)90426-4	37	0	0	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4904	4910						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537868				2022-12-27	WOS:A1992HF64200091
J	TAIRA, K; HIROSE, J; HAYASHIDA, S; FURUKAWA, K				TAIRA, K; HIROSE, J; HAYASHIDA, S; FURUKAWA, K			ANALYSIS OF BPH OPERON FROM THE POLYCHLORINATED BIPHENYL-DEGRADING STRAIN OF PSEUDOMONAS-PSEUDOALCALIGENES KF707	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2,3-DIHYDROXYBIPHENYL DIOXYGENASE GENE; MULTICOMPONENT PHENOL HYDROXYLASE; PHOSPHOROTHIOATE-MODIFIED DNA; COMPLETE NUCLEOTIDE-SEQUENCE; IRON-SULFUR PROTEIN; TOLUENE DIOXYGENASE; ENCODING BIPHENYL; PUTIDA F1; TRANSCRIPTION TERMINATION; ABSOLUTE STEREOCHEMISTRY	The entire nucleotide sequences (6.8 kilobase pairs) of the bphABC genes and their products involved in the initial dioxygenation and ring-meta-cleavage of biphenyls and polychlorinated biphenyls were determined. The first bphA gene starts about a 100 base pairs downstream from the transcriptional initiation site. The bphA region, which encodes a cluster of enzymes including biphenyl dioxygenase catalyzing the initial catabolic step, consists of five open reading frames (ORFs). Five proteins corresponding to these ORFs in the molecular masses were detected by in vitro protein synthesis, of which four ORFs are very similar to the recently reported todC1C2BA genes coding for the corresponding enzymes catalyzing the initial dioxygenation reactions of toluene (Zylstra, G. J., and Gibson, D. T. (1989) J. Biol. Chem. 264, 14940-14946). The third open reading frame (ORF3) of the bphA region, missing its counterpart in the toluene dioxygenase gene cluster, was site-specifically deleted, and the resulting enzymatically active mutant reveals that this ORF3 is not mandatory for the catabolism of biphenyls. Thus the biphenyl degradation pathway and the responsible enzymes/genes are very similar to those of toluene degradation despite their discrete substrate specificity.	MINIST INT TRADE & IND, AGCY IND SCI & TECHNOL, FERMENTAT RES INST, TSUKUBA 305, JAPAN; KYUSHU UNIV, FAC AGR, DEPT AGR CHEM, FUKUOKA 812, JAPAN	National Institute of Advanced Industrial Science & Technology (AIST); Kyushu University								ADHYA S, 1978, ANNU REV BIOCHEM, V47, P967, DOI 10.1146/annurev.bi.47.070178.004535; AHMED M, 1973, CAN J MICROBIOL, V19, P47, DOI 10.1139/m73-007; BEDAERD DL, 1984, 1983 P PCB SEM; BEDARD DL, 1987, APPL ENVIRON MICROB, V53, P1094, DOI 10.1128/AEM.53.5.1094-1102.1987; BEDARD DL, 1986, APPL ENVIRON MICROB, V51, P761, DOI 10.1128/AEM.51.4.761-768.1986; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BROWN NL, 1983, BIOCHEMISTRY-US, V22, P4089, DOI 10.1021/bi00286a015; DERETIC V, 1987, BIO-TECHNOL, V5, P469, DOI 10.1038/nbt0587-469; FEE JA, 1984, J BIOL CHEM, V259, P124; FURUKAWA K, 1987, J BACTERIOL, V169, P427, DOI 10.1128/jb.169.1.427-429.1987; FURUKAWA K, 1991, GENE, V98, P21; FURUKAWA K, 1982, APPL ENVIRON MICROB, V44, P619, DOI 10.1128/AEM.44.3.619-626.1982; FURUKAWA K, 1986, J BACTERIOL, V166, P392, DOI 10.1128/jb.166.2.392-398.1986; FURUKAWA K, 1978, AGR BIOL CHEM TOKYO, V42, P543, DOI 10.1080/00021369.1978.10863017; FURUKAWA K, 1983, J BACTERIOL, V154, P1356, DOI 10.1128/JB.154.3.1356-1362.1983; FURUKAWA K, 1989, J BACTERIOL, V171, P5467, DOI 10.1128/jb.171.10.5467-5472.1989; FURUKAWA K, 1982, BIODEGRADATION DETOX, P33; GIBSON DT, 1970, BIOCHEMISTRY-US, V9, P1626, DOI 10.1021/bi00809a023; GIBSON DT, 1970, BIOCHEMISTRY-US, V9, P1631, DOI 10.1021/bi00809a024; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; HAIGLER BE, 1990, J BACTERIOL, V172, P457, DOI 10.1128/JB.172.1.457-464.1990; HAIGLER BE, 1990, J BACTERIOL, V172, P465, DOI 10.1128/JB.172.1.465-468.1990; HAYASE N, 1990, J BACTERIOL, V172, P1160, DOI 10.1128/jb.172.2.1160-1164.1990; IRIE S, 1987, J BACTERIOL, V169, P5174, DOI 10.1128/jb.169.11.5174-5179.1987; KIMBARA K, 1989, J BACTERIOL, V171, P2740, DOI 10.1128/jb.171.5.2740-2747.1989; KOBAL VM, 1973, J AM CHEM SOC, V95, P4420, DOI 10.1021/ja00794a048; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; NAKAI C, 1983, J BIOL CHEM, V258, P2923; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NORDLUND I, 1990, J BACTERIOL, V172, P6826, DOI 10.1128/jb.172.12.6826-6833.1990; NORMORE MW, 1976, HDB BIOCH MOL BIOL, P65; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; POWLOWSKI J, 1990, J BACTERIOL, V172, P6834, DOI 10.1128/jb.172.12.6834-6840.1990; ROGERS JE, 1977, J BACTERIOL, V130, P1117, DOI 10.1128/JB.130.3.1117-1124.1977; RUISINGER S, 1976, ARCH MICROBIOL, V110, P253, DOI 10.1007/BF00690235; SUBRAMANIAN V, 1981, J BIOL CHEM, V256, P2723; SUBRAMANIAN V, 1979, BIOCHEM BIOPH RES CO, V91, P1131, DOI 10.1016/0006-291X(79)91998-3; SUBRAMANIAN V, 1985, J BIOL CHEM, V260, P2355; TAIRA K, 1988, BIOCHEMISTRY-US, V27, P3990, DOI 10.1021/bi00411a015; TAIRA K, 1990, ANN M JAPANNESE SOC, P496; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TSANG HT, 1989, BIOCHEMISTRY-US, V28, P7233, DOI 10.1021/bi00444a015; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YAGI O, 1980, J WATER POLLUT CON F, V52, P1035; YEH WK, 1977, BIOCHEM BIOPH RES CO, V78, P401, DOI 10.1016/0006-291X(77)91268-2; ZIFFER H, 1973, J AM CHEM SOC, V95, P4048, DOI 10.1021/ja00793a036; ZYLSTRA GJ, 1988, APPL ENVIRON MICROB, V54, P1498, DOI 10.1128/AEM.54.6.1498-1503.1988; ZYLSTRA GJ, 1989, J BIOL CHEM, V264, P14940	50	247	255	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4844	4853						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537863				2022-12-27	WOS:A1992HF64200083
J	MASSIA, SP; HUBBELL, JA				MASSIA, SP; HUBBELL, JA			IMMOBILIZED AMINES AND BASIC-AMINO-ACIDS AS MIMETIC HEPARIN-BINDING DOMAINS FOR CELL-SURFACE PROTEOGLYCAN-MEDIATED ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; SUBSTRATUM ADHESION; DISSOCIATED NEURONS; FIBRONECTIN; FIBROBLASTS; RECEPTORS; INTEGRINS; ATTACHMENT; MOLECULES; FRAGMENTS	Diamines covalently coupled to glass substrates promoted human foreskin fibroblast adhesion in the absence of serum. These diamine-derivatized substrates were produced by coupling ethylene diamine, N-methylaminoethylamine, and N,N-dimethylaminoethylamine (NNDMAEA), to sulfonyl chloride-activated glass. Electron spectroscopy for chemical analysis demonstrated that the diamines were coupled via their primary amine ends to produce a surface-bound secondary amine linked to a free amino moiety via a two-carbon spacer. NNDMAEA-modified substrates containing free tertiary amines supported the highest degree of cell spreading (73 +/- 7% actively spreading cells) and the most extensive cytoskeletal organization. Both the free tertiary and surface-bound secondary amines were shown to be required for cell spreading. Lysine- and arginine-grafted substrates supported cell spreading and cytoskeletal organization similar to that on NNDMAEA-modified substrates. Although some stress fibers were observed within spread cells on these substrates, focal contacts did not form. Heparinase treatment did not inhibit cell attachment or spreading to the diamine-derivatized substrates, however chondroitinase ABC inhibited cell attachment and spreading on all substrates; heparinase inhibited spreading on lysine- and arginine-derivatized substrates to a lesser extent. These results imply that cell attachment to these substrates was mediated primarily by cell surface chondroitin sulfate proteoglycans. This study demonstrates that covalently grafted NNDMAEA, lysine, and arginine can mimic the adhesion-promoting activity of the glycosaminoglycan-binding domains of cell adhesion proteins. This study also demonstrates that the interaction with these proteoglycans depends in a very sensitive manner on the particular structure of the immobilized amine.	UNIV TEXAS,DEPT CHEM ENGN,AUSTIN,TX 78712; UNIV TEXAS,DEPT BIOL SCI,AUSTIN,TX 78712	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin			Hubbell, Jeffrey A/A-9266-2008	Hubbell, Jeffrey A/0000-0003-0276-5456				ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BRUNS RR, 1980, EXP CELL RES, V128, P1, DOI 10.1016/0014-4827(80)90379-1; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; COSTELLO CA, 1987, MACROMOLECULES, V20, P2819, DOI 10.1021/ma00177a030; CULP LA, 1979, J SUPRAMOL STR CELL, V11, P401, DOI 10.1002/jss.400110314; CULP LA, 1978, J CELL BIOL, V78, P788; HAUGEN PK, 1990, J CELL BIOL, V111, P2733, DOI 10.1083/jcb.111.6.2733; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IZZARD CS, 1986, EXP CELL RES, V165, P320, DOI 10.1016/0014-4827(86)90586-0; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JULIANO RL, 1987, BIOCHIM BIOPHYS ACTA, V907, P261, DOI 10.1016/0304-419X(87)90009-6; KLEINFELD D, 1988, J NEUROSCI, V8, P4098; KOUZIKOLIAKOS K, 1989, J BIOL CHEM, V264, P17971; LARK MW, 1985, FED PROC, V44, P394; LATERRA J, 1983, J CELL BIOL, V96, P112, DOI 10.1083/jcb.96.1.112; LATERRA J, 1983, EXP CELL RES, V146, P15, DOI 10.1016/0014-4827(83)90320-8; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LETOURNEAU PC, 1975, DEV BIOL, V44, P77, DOI 10.1016/0012-1606(75)90378-4; MASSIA SP, 1990, ANAL BIOCHEM, V187, P292, DOI 10.1016/0003-2697(90)90459-M; MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; MCKEEHAN WL, 1976, J CELL BIOL, V71, P727, DOI 10.1083/jcb.71.3.727; NILSSON K, 1981, BIOCHEM BIOPH RES CO, V102, P449, DOI 10.1016/0006-291X(81)91541-2; PIEPKORN MW, 1985, LAB INVEST, V53, P22; RATNR BD, 1987, J BIOMED MATER RES-A, V21, P59; RUEGG UT, 1984, NEUROSCI LETT, V49, P319, DOI 10.1016/0304-3940(84)90309-4; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; YAVIN E, 1974, J CELL BIOL, V62, P540, DOI 10.1083/jcb.62.2.540	37	83	92	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10133	10141						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577783				2022-12-27	WOS:A1992HT96500103
J	RODRIGUEZAPARICIO, LB; LUENGO, JM; GONZALEZCLEMENTE, C; REGLERO, A				RODRIGUEZAPARICIO, LB; LUENGO, JM; GONZALEZCLEMENTE, C; REGLERO, A			PURIFICATION AND CHARACTERIZATION OF THE NUCLEAR CYTIDINE 5'-MONOPHOSPHATE N-ACETYLNEURAMINIC ACID SYNTHETASE FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 2-ACETYLAMINOFLUORENE-INDUCED HEPATOCARCINOGENESIS; SIALOGLYCOCONJUGATE CHANGES; COLOMINIC ACID; BIOSYNTHESIS; METABOLISM; GLUTAMATE; LOCATION; BINDING	N-Acetylneuraminic acid cytidylyltransferase (EC 2.7.7.43) (CMP-NeuAc synthetase) from rat liver catalyzes the formation of cytidine monophosphate N-acetylneuraminic acid from CTP and NeuAc. We have purified this enzyme to apparent homogeneity (241-fold) using gel filtration on Sephacryl S-200 and two types of affinity chromatographies (Reactive Brown-10 Agarose and Blue Sepharose CL-6B columns). The pure enzyme, whose amino acid composition and NH2-terminal amino acid sequence are also established, migrates as a single protein band on non-denaturing polyacrylamide gel electrophoresis. The molecular mass of the native enzyme, estimated by gel filtration, was 116 +/- 2 kDa whereas its M(r) in sodium dodecyl sulfate-polyacrylamide gel electrophoresis was 58 +/- 1 kDa. CMP-NeuAc synthetase requires Mg2+ for catalysis although this ion can be replaced by Mn2+, Ca2+, or Co2+. The optimal pH was 8.0 in the presence of 10 mM Mg2+ and 5 mm dithiothreitol. The apparent K(m) for CTP and NeuAc are 1.5 and 1.3 mM, respectively. The enzyme also converts N-glycolylneuraminic acid to its corresponding CMP-sialic acid (K(m), 2.6 mM), whereas CMP-NeuAc, high CTP concentrations, and other nucleotides (CDP, CMP, ATP, UTP, GTP, and TTP) inhibited the enzyme to different extents.	UNIV LEON,DEPT BIOQUIM & BIOL MOLEC,E-24007 LEON,SPAIN	Universidad de Leon			Luengo, Jose M./E-1935-2016	Luengo, Jose M./0000-0002-4984-6256; Rodriguez-Aparicio, Leandro B./0000-0002-0372-2055				BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BLACKLOW RS, 1962, J BIOL CHEM, V237, P3520; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COATES SW, 1980, J BIOL CHEM, V255, P9225; Corfield A. P., 1982, CELL BIOL MONOGR, V10, P195; CORFIELD AP, 1985, BIOCHEM J, V226, P163, DOI 10.1042/bj2260163; CREEK KE, 1984, BIOCHIM BIOPHYS ACTA, V793, P133, DOI 10.1016/0005-2760(84)90314-X; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; ELLIOTT WL, 1984, BIOCHIM BIOPHYS ACTA, V800, P194, DOI 10.1016/0304-4165(84)90060-6; ELLIS DB, 1972, BIOCHIM BIOPHYS ACTA, V289, P108, DOI 10.1016/0005-2744(72)90113-1; GIELEN W, 1974, H-S Z PHYSIOL CHEM, V355, P895, DOI 10.1515/bchm2.1974.355.2.895; GONZALEZCLEMENTE C, 1989, FEBS LETT, V250, P429, DOI 10.1016/0014-5793(89)80770-7; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIGA HH, 1985, J BIOL CHEM, V260, P8838; KEAN EL, 1970, J BIOL CHEM, V245, P2301; KEAN EL, 1966, J BIOL CHEM, V241, P5643; KIRSCHBAUM BB, 1974, CHEM-BIOL INTERACT, V8, P207, DOI 10.1016/0009-2797(74)90029-5; KISHORE GS, 1981, CANCER LETT, V13, P281, DOI 10.1016/0304-3835(81)90055-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McGuire E. J., 1976, BIOL ROLES SIALIC AC, P123; OZTURK DH, 1990, BIOCHEMISTRY-US, V29, P7112, DOI 10.1021/bi00482a024; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PEREZ M, 1982, FED PROC, V41, P662; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; RODRIGUEZAPARICIO LB, 1988, APPL MICROBIOL BIOT, V27, P474, DOI 10.1007/BF00451616; SCHAUER R, 1980, H-S Z PHYSIOL CHEM, V361, P641, DOI 10.1515/bchm2.1980.361.1.641; SCHAUER R, 1972, H-S Z PHYSIOL CHEM, V353, P883, DOI 10.1515/bchm2.1972.353.1.883; SHAILUBHAI K, 1990, J BIOL CHEM, V265, P14105; SLAMA JT, 1991, BIOCHEMISTRY-US, V30, P2527, DOI 10.1021/bi00223a033; Tuppy H., 1972, GLYCOPROTEINS THEIR, P403; VANDENEIJNDEN DH, 1973, J NEUROCHEM, V21, P949, DOI 10.1111/j.1471-4159.1973.tb07539.x; VANDENEIJNDEN DH, 1972, H-S Z PHYSIOL CHEM, V353, P1817, DOI 10.1515/bchm2.1972.353.2.1817; VANN WF, 1987, J BIOL CHEM, V262, P17556; VIMR ER, 1985, J BACTERIOL, V164, P854, DOI 10.1128/JB.164.2.854-860.1985; WARREN L, 1962, J BIOL CHEM, V237, P3527; ZAPATA G, 1989, J BIOL CHEM, V264, P14769	36	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9257	9263						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577759				2022-12-27	WOS:A1992HR85400084
J	USHA, R; SAVITHRI, HS; RAO, NA				USHA, R; SAVITHRI, HS; RAO, NA			ARGININE RESIDUES INVOLVED IN BINDING OF TETRAHYDROFOLATE TO SHEEP LIVER SERINE HYDROXYMETHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT LIVER; ESCHERICHIA-COLI; ACTIVE-SITE; SEQUENCE; ACID; IDENTIFICATION; MECHANISM	The arginine residue(s) necessary for tetrahydrofolate binding to sheep liver serine hydroxymethyltransferase were located by phenylglyoxal modification. The incorporation of [7-C-14]phenylglyoxal indicated that 2 arginine residues were modified per subunit of the enzyme and the modification of these residues was prevented by tetrahydrofolate. In order to locate the sites of phenylglyoxal modification, the enzyme was reacted in the presence and absence of tetrahydrofolate using unlabeled and radioactive phenylglyoxal, respectively. The labeled phenylglyoxal-treated enzyme was digested with trypsin, and the radiolabeled peptides were purified by high-performance liquid chromatography on reversed-phase columns. Sequencing the tryptic peptides indicated that Arg-269 and Arg-462 were the sites of phenylglyoxal modification. Neither a spectrally discernible 495-nm intermediate (characteristic of the native enzyme when substrates are added) nor its enhancement by the addition of tetrahydrofolate, was observed with the phenylglyoxal-modified enzyme. There was no enhancement of the rate of the exchange of the alpha-proton of glycine upon addition of tetrahydrofolate to the modified enzyme as was observed with the native enzyme. These results demonstrate the requirement of specific arginine residues for the interaction of tetrahydrofolate with sheep liver serine hydroxymethyltransferase.	INDIAN INST SCI,DEPT BIOCHEM,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore								ACHARYA JK, 1991, INDIAN J BIOCHEM BIO, V28, P381; BASKARAN N, 1989, BIOCHEMISTRY-US, V28, P9613, DOI 10.1021/bi00451a010; BASKARAN N, 1989, BIOCHEMISTRY-US, V28, P9607, DOI 10.1021/bi00451a009; CHANG JY, 1978, FEBS LETT, V93, P205, DOI 10.1016/0014-5793(78)81105-3; CHEN MS, 1973, J BIOL CHEM, V248, P3631; CHOI JD, 1981, BIOCHEMISTRY-US, V20, P5722, DOI 10.1021/bi00523a014; HATEFI Y, 1960, BIOCHEM PREP, V7, P89; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; JORDAN PM, 1970, BIOCHEM J, V116, P277, DOI 10.1042/bj1160277; KAZARINOFF MN, 1977, J BIOL CHEM, V252, P7598; KAZARINOFF MN, 1976, J BIOL CHEM, V251, P6179; MALEY GF, 1980, ARCH BIOCHEM BIOPHYS, V216, P551; MANOHAR R, 1984, BIOCHEM J, V224, P703, DOI 10.1042/bj2240703; MARTINI F, 1987, J BIOL CHEM, V262, P5499; MARTINI F, 1989, J BIOL CHEM, V264, P8509; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; PALEKAR AG, 1973, J BIOL CHEM, V248, P1158; PLAMANN MD, 1983, NUCLEIC ACIDS RES, V11, P2065, DOI 10.1093/nar/11.7.2065; RAO DN, 1983, INDIAN J BIOCHEM BIO, V20, P362; RUNSWICK MJ, 1983, J BIOL CHEM, V258, P3081; SCHIRCH L, 1964, J BIOL CHEM, V239, P3801; SCHIRCH L, 1982, ADV ENZYMOL RAMB, V53, P83; SCHIRCH L, 1984, FOLATES PTERINS, V1, P135; SNELL K, 1984, ADV ENZYME REGUL, V22, P325, DOI 10.1016/0065-2571(84)90021-9; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; THOMPSON PD, 1991, BIOCHEMISTRY-US, V30, P8124, DOI 10.1021/bi00247a005; VIJAYALAKSHMI D, 1989, BIOCHEM INT, V19, P625	27	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9289	9293						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577761				2022-12-27	WOS:A1992HR85400089
J	ALONSO, WR; RAJAONARIVONY, JIM; GERSHENZON, J; CROTEAU, R				ALONSO, WR; RAJAONARIVONY, JIM; GERSHENZON, J; CROTEAU, R			PURIFICATION OF 4S-LIMONENE SYNTHASE, A MONOTERPENE CYCLASE FROM THE GLANDULAR TRICHOMES OF PEPPERMINT (MENTHA-X-PIPERITA) AND SPEARMINT (MENTHA-SPICATA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SAGE SALVIA-OFFICINALIS; SESQUITERPENE CYCLASE; KAURENE SYNTHETASE; CASBENE SYNTHETASE; MARAH-MACROCARPUS; BIOSYNTHESIS; PYROPHOSPHATE; PROTEINS; ENZYMES; CONVERSION	The p- menthane monoterpenes of the Mentha species are biosynthesized from geranyl pyrophosphate via the monocyclic olefin 4S-limonene. A monoterpene cyclase was isolated from both Mentha x piperita (peppermint) and Mentha spicata (spearmint) that catalyzes the cyclization of geranyl pyrophosphate to 4S-limonene. This enzyme, 4S-limonene synthase, was purified to apparent homogeneity by dye ligand, anion exchange, and hydrophobic interaction chromatography. Since the monoterpenes of Mentha are synthesized and secreted in modified epidermal hairs called glandular trichomes, an extract of isolated glandular trichome cells was used as the source of this enzyme. A combination of gel permeation chromatography and sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed that purified 4S-limonene synthase had a native molecular weight of 56,000 and was monomeric. The principal product of the enzyme was enantiomerically pure (-)-4S-limonene, and a catalytic constant of 0.3/s was determined. The basic properties of 4S-limonene synthase from both M. x piperita and M. spicata are identical and, in general, are similar to those of other monoterpene, sesquiterpene, and diterpene cyclases isolated from microorganisms and higher plants.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA	Washington State University			Gershenzon, Jonathan/K-1331-2013	Gershenzon, Jonathan/0000-0002-1812-1551	NIGMS NIH HHS [GM-31354] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031354, R01GM031354] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO WR, 1991, ARCH BIOCHEM BIOPHYS, V286, P511, DOI 10.1016/0003-9861(91)90073-R; ALONSO WR, 1992, IN PRESS METHODS PLA, V9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANE DE, 1990, CHEM REV, V90, P1089, DOI 10.1021/cr00105a002; CANE DE, 1987, ARCH BIOCHEM BIOPHYS, V254, P421, DOI 10.1016/0003-9861(87)90120-2; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; CROTEAU R, 1981, PLANT PHYSIOL, V67, P820, DOI 10.1104/pp.67.4.820; CROTEAU R, 1976, ARCH BIOCHEM BIOPHYS, V176, P734, DOI 10.1016/0003-9861(76)90217-4; CROTEAU R, 1985, METHOD ENZYMOL, V110, P383; CROTEAU R, 1986, BIOGENERATION AROMAS, P134; DAUBEN WG, 1969, J ORG CHEM, V34, P3587, DOI 10.1021/jo01263a079; DEHAL SS, 1988, ARCH BIOCHEM BIOPHYS, V261, P346, DOI 10.1016/0003-9861(88)90350-5; DUEBER MT, 1978, PLANT PHYSIOL, V62, P598, DOI 10.1104/pp.62.4.598; DUNCAN JD, 1981, PLANT PHYSIOL, V68, P1128, DOI 10.1104/pp.68.5.1128; Fahn A., 1979, SECRETORY TISSUES PL; FROST RG, 1977, PLANT PHYSIOL, V59, P22, DOI 10.1104/pp.59.1.22; GAMBLIEL H, 1984, J BIOL CHEM, V259, P740; GERSHENZON J, 1990, RECENT ADV PHYTOCHEM, V24, P99; GERSHENZON J, 1987, ANAL BIOCHEM, V163, P159, DOI 10.1016/0003-2697(87)90106-0; GERSHENZON J, 1992, ANAL BIOCHEM, V200, P130, DOI 10.1016/0003-2697(92)90288-I; GERSHENZON J, 1989, PLANT PHYSIOL, V89, P1351, DOI 10.1104/pp.89.4.1351; GERSHENZON J, 1991, RECENT ADV PHYTOCHEM, V25, P347; GIJZEN M, 1991, ARCH BIOCHEM BIOPHYS, V289, P267, DOI 10.1016/0003-9861(91)90471-T; HOHN TM, 1986, ARCH BIOCHEM BIOPHYS, V251, P756, DOI 10.1016/0003-9861(86)90386-3; HOHN TM, 1989, ARCH BIOCHEM BIOPHYS, V272, P137, DOI 10.1016/0003-9861(89)90204-X; JOVIN TM, 1973, BIOCHEMISTRY-US, V12, P871, DOI 10.1021/bi00729a014; KARP F, 1990, ARCH BIOCHEM BIOPHYS, V276, P219, DOI 10.1016/0003-9861(90)90029-X; KJONAAS R, 1983, ARCH BIOCHEM BIOPHYS, V220, P79, DOI 10.1016/0003-9861(83)90389-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanznaster N, 1991, Protein Expr Purif, V2, P69, DOI 10.1016/1046-5928(91)90013-9; LOOMIS WD, 1979, PHYTOCHEMISTRY, V18, P1049, DOI 10.1016/S0031-9422(00)91475-4; MOESTA P, 1985, ARCH BIOCHEM BIOPHYS, V238, P325, DOI 10.1016/0003-9861(85)90171-7; MOOS M, 1988, J BIOL CHEM, V263, P6005; MUNCK SL, 1990, ARCH BIOCHEM BIOPHYS, V282, P58, DOI 10.1016/0003-9861(90)90086-E; RATCLIFF.R, 1970, J ORG CHEM, V35, P4000, DOI 10.1021/jo00836a108; SATTERWHITE DM, 1988, J CHROMATOGR, V452, P61, DOI 10.1016/S0021-9673(01)81437-0; SCHURIG V, 1990, NATURWISSENSCHAFTEN, V77, P133, DOI 10.1007/BF01134476; SCHURIG V, 1990, ANGEW CHEM INT EDIT, V29, P939, DOI 10.1002/anie.199009393; VOGELI U, 1990, PLANT PHYSIOL, V93, P182, DOI 10.1104/pp.93.1.182; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	40	100	113	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7582	7587						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559995				2022-12-27	WOS:A1992HN48500056
J	LACKMANN, M; CORNISH, CJ; SIMPSON, RJ; MORITZ, RL; GECZY, CL				LACKMANN, M; CORNISH, CJ; SIMPSON, RJ; MORITZ, RL; GECZY, CL			PURIFICATION AND STRUCTURAL-ANALYSIS OF A MURINE CHEMOTACTIC CYTOKINE (CP-10) WITH SEQUENCE HOMOLOGY TO S100 PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CALCIUM-BINDING PROTEINS; NEUTROPHIL-ACTIVATING PROTEIN; PROCOAGULANT-INDUCING FACTOR; TUMOR NECROSIS FACTOR; BOVINE BRAIN; CYSTIC-FIBROSIS; AFFINITY-CHROMATOGRAPHY; CELL-DIFFERENTIATION; MODULATED PROTEINS	In delayed-type hypersensitivity reactions, cytokine-mediated cell migration leads to localized accumulation of neutrophils and mononuclear cells over 4-48 h. In contrast to transient (2-6 h) responses elicited by other chemotactic factors, earlier studies indicated that a chemotactic activity previously described in our laboratory elicited skin test responses over 24 h, identical to those induced by injection of antigen into a sensitized test subject. We have isolated this factor, a 10.3-kDa chemotactic protein designated CP-10, from supernatants of activated murine spleen cells. Purification to homogeneity was achieved using affinity chromatography on iminodiacetic acid-immobilized copper and cation-exchange, mixed mode (cation exchange/metal affinity), reversed-phase, and size-exclusion high performance liquid chromatography. CP-10 had maximal chemotactic activity for neutrophils at 10(-13) M. The 76-amino acid sequence, obtained by automated N-terminal microsequence analysis of native CP-10, and fragments derived from trypsin digestion and cyanogen bromide cleavage indicated no sequence identity with any known cytokine or chemotactic factor but revealed up to 55% sequence homology with S100, Ca2+-binding proteins. CP-10 appears to be the first protein of this family with a well defined function affecting cell migration, and its biological potency suggests an important role for this cytokine in cellular immune reactions.	LUDWIG INST CANC RES,JOINT PROT STRUCT LAB,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute	LACKMANN, M (corresponding author), HEART RES INST,145 MISSENDEN RD,CAMPERDOWN,NSW 2050,AUSTRALIA.		Moritz, Robert L/B-9222-2011	Simpson, Richard/0000-0002-9834-0796				AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BAUDIER J, 1989, BIOCHEM J, V264, P79, DOI 10.1042/bj2640079; BAUDIER J, 1982, FEBS LETT, V147, P164; BEGG GS, 1989, TECHNIQUES PROTEIN C, P79; BENNETT B, 1968, P NATL ACAD SCI USA, V59, P756, DOI 10.1073/pnas.59.3.756; COHEN S, 1973, CELL IMMUNOL, V9, P363, DOI 10.1016/0008-8749(73)90051-8; DELOULME JC, 1989, ADV EXP MD BIOL, V269, P153; DEUEL TF, 1981, P NATL ACAD SCI-BIOL, V78, P4584, DOI 10.1073/pnas.78.7.4584; DORIN JR, 1987, NATURE, V326, P614, DOI 10.1038/326614a0; DUNN R, 1987, J BIOL CHEM, V262, P3562; FERNANDEZ HN, 1978, J IMMUNOL, V120, P109; GECZY CL, 1984, SPRINGER SEMIN IMMUN, V7, P321; GECZY CL, 1975, CELL IMMUNOL, V19, P65, DOI 10.1016/0008-8749(75)90292-0; HEIZMANN CW, 1988, J CARDIOVASC PHARM, V12, pS30; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEE TH, 1988, CLIN SCI, V74, P467, DOI 10.1042/cs0740467; MING WJ, 1987, J IMMUNOL, V138, P1469; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; POSTLETHWAITE AE, 1979, J IMMUNOL, V123, P561; RYAN J, 1988, J IMMUNOL, V141, P2110; RYAN J, 1987, IMMUNOL CELL BIOL, V65, P127, DOI 10.1038/icb.1987.14; RYAN J, 1986, J IMMUNOL, V137, P2864; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SIMPSON RJ, 1988, EUR J BIOCHEM, V175, P541, DOI 10.1111/j.1432-1033.1988.tb14226.x; SIMPSON RJ, 1989, EUR J BIOCHEM, V183, P715, DOI 10.1111/j.1432-1033.1989.tb21103.x; SIMPSON RJ, 1988, EUR J BIOCHEM, V176, P187, DOI 10.1111/j.1432-1033.1988.tb14267.x; SOHNLE PG, 1991, J INFECT DIS, V163, P187, DOI 10.1093/infdis/163.1.187; SWERGOLD GD, 1983, ANAL BIOCHEM, V131, P295, DOI 10.1016/0003-2697(83)90173-2; VANHEYNINGEN V, 1990, ADV EXP MED BIOL, V269, P139; VANHEYNINGEN V, 1985, NATURE, V315, P513, DOI 10.1038/315513a0; WARD PA, 1969, SCIENCE, V163, P1079, DOI 10.1126/science.163.3871.1079; WILKINSON MM, 1988, J CELL SCI, V91, P221; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; YANCEY KB, 1989, J INVEST DERMATOL, V92, P184, DOI 10.1111/1523-1747.ep12276710; YIP TT, 1989, ANAL BIOCHEM, V183, P159, DOI 10.1016/0003-2697(89)90184-X; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1987, J IMMUNOL, V139, P788; ZIMMER DB, 1989, J CELL BIOL, V108, P141, DOI 10.1083/jcb.108.1.141; ZWADLO G, 1988, CLIN EXP IMMUNOL, V72, P510	51	98	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7499	7504						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559987				2022-12-27	WOS:A1992HN48500045
J	WU, GD; WANG, W; TRABER, PG				WU, GD; WANG, W; TRABER, PG			ISOLATION AND CHARACTERIZATION OF THE HUMAN SUCRASE-ISOMALTASE GENE AND DEMONSTRATION OF INTESTINE-SPECIFIC TRANSCRIPTIONAL ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL TYPES; MOUSE SMALL INTESTINE; POLYMERASE CHAIN-REACTION; ENHANCER-BINDING-PROTEIN; MESSENGER-RNA; ALKALINE-PHOSPHATASE; TRANSGENIC MICE; REPORTER GENE; DIFFERENTIATION; EXPRESSION	The molecular mechanisms that regulate intestine-specific gene expression and the transition from proliferating, undifferentiated crypt cells to nonproliferating, differentiated villus cells are unknown. Sucrase-isomaltase is an apical membrane disaccharidase that is found exclusively in enterocytes of adult intestine and is expressed in a complex pattern along the intestinal crypt-villus axis. To investigate the regulation of sucrase-isomaltase, we have cloned and sequenced 3.6 kilobases of the 5'-flanking region of the human sucrase-isomaltase gene. The transcriptional start site was mapped in human small intestine and in a colonic adenocarcinoma cell line (Caco-2) using an anchored polymerase chain reaction, primer extension, and RNase protection assays. The 5'-flanking DNA of the gene was linked to either chloramphenicol acetyltransferase or luciferase reporter genes and used for transfection into Caco-2, HeLa, and HepG2 cells. This analysis demonstrated that intestine-specific transcription of the sucrase-isomaltase gene involves both proximal and distal regulatory elements. Use of sucrase-isomaltase as a model gene will allow investigation of the mechanisms that regulate transcription of enterocyte-specific genes, developmental gene expression in the small intestine and colon, and the process of differentiation as epithelial cells migrate from intestinal crypts onto the villus in adult intestine.	UNIV MICHIGAN, SCH MED,DEPT INTERNAL MED,6520A MSRB-1, 1150 W MED CTR DR, ANN ARBOR, MI 48109 USA; VET ADM MED CTR, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041393] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41393] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON JM, 1989, J CELL BIOL, V109, P1047, DOI 10.1083/jcb.109.3.1047; Ausubel FM, 1988, MOL REPROD DEV; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOLL W, 1991, AM J HUM GENET, V48, P889; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; DENG GR, 1983, METHOD ENZYMOL, V100, P96; DIGNAM JD, 1983, METH ENZYUMOL, V101, P852; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GALAND G, 1989, COMP BIOCHEM PHYS B, V94, P1, DOI 10.1016/0305-0491(89)90002-3; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; HARRIS H, 1990, CLIN CHIM ACTA, V186, P133, DOI 10.1016/0009-8981(90)90031-M; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; Henning Susan J., 1987, PHYSL GASTROINTESTIN, V1, P285; HENTHORN PS, 1988, J BIOL CHEM, V263, P12011; HERBOMEL P, 1989, TISSUE SPECIFIC GENE, P165; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEEPER LL, 1990, AM J PHYSIOL, V258, pG52, DOI 10.1152/ajpgi.1990.258.1.G52; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; Lorenzsonn V, 1987, GASTROENTEROLOGY, V92, P98, DOI 10.1016/0016-5085(87)90844-4; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Neutra M, 1989, FUNCTIONAL EPITHELIA, P363; PINTO M, 1983, BIOL CELL, V47, P323; POTTER GD, 1989, HUMAN GASTROINTESTIN, P545; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHIELDS HM, 1982, GASTROENTEROLOGY, V82, P39; SHIELDS HM, 1984, GASTROENTEROLOGY, V87, P827; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TRABER PG, 1991, AM J PHYSIOL, V260, pG895, DOI 10.1152/ajpgi.1991.260.6.G895; TRABER PG, 1990, BIOCHEM BIOPH RES CO, V173, P765, DOI 10.1016/S0006-291X(05)80853-8; TRABER PG, 1990, MOL PHARMACOL, V37, P810; TRABER PG, 1992, AM J PHYSIOL, V262, pG123, DOI 10.1152/ajpgi.1992.262.1.G123; TRABER PG, 1988, J BIOL CHEM, V263, P9449; WILTZ O, 1991, GASTROENTEROLOGY, V100, P1266; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YAMAMOTO N, 1973, Acta Histochemica et Cytochemica, V6, P107	52	82	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7863	7870						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560017				2022-12-27	WOS:A1992HN48500093
J	SHIBATA, S; MIDURA, RJ; HASCALL, VC				SHIBATA, S; MIDURA, RJ; HASCALL, VC			STRUCTURAL-ANALYSIS OF THE LINKAGE REGION OLIGOSACCHARIDES AND UNSATURATED DISACCHARIDES FROM CHONDROITIN SULFATE USING CARBOPAC PA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWARM RAT CHONDROSARCOMA; PERFORMANCE LIQUID-CHROMATOGRAPHY; ANION-EXCHANGE CHROMATOGRAPHY; PULSED AMPEROMETRIC DETECTION; PROTEOGLYCAN BIOSYNTHESIS; CARTILAGE PROTEOGLYCAN; EMBRYONIC CHICKEN; DERMATAN SULFATE; CORNEAL EXPLANTS; HYALURONIC-ACID	Swarm rat chondrosarcoma cell cultures were metabolically labeled with [S-35]sulfate, [H-3]glucose, or [H-3]glucosamine. Chondroitin sulfate chains were isolated from purified aggrecan using alkaline borohydride treatment and Superose 6 chromatography. Various linkage region oligosaccharide alditols were derived from these chains using sequential chondroitinase digestions (ABC lyase followed by ACII lyase). They were then further processed by mercuric acetate treatment, which removed the 4,5-unsaturated uronosyl residue from the nonreducing end of the linkage, and then beta-galactosidase digestion which liberated the 2 galactose residues from the xylitol reducing terminus. Alkaline phosphatase digestions were performed to verify the presence of phosphate esters. All linkage region structures were isolated and identified using a combination of Progel-TSK G2500 and CarboPac PA1 chromatography steps in conjunction with monosaccharide analyses. This study revealed that chondroitin sulfate chains from aggrecan synthesized by rat chondrosarcoma cells in vitro have the following properties: 1) three out of every four of their linkage regions carry a phosphate ester on xylose, 2) nearly three out of every five chains begin the repeating disaccharide region with an unsulfated first disaccharide unit, 3) nearly twice as many nonphosphorylated chains have a sulfated first disaccharide than their phosphorylated counterparts, and 4) the vast majority of these chains do not contain sulfated galactose in their linkage regions. This report also describes a borohydride reduction procedure to confer alkali stability to the 3-substituted, unsaturated disaccharides derived from chondroitinase digests of chondroitin sulfate. Furthermore, a CarboPac PA1 method is demonstrated that separates these reduced disaccharides with exceptional resolution.	NIDR,BONE RES BRANCH,PROTEOGLYCAN CHEM SECT,BLDG 30,RM 106,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Shibata, Shunichi/AAQ-7252-2021					BALLOU CE, 1954, ADV CARBOHYD CHEM, V9, P59, DOI 10.1016/S0096-5332(08)60372-0; CARLSON DM, 1968, J BIOL CHEM, V243, P616; DISTLER JJ, 1973, J BIOL CHEM, V248, P6772; FEDARKO NS, 1990, ANAL BIOCHEM, V188, P398, DOI 10.1016/0003-2697(90)90627-L; FRANSSON LA, 1990, BIOCHEM J, V269, P381, DOI 10.1042/bj2690381; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; FRANSSON LA, 1968, ANAL BIOCHEM, V23, P317, DOI 10.1016/0003-2697(68)90362-X; FRANSSON LA, 1985, POLYSACCHARIDES, V3, P337; GLASER JH, 1979, J BIOL CHEM, V254, P6588; GUNNARSSON A, 1984, CARBOHYD RES, V133, P75, DOI 10.1016/0008-6215(84)85184-8; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HARDY MR, 1988, P NATL ACAD SCI USA, V85, P3289, DOI 10.1073/pnas.85.10.3289; HASCALL VC, 1972, J BIOL CHEM, V247, P4521; HASCALL VC, 1982, METHOD ENZYMOL, V82, P769; HJERPE A, 1982, J CHROMATOGR, V235, P221, DOI 10.1016/S0021-9673(00)95803-5; INOUE H, 1986, CARBOHYD RES, V155, P277, DOI 10.1016/S0008-6215(00)90159-9; KIMURA JH, 1979, J BIOL CHEM, V254, P2600; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; LLOYD KO, 1969, CARBOHYD RES, V9, P41, DOI 10.1016/S0008-6215(00)82887-6; LOHMANDER LS, 1986, ANAL BIOCHEM, V154, P75, DOI 10.1016/0003-2697(86)90498-7; LOHMANDER LS, 1980, J BIOL CHEM, V255, P6084; LOHMANDER LS, 1986, ARCH BIOCHEM BIOPHYS, V250, P211, DOI 10.1016/0003-9861(86)90719-8; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; MAYO JW, 1970, CARBOHYD RES, V15, P300, DOI 10.1016/S0008-6215(00)88014-3; MIDURA RJ, 1989, J BIOL CHEM, V264, P1423; MIDURA RJ, 1989, J BIOL CHEM, V264, P1414; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; STEVENS RL, 1981, J BIOL CHEM, V256, P2045; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; TOWNSEND RR, 1988, ANAL BIOCHEM, V174, P459, DOI 10.1016/0003-2697(88)90044-9; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WEBER P, 1969, ARCH BIOCHEM BIOPHYS, V129, P534, DOI 10.1016/0003-9861(69)90211-2; WHISTLER RL, 1958, ADV CARBOHYD CHEM, V13, P289; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YANAGISHITA M, 1979, J BIOL CHEM, V254, P2355; ZEBROWER ME, 1986, ANAL BIOCHEM, V157, P93, DOI 10.1016/0003-2697(86)90201-0	39	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6548	6555						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551866				2022-12-27	WOS:A1992HM05300018
J	SUMIKAWA, K; GEHLE, VM				SUMIKAWA, K; GEHLE, VM			ASSEMBLY OF MUTANT SUBUNITS OF THE NICOTINIC ACETYLCHOLINE-RECEPTOR LACKING THE CONSERVED DISULFIDE LOOP STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; BINDING-SITE; SUPERFAMILY; EXPRESSION; BETA	Each subunit of the nicotinic acetylcholine receptor (AChR) contains two conserved cysteine residues, which are known to form a disulfide bond, in the N-terminal extracellular domain. The role of this retained structural feature in the biogenesis of the AChR was studied by expressing site-directed mutant-alpha and beta-subunits together with other normal subunits from Torpedo californica AChR in Xenopus oocytes. Mutation of the cysteines at position 128 or 142 in the alpha-subunit, or in the beta-subunit, did not prevent subunit assembly. All Cys128 and Cys142 mutants of the alpha and beta-subunits were able to associate with coexpressed other normal subunits, although associational efficiency of the mutant alpha-subunits with the delta-subunit was reduced. Functional studies of the mutant AChR complexes showed that the mutations in the alpha-subunit abolished detectable I-125-alpha-bungarotoxin (alpha-BuTX) binding in whole oocytes, whereas the mutations in the beta-subunit resulted in decreased total binding of I-125-alpha-BuTX and no detectable surface I-125-alpha-BuTX binding. Additionally, all mutant subunits, when co-expressed with the other normal subunits in oocytes, produced small acetylcholine-activated membrane currents, suggesting incorporation of only small numbers of functional mutant AChRs into the plasma membrane. The functional acetylcholine-gated ion channel formed with mutant alpha-subunits, but not mutant beta-subunits, could not be blocked by alpha-BuTX. Thus, a disulfide bond between Cys128 and Cys142 of the AChR-alpha or beta-subunits is not needed for acetylcholine-binding. However, this disulfide bond on the alpha-subunit is necessary for formation of the alpha-BuTX-binding site. These results also suggest that the most significant effect caused by disrupting the conserved disulfide loop structure is intracellular retention of most of the assembled AChR complexes.			SUMIKAWA, K (corresponding author), UNIV CALIF IRVINE,DEPT PSYCHOBIOL,IRVINE,CA 92717, USA.				NINDS NIH HHS [NS25928] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025928] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKAGI H, 1991, NEUROSCI RES, V11, P28, DOI 10.1016/0168-0102(91)90064-6; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BULLER AL, 1990, MOL PHARMACOL, V37, P423; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GEHLE VM, 1991, MOL BRAIN RES, V11, P17, DOI 10.1016/0169-328X(91)90016-Q; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GREEN MR, 1983, CELL, V32, P681, DOI 10.1016/0092-8674(83)90054-5; HARTMAN DS, 1990, NATURE, V343, P372, DOI 10.1038/343372a0; KAO PN, 1986, J BIOL CHEM, V261, P8085; KELLARIS KV, 1989, BIOCHEMISTRY-US, V28, P3469, DOI 10.1021/bi00434a048; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KUROSAKI T, 1987, FEBS LETT, V214, P253, DOI 10.1016/0014-5793(87)80065-0; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; NUMA S, 1983, COLD SPRING HARB SYM, V48, P57, DOI 10.1101/SQB.1983.048.01.008; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; SAMBROOK J, 1989, MOL CLONINGS LABORAT; SMITH MM, 1987, J BIOL CHEM, V262, P4367; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; SUMIKAWA K, 1989, MOL BRAIN RES, V5, P183, DOI 10.1016/0169-328X(89)90034-X; SUMIKAWA K, 1989, METHODS NEUROSCIENCE, V1, P30; WHITE MM, 1985, P NATL ACAD SCI USA, V82, P4852, DOI 10.1073/pnas.82.14.4852	25	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6286	6290						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556136				2022-12-27	WOS:A1992HK31800085
J	GIBBS, CS; KNIGHTON, DR; SOWADSKI, JM; TAYLOR, SS; ZOLLER, MJ				GIBBS, CS; KNIGHTON, DR; SOWADSKI, JM; TAYLOR, SS; ZOLLER, MJ			SYSTEMATIC MUTATIONAL ANALYSIS OF CAMP-DEPENDENT PROTEIN-KINASE IDENTIFIES UNREGULATED CATALYTIC SUBUNITS AND DEFINES REGIONS IMPORTANT FOR THE RECOGNITION OF THE REGULATORY SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE INHIBITOR; TYROSINE PHOSPHORYLATION; BINDING; SITE; MUTAGENESIS; CEREVISIAE; ACTIVATION; PEPTIDES; DOMAINS; MGATP	A library of mutants of the catalytic subunit of the Saccharomyces cerevisiae cAMP-dependent protein kinase was screened in vitro for mutants defective in the recognition of the regulatory subunit. The mutations identified were mapped onto the three-dimensional structure of the mouse catalytic subunit with a peptide inhibitor. Mutations defective in the recognition of both the regulatory subunit and the peptide substrate Leu-Arg-Arg-Ala-Ser-Leu-Gly (Kemptide) mapped to the peptide-binding site shared by all substrates and inhibitors of the catalytic subunit and functionally define the binding site for the autoinhibitor sequence in the hinge region of the regulatory subunit. Mutants defective only in the recognition of the regulatory subunit identified residues that comprise additional binding sites for the regulatory subunit. The majority of these residues are clustered on the surface of the catalytic subunit in a region flanking the distal portion of the autoinhibitor/peptide-binding site. The simultaneous substitution of Lys233, Asp237, Lys257, and Lys261 in this region caused a 260-fold decrease in affinity for the regulatory subunit, whereas the catalytic efficiency toward Kemptide decreased by only 1.8-fold. The substitution of autophosphorylated Thr241, also in this region, and the 3 residues interacting with the phosphate also caused an unregulated phenotype.	UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	GIBBS, CS (corresponding author), GENENTECH INC, DEPT PROT ENGN, 460 POINT SAN BRUNO BLVD, SAN FRANCISCO, CA 94080 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037674, R01GM034921, R37GM019301, R01GM019301] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37674-01, GM34921-06, GM19301-20] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P5997, DOI 10.1021/bi00393a008; BUECHLER JA, 1990, BIOCHEMISTRY-US, V29, P1937, DOI 10.1021/bi00459a039; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P3018, DOI 10.1021/bi00433a042; BUECHLER JA, 1988, BIOCHEMISTRY-US, V27, P7356, DOI 10.1021/bi00419a027; BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CANNON JF, 1990, J BIOL CHEM, V265, P11897; CHENG HC, 1986, J BIOL CHEM, V261, P989; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; DENIS CL, 1991, J BIOL CHEM, V266, P17932; DOSTMANN WRG, 1991, BIOCHEMISTRY-US, V30, P8710, DOI 10.1021/bi00099a032; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DURGERIAN S, 1989, J BIOL CHEM, V264, P9807; FIRST EA, 1988, J BIOL CHEM, V263, P5176; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; GLASS DB, 1989, J BIOL CHEM, V264, P8802; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDIE G, 1988, NATURE, V335, P592, DOI 10.1038/335592a0; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON KE, 1987, J BIOL CHEM, V262, P8636; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KURET J, 1988, J BIOL CHEM, V263, P9149; LEVIN LR, 1988, SCIENCE, V240, P68, DOI 10.1126/science.2832943; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; MILLER WT, 1988, P NATL ACAD SCI USA, V85, P5429, DOI 10.1073/pnas.85.15.5429; NEITZEL JJ, 1988, BIOCHEMISTRY-US, V85, P5429; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RINGHEIM GE, 1990, J BIOL CHEM, V265, P4800; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; Sherman F., 1982, METHODS YEAST GENETI; SHOJI S, 1979, J BIOL CHEM, V254, P6211; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WANG YH, 1991, P NATL ACAD SCI USA, V88, P2446, DOI 10.1073/pnas.88.6.2446; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WELDON SL, 1985, J BIOL CHEM, V260, P4203; WETZEL R, 1988, PROTEIN ENG, V2, P1, DOI 10.1093/protein/2.1.1; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; WOODFORD TA, 1989, J BIOL CHEM, V264, P13321; YONEMOTO WM, 1991, METHOD ENZYMOL, V200, P581; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZOLLER MJ, 1991, GENE, V99, P171, DOI 10.1016/0378-1119(91)90124-T; ZOLLER MJ, 1988, J BIOL CHEM, V263, P9142	54	109	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4806	4814						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537860				2022-12-27	WOS:A1992HF64200079
J	MATRINGE, M; CAMADRO, JM; BLOCK, MA; JOYARD, J; SCALLA, R; LABBE, P; DOUCE, R				MATRINGE, M; CAMADRO, JM; BLOCK, MA; JOYARD, J; SCALLA, R; LABBE, P; DOUCE, R			LOCALIZATION WITHIN CHLOROPLASTS OF PROTOPORPHYRINOGEN OXIDASE, THE TARGET ENZYME FOR DIPHENYLETHER-LIKE HERBICIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL ISOCYCLIC RING; 3 PEROXIDIZING HERBICIDES; ISOLATED PEA-CHLOROPLASTS; IX MONOMETHYL ESTER; B-F COMPLEX; SPINACH-CHLOROPLASTS; ACIFLUORFEN-METHYL; CUCUMBER COTYLEDONS; ENVELOPE MEMBRANES; OXIDATIVE CYCLASE	Plant protoporphyrinogen oxidase is of particular interest since it is the last enzyme of the common branch for chlorophyll and heme biosynthetic pathways. In addition, it is the target enzyme for diphenyl ether-type herbicides, such as acifluorfen. Two distinct methods were used to investigate the localization of this enzyme within Percoll-purified spinach chloroplasts. We first assayed the enzymatic activity by spectrofluorimetry and we analyzed the specific binding of the herbicide acifluorfen, using highly purified chloroplast fractions. The results obtained give clear evidence that chloroplast protoporphyrinogen oxidase activity is membrane-bound and is associated with both chloroplast membranes, i.e. envelope and thylakoids. Protoporphyrinogen oxidase specific activity was 7-8 times higher in envelope membranes than in thylakoids, in good agreement with the number of [H-3]acifluorfen binding sites in each membrane system: 21 and 3 pmol/mg protein, respectively, in envelope membranes and thylakoids. On a total activity basis, 25% of protoporphyrinogen oxidase activity were associated with envelope membranes. The presence of protoporphyrinogen oxidase in chloroplast envelope membranes provides further evidence for a role of this membrane system in chlorophyll biosynthesis. In contrast, the physiological significance of the enzyme associated with thylakoids is still unknown, but it is possible that thylakoid protoporphyrinogen oxidase could be involved in heme biosynthesis.	INRA,XENOBIOT LAB,F-31931 TOULOUSE,FRANCE; UNIV PARIS 07,INST JACQUES MONOD,CNRS,BIOCHIM PORPHYRINES LAB,F-75251 PARIS,FRANCE; UNIV JOSEPH FOURIER,F-38041 GRENOBLE,FRANCE	INRAE; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	MATRINGE, M (corresponding author), CEN,DEPT BIOL MOLEC & STRUCT,PHYSIOL CELLULAIRE VEGETALE LAB,CNRS,F-38041 GRENOBLE,FRANCE.			Camadro, Jean-Michel/0000-0002-8549-2707				[Anonymous], METHODS CHLOROPLAST; Beale S. I., 1990, BIOSYNTHESIS HEME CH, P287; BHAYA D, 1986, PLANT PHYSIOL, V81, P960, DOI 10.1104/pp.81.4.960; BLOCK MA, 1980, BIOCHIM BIOPHYS ACTA, V631, P210, DOI 10.1016/0304-4165(80)90069-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMADRO JM, 1991, BIOCHEM J, V277, P17, DOI 10.1042/bj2770017; CASTELFRANCO PA, 1983, ANNU REV PLANT PHYS, V34, P241, DOI 10.1146/annurev.pp.34.060183.001325; CHERESKIN BM, 1982, PLANT PHYSIOL, V70, P987, DOI 10.1104/pp.70.4.987; DERRICK PM, 1988, PESTIC BIOCHEM PHYS, V32, P153, DOI 10.1016/0048-3575(88)90008-9; DORNE AJ, 1990, P NATL ACAD SCI USA, V87, P71, DOI 10.1073/pnas.87.1.71; DOUCE R, 1974, SCIENCE, V183, P852, DOI 10.1126/science.183.4127.852; DOUCE R, 1973, J BIOL CHEM, V248, P7215; DOUCE R, 1990, ANNU REV CELL BIOL, V6, P173, DOI 10.1146/annurev.cb.06.110190.001133; DOUCE R, 1990, METHODS PLANT BIOCH, V4, P71; ELLIS RJ, 1985, SUBCELL BIOCH, V9, P237; FUESLER TP, 1984, PLANT PHYSIOL, V75, P662, DOI 10.1104/pp.75.3.662; JACOBS JM, 1987, BIOCHEM J, V244, P219, DOI 10.1042/bj2440219; JACOBS JM, 1984, ARCH BIOCHEM BIOPHYS, V229, P312, DOI 10.1016/0003-9861(84)90157-7; JACOBS NJ, 1982, ENZYME, V28, P206, DOI 10.1159/000459103; JOHANNINGMEIER U, 1984, J BIOL CHEM, V259, P3541; JONES OTG, 1968, BIOCHEM J, V107, P113, DOI 10.1042/bj1070113; JOYARD J, 1991, EUR J BIOCHEM, V199, P489, DOI 10.1111/j.1432-1033.1991.tb16148.x; JOYARD J, 1990, J BIOL CHEM, V265, P21820; LABBE P, 1985, ANAL BIOCHEM, V149, P248, DOI 10.1016/0003-2697(85)90502-0; LEHNEN LP, 1990, PESTIC BIOCHEM PHYS, V37, P239, DOI 10.1016/0048-3575(90)90130-T; LYDON J, 1988, PESTIC BIOCHEM PHYS, V31, P74, DOI 10.1016/0048-3575(88)90031-4; MATRINGE M, 1990, PESTIC BIOCHEM PHYS, V36, P300, DOI 10.1016/0048-3575(90)90039-5; MATRINGE M, 1988, PESTIC BIOCHEM PHYS, V32, P164, DOI 10.1016/0048-3575(88)90009-0; MATRINGE M, 1988, PLANT PHYSIOL, V86, P619, DOI 10.1104/pp.86.2.619; MATRINGE M, 1989, BIOCHEM J, V260, P231, DOI 10.1042/bj2600231; MATRINGE M, 1989, FEBS LETT, V245, P35, DOI 10.1016/0014-5793(89)80186-3; NASRULHAQBOYCE A, 1987, BIOCHEM J, V243, P23, DOI 10.1042/bj2430023; PHILLIPS AL, 1984, EUR J BIOCHEM, V138, P591, DOI 10.1111/j.1432-1033.1984.tb07955.x; PINEAU B, 1986, J BIOL CHEM, V261, P9210; SANDMANN G, 1988, Z NATURFORSCH C, V43, P699; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH BB, 1979, PLANT PHYSIOL, V63, P227, DOI 10.1104/pp.63.2.227; TISCHER W, 1977, BIOCHIM BIOPHYS ACTA, V460, P113, DOI 10.1016/0005-2728(77)90157-8; VARSANO R, 1990, FEBS LETT, V272, P106, DOI 10.1016/0014-5793(90)80459-V; WALKER CJ, 1991, P NATL ACAD SCI USA, V88, P5789, DOI 10.1073/pnas.88.13.5789; WILLEY DL, 1988, PHOTOSYNTH RES, V17, P125, DOI 10.1007/BF00047685; WITKOWSKI DA, 1988, PLANT PHYSIOL, V87, P632, DOI 10.1104/pp.87.3.632; WITKOWSKI DA, 1989, PLANT PHYSIOL, V90, P1239, DOI 10.1104/pp.90.4.1239	43	107	120	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4646	4651						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537847				2022-12-27	WOS:A1992HF64200057
J	JAN, CR; SCHNEIDER, AS				JAN, CR; SCHNEIDER, AS			SODIUM-DEPENDENT CALCIUM EFFLUX FROM ADRENAL CHROMAFFIN CELLS FOLLOWING EXOCYTOSIS - POSSIBLE ROLE OF SECRETORY VESICLE MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOLAMINE SECRETION; PERTUSSIS TOXIN; CA-2+; MEDULLA; RELEASE; GRANULES; NA+; MOBILIZATION; EXCHANGE; PROTEIN	Although cytosolic Ca2+ transients are known to influence the magnitude and duration of hormone and neurotransmitter release, the processes regulating the decay of such transients after cell stimulation are not well understood. Na2+-dependent Ca2+ efflux across the secretory vesicle membrane, following its incorporation into the plasma membrane, may play a significant role in Ca2+ efflux after stimulation of secretion. We have measured an enhanced Ca-45(2+) efflux from cultured bovine adrenal chromaffin cells following cell stimulation with depolarizing medium (75 mM K+) or nicotine (10-mu-M). Such stimulation also causes Ca2+ uptake via voltage-gated Ca2+ channels and secretion of catecholamines. Na+ replacement with any of several substitutes (N-methyl-glucamine, Li+, choline, or sucrose) during cell stimulation inhibited the enhanced Ca-45(2+) efflux, indicating an Na+-dependent Ca2+ efflux process. Na+ deprivation did not inhibit Ca-45(2+) uptake or catecholamine secretion evoked by elevated K+. Suppression of exocytotic incorporation of secretory vesicle membranes into the plasma membrane with hypertonic medium (620 mOsm) or by lowering temperature to 12-degrees-C inhibited K+-stimulated Ca-45(2+) efflux in Na+-containing medium but did not inhibit the stimulated Ca-45(2+) uptake. Enhancement of exocytotic secretion with pertussis toxin resulted in an enhanced Ca-45(2+) efflux without affecting calcium uptake. The combined results suggest that Na+-dependent Ca2+ efflux across secretory vesicle membranes, following their incorporation into the plasma membrane during exocytosis, plays a significant role in regulating calcium efflux and the decay of cytosolic Ca2+ in adrenal chromaffin cells and possibly in related secretory cells.	UNION UNIV,DEPT PHARMACOL & TOXICOL,ALBANY,NY 12208	Union College					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039220] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39220] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY CA, 1987, FASEB J, V46, P367; BROCKLEHURST KW, 1988, FEBS LETT, V234, P439, DOI 10.1016/0014-5793(88)80133-9; Carmichael S, 1987, STIMULUS SECRETION C, V1, P1; DOUGLAS WW, 1961, J PHYSIOL-LONDON, V159, P40, DOI 10.1113/jphysiol.1961.sp006791; GOH Y, 1990, BIOCHEM BIOPH RES CO, V166, P1346, DOI 10.1016/0006-291X(90)91014-J; HAMPTON RY, 1983, J CELL BIOL, V96, P1082, DOI 10.1083/jcb.96.4.1082; HIRAM Y, 1984, BIOPHYS J, V45, P651, DOI 10.1016/S0006-3495(84)84206-X; HOLZ RW, 1982, J NEUROCHEM, V39, P635, DOI 10.1111/j.1471-4159.1982.tb07940.x; JAN CR, 1990, J NEUROCHEM, V54, P355, DOI 10.1111/j.1471-4159.1990.tb13323.x; JAN CR, 1991, BIOPHYS J, V59, P449; KAO LS, 1985, J BIOL CHEM, V260, P2019; KAO LS, 1986, J BIOL CHEM, V261, P4881; KAO LS, 1984, J NEUROCHEM, V43, P590, DOI 10.1111/j.1471-4159.1984.tb00940.x; KAO LS, 1988, J NEUROCHEM, V51, P221, DOI 10.1111/j.1471-4159.1988.tb04859.x; KILPATRICK DL, 1982, J NEUROCHEM, V38, P427, DOI 10.1111/j.1471-4159.1982.tb08647.x; KRIEGERBRAUER H, 1981, FEBS LETT, V133, P244, DOI 10.1016/0014-5793(81)80515-7; KRIEGERBRAUER H, 1982, BIOCHIM BIOPHYS ACTA, V691, P61, DOI 10.1016/0005-2736(82)90214-0; KRIEGERBRAUER HI, 1983, J NEUROCHEM, V41, P1269, DOI 10.1111/j.1471-4159.1983.tb00821.x; LADONA MG, 1987, BIOCHIM BIOPHYS ACTA, V927, P18, DOI 10.1016/0167-4889(87)90061-9; MCKAY DB, 1984, J PHARMACOL EXP THER, V231, P102; MOHINDER KB, 1990, FEBS LETT, V276, P165; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OHARAIMAIZUMI M, 1990, NEUROSCI LETT, V110, P167, DOI 10.1016/0304-3940(90)90806-K; ORNBERG RL, 1988, J BIOL CHEM, V263, P1488; OSULLIVAN AJ, 1988, BIOCHIM BIOPHYS ACTA, V969, P211, DOI 10.1016/0167-4889(88)90054-7; OSULLIVAN AJ, 1989, BIOSCIENCE REP, V9, P243, DOI 10.1007/BF01116001; PATZAK A, 1984, J CELL BIOL, V98, P1817, DOI 10.1083/jcb.98.5.1817; PHILIPSON KD, 1982, CIRC RES, V50, P287, DOI 10.1161/01.RES.50.2.287; PHILLIPS JH, 1983, J CELL BIOL, V97, P1906, DOI 10.1083/jcb.97.6.1906; PHILLIPS JH, 1981, BIOCHEM J, V200, P99, DOI 10.1042/bj2000099; SASAKAWA N, 1988, BIOCHEM PHARMACOL, V37, P2485; SERCKHAN.G, 1973, BIOCHIM BIOPHYS ACTA, V307, P404, DOI 10.1016/0005-2736(73)90106-5; SONTAG JM, 1991, BIOCHEM J, V274, P339, DOI 10.1042/bj2740339; STOEHR SJ, 1986, J NEUROCHEM, V46, P637, DOI 10.1111/j.1471-4159.1986.tb13014.x; TANAKA T, 1987, BIOCHEM BIOPH RES CO, V144, P907, DOI 10.1016/S0006-291X(87)80050-5; VONGRAFENSTEIN H, 1986, J CELL BIOL, V103, P2343, DOI 10.1083/jcb.103.6.2343; VONGRAFENSTEIN HRK, 1989, J NEUROCHEM, V53, P423	37	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9695	9700						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577804				2022-12-27	WOS:A1992HT96500039
J	GAO, EN; SHIER, P; SIU, CH				GAO, EN; SHIER, P; SIU, CH			PURIFICATION AND PARTIAL CHARACTERIZATION OF A CELL-ADHESION MOLECULE (GP150) INVOLVED IN POSTAGGREGATION STAGE CELL-CELL BINDING IN DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-A GLYCOPROTEIN; PLASMA-MEMBRANE; SURFACE GLYCOPROTEIN; CONTACT SITE; MONOCLONAL-ANTIBODIES; BLOCKING FAB; GP80; AGGREGATION; COHESION; PROTEINS	A cell surface glycoprotein of apparent M(r) 150,000 (gp150) has been implicated in mediating EDTA-resistant cell-cell adhesion in Dictyostelium discoideum. A simple purification scheme making use of high-performance liquid chromatography has been devised to purify gp150 to near homogeneity. Purified gp150 was capable of neutralizing the effect of a rabbit antiserum raised against gel-purified gp150, which was previously reported to be a potent inhibitor of cell-cell adhesion (Geltosky, J. E., Weseman, J., Bakke, A., and Lerner, R. A. (1979) Cell 18, 391-398). The binding of I-125-labeled gp150 to intact cells was both dose-dependent and saturable, demonstrating the presence of specific cell surface binding sites for gp150. When reassociation of postaggregation stage cells was carried out in the presence of soluble gp150, aggregate formation was strongly inhibited. In contrast, gp150 failed to exert any effect on cells at the aggregation stage. The inhibitory effect of gp150 was sensitive to protease treatment, suggesting that the protein moiety is crucial to gp150 function. These results, taken together, provide direct evidence that gp150 is a cell-cell adhesion molecule involved in cell-cell binding in the postaggregation stage of Dictyostelium development.	UNIV TORONTO,DEPT BIOCHEM,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto; University of Toronto								BEUG H, 1973, J CELL BIOL, V56, P647, DOI 10.1083/jcb.56.3.647; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BONNER JT, 1959, P NATL ACAD SCI USA, V56, P379; BRODIE C, 1983, CELL, V32, P1115, DOI 10.1016/0092-8674(83)90295-7; CHOI AHC, 1987, J CELL BIOL, V104, P1375, DOI 10.1083/jcb.104.5.1375; DECHASTELLIER C, 1980, BIOL CELL, V38, P121; DESILVA NS, 1980, J BIOL CHEM, V255, P8489; DESILVA NS, 1981, J BIOL CHEM, V256, P5845; FEINBERG AP, 1979, P NATL ACAD SCI USA, V76, P3977, DOI 10.1073/pnas.76.8.3977; GARROD DR, 1972, EXP CELL RES, V72, P588, DOI 10.1016/0014-4827(72)90041-9; GELTOSKY JE, 1979, CELL, V18, P391, DOI 10.1016/0092-8674(79)90058-8; GELTOSKY JE, 1980, CELL, V21, P339, DOI 10.1016/0092-8674(80)90470-5; GELTOSKY JE, 1976, CELL, V8, P391, DOI 10.1016/0092-8674(76)90151-3; GERISCH G, 1961, EXP CELL RES, V25, P535, DOI 10.1016/0014-4827(61)90189-6; GERISCH G, 1980, CURR TOP DEV BIOL, V14, P234; GREEN AA, 1974, BIOCHEM J, V140, P313, DOI 10.1042/bj1400313; KAMBOJ RK, 1989, CELL, V59, P615, DOI 10.1016/0092-8674(89)90007-X; KAMBOJ RK, 1990, CELL REGUL, V1, P715, DOI 10.1091/mbc.1.10.715; KAMBOJ RK, 1988, J CELL BIOL, V107, P1835, DOI 10.1083/jcb.107.5.1835; KNECHT DA, 1987, DEV BIOL, V121, P277, DOI 10.1016/0012-1606(87)90160-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM TY, 1981, DIFFERENTIATION, V20, P22, DOI 10.1111/j.1432-0436.1981.tb01151.x; LOOMIS WF, 1983, EXP CELL RES, V147, P231, DOI 10.1016/0014-4827(83)90290-2; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MA PCC, 1990, MOL CELL BIOL, V10, P3297, DOI 10.1128/MCB.10.7.3297; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MULLER K, 1978, NATURE, V274, P445, DOI 10.1038/274445a0; NELLEN W, 1987, METHOD CELL BIOL, V28, P209; NOEGEL A, 1986, EMBO J, V5, P1473, DOI 10.1002/j.1460-2075.1986.tb04384.x; SAXE CL, 1982, CELL, V29, P755, DOI 10.1016/0092-8674(82)90437-8; SIU CH, 1988, EXP CELL RES, V177, P338, DOI 10.1016/0014-4827(88)90467-3; SIU CH, 1990, DEV GENET, V11, P377, DOI 10.1002/dvg.1020110509; SIU CH, 1988, BIOCHEM CELL BIOL, V66, P1089, DOI 10.1139/o88-126; SIU CH, 1988, BIOCHIM BIOPHYS ACTA, V968, P283, DOI 10.1016/0167-4889(88)90019-5; SIU CH, 1987, J CELL BIOL, V105, P2523, DOI 10.1083/jcb.105.6.2523; SIU CH, 1983, P NATL ACAD SCI-BIOL, V80, P6596, DOI 10.1073/pnas.80.21.6596; SIU CH, 1977, J MOL BIOL, V116, P469, DOI 10.1016/0022-2836(77)90080-8; SIU CH, 1976, J MOL BIOL, V100, P157, DOI 10.1016/S0022-2836(76)80146-5; SIU CH, 1990, BIOESSAYS, V12, P357, DOI 10.1002/bies.950120802; SMART JE, 1974, NATURE, V251, P319, DOI 10.1038/251319a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONNEBORN DR, 1964, J BACTERIOL, V87, P1312; STEINEMANN C, 1980, NATURE, V286, P621, DOI 10.1038/286621a0; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; Sussman M., 1966, METHOD CELL PHYSIOL, V2, P397; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Takeuchi I., 1969, NUCL ACID METABOLISM, P297; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WONG LM, 1986, P NATL ACAD SCI USA, V83, P4248, DOI 10.1073/pnas.83.12.4248; ZISKA SE, 1988, P NATL ACAD SCI USA, V85, P817, DOI 10.1073/pnas.85.3.817	51	36	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9409	9415						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577768				2022-12-27	WOS:A1992HR85400106
J	GARFINKEL, MS; KATZE, MG				GARFINKEL, MS; KATZE, MG			TRANSLATIONAL CONTROL BY INFLUENZA-VIRUS - SELECTIVE AND CAP-DEPENDENT TRANSLATION OF VIRAL MESSENGER-RNAS IN INFECTED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS TRIPARTITE LEADER; BINDING-PROTEIN COMPLEX; INITIATION FACTOR-II; POLIOVIRUS INFECTION; EUKARYOTIC RIBOSOMES; ALPHA-SUBUNIT; SHUT-OFF; EXPRESSION; KINASE; PHOSPHORYLATION	In cells infected by influenza virus type A, host protein synthesis undergoes a rapid and dramatic shutoff. To define the molecular mechanisms underlying this selective translation, a transfection/infection protocol was developed utilizing viral and cellular cDNA clones. When COS-1 cells were transfected with cDNAs encoding nonviral genes and subsequently infected with influenza virus, protein expression from the exogenous genes was diminished, similar to the endogenous cellular genes. However, when cells were transfected with a truncated influenza viral nucleocapsid protein (NP-S) gene, the NP-S protein was made as efficiently in influenza virus infected cells as in uninfected cells, showing that the NP-S mRNA, although expressed independently of the influenza virus replication machinery, was still recognized as a viral and not a cellular mRNA. Northern blot analysis demonstrated that the selective blocks to nonviral protein synthesis were at the level of translation. Moreover, polysome experiments revealed that the translational blocks occurred at both the initiation and elongation stages of cellular protein synthesis. Finally, we utilized this transfection/infection system as well as double infection experiments to demonstrate that the translation of influenza viral mRNAs probably occurred in a cap-dependent manner as poliovirus infection inhibited influenza viral mRNA translation.	UNIV WASHINGTON, SCH MED, DEPT MICROBIOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NCRR NIH HHS [RR-00166] Funding Source: Medline; NIAID NIH HHS [AI-22646] Funding Source: Medline; NIGMS NIH HHS [T32-GM07270] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSOCAPLEN FV, 1988, J VIROL, V62, P1606, DOI 10.1128/JVI.62.5.1606-1616.1988; BABICH A, 1983, MOL CELL BIOL, V3, P1212, DOI 10.1128/MCB.3.7.1212; BABLANIAN R, 1991, J VIROL, V65, P4449, DOI 10.1128/JVI.65.8.4449-4460.1991; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; CARRASCO L, 1977, FEBS LETT, V76, P11, DOI 10.1016/0014-5793(77)80110-5; CARRASCO L, 1983, PHARMACOL THERAPEUT, V23, P109, DOI 10.1016/0163-7258(83)90028-1; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DEBENEDETTI A, 1983, J BIOL CHEM, V258, P4556; DEBENEDETTI A, 1984, NATURE, V311, P79, DOI 10.1038/311079a0; DOLPH PJ, 1988, J VIROL, V62, P2059, DOI 10.1128/JVI.62.6.2059-2066.1988; DOLPH PJ, 1990, J VIROL, V64, P2669, DOI 10.1128/JVI.64.6.2669-2677.1990; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; ETKIND PR, 1975, J VIROL, V16, P1464, DOI 10.1128/JVI.16.6.1464-1475.1975; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALLIE DR, 1987, NUCLEIC ACIDS RES, V15, P8693, DOI 10.1093/nar/15.21.8693; GODCHAUX W, 1967, J MOL BIOL, V27, P57, DOI 10.1016/0022-2836(67)90351-8; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KATZ RA, 1986, MOL CELL BIOL, V6, P372, DOI 10.1128/MCB.6.2.372; KATZE MG, 1988, J VIROL, V62, P3710, DOI 10.1128/JVI.62.10.3710-3717.1988; KATZE MG, 1984, MOL CELL BIOL, V4, P2198, DOI 10.1128/MCB.4.10.2198; KATZE MG, 1986, J VIROL, V60, P1027, DOI 10.1128/JVI.60.3.1027-1039.1986; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1984, CELL, V37, P483, DOI 10.1016/0092-8674(84)90378-7; KATZE MG, 1986, MOL CELL BIOL, V6, P1741, DOI 10.1128/MCB.6.5.1741; KATZE MG, 1991, IN PRESS TRANSLATION; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOZAK M, 1986, ADV VIRUS RES, V31, P229, DOI 10.1016/S0065-3527(08)60265-1; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRUG RM, 1980, P NATL ACAD SCI-BIOL, V77, P5874, DOI 10.1073/pnas.77.10.5874; KRUG RM, 1989, INFLUENZA VIRUSES, P89; LAZAROWITZ SG, 1971, VIROLOGY, V46, P830, DOI 10.1016/0042-6822(71)90084-5; LEE KAW, 1982, P NATL ACAD SCI-BIOL, V79, P3447, DOI 10.1073/pnas.79.11.3447; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LENK R, 1979, CELL, V16, P289, DOI 10.1016/0092-8674(79)90006-0; LODISH HF, 1977, J BIOL CHEM, V252, P8804; LODISH HF, 1980, J VIROL, V36, P719, DOI 10.1128/JVI.36.3.719-733.1980; LODISH HF, 1976, ANNU REV BIOCHEM, V45, P39, DOI 10.1146/annurev.bi.45.070176.000351; OMALLEY RP, 1989, VIROLOGY, V168, P112, DOI 10.1016/0042-6822(89)90409-1; ONEILL RE, 1989, J VIROL, V63, P5069, DOI 10.1128/JVI.63.12.5069-5075.1989; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PENSIERO MN, 1985, J VIROL, V56, P161, DOI 10.1128/JVI.56.1.161-171.1985; RAGHOW R, 1983, J BIOL CHEM, V258, P571; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SKEHEL JJ, 1978, NUCLEIC ACIDS RES, V5, P1207, DOI 10.1093/nar/5.4.1207; SKEHEL JJ, 1972, VIROLOGY, V49, P23, DOI 10.1016/S0042-6822(72)80004-7; SONENBERG N, 1990, New Biologist, V2, P402; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WALDEN WE, 1981, J BIOL CHEM, V256, P1739	56	44	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9383	9390						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577765				2022-12-27	WOS:A1992HR85400103
J	GREGORY, RB; BERRY, MN				GREGORY, RB; BERRY, MN			STIMULATION BY THYROID-HORMONE OF COUPLED RESPIRATION AND OF RESPIRATION APPARENTLY NOT COUPLED TO THE SYNTHESIS OF ATP IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OXIDATIVE-PHOSPHORYLATION; LIVER-MITOCHONDRIA; INNER MEMBRANE; METABOLISM; INVIVO; MECHANISM; POLYPEPTIDES; EFFICIENCY; TRANSPORT; INVITRO	Maximal rates of O2 uptake by hepatocytes from hypothyroid, euthyroid, and hyperthyroid rats, in the absence of uncoupling agents or ionophores, were achieved by simultaneously stimulating ureogenesis and gluconeogenesis. Rates were increased by pretreatment of the donor animals with thyroid hormone. Only a minor part of the increase could be attributed to stimulation of the activity of plasma membrane (Na+ + K+)-ATPase. No synthesis of glycogen occurred, nor was there any evidence of pyruvate cycling under the conditions used, thus ruling out these processes as potential sources of ATP turnover. Calculation of the O2 uptake necessary to satisfy the energy requirements of gluconeogenesis and ureogenesis, based on anticipated ATP demand and an assumed P:O ratio of 3:1, invariably yielded a theoretical quantity that was less than the experimentally measured increase in O2 uptake. The difference between measured and calculated rates of respiration, possibly representing noncoupled respiration, was related to the thyroid status of the animal, being greatest in cells from hyperthyroid rats. In another experimental approach the O2 uptake associated with ATP synthesis was inhibited by the addition of oligomycin to hepatocytes incubated in the presence of substrates, thus abolishing ATP-coupled respiration. The magnitude of the ATP-coupled as well as the residual respiration was increased in response to thyroid hormone. Thyroid hormone increased the turnover of intramitochondrial ATP. These results imply that a considerable portion of the thermogenic effect of thyroid hormone may be mediated by a stimulatory action on metabolism not directly associated with extramitochondrial ATP-dependent synthetic processes.			GREGORY, RB (corresponding author), FLINDERS UNIV,SCH MED,DEPT MED BIOCHEM,GPO BOX 2100,ADELAIDE,SA 5001,AUSTRALIA.							BARANYAI JM, 1989, BIOCHEM J, V258, P121, DOI 10.1042/bj2580121; BARKER SB, 1951, PHYSIOL REV, V31, P205, DOI 10.1152/physrev.1951.31.3.205; BERGMEYER HU, 1974, METHODS ENZYMATIC AN; BERRY MN, 1980, FEBS LETT, V117, pK106, DOI 10.1016/0014-5793(80)80575-8; BERRY MN, 1983, EUR J BIOCHEM, V131, P205, DOI 10.1111/j.1432-1033.1983.tb07251.x; BERRY MN, 1965, BIOCHEM J, V95, P587, DOI 10.1042/bj0950587; BERRY MN, 1991, ISOLATED HEPATOCYTES, P15, DOI DOI 10.1016/S0075-7535(08)70023-8; BERTINA RM, 1973, BIOCHIM BIOPHYS ACTA, V305, P503, DOI 10.1016/0005-2728(73)90072-8; BRONK JR, 1962, J BIOL CHEM, V237, P897; CAPALDI RA, 1982, BIOCHIM BIOPHYS ACTA, V694, P291, DOI 10.1016/0304-4157(82)90009-0; CHEN RF, 1967, J BIOL CHEM, V242, P173; CLARK DG, 1982, BIOCHEM J, V202, P661, DOI 10.1042/bj2020661; CORRIGALL J, 1984, EUR J BIOCHEM, V141, P435, DOI 10.1111/j.1432-1033.1984.tb08210.x; CRESPOARMAS A, 1987, BIOCHEM J, V241, P657, DOI 10.1042/bj2410657; DEBEER LJ, 1974, EUR J BIOCHEM, V47, P591, DOI 10.1111/j.1432-1033.1974.tb03730.x; FOLKE M, 1977, J PHYSIOL-LONDON, V269, P407, DOI 10.1113/jphysiol.1977.sp011909; FORMAN NG, 1983, J BIOL CHEM, V258, P8649; FREAKE HC, 1989, ENDOCRINOLOGY, V125, P2868, DOI 10.1210/endo-125-6-2868; Good CA, 1933, J BIOL CHEM, V100, P485; GREGORY RB, 1989, BIOCHEM PHARMACOL, V38, P2867, DOI 10.1016/0006-2952(89)90443-7; GREGORY RB, 1991, BIOCHIM BIOPHYS ACTA, V1098, P61; GREGORY RB, 1991, P AUST SOC BIOCH MOL, V23, P44; HAFNER RP, 1988, EUR J BIOCHEM, V178, P511, DOI 10.1111/j.1432-1033.1988.tb14477.x; HAFNER RP, 1988, BIOCHEM J, V250, P477, DOI 10.1042/bj2500477; HASSINEN I, 1990, BIOCHIM BIOPHYS ACTA, V1019, P73, DOI 10.1016/0005-2728(90)90126-O; HEMS R, 1966, BIOCHEM J, V101, P284, DOI 10.1042/bj1010284; HENKE W, 1991, BIOCHIM BIOPHYS ACTA, V1056, P71, DOI 10.1016/S0005-2728(05)80074-X; HOCH FL, 1968, ARCH BIOCHEM BIOPHYS, V124, P238, DOI 10.1016/0003-9861(68)90324-X; HORRUM MA, 1990, MOL CELL ENDOCRINOL, V68, P137, DOI 10.1016/0303-7207(90)90186-C; HORRUM MA, 1985, MOL CELL ENDOCRINOL, V41, P163, DOI 10.1016/0303-7207(85)90019-X; ISMAILBEIGI F, 1971, J GEN PHYSIOL, V57, P710, DOI 10.1085/jgp.57.6.710; JOSTE V, 1989, EUR J BIOCHEM, V184, P255, DOI 10.1111/j.1432-1033.1989.tb15015.x; Keogh J M, 1985, Adv Myocardiol, V6, P299; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; Krebs H.A., 1974, REGULATION HEPATIC M, P726; KREBS HA, 1964, BIOCHEM J, V93, P112, DOI 10.1042/bj0930112; KREBS HA, 1976, GLUCONEOGENESIS ITS, P269; LAHTELA JT, 1990, AM J PHYSIOL, V259, pE389, DOI 10.1152/ajpendo.1990.259.3.E389; LARDY HA, 1951, ANN NY ACAD SCI, V54, P636, DOI 10.1111/j.1749-6632.1951.tb54465.x; LEE YP, 1965, J BIOL CHEM, V240, P1427; MARTI J, 1988, ENDOCRINOLOGY, V123, P2167, DOI 10.1210/endo-123-5-2167; MARTIUS C, 1951, ARCH BIOCHEM BIOPHYS, V33, P486, DOI 10.1016/0003-9861(51)90137-3; MUTVEI A, 1989, ARCH BIOCHEM BIOPHYS, V268, P215, DOI 10.1016/0003-9861(89)90582-1; NOBES CD, 1989, BIOCHIM BIOPHYS ACTA, V976, P241, DOI 10.1016/S0005-2728(89)80236-1; PALACIOSROMERO R, 1979, BIOCHEM J, V184, P527, DOI 10.1042/bj1840527; SEITZ HJ, 1985, BIOCHEM J, V227, P149, DOI 10.1042/bj2270149; SESTOFT L, 1980, CLIN ENDOCRINOL, V13, P489, DOI 10.1111/j.1365-2265.1980.tb03415.x; SHEARS SB, 1981, FEBS LETT, V126, P9, DOI 10.1016/0014-5793(81)81020-4; SHEARS SB, 1979, BIOCHEM J, V178, P505, DOI 10.1042/bj1780505; TATA JR, 1963, BIOCHEM J, V86, P408, DOI 10.1042/bj0860408; THOMAS WE, 1987, BIOCHEM J, V247, P315, DOI 10.1042/bj2470315; VERHOEVEN AJ, 1985, BIOCHEM J, V226, P183, DOI 10.1042/bj2260183; VIGNAIS PV, 1973, BIOCHEMISTRY-US, V12, P1508, DOI 10.1021/bi00732a007; WALLICK ET, 1974, J PHARMACOL EXP THER, V189, P434; WILLIAMSON JR, 1969, J BIOL CHEM, V244, P5044; WILLIAMSON JR, 1969, ENERGY LEVEL METABOL, P385	56	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8903	8908						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577728				2022-12-27	WOS:A1992HR85400033
J	KATAYAMA, Y; NARAHARA, Y; INOUE, Y; AMANO, F; KANAGAWA, T; KURAISHI, H				KATAYAMA, Y; NARAHARA, Y; INOUE, Y; AMANO, F; KANAGAWA, T; KURAISHI, H			A THIOCYANATE HYDROLASE OF THIOBACILLUS-THIOPARUS - A NOVEL ENZYME CATALYZING THE FORMATION OF CARBONYL SULFIDE FROM THIOCYANATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; PROTEINS; OXIDATION; CYANIDE	A thiocyanate hydrolase that catalyzes the first step in thiocyanate degradation was purified to homogeneity from Thiobacillus thioparus, an obligate chemolithotrophic eubacterium metabolizing thiocyanate to sulfate as an energy source. The thiocyanate hydrolase was purified 52-fold by steps involving ammonium sulfate precipitation, DEAE-Sephacel column chromatography, and hydroxylapatite column chromatography. The enzyme hydrolyzed 1 mol of thiocyanate to form 1 mol of carbonyl sulfide and 1 mol of ammonia as follows: SCN- + 2H2O --> COS + NH3 + OH-. This is the first report describing the hydrolysis of thiocyanate to carbonyl sulfide by an enzyme. The enzyme had a molecular mass of 126 kDa and was composed of three different subunits: alpha (19 kDa), beta (23 kDa), and gamma (32 kDa). The enzyme exhibited optimal activities at pH 7.5-8.0 and at temperatures ranging from 30 to 40-degrees-C. The K(m) value for thiocyanate was approximately 11 mM. Immunoblot analysis with polyclonal antibodies against the purified enzyme suggested that it was induced in T. thioparus cells when the cells were grown with thiocyanate.	AGCY IND SCI & TECHNOL,FERMENTAT RES INST,TSUKUBA 305,JAPAN; NATL INST HLTH,DEPT CHEM,SINAGAWA KU,TOKYO 141,JAPAN	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Health Sciences - Japan	KATAYAMA, Y (corresponding author), TOKYO UNIV AGR & TECHNOL,FAC AGR,SAIWAICHO 3,FUCHU,TOKYO 183,JAPAN.		KATAYAMA, Yoko/G-1114-2013	Kanagawa, Takahiro/0000-0003-2476-6767				BETTS PM, 1979, CAN J MICROBIOL, V25, P1277, DOI 10.1139/m79-201; CERLETTI P, 1986, TRENDS BIOCHEM SCI, V129, P369; CHUNG J, 1970, ARCH BIOCHEM BIOPHYS, V141, P73, DOI 10.1016/0003-9861(70)90108-6; COVAL ML, 1967, J BIOL CHEM, V242, P5510; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DAVIS RE, 1962, J PHYS CHEM-US, V66, P956, DOI 10.1021/j100811a512; HAPPOLD FC, 1954, J GEN MICROBIOL, V10, P261, DOI 10.1099/00221287-10-2-261; HAPPOLD FC, 1958, NATURE, V182, P266, DOI 10.1038/182266a0; KATAYAMA Y, 1978, CAN J MICROBIOL, V24, P804, DOI 10.1139/m78-135; KATAYAMAFUJIMURA Y, 1982, J GEN MICROBIOL, V128, P1599; Kelly DP, 1989, BERGEYS MANUAL SYSTE, P1842; KNOWLES CJ, 1976, BACTERIOL REV, V40, P652, DOI 10.1128/MMBR.40.3.652-680.1976; KUNZ DA, 1989, APPL ENVIRON MICROB, V55, P256, DOI 10.1128/AEM.55.1.256-258.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; ORAM JD, 1966, BIOCHEM J, V100, P382, DOI 10.1042/bj1000382; PECK HD, 1968, ANNU REV MICROBIOL, V22, P489, DOI 10.1146/annurev.mi.22.100168.002421; PUTILINA NT, 1961, MIKROBIOLOGIYA, V30, P294; SORBO B, 1958, ACTA CHEM SCAND, V12, P470, DOI 10.3891/acta.chem.scand.12-0470; STAFFORD DA, 1969, J GEN MICROBIOL, V55, P285, DOI 10.1099/00221287-55-2-285; SUZUKI I, 1974, ANNU REV MICROBIOL, V28, P85, DOI 10.1146/annurev.mi.28.100174.000505; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESTLEY J, 1973, ADV ENZYMOL RAMB, V39, P327; WOOD JL, 1975, CHEM BIOCH THIOCYANI, P156; YOUATT JB, 1954, J GEN MICROBIOL, V11, P139, DOI 10.1099/00221287-11-2-139; 1971, TESTING METHODS IND, P90	27	106	112	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9170	9175						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577754				2022-12-27	WOS:A1992HR85400072
J	YU, YT; NILSEN, TW				YU, YT; NILSEN, TW			SEQUENCE REQUIREMENTS FOR MATURATION OF THE 5' TERMINUS OF HUMAN 18-S RIBOSOMAL-RNA INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' END-FORMATION; RIBOSOMAL-RNA; MODIFICATION INTERFERENCE; CLEAVAGE SITE; TRANSCRIPTION; INITIATION; ELEMENTS; POLY(A)	Creation of the mature 5' terminus of human 18 S rRNA in vitro occurs via a two-step processing reaction. In the first step, an endonucleolytic activity found in HeLa cell nucleolar extract cleaves an rRNA precursor spanning the external transcribed spacer-18 S boundary at a position 3 bases upstream from the mature 18 S terminus leaving 2',3'-cyclic phosphate, 5' hydroxyl termini. In the second step, a nucleolytic activity(s) found in HeLa cell cytoplasmic extract removes the 3 extra bases and creates the authentic 5'-phosphorylated terminus of 18 S rRNA. Here we have examined the sequence requirements for the trimming reaction. The trimming activity(s), in addition to requiring a 5' hydroxyl terminus, prefers the naturally occurring adenosine as the 5'-terminal base. By a combination of deletion, site-directed mutagenesis, and chemical modification interference approaches we have also identified a region of 18 S rRNA spanning bases +6 to +25 (with respect to the mature 5' end) which comprises a critical recognition sequence for the trimming activity(s).	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,10900 EUCLID AVE,CLEVELAND,OH 44106	Case Western Reserve University					NIGMS NIH HHS [GM-31528] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031528] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD VD, 1985, BIOCHEMISTRY-US, V24, P5716, DOI 10.1021/bi00342a005; CONWAY L, 1987, EMBO J, V6, P4177, DOI 10.1002/j.1460-2075.1987.tb02764.x; CRAIG N, 1987, P NATL ACAD SCI USA, V84, P629, DOI 10.1073/pnas.84.3.629; CRAIG N, 1991, MOL CELL BIOL, V11, P458, DOI 10.1128/MCB.11.1.458; CROUCH R, 1984, PROCESSING RNA, P214; ENGLAND TE, 1978, NATURE, V275, P560, DOI 10.1038/275560a0; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; HANNON GJ, 1989, MOL CELL BIOL, V9, P4422, DOI 10.1128/MCB.9.10.4422; KASS S, 1987, MOL CELL BIOL, V7, P2891, DOI 10.1128/MCB.7.8.2891; KASS S, 1990, MOL CELL BIOL, V10, P4920, DOI 10.1128/MCB.10.9.4920; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANG KM, 1990, MOL CELL BIOL, V10, P4942, DOI 10.1128/MCB.10.9.4942; MILLER KG, 1981, CELL, V27, P165, DOI 10.1016/0092-8674(81)90370-6; MOWRY KL, 1989, MOL CELL BIOL, V9, P3105, DOI 10.1128/MCB.9.7.3105; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PERRY RP, 1976, ANNU REV BIOCHEM, V45, P605, DOI 10.1146/annurev.bi.45.070176.003133; RYMOND BC, 1988, GENE DEV, V2, P428, DOI 10.1101/gad.2.4.428; SHUMARD CM, 1990, MOL CELL BIOL, V10, P3868, DOI 10.1128/MCB.10.8.3868; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F	21	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9264	9268						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577760				2022-12-27	WOS:A1992HR85400085
J	BUSSOLATI, O; LARIS, PC; ROTOLI, BM; DALLASTA, V; GAZZOLA, GC				BUSSOLATI, O; LARIS, PC; ROTOLI, BM; DALLASTA, V; GAZZOLA, GC			TRANSPORT-SYSTEM ASC FOR NEUTRAL AMINO-ACIDS - AN ELECTRONEUTRAL SODIUM AMINO-ACID COTRANSPORT SENSITIVE TO THE MEMBRANE-POTENTIAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; HAMSTER OVARY CELLS; DEPENDENCE; PROTEIN	The influx of L-threonine through system ASC does not influence the membrane potential in cultured human fibroblasts although comparable fluxes of amino acids through another Na+-dependent agency, system A, effectively depolarize the cells. The membrane potential, however, stimulates the influx of amino acids through system ASC with a maximal effect at -50 mV. The sensitivity of amino acid influx through system ASC to the membrane potential is not constant, but rather, is dependent on intracellular and extracellular concentrations of the substrates, Na+ and amino acids, of the system. Conditions which favor the loading of the ASC carrier at the external surface reduce the sensitivity of ASC-mediated amino acid influx to the membrane potential; in contrast, the sensitivity of this amino acid influx increases under conditions which favor loading of the carrier at the internal surface. Trans-stimulation, a well known characteristic of system ASC, also varies with the concentrations of the substrates of the system and, in fact, this characteristic is not observed when external Na+ is low. These data may be accommodated by a model in which an electrically silent mode of operation of the transporter is dominant. The influence of the membrane potential on the transport system is dependent on the extent to which a charge-translocating step in the cycling of the carrier is rate limiting (relative rate limitance).	UNIV CALIF SANTA BARBARA,DEPT BIOL SCI,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara	BUSSOLATI, O (corresponding author), UNIV PARMA,IST PATOL GEN,VIA GRAMSCI 14,I-43100 PARMA,ITALY.		Dall'Asta, Valeria/M-6698-2015; Bussolati, Ovidio/B-7589-2013	Dall'Asta, Valeria/0000-0001-8540-0916; Bussolati, Ovidio/0000-0002-4301-2939				BASS R, 1981, J BIOL CHEM, V256, P259; BUSSOLATI O, 1991, BIOCHIM BIOPHYS ACTA, V1070, P305, DOI 10.1016/0005-2736(91)90071-F; BUSSOLATI O, 1986, BIOCHIM BIOPHYS ACTA, V854, P240, DOI 10.1016/0005-2736(86)90116-1; BUSSOLATI O, 1987, AM J PHYSIOL, V253, pC391, DOI 10.1152/ajpcell.1987.253.3.C391; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; CHRISTENSEN HN, 1967, J BIOL CHEM, V242, P5237; CHRISTENSEN HN, 1972, NA LINKED TRANSPORT, P161; DALLASTA V, 1991, J BIOL CHEM, V266, P1591; EAVENSON E, 1967, J BIOL CHEM, V242, P5386; FRANCHIGAZZOLA R, 1981, J BIOL CHEM, V257, P9582; GAZZOLA GC, 1980, J BIOL CHEM, V255, P929; GAZZOLA GC, 1981, J BIOL CHEM, V256, P3191; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; GAZZOLA GC, 1984, FED PROC, V43, P1777; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GRYGORCZYK R, 1987, J MEMBRANE BIOL, V99, P127, DOI 10.1007/BF01871232; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P329, DOI 10.1016/0304-4157(78)90009-6; HEINZ E, 1988, BIOCHIM BIOPHYS ACTA, V937, P300, DOI 10.1016/0005-2736(88)90252-0; KILBERG MS, 1981, J BIOL CHEM, V256, P3304; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; OXENDER DL, 1963, J BIOL CHEM, V238, P3686; SHOTWELL MA, 1981, J BIOL CHEM, V256, P5422; VALDEOLMILLOS M, 1986, BIOCHIM BIOPHYS ACTA, V858, P181, DOI 10.1016/0005-2736(86)90304-4; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2; WHEELER KP, 1967, J BIOL CHEM, V242, P3782	25	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8330	8335						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569087				2022-12-27	WOS:A1992HQ18500058
J	MAITY, SN; DECROMBRUGGHE, B				MAITY, SN; DECROMBRUGGHE, B			BIOCHEMICAL-ANALYSIS OF THE B-SUBUNIT OF THE HETEROMERIC CCAAT-BINDING FACTOR - A DNA-BINDING DOMAIN AND A-SUBUNIT INTERACTION DOMAIN ARE SPECIFIED BY 2 SEPARATE SEGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR; YEAST HAP2; DIMERIZATION; PROTEINS; CONTAINS; PROMOTER; SEQUENCE; SITE	CCAAT-binding factors A (CBF-A) and B (CBF-B) are two subunits of the heteromeric CCAAT-binding factor. Portions of CBF-A and CBF-B have a high degree of amino acid sequence identity to segments of the HAP3 and HAP2 subunits of a yeast multimeric transcription factor. We show here that the subunits of CBF interact with each other in the absence of DNA binding. This interaction was revealed by cross-linking and coimmunoprecipitation studies. Both the DNA binding and subunit interaction functions of CBF-B have been examined by mutational analysis. A segment of 83 amino acids from residues 252 to 334, which corresponds to the evolutionarily conserved portion of CBF-B, is necessary and sufficient for CBF-A-dependent DNA binding. Carboxyl-terminal deletions of this segment (or mutations in arginine residues in this carboxyl-terminal part) abolish DNA binding, but do not alter subunit interactions between CBF-A and CBF-B. Mutations in hydrophobic amino acids within the amino-terminal part of the evolutionarily conserved sequence at positions 252-334 result in loss of both DNA binding and subunit interaction activities. Our results indicate that the evolutionarily conserved segment of CBF-B contains both DNA-binding and subunit interaction domains and that the integrity of both domains is essential for DNA binding.			MAITY, SN (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030, USA.			Maity, Sankar/0000-0002-2387-6545	NATIONAL CANCER INSTITUTE [R01CA049515, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 49515] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; OLESEN JT, 1991, MOL CELL BIOL, V11, P611, DOI 10.1128/MCB.11.2.611; PINKHAM JL, 1987, MOL CELL BIOL, V7, P575; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VUORIO T, 1990, J BIOL CHEM, V265, P22480	27	71	75	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8286	8292						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569083				2022-12-27	WOS:A1992HQ18500051
J	PEREIRA, ME; NGUYEN, T; WAGNER, BJ; MARGOLIS, JW; WILK, S				PEREIRA, ME; NGUYEN, T; WAGNER, BJ; MARGOLIS, JW; WILK, S			3,4-DICHLOROISOCOUMARIN-INDUCED ACTIVATION OF THE DEGRADATION OF BETA-CASEIN BY THE BOVINE PITUITARY MULTICATALYTIC PROTEINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NEUTRAL ENDOPEPTIDASE; RAT HEPATOMA-CELLS; CDNA CLONING; PROTEASE COMPLEX; GENE FAMILY; PURIFICATION; LENS; SPECIFICITY; ENZYME; MEMBER	The breakdown of beta-casein (caseinolytic activity) by the bovine pituitary multicatalytic proteinase complex (MPC) is initiated by a fourth active site different from the previously described chymotrypsin-like activity (cleavage of Cbz-Gly-Gly-Leu-p-nitroanilide, where Cbz is benzyloxycarbonyl), trypsin-like activity (cleavage of CbZ-D-Ala-Leu-Arg-2-naphthylamide), and peptidylglutamyl peptide bond-hydrolyzing (PGP) activity (cleavage of Cbz-Leu-Leu-Glu-2-naphthylamide) (Yu, B., Pereira, M. E., and Wilk, S. (1991) J. Biol. Chem. 266, 17396-17400). 3,4-Dichloroisocoumarin, a serine proteinase inhibitor, stimulated the caseinolytic activity of bovine pituitary or lens MPC, 3-18-fold under conditions under which the other three catalytic activities were inactivated. Addition of hydroxylamine to the modified enzyme did not reverse the effects of the inhibitor. A form of the proteinase exhibiting only 2-4% of control chymotrypsin-like, trypsin-like, and PGP activities degraded beta-casein with no accumulation of intermediate peptides. 3,4-Dichloroisocoumarin, by reacting with the chymotrypsin-like, trypsin-like, and/or PGP-active sites, may promote a conformational change of MPC, rendering the caseinolytic active site accessible to the substrate. Once bound to the active site, beta-casein is rapidly degraded either by the caseinolytic component itself or by a cooperative interaction with catalytic centers that are not affected by the serine proteinase inhibitor. These results imply that the caseinolytic component does not belong to the class of serine proteinases. Other proteins tested were not degraded by the 3,4-dichloroisocoumarin-treated enzyme, suggesting that the conformation of beta-casein may be more adequate for degradation by the caseinolytic component.	CUNY MT SINAI SCH MED,DEPT PHARMACOL,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT BIOCHEM & MOLEC BIOL,NEWARK,NJ 07103	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rutgers State University New Brunswick; Rutgers State University Medical Center			Pereira, Maria/GZA-9681-2022		NATIONAL EYE INSTITUTE [R01EY002299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017392] Funding Source: NIH RePORTER; NEI NIH HHS [EY 02299] Funding Source: Medline; NIMH NIH HHS [MH 00350] Funding Source: Medline; NINDS NIH HHS [NS-17392] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOW AMJ, 1975, BIOCHEM J, V145, P591, DOI 10.1042/bj1450591; DAHLMANN B, 1985, BIOCHEM J, V228, P161, DOI 10.1042/bj2280161; EMORI Y, 1991, MOL CELL BIOL, V11, P344, DOI 10.1128/MCB.11.1.344; FENNER C, 1975, ANAL BIOCHEM, V63, P595, DOI 10.1016/0003-2697(75)90386-3; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; HAASS C, 1989, EMBO J, V8, P2373, DOI 10.1002/j.1460-2075.1989.tb08366.x; HAASS C, 1990, GENE, V90, P235, DOI 10.1016/0378-1119(90)90185-T; HAASS C, 1990, NUCLEIC ACIDS RES, V18, P4018, DOI 10.1093/nar/18.13.4018; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; KUMATORI A, 1990, FEBS LETT, V264, P279, DOI 10.1016/0014-5793(90)80267-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASON RW, 1990, BIOCHEM J, V265, P479, DOI 10.1042/bj2650479; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MELLGREN RL, 1990, BIOCHIM BIOPHYS ACTA, V1040, P28, DOI 10.1016/0167-4838(90)90142-3; MYKLES DL, 1991, ARCH BIOCHEM BIOPHYS, V288, P543, DOI 10.1016/0003-9861(91)90233-9; MYKLES DL, 1989, ARCH BIOCHEM BIOPHYS, V274, P216, DOI 10.1016/0003-9861(89)90433-5; ORLOWSKI M, 1991, BIOCHEMISTRY-US, V30, P5999, DOI 10.1021/bi00238a025; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; ORLOWSKI M, 1981, BIOCHEM BIOPH RES CO, V101, P814; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PEREIRA ME, 1990, ARCH BIOCHEM BIOPHYS, V283, P68, DOI 10.1016/0003-9861(90)90613-4; PEREIRA ME, 1992, IN PRESS ARCH BIOCH; RAY K, 1986, FEBS LETT, V194, P91, DOI 10.1016/0014-5793(86)80057-6; RAY K, 1985, P NATL ACAD SCI USA, V82, P7545, DOI 10.1073/pnas.82.22.7545; RIORDAN JF, 1965, BIOCHEMISTRY-US, V4, P1765; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1991, BIOCHEM J, V278, P171, DOI 10.1042/bj2780171; SACCHETTA P, 1990, BIOCHIM BIOPHYS ACTA, V1089, P95; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TANAKA K, 1990, CELL STRUCT FUNCT, V15, P127, DOI 10.1247/csf.15.127; TANAKA K, 1990, BIOCHEM BIOPH RES CO, V171, P676, DOI 10.1016/0006-291X(90)91199-3; TANAKA K, 1986, J BIOL CHEM, V261, P5197; WAGNER BJ, 1982, EXP EYE RES, V35, P293, DOI 10.1016/S0014-4835(82)80054-7; WAXMAN L, 1987, J BIOL CHEM, V262, P2451; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WILK S, 1979, LIFE SCI, V24, P457, DOI 10.1016/0024-3205(79)90218-2; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; WILK S, 1991, BIOMED BIOCHIM ACTA, V50, P471; YU B, 1991, J BIOL CHEM, V266, P17396; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R	44	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7949	7955						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560024				2022-12-27	WOS:A1992HN48500104
J	DHAUNSI, GS; GULATI, S; SINGH, AK; ORAK, JK; ASAYAMA, K; SINGH, I				DHAUNSI, GS; GULATI, S; SINGH, AK; ORAK, JK; ASAYAMA, K; SINGH, I			DEMONSTRATION OF CU-ZN SUPEROXIDE-DISMUTASE IN RAT-LIVER PEROXISOMES - BIOCHEMICAL AND IMMUNOCHEMICAL EVIDENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED SUBCELLULAR MEMBRANES; REPERFUSION INJURY; LOCALIZATION; MICROSOMES; FRACTIONS; PROTEINS; CATALASE	In this study, by using highly purified rat liver peroxisomes, we provide evidence from analytical cell fractionation, Western blot, and immunocytochemical analysis that Cu-Zn superoxide dismutase is present in animal peroxisomes. Treatment with ciprofibrate, a peroxisome proliferator, increased the peroxisomal superoxide dismutase activity by 3-fold with no effect on mitochondrial activity but a marked decrease in cytosolic superoxide dismutase activity, further supporting that besides cytosolic and mitochondrial localization, Cu-Zn superoxide dismutase is present in peroxisomes also. Demonstration of superoxide dismutase in peroxisomes suggests a new role for this organelle in pathophysiological conditions, such as ischemia-reperfusion injury.	MED UNIV S CAROLINA, DEPT PEDIAT & PATHOL, CHARLESTON, SC 29425 USA; VET AFFAIRS MED CTR, CHARLESTON, SC 29425 USA; YAMANASHI MED COLL, DEPT PEDIAT, YAMANASHI 40938, JAPAN	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Yamanashi					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS022576, R01NS022576] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-22576] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABERNETHY JL, 1974, J BIOL CHEM, V249, P7339; AMES GFL, 1974, J BIOL CHEM, V249, P634; ANGERMULLER S, 1987, EUR J CELL BIOL, V45, P137; ASAYAMA K, 1985, J BIOL CHEM, V260, P2212; BABIOR BM, 1984, J CLIN INVEST, V73, P599, DOI 10.1172/JCI111249; BARRET AJ, 1977, LYSOSOMES LABORATORY, V2, P19; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; DELRIO LA, 1990, EXPERIENTIA, V46, P989, DOI 10.1007/BF01940651; DOBASHI K, 1989, ACTA HISTOCHEM CYTOC, V22, P351, DOI 10.1267/ahc.22.351; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; FLAHERTY JT, 1988, FREE RADICAL BIO MED, V5, P409, DOI 10.1016/0891-5849(88)90115-3; FOWLER S, 1976, J CELL BIOL, V71, P535, DOI 10.1083/jcb.71.2.535; GELLER BL, 1984, METHOD ENZYMOL, V105, P105; Grisham MB, 1986, PHYSL OXYGEN RADICAL, P01; GULATI S, 1991, FASEB J, V5, pA890; GUTIERREZ C, 1988, J LIPID RES, V29, P613; JOHNSON KJ, 1988, OXYGEN RADICALS TISS, P115; JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277; KONO Y, 1982, J BIOL CHEM, V257, P5751; KUKIELKA E, 1990, ARCH BIOCHEM BIOPHYS, V283, P326, DOI 10.1016/0003-9861(90)90650-N; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LAZO O, 1991, MOL CELL BIOCHEM, V100, P159; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; MATSUDA Y, 1990, EUR J BIOCHEM, V194, P713, DOI 10.1111/j.1432-1033.1990.tb19461.x; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MICHIELS C, 1988, EXP CELL RES, V179, P581, DOI 10.1016/0014-4827(88)90296-0; OSUDA N, 1988, LAB INVEST, V58, P100; OSUMI T, 1990, BIOESSAYS, V12, P217, DOI 10.1002/bies.950120505; RATYCH R E, 1986, Journal of Free Radicals in Biology and Medicine, V2, P311, DOI 10.1016/S0748-5514(86)80030-7; REILLY PM, 1991, AM J SURG, V161, P488, DOI 10.1016/0002-9610(91)91120-8; ROISE D, 1988, J BIOL CHEM, V263, P4509; RUIDERA E, 1988, LIPIDS, V23, P882, DOI 10.1007/BF02536209; SINGH I, 1988, AM J DIS CHILD, V142, P1297, DOI 10.1001/archpedi.1988.02150120051039; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025	39	98	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6870	6873						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551895				2022-12-27	WOS:A1992HM05300064
J	KASURINEN, J; SOMERHARJU, P				KASURINEN, J; SOMERHARJU, P			METABOLISM OF PYRENYL FATTY-ACIDS IN BABY HAMSTER-KIDNEY FIBROBLASTS - EFFECT OF THE ACYL CHAIN-LENGTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID STORAGE MYOPATHY; LYMPHOID-CELL LINES; APOLIPOPROTEIN-PHOSPHOLIPID RECOMBINANTS; PERFORMANCE LIQUID-CHROMATOGRAPHY; TRANSFER PROTEIN; PHOSPHATIDYLCHOLINE TRANSFER; CULTURED FIBROBLASTS; BINDING-SITES; ANIMAL-CELLS; LIVING CELLS	Biosynthetic labeling of cellular lipids with a fluorescent pyrenyl fatty acid (PyrxFA) moiety was studied in order to assess the usefulness of this approach in the introduction of fluorescent lipid molecules to living cells for transport and metabolic studies. PyrxFAs containing 4-14 aliphatic carbons were added to the culture medium of baby hamster kidney (BHK) fibroblasts, and their incorporation to various lipid species was monitored by thin layer and high pressure liquid chromatography. The results show that the length of the acyl chain has a remarkable effect on the efficiency of incorporation as well as distribution of the label between lipid species. Accordingly, PyrxFAs can be divided into two groups: the short chain ones including the pyrene butyrate and hexanoate derivatives, which show only modest incorporation to phospholipids and negligible labeling of triglycerides and cholesterol esters, and the long chain PyrxFAs including pyrene octanoate, decanoate, dodecanoate, and myristate derivatives, which incorporate efficiently both to phospholipids, mainly phosphatidylcholine (PC) and -ethanolamine (PE), and neutral lipids, i.e. di- and triglycerides and cholesterol esters. Positional analysis showed that the longer PyrxFAs are esterified preferentially to the sn-1 position of the glycerol moiety of PC and PE while the shorter ones are found exclusively in the sn-2 position indicating that the longer PyrxFAs mimic natural saturated fatty acids whereas the shorter ones may be recognized as polyunsaturated fatty acids by the acylating enzymes. Reverse phase chromatography of PC and PE revealed the presence of a variety of labeled molecular species among which the palmitate and oleate containing species were the major ones. Reverse phase analysis with simultaneous monitoring at the monomer and excimer channels showed the presence of tri- and diglyceride species with either 1 or 2 pyrenyl acyl residues. Analysis of the total cellular fatty acids demonstrated that PyrxFAs are shortened, probably by beta-oxidation in peroxisomes, up to pyrene butyrate. It is concluded that metabolic labeling with PyrxFAs is a promising alternative for studies on intracellular lipid traffic, especially because it allows introduction of fluorescent phospholipid species of very different hydrophobicity into intracellular membrane(s).			KASURINEN, J (corresponding author), UNIV HELSINKI,DEPT MED CHEM,SILTAVUORENPENGER 10,SF-00170 HELSINKI 17,FINLAND.							BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROTHERUS J, 1977, J LIPID RES, V18, P191; Christie W. W., 1987, HIGH PERFORMANCE LIQ; CHRISTIE WW, 1985, J LIPID RES, V26, P507; DERZKO Z, 1980, BIOCHEMISTRY-US, V19, P6050, DOI 10.1021/bi00567a016; DIX JA, 1990, BIOCHEMISTRY-US, V29, P1949, DOI 10.1021/bi00459a041; ESKO JD, 1980, J BIOL CHEM, V255, P4474; Galla H J, 1981, Methods Enzymol, V72, P471; GALLA HJ, 1980, CHEM PHYS LIPIDS, V27, P199, DOI 10.1016/0009-3084(80)90036-5; GATT S, 1988, BIOCHEM J, V253, P377, DOI 10.1042/bj2530377; GATT S, 1988, BIOCHIM BIOPHYS ACTA, V958, P130, DOI 10.1016/0005-2760(88)90254-8; Holub B J, 1978, Adv Lipid Res, V16, P1; HOMAN R, 1989, ANAL BIOCHEM, V178, P166, DOI 10.1016/0003-2697(89)90374-6; JONES JD, 1989, BIOCHEMISTRY-US, V28, P129, DOI 10.1021/bi00427a019; KASURINEN J, 1990, BIOCHEMISTRY-US, V29, P8548, DOI 10.1021/bi00489a007; LEVADE T, 1987, BIOCHIM BIOPHYS ACTA, V918, P250, DOI 10.1016/0005-2760(87)90228-1; Markwell M A, 1981, Methods Enzymol, V72, P296; MASSEY JB, 1985, BIOCHIM BIOPHYS ACTA, V835, P124, DOI 10.1016/0005-2760(85)90038-4; MASSEY JB, 1982, J BIOL CHEM, V257, P5444; MASSEY JB, 1984, BIOCHIM BIOPHYS ACTA, V794, P274, DOI 10.1016/0005-2760(84)90156-5; MASSEY JB, 1982, BIOCHEMISTRY-US, V21, P3630, DOI 10.1021/bi00258a016; MORAND O, 1982, BIOCHIM BIOPHYS ACTA, V711, P539, DOI 10.1016/0005-2760(82)90070-4; NEGRE A, 1987, BIOCHIM BIOPHYS ACTA, V918, P76, DOI 10.1016/0005-2760(87)90011-7; Pagano RE, 1990, CURR OPIN CELL BIOL, V2, P652, DOI 10.1016/0955-0674(90)90107-P; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; PAL R, 1988, BIOCHEMISTRY-US, V27, P30, DOI 10.1021/bi00401a006; PATEL KM, 1979, LIPIDS, V14, P816, DOI 10.1007/BF02533521; PATTON GM, 1982, J LIPID RES, V23, P190; POWNALL HJ, 1989, CHEM PHYS LIPIDS, V50, P191, DOI 10.1016/0009-3084(89)90050-9; RADOM J, 1989, BIOCHIM BIOPHYS ACTA, V1005, P130, DOI 10.1016/0005-2760(89)90178-1; RADOM J, 1987, BIOCHIM BIOPHYS ACTA, V920, P131, DOI 10.1016/0005-2760(87)90252-9; RADOM J, 1990, BIOCHEM J, V269, P107, DOI 10.1042/bj2690107; RENKONEN O, 1966, BIOCHIM BIOPHYS ACTA, V125, P288, DOI 10.1016/0005-2760(66)90070-1; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SOMERHARJU PJ, 1987, BIOCHEMISTRY-US, V26, P7193, DOI 10.1021/bi00396a048; SOMERHARJU PJ, 1985, BIOCHEMISTRY-US, V24, P2773, DOI 10.1021/bi00332a027; USTER PS, 1986, J CELL BIOL, V103, P1221, DOI 10.1083/jcb.103.4.1221; VAN GOLDE L. M. G., 1967, CHEM PHYS LIPIDS, V1, P157, DOI 10.1016/0009-3084(67)90007-2; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VANAMERONGEN A, 1989, BIOCHIM BIOPHYS ACTA, V1004, P36, DOI 10.1016/0005-2760(89)90209-9; VANMEER G, 1988, BIOCHEMISTRY-US, V27, P6197; VANPARIDON PA, 1988, BIOCHEMISTRY-US, V27, P6208, DOI 10.1021/bi00417a003; VAUHKONEN M, 1990, BIOPHYS J, V57, P291, DOI 10.1016/S0006-3495(90)82531-5; VIA DP, 1985, BIOCHIM BIOPHYS ACTA, V837, P27, DOI 10.1016/0005-2760(85)90082-7	45	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6563	6569						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551867				2022-12-27	WOS:A1992HM05300020
J	GITAYGOREN, H; SOKER, S; VLODAVSKY, I; NEUFELD, G				GITAYGOREN, H; SOKER, S; VLODAVSKY, I; NEUFELD, G			THE BINDING OF VASCULAR ENDOTHELIAL GROWTH-FACTOR TO ITS RECEPTORS IS DEPENDENT ON CELL SURFACE-ASSOCIATED HEPARIN-LIKE MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; EXTRACELLULAR-MATRIX; FACTOR-BETA; MITOGEN; PROTEOGLYCAN; EXPRESSION; CLONING; LIGAND	Vascular endothelial growth factor (VEGF) induces the proliferation of endothelial cells and is a potent angiogenic factor that binds to heparin. We have therefore studied the effect of heparin upon the interaction of VEGF with its receptors. Heparin, at concentrations ranging from 0.1 to 10-mu-g/ml, strongly potentiated the binding of I-125-VEGF to its receptors on endothelial cells. Scatchard analysis of I-125-VEGF binding indicates that 1-mu-g/ml heparin induces an 8-fold increase in the apparent density of high affinity binding sites for VEGF, but does not significantly affect the dissociation constant of VEGF. Cross-linking experiments showed that heparin strongly potentiates the formation of the 170-, 195-, and 225-kDa I-125-VEGF-receptor complexes on endothelial cells. At high I-125-VEGF concentrations (4 ng/ml), heparin preferentially enhanced the formation of the 170- and 195-kDa complexes. Preincubation of the cells with heparin, followed by extensive washes, produced a similar enhancement of subsequent I-125-VEGF binding. The binding of I-125-VEGF was completely inhibited following digestion of endothelial cells with heparinase and could be restored by the addition of exogenous heparin to the digested cells. The enhancing effect of heparin facilitated the detection of VEGF receptors on cell types that were not known previously to express such receptors. Our results suggest that cell surface-associated heparin-like molecules are required for the interaction of VEGF with its cell surface receptors.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL; HADASSAH UNIV HOSP,DEPT ONCOL,IL-91120 JERUSALEM,ISRAEL	Technion Israel Institute of Technology; Hebrew University of Jerusalem			Neufeld, Gera/F-1524-2019					ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FOLKMAN J, 1986, CANCER RES, V46, P467; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; GOSPODAROWICZ D, 1983, J CELL BIOL, V97, P1677, DOI 10.1083/jcb.97.6.1677; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HICKS K, 1989, BIOCHEM BIOPH RES CO, V164, P1323, DOI 10.1016/0006-291X(89)91814-7; ISHAIMICHAELI R, 1991, IN PRESS BIOCHEMISTR; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUFELD G, 1987, J CELL PHYSIOL, V132, P287, DOI 10.1002/jcp.1041320213; NEUFELD G, 1987, ENDOCRINOLOGY, V121, P597, DOI 10.1210/endo-121-2-597; OLANDER JV, 1991, BIOCHEM BIOPH RES CO, V175, P68, DOI 10.1016/S0006-291X(05)81201-X; PLOUET J, 1990, J BIOL CHEM, V265, P22071; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819	37	440	461	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6093	6098						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556117				2022-12-27	WOS:A1992HK31800058
J	REISS, Y; BROWN, MS; GOLDSTEIN, JL				REISS, Y; BROWN, MS; GOLDSTEIN, JL			DIVALENT-CATION AND PRENYL PYROPHOSPHATE SPECIFICITIES OF THE PROTEIN FARNESYLTRANSFERASE FROM RAT-BRAIN, A ZINC METALLOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERASE; CATALYSIS; FARNESYL; CELLS	The separate catalytic roles of Zn2+ and Mg2+ and the specificity of the prenyl pyrophosphate-binding site of the rat brain protein farnesyltransferase were explored using a purified enzyme preparation. The binding of p21Hras to the enzyme was abolished by dialysis against EDTA and restored by addition of ZnCl2, as demonstrated by chemical cross-linking. The binding of the other substrate, farnesyl pyrophosphate, was independent of divalent cations, as demonstrated by gel filtration. Transfer of the enzyme-bound farnesyl group to the bound p21Hras required Mg2+. Geranylgeranyl pyrophosphate bound to the prenyl pyrophosphate-binding site with an affinity equal to that of farnesyl pyrophosphate, but the geranylgeranyl group was not transferred efficiently to p21Hras. It also was not transferred to a modified p21Hras containing COOH-terminal leucine, a protein that was shown previously to be a good substrate for a rat brain geranylgeranyltransferase. We conclude that the protein farnesyltransferase is a metalloenzyme that most likely contains Zn2+ at the peptide-binding site. It thus resembles certain metallopeptidases, including carboxypeptidase A and the angiotensin-converting enzyme. Strategies previously developed to screen for inhibitors of those enzymes may aid in the search for inhibitors of the protein farnesyltransferase.			REISS, Y (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; KING HL, 1977, BIOCHEMISTRY-US, V16, P3815, DOI 10.1021/bi00636a015; LIPSCOMB WN, 1974, TETRAHEDRON, V30, P1725, DOI 10.1016/S0040-4020(01)97306-5; MOORES SL, 1991, J BIOL CHEM, V266, P14603; PETRILLO EW, 1982, MED RES REV, V2, P1, DOI 10.1002/med.2610020103; REISS Y, 1990, Methods (Orlando), V1, P241, DOI 10.1016/S1046-2023(05)80323-8; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; RILLING HC, 1985, METHOD ENZYMOL, V110, P145; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	24	176	182	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6403	6408						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556143				2022-12-27	WOS:A1992HK31800101
J	COOPER, TA				COOPER, TA			INVITRO SPLICING OF CARDIAC TROPONIN-T PRECURSORS - EXON MUTATIONS DISRUPT SPLICING OF THE UPSTREAM INTRON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; BRANCH POINT SELECTION; BETA-TROPOMYOSIN GENE; SITE SELECTION; SECONDARY STRUCTURE; SEQUENCES; TRANSCRIPTS; POLYMERASE; LOCATION; PATTERNS	A single cardiac troponin T (cTNT) gene generates two mRNAs by including or excluding the 30-nucleotide exon 5 during pre-mRNA processing. Transfection analysis of cTNT minigenes has previously demonstrated that both mRNAs are expressed from unmodified minigenes, and mutations within exon 5 can lead to complete skipping of the exon. These results suggested a role for exon sequence in splice site recognition. To investigate this potential role, an in vitro splicing system using cTNT precursors has been established. Two-exon precursors containing the alternative exon and either the upstream exon or downstream exon were spliced accurately and efficiently in vitro. The mutations within the alternative exon that resulted in exon skipping in vivo specifically blocked splicing of the upstream intron in vitro and had no effect on removal of the downstream intron. In addition, the splicing intermediates of these two precursors have been characterized, and the branch sites utilized on the introns flanking the alternative exon have been determined. Potential roles of exon sequence in splice site selection are discussed. These results establish a system that will be useful for the biochemical characterization of the role of exon sequence in splice site selection.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	COOPER, TA (corresponding author), BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030, USA.							ADEMA GJ, 1988, NUCLEIC ACIDS RES, V16, P9513, DOI 10.1093/nar/16.20.9513; BLACK DL, 1991, GENE DEV, V5, P389, DOI 10.1101/gad.5.3.389; CHAIN AC, 1991, MOL CELL BIOL, V11, P1538, DOI 10.1128/MCB.11.3.1538; CHEBLI K, 1989, MOL CELL BIOL, V9, P4852, DOI 10.1128/MCB.9.11.4852; CHENG J, 1990, Molecular and Cellular Biology, V10, P5215; COOPER TA, 1988, NUCLEIC ACIDS RES, V16, P8443, DOI 10.1093/nar/16.17.8443; COOPER TA, 1989, NUCLEIC ACIDS RES, V17, P7905, DOI 10.1093/nar/17.19.7905; COOPER TA, 1985, J BIOL CHEM, V260, P1140; COOPER TA, 1984, SCIENCE, V226, P979, DOI 10.1126/science.6095446; COTE GJ, 1990, MOL ENDOCRINOL, V4, P1744, DOI 10.1210/mend-4-11-1744; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMENJOUD L, 1991, MOL CELL BIOL, V11, P4581, DOI 10.1128/MCB.11.9.4581; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; FU XD, 1991, GENE DEV, V5, P211, DOI 10.1101/gad.5.2.211; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; HAMPSON RK, 1989, MOL CELL BIOL, V9, P1604, DOI 10.1128/MCB.9.4.1604; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HELFMAN DM, 1989, NUCLEIC ACIDS RES, V17, P5633, DOI 10.1093/nar/17.14.5633; KAKIZUKA A, 1990, J BIOL CHEM, V265, P10102; KATZ RA, 1990, MOL CELL BIOL, V10, P696, DOI 10.1128/MCB.10.2.696; KEDES DH, 1987, P NATL ACAD SCI USA, V84, P7928, DOI 10.1073/pnas.84.22.7928; KELLER EB, 1984, P NATL ACAD SCI-BIOL, V81, P7417, DOI 10.1073/pnas.81.23.7417; KOU H, 1991, SCIENCE, V251, P1045; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAINER AR, 1988, FRONTIERS MOL BIOL T, P131; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; LOWERY DE, 1987, MOL CELL BIOL, V7, P1346, DOI 10.1128/MCB.7.4.1346; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MARDON HJ, 1987, NUCLEIC ACIDS RES, V15, P7725, DOI 10.1093/nar/15.19.7725; MATSUO M, 1991, J CLIN INVEST, V87, P2127, DOI 10.1172/JCI115244; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NASIM FH, 1990, GENE DEV, V4, P1172, DOI 10.1101/gad.4.7.1172; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; NOBLE JCS, 1988, GENE DEV, V2, P1460, DOI 10.1101/gad.2.11.1460; NOBLE JCS, 1987, CELL, V50, P227, DOI 10.1016/0092-8674(87)90218-2; NORTON PA, 1990, NUCLEIC ACIDS RES, V18, P4089, DOI 10.1093/nar/18.14.4089; OSHIMA Y, 1987, J MOL BIOL, V195, P247; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RICKETTS MH, 1987, P NATL ACAD SCI USA, V84, P3181, DOI 10.1073/pnas.84.10.3181; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITT P, 1987, CELL, V50, P31, DOI 10.1016/0092-8674(87)90659-3; SHELNESS GS, 1987, MOL BIOL RNA NEW PER, P381; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOLNICK D, 1985, CELL, V43, P667, DOI 10.1016/0092-8674(85)90239-9; SOMASEKHAR MB, 1985, NUCLEIC ACIDS RES, V13, P5591, DOI 10.1093/nar/13.15.5591; STEITZ JA, 1988, STRUCTURE FUNCTION M; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; TALERICO M, 1990, MOL CELL BIOL, V10, P6299, DOI 10.1128/MCB.10.12.6299; TSAI AYM, 1989, MOL CELL BIOL, V9, P4550, DOI 10.1128/MCB.9.10.4550; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752	64	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5330	5338						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544914				2022-12-27	WOS:A1992HH74700052
J	RAMSAY, RG; ISHII, S; GONDA, TJ				RAMSAY, RG; ISHII, S; GONDA, TJ			INTERACTION OF THE MYB PROTEIN WITH SPECIFIC DNA-BINDING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYB; V-MYB; TRANSCRIPTIONAL ACTIVATION; HEMATOPOIETIC-CELLS; TRANSFORMING GENE; ONCOGENE PRODUCT; LEUCINE ZIPPER; EXPRESSION; SEQUENCE; PROTOONCOGENE	c-myb is expressed predominantly in proliferating immature hemopoietic cells and, like v-myb, functions as a transcriptional activator that displays sequence-specific DNA binding. Oncogenic activation of the c-myb protein (Myb) is associated with carboxyl-terminal and/or amino-terminal truncations, the former of which also potentiates Myb's transcriptional activation capacity. We show here that a carboxyl-truncated Myb protein binds with a 7-fold higher affinity to an oligonucleotide bearing a Myb recognition sequence than does the full-length form. In addition, data are presented which show that Myb binds with different apparent affinities to variants of the recognition site and that Myb binds independently to adjacent sites regardless of the orientation of these sites.	INST PHYS & CHEM RES,RIKEN TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN	RIKEN	RAMSAY, RG (corresponding author), LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,PO ROYAL MELBOURNE HOSP,PARKVILLE 3050,AUSTRALIA.		Ramsay, Robert G/C-3291-2015; Ishii, Shunsuke/A-5271-2016	Ramsay, Robert G/0000-0001-5003-0433; Ishii, Shunsuke/0000-0002-6530-2478				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEUG H, 1982, EMBO J, V1, P1069, DOI 10.1002/j.1460-2075.1982.tb01298.x; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; Maniatis T., 1982, MOL CLONING; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P9; SHLEIF R, 1988, SCIENCE, V241, P1182; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	38	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5656	5662						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544939				2022-12-27	WOS:A1992HH74700098
J	KUMAGAI, I; SUNADA, F; TAKEDA, S; MIURA, K				KUMAGAI, I; SUNADA, F; TAKEDA, S; MIURA, K			REDESIGN OF THE SUBSTRATE-BINDING SITE OF HEN EGG-WHITE LYSOZYME BASED ON THE MOLECULAR EVOLUTION OF C-TYPE LYSOZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE; MUTAGENESIS; CONVERSION	On the basis of the molecular evolution of hen egg white, human, and turkey lysozymes, three replacements (Trp62 with Tyr, Asn37 with Gly, and Asp101 with Gly) were introduced into the active-site cleft of hen egg white lysozyme by site-directed mutagenesis. The replacement of Trp62 with Tyr led to enhanced bacteriolytic activity at pH 6.2 and a lower binding constant for chitotriose. The fluorescence spectral properties of this mutant hen egg white lysozyme were found to be similar to those of human lysozyme, which contains Tyr at position 62. The replacement of Asn37 with Gly had little effect on the enzymatic activity and binding constant for chitotriose. However, the combination of Asn37 --> Gly (N37G) replacement with Asp101 --> Gly (D101G) and Trp62 --> Tyr (W62Y) conversions enhanced bacteriolytic activity much more than each single mutation and restored hydrolytic activity toward glycol chitin. Consequently, the mutant lysozyme containing triple replacements (N37G, W62Y, and D101G) showed about 3-fold higher bacteriolytic activity than the wild-type hen lysozyme at pH 6.2, which is close to the optimum pH of the wild-type enzyme.			KUMAGAI, I (corresponding author), UNIV TOKYO,FAC ENGN,DEPT IND CHEM,HONGO 7-3-1,BUNKYO KU,TOKYO 113,JAPAN.			Takeda, Shigeki/0000-0001-8979-1133				BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; CASSELS R, 1978, EUR J BIOCHEM, V93, P81; HAYASHI K, 1965, J BIOCHEM-TOKYO, V58, P227, DOI 10.1093/oxfordjournals.jbchem.a128190; IMOTO T, 1971, AGR BIOL CHEM TOKYO, V35, P1154, DOI 10.1080/00021369.1971.10860050; Imoto T., 1971, P NATL ACAD SCI USA, V69, P1151; JOLLES P, 1984, MOL CELL BIOCHEM, V63, P165; KIRSCH JF, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P59; KUMAGAI I, 1989, J BIOCHEM-TOKYO, V105, P946, DOI 10.1093/oxfordjournals.jbchem.a122784; KUMAGAI I, 1987, J BIOCHEM-TOKYO, V102, P733, DOI 10.1093/oxfordjournals.jbchem.a122111; KURAMITSU S, 1975, J BIOCHEM-TOKYO, V77, P291, DOI 10.1093/oxfordjournals.jbchem.a130726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARUE JN, 1970, J BIOL CHEM, V245, P1985; MORINAGA Y, 1984, BIO-TECHNOL, V2, P636, DOI 10.1038/nbt0784-636; MULVEY RS, 1973, BIOCHEMISTRY-US, V12, P2683, DOI 10.1021/bi00738a021; MULVEY RS, 1974, BIOCHEMISTRY-US, V13, P782, DOI 10.1021/bi00701a021; PARRY RM, 1965, P SOC EXP BIOL MED, V119, P384; PINCUS MR, 1957, BIOCHEM J, V65, P476	18	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4608	4612						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537843				2022-12-27	WOS:A1992HF64200051
J	RUSSELL, RRB; ADUSEOPOKU, J; SUTCLIFFE, IC; TAO, L; FERRETTI, JJ				RUSSELL, RRB; ADUSEOPOKU, J; SUTCLIFFE, IC; TAO, L; FERRETTI, JJ			A BINDING PROTEIN-DEPENDENT TRANSPORT-SYSTEM IN STREPTOCOCCUS-MUTANS RESPONSIBLE FOR MULTIPLE SUGAR METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; REGULATORY REGION; MELIBIOSE-OPERON; AFFINITY; CLONING; GENES; GTFA; GLUCOSYLTRANSFERASE	An 11-kilobase gene region of Streptococcus mutans has been identified which contains eight contiguous genes involved with the uptake and metabolism of multiple sugars (the msm system). Sequence analysis of this region indicates that several of these genes specify proteins with strong homology to components of periplasmic binding protein-dependent transport systems of Gram-negative bacteria. Additionally, this operon is controlled by a regulatory gene (msmR) that acts as a positive effector. The proteins specified by the structural genes of the msm operon include alpha-galactosidase (aga), a "periplasmic-like" sugar-binding protein (msmE), two membrane proteins (msmF, msmG), sucrose phosphorylase (gtfA), an ATP-binding protein (msmK), and dextran glucosidase (dexB). Insertional inactivation of each of these genes along with uptake data indicate that this system is responsible for the uptake of melibiose, raffinose, and isomaltotriose and the metabolism of melibiose, sucrose, and isomaltosaccharides.	UNIV OKLAHOMA, HLTH SCI CTR, DEPT MICROBIOL & IMMUNOL, OKLAHOMA CITY, OK 73190 USA; UNIV NEWCASTLE UPON TYNE, DEPT ORAL BIOL, NEWCASTLE NE2 4BW, ENGLAND	University of Oklahoma System; University of Oklahoma Health Sciences Center; Newcastle University - UK			Sutcliffe, Iain C./A-5354-2009; Russell, Roy/A-1685-2008; Aduse-Opoku, Joseph/CAF-0056-2022	Sutcliffe, Iain C./0000-0002-9036-2683; opoku, anita/0000-0001-7243-8157	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008191] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 08191] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADUSEOPOKU J, 1991, J GEN MICROBIOL, V137, P2271, DOI 10.1099/00221287-137-9-2271; ADUSEOPOKU J, 1991, J GEN MICROBIOL, V137, P757, DOI 10.1099/00221287-137-4-757; ALLOING G, 1990, MOL MICROBIOL, V4, P633, DOI 10.1111/j.1365-2958.1990.tb00632.x; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; BAHL H, 1991, FEMS MICROBIOL LETT, V81, P83; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BARLETTA RG, 1989, INFECT IMMUN, V57, P992, DOI 10.1128/IAI.57.3.992-995.1989; BINDER TP, 1983, CARBOHYD RES, V124, P275, DOI 10.1016/0008-6215(83)88463-8; DASHPER SG, 1990, J BACTERIOL, V172, P556, DOI 10.1128/jb.172.2.556-563.1990; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; DUDLER R, 1988, EMBO J, V7, P3963, DOI 10.1002/j.1460-2075.1988.tb03283.x; FERRETTI JJ, 1988, INFECT IMMUN, V56, P1585, DOI 10.1128/IAI.56.6.1585-1588.1988; GILSON E, 1988, EMBO J, V7, P3971, DOI 10.1002/j.1460-2075.1988.tb03284.x; HAMADA S, 1980, MICROBIOL REV, V44, P331, DOI 10.1128/MMBR.44.2.331-384.1980; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; HIGGINS CF, 1990, PHILOS T R SOC B, V326, P353, DOI 10.1098/rstb.1990.0017; HIGGINS CF, 1988, BIOESSAYS, V8, P111, DOI 10.1002/bies.950080406; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOESCHE WJ, 1986, MICROBIOL REV, V50, P353, DOI 10.1128/MMBR.50.4.353-380.1986; MACRINA FL, 1983, GENE, V25, P145; Maniatis T., 1982, MOL CLONING; NIELSEN JBK, 1982, J BIOL CHEM, V257, P4490; OVERDUIN P, 1988, MOL MICROBIOL, V2, P767, DOI 10.1111/j.1365-2958.1988.tb00088.x; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; PERRY D, 1981, INFECT IMMUN, V32, P1295, DOI 10.1128/IAI.32.3.1295-1297.1981; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; RUSSELL RRB, 1979, FEMS MICROBIOL LETT, V6, P197, DOI 10.1016/0378-1097(79)90059-4; RUSSELL RRB, 1985, FEMS MICROBIOL LETT, V30, P37; RUSSELL RRB, 1990, J GEN MICROBIOL, V136, P803, DOI 10.1099/00221287-136-5-803; RUSSELL RRB, 1988, INFECT IMMUN, V56, P2763, DOI 10.1128/IAI.56.10.2763-2765.1988; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLEE AM, 1982, BIOCHIM BIOPHYS ACTA, V692, P415, DOI 10.1016/0005-2736(82)90392-3; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VONHEIJNE G, 1989, PROTEIN ENG, V2, P531, DOI 10.1093/protein/2.7.531; WALKER GJ, 1973, CARBOHYD RES, V30, P1; WEBSTER C, 1988, GENE, V68, P297, DOI 10.1016/0378-1119(88)90032-7; WEBSTER C, 1987, GENE, V59, P253, DOI 10.1016/0378-1119(87)90333-7; WEBSTER C, 1989, GENE, V83, P207, DOI 10.1016/0378-1119(89)90106-6; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	42	206	218	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4631	4637						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537846				2022-12-27	WOS:A1992HF64200055
J	LOPEZ, JA; LUDWIG, EH; MCCARTHY, BJ				LOPEZ, JA; LUDWIG, EH; MCCARTHY, BJ			POLYMORPHISM OF HUMAN GLYCOPROTEIN-IB-ALPHA RESULTS FROM A VARIABLE NUMBER OF TANDEM REPEATS OF A 13-AMINO ACID SEQUENCE IN THE MUCIN-LIKE MACROGLYCOPEPTIDE REGION - STRUCTURE-FUNCTION IMPLICATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVINE SUBMAXILLARY MUCIN; O-LINKED GLYCOPROTEINS; GENETIC-POLYMORPHISM; SHEAR RATE; PLATELET INTERACTION; HUMAN-BLOOD; SUBENDOTHELIUM; CLONING; PROTEIN; CHAIN	Four polymorphic variants of the platelet receptor for von Willebrand factor, glycoprotein Ib, have been described that differ in molecular weight on sodium dodecyl sulfate-polyacrylamide gels (Moroi, M., Jung, S. M., and Yoshida, N. (1984) Blood 64, 622-629). A recent report localized the polymorphic site to the heavily O-glycosylated region of the glycoprotein Ib alpha-chain known as the macroglycopeptide (Meyer, M., and Schellenberg, I. (1990) Thromb. Res. 58, 233-242). This region contains several tandem repeats of a mucin-like sequence, which appeared to be a likely site for polymorphic variation. We amplified genomic DNA corresponding to the macroglycopeptide from 206 individuals from four ethnic groups and identified three length variants based on the migration of the amplified DNA on denaturing polyacrylamide gels. DNA sequencing revealed that the three variants represented four alleles, two of which varied by only one base pair, a difference that did not result in an amino acid change. The three length variants differed in the number of tandem repeats of a 39-base pair sequence that results in perfect duplication of a 13-amino acid sequence that originated within a region flanked by Glu-396 and Thr-411. The smallest isoform contained one such sequence; the next largest, two repeats; and the largest, three repeats. The DNA sequence containing the tandem repeats was flanked by direct repeats typical of the target site duplications found flanking transposed DNA, suggesting a mechanism for acquisition of this region by the primordial glycoprotein Ib(alpha) precursor. The amino acid sequence of the repeated element that accounts for the polymorphism contained five sites for potential O-glycosylation, which together with the repeated amino acids would result in incremental differences in molecular weight of approximately 6,000 between the different isoforms. The addition of repeats to the macroglycopeptide is predicted to increase the length of this elongated glycosylated region and extend the distance between the ligand-binding domain of glycoprotein Ib and the platelet plasma membrane, an effect that would project the ligand-binding domain farther into the bloodstream. Such a change may alter the susceptibility of platelets to shear-induced activation, a process that requires an interaction between glycoprotein Ib and von Willebrand factor.	UNIV CALIF SAN FRANCISCO,DEPT MED,DIV HEMATOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	LOPEZ, JA (corresponding author), GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,POB 19100,SAN FRANCISCO,CA 94141, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002463, R01HL038781] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38781, HL02463] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARTS PAMM, 1988, ARTERIOSCLEROSIS, V8, P819, DOI 10.1161/01.ATV.8.6.819; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; COLMAN RW, 1989, HEMOSTASIS THROMBOSI, P3; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FOX JEB, 1988, J BIOL CHEM, V263, P4882; FOX JEB, 1985, J BIOL CHEM, V260, P1970; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GERARD C, 1990, J CLIN INVEST, V86, P1921, DOI 10.1172/JCI114925; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GUM JR, 1989, J BIOL CHEM, V264, P6480; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HICKEY MJ, 1991, CLIN RES, V39, pA337; HIGUCHI R, 1989, AMPLIFICATIONS, V2, P3; HIGUCHI R, 1989, AMPLIFICATIONS, V2, P1; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JUNG SM, 1986, THROMB RES, V42, P83, DOI 10.1016/0049-3848(86)90199-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN MS, 1990, J BIOL CHEM, V265, P15294; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MEYER M, 1990, THROMB RES, V58, P233, DOI 10.1016/0049-3848(90)90093-R; MOAKE JL, 1988, BLOOD, V71, P1366; MOROI M, 1984, BLOOD, V64, P622; MURATA M, 1991, J BIOL CHEM, V266, P15474; MUSTARD JF, 1990, CIRCULATION S1, V81, P24; OKUMURA T, 1976, J BIOL CHEM, V251, P5950; OLSON JD, 1989, J LAB CLIN MED, V14, P6; PERUTZ MF, 1960, NATURE, V185, P416, DOI 10.1038/185416a0; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; ROTH GJ, 1991, BLOOD, V77, P5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PA, 1983, NATURE, V301, P471, DOI 10.1038/301471a0; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; SIMON M, 1991, GENOMICS, V9, P576, DOI 10.1016/0888-7543(91)90349-J; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TURITTO VT, 1979, MICROVASC RES, V17, P38, DOI 10.1016/0026-2862(79)90006-2; TURITTO VT, 1980, MICROVASC RES, V19, P352, DOI 10.1016/0026-2862(80)90054-0; WEISS HJ, 1986, J CLIN INVEST, V78, P1072, DOI 10.1172/JCI112663; WELLER P, 1984, EMBO J, V3, P439, DOI 10.1002/j.1460-2075.1984.tb01825.x; WENGER RH, 1988, BIOCHEM BIOPH RES CO, V156, P389, DOI 10.1016/S0006-291X(88)80853-2	44	141	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10055	10061						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577776				2022-12-27	WOS:A1992HT96500092
J	LUO, GX; NISHIMURA, JS				LUO, GX; NISHIMURA, JS			ADENOSINE 5'-TETRAPHOSPHATE IS SYNTHESIZED BY THE HISTIDINE ALPHA-142-]ASPARAGINE MUTANT OF ESCHERICHIA-COLI SUCCINYL-COA SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; COENZYME; TETRAPHOSPHATE; MUTAGENESIS; RESIDUE	Recently, we described the properties of a mutant (H142N) of Escherichia coli succinyl coenzyme A (CoA) synthetase in which His-142 of the alpha-subunit was changed to Asn (Luo, G.-X., and Nishimura, J. S. (1991) J. Biol. Chem. 266, 20781-20785). The mutant enzyme was practically devoid of ability to catalyze the overall reaction but was able to catalyze half-reactions at significant rates. Thus, phosphorylation by ATP and dephosphorylation by ADP of the mutant enzyme occurred at rates that were at least 10 times greater than those with wild type enzyme, and dephosphorylation by succinate plus CoA (succinyl-CoA formation) proceeded with a V(max) of 10% that of wild type, with no change in K(m) for succinate and very little change in K(m) for CoA. In the present work, it has been shown that incubation of P-32-labeled H142N with ATP caused a rapid depletion of label from the enzyme and incorporation of radioactivity into a nucleotide species that was neither ATP nor ADP. This reaction was catalyzed at comparatively negligible rates by wild type enzyme. Analysis of the labeled product by high pressure liquid chromatography and P-31 NMR revealed that it was adenosine 5'-tetraphosphate (AP4). Incubation of labeled H142N with the ATP analog beta, gamma-methylene adenosine triphosphate also gave a product that appeared to be the corresponding tetraphosphate. The reaction in which AP4 was formed was greatly stimulated by the addition of phosphoenolpyruvate plus pyruvate kinase and strongly inhibited by ADP and by CoA plus succinate. The results are consistent with binding of ATP to, and reaction with, phosphorylated succinyl-CoA synthetase to form AP4. In this reaction, it was determined that the K(m) for ATP and the turnover number of phosphorylated enzyme were 14.5-mu-M and 0.024 s-1, respectively.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017534] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-17534] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkinson T., 1984, OLIGONUCLEOTIDE SYNT, P35; BOWMAN CM, 1975, J BIOL CHEM, V250, P5609; Bridger W. A., 1974, ENZYMES, P581; BUCK D, 1985, BIOCHEMISTRY-US, V24, P6245, DOI 10.1021/bi00343a031; Cha S, 1969, METHOD ENZYMOL, V13, P62, DOI 10.1016/0076-6879(69)13017-7; COLLIER GE, 1978, J BIOL CHEM, V253, P4938; COLLIER GE, 1979, J BIOL CHEM, V254, P925; Fiske CH, 1925, J BIOL CHEM, V66, P375; GRINNELL FL, 1969, BIOCHEMISTRY-US, V8, P568, DOI 10.1021/bi00830a016; KAUFMAN S, 1955, J BIOL CHEM, V216, P153; KLAUS W, 1984, RES EXP MED, V185, P145; KREBS A, 1974, CAN J BIOCHEM CELL B, V52, P594, DOI 10.1139/o74-086; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUPRIYANOV VV, 1986, BIOCHIM BIOPHYS ACTA, V869, P107, DOI 10.1016/0167-4838(86)90316-X; LIEBERMAN I, 1955, J AM CHEM SOC, V77, P3373, DOI 10.1021/ja01617a064; LOBATON CD, 1975, EUR J BIOCHEM, V50, P495, DOI 10.1111/j.1432-1033.1975.tb09888.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUO GX, 1991, J BIOL CHEM, V266, P20781; MAJUMDAR R, 1991, BIOCHIM BIOPHYS ACTA, V1076, P86, DOI 10.1016/0167-4838(91)90223-M; MANN CJ, 1989, J BIOL CHEM, V264, P1457; MANN CJ, 1991, BIOCHEMISTRY-US, V30, P1497, DOI 10.1021/bi00220a008; MARRIAN DH, 1954, BIOCHIM BIOPHYS ACTA, V13, P278, DOI 10.1016/0006-3002(54)90314-5; MEJBAUM W, 1934, Z PHYSL CHEM, V258, P177; NISHIMURA JS, 1972, ADV ENZYMOL RAMB, V36, P183; NISHIMURA JS, 1986, ADV ENZYMOL, V58, P142; NISHIYAMA M, 1991, MOL GEN GENET, V226, P1, DOI 10.1007/BF00273580; PEARSON PH, 1975, J BIOL CHEM, V250, P8524; SACKS J, 1955, BIOCHIM BIOPHYS ACTA, V16, P436, DOI 10.1016/0006-3002(55)90253-5; SILVERMAN RH, 1979, MICROBIOL REV, V43, P27, DOI 10.1128/MMBR.43.1.27-41.1979; SMALL GD, 1966, BIOCHEMISTRY-US, V5, P14, DOI 10.1021/bi00865a003; SMALL GD, 1966, BIOCHEMISTRY-US, V5, P26, DOI 10.1021/bi00865a004; VOGEL HJ, 1982, J BIOL CHEM, V257, P4834; WANG T, 1972, BIOCHEMISTRY-US, V11, P2067, DOI 10.1021/bi00761a011	33	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9516	9520						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577794				2022-12-27	WOS:A1992HT96500014
J	BUTTKE, TM; FOLKS, TM				BUTTKE, TM; FOLKS, TM			COMPLETE REPLACEMENT OF MEMBRANE CHOLESTEROL WITH 4,4',14-TRIMETHYL STEROLS IN A HUMAN T-CELL LINE DEFECTIVE IN LANOSTEROL DEMETHYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MUTANT STRAIN-GL7; METABOLISM; GROWTH; BIOSYNTHESIS; CYCLOARTENOL; REQUIREMENT; LYMPHOCYTES; INHIBITION; RETROVIRUS	A3.01 is a hypoxanthine/aminopterin/thymidine-sensitive, human immunodeficiency virus-susceptible, human T cell line derived by Folks et al. (Folks, T., Benn, S., Rabson, A., Theodore, T., Hoggan, M. D., Martin, M., Lightfoote, M., and Sell, K. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 4539-4543) following exposure of CEM cells to 8-azaguanine. In the present study, it is shown that A3.01 also contains a heretofore unrecognized mutation in cholesterol biosynthesis. A3.01 cells grown in the presence of 10% fetal bovine serum (FBS) contain primarily cholesterol in their membranes, but based on [C-14]acetate labeling, synthesize only lanosterol and 24,25-dihydrolanosterol. Reduction in the amount of FBS provided resulted in decreased cellular levels of cholesterol with corresponding increases in the two 4,4',14-trimethyl sterols. In A3.01 cells cultured in 1% FBS medium, lanosterol and 24,25-dihydrolanosterol accounted for 7 and 45%, respectively, of total cellular sterols. Following dilution of the 1% FBS-grown cells into serum-free media, the level of membrane cholesterol gradually declined, such that after three passages it became virtually undetectable, whereas the proportions of lanosterol and 24,25-dihydrolanosterol rose to 25 and 75%, respectively. Even after eight passages in the serum-free media, A3.01 cells displayed a complete absence of cholesterol with no obvious effect on cell growth. Membranes isolated from A3.01 cells grown in the presence or absence of 10-mu-g/ml of cholesterol displayed similar phospholipid:sterol ratios, but membranes from the unsupplemented cells contained only approximately 5% as much cholesterol as the supplemented cell membranes. Finally, A3.01 cells grown in the absence of cholesterol were extremely resistant to the cytotoxic effectS of amphotericin B, whereas cells cultured in the combined presence of 1% FCS and 10-mu-g/ml of cholesterol were sensitive to the drug. Collectively, these results demonstrate that 4,4', 14-trimethyl sterols can effectively replace cholesterol in a human T cell lineage, indicating that not all mammalian cells have a requirement for cholesterol, per se. The A3.01 T cell lineage should prove useful in defining the role of cholesterol in membrane fusion and human immunodeficiency virus-mediated syncitia formation and cytopathic effects.	CTR DIS CONTROL,RETROVIRUS DIS BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	BUTTKE, TM (corresponding author), E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858, USA.							Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BERRY DJ, 1982, BIOCHEMISTRY-US, V21, P573, DOI 10.1021/bi00532a025; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; BROOKS CJW, 1968, LIPIDS, V3, P391, DOI 10.1007/BF02531277; BUTTKE TM, 1981, BIOCHEMISTRY-US, V20, P3267, DOI 10.1021/bi00514a044; BUTTKE TM, 1980, BIOCHEM BIOPH RES CO, V92, P229, DOI 10.1016/0006-291X(80)91543-0; BUTTKE TM, 1983, ANTIMICROB AGENTS CH, V24, P478, DOI 10.1128/AAC.24.4.478; BUTTKE TM, 1980, J BACTERIOL, V144, P124, DOI 10.1128/JB.144.1.124-130.1980; CHANG TY, 1977, P NATL ACAD SCI USA, V74, P832, DOI 10.1073/pnas.74.3.832; CHEN HW, 1988, J BIOL CHEM, V263, P1248; CUTHBERT JA, 1981, J IMMUNOL, V126, P2093; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DAHL CE, 1980, BIOCHEM BIOPH RES CO, V92, P221, DOI 10.1016/0006-291X(80)91542-9; DAHL CE, 1981, BIOCHEMISTRY-US, V20, P7158, DOI 10.1021/bi00528a016; DAHL JS, 1983, P NATL ACAD SCI-BIOL, V80, P692, DOI 10.1073/pnas.80.3.692; DAHL JS, 1980, BIOCHEMISTRY-US, V19, P1467, DOI 10.1021/bi00548a032; ESFAHANI M, 1984, J CELL BIOCHEM, V25, P87, DOI 10.1002/jcb.240250204; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FOLKS T, 1985, P NATL ACAD SCI USA, V82, P4539, DOI 10.1073/pnas.82.13.4539; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; FREEMAN CP, 1966, J LIPID RES, V7, P324; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HEINIGER HJ, 1978, P NATL ACAD SCI USA, V75, P5683, DOI 10.1073/pnas.75.11.5683; HIDAKA K, 1978, CELL, V14, P415, DOI 10.1016/0092-8674(78)90126-5; HOWELL DN, 1982, IMMUNOGENETICS, V15, P199, DOI 10.1007/BF00621951; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; LALA AK, 1978, BIOORG CHEM, V7, P437, DOI 10.1016/0045-2068(78)90034-2; LIMANEK JS, 1978, P NATL ACAD SCI USA, V75, P5452, DOI 10.1073/pnas.75.11.5452; LO SC, 1991, SCIENCE, V251, P1074, DOI 10.1126/science.1705362; MAEDA T, 1983, BIOCHIM BIOPHYS ACTA, V731, P115, DOI 10.1016/0005-2736(83)90404-2; MINOWADA J, 1972, J NATL CANCER I, V49, P891; PARKS LW, 1978, CRC CR REV MICROBIOL, V6, P301, DOI 10.3109/10408417809090625; RAMGOPAL M, 1983, P NATL ACAD SCI-BIOL, V80, P712, DOI 10.1073/pnas.80.3.712; RODRIGUEZ RJ, 1982, BIOCHEM BIOPH RES CO, V106, P435, DOI 10.1016/0006-291X(82)91129-9; RUJANAVECH C, 1986, J BIOL CHEM, V261, P7196; SAITO Y, 1977, P NATL ACAD SCI USA, V74, P3730, DOI 10.1073/pnas.74.9.3730; SCHULER I, 1991, P NATL ACAD SCI USA, V88, P6926, DOI 10.1073/pnas.88.16.6926; VINSON JA, 1977, J CHROMATOGR, V135, P226, DOI 10.1016/S0021-9673(00)86325-6; YEAGLE PL, 1977, P NATL ACAD SCI USA, V74, P4924, DOI 10.1073/pnas.74.11.4924	41	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8819	8826						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577721				2022-12-27	WOS:A1992HR85400021
J	KINDT, JT; WOODS, A; MARTIN, BM; COTTER, RJ; OSAWA, Y				KINDT, JT; WOODS, A; MARTIN, BM; COTTER, RJ; OSAWA, Y			COVALENT ALTERATION OF THE PROSTHETIC HEME OF HUMAN HEMOGLOBIN BY BRCCL3 - CROSS-LINKING OF HEME TO CYSTEINE RESIDUE-93	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADDUCT FORMATION; BINDING; BENZO<A>PYRENE; DENATURATION; RESOLUTION; MECHANISM; MYOGLOBIN; PROTEIN; MOUSE; RATS	Recent studies have shown that a protein-bound heme adduct formed from the reaction of BrCCl3 with myoglobin was due to bonding of the proximal histidine residue through the ring I vinyl of a heme-CCl2 moiety. The present study reveals that BrCCl3 also reacts with the heme of reduced human hemoglobin to form two protein-bound heme adducts. Edman degradation and mass spectrometry provided evidence that these protein-bound heme adducts were addition products in which heme-CCl2 or heme-CCl3 were bound to cysteine residue 93 of the beta-chain of hemoglobin. It appeared that the cysteine residue was bonded regiospecifically to the ring I vinyl group of the altered heme moiety, because the nonprotein-bound products of the reaction included the beta-carboxyvinyl and alpha-hydroxy-beta-trichloromethylethyl derivatives of the ring I vinyl moiety of heme. The absorption spectra of the protein-bound adducts in both the oxidized and reduced states were highly similar to those described for hemichromes, which are thought to be involved in the formation of Heinz bodies and subsequent red cell lysis.	NHLBI,CHEM PHARMACOL LAB,BETHESDA,MD 20892; NIMH,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,MIDDLE ATLANTIC MASS SPECTROMETRY LAB,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Johns Hopkins University								AKHREM AA, 1989, BIOCHIM BIOPHYS ACTA, V992, P191, DOI 10.1016/0304-4165(89)90009-3; AXWORTHY DB, 1988, CHEM-BIOL INTERACT, V68, P99, DOI 10.1016/0009-2797(88)90009-9; BEAVEN GH, 1954, NATURE, V173, P389, DOI 10.1038/173389b0; BRYANT MS, 1987, CANCER RES, V47, P602; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; Dayhoff MO, 1978, ATLAS PROTEIN SEQUEN, V5; FARMER PB, 1987, ARCH TOXICOL, V60, P251, DOI 10.1007/BF01234663; FERMI G, 1975, J MOL BIOL, V97, P237, DOI 10.1016/S0022-2836(75)80037-4; Gordon A. J., 1972, CHEM COMPANION; GORELICK NJ, 1989, CARCINOGENESIS, V10, P1579, DOI 10.1093/carcin/10.9.1579; HAUGEN DA, 1989, CHEM RES TOXICOL, V2, P379, DOI 10.1021/tx00012a005; HEBBEL RP, 1989, SEMIN HEMATOL, V26, P136; ITANO HA, 1975, NATURE, V256, P665, DOI 10.1038/256665a0; JANDL JH, 1960, J CLIN INVEST, V39, P1818, DOI 10.1172/JCI104206; KAUR S, 1989, J BIOL CHEM, V264, P16981; LADNER RC, 1977, J MOL BIOL, V114, P385, DOI 10.1016/0022-2836(77)90256-X; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; NAYLOR S, 1990, CHEM RES TOXICOL, V3, P111, DOI 10.1021/tx00014a005; OLSON JS, 1987, J BIOL CHEM, V262, P12930; Orten JM, 1975, HUMAN BIOCH; OSAWA Y, 1990, J BIOL CHEM, V265, P10340; OSAWA Y, 1991, P NATL ACAD SCI USA, V88, P7081, DOI 10.1073/pnas.88.16.7081; OSAWA Y, 1991, J BIOL CHEM, V266, P3208; OSAWA Y, 1989, CHEM RES TOXICOL, V2, P131, DOI 10.1021/tx00009a001; OSAWA Y, 1989, J AM CHEM SOC, V111, P4462, DOI 10.1021/ja00194a048; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PERUTZ MF, 1968, NATURE, V219, P131, DOI 10.1038/219131a0; RACHMILEWITZ EA, 1974, SEMIN HEMATOL, V11, P441; SABBIONI G, 1990, ARCH TOXICOL, V64, P451, DOI 10.1007/BF01977626; SABBIONI G, 1990, CARCINOGENESIS, V11, P111, DOI 10.1093/carcin/11.1.111; SHELTON JB, 1984, J LIQ CHROMATOGR, V7, P1969, DOI 10.1080/01483918408068849; SKIPPER PL, 1989, CHEM RES TOXICOL, V2, P280, DOI 10.1021/tx00011a002; Stryer L., 1988, BIOCHEMISTRY-US; SUN JD, 1989, TOXICOL APPL PHARM, V100, P86, DOI 10.1016/0041-008X(89)90093-8; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; WINTERBOURN CC, 1990, SEMIN HEMATOL, V27, P41	36	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8739	8743						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577716				2022-12-27	WOS:A1992HR85400008
J	DELISLE, S; WELSH, MJ				DELISLE, S; WELSH, MJ			INOSITOL TRISPHOSPHATE IS REQUIRED FOR THE PROPAGATION OF CALCIUM WAVES IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTRACELLULAR CALCIUM; MYOINOSITOL 1,4,5-TRISPHOSPHOROTHIOATE; CA-2+ RELEASE; SMOOTH-MUSCLE; HEPARIN; CELLS; RECEPTOR	Stimuli which act through the second messenger inositol 1,4,5-trisphosphate (InsP3) often increase free intracellular Ca2+ concentration ([Ca2+]i) in a localized subcellular area. Actively propagated Ca2+ waves then extend this focal Ca2+ signal to other parts of the cell. To understand how cells may control the spatial distribution of Ca2+, we investigated the mechanism by which Ca2+ waves propagate through the cytoplasm of Xenopus oocytes. Heparin, which inhibits the binding of InsP3 to its receptor, prevented the migration of Ca2+ waves induced by a poorly metabolized InsP3 (InsP3S3). This result suggested that Ca2+ waves move through the cell via the serial release of Ca2+ from InsP3-sensitive stores. Interventions which caused a localized increase in [Ca2+]i without elevations of InsP3 did not trigger Ca2+ waves. In the presence of a InsP3S3, however, endogenously released or locally injected Ca2+ elicited Ca2+ waves. A cooperative interaction between Ca2+ and InsP3 may therefore be responsible for the propagation of Ca2+ waves.	UNIV IOWA, COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED, 500 EMRB, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa				Welsh, Michael/0000-0002-1646-6206				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; COOKE AM, 1987, J CHEM SOC CHEM COMM, P1525, DOI 10.1039/c39870001525; COOKE AM, 1989, FEBS LETT, V242, P373, DOI 10.1016/0014-5793(89)80504-6; DELISLE S, 1990, J BIOL CHEM, V265, P11726; FERGUSON JE, 1990, BIOCHEM BIOPH RES CO, V172, P229, DOI 10.1016/S0006-291X(05)80198-6; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KOBAYASHI S, 1988, BIOCHEM BIOPH RES CO, V153, P625, DOI 10.1016/S0006-291X(88)81141-0; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MINTA A, 1989, J BIOL CHEM, V264, P8171; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; NILSSON T, 1988, FEBS LETT, V229, P211, DOI 10.1016/0014-5793(88)80829-9; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; PETERSEN OH, 1991, NEWS PHYSIOL SCI, V6, P242; ROONEY TA, 1991, PHARMACOL THERAPEUT, V49, P223, DOI 10.1016/0163-7258(91)90056-R; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAYLOR CW, 1988, BIOCHEM BIOPH RES CO, V150, P626, DOI 10.1016/0006-291X(88)90438-X; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9	28	120	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					7963	7966						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569053				2022-12-27	WOS:A1992HQ18500002
J	LI, M; SMITH, LJ; CLARK, DC; WILSON, R; MURPHY, DJ				LI, M; SMITH, LJ; CLARK, DC; WILSON, R; MURPHY, DJ			SECONDARY STRUCTURES OF A NEW CLASS OF LIPID BODY PROTEINS FROM OILSEEDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN PLEATED SHEET; AMIDE-ONE VIBRATION; CIRCULAR-DICHROISM; BRASSICA-NAPUS; RESONANCE INTERACTION; PLASMA LIPOPROTEINS; MEMBRANE-PROTEINS; INFRARED-SPECTRA; NORMAL-MODES; OIL-BODIES	The three main isoforms of the 19-kDa lipid body proteins (oleosin) have been purified to homogeneity from embryos of rapeseed. The secondary structures of these proteins as derived from circular dichroism (CD) and Fourier transform infrared (FTIR) spectroscopy were compared with the secondary structures predicted from the primary sequences. The salient feature of the primary sequence of all oleosins is its division into three defined structural domains: a central hydrophobic domain flanked on either side by relatively hydrophilic domains, respectively. Using a variety of predictive methods based on primary amino acid sequence data, the oleosins exhibited a high probability of beta-strand structure in the 70-residue central hydrophobic domain, with relatively little alpha-helical content. Secondary structure data derived from CD and FTIR were consistent with the predictions from primary sequence, showing that the oleosins contained about 45% beta-strand and 13% alpha-helical structure. Under high salt conditions, a 40-kDa polypeptide was obtained from purified preparations of the 19-kDa oleosins. The 40-kDa polypeptide has a very similar secondary structure, as analyzed by CD and FTIR, to that of the 19-kDa oleosins. This polypeptide is therefore probably a dimer of the 19-kDa oleosins that is formed in high salt environments. A model of the general structure of oleosins is proposed whereby the central hydrophobic domain of the protein with a predominantly beta-strand structure is embedded into the non-aqueous phase of lipid-bodies. This hydrophobic region is flanked by putative alpha-helical structures in the polar N- and C-terminal domains which are probably oriented at the lipid-water interface.	JOHN INNES CTR PLANT SCI RES, DEPT BRASSICA & OILSEEDS RES, CAMBRIDGE LAB, NORWICH NR4 7UH, ENGLAND; INST FOOD RES, NORWICH LAB, NORWICH NR4 7UA, NORFOLK, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia			Murphy, Denis J/ABC-1734-2020	Murphy, Denis J/0000-0002-5291-2445				AU DMY, 1989, ARCH BIOCHEM BIOPHYS, V273, P516, DOI 10.1016/0003-9861(89)90511-0; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHIRGADZE YN, 1976, BIOPOLYMERS, V15, P627, DOI 10.1002/bip.1976.360150403; CHIRGADZE YN, 1976, BIOPOLYMERS, V15, P607, DOI 10.1002/bip.1976.360150402; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARK DC, 1989, J AGR FOOD CHEM, V37, P627, DOI 10.1021/jf00087a011; HATZOPOULOS P, 1990, PLANT CELL, V2, P457, DOI 10.1105/tpc.2.5.457; ISHIZAKI H, 1979, J BIOL CHEM, V254, P9651; ISHIZAKI H, 1981, BIOPHYS J, V36, P509, DOI 10.1016/S0006-3495(81)84749-2; JAHNIG F, 1990, TRENDS BIOCHEM SCI, V15, P93, DOI 10.1016/0968-0004(90)90188-H; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KINNUNEN PKJ, 1977, P NATL ACAD SCI USA, V74, P4848, DOI 10.1073/pnas.74.11.4848; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KOENIG JL, 1971, BIOPOLYMERS, V10, P89, DOI 10.1002/bip.360100108; Koening J. K., 1980, ANAL APPLICATIONS FT, P241; KONNO T, 1975, ANAL BIOCHEM, V67, P226, DOI 10.1016/0003-2697(75)90290-0; KRIMM S, 1982, SCIENCE, V216, P407, DOI 10.1126/science.6280277; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAGANT P, 1984, EUR J BIOCHEM, V139, P137, DOI 10.1111/j.1432-1033.1984.tb07987.x; LAGANT P, 1984, EUR J BIOCHEM, V139, P149, DOI 10.1111/j.1432-1033.1984.tb07988.x; LI WH, 1988, J LIPID RES, V29, P245; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; MARKWELL MAK, 1988, METHOD ENZYMOL, V72, P269; MURPHY DJ, 1989, PHYTOCHEMISTRY, V28, P2063, DOI 10.1016/S0031-9422(00)97921-4; MURPHY DJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P86, DOI 10.1016/0167-4781(91)90156-G; MURPHY DJ, 1989, J SCI FOOD AGR, V48, P209, DOI 10.1002/jsfa.2740480208; MURPHY DJ, 1989, BIOCHEM J, V258, P285, DOI 10.1042/bj2580285; MURPHY DJ, 1987, LIPIDS, V22, P293, DOI 10.1007/BF02533995; PARKER FS, 1983, APPLICATION IR RAMAN; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; QU R, 1986, BIOCHEM J, V235, P57, DOI 10.1042/bj2350057; QU R, 1990, J BIOL CHEM, V265, P2238; RENUGOPALAKRISHNAN V, 1985, BIOCHEM BIOPH RES CO, V126, P1029, DOI 10.1016/0006-291X(85)90288-8; RENUGOPALAKRISHNAN V, 1985, J BIOL CHEM, V260, P1406; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEATON BA, 1983, THESIS MIT CAMBRIDGE; SEGREST JP, 1977, CHEM PHYS LIPIDS, V18, P7, DOI 10.1016/0009-3084(77)90023-8; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SWANEY JB, 1980, J BIOL CHEM, V255, P8791; Takakuwa T, 1985, ANAL SCI, V1, P215, DOI DOI 10.2116/ANALSCI.1.215; VANCE VB, 1987, J BIOL CHEM, V262, P11275; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YANG JT, 1986, METHOD ENZYMOL, V130, P208	45	67	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8245	8253						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569078				2022-12-27	WOS:A1992HQ18500045
J	PRESCOTT, JC; FALCKPEDERSEN, E				PRESCOTT, JC; FALCKPEDERSEN, E			VARIED POLY(A) SITE EFFICIENCY IN THE ADENOVIRUS MAJOR LATE TRANSCRIPTION UNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA 3'-END FORMATION; THYMIDINE KINASE GENE; PRE-MESSENGER-RNAS; POLYADENYLATION SITE; LATE PROMOTER; DOWNSTREAM SEQUENCES; ELEMENTS DOWNSTREAM; MULTIPLE FACTORS; ADDITION SITE; 1ST INTRON	Regulation of adenovirus major late transcription unit (MLTU) mRNA biosynthesis involves poly(A) site selection between five available sites, L1 through L5. The 5' proximal site completely dominates during early infection, whereas all five sites are used during late infection with L3 being favored slightly over the others. Previous studies have shown this early to late poly(A) switch will occur in the absence of MLTU-specific splicing patterns and hinges in large part on the character of the first poly(A) site. We have used in vitro assays to characterize basic features of the L1 and L3 pre-mRNAs which may help define how processing at poly(A) sites is controlled. We have found that L1 is 5-10-fold less efficient than L3 as a substrate for RNA cleavage. A primary difference between the L1 and L3 sites lies in the kinetics of their use, with cleavage at L3 occurring at twice the rate of cleavage at L1. In addition, L1 is 20-fold less effective than L3 in competing for processing factors. To investigate the sequence elements that contribute to poly(A) site efficiency, we have used competition assays in which the competitor RNAs lack upstream or downstream elements.	CORNELL UNIV,SCH MED,PROGRAM MOLEC BIOL,WR HEARST DEPT MICROBIOL,NEW YORK,NY 10021	Cornell University					NIGMS NIH HHS [GM41967] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041967] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKUSJARVI G, 1981, NATURE, V292, P420, DOI 10.1038/292420a0; BELLO LEONARD J., 1967, J VIROL, V1, P843; BELTZ GA, 1979, J MOL BIOL, V131, P353, DOI 10.1016/0022-2836(79)90081-0; BHAT BM, 1985, MOL CELL BIOL, V5, P3183, DOI 10.1128/MCB.5.11.3183; CARSWELL S, 1989, MOL CELL BIOL, V9, P4248, DOI 10.1128/MCB.9.10.4248; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; COLE CN, 1985, MOL CELL BIOL, V5, P2104, DOI 10.1128/MCB.5.8.2104; DEZAZZO JD, 1989, MOL CELL BIOL, V9, P4951, DOI 10.1128/MCB.9.11.4951; DEZAZZO JD, 1991, MOL CELL BIOL, V11, P5977, DOI 10.1128/MCB.11.12.5977; FALCKPEDERSEN E, 1989, J VIROL, V63, P532, DOI 10.1128/JVI.63.2.532-541.1989; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; GALLI G, 1987, GENE DEV, V1, P471, DOI 10.1101/gad.1.5.471; GIL A, 1984, NATURE, V312, P473, DOI 10.1038/312473a0; GIL A, 1987, CELL, V49, P399, DOI 10.1016/0092-8674(87)90292-3; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GILMARTIN GM, 1988, GENE DEV, V2, P578, DOI 10.1101/gad.2.5.578; HALES KH, 1988, J VIROL, V62, P1464, DOI 10.1128/JVI.62.4.1464-1468.1988; HART RP, 1985, MOL CELL BIOL, V5, P2975, DOI 10.1128/MCB.5.11.2975; HIGGS DR, 1983, NATURE, V306, P398, DOI 10.1038/306398a0; IWAMOTO S, 1986, J VIROL, V59, P112, DOI 10.1128/JVI.59.1.112-119.1986; JANSENDURR P, 1988, NUCLEIC ACIDS RES, V16, P3771, DOI 10.1093/nar/16.9.3771; JANSENDURR P, 1989, J VIROL, V63, P5124, DOI 10.1128/JVI.63.12.5124-5132.1989; KESSLER MM, 1986, NUCLEIC ACIDS RES, V14, P4939, DOI 10.1093/nar/14.12.4939; LEMOULLEC JM, 1983, J VIROL, V48, P127, DOI 10.1128/JVI.48.1.127-134.1983; LEONG K, 1990, J VIROL, V64, P51, DOI 10.1128/JVI.64.1.51-60.1990; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MCDEVITT MA, 1988, GENE DEV, V2, P588, DOI 10.1101/gad.2.5.588; MCDEVITT MA, 1984, CELL, V37, P993, DOI 10.1016/0092-8674(84)90433-1; MCDEVITT MA, 1986, EMBO J, V5, P2907, DOI 10.1002/j.1460-2075.1986.tb04586.x; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; MONTELL C, 1983, NATURE, V305, P600, DOI 10.1038/305600a0; MOORE CL, 1984, CELL, V36, P581, DOI 10.1016/0092-8674(84)90337-4; MOORE CL, 1988, EMBO J, V7, P3159, DOI 10.1002/j.1460-2075.1988.tb03183.x; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; MOORE CL, 1986, EMBO J, V5, P1929, DOI 10.1002/j.1460-2075.1986.tb04446.x; Nevins J R, 1981, Adv Virus Res, V26, P1, DOI 10.1016/S0065-3527(08)60419-4; NEVINS JR, 1978, J VIROL, V25, P811, DOI 10.1128/JVI.25.3.811-823.1978; NEVINS JR, 1981, NATURE, V290, P113, DOI 10.1038/290113a0; PETERSON ML, 1989, MOL CELL BIOL, V9, P726, DOI 10.1128/MCB.9.2.726; PETERSON ML, 1991, MOL CELL BIOL, V11, P2324, DOI 10.1128/MCB.11.4.2324; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; SADOFSKY M, 1985, MOL CELL BIOL, V5, P2713, DOI 10.1128/MCB.5.10.2713; SADOFSKY M, 1984, MOL CELL BIOL, V4, P1460, DOI 10.1128/MCB.4.8.1460; SCHAACK J, 1990, GENE DEV, V4, P1197, DOI 10.1101/gad.4.7.1197; SHAW AR, 1980, CELL, V22, P905, DOI 10.1016/0092-8674(80)90568-1; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TERNS MP, 1989, MOL CELL BIOL, V9, P1435, DOI 10.1128/MCB.9.4.1435; THOMAS GP, 1980, CELL, V22, P523; VALSAMAKIS A, 1991, P NATL ACAD SCI USA, V88, P2108, DOI 10.1073/pnas.88.6.2108; VIRTANEN A, 1988, EMBO J, V7, P1421, DOI 10.1002/j.1460-2075.1988.tb02959.x; WEISS EA, 1991, EMBO J, V10, P215, DOI 10.1002/j.1460-2075.1991.tb07938.x; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; WILUSZ J, 1988, MOL CELL BIOL, V8, P4477, DOI 10.1128/MCB.8.10.4477; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHANG F, 1986, MOL CELL BIOL, V6, P4611, DOI 10.1128/MCB.6.12.4611	62	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8175	8181						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1575826				2022-12-27	WOS:A1992HQ18500034
J	VANDEWETERING, M; OOSTERWEGEL, M; HOLSTEGE, F; DOOYES, D; SUIJKERBUIJK, R; VANKESSEL, AG; CLEVERS, H				VANDEWETERING, M; OOSTERWEGEL, M; HOLSTEGE, F; DOOYES, D; SUIJKERBUIJK, R; VANKESSEL, AG; CLEVERS, H			THE HUMAN T-CELL TRANSCRIPTION FACTOR-I GENE - STRUCTURE, LOCALIZATION, AND PROMOTER CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX-DETERMINING REGION; DNA-BINDING MOTIF; INSITU HYBRIDIZATION; PROTEIN; EXPRESSION; CHROMOSOME; CONTAINS; HOMOLOGY	We have recently isolated cDNA clones representing four alternative splice forms of a T cell-specific transcription factor, TCF-1. Here we report the characterization of the human gene encoding this factor. The TCF-1 gene is contained in 10 exons including an untranslated first exon. The DNA-binding high mobility group (HMG) box of TCF-1 is encoded by the closely spaced exons VI and VII. Differential splicing involves an alternative exon (IX) and three splice acceptor sites in exon X. Based on comparison of sequence and on the placement of an alternative exon, TCF-1 appears closely related to the recently characterized HMG box transcription factor TCF-1-alpha/LEF. In particular, the HMG boxes encoded by the two TCF genes are virtually identical. The TCF-1 gene resides on chromosome 5 band q31.1. The TCF-1 promoter coincides with a CpG island. As determined by chloramphenicol acetyltransferase analysis, the promoter is preferentially active in T cells. The promoter does not contain TCF-1/TCF-1-alpha-binding sites and is therefore not autoregulated. This observation implies the existence of yet uncharacterized T cell transcription factors that are active during early T cell differentiation.	UNIV HOSP UTRECHT,DEPT CLIN IMMUNOL,POB 85500,3508 GA UTRECHT,NETHERLANDS; UNIV HOSP NIJMEGEN,DEPT HUMAN GENET,6500 HB NIJMEGEN,NETHERLANDS	Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen			Holstege, Frank/AAM-9944-2021; van Kessel, Ad Geurts/A-2810-2010					ATCHISON ML, 1988, ANNU REV CELL BIOL, V4, P127, DOI 10.1146/annurev.cellbio.4.1.127; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHERIF D, 1990, P NATL ACAD SCI USA, V87, P6639, DOI 10.1073/pnas.87.17.6639; CLEVERS H, 1989, EMBO J, V8, P2527, DOI 10.1002/j.1460-2075.1989.tb08390.x; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CLEVERS HC, 1988, P NATL ACAD SCI USA, V85, P8156, DOI 10.1073/pnas.85.21.8156; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KIEVITS T, 1990, CYTOMETRY, V11, P105, DOI 10.1002/cyto.990110112; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MUELLER M M, 1988, Nature (London), V336, P544; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; OOSTERWEGEL M, 1991, INT IMMUNOL, V11, P1189; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; Sambrook J, 1989, MOL CLONING LABORATO; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCOTT MP, 1987, CELL, V51, P689, DOI 10.1016/0092-8674(87)90092-4; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VANKESSEL AHMG, 1983, P NATL ACAD SCI-BIOL, V80, P3748; WASMUTH JJ, 1989, CYTOGENET CELL GENET, V51, P137, DOI 10.1159/000132789; WATGERMAN ML, 1991, GENE DEV, V5, P656; WETERMAN ML, 1990, NEW BIOL, V2, P621	33	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8530	8536						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569101				2022-12-27	WOS:A1992HQ18500087
J	KATO, K; SHINOHARA, H; GOTO, S; INAGUMA, Y; MORISHITA, R; ASANO, T				KATO, K; SHINOHARA, H; GOTO, S; INAGUMA, Y; MORISHITA, R; ASANO, T			COPURIFICATION OF SMALL HEAT-SHOCK PROTEIN WITH ALPHA-B CRYSTALLIN FROM HUMAN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-LENTICULAR TISSUES; LENS; GENE; IMMUNOASSAY; EXPRESSION; DROSOPHILA; PHOSPHORYLATION; LOCALIZATION; FIBROBLASTS; SEPARATION	Immunoreactive alpha-B crystallin and a 28-kDa protein in an extract of human pectoral muscle were precipitated by (NH4)2SO4 at 40% saturation, and coeluted during column chromatography on DEAE-Sepharose and on Bio-Gel A-5m. The two proteins were separated on a column of S-Sepharose HP in the presence of 7 M urea. Further chromatography of each of the two resultant fractions on a column of Superdex 75 pg and on a TSK-SP 5PW column in the presence of urea yielded preparations of alpha-B-crystallin and the 28-kDa protein each of which gave a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The final preparation of 28-kDa protein contained at least two subtypes, which were separable on the TSK-SP column. However, fragmentation patterns of the two major 28-kDa proteins after digestion with endoproteinase Asp-N were identical. Amino acid sequences of peptides formed by cleavage of the purified 28-kDa protein and alpha-B crystallin were identical to those of particular regions of the deduced amino acid sequences of human small heat shock protein (HSP28) and lens alpha-B-crystallin, respectively. Using an immunoassay method, with antibodies raised in rabbits, we found that HSP28 was present in all human tissues tested and at high levels (> 1-mu-g/mg protein) in the heart and other tissues composed of striated and smooth muscles. HSP28, found with alpha-B crystallin, in extracts of several human and bovine tissues was trapped on and coeluted with alpha-B crystallin from an affinity column prepared with antibodies against alpha-B crystallin. This result suggests that the two proteins are associated in cells.			KATO, K (corresponding author), AICHI PREFECTURAL COLONY,INST DEV RES,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN.							ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1985, EMBO J, V4, P399, DOI 10.1002/j.1460-2075.1985.tb03642.x; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BLOEMENDAL H, 1981, ANAL BIOCHEM, V117, P327, DOI 10.1016/0003-2697(81)90787-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKENHOFF RH, 1990, HUM GENET, V85, P237, DOI 10.1007/BF00193203; CORCES V, 1980, P NATL ACAD SCI-BIOL, V77, P5390, DOI 10.1073/pnas.77.9.5390; DUBIN RA, 1990, GENOMICS, V7, P594, DOI 10.1016/0888-7543(90)90204-8; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; GOLDMAN JE, 1988, AM J PATHOL, V130, P569; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KATO K, 1983, METHOD ENZYMOL, V92, P345; KATO K, 1977, J BIOCHEM-TOKYO, V81, P1557; KATO K, 1976, J IMMUNOL, V116, P1554; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; KIM YJ, 1984, MOL CELL BIOL, V4, P468, DOI 10.1128/MCB.4.3.468; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KRAMPS JA, 1977, FEBS LETT, V74, P82, DOI 10.1016/0014-5793(77)80757-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P113, DOI 10.1007/BF00221052; NAGINENI CN, 1989, FEBS LETT, V249, P89, DOI 10.1016/0014-5793(89)80022-5; QUAXJEUKEN Y, 1985, P NATL ACAD SCI USA, V82, P5819, DOI 10.1073/pnas.82.17.5819; SPECTOR A, 1971, BIOCHEM J, V124, P337, DOI 10.1042/bj1240337; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; TSSIERES A, 1979, J MOL BIOL, V84, P389; VANDEROU.FJ, 1974, EUR J BIOCHEM, V49, P157; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403	33	177	180	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7718	7725						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560006				2022-12-27	WOS:A1992HN48500074
J	VUORI, K; MYLLYLA, R; PIHLAJANIEMI, T; KIVIRIKKO, KI				VUORI, K; MYLLYLA, R; PIHLAJANIEMI, T; KIVIRIKKO, KI			EXPRESSION AND SITE-DIRECTED MUTAGENESIS OF HUMAN PROTEIN DISULFIDE ISOMERASE IN ESCHERICHIA-COLI - THIS MULTIFUNCTIONAL POLYPEPTIDE HAS 2 INDEPENDENTLY ACTING CATALYTIC SITES FOR THE ISOMERASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HORMONE-BINDING-PROTEIN; HUMAN PROLYL 4-HYDROXYLASE; BETA-SUBUNIT; MONOCLONAL-ANTIBODIES; DISULPHIDE-ISOMERASE; SECRETORY PROTEINS; MOLECULAR-CLONING; FOREIGN PROTEINS; THIOREDOXIN; SEQUENCE	Protein disulfide isomerase (PDI, EC 5.3.4.1) is a highly unusual multifunctional polypeptide, being identical to the beta-subunit of prolyl 4-hydroxylase, a cellular thyroid hormone binding protein and a component of the microsomal triglyceride transfer protein complex, and highly similar to a polypeptide acting in vitro as a glycosylation site binding protein. It has two -Cys-Gly-His-Cys- sequences which, it has been proposed, act as catalytic sites for the isomerase activity, but few data have been available to indicate whether one or both of them do indeed act as catalytic sites and whether the two presumed catalytic sites act independently or cooperatively. We report here on the expression of human PDI in Escherichia coli with three different signal sequences. All three polypeptide variants were secreted into the periplasmic space as fully active enzymes. Oligonucleotide-directed mutagenesis was used to convert either one or both of the -Cys-Gly-His-Cys- sequences to -Ser-Gly-His-Cys-. The PDI activity of both polypeptides containing a single modified sequence was about 50% of that of the wild-type polypeptide, whereas the polypeptide with two modified sequences had no isomerase activity. It is thus concluded that both -Cys-Gly-His-Cys- sequences act as catalytic sites for the isomerase activity, and the two catalytic sites appear to operate independently of one another.	UNIV OULU, DEPT MED BIOCHEM, SF-90220 OULU, FINLAND; UNIV OULU, BIOCTR, COLLAGEN RES UNIT, SF-90220 OULU, FINLAND	University of Oulu; University of Oulu				Pihlajaniemi, Taina/0000-0002-1664-9045				AMANN E, 1984, GENE, V32, P203, DOI 10.1016/0378-1119(84)90048-9; Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; BULLEID NJ, 1990, EMBO J, V9, P3527, DOI 10.1002/j.1460-2075.1990.tb07561.x; CHENG SY, 1987, J BIOL CHEM, V262, P11221; DENG TL, 1990, GENE, V93, P229, DOI 10.1016/0378-1119(90)90229-K; DUFFAUD GD, 1987, METHOD ENZYMOL, V153, P492; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FREEDMAN RB, 1988, BIOCHEM SOC T, V16, P96, DOI 10.1042/bst0160096; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GILBERT HF, 1989, BIOCHEMISTRY-US, V28, P7298, DOI 10.1021/bi00444a023; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOYHTYA M, 1984, EUR J BIOCHEM, V141, P477, DOI 10.1111/j.1432-1033.1984.tb08217.x; IBBETSON AL, 1976, BIOCHEM J, V159, P377, DOI 10.1042/bj1590377; KAETZEL CS, 1987, BIOCHEM J, V241, P39, DOI 10.1042/bj2410039; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1990, ANN NY ACAD SCI, V580, P132, DOI 10.1111/j.1749-6632.1990.tb17925.x; KOIVU J, 1987, J BIOL CHEM, V262, P6447; KOSHLAND D, 1980, CELL, V20, P749, DOI 10.1016/0092-8674(80)90321-9; NOIVA R, 1991, P NATL ACAD SCI USA, V88, P1986, DOI 10.1073/pnas.88.5.1986; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; Sambrook J, 1989, MOL CLONING LABORATO; TASANEN K, 1988, J BIOL CHEM, V263, P16218; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; YAMAUCHI K, 1987, BIOCHEM BIOPH RES CO, V146, P1485, DOI 10.1016/0006-291X(87)90817-5	29	128	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7211	7214						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559965				2022-12-27	WOS:A1992HN48500005
J	STOLTZFUS, LJ; SOSAPINEDA, B; MOSKOWITZ, SM; MENON, KP; DLOTT, B; HOOPER, L; TEPLOW, DB; SHULL, RM; NEUFELD, EF				STOLTZFUS, LJ; SOSAPINEDA, B; MOSKOWITZ, SM; MENON, KP; DLOTT, B; HOOPER, L; TEPLOW, DB; SHULL, RM; NEUFELD, EF			CLONING AND CHARACTERIZATION OF CDNA-ENCODING CANINE ALPHA-L-IDURONIDASE - MESSENGER-RNA DEFICIENCY IN MUCOPOLYSACCHARIDOSIS-I DOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MARROW TRANSPLANTATION; CULTURED HUMAN-FIBROBLASTS; LYSOSOMAL-ENZYME; SEQUENCE-ANALYSIS; MOLECULAR-CLONING; PURIFICATION; EXPRESSION; LOCALIZATION; SUBUNIT; BINDING	Alpha-L-Iduronidase is a lysosomal enzyme, the deficiency of which causes mucopolysaccharidosis I (MPS I); a canine MPS I colony has been bred to test therapeutic intervention. The enzyme was purified to apparent homogeneity from canine testis and found to consist of two electrophoretically separable proteins that had common internal peptides but differed at their amino termini. A 57-base oligonucleotide, corresponding to the most probable codons of the longest peptide, was used to screen a canine testis cDNA library. Three cDNAs were isolated, two of which lacked the 5'-end whereas the third was full-length except for a small internal deletion. The composite sequence encodes an open reading frame of 655 amino acids that includes all sequenced peptides. The amino terminus of the larger protein, glutamic acid 26, is at the predicted signal peptide cleavage site, whereas the amino terminus of the smaller protein is leucine 106. There are six potential N-glycosylation sites and a non-canonical polyadenylation signal, CTTAAA. A search of Gen-Bank showed that the amino acid sequence of alpha-L-iduronidase has similarity to that of a bacterial beta-xylosidase. A full-length cDNA corresponding to the composite sequence was constructed (pcIdu) and inserted into the pSVL expression vector (pSVcIdu). Two days after Cos-1 cells were transfected with pSVcIdu, their intracellular and secreted level of alpha-L-iduronidase activity had increased 8- and 22-fold, respectively, over the endogenous activity. Fibroblasts of MPS I dogs, which have no alpha-L-iduronidase activity, lacked the normal alpha-L-iduronidase mRNA of 2.2 kilobase and contained instead a trace amount of a 2.8-kilobase species. Isolation and characterization of an expressible alpha-L-iduronidase cDNA represents the first step toward mutation analysis and replacement therapy.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; CALTECH,DIV BIOL,PASADENA,CA 91125; UNIV TENNESSEE,COLL VET MED,DEPT PATHOBIOL,KNOXVILLE,TN 37916	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; California Institute of Technology; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038857] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38857] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BACH G, 1972, P NATL ACAD SCI USA, V69, P2048, DOI 10.1073/pnas.69.8.2048; BARTON RW, 1971, J BIOL CHEM, V246, P7773; BREIDER MA, 1989, AM J PATHOL, V134, P677; BROWN TA, 1987, BIOCHIM BIOPHYS ACTA, V912, P244, DOI 10.1016/0167-4838(87)90095-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEMENTS PR, 1989, BIOCHEM J, V259, P199, DOI 10.1042/bj2590199; CLEMENTS PR, 1985, EUR J BIOCHEM, V152, P29, DOI 10.1111/j.1432-1033.1985.tb09159.x; CLEMENTS PR, 1985, EUR J BIOCHEM, V152, P21, DOI 10.1111/j.1432-1033.1985.tb09158.x; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; Drapeau G R, 1977, Methods Enzymol, V47, P189; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRIVIT W, 1990, BONE MARROW TRANSPL, P261; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTHI E, 1990, APPL ENVIRON MICROB, V56, P1017; Maniatis T., 1982, MOL CLONING; MORREAU H, 1989, J BIOL CHEM, V264, P20655; MOSKOWITZ SM, 1992, FASEB J, V6, pA77; MYEROWITZ R, 1981, J BIOL CHEM, V256, P3044; Neufeld EF, 1989, METABOLIC BASIS INHE, P1565; OHSHITA T, 1989, EUR J BIOCHEM, V179, P201, DOI 10.1111/j.1432-1033.1989.tb14541.x; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROME LH, 1980, BIOCHEM BIOPH RES CO, V92, P986, DOI 10.1016/0006-291X(80)90799-8; ROME LH, 1979, P NATL ACAD SCI USA, V76, P2331, DOI 10.1073/pnas.76.5.2331; ROME LH, 1978, ARCH BIOCHEM BIOPHYS, V189, P344, DOI 10.1016/0003-9861(78)90221-7; SANDO GN, 1977, CELL, V12, P619, DOI 10.1016/0092-8674(77)90262-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCHMAN EH, 1984, ENZYME, V31, P166, DOI 10.1159/000469519; SCHUCHMAN EH, 1984, J BIOL CHEM, V259, P3132; SCOTT HS, 1991, P NATL ACAD SCI USA, V88, P9695, DOI 10.1073/pnas.88.21.9695; SCOTT HS, 1990, AM J HUM GENET, V47, P802; SHULL RM, 1988, PEDIATR RES, V24, P347, DOI 10.1203/00006450-198809000-00015; SPELLACY E, 1983, P NATL ACAD SCI-BIOL, V80, P6091, DOI 10.1073/pnas.80.19.6091; STOLTZFUS LJ, 1990, AM J HUM GENET, V47, pA167; TAYLOR JA, 1991, BIOCHEM J, V274, P263, DOI 10.1042/bj2740263; ULLRICH A, 1984, EMBO J, V3, P361, DOI 10.1002/j.1460-2075.1984.tb01812.x; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; YAMAUCHI T, 1990, BIOCHEM BIOPH RES CO, V170, P231, DOI 10.1016/0006-291X(90)91264-S	42	57	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6570	6575						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551868				2022-12-27	WOS:A1992HM05300021
J	YANG, CH; PAIN, J; SIROTNAK, FM				YANG, CH; PAIN, J; SIROTNAK, FM			ALTERATION OF FOLATE ANALOG TRANSPORT INWARD AFTER INDUCED MATURATION OF HL-60 LEUKEMIA-CELLS - MOLECULAR-PROPERTIES OF THE TRANSPORTER IN AN OVERPRODUCING VARIANT AND EVIDENCE FOR DOWN-REGULATION OF ITS SYNTHESIS IN MATURATING CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHOTREXATE TRANSPORT; GENETIC-VARIANTS; L1210 CELLS; PROTEIN; CARRIER; LINE	Studies are described examining further the decline in folate analogue influx mediated by the one-carbon reduced-folate transport system in HL-60 cells following induction of maturation by cytodifferentiation agents. To facilitate the investigation of the underlying basis of this phenomenon, we derived a variant (HL-60/LCV) with 4-5-fold elevated influx capacity (V(max)) for folate analogues. A commensurate increase in the putative transporter for this system was documented by affinity labeling of these cells with N-hydroxysuccinimide-[H-3]aminopterin. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the affinity labeled plasma membrane in HL-60/LCV cells delineated a protein peak at M(r) = 75,000-80,000. This was substantially greater than the analogous transporter (M(r) = 45,000-47,000) we had delineated (Yang, C.-H., Sirotnak, F.M., and Mines, L.S. (1988) J. Biol. Chem. 263, 9703-9709) with the same methodology in the L1210 cell plasma membrane. In addition, the rate of translocation of the M(r) = 75,000-80,000 transporter in HL-60 and HL-60/LCV cells was 2-fold lower than the rate of translocation determined for the M(r) = 45,000-47,000 transporter in L1210 cells. During induced maturation of HL-60/LCV cells toward the granulocyte pathway, [H-3]methotrexate (MTX) influx capacity and the amount of the affinity labeled transporter decreased rapidly in a parallel fashion. The decrease in [H-3]MTX influx and in affinity labeling and in the amount of the M(r) = 75,000-80,000 transporter was 5-fold following exposure to 210 mM dimethyl sulfoxide (Me2SO) for 5 days during growth in culture. Moreover, during cycloheximide treatment, the decay in [H-3]MTX influx at 37-degrees-C and in amount of affinity labeled transporter was the same (t1/2 = 144-155 min) for both control and Me2SO-treated HL-60/LCV cells. These results, which reveal no difference in metabolic turnover for control and Me2SO-treated cells, suggest that the decline in folate analogue influx in HL-60/LCV influx cells is a very early event in the program of differentiation and probably occurs by down-regulation of synthesis of the transporter for the one-carbon reduced-folate transport system.	MEM SLOAN KETTERING CANC CTR,MOLEC THERAPEUT LAB,PROGRAM MOLEC PHARMACOL & THERAPEUT,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NCI NIH HHS [CA 46673, CA 08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA046673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CASHMORE AR, 1980, METHOD ENZYMOL, V68, P457; CORIN RE, 1984, J BIOL CHEM, V259, P206; CRAIG RW, 1984, CANCER RES, V44, P2421; DEMBO M, 1984, FOLATE ANTAGONISTS T, V1, P173; FAN JG, 1991, J BIOL CHEM, V266, P14862; GALLAGHER R, 1979, BLOOD, V54, P713; GOLDMAN ID, 1986, MEMBRANE TRANSPORT A, P283; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1986, CANCER RES, V46, P1633; JANSEN G, 1990, J BIOL CHEM, V265, P18272; JANSEN G, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P323; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHERLY LH, 1991, CANCER RES, V51, P3420; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PLAGEMANN PGW, 1974, BIOCHIM BIOPHYS ACTA, V344, P263, DOI 10.1016/0304-4157(74)90010-0; PRICE EM, 1987, BIOCHEMISTRY-US, V26, P4757, DOI 10.1021/bi00389a024; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1980, PHARMACOL THERAPEUT, V8, P71, DOI 10.1016/0163-7258(80)90060-1; SIROTNAK FM, 1984, J BIOL CHEM, V259, P3139; SIROTNAK FM, 1986, J BIOL CHEM, V261, P1150; YANG CH, 1988, J BIOL CHEM, V263, P9703; ZAR JH, 1984, BIOSTAT ANAL, P145	24	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6628	6634						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551871				2022-12-27	WOS:A1992HM05300029
J	CHIODO, AA; HOCKEY, A; COLE, WG				CHIODO, AA; HOCKEY, A; COLE, WG			A BASE SUBSTITUTION AT THE SPLICE ACCEPTOR SITE OF INTRON-5 OF THE COL1A2 GENE ACTIVATES A CRYPTIC SPLICE SITE WITHIN EXON-6 AND GENERATES ABNORMAL TYPE-I PROCOLLAGEN IN A PATIENT WITH EHLERS-DANLOS SYNDROME TYPE-VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; PRO-ALPHA-2(I) COLLAGEN GENE; ENZYMATIC AMPLIFICATION; III COLLAGENS; MUTATION; FIBROBLASTS; PEPTIDES; DEFECT; CHAINS; DNA	The dermal type I collagen of a patient with Ehlers-Danlos type VIIB (EDS-VIIB) contained normal alpha-2(I) chains and mutant pN-alpha-2(I)' chains in which the amino-terminal propeptide (N-propeptide) remained attached to the alpha-2(I) chain. Similar alpha-2(I) chains were produced by cultured dermal fibroblasts. Amino acid sequencing of tryptic peptides, prepared from the mutant amino-terminal pN-alpha-2(I) CB1' peptide, indicated that five amino acids, including the N-proteinase (the specific proteinase that cleaves the procollagen N-propeptide) cleavage site, had been deleted from the junction of the N-propeptide and the N-telopeptide (the nonhelical domain at the amino-terminus of the alpha-chains of fully processed type I polypeptide chains) of the mutant pro-alpha-2(I)' chain. The corresponding 15 nucleotides, which were deleted from approximately half of the alpha-2(I) cDNA polymerase chain reaction products, were encoded by the +1 to +15 nucleotides of exon 6 of the normal alpha-2(I) gene (COL1A2). These 15 nucleotides were deleted in the splicing of alpha-2(I) pre-RNA to mRNA as a result of inactivation of the 3' splice site of intron 5 by an AG to AC mutation and the activation of a cryptic AG splice acceptor site corresponding to positions +14 and +15 of exon 6. Loss of the N-proteinase cleavage site explained the persistence of the pN-alpha-2(I)' chains in the dermis and in fibroblast cultures. Collagen production by cultured dermal fibroblasts was doubled, possibly due to reduced feedback inhibition by the N-propeptides. In contrast to previously reported cases of EDS-VIIB, Lys5 of the N-telopeptide was not deleted and appeared to take part in the formation of intramolecular cross-linkages. However, increased collagen solubility and abnormal extraction profiles of the mutant type I collagen molecules indicated that collagen cross-linking was abnormal in the dermis. The proband and her son were heterozygous for the mutation. It is likely that the heterozygous loss of the N-proteinase cleavage site, with persistence of a shortened N-propeptide, was the major factor responsible for the EDS-VIIB phenotype.	UNIV MELBOURNE,DEPT PAEDIAT,PARKVILLE,VIC 3052,AUSTRALIA; KING EDWARD MEM HOSP WOMEN,DEPT GENET,SUBIACO,WA 6008,AUSTRALIA	University of Melbourne; King Edward Memorial Hospital; University of Western Australia								AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P1154, DOI 10.1073/pnas.81.4.1154; Bateman J F, 1988, Ann N Y Acad Sci, V543, P95, DOI 10.1111/j.1749-6632.1988.tb55321.x; BATEMAN JF, 1986, ANAL BIOCHEM, V154, P338, DOI 10.1016/0003-2697(86)90534-8; BATEMAN JF, 1990, BIOCHEM J, V267, P573, DOI 10.1042/bj2670573; CHAN D, 1984, ANAL BIOCHEM, V139, P322, DOI 10.1016/0003-2697(84)90012-5; CLADARAS C, 1987, J BIOL CHEM, V262, P2310; COLE WG, 1986, J BIOL CHEM, V261, P5496; DEWET W, 1987, J BIOL CHEM, V262, P16032; EYRE DR, 1985, J BIOL CHEM, V260, P1322; HORLEIN D, 1981, P NATL ACAD SCI-BIOL, V78, P6163, DOI 10.1073/pnas.78.10.6163; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; KUIVANIEMI H, 1988, J BIOL CHEM, V263, P11407; LAMOND AI, 1990, NUCLEIC ACIDS MOL BI, V4, P243; LENAERS A, 1971, EUR J BIOCHEM, V23, P533, DOI 10.1111/j.1432-1033.1971.tb01651.x; LICHTENSTEIN JR, 1973, SCIENCE, V182, P298, DOI 10.1126/science.182.4109.298; LIGHT ND, 1982, METHOD ENZYMOL, V82, P360; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; MILLER EJ, 1987, METHOD ENZYMOL, V144, P3; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P1926, DOI 10.1128/MCB.6.6.1926; NICHOLLS AC, 1991, HUM GENET, V87, P193, DOI 10.1007/BF00204180; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; STEINMANN B, 1980, J BIOL CHEM, V255, P8887; SU TS, 1990, J BIOL CHEM, V265, P19716; TROMP G, 1988, P NATL ACAD SCI USA, V85, P5254, DOI 10.1073/pnas.85.14.5254; VASAN NS, 1991, AM J HUM GENET, V48, P305; WAKE SA, 1985, BIOCHEM J, V228, P425, DOI 10.1042/bj2280425; WEIL D, 1990, J BIOL CHEM, V265, P16007; WEIL D, 1989, J BIOL CHEM, V264, P16804; WEIL D, 1989, EMBO J, V8, P1705, DOI 10.1002/j.1460-2075.1989.tb03562.x; WEIL D, 1988, J BIOL CHEM, V263, P8561; WIESTNER M, 1979, J BIOL CHEM, V254, P7016; WIESTNER M, 1982, EMBO J, V1, P513, DOI 10.1002/j.1460-2075.1982.tb01200.x; WIRTZ MK, 1990, J BIOL CHEM, V265, P6312; WU CH, 1986, J BIOL CHEM, V261, P482	39	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6361	6369						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556139				2022-12-27	WOS:A1992HK31800095
J	SIROIS, J; RICHARDS, JS				SIROIS, J; RICHARDS, JS			PURIFICATION AND CHARACTERIZATION OF A NOVEL, DISTINCT ISOFORM OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE INDUCED BY HUMAN CHORIONIC-GONADOTROPIN IN GRANULOSA-CELLS OF RAT PREOVULATORY FOLLICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-OVULATORY CHANGES; H-SYNTHASE; GRAAFIAN FOLLICLES; FOLLICULAR-FLUID; SYNTHETASE; CYCLOOXYGENASE; INDOMETHACIN; GENE; ACID; IDENTIFICATION	To purify and characterize the isoform of prostaglandin endoperoxide synthase (rPGS(i)) induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles, solubilized cell extracts were subjected to anionic exchange chromatography, column fractions were resolved by one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and rPGS(i) was visualized by immunoblotting and silver staining techniques. Immunoreactive rPGS(i) and peroxidase activity co-eluted at pH 6.5 and 6.0. Amino-terminal aminoacid sequence of three immunoreactive rPGS(i) bands (M(r) = 72,000, 70,000, and 59,000) were identical, M(r) = 59,000 being a proteolytic fragment. Alignment of the amino-terminal sequences of rPGS(i) with those of ovine PGS (oPGS) indicated that only 15 of 26 residues were identical (58% identity). In contrast, rPGS(i) was closely related to the deduced amino acid sequence of PGS-related cDNA clones isolated from chicken and mouse cell lines, with 77% (20/26 residues) and 96% (25/26 residues) identity, respectively. Whereas tryptic digests of oPGS generated fragments of M(r) = 38,000 and M(r) = 33,000, only a small peptide appeared cleaved from the carboxyl terminus of rPGS(i). Peroxidase activity of partially purified rPGS(i) exhibited lower apparent K(m) and maximal velocity than that of oPGS. Collectively, these results document the existence of a novel rat PGS isoform (based on purification, enzymatic activity, and amino-terminal amino acid sequence) which is hormonally induced and obligatory for a known biological process, ovulation.	BAYLOR COLL MED, DEPT CELL BIOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA	Baylor College of Medicine					NICHD NIH HHS [HD-16229] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD016229] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016229] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AINSWORTH L, 1979, BIOL REPROD, V21, P401, DOI 10.1095/biolreprod21.2.401; AINSWORTH L, 1975, PROSTAGLANDINS, V9, P915, DOI 10.1016/0090-6980(75)90079-9; ARMSTRONG DT, 1972, PROSTAGL, V1, P21, DOI 10.1016/0090-6980(72)90062-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YNP, 1987, J BIOL CHEM, V262, P16892; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; ESPEY LL, 1982, PROSTAGLANDINS, V23, P329, DOI 10.1016/0090-6980(82)90078-8; ESPEY LL, 1980, BIOL REPROD, V22, P73, DOI 10.1095/biolreprod22.1.73; HEDIN L, 1987, ENDOCRINOLOGY, V121, P722, DOI 10.1210/endo-121-2-722; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HUSLIG RL, 1987, MOL CELL ENDOCRINOL, V50, P237, DOI 10.1016/0303-7207(87)90022-0; KILLICK S, 1987, FERTIL STERIL, V47, P773; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ R, 1987, PROSTAGLANDINS RELAT, P202; KULMACZ RJ, 1987, PROSTAGLANDINS, V34, P225, DOI 10.1016/0090-6980(87)90246-2; KULMACZ RJ, 1984, J BIOL CHEM, V259, P6358; KULMACZ RJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P502, DOI 10.1016/0003-9861(89)90317-2; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; KULMACZ RJ, 1987, CRC HDB EICOSANOID A, V1, P163; LAU IF, 1974, J REPROD FERTIL, V40, P467, DOI 10.1530/jrf.0.0400467; LEMAIRE WJ, 1975, PROSTAGLANDINS, V9, P221, DOI 10.1016/0090-6980(75)90027-1; LEMAIRE WJ, 1973, PROSTAGLANDINS, V3, P367, DOI 10.1016/0090-6980(73)90075-0; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MEVKH AT, 1985, ANAL BIOCHEM, V150, P91, DOI 10.1016/0003-2697(85)90444-0; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; NELSON PH, 1987, CRC HDB EICOSANOIDS, V2, P59; OGRADY JP, 1972, PROSTAGL, V1, P97, DOI 10.1016/0090-6980(72)90072-X; ORCZYK GP, 1972, PROSTAGL, V1, P3, DOI 10.1016/0090-6980(72)90061-5; RAZ A, 1990, BIOCHEM J, V269, P603, DOI 10.1042/bj2690603; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SIGAL E, 1991, AM J PHYSIOL, V260, pL13, DOI 10.1152/ajplung.1991.260.2.L13; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SMITH WL, 1990, STROKE, V21, P24; TSAFRIRI A, 1972, PROSTAGL, V2, P1, DOI 10.1016/0090-6980(72)90024-X; TSAFRIRI A, 1990, BIOL REPROD S1, V42, P120; TSANG BK, 1979, PROSTAG OTH LIPID M, V17, P141, DOI 10.1016/0090-6980(79)90086-8; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V109, P1; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; VANDEROUDERAA FJ, 1979, BIOCHIM BIOPHYS ACTA, V572, P29, DOI 10.1016/0005-2760(79)90197-8; WONG WY, 1989, MOL ENDOCRINOL, V3, P114; WONG WYL, 1992, IN PRESS ENDOCRINOLO; WONG YL, 1991, MOL ENDOCRINOL, V5, P1269; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	52	303	312	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6382	6388						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556140				2022-12-27	WOS:A1992HK31800098
J	YU, Y; RUSSELL, RN; THORSON, JS; LIU, LD; LIU, HW				YU, Y; RUSSELL, RN; THORSON, JS; LIU, LD; LIU, HW			MECHANISTIC STUDIES OF THE BIOSYNTHESIS OF 3,6-DIDEOXYHEXOSES IN YERSINIA-PSEUDOTUBERCULOSIS - PURIFICATION AND STEREOCHEMICAL ANALYSIS OF CDP-D-GLUCOSE OXIDOREDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE DIPHOSPHATE 3,6-DIDEOXYHEXOSES; NICOTINAMIDE ADENINE-DINUCLEOTIDE; ENZYMATIC-SYNTHESIS; METHYL-GROUPS; 4,6-DEHYDRATASE; E1; E3	An NAD+-dependent CDP-D-glucose oxidoreductase which catalyzes the first step of the biosynthesis of CDP-ascarylose (CDP-3,6-dideoxy-L-arabino-hexose), converting CDP-D-glucose to CDP-4-keto-6-deoxy-D-glucose, was isolated from Yersinia pseudotuberculosis. A protocol consisting of DEAE-cellulose, Matrex Blue-A, hydroxylapatite, DEAE-Sephadex, Sephadex G-100, and NAD+-agarose column chromatography was used to purify this enzyme 6000-fold to homogeneity. This enzyme consists of two identical subunits, each with a molecular weight of 42,500. Using CDP-D-glucose as the substrate, the K(m) and V(max), of this catalysis were determined to be 222-mu-M and 8.3-mu-mol mg-1 min-1, respectively. Unlike most other oxidoreductases of its class which have a tightly bound NAD+, this highly purified CDP-D-glucose oxidoreductase showed an absolute requirement of NAD+ for its activity. Using chemically synthesized (6S)- and (6R)-CDP-D-[4-H-2,6-H-3]glucose as substrates, a stereo-chemical analysis showed this enzymatic reaction involves an intramolecular hydrogen migration from C4 to C-6, and the displacement of C-6 hydroxyl group by the C-4 hydrogen occurs with inversion. Thus, despite the low cofactor affinity, this enzyme undergoes a mechanism consistent with that followed by other members of its type. Such a mechanistic and stereo-chemical convergency found for all sugar oxidoreductases so far characterized suggests the presence of a common progenitor of this class of enzyme.	UNIV MINNESOTA,DEPT CHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities			Thorson, Jon S/L-3696-2013	Thorson, Jon S/0000-0002-7148-0721	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035906, K04GM000559, R37GM035906] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35906, GM-00559] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arigoni D., 1978, CIBA FDN S, P243; BANAIT NS, 1990, J AM CHEM SOC, V112, P6950, DOI 10.1021/ja00175a032; BENDER SL, 1989, BIOCHEMISTRY-US, V28, P7555, DOI 10.1021/bi00445a009; BENNER SA, 1988, MECHANISTIC PRINCIPL, P27; BISHOP CT, 1982, POLYSACCHARIDES, V1, P291; BROSCHAT KO, 1985, EUR J BIOCHEM, V153, P397, DOI 10.1111/j.1432-1033.1985.tb09315.x; CASTRO CE, 1964, J AM CHEM SOC, V86, P4358, DOI 10.1021/ja01074a025; CORNFORT.JW, 1970, EUR J BIOCHEM, V14, P1, DOI 10.1111/j.1432-1033.1970.tb00254.x; CORNFORTH JW, 1969, NATURE, V221, P1212, DOI 10.1038/2211212a0; CREE GM, 1968, CAN J BIOCHEM CELL B, V46, P765, DOI 10.1139/o68-117; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; DAVIES DAL, 1960, ADV CARBOHYD CHEM, V15, P271; ELBEIN AD, 1965, J BIOL CHEM, V240, P1926; Floss H G, 1979, Adv Enzymol Relat Areas Mol Biol, V50, P243; FREY PA, 1987, PYRIDINE NUCLEOTID B, P461; GABRIEL O, 1968, J BIOL CHEM, V243, P1479; GABRIEL O, 1973, ADV CHEM SER, V117, P387; GINSBURG V, 1961, J BIOL CHEM, V236, P2389; GLASER L, 1971, ENZYMES, V5, P465; GONZALEZPORQUE P, 1972, J BIOL CHEM, V247, P6748; GONZALEZPORQUE P, 1986, VITAMIN B6 PYRIDOXAL, P391; GORSHKOVA RP, 1983, EUR J BIOCHEM, V131, P345, DOI 10.1111/j.1432-1033.1983.tb07268.x; HAN O, 1988, J AM CHEM SOC, V110, P7893, DOI 10.1021/ja00231a059; HAN O, 1990, J BIOL CHEM, V265, P8033; Hanessian S, 1966, Adv Carbohydr Chem Biochem, V21, P143; KAKINUMA K, 1977, TETRAHEDRON LETT, P4413; KAKINUMA K, 1984, TETRAHEDRON, V40, P2089, DOI 10.1016/S0040-4020(01)88450-7; KOCH HJ, 1970, CARBOHYD RES, V15, P403, DOI 10.1016/S0008-6215(00)80457-7; KUHN R, 1933, CHEM BER, V66, P1274; LIAO TH, 1972, BIOCHIM BIOPHYS ACTA, V276, P85, DOI 10.1016/0005-2744(72)90010-1; LUDERITZ O, 1966, BACTERIOL REV, V30, P192; LUTHY J, 1969, NATURE, V221, P1213, DOI 10.1038/2211213a0; MACIAK G, 1962, METHODS CARBOHYDR CH, V1, P461; MATERN H, 1973, ARCH MIKROBIOL, V88, P37, DOI 10.1007/BF00408839; MATSUHASHI S, 1966, J BIOL CHEM, V241, P4283; MATSUHASHI S, 1966, J BIOL CHEM, V241, P4267; MELO A, 1968, J BIOL CHEM, V243, P1475; MELO A, 1968, J BIOL CHEM, V243, P1467; NIKAIDO H, 1968, ADV ENZYMOL, V31, P78; OTHS PJ, 1990, CARBOHYD RES, V198, P91, DOI 10.1016/0008-6215(90)84279-4; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RITCHIE RGS, 1975, CAN J CHEM, V53, P1424, DOI 10.1139/v75-197; RUBENSTEIN PA, 1974, J BIOL CHEM, V249, P3776; RUBENSTEIN PA, 1974, J BIOL CHEM, V249, P3782; SHIH YN, 1990, J AM CHEM SOC, V112, P9652, DOI 10.1021/ja00182a042; SLESSOR KN, 1969, CAN J CHEMISTRY, V47, P3989, DOI 10.1139/v69-664; SNIPES CE, 1977, J BIOL CHEM, V252, P8113; Stevens J. D., 1972, METHODS CARBOHYD CHE, V6, P123; TRONCHET JM, 1974, HELV CHIM ACTA, V57, P1505, DOI 10.1002/hlca.19740570605; Van Rheenan V., 1988, ORG SYNTH, V6, P342; VARA JA, 1988, J BIOL CHEM, V263, P14992; WANG SF, 1970, J BIOL CHEM, V245, P8; WANG SF, 1969, J BIOL CHEM, V244, P3430; WEIGEL TM, 1992, IN PRESS BIOCHEMISTR; WESTPHAL O, 1960, ANGEW CHEM INT EDIT, V72, P881, DOI 10.1002/ange.19600722303; Williams N. R., 1980, CARBOHYDRATES B, VIB, P761; WONG SS, 1977, BIOCHEMISTRY-US, V16, P298, DOI 10.1021/bi00621a022; ZARKOWSKY H, 1970, J BIOL CHEM, V245, P6599; ZARKOWSKY H, 1970, BIOCHEM BIOPH RES CO, V38, P787, DOI 10.1016/0006-291X(70)90650-9; ZARKOWSKY H, 1969, J BIOL CHEM, V244, P4750	60	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5868	5875						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556102				2022-12-27	WOS:A1992HK31800026
J	ZARDENETA, G; HOROWITZ, PM				ZARDENETA, G; HOROWITZ, PM			MICELLE-ASSISTED PROTEIN FOLDING - DENATURED RHODANESE BINDING TO CARDIOLIPIN-CONTAINING LAURYL MALTOSIDE MICELLES RESULTS IN SLOWER REFOLDING KINETICS BUT GREATER ENZYME REACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANIDINIUM CHLORIDE; MITOCHONDRIA; DETERGENT	Unfolded (inactive) rhodanese (thiosulfate:cyanide sulfurtransferase, EC 2.8.1.1) can be reactivated in the presence of detergents, e.g. lauryl maltoside (LM). Here, we report the reactivation of urea-unfolded rhodanese in the presence of mixed micelles containing LM and the anionic mitochondrial phospholipid, cardiolipin (CL). Reactivation times increased as the number of CL molecules/micelle was increased. A maximum of 94% of the activity was recovered at 2.2 CL/micelle. Only 71% of the activity was recovered in the absence of CL. The major zwitterionic mitochondrial phospholipid, phosphatidylcholine (PC), had no effect on the LM-assisted reactivation of rhodanese. Size exclusion chromatography showed that denatured, but not native, rhodanese apparently binds to micellar amounts of LM and CL/LM, but not to PC/LM micelles. The lifetime of the enzyme-micelle complex increased with the number of CL molecules/micelle. Furthermore, chromatographic fractions containing micelle-bound enzyme had no activity, while renatured rhodanese-containing fractions were active. These results suggest that transient complexes form between enzyme and both LM and CL/LM micelles, and that this complex formation may be necessary for reactivation. For CL/LM micelles, interactions may occur between the positively charged amino-terminal sequence of rhodanese and the negatively charged CL phosphate. Finally, this work shows that there are similarities between "micelle-assisted" and chaperonin-assisted rhodanese refolding.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGGARAM V, 1985, BIOCHEM BIOPH RES CO, V130, P407, DOI 10.1016/0006-291X(85)90431-0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; HOROWITZ PM, 1989, J BIOL CHEM, V264, P3311; HOROWITZ PM, 1986, J BIOL CHEM, V261, P13887; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER DM, 1991, J BIOL CHEM, V266, P4686; Pain D, 1991, Genet Eng (N Y), V13, P153; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; ROBINSON NC, 1980, BIOCHEMISTRY-US, V19, P3656, DOI 10.1021/bi00557a003; ROUSER G, 1968, BIOL MEMBR, V1, P37; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1123; TANDON S, 1989, J BIOL CHEM, V264, P9859; TANDON S, 1986, J BIOL CHEM, V261, P5615; TANDON S, 1987, J BIOL CHEM, V262, P4486; THOMPSON DA, 1983, BIOCHEMISTRY-US, V22, P3178, DOI 10.1021/bi00282a022	21	75	78	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5811	5816						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556097				2022-12-27	WOS:A1992HK31800017
J	ZECHERLE, GN; OLEINIKOV, A; TRAUT, RR				ZECHERLE, GN; OLEINIKOV, A; TRAUT, RR			THE PROXIMITY OF THE C-TERMINAL DOMAIN OF ESCHERICHIA-COLI RIBOSOMAL PROTEIN-L7/L12 TO L10 DETERMINED BY CYSTEINE SITE-DIRECTED MUTAGENESIS AND PROTEIN-PROTEIN CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNE ELECTRON-MICROSCOPY; MONOCLONAL-ANTIBODIES; MICROGRAM QUANTITIES; LARGE SUBUNIT; M13 VECTORS; L7/L12; LOCALIZATION; DNA; REQUIREMENT; EXPRESSION	Oligonucleotide-directed mutagenesis was used to produce a serine 89 to cysteine 89 substitution in the C-terminal globular domain of Escherichia coli ribosomal protein L7/L12. Cys-89 represented the only cysteine residue in the protein. L7/L12Cys89 was overproduced in E. coli and purified. An allele replacement strain was also constructed. Growth of this strain was indistinguishable from that of wild type. Ribosomes from the allele replacement strain were used to determine the location of the C-terminal domains of L7/L12 by disulfide cross-linking. A new homobifunctional cysteine-specific cross-linking reagent, 1,4-di[3'-(2'-pyridyldithio)-propionamido]butane, and diagonal gel electrophoresis were used to identify ribosomal proteins cross-linked to L7/L12Cys89. A cross-link between L7/L12 and the single cysteine in L10 was found, in addition to L7/L12 dimers. The L7/L12Cys89-L10 cross-link locates the C-terminal domain of at least one L7/L12 dimer on the body of the large subunit and supports our previous model (Olson, H. M., Sommer, A., Tewari, D. S., Traut, R. R., and Glitz, D. G. (1986) J. Biol. Chem. 261, 6924-6932) that depicts one of the two dimers of L7/L12 on the surface of the body of the 50 S subunit in a bent conformation with the C-terminal domain in close proximity to the N-terminal domain at the base of the stalk.	UNIV CALIF DAVIS, SCH MED, DEPT BIOL CHEM, DAVIS, CA 95616 USA	University of California System; University of California Davis					NIGMS NIH HHS [GM 17924, 5 T32 GM07467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007467, R37GM017924, R01GM017924] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN G, 1981, SEQUENCING PROTEINS, P58; BARTETZKO A, 1988, METHOD ENZYMOL, V164, P650; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; COLE JR, 1987, J MOL BIOL, V198, P383, DOI 10.1016/0022-2836(87)90288-9; DENNIS PP, 1984, J BIOL CHEM, V259, P3202; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FIIL NP, 1979, MOL GEN GENET, V173, P39, DOI 10.1007/BF00267689; GIRSHOVICH AS, 1981, FEBS LETT, V130, P54, DOI 10.1016/0014-5793(81)80664-3; GUTTERSON NI, 1983, P NATL ACAD SCI-BIOL, V80, P4894, DOI 10.1073/pnas.80.16.4894; HAMEL E, 1972, J BIOL CHEM, V247, P805; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARDY SJS, 1975, MOL GEN GENET, V140, P253, DOI 10.1007/BF00334270; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; Kenny J W, 1979, Methods Enzymol, V59, P534; KNOPF UC, 1975, MOL BIOL REP, V2, P35, DOI 10.1007/BF00357295; KOTELIANSKY VE, 1978, EUR J BIOCHEM, V90, P319, DOI 10.1111/j.1432-1033.1978.tb12607.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIJONMARCK M, 1987, J MOL BIOL, V195, P555, DOI 10.1016/0022-2836(87)90183-5; LI K, 1975, ANAL BIOCHEM, V64, P121, DOI 10.1016/0003-2697(75)90413-3; LILJAS A, 1982, PROG BIOPHYS MOL BIO, V40, P161, DOI 10.1016/0079-6107(82)90013-X; Liljas A, 1986, STRUCTURE FUNCTION G, P379; Maniatis T., 1982, MOL CLONING; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOLLER W, 1983, J MOL BIOL, V163, P553, DOI 10.1016/0022-2836(83)90112-2; OLSON HM, 1986, J BIOL CHEM, V261, P6924; POST LE, 1979, P NATL ACAD SCI USA, V76, P1697, DOI 10.1073/pnas.76.4.1697; RODRIGUEZ RL, 1983, RECOMBINANT DNA TECH, P48; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMMER A, 1985, J BIOL CHEM, V260, P6522; STOFFLER G, 1986, STRUCTURE FUNCTION G, P28; STRYCHARZ WA, 1978, J MOL BIOL, V126, P123, DOI 10.1016/0022-2836(78)90355-8; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; SUN TT, 1974, BIOCHEMISTRY-US, V13, P2334, DOI 10.1021/bi00708a015; TERHORST C, 1972, EUR J BIOCHEM, V25, P13, DOI 10.1111/j.1432-1033.1972.tb01661.x; TEWARI DS, 1986, J BIOL CHEM, V261, P6919; TOLAN DR, 1980, ANAL BIOCHEM, V103, P101, DOI 10.1016/0003-2697(80)90243-2; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; TRAUT RR, 1983, J BIOL CHEM, V258, P4592; VANAGTHOVEN AJ, 1975, BIOCHEM BIOPH RES CO, V64, P1184, DOI 10.1016/0006-291X(75)90818-9; WALLACE RB, 1979, NUCLEIC ACIDS RES, V6, P3543, DOI 10.1093/nar/6.11.3543; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	44	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5889	5896						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556104				2022-12-27	WOS:A1992HK31800029
J	LAM, SCT				LAM, SCT			ISOLATION AND CHARACTERIZATION OF A CHYMOTRYPTIC FRAGMENT OF PLATELET GLYCOPROTEIN-IIB-IIIA RETAINING ARG-GLY-ASP BINDING-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACHAIN DISULFIDE BONDS; FIBRINOGEN BINDING; SYNTHETIC PEPTIDES; RECOGNITION SITE; THROMBASTHENIC PLATELETS; FIBRONECTIN-BINDING; ACTIVATED PLATELETS; MONOCLONAL-ANTIBODY; POLYACRYLAMIDE GELS; ADHESION RECEPTORS	Platelet membrane glycoprotein (GP)IIb-IIIa exists as a divalent cation-dependent heterodimer which recognizes the Arg-Gly-Asp (RGD) sequence of adhesive proteins. To isolate the RGD binding domain of GPIIb-IIIa we performed proteolysis of GPIIb-IIIa with alpha-chymotrypsin. GPIIb-IIIa was bound to an affinity matrix of GRGDSPK-coupled Sepharose 4B and was then treated with chymotrypsin. After washing the unbound fragments, two discrete polypeptides of 55 and 85 kDa remained bound to the RGD affinity matrix and were specifically eluted by soluble HHLGGAKQ-AGDV (H12) or by GRGDSP, but not by GRGESP. Immunoblotting with subunit-specific polyclonal antibodies showed that the 55- and 85-kDa fragments were derived from GPIIb and GPIIIa, respectively. Amino-terminal sequencing and immunoblotting using site-specific antibodies indicated that these fragments contained the amino termini of their parent molecules. In the presence of 1 mM Ca2+ and 1 mM Mg2+, these two fragments were maintained as a heterodimer inasmuch as both fragments were immunoprecipitated by the polyclonal anti-GPIIIa antibodies. In contrast, chelating the divalent cations with 5 mm EDTA resulted in the lack of co-immunoprecipitation of the 55-kDa GPIIb fragment. After removal of the H12 peptide, the 55/85-kDa heterodimer bound to immobilized fibrinogen in an enzyme-linked immunosorbent assay by an RGD-dependent mechanism. These findings suggest that the RGD binding domain and structures required for heterodimer maintenance are present within the 55/85-kDa chymotryptic fragment of GPIIb-IIIa.			LAM, SCT (corresponding author), UNIV ILLINOIS,DEPT PHARMACOL,MC 868,835 S WOLCOTT AVE,CHICAGO,IL 60612, USA.				NHLBI NIH HHS [HL-41793] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041793, R01HL041793] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEER J, 1989, J BIOL CHEM, V264, P17564; BRASS LF, 1985, J BIOL CHEM, V260, P7875; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1989, BIOCHEM J, V261, P551, DOI 10.1042/bj2610551; CALVETE JJ, 1991, BIOCHEM J, V273, P767, DOI 10.1042/bj2730767; CALVETE JJ, 1989, BIOCHEM J, V261, P561, DOI 10.1042/bj2610561; CHARO IF, 1991, J BIOL CHEM, V266, P1415; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GARTNER TK, 1990, THROMB RES, V60, P291, DOI 10.1016/0049-3848(90)90108-O; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1980, BLOOD, V55, P661; GINSBERG MH, 1983, METHODS HEMATOLOGY, P158; GREENBERG JP, 1979, BLOOD, V54, P753; HAVERSTICK DM, 1985, BLOOD, V66, P946; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KIEFFER N, 1984, BLOOD, V64, P1212; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KORNECKI E, 1983, J BIOL CHEM, V258, P9349; KORNECKI E, 1981, J BIOL CHEM, V256, P5696; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1989, BLOOD, V73, P1513; LAM SCT, 1987, J BIOL CHEM, V262, P947; LAM SCT, 1989, J BIOL CHEM, V264, P3742; LOFTUS JC, 1988, J BIOL CHEM, V263, P11025; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LOFTUS JC, 1987, P NATL ACAD SCI USA, V840, P7114; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGREGOR JL, 1985, EUR J BIOCHEM, V148, P97, DOI 10.1111/j.1432-1033.1985.tb08812.x; MUSTARD JF, 1979, BLOOD, V54, P987; NIEWIAROWSKI S, 1989, BIOCHIM BIOPHYS ACTA, V983, P91, DOI 10.1016/0005-2736(89)90384-2; PARISE LV, 1985, J BIOL CHEM, V260, P698; PARISE LV, 1986, J BIOL CHEM, V261, P14011; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PASQUALINI R, 1989, J BIOL CHEM, V264, P14566; PEERSCHKE EIB, 1984, BLOOD, V64, P59; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; PHILLIPS DR, 1988, BLOOD, V71, P831; PIDARD D, 1986, BLOOD, V67, P604; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PLOW EF, 1986, BIOCH PLATELETS, P226; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RUGGERI ZM, 1986, P NATL ACAD SCI USA, V83, P5708, DOI 10.1073/pnas.83.15.5708; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; STEINER B, 1989, J BIOL CHEM, V264, P13102; STEINER B, 1988, CIRCULATION, V78, P621; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UZAN G, 1988, EUR J BIOCHEM, V171, P87, DOI 10.1111/j.1432-1033.1988.tb13762.x; 1968, J BIOL CHEM, V243, P3557	63	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5649	5655						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544938				2022-12-27	WOS:A1992HH74700097
J	SPROUS, D; HARVEY, SC				SPROUS, D; HARVEY, SC			A 3-DIMENSIONAL MODEL FOR NODULE DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOPURINE		UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	SPROUS, D (corresponding author), UNIV ALABAMA,SCH MED,DEPT BIOCHEM,BIRMINGHAM,AL 35294, USA.				NIGMS NIH HHS [GM-34015] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034015] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; Arnott S, 1976, HDB BIOCHEMISTRY MOL, VII, P411; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; HARVEY SC, 1988, NUCLEIC ACIDS RES, V16, P11795, DOI 10.1093/nar/16.24.11795; LAVERY R, 1987, UNUSUAL DNA STRUCTUR, P189; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	7	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5502	5502						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544924				2022-12-27	WOS:A1992HH74700076
J	BEDOWS, E; HUTH, JR; RUDDON, RW				BEDOWS, E; HUTH, JR; RUDDON, RW			KINETICS OF FOLDING AND ASSEMBLY OF THE HUMAN CHORIONIC GONADOTROPIN-BETA SUBUNIT IN TRANSFECTED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIOCARCINOMA CELLS; DISULFIDE BONDS; ALPHA-SUBUNITS; SECRETION; PROTEIN; FORM; MUTAGENESIS; ISOMERASE; CULTURES; LUTROPIN	We have employed Chinese hamster ovary (CHO) cell lines transfected with either the wild type human chorionic gonadotropin-beta (hCG-beta) gene alone (CHO beta-cells) or in conjunction with the gene expressing the alpha-subunit (CHO alpha,beta-cells) to study the folding pathway of the hCG-beta subunit. In both CHO-beta and CHO alpha,beta-cells, the earliest detectable hCG-beta precursor, p-beta-1, which had two of six potential disulfide bonds (34-88 and 38-57) formed, was converted to p-beta-2, a form that, following the formation of disulfide bonds between cysteines 9-90 and 23-72, migrated more slowly than p-beta-1 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under nonreducing conditions. The t1/2 for the conversion of p-beta-1 to p-beta-2 in CHO-alpha,beta and CHO beta-cells was 5 min, demonstrating that the alpha-subunit had no effect on the rate of this conversion. Furthermore, the tryptic-releasable peptides generated from nonreduced p-beta-1 or p-beta-2 were the same in both CHO-alpha,beta and CHO-beta cells. Thus, both the rate and order of disulfide bond formation during the conversion of the folding intermediate p-beta-1 into p-beta-2 were the same whether or not the alpha-subunit was present. A comparison between cell types expressing different alpha/beta-subunit ratios revealed that the higher the glycoprotein hormone alpha-subunit to beta-subunit ratio, the greater the rate and extent of hCG heterodimer assembly.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198; UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Michigan System; University of Michigan					NCI NIH HHS [CA32949] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEEBE JS, 1990, J BIOL CHEM, V265, P312; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; COLE LA, 1983, ENDOCRINOLOGY, V113, P1176, DOI 10.1210/endo-113-3-1176; Creighton T E, 1986, Methods Enzymol, V131, P83; Ellis R J, 1990, Semin Cell Biol, V1, P1; HUTH JR, 1992, J BIOL CHEM, V267, P8870; KAETZEL DM, 1988, J BIOL CHEM, V263, P6344; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MATZUK MM, 1989, J CELL BIOL, V109, P1429, DOI 10.1083/jcb.109.4.1429; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MATZUK MM, 1988, J BIOL CHEM, V263, P17106; OZTURK M, 1987, ENDOCRINOLOGY, V120, P549, DOI 10.1210/endo-120-2-549; PATTILLO RA, 1979, IN VITRO, V6, P398; PETERS BP, 1984, J BIOL CHEM, V259, P5123; RUDDON RW, 1979, P NATL ACAD SCI USA, V76, P5143, DOI 10.1073/pnas.76.10.5143; RUDDON RW, 1989, ENDOCRINOLOGY, V124, P862, DOI 10.1210/endo-124-2-862; RUDDON RW, 1987, J BIOL CHEM, V262, P12533; RUDDON RW, 1981, J BIOL CHEM, V256, P1389; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; STRICKLAND TW, 1982, J BIOL CHEM, V257, P2954; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; Vaitukaitis J L, 1976, Recent Prog Horm Res, V32, P289	25	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8880	8886						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577726				2022-12-27	WOS:A1992HR85400030
J	JOHNSON, CA; DENSEN, P; HURFORD, RK; COLTEN, HR; WETSEL, RA				JOHNSON, CA; DENSEN, P; HURFORD, RK; COLTEN, HR; WETSEL, RA			TYPE-I HUMAN-COMPLEMENT C2 DEFICIENCY - A 28-BASE PAIR GENE DELETION CAUSES SKIPPING OF EXON-6 DURING RNA SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; CDNA CLONING; PLASMID DNA; FACTOR-B; SITE; COMPONENT; IDENTIFICATION; EXPRESSION; MUTATION; INVITRO	Two variants of a genetic deficiency of complement protein C2 (C2D) have been previously identified. No C2 protein translation is detected in type I deficiency, while type II deficiency is characterized by a selective block in C2 secretion. Type I C2 deficiency was described in a family in which the C2 null allele (C2Q0) is associated with the major histocompatibility haplotype/complotype HLA-A25,B18,C2Q0,BfS,C4A4, C4B2,Drw2; this extended haplotype occurs in over 90% of C2-deficient individuals (common complotype/haplotype). To determine the molecular basis of type I C2 deficiency, the C2 gene and cDNA were characterized from a homozygous type I C2-deficient individual with the common associated haplotype/complotype. We found a 28-base pair deletion in the type I C2Q0 gene, beginning 9 base pairs upstream of the 3'-end of exon 6, that generates a C2 transcript with a complete deletion of exon 6 (134 base pair) and a premature termination codon. In studies of eight kindred, the 28-base pair deletion was observed in all C2Q0 alleles associated with the common type I deficient complotype/haplotype; this deletion was not present in normal C2 nor in type II C2-deficient genes. These data demonstrate that: 1) type I human complement C2 deficiency is caused by a 28-base pair genomic deletion that causes skipping of exon 6 during RNA splicing, resulting in generation of a premature termination codon, 2) the 28-base pair deletion in the type I C2Q0 gene is strongly associated with the HLA haplotype/complo-type A25,B18,C2Q0,BfS,C4A4,C4B2,Drw2, suggesting that all C2-deficient individuals with this haplotype/complotype will harbor the 28-base pair C2 gene deletion, and 3) type II C2 deficiency is caused by a different, as yet uncharacterized, molecular genetic defect.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; VET ADM MED CTR,DEPT INTERNAL MED,IOWA CITY,IA 52240; UNIV IOWA,COLL MED,IOWA CITY,IA 52242	Washington University (WUSTL); Washington University (WUSTL); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa			Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024739, R55AI025011, R01AI024739, R01AI024836, R01AI025011] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25011, AI24836, AI24739] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALPER CA, 1987, IMMUNOL LETT, V14, P175, DOI 10.1016/0165-2478(87)90098-8; AMOS DB, 1980, NIH83545 DHEW PUBL, P42; AWDEH ZL, 1981, J CLIN INVEST, V67, P581, DOI 10.1172/JCI110070; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CARROLL MC, 1984, NATURE, V307, P237, DOI 10.1038/307237a0; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FIGUEROA JE, 1991, CLIN MICROBIOL REV, V4, P359, DOI 10.1128/CMR.4.3.359-395.1991; FU SM, 1974, J EXP MED, V140, P1108, DOI 10.1084/jem.140.4.1108; GLASS D, 1976, J CLIN INVEST, V58, P853, DOI 10.1172/JCI108538; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; HIDAKA Y, 1987, J CLIN INVEST, V80, P1409, DOI 10.1172/JCI113219; HORIUCHI T, 1989, J IMMUNOL, V142, P2105; ISHII Y, 1991, Complement and Inflammation, V8, P167; ISHIKAWA N, 1990, J BIOL CHEM, V265, P19040; JACOB M, 1989, NUCLEIC ACIDS RES, V17, P2159, DOI 10.1093/nar/17.6.2159; JOHNSON CA, 1992, IN PRESS N ENGL J ME; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; KONTUSAARI S, 1990, AM J HUM GENET, V47, P112; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; MATSUO M, 1991, J CLIN INVEST, V87, P2127, DOI 10.1172/JCI115244; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RYNES RI, 1982, ANN RHEUM DIS, V41, P93, DOI 10.1136/ard.41.1.93; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TREISMAN R, 1982, CELL, V29, P903, DOI 10.1016/0092-8674(82)90452-4; VASAN NS, 1991, AM J HUM GENET, V48, P305; WEIL D, 1988, J BIOL CHEM, V263, P8561; WETSEL RA, 1990, J BIOL CHEM, V265, P2435; WOODS DE, 1984, J CLIN INVEST, V74, P634, DOI 10.1172/JCI111461; ZITNAN D, 1988, RHEUMATOLOGIA, V2, P15; [No title captured]	38	97	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9347	9353						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577763				2022-12-27	WOS:A1992HR85400098
J	SOBEL, M; SOLER, DF; KERMODE, JC; HARRIS, RB				SOBEL, M; SOLER, DF; KERMODE, JC; HARRIS, RB			LOCALIZATION AND CHARACTERIZATION OF A HEPARIN BINDING DOMAIN PEPTIDE OF HUMAN VONWILLEBRAND-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; COLLAGEN	Human von Willebrand factor, a plasma glycoprotein which plays a critical role in regulating hemostasis, binds heparin, but the physiological importance and mode of this interaction is poorly understood. Using the motif of an amino acid sequence of a consensus heparin binding synthetic peptide, a 23-residue sequence (Tyr565-Ala587) of human von Willebrand factor was identified that retains the consensus motif and binds heparin with affinity comparable with native von Willebrand factor and the consensus peptide. In a fluid phase binding assay, the Tyr566-Ala587 peptide competed effectively with von Willebrand factor for binding heparin. Synthesis and testing of peptides overlapping Tyr565-Ala587, as well as adjacent cationic regions, showed this core sequence to be the optimal linear binding domain. Far ultraviolet circular dichroism spectrometry of the Tyr566-Ala587 peptide suggested that the peptide undergoes conformational change upon binding heparin. The Tyr565-Ala587 peptide thus encompasses part (or all) of a functionally important heparin binding domain of von Willebrand factor. Further study of this and related peptides may be useful for exploring how heparin may influence von Willebrand factor-mediated platelet hemostasis.	VIRGINIA COMMONWEALTH UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, RICHMOND, VA 23298 USA	Virginia Commonwealth University	SOBEL, M (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA,DEPT SURG,DIV VASC SURG,BOX 108, MCV STN, RICHMOND, VA 23298 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039903, R29HL039903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024933] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39903] Funding Source: Medline; NINDS NIH HHS [NS 24933] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; FUJIMURA Y, 1987, J BIOL CHEM, V262, P1734; FURLAN M, 1986, BLUT, V52, P329, DOI 10.1007/BF00320779; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MCCARTHY JB, 1989, Patent No. 4839464; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOROOSE R, 1986, ANNU REV MED, V37, P157; RUGGERI ZM, 1987, BLOOD, V70, P895; SOBEL M, 1991, J CLIN INVEST, V87, P1787, DOI 10.1172/JCI115198; SOBEL M, 1988, CLIN RES, V36, pA420; SOBEL M, 1991, ACS SYM SER, V469, P60; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; VILLANUEVA GB, 1984, J BIOL CHEM, V259, P2531	17	166	169	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8857	8862						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577724				2022-12-27	WOS:A1992HR85400027
J	CHEN, Q; YU, KF; HOLBROOK, NJ; STEVENS, JL				CHEN, Q; YU, KF; HOLBROOK, NJ; STEVENS, JL			ACTIVATION OF THE GROWTH ARREST AND DNA DAMAGE-INDUCIBLE GENE GADD-153 BY NEPHROTOXIC CYSTEINE CONJUGATES AND DITHIOTHREITOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK RESPONSE; BETA-LYASE; MECHANISM; BINDING; CELLS; METABOLISM; CALCIUM; EXPRESSION; ONCOGENES; TOXICITY	The cellular and biochemical events which transduce chemical insults into signals for increased expression of the stress-responsive gene gadd 153 were investigated using nephrotoxic cysteine conjugates. In LLC-PK1 cells, cysteine conjugate toxicity is initiated by covalent binding, but depletion of cellular thiols, an increase in cytosolic free calcium, and lipid peroxidation couple the binding to cell death (Chen, Q., Jones, T. W., Brown, P. C., and Stevens, J. L. (1990) J. Biol. Chem. 265, 21603-2161 1; Chen, Q., Jones, T. W., and Stevens, J. L. (1991) Toxicologist 11, 101, 1991). Three different toxic cysteine conjugates induced gadd 153 mRNA. With S-(1,2-dichlorovinyl)-L-cysteine (DCVC), the induction was both concentration and time-dependent. Preventing the metabolism of DCVC and covalent binding of DCVC-derived reactive metabolites to cellular macromolecules with the beta-lyase inhibitor (aminooxy)acetic acid blocked the induction. However, buffering free calcium with a cell permeable calcium chelator or blocking lipid peroxidation with an antioxidant did not affect the induction of gadd 153 mRNA by DCVC even though these treatments inhibit toxicity. These data suggest that covalent binding of reactive metabolites to cellular macromolecules may serve as a primary signal for the induction of gadd 153 mRNA by nephrotoxic cysteine conjugates. Interestingly, the sulfhydryl agent dithiothreitol, which was nontoxic and prevented the toxicity of DCVC, also induced an increase in gadd 153 mRNA. When both dithiothreitol and DCVC were added to cells, there were no inhibitory or additive effects on expression. Therefore, cellular thiol-disulfide status may also play a role in gadd 153 induction.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946; NIA,MOLEC GENET LAB,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005670] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38925] Funding Source: Medline; NIEHS NIH HHS [ES05670] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BASAL S, 1990, ANN REV CELL BIOL, V6, P41; BEELER T, 1976, J BIOL CHEM, V251, P5267; BERK AJ, 1989, BIOCHIM BIOPHYS ACTA, V1009, P103, DOI 10.1016/0167-4781(89)90087-0; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHEN Q, 1990, J BIOL CHEM, V265, P21603; CHEN Q, 1991, ARCH BIOCHEM BIOPHYS, V284, P422, DOI 10.1016/0003-9861(91)90318-D; CHEN Q, 1991, TOXICOLOGIST, V11, P101; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; COMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; COMMANDEUR JNM, 1990, CHEM RES TOXICOL, V3, P171, DOI 10.1021/tx00015a001; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DEKANT W, 1989, DRUG METAB REV, V20, P43, DOI 10.3109/03602538908994144; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; ELFARRA AA, 1986, BIOCHEM PHARMACOL, V35, P283, DOI 10.1016/0006-2952(86)90527-7; FARBER JL, 1990, CHEM RES TOXICOL, V3, P503, DOI 10.1021/tx00018a003; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORNACE AJ, 1989, MOL CELL BIOL, V9, P5196; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; HAYDEN PJ, 1991, BIOCHEMISTRY-US, V30, P5935, DOI 10.1021/bi00238a018; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; LEUTHY JD, 1992, CANCER RES, V52, P5; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; MACARA IG, 1989, PHYSIOL REV, V69, P797, DOI 10.1152/physrev.1989.69.3.797; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NICOTERA P, 1990, CHEM RES TOXICOL, V3, P484, DOI 10.1021/tx00018a001; REED DJ, 1990, CHEM RES TOXICOL, V3, P495, DOI 10.1021/tx00018a002; RIZZINO A, 1988, DEV BIOL, V130, P411, DOI 10.1016/0012-1606(88)90337-5; Sambrook J, 1989, MOL CLONING LABORATO; STEVENS J, 1986, J BIOL CHEM, V261, P3325; STEVENS JL, 1986, J BIOL CHEM, V261, P5529; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; VAMVAKAS S, 1990, MOL PHARMACOL, V38, P455; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; YOST HJ, 1990, TRENDS GENET, V6, P223, DOI 10.1016/0168-9525(90)90183-7; YU K, 1991, TOXICOLOGIST, V11, P250	47	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8207	8212						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569075				2022-12-27	WOS:A1992HQ18500039
J	MURDOCH, AD; DODGE, GR; COHEN, I; TUAN, RS; IOZZO, RV				MURDOCH, AD; DODGE, GR; COHEN, I; TUAN, RS; IOZZO, RV			PRIMARY STRUCTURE OF THE HUMAN HEPARAN-SULFATE PROTEOGLYCAN FROM BASEMENT-MEMBRANE (HSPG2/PERLECAN) - A CHIMERIC MOLECULE WITH MULTIPLE DOMAINS HOMOLOGOUS TO THE LOW-DENSITY-LIPOPROTEIN RECEPTOR, LAMININ, NEURAL CELL-ADHESION MOLECULES, AND EPIDERMAL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA-CELLS; AMINO-ACID-SEQUENCE; MESSENGER-RNA; CORE PROTEIN; ENDOTHELIAL-CELLS; NUCLEIC-ACID; LDL RECEPTOR; MOUSE-TUMOR; SURFACE; CDNA	We have determined the complete nucleotide and deduced amino acid sequence of the major protein core of the human heparan sulfate proteoglycan HSPG2/perlecan of basement membranes. Eighteen overlapping cDNA clones comprise 14.35 kilobase pairs (kb) of contiguous sequence with an open reading frame of 13.2 kb. The mature protein core, without the signal peptide of 21 amino acids, has a M(r) of 466,564. This large protein is composed of multiple modules homologous to the receptor of low density lipoprotein, laminin, neural cell adhesion molecules, and epidermal growth factor. Domain I, near the amino terminus, appears unique for the proteoglycan since it shares no significant homology with any other proteins. It contains three Ser-Gly-Asp sequences that could act as attachment sites for heparan sulfate glycosaminoglycans. Domain II is highly homologous to the LDL receptor and contains four repeats with perfect conservation of all 6 consecutive cysteines. Next is domain III which shares homology to the short arm of laminin A chain and contains four cysteine-rich regions intercalated among three globular domains. Domain IV, the largest module with > 2000 residues, contains 21 repeats of the immunoglobulin type as found in neural cell adhesion molecule. Near the beginning of this domain, there is a stretch of 29 hydrophobic amino acids which could allow the molecule to interact with the plasma membrane. Domain V, similar to the carboxyl-terminal globular G-domain of laminin A and to the related protein merosin, contains three globular regions and four EGF-like repeats. In situ hybridization and immunoenzymatic studies show a close association of this gene product with a variety of cells involved in the assembly of basement membranes, in addition to being localized within the stromal elements of various connective tissues. Our studies show that this proteoglycan is present in all vascularized tissues and suggest that this unique molecule has evolved from the utilization of modular structures with adhesive and growth regulatory properties.	THOMAS JEFFERSON UNIV,DEPT PATHOL & CELL BIOL,RM 249,JEFFERSON ALUMNI HALL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT ORTHOPAED SURG,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University; Jefferson University			Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [CA-39481, CA-47282] Funding Source: Medline; NICHD NIH HHS [HD-15822] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD015822] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DANIELSON KG, 1992, MATRIX, V12, P22, DOI 10.1016/S0934-8832(11)80101-0; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DISCIPIO RG, 1984, P NATL ACAD SCI-BIOL, V81, P7298, DOI 10.1073/pnas.81.23.7298; DODGE GR, 1990, J BIOL CHEM, V265, P18023; DODGE GR, 1991, GENOMICS, V10, P673, DOI 10.1016/0888-7543(91)90451-J; DOOLITTLE RF, 1989, TRENDS BIOCHEM SCI, V14, P244, DOI 10.1016/0968-0004(89)90055-8; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGEL J, 1991, INT J BIOL MACROMOL, V13, P147, DOI 10.1016/0141-8130(91)90039-W; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P4494, DOI 10.1073/pnas.77.8.4494; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; HEREMANS A, 1989, J CELL BIOL, V109, P3199, DOI 10.1083/jcb.109.6.3199; HUBER S, 1988, J BIOL CHEM, V263, P752; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; IOZZO RV, 1987, J BIOL CHEM, V262, P11188; IOZZO RV, 1989, ARCH BIOCHEM BIOPHYS, V269, P239, DOI 10.1016/0003-9861(89)90105-7; IOZZO RV, 1988, J CELL BIOCHEM, V37, P61, DOI 10.1002/jcb.240370107; IOZZO RV, 1990, J BIOL CHEM, V265, P19980; IOZZO RV, 1984, J CELL BIOL, V99, P403, DOI 10.1083/jcb.99.2.403; IOZZO RV, 1989, J BIOL CHEM, V264, P2960; ISEMURA M, 1987, J BIOL CHEM, V262, P8926; KALLUNKI P, 1991, GENOMICS, V11, P389, DOI 10.1016/0888-7543(91)90147-7; KANWAR YS, 1981, J CELL BIOL, V90, P527, DOI 10.1083/jcb.90.2.527; KATO M, 1987, J BIOL CHEM, V262, P7180; KLEIN DJ, 1988, J CELL BIOL, V106, P963, DOI 10.1083/jcb.106.3.963; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LAURIE GW, 1988, AM J ANAT, V181, P320, DOI 10.1002/aja.1001810308; MAIZEL JV, 1981, P NATL ACAD SCI-BIOL, V78, P7665, DOI 10.1073/pnas.78.12.7665; MALI M, 1990, J BIOL CHEM, V265, P6884; MCDONALD SA, 1989, DEV BIOL, V133, P221, DOI 10.1016/0012-1606(89)90313-8; MOHAN PS, 1991, J BIOL CHEM, V266, P8567; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NOONAN DM, 1988, J BIOL CHEM, V263, P16379; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SAKU T, 1989, J BIOL CHEM, V264, P3514; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCHWARTING R, 1989, BLOOD, V74, P1678; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SKUBITZ APN, 1991, J CELL BIOL, V115, P1137, DOI 10.1083/jcb.115.4.1137; SOROKA CJ, 1991, J CELL BIOL, V113, P1231, DOI 10.1083/jcb.113.5.1231; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TUAN RS, 1988, DIFFERENTIATION, V37, P198, DOI 10.1111/j.1432-0436.1988.tb00722.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEWER UM, 1985, DIFFERENTIATION, V30, P61, DOI 10.1111/j.1432-0436.1985.tb00514.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINTLE RF, 1990, CYTOGENET CELL GENET, V54, P60, DOI 10.1159/000132956; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; YURCHENCO PD, 1987, J BIOL CHEM, V262, P17668; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	77	296	302	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8544	8557						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569102				2022-12-27	WOS:A1992HQ18500089
J	OLEARY, ME; WHITE, MM				OLEARY, ME; WHITE, MM			MUTATIONAL ANALYSIS OF LIGAND-INDUCED ACTIVATION OF THE TORPEDO ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; BINDING-SITE; GAMMA-SUBUNIT; EXPRESSION; AGONISTS; DROSOPHILA; SEQUENCES; CHANNELS; MODEL	A number of studies have demonstrated that a major portion of the ligand binding site of the Torpedo nicotinic acetylcholine receptor is near cysteines 192 and 193 of the alpha-subunit. The role of conserved tyrosine and aspartate residues within this region in ligand binding and receptor activation was investigated using a combination of site-directed mutagenesis and expression in Xenopus oocytes. Wild-type receptors are half-maximally activated (K1/2) by 20-mu-M acetylcholine with a Hill coefficient, n, of 1.9. Substitution of alpha-Y190 and alpha-Y198 with phenylalanines (alpha-Y190F, alpha-Y198F) or alpha-D200 with asparagine (alpha-D200N) shifts the K1/2 to 408, 117, and 75-mu-M, respectively, with no effect on the Hill coefficient. To further study the effects of these mutations on activation, the responses of the receptors to the partial agonists phenyltrimethylammonium (PTMA) and tetramethylammonium (TMA) were examined. Wild-type receptors are half-maximally activated by 73-mu-M PTMA and 2 mM TMA. In contrast, alpha-Y190F, alpha-Y198F, and alpha-D200N receptors are not activated by PTMA and TMA by concentrations of up to 500-mu-M or 5 mM, respectively. However, PTMA and TMA do act as competitive antagonists of the mutant receptors, an indication that the binding of these compounds is not abolished by these mutations. Comparison of the K(i) values for TMA and PTMA inhibition with the K1/2 values for TMA and PTMA activation of wild-type receptors indicates that the affinities of these compounds are similar in wild-type and mutant receptors. Therefore, alpha-Y190F, alpha-Y198F, and alpha-D200N mutations do not significantly alter the affinity of the ligand binding site; rather, these mutations appear to interfere with the coupling of ligand binding to channel opening.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS008880, R01NS023885] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 23885, F32 NS 08880] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; BALDWIN TJ, 1988, J CELL BIOL, V106, P469, DOI 10.1083/jcb.106.2.469; BALLIVET M, 1982, P NATL ACAD SCI-BIOL, V79, P4466, DOI 10.1073/pnas.79.14.4466; BOSSY B, 1988, EMBO J, V7, P611, DOI 10.1002/j.1460-2075.1988.tb02854.x; BOULTER J, 1985, J NEUROSCI, V5, P2545; BOULTER J, 1986, NATURE, V319, P368, DOI 10.1038/319368a0; BULLER AL, 1988, P NATL ACAD SCI USA, V85, P8717, DOI 10.1073/pnas.85.22.8717; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; CLAUDIO T, 1987, P NATL ACAD SCI USA, V84, P5967, DOI 10.1073/pnas.84.16.5967; COLQUHOUN D, 1988, J PHYSIOL-LONDON, V395, P131, DOI 10.1113/jphysiol.1988.sp016912; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; GALZI JL, 1991, P NATL ACAD SCI USA, V88, P5051, DOI 10.1073/pnas.88.11.5051; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GOLDMAN D, 1987, CELL, V48, P965, DOI 10.1016/0092-8674(87)90705-7; HASAN FB, 1980, J BIOL CHEM, V255, P3898; KAO PN, 1986, J BIOL CHEM, V261, P8085; KARLIN A, 1969, J GEN PHYSIOL, V54, pS245; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LUYTEN WHML, 1986, J NEUROSCI RES, V16, P51, DOI 10.1002/jnr.490160107; MANTHEY AA, 1966, J GEN PHYSIOL, V49, P963, DOI 10.1085/jgp.49.5.963; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; NODA M, 1983, NATURE, V301, P251, DOI 10.1038/301251a0; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; PULLMAN B, 1972, MOL PHARMACOL, V8, P612; PULLMAN B, 1971, MOL PHARMACOL, V7, P397; SAWRUK E, 1990, EMBO J, V9, P2671, DOI 10.1002/j.1460-2075.1990.tb07452.x; SINE SM, 1984, BIOPHYS J, V46, P277, DOI 10.1016/S0006-3495(84)84022-9; STROUD RM, 1985, ANN REV CELL BIOL, V1, P369; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; WADA K, 1988, SCIENCE, V240, P330, DOI 10.1126/science.2832952; WEBER M, 1974, MOL PHARMACOL, V10, P15	35	103	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8360	8365						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569088				2022-12-27	WOS:A1992HQ18500063
J	VERKAMP, E; JAHN, M; JAHN, D; KUMAR, AM; SOLL, D				VERKAMP, E; JAHN, M; JAHN, D; KUMAR, AM; SOLL, D			GLUTAMYL-TRANSFER RNA REDUCTASE FROM ESCHERICHIA-COLI AND SYNECHOCYSTIS 6803 - GENE STRUCTURE AND EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL BIOSYNTHESIS; HEMA GENE; 1-SEMIALDEHYDE AMINOTRANSFERASE; CHLAMYDOMONAS-REINHARDTII; SACCHAROMYCES-CEREVISIAE; SALMONELLA-TYPHIMURIUM; DELTA-AMINOLEVULINATE; NUCLEOTIDE-SEQUENCE; ALA SYNTHESIS; CLONING	In the cyanobacterium Synechocystis sp. PCC 6803 and in the enterobacterium Escherichia coli delta-amino-levulinic acid (ALA) is formed from glutamyl-tRNA by the sequential action of two enzymes, glutamyl-tRNA reductase (GluTR) and glutamate-1-semialdehyde aminotransferase. E. coli has two GluTR proteins with sizes of 45 kDa (GluTR45) and 85 kDa (GluTR85) (Jahn, D., Michelsen, U., and Soll, D. (1991) J. Biol. Chem. 266, 2542-2548). The hemA gene, isolated from E. coli and several other eubacteria, has been proposed to encode a structural component of GluTR. Because of the inability to overexpress this gene in E. coli, we demonstrate directly GluTR function for the E. coli hemA gene product by its expression and functional analysis in yeast, which does not form ALA from Glu-tRNA. Gel filtration experiments demonstrated definitively that the yeast-expressed HemA protein corresponded to GluTR45. Furthermore, analysis of GluTR activity in an E. coli strain with a disrupted hemA gene displayed GluTR85, but not GluTR45 activity. The hemA gene from Synechocystis 6803 was cloned by functional complementation in E. coli. DNA sequence analysis revealed an open reading frame capable of encoding a 427-amino acid polypeptide (molecular mass of 47,525 Da). The Synechocystis 6803 amino acid sequence shows significant similarity upon alignment with HemA sequences from E. coli, Bacillus subtilis, Salmonella typhimurium, and Chlorobium vibrioforme but does not contain the amino acid sequence derived from the N terminus of the previously purified GluTR protein (Rieble, S., and Beale, S. I. (1991) J. Biol. Chem. 266, 9740-9745). These experiments are the first direct demonstration of GluTR activity of the HemA protein and provide further evidence for two pathways of ALA formation in prokaryotes.	YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, POB 6666, NEW HAVEN, CT 06511 USA	Yale University				Jahn, Dieter/0000-0002-4064-9205				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AVISSAR YJ, 1989, J BACTERIOL, V171, P2919, DOI 10.1128/jb.171.6.2919-2924.1989; AVISSAR YJ, 1990, J BACTERIOL, V172, P1656, DOI 10.1128/jb.172.3.1656-1659.1990; Beale S. I., 1990, BIOSYNTHESIS HEME CH, P287; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; CHEN MW, 1990, J BIOL CHEM, V265, P4058; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DROLET M, 1989, MOL GEN GENET, V216, P347, DOI 10.1007/BF00334375; ELLIOTT T, 1989, MOL GEN GENET, V216, P303, DOI 10.1007/BF00334369; ELLIOTT T, 1990, J BACTERIOL, V172, P7071, DOI 10.1128/jb.172.12.7071-7084.1990; GARCIA PD, 1991, METHOD ENZYMOL, V194, P675; GRIMM B, 1990, P NATL ACAD SCI USA, V87, P4169, DOI 10.1073/pnas.87.11.4169; GRIMM B, 1991, MOL GEN GENET, V225, P1; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HANSSON M, 1991, J BACTERIOL, V173, P2590, DOI 10.1128/jb.173.8.2590-2599.1991; HOOBER JK, 1988, CARLSBERG RES COMMUN, V53, P11, DOI 10.1007/BF02908411; HUANG LQ, 1990, PLANT PHYSIOL, V92, P172, DOI 10.1104/pp.92.1.172; ILAG LL, 1991, J BACTERIOL, V173, P3408, DOI 10.1128/jb.173.11.3408-3413.1991; JAHN D, 1990, J BIOL CHEM, V265, P8059; JAHN D, 1991, J BIOL CHEM, V266, P2542; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Labbe-Bois R, 1990, BIOSYNTHESIS HEME CH, P235; LAPOINTE J, 1972, J BIOL CHEM, V247, P4966; LI JM, 1989, GENE, V82, P209, DOI 10.1016/0378-1119(89)90046-2; MAJUMDAR D, 1991, ARCH MICROBIOL, V156, P281, DOI 10.1007/BF00262999; MAU YH, 1987, ARCH BIOCHEM BIOPHYS, V255, P75, DOI 10.1016/0003-9861(87)90295-5; MAY BK, 1986, CURR TOP CELL REGUL, V28, P233; O'NEILL G P, 1990, Biofactors, V2, P227; ONEILL GP, 1990, J BACTERIOL, V172, P6363, DOI 10.1128/jb.172.11.6363-6371.1990; ONEILL GP, 1991, J BACTERIOL, V173, P94, DOI 10.1128/jb.173.1.94-100.1991; PETRICEK M, 1990, J BACTERIOL, V172, P2250, DOI 10.1128/jb.172.5.2250-2258.1990; RIEBLE S, 1991, J BIOL CHEM, V266, P9740; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; SHEMIN D, 1953, J AM CHEM SOC, V75, P4873, DOI 10.1021/ja01115a546; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; VERKAMP E, 1989, J BACTERIOL, V171, P4728, DOI 10.1128/jb.171.9.4728-4735.1989; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WEYGANDDURASEVIC I, 1987, NUCLEIC ACIDS RES, V15, P1887, DOI 10.1093/nar/15.5.1887; WULFF DL, 1967, J BACTERIOL, V93, P1473, DOI 10.1128/JB.93.4.1473-1474.1967	40	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8275	8280						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569081				2022-12-27	WOS:A1992HQ18500049
J	DUPRET, JM; GRANT, DM				DUPRET, JM; GRANT, DM			SITE-DIRECTED MUTAGENESIS OF RECOMBINANT HUMAN ARYLAMINE N-ACETYLTRANSFERASE EXPRESSED IN ESCHERICHIA-COLI - EVIDENCE FOR DIRECT INVOLVEMENT OF CYS68 IN THE CATALYTIC MECHANISM OF POLYMORPHIC HUMAN NAT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID ACETYLATOR RABBITS; HUMAN-LIVER; NUCLEOTIDE-SEQUENCE; CLONING; PURIFICATION; COA	The single coding exons of the cloned genes encoding two human arylamine N-acetyltransferases (NAT1 and NAT2) were amplified by expression-cassette polymerase chain reaction and subcloned into the tac promoter-based phagemid vector pKEN2 for production of the recombinant proteins in Escherichia coli strain XA90. Induction of cultures grown from selected bacterial transformants resulted in the production of substantial quantities of soluble recombinant human NAT1 and NAT2 with identical electrophoretic, immunologic and catalytic properties to those expressed in mammalian cell culture or in human liver. Oligonucleotide-directed mutagenesis of recombinant human NAT2 was then employed to determine the relative importance of 3 highly conserved cysteine residues in the enzyme's catalytic mechanism. Substitution of cysteine with glycine at position 68 of the 290 amino acid protein molecule (Cys68 --> Gly) resulted in the production of normal quantities of immunoreactive NAT2 which was completely devoid of enzyme activity, suggesting that the sulfhydryl group of Cys68 is directly involved in the transfer of acetate from the essential cofactor CoASAc to acceptor amine substrates. On the other hand, the mutations producing Cys44 --> Gly and Cys223 --> Gly led to the production of enzymatically active NAT2 proteins with markedly reduced in vitro stability, suggesting that substitution of either of these amino acids may cause alterations in the tertiary structure of the native enzyme.	HOSP SICK CHILDREN, RES INST, DIV CLIN PHARMACOL & TOXICOL, 555 UNIV AVE, TORONTO M5G 1X8, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								ABUZEID M, 1991, MOL CARCINOGEN, V4, P81, DOI 10.1002/mc.2940040112; ANDRES HH, 1988, J BIOL CHEM, V263, P7521; ANDRES HH, 1987, MOL PHARMACOL, V31, P446; BESSMAN SP, 1953, ARCH BIOCHEM BIOPHYS, V46, P252, DOI 10.1016/0003-9861(53)90192-1; BLUM M, 1990, NUCLEIC ACIDS RES, V18, P5295, DOI 10.1093/nar/18.17.5295; BLUM M, 1990, NUCLEIC ACIDS RES, V18, P5287, DOI 10.1093/nar/18.17.5287; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; BLUM M, 1990, DNA CELL BIOL, V9, P193, DOI 10.1089/dna.1990.9.193; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEGUCHI T, 1990, J BIOL CHEM, V265, P12757; EVANS DAP, 1989, PHARMACOL THERAPEUT, V42, P157; GRANT DM, 1990, J CLIN INVEST, V85, P968, DOI 10.1172/JCI114527; GRANT DM, 1989, FEBS LETT, V244, P203, DOI 10.1016/0014-5793(89)81193-7; GRANT DM, 1991, MOL PHARMACOL, V39, P184; HAWLOW E, 1988, ANTIBODIES LABORATOR, P505; HOFSTEE BHJ, 1952, SCIENCE, V116, P329, DOI 10.1126/science.116.3013.329; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MARTELL KJ, 1991, MOL PHARMACOL, V40, P218; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; OHSAKO S, 1990, J BIOL CHEM, V265, P4630; OHSAKO S, 1988, J BIOL CHEM, V263, P7534; Sambrook J, 1989, MOL CLONING LABORATO; SOUICH PD, 1979, CLIN PHARMACOL THER, V25, P172; VATSIS KP, 1991, P NATL ACAD SCI USA, V88, P6333, DOI 10.1073/pnas.88.14.6333; WEBER WW, 1967, MOL PHARMACOL, V3, P266; WEBER WW, 1968, BIOCHIM BIOPHYS ACTA, V151, P276, DOI 10.1016/0005-2744(68)90184-8	27	129	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7381	7385						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559981				2022-12-27	WOS:A1992HN48500028
J	ROULEAU, J; TANIGAWA, G; SZYF, M				ROULEAU, J; TANIGAWA, G; SZYF, M			THE MOUSE DNA METHYLTRANSFERASE 5'-REGION - A UNIQUE HOUSEKEEPING GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENOVO METHYLATION PATTERNS; THYMIDINE KINASE GENE; EMBRYONIC STEM-CELLS; RNA POLYMERASE-II; TRANSCRIPTION FACTOR; MESSENGER-RNA; DAM METHYLTRANSFERASE; ESCHERICHIA-COLI; INITIATION SITE; EXPRESSION	We have cloned and characterized 5'-flanking sequences of the DNA methyltransferase (MeTase) gene. DNA MeTase gene transcription is initiated at a few discrete sites: 343 and 90 base pairs upstream of the translation initiation site as determined by RNase protection and primer extension assays. The promoter sequences that regulate expression of DNA MeTase, as defined by chloramphenicol acetyltransferase assays, reside between position -171 and the transcription start site. The promoter of DNA MeTase does not contain TATAA or CAAT boxes and is unusual because it does not contain the CG-rich elements characteristic of TATAA-less housekeeping genes. The 5'-flanking region of DNA MeTase contains AP-1, AP-2 and glucocorticoid response elements, suggesting possible regulation by cellular signal transduction pathways. The base composition of the DNA MeTase promoter is markedly different from that of other housekeeping genes. Whereas most housekeeping genes are characterized by CG-rich areas in their 5'-flanking regions, the TG dinucleotide is over-represented in DNA MeTase 5'-flanking sequences, including a perfect tandem repeat of T/G between positions -685 and -650. DNA methylation patterns play an important role in the developmental regulation of gene expression in vertebrates. DNA MeTase activity is probably regulated to maintain this pattern of methylation. We suggest that the DNA MeTase promoter represents a new class of housekeeping gene promoters that was designed to ensure high fidelity regulation of gene expression.	MCGILL UNIV, DEPT PHARMACOL & THERAPEUT, 3655 DRUMMOND ST, MONTREAL H3G 1Y6, QUEBEC, CANADA; SLOAN KETTERING MEM CANC CTR, NEW YORK, NY 10021 USA	McGill University; Memorial Sloan Kettering Cancer Center								ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; Carey M, 1991, CURR OPIN CELL BIOL, V3, P452, DOI 10.1016/0955-0674(91)90073-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; GATERMANN KB, 1988, BIOTECHNIQUES, V6, P951; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HERMANSON GG, 1989, P NATL ACAD SCI USA, V86, P7341, DOI 10.1073/pnas.86.19.7341; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOFBAUER R, 1991, CRIT REV EUKAR GENE, V1, P347; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LATHAM KE, 1989, MOL CELL BIOL, V9, P3203, DOI 10.1128/MCB.9.8.3203; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P5280, DOI 10.1128/MCB.8.12.5280; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P425, DOI 10.1128/MCB.6.2.425; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PELLMAN D, 1990, NATURE, V348, P82, DOI 10.1038/348082a0; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; RAZIN A, 1985, BIOCH BIOL DNA METHY, P239; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEISER C, 1989, NUCLEIC ACIDS RES, V17, P185, DOI 10.1093/nar/17.1.185; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P1255, DOI 10.1093/nar/18.5.1255; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SZYF M, 1985, P NATL ACAD SCI USA, V82, P8090, DOI 10.1073/pnas.82.23.8090; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; SZYF M, 1991, J BIOL CHEM, V266, P10027; SZYF M, 1984, P NATL ACAD SCI-BIOL, V81, P3278, DOI 10.1073/pnas.81.11.3278; SZYF M, 1991, IN PRESS BIOCH CELL; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TRAVALI S, 1988, MOL CELL BIOL, V8, P1551, DOI 10.1128/MCB.8.4.1551; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; YASUMURA Y, 1966, CANCER RES, V26, P529; YISRAELI J, 1985, DNA METHYLATION BIOC, P353	62	76	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7368	7377						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559980				2022-12-27	WOS:A1992HN48500026
J	HAUSER, MA; SCOCCA, JJ				HAUSER, MA; SCOCCA, JJ			SITE-SPECIFIC INTEGRATION OF THE HAEMOPHILUS-INFLUENZAE BACTERIOPHAGE HP1 - IDENTIFICATION OF THE POINTS OF RECOMBINATIONAL STRAND EXCHANGE AND THE LIMITS OF THE HOST ATTACHMENT SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA GENES; ESCHERICHIA-COLI; FLP RECOMBINASE; 2-MU-M PLASMID; PHAGE-LAMBDA; DNA; SEQUENCES; MECHANISM; PROTEIN; YEAST	Isotopic transfer experiments and boundary replacement studies were used to define the size and cleavage points of the Haemophilus influenzae attB site for phage HP1 integration. The points of strand cleavage and transfer were separated by 5' extensions with a spacing or overlap region most probably 7 residues long. The complete HP1 attB site is included within an 18-base pair (bp) sequence surrounding the cleavage sites. The sequence of HP1 attB is remarkably symmetric. Two 8-bp inverted repeats surround the central residue of the 7-bp overlap sequence; this central residue is the second residue of the anticodon sequence of the H. influenzae tRNA(leu)(UUR) gene which contains attB, and this symmetric segment encodes the anticodon stem and loop.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University								ANDREWS BJ, 1985, CELL, V40, P795, DOI 10.1016/0092-8674(85)90339-3; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; AUSTIN S, 1981, CELL, V25, P729, DOI 10.1016/0092-8674(81)90180-X; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL AM, 1962, ADV GENET, V11, P101; CRAIG NL, 1983, CELL, V35, P795, DOI 10.1016/0092-8674(83)90112-5; CRAIG NL, 1988, ANNU REV GENET, V22, P77; GOODMAN SD, 1989, J BACTERIOL, V171, P4232, DOI 10.1128/JB.171.8.4232-4240.1989; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; HAKIMIASTUMIAN J, 1989, J BACTERIOL, V173, P1747; HAUSER MA, 1990, NUCLEIC ACIDS RES, V18, P5305, DOI 10.1093/nar/18.17.5305; HOESS RH, 1985, J MOL BIOL, V181, P351, DOI 10.1016/0022-2836(85)90224-4; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; HWANG ES, 1990, J BACTERIOL, V172, P4852, DOI 10.1128/jb.172.9.4852-4860.1990; INOUYE S, 1991, SCIENCE, V252, P969, DOI 10.1126/science.1709758; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEONG JM, 1985, J BIOL CHEM, V260, P4468; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MCLEOD M, 1986, MOL CELL BIOL, V6, P3357, DOI 10.1128/MCB.6.10.3357; MIZUUCHI K, 1980, COLD SPRING HARB SYM, V45, P429; MIZUUCHI M, 1985, NUCLEIC ACIDS RES, V13, P1193, DOI 10.1093/nar/13.4.1193; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PIERSON LS, 1987, J MOL BIOL, V196, P487, DOI 10.1016/0022-2836(87)90026-X; REITER WD, 1989, NUCLEIC ACIDS RES, V17, P1907, DOI 10.1093/nar/17.5.1907; ROSS W, 1983, CELL, V33, P261, DOI 10.1016/0092-8674(83)90355-0; SENECOFF JF, 1986, J BIOL CHEM, V261, P7380; SENECOFF JF, 1985, P NATL ACAD SCI USA, V82, P7270, DOI 10.1073/pnas.82.21.7270; VOLKERT FC, 1986, CELL, V46, P541, DOI 10.1016/0092-8674(86)90879-2; WALDMAN AS, 1987, J BACTERIOL, V169, P238, DOI 10.1128/jb.169.1.238-246.1987; WALDMAN AS, 1986, J BACTERIOL, V165, P297, DOI 10.1128/jb.165.1.297-300.1986	33	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6859	6864						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551893				2022-12-27	WOS:A1992HM05300062
J	HUYNH, QK; HIRONAKA, CM; LEVINE, EB; SMITH, CE; BORGMEYER, JR; SHAH, DM				HUYNH, QK; HIRONAKA, CM; LEVINE, EB; SMITH, CE; BORGMEYER, JR; SHAH, DM			ANTIFUNGAL PROTEINS FROM PLANTS - PURIFICATION, MOLECULAR-CLONING, AND ANTIFUNGAL PROPERTIES OF CHITINASES FROM MAIZE SEED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-LOCALIZATION; ENDOCHITINASE; GENES; BETA-1,3-GLUCANASE; EXPRESSION; TOBACCO; BARLEY	We have purified two 28-kDa chitinases, designated Chitinase A (Chit A) and Chitinase B (Chit B), from maize seeds to homogeneity and isolated cDNA clones encoding these two enzymes using an oligonucleotide probe based on an amino acid sequence of a peptide derived from Chit A. Although these two enzymes share 87% homology in their amino acid sequences, which were deduced from the nucleotide sequences of the isolated cDNA clones, they are significantly different in their biochemical and in vitro antifungal activities. When tested in vitro for antifungal activity against the growth of Trichoderma reesei, Alternaria solani, and Fusarium oxysporum, Chit A showed greater antifungal activity than Chit B. The specific activity of Chit A was determined to be 3-fold higher than that of Chit B. Chit A also had a 10-fold lower binding constant (K(d)) against the substrate analogue N,N',N'',N'''-tetraacetyl chitotetrose than Chit B, indicating that the two enzyme may differ in their affinities for binding to the substrate chitin. Comparison of the amino acid sequences of maize seed chitinases with those of previously published chitinases from monocot and dicot plants indicates that maize seed chitinases have diverged significantly from other chitinases.	MONSANTO CORP RES, DEPT PROT BIOCHEM, ST LOUIS, MO 63198 USA	Monsanto	HUYNH, QK (corresponding author), MONSANTO CO, MONSANTO AGR CO, DEPT CROP PROTECT & IMPROVEMENT, MAIL ZONE AA4E, ST LOUIS, MO 63198 USA.		Shah, Dilip/M-2850-2013	SHAH, DILIP/0000-0001-9503-4729				[Anonymous], 1989, GENETIC ENG PRINCIPL; BELL AA, 1981, ANNU REV PLANT PHYS, V32, P21, DOI 10.1146/annurev.pp.32.060181.000321; BENHAMOU N, 1990, PLANT PHYSIOL, V92, P1108, DOI 10.1104/pp.92.4.1108; BOL JF, 1990, ANNU REV PHYTOPATHOL, V28, P113, DOI 10.1146/annurev.py.28.090190.000553; Boller T., 1988, Oxford Surveys of Plant Molecular and Cell Biology, V5, P145; Boller T, 1988, METHOD ENZYMOL, V161, P430; BOWLES DJ, 1990, ANNU REV BIOCHEM, V59, P873, DOI 10.1146/annurev.bi.59.070190.004301; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P2413; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FUKUDA Y, 1991, PLANT MOL BIOL, V16, P1, DOI 10.1007/BF00017912; GAYNOR JJ, 1988, NUCLEIC ACIDS RES, V16, P5210, DOI 10.1093/nar/16.11.5210; GROSS E, 1962, J BIOL CHEM, V237, P1856; HAHLBROCK K, 1979, ANNU REV PLANT PHYS, V30, P105, DOI 10.1146/annurev.pp.30.060179.000541; HIRANO S, 1976, CARBOHYD RES, V47, P315, DOI 10.1016/S0008-6215(00)84198-1; HUANG JK, 1991, PLANT MOL BIOL, V16, P479, DOI 10.1007/BF00023999; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAH R, 1991, J BIOL CHEM, V266, P1564; LINTHORST HJM, 1991, CRIT REV PLANT SCI, V10, P123, DOI 10.1080/07352689109382309; Maniatis T., 1982, MOL CLONING; MAUCH F, 1988, PLANT PHYSIOL, V88, P936, DOI 10.1104/pp.88.3.936; MAUCH F, 1989, PLANT CELL, V1, P447, DOI 10.2307/3869105; METRAUX JP, 1989, P NATL ACAD SCI USA, V86, P896, DOI 10.1073/pnas.86.3.896; PAYNE G, 1990, P NATL ACAD SCI USA, V87, P98, DOI 10.1073/pnas.87.1.98; REISSIG JL, 1955, J BIOL CHEM, V217, P959; ROBERTS WK, 1986, BIOCHIM BIOPHYS ACTA, V880, P161, DOI 10.1016/0304-4165(86)90076-0; ROBERTS WK, 1988, J GEN MICROBIOL, V134, P169; ROCHESTER DE, 1986, EMBO J, V5, P451, DOI 10.1002/j.1460-2075.1986.tb04233.x; SAMAC DA, 1990, PLANT PHYSIOL, V93, P907, DOI 10.1104/pp.93.3.907; SHINSHI H, 1990, PLANT MOL BIOL, V14, P357, DOI 10.1007/BF00028772; SWEGLE M, 1989, PLANT MOL BIOL, V12, P403, DOI 10.1007/BF00017580; VERBURG JG, 1991, PLANT PHYSIOL, V95, P450, DOI 10.1104/pp.95.2.450; ZHU Q, 1991, MOL GEN GENET, V226, P289, DOI 10.1007/BF00273615	35	146	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6635	6640						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551872				2022-12-27	WOS:A1992HM05300030
J	ILG, T; ETGES, R; OVERATH, P; MCCONVILLE, MJ; THOMASOATES, J; THOMAS, J; HOMANS, SW; FERGUSON, MAJ				ILG, T; ETGES, R; OVERATH, P; MCCONVILLE, MJ; THOMASOATES, J; THOMAS, J; HOMANS, SW; FERGUSON, MAJ			STRUCTURE OF LEISHMANIA-MEXICANA LIPOPHOSPHOGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMASTIGOTE SURFACE PROTEASE; MONOCLONAL-ANTIBODIES; DONOVANI LIPOPHOSPHOGLYCAN; CUTANEOUS LEISHMANIASIS; POLYACRYLAMIDE GELS; TRYPANOSOMA-BRUCEI; ACID-PHOSPHATASE; MACROPHAGES; MEMBRANE; PROTEINS	Lipophosphoglycan (LPG) was isolated from the culture supernatant of Leishmania mexicana promastigotes and its structure elucidated by a combination of H-1 NMR, fast atom bombardment mass spectrometry, methylation analysis, and chemical and enzymatic modifications. It consists of the repeating phosphorylated oligosaccharides PO4-6Gal-beta-1-4Man-alpha-1- and PO4-6[Glc-beta-1-3]Gal-beta-1-4Man-alpha-1-, which are linked together in linear chains by phosphodiester linkages. Each chain of repeat units is linked to a phosphosaccharide core with the structure PO4-6Gal-alpha-1-6Gal-alpha-1-3Gal(f)-beta-1-3[Glc-alpha-1-PO4-6]Man-alpha-1-3Man-alpha-1-4GlcNH2-alpha 1-6 myo-inositol, where the myo-inositol residue forms the head group of a lyso-alkylphosphatidylinositol moiety. The nonreducing terminus of the repeat chains appear to be capped with the neutral oligosaccharides Man-alpha-1-2Man, Man-alpha-1-2Man-alpha-1-2Man, or Man-alpha-1-2[Gal-beta-1-4]Man. Cellular LPG, isolated from promastigotes, has a very similar structure to the culture supernatant LPG. However, it differs from culture supernatant LPG in the average number of phosphorylated oligosaccharide repeat units (20 versus 28) and in alkyl chain composition. Although culture supernatant LPG contained predominantly C24:0 alkyl chains, cellular LPG contained approximately equal amounts of C24:0 and C26:0 alkyl chains. It is suggested that culture supernatant LPG is passively shed from promastigotes and that it may contribute significantly, but not exclusively, to the "excreted factor" used for serotyping Leishmania spp. Comparison of L. mexicana LPG with the LPGs of Leishmania major and Leishmania donovani indicate that these molecules are highly conserved but that species-specific differences occur in the phosphorylated oligosaccharide repeat branches and in the relative abundance of the neutral cap structures.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND; MAX PLANCK INST BIOL,MEMBRANBIOCHEM ABT,W-7400 TUBINGEN,GERMANY	University of Dundee; Max Planck Society			Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BOUVIER J, 1989, MOL BIOCHEM PARASIT, V37, P235, DOI 10.1016/0166-6851(89)90155-2; BOUVIER J, 1985, J BIOL CHEM, V260, P5504; BRUN R, 1979, ACTA TROP, V36, P289, DOI DOI 10.5169/SEALS-312533; CHAUDHURI G, 1989, J BIOL CHEM, V264, P7483; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DEIBARRA AAL, 1982, PARASITOLOGY, V85, P523, DOI 10.1017/S0031182000056304; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ELON J, 1980, EXP PARASITOL, V49, P167, DOI 10.1016/0014-4894(80)90114-9; ETGES R, 1986, J BIOL CHEM, V261, P9098; FERGUSON MAJ, 1988, PARASITE IMMUNOL, V10, P465, DOI 10.1111/j.1365-3024.1988.tb00236.x; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GLASER TA, 1991, MOL BIOCHEM PARASIT, V45, P337, DOI 10.1016/0166-6851(91)90102-C; GREENBLATT CL, 1983, J CLIN MICROBIOL, V18, P191, DOI 10.1128/JCM.18.1.191-193.1983; HANDMAN E, 1987, IMMUNOL TODAY, V8, P181, DOI 10.1016/0167-5699(87)90036-3; HANDMAN E, 1984, EMBO J, V3, P2301, DOI 10.1002/j.1460-2075.1984.tb02130.x; HANDMAN E, 1985, EMBO J, V4, P329, DOI 10.1002/j.1460-2075.1985.tb03633.x; HANDMAN E, 1982, INFECT IMMUN, V37, P28, DOI 10.1128/IAI.37.1.28-33.1982; HOMANS SW, 1992, IN PRESS BIOCHEMISTR; ILG T, 1991, J CELL SCI, V99, P175; JAFFE CL, 1990, MOL BIOCHEM PARASIT, V41, P233, DOI 10.1016/0166-6851(90)90186-P; KING DL, 1987, MOL BIOCHEM PARASIT, V24, P47, DOI 10.1016/0166-6851(87)90114-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELOIR LF, 1957, METHOD ENZYMOL, V3, P840, DOI 10.1016/S0076-6879(57)03459-X; MAGNANI JL, 1987, METHOD ENZYMOL, V138, P208; MCCONVILLE MJ, 1987, P NATL ACAD SCI USA, V84, P8941, DOI 10.1073/pnas.84.24.8941; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MCCONVILLE MJ, 1991, BIOCH PROTOZOOLOGY B, P504; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; MOLL H, 1989, INFECT IMMUN, V57, P3349, DOI 10.1128/IAI.57.11.3349-3356.1989; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PUENTES SM, 1990, J IMMUNOL, V145, P4311; PUENTES SM, 1988, J EXP MED, V167, P887, DOI 10.1084/jem.167.3.887; ROSEN G, 1989, J BIOL CHEM, V264, P10457; RUSSELL DG, 1988, J IMMUNOL, V140, P1274; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; SCHAEFER FW, 1970, EXP PARASITOL, V28, P465, DOI 10.1016/0014-4894(70)90114-1; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; Schnur L. F., 1982, Biochemical characterization of Leishmania. Proceedings of a Workshop held at Pan American Health Organization, Washington, DC, 9-11 December 1980. [Editors: Chance, M.L.; Walton, B.C.], P25; SCHNUR LF, 1972, ISRAEL J MED SCI, V8, P932; SLUTZKY GM, 1982, INFECT IMMUN, V37, P10, DOI 10.1128/IAI.37.1.10-14.1982; STIERHOF YD, 1991, J CELL SCI, V99, P181; TALAMASROHANA P, 1990, J IMMUNOL, V144, P4817; THOMAS JR, 1992, J BIOL CHEM, V267, P6829; TOLSON DL, 1990, INFECT IMMUN, V58, P3500, DOI 10.1128/IAI.58.11.3500-3507.1990; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; TURCO SJ, 1990, EXP PARASITOL, V70, P241, DOI 10.1016/0014-4894(90)90105-L; TURCO SJ, 1991, MOL BIOCHEM PARASIT, V45, P91, DOI 10.1016/0166-6851(91)90030-A; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042; TURCO SJ, 1989, J BIOL CHEM, V264, P6711	58	113	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6834	6840						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551890				2022-12-27	WOS:A1992HM05300058
J	KAARTINEN, V; MONONEN, T; LAATIKAINEN, R; MONONEN, I				KAARTINEN, V; MONONEN, T; LAATIKAINEN, R; MONONEN, I			SUBSTRATE-SPECIFICITY AND REACTION-MECHANISM OF HUMAN GLYCOASPARAGINASE - THE N-GLYCOSIDIC LINKAGE OF VARIOUS GLYCOASPARAGINES IS CLEAVED THROUGH A REACTION-MECHANISM SIMILAR TO L-ASPARAGINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; ESCHERICHIA-COLI; ASPARTYLGLYCOSAMINURIA; GLYCOPROTEINS; PATIENT; URINE	Human glycoasparaginase (N4-(beta-N-acetyl-D-glucosaminyl)-L-asparaginase, EC 3.5.1.26) hydrolyzes a series of compounds that contain L-asparagine residue with free alpha-amino and alpha-carboxyl groups. Substrates include high mannose and complex type glycoasparagines as well as those that lack the di-N-acetylchitobiose moiety, L-aspartic acid beta-methyl ester and L-aspartic acid beta-hydroxamate. The enzyme is inactive toward L-asparagine and L-glutamine and glycoasparagines containing substituted alpha-amino and/or alpha-carboxyl groups. In the presence of the acyl acceptor hydroxylamine, glycoasparaginase catalyzes the synthesis of L-aspartic acid beta-hydroxamate from aspartyl-glucosamine, L-aspartic acid beta-methyl ester, and L-aspartic acid. C-13 NMR studies using O-18-labeled L-aspartic acid demonstrate that glycoasparaginase catalyzes an oxygen exchange between water and the carboxyl group at C-4 of L-aspartic acid. These results indicate that glycoasparaginase reacts as an exo-hydrolase toward the L-asparagine moiety of the substrates and the free alpha-amino and alpha-carboxyl groups are required for the enzyme reaction. The results are consistent with an L-asparaginase-like reaction pathway which involves a beta-aspartyl enzyme intermediate. Since glycoasparaginase is active toward a series of structurally different glycoasparagines, we suggest the revised systematic name of N4-(beta-glycosyl)-L-asparaginase for the enzyme.	KUOPIO UNIV HOSP,DEPT CLIN CHEM,KUOPIO,FINLAND; UNIV KUOPIO,DEPT CHEM,KUOPIO,FINLAND; AI VIRTANEN INST,CTR DIAGNOST BIOTECHNOL,SF-70210 KUOPIO,FINLAND; CHILDRENS HOSP LOS ANGELES,DIV MED GENET,LOS ANGELES,CA 90054	Kuopio University Hospital; University of Eastern Finland; University of Eastern Finland; Children's Hospital Los Angeles			Kaartinen, Vesa/AAU-5396-2021	Kaartinen, Vesa/0000-0002-9432-510X				ARONSON NN, 1989, FASEB J, V3, P2615, DOI 10.1096/fasebj.3.14.2531691; BEAUDET AL, 1989, METABOLIC BASIS INHE, P1603; DEGASPERI R, 1989, J BIOL CHEM, V264, P9329; EHRMAN M, 1971, J BIOL CHEM, V246, P88; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; KAARTINEN V, 1990, ANAL BIOCHEM, V190, P98, DOI 10.1016/0003-2697(90)90140-5; LIPMANN F, 1945, J BIOL CHEM, V159, P21; LUNDBLAD A, 1976, EUR J BIOCHEM, V67, P209, DOI 10.1111/j.1432-1033.1976.tb10651.x; MAKINO M, 1966, BIOCHEM BIOPH RES CO, V24, P961, DOI 10.1016/0006-291X(66)90344-5; MONONEN I, 1982, CARBOHYD RES, V104, P1, DOI 10.1016/S0008-6215(00)82215-6; MONONEN I, 1991, P NATL ACAD SCI USA, V88, P2941, DOI 10.1073/pnas.88.7.2941; PETERSON RG, 1977, J BIOL CHEM, V252, P2072; POLLITT RJ, 1974, BIOCHEM J, V141, P141, DOI 10.1042/bj1410141; ROHM KH, 1986, ARCH BIOCHEM BIOPHYS, V244, P128, DOI 10.1016/0003-9861(86)90101-3; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P467; SUGAHARA K, 1975, J BIOCHEM-TOKYO, V78, P673, DOI 10.1093/oxfordjournals.jbchem.a130954; TARENTINO AL, 1969, ARCH BIOCHEM BIOPHYS, V130, P295, DOI 10.1016/0003-9861(69)90036-8; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WRISTON JC, 1971, ENZYMES, V4, P101, DOI DOI 10.1016/S1874-6047(08)60365-0	20	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6855	6858						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551892				2022-12-27	WOS:A1992HM05300061
J	RAPAPORT, D; SHAI, Y				RAPAPORT, D; SHAI, Y			AGGREGATION AND ORGANIZATION OF PARDAXIN IN PHOSPHOLIPID-MEMBRANES - A FLUORESCENCE ENERGY-TRANSFER STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA MOSES SOLE; LIPID BILAYERS; MELITTIN; CHANNEL; POLYPEPTIDE; SECRETION; PEPTIDES; PORES	Fluorescence resonance energy transfer has been used to study the aggregation and organization of pardaxin and its analogues within lipid membranes. Peptide molecules labeled with 5- (and 6-) carboxyfluorescein at their N-terminal amino acid served as donors in these energy transfer measurements, whereas peptides labeled with 5- (and 6-) carboxytetramethylrhodamine at either their N- or C-terminal amino acid, served as acceptors. The membrane-permeating activity of the native molecule was maintained in the labeled peptides. Upon aggregation of the labeled peptides, fluorescence energy transfer was detected as a quenching of the donor fluorescence (520 nm), as well as an enhancement of the acceptor fluorescence (575 nm). Correlation exists between self-aggregation of the different analogues within membranes and their pore-forming abilities. A comparison of the degrees of fluorescence energy transfer from N1-donor-labeled pardaxin to N1-acceptor-labeled pardaxin with the transfer efficiency observed in the interaction between the same donor and C1-acceptor-labeled pardaxin suggests that aggregates are formed in an ordered manner, with a preferentially parallel orientation of monomers within the aggregate. The extent of hetero-oligomer formation, i.e. complexes composed of two different analogue species, revealed that complementary charges contribute to peptide-peptide recognition within the lipid bilayer. Taken together, these results provide further support for the barrel stave model, involving parallel organization of monomers within the aggregate, as a description of the pore formation mechanism of pardaxin and its analogues.	WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								[Anonymous], [No title captured]; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; CARRAWAY KL, 1989, J BIOL CHEM, V264, P8699; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DALE RE, 1974, BIOPOLYMERS, V13, P1573, DOI 10.1002/bip.1974.360130807; ESTEP TN, 1979, BIOPHYS J, V26, P195, DOI 10.1016/S0006-3495(79)85244-3; Fairclough R H, 1978, Methods Enzymol, V48, P347; Forster T., 1959, DISCUSS FARADAY SOC, V27, P7, DOI DOI 10.1039/DF9592700007; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; HARRIS RW, 1991, J BIOL CHEM, V266, P6936; HERMETTER A, 1986, J BIOL CHEM, V261, P8243; JOHN E, 1991, BIOPHYS J, V60, P319, DOI 10.1016/S0006-3495(91)82056-2; LAZAROVICI P, 1990, ACS SYM SER, V418, P347; LAZAROVICI P, 1986, J BIOL CHEM, V261, P6704; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; LOEW LM, 1985, BIOCHEMISTRY-US, V24, P2101, DOI 10.1021/bi00330a001; LOEW LM, 1983, BIOCHEMISTRY-US, V22, P837, DOI 10.1021/bi00273a020; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; Moran A., 1984, P13; PARNESS J, 1976, TOXICON, V14, P85, DOI 10.1016/0041-0101(76)90097-0; PRIMOR N, 1984, BRIT J PHARMACOL, V82, P43, DOI 10.1111/j.1476-5381.1984.tb16440.x; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SHAI Y, 1991, J BIOL CHEM, V266, P22346; SHAI Y, 1987, BIOCHEMISTRY-US, V26, P669, DOI 10.1021/bi00377a002; SHAI Y, 1988, FEBS LETT, V242, P161, DOI 10.1016/0014-5793(88)81007-X; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; TALBOT JC, 1987, EUR BIOPHYS J BIOPHY, V15, P147, DOI 10.1007/BF00263679; THOMPSON SA, 1986, SCIENCE, V233, P341, DOI 10.1126/science.233.4761.341; VEATCH W, 1977, J MOL BIOL, V113, P89, DOI 10.1016/0022-2836(77)90042-0; VOGEL H, 1986, BIOPHYS J, V50, P573, DOI 10.1016/S0006-3495(86)83497-X; ZAGORSKI MG, 1991, BIOCHEMISTRY-US, V30, P8009, DOI 10.1021/bi00246a019	33	117	118	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6502	6509						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551864				2022-12-27	WOS:A1992HM05300012
J	ELLISTON, JF; BEEKMAN, JM; TSAI, SY; OMALLEY, BW; TSAI, MJ				ELLISTON, JF; BEEKMAN, JM; TSAI, SY; OMALLEY, BW; TSAI, MJ			HORMONE ACTIVATION OF BACULOVIRUS EXPRESSED PROGESTERONE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLUCOCORTICOID RECEPTOR; CELL-FREE TRANSCRIPTION; MAMMARY-TUMOR VIRUS; DEOXYRIBONUCLEIC-ACID; ESTROGEN-RECEPTOR; STEROID-HORMONES; DNA-BINDING; MONOCLONAL-ANTIBODIES; ENHANCER ELEMENT; ESCHERICHIA-COLI	Human and chicken progesterone receptors (A form) were overproduced in a baculovirus expression system. These recombinant progesterone receptors were full-length bound progesterone specifically and were recognized by monoclonal antibodies, AB52 and PR22, specific for human and chicken progesterone receptor, respectively. In gel retardation studies, binding of recombinant human and chicken progesterone receptors to their progesterone response element (PRE) was specific and was enhanced in the presence of progesterone. Binding of human progesterone receptor to the PRE was also enhanced in the presence of the antiprogestin, RU486, but very little effect was observed in the presence of estradiol, dexamethasone, testosterone, and vitamin D. In our cell-free transcription system, human progesterone receptor induced transcription in a receptor-dependent and hormone-activable manner. Receptor-stimulated transcription required the presence of the PRE in the test template and could be specifically inhibited by excess PRE oligonucleotides. Furthermore, chicken progesterone receptor also induced in vitro transcription in a hormone-activable manner. These results demonstrate that steroid receptors overexpressed in a baculovirus expression system are functional and exhibit steroid-responsive binding and transcription. These observations support our present understanding of the mechanism of steroid receptor-regulated gene expression and provide a technological format for studies of the role of hormone and antihormone in altering gene expression.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine								BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BAGCHI MK, 1988, MOL ENDOCRINOL, V2, P1221, DOI 10.1210/mend-2-12-1221; BAILLY A, 1986, EMBO J, V5, P3235, DOI 10.1002/j.1460-2075.1986.tb04634.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CARSON MA, 1987, MOL ENDOCRINOL, V1, P791, DOI 10.1210/mend-1-11-791; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CONNEELY OM, 1986, SCIENCE, V233, P767, DOI 10.1126/science.2426779; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1989, ENDOCRINOLOGY, V125, P3051, DOI 10.1210/endo-125-6-3051; DOBSON ADW, 1989, J BIOL CHEM, V264, P4207; EDWARDS DP, 1989, MOL ENDOCRINOL, V3, P381, DOI 10.1210/mend-3-2-381; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; EUL J, 1989, EMBO J, V8, P83, DOI 10.1002/j.1460-2075.1989.tb03351.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; Gorski J, 1968, Recent Prog Horm Res, V24, P45; GORSKI J, 1976, ANNU REV PHYSIOL, V38, P415; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JENSEN EV, 1968, P NATL ACAD SCI USA, V59, P632, DOI 10.1073/pnas.59.2.632; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MAK P, 1989, J BIOL CHEM, V264, P21613; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MIGLIACCIO A, 1981, J STEROID BIOCHEM, V15, P369, DOI 10.1016/0022-4731(81)90299-5; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MUNCK A, 1968, J BIOL CHEM, V243, P5556; NIELSEN CJ, 1977, P NATL ACAD SCI USA, V74, P1398, DOI 10.1073/pnas.74.4.1398; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OMALLEY BW, 1974, SCIENCE, V183, P610, DOI 10.1126/science.183.4125.610; OMALLEY BW, 1976, SCI AM, V234, P32, DOI 10.1038/scientificamerican0276-32; PARKER MG, 1991, NUCLEAR HORMONE RECE; POWER RF, 1990, J BIOL CHEM, V265, P1419; RODRIGUEZ R, 1989, MOL ENDOCRINOL, V3, P356, DOI 10.1210/mend-3-2-356; ROUSSEAU GG, 1975, J STEROID BIOCHEM, V6, P75, DOI 10.1016/0022-4731(75)90032-1; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TSAI SY, 1990, J BIOL CHEM, V265, P17055; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VONDERAHE D, 1985, NATURE, V313, P706, DOI 10.1038/313706a0; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	52	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5193	5198						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544902				2022-12-27	WOS:A1992HH74700032
J	MCSHAN, WM; ROSSEN, RD; LAUGHTER, AH; TRIAL, J; KESSLER, DJ; ZENDEGUI, JG; HOGAN, ME; ORSON, FM				MCSHAN, WM; ROSSEN, RD; LAUGHTER, AH; TRIAL, J; KESSLER, DJ; ZENDEGUI, JG; HOGAN, ME; ORSON, FM			INHIBITION OF TRANSCRIPTION OF HIV-1 IN INFECTED HUMAN-CELLS BY OLIGODEOXYNUCLEOTIDES DESIGNED TO FORM DNA TRIPLE HELICES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY VIRUS INVITRO; C-MYC GENE; INTERCALATING AGENT; VIRAL-RNA; SEQUENCE; EXPRESSION; SITE; CLEAVAGE; OLIGONUCLEOTIDES; COMPLEMENTARY	The effect on human immunodeficiency virus 1 (HIV-1) viral transcription and subsequent gene expression mediated by mixed purine-pyrimidine oligodeoxyribonucleotides (oligodeoxynucleotides) designed to form collinear DNA triplexes with purine-rich elements in the viral promoter was evaluated in intact mammalian cell lines (MT4 and U937). Oligonucleotides HIV31 (5'-GTTTTTGGGTGTTGTGGGTGTGTGTGGTTTG-3') and HIV38 (5'-TGGGTGGGGTGGGGTGGGGGGGTGTGGGGTGTGGGGTG-3') were designed to interact with the transcription initiation site (-16 to +13) and nuclear factor Sp1 binding site (-81 to -44) of HIV-1, respectively. Oligonucleotides, synthesized with a 3' amine blocking group (5'-R-O-PO2-OCH (CHOH)-CH2-NH3+-3') to prevent degradation by cellular nucleases, were readily taken up by MT4 cells from the culture medium, achieving measured intranuclear concentrations higher than the medium in less than 2 h of incubation. The 3' amine modified oligonucleotides were recoverable from the cells after 24 h as > 90% intact material. Treatment of acutely infected MT4 cells with either HIV31 or HIV38 significantly inhibited viral-associated cytopathology and P24 antigen production (p < 0.001). Additionally, inhibition of P24 antigen release, culture supernatant viral titer, and expression of the intact 9.2-kb HIV-1 mRNA was observed when the chronically infected promonocyte cell line, U937, was treated with 10-mu-M HIV38. Control oligonucleotides with similar base composition did not inhibit virus expression in either cell line. Furthermore, inhibition of viral expression was not due to alpha-interferon induction resulting from oligonucleotide treatment. Both HIV31 and HIV38 associate with their respective DNA target duplexes at micromolar concentrations, and a strong negative ellipticity near 210 nm, characteristic of DNA triplexes, was observed in the circular dichroism spectrum of either target-oligonucleotide complex. These observations suggest that oligonucleotides, designed to form nucleic acid triplexes with specific proviral target sequences, can selectively inhibit transcription of viral mRNA in intact cells and suppress accumulation of viral products.	TRIPLEX PHARMACEUT CORP,THE WOODLANDS,TX 77387; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030; BAYLOR COLL MED,CTR BIOTECHNOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	MCSHAN, WM (corresponding author), VET AFFAIRS MED CTR,BLDG 211,RM 226,2002 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.			Trial, JoAnn/0000-0001-7145-7786	NIAID NIH HHS [AI28071] Funding Source: Medline; NIA NIH HHS [AGO7068] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007068] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGRIS CH, 1986, BIOCHEMISTRY-US, V25, P6268, DOI 10.1021/bi00368a065; AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; [Anonymous], [No title captured]; ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; Battey, 1986, BASIC METHODS MOL BI; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BIRG F, 1990, NUCLEIC ACIDS RES, V18, P2901, DOI 10.1093/nar/18.10.2901; BLACKBURN GM, 1990, NUCLEIC ACIDS CHEM B; BOIDOTFORGET M, 1988, GENE, V72, P361, DOI 10.1016/0378-1119(88)90163-1; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; BRAHMS J, 1970, FINE STRUCTURE PROTE, P191; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIER DA, 1988, J BIOL CHEM, V263, P7397; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; FRITZ HJ, 1978, BIOCHEMISTRY-US, V17, P1257, DOI 10.1021/bi00600a020; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HARDY KJ, 1985, P NATL ACAD SCI USA, V82, P8173, DOI 10.1073/pnas.82.23.8173; HARTSHORN KL, 1987, ANTIMICROB AGENTS CH, V31, P168, DOI 10.1128/AAC.31.2.168; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HORNE DA, 1990, J AM CHEM SOC, V112, P2435, DOI 10.1021/ja00162a063; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JACK A, 1976, J MOL BIOL, V108, P619, DOI 10.1016/S0022-2836(76)80109-X; Junqueira L.E., 1980, BASIC HISTOLOGY, Vthird; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LEE JS, 1979, NUCLEIC ACIDS RES, V6, P3073, DOI 10.1093/nar/6.9.3073; LEMAITRE M, 1987, P NATL ACAD SCI USA, V84, P648, DOI 10.1073/pnas.84.3.648; LIPSETT MN, 1964, J BIOL CHEM, V239, P1256; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MANZINI G, 1990, J MOL BIOL, V213, P833, DOI 10.1016/S0022-2836(05)80267-0; MARCK C, 1978, NUCLEIC ACIDS RES, V5, P1017, DOI 10.1093/nar/5.3.1017; MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER JH, 1966, P NATL ACAD SCI USA, V55, P1201, DOI 10.1073/pnas.55.5.1201; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; PAUWELS R, 1987, J VIROL METHODS, V16, P171, DOI 10.1016/0166-0934(87)90002-4; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; POVSIC TJ, 1990, J AM CHEM SOC, V112, P9428, DOI 10.1021/ja00181a075; ROSSEN RD, 1985, J IMMUNOL, V135, P3289; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; Stout J T, 1987, Methods Enzymol, V151, P519; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; Voet D, 1970, Prog Nucleic Acid Res Mol Biol, V10, P183; WAINHOBSON S, 1991, SCIENCE, V252, P961, DOI 10.1126/science.2035026; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; WYDE PR, 1985, ANTIMICROB AGENTS CH, V27, P60, DOI 10.1128/AAC.27.1.60; ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143	57	147	182	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5712	5721						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544943				2022-12-27	WOS:A1992HH74700106
J	LYONS, SE; BRUCK, ME; BOWIE, EJW; GINSBURG, D				LYONS, SE; BRUCK, ME; BOWIE, EJW; GINSBURG, D			IMPAIRED INTRACELLULAR-TRANSPORT PRODUCED BY A SUBSET OF TYPE-IIA VONWILLEBRAND DISEASE MUTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; ENDOTHELIAL-CELLS; MULTIMERIC STRUCTURE; HETEROLOGOUS CELLS; MOLECULAR-BASIS; FACTOR VWF; EXPRESSION; BIOSYNTHESIS; CLEAVAGE; VARIANT	Type IIA von Willebrand disease (vWD) results from abnormalities in von Willebrand factor (vWF) characterized by absence of plasma high molecular weight (HMW) vWF multimers. In this report, 5 distinct point mutations were identified in 6 Type IIA vWD families. A total of 7 mutations, all clustered within a 124-amino acid segment of the vWF A2 domain, now account for 9 of a panel of 11 Type IIA families. In COS-7 cells, 3 single amino acid substitutions, Val844 --> Asp, Ser743 --> Leu, and Gly742 --> Arg, impaired the transport of vWF multimers between the endoplasmic reticulum and the Golgi complex, with more profound effects on the secretion of HMW multimers than lower molecular weight forms. In contrast, 2 substitutions, Arg834 --> Trp and Gly742 --> Glu, resulted in secretion of HMW multimers similar to wild-type vWF. The vWF structure observed within patient platelets correlated closely with the synthesis pattern seen for the corresponding mutants in COS-7 cells. These findings demonstrate that structural alterations within the A2 domain of vWF can produce the characteristic phenotype of Type IIA vWD via two distinct molecular mechanisms.	HOWARD HUGHES MED INST, DEPT HUMAN GENET, 4520 MSRB I, 1150 W MED CTR DR, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, PROGRAM CELLULAR & MOLEC BIOL, ANN ARBOR, MI 48109 USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; HOWARD HUGHES MED INST, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Mayo Clinic; Howard Hughes Medical Institute				Lyons, Susan/0000-0001-5601-1938	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039693] Funding Source: NIH RePORTER; NHLBI NIH HHS [1-R01-HL39693] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BATLLE J, 1986, BLOOD, V68, P1207; BERKOWITZ SD, 1987, J CLIN INVEST, V79, P524, DOI 10.1172/JCI112843; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; CACHERIS PM, 1991, J BIOL CHEM, V266, P13499; CHANG HY, 1989, BLOOD S, V74, pA482; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COONEY KA, 1991, J CLIN INVEST, V87, P1227, DOI 10.1172/JCI115123; DENT JA, 1990, P NATL ACAD SCI USA, V87, P6306, DOI 10.1073/pnas.87.16.6306; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; GINSBURG D, 1989, P NATL ACAD SCI USA, V86, P3723, DOI 10.1073/pnas.86.10.3723; GINSBURG D, 1992, IN PRESS THROMB HAEM; GIRMA JP, 1987, BLOOD, V70, P605; GRALNICK HR, 1985, P NATL ACAD SCI USA, V82, P5968, DOI 10.1073/pnas.82.17.5968; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; IANNUZZI MC, 1991, AM J HUM GENET, V48, P757; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVENE RB, 1987, P NATL ACAD SCI USA, V84, P6550, DOI 10.1073/pnas.84.18.6550; LYNCH DC, 1983, P NATL ACAD SCI-BIOL, V80, P2738, DOI 10.1073/pnas.80.9.2738; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; NICHOLS WC, 1991, P NATL ACAD SCI USA, V88, P3857, DOI 10.1073/pnas.88.9.3857; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PERSELLIN ST, 1985, MAYO CLIN PROC, V60, P457, DOI 10.1016/S0025-6196(12)60869-6; RAINES G, 1990, THROMB RES, V60, P201, DOI 10.1016/0049-3848(90)90181-B; ROTH MS, 1990, J IMMUNOL, V145, P768; RUGGERI ZM, 1987, BLOOD, V70, P895; TOLLESHAUG H, 1983, CELL, V32, P941, DOI 10.1016/0092-8674(83)90079-X; VERBANAC KM, 1986, J BIOL CHEM, V261, P9979; VERWEIJ CL, 1987, EMBO J, V6, P2885, DOI 10.1002/j.1460-2075.1987.tb02591.x; WAGNER DD, 1984, J CELL BIOL, V99, P2123, DOI 10.1083/jcb.99.6.2123; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; WEISS HJ, 1983, J LAB CLIN MED, V101, P411; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9; ZIMMERMAN TS, 1986, J CLIN INVEST, V77, P947, DOI 10.1172/JCI112394	39	199	200	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4424	4430						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537829				2022-12-27	WOS:A1992HF64200027
J	TANIYAMA, Y; OGASAHARA, K; YUTANI, K; KIKUCHI, M				TANIYAMA, Y; OGASAHARA, K; YUTANI, K; KIKUCHI, M			FOLDING MECHANISM OF MUTANT HUMAN LYSOZYME C77/95A WITH INCREASED SECRETION EFFICIENCY IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LACTALBUMIN; DISULFIDE BONDS; INTERMEDIATE; RESIDUES; STATE	A mutant human lysozyme C77/95A, in which Cys77 and Cys95 are replaced with alanine, has been characterized by 8-fold greater secretion in yeast (Taniyama, Y., Yamamoto, Y., Nakao, M., Kikuchi, M., and Ikehara, M. (1988) Biochem. Biophys. Res. Commun. 152, 962-967) and almost the same three-dimensional structure as wild-type human lysozyme (Inaka, K., Taniyama, Y., Kikuchi, M., Morikawa, K., and Matsushima, M. (1991) J. Biol. Chem. 266, 1259912603). To clarify the molecular features of C77/95A and the reason for its increased secretion in yeast, the stabilities of the mutant C77/95A and the wild-type proteins were examined by guanidine hydrochloride denaturation, and the unfolding-refolding kinetics were determined from circular dichroism and fluorescence stopped-flow measurements. Equilibrium experiments showed that the DELTA-G of unfolding of C77/95A in water was 5.8 kcal/mol less stable than that of the wild-type protein at pH 4.0 and 10-degrees-C. The unfolding rate of C77/95A was 4 orders of magnitude faster than that of the wild-type protein whereas the two proteins shared similar refolding rates. The slowly refolding phase of the wild-type protein disappeared in C77/95A, indicating that the disulfide bond affects this phase. These observations show that the disulfide bond Cys77-Cys95 contributes to the stabilization of the folded form of human lysozyme by suppressing the unfolding rate and that the increase in the unfolding rate, or the disappearance of the slowly refolding phase in vitro, could correlate with the increase in secretion efficiency in vivo.	PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Osaka University								ANDERSON WD, 1990, BIOCHEMISTRY-US, V29, P3331, DOI 10.1021/bi00465a026; ARTYMIUK PJ, 1981, J MOL BIOL, V152, P737, DOI 10.1016/0022-2836(81)90125-X; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FROST AA, 1961, KINETICS MECH, P93; GILMANSHIN RI, 1987, FEBS LETT, V223, P327, DOI 10.1016/0014-5793(87)80313-7; HERNING T, 1991, BIOCHEMISTRY-US, V30, P9882, DOI 10.1021/bi00105a011; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; INAKA K, 1991, J BIOL CHEM, V266, P12599; KATO S, 1982, BIOCHEMISTRY-US, V21, P38, DOI 10.1021/bi00530a007; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; MATOUSCHEK A, 1989, NATURE, V340, P122, DOI 10.1038/340122a0; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; MIRANKER A, 1991, NATURE, V349, P633, DOI 10.1038/349633a0; PACE CN, 1988, J BIOL CHEM, V263, P11820; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; SUGAWARA T, 1991, BIOCHEMISTRY-US, V30, P2698, DOI 10.1021/bi00224a018; TANIYAMA Y, 1990, J BIOL CHEM, V265, P7570; TANIYAMA Y, 1988, BIOCHEM BIOPH RES CO, V152, P962, DOI 10.1016/S0006-291X(88)80377-2; TANIYAMA Y, 1990, J BIOL CHEM, V265, P16767	20	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4619	4624						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537844				2022-12-27	WOS:A1992HF64200053
J	CHAN, T; LEE, M; SAKMAR, TP				CHAN, T; LEE, M; SAKMAR, TP			INTRODUCTION OF HYDROXYL-BEARING AMINO-ACIDS CAUSES BATHOCHROMIC SPECTRAL SHIFTS IN RHODOPSIN - AMINO-ACID SUBSTITUTIONS RESPONSIBLE FOR RED-GREEN COLOR PIGMENT SPECTRAL TUNING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SCHIFF-BASE COUNTERION; BOVINE RHODOPSIN; VISUAL PIGMENTS; GENE; DETERMINANTS; SEQUENCE	Comparisons of the deduced amino acid sequences of eight primate photopigment genes led to the proposal that three amino acid substitutions produce the approximately 1,000 cm-1 difference in the absorption maxima of human red and green pigments (Neitz, M., Neitz, J., and Jacobs, G. H. (1991) Science 252, 971-974). We tested this proposal by mutating these three residues in rhodopsin and evaluating the effects on spectral properties. Nonpolar residues normally present in rhodopsin and in the green pigment were substituted by hydroxyl-bearing residues normally present in the red pigment. Two of these substitutions (Phe-261 to Tyr or Ala-269 to Thr) caused significant red shifts in the absorption maxima of the resulting mutant pigments. A third substitution (Ala-164 to Ser) caused only a slight effect. Combinations of substitutions caused additive shifts in absorption maxima. A double mutant (Phe-261 to Tyr/Ala-269 to Thr) displayed an absorption maximum that was red-shifted by 775 cm-1. Wavelength modulation in the visual pigments responsible for red-green color vision is likely to be governed by retinal-protein interactions involving primarily these two amino acid residues. Furthermore, interactions of hydroxyl-bearing amino acids with the chromophore may be a general mechanism of the opsin shift in visual pigments.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,BOX 284,1230 YORK AVE,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University			Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953				BIRGE RR, 1988, BIOPHYS J, V53, P367, DOI 10.1016/S0006-3495(88)83114-X; DARTNALL HJA, 1983, PROC R SOC SER B-BIO, V220, P115, DOI 10.1098/rspb.1983.0091; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; LO KM, 1984, P NATL ACAD SCI-BIOL, V81, P2285, DOI 10.1073/pnas.81.8.2285; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P937, DOI 10.1021/bi00456a013; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; SAKMAR TP, 1988, NUCLEIC ACIDS RES, V16, P6361, DOI 10.1093/nar/16.14.6361; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	21	151	152	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9478	9480						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577792				2022-12-27	WOS:A1992HT96500008
J	DALBIS, A; TOBIN, C; JANMOT, C; COUTEAUX, R				DALBIS, A; TOBIN, C; JANMOT, C; COUTEAUX, R			EFFECT OF TESTOSTERONE AND THYROID-HORMONE ON THE EXPRESSION OF MYOSIN IN THE SEXUALLY DIMORPHIC LEVATOR ANI MUSCLE OF RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTNATAL-DEVELOPMENT; SKELETAL-MUSCLE; FEMALE RATS; TRANSITIONS; ISOFORMS	During postnatal development, the myosin transition from embryonic and neonatal isoforms to adult isoforms has been shown to occur with half-transition times of about 20 and 32 days in the male and female levator ani muscles, respectively. We show that this difference could not be attributed to the testosterone male hormone, since treatment of newborn females by testosterone did not modify the half-transition time. However, treatment of females by thyroid hormone accelerated the myosin transition of the female muscle, which then,occurred at almost the same time as the transition of the male muscle. This suggests that the difference between the half-transition times of the male and female levator ani muscles may be largely attributed to different sensitivities of the male and female muscles to thyroid hormone. This is the first example of sexually dimorphic muscle response to thyroid hormone.	UNIV PARIS 06,DEPT CYTOL,CNRS,INST NEUROSCI,F-75230 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	DALBIS, A (corresponding author), UNIV PARIS 11,BIOL PHYSICOCHIM,CNRS,URA 1131,F-91405 ORSAY,FRANCE.							BANDMAN E, 1985, INT REV CYTOL, V97, P97, DOI 10.1016/S0074-7696(08)62349-9; BUTLERBROWNE GS, 1984, FEBS LETT, V166, P71, DOI 10.1016/0014-5793(84)80047-2; CHIZZONITE RA, 1984, J BIOL CHEM, V259, P2628; CIHAK R, 1970, J ANAT, V106, P93; DALBIS A, 1987, CR ACAD SCI III-VIE, V305, P697; DALBIS A, 1990, EUR J BIOCHEM, V193, P155, DOI 10.1111/j.1432-1033.1990.tb19317.x; DALBIS A, 1989, EUR J BIOCHEM, V183, P583, DOI 10.1111/j.1432-1033.1989.tb21087.x; DALBIS A, 1991, FEBS LETT, V278, P41, DOI 10.1016/0014-5793(91)80079-I; GALAVAZI G, 1971, Z ZELLFORSCH MIK ANA, V121, P507, DOI 10.1007/BF00560157; GAMBKE B, 1983, FEBS LETT, V156, P335, DOI 10.1016/0014-5793(83)80524-9; GUTMANN E, 1967, EXPERIENTIA, V23, P852, DOI 10.1007/BF02146886; HAYES KJ, 1965, ACTA ENDOCRINOL-COP, V48, P337, DOI 10.1530/acta.0.0480337; HOLMANG A, 1990, AM J PHYSIOL, V259, pE555, DOI 10.1152/ajpendo.1990.259.4.E555; LYONS GE, 1986, J BIOL CHEM, V261, P3278; SASSOON DA, 1987, J NEUROSCI, V7, P3198; SWINGHEDAUW B, 1986, PHYSIOL REV, V66, P710; TOBIN C, 1988, Biological Structures and Morphogenesis, V1, P28; TOBIN C, 1991, DEV BIOL, V146, P131, DOI 10.1016/0012-1606(91)90453-A; VIGNERON P, 1989, REPROD NUTR DEV, V29, P27, DOI 10.1051/rnd:19890102; Wainman P, 1941, ENDOCRINOLOGY, V29, P975, DOI 10.1210/endo-29-6-975	20	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10052	10054						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577775				2022-12-27	WOS:A1992HT96500091
J	IM, MJ; GRAY, C; RIM, AJ				IM, MJ; GRAY, C; RIM, AJ			CHARACTERIZATION OF A PHOSPHOLIPASE-C ACTIVITY REGULATED BY THE PURIFIED GH IN RECONSTITUTION SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-ADRENERGIC RECEPTOR SUBTYPES; LIVER PLASMA-MEMBRANES; GUANINE-NUCLEOTIDE; RAT-BRAIN; G-PROTEIN; INOSITOL TRISPHOSPHATE; ADENYLATE-CYCLASE; BINDING-PROTEINS; BOVINE BRAIN; PURIFICATION	Recently, we have reported that the isolated guanine nucleotide-binding regulatory protein, G(h), couples to the alpha-1-adrenergic receptor (Im, M.-J., and Graham, R. M. (1990) J. Biol. Chem. 265, 18944-18951 and Im, M.-J., Riek, R. P., and Graham, R. M. (1990) J. Biol. Chem. 265, 18952-18960) and has a molecular mass of approximately 74 kDa, and the approximately 50-kDa protein which is co-purified probably regulates guanine nucleotide binding of the 74-kDa GTP-binding protein. In this paper, we describe the role of purified G(h) in the regulation of phospholipase C in the reconstitution system. The stimulation of phospholipase C activity by G(h) effectively occurred at a low calcium concentration (less-than-or-equal-to 2-mu-M), but the phospholipase C (PLC) itself required at least 50-100 times more calcium to become fully activated. The characteristic nature of phospholipase C stimulation by G(h) is its response to the calcium concentration. Thus, the enzyme activity changes in narrow submicromolar ranges and reaches maximal stimulation, but it does not extend to the levels above those stimulated by calcium alone. The calcium concentrations for the maximal stimulation of phospholipase C activity were 10-20-mu-M with phospholipid vesicles and 100-200-mu-M with detergent solution. These calcium concentrations were further decreased when G(h) and phospholipase C were co-reconstituted into the phospholipid vesicles or in the detergent solution. The maximal stimulations of the PLC activity were reached at < 5-mu-M calcium in both the vesicles and the detergent solution. The changes of calcium concentration for the activation of PLC are quite different from those obtained by reconstituting PLC-beta-1 with G(q)-like G-proteins (Smarcka, A. V., Hepler, J. R., Brown, K. O., and Sternweis, P. C. (1991) Science 251, 804-807 and Taylor, S. J., Chae, H. Z., Rhee, S. G., and Exton, J. H. (1991) Nature 350, 516-518). The phospholipase C activity was stimulated in a G(h) concentration-dependent manner in the presence of GTP-gamma-S. The phospholipase C activity was activated by G(h-alpha) in the presence of aluminum fluoride, but not by G(h-beta). Furthermore, a G(h).PLC complex can be induced by incubation with aluminum fluoride in a detergent solution and partially purified without the dissociation of related proteins. Thus, our reconstitution studies show that the pattern of stimulation of PLC by AlF4--activated G(h) in the ternary complex is similar to the stimulation of PLC activated by G(h) in both detergent solution and phospholipid vesicles.			IM, MJ (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT HEART & HYPERTENS RES FFB37,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL033713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045985] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33713-06] Funding Source: Medline; NIGMS NIH HHS [GM45985] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEHR W, 1982, J BIOL CHEM, V257, P6452; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; DAWSON MC, 1980, EUR J BIOCHEM, V112, P33, DOI 10.1111/j.1432-1033.1980.tb04983.x; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; FEDER D, 1986, EMBO J, V5, P1509, DOI 10.1002/j.1460-2075.1986.tb04390.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GONZALES RA, 1985, BIOCHEM J, V232, P799, DOI 10.1042/bj2320799; HAN C, 1987, MOL PHARMACOL, V32, P505; HAN C, 1987, NATURE, V329, P333, DOI 10.1038/329333a0; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; IRVINE RF, 1984, BIOCHEM J, V218, P177, DOI 10.1042/bj2180177; IRVINE RF, 1978, BIOCHEM J, V176, P475, DOI 10.1042/bj1760475; JOHNSON RD, 1987, MOL PHARMACOL, V31, P239; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KIM UH, 1991, J BIOL CHEM, V266, P1359; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LEE CO, 1980, SCIENCE, V209, P699, DOI 10.1126/science.7394527; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MINNEMAN KP, 1988, MOL PHARMACOL, V33, P509; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; MORROW AL, 1985, EUR J PHARMACOL, V109, P285, DOI 10.1016/0014-2999(85)90432-7; MORROW AL, 1986, MOL PHARMACOL, V29, P321; NEER EJ, 1988, NATURE, V333, P12; NIJJAR MS, 1977, BIOCHIM BIOPHYS ACTA, V480, P390, DOI 10.1016/0005-2744(77)90032-8; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PFEUFFER E, 1985, P NATL ACAD SCI USA, V82, P3086, DOI 10.1073/pnas.82.10.3086; PFEUFFER T, 1988, CURR TOP CELL REGUL, V29, P129; Razin S, 1974, Methods Enzymol, V32, P459; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, J BIOL CHEM, V262, P12511; SLIVKA SR, 1987, J BIOL CHEM, V262, P4200; SMITH GL, 1985, BIOCHIM BIOPHYS ACTA, V839, P287, DOI 10.1016/0304-4165(85)90011-X; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAKENAWA T, 1981, J BIOL CHEM, V256, P6769; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; TERMAN BI, 1990, MOL PHARMACOL, V37, P526; TSIEN RY, 1980, BIOCHIM BIOPHYS ACTA, V599, P623, DOI 10.1016/0005-2736(80)90205-9; TSUJIMOTO G, 1989, MOL PHARMACOL, V36, P166; UHING RJ, 1986, J BIOL CHEM, V261, P2140; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114	48	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8887	8894						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577727				2022-12-27	WOS:A1992HR85400031
J	PRIVALLE, CT; FRIDOVICH, I				PRIVALLE, CT; FRIDOVICH, I			TRANSCRIPTIONAL AND MATURATIONAL EFFECTS OF MANGANESE AND IRON ON THE BIOSYNTHESIS OF MANGANESE-SUPEROXIDE DISMUTASE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC BIOSYNTHESIS; INDUCTION; DIAMIDE; ENZYME; OPERON	Anaerobically grown Escherichia coli contain an enzymatically active iron superoxide dismutase (Fe2-FeSOD) and an inactive iron-substituted manganese superoxide dismutase (Fe2-MnSOD). The anaerobic electron sink, nitrate plus paraquat, enhanced biosynthesis of the MnSOD polypeptide, with accumulation of inactive Fe2-MnSOD. The oxidant, diamide, in contrast, allowed anaerobic production of the active forms of MnSOD, i.e. Mn2-MnSOD and Mn/Fe-MnSOD. Nutritional supplementation with Mn(II) favored occupancy of the MnSOD active site with manganese and allowed anaerobic accumulation of Mn2-MnSOD in the absence of diamide. Enrichment of the anaerobic growth medium with Fe(II) both suppressed biosynthesis of the MnSOD polypeptide and inhibited formation of the active manganese-containing forms. A tac-sodA operon fusion was used to examine the effects of chelating agents and metals on maturation of nascent MnSOD, independent from the transcriptional effects these agents impose. Isopropyl-1-thio-beta-D-galactopyranoside (IPTG) elicited anaerobic biosynthesis of MnSOD, which accumulated as the inactive Fe2-MnSOD. Diamide, with IPTG, allowed formation of active Mn/Fe-MnSOD while 1,10-phenanthroline with IPTG resulted in accumulation of Mn2-MnSOD. These results suggest that iron participates in the redox-sensitive control of the formation of active MnSOD at two levels, i.e. that of transcription as well as that of maturation. During maturation of the nascent MnSOD polypeptide, iron and manganese compete for the metal-binding site; anaerobic conditions favor iron-binding, whereas oxidants, such as dioxygen or diamide, favor binding of manganese.			PRIVALLE, CT (corresponding author), DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710, USA.							BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BEYER WF, 1991, J BIOL CHEM, V266, P303; BEYER WF, 1989, BIOCHEMISTRY-US, V28, P4403, DOI 10.1021/bi00436a042; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; GARDNER PR, 1987, J BIOL CHEM, V262, P17591; HASSAN HM, 1987, J BIOL CHEM, V262, P17173; KEELE BB, 1970, J BIOL CHEM, V245, P6176; KIRBY T, 1980, ARCH BIOCHEM BIOPHYS, V201, P551, DOI 10.1016/0003-9861(80)90544-5; KOSOWER EM, 1972, BIOCHIM BIOPHYS ACTA, V264, P39, DOI 10.1016/0304-4165(72)90114-6; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; LAWRENCE GD, 1979, BIOCHEMISTRY-US, V18, P3045, DOI 10.1021/bi00581a021; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MIYAKE K, 1988, J GEN APPL MICROBIOL, V34, P105, DOI 10.2323/jgam.34.105; MOODY CS, 1984, J BIOL CHEM, V259, P2821; OSE DE, 1979, ARCH BIOCHEM BIOPHYS, V194, P360, DOI 10.1016/0003-9861(79)90628-3; PRIVALLE CT, 1991, FREE RADICAL RES COM, V12-3, P419, DOI 10.3109/10715769109145812; PRIVALLE CT, 1988, J BIOL CHEM, V263, P4274; PRIVALLE CT, 1989, J BIOL CHEM, V264, P2758; PRIVALLE CT, 1990, J BIOL CHEM, V265, P21966; PUGH SYR, 1985, J BACTERIOL, V162, P196, DOI 10.1128/JB.162.1.196-202.1985; SCHIAVONE JR, 1988, J BIOL CHEM, V263, P4269; TARDAT B, 1991, MOL MICROBIOL, V5, P455, DOI 10.1111/j.1365-2958.1991.tb02129.x; TOUATI D, 1989, FREE RADICAL RES COM, V8, P1, DOI 10.3109/10715768909087967; TOUATI D, 1988, J BACTERIOL, V170, P2511, DOI 10.1128/jb.170.6.2511-2520.1988; TOUATI D, 1988, OXYRADICALS MOL BIOL, P247	30	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9140	9145						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577750				2022-12-27	WOS:A1992HR85400068
J	BARKER, CW; FAGAN, JB; PASCO, DS				BARKER, CW; FAGAN, JB; PASCO, DS			INTERLEUKIN-1-BETA SUPPRESSES THE INDUCTION OF P4501A1 AND P4501A2 MESSENGER-RNAS IN ISOLATED HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; LIVER DRUG-METABOLISM; ACUTE-PHASE RESPONSE; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; HEPATIC CYTOCHROME-P-450; BETA-NAPHTHOFLAVONE; NUCLEOTIDE-SEQUENCE; PLASMA-FIBRINOGEN; FACTOR-ALPHA	Animals subjected to immunostimulatory conditions exhibit reduced tissue levels of total cytochrome P450 and P450-dependent drug metabolism. We have investigated the possibility that depressed levels of two carcinogen-metabolizing cytochrome P450s may be due to decreased levels of the mRNAs encoding these enzymes by studying the effect of monocyte-derived cytokines on the induction of CYP1A1 and CYP1A2 mRNAs in isolated rat hepatocytes. Medium conditioned by activated human peripheral blood monocytes or by the U937 monocyte cell line suppressed the induction of both mRNAs by 2,3,7,8-tetrachlorodibenzo-p-dioxin, whereas beta-fibrinogen mRNA levels increased 30-40-fold. CYP1A2 mRNA induction was maximally inhibited more than CYP1A1 mRNA (approximately 95 and 65%, respectively), and lower concentrations of conditioned medium suppressed CYP1A2 mRNA induction (half-maximal at 1.9 and 3.1%, respectively). Low concentrations of recombinant interleukin-1 suppressed the inducer-dependent accumulation of both CYP1A1 and CYP1A2 mRNAs in a dose-dependent fashion (half-maximal at 2 and 0.5 units/ml, respectively), while two other monocyte-derived cytokines, interleukin-6 and transforming growth factor-beta, did not. Run-on transcription analysis demonstrated that conditioned medium and interleukin-1 rapidly suppressed the transcription rate of CYP1A1 and CYP1A2 in inducer-treated hepatocytes. The close correspondence between the reductions in CYP1A1 and CYP1A2 transcription rates and mRNA levels suggest that conditioned medium and interleukin-1 suppress the induction of these mRNAs principally through a transcriptional mechanism.	MAHARISHI INT UNIV,MOLEC BIOL LAB,FAIRFIELD,IA 52557						NATIONAL CANCER INSTITUTE [R01CA038655] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA38655] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; ANDUS T, 1988, EUR J IMMUNOL, V18, P739, DOI 10.1002/eji.1830180513; AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P4790, DOI 10.1073/pnas.87.12.4790; BACK DW, 1986, J BIOL CHEM, V261, P2555; BARTINI R, 1989, J LEUK BIL, V3, P254; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1988, J BIOL CHEM, V263, P17390; BERTINI R, 1988, INT J IMMUNOPHARMACO, V10, P525, DOI 10.1016/0192-0561(88)90069-0; BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696; BUTLER MA, 1989, CANCER RES, V49, P25; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; FAGAN JB, 1986, ARCH BIOCHEM BIOPHYS, V244, P261, DOI 10.1016/0003-9861(86)90116-5; FALETTO MB, 1988, J BIOL CHEM, V263, P12187; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FREIMUTH WW, 1989, J IMMUNOL, V143, P3064; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEHRING MR, 1987, J BIOL CHEM, V262, P446; GELBOIN HV, 1980, PHYSIOL REV, V60, P1107, DOI 10.1152/physrev.1980.60.4.1107; GHEZZI P, 1985, CANCER RES, V45, P3444; GHEZZI P, 1986, INFECT IMMUN, V54, P837, DOI 10.1128/IAI.54.3.837-840.1986; GONZALEZ FJ, 1984, MOL PHARMACOL, V26, P117; GOODERHAM NJ, 1986, DEV DRUGS MODERN MED, P339; GUIRGIS HA, 1976, ONCOLOGY, V33, P105, DOI 10.1159/000225116; GURTOO HL, 1985, CARCINOGENESIS, V6, P675, DOI 10.1093/carcin/6.5.675; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; KELLERMANN G, 1973, NEW ENGL J MED, V289, P934, DOI 10.1056/NEJM197311012891802; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; KOJ A, 1985, ACUTE PHASE RESPONSE, pR22; KOURI RE, 1982, CANCER RES, V42, P5030; KRAEMER BL, 1986, IN VITRO, V22, P201; KRAEMER MJ, 1982, PEDIATRICS, V69, P476; KUCHNER I, 1987, DIS MARKERS, V5, P1; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LINDEN M, 1989, INFLAMMATION, V13, P651, DOI 10.1007/BF00914309; LU AYH, 1980, PHARMACOL REV, V31, P277; MACKIEWICZ A, 1990, P NATL ACAD SCI USA, V87, P1491, DOI 10.1073/pnas.87.4.1491; MANNERING GJ, 1986, ANNU REV PHARMACOL, V26, P455, DOI 10.1146/annurev.pa.26.040186.002323; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MOOCHHALA SM, 1989, BIOCHEM PHARMACOL, V38, P439, DOI 10.1016/0006-2952(89)90383-3; MORGAN ET, 1989, MOL PHARMACOL, V36, P699; MORTENSEN RF, 1988, J IMMUNOL, V140, P2260; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; PASCO DS, 1988, J BIOL CHEM, V263, P8671; PELKONEN O, 1982, PHARMACOL REV, V34, P190; PETERSON TC, 1984, J PHARMACOL EXP THER, V229, P299; RAMADORI G, 1988, EUR J IMMUNOL, V18, P1259, DOI 10.1002/eji.1830180817; REILLY JJ, 1988, AM REV RESPIR DIS, V138, P1422, DOI 10.1164/ajrccm/138.6.1422; RENTON KW, 1980, CAN MED ASSOC J, V123, P288; RENTON KW, 1990, CAN J PHYSIOL PHARM, V68, P777, DOI 10.1139/y90-119; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; RON D, 1990, MOL CELL BIOL, V10, P4389, DOI 10.1128/MCB.10.8.4389; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SALATI LM, 1991, J BIOL CHEM, V266, P4010; SANTHANAM K, 1989, CANCER LETT, V45, P129, DOI 10.1016/0304-3835(89)90147-X; SHIMADA T, 1989, CANCER RES, V49, P3218; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SILVER G, 1990, J BIOL CHEM, V265, P3134; SILVER G, 1988, J BIOL CHEM, V263, P11802; SOGAWA K, 1985, J BIOL CHEM, V260, P5026; STANLEY LA, 1988, EUR J BIOCHEM, V174, P31, DOI 10.1111/j.1432-1033.1988.tb14058.x; SUJITA K, 1990, BIOCHEM BIOPH RES CO, V168, P1217, DOI 10.1016/0006-291X(90)91158-O; TRELL E, 1976, LANCET, V2, P140; WALKER SB, 1982, PEDIATRICS, V70, P508; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; WRIGHT K, 1990, FEBS LETT, V271, P59, DOI 10.1016/0014-5793(90)80371-O; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	74	146	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8050	8055						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569064				2022-12-27	WOS:A1992HQ18500017
J	BJORNSTEDT, M; KUMAR, S; HOLMGREN, A				BJORNSTEDT, M; KUMAR, S; HOLMGREN, A			SELENODIGLUTATHIONE IS A HIGHLY EFFICIENT OXIDANT OF REDUCED THIOREDOXIN AND A SUBSTRATE FOR MAMMALIAN THIOREDOXIN REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE REDUCTASE; RAT-LIVER; SELENIUM; PURIFICATION; GLUTAREDOXIN; DISULFIDES; MECHANISM; INSULIN; GROWTH	Selenium compounds like selenite (SeO32-) may form a covalent adduct with glutathione (GSH) in the form of selenodiglutathione (GS-Se-SG), which is assumed to be important in the metabolism of selenium. We have isolated GS-Se-SG and studied its reactions with NADPH and thioredoxin reductase from calf thymus or with thioredoxin reductase and thioredoxin from Escherichia coli. Incubation of 0.1-mu-M calf thymus thioredoxin reductase or 0.1-mu-M thioredoxin reductase and 1-mu-M thioredoxin from E. coli with 5, 10, or 20-mu-M GS-Se-SG resulted in a fast initial reaction, followed by a large and continued oxidation of NADPH. However, anaerobic incubation of 0.1-mu-M calf thymus thioredoxin reductase and 20-mu-M GS-Se-SG resulted only in oxidation of a stoichiometric amount of NADPH; admission of oxygen started continuous NADPH oxidation. Contrary to the mammalian enzyme, GS-Se-SG was not a substrate for thioredoxin reductase from E. coli. The rate of the oxygen-dependent reaction between calf thymus thioredoxin reductase and GS-Se-SG was increased 2-fold in the presence of 4 mM GSH, indicating that HSe- was the reactive intermediate. Glutathione reductase from rat liver reduced GS-Se-SG with a very slow continued oxidation of NADPH, and the presence of the enzyme did not affect the oxygen-dependent nonstoichiometric oxidation of NADPH by GS-Se-SG and thioredoxin reductase. Fluorescence spectroscopy showed GS-Se-SG to be a very efficient oxidant of reduced thioredoxin from E. coli and kinetically superior to insulin disulfides. Thioredoxin-dependent reduction of CDP to dCDP by ribonucleotide reductase was effectively inhibited by GS-Se-SG.			BJORNSTEDT, M (corresponding author), KAROLINSKA INST, DEPT PHYSIOL CHEM, S-10401 STOCKHOLM 60, SWEDEN.							BATIST G, 1986, CANCER RES, V46, P5482; CARLBERG I, 1975, J BIOL CHEM, V250, P5475; GANTHER HE, 1971, BIOCHEMISTRY-US, V10, P4089, DOI 10.1021/bi00798a013; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1967, EUR J BIOCHEM, V2, P187, DOI 10.1111/j.1432-1033.1967.tb00125.x; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HSIEH HS, 1975, BIOCHEMISTRY-US, V14, P1632, DOI 10.1021/bi00679a014; KRAUSE G, 1991, J BIOL CHEM, V266, P4056; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MCKEEHAN WL, 1976, P NATL ACAD SCI USA, V73, P2023, DOI 10.1073/pnas.73.6.2023; MEDINA D, 1984, CANCER RES, V154, P29; NAKAGAWA T, 1988, BIOCHEM BIOPH RES CO, V150, P1149, DOI 10.1016/0006-291X(88)90749-8; Painter EP, 1941, CHEM REV, V28, P179, DOI 10.1021/cr60090a001; POIRIER KA, 1983, J NUTR, V113, P2147, DOI 10.1093/jn/113.11.2147; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; SHAMBERGER RJ, 1985, MUTAT RES, V154, P29, DOI 10.1016/0165-1110(85)90008-9; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; VERNIE LN, 1979, BIOCHEM J, V180, P213, DOI 10.1042/bj1800213; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WEISBERGER AS, 1956, BLOOD, V11, P19, DOI 10.1182/blood.V11.1.19.19; WORTHINGTON DJ, 1974, EUR J BIOCHEM, V48, P167, DOI 10.1111/j.1432-1033.1974.tb03754.x	29	171	177	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8030	8034						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569062				2022-12-27	WOS:A1992HQ18500014
J	GASBARRINI, A; BORLE, AB; FARGHALI, H; FRANCAVILLA, A; VANTHIEL, D				GASBARRINI, A; BORLE, AB; FARGHALI, H; FRANCAVILLA, A; VANTHIEL, D			FRUCTOSE PROTECTS RAT HEPATOCYTES FROM ANOXIC INJURY - EFFECT ON INTRACELLULAR ATP, CA2+I, MG2+I, NA+I, AND PHI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CALCIUM; CELL-DEATH; HEPATIC GLYCOGENOLYSIS; P-31-NMR SPECTROSCOPY; ADRENERGIC REGULATION; SEXUAL DIMORPHISM; CHEMICAL HYPOXIA; FREE-RADICALS; LIVER; ACIDOSIS	The effects of fructose on the intracellular ionic changes evoked by anoxia were studied in freshly isolated rat hepatocytes maintained in agarose gel threads and perfused with Krebs-Henseleit bicarbonate buffer (KHB). Cytosolic free calcium (Ca2+i) was measured with aequorin, intracellular sodium (Na+i) with sodium-binding benzofuran isophthalate, intracellular pH (pH(i)) with 2'-7'-bis(carboxyethyl)-5,6-carboxyfluorescein, lactic dehydrogenase (LDH) by the increase in NADH absorbance during lactate oxidation to pyruvate, and viability by trypan blue exclusion. ATP, P(i), phosphomonoesters, and the cell phosphorylation potential assessed by the reciprocal of the P(i)/ATP ratio were measured by P-31 NMR spectroscopy in real time. Intracellular free Mg2+ (Me2+i) was calculated from the chemical shift of beta-ATP relative to alpha-ATP in the NMR spectra. Anoxia was induced by perfusing the cells with KHB saturated with 95% N2, 5% CO2. When the perfusate contained 5 mM glucose as substrate, anoxia caused a fall in ATP, a rise in P(i), and in the P(i)/ATP ratio, a biphasic increase in Ca2+i that reached 1.45 +/- 0.42-mu-M and a 6-fold increase in LDH. When 15 mM fructose was used as substrate during the anoxic period, intracellular ATP decreased much faster than with glucose, P(i) did not increase, and the concentration of phosphomonoesters increased 2.5-fold. During the first hour of anoxia, the P(i)/ATP ratio was higher in the fructose than in the glucose group indicating that the hepatocyte phosphorylation potential and ATP decreased faster and to lower levels with fructose than with glucose. On the other hand, ATP and the phosphorylation potential of the fructose group increased during the second hour of anoxia, in contrast to their continuous decline in the glucose group. The major surge in Ca2+i was depressed 52% when glucose was replaced by fructose: Ca2+i reached only 0.7 +/- 0.2-mu-M instead of 1.45 +/- 0.42-mu-M (p < 0.01). Anoxia also caused an increase in Na+i and an intracellular acidosis. The rise in Na+i was significantly greater with fructose than with glucose. Na+i rose from a control value of 15.9 +/- 2.4 to 32.2 +/- 0.4 mM with glucose and to 48.7 +/- 0.7 mM with fructose (p < 0.001). The decrease in pH(i) from a control value of 7.43 +/- 0.03 was consistently greater and faster with fructose than with glucose: 6.59 +/- 0.03 and 7.04 +/- 0.01, respectively. At the same time, fructose completely suppressed LDH release and reduced the loss of viability produced by anoxia from 27.7 +/- 2.9 to 14 +/- 3.1% (p < 0.05).	UNIV PITTSBURGH,SCH MED,DEPT PHYSIOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT SURG,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Farghali, Hassan/K-6582-2017	Farghali, Hassan/0000-0001-6467-9532	NCRR NIH HHS [P41RR03631] Funding Source: Medline; NIAAA NIH HHS [AA04425] Funding Source: Medline; NIADDK NIH HHS [AM39789] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA004425, R37AA004425] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALLEN DG, 1983, J PHYSIOL-LONDON, V335, P555, DOI 10.1113/jphysiol.1983.sp014550; ANUNDI I, 1987, AM J PHYSIOL, V253, pG390, DOI 10.1152/ajpgi.1987.253.3.G390; ANUNDI I, 1987, RES COMMUN CHEM PATH, V55, P111; ANUNDI I, 1989, AM J PHYSIOL, V257, pG58, DOI 10.1152/ajpgi.1989.257.1.G58; BERGER ML, 1990, HEPATOLOGY, V9, P219; BONVENTRE JV, 1985, AM J PHYSIOL, V249, pC149, DOI 10.1152/ajpcell.1985.249.1.C149; Borle A B, 1986, Methods Enzymol, V124, P90; BORLE AB, 1990, J BIOL CHEM, V265, P19495; BORLE AB, 1986, AM J PHYSIOL, V251, pC323, DOI 10.1152/ajpcell.1986.251.2.C323; BORLE AB, 1990, AM J PHYSIOL, V259, pC19, DOI 10.1152/ajpcell.1990.259.1.C19; BROSH S, 1982, BIOCHIM BIOPHYS ACTA, V717, P459, DOI 10.1016/0304-4165(82)90288-4; CUNNINGHAM CC, 1986, BIOCHIM BIOPHYS ACTA, V885, P12, DOI 10.1016/0167-4889(86)90033-9; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FREUDENRICH CC, 1988, J BIOL CHEM, V263, P8604; GASBARRINI A, 1990, HEPATOLOGY, V12, P928; GASBARRINI A, 1992, J BIOL CHEM, V267, P6654; GASBARRINI A, 1991, GASTROENTEROLOGY, V100, P744; GORES GJ, 1989, J CLIN INVEST, V83, P386, DOI 10.1172/JCI113896; GORES GJ, 1988, AM J PHYSIOL, V255, pC315, DOI 10.1152/ajpcell.1988.255.3.C315; GRINWALD PM, 1987, J MOL CELL CARDIOL, V19, P487, DOI 10.1016/S0022-2828(87)80400-5; HARMAN AW, 1990, BIOCHEM BIOPH RES CO, V170, P477, DOI 10.1016/0006-291X(90)92116-H; HEMS DA, 1970, BIOCHEM J, V120, P105, DOI 10.1042/bj1200105; ILES RA, 1980, BIOCHEM J, V192, P191, DOI 10.1042/bj1920191; JAWOREK D, 1974, METHOD ENZYMAT AN, V4, P2097; LAZDUNSKI M, 1985, J MOL CELL CARDIOL, V17, P1029, DOI 10.1016/S0022-2828(85)80119-X; MAENPAA PH, 1968, SCIENCE, V161, P1253, DOI 10.1126/science.161.3847.1253; MALLOY CR, 1986, BIOCHIM BIOPHYS ACTA, V885, P1, DOI 10.1016/0167-4889(86)90032-7; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MURPHY JG, 1988, AM J PHYSIOL, V254, pH1133, DOI 10.1152/ajpheart.1988.254.6.H1133; NIEMINEN AL, 1990, BIOCHEM BIOPH RES CO, V167, P600, DOI 10.1016/0006-291X(90)92067-A; RIESER S, 1987, METABOLIC EFFECTS DI, P113; SHARMA RJ, 1980, BIOCHIM BIOPHYS ACTA, V630, P414, DOI 10.1016/0304-4165(80)90290-1; SNOWDOWNE KW, 1985, J BIOL CHEM, V260, P1619; STUDER RK, 1987, AM J PHYSIOL, V252, pE467, DOI 10.1152/ajpendo.1987.252.4.E467; STUDER RK, 1989, ENDOCRINOLOGY, V125, P2421, DOI 10.1210/endo-125-5-2421; STUDER RK, 1982, J BIOL CHEM, V257, P7987; STUDER RK, 1989, AM J PHYSIOL, V256, pE392, DOI 10.1152/ajpendo.1989.256.3.E392; TANI M, 1989, CIRC RES, V65, P1054; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Van den Berghe G, 1986, Prog Biochem Pharmacol, V21, P1; YOUNES M, 1988, PHARMACOL TOXICOL, V63, P382, DOI 10.1111/j.1600-0773.1988.tb00972.x	41	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7545	7552						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559992				2022-12-27	WOS:A1992HN48500051
J	TURNER, SR; IRELAND, R; RAWSTHORNE, S				TURNER, SR; IRELAND, R; RAWSTHORNE, S			PURIFICATION AND PRIMARY AMINO-ACID-SEQUENCE OF THE L-SUBUNIT OF GLYCINE DECARBOXYLASE - EVIDENCE FOR A SINGLE LIPOAMIDE DEHYDROGENASE IN PLANT-MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEA LEAF MITOCHONDRIA; RAT-LIVER MITOCHONDRIA; PYRUVATE-DEHYDROGENASE; PSEUDOMONAS-PUTIDA; GLUTATHIONE-REDUCTASE; NUCLEOTIDE-SEQUENCE; MULTIENZYME COMPLEX; MERCURIC REDUCTASE; CLEAVAGE REACTION; H-PROTEIN	In order to purify the lipoamide dehydrogenase associated with the glycine decarboxylase complex of pea leaf mitochondria, the activity of free lipoamide dehydrogenase has been separated from those of the pyruvate and 2-oxoglutarate dehydrogenase complexes under conditions in which the glycine decarboxylase dissociates into its component subunits. This free lipoamide dehydrogenase which is normally associated with the glycine decarboxylase complex has been further purified and the N-terminal amino acid sequence determined. Positive cDNA clones isolated from both a pea leaf and embryo lambda-gt11 expression library using an antibody raised against the purified lipoamide dehydrogenase proved to be the product of a single gene. The amino acid sequence deduced from the open reading frame included a sequence matching that determined directly from the N terminus of the mature protein. The deduced amino acid sequence shows good homology to the sequence of lipoamide dehydrogenase associated with the pyruvate dehydrogenase complex from Escherichia coli, yeast, and humans. The corresponding mRNA is strongly light-induced both in etiolated pea seedlings and in the leaves of mature plants following a period of darkness. The evidence suggests that the mitochondrial enzyme complexes: pyruvate dehydrogenase, 2-oxoglutarate dehydrogenase, and glycine decarboxylase all use the same lipoamide dehydrogenase subunit.	AFRC, JOHN INNES CTR,INST PLANT SCI RES,CAMBRIDGE LAB, COLNEY LANE, NORWICH NR4 7UJ, ENGLAND; MT ALLISON UNIV, DEPT BIOL, SACKVILLE E0A 3C0, NB, CANADA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Mount Allison University			Turner, Simon/K-7580-2012	Turner, Simon/0000-0003-4859-1068				BOURGUIGNON J, 1988, BIOCHEM J, V255, P169, DOI 10.1042/bj2550169; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NL, 1983, BIOCHEMISTRY-US, V22, P4089, DOI 10.1021/bi00286a015; BURNS G, 1989, J BACTERIOL, V171, P665, DOI 10.1128/jb.171.2.665-668.1989; CAROTHERS DJ, 1987, ARCH BIOCHEM BIOPHYS, V256, P597, DOI 10.1016/0003-9861(87)90617-5; CAROTHERS DJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P409, DOI 10.1016/0003-9861(89)90309-3; COVEY SN, 1981, NUCLEIC ACIDS RES, V9, P6735, DOI 10.1093/nar/9.24.6735; DICKINSON JR, 1986, MOL GEN GENET, V204, P103; FOX BS, 1983, BIOCHEMISTRY-US, V22, P4082, DOI 10.1021/bi00286a014; FREUDENBERG W, 1989, J BACTERIOL, V171, P1346, DOI 10.1128/jb.171.3.1346-1354.1989; GUEST JR, 1984, BIOCHEM SOC T, V12, P220, DOI 10.1042/bst0120220; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KIM YH, 1990, J BIOL CHEM, V265, P848; MACHEREL D, 1990, BIOCHEM J, V268, P783, DOI 10.1042/bj2680783; MATUDA S, 1985, BIOCHEM BIOPH RES CO, V129, P479, DOI 10.1016/0006-291X(85)90176-7; MOTOKAWA Y, 1974, ARCH BIOCHEM BIOPHYS, V164, P634, DOI 10.1016/0003-9861(74)90075-7; NEUBURGER M, 1986, FEBS LETT, V207, P18, DOI 10.1016/0014-5793(86)80005-9; OKUMARAIKEDA K, 1991, J BIOL CHEM, V266, P4917; OLIVER DJ, 1990, PLANT PHYSIOL, V94, P833, DOI 10.1104/pp.94.2.833; Randall D. D., 1990, METHODS PLANT BIOCH, V3, P175, DOI [10.1016/B978-0-12-461013-2.50017-4, DOI 10.1016/B978-0-12-461013-2.50017-4]; RICE DW, 1984, J MOL BIOL, V174, P483, DOI 10.1016/0022-2836(84)90332-2; SAKURAI Y, 1970, J BIOL CHEM, V245, P4453; SOKATCH JR, 1984, ARCH BIOCHEM BIOPHYS, V228, P660, DOI 10.1016/0003-9861(84)90036-5; SOKATCH JR, 1983, J BACTERIOL, V153, P969, DOI 10.1128/JB.153.2.969-975.1983; STANSBIE D, 1986, J INHERIT METAB DIS, V9, P105, DOI 10.1007/BF01799447; STEPHENS PE, 1983, EUR J BIOCHEM, V135, P519, DOI 10.1111/j.1432-1033.1983.tb07683.x; TAKENAKA A, 1988, J BIOCHEM-TOKYO, V103, P463, DOI 10.1093/oxfordjournals.jbchem.a122293; TURNER S, 1982, J BIOL CHEM, V267, P5355; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WALKER JL, 1986, J BIOL CHEM, V261, P2214; WALTON NJ, 1986, PLANTA, V167, P119, DOI 10.1007/BF00446378	33	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7745	7750						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560008				2022-12-27	WOS:A1992HN48500077
J	MARKLUND, SL				MARKLUND, SL			REGULATION BY CYTOKINES OF EXTRACELLULAR SUPEROXIDE-DISMUTASE AND OTHER SUPEROXIDE-DISMUTASE ISOENZYMES IN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; OXIDATIVE BURST RESPONSE; HUMAN CELL-LINES; INTERFERON-GAMMA; FACTOR-ALPHA; HYDROGEN-PEROXIDE; MACROPHAGES; RELEASE; BINDING; EXPRESSION	The influence of cytokines on extracellular superoxide dismutase (EC-SOD) expression by human dermal fibroblasts was investigated. The expression was markedly stimulated by interferon-gamma (IFN-gamma), was varying between fibroblast lines stimulated or depressed by interleukin-1-alpha (IL-1-alpha), was intermediately depressed by tumor necrosis factor-alpha (TNF-alpha), and markedly depressed by transforming growth factor-beta (TGF-beta). TNF-alpha, however, enhanced the stimulation by a high dose of IFN-gamma, whereas TGF-beta markedly depressed the stimulations given by IFN-gamma and IL-1-alpha. The ratio between the maximal stimulation and depression observed was around 30-fold. The responses were generally slow and developed over periods of several days. There were no effects of IFN-alpha, IL-2, IL-3, IL-4, IL-6, IL-8, granulocyte-macrophage colony-stimulating factor, human growth hormone, Escherichia coli lipopolysaccharide, leukotriene B4, prostaglandin E2, formylmethionylleucylphenylalanine, platelet-activating factor, and indomethacin. The cytokines influencing the EC-SOD expression are also known to influence superoxide production by leukocytes and other cell types, and the EC-SOD response pattern is roughly compatible with the notion that its function is to protect cells against extracellular superoxide radicals. The results show that EC-SOD is a participant in the complex inflammatory response orchestrated by cytokines. The CuZn-SOD activity of the fibroblasts was not influenced by any of the cytokines, whereas the Mn-SOD activity was depressed by TGF-beta. TNF-alpha, IL-1-alpha, and IFN-gamma stimulated the Mn-SOD activity, as previously known, and these responses were reduced by TGF-beta. The different responses of the three SOD isoenzymes illustrate their different physiological roles.			MARKLUND, SL (corresponding author), UMEA UNIV HOSP, DEPT CLIN CHEM, S-90185 UMEA, SWEDEN.							BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BECKER S, 1990, CELL IMMUNOL, V129, P351, DOI 10.1016/0008-8749(90)90211-9; BERKOW RL, 1987, J IMMUNOL, V139, P3783; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; EDWARDS CK, 1988, SCIENCE, V239, P769, DOI 10.1126/science.2829357; HANCOCK JT, 1990, IMMUNOLOGY, V71, P213; HARRIS CA, 1991, J IMMUNOL, V147, P149; HOFFMAN M, 1987, J LEUKOCYTE BIOL, V42, P704, DOI 10.1002/jlb.42.6.704; KAPP A, 1990, J INVEST DERMATOL, V95, pS94, DOI 10.1111/1523-1747.ep12874836; KARLSSON K, 1988, BIOCHEM J, V255, P223; KARLSSON K, 1988, BIOCHEM J, V256, P29, DOI 10.1042/bj2560029; KARLSSON K, 1987, BIOCHEM J, V242, P55, DOI 10.1042/bj2420055; KARLSSON K, 1988, J CLIN INVEST, V82, P762, DOI 10.1172/JCI113676; KARLSSON K, 1989, LAB INVEST, V60, P659; KHARAZMI A, 1989, IMMUNOL LETT, V21, P177, DOI 10.1016/0165-2478(89)90056-4; KHARAZMI A, 1988, IMMUNOBIOLOGY, V177, P32, DOI 10.1016/S0171-2985(88)80089-5; KOHASE M, 1986, CELL, V45, P659, DOI 10.1016/0092-8674(86)90780-4; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LARRICK JW, 1987, BLOOD, V69, P640; MARKLUND S, 1976, J BIOL CHEM, V251, P7504; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MARKLUND SL, 1990, BIOCHEM J, V266, P213, DOI 10.1042/bj2660213; MARKLUND SL, 1984, BIOCHEM J, V222, P649, DOI 10.1042/bj2220649; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; MARKLUND SL, 1982, CLIN CHIM ACTA, V126, P41, DOI 10.1016/0009-8981(82)90360-6; MARKLUND SL, 1986, ANN RHEUM DIS, V45, P847, DOI 10.1136/ard.45.10.847; MARKLUND SL, 1985, CRC HDB METHODS OXYG, P249; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEIER B, 1990, BIOL CHEM H-S, V371, P1021, DOI 10.1515/bchm3.1990.371.2.1021; NATHAN CF, 1984, J EXP MED, V160, P600, DOI 10.1084/jem.160.2.600; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; PLUTHERO FG, 1990, J CELL BIOL, V111, P1217, DOI 10.1083/jcb.111.3.1217; RADEKE HH, 1990, KIDNEY INT, V37, P767, DOI 10.1038/ki.1990.44; RAITANO AB, 1990, J BIOL CHEM, V265, P10466; SLUNGAARD A, 1990, J EXP MED, V171, P2025, DOI 10.1084/jem.171.6.2025; SMITH PD, 1990, J INFECT DIS, V161, P999, DOI 10.1093/infdis/161.5.999; TIBELL L, 1987, P NATL ACAD SCI USA, V84, P6634, DOI 10.1073/pnas.84.19.6634; TIKU ML, 1990, J IMMUNOL, V145, P690; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; WAHL SM, 1990, ANN NY ACAD SCI, V593, P188, DOI 10.1111/j.1749-6632.1990.tb16111.x; WALTHER Z, 1988, J IMMUNOL, V140, P974; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; YOSHIE O, 1989, J LEUKOCYTE BIOL, V45, P10, DOI 10.1002/jlb.45.1.10	48	191	192	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6696	6701						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551878				2022-12-27	WOS:A1992HM05300038
J	ELENIUS, K; MAATTA, A; SALMIVIRTA, M; JALKANEN, M				ELENIUS, K; MAATTA, A; SALMIVIRTA, M; JALKANEN, M			GROWTH-FACTORS INDUCE 3T3 CELLS TO EXPRESS BFGF-BINDING SYNDECAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; HEPARAN-SULFATE PROTEOGLYCANS; SURFACE PROTEOGLYCAN; FACTOR-BETA; EXTRACELLULAR-MATRIX; MESSENGER-RNA; MESENCHYMAL INTERACTIONS; MONOCLONAL-ANTIBODY; CHONDROITIN SULFATE; MEMBRANE	Syndecan is an integral membrane proteoglycan that putatively binds extracellular matrix molecules and growth factors at the surfaces of several cell types. Syndecan is also transiently expressed in several condensing mesenchymes after epithelial induction. In order to understand the mechanism(s) that regulate(s) syndecan expression in early mesenchymal cells, we have studied the effects of growth factors on the expression of syndecan in 3T3 fibroblasts and compared these results to NMuMG epithelial cells. Our studies indicate that (i) two developmentally important growth factors, basic fibroblast growth factor (bFGF) and transforming growth factor beta(TGF-beta), especially when administrated at the same time, increase syndecan expression in 3T3 cells both at the mRNA and protein level. (ii) Furthermore, the same growth factors also increase syndecan shedding into the culture medium of 3T3 cells. No such stimulation of syndecan synthesis or shedding was observed with NMuMG cells. (iii) Syndecan isolated from the cell surface of bFGF + TGF-beta-treated 3T3 cells binds bFGF. (iv) Induced expression of syndecan correlates with enhanced binding of bFGF to the cell surface of 3T3 cells, and (v) this interaction can be inhibited by exogenous ectodomain of syndecan. These results suggest a key role for growth factors in the regulation of syndecan expression during organogenesis and, moreover, an involvement of syndecan in the regulation of growth factor action.	UNIV TURKU, DEPT MED BIOCHEM, KIINAMYLLYNKATU 10, SF-20520 TURKU 52, FINLAND; TURKU BIOTECHNOL CTR, SF-20521 TURKU, FINLAND	University of Turku				Elenius, Klaus/0000-0001-5700-0827; Maatta, Arto/0000-0003-3759-1310	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009399] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE09399-01] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAVISOTTO LM, 1990, J CELL PHYSIOL, V143, P39, DOI 10.1002/jcp.1041430106; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHIQUET M, 1984, J CELL BIOL, V98, P1926, DOI 10.1083/jcb.98.6.1926; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; HEINO J, 1989, J BIOL CHEM, V264, P380; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INKI P, 1991, IN PRESS AM J PATHOL, V139; INKI P, 1992, IN PRESS LAB INVEST; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; JALKANEN M, 1988, J CELL BIOL, V106, P953, DOI 10.1083/jcb.106.3.953; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; JALKANEN M, 1991, IN PRESS BIOL EXTRAC; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KODA JE, 1985, J BIOL CHEM, V260, P8157; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LEPPA S, 1991, CELL REGUL, V2, P1; LI SW, 1991, CELL GROWTH DIFFER, V2, P195; MALI M, 1990, J BIOL CHEM, V265, P6884; MASSAGUE J, 1984, J BIOL CHEM, V259, P9756; MASSAGUE J, 1991, Current Biology, V1, P117, DOI 10.1016/0960-9822(91)90296-9; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; OFARRELL PH, 1975, J BIOL CHEM, V250, P4004; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RASMUSSEN S, 1988, J CELL BIOL, V107, P1959, DOI 10.1083/jcb.107.5.1959; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROUBIN R, 1990, J CELL BIOL, V111, P673, DOI 10.1083/jcb.111.2.673; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; STAHLI C, 1983, METHOD ENZYMOL, V92, P242; Stoker AW, 1990, CURR OPIN CELL BIOL, V2, P864, DOI 10.1016/0955-0674(90)90085-S; THESLEFF I, 1988, DEV BIOL, V129, P565, DOI 10.1016/0012-1606(88)90401-0; THESLEFF I, 1987, DEVELOPMENT, V101, P289; TRAUTMAN MS, 1991, DEVELOPMENT, V111, P213; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; VAAHTOKARI A, 1991, DEVELOPMENT, V113, P985; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; VAINIO S, 1991, DEV BIOL, V147, P322, DOI 10.1016/0012-1606(91)90290-J; VOGEL A, 1978, P NATL ACAD SCI USA, V75, P2810, DOI 10.1073/pnas.75.6.2810; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	66	126	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6435	6441						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556147				2022-12-27	WOS:A1992HK31800107
J	WAITES, GT; GRAHAM, IR; JACKSON, P; MILLAKE, DB; PATEL, B; BLANCHARD, AD; WELLER, PA; EPERON, IC; CRITCHLEY, DR				WAITES, GT; GRAHAM, IR; JACKSON, P; MILLAKE, DB; PATEL, B; BLANCHARD, AD; WELLER, PA; EPERON, IC; CRITCHLEY, DR			MUTUALLY EXCLUSIVE SPLICING OF CALCIUM-BINDING DOMAIN EXONS IN CHICK ALPHA-ACTININ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-TROPOMYOSIN GENE; BRANCH POINT LOCATION; PRE-MESSENGER-RNA; SKELETAL-MUSCLE; SMOOTH-MUSCLE; SINGLE GENE; STRESS FIBERS; GROWTH-FACTOR; EXPRESSION; PROTEINS	We have determined the complete sequence of chick brain alpha-actinin (892 amino acids; 107,644 Da). The sequence differs from that of smooth muscle alpha-actinin only in the region of the first EF-hand calcium-binding motif, where 27 residues in brain alpha-actinin are replaced by just 22 residues in the smooth muscle isoform. This probably accounts for the different calcium sensitivities of the two isoforms with respect to actin binding. Analysis of the gene structure showed that this region of sequence divergence is encoded by two separate exons whose incorporation is mutually exclusive. We have determined the proportion of the two transcripts in various tissues and cell lines using poly(A)+ RNA and a quantitative assay based on the polymerase chain reaction. MRC-5 fibroblasts and HeLa cells express mRNAs encoding both isoforms, whereas Namalwa lymphoblastoid cells, which lack actin stress fibers, express only the non-muscle mRNA. Both isoforms of alpha-actinin became incorporated into stress fibers and cell-matrix junctions when full-length chick alpha-actinin cDNAs were expressed in monkey COS cells. The levels of chick alpha-actinin mRNAs were found to be serum-inducible, suggesting that alpha-actinin may be an early response gene.	UNIV LEICESTER, DEPT BIOCHEM, UNIV RD, LEICESTER LE1 7RH, ENGLAND	University of Leicester			Eperon, Ian C./E-8799-2011	Eperon, Ian C./0000-0002-4903-1911				ARIMURA C, 1988, EUR J BIOCHEM, V177, P649, DOI 10.1111/j.1432-1033.1988.tb14419.x; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BARON MD, 1987, J BIOL CHEM, V262, P17623; BARON MD, 1987, J BIOL CHEM, V262, P2558; BENNETT JP, 1984, BIOCHEMISTRY-US, V23, P5081, DOI 10.1021/bi00316a039; BENZEEV A, 1990, CELL REGUL, V1, P621, DOI 10.1091/mbc.1.9.621; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; BLATTI SP, 1988, P NATL ACAD SCI USA, V85, P1119, DOI 10.1073/pnas.85.4.1119; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; CLAYTON L, 1988, J MOL BIOL, V201, P507, DOI 10.1016/0022-2836(88)90633-X; DASILVA ACR, 1991, TRENDS BIOCHEM SCI, V16, P53, DOI 10.1016/0968-0004(91)90024-P; DAVISON MD, 1989, INT J BIOL MACROMOL, V11, P81, DOI 10.1016/0141-8130(89)90047-0; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; DRENCKHAHN D, 1986, J CELL BIOL, V102, P1738, DOI 10.1083/jcb.102.5.1738; DUHAIMAN AS, 1984, BIOCHEMISTRY-US, V23, P1600, DOI 10.1021/bi00303a003; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FAY FS, 1983, J CELL BIOL, V96, P783, DOI 10.1083/jcb.96.3.783; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FERAMISCO JR, 1979, P NATL ACAD SCI USA, V76, P3967, DOI 10.1073/pnas.76.8.3967; FYRBERG E, 1990, J CELL BIOL, V110, P1999, DOI 10.1083/jcb.110.6.1999; GALLEGO ME, 1990, MOL CELL BIOL, V10, P2133, DOI 10.1128/MCB.10.5.2133; GEIGER B, 1981, J CELL BIOL, V91, P614, DOI 10.1083/jcb.91.3.614; GEORGE EL, 1989, MOL CELL BIOL, V9, P2957, DOI 10.1128/MCB.9.7.2957; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOBLET C, 1989, NUCLEIC ACIDS RES, V17, P2144, DOI 10.1093/nar/17.5.2144; GOODWIN LO, 1991, J BIOL CHEM, V266, P8408; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; HANKE PD, 1988, MOL CELL BIOL, V8, P3591, DOI 10.1128/MCB.8.9.3591; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; IMAMURA M, 1988, J BIOL CHEM, V263, P7800; JACKSON P, 1989, EUR J CELL BIOL, V50, P162; JACOBS JP, 1970, NATURE, V227, P168, DOI 10.1038/227168a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRINKS MH, 1988, J NEUROSCI, V8, P2172; LANDON F, 1985, EUR J BIOCHEM, V153, P231, DOI 10.1111/j.1432-1033.1985.tb09291.x; LANGANGER G, 1986, J CELL BIOL, V102, P200, DOI 10.1083/jcb.102.1.200; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LIBRI D, 1989, J BIOL CHEM, V264, P2935; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; LINDQUESTER GJ, 1989, NUCLEIC ACIDS RES, V17, P2099, DOI 10.1093/nar/17.5.2099; MACLEOD AR, 1988, MOL CELL BIOL, V8, P433, DOI 10.1128/MCB.8.1.433; Maniatis T., 1982, MOL CLONING; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEDFORD RM, 1984, CELL, V38, P409, DOI 10.1016/0092-8674(84)90496-3; MEIGS JB, 1986, J CELL BIOL, V102, P1430, DOI 10.1083/jcb.102.4.1430; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; MIMURA N, 1986, J BIOL CHEM, V261, P680; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; NADALGINARD B, 1991, ADV ENZYME REGUL, V31, P261, DOI 10.1016/0065-2571(91)90017-G; NISHIYAMA M, 1990, CANCER RES, V50, P6291; NOBLE JCS, 1988, GENE DEV, V2, P1460, DOI 10.1101/gad.2.11.1460; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; NOEGEL AA, 1989, CELL MOTIL CYTOSKEL, V14, P69, DOI 10.1002/cm.970140114; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; NYORMOI O, 1973, INT J CANCER, V12, P396, DOI 10.1002/ijc.2910120211; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; RIVERA V M, 1990, New Biologist, V2, P751; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; Rosenthal N, 1989, CURR OPIN CELL BIOL, V1, P1094, DOI 10.1016/S0955-0674(89)80056-0; RYSECK RP, 1989, EXP CELL RES, V180, P537, DOI 10.1016/0014-4827(89)90080-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; WALLRAFF E, 1986, EMBO J, V5, P61, DOI 10.1002/j.1460-2075.1986.tb04178.x; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WIECZOREK DF, 1988, MOL CELL BIOL, V8, P679, DOI 10.1128/MCB.8.2.679; WIRZ T, 1990, J BIOL CHEM, V265, P11656; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752	79	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6263	6271						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556133				2022-12-27	WOS:A1992HK31800082
J	BANERJEE, A; ROACH, MC; TRCKA, P; LUDUENA, RF				BANERJEE, A; ROACH, MC; TRCKA, P; LUDUENA, RF			PREPARATION OF A MONOCLONAL-ANTIBODY SPECIFIC FOR THE CLASS-IV ISOTYPE OF BETA-TUBULIN - PURIFICATION AND ASSEMBLY OF ALPHA-BETA-II, ALPHA-BETA-III, AND ALPHA-BETA-IV TUBULIN DIMERS FROM BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TAU; MICROTUBULE; IDENTIFICATION; LOCALIZATION; EXPRESSION; SEQUENCES	Tubulin, the 100-kDa subunit protein of microtubules, is a heterodimer of two 50-kDa subunits, alpha and beta. Both alpha and beta-subunits exist as numerous isotypic forms. There are four isotypes of beta-tubulin in bovine brain tubulin preparations; their designations and relative abundances in these preparations are as follows: beta(I), 3%; beta(II), 58%; beta(III), 25%; and beta(IV), 13%. We have previously reported the preparation of monoclonal antibodies specific for beta(II) and beta(III) (Banerjee, A., Roach, M. C., Wall, K. A., Lopata, M. A., Cleveland, D. W., and Luduena, R. F. (1988) J. Biol. Chem. 263, 3029-3034; Banerjee, A., Roach, M. C., Trcka, P., and Luduena, R. F. (1990) J. Biol. Chem. 265, 1794-1799). We here report the preparation of a monoclonal antibody specific for beta(IV). By using this antibody together with those specific for beta(II) and beta(III), we have prepared isotypically pure tubulin dimers with the composition alpha-beta(II), alpha-beta(III), and alpha-beta(IV). We have found that, in the presence of microtubule-associated proteins, all three dimers assemble into microtubules considerably faster and to a greater extent than does unfractionated tubulin. More assembly was noted with alpha-beta(II) and alpha-beta(III) than with alpha-beta(IV). When assembly is measured in the presence of taxol (10-mu-M), little difference is seen among the isotypically purified dimers or between them and unfractionated tubulin. These results indicate that the assembly properties of a tubulin preparation are influenced by its isotypic composition and raise the possibility that the structural differences among tubulin isotypes may have functional significance.			BANERJEE, A (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023476] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23476] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE A, 1989, Journal of Cell Biology, V109, p338A; BANERJEE A, 1990, J BIOL CHEM, V265, P1794; BANERJEE A, 1988, J BIOL CHEM, V263, P3029; BANERJEE A, 1991, J BIOL CHEM, V266, P1689; BHATTACHARYYA B, 1985, J BIOL CHEM, V260, P208; CROSS D, 1991, BIOCHEMISTRY-US, V30, P4362, DOI 10.1021/bi00231a036; DEGARCINI EM, 1986, BIOCHIM BIOPHYS ACTA, V881, P456, DOI 10.1016/0304-4165(86)90039-5; Dustin P., 1984, MICROTUBULES; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; Fulton C., 1976, CELL MOTILITY, P987; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; HIGGINS RC, 1979, ANAL BIOCHEM, V93, P257, DOI 10.1016/S0003-2697(79)80077-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LITTLE M, 1988, COMP BIOCHEM PHYS B, V90, P655, DOI 10.1016/0305-0491(88)90320-3; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDUENA RF, 1977, J BIOL CHEM, V252, P7006; LUDUENA RF, 1982, BIOCHEMISTRY-US, V21, P4787, DOI 10.1021/bi00262a041; MACCIONI RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P568, DOI 10.1016/0003-9861(89)90403-7; ROACH M C, 1988, Journal of Cell Biology, V107, p22A; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WANG D, 1986, J CELL BIOL, V103, P1903, DOI 10.1083/jcb.103.5.1903; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043	28	121	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5625	5630						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544937				2022-12-27	WOS:A1992HH74700093
J	KNOLL, LJ; LEVY, MA; STAHL, PD; GORDON, JI				KNOLL, LJ; LEVY, MA; STAHL, PD; GORDON, JI			ANALYSIS OF THE COMPARTMENTALIZATION OF MYRISTOYL-COA - PROTEIN N-MYRISTOYLTRANSFERASE IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS-1; ADP-RIBOSYLATION FACTOR; MURINE LEUKEMIA-VIRUS; FATTY-ACID SYNTHETASE; ACYL-COENZYME-A; ALPHA-ACETYLTRANSFERASE; ESCHERICHIA-COLI; ANTIBIOTIC CERULENIN; NUCLEOTIDE-SEQUENCE; FAS1 GENE	Myristoyl-CoA:protein N-myristoyltransferase (NMT) catalyzes the cotranslational, covalent attachment of a rare fatty acid, myristic acid (C14:0), to the amino-terminal glycine residue of a number of eukaryotic proteins involved in cellular growth and signal transduction as well as several viral proteins necessary for assembly-replication. NMT has become a target for both anti-viral and anti-fungal therapy. Analysis of purified Saccharomyces cerevisiae NMT plus yeast strains with conditional lethal nmt1 mutations have provided insights about how this process is regulated in vivo. We have now defined the location of NMT in two strains of S. cerevisiae to better understand the functional and spatial relationships between this enzyme and cellular systems that generate its acyl-CoA and peptide ligands. Western blot studies using an affinity purified antibody raised in rabbits against purified S. cerevisiae NMT indicate that the acyltransferase represents 0.06% of total cellular proteins in an exponentially growing haploid strain with a wild type NMT1 allele. Another strain containing a single, integrated copy of a GAL1/NMT1 fusion gene and a nmt1 null allele had 12-fold higher levels of NMT when grown on galactose-containing media. This increase in NMT production had no detectable effects on growth or cellular morphology. Cell fractionation studies, confocal fluorescence immunocytochemical analysis, and immunogold electron microscopic surveys of fixed, gelatin-embedded cryosections of both strains revealed that NMT is a cytosolic protein that is not associated with cellular membranes (including the endoplasmic reticulum and plasma membrane), the nucleus, mitochondria, Golgi apparatus, or vacuoles. This finding is discussed in light of what is known about the location and activities of enzymes involved in de novo fatty acid biosynthesis and in amino-terminal processing of nascent proteins.	WASHINGTON UNIV, SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Stahl, Philip/D-6315-2012		NIAID NIH HHS [AI27179, AI30188] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030188, U01AI027179] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; AWAYA J, 1975, BIOCHIM BIOPHYS ACTA, V409, P267, DOI 10.1016/0005-2760(75)90022-3; BLACK PN, 1987, J BIOL CHEM, V262, P1412; BLACK PN, 1991, J BACTERIOL, V173, P435, DOI 10.1128/jb.173.2.435-442.1991; BLUMER KJ, 1991, ANNU REV PHYSIOL, V53, P37; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BRYANT ML, 1991, P NATL ACAD SCI USA, V88, P2055, DOI 10.1073/pnas.88.6.2055; BRYANT ML, 1989, P NATL ACAD SCI USA, V86, P8655, DOI 10.1073/pnas.86.22.8655; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHIRALA SS, 1987, J BIOL CHEM, V262, P4231; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CYERT MS, 1991, YEAST CELL BIOL, P224; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; Erwin J., 1973, LIPIDS BIOMEMBRANES, P41, DOI [10.1016/B978-0-12-242050-4.50008-2, DOI 10.1016/B978-0-12-242050-4.50008-2]; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; FULCO AJ, 1974, ANNU REV BIOCHEM, V43, P215, DOI 10.1146/annurev.bi.43.070174.001243; GEUZE HJ, 1980, EUR J CELL BIOL, V21, P93; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HEUCKEROTH RO, 1990, J LIPID RES, V31, P1121; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KAMEDA K, 1981, J BIOL CHEM, V256, P5702; KAMIRYO T, 1977, AGR BIOL CHEM TOKYO, V41, P1295, DOI 10.1080/00021369.1977.10862664; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KLEIN K, 1971, EUR J BIOCHEM, V19, P442, DOI 10.1111/j.1432-1033.1971.tb01334.x; KUMAR GB, 1991, J BIOL CHEM, V266, P1348; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE FJS, 1990, J BIOL CHEM, V265, P3603; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; LEE FJS, 1989, FEBS LETT, V256, P139, DOI 10.1016/0014-5793(89)81734-X; LEE FJS, 1988, J BIOL CHEM, V263, P14948; LEE FJS, 1989, J BIOL CHEM, V264, P12339; LEE FJS, 1990, J BIOL CHEM, V265, P11576; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNEN F, 1980, EUR J BIOCHEM, V112, P431; LYNEN F, 1969, METHOD ENZYMOL, V14, P17; MEYER KH, 1974, J BACTERIOL, V117, P345, DOI 10.1128/JB.117.2.345-350.1974; MISHINA M, 1980, EUR J BIOCHEM, V111, P79; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MOHAMED AH, 1988, J BIOL CHEM, V263, P12315; OLMSTED JB, 1986, METHOD ENZYMOL, V134, P467; ORME TW, 1972, EUR J BIOCHEM, V24, P407, DOI 10.1111/j.1432-1033.1972.tb19700.x; PERSSON B, 1985, EUR J BIOCHEM, V152, P523, DOI 10.1111/j.1432-1033.1985.tb09227.x; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RHEE SS, 1987, J VIROL, V61, P1045, DOI 10.1128/JVI.61.4.1045-1053.1987; ROISE D, 1988, J BIOL CHEM, V263, P4509; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; SCHWEIZER E, 1978, MOL CELL BIOCHEM, V21, P95; SCHWEIZER E, 1987, FETT WISS TECHNOL, V89, P570; SCHWEIZER M, 1986, MOL GEN GENET, V203, P479, DOI 10.1007/BF00422073; SHOJI S, 1988, J BIOCHEM-TOKYO, V103, P747, DOI 10.1093/oxfordjournals.jbchem.a122340; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SMITH RH, 1986, ARCH BIOCHEM BIOPHYS, V244, P357, DOI 10.1016/0003-9861(86)90124-4; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978	85	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5366	5373						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544917				2022-12-27	WOS:A1992HH74700057
J	BOUDIER, C; BIETH, JG				BOUDIER, C; BIETH, JG			THE PROTEINASE - MUCUS PROTEINASE-INHIBITOR BINDING STOICHIOMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE PROTEASE INHIBITOR; COOH-TERMINAL DOMAIN; AMINO-ACID SEQUENCE; BRONCHIAL INHIBITOR; ALPHA-1-PROTEINASE INHIBITOR; ALPHA-CHYMOTRYPSIN; HUMAN SPUTUM; HUSI-I; ELASTASE; ANTILEUKOPROTEASE	In the nanomolar enzyme and inhibitor concentration range, 1 mol of mucus proteinase inhibitor (MPI) inhibits 1 mol of neutrophil elastase, cathepsin G, trypsin, and chymotrypsin. In the micromolar concentration range, the enzyme:inhibitor binding stoichiometry is still 1:1 for elastase but shifts to 2:1 for the three other proteinases. These data could be confirmed by three nonenzymatic methods: (i) fluorescence anisotropy measurements of mixtures of proteinases with 5-dimethylaminonaphthalene-1-sulfonylated or fluoresceinylated MPI, (ii) absorption spectroscopy of fluorescein-MPI-proteinase complexes isolated by gel filtration, (iii) analytical ultracentrifugation which showed that the molecular mass of the MPI-chymotrypsin complex is 56 kDa, whereas that of the MPI-elastase complex is 39 kDa. The binary MPI-elastase complex is unable to inhibit trypsin or cathepsin G. On the other hand, 1 mol of elastase displaces 2 mol of trypsin or cathepsin G from their ternary complexes with MPI.			BOUDIER, C (corresponding author), UNIV LOUIS PASTEUR,INSERM,U237,ENZYMOL LAB,F-67400 ILLKIRCH GRAFFENS,FRANCE.		Boudier, Christian/N-3841-2018	Boudier, Christian/0000-0002-5534-6389				BIETH J, 1974, BIOCHEM MED METAB B, V11, P350, DOI 10.1016/0006-2944(74)90134-3; Bieth J., 1974, BAYER S, P463; BOUDIER C, 1989, BIOCHIM BIOPHYS ACTA, V995, P36, DOI 10.1016/0167-4838(89)90230-6; BOUDIER C, 1987, BIOL CHEM H-S, V368, P981, DOI 10.1515/bchm3.1987.368.2.981; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCH M, 1986, BIOCHEM J, V238, P269, DOI 10.1042/bj2380269; CH'U HSIEN-MIN, 1965, ACTA BIOCHIM ET BIOPHYS SINICA, V5, P519; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CHEN RF, 1968, ANAL BIOCHEM, V25, P412, DOI 10.1016/0003-2697(68)90116-4; EISENBERG SP, 1990, J BIOL CHEM, V265, P7976; FRITZ H, 1988, BIOL CHEM H-S, V369, P79; GENNIS LS, 1972, BIOCHEMISTRY-US, V11, P2517, DOI 10.1021/bi00763a021; GRUTTER MG, 1988, EMBO J, V7, P345, DOI 10.1002/j.1460-2075.1988.tb02819.x; KRAMPS JA, 1990, BIOCHIM BIOPHYS ACTA, V1038, P178, DOI 10.1016/0167-4838(90)90202-Q; KRAMPS JA, 1984, AM REV RESPIR DIS, V129, P959; MARTODAM RR, 1979, PREP BIOCHEM, V9, P15, DOI 10.1080/00327487908061669; MECKELEIN B, 1990, PROTEIN ENG, V3, P215, DOI 10.1093/protein/3.3.215; MERCOLA DA, 1972, BIOCHEMISTRY-US, V11, P3860, DOI 10.1021/bi00771a005; OHLSSON K, 1976, SCAND J CLIN LAB INV, V36, P437, DOI 10.3109/00365517609054461; POWERS JC, 1984, J BIOL CHEM, V259, P4288; SCHIESSLER H, 1978, NEUTRAL PROTEASES HU, P185; SCHONBAUM G, 1961, J BIOL CHEM, V236, P2930; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; SMITH CE, 1985, BIOCHEM J, V225, P463, DOI 10.1042/bj2250463; STELLER G, 1986, NUCLEIC ACIDS RES, V14, P7883; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; TOURNIER JM, 1983, ANAL BIOCHEM, V131, P345, DOI 10.1016/0003-2697(83)90181-1; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255	28	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4370	4375						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537827				2022-12-27	WOS:A1992HF64200020
J	SHAPIRO, SD; GRIFFIN, GL; GILBERT, DJ; JENKINS, NA; COPELAND, NG; WELGUS, HG; SENIOR, RM; LEY, TJ				SHAPIRO, SD; GRIFFIN, GL; GILBERT, DJ; JENKINS, NA; COPELAND, NG; WELGUS, HG; SENIOR, RM; LEY, TJ			MOLECULAR-CLONING, CHROMOSOMAL LOCALIZATION, AND BACTERIAL EXPRESSION OF A MURINE MACROPHAGE METALLOELASTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALVEOLAR MACROPHAGES; HUMAN FIBROBLAST COLLAGENASE; HUMAN SYNOVIAL-CELLS; STIMULATES COLLAGENASE; ELASTIN DEGRADATION; CATHEPSIN-G; HUMAN-LUNG; INHIBITOR; GENE; METALLOPROTEINASE	Murine macrophages have previously been shown to secrete a zinc-dependent proteinase that can degrade elastin. In this report, we identify murine macrophage elastase (MME) cDNA and show that it is a distinct member of the metalloproteinase gene family. Small amounts of MME were purified to homogeneity, and N-terminal amino acid sequence was obtained. This sequence was used to obtain a partial cDNA clone by the polymerase chain reaction; a cDNA library derived from a mouse macrophage-like cell line (P388D1) was screened with this probe. A full-length MME cDNA spanning approximately 1.8 kilobases contained an open reading frame of 1386 base pairs; the predicted molecular mass of the MME proenzyme is 53 kDa. The gene encoding MME is represented only once in the mouse genome and is located on chromosome 9. Despite a size that is similar to other metalloproteinases, MME is distinct, sharing only 33-48% amino acid homology with other metalloproteinases. In contrast to other metalloenzymes, MME appears to be rapidly processed to an active truncated form (N-terminal and C-terminal cleavage). We expressed recombinant MME in Escherichia coli and demonstrated that it has significant elastolytic activity that is specifically inhibited by the tissue inhibitor of metalloproteinases. MME is therefore a true metalloproteinase that may be involved in tissue injury and remodeling.	NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT GENET,DIV DERMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	SHAPIRO, SD (corresponding author), WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DIV RESP & CRIT CARE,ST LOUIS,MO 63110, USA.				NCI NIH HHS [N01-CO-74101, CA49712] Funding Source: Medline; NHLBI NIH HHS [HL29594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBIN RJ, 1987, AM REV RESPIR DIS, V135, P1281; BANDA MJ, 1985, J CLIN INVEST, V75, P1758, DOI 10.1172/JCI111887; BANDA MJ, 1987, METHOD ENZYMOL, V144, P288; BANDA MJ, 1981, BIOCHEM J, V193, P589, DOI 10.1042/bj1930589; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; BUDARF M, 1990, GENOMICS, V8, P575, DOI 10.1016/0888-7543(90)90047-X; CAMPBELL EJ, 1979, J CLIN INVEST, V64, P824, DOI 10.1172/JCI109530; CHARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CURY JD, 1988, J IMMUNOL, V141, P4306; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DAYER JM, 1979, J CLIN INVEST, V64, P1386, DOI 10.1172/JCI109596; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Green EL, 1981, GENETICS PROBABILITY, P77; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HOHN PA, 1989, J BIOL CHEM, V264, P13412; HUNNINGHAKE GW, 1979, AM J PATHOL, V97, P149; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KESHET E, 1989, EMBO J, V8, P2917, DOI 10.1002/j.1460-2075.1989.tb08441.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LES EP, 1975, MOUSE NEWS LETT, V53, P34; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NIEWOEHNER DE, 1988, J LAB CLIN MED, V111, P15; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; OKADA Y, 1989, FEBS LETT, V249, P353, DOI 10.1016/0014-5793(89)80657-X; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; REILLY JJ, 1989, BIOCHEM J, V257, P493, DOI 10.1042/bj2570493; Roths J. B., 1978, MOUSE NEWS LETT, V58, P50; Sambrook J, 1989, MOL CLONING LABORATO; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SENIOR RM, 1989, AM REV RESPIR DIS, V139, P1251, DOI 10.1164/ajrccm/139.5.1251; SENIOR RM, 1988, PULMONARY DISEASES D, P1209; SHAPIRO SD, 1991, J IMMUNOL, V146, P2724; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WERB Z, 1975, J EXP MED, V142, P361, DOI 10.1084/jem.142.2.361; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	52	191	197	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4664	4671						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537850				2022-12-27	WOS:A1992HF64200060
J	CHOW, KC; XUE, H; SHI, W; WONG, JT				CHOW, KC; XUE, H; SHI, W; WONG, JT			MUTATIONAL IDENTIFICATION OF AN ESSENTIAL TRYPTOPHAN IN TRYPTOPHANYL RNA-TRANSFER SYNTHETASE OF BACILLUS-SUBTILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; STRUCTURAL GENE; CLONING; MUTAGENESIS; PROTEIN	The strongly conserved single tryptophan residue, Trp92, in Bacillus subtilis tryptophanyl-tRNA synthetase has been mutagenized via site direction singly into Gln, Ala, and Phe. All three mutant enzymes were inactive toward the catalysis of tRNA tryptophanylation. The Trp92 --> Phe mutant has been subcloned into the high expression plasmid pKK223-3 to yield the recombinant plasmid pKSW-F92. Growth of bacteria carrying the latter plasmid made possible the purification of the mutant TrpRS-F92 enzyme to homogeneity. This mutant enzyme was deficient in ultraviolet absorbance and fluorescence relative to the wild type enzyme and inactive in the partial reaction of Trp-activation as well as the overall reaction of tRNA tryptophanylation. Furthermore, unlike the wild type B. subtilis trpS gene, the mutant trpS-F92 gene upon transformation into Escherichia coli trpS 10343 failed to complement the temperature sensitive trpS mutation of the host cells. Trp92 therefore represents an essential residue both in vitro and in vivo for the function of the tryptophanyl-tRNA synthetase.			CHOW, KC (corresponding author), UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA.			Wong, J. Tze-Fei/0000-0001-8539-8537				BARSTOW DA, 1986, GENE, V46, P37, DOI 10.1016/0378-1119(86)90164-2; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CHOW KC, 1988, GENE, V73, P537; DAVIE EW, 1962, METHOD ENZYMOL, V5, P718, DOI 10.1016/S0076-6879(62)05300-8; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DOOLITTLE WF, 1968, J BACTERIOL, V95, P1283, DOI 10.1128/JB.95.4.1283-1294.1968; HALL CV, 1982, J BIOL CHEM, V257, P6132; KHAMIS MI, 1987, J BIOL CHEM, V262, P10938; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P342; MYERS AM, 1985, J BIOL CHEM, V260, P5371; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; SHI W, 1989, BIOCH CELL BIOL, V68, P492; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; XU ZJ, 1989, J BIOL CHEM, V264, P4304; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	15	11	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9146	9149						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577751				2022-12-27	WOS:A1992HR85400069
J	PAN, YT; DEGESPARI, R; WARREN, CD; ELBEIN, AD				PAN, YT; DEGESPARI, R; WARREN, CD; ELBEIN, AD			FORMATION OF UNUSUAL MANNOSAMINE-CONTAINING LIPID-LINKED OLIGOSACCHARIDES IN MADIN-DARBY CANINE KIDNEY-CELL-CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLCNAC; PROTEIN GLYCOSYLATION; PARTIAL-PURIFICATION; GLUCOSE STARVATION; BIOSYNTHESIS; MANNOSYLTRANSFERASE; PATHWAY; SACCHARIDES; TRANSFERASE; AMPHOMYCIN	Glc3Man9(GlcNAC)2-pyrophosphoryl-dolichol is the major lipid-linked oligosaccharide (LLO) produced by Madin-Darby canine kidney cells in culture. However, when these cells are incubated in the presence of millimolar concentrations of mannosamine and labeled with [2-H-3]mannose, they accumulate various LLO that have smaller-sized oligosaccharides with unusual structures and the GlC3Man9(GlcNAc)2-pyrophosphoryl-dolichol is not detected. Thus in the presence of 10 mm mannosamine, more than 80% of the oligosaccharides are eluted from concanavalin A-Sepharose with 10 mM alpha-methylglucoside, indicating that they no longer have the tight-binding characteristics of control oligosaccharides. In addition, 20-40% of these oligosaccharides bind to Dowex 50-H+, indicating the presence of mannosamine in these structures. Interestingly enough, these abnormal oligosaccharides are still transferred to protein. The mannosamine-induced oligosaccharides were separated into neutral and basic fractions on a cation exchange resin. The neutral oligosaccharides ranged in size from hexose3(GlcNAc)2 to hexose10(GlcNAc)2 with the major species being Man5(GlcNAC)2 to Man7(GlcNAC)2. These oligosaccharides were almost completely susceptible to digestion by alpha-mannosidase and by endoglucosaminidase H. The basic oligosaccharides showed anomolous behavior on the Bio-Gel P-4 columns and appeared to be of small size on the standard columns, ranging from hexose2 to hexose4. However, most of these oligosaccharides were susceptible to digestion by endoglucosaminidase H as well as by alpha-mannosidase, suggesting that they were of different size and structure than would be predicted from the gel filtration patterns. Significantly, when the basic oligosaccharides were subjected to chemical N-acetylation, or when the gel filtration columns were run at high pH rather than at the usual pH of 3.0, the basic oligosaccharides migrated like much larger oligosaccharides. These data provide strong evidence to indicate that some mannosamine can be incorporated into the LLO, and that these mannosamine-containing oligosaccharides exhibit unusual properties. Preliminary studies indicated that Madin-Darby canine kidney cells do incorporate label from [H-3]mannosamine into the LLO.	HARVARD UNIV,SCH MED,LOVETT LABS,CARBOHYDRATE UNIT,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP E,BOSTON,MA 02129	Harvard University; Harvard Medical School	PAN, YT (corresponding author), UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040930, R01DK021800] Funding Source: NIH RePORTER; NCRR NIH HHS [SO7RR05486-28] Funding Source: Medline; NIDDK NIH HHS [DK-21800, DK-40930] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODANSZKY M, 1973, J AM CHEM SOC, V95, P2352, DOI 10.1021/ja00788a040; CHAMBERS J, 1977, J BIOL CHEM, V252, P2498; COUTO JR, 1984, J BIOL CHEM, V259, P378; DATEMA R, 1980, EUR J BIOCHEM, V110, P355, DOI 10.1111/j.1432-1033.1980.tb04875.x; DEGESPARI R, 1991, J BIOL CHEM, V266, P16556; DISTLER JJ, 1958, J BIOL CHEM, V230, P497; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELBEIN AD, 1979, ANNU REV PLANT PHYS, V30, P239, DOI 10.1146/annurev.pp.30.060179.001323; GERSHMAN H, 1981, J BIOL CHEM, V256, P7774; HASELBECK A, 1982, P NATL ACAD SCI-BIOL, V79, P1520, DOI 10.1073/pnas.79.5.1520; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JENSEN JW, 1981, J BIOL CHEM, V256, P2899; JENSEN JW, 1985, EUR J BIOCHEM, V153, P41, DOI 10.1111/j.1432-1033.1985.tb09264.x; KANG MS, 1978, BIOCHEM BIOPH RES CO, V82, P568, DOI 10.1016/0006-291X(78)90912-9; KANG MS, 1978, J BIOL CHEM, V253, P8860; KAUSHAL GP, 1986, PLANT PHYSIOL, V82, P748, DOI 10.1104/pp.82.3.748; KAUSHAL GP, 1985, J BIOL CHEM, V260, P6303; KAUSHAL GP, 1986, PLANT PHYSIOL, V81, P1086, DOI 10.1104/pp.81.4.1086; KAUSHAL GP, 1987, BIOCHEMISTRY-US, V26, P7953, DOI 10.1021/bi00398a061; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; MATERN H, 1990, EUR J BIOCHEM, V190, P99, DOI 10.1111/j.1432-1033.1990.tb15551.x; MATSUMOTO A, 1983, BIOCHEMISTRY-US, V22, P188, DOI 10.1021/bi00270a028; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; PAN YT, 1985, ARCH BIOCHEM BIOPHYS, V242, P447, DOI 10.1016/0003-9861(85)90229-2; PAN YT, 1979, J BACTERIOL, V139, P507, DOI 10.1128/JB.139.2.507-514.1979; PAN YT, 1982, J BIOL CHEM, V257, P2795; PLOUHAR PL, 1983, J BIOL CHEM, V258, P2988; REARICK JI, 1981, J BIOL CHEM, V256, P6255; SCHUTZBACH JS, 1980, J BIOL CHEM, V255, P4170; SCHWARZ RT, 1982, ADV CARBOHYD CHEM BI, V40, P287, DOI 10.1016/S0065-2318(08)60111-0; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; SHARMA CB, 1990, BIOCHEMISTRY-US, V29, P8901, DOI 10.1021/bi00490a004; SHARMA CB, 1982, EUR J BIOCHEM, V126, P319; TURCO SJ, 1980, ARCH BIOCHEM BIOPHYS, V205, P330, DOI 10.1016/0003-9861(80)90115-0; WAECHTER CJ, 1976, ANNU REV BIOCHEM, V45, P95, DOI 10.1146/annurev.bi.45.070176.000523; WARREN CD, 1983, CARBOHYD RES, V116, P171, DOI 10.1016/0008-6215(83)88107-5; [No title captured]	39	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8991	8999						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577737				2022-12-27	WOS:A1992HR85400046
J	YANG, SW; CHAN, JYH				YANG, SW; CHAN, JYH			ANALYSIS OF THE FORMATION OF AMP-DNA INTERMEDIATE AND THE SUCCESSIVE REACTION BY HUMAN DNA LIGASE-I AND LIGASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE COMPLEX; MOLECULAR-FORMS; RAT-LIVER; IDENTIFICATION; PURIFICATION; MECHANISM; RESIDUE; CELLS; SITE	DNA ligation catalyzed by all DNA ligases involves two intermediary steps, the formation of the ligase-AMP and the AMP-DNA complexes. A method was developed to purify and analyze the AMP-DNA intermediate from the DNA ligation reaction catalyzed by DNA ligases. This AMP-DNA complex was maximally accumulated by preincubation of human DNA ligase I or II with ATP, followed by interaction with the DNA substrate for 5 s at 0-degrees-C. The gel-purified AMP-DNA complex maintained its property as a ligation intermediate. The AMP was directly linked to the 5'-phosphate of DNA with a pyrophosphate bond. The successive ligation reaction following the AMP-DNA complex formation required DNA ligase and Mg2+ ion but was inhibited by ATP and pyridoxal 5'-phosphate, indicating that the availability of the AMP binding site in the enzyme is essential for the completion of the reaction. Furthermore, the formation of the AMP-DNA complex and the subsequent DNA ligation were substrate specific for human DNA ligases I and II. These data, together with previously reported results, suggest that a major difference between human DNA ligases I and II is in their DNA-binding domains. The methods make it convenient to study in depth the kinetics of the overall DNA ligation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA047276, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA47276, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRAND JE, 1986, J BIOL CHEM, V261, P9079; BANKS GR, 1985, BIOCHIM BIOPHYS ACTA, V826, P180, DOI 10.1016/0167-4781(85)90004-1; DIFFLEY JFX, 1988, J BIOL CHEM, V263, P14669; DONG Q, 1990, J BIOL CHEM, V265, P6235; ELDER RH, 1990, BIOCHEMISTRY-US, V29, P6009, DOI 10.1021/bi00477a019; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; GELLERT M, 1967, P NATL ACAD SCI USA, V57, P148, DOI 10.1073/pnas.57.1.148; GUMPORT RI, 1971, P NATL ACAD SCI USA, V68, P2559, DOI 10.1073/pnas.68.10.2559; HALL ZW, 1969, J BIOL CHEM, V244, P43; HARVEY CL, 1971, J BIOL CHEM, V246, P4523; HINZ HR, 1990, J BIOL CHEM, V265, P10260; LASKO DD, 1990, MUTAT RES, V236, P277, DOI 10.1016/0921-8777(90)90011-S; LEHMAN IR, 1974, SCIENCE, V186, P790; LITTLE JW, 1967, P NATL ACAD SCI USA, V58, P2004, DOI 10.1073/pnas.58.5.2004; MANIATIS T, 1982, MOL CLONING LABORATO, P133; MEZZINA M, 1987, EUR J BIOCHEM, V162, P325, DOI 10.1111/j.1432-1033.1987.tb10604.x; NOY GCF, 1973, EUR J BIOCHEM, V39, P343; OLIVERA BM, 1968, P NATL ACAD SCI USA, V61, P237, DOI 10.1073/pnas.61.1.237; OLIVERA BM, 1967, P NATL ACAD SCI USA, V57, P1426, DOI 10.1073/pnas.57.5.1426; RABIN BA, 1987, J BIOL CHEM, V262, P14105; SODERHALL S, 1976, FEBS LETT, V67, P1, DOI 10.1016/0014-5793(76)80858-7; SODERHALL S, 1975, EUR J BIOCHEM, V51, P129, DOI 10.1111/j.1432-1033.1975.tb03913.x; SODERHALL S, 1973, J BIOL CHEM, V248, P672; SODERHALL S, 1975, J BIOL CHEM, V250, P8438; TERAOKA H, 1986, BIOCHIM BIOPHYS ACTA, V873, P297, DOI 10.1016/0167-4838(86)90057-9; TERAOKA H, 1986, J BIOL CHEM, V261, P6888; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; YANG SW, 1990, J BIOL CHEM, V265, P18130; YANG SW, 1992, J BIOL CHEM, V267, P2345; YANG SW, 1992, IN PRESS P NATL ACAD	31	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8117	8122						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569068				2022-12-27	WOS:A1992HQ18500025
J	ANDREWS, LG; MARKERT, ML				ANDREWS, LG; MARKERT, ML			EXON SKIPPING IN PURINE NUCLEOSIDE PHOSPHORYLASE MESSENGER-RNA PROCESSING LEADING TO SEVERE IMMUNODEFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN GENE; ADENOSINE-DEAMINASE; SPLICE SITE; DNA; THALASSEMIA; SEQUENCE; POLYMERASE; EXPRESSION; MUTATIONS; ACID	We report a defect in splicing of precursor messenger RNA (pre-mRNA) resulting from a naturally occurring mutation of the gene encoding purine nucleoside phosphorylase (PNP) in a patient with PNP-deficient severe combined immunodeficiency. This defect results from a G to T transversion at the terminal nucleotide of exon 2 within the 5' splice site of intron 2 and causes skipping of exon 2 during processing of PNP pre-mRNA. Translation of the misspliced mRNA results in a reading frameshift at the exon 1-exon 3 junction. The predicted polypeptide encoded by the aberrant mRNA is severely truncated, terminating at 31 amino acids. Only 4 residues at the NH2 terminus of the polypeptide correspond to PNP amino acids. Otherwise the translation product of the misspliced mRNA differs completely from PNP in amino acid sequence and has no PNP activity. The finding of exon skipping in PNP is the first report of a splicing defect resulting in PNP-deficient severe combined immunodeficiency. Analysis of the genomic context of the G-1 to T mutation of the 5' splice site lends support for the exon definition model of pre-mRNA splicing and contributes to the understanding of splice site selection.	DUKE UNIV,MED CTR,DEPT PEDIAT,BOX 3068,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University; Duke University					NCRR NIH HHS [M01-RR-30] Funding Source: Medline; NIAID NIH HHS [AI-23791] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023791, R23AI023791, R29AI023791] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL RP, 1969, J BIOL CHEM, V244, P644; AKLI S, 1990, J BIOL CHEM, V265, P7324; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GODDARD JM, 1983, P NATL ACAD SCI-BIOL, V80, P4281, DOI 10.1073/pnas.80.14.4281; GREENBERG ML, 1989, J BIOL CHEM, V264, P795; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUSTAFSON S, 1987, ANAL BIOCHEM, V165, P294, DOI 10.1016/0003-2697(87)90272-7; HERSHFIELD MS, 1991, P NATL ACAD SCI USA, V88, P7185, DOI 10.1073/pnas.88.16.7185; IIDA Y, 1990, J THEOR BIOL, V145, P523, DOI 10.1016/S0022-5193(05)80486-2; KATSUKI T, 1975, INT J CANCER, V15, P203, DOI 10.1002/ijc.2910150205; KREDICH NM, 1989, METABOLIC BASIS INHE, P1045; KUIVANIEMI H, 1990, J BIOL CHEM, V265, P12067; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MARKERT M L, 1991, Immunodeficiency Reviews, V3, P45; MARKERT ML, 1987, J IMMUNOL, V138, P3203; MARKERT ML, 1987, J CLIN IMMUNOL, V7, P389, DOI 10.1007/BF00917017; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; MITSUBUCHI H, 1991, J CLIN INVEST, V87, P1207, DOI 10.1172/JCI115120; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TACCHINICOTTIER FM, 1988, J IMMUNOL, V141, P3647; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; VIDAUD M, 1989, P NATL ACAD SCI USA, V86, P1041, DOI 10.1073/pnas.86.3.1041; WANG LM, 1988, BIOTECHNIQUES, V6, P839; WEIL D, 1989, EMBO J, V8, P1705, DOI 10.1002/j.1460-2075.1989.tb03562.x; WILLIAMS SR, 1987, J BIOL CHEM, V262, P2332; WILLIAMS SR, 1984, NUCLEIC ACIDS RES, V12, P5779, DOI 10.1093/nar/12.14.5779	37	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7834	7838						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560016				2022-12-27	WOS:A1992HN48500089
J	COLLEY, KJ; LEE, EU; PAULSON, JC				COLLEY, KJ; LEE, EU; PAULSON, JC			THE SIGNAL ANCHOR AND STEM REGIONS OF THE BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE MAY EACH ACT TO LOCALIZE THE ENZYME TO THE GOLGI-APPARATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; INTEGRAL MEMBRANE-PROTEIN; ENDOPLASMIC-RETICULUM; N-ACETYLGLUCOSAMINIDASE; TERMINAL GLYCOSYLATION; MAMMALIAN-CELLS; E1 GLYCOPROTEIN; BREFELDIN-A; EXPRESSION; RETENTION	The beta-galactoside alpha-2,6-sialyltransferase has been localized to the trans cisternae of the Golgi apparatus and the trans Golgi network where it transfers sialic acid residues to terminal Positions on N-linked oligosaccharides. It is a type II transmembrane protein possessing a 9-amino acid amino-terminal cytoplasmic tail, a 17-amino acid signal anchor domain, and a 35-amino acid stem region which tethers the large luminal catalytic domain to the membrane anchor. Previous work has demonstrated that the soluble sialyltransferase catalytic domain is rapidly secreted from Chinese hamster ovary cells. These results suggest that the signals for Golgi apparatus localization do not reside in the catalytic domain of the enzyme but must reside in the cytoplasmic tail, signal anchor domain, and/or stem region. To determine which amino-terminal regions are required for Golgi apparatus localization, mutant sialyltransferase proteins were constructed by in vitro oligonucleotide-directed mutagenesis, expressed in Cos-1 cells, and localized by indirect immunofluorescence microscopy. Signal cleavage-sialyltransferase mutants which consist of only the stem and catalytic domain of the enzyme are not rapidly secreted but are retained intracellularly and predominantly localized to the Golgi apparatus. However, deletion of either the stem region or the cytoplasmic tail of the membrane-bound sialyltransferase does not alter its Golgi apparatus localization. In addition, sequential replacement of the amino acids of the sialyltransferase signal anchor domain with amino acids from the signal anchor domain of a plasma membrane protein, the influenza virus neuraminidase does not alter the Golgi apparatus localization of the sialyltransferase. These observations suggest that sequences in the signal anchor region and stem region allow the Golgi apparatus localization of the membrane-bound and soluble forms of the sialytransferase, respectively, and that both regions may contain Golgi apparatus localization signals.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; CYTEL CORP, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT CHEM, SAN DIEGO, CA 92121 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, SAN DIEGO, CA 92121 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Scripps Research Institute; Scripps Research Institute			Paulson, James/AAG-3565-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011557, R01GM027904] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-11557, GM-27904] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI D, 1990, GLYCOCONJUGATE J, V7, P410; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HITI AL, 1982, J VIROL, V41, P730, DOI 10.1128/JVI.41.2.730-734.1982; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EU, 1989, J BIOL CHEM, V264, P13848; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; ORCI L, 1991, CELL, V64, P1183; PAABO S, 1987, CELL, V50, P311, DOI 10.1016/0092-8674(87)90226-1; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; PORUCHYNSKY MS, 1988, J CELL BIOL, V107, P1697, DOI 10.1083/jcb.107.5.1697; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHEKMAN R, 1985, ANNU REV CELL BIOL, V1, P115, DOI 10.1146/annurev.cellbio.1.1.115; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SHAPER JH, 1991, GLYCOCONJUGATE J, V8, P150; STAMENKOVIC I, 1990, J EXP MED, V172, P641, DOI 10.1084/jem.172.2.641; STIRZAKER SC, 1989, CELL, V56, P741, DOI 10.1016/0092-8674(89)90677-6; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	69	131	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7784	7793						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560012				2022-12-27	WOS:A1992HN48500083
J	MINOTTI, G; IKEDASAITO, M				MINOTTI, G; IKEDASAITO, M			FE(II) OXIDATION AND FE(III) INCORPORATION BY THE MR 66,000 MICROSOMAL IRON PROTEIN THAT STIMULATES NADPH OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT LIPID-PEROXIDATION; FERRITIN; RAT; CERULOPLASMIN; SUPEROXIDE; INVOLVEMENT; EXPRESSION; INITIATION; HEART; LIVER	In a previous study (Minotti, G., and Ikeda-Saito, M. (1991) J. Biol. Chem. 266,20011-20017) we demonstrated the existence of a Mr 66,000 microsomal iron protein (MIP) which stimulates NADPH oxidation by shunting electrons from NADPH-cytochrome P-450 reductase to its bound Fe(III). In the present study, purified MIP was depleted of iron and the apoMIP was examined for its ability to incorporate Fe(III) upon an incubation with Fe(II). It was found that apoMIP had an oxygen-dependent ferroxidase activity coupled with the incorporation of Fe(III). The reconstituted MIP exhibited a Fe(III) content and an NADPH oxidation activity similar to those of native MIP. However, the reconstitution of MIP from apoMIP and Fe(II) had to be performed in the presence of detergents to prevent the formation of protein aggregates and the oxidative incorporation of an iron which could not react with NADPH-cytochrome P-450 reductase. This redox inactive iron was probably bound nonspecifically to artifactual sites formed by the protein aggregates.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Case Western Reserve University	MINOTTI, G (corresponding author), UNIV CATTOLICA SACRO CUORE, SCH MED, INST GEN PATHOL, I-00168 ROME, ITALY.		Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015	Minotti, Giorgio/0000-0002-5678-6175	NIGMS NIH HHS [GM39359, GM39492] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039359, R01GM039492] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDRED AR, 1987, J BIOL CHEM, V262, P2875; AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; AUST SD, 1988, OXYGEN RADICALS BIOL, P137; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; FISHER DB, 1972, J BIOL CHEM, V247, P5161; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; GRADY JK, 1989, J BIOL CHEM, V264, P20224; GUTTERIDGE JMC, 1990, IRON TRANSPORT STORA, P55; LAMBETH DO, 1982, BIOCHIM BIOPHYS ACTA, V719, P501, DOI 10.1016/0304-4165(82)90239-2; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; LINDER MC, 1977, BIOCHIM BIOPHYS ACTA, V499, P329, DOI 10.1016/0304-4165(77)90064-2; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; MINOTTI G, 1990, ARCH BIOCHEM BIOPHYS, V277, P268, DOI 10.1016/0003-9861(90)90578-M; MINOTTI G, 1987, J BIOL CHEM, V262, P1098; MINOTTI G, 1990, ARCH BIOCHEM BIOPHYS, V282, P270, DOI 10.1016/0003-9861(90)90116-G; MINOTTI G, 1991, J BIOL CHEM, V266, P20011; MINOTTI G, 1992, IN PRESS LIPIDS, V27; SAMOKYSZYN VM, 1989, J BIOL CHEM, V264, P21; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; THOMAS CE, 1985, J BIOL CHEM, V260, P3275	22	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7611	7614						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559997				2022-12-27	WOS:A1992HN48500059
J	HILTUNEN, JK; WENZEL, B; BEYER, A; ERDMANN, R; FOSSA, A; KUNAU, WH				HILTUNEN, JK; WENZEL, B; BEYER, A; ERDMANN, R; FOSSA, A; KUNAU, WH			PEROXISOMAL MULTIFUNCTIONAL BETA-OXIDATION PROTEIN OF SACCHAROMYCES-CEREVISIAE - MOLECULAR ANALYSIS OF THE FOX2 GENE AND GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ENOYL-COA HYDRATASE; RAT-LIVER PEROXISOMES; ESCHERICHIA-COLI; CANDIDA-TROPICALIS; 3-HYDROXYACYL-COA DEHYDROGENASE; BIFUNCTIONAL ENZYME; FIREFLY LUCIFERASE; TARGETING SIGNAL; MESSENGER-RNA	The gene encoding the multifunctional protein (MFP) of peroxisomal beta-oxidation in Saccharomyces cerevisiae was isolated from a genomic library via functional complementation of a fox2 mutant strain. The open reading frame consists of 2700 base pairs encoding a protein of 900 amino acids. The predicted molecular weight (98,759) is in close agreement with that of the isolated polypeptide (96,000). Analysis of the deduced amino acid sequence revealed similarity to the MFPs of two other fungi but not to that of rat peroxisomes or the multifunctional subunit of the Escherichia coli beta-oxidation complex. The FOX2 gene was overexpressed from a multicopy vector (YEp352) in S. cerevisiae and the gene product purified to apparent homogeneity. A truncated version of MFP lacking 271 carboxyl-terminal amino acids was also overexpressed and purified. Experiments to study the enzymatic properties of the wild-type MFP demonstrated an absence of activities originally assigned to an MFP of S. cerevisiae (crotonase, L-3-hydroxyacyl-CoA dehydrogenase, and 3-hydroxyacyl-CoA epimerase), whereas two other activities were found: 2-enoyl-CoA hydratase 2 (converting trans-2-enoyl-CoA to D-3-hydroxyacyl-CoA) and D-3-hydroxyacyl CoA dehydrogenase (converting D-3-hydroxyacyl-CoA to 3-ketoacyl-CoA). The truncated form contained only the D-3-hydroxyacyl-CoA dehydrogenase activity. These results clearly demonstrate that the beta-oxidation of fatty acids in S. cerevisiae follows a previously unknown stereochemical course, namely it occurs via a D-3-hydroxyacyl-CoA intermediate.	RUHR UNIV BOCHUM,FAK MED,INST PHYSIOL CHEM,ZELLBIOCHEM ABT,POSTFACH 102148,W-4630 BOCHUM,GERMANY; UNIV OULU,DEPT MED BIOCHEM,SF-90220 OULU,FINLAND; UNIV OULU,BIOCTR OULU,SF-90220 OULU,FINLAND	Ruhr University Bochum; University of Oulu; University of Oulu								BEHRENDS W, 1988, ARCH BIOCHEM BIOPHYS, V263, P161, DOI 10.1016/0003-9861(88)90624-8; Binstock J F, 1981, Methods Enzymol, V71 Pt C, P403; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; DELAGARZA MM, 1985, EUR J BIOCHEM, V148, P285, DOI 10.1111/j.1432-1033.1985.tb08837.x; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HASHIMOTO T, 1987, PEROXISOMES BIOL MED, P97; HILTUNEN JK, 1989, J BIOL CHEM, V264, P13536; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kunau W.-H., 1987, PEROXISOMES BIOL MED, P128; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; MINAMIISHII N, 1989, EUR J BIOCHEM, V185, P73, DOI 10.1111/j.1432-1033.1989.tb15083.x; NAKAHIGASHI K, 1990, NUCLEIC ACIDS RES, V18, P4937, DOI 10.1093/nar/18.16.4937; NUTTLEY WM, 1988, GENE, V69, P171, DOI 10.1016/0378-1119(88)90428-3; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PALOSAARI PM, 1991, J BIOL CHEM, V266, P10750; PRAMANIK A, 1979, J BACTERIOL, V137, P469, DOI 10.1128/JB.137.1.469-473.1979; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SIMON M, 1991, MOL CELL BIOL, V11, P699, DOI 10.1128/MCB.11.2.699; SKONECZNY M, 1988, EUR J BIOCHEM, V174, P297, DOI 10.1111/j.1432-1033.1988.tb14097.x; SMELAND TE, 1989, BIOCHEM BIOPH RES CO, V160, P988, DOI 10.1016/S0006-291X(89)80098-1; STERN JR, 1955, J AM CHEM SOC, V77, P1073, DOI 10.1021/ja01609a105; Stoffel W, 1964, Hoppe Seylers Z Physiol Chem, V339, P167, DOI 10.1515/bchm2.1964.339.1.167; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; TANAKA A, 1982, ANN NY ACAD SCI, V386, P183, DOI 10.1111/j.1749-6632.1982.tb21416.x; THIERINGER R, 1991, J BIOL CHEM, V266, P13110; THIERINGER R, 1991, J BIOL CHEM, V266, P13118; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; UEDA M, 1987, AGR BIOL CHEM TOKYO, V51, P2197; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; YANG SY, 1983, J BIOL CHEM, V258, P9780; YANG XYH, 1991, BIOCHEMISTRY-US, V30, P6788, DOI 10.1021/bi00241a023; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	40	174	184	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6646	6653						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551874				2022-12-27	WOS:A1992HM05300032
J	SCHWARTZ, BS; BRADSHAW, JD				SCHWARTZ, BS; BRADSHAW, JD			REGULATION OF PLASMINOGEN-ACTIVATOR INHIBITOR MESSENGER-RNA LEVELS IN LIPOPOLYSACCHARIDE-STIMULATED HUMAN MONOCYTES - CORRELATION WITH PRODUCTION OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; CULTURED HUMAN-MONOCYTES; HUMAN MONONUCLEAR-CELLS; 3' UNTRANSLATED REGION; TISSUE FACTOR; HUMAN-PLACENTA; ENDOTOXIN; STABILITY; UROKINASE; EXPRESSION	Peripheral blood monocytes are essential participants in processes that require pericellular plasminogen activation, a regulated proteolytic pathway that is greatly influenced by the relative concentrations of urokinase-type plasminogen activator (profibrinolytic) and plasminogen activator inhibitor type 2 (PAI-2) (anti-fibrinolytic). Monocyte synthesis of these molecules is inducible by bacterial lipopolysaccharide (LPS) although PAI-2 production is regulated over a much wider concentration range than is urokinase-type PA. The PAI-2 response of LPS-stimulated monocytes was investigated and found to be biphasic, with a peak of mRNA at 4-6 h after stimulation, a decrement in mRNA levels at 8-10 h, and a secondary increase at 16 h. The primary (early phase) response was studied in detail wherein PAI-2 protein production was found to depend on the levels of PAI-2 mRNA. The profiles of steady-state PAI-2 mRNA levels and PAI-2 protein production were parallel with respect to LPS concentration, time of exposure to LPS, and persistence of the response. PAI-2 mRNA accumulation was inducible by cycloheximide but prevented by actinomycin D. The increase in steady-state PAI-2 mRNA was mediated both by an increase in gene transcription and by stabilization of the mRNA once formed. Therefore, the initial phase of PAI-2 production by LPS-stimulated monocytes is determined by the amount of PAI-2 mRNA in these cells; levels of PAI-2 mRNA are controlled by several mechanisms, allowing for rapid variations in production of this molecule.			SCHWARTZ, BS (corresponding author), UNIV WISCONSIN,DEPT MED,HEMATOL SECT,MADISON,WI 53706, USA.				NHLBI NIH HHS [HL-43506, HL-01870] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL001870, R01HL043506] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AREND WP, 1989, J IMMUNOL, V143, P118; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CARNEIRO M, 1984, J MOL BIOL, V178, P869, DOI 10.1016/0022-2836(84)90316-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLVIN RB, 1973, J EXP MED, V138, P686, DOI 10.1084/jem.138.3.686; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1989, J BIOL CHEM, V264, P2185; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; KRUITHOF EKO, 1986, J BIOL CHEM, V261, P1207; KRUITHOF EKO, 1987, BLOOD, V69, P460; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MANCHANDA N, 1990, J IMMUNOL, V145, P4171; MARZLUFF WF, 1988, TRENDS BIOCHEM SCI, V13, P49, DOI 10.1016/0968-0004(88)90027-8; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; POLLANEN J, 1990, P NATL ACAD SCI USA, V87, P2230, DOI 10.1073/pnas.87.6.2230; PRESS RD, 1988, BIOCHEMISTRY-US, V27, P5736, DOI 10.1021/bi00415a051; RICKLES FR, 1977, J LAB CLIN MED, V89, P792; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCARPATI EM, 1990, J BIOL CHEM, V265, P14696; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; SCARPIRO DJ, 1987, BIOESSAYS, V6, P221; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; SCHWARTZ BS, 1989, BLOOD, V74, P1644; SCHWARTZ BS, 1989, BLOOD, V73, P2188; SCHWARTZ BS, 1988, BLOOD, V71, P734; SCHWARTZ BS, 1985, J CLIN INVEST, V76, P970, DOI 10.1172/JCI112097; SHAPIRO DJ, 1987, BIOESSAYS, V6, P221, DOI 10.1002/bies.950060507; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WOHLWEND A, 1987, J EXP MED, V165, P320, DOI 10.1084/jem.165.2.320; WUN TC, 1987, J BIOL CHEM, V262, P3646; YE RD, 1988, J BIOL CHEM, V263, P4869; YE RD, 1987, J BIOL CHEM, V262, P3718	41	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7089	7094						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551915				2022-12-27	WOS:A1992HM05300097
J	MORENO, SNJ; DOCAMPO, R; VERCESI, AE				MORENO, SNJ; DOCAMPO, R; VERCESI, AE			CALCIUM HOMEOSTASIS IN PROCYCLIC AND BLOOD-STREAM FORMS OF TRYPANOSOMA-BRUCEI - LACK OF INOSITOL 1,4,5-TRISPHOSPHATE-SENSITIVE CA2+ RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; EPIDERMAL GROWTH-FACTOR; LEYDIG TUMOR-CELLS; PROTEIN KINASE-C; INTRACELLULAR CALCIUM; PARTIAL-PURIFICATION; SURFACE-COAT; ARSENAZO-III; CA-2+; MEMBRANE	When Trypanosoma brucei procyclic trypomastigotes were permeabilized with digitonin in a reaction medium containing MgATP, succinate, and 3.5-mu-M free Ca2+, they lowered the medium Ca2+ concentration to the submicromolar level (0-05-0.1-mu-M), a range that correlates favorably with that detected in the intact cells with fura-2. The carbonyl cyanide p-trifluoromethoxyphenylhydrazone-insensitive Ca2+ uptake, certainly represented by the endoplasmic reticulum, was completely inhibited by 500-mu-M vanadate. When vanadate instead of carbonyl cyanide p-trifluoromethoxyphenylhydrazone was present, the Ca2+ set point was increased to 0.6-0.7-mu-M. The succinate dependence and carbonyl cyanide p-trifluoromethoxyphenylhydrazone sensitivity of the later Ca2+ uptake indicate that it may be exerted by the mitochondria. When bloodstream trypomastigotes were used, neither succinate nor alpha-glycerophosphate stimulated the mitochondrial Ca2+ uptake. The mitochondrial Ca2+ transport could be measured only in the presence of ATP and 500-mu-M vanadate to inhibit the endoplasmic reticulum uptake. Bloodstream trypomastigotes have a lower cytosolic Ca2+ Concentration, as detected with fura-2 and a smaller extramitochondrial Ca2+ pool than procyclic trypomastigotes. Despite the presence of inositol phosphates, as determined by [H-3]inositol incorporation, and the large extramitochondrial Ca2+ pool of procyclic trypomastigotes (61.7 nmol of Ca2+/mg of protein), no inositol 1,4,5-trisphosphate-sensitive Ca2+ release could be detected in these parasites.	UNIV ESTADUAL CAMPINAS,DEPT BIOQUIM,BR-13081 CAMPINAS,SP,BRAZIL	Universidade Estadual de Campinas	MORENO, SNJ (corresponding author), UNIV ILLINOIS,DEPT VET PATHOBIOL,2001 S LINCOLN AVE,URBANA,IL 61801, USA.		Vercesi, Aníbal E/C-8767-2012	Vercesi, Anibal Eugenio/0000-0001-6671-7125				BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BIENEN EJ, 1981, EXP PARASITOL, V51, P408, DOI 10.1016/0014-4894(81)90128-4; BOWLES DJ, 1982, FEBS LETT, V139, P17, DOI 10.1016/0014-5793(82)80477-8; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARONI P, 1981, J BIOL CHEM, V256, P3263; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAMPER D, 1976, J PROTOZOOL, V23, P349, DOI 10.1111/j.1550-7408.1976.tb03787.x; DANSON MJ, 1987, BIOCHEM J, V243, P661, DOI 10.1042/bj2430661; DESMEDT H, 1991, BIOCHEM J, V273, P219, DOI 10.1042/bj2730219; DOCAMPO R, 1990, CELLULAR MOL EVENTS, P285; DOCAMPO R, 1991, J BIOL CHEM, V275, P407; DOERING TL, 1990, J BIOL CHEM, V265, P611; DOLAN MT, 1986, J CELL SCI, V80, P123; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; GOMEZ ML, 1989, MOL BIOCHEM PARASIT, V36, P101, DOI 10.1016/0166-6851(89)90182-5; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GRANT PT, 1960, BIOCHEM J, V76, P229, DOI 10.1042/bj0760229; HARRISON RAP, 1990, CELL SIGNAL, V2, P277, DOI 10.1016/0898-6568(90)90055-F; INESI G, 1980, J BIOL CHEM, V255, P3025; MCCORMACK JG, 1986, TRENDS BIOCHEM SCI, V11, P258, DOI 10.1016/0968-0004(86)90190-8; MILLER PGG, 1976, PARASITOLOGY, V73, P16; MORCOS NC, 1982, BIOCHIM BIOPHYS ACTA, V688, P747, DOI 10.1016/0005-2736(82)90288-7; MORENO SNJ, 1984, J BIOL CHEM, V259, P4609; MORENO SNJ, 1985, FEBS LETT, V180, P229, DOI 10.1016/0014-5793(85)81076-0; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOLAN DP, 1990, BIOCHEM SOC T, V18, P735, DOI 10.1042/bst0180735; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; OPPERDOES FR, 1977, EUR J BIOCHEM, V76, P29, DOI 10.1111/j.1432-1033.1977.tb11567.x; ORRENIUS S, 1986, CALCIUM CELL FUNCTIO, V6, P185; PHILOSOPH H, 1989, J BIOL CHEM, V264, P10420; PIGNATARO OP, 1990, MOL ENDOCRINOL, V4, P758, DOI 10.1210/mend-4-5-758; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; REGA AF, 1986, CALCIUM PUMP PLASMA, P13; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; SEEBECK T, 1983, MOL BIOCHEM PARASIT, V9, P197, DOI 10.1016/0166-6851(83)90097-X; SHAPIRO SZ, 1987, J PROTOZOOL, V34, P58, DOI 10.1111/j.1550-7408.1987.tb03132.x; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; TRAGER W, 1989, J PROTOZOOL, V36, P451; VERCESI AE, 1991, CELL CALCIUM, V12, P361, DOI 10.1016/0143-4160(91)90052-G; VONBRAND T, 1973, BIOCH PARASITES, P89; VOORHEIS HP, 1981, EUR J BIOCHEM, V116, P471, DOI 10.1111/j.1432-1033.1981.tb05360.x; WEIKEL CS, 1988, INFECT IMMUN, V56, P1485, DOI 10.1128/IAI.56.6.1485-1491.1988; WILLIAMS DA, 1990, CELL CALCIUM, V11, P75, DOI 10.1016/0143-4160(90)90061-X; WU JT, 1991, J BIOL CHEM, V266, P14893	49	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6020	6026						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556113				2022-12-27	WOS:A1992HK31800048
J	ROVERI, A; CASASCO, A; MAIORINO, M; DALAN, P; CALLIGARO, A; URSINI, F				ROVERI, A; CASASCO, A; MAIORINO, M; DALAN, P; CALLIGARO, A; URSINI, F			PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE-PEROXIDASE OF RAT TESTIS - GONADOTROPIN DEPENDENCE AND IMMUNOCYTOCHEMICAL IDENTIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; LIPID-PEROXIDATION; SELENIUM; SPERM; PROTEIN; MOUSE; NITROCELLULOSE; ANTIBODY; TISSUES; LIVER	A high glutathione peroxidase activity toward phospholipid hydroperoxides is present in rat testis. The attribution of this activity to the selenoenzyme phospholipid hydroperoxide glutathione peroxidase (PHGPX) was supported by cross-reactivity with antibodies raised against pig heart PHGPX which had been purified and characterized. Rat testis PHGPX is partially cytosolic and partially linked to nuclei and mitochondria. The soluble and organelle-bound enzymes appear identical by Western blot analysis. PHGPX, but neither selenium-dependent nor nonselenium-dependent glutathione peroxidase activity, is expressed in testes only after puberty, disappears after hypophysectomy, and is partially restored by gonadotropin treatment. Specific immunostaining of testes by antiserum against PHGPX appears as a fine granular brown pattern localized throughout the cytoplasm in more immature cells but is confined to the peripheral part of the cytoplasm, the nuclear membrane, and mitochondria in maturating spermatogenic cells. As expected, immunostaining of spermatogenic cells in hypophysectomized animals was negative, but gonadotropin treatment only marginally increased the immunoreactivity. The expression of PHGPX in testes is consistent with the previously described specific requirement for selenium for synthesis of a 15-20-kDa selenoprotein which is related to the production of functional spermatozoa.	UNIV PAVIA,INST HISTOL & EMBRIOL,I-27100 PAVIA,ITALY; UNIV UDINE,INST CHEM,I-33100 UDINE,ITALY	University of Pavia; University of Udine	ROVERI, A (corresponding author), UNIV PADUA,DEPT BIOL CHEM,I-35100 PADUA,ITALY.		Roveri, Antonella/AAF-3669-2019	Roveri, Antonella/0000-0002-3252-0559				ARTHUR JR, 1990, BIOCHEM J, V272, P537, DOI 10.1042/bj2720537; BEHNE D, 1990, BIOCHEM BIOPH RES CO, V173, P1143, DOI 10.1016/S0006-291X(05)80905-2; BEHNE D, 1982, J NUTR, V112, P1682, DOI 10.1093/jn/112.9.1682; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BROWN DG, 1973, J NUTR, V103, P102, DOI 10.1093/jn/103.1.102; CALVIN HI, 1981, GAMETE RES, V4, P139, DOI 10.1002/mrd.1120040208; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; DANIELSON KG, 1986, CANCER RES, V46, P4582; FLOHE L, 1989, COENZYME COFACTORS, V3, P643; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KLEENE KC, 1990, DEV BIOL, V137, P395, DOI 10.1016/0012-1606(90)90263-I; MAIORINO M, 1989, LIPIDS, V24, P721, DOI 10.1007/BF02535211; MAIORINO M, 1990, METHOD ENZYMOL, V186, P488; MEYER SA, 1983, J NUTR, V113, P394, DOI 10.1093/jn/113.2.394; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; SCHWARZ K, 1957, J AM CHEM SOC, V79, P3292, DOI 10.1021/ja01569a087; SZEWCZYK B, 1985, ANAL BIOCHEM, V150, P403, DOI 10.1016/0003-2697(85)90528-7; TAKAHASHI K, 1990, J BIOCHEM-TOKYO, V108, P145, DOI 10.1093/oxfordjournals.jbchem.a123172; THOMAS JP, 1990, J BIOL CHEM, V265, P454; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URSINI F, 1982, BIOCHIM BIOPHYS ACTA, V710, P197, DOI 10.1016/0005-2760(82)90150-3; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; Ursini F., 1991, OXIDANTS ANTIOXIDANT, P319; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; WHANGER PD, 1987, SELENIUM BIOL MED A, P133; WU ASH, 1979, BIOL REPROD, V20, P793, DOI 10.1095/biolreprod20.4.793; ZHANG LP, 1989, BIOCHIM BIOPHYS ACTA, V1006, P140, DOI 10.1016/0005-2760(89)90336-6	28	224	231	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6142	6146						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556123				2022-12-27	WOS:A1992HK31800065
J	SAITTA, B; TIMPL, R; CHU, ML				SAITTA, B; TIMPL, R; CHU, ML			HUMAN ALPHA-2(VI) COLLAGEN GENE - HETEROGENEITY AT THE 5'-UNTRANSLATED REGION GENERATED BY AN ALTERNATE EXON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION SITES; TISSUE-SPECIFIC EXPRESSION; CARTILAGE MATRIX PROTEIN; TRIPLE-HELICAL DOMAIN; VI COLLAGEN; VONWILLEBRAND-FACTOR; MESSENGER-RNAS; GLOBULAR DOMAINS; GROWTH-FACTOR; MOLECULAR-CLONING	Cosmid clones containing the 5' region of the human alpha-2(VI) collagen gene have been isolated and characterized. DNA sequencing indicates that the signal peptide and the amino-globular domain are encoded by four exons of 142, 596, 21, and 66 base pairs (bp). However, Sl nuclease and primer extension analyses show that the transcription start site is not present in the 142-bp exon. Two different 5' cDNA clones are generated by the anchored polymerase chain reaction. Using the 5' cDNA clones as probes, two untranslated exons (1, 1A) are found 12 kilobase pairs upstream of the first coding exon. These two exons are alternatively used in human fibroblasts, and most transcripts contain exon 1 sequence. Exon 1 shows, by primer extension and Sl nuclease protection assay, two major and several minor transcription start sites. The promoter region contains a canonical TATA box, seven GGGCGG sequences, two possible CAAT boxes, and two sequences resembling AP2 binding sites. Exon 1A contains three alternative splice donor sites and is located 650 bp downstream of exon 1. The most 3' splice donor site of exon 1A is found within an Alu repeat sequence. Exon 1A is preceded by five GGGCGG sequences and one resembling the AP2 binding site although neither TATA or CAAT boxes are found. Two additional GGGCGG sequences are located at the beginning of exon 1A. This study establishes that the human alpha-2(VI) collagen gene is 36 kilobase pairs long and contains 30 exons. The 5'-untranslated and promoter regions are significantly different from the corresponding segments of the chicken gene. The human gene produces by alternative processing multiple mRNAs differing in the 5'-untranslated region as well as the 3'-coding and noncoding sequences.	THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,233 S 10TH ST,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,DEPT DERMATOL,PHILADELPHIA,PA 19107; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Jefferson University; Jefferson University; Max Planck Society					NIAMS NIH HHS [AR 19616, AR 38923, AR 38912] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019616, R01AR038912, P01AR038923] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BONALDO P, 1989, J BIOL CHEM, V264, P5575; BONALDO P, 1989, J BIOL CHEM, V264, P20235; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BOND BJ, 1986, MOL CELL BIOL, V6, P2080, DOI 10.1128/MCB.6.6.2080; BRUNS R, 1986, J CELL BIOL, V103, P394; BURMEISTER M, 1991, GENOMICS, V9, P19, DOI 10.1016/0888-7543(91)90216-2; CAMPBELL RD, 1983, P NATL ACAD SCI-BIOL, V80, P4464, DOI 10.1073/pnas.80.14.4464; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1988, J BIOL CHEM, V263, P18601; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; COLOBATTI A, 1987, J BIOL CHEM, V2622, P14454; CORBI AL, 1990, J BIOL CHEM, V265, P2782; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GARRITY PA, 1990, MOL CELL BIOL, V10, P5646, DOI 10.1128/MCB.10.11.5646; GHOSH PK, 1981, P NATL ACAD SCI-BIOL, V78, P100, DOI 10.1073/pnas.78.1.100; HAYMAN AR, 1990, J BIOL CHEM, V265, P9864; HAYMAN AR, 1991, EUR J BIOCHEM, V197, P177, DOI 10.1111/j.1432-1033.1991.tb15896.x; HORIUCHI T, 1990, J BIOL CHEM, V265, P6521; IZZO P, 1988, EUR J BIOCHEM, V174, P569, DOI 10.1111/j.1432-1033.1988.tb14136.x; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; KISS I, 1989, J BIOL CHEM, V264, P8126; KOLLER E, 1991, NUCLEIC ACIDS RES, V19, P485, DOI 10.1093/nar/19.3.485; KOLLER E, 1989, EMBO J, V8, P1073, DOI 10.1002/j.1460-2075.1989.tb03475.x; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LOWE WL, 1987, P NATL ACAD SCI USA, V84, P8946, DOI 10.1073/pnas.84.24.8946; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P59; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; NISHIMURA I, 1989, J BIOL CHEM, V264, P2003; OTTE AP, 1990, J CELL BIOL, V111, P271, DOI 10.1083/jcb.111.1.271; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; ROBERTS CT, 1987, BIOCHEM BIOPH RES CO, V146, P1154, DOI 10.1016/0006-291X(87)90768-6; SAITTA B, 1990, J BIOL CHEM, V265, P6473; SAITTA B, 1991, GENOMICS, V11, P145, DOI 10.1016/0888-7543(91)90111-Q; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STOKES DG, 1991, J BIOL CHEM, V266, P8626; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; TRUEB B, 1989, J BIOL CHEM, V264, P136; TRUEB B, 1986, EMBO J, V5, P2815, DOI 10.1002/j.1460-2075.1986.tb04573.x; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEIL D, 1988, AM J HUM GENET, V42, P435; YOUNG RA, 1981, CELL, V23, P451, DOI 10.1016/0092-8674(81)90140-9	52	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6188	6196						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556127				2022-12-27	WOS:A1992HK31800072
J	SUGAHARA, K; OHI, Y; HARADA, T; DEWAARD, P; VLIEGENTHART, JFG				SUGAHARA, K; OHI, Y; HARADA, T; DEWAARD, P; VLIEGENTHART, JFG			STRUCTURAL STUDIES ON SULFATED OLIGOSACCHARIDES DERIVED FROM THE CARBOHYDRATE-PROTEIN LINKAGE REGION OF CHONDROITIN-6-SULFATE PROTEOGLYCANS OF SHARK CARTILAGE .1. 6 COMPOUNDS CONTAINING 0 OR 1 SULFATE AND OR PHOSPHATE RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECHO DIFFERENCE SPECTROSCOPY; SWARM RAT CHONDROSARCOMA; SELECTIVE OBSERVATION; MAGNETIC-RESONANCE; NMR-SPECTROSCOPY; HEPARAN-SULFATE; BIOSYNTHESIS; PURIFICATION; SEPARATION	Shark cartilage proteoglycans bear predominantly chondroitin 6-sulfate. After exhaustive protease digestion, reductive beta-elimination, and subsequent chondroitinase ABC digestion, 13 hexasaccharide alditols, which are nonsulfated, sulfated, and/or phosphorylated, were obtained from the carbohydrate-protein linkage region. Six compounds, containing 0 or 1 sulfate and/or phosphate residue, represent approximately 40% of the isolated linkage hexasaccharide alditols. They were analyzed by chondroitinase ACII or alkaline phosphatase digestion in conjunction with high performance liquid chromatography, and by 500 MHz one- and two-dimensional H-1 NMR spectroscopy. All six compounds have the conventional structure in common. DELTA-4,5-GlcA-beta-1-3GalNAc-beta-1-4GlcA-beta-1-3Gal-beta-1-3Gal-beta-1-4Xyl-ol One compound has no sulfate nor phosphate. Two of the monosulfated compounds have an O-sulfate on C-6 or on C-4 of the GalNAc residue. The third monosulfated compound has a novel O-sulfate on C-6 of the Gal residue attached to xylitol. The two phosphorylated compounds have O-phosphate on C-2 of Xyl-ol, and one of them has in addition sulfate on C-6 of GalNAc.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,SAKYO KU,KYOTO 606,JAPAN; SEIKAGAKU KOGYO CO,KURIHAMA PLANT,YOKOSUKA,KANAGAWA 239,JAPAN; UNIV UTRECHT,DEPT BIOORGAN CHEM,BIJVOET CTR,UTRECHT,NETHERLANDS	Kyoto University; Utrecht University								BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; COHEN JS, 1984, J MAGN RESON, V59, P181, DOI 10.1016/0022-2364(84)90299-3; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; DEWAARD P, 1989, J BIOL CHEM, V264, P12141; DEWAARD P, 1989, J MAGN RESON, V81, P173, DOI 10.1016/0022-2364(89)90276-X; Ernst RR, 1966, ADV MAGN RESON, V2, P1; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; FURUHASHI T, 1961, SEIKAGAKU, V33, P537; HARRIS MJ, 1970, CARBOHYD RES, V15, P57, DOI 10.1016/S0008-6215(00)80294-3; KESSLER H, 1987, J AM CHEM SOC, V109, P607, DOI 10.1021/ja00236a063; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RICE KG, 1985, ANAL BIOCHEM, V150, P325, DOI 10.1016/0003-2697(85)90518-4; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROSENFELD L, 1988, J BIOL CHEM, V263, P262; SCHWARTZ NB, 1975, J BIOL CHEM, V250, P5200; STOOLMILLER AC, 1972, J BIOL CHEM, V247, P3525; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; SUGAHARA K, 1992, IN PRESS EUR J BIOCH; SUGAHARA K, 1992, IN PRESS J BIOL CHEM; TANTRAVAHI RV, 1986, P NATL ACAD SCI USA, V83, P9207, DOI 10.1073/pnas.83.23.9207; VANHALBEEK H, 1982, EUR J BIOCHEM, V127, P1; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4; ZINN AB, 1977, GLYCOCONJUGATES, V1, P69	36	97	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6027	6035						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556114				2022-12-27	WOS:A1992HK31800049
J	HORIUCHI, M; KOBAYASHI, K; TOMOMURA, M; KUWAJIMA, M; IMAMURA, Y; KOIZUMI, T; NIKAIDO, H; HAYAKAWA, J; SAHEKI, T				HORIUCHI, M; KOBAYASHI, K; TOMOMURA, M; KUWAJIMA, M; IMAMURA, Y; KOIZUMI, T; NIKAIDO, H; HAYAKAWA, J; SAHEKI, T			CARNITINE ADMINISTRATION TO JUVENILE VISCERAL STEATOSIS MICE CORRECTS THE SUPPRESSED EXPRESSION OF UREA CYCLE ENZYMES BY NORMALIZING THEIR TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHATE SYNTHETASE-I; ARGININOSUCCINATE SYNTHETASE; RAT-LIVER; HORMONAL-REGULATION; GENE-EXPRESSION; MESSENGER-RNAS; REYES-SYNDROME; ACID; DEFICIENCY; RECEPTOR	Previous studies in our laboratories have revealed that juvenile visceral steatosis mice show suppressed transcription of urea cycle enzyme genes during development and are systemically deficient in carnitine. It has not yet been explained, however, how this carnitine deficiency relates to the abnormal gene expression. We investigated the effect of carnitine on abnormal gene expression, growth retardation, and fatty liver. Carnitine administration relieved the suppression of the developmental induction of two urea cycle enzymes examined, carbamoyl-phosphate synthetase and argininosuccinate synthase, and kept the activities of enzymes normal. However, carnitine did not reduce accumulated lipid in the liver to the normal level. These results suggest that carnitine deficiency plays an important role in the abnormal expression of urea cycle enzyme genes and that the abnormal expression of the genes is not directly caused by lipid accumulation in the liver.	OSAKA UNIV,SCH MED,DEPT INTERNAL MED,OSAKA 553,JAPAN; KANAZAWA UNIV,SCH MED,INST EXPTL ANIM,KANAZAWA,ISHIKAWA 920,JAPAN	Osaka University; Kanazawa University	HORIUCHI, M (corresponding author), KAGOSHIMA UNIV,FAC MED,DEPT BIOCHEM,8-35-1 SAKURAGAOKA,KAGOSHIMA 890,JAPAN.							ADCOCK MW, 1984, J BIOL CHEM, V259, P3471; BRENINGSTALL GN, 1990, PEDIATR NEUROL, V6, P75, DOI 10.1016/0887-8994(90)90037-2; BROWN GW, 1959, J BIOL CHEM, V234, P1769; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGROOT CJ, 1986, BIOCHIM BIOPHYS ACTA, V866, P61, DOI 10.1016/0167-4781(86)90101-6; FREINBERG AP, 1983, ANAL BIOCHEM, V132, P6; GADALETA MN, 1990, FEBS LETT, V277, P191, DOI 10.1016/0014-5793(90)80841-6; HAYAKAWA J, 1990, MOUSE GENOME, V86, P261; HUSSON A, 1990, EUR J BIOCHEM, V192, P677, DOI 10.1111/j.1432-1033.1990.tb19275.x; IMAMURA Y, 1990, FEBS LETT, V260, P119, DOI 10.1016/0014-5793(90)80081-S; INOUE A, 1989, EUR J BIOCHEM, V183, P565, DOI 10.1111/j.1432-1033.1989.tb21085.x; KOIZUMI T, 1988, LAB ANIM, V22, P83, DOI 10.1258/002367788780746511; KURIYAMA M, 1990, J LIPID RES, V31, P1605; KUWAJIMA M, 1991, BIOCHEM BIOPH RES CO, V174, P1090, DOI 10.1016/0006-291X(91)91532-H; LI QL, 1990, J BIOCHEM-TOKYO, V107, P699, DOI 10.1093/oxfordjournals.jbchem.a123111; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1989, DECONTAMINATION DILU; MORRIS SM, 1989, ARCH BIOCHEM BIOPHYS, V269, P175, DOI 10.1016/0003-9861(89)90097-0; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; OBRIEN WE, 1979, BIOCHEMISTRY-US, V18, P5353, DOI 10.1021/bi00591a015; PIERSON DL, 1977, J BIOL CHEM, V252, P6464; RAIHA NCR, 1976, UREA CYCLE, P261; RYALL JC, 1986, EUR J BIOCHEM, V156, P453, DOI 10.1111/j.1432-1033.1986.tb09603.x; SAKAKIBARA M, 1985, NUCLEIC ACIDS RES, V13, P5055, DOI 10.1093/nar/13.14.5055; SU TS, 1981, J BIOL CHEM, V256, P1826; SU TS, 1981, BIOCHEMISTRY-US, V20, P2956, DOI 10.1021/bi00513a037; TONOMURA M, 1992, IN PRESS BIOCH BIOPH; TREEM WR, 1988, NEW ENGL J MED, V319, P385	29	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5032	5035						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544887				2022-12-27	WOS:A1992HH74700005
J	ALONSO, E; CERVERA, J; GARCIAESPANA, A; BENDALA, E; RUBIO, V				ALONSO, E; CERVERA, J; GARCIAESPANA, A; BENDALA, E; RUBIO, V			OXIDATIVE INACTIVATION OF CARBAMOYL PHOSPHATE SYNTHETASE (AMMONIA) - MECHANISM AND SITES OF OXIDATION, DEGRADATION OF THE OXIDIZED ENZYME, AND INACTIVATION BY GLYCEROL, EDTA, AND THIOL PROTECTING AGENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-L-GLUTAMATE; PROTEIN-TURNOVER; RAT; BINDING; LIVER; PROTEOLYSIS; OXYGEN; ATP; ACETYLGLUTAMATE; ASCORBATE	Acetylglutamate and ATP accelerate the oxidative inactivation of carbamoyl phosphate synthetase I by mixtures of Fe3+, ascorbate, and O-2, but the mechanism of the inactivation differs with each ligand. In the presence of acetylglutamate, MgATP prevents, Mg2+, Mn2+, and catalase have no effect, and EDTA increases the inactivation, and the two phosphorylation steps of the enzyme reaction are lost simultaneously. The inactivation appears to be mediated by dehydroascorbate and is associated with the reversible oxidation of the highly reactive cysteines 1327 and 1337 and with oxidation of non-thiolic groups in the second 40-kDa domain (the enzyme consists of 4 domains of 40, 40, 60, and 20 kDa, from the amino terminus). The data are consistent with oxidation of groups at or near the site for ATP(A) (ATP(A) yields P(i); ATP(B) yields carbamoyl phosphate), and with the location of this site at the interphase between the second 40-kDa and the COOH-terminal domains. The oxidative inactivation promoted by ATP is inhibited by Mg2+, Mn2+, catalase, and EDTA, is not mediated by dehydroascorbate, and is not associated with oxidation of cysteines 1327 and 1337. Groups in the 60-kDa domain are oxidized. The phosphorylation step involving ATP(B) is lost preferentially, and the inactivation and the binding of ATP(B) exhibit the same dependency on the concentration of ATP. The results indicate that the oxidation is catalyzed by FeATP bound at the site for ATP(B) and support the binding of ATP(B) in the 60-kDa domain. We also demonstrate that mercaptoethanol, reducing impurities in glycerol, and dithioerythritol, in the presence of EDTA, replace ascorbate in the oxidative system. In addition, we study the influence of the oxidation on the degradation of the enzyme by rat liver lysosomes, mitochondria, and cytosol.	UNIV VALENCIA, FAC MED, DEPT BIOQUIM & BIOL MOLEC, E-46010 VALENCIA, SPAIN	University of Valencia	ALONSO, E (corresponding author), CSIC, CTR ASOCIADO, FIB, INST INVEST CITOL, AMADEO SABOYA 4, E-46010 VALENCIA, SPAIN.		garcia-españa, antonio/I-4756-2015; Bendala-Tufanisco, Elena/L-4531-2017; Alonso, Eulalia/L-9758-2014; Rubio, Vicente/K-7919-2014	garcia-españa, antonio/0000-0002-9957-3161; Bendala-Tufanisco, Elena/0000-0002-7261-4074; Alonso, Eulalia/0000-0001-5780-6345; Rubio, Vicente/0000-0001-8124-1196				ALONSO E, 1987, ARCH BIOCHEM BIOPHYS, V258, P342, DOI 10.1016/0003-9861(87)90353-5; ALONSO E, 1983, EUR J BIOCHEM, V135, P331, DOI 10.1111/j.1432-1033.1983.tb07658.x; ANNINO JS, 1960, CLIN CHEM PRINCIPLES, P296; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITTON HG, 1979, EUR J BIOCHEM, V102, P521, DOI 10.1111/j.1432-1033.1979.tb04268.x; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DETRICH HW, 1976, BIOCHEM BIOPH RES CO, V68, P961, DOI 10.1016/0006-291X(76)91239-0; EVANS DR, 1988, BIOCHIM BIOPHYS ACTA, V953, P185, DOI 10.1016/0167-4838(88)90023-4; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GESCHWILL K, 1989, BIOCHEM J, V260, P573, DOI 10.1042/bj2600573; GUADALAJARA A, 1987, EUR J BIOCHEM, V165, P163, DOI 10.1111/j.1432-1033.1987.tb11207.x; GUADALAJARA AM, 1987, THESIS U VALENCIA VA; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; GUTHOHRL.G, 1968, EUR J BIOCHEM, V7, P119, DOI 10.1111/j.1432-1033.1968.tb19582.x; JACOBS EE, 1956, J BIOL CHEM, V223, P147; JOCELYN PC, 1972, BIOCH SH GROUP; JONES ME, 1976, UREA CYCLE, P107; KIM K, 1985, J BIOL CHEM, V260, P5394; Kun E, 1979, Methods Enzymol, V55, P115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LENZ AG, 1989, ANAL BIOCHEM, V177, P419, DOI 10.1016/0003-2697(89)90077-8; LEVINE RL, 1983, J BIOL CHEM, V258, P1828; MARSHALL M, 1988, ARCH BIOCHEM BIOPHYS, V262, P455, DOI 10.1016/0003-9861(88)90397-9; MARSHALL M, 1985, ARCH BIOCHEM BIOPHYS, V241, P200, DOI 10.1016/0003-9861(85)90376-5; METZENBERG RL, 1958, J BIOL CHEM, V233, P1560; NOVOA WB, 1966, BIOCHIM BIOPHYS ACTA, V113, P84, DOI 10.1016/S0926-6593(66)80124-8; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; POST LE, 1990, J BIOL CHEM, V265, P7742; POTTER MD, 1990, FASEB J, V4, pA1834; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; RUBIO V, 1983, EUR J BIOCHEM, V134, P337, DOI 10.1111/j.1432-1033.1983.tb07572.x; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; RUBIO V, 1979, EUR J BIOCHEM, V93, P245, DOI 10.1111/j.1432-1033.1979.tb12817.x; SCOPES RK, 1982, PROTEIN PURIFICATION; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349	41	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4524	4532						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537838				2022-12-27	WOS:A1992HF64200040
J	JOHNSON, RL; VANHAASTERT, PJM; KIMMEL, AR; SAXE, CL; JASTORFF, B; DEVREOTES, PN				JOHNSON, RL; VANHAASTERT, PJM; KIMMEL, AR; SAXE, CL; JASTORFF, B; DEVREOTES, PN			THE CYCLIC-NUCLEOTIDE SPECIFICITY OF 3 CAMP RECEPTORS IN DICTYOSTELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; DISCOIDEUM CELLS; DEVELOPMENTAL REGULATION; AMP RECEPTOR; BINDING; EXPRESSION; ACTIVATION; PROTEIN; LIGAND; DIFFERENTIATION	cAMP receptors mediate signal transduction pathways during development in Dictyostelium. A cAMP receptor (cAR1) has been cloned and sequenced (Klein, P., Sun, T. J., Saxe, C. L., Kimmel, A. R., Johnson, R. L., and Devreotes, P. N. (1988) Science 241, 1467-1472) and recently several other cAR genes have been identified (Saxe, C. L., Johnson, R., Devreotes, P. N., and Kimmel, A. R. (1991a) Dev. Genet. 12, 6-13; Saxe, C. L., Johnson, R. L., Devreotes, P. N., and Kimmel, A. R. (1991b) Genes Dev. 5, 1-8). We have expressed three receptor subtypes, cAR1, cAR2, and cAR3, in growing cells and have investigated their affinity and pharmacological specificity in a series of [H-3]cAMP binding studies. In phosphate buffer, there were two affinity states of about 30 and 300 nM for cAR1 and 20 and 500 nM for cAR3 but no detectable affinity for cAR2. In the presence of 3 M ammonium sulfate, there was one affinity state of 4 nM for cAR1 and 11 nM for cAR2 and two affinity states of approximately 4 and 200 nM for cAR3. The relative affinities of 14 cyclic nucleotide derivatives were tested for each cAR in ammonium sulfate. These studies suggest a model (Van Haastert, P. J. M., and Kien, E. (1983) J. Biol. Chem. 258, 9636-9642) in which cAMP binds to all three receptor subtypes by maintaining hydrogen bond interactions at the N6 and O3' positions. Interactions at the exocyclic oxygens of cAMP varied between the receptors; cAR2 and cAR3 lacked a stereoselective interaction at the axial oxygen which was present in cAR1. The cleft, which binds the adenine ring of cAMP, was hydrophobic in cAR1 and cAR3 but relatively polar in cAR2. The analog specificity of cAR1 and cAR3 in phosphate buffer was similar to that measured in ammonium sulfate though the derivatives' relative affinity to cAMP was reduced. We conclude that these cAMP receptor subtypes can be distinguished by distinct pharmacological properties which will allow selective activation of each cAR during development.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; UNIV GRONINGEN,DEPT BIOCHEM,9747 AG GRONINGEN,NETHERLANDS; NIDDKD,CELLULAR & DEV BIOL LAB,BETHESDA,MD 20892; UNIV BREMEN,INST ORGAN CHEM,W-280 BREMEN,GERMANY	Johns Hopkins University; University of Groningen; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Bremen					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028007, R01GM034933, R37GM028007] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28007, GM34933] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARANIAK J, 1979, J CHEM SOC CHEM COMM, P940, DOI 10.1039/c39790000940; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; DEVREOTES PN, 1982, DEV DICTYOSTELIUM DI, P117; DEWIT RJW, 1982, FEBS LETT, V145, P150, DOI 10.1016/0014-5793(82)81225-8; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; FREY PA, 1985, SCIENCE, V228, P541, DOI 10.1126/science.2984773; GERISCH G, 1987, ANNU REV BIOCHEM, V56, P853, DOI 10.1146/annurev.biochem.56.1.853; GOMER RH, 1986, P NATL ACAD SCI USA, V83, P8624, DOI 10.1073/pnas.83.22.8624; HARIBABU B, 1986, MOL CELL BIOL, V6, P2402, DOI 10.1128/MCB.6.7.2402; HEMMES P, 1976, J CHEM SOC CHEM COMM, P929, DOI 10.1039/c39760000929; JANSSENS PMW, 1984, FEBS LETT, V176, P245, DOI 10.1016/0014-5793(84)80950-3; JASTORFF B, 1979, EUR J BIOCHEM, V101, P555, DOI 10.1111/j.1432-1033.1979.tb19750.x; JASTORFF B, 1974, BIOORG CHEM, V3, P103, DOI 10.1016/0045-2068(74)90034-0; JOHNSON RL, 1991, BIOCHEMISTRY-US, V30, P6982, DOI 10.1021/bi00242a025; JULIANI MH, 1977, BIOCHIM BIOPHYS ACTA, V497, P369, DOI 10.1016/0304-4165(77)90194-5; KESSIN RH, 1988, MICROBIOL REV, V52, P29, DOI 10.1128/MMBR.52.1.29-49.1988; KLEIN P, 1985, COLD SPRING HARB SYM, V50, P787, DOI 10.1101/SQB.1985.050.01.097; KLEIN P, 1987, J BIOL CHEM, V262, P358; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA PCC, 1990, MOL CELL BIOL, V10, P3297, DOI 10.1128/MCB.10.7.3297; MORR M, 1974, ANGEW CHEM, V86, P308; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURAYAMA A, 1971, J ORG CHEM, V36, P3029; OYAMA M, 1986, P NATL ACAD SCI USA, V83, P4819, DOI 10.1073/pnas.83.13.4819; SAXE CL, 1991, DEV GENET, V12, P6, DOI 10.1002/dvg.1020120104; SAXE CL, 1991, GENE DEV, V5, P1, DOI 10.1101/gad.5.1.1; SCHAAP P, 1984, DIFFERENTIATION, V27, P83, DOI 10.1111/j.1432-0436.1984.tb01411.x; SCHAAP P, 1985, EXP CELL RES, V159, P388, DOI 10.1016/S0014-4827(85)80012-4; SCHENK PW, 1991, DEV BIOL, V145, P110, DOI 10.1016/0012-1606(91)90217-Q; SCHWEIZER MP, 1973, CONFORMATION BIOLOGI, P329; SUN TJ, 1990, J CELL BIOL, V110, P1549, DOI 10.1083/jcb.110.5.1549; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; THEIBERT A, 1986, DEV BIOL, V114, P529, DOI 10.1016/0012-1606(86)90216-2; THEIBERT A, 1984, J BIOL CHEM, V259, P2318; VANHAASTERT PJM, 1983, J BIOL CHEM, V258, P9643; VANHAASTERT PJM, 1985, BIOCHIM BIOPHYS ACTA, V846, P324, DOI 10.1016/0167-4889(85)90002-3; VANHAASTERT PJM, 1985, BIOCHIM BIOPHYS ACTA, V845, P254, DOI 10.1016/0167-4889(85)90184-3; VANHAASTERT PJM, 1983, J BIOL CHEM, V258, P9636; VANHAASTERT PJM, 1983, EUR J BIOCHEM, V131, P659; VANHAASTERT PJM, 1991, ADV 2ND MESSENGER PH, V23, P186; VANMENTSCOHEN M, 1989, J BIOL CHEM, V264, P8717; VANMENTSCOHEN M, 1991, FEMS MICROBIOL LETT, V82, P9, DOI 10.1016/0378-1097(91)90412-4; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WILLIAMS JG, 1989, DEVELOPMENT, V107, P91; YAGURA TS, 1980, BIOCHEM BIOPH RES CO, V97, P737, DOI 10.1016/0006-291X(80)90326-5	47	85	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4600	4607						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537842				2022-12-27	WOS:A1992HF64200050
J	LEE, CG; HURWITZ, J				LEE, CG; HURWITZ, J			A NEW RNA HELICASE ISOLATED FROM HELA-CELLS THAT CATALYTICALLY TRANSLOCATES IN THE 3' TO 5' DIRECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION-FACTORS; MESSENGER-RNA; SEQUENCE HOMOLOGY; DEPENDENT ATPASE; PROTEIN; FRACTIONS; SHARES; DNA	We have purified an RNA helicase to near homogeneity from nuclear extracts of HeLa cells. The enzyme migrated as a 130-kDa protein upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis and exhibited a sedimentation coefficient of 6.4 on glycerol gradient centrifugation. The enzyme translocated in a 3' to 5' direction and acted catalytically, displacing at least a 4-fold molar excess of duplex RNA compared with the enzyme added. All eight common nucleoside triphosphates supported RNA helicase activity at relatively low concentrations (K(m) in values in the 15-20-mu-M level). In the presence of RNA and some single-stranded DNAs, the RNA helicase hydrolyzed all nucleoside triphosphates to nucleoside diphosphates and inorganic phosphate. The enzyme displaced deoxyribooligonucleotides provided they were hydrogen-bonded to RNA possessing 3' single-stranded regions, but it did not displace ribooligonucleotides hydrogen-bonded to DNA containing 3' single-stranded regions. The enzyme, in the absence of ATP, binds to both single-stranded RNA and DNA, but the amount of complex formed with RNA was 20-fold greater than the complex formed with DNA. In both cases, the complex formed in the absence of ATP was rapidly reversed by the addition of ATP and not by adenyl-5'-yl (beta,gamma-methylene)-diphosphate. We propose that the enzyme can bind to both single-stranded RNA and DNA and hydrolyze ATP, but by virtue of its greater stability on RNA, the enzyme can only translocate on RNA possessing 3' single-stranded regions.			LEE, CG (corresponding author), MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST, GRAD PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA.							BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CHEN JH, 1990, NUCLEIC ACIDS RES, V18, P6447, DOI 10.1093/nar/18.21.6447; CLAUDE A, 1991, J BIOL CHEM, V266, P10358; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; FURNEAUX HM, 1985, P NATL ACAD SCI USA, V82, P4351, DOI 10.1073/pnas.82.13.4351; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GRIFO JA, 1982, J BIOL CHEM, V257, P5246; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIN S, 1990, NUCLEIC ACIDS RES, V18, P7003, DOI 10.1093/nar/18.23.7003; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MCFARLAND G, 1991, P NATL ACAD SCI USA, V87, P4236; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; PRUZAN R, 1990, J BIOL CHEM, V265, P2804; RAY BK, 1985, J BIOL CHEM, V260, P7651; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SEO YS, 1991, J BIOL CHEM, V266, P13161; STRAUSS EJ, 1991, GENE DEV, V5, P629, DOI 10.1101/gad.5.4.629; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0	27	179	182	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4398	4407						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537828				2022-12-27	WOS:A1992HF64200024
J	XIE, YB; SUI, YP; SHAN, LX; PALVIMO, JJ; PHILLIPS, DM; JANNE, OA				XIE, YB; SUI, YP; SHAN, LX; PALVIMO, JJ; PHILLIPS, DM; JANNE, OA			EXPRESSION OF ANDROGEN RECEPTOR IN INSECT CELLS - PURIFICATION OF THE RECEPTOR AND RENATURATION OF ITS STEROID-BINDING AND DNA-BINDING FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; SPODOPTERA-FRUGIPERDA CELLS; RAT VENTRAL PROSTATE; ESTROGEN-RECEPTOR; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; DEOXYRIBONUCLEIC-ACID; MOLECULAR-WEIGHT; RESPONSE ELEMENT; PROTEIN	A full-length rat androgen receptor cDNA was used to produce a recombinant baculovirus (AcrAR) by homologous recombination. Spodoptera frugiperda (Sf9) cells infected with this virus expressed a 110-kDa polypeptide that amounted up to about one-third of total cell protein. Studies with AR antibodies confirmed that this protein was indeed rAR. Only a minor portion of the recombinant AR was soluble in buffers without ionic detergents, but its complete solubilization was achieved in 6 M guanidine HCl (GdnHCl). Electron microscopy of cell pellets revealed that AR was localized to electron-dense cytoplasmic aggregates. The soluble cytosolic receptor was biologically active, in that it bound [H-3]mibolerone with high affinity and specificity and interacted with an androgen-responsive element. The functions of the GdnHCl-solubilized AR were partially restored by a 20-50-fold dilution. The solubilized receptor was purified to an apparent homogeneity in a single step by gel filtration on a Sephacryl S-400 column in the presence of 6 M GdnHCl. The homogeneous AR protein could be renatured to bind [H-3]mibolerone, interact specifically with a DNA element, and be recognized by receptor antibodies. Receptor-DNA interaction was stabilized by an antibody directed against the N-terminal part and abolished by an antibody against the hinge region of the receptor. Zn2+ ions were essential for the purified receptor to refold into a specific DNA-binding form during the renaturation, with the optimal ZnCl2 concentration being 50-100-mu-M depending on the buffer conditions. Cd2+ ions were also capable of restoring the receptor's DNA-binding activity and did so at concentrations 10-fold lower than those of the Zn2+ ions.	POPULAT COUNCIL, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Population Council; Rockefeller University				Palvimo, Jorma/0000-0003-2373-0578	NICHD NIH HHS [HD13541] Funding Source: Medline; NIDDK NIH HHS [DK37692] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037692] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALNEMRI ES, 1991, J BIOL CHEM, V266, P3925; Ausubel FM, 1988, MOL REPROD DEV; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGER FG, 1989, ANNU REV PHYSIOL, V51, P51, DOI 10.1146/annurev.ph.51.030189.000411; BERNDT N, 1990, EUR J BIOCHEM, V190, P291, DOI 10.1111/j.1432-1033.1990.tb15575.x; BROWN M, 1990, J BIOL CHEM, V265, P11238; CATTERALL JF, 1986, RECENT PROG HORM RES, V42, P71; CHANG CH, 1983, BIOCHEMISTRY-US, V22, P6170, DOI 10.1021/bi00295a020; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; DENISON SH, 1989, ENDOCRINOLOGY, V124, P1091, DOI 10.1210/endo-124-2-1091; DEVOS P, 1991, J BIOL CHEM, V266, P3439; EDWARDS DP, 1989, MOL ENDOCRINOL, V3, P381, DOI 10.1210/mend-3-2-381; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; ISOMAA V, 1982, ENDOCRINOLOGY, V111, P833, DOI 10.1210/endo-111-3-833; JANNE OA, 1991, ANN NY ACAD SCI, V626, P81; JOHNSON MP, 1987, BIOCHEMISTRY-US, V26, P3174, DOI 10.1021/bi00385a035; KRIEG A, 1969, J INVERTEBR PATHOL, V13, P272, DOI 10.1016/0022-2011(69)90219-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; OHARANEMOTO Y, 1991, J BIOCHEM, V109, P113, DOI 10.1093/oxfordjournals.jbchem.a123330; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PHILLIPS DM, 1990, CELL TISSUE RES, V261, P249, DOI 10.1007/BF00318666; ROBEL P, 1983, HORM RES, V18, P28, DOI 10.1159/000179776; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; SAKAI D, 1984, ENDOCRINOLOGY, V115, P2379, DOI 10.1210/endo-115-6-2379; SHAN LX, 1990, MOL ENDOCRINOL, V4, P1636, DOI 10.1210/mend-4-11-1636; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SONE T, 1990, J BIOL CHEM, V265, P21997; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; Summers MD, 1987, TEXAS AGR EXPT STATI; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P798, DOI 10.1021/bi00781a012; THEVENY B, 1987, NATURE, V329, P79, DOI 10.1038/329079a0; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; VANDERWILK F, 1987, J GEN VIROL, V68, P2615, DOI 10.1099/0022-1317-68-10-2615; WILSON JD, 1981, SCIENCE, V211, P1278, DOI 10.1126/science.7010602; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YOUNG CYF, 1990, MOL ENDOCRINOL, V4, P1841, DOI 10.1210/mend-4-12-1841	48	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4939	4948						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537872				2022-12-27	WOS:A1992HF64200096
J	LEBARON, RG; ZIMMERMANN, DR; RUOSLAHTI, E				LEBARON, RG; ZIMMERMANN, DR; RUOSLAHTI, E			HYALURONATE BINDING-PROPERTIES OF VERSICAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCANS; LYMPHOCYTE HOMING RECEPTOR; LINK PROTEIN; CARTILAGE PROTEOGLYCAN; CELL-MIGRATION; CHICK-EMBRYO; CDNA CLONES; SEQUENCE; EXPRESSION; ADHESION	We have previously cloned a large chondroitin sulfate proteoglycan (versican) from human fibroblasts. The primary sequence shows that the N terminus contains sequence homology with known hyaluronate-binding molecules, suggesting that versican can bind hyaluronate. To test this hypothesis we have reconstructed a full-length versican cDNA and a versican cDNA fragment encoding the N terminus and have transfected Chinese hamster ovary cells and mouse 3T3 fibroblasts, respectively, with these constructs. The transfected Chinese hamster ovary cells make a proteoglycan shown to be versican by enzymatic and immunologic analysis. No corresponding proteoglycan was seen in the control cells. Using hyaluronate affinity chromatography, we show that recombinant versican specifically binds hyaluronate and does not bind to heparin or chondroitin sulfate. The transfected fibroblasts make a 78-kDa truncated form of versican that also binds hyaluronate and does not bind the related polysaccharides, showing that the hyaluronate binding activity resides at the N terminus of versican. The binding of versican to hyaluronate is substrate-concentration dependent and time dependent and can be competed with unlabeled versican. The dissociation constant for versican binding to hyaluronate was determined to be 4 x 10(-9)M.	UNIV ZURICH,INST CLIN PATHOL,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich	LEBARON, RG (corresponding author), LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037, USA.		Lebaron, Richard/K-4722-2013	Lebaron, Richard/0000-0002-7770-305X	NCI NIH HHS [CA30199, CA42507] Funding Source: Medline; NIAMS NIH HHS [AR08131] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042507, P30CA030199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008131] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; BAKER JR, 1987, METHOD ENZYMOL, V144, P401; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRAY B, 1989, BIOCHEM J, V262, P225, DOI 10.1042/bj2620225; BRENNAN MJ, 1983, CANCER RES, V43, P4302; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; DOEGE K, 1986, P NATL ACAD SCI USA, V83, P3761, DOI 10.1073/pnas.83.11.3761; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FICHARD A, 1991, DEV BIOL, V148, P1, DOI 10.1016/0012-1606(91)90312-Q; FOSANG AJ, 1990, MATRIX, V10, P306, DOI 10.1016/S0934-8832(11)80186-1; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FROST E, 1978, VIROLOGY, V91, P39, DOI 10.1016/0042-6822(78)90353-7; FUNDERBURG FM, 1986, J CELL BIOL, V103, P2475, DOI 10.1083/jcb.103.6.2475; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GOLDBERG RL, 1984, J CELL BIOL, V99, P2114, DOI 10.1083/jcb.99.6.2114; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; Hascall V.C., 1981, CELL BIOL EXTRACELLU, P39; JOHANSSON S, 1985, BIOCHEM J, V232, P161, DOI 10.1042/bj2320161; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KAUFMAN RJ, 1982, J MOL BIOL, V159, P601, DOI 10.1016/0022-2836(82)90103-6; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KIMURA JH, 1987, METHOD ENZYMOL, V144, P372; KISS I, 1987, P NATL ACAD SCI USA, V84, P6399, DOI 10.1073/pnas.84.18.6399; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; MORGELIN M, 1988, BIOCHEM J, V253, P175; MUNAIM SI, 1991, DEV BIOL, V143, P297, DOI 10.1016/0012-1606(91)90080-M; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; OAKLEY RA, 1991, DEV BIOL, V147, P187, DOI 10.1016/S0012-1606(05)80017-X; OOHIRA A, 1991, J NEUROSCI, V11, P822; ORKIN RW, 1985, DEV BIOL, V107, P527, DOI 10.1016/0012-1606(85)90333-1; PERIDES G, 1989, J BIOL CHEM, V264, P5981; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; UNDERHILL CB, 1982, J CELL PHYSIOL, V110, P123, DOI 10.1002/jcp.1041100204; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; VERNA JM, 1989, INT J DEV NEUROSCI, V7, P389, DOI 10.1016/0736-5748(89)90060-9; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZABEAU M, 1982, EMBO J, V1, P1217, DOI 10.1002/j.1460-2075.1982.tb00016.x; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	59	284	285	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10003	10010						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577773				2022-12-27	WOS:A1992HT96500084
J	UCHIDA, T; YAMASHITA, S				UCHIDA, T; YAMASHITA, S			MOLECULAR-CLONING, CHARACTERIZATION, AND EXPRESSION IN ESCHERICHIA-COLI OF A CDNA-ENCODING MAMMALIAN CHOLINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENOVO PHOSPHATIDYLCHOLINE BIOSYNTHESIS; MITOGENIC GROWTH-FACTORS; GLOBIN MESSENGER-RNA; RAT-LIVER; NUCLEOTIDE-SEQUENCE; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; ETHANOLAMINE KINASE; FUNCTIONAL-ANALYSIS; RESISTANCE GENES	A rat liver lambda-gt11 cDNA library was screened with antibody against rat liver choline kinase. One of the putative phage clones obtained was found to express choline kinase activity in infected Escherichia coli cells and used for the isolation of fully extended cDNA clones by hybridization. The obtained clones had identical overlapping nucleotide sequences and gave a composite cDNA sequence of 2540 bases. Poly(A)+ tails were found at three different sites of the cDNA sequence. Within the sequence there was a large open reading frame encoding 435 amino acids with a molecular mass of 49,743 Da. When this open reading frame was placed after the trc promoter and introduced into E. coli cells, fully active choline kinase was produced. This enzyme was partially purified using a published choline kinase purification method and was found to mediate the phosphorylation of choline, N,N-dimethylethanolamine, N-monomethylethanolamine, and ethanolamine. Similar to the case with choline kinases from various sources, K(m) decreased as the number of N-methyl groups increased. The deduced amino acid sequence significantly resembled the yeast choline kinase sequence. It also showed local sequence similarity to protein kinases and some bacterial phosphotransferases. Northern blot analysis revealed that the cDNA probe hybridized to 2.8- and 1.8-kilobase RNA in various rat tissues. The sizes of the transcripts were fairly consistent with that of cDNA. The order of mRNA abundance was testis, brain, lung, kidney, and liver, but did not coincide with the order of the activity levels in these tissues. These results show that the cloned cDNA encodes one of the choline kinase isoforms present in mammalian tissues.			UCHIDA, T (corresponding author), GUNMA UNIV,SCH MED,DEPT BIOCHEM,MAEBASHI,GUNMA 371,JAPAN.							AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIBB MJ, 1985, MOL GEN GENET, V199, P26, DOI 10.1007/BF00327505; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BROPHY PJ, 1977, EUR J BIOCHEM, V78, P491, DOI 10.1111/j.1432-1033.1977.tb11761.x; BURT AM, 1975, ANAL BIOCHEM, V65, P215, DOI 10.1016/0003-2697(75)90506-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARY GL, 1987, ARCH BIOCHEM BIOPHYS, V254, P214, DOI 10.1016/0003-9861(87)90097-X; FARRELL PM, 1974, BIOCHEM BIOPH RES CO, V57, P696, DOI 10.1016/0006-291X(74)90602-0; FERRETTI JJ, 1986, J BACTERIOL, V167, P631, DOI 10.1128/jb.167.2.631-638.1986; GIL A, 1987, CELL, V49, P399, DOI 10.1016/0092-8674(87)90292-3; GILAD GM, 1984, J NEUROCHEM, V43, P1538, DOI 10.1111/j.1471-4159.1984.tb06075.x; GILAD GM, 1981, BRAIN RES, V220, P420, DOI 10.1016/0006-8993(81)91236-1; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HISE MK, 1984, AM J PHYSIOL, V247, pF260, DOI 10.1152/ajprenal.1984.247.2.F260; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHIDATE K, 1985, BIOCHIM BIOPHYS ACTA, V836, P119; ISHIDATE K, 1980, BIOCHIM BIOPHYS ACTA, V620, P49; ISHIDATE K, 1983, BIOCHEM BIOPH RES CO, V111, P683, DOI 10.1016/0006-291X(83)90360-1; ISHIDATE K, 1984, J BIOL CHEM, V259, P4706; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KANEHISA M, 1982, NUCLEIC ACIDS RES, V10, P183, DOI 10.1093/nar/10.1.183; KAPLAN O, 1991, J BIOL CHEM, V266, P3688; KENNEDY EP, 1961, FED PROC, V20, P934; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KO KWS, 1986, J BIOL CHEM, V261, P7846; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MANIATIS T, 1982, MOL CLONING LABORATO, P371; MAZODIER P, 1985, NUCLEIC ACIDS RES, V13, P195, DOI 10.1093/nar/13.1.195; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; OKA T, 1979, DEV BIOL, V68, P311, DOI 10.1016/0012-1606(79)90264-1; PADDON HB, 1982, BIOCHIM BIOPHYS ACTA, V710, P112, DOI 10.1016/0005-2760(82)90197-7; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PORTER TJ, 1990, J BIOL CHEM, V265, P414; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; TADOKORO K, 1985, BIOCHIM BIOPHYS ACTA, V835, P501; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; UCHIDA T, 1990, BIOCHIM BIOPHYS ACTA, V1043, P281, DOI 10.1016/0005-2760(90)90028-V; ULANE RE, 1980, LIFE SCI, V26, P2143, DOI 10.1016/0024-3205(80)90601-3; ULANE RE, 1978, BIOCHIM BIOPHYS ACTA, V531, P295, DOI 10.1016/0005-2760(78)90211-4; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VIGO C, 1981, BIOCHIM BIOPHYS ACTA, V665, P546, DOI 10.1016/0005-2760(81)90269-1; VIGO C, 1981, BIOCHEM J, V200, P321, DOI 10.1042/bj2000321; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WARDEN CH, 1984, BIOCHIM BIOPHYS ACTA, V792, P270, DOI 10.1016/0005-2760(84)90194-2; WEINHOLD PA, 1973, BIOCHIM BIOPHYS ACTA, V326, P43, DOI 10.1016/0005-2760(73)90026-X; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; WITTENBERG J, 1953, J BIOL CHEM, V202, P431; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	66	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10156	10162						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577786				2022-12-27	WOS:A1992HT96500106
J	VENEMA, J; BARTOSOVA, Z; NATARAJAN, AT; VANZEELAND, AA; MULLENDERS, LHF				VENEMA, J; BARTOSOVA, Z; NATARAJAN, AT; VANZEELAND, AA; MULLENDERS, LHF			TRANSCRIPTION AFFECTS THE RATE BUT NOT THE EXTENT OF REPAIR OF CYCLOBUTANE PYRIMIDINE DIMERS IN THE HUMAN ADENOSINE-DEAMINASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-IX; SACCHAROMYCES-CEREVISIAE; DIFFERENTIAL REPAIR; HEMOPHILIA-B; DNA-REPAIR; ACTIVE DNA; DHFR GENE; UV DAMAGE; FIBROBLASTS; DEFICIENCY	To study the relationship between transcription and strand-specific repair of UV-induced cyclobutane pyrimidine dimers, dimer removal was analyzed in a cell line containing two alleles of an inactivated adenosine deaminase (ADA) gene. The cell line was derived from a patient suffering from severe combined immunodeficiency. The disease was caused by a deletion of the complete promoter of the gene as well as the first exon of the ADA gene. This resulted in a true null allele without any detectable transcription (Berkvens, T. M., Gerritsen, E. J. A., Oldenburg, M., Breukel, C., Wijnen, J. T. H., Van Ormondt, H., Vossen, J. M., Van der Eb, A. J., and Meera Khan, P. (1987) Nucleic Acids Res. 15, 9365-9378). Despite this lack of transcription, repair of the ADA gene in this cell line was found to be very efficient with 80% of the dimers being removed within 24 h after UV irradiation. However, the initial rapid repair which is associated with the transcribed strand in normal cells is absent. Dimer removal from two inactive loci, 754 and coagulation factor IX, was much less efficient with only 40% dimers removed after 24 h. From this data, we conclude that transcription is not required for efficient repair of a gene, but forms an additional signal for accelerated repair of the transcribed strand. Furthermore, we suggest that different levels of repair exist between non-transcribed sequences in active genes and those in repressed loci. The results are discussed in terms of the current ideas about the mechanism of preferential DNA repair in human cells.	LEIDEN UNIV, DEPT RADIAT GENET & CHEM MUTAGENESIS, MGC, 2333 AL LEIDEN, NETHERLANDS; INTERUNIV RES INST RADIAT PROTECT & RADIOPATHOL, JA COHEN INST, LEIDEN, NETHERLANDS; SLOVAK ACAD SCI, CANC RES INST, CS-80936 BRATISLAVA, CZECHOSLOVAKIA	Leiden University; Leiden University - Excl LUMC; Slovak Academy of Sciences								ANSON DS, 1984, EMBO J, V3, P1053, DOI 10.1002/j.1460-2075.1984.tb01926.x; ANTONARAKIS SE, 1988, ADV HUM GENET, V17, P27; BERKVENS TM, 1990, GENOMICS, V7, P486, DOI 10.1016/0888-7543(90)90190-6; BERKVENS TM, 1987, NUCLEIC ACIDS RES, V15, P9365, DOI 10.1093/nar/15.22.9365; BIERNAT J, 1989, J BIOCHEM BIOPH METH, V19, P155, DOI 10.1016/0165-022X(89)90023-7; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; DECOCK JGR, 1991, NUCLEIC ACIDS RES, V19, P3289, DOI 10.1093/nar/19.12.3289; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HOFKER MH, 1986, HUM GENET, V74, P270, DOI 10.1007/BF00282547; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LATTIER DL, 1989, NUCLEIC ACIDS RES, V17, P1061, DOI 10.1093/nar/17.3.1061; LEADON SA, 1991, MUTAT RES, V255, P67, DOI 10.1016/0921-8777(91)90019-L; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MULLENDERS LHF, 1988, NUCLEIC ACIDS RES, V16, P10607, DOI 10.1093/nar/16.22.10607; NAKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; PALMER TD, 1989, BLOOD, V73, P438; TERLETH C, 1990, EMBO J, V9, P2899, DOI 10.1002/j.1460-2075.1990.tb07480.x; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; TERLETH C, 1991, THESIS STATE U LEIDE; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; WILL CL, 1986, MOL PHARMACOL, V29, P643; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	26	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8852	8856						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577723				2022-12-27	WOS:A1992HR85400026
J	EDWARDS, GM; HUBER, HE; DEFEOJONES, D; VUOCOLO, G; GOODHART, PJ; MAIGETTER, RZ; SANYAL, G; OLIFF, A; HEIMBROOK, DC				EDWARDS, GM; HUBER, HE; DEFEOJONES, D; VUOCOLO, G; GOODHART, PJ; MAIGETTER, RZ; SANYAL, G; OLIFF, A; HEIMBROOK, DC			PURIFICATION AND CHARACTERIZATION OF A FUNCTIONALLY HOMOGENEOUS 60-KDA SPECIES OF THE RETINOBLASTOMA GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LARGE T-ANTIGEN; SUSCEPTIBILITY GENE; CELL-CYCLE; PROTEIN; BINDING; EXPRESSION; ADENOVIRUS-E1A; COMPLEX; ENCODES; REGIONS	The retinoblastoma susceptibility gene (RB) encodes a 928-amino acid protein (pRB) that is hypothesized to function in a pathway that restricts cell proliferation. The immortalizing proteins from three distinct DNA tumor viruses (SV40 large T antigen, adenovirus E1a, and human papilloma virus Type 16 E7) have been shown to interact with RB protein through two noncontiguous regions comprised of amino acids 393-572 (domain A) and 646-772 (domain B). We constructed a truncated form of RB (RB p60) that retains these two domains but eliminates the N-terminal 386 amino acids of RB. RB p60 was expressed in Escherichia coli in inclusion bodies. After solubilization, it was refolded in the presence of magnesium chloride, and the active protein was isolated with an E7 peptide affinity column. The protein that elutes from this column is functionally homogenous in its ability to bind immobilized E7 protein. Thermal denaturation studies provide additional evidence for the conformational homogeneity of the isolated protein. This purification scheme allows the isolation of significant amounts of RB p60 protein that is suitable for structural and functional studies.	MERCK SHARP & DOHME LTD,DEPT CANC RES,BLDG WP16-101,W POINT,PA 19486; MERCK SHARP & DOHME LTD,DEPT CELLULAR & MOLEC BIOL,W POINT,PA 19486; MERCK SHARP & DOHME LTD,DEPT PHARMACEUT RES,W POINT,PA 19486	Merck & Company; Merck & Company; Merck & Company								BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; Brandford M.M., 1976, ANAL BIOCHEM, V72, P248; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; HAUSEN HZ, 1987, PAPOVAVIRIDAE, V2, P245; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JONES RE, 1990, J BIOL CHEM, V265, P12782; JONES RE, 1992, J BIOL CHEM, V266, P908; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P51; LINEMEYER DL, 1987, BIO-TECHNOL, V5, P960, DOI 10.1038/nbt0987-960; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; STEWART J, 1984, SOLID PHASE PEPTIDE, P71; STIRDIVANT SM, 1992, IN PRESS MOL CELL BI; WANG NP, 1990, CELL GROWTH DIFFER, V1, P429; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	32	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					7971	7974						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569054				2022-12-27	WOS:A1992HQ18500004
J	MENGELE, R; SUMPER, M				MENGELE, R; SUMPER, M			DRASTIC DIFFERENCES IN GLYCOSYLATION OF RELATED S-LAYER GLYCOPROTEINS FROM MODERATE AND EXTREME HALOPHILES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOBACTERIUM-VOLCANII; METHYLATION ANALYSIS; BIOSYNTHESIS; PURIFICATION; PROTEIN; LINKAGE	The outer surface of the moderate halophilic archaebacterium Haloferax volcanii (formerly named Halobacterium volcanii) is covered with a hexagonally packed surface (S) layer glycoprotein. The polypeptide (794 amino acid residues) contains 7 N-glycosylation sites. Four of these sites were isolated as glycopeptides and the structure of one of the corresponding saccharides was determined. Oligosaccharides consisting of beta-1,4-linked glucose residues are attached to the protein via the linkage unit asparaginyl-glucose. In the related glycoprotein from the extreme halophile Halobacterium halobium, the glucose residues are replaced by sulfated glucuronic acid residues, causing a drastic increase in surface charge density. This is discussed in terms of a recent model explaining the stability of halophilic proteins.	UNIV REGENSBURG,LEHRSTUHL BIOCHEM 1,W-8400 REGENSBURG,GERMANY	University of Regensburg								HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HARRIS PJ, 1984, CARBOHYD RES, V127, P59, DOI 10.1016/0008-6215(84)85106-X; Jansson P-E., 1976, CHEM COMMUN U STOCKH, V8, P1; KESSEL M, 1988, EMBO J, V7, P1549, DOI 10.1002/j.1460-2075.1988.tb02974.x; LECHNER J, 1987, J BIOL CHEM, V262, P9724; LECHNER J, 1989, ANNU REV BIOCHEM, V58, P173, DOI 10.1146/annurev.bi.58.070189.001133; LECHNER J, 1985, J BIOL CHEM, V260, P860; MESCHER MF, 1976, J BIOL CHEM, V251, P2005; MEVARECH M, 1985, J BACTERIOL, V162, P461, DOI 10.1128/JB.162.1.461-462.1985; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; PAUL G, 1987, J BIOL CHEM, V262, P9587; RAO JKM, 1981, BIOCHEMISTRY-US, V20, P6536, DOI 10.1021/bi00526a004; SUMPER M, 1990, J BACTERIOL, V172, P7111, DOI 10.1128/jb.172.12.7111-7118.1990; SUMPER M, 1987, BIOCHIM BIOPHYS ACTA, V906, P69, DOI 10.1016/0304-4157(87)90005-0; VASKOVSKY VE, 1970, COMP BIOCHEM PHYSIOL, V34, P163, DOI 10.1016/0010-406X(70)90064-2; WAEGHE TJ, 1983, CARBOHYD RES, V123, P281, DOI 10.1016/0008-6215(83)88484-5; WIELAND F, 1983, P NATL ACAD SCI-BIOL, V80, P5470, DOI 10.1073/pnas.80.18.5470; ZACCAI G, 1989, J MOL BIOL, V208, P491, DOI 10.1016/0022-2836(89)90512-3	18	79	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8182	8185						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569073				2022-12-27	WOS:A1992HQ18500035
J	ADEMA, GJ; BAAS, PD				ADEMA, GJ; BAAS, PD			A NOVEL CALCITONIN-ENCODING MESSENGER-RNA IS PRODUCED BY ALTERNATIVE PROCESSING OF CALCITONIN CALCITONIN GENE-RELATED PEPTIDE-I PRE-MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED PRODUCTION; EXPRESSION; PROCALCITONIN; INVITRO; SPLICE; MODEL; CELL	The calcitonin/calcitonin gene-related peptide-I (CALC-1) gene was one of the first examples of a cellular gene exhibiting alternative, tissue-specific processing of its primary RNA transcript. Calcitonin (CT) mRNA is the predominant product in thyroid C cells, whereas calcitonin gene-related peptide-I mRNA is the main product in neurons of the central and peripheral nervous systems. In this study, we report the existence of a novel CT-like (CT*) mRNA derived from the human CALC-I gene. CT* mRNA is the result of a novel splicing reaction which was initially detected in vitro. Translation of CT* mRNA will result in a prohormone (proCT*) which only differs from proCalcitonin (proCT) in its carboxyl terminus. Proteolytic processing of proCT* predicts, beside the amino-terminal cleavage peptide and CT, the existence of a novel carboxyl-terminal protein of 21 amino acids.	UNIV UTRECHT,INST MOLEC BIOL & MED BIOTECHNOL,PADWALAAN 8,3584 CH UTRECHT,NETHERLANDS; UNIV UTRECHT,PHYSIOL CHEM LAB,3584 CH UTRECHT,NETHERLANDS	Utrecht University; Utrecht University			Adema, G.J./H-8007-2014					ADEMA GJ, 1988, NUCLEIC ACIDS RES, V16, P9513, DOI 10.1093/nar/16.20.9513; ADEMA GJ, 1990, NUCLEIC ACIDS RES, V18, P5365, DOI 10.1093/nar/18.18.5365; AMARA SG, 1984, MOL CELL BIOL, V4, P2151, DOI 10.1128/MCB.4.10.2151; BIRNBAUM RS, 1982, J BIOL CHEM, V257, P241; BOVENBERG RAL, 1989, BIOCHIM BIOPHYS ACTA, V1008, P223, DOI 10.1016/0167-4781(80)90013-5; BOVENBERG RAL, 1986, NUCLEIC ACIDS RES, V14, P8785, DOI 10.1093/nar/14.22.8785; BOVENBERG RAL, 1986, NUCLEIC ACIDS RES, V16, P7867; BREIMER LH, 1988, BIOCHEM J, V255, P377, DOI 10.1042/bj2550377; BURNS DM, 1989, MOL ENDOCRINOL, V3, P140, DOI 10.1210/mend-3-1-140; BURNS DM, 1989, P NATL ACAD SCI USA, V86, P9519, DOI 10.1073/pnas.86.23.9519; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COTE GJ, 1990, J BONE MINER RES, V5, P165, DOI 10.1002/jbmr.5650050210; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; EDBROOKE MR, 1985, EMBO J, V4, P715, DOI 10.1002/j.1460-2075.1985.tb03688.x; GALLI G, 1988, P NATL ACAD SCI USA, V85, P2439, DOI 10.1073/pnas.85.8.2439; JACOBS JW, 1981, SCIENCE, V213, P457, DOI 10.1126/science.6264603; LEMOULLEC JM, 1984, FEBS LETT, V167, P93, DOI 10.1016/0014-5793(84)80839-X; Leong S, 1981, ADV THYROID NEOPLASI, P95; MARTIAL K, 1990, BIOCHEM BIOPH RES CO, V172, P1111; MOSSELMAN S, 1988, FEBS LETT, V239, P227, DOI 10.1016/0014-5793(88)80922-0; PETERSON ML, 1989, MOL CELL BIOL, V9, P726, DOI 10.1128/MCB.9.2.726; ROSENFELD MG, 1983, NATURE, V304, P1129; SCHMITT P, 1987, CELL, V50, P31, DOI 10.1016/0092-8674(87)90659-3; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STEENBERGH PH, 1986, FEBS LETT, V209, P97, DOI 10.1016/0014-5793(86)81091-2; STEENBERGH PH, 1985, CALCITONIN 1984, P23; STEPHENS C, 1987, EMBO J, V6, P227; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; ZAIDI M, 1987, Q J EXP PHYSIOL CMS, V72, P371, DOI 10.1113/expphysiol.1987.sp003084	29	30	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7943	7948						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560023				2022-12-27	WOS:A1992HN48500103
J	DENTON, RR; KOSZEWSKI, NJ; NOTIDES, AC				DENTON, RR; KOSZEWSKI, NJ; NOTIDES, AC			ESTROGEN-RECEPTOR PHOSPHORYLATION - HORMONAL DEPENDENCE AND CONSEQUENCE ON SPECIFIC DNA-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGESTERONE-RECEPTOR; RESPONSIVE ELEMENT; GLUCOCORTICOID RECEPTORS; ESTRADIOL; CELLS; GENE; TRANSFORMATION; TRANSCRIPTION; TYROSINE; IDENTIFICATION	We have shown that the P-32-phosphorylation of the nuclear estrogen receptor from human MCF-7 cells or the calf uterus is estrogen-dependent. Within 2 min of estradiol treatment the phosphorylation of the estrogen receptor from MCF-7 cells doubled, and increased 4-fold within 20-40 min of estradiol treatment. Progesterone was ineffective in stimulating the phosphorylation of the estrogen receptor. Phosphoamino acid analysis indicated that the estrogen-stimulated phosphorylation of the human or calf estrogen receptor occurred only on serine residue(s). Phosphotryptic peptide analysis of the human estrogen receptor by two-dimensional peptide mapping or reverse-phase high pressure liquid chromatography revealed that only a single tryptic peptide (site) was phosphorylated. Treatment of the estrogen receptor with potato acid phosphatase resulted in the dephosphorylation of the P-32-labeled estrogen receptor and a decrease of the receptor's affinity for specific DNA sequences. These data suggest that transcriptional activation by the estrogen receptor involves an estrogen-dependent phosphorylation of the receptor resulting in its increased affinity for specific DNA sequences.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOPHYS,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR ENVIRONM HLTH SCI,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NICHD NIH HHS [HD 06707] Funding Source: Medline; NIEHS NIH HHS [ES07026, ES 01247] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BURCH JBE, 1988, MOL CELL BIOL, V8, P1123, DOI 10.1128/MCB.8.3.1123; DENNER LA, 1990, J BIOL CHEM, V265, P16548; HOECK W, 1990, J BIOL CHEM, V265, P5403; HORWITZ KB, 1978, J BIOL CHEM, V253, P8185; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES BB, 1991, MOL ENDOCRINOL, V5, P1137, DOI 10.1210/mend-5-8-1137; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KOSZEWSKI NJ, 1991, MOL ENDOCRINOL, V5, P1129, DOI 10.1210/mend-5-8-1129; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LOGEAT F, 1985, BIOCHEM BIOPH RES CO, V131, P421, DOI 10.1016/0006-291X(85)91819-4; MAGASANIK B, 1989, BIOCHIMIE, V71, P1005, DOI 10.1016/0300-9084(89)90104-1; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MENDEL DB, 1986, NATURE, V324, P478, DOI 10.1038/324478a0; MIGLIACCIO A, 1989, MOL ENDOCRINOL, V3, P1061, DOI 10.1210/mend-3-7-1061; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; MUNCK A, 1968, J BIOL CHEM, V243, P5556; NIELSEN S, 1975, BIOCHIM BIOPHYS ACTA, V381, P377, DOI 10.1016/0304-4165(75)90243-3; NOTIDES AC, 1975, J BIOL CHEM, V250, P3945; NOTIDES AC, 1981, P NATL ACAD SCI-BIOL, V78, P4926, DOI 10.1073/pnas.78.8.4926; NOTIDES AC, 1974, J BIOL CHEM, V249, P1866; ORTI E, 1989, J BIOL CHEM, V264, P9728; PIKE JW, 1985, BIOCHEM BIOPH RES CO, V131, P378, DOI 10.1016/0006-291X(85)91813-3; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; SASSON S, 1988, MOL ENDOCRINOL, V2, P307, DOI 10.1210/mend-2-4-307; SHERIDAN PL, 1988, MOL ENDOCRINOL, V2, P1329, DOI 10.1210/mend-2-12-1329; SHERIDAN PL, 1989, J BIOL CHEM, V264, P7054; SKAFAR DF, 1985, J BIOL CHEM, V260, P2208; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; TIERUNGROJ W, 1987, J BIOL CHEM, V262, P17342; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WASHBURN T, 1991, MOL ENDOCRINOL, V5, P235, DOI 10.1210/mend-5-2-235; WEI LL, 1987, BIOCHEMISTRY-US, V26, P6262, DOI 10.1021/bi00393a046; WEICHMAN BM, 1977, J BIOL CHEM, V252, P8856	44	127	128	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7263	7268						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559970				2022-12-27	WOS:A1992HN48500014
J	HIGUCHI, M; OHEDA, M; KUBONIWA, H; TOMONOH, K; SHIMONAKA, Y; OCHI, N				HIGUCHI, M; OHEDA, M; KUBONIWA, H; TOMONOH, K; SHIMONAKA, Y; OCHI, N			ROLE OF SUGAR CHAINS IN THE EXPRESSION OF THE BIOLOGICAL-ACTIVITY OF HUMAN ERYTHROPOIETIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; RECOMBINANT HUMAN ERYTHROPOIETIN; HAMSTER OVARY CELLS; N-LINKED OLIGOSACCHARIDES; MOUSE BONE-MARROW; URINARY; LIVER; CARBOHYDRATE; BIOASSAY; CULTURE	Various deglycosylated derivatives of recombinant human erythropoietin (hEPO) were prepared and used to determine the role of the sugar chains in the expression of its biological activity in vivo and in vitro. Three N-linked oligosaccharides of hEPO have been partially or fully removed to obtain N-glycan (NG) (2)-, NG(1)-, and NG(0)-hEPO carrying two, one, and no N-linked sugar chains, respectively. The preparation. lacking only O-linked sugar chain O O-glycan (OG) (0)-hEPO was also used. As de-N-glycosylation proceeded, the in vivo activity of the hormone decreased drastically, and the activity of these derivatives was correlated with the number of sialic acids hound to them. On the contrary, the in vitro activity was increased by the de-N-glycosylation; NG(0)-hEPO showed a 3-fold higher specific activity than the intact hormone. This was confirmed by binding experiments of the derivatives to target cells. The in vitro activity and the affinity also correlated with the number of sialic acids bound to the deglycosylated hEPO preparations. On the other hand, OG(0)-hEPO was as active as the intact hormone in vivo and in vitro. In conclusion, the N-linked sugar chains are not required for in vitro activity but required for in vivo activity, acting as anchors for the essential terminal sialic acids. The O-linked sugar chain has no essential role in the biological activity of the hormone in vivo or in vitro.	CHUGAI PHARMACEUT CO LTD, RES SECT 2, FUJI GOTEMBA RES LABS, 1-135 KOMAKADO, GOTEMBA, SHIZUOKA 412, JAPAN	Chugai Pharmaceutical Co., Ltd.; Roche Holding								ANNABLE L, 1972, B WORLD HEALTH ORGAN, V47, P99; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRIED W, 1972, BLOOD-J HEMATOL, V40, P671, DOI 10.1182/blood.V40.5.671.671; FUKUDA MN, 1989, BLOOD, V73, P84; GOLDWASSER E, 1974, J BIOL CHEM, V249, P4202; GOLDWASSER E, 1968, ANN NY ACAD SCI, V149, P49, DOI 10.1111/j.1749-6632.1968.tb15135.x; HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HASE S, 1986, J BIOCHEM-TOKYO, V100, P1; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; IMAI N, 1990, EUR J BIOCHEM, V194, P457, DOI 10.1111/j.1432-1033.1990.tb15639.x; IMAI N, 1990, J BIOCHEM, V107, P352, DOI 10.1093/oxfordjournals.jbchem.a123050; ISCOVE NN, 1975, EXP HEMATOL, V3, P32; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; KAWAMURA A, 1991, BRIT J HAEMATOL, V77, P424, DOI 10.1111/j.1365-2141.1991.tb08595.x; KRYSTAL G, 1981, J LAB CLIN MED, V97, P144; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWY PH, 1960, NATURE, V185, P102, DOI 10.1038/185102a0; LUKOWSKY WA, 1972, CAN J BIOCHEM CELL B, V50, P909, DOI 10.1139/o72-127; RAMBACH WA, 1958, P SOC EXP BIOL MED, V99, P482; RIGHETTI PG, 1974, J CHROMATOGR, V98, P271, DOI 10.1016/S0021-9673(00)92076-4; SASAKI H, 1988, BIOCHEMISTRY-US, V27, P8618, DOI 10.1021/bi00423a017; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SPIVAK JL, 1989, BLOOD, V73, P90; TAKEMOTO H, 1985, ANAL BIOCHEM, V145, P245, DOI 10.1016/0003-2697(85)90357-4; TAKEUCHI M, 1990, J BIOL CHEM, V265, P12127; TAKEUCHI M, 1988, J BIOL CHEM, V263, P3657; TOJO A, 1987, BIOCHEM BIOPH RES CO, V148, P443, DOI 10.1016/0006-291X(87)91131-4; TOMIYA N, 1987, ANAL BIOCHEM, V163, P489, DOI 10.1016/0003-2697(87)90253-3; TSUDA E, 1988, BIOCHEMISTRY-US, V27, P5646, DOI 10.1021/bi00415a038; TSUDA E, 1990, EUR J BIOCHEM, V188, P405, DOI 10.1111/j.1432-1033.1990.tb15417.x; ZANJANI ED, 1981, J CLIN INVEST, V67, P1183, DOI 10.1172/JCI110133	32	147	171	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7703	7709						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560005				2022-12-27	WOS:A1992HN48500072
J	KHACHIGIAN, LM; CHESTERMAN, CN				KHACHIGIAN, LM; CHESTERMAN, CN			SYNTHETIC PEPTIDES REPRESENTING THE ALTERNATIVELY SPLICED EXON OF THE PLATELET-DERIVED GROWTH FACTOR-A-CHAIN MODULATE MITOGENESIS STIMULATED BY NORMAL HUMAN SERUM AND SEVERAL GROWTH-FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-GROWTH; STRUCTURAL CHARACTERIZATION; ENDOTHELIAL-CELLS; BINDING DOMAINS; FACTOR-ALPHA; PDGF-BB; PURIFICATION; EXPRESSION; RECEPTORS; LOCALIZATION	Alternative splicing results in two distinct forms of the platelet-derived growth factor (PDGF) A-chain that differ by a hydrophilic carboxyl terminus consisting of 18 amino acids (A194-211). The functional significance of this region is unclear. Previous results indicate that a radioiodinated tyrosinated synthetic peptide corresponding to A194-211 binds specifically, saturably, and with low affinity to a large population of sites on Balb/c 3T3 and several other cell lines (Khachigian, L. M., Owensby, D. A., and Chesterman, C. N. (1992) J. Biol. Chem. 267, 1660-1666). In this paper, we report that (Y)A194-211 and A194-211 can modulate the cellular proliferative response to normal human serum and several individual polypeptide growth factors as a consequence. When these peptides were coincubated separately with whole serum, PDGF, epidermal growth factor, or fibroblast growth factor, DNA synthesis was inhibited in a dose-dependent fashion and maximally by 200-mu-M peptide. In addition, both peptides could attenuate the stimulation of cell division by serum and PDGF. Peptides with similar charge or length failed to modify the level of proliferation. These observations were not due to cytotoxicity. Synthetic peptides such as (Y)A194-211 and A194-211 that influence cellular proliferation may be useful in modulating the cellular response to selected growth factors.	UNIV NEW S WALES,PRINCE OF WALES HOSP,DEPT HAEMATOL,RANDWICK,NSW 2031,AUSTRALIA	University of New South Wales Sydney			Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				ABELL TJ, 1989, BIOCHEM BIOPH RES CO, V164, P108, DOI 10.1016/0006-291X(89)91689-6; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BERMAN P, 1987, CELL, V51, P135, DOI 10.1016/0092-8674(87)90018-3; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BETSHOLTZ C, 1990, NATURE, V344, P299, DOI 10.1038/344299a0; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BOWENPOPE DF, 1984, BLOOD, V64, P458; BUCHMAN C, 1990, MOL CELL BIOL, V10, P4778, DOI 10.1128/MCB.10.9.4778; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BYWATER M, 1988, MOL CELL BIOL, V8, P2753, DOI 10.1128/MCB.8.7.2753; CARA JF, 1988, ENDOCRINOLOGY, V122, P2881, DOI 10.1210/endo-122-6-2881; COLLINS T, 1987, NATURE, V328, P621, DOI 10.1038/328621a0; DAMORE PA, 1990, HAEMOSTASIS, V20, P159; DEUEL TF, 1984, J CLIN INVEST, V74, P669, DOI 10.1172/JCI111482; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; EPPSTEIN DA, 1989, J CELL PHYSIOL, V141, P420, DOI 10.1002/jcp.1041410224; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOUSTIN AS, 1986, CANCER RES, V46, P1015; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAMMACHER A, 1988, EUR J BIOCHEM, V176, P179, DOI 10.1111/j.1432-1033.1988.tb14266.x; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; KHACHIGIAN LM, 1991, J IMMUNOL METHODS, V140, P249, DOI 10.1016/0022-1759(91)90378-S; KHACHIGIAN LM, 1992, J BIOL CHEM, V267, P1660; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LIU MW, 1990, CIRCULATION, V81, P1089, DOI 10.1161/01.CIR.81.3.1089; LOBB R, 1986, J BIOL CHEM, V261, P1924; MAHER DW, 1989, MOL CELL BIOL, V9, P2251, DOI 10.1128/MCB.9.5.2251; MATOSKOVA B, 1989, MOL CELL BIOL, V9, P2251; MERCOLA M, 1988, SCIENCE, V241, P1223, DOI 10.1126/science.3413486; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NILSSON J, 1985, ATHEROSCLEROSIS, V58, P109, DOI 10.1016/0021-9150(85)90059-0; NISTER M, 1988, CANCER RES, V48, P3910; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; PELTON JT, 1985, PEPTIDES, V6, P159, DOI 10.1016/0196-9781(85)90026-9; RAINES EW, 1985, METHOD ENZYMOL, V109, P749; RAINES EW, 1982, J BIOL CHEM, V257, P5154; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROUYERFESSARD C, 1989, LIFE SCI, V45, P829, DOI 10.1016/0024-3205(89)90176-8; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SJOLUND M, 1989, CELL TISSUE RES, V256, P35; THYBERG J, 1990, J CELL SCI, V97, P219; TRIMBLE ER, 1987, P NATL ACAD SCI USA, V84, P3146, DOI 10.1073/pnas.84.10.3146; VOGEL S, 1989, BIOCHEMISTRY-US, V28, P2961, DOI 10.1021/bi00433a033	47	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7478	7482						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559986				2022-12-27	WOS:A1992HN48500042
J	TOKUMURA, A; TSUTSUMI, T; TSUKATANI, H				TOKUMURA, A; TSUTSUMI, T; TSUKATANI, H			TRANSBILAYER MOVEMENT AND METABOLIC-FATE OF ETHER-LINKED PHOSPHATIDIC-ACID (1-O-OCTADECYL-2-ACETYL-SN-GLYCEROL 3-PHOSPHATE) IN GUINEA-PIG PERITONEAL POLYMORPHONUCLEAR LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING FACTOR; PROTEIN-KINASE-C; PHOSPHOLIPASE-D; HUMAN-NEUTROPHILS; LYSOPHOSPHATIDIC ACIDS; GLYCEROLIPID SYNTHESIS; STRUCTURAL ANALOGS; PLASMA-MEMBRANES; AGGREGATION; PHOSPHOHYDROLASE	1-O-Octadecyl-2-acetyl-sn-glycerol 3-phosphate (octadecylacetyl-GP) and its deacetylation product were used as a model of phosphatidic acid and its lyso derivatives, respectively. The binding, transbilayer movement, and intermembranous transport, which should be related to its metabolism in guinea pig peritoneal polymorphonuclear leukocytes, were studied. The albumin extraction procedure (Tokumura, A., Tsutsumi, T., Yoshida, J., and Tsukatani, H. (1990) Biochim. Biophys. Acta 1044, 91-100) was used for studying the transbilayer movement of [H-3]octadecylacetyl-GP. The binding, translocation, and metabolism of octadecylacetylglycerol, a dephosphorylated product of octadecylacetyl-GP, in polymorphonuclear leukocytes were also investigated for comparison. The translocation of octadecylacetyl-GP was dependent on temperature, but not on its concentration (in the range of 1-100 nM). The rate of translocation of octadecylacetyl-GP was much slower than that of octadecylacetylglycerol. Treatment of polymorphonuclear leukocytes with N-ethylmaleimide did not affect the translocation of octadecylacetyl-GP. These results suggest that the transbilayer movement of octadecylacetyl-GP is driven by a diffusion process, not by a carrier protein. From these findings, the process of translocation of octadecylacetyl-GP is concluded to be a rate-limiting step in its metabolic conversion to triglyceride, phosphatidylethanolamine, and phosphatidylcholine.			TOKUMURA, A (corresponding author), UNIV TOKUSHIMA,FAC PHARMACEUT SCI,TOKUSHIMA 770,JAPAN.							AGWU DE, 1989, BIOCHEM BIOPH RES CO, V159, P79, DOI 10.1016/0006-291X(89)92407-8; ALLAN D, 1978, NATURE, V276, P289, DOI 10.1038/276289a0; ANDO Y, 1989, AM J PHYSIOL, V257, pF524, DOI 10.1152/ajprenal.1989.257.4.F524; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BENTON AM, 1982, BLOOD, V60, P642; BERGMANN WL, 1984, BIOCHIM BIOPHYS ACTA, V772, P328, DOI 10.1016/0005-2736(84)90150-0; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BLANK ML, 1974, BIOCHIM BIOPHYS ACTA, V348, P397, DOI 10.1016/0005-2760(74)90219-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BRINDLEY DN, 1984, PROG LIPID RES, V23, P115, DOI 10.1016/0163-7827(84)90001-8; CHAE K, 1973, BIOCHEM BIOPH RES CO, V51, P119, DOI 10.1016/0006-291X(73)90516-0; DAKHIL T, 1965, N-S ARCH EX PATH PH, V251, P344; ENGLISH D, 1991, BIOCHEM BIOPH RES CO, V175, P423, DOI 10.1016/0006-291X(91)91581-V; GANONG BR, 1984, BIOCHEMISTRY-US, V23, P4977, DOI 10.1021/bi00316a023; HOLMSEN H, 1983, ANAL BIOCHEM, V131, P266, DOI 10.1016/0003-2697(83)90165-3; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JELSEMA CL, 1978, J BIOL CHEM, V253, P7960; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; KROLL MH, 1989, J CELL PHYSIOL, V139, P558, DOI 10.1002/jcp.1041390315; METZ SA, 1990, BIOCHEM J, V270, P427, DOI 10.1042/bj2700427; MORROT G, 1989, BIOCHEMISTRY-US, V28, P3456, DOI 10.1021/bi00434a046; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; OHATA H, 1990, RES COMMUN CHEM PATH, V68, P329; OHTSUKA T, 1989, J BIOCHEM-TOKYO, V106, P259, DOI 10.1093/oxfordjournals.jbchem.a122841; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; PAI JK, 1988, J BIOL CHEM, V263, P12472; RECORD M, 1985, BIOCHIM BIOPHYS ACTA, V819, P1, DOI 10.1016/0005-2736(85)90188-9; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; SCHUMACHER KA, 1979, THROMB HAEMOSTASIS, V42, P631; SIMON MF, 1982, BIOCHEM BIOPH RES CO, V108, P1743, DOI 10.1016/S0006-291X(82)80113-7; SNYDER F, 1970, BIOCHIM BIOPHYS ACTA, V202, P244, DOI 10.1016/0005-2760(70)90185-2; TOKUMURA A, 1981, BIOCHEM BIOPH RES CO, V99, P391, DOI 10.1016/0006-291X(81)91758-7; TOKUMURA A, 1985, ARZNEIMITTEL-FORSCH, V35-1, P587; TOKUMURA A, 1990, BIOCHIM BIOPHYS ACTA, V1044, P91, DOI 10.1016/0005-2760(90)90223-K; TOKUMURA A, 1981, J PHARMACOL EXP THER, V219, P219; TOKUMURA A, 1987, THROMB RES, V46, P51, DOI 10.1016/0049-3848(87)90206-4; TOKUMURA A, 1980, ARCH INT PHARMACOD T, V245, P74; TOKUMURA A, 1982, J PHARM PHARMACOL, V34, P514, DOI 10.1111/j.2042-7158.1982.tb04776.x; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VOGT W, 1963, BIOCHEM PHARMACOL, V12, P415, DOI 10.1016/0006-2952(63)90074-1	41	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7275	7283						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559972				2022-12-27	WOS:A1992HN48500016
J	NIKLINSKA, BB; YAMADA, H; OSHEA, JJ; JUNE, CH; ASHWELL, JD				NIKLINSKA, BB; YAMADA, H; OSHEA, JJ; JUNE, CH; ASHWELL, JD			TYROSINE KINASE-REGULATED AND INOSITOL PHOSPHATE-INDEPENDENT CA2+ ELEVATION AND MOBILIZATION IN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; PROTEIN-PHOSPHORYLATION; PHOSPHOLIPID BREAKDOWN; MONOCLONAL-ANTIBODY; ACTIVATION; CALCIUM; EXPRESSION; COMPLEX; CA-2+	Perturbation of the T cell antigen-specific receptor leads to a series of signaling events that includes a rapid increase in phosphoinositide hydrolysis, intracellular Ca2+, and tyrosine phosphorylation. We have examined the function of tyrosine phosphorylation in isolation by introducing the v-src tyrosine kinase into a T cell hybridoma. T cell receptor-mediated increases in phosphoinositide hydrolysis and, in particular the generation of inositol 1,4,5-trisphosphate, were comparable between v-src+ and v-src- cells. Unexpectedly, the v-src+ cells exhibited spontaneously elevated intracellular Ca2+ and exaggerated Ca2+ increases when stimulated via the T cell receptor. The enhanced Ca2+ response was not due to tyrosine phosphorylation of the T cell receptor itself, since the phenotype was evident in T cell receptor zeta-chain-/v-src+ cells as well. These results demonstrate that an active protein tyrosine kinase can markedly affect intracellular Ca2+ handling by a process independent of inositol 1,4,5-trisphosphate production and T cell receptor tyrosine phosphorylation and raise the possibility that tyrosine kinases may directly regulate T cell receptor-mediated changes in intracellular Ca2+.	USN,IMMUNE CELL BIOL PROGRAM,MED RES INST,BETHESDA,MD 20889; NCI,FREDERICK CANC RES & DEV CTR,EXPTL IMMUNOL LAB,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	NIKLINSKA, BB (corresponding author), NIH,IMMUNE CELL BIOL SECT,BIOL RESPONSE MODIFIERS PROGRAM,BETHESDA,MD 20892, USA.							ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; BIJSTERBOSCH MK, 1986, J IMMUNOL, V137, P1294; CHOW SC, 1990, J BIOL CHEM, V265, P902; CHUEH SH, 1987, J BIOL CHEM, V262, P13857; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; FOSKETT JK, 1988, AM J PHYSIOL, V255, pC566, DOI 10.1152/ajpcell.1988.255.4.C566; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GRABER M, 1991, J IMMUNOL, V146, P2935; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MAGNALDO I, 1986, J BIOL CHEM, V261, P6916; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; MERCEP M, 1988, J IMMUNOL, V140, P324; MERCEP M, 1988, SCIENCE, V242, P571, DOI 10.1126/science.2845582; MONROE JG, 1989, J EXP MED, V169, P1059, DOI 10.1084/jem.169.3.1059; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OSHEA JJ, 1987, J IMMUNOL, V139, P3463; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P1741, DOI 10.1073/pnas.88.5.1741; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; ROSOFF PM, 1987, CELL, V49, P845, DOI 10.1016/0092-8674(87)90622-2; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; STEWART SJ, 1991, CELL REGUL, V2, P841, DOI 10.1091/mbc.2.10.841; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Weissman A M, 1989, Year Immunol, V4, P74; WILLCOCKS AL, 1989, BIOCHEM J, V257, P297, DOI 10.1042/bj2570297; YELLEN AJ, 1991, J IMMUNOL, V146, P1446	41	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7154	7159						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551921				2022-12-27	WOS:A1992HM05300107
J	DEWAARD, P; VLIEGENTHART, JFG; HARADA, T; SUGAHARA, K				DEWAARD, P; VLIEGENTHART, JFG; HARADA, T; SUGAHARA, K			STRUCTURAL STUDIES ON SULFATED OLIGOSACCHARIDES DERIVED FROM THE CARBOHYDRATE-PROTEIN LINKAGE REGION OF CHONDROITIN-6-SULFATE PROTEOGLYCANS OF SHARK CARTILAGE .2. 7 COMPOUNDS CONTAINING 2 OR 3 SULFATE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEOGLYCAN; NMR-SPECTROSCOPY	Shark cartilage proteoglycans bear predominantly chondroitin 6-sulfate. After exhaustive protease digestion, reductive beta-elimination and subsequent chondroitinase ABC digestion, 13 hexasaccharide alditols were obtained from the carbohydrate-protein linkage region and six of them contain 0 or 1 sulfate and/or 1 phosphate residue (Sugahara, K., Ohi, Y., Harada, T., de Waard, P., and Vliegenthart, J. F. G. (1992) J. Biol. Chem. 267, 6027-6035). The other seven compounds, which represent approximately 60% of the isolated linkage hexasaccharides, were analyzed by chondroitinase ACII digestion in conjunction with high performance liquid chromatography and by 500-MHz one- and two dimensional H-1 NMR spectroscopy. All seven compounds have the following conventional structure in common. [GRAPHICS] Two disulfated compounds have an O-sulfate on C-6 of the Gal-2 residue attached to xylitol in combination with an O-sulfate on C-4 or on C-6 of the GalNAc residue. The third disulfated compound has O-sulfate on C-6 of Gal-2, and also on C-6 of Gal-3. Two of the trisulfated compounds also have O-sulfate on C-6 of both Gal-2 and Gal-3 with in addition sulfate on C-6 or C-4 of GalNAc. The other two trisulfated Compounds have O-sulfate on C-6 of Gal-2 and on C-4 of Gal-3 in conjunction with sulfate on C-6 or C-4 of GalNAc.	UNIV UTRECHT,DEPT BIOORGAN CHEM,BIJVOET CTR,UTRECHT,NETHERLANDS; SEIKAGAKU KOGYO CO,KURIHAMA PLANT,YOKOSUKA,KANAGAWA 239,JAPAN; KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,SAKYO KU,KYOTO 606,JAPAN	Utrecht University; Kyoto University								BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; Ernst RR, 1966, ADV MAGN RESON, V2, P1; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; HARRIS MJ, 1970, CARBOHYD RES, V15, P57, DOI 10.1016/S0008-6215(00)80294-3; KESSLER H, 1987, J AM CHEM SOC, V109, P607, DOI 10.1021/ja00236a063; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; POOLE AR, 1986, BIOCHEM J, V236, P1; RASMUSSEN S, 1988, J CELL BIOL, V107, P1959, DOI 10.1083/jcb.107.5.1959; RODEN L, 1980, BIOCH GLYCOPROTEINS, P491; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1991, IN PRESS EUR J BIOCH; SUGAHARA K, 1992, IN PRESS EUR J BIOCH	17	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6036	6043						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556115				2022-12-27	WOS:A1992HK31800050
J	HUNTER, I; SCHULTHESS, T; ENGEL, J				HUNTER, I; SCHULTHESS, T; ENGEL, J			LAMININ CHAIN ASSEMBLY BY TRIPLE AND DOUBLE-STRANDED COILED-COIL STRUCTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE PROTEINS; NEUROMUSCULAR-JUNCTION; A-CHAIN; CELLS; EXPRESSION; SUBUNITS; COLLAGEN; BIOSYNTHESIS; MECHANISM; REGIONS	We have previously provided evidence that laminin assembly occurs by the specific interaction of the alpha-helical domains of the A, B1, and B2 chains, located within the long arm of the molecule (Hunter, I., Schulthess, T., Bruch, M., Beck, K., and Engel, J. (1990) Eur. J. Biochem. 188, 205-211). Recent evidence for noncoordinate synthesis of the laminin chains, and in particular, the absence of the 400-kDa A chain from laminins produced by a number of cell types, has led us to examine the molecular mechanism of laminin assembly using the isolated A and B1-B2 chains of laminin fragment E8. E8A shows little tendency to self-associate, and when renatured from urea forms globular structures with little detectable alpha-helix. In contrast, E8B1-B2 renatures to form rod-like molecules, 30 nm in length. The rod-like structure, high alpha-helix content, and sharp thermal transition indicate that they are double stranded coiled coils. When mixed in equimolar amounts, E8A and E8B1-B2 renature to form molecules which are biochemically and ultrastructurally indistinguishable from native E8. If E8A and E8B1-B2 are renatured separately and mixed at a 1:1 molar ratio, they also form E8 molecules. These results suggest a mechanism of laminin assembly which involves the formation of a double coiled-coil B1-B2 intermediate with which the A chain subsequently interacts to form a triple coiled-coil laminin molecule. In addition, our results indicate that isoforms consisting of the B1 and B2 chains only would form stable "laminin-like" structures.	UNIV BASEL, BIOCTR, BIOPHYS CHEM ABT, CH-4056 BASEL, SWITZERLAND	University of Basel								ARUMUGHAM RG, 1988, CONNECT TISSUE RES, V18, P135, DOI 10.3109/03008208809008065; BARLOW DP, 1984, EMBO J, V3, P2355, DOI 10.1002/j.1460-2075.1984.tb02140.x; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; CONWAY JF, 1991, INT J BIOL MACROMOL, V13, P14, DOI 10.1016/0141-8130(91)90004-E; COOPER AR, 1983, DEV BIOL, V96, P467, DOI 10.1016/0012-1606(83)90183-5; COOPER AR, 1981, EUR J BIOCHEM, V119, P189, DOI 10.1111/j.1432-1033.1981.tb05593.x; CORNBROOKS CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3850, DOI 10.1073/pnas.80.12.3850; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; ENGEL J, 1991, BIOCHEM SOC T, V19, P839, DOI 10.1042/bst0190839; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; HAAS C, 1991, EUR J BIOCHEM, V197, P799; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUNTER I, 1990, EUR J BIOCHEM, V188, P205, DOI 10.1111/j.1432-1033.1990.tb15391.x; KLEIN G, 1990, DEVELOPMENT, V110, P823; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; KUHL U, 1982, DEV BIOL, V93, P344, DOI 10.1016/0012-1606(82)90122-1; LEHRER SS, 1990, J BIOL CHEM, V265, P1134; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; MO JM, 1991, P NATL ACAD SCI USA, V88, P916, DOI 10.1073/pnas.88.3.916; MORITA A, 1985, BIOCHEM J, V229, P259, DOI 10.1042/bj2290259; OLSEN D, 1989, LAB INVEST, V60, P772; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAULSSON M, 1989, J BIOL CHEM, V264, P18726; PAULSSON M, 1985, EMBO J, V4, P309, DOI 10.1002/j.1460-2075.1985.tb03630.x; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PAULSSON M, 1991, IN PRESS J BIOL CHEM; PETERS BP, 1985, J BIOL CHEM, V260, P4732; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123; WU CY, 1988, BIOCHEMISTRY-US, V27, P8780, DOI 10.1021/bi00424a014	39	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6006	6011						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556112				2022-12-27	WOS:A1992HK31800046
J	LEE, CS; OKA, T				LEE, CS; OKA, T			A PREGNANCY-SPECIFIC MAMMARY NUCLEAR FACTOR INVOLVED IN THE REPRESSION OF THE MOUSE BETA-CASEIN GENE-TRANSCRIPTION BY PROGESTERONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIGENE FAMILY; TRANSGENIC MICE; FINE-STRUCTURE; MESSENGER-RNA; PLASMID DNA; EXPRESSION; GLAND; PROTEIN; QUANTITATION; PROLACTIN	The sequence-specific binding pattern of mammary nuclear proteins to the 545-base pair (bp) 5'-flanking region of the mouse beta-casein gene was compared between pregnant and lactating mice by a gel mobility shift assay. By using appropriate probes, two complexes were detected only during pregnancy, whereas an additional four complexes were detected during both pregnancy and lactation. The two pregnancy-specific complexes showed identical electrophoretic mobility and were cross-competed with two unlabeled DNA fragments used to generate the probes. Methylation interference experiments indicated that the two binding regions involved guanosine residues at nucleotides -350 and -8, and the sequences around each guanosine residue have a common palindromic sequence, 5'-TGAT/ATCA-3'. This binding factor is termed pregnancy-specific mammary nuclear factor. In gene transfection experiments, expression of the chimeric beta-casein-CAT gene linked to the 545 bp of mouse beta-casein gene promoter region was maximally induced when transfected mammary epithelial cells were cultured with the lactogenic hormones prolactin, hydrocortisone, and insulin, whereas it was very low when insulin alone was added. The addition of progesterone together with the lactogenic hormones inhibited the hormonal induction of the chimeric gene, whereas co-transfection with an oligonucleotide containing the pregnancy-specific mammary nuclear factor binding site substantially overcame the progesterone-mediated repression of transcription. Furthermore, mutation of the pregnancy-specific mammary nuclear factor binding sites of the chimeric beta-casein-CAT gene resulted in attenuation of the inhibitory effect of progesterone without blocking the stimulatory effect of the lactogenic hormones. These results indicate the presence of a pregnancy-specific mammary nuclear factor(s) that bind to two separate sites of the beta-casein gene promoter and suggest that it may serve as a repressor that mediates the inhibitory action of progesterone on beta-casein gene transcription.			LEE, CS (corresponding author), NIDDKD,MOLEC & CELLULAR BIOL LAB,BETHESDA,MD 20892, USA.							ALEXANDER LJ, 1988, EUR J BIOCHEM, V178, P395, DOI 10.1111/j.1432-1033.1988.tb14463.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DEVINOY E, 1988, REPROD NUTR DEV, V28, P1145, DOI 10.1051/rnd:19880711; DOPPLER W, 1990, MOL ENDOCRINOL, V4, P912, DOI 10.1210/mend-4-6-912; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; GORHAM C, 1982, MOL CELL BIOL, V2, P1044; GORODETSKY SI, 1988, GENE, V66, P87, DOI 10.1016/0378-1119(88)90227-2; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; JONES WK, 1985, J BIOL CHEM, V260, P7042; LEE CS, 1987, ENDOCRINOL JAPON, V34, P857; LEE KF, 1989, MOL CELL BIOL, V9, P560, DOI 10.1128/MCB.9.2.560; LEE KF, 1988, NUCLEIC ACIDS RES, V16, P1027, DOI 10.1093/nar/16.3.1027; MATUSIK RJ, 1978, J BIOL CHEM, V253, P2343; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCORMACK JT, 1974, J ENDOCRINOL, V62, P101, DOI 10.1677/joe.0.0620101; NAKHASI HL, 1979, J BIOL CHEM, V254, P6016; Rosen J M, 1980, Recent Prog Horm Res, V36, P157; ROSEN JM, 1978, BIOCHEMISTRY-US, V17, P290, DOI 10.1021/bi00595a016; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; STEWART AF, 1984, NUCLEIC ACIDS RES, V12, P3895, DOI 10.1093/nar/12.9.3895; TERADA N, 1988, J STEROID BIOCHEM, V29, P99, DOI 10.1016/0022-4731(88)90382-2; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; YOSHIMURA M, 1989, GENE, V78, P267, DOI 10.1016/0378-1119(89)90229-1; YOSHIMURA M, 1990, P NATL ACAD SCI USA, V87, P3670, DOI 10.1073/pnas.87.10.3670; YULEE LY, 1983, J BIOL CHEM, V258, P794; YULEE LY, 1986, NUCLEIC ACIDS RES, V14, P1883, DOI 10.1093/nar/14.4.1883	31	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5797	5801						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556095				2022-12-27	WOS:A1992HK31800015
J	NETZKER, R; GREINER, E; EIGENBRODT, E; NOGUCHI, T; TANAKA, T; BRAND, K				NETZKER, R; GREINER, E; EIGENBRODT, E; NOGUCHI, T; TANAKA, T; BRAND, K			CELL CYCLE-ASSOCIATED EXPRESSION OF M2-TYPE ISOZYME OF PYRUVATE-KINASE IN PROLIFERATING RAT THYMOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PERIPHERAL LYMPHOCYTES; RNA; GENE; SEQUENCES; ELECTROPHORESIS; HYBRIDIZATION; NUCLEOTIDE; MICE	During a complete cell cycle of rat thymocytes stimulated by concanavalin A and interleukin 2, the activity and mRNA level of pyruvate kinase reached a maximum (8-12-fold increase) 48 h after stimulation coinciding with the S-phase of the cell cycle. Increases of cellular enzyme activity, pyruvate kinase protein, and mRNA levels are correlated up to 48 h of culture. Afterwards pyruvate kinase activity and mRNA levels decrease, whereas the pyruvate kinase protein continues to increase throughout mitosis. This change of specific pyruvate kinase activity points to a posttranslational modification of the enzyme besides its transcriptional regulation. The presence of the M2-type isozyme was determined by the following methods: (a) native cellulose acetate electrophoresis and activity staining, (b) Northern blot hybridization with M1- and M2-specific cDNA probes, and (c) determination of kinetic parameters. The isozyme pattern did not change during the cell cycle progression. The induction of pyruvate kinase is completely abolished by 2-difluoromethylornithine-mediated polyamine depletion. However, the proportion of hybridizable pyruvate kinase mRNA was not affected. These data suggest the requirement of polyamines for efficient translation rather than transcription during cell growth.	UNIV ERLANGEN NURNBERG,FAC MED,INST BIOCHEM,FAHRSTR 17,W-8520 ERLANGEN,GERMANY; UNIV GIESSEN,INST BIOCHEM & ENDOCRINOL,W-6300 GIESSEN,GERMANY; OSAKA UNIV,SCH MED,DEPT NUTR & PHYSIOL CHEM,OSAKA 530,JAPAN	University of Erlangen Nuremberg; Justus Liebig University Giessen; Osaka University								ASHWELL G, 1957, METHOD ENZYMOL, V3, P73, DOI 10.1016/S0076-6879(57)03350-9; BAHNEMANN R, 1990, VERH DEUT G, V74, P373; BRAND K, 1987, J BIOL CHEM, V262, P15232; BRAND K, 1988, EUR J BIOCHEM, V172, P695, DOI 10.1111/j.1432-1033.1988.tb13944.x; BRUNN H, 1979, H-S Z PHYSIOL CHEM, V360, P1357; CHELEY S, 1984, ANAL BIOCHEM, V137, P15, DOI 10.1016/0003-2697(84)90339-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULVENOR JG, 1976, BIOCHIM BIOPHYS ACTA, V437, P354, DOI 10.1016/0304-4165(76)90005-2; EIGENBRODT E, 1977, H-S Z PHYSIOL CHEM, V358, P1057, DOI 10.1515/bchm2.1977.358.2.1057; FISTER P, 1983, BIOCHEM BIOPH RES CO, V115, P409, DOI 10.1016/S0006-291X(83)80159-4; FUJII H, 1983, METHOD ENZYMAT AN, V3, P496; IMAMURA K, 1982, METHOD ENZYMOL, V90, P150; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LONE YC, 1986, FEBS LETT, V195, P97, DOI 10.1016/0014-5793(86)80138-7; Maniatis T., 1982, MOL CLONING; MARJANOVIC S, 1988, BIOCHIM BIOPHYS ACTA, V970, P1, DOI 10.1016/0167-4889(88)90215-7; MARJANOVIC S, 1990, BIOCHIM BIOPHYS ACTA, V1087, P1, DOI 10.1016/0167-4781(90)90113-G; MUIRHEAD H, 1990, BIOCHEM SOC T, V18, P193, DOI 10.1042/bst0180193; NOGUCHI T, 1984, J BIOL CHEM, V259, P2651; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; OSKAM R, 1985, TUMOUR BIOL, V6, P75; PRESEK P, 1988, FEBS LETT, V242, P194, DOI 10.1016/0014-5793(88)81014-7; RIJKSEN G, 1988, FEBS LETT, V233, P69, DOI 10.1016/0014-5793(88)81357-7; SALISBURY JG, 1979, J BIOCHEM BIOPH METH, V1, P341, DOI 10.1016/0165-022X(79)90025-3; SUSOR WA, 1971, ANAL BIOCHEM, V43, P147, DOI 10.1016/0003-2697(71)90119-9; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; TREMP GL, 1989, J BIOL CHEM, V264, P19904	30	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6421	6424						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556146				2022-12-27	WOS:A1992HK31800104
J	ZEHNDER, JL; HIRAI, K; SHATSKY, M; MCGREGOR, JL; LEVITT, LJ; LEUNG, LLK				ZEHNDER, JL; HIRAI, K; SHATSKY, M; MCGREGOR, JL; LEVITT, LJ; LEUNG, LLK			THE CELL-ADHESION MOLECULE CD31 IS PHOSPHORYLATED AFTER CELL ACTIVATION - DOWN-REGULATION OF CD31 IN ACTIVATED LYMPHOCYTES-T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN GENE SUPERFAMILY; DEPENDENT PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; IMMUNE-SYSTEM; RECEPTOR; ANTIGEN; MONOCYTES; PLATELETS; FRAGMENTS; CLONING	We report the independent cloning of the cDNA for CD31, a recently described cell adhesion molecule of the immunoglobulin gene superfamily present on platelets, granulocytes, monocytes, lymphocytes, and endothelial cells. Northern analysis revealed three major mRNA transcripts in Jurkat (a human T cell line) and K562 and HEL (leukemia cell lines) cells with an additional 5.3-kilobase transcript seen in cultured human umbilical vein endothelial cells. Following T cell activation, CD31 mRNA was down-regulated by Northern analysis, and decreased CD31 protein expression was confirmed by immunoblots. The down-regulation of CD31 was partially mediated by decreased transcription as demonstrated by nuclear run-on studies. CD31 became rapidly phosphorylated in platelets, Jurkat cells, and endothelial cells after cell activation. We were unable to demonstrate the presence of a phosphotyrosine in CD31 using monoclonal and polyclonal phosphotyrosine antibodies. In addition, CD31 phosphorylation in platelets was induced by phorbol ester and was blocked by staurosporin, a protein kinase C inhibitor, suggesting that CD31 phosphorylation is mediated by protein kinase C and involves serine and/or threonine residues. The phosphorylation of CD31 following cell activation may modulate its cellular adhesiveness, and the down-regulation of its expression may serve to impart target specificity and to localize effector lymphocytes to areas of inflammation.	INSERM, U331, F-69008 LYONS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	ZEHNDER, JL (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DIV HEMATOL, STANFORD, CA 94305 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002213, R01HL035774] Funding Source: NIH RePORTER; NHLBI NIH HHS [1RO1-HL35774, K04 HL02213-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOYERT SM, 1986, J IMMUNOL, V137, P3909; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HARA T, 1986, LEUKOCYTE TYPING 2, V3, P77; HESSION C, 1991, J BIOL CHEM, V266, P6682; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JUNE CH, 1990, J IMMUNOL, V144, P1591; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LEVITT L, 1985, BLOOD, V65, P663; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LYONS AB, 1988, PATHOLOGY, V20, P137, DOI 10.3109/00313028809066624; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; OHTO H, 1985, BLOOD, V66, P873; PARISE LV, 1990, BLOOD, V75, P2363; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1983, J BIOL CHEM, V258, P2010; SIMMONS DL, 1990, J EXP MED, V171, P2147, DOI 10.1084/jem.171.6.2147; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; VANMOURIK JA, 1985, J BIOL CHEM, V260, P1300; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZIMMERMANN W, 1988, CANCER RES, V48, P2550	37	95	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5243	5249						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544907				2022-12-27	WOS:A1992HH74700040
J	WINSTON, LA; BERTICS, PJ				WINSTON, LA; BERTICS, PJ			GROWTH-HORMONE STIMULATES THE TYROSINE PHOSPHORYLATION OF 42-KDA AND 45-KDA ERK-RELATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; ADIPOSE DIFFERENTIATION; 3T3-F442A FIBROBLASTS; RAT ADIPOCYTES; MAP KINASE; INSULIN; CELLS; IDENTIFICATION; SERINE; PHOSPHOTYROSINE	Growth hormone (GH) influences a number of tissue-specific biological activities in diverse cell types. However, little is known about the biochemical pathway by which the signal initiated by GH binding to its cell-surface receptor is transduced. The GH receptor has been reported to be phosphorylated on tyrosine in 3T3-F442A cells, a cell line in which GH promotes differentiation and inhibits mitogen-stimulated growth; however, it is not known whether tyrosine phosphorylation plays a role in GH signal transduction. We report that GH treatment of 3T3-F442A cells resulted in the rapid tyrosine phosphorylation of at least four proteins. These included 42- (pp42) and 45-kDa (pp45) proteins immunologically related to ERK1 (extracellular signal-regulated kinase 1), a member of a family of serine/threonine protein kinases that are phosphorylated on tyrosine in response to mitogens. Prolonged phorbol ester pretreatment attenuated the tyrosine phosphorylation of pp42 and pp45 in platelet-derived growth factor-treated cells, but not in GH-treated cells. Maximal GH-stimulated tyrosine phosphorylation of pp42 and pp45 coincided with peak levels of a 42-kDa renaturable MBP kinase activity in lysates of GH-treated cells resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The observation that multiple cellular proteins are rapidly phosphorylated on tyrosine in response to physiological concentrations of GH suggests that tyrosine phosphorylation plays a role in GH signal transduction. Moreover, the stimulation of tyrosine phosphorylation of ERK-related proteins by GH suggests that mitogens and nonmitogens may employ common phosphotyrosyl proteins in the activation of ultimately distinct cellular programs.			WINSTON, LA (corresponding author), UNIV WISCONSIN,DEPT PHYSIOL CHEM,1300 UNIV AVE,MADISON,WI 53706, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007259] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-7259-08] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COOPER JA, 1989, MOL CELL BIOL, V9, P3143, DOI 10.1128/MCB.9.7.3143; COOPER JA, 1982, CELL, V31, P263, DOI 10.1016/0092-8674(82)90426-3; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; CORIN RE, 1990, P NATL ACAD SCI USA, V87, P7507, DOI 10.1073/pnas.87.19.7507; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; Dewald B, 1986, Methods Enzymol, V132, P267; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GULLER S, 1989, ENDOCRINOLOGY, V125, P2360, DOI 10.1210/endo-125-5-2360; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; JOHNSON RM, 1990, ENDOCRINOLOGY, V127, P2099, DOI 10.1210/endo-127-5-2099; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAMPS MP, 1988, ONCOGENE, V2, P305; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NIXON T, 1983, J CELL PHYSIOL, V115, P291, DOI 10.1002/jcp.1041150312; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; QUELLE FW, 1991, J BIOL CHEM, V266, P609; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROGERS SA, 1989, P NATL ACAD SCI USA, V86, P6363, DOI 10.1073/pnas.86.16.6363; SMAL J, 1989, P NATL ACAD SCI USA, V86, P4705, DOI 10.1073/pnas.86.12.4705; SMAL J, 1987, BIOCHEM BIOPH RES CO, V147, P1232, DOI 10.1016/S0006-291X(87)80202-4; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VILA J, 1988, J CELL PHYSIOL, V135, P285, DOI 10.1002/jcp.1041350216; Wallis M., 1988, Hormones and their actions. Part II. Specific actions of protein hormones., P265; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; Woodgett JR., 1987, CELL MEMBRANES, P215, DOI [10.1007/978-1-4613-1915-3_6, DOI 10.1007/978-1-4613-1915-3_6]	47	126	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4747	4751						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537856				2022-12-27	WOS:A1992HF64200070
J	ROBINSON, KM; LEMIRE, BD				ROBINSON, KM; LEMIRE, BD			ISOLATION AND NUCLEOTIDE-SEQUENCE OF THE SACCHAROMYCES-CEREVISIAE GENE FOR THE SUCCINATE-DEHYDROGENASE FLAVOPROTEIN SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; FUMARATE REDUCTASE; ESCHERICHIA-COLI; GLUTATHIONE-REDUCTASE; FAD-BINDING; MITOCHONDRIA; FLAVINS; COMPLEX; OPERON; IMPORT	Succinate dehydrogenase (EC 1.3.99.1) of the mitochondrial inner membrane is a four-subunit membrane-bound enzyme that catalyzes the oxidation of succinate to fumarate and the transfer of electrons into the electron transport chain to oxygen. The catalytic domain of the enzyme is composed of a flavoprotein subunit which contains a covalently attached FAD cofactor and an iron-sulfur subunit with three nonidentical iron-sulfur clusters. We have isolated a complete genomic clone for the flavoprotein subunit of the succinate dehydrogenase from Saccharomyces cerevisiae and determined its nucleotide sequence. The sequence predicts a protein of 70,185 Da (640 amino acids) that shows more similarity to the Escherichia coli succinate dehydrogenase flavoprotein subunit than it does to the only other mitochondrial homologue, the human flavoprotein subunit. The yeast flavoprotein subunit precursor was synthesized in a cell-free translation system and shown to possess a mitochondrial targeting sequence that directs its import into isolated, energized mitochondria where it is processed by the matrix-localized protease. The genes for the flavoprotein and the iron-sulfur subunits reside on different chromosomes and hence form different transcriptional units.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA	University of Alberta								ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BLAUT M, 1989, J BIOL CHEM, V264, P13599; BRUTLAG DL, 1990, COMPUT APPL BIOSCI, V6, P237; CECCHINI G, 1985, FED PROC, V44, P1766; COLE ST, 1987, EUR J BIOCHEM, V167, P481, DOI 10.1111/j.1432-1033.1987.tb13362.x; COLE ST, 1982, EUR J BIOCHEM, V122, P479; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; DAUM G, 1982, J BIOL CHEM, V257, P3028; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GOULD SJ, 1989, P NATL ACAD SCI USA, V86, P1934, DOI 10.1073/pnas.86.6.1934; GRAY MW, 1982, MICROBIOL REV, V46, P1; HAMM HH, 1978, EUR J BIOCHEM, V92, P449, DOI 10.1111/j.1432-1033.1978.tb12766.x; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; IRNIGER S, 1991, MOL CELL BIOL, V11, P3060, DOI 10.1128/MCB.11.6.3060; LANG H, 1991, EUR J BIOCHEM, V198, P793, DOI 10.1111/j.1432-1033.1991.tb16083.x; LAUTERBACH F, 1990, ARCH MICROBIOL, V154, P386, DOI 10.1007/BF00276536; LOMBARDO A, 1990, J BIOL CHEM, V265, P10419; MALCOVATI M, 1991, FLAVINS AND FLAVOPROTEINS 1990, P727; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; PHILLIPS MK, 1987, J BACTERIOL, V169, P864, DOI 10.1128/jb.169.2.864-873.1987; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P3643; SCHULZ GE, 1982, J MOL BIOL, V160, P287, DOI 10.1016/0022-2836(82)90177-2; SINGER THOMAS P., 1957, ARCH BIOCHEM AND BIOPHYS, V69, P405, DOI 10.1016/0003-9861(57)90506-4; SINGER TP, 1974, FEBS LETT, V42, P1, DOI 10.1016/0014-5793(74)80266-8; SINGER TP, 1973, ADV ENZYMOL RAMB, V37, P189; SINGER TP, 1965, FLAVINS FLAVOPROTEIN, P391; TARONI F, 1991, J BIOL CHEM, V266, P13267; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519	33	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10101	10107						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577780				2022-12-27	WOS:A1992HT96500098
J	WEINBERG, RB; IBDAH, JA; PHILLIPS, MC				WEINBERG, RB; IBDAH, JA; PHILLIPS, MC			ADSORPTION OF APOLIPOPROTEIN-A-IV TO PHOSPHOLIPID MONOLAYERS SPREAD AT THE AIR-WATER-INTERFACE - A MODEL FOR ITS LABILE BINDING TO HIGH-DENSITY-LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PROTEIN INTERACTIONS; ESTER TRANSFER PROTEIN; HUMAN-PLASMA; CHOLESTEROL ACYLTRANSFERASE; SURFACE-ACTIVITIES; PERIPHERAL LYMPH; HUMAN-SERUM; RAT PLASMA; C-II; ACTIVATION	The mechanisms that mediate the labile binding of apolipoprotein A-IV (apoA-IV) to high density lipoproteins (HDL) are not known. We therefore used a surface balance and surface radioactivity detector to investigate the adsorption of apoA-IV to egg phosphatidylcholine monolayers spread at the air/water interface. ApoA-IV bound rapidly and reversibly to phospholipid monolayers and generated a maximum increase in surface pressure of 19 millinewtons (mN)/m at a subphase concentration of 2 x 10(-5) g/dl. Binding decreased linearly with increasing initial surface pressure; at pressures > 28-29 mN/m, apoA-IV could no longer penetrate the lipid monolayer. The area occupied by the amino acid residues in apoA-IV reached an unusually low limiting molecular area of 10-12 angstrom2/residue at surface saturation. The surface pressure of native HDL3 was calculated to be 33 mN/m, and it rapidly decreased with the action of lecithin: cholesterol acyltransferase on the particle surface. We conclude that the surface activity of apoA-IV is lower than that of any other human apolipoprotein; its binding and surface conformation are particularly sensitive to pressure; and at saturation, a significant portion of the molecule is excluded from the interface. The exclusion pressure of apoA-IV may be only slightly lower than the surface pressure of HDL; in vivo, the action of lecithin:cholesterol acyltransferase and lipid transfer proteins may cause the HDL3 surface pressure to oscillate about a narrow range that spans the exclusion pressure of apoA-IV. The resultant labile association of apoA-IV and HDL may be of central importance to its role in lipoprotein metabolism.	MED COLL PENN,DEPT PHYSIOL & BIOCHEM,PHILADELPHIA,PA 19129; BOWMAN GRAY SCH MED,GASTROENTEROL SECT,WINSTON SALEM,NC 27157	Drexel University; Wake Forest University; Wake Forest Baptist Medical Center	WEINBERG, RB (corresponding author), BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27157, USA.			Ibdah, Jamal/0000-0002-5646-9014; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030897, R23HL030897] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; BARTER PJ, 1988, BIOCHEM J, V254, P179, DOI 10.1042/bj2540179; BEISIEGEL U, 1979, EUR J BIOCHEM, V93, P601, DOI 10.1111/j.1432-1033.1979.tb12860.x; BISGAIER CL, 1985, J LIPID RES, V26, P11; BISGAIER CL, 1987, J LIPID RES, V28, P693; BISGAIER CL, 1989, J LIPID RES, V30, P1025; CHEN CH, 1985, BIOCHIM BIOPHYS ACTA, V836, P279, DOI 10.1016/0005-2760(85)90131-6; DELAMATRE JG, 1983, J LIPID RES, V24, P1578; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; ELSHOURBAGY NA, 1987, J BIOL CHEM, V262, P7973; FIDGE NH, 1980, BIOCHIM BIOPHYS ACTA, V619, P129, DOI 10.1016/0005-2760(80)90249-0; GHISELLI G, 1986, BIOCHEM BIOPH RES CO, V139, P122, DOI 10.1016/S0006-291X(86)80088-2; GHISELLI G, 1986, J LIPID RES, V27, P813; GOLDBERG IJ, 1990, J BIOL CHEM, V265, P4266; GREEN PHR, 1979, J CLIN INVEST, V64, P233, DOI 10.1172/JCI109444; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; IBDAH JA, 1989, BIOCHEMISTRY-US, V28, P1126, DOI 10.1021/bi00429a029; IBDAH JA, 1988, BIOCHEMISTRY-US, V27, P7155, DOI 10.1021/bi00418a073; IBDAH JA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P300, DOI 10.1016/0005-2760(89)90077-5; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; JONES MN, 1975, BIOL INTERFACES, pCH3; KREBS KE, 1983, BIOCHIM BIOPHYS ACTA, V754, P227, DOI 10.1016/0005-2760(83)90165-0; KREBS KE, 1984, FEBS LETT, V175, P263, DOI 10.1016/0014-5793(84)80748-6; KREBS KE, 1988, BIOCHIM BIOPHYS ACTA, V959, P229, DOI 10.1016/0005-2760(88)90195-6; KREBS KE, 1983, BIOCHIM BIOPHYS ACTA, V751, P470, DOI 10.1016/0005-2760(83)90308-9; LAGROST L, 1989, J LIPID RES, V30, P1525; LAGROST L, 1990, J LIPID RES, V31, P1569; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1984, BIOCHEMISTRY-US, V23, P1130, DOI 10.1021/bi00301a015; Macritchie F, 1978, Adv Protein Chem, V32, P283, DOI 10.1016/S0065-3233(08)60577-X; MALCOLM BR, 1973, PROGR SURFACE MEMBRA, V7, P183; MORRISETT JD, 1977, BIOCHIM BIOPHYS ACTA, V472, P93, DOI 10.1016/0304-4157(77)90015-6; NOWICKA G, 1990, J LIPID RES, V31, P1947; OHTA T, 1985, J CLIN INVEST, V76, P1252, DOI 10.1172/JCI112081; Osborne J C Jr, 1980, Ann N Y Acad Sci, V348, P104, DOI 10.1111/j.1749-6632.1980.tb21294.x; PHILLIPS MC, 1986, METHOD ENZYMOL, V128, P387; RIFICI VA, 1985, BIOCHIM BIOPHYS ACTA, V834, P205, DOI 10.1016/0005-2760(85)90157-2; SAVION N, 1988, ARTERIOSCLEROSIS, V8, P178, DOI 10.1161/01.ATV.8.2.178; SCANU A, 1969, BIOCHEMISTRY-US, V8, P3309, DOI 10.1021/bi00836a027; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; SLOOP CH, 1983, J LIPID RES, V24, P1429; SLOOP CH, 1983, ATHEROSCLEROSIS, V49, P9, DOI 10.1016/0021-9150(83)90003-5; SLOTTE JP, 1990, J LIPID RES, V31, P2235; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; STEINMETZ A, 1989, J CHROMATOGR-BIOMED, V487, P154, DOI 10.1016/S0378-4347(00)83018-2; STEINMETZ A, 1985, EUR J BIOCHEM, V152, P747, DOI 10.1111/j.1432-1033.1985.tb09256.x; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; STEINMETZ A, 1985, J BIOL CHEM, V260, P2258; THUREN T, 1991, J BIOL CHEM, V266, P4853; UTERMANN G, 1979, EUR J BIOCHEM, V99, P333, DOI 10.1111/j.1432-1033.1979.tb13261.x; VAINIO P, 1983, BIOCHEMISTRY-US, V22, P2270, DOI 10.1021/bi00278a033; WEINBERG RB, 1985, BIOCHEM BIOPH RES CO, V129, P576, DOI 10.1016/0006-291X(85)90190-1; WEINBERG RB, 1983, J LIPID RES, V24, P52; WEINBERG RB, 1985, J LIPID RES, V26, P26; WEINBERG RB, 1986, BIOCHEM BIOPH RES CO, V135, P756, DOI 10.1016/0006-291X(86)90993-9; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WEINBERG RB, 1985, J BIOL CHEM, V260, P4279; WEINBERG RB, 1990, J BIOL CHEM, V265, P8081; WEINBERG RB, 1987, BIOCHIM BIOPHYS ACTA, V918, P299, DOI 10.1016/0005-2760(87)90234-7; WEISGRABER KH, 1978, BIOCHEM BIOPH RES CO, V85, P287, DOI 10.1016/S0006-291X(78)80041-2	62	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8977	8983						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577735				2022-12-27	WOS:A1992HR85400044
J	HUTCHCROFT, JE; HARRISON, ML; GEAHLEN, RL				HUTCHCROFT, JE; HARRISON, ML; GEAHLEN, RL			ASSOCIATION OF THE 72-KDA PROTEIN-TYROSINE KINASE PTK72 WITH THE B-CELL ANTIGEN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTES-B; MOLECULAR MECHANISMS; PHOSPHORYLATION; MEMBRANE; STIMULATION; PROTEOLYSIS; IGD	The antigen receptors on B lymphocytes are cell-surface immunoglobulins. Antibodies against surface IgM (sIgM) coimmunoprecipitate several sIgM-associated proteins. Incubation of anti-IgM complexes with [gamma-P-32]ATP leads to the phosphorylation on tyrosine of IgM-associated proteins including MB-1 and a protein of 72 kDa. Peptide mapping and reimmunoprecipitation experiments indicate that the 72-kDa phosphoprotein is PTK72, a protein-tyrosine kinase that is expressed at highest levels in B lymphocytes. MB-1 is also phosphorylated in immune complexes prepared with antibodies to PTK72, indicating that components of the IgM complex are associated with PTK72. In addition, PTK72 is associated with sIgD complexes isolated from spleen B lymphocytes. The cross-linking of sIgM antigen receptors on B lymphocytes leads to the rapid phosphorylation of PTK72 on tyrosine and to the activation of PTK72 as measured by autophosphorylation and by the phosphorylation of an exogenous substrate in anti-PTK72 immune complexes. These results suggest that the signaling cascade initiated by engagement of the B cell antigen receptor involves the increased enzymatic activity of PTK72, which is already present in a preformed antigen receptor complex.	PURDUE UNIV,DEPT MED CHEM & PHARMACOGNOSY,W LAFAYETTE,IN 47907; PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Geahlen, Robert/0000-0001-8400-2924	NCI NIH HHS [CA09634, CA37372] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037372, T32CA009634] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESMARTINEZ JE, 1991, IMMUNOL TODAY, V12, P201, DOI 10.1016/0167-5699(91)90054-W; BARTLETT GL, 1978, CANCER RES, V38, P4401; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1990, J IMMUNOL, V145, P13; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, J IMMUNOL, V147, P1575; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN JZ, 1990, EMBO J, V9, P2117, DOI 10.1002/j.1460-2075.1990.tb07380.x; CHENG HL, 1982, NATURE, V296, P410, DOI 10.1038/296410a0; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; KAMPS MP, 1988, ONCOGENE, V2, P305; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LANE PJL, 1990, J IMMUNOL, V144, P3684; LOW PS, 1987, J BIOL CHEM, V262, P4592; MAHRENHOLZ AM, 1988, BIOCHEM BIOPH RES CO, V135, P720; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SEVERSON CD, 1987, IMMUNOL LETT, V15, P291, DOI 10.1016/0165-2478(87)90130-1; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WATTS C, 1988, EMBO J, V7, P1937, DOI 10.1002/j.1460-2075.1988.tb03031.x; WEINANDS J, 1991, EUR J IMMUNOL, V21, P2373; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	35	297	312	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8613	8619						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569106				2022-12-27	WOS:A1992HQ18500098
J	MARTIN, PD; ROBERTSON, W; TURK, D; HUBER, R; BODE, W; EDWARDS, BFP				MARTIN, PD; ROBERTSON, W; TURK, D; HUBER, R; BODE, W; EDWARDS, BFP			THE STRUCTURE OF RESIDUES 7-16 OF THE A-ALPHA-CHAIN OF HUMAN FIBRINOGEN BOUND TO BOVINE THROMBIN AT 2.3-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEAST-SQUARES REFINEMENT; CRYSTAL-STRUCTURE; BINDING-SITE; B-CHAIN; PEPTIDES; CLEAVAGE; PROTEINS; CHYMOTRYPSIN; PROTHROMBIN; ACTIVATION	The tetradecapeptide Ac-D-F-L-A-E-G-G-G-V-R-G-P-R-V-OMe, which mimics residues 7f-20f of the A-alpha-chain of human fibrinogen, has been co-crystallized with bovine thrombin from ammonium sulfate solutions in space group P2(1) with unit cell dimensions of a = 83.0 angstrom, b = 89.4 angstrom, c = 99.3 angstrom, and beta = 106.6-degrees. Three crystallographically independent complexes were located in the asymmetric unit by molecular replacement using the native bovine thrombin structure as a model. The standard crystallographic R-factor is 0.167 at 2.3-angstrom resolution. Excellent electron density could be traced for the decapeptide, beginning with Asp-7f and ending with Arg-16f in the active site of thrombin; the remaining 4 residues, which have been cleaved from the tetradecapeptide at the Arg-16f/Gly-17f bond, are not seen. Residues 7f-11f at the NH2 terminus of the peptide form a single turn of alpha-helix that is connected by Gly-12f, which has a positive phi-angle, to an extended chain containing residues 13f-16f. The major specific interactions between the peptide and thrombin are 1) a hydrophobic cage formed by residues Tyr-60A, Trp-60D, Leu-99, Ile-174, Trp215, Leu-9f, Gly-13f, and Val-15f that surrounds Phe-8f; 2) a hydrogen bond linking Phe-8f NH to Lys-97 O; 3) a salt link between Glu-11f and Arg-173; 4) two antiparallel beta-sheet hydrogen bonds between Gly-14f and Gly-216; and 5) the insertion of Arg-16f into the specificity pocket. Binding of the peptide is accompanied by a considerable shift in two of the loops near the active site relative to human D-phenyl-L-prolyl-L-arginyl chloromethyl ketone (PPACK)-thrombin.	WAYNE STATE UNIV, DEPT BIOCHEM, DETROIT, MI 48201 USA; MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY	Wayne State University; Max Planck Society				Turk, Dusan/0000-0003-0205-6609	NIGMS NIH HHS [GM 33192] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033192] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL RC, 1978, ACTA CRYSTALLOGR A, V34, P791, DOI 10.1107/S0567739478001618; BERLINER LJ, 1977, BIOCHEMISTRY-US, V16, P4622, DOI 10.1021/bi00640a015; Bing D H, 1981, Ann N Y Acad Sci, V370, P496, DOI 10.1111/j.1749-6632.1981.tb29758.x; BLOMBACK B, 1986, ANN NY ACAD SCI, V485, P120, DOI 10.1111/j.1749-6632.1986.tb34573.x; BLOMBACK B, 1969, SCAND J CLIN LAB INV, VS 24, P59; BLOMBACK B, 1967, NATURE, V215, P1445, DOI 10.1038/2151445a0; Blomback B., 1967, BLOOD CLOTTING ENZYM, P143; BLOMBACK B, 1968, CHEMOTAXON SEROTAXON, P3; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Bode W, 1991, CURR OPIN STRUC BIOL, V1, P45, DOI 10.1016/0959-440X(91)90010-Q; BREZNIAK DV, 1990, BIOCHEMISTRY-US, V29, P3536, DOI 10.1021/bi00466a017; BROWER MS, 1987, BLOOD, V69, P813; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; COHEN GH, 1981, J MOL BIOL, V148, P449, DOI 10.1016/0022-2836(81)90186-8; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; DOOLITTL.RF, 1965, BIOCHEM J, V94, P735, DOI 10.1042/bj0940735; Ebert RF, 1991, INDEX VARIANT HUMAN; EDWARDS BFP, 1986, ANN NY ACAD SCI, V485, P411, DOI 10.1111/j.1749-6632.1986.tb34604.x; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V23, P544; Furlan M., 1988, FIBRINOGEN FIBRIN ST, P17; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JACK A, 1978, ACTA CRYSTALLOGR A, V34, P931, DOI 10.1107/S0567739478001904; JANIN J, 1976, J MOL BIOL, V100, P197, DOI 10.1016/S0022-2836(76)80148-9; KAWABATA S, 1985, J BIOCHEM, V97, P325, DOI 10.1093/oxfordjournals.jbchem.a135057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATTMAN EE, 1970, ACTA CRYSTALLOGR, V26, P184; MACGILLIVRAY RTA, 1984, BIOCHEMISTRY-US, V23, P1626, DOI 10.1021/bi00303a007; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; MARSH HC, 1983, BIOCHEMISTRY-US, V22, P4170, DOI 10.1021/bi00287a002; MARTIN PD, 1983, FED PROC, V42, P1861; MARTIN PD, 1991, FASEB J, V5, pA515; MENACHE D, 1983, ANN NY ACAD SCI, V408, P121, DOI 10.1111/j.1749-6632.1983.tb23240.x; MORRIS S, 1981, THROMB HAEMOSTASIS, V46, P104; MROSS GA, 1967, ARCH BIOCHEM BIOPHYS, V122, P674, DOI 10.1016/0003-9861(67)90177-4; NI F, 1989, BIOCHEMISTRY-US, V28, P3094, DOI 10.1021/bi00433a053; NI F, 1989, BIOCHEMISTRY-US, V28, P3082, DOI 10.1021/bi00433a052; NI F, 1989, BIOCHEMISTRY-US, V28, P3106, DOI 10.1021/bi00433a054; NOE G, 1988, J BIOL CHEM, V263, P11729; PIRKLE H, 1989, THROMB RES, V55, P737, DOI 10.1016/0049-3848(89)90304-6; POLGAR L, 1989, MECHANISMS PROTEASE, P87; RAE ID, 1979, INT J PEPT PROT RES, V13, P304; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHERAGA HA, 1986, ANN NY ACAD SCI, V485, P124, DOI 10.1111/j.1749-6632.1986.tb34574.x; SONDER SA, 1984, BIOCHEMISTRY-US, V23, P1818, DOI 10.1021/bi00303a037; SOUTHAN C, 1988, FIBRINOGEN FIBRIN ST, P65; TOLLIN P, 1966, ACTA CRYSTALLOGR, V20, P404, DOI 10.1107/S0365110X66000926; VINOGRADOV SN, 1980, MOL INTERACTIONS, V2, P179; WARD KB, 1975, J MOL BIOL, V98, P161, DOI 10.1016/S0022-2836(75)80107-0; WLODAWER A, 1983, BIOCHEMISTRY-US, V22, P2720, DOI 10.1021/bi00280a021	64	160	167	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7911	7920						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560020				2022-12-27	WOS:A1992HN48500099
J	BARBER, MJ; NEAME, PJ; LIM, LW; WHITE, S; MATHEWS, FS				BARBER, MJ; NEAME, PJ; LIM, LW; WHITE, S; MATHEWS, FS			CORRELATION OF X-RAY DEDUCED AND EXPERIMENTAL AMINO-ACID-SEQUENCES OF TRIMETHYLAMINE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR FLAVOPROTEIN; INTRAMOLECULAR ELECTRON-TRANSFER; DIMETHYLAMINE DEHYDROGENASE; METHYLOTROPHIC BACTERIA; 3-DIMENSIONAL STRUCTURE; PROSTHETIC GROUPS; RESOLUTION; CRYSTALLOGRAPHY; IDENTIFICATION; CLUSTER	The amino acid sequence of the iron-sulfur-flavoprotein, trimethylamine dehydrogenase, isolated from the bacterium W3A1 has been deduced from the x-ray diffraction pattern obtained at 2.4-angstrom resolution. This sequence has been compared to portions of the primary sequence derived by gas-phase sequencing of isolated peptides obtained from cyanogen bromide and endoprotease Arg-C and Asp-N digestions of the purified enzyme. A consensus sequence has resulted and is comprised of 729 amino acids with Ala at both NH2- and COOH-terminal positions. The consensus sequence contains 13 cysteine residues. Approximately 80% of the sequence has been confirmed by direct sequencing with approximately 81% agreement with the x-ray deduced sequence. The calculated subunit molecular mass of the apoenzyme is 78,899 Da, in good agreement with published values of approximately 83,000. The anomalous scattering map from the native protein has also been shown to provide accurate information about the positions of most of the weak anomalous scattering centers such as sulfur or phosphorus atoms and to complement x-ray or chemical sequencing methods.	UNIV S FLORIDA,SHRINERS HOSP,COLL MED,TAMPA,FL 33612; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	State University System of Florida; University of South Florida; Washington University (WUSTL)	BARBER, MJ (corresponding author), UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612, USA.		White, Scott/C-6684-2008	White, Scott/0000-0002-0202-6154	NIAMS NIH HHS [AR 35322] Funding Source: Medline; NIGMS NIH HHS [GM 32696, GM 31611] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031611, R01GM032696] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; Batie C. J., 1991, CHEM BIOCH FLAVOENZY, V3, P543; BELLAMY HD, 1989, J BIOL CHEM, V624, P11887; COLBY J, 1974, BIOCHEM J, V143, P555, DOI 10.1042/bj1430555; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; KENNEY WC, 1978, FEBS LETT, V85, P137, DOI 10.1016/0014-5793(78)81265-4; LEDERER F, 1981, J MOL BIOL, V148, P427, DOI 10.1016/0022-2836(81)90185-6; LIM LW, 1988, J BIOL CHEM, V263, P3075; LIM LW, 1986, J BIOL CHEM, V261, P5140; LINDQVIST Y, 1985, P NATL ACAD SCI USA, V82, P6855, DOI 10.1073/pnas.82.20.6855; LINDQVIST Y, 1991, J BIOL CHEM, V266, P3198; MALLONEE DH, 1990, J BACTERIOL, V172, P7011, DOI 10.1128/jb.172.12.7011-7019.1990; MATHEWS FS, 1987, FLAVINS FLAVOPROTEIN, P663; MEIBERG JBM, 1979, J GEN MICROBIOL, V115, P49, DOI 10.1099/00221287-115-1-49; NEAME PJ, 1989, J BIOL CHEM, V264, P20894; STEENKAMP DJ, 1982, BIOCHEM J, V207, P233, DOI 10.1042/bj2070233; STEENKAMP DJ, 1982, BIOCHEM J, V207, P241, DOI 10.1042/bj2070241; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STEENKAMP DJ, 1991, CHEM BIOCH FLAVOENZY, V2, P395; STEVENSON RC, 1986, BIOCHIM BIOPHYS ACTA, V869, P81, DOI 10.1016/0167-4838(86)90313-4; THIEME R, 1981, J MOL BIOL, V152, P763, DOI 10.1016/0022-2836(81)90126-1; THOMSON AJ, 1991, FEBS LETT, V285, P230, DOI 10.1016/0014-5793(91)80807-F; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; XUONG NH, 1985, ACTA CRYSTALLOGR B, V41, P267, DOI 10.1107/S0108768185002105	31	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6611	6619						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551870				2022-12-27	WOS:A1992HM05300027
J	SIMPSON, AM; BAKALARA, N; SIMPSON, L				SIMPSON, AM; BAKALARA, N; SIMPSON, L			A RIBONUCLEASE-ACTIVITY IS ACTIVATED BY HEPARIN OR BY DIGESTION WITH PROTEINASE-K IN MITOCHONDRIAL EXTRACTS OF LEISHMANIA-TARENTOLAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUG INITIATION CODONS; NUCLEUS-ENCODED RNA; TRYPANOSOMA-BRUCEI; KINETOPLASTID MITOCHONDRIA; URIDINE ADDITION; GENE-EXPRESSION; P-ACTIVITY; TRANSCRIPTS; CONTAINS; DNA	A ribonuclease activity in a 100,000 x g supernatant of a Triton lysate of a mitochondrial-kinetoplast fraction from Leishmania tarentolae is activated by incubation with heparin or by predigestion of the lysate with proteinase k or pronase. In vitro-transcribed pre-edited cytochrome b mRNA is cleaved at several sites. With time, complete degradation of the RNA occurs. All cleavages occurred within putative single-stranded regions of the RNA. No cleavage was observed with 9 S rRNA. The presence of a nonspecific nucleotide or nucleoside slows the rate of cleavage. The cleavage activity is inhibited by sodium dodecyl sulfate or phenol/chloroform extraction, is retained by a 10-kDa cutoff filter, and passes through a 30-kDa filter. Micrococcal nuclease inhibits the proteinase-induced activity but not the heparin-induced activity.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIAID NIH HHS [AI-09102] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CHANG DD, 1989, CELL, V56, P131, DOI 10.1016/0092-8674(89)90991-4; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CHEN JY, 1988, J BIOL CHEM, V263, P13677; DELACRUZ VF, 1985, P NATL ACAD SCI USA, V82, P1401, DOI 10.1073/pnas.82.5.1401; DOERSEN CJ, 1985, J BIOL CHEM, V260, P5942; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FEAGIN JE, 1986, MOL BIOCHEM PARASIT, V20, P207, DOI 10.1016/0166-6851(86)90100-3; FEAGIN JE, 1988, MOL CELL BIOL, V8, P1259, DOI 10.1128/MCB.8.3.1259; GOLD HA, 1989, SCIENCE, V245, P1377, DOI 10.1126/science.2476849; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HOLLINGSWORTH MJ, 1986, MOL CELL BIOL, V6, P1058, DOI 10.1128/MCB.6.4.1058; MICHELOTTI EF, 1987, J BIOL CHEM, V262, P927; MORALES MJ, 1989, NUCLEIC ACIDS RES, V17, P6865, DOI 10.1093/nar/17.17.6865; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SHU HH, 1991, MOL CELL BIOL, V11, P1662, DOI 10.1128/MCB.11.3.1662; SIMPSON AM, 1985, NUCLEIC ACIDS RES, V13, P5977, DOI 10.1093/nar/13.16.5977; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; WANG MJ, 1990, NUCLEIC ACIDS RES, V18, P6625, DOI 10.1093/nar/18.22.6625; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	29	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6782	6788						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551886				2022-12-27	WOS:A1992HM05300050
J	CHATTERJEE, D; LOWELL, K; RIVOIRE, B; MCNEIL, MR; BRENNAN, PJ				CHATTERJEE, D; LOWELL, K; RIVOIRE, B; MCNEIL, MR; BRENNAN, PJ			LIPOARABINOMANNAN OF MYCOBACTERIUM-TUBERCULOSIS - CAPPING WITH MANNOSYL RESIDUES IN SOME STRAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; ARABINOMANNAN; SMEGMATIS; ANTIGENS; LEPRAE	Previously we had demonstrated that the termini of the arabinan component of mycobacterial cell wall arabinogalactan, the site of mycolic acid location, consists mostly of clusters of a pentaarabinofuranoside, [beta-D-Araf-(1 --> 2)-alpha-D-Araf-(1 --> ]2 --> (3 and 5)-alpha-D-Araf. Subsequently, the same arrangement was shown to dominate the non-reducing ends of lipoarabinomannan (LAM), a key component in the interaction of mycobacteria with host cell. Accordingly, we had proposed that mycobacteria universally elaborate the same Araf-containing motifs in two settings for different Pathophysiological purposes. However, we now report that the termini of LAM from the virulent, Erdman, strain of Mycobacterium tuberculosis, unlike those from the attenuated H37Ra strain, are extensively capped with mannosyl (Manp) residues, either a single alpha-D-Manp, a dimannoside (alpha-D-Manp-(1 --> 2)-alpha-D-Manp), or a trimannoside (alpha-D-Manp-(1 --> 2)-alpha-D-Manp-(1 --> 2)-alpha-D-Manp). The use of monoclonal antibodies demonstrates a clear difference in the antigenicity of the basic and mannose-capped LAM. The possibility that these structures are a factor in the virulence of some strains of M. tuberculosis and represent an example of carbohydrate mimicry in mycobacterial infections is discussed.	COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523	Colorado State University			McNeil, Michael/G-3325-2019		NIAID NIH HHS [AI-18357, AI-05074] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018357, R37AI018357, R22AI018357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BISNO AL, 1990, PRINCIPLES PRACTICE, P1528; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; CHATTERJEE D, 1988, CARBOHYD RES, V183, P241, DOI 10.1016/0008-6215(88)84078-3; CHATTERJEE D, 1992, IN PRESS INFECT IMMU; DAFFE M, 1990, J BIOL CHEM, V265, P6734; FILLIT HM, 1986, J EXP MED, V164, P762, DOI 10.1084/jem.164.3.762; GAYLORD H, 1987, INFECT IMMUN, V55, P2860, DOI 10.1128/IAI.55.11.2860-2863.1987; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; GRAY GR, 1971, J BIOL CHEM, V246, P6835; GRIFFISS JM, 1988, REV INFECT DIS, V10, pS287; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; KHANOLKAR SR, 1989, J MED MICROBIOL, V28, P157, DOI 10.1099/00222615-28-3-157; KORNFELD R, 1981, BIOCH GLYCOPROTEINS; LIPKIND GM, 1988, CARBOHYD RES, V175, P59, DOI 10.1016/0008-6215(88)80156-3; MAITRA SK, 1976, BIOCHEM BIOPH RES CO, V73, P1101, DOI 10.1016/0006-291X(76)90236-9; MANDRELL RE, 1990, J EXP MED, V171, P1649, DOI 10.1084/jem.171.5.1649; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; MISAKI A, 1977, J BIOCHEM-TOKYO, V82, P1759, DOI 10.1093/oxfordjournals.jbchem.a131874; OHASHI M, 1970, JPN J EXP MED, V40, P1; PETERSON AA, 1985, J BACTERIOL, V162, P738, DOI 10.1128/JB.162.2.738-745.1985; RIVOIRE B, 1989, INFECT IMMUN, V57, P3147, DOI 10.1128/IAI.57.10.3147-3158.1989; SUGDEN EA, 1987, INFECT IMMUN, V55, P762, DOI 10.1128/IAI.55.3.762-770.1987; TAKAYAMA K, 1975, J LIPID RES, V16, P308; WEBER PL, 1979, CARBOHYD RES, V74, P259, DOI 10.1016/S0008-6215(00)84781-3; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83	28	234	240	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6234	6239						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556132				2022-12-27	WOS:A1992HK31800078
J	HANASAKI, K; ARITA, H				HANASAKI, K; ARITA, H			CHARACTERIZATION OF A HIGH-AFFINITY BINDING-SITE FOR PANCREATIC-TYPE PHOSPHOLIPASE-A2 IN THE RAT - ITS CELLULAR AND TISSUE DISTRIBUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; MESSENGER-RNA; EXPRESSION; INTERNALIZATION; PURIFICATION; RADIOIMMUNOASSAY; THROMBOXANE-A2; GENERATION; METABOLISM	We showed in an earlier study (Arita, H., Hanasaki, K., Nakano, T., Oka, S., Teraoka, H., and Matsumoto, K. (1991) J. Biol. Chem. 266, 19139-19141) that there is a high affinity and specific binding site for mammalian group I phospholipase A2 (PLA2-I) in Swiss 3T3 fibroblast cells. Analysis of the cellular distribution in rat using I-125-PLA2-I as a radioligand indicated the presence of this site in various cells, including vascular smooth muscle cells (VSMC), vascular endothelial cells, synovial cells, chondrocytes, and gastric mucosal cells. Scatchard analysis of rat VSMC revealed the existence of a single class of binding site with a K(d) value of 1.60 nM and a B(max) value of 51.0 fmol/10(6) cells. The mammalian mature type of PLA2s-I derived from several animal species specifically recognized the same site in cells and stimulated DNA synthesis, whereas its inactive zymogen, mammalian group II PLA2s, and snake and bee venom PLA2s showed much lesser activities. I-125-PLA2-I bound to VSMC was rapidly internalized and subsequently released from the cells as trichloroacetic acid-soluble radioactivity. Down-regulation of the PLA2-1 site was observed in the treatment of VSMC with cAMP-elevating agents, as well as glucocorticoids. Affinity labeling experiments indicated that PLA2-I binds to a single polypeptide with a mass of approximately 200,000 daltons. These results suggest a novel PLA2-I action on the cellular function via its specific binding site.	SHIONOGI & CO LTD,SHIONOGI RES LAB,12-4 SAGISU 5-CHOME,FUKUSHIMA KU,OSAKA 553,JAPAN	Shionogi & Company Limited								ARITA H, 1989, PROG LIPID RES, V28, P273, DOI 10.1016/0163-7827(89)90002-7; ARITA H, 1991, J BIOL CHEM, V266, P19139; BENYA PD, 1977, BIOCHEMISTRY-US, V16, P865, DOI 10.1021/bi00624a009; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; FACCHIANO A, 1991, LIFE SCI, V48, P453, DOI 10.1016/0024-3205(91)90501-2; FLOWER RJ, 1979, NATURE, V278, P456, DOI 10.1038/278456a0; GOLDFINE ID, 1981, BIOCHIM BIOPHYS ACTA, V650, P53, DOI 10.1016/0304-4157(81)90008-3; GORDEN P, 1978, P NATL ACAD SCI USA, V75, P5025, DOI 10.1073/pnas.75.10.5025; GREENBERGER NJ, 1973, NEW ENGL J MED, V289, P586, DOI 10.1056/NEJM197309132891112; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HANASAKI K, 1988, BIOCHEM BIOPH RES CO, V151, P1352, DOI 10.1016/S0006-291X(88)80511-4; HANASAKI K, 1990, J BIOL CHEM, V265, P4871; HANASAKI K, 1989, BIOCHEM PHARMACOL, V38, P2967, DOI 10.1016/0006-2952(89)90004-X; HASHIDA R, 1986, CELL STRUCT FUNCT, V11, P343, DOI 10.1247/csf.11.343; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HIRATA M, 1986, BIOCHEM BIOPH RES CO, V141, P488, DOI 10.1016/S0006-291X(86)80199-1; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JOHNSON WJ, 1990, ARTHRITIS RHEUM, V33, P261, DOI 10.1002/art.1780330216; KISHINO J, 1991, FEBS LETT, V280, P103, DOI 10.1016/0014-5793(91)80214-N; KRANE SM, 1975, ANN NY ACAD SCI, V256, P289, DOI 10.1111/j.1749-6632.1975.tb36056.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUSHIMA K, 1986, J IMMUNOL, V137, P3183; MIZUSHIMA Y, 1989, BIOCHEM PHARMACOL, V38, P4419; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NAKANO T, 1990, FEBS LETT, V273, P23, DOI 10.1016/0014-5793(90)81042-M; NISHIJIMA J, 1983, J BIOCHEM, V94, P137, DOI 10.1093/oxfordjournals.jbchem.a134322; OKA S, 1991, J BIOL CHEM, V266, P9956; PIETERSON WA, 1974, BIOCHEMISTRY-US, V13, P1439, DOI 10.1021/bi00704a019; POMERANTZ KB, 1989, ARTERIOSCLEROSIS, V9, P413, DOI 10.1161/01.ATV.9.4.413; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; STEMERMAN MB, 1984, PROG HEMOST THROMB, V7, P289; TAKUWA N, 1987, J BIOL CHEM, V262, P182; THORGEIRSSON G, 1978, AM J PATHOL, V93, P801; TOJO H, 1988, J BIOL CHEM, V263, P5724; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; VADAS P, 1986, LAB INVEST, V55, P391; YASUDA T, 1990, BIOCHIM BIOPHYS ACTA, V1046, P189, DOI 10.1016/0005-2760(90)90188-4	40	114	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6414	6420						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556145				2022-12-27	WOS:A1992HK31800103
J	RAWLINGS, M; CRONAN, JE				RAWLINGS, M; CRONAN, JE			THE GENE ENCODING ESCHERICHIA-COLI ACYL CARRIER PROTEIN LIES WITHIN A CLUSTER OF FATTY-ACID BIOSYNTHETIC GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACETOACETYL-COA REDUCTASE; NUCLEOTIDE-SEQUENCE; RHIZOBIUM-MELILOTI; BETA-KETOTHIOLASE; HOST-SPECIFICITY; SYNTHASE; CLONING; POLYPEPTIDES; MUTANTS	The gene encoding Escherichia coli acyl carrier protein (ACP) has been isolated and sequenced. The ACP gene (called acpP) was located on the genetic map between fabF and fabD which encode two fatty acid biosynthetic enzymes, 3-ketoacyl-ACP synthase II and malonyl CoA-ACP transacylase, respectively. An open reading frame between acpP and fabD encodes a 26.5-kDa protein that has significant sequence identity (> 40%) with two acetoacetyl-CoA reductases and thus is believed to encode a 3-ketoacyl-ACP reductase. This gene (called fabG) is cotranscribed with acpP. Thus, the gene encoding ACP, the key carrier protein of fatty acid synthesis, is located within a cluster of fatty acid biosynthetic genes.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign			Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15650] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHIRALA SS, 1987, J BIOL CHEM, V262, P4231; CRONAN JE, 1988, GENE, V70, P161, DOI 10.1016/0378-1119(88)90114-X; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1, P474; DEBELLE F, 1986, NUCLEIC ACIDS RES, V14, P7453, DOI 10.1093/nar/14.18.7453; DEVEAUX LC, 1986, J BACTERIOL, V167, P920, DOI 10.1128/jb.167.3.920-927.1986; GARWIN JL, 1980, J BIOL CHEM, V265; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P537; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOLAK TA, 1989, BIOCHEMISTRY-US, V25, P5766; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; JACKOWSKI S, 1987, J BACTERIOL, V169, P1469, DOI 10.1128/jb.169.4.1469-1473.1987; KIM Y, 1989, BIOCHEMISTRY-US, V28, P8792, DOI 10.1021/bi00448a017; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORNBLUM JS, 1988, GENE, V63, P75, DOI 10.1016/0378-1119(88)90547-1; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; Lipmann F, 1980, Adv Microb Physiol, V21, P227; MAGNUSON K, 1992, IN PRESS FEBS LETT; Maniatis T., 1982, MOL CLONING; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; OHLROGGE JB, 1991, BIOCHIM BIOPHYS ACTA, V1082, P1, DOI 10.1016/0005-2760(91)90294-R; PAZIRANDEH M, 1989, J BIOL CHEM, V264, P18195; PEOPLES OP, 1989, MOL MICROBIOL, V3, P349, DOI 10.1111/j.1365-2958.1989.tb00180.x; PEOPLES OP, 1989, J BIOL CHEM, V264, P15293; PRESCOTT DJ, 1972, ADV ENZYMOL RAMB, V36, P269; RAWLINGS M, 1988, FASEB J, V2; REVILL WP, 1991, J BACTERIOL, V173, P4379, DOI 10.1128/JB.173.14.4379-4385.1991; ROCK CO, 1979, J BIOL CHEM, V254, P9778; RUCH FE, 1973, J BIOL CHEM, V248, P8086; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; SACKMAN V, 1991, EUR J BIOCHEM, V200, P463; SINGER M, 1989, MICROBIOL REV, V53, P1; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; THERISOD H, 1987, P NATL ACAD SCI USA, V84, P8235, DOI 10.1073/pnas.84.23.8235; TSAY TT, 1992, J BIOL CHEM, V267, P6807; ULRICH AK, 1983, J BACTERIOL, V154, P221, DOI 10.1128/JB.154.1.221-230.1983; VANAMAN TC, 1968, J BIOL CHEM, V243, P6420; WEI YG, 1986, GENE, V48, P251, DOI 10.1016/0378-1119(86)90083-1; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985	41	134	158	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5751	5754						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556094				2022-12-27	WOS:A1992HK31800008
J	DAY, PJ; SHAW, WV				DAY, PJ; SHAW, WV			ACETYL COENZYME-A BINDING BY CHLORAMPHENICOL ACETYLTRANSFERASE - HYDROPHOBIC DETERMINANTS OF RECOGNITION AND CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; RESOLUTION; MECHANISM; STABILIZATION; SPECIFICITY; MUTAGENESIS	The preponderance of nonpolar contacts between CoA and chloramphenicol acetyltransferase in the high resolution structure of the binary complex prompted a study of selected hydrophobic residues by site-directed mutagenesis and steady-state kinetic analysis. Substitutions of three aromatic residues were used to evaluate binding contacts with the adenine moiety of CoA (Tyr-178), the pantetheine arm of the coenzyme (Tyr-56), and the S-acyl substituent (Phe-33). For those substitutions at residues 56 and 178 that cannot promote alternative polar interactions there is a correlation between residue hydrophobicity and the free energy of formation of the binary and ternary complexes of acetyl-CoA and chloramphenicol acetyltransferase and of the transition-state complex. Substitutions at Tyr-178 destabilize all such complexes to approximately the same extent (uniform binding changes), whereas those at Tyr-56 and Phe-33 cause differential binding changes, having a greater effect on the transition state than on either of the other complexes with acetyl-CoA.	UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,ENGLAND	University of Leicester					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENKOVIC SJ, 1988, SCIENCE, V239, P1105, DOI 10.1126/science.3125607; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CULLIS PM, 1991, BIOCHEMISTRY-US, V30, P3758, DOI 10.1021/bi00229a024; DAY PJ, 1992, IN PRESS BIOCHEMISTR; ELLIS J, 1991, IN PRESS; ESTELL DA, 1986, SCIENCE, V233, P659, DOI 10.1126/science.233.4764.659; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; KLEANTHOUS C, 1985, BIOCHEMISTRY-US, V24, P5307, DOI 10.1021/bi00341a006; KLEANTHOUS C, 1984, BIOCHEM J, V223, P211, DOI 10.1042/bj2230211; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU FTK, 1986, BIOCHEMISTRY-US, V26, P4143; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; LESLIE AGW, 1990, J MOL BIOL, V213, P167, DOI 10.1016/S0022-2836(05)80129-9; LEWENDON A, 1988, BIOCHEMISTRY-US, V27, P7385, DOI 10.1021/bi00419a032; LEWENDON A, 1990, BIOCHEMISTRY-US, V29, P2075, DOI 10.1021/bi00460a016; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURRAY IA, 1991, BIOCHEMISTRY-US, V30, P3763, DOI 10.1021/bi00229a025; MURRAY IA, 1988, BIOCHEM J, V252, P173, DOI 10.1042/bj2520173; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; RUSSELL AJ, 1987, J MOL BIOL, V193, P803, DOI 10.1016/0022-2836(87)90360-3; Shaw W V, 1975, Methods Enzymol, V43, P737; SHAW WV, 1983, CRC CR REV BIOCH MOL, V14, P1, DOI 10.3109/10409238309102789; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363; SIMON EJ, 1953, J AM CHEM SOC, V75, P2520, DOI 10.1021/ja01106a522; WELLS JA, 1987, P NATL ACAD SCI USA, V84, P1219, DOI 10.1073/pnas.84.5.1219; WELLS TNC, 1986, BIOCHEMISTRY-US, V25, P1881, DOI 10.1021/bi00356a007	27	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5122	5127						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544895				2022-12-27	WOS:A1992HH74700021
J	RISINGER, MA; DOTIMAS, EM; COHEN, CM				RISINGER, MA; DOTIMAS, EM; COHEN, CM			HUMAN ERYTHROCYTE PROTEIN 4.2, A HIGH COPY NUMBER MEMBRANE-PROTEIN, IS N-MYRISTYLATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID ACYLATION; CYTOPLASMIC DOMAIN; BAND 4.2; HEREDITARY SPHEROCYTOSIS; ANKYRIN; BINDING; ASSOCIATION; SEQUENCE; RECEPTOR; CELLS	Band 4.2 is a major protein of the erythrocyte membrane which has been immunologically detected in a variety of cell types and is apparently essential for normal erythrocyte membrane function. Since band 4.2 has unusual solubility and membrane binding properties and has an N-terminal glycine following the initiating methionine, we explored the possibility that band 4.2 is myristylated. When Sf9 cells infected with a recombinant band 4.2 Baculovirus were incubated with [H-3]myristic acid, label became incorporated into recombinant band 4.2 protein and resisted extraction with hydroxylamine. Consistent with N-terminal myristylation, the incorporation of label was dependent upon protein synthesis. The fatty acid covalently bound to recombinant band 4.2 was definitively identified as myristic acid by recovering the fatty acid after hydrolysis of band 4.2 and examining its migration relative to standards in thin layer chromatography. It was determined that native erythrocyte band 4.2 is an N-myristylated protein by reverse phase high performance liquid chromatography detection of an azlactone derivative of N-myristylglycine after mild acid hydrolysis and azlactone derivatization of the purified protein. Study of myristylation of band 4.2, an abundant normal cellular protein, and its role in membrane binding may produce insights relevant to other myristylated cellular proteins.	TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02111	Tufts University; Tufts University	RISINGER, MA (corresponding author), ST ELIZABETH HOSP,DEPT BIOMED RES,BOSTON,MA 02135, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037462] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 37462] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVELDANO MI, 1983, J LIPID RES, V24, P1101; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1985, ANNU REV BIOCHEM, V54, P273, DOI 10.1146/annurev.biochem.54.1.273; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; DEVETTEN MP, 1988, J BIOL CHEM, V263, P18193; DOLCI ED, 1985, J BIOL CHEM, V260, P728; FRIEDRICHS B, 1989, EUR J CELL BIOL, V48, P121; GHANEM A, 1990, BRIT J HAEMATOL, V75, P414, DOI 10.1111/j.1365-2141.1990.tb04357.x; GODDARD C, 1989, J BIOL CHEM, V264, P15173; GODDARD C, 1988, BIOCHEM J, V25, P839; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; HAYASHI S, 1974, BIOCHEM BIOPH RES CO, V57, P1038, DOI 10.1016/0006-291X(74)90801-8; IDEGUCHI H, 1990, BRIT J HAEMATOL, V74, P347, DOI 10.1111/j.1365-2141.1990.tb02594.x; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KEENAN TW, 1982, EUR J CELL BIOL, V26, P270; KORSGREN C, 1986, J BIOL CHEM, V261, P5536; KORSGREN C, 1991, P NATL ACAD SCI USA, V88, P4840, DOI 10.1073/pnas.88.11.4840; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; KORSGREN C, 1988, J BIOL CHEM, V263, P10212; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MARETZKI D, 1990, FEBS LETT, V259, P305, DOI 10.1016/0014-5793(90)80033-F; MARINETTI GV, 1982, BIOCHIM BIOPHYS ACTA, V685, P109, DOI 10.1016/0005-2736(82)90086-4; MCILHINNEY RAJ, 1990, BIOCHEM J, V271, P681, DOI 10.1042/bj2710681; OKUBO K, 1991, J BIOL CHEM, V266, P16420; OLSON EN, 1986, J BIOL CHEM, V261, P2458; OLSON EN, 1984, J BIOL CHEM, V259, P5364; OLSTED JB, 1981, J BIOL CHEM, V256, P11955; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; RYBICKI AC, 1988, J CLIN INVEST, V81, P893, DOI 10.1172/JCI113400; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; STAUFENBIEL M, 1988, J BIOL CHEM, V263, P13615; STAUFENBIEL M, 1986, P NATL ACAD SCI USA, V83, P318, DOI 10.1073/pnas.83.2.318; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; Summers MD, 1987, MANUAL METHODS BACUL; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978	42	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5680	5685						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544941				2022-12-27	WOS:A1992HH74700102
J	HAYDEN, MA; HUANG, I; BUSSIERE, DE; ASHLEY, GW				HAYDEN, MA; HUANG, I; BUSSIERE, DE; ASHLEY, GW			THE BIOSYNTHESIS OF LIPOIC ACID - CLONING OF LIP, A LIPOATE BIOSYNTHETIC LOCUS OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOTIN; CHROMOSOME; PLASMIDS; PRODUCTS; SULFUR; GENES	The lip gene of Escherichia coli has been cloned and sequenced. Subcloning of a 3-kilobase EcoRI/EcoRV restriction fragment from Clark-Carbon plasmid pLC15-5 into pUC18 gives a plasmid that complements two lipoate auxotrophs, W1485-lip2 and JRG33-lip9, and which expresses a protein of approximately 36,000 Da. Sequencing suggests that lip codes for a protein of 281 amino acids (31,350 Da), showing sequence similarity to biotin synthase. It is thus likely that lip encodes a sulfur insertion enzyme analogous to biotin synthase and that the sulfur insertion chemistries of the two systems are related. Unidirectional nested deletion experiments show that both lipoate auxotrophs are complemented by the same 500-base pair region at the 3' terminus of the lip gene, indicating that the mutations affecting lipoate biosynthesis are located in this region of the protein. A small open reading frame located immediately downstream of the lip gene codes for a small protein of unknown function.	NORTHWESTERN UNIV,DEPT CHEM,EVANSTON,IL 60208	Northwestern University					NIGMS NIH HHS [GM42017] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042017] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN JE, 1990, J HETEROCYCLIC CHEM, V27, P71, DOI 10.1002/jhet.5570270106; CHANG YY, 1991, J BACTERIOL, V173, P5258, DOI 10.1128/jb.173.17.5258-5259.1991; DEMOLL E, 1983, BIOCHEM BIOPH RES CO, V110, P243, DOI 10.1016/0006-291X(83)91286-X; DOOLITTLE RF, 1987, URFS ORFS PRIMER ANA, P1; Eisenberg M. A., 1975, Metabolism of sulphur compounds., P27; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERBERT AA, 1968, J GEN MICROBIOL, V53, P363, DOI 10.1099/00221287-53-3-363; HERBERT AA, 1970, METHOD ENZYMOL, V17, P269; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOZAK M, 1983, MICROBIOL REV, V47, P1; LEVINE L, 1970, LABORATORY EXERCISES, P89; Maniatis T, 1982, MOL CLONING LABORATO, P68; OHSAWA I, 1989, GENE, V80, P39, DOI 10.1016/0378-1119(89)90248-5; OTSUKA AJ, 1988, J BIOL CHEM, V263, P19577; PARRY RJ, 1983, TETRAHEDRON, V39, P1215, DOI 10.1016/S0040-4020(01)91887-3; PARRY RJ, 1977, J AM CHEM SOC, V99, P6464, DOI 10.1021/ja00461a061; REED LJ, 1964, 1964 INT S CHEM NUTR, P218; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRATT BG, 1980, J BACTERIOL, V143, P569, DOI 10.1128/JB.143.2.569-581.1980; TAKEDA Y, 1981, PLASMID, V6, P86, DOI 10.1016/0147-619X(81)90056-1; VISE AB, 1967, J GEN MICROBIOL, V48, P87, DOI 10.1099/00221287-48-1-87; WHITE RH, 1980, BIOCHEMISTRY-US, V19, P15, DOI 10.1021/bi00542a003	23	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9512	9515						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577793				2022-12-27	WOS:A1992HT96500013
J	QUEST, AFG; BLOOMENTHAL, J; BARDES, ESG; BELL, RM				QUEST, AFG; BLOOMENTHAL, J; BARDES, ESG; BELL, RM			THE REGULATORY DOMAIN OF PROTEIN-KINASE-C COORDINATES 4 ATOMS OF ZINC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; DILUTE-SOLUTION; ACTIVATION; PHOSPHATIDYLSERINE; PHOSPHOLIPIDS; BINDING; FAMILY	Protein kinase C (PKC) was found to be a zine metallo-enzyme. Atomic absorption measurements on the intact enzyme indicated that four zine atoms (4.2 +/- 0.5) were bound per PKC-alpha-molecule. Similar stoichiometric ratios were determined for PKC beta-II and PKC-gamma, other PKC isoforms individually expressed in the baculovirus-insect cell expression system, as well as for purified rat brain PKC. By trypsin treatment of PKC-alpha, a 32-kDa lipid binding regulatory and a 50-kDa catalytic domain were generated that were subsequently completely separated by gel filtration in the presence of Triton X-100/phosphatidylserine mixed micelles. Zinc was present at levels significantly above background in fractions that contained the 32-kDa fragment and displayed phorbol ester binding activity. Lipid association and phorbol ester binding did not lead to displacement of zinc from the protein. The stoichiometry determined for this fragment (4.7 +/- 0.9) suggested that zinc was bound exclusively within the lipid binding regulatory domain of intact PKC. Furthermore, this stoichiometry is consistent with zinc being coordinated between 6 cysteine residues in a structural motif related to the Zn(II)2Cys6 binuclear cluster identified in the GAL4 transcriptional factor (Pan, T., and Coleman, J. E. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2077-2081).	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NIGMS NIH HHS [GM 38737] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038737] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BELL RM, 1991, J BIOL CHEM, V266, P4661; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; EBELING JG, 1985, P NATL ACAD SCI USA, V82, P815, DOI 10.1073/pnas.82.3.815; FALCHUK KH, 1988, METHOD ENZYMOL, V158, P422, DOI 10.1016/0076-6879(88)58073-4; GESCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1986, J BIOL CHEM, V261, P4867; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	30	121	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10193	10197						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577787				2022-12-27	WOS:A1992HT96500111
J	VANDERREST, ME; SIEWE, RM; ABEE, T; SCHWARZ, E; OESTERHELT, D; KONINGS, WN				VANDERREST, ME; SIEWE, RM; ABEE, T; SCHWARZ, E; OESTERHELT, D; KONINGS, WN			NUCLEOTIDE-SEQUENCE AND FUNCTIONAL-PROPERTIES OF A SODIUM-DEPENDENT CITRATE TRANSPORT-SYSTEM FROM KLEBSIELLA-PNEUMONIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-SEQUENCE; MEMBRANE; CLONING; GENE; EXPRESSION; BACTERIA	The gene of the sodium-dependent citrate transport system from Klebsiella pneumoniae (citS) is located on plasmid pES3 (Schwarz, E., and Oesterhelt, D. (1985) EMBO J. 4, 1599-1603) and encodes a 446-amino acid protein. Transport of citrate via this citrate transport protein (CitS) is dependent on the presence of sodium ions and is inhibited by magnesium ions. The DELTA-pH (pH gradient across the membrane) is the major driving force for uptake. It is postulated that, in analogy with the proton-dependent citrate carrier (CitH) of K. pneumoniae (van der Rest, M. E., Abee, T., Molenaar, D., and Konings, W. N. (1990) Eur. J. Biochem. 195, 71-77), only one of the protonated species of citrate is recognized by CitS and that citrate is translocated across the membrane in symport with protons and sodium ions. The hydrophobicity profile of CitS suggests that the protein is very hydrophobic and contains 12 membrane-spanning segments. These segments are not centered around a hydrophilic core as has been suggested for other transport proteins, but the protein is asymmetrical with seven transmembrane segments in front of a large hydrophilic loop and five after this loop. The amino acid sequence is highly similar to a citrate transport system of Lactococcus lactis subsp. lactis var. diacetylactis (CitP) (David, S., van der Rest, M. E., Driessen, A. J. M., Simons, G., and de Vos, W. M. (1990) J. Bacteriol. 172, 5789-5794) and less similar to CitH of K. pneumoniae. We conclude that the citS gene of K. pneumoniae encodes a sodium-dependent citrate transport system that belongs to a novel subclass of transport proteins.	UNIV GRONINGEN, CTR BIOL, MICROBIOL LAB, KERKLAAN 30, 9751 NN HAREN, NETHERLANDS; MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY	University of Groningen; Max Planck Society			Konings, Wilhelmus N./C-7063-2013					BALDWIN SA, 1989, ANNU REV PHYSIOL, V51, P459, DOI 10.1146/annurev.physiol.51.1.459; BERGSMA J, 1983, EUR J BIOCHEM, V134, P151, DOI 10.1111/j.1432-1033.1983.tb07545.x; DAIMON H, 1989, J BACTERIOL, V171, P620, DOI 10.1128/jb.171.1.620-623.1989; DAVID S, 1990, J BACTERIOL, V172, P5789, DOI 10.1128/jb.172.10.5789-5794.1990; DIMROTH P, 1990, J BIOL CHEM, V265, P7221; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; DIMROTH P, 1986, BIOL CHEM HOPPESEYLE, V376, P813; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIRATO T, 1986, J BACTERIOL, V165, P324, DOI 10.1128/jb.165.1.324-327.1986; INOUYE M, 1983, EXPT MANIPULATION GE; ISHIGURO N, 1985, J BACTERIOL, V164, P977, DOI 10.1128/JB.164.3.977-982.1985; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Koser SA, 1924, J BACTERIOL, V9, P59, DOI 10.1128/JB.9.1.59-77.1924; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LARA FJS, 1952, J BACTERIOL, V63, P415, DOI 10.1128/JB.63.3.415-420.1952; LAUSSERMAIR E, 1989, J BIOL CHEM, V264, P14710; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; Maniatis T., 1982, MOL CLONING; Martin WJ, 1980, MANUAL CLIN MICROBIO, P195; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASATSU M, 1985, J BACTERIOL, V164, P983, DOI 10.1128/JB.164.3.983-993.1985; SATO G, 1978, MICROBIOL IMMUNOL, V22, P357, DOI 10.1111/j.1348-0421.1978.tb00380.x; SCHWARZ E, 1985, EMBO J, V4, P1599, DOI 10.1002/j.1460-2075.1985.tb03823.x; SCHWARZ E, 1986, THESIS LUDWIGMAXIMIL; SHIMAMOTO T, 1991, J BIOCHEM-TOKYO, V110, P22, DOI 10.1093/oxfordjournals.jbchem.a123537; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SMITH LM, 1987, METHOD ENZYMOL, V155, P260; VANDERREST ME, 1991, EUR J BIOCHEM, V195, P71; VANDERREST ME, 1990, EUR J BIOCHEM, V189, P401; VANSCHIE BJ, 1985, J BACTERIOL, V163, P493, DOI 10.1128/JB.163.2.493-499.1985; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	34	63	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8971	8976						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577734				2022-12-27	WOS:A1992HR85400043
J	HUDGINS, WR; HAMPTON, B; BURGESS, WH; PERDUE, JF				HUDGINS, WR; HAMPTON, B; BURGESS, WH; PERDUE, JF			THE IDENTIFICATION OF O-GLYCOSYLATED PRECURSORS OF INSULIN-LIKE GROWTH FACTOR-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; HUMAN-PLASMA; PROTEINS; PURIFICATION; HYPOGLYCEMIA; SERUM; SECRETION; PEPTIDE; VARIANT; BINDING	A procedure that combined ion exchange, gel permeation, and insulin-like growth factor-binding protein 3 (IGF-BP-3) affinity chromatography with chromatofocusing and reversed-phase high pressure liquid chromatography was used to isolate high molecular weight precursors of human insulin-like growth factor II (IGF-II) from acetic acid extracts of Cohn fraction IV1. Two precursors had isoelectric points (pI) of 5.1 and 5.4 and apparent M(r) values of 15,000 and 11,500, respectively. An apparent M(r) = 16,000 RLPG/Ser29 variant of IGF-II was also identified in the acetic acid extracts. Amino-terminal amino acid sequencing of the major E domain-containing peptide that had been isolated from apparent M(r) = 15,000 IGF-II (pI 5.1), following its digestion with the endoprotease Lys-C, indicated the carboxyl terminus of this precursor was near or at Lys88. During the sequencing of this peptide, a sharply reduced yield of derivatized amino acid occurred at cycle 10, indicating that Thr75 had been post-translationally modified, possibly by O-glycosylation. To evaluate this possibility, the I-125-labeled high molecular weight IGF-IIs and their endoprotease-generated peptides were treated with glycosidases, and their effects were determined from the change in relative mobilities of the polypeptide and peptides during sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Neuraminidase treatment of apparent M(r) = 15,000 and 11,500 IGF-II reduced their M(r) values to a common value of 10,500. When the desialylated precursors of IGF-II were treated with O-glycosidase, but not when treated with N-glycosidase, the M(r) values were reduced further to about 10,000. This was the M(r) value that would be predicted for an unglycosylated form of precursor IGF-II that had a carboxyl-terminal end at or near Lys88. When the Ser66-Lys88 endoprotease-generated E domain peptides from pI 5.1 and 5.4 high M(r) IGF-II were treated with the glycosidases, they had relative mobility changes during sodium dodecyl sulfate-polyacrylamide gel electrophoresis that were similar to those of the intact precursors. Finally, the association of O-linked oligosaccharide with the E domain peptide of IGF-II was confirmed by demonstrating the specificity of binding of the Ser66-Lys88 asialoglycopeptide to jackfruit lectin.	AMER RED CROSS,JEROME H HOLLAND LAB BIOMED SCI,DEPT MOLEC BIOL,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855	American Red Cross			Hampton, Brian/G-8427-2015	Hampton, Brian/0000-0003-4650-2869	NCI NIH HHS [CA-47150] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047150] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BELL GI, 1984, NATURE, V310, P775, DOI 10.1038/310775a0; BLUM WF, 1987, ACTA ENDOCRINOL-COP, V111, P271; CORNELL HJ, 1982, PREP BIOCHEM, V12, P57, DOI 10.1080/00327488208065550; DAUGHADAY WH, 1988, NEW ENGL J MED, V319, P1434, DOI 10.1056/NEJM198812013192202; DAUGHADAY WH, 1989, P NATL ACAD SCI USA, V86, P6778, DOI 10.1073/pnas.86.17.6778; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DELI E, 1990, 72D END SOC ANN M AT, P306; DULL TJ, 1984, NATURE, V310, P777, DOI 10.1038/310777a0; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; GOWAN LK, 1987, ENDOCRINOLOGY, V121, P449, DOI 10.1210/endo-121-2-449; HAMPTON B, 1989, J BIOL CHEM, V264, P19155; HASELBACHER G, 1982, ENDOCRINOLOGY, V110, P1822, DOI 10.1210/endo-110-5-1822; HERINGTON AC, 1983, INSULIN LIKE GROWTH, P113; HILL DJ, 1990, EARLY HUM DEV, V21, P49, DOI 10.1016/0378-3782(90)90110-5; HORTIN GL, 1990, ANAL BIOCHEM, V188, P271, DOI 10.1016/0003-2697(90)90605-9; HUDGINS WR, 1987, J LIQ CHROMATOGR, V10, P3329, DOI 10.1080/01483918708081876; HUDGINS WR, 1991, MODERN CONCEPTS INSU, P253; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; HYLKA VW, 1987, ENDOCRINOLOGY, V120, P2050, DOI 10.1210/endo-120-5-2050; HYLKA VW, 1990, BIOCH BIOPHYSACTA, V105, P6; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; PELLEGRINI I, 1990, ENDOCRINOLOGY, V126, P1087; PERDUE JF, 1991, ENDOCRINOLOGY, V129, P3101, DOI 10.1210/endo-129-6-3101; PERDUE JF, 1991, ADV EXP MED BIOL, V293, P45; SAIRAM MR, 1989, FASEB J, V3, P1915, DOI 10.1096/fasebj.3.8.2542111; SCHWARTZ G N, 1990, Experimental Hematology (Charlottesville), V18, P610; SHAPIRO ET, 1990, J CLIN INVEST, V85, P1672, DOI 10.1172/JCI114619; SVOBODA ME, 1980, BIOCHEMISTRY-US, V19, P90; TOMITA M, 1978, BIOCHEMISTRY-US, V17, P4756, DOI 10.1021/bi00615a025; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG YWH, 1985, J BIOL CHEM, V260, P2570; ZUMSTEIN PP, 1985, P NATL ACAD SCI USA, V82, P3169, DOI 10.1073/pnas.82.10.3169	35	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8153	8160						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569071				2022-12-27	WOS:A1992HQ18500031
J	LUTZ, RJ; MCLAIN, TM; SINENSKY, M				LUTZ, RJ; MCLAIN, TM; SINENSKY, M			FEEDBACK INHIBITION OF POLYISOPRENYL PYROPHOSPHATE SYNTHESIS FROM MEVALONATE INVITRO - IMPLICATIONS FOR PROTEIN PRENYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-LIVER; ISOPRENOID SYNTHESIS; PIG-LIVER; SYNTHETASE; PRENYLTRANSFERASE; BIOSYNTHESIS; IDENTIFICATION; ISOPRENYLATION; MITOCHONDRIA; PURIFICATION	The prenylation of proteins utilizes the polyisoprenyl pyrophosphates (FPP) and geranylgeranyl pyrophosphate (GGPP) as prenyl donors. These polyisoprenoids are also precursors to ubiquinone and dolichol synthesis. We have previously described the geranylgeranylation of rab1b from labeled mevalonate in rabbit reticulocyte lysates (Khosravi-Far, R., Lutz, R. J., Cox, A. D., Conroy, L., Bourne, J. R., Sinensky, M., Balch, W. E., Buss, J. C., and Der, C. J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 6264-6268). We now directly demonstrate the incorporation of mevalonate into FPP and GGPP in rabbit reticulocyte cytosol. High pressure liquid chromatography analysis reveals that only all-trans-E,E-GGPP, the prenyl donor for in vivo protein geranylgeranylation, is synthesized. Incubations with recombinant H-ras and rab1b result in an increased synthesis of farnesyl and geranylgeranyl derivatives, respectively. The increase is wholly accounted for by protein-incorporated polyisoprenoids with no change in the polyisoprenyl pyrophosphate pools. Further, GGPP inhibits its own synthesis, without affecting FPP synthesis, with half-maximal inhibition at approximately 3-mu-M GGPP. Inhibition of FPP synthesis by the inhibition of isopentenyl isomerase causes a dramatic increase in isopentenyl pyrophosphate synthesis. FPP also inhibits conversion of mevalonate into FPP. These findings indicate that these polyisoprenyl pyrophosphates can down-regulate their own synthesis in vitro, and this regulation may control the levels of these polyisoprenoids in vivo.	ELEANOR ROOSEVELT INST CANC RES,DENVER,CO 80206						NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040804] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40804] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHBY MN, 1989, J BIOL CHEM, V264, P635; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P131; DORSEY JK, 1968, J BIOL CHEM, V243, P4667; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P169; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; GOLDSTEIN JL, 1984, J LIPID RES, V25, P1450; ISHII K, 1983, BIOCHEM BIOPH RES CO, V116, P500, DOI 10.1016/0006-291X(83)90551-X; KALEN A, 1990, J BIOL CHEM, V265, P1158; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; LASKOVICS FM, 1979, J BIOL CHEM, V254, P9458; LEONARD S, 1990, J BIOL CHEM, V265, P5157; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MOMOSE K, 1972, J BIOL CHEM, V247, P3930; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; REARDON JE, 1986, BIOCHEMISTRY-US, V25, P5609, DOI 10.1021/bi00367a040; REED BC, 1976, BIOCHEMISTRY-US, V15, P3739, DOI 10.1021/bi00662a015; REPKO EM, 1989, J BIOL CHEM, V264, P9945; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SAGAMI H, 1991, J BIOL CHEM, V266, P3458; SAGAMI H, 1981, BIOCHEM INT, V3, P669; SAITO A, 1979, J BIOL CHEM, V254, P8511; SHECHTER I, 1971, J BIOL CHEM, V246, P7690; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; TANAKA RD, 1990, J BIOL CHEM, V265, P2391; WATSON JA, 1985, J BIOL CHEM, V260, P4083	29	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					7983	7986						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569056				2022-12-27	WOS:A1992HQ18500007
J	TORTI, M; MARTI, KB; ALTSCHULER, D; YAMAMOTO, K; LAPETINA, EG				TORTI, M; MARTI, KB; ALTSCHULER, D; YAMAMOTO, K; LAPETINA, EG			ERYTHROPOIETIN INDUCES P21(RAS) ACTIVATION AND P120GAP TYROSINE PHOSPHORYLATION IN HUMAN ERYTHROLEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR-FREE CALCIUM; INFECTED ERYTHROID-CELLS; PROTEIN GAP; GROWTH-FACTOR; RAS; GTPASE; IDENTIFICATION; STIMULATION; RECEPTOR; P21RAS	Erythropoietin is the major regulator of the proliferation and differentiation of erythroid precursors, but little is known about its molecular mechanism of action. Using a human erythroleukemic cell line (HEL), we investigated whether p21ras is involved in erythropoietin signal transduction. We found that stimulation of HEL cells with erythropoietin induces a 5-fold increase in the amount of GTP bound to the endogenous p21ras. This effect is dose-dependent and occurs very rapidly. We also observed that erythropoietin causes tyrosine phosphorylation of several proteins in a time-dependent manner that correlates with the p21ras activation. Moreover, inhibition of tyrosine kinases by genistein totally prevents the erythropoietin-induced accumulation of a p21ras . GTP complex. By using an antiserum against the GTPase-activating protein, we found that p120GAP is rapidly phosphorylated in tyrosine in response to erythropoietin. Furthermore, the ability of a lysate from erythropoietin-stimulated HEL cells to induce in vitro hydrolysis of GTP bound to p21ras was strongly reduced. These results demonstrate that activation of p21ras is an early event in the erythropoietin signal transduction pathway, and they suggest that accumulation of the p21ras . GTP complex may be triggered by inhibition of GTPase-activating protein activity.	BURROUGHS WELLCOME CO, DIV CELL BIOL, 3030 CORNWALLIS RD, RES TRIANGLE PK, NC 27709 USA	Burroughs Wellcome Fund								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKMAN BS, 1987, BIOCHEM BIOPH RES CO, V147, P392, DOI 10.1016/S0006-291X(87)80134-1; BONANOUTZEDAKI SA, 1986, EUR J BIOCHEM, V155, P363, DOI 10.1111/j.1432-1033.1986.tb09499.x; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BUNN HF, 1990, YALE J BIOL MED, V63, P381; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHOI HS, 1987, J BIOL CHEM, V262, P2933; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUKUMOTO H, 1989, DEVELOPMENT, V105, P109; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; IMAGAWA S, 1989, BLOOD, V73, P1452; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KRANTZ SB, 1991, BLOOD, V77, P419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROWSKI ER, 1989, BIOCHEM BIOPH RES CO, V161, P972, DOI 10.1016/0006-291X(89)91338-7; LAZAROWSKI ER, 1990, J BIOL CHEM, V265, P13118; MILLER BA, 1989, BLOOD, V73, P1188; MILLER BA, 1988, J CLIN INVEST, V82, P309, DOI 10.1172/JCI113588; MLADENOVIC J, 1988, J LAB CLIN MED, V112, P23; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SAWYER ST, 1989, BLOOD, V74, P103; SAWYER ST, 1984, J BIOL CHEM, V259, P2769; SAWYER ST, 1987, P NATL ACAD SCI USA, V84, P3690, DOI 10.1073/pnas.84.11.3690; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSUDA H, 1989, EXP HEMATOL, V17, P211; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667	42	137	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8293	8298						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569084				2022-12-27	WOS:A1992HQ18500052
J	LEMMON, MA; FLANAGAN, JM; HUNT, JF; ADAIR, BD; BORMANN, BJ; DEMPSEY, CE; ENGELMAN, DM				LEMMON, MA; FLANAGAN, JM; HUNT, JF; ADAIR, BD; BORMANN, BJ; DEMPSEY, CE; ENGELMAN, DM			GLYCOPHORIN-A DIMERIZATION IS DRIVEN BY SPECIFIC INTERACTIONS BETWEEN TRANSMEMBRANE ALPHA-HELICES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; STAPHYLOCOCCAL NUCLEASE; MEMBRANE; PROTEIN; RESOLUTION; BACTERIORHODOPSIN; MUTAGENESIS; RECEPTORS; CLEAVAGE; COMPLEX	Specific side-by-side interactions between transmembrane alpha-helices may be important in the assembly and function of integral membrane proteins. We describe a system for the genetic and biophysical analysis of these interactions. The trans membrane alpha-helical domain of interest is fused to the C-terminus of staphylococcal nuclease. The resulting chimera can be expressed at high levels in Escherichia coli and is readily purified. In our initial application we study the single transmembrane alpha-helix of human glycophorin A (GpA), thought to mediate the SDS-stable dimerization of this protein. The resulting chimera forms a dimer in SDS, which is disrupted upon addition of a peptide corresponding to the transmembrane domain of GpA. Deletion mutagenesis has been used to delineate the minimum transmembrane domain sufficient for this behavior. Site-specific mutagenesis shows that a methionine residue, previously implicated as a potential interfacial residue, can be replaced with other hydrophobic residues without disrupting dimerization. By contrast, rather conservative substitutions at a valine on a different face of the alpha-helix disrupt dimerization, suggesting a high degree of specificity in the helix-helix interactions. This approach allows the interface between interacting helices to be defined.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,260 WHITNEY AVE,NEW HAVEN,CT 06511; BOEHRINGER INGELHEIM PHARMACEUT,RIDGEFIELD,CT 06877	Yale University; Boehringer Ingelheim				Lemmon, Mark/0000-0002-3379-5319; Dempsey, Christopher/0000-0002-1933-7805	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039546] Funding Source: NIH RePORTER; NIGMS NIH HHS [5PO1-GM39546] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FLANAGAN JM, 1992, P NATL ACAD SCI USA, V89, P748, DOI 10.1073/pnas.89.2.748; FURTHMAYR H, 1976, BIOCHEMISTRY-US, V15, P1137, DOI 10.1021/bi00650a028; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOLL PJ, 1989, PROTEINS, V5, P183, DOI 10.1002/prot.340050302; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; POPOT JL, 1987, J MOL BIOL, V198, P655, DOI 10.1016/0022-2836(87)90208-7; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGREST JP, 1973, ARCH BIOCHEM BIOPHYS, V155, P167, DOI 10.1016/S0003-9861(73)80019-0; SHORTLE D, 1983, GENE, V22, P181, DOI 10.1016/0378-1119(83)90102-6; SILVERBERG M, 1976, BIOCHEMISTRY-US, V15, P1448, DOI 10.1021/bi00652a015; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WELSH EJ, 1985, BIOPOLYMERS, V24, P2301, DOI 10.1002/bip.360241210	34	435	438	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7683	7689						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560003				2022-12-27	WOS:A1992HN48500069
J	SUSA, M; VULEVIC, D; LANE, HA; THOMAS, G				SUSA, M; VULEVIC, D; LANE, HA; THOMAS, G			INHIBITION OR DOWN-REGULATION OF PROTEIN-KINASE-C ATTENUATES LATE PHASE P70(S6K) ACTIVATION INDUCED BY EPIDERMAL GROWTH-FACTOR BUT NOT BY PLATELET-DERIVED GROWTH-FACTOR OR INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S6 KINASE; TYROSINE PHOSPHORYLATION; INDEPENDENT PATHWAYS; 3T3 CELLS; IDENTIFICATION; INVITRO; INVIVO; POTENT; PDGF	The late phase of the time-dependent epidermal growth factor (EGF)-induced biphasic activation of the p70s6k is selectively attenuated by the specific PKC inhibitor, CGP 41 251, a staurosporine derivative. At a 40-fold lower concentration than CGP 41 251, staurosporine inhibits both phases of S6 kinase activation to the same extent, whereas the inactive staurosporine derivative CGP 42 700 shows no effect on either phase. Platelet-derived growth factor (PDGF) and insulin also induce biphasic S6 kinase activation, but in neither case is either phase of activation affected by the presence of CGP 41 251. This finding was unexpected in the case of PDGF, which is a potent activator of PKC and whose receptor directly interacts with phospholipase C(gamma)1. However, similar results were obtained following down-regulation of PKC by prolonged 12-O-tetradecanoylphorbol-13-acetate treatment. Therefore, even though EGF and PDGF induce PKC activation, PDGF, unlike EGF, does not appear to use this signaling pathway for late phase p70s6k activation.	FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERRARI S, 1991, J BIOL CHEM, V266, P22770; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KRISHNAMURTHI S, 1989, BIOCHEM J, V261, P687, DOI 10.1042/bj2610687; LAMBETH JD, 1988, J BIOL CHEM, V263, P3818; LANE HA, 1992, IN PRESS EMBO J; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PELECH SL, 1987, J BIOL CHEM, V262, P11598; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SHAAFI RI, 1989, BIOCHEM J, V261, P688, DOI 10.1042/bj2610688; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUSA M, 1990, P NATL ACAD SCI USA, V87, P7040, DOI 10.1073/pnas.87.18.7040; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254	33	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6905	6909						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551899				2022-12-27	WOS:A1992HM05300070
J	DENKER, BM; NEER, EJ; SCHMIDT, CJ				DENKER, BM; NEER, EJ; SCHMIDT, CJ			MUTAGENESIS OF THE AMINO TERMINUS OF THE ALPHA-SUBUNIT OF THE G-PROTEIN G0 - INVITRO CHARACTERIZATION OF ALPHA-0-BETA-GAMMA-INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; ROD OUTER SEGMENTS; ADENYLATE-CYCLASE; LIMITED PROTEOLYSIS; ADP-RIBOSYLATION; PERTUSSIS TOXIN; TRANSDUCIN; MEMBRANE; PHOSPHOLIPASE-A2; MYRISTOYLATION	Heterotrimeric guanine nucleotide-binding proteins are composed of alpha and beta-gamma-subunits and couple a variety of cell-surface receptors to intracellular enzymes or ion channels. The heterotrimer dissociates into alpha and beta-gamma-subunits when the alpha-subunit is activated by guanine nucleoside triphosphates. Several lines of evidence show that the amino terminus of the alpha-subunit is important for the interaction with the beta-gamma-subunit (Neer, E. J., Pulsifer, L., and Wolf, L. G. (1988) J. Biol. Chem. 263, 8996-9000; Fung, B. K.-K., and Nash, C. R. (1983) J. Biol. Chem. 258, 10503-10510). We have mutagenized the amino terminus of alpha(o) to dissect the relative contributions of amino-terminal myristoylation and specific amino acid sequences to subunit interaction. Wild-type and mutant-alpha(o) cDNAs were translated in vitro in a rabbit reticulocyte lysate. All proteins were able to bind guanosine 5'-(gamma-thio)triphosphate and to achieve the necessary conformation for protection from tryptic digestion. Two assays of alpha(o)beta-gamma-interactions were used: sucrose density gradients to look for stable heterotrimer formation and ADP-ribosylation by pertussis toxin to detect weak or transient alpha(o)beta-gamma-interactions. Our results indicate that myristoylation is essential for stable heterotrimer formation, but that nonmyristoylated proteins are also capable of interacting with the beta-gamma-subunit. Aminoacids 7-10 have an important role in alpha(o)beta-gamma-interactions whether alpha(o) is myristoylated or not. Deletion of this region diminishes the ability of alpha(o) to interact with the beta-gamma-subunit, but substitutions at this position indicate that other amino acids can be tolerated without affecting subunit interaction.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	DENKER, BM (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115, USA.			Schmidt, Carl/0000-0002-8386-4781	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035417, F32GM012578, R01GM036259, R37GM036259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM12578-03, GM35417, GM36259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUDIGIER Y, 1990, J CELL BIOL, V111, P1427, DOI 10.1083/jcb.111.4.1427; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DENKER BM, 1991, FEBS LETT, V1, P98; FUNG BKK, 1983, J BIOL CHEM, V258, P503; HUFF RM, 1985, J BIOL CHEM, V260, P864; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KATADA T, 1984, J BIOL CHEM, V259, P3568; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OLATE J, 1988, J BIOL CHEM, V263, P10394; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TSAI SC, 1984, J BIOL CHEM, V259, P5320; WEST RE, 1985, J BIOL CHEM, V260, P4428; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571; YI F, 1991, J BIOL CHEM, V266, P3900	31	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6272	6277						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556134				2022-12-27	WOS:A1992HK31800083
J	SCOTT, LJ; HUBBARD, AL				SCOTT, LJ; HUBBARD, AL			DYNAMICS OF 4 RAT-LIVER PLASMA-MEMBRANE PROTEINS AND POLYMERIC IGA RECEPTOR - RATES OF SYNTHESIS AND SELECTIVE LOSS INTO THE BILE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-CELLULAR TRANSPORT; DIPEPTIDYL PEPTIDASE-IV; EPIDERMAL GROWTH-FACTOR; CANINE KIDNEY-CELLS; IMMUNOGLOBULIN RECEPTOR; POLYACRYLAMIDE GELS; MONOCLONAL-ANTIBODIES; MEDIATED ENDOCYTOSIS; SECRETORY COMPONENT; CANALICULAR DOMAIN	We have determined the half-lives and amounts per hepatocyte of the polymeric IgA receptor (pIgA-R) and four rat hepatocyte plasma membrane proteins and subsequently have predicted their rates of synthesis and possible routes of degradation. Using in vivo pulse-chase metabolic labeling with L-[S-35]cysteine, we found that the pIgA-R had an apparent half-life of 1.1 h. Additional metabolic labeling experiments showed that CE9, HA4, and HA321 had apparent half-lives of 4-5 days, and dipeptidyl peptidase IV had an apparent half-life of 9 days. To quantify the amount of each protein per hepatocyte, homogenates and a standard curve of purified protein were compared by immunoblotting. We found that these proteins were present at 1-8 x 10(6) molecules/hepatocyte. The calculated rate of synthesis for pIgA-R was 1.6 x 10(6) molecules/hepatocyte/h, whereas the others were synthesized at much lower rates (0.9-5 x 10(4) molecules/hepatocyte/h). Using immunoblot analysis, we found that pIgA-R was released into bile at a rate of 30%/h (700%/day), whereas dipeptidyl peptidase IV and HA4 were released at a rate of 2-3%/day. While the majority of the loss of pIgA-R from hepatocytes occurred by release into the bile, less than 30% of the degradation of dipeptidyl peptidase IV and HA4 could be accounted for by this pathway, suggesting that the remaining molecules must be retrieved from the apical surface before degradation.	JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, 725 N WOLFE ST, BALTIMORE, MD 21205 USA	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029185] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANANTHANARAYANAN M, 1988, J BIOL CHEM, V263, P8338; BANTING G, 1989, FEBS LETT, V254, P177, DOI 10.1016/0014-5793(89)81034-8; BARNWELL SG, 1983, BIOCHEM J, V210, P549, DOI 10.1042/bj2100549; BARTLES JR, 1986, DEV BIOL, V118, P286, DOI 10.1016/0012-1606(86)90095-3; BARTLES JR, 1985, J CELL BIOL, V100, P1126, DOI 10.1083/jcb.100.4.1126; BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BRAITERMAN LT, 1985, J CELL BIOL, V101, P61; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BROWN WR, 1989, IMMUNOL INVEST, V18, P269, DOI 10.3109/08820138909112242; CADMAN E, 1979, ANAL BIOCHEM, V96, P21, DOI 10.1016/0003-2697(79)90548-7; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHRISTENSEN EI, 1982, EUR J CELL BIOL, V29, P43; COLEMAN R, 1987, BIOCHEM J, V244, P249, DOI 10.1042/bj2440249; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; DUNN WA, 1986, J CELL BIOL, V102, P24, DOI 10.1083/jcb.102.1.24; ELIAS H, 1949, AM J ANAT, V85, P379, DOI 10.1002/aja.1000850303; ELOVSON J, 1980, J BIOL CHEM, V255, P5816; GODFREY PP, 1981, BIOCHEM J, V196, P11, DOI 10.1042/bj1960011; GONNELLA PA, 1984, J CELL BIOL, V99, P909, DOI 10.1083/jcb.99.3.909; HANSKI C, 1985, BIOL CHEM H-S, V366, P1169, DOI 10.1515/bchm3.1985.366.2.1169; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; HOPSUHAVU VK, 1967, H-S Z PHYSIOL CHEM, V348, P1540, DOI 10.1515/bchm2.1967.348.1.1540; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; HUBBARD AL, 1985, J CELL BIOL, V100, P1115, DOI 10.1083/jcb.100.4.1115; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HUGHSON EJ, 1990, J CELL BIOL, V110, P337, DOI 10.1083/jcb.110.2.337; JACOBS E, 1986, ANAL BIOCHEM, V154, P583, DOI 10.1016/0003-2697(86)90033-3; JONES AL, 1984, HEPATOLOGY, V4, P1173, DOI 10.1002/hep.1840040613; Krebs H.A., 1974, REGULATION HEPATIC M, P726; KUHN LC, 1983, ANN NY ACAD SCI, V409, P751, DOI 10.1111/j.1749-6632.1983.tb26914.x; LARKIN JM, 1986, P NATL ACAD SCI USA, V83, P4759, DOI 10.1073/pnas.83.13.4759; LEWANDOWSKI AE, 1988, AM J PHYSIOL, V254, pC634, DOI 10.1152/ajpcell.1988.254.5.C634; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LIBBY P, 1980, CELL, V19, P481, DOI 10.1016/0092-8674(80)90523-1; LIN SH, 1989, J BIOL CHEM, V264, P14408; MAHER JJ, 1988, HEPATOLOGY, V8, P1162, DOI 10.1002/hep.1840080534; Maizel JV, 1971, METHOD VIROL, V5, P179; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256; Matter A, 1969, J Ultrastruct Res, V11, P1; MATTER K, 1990, J BIOL CHEM, V265, P3503; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MUSIL LS, 1987, J CELL BIOL, V104, P1725, DOI 10.1083/jcb.104.6.1725; NAGATSU T, 1976, ANAL BIOCHEM, V74, P466, DOI 10.1016/0003-2697(76)90227-X; OGATA S, 1989, J BIOL CHEM, V264, P3596; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROMAN LM, 1983, J CELL BIOL, V96, P1548, DOI 10.1083/jcb.96.6.1548; SALAMERO J, 1990, P NATL ACAD SCI USA, V87, P7717, DOI 10.1073/pnas.87.19.7717; SCOTT L J, 1990, Journal of Cell Biology, V111, p457A; SCOTT L J, 1988, Journal of Cell Biology, V107, p777A; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SOLARI R, 1989, BIOCHEM J, V257, P759, DOI 10.1042/bj2570759; STROUS GJAM, 1983, J CELL BIOL, V97, P1815, DOI 10.1083/jcb.97.6.1815; SVENBERG T, 1976, INT J CANCER, V17, P588, DOI 10.1002/ijc.2910170506; SZTUL ES, 1985, J CELL BIOL, V100, P1255, DOI 10.1083/jcb.100.4.1255; SZTUL ES, 1983, J CELL BIOL, V97, P1582, DOI 10.1083/jcb.97.5.1582; TIFFANY JM, 1970, VIROLOGY, V41, P392, DOI 10.1016/0042-6822(70)90096-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOLK BA, 1983, FEBS LETT, V163, P150, DOI 10.1016/0014-5793(83)81183-1; VONBONSDORFF CH, 1985, EMBO J, V4, P2781, DOI 10.1002/j.1460-2075.1985.tb04004.x; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68; WEIBEL ER, 1976, 6TH EUR C EL MICR JE, P6	67	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6099	6106						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556118				2022-12-27	WOS:A1992HK31800059
J	SOPHER, BL; TRAVISS, CE; CAVANAGH, KT; JONES, MZ; FRIDERICI, KH				SOPHER, BL; TRAVISS, CE; CAVANAGH, KT; JONES, MZ; FRIDERICI, KH			PURIFICATION AND CHARACTERIZATION OF GOAT LYSOSOMAL BETA-MANNOSIDASE USING MONOCLONAL AND POLYCLONAL ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE DISEASE; HUMAN-PLACENTA; DEFICIENCY; OLIGOSACCHARIDES; ACCUMULATION; BRAIN; URINE; FORMS	Goat beta-mannosidase was purified 120,000-fold in 26% yield from kidney using concanavalin A-Sepharose chromatography followed by immunoaffinity and cation-exchange chromatography. When analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and visualized by Coomassie Blue staining, the purified enzyme preparation consists of 90- and 100-kDa peptides. Both these peptides react with anti-beta-mannosidase monoclonal antibodies and produce similar electrophoretic peptide patterns when subjected to limited proteolysis. Deglycosylation reduces the size of the 90- and 100-kDa peptides to 86 and 91 kDa, respectively. Goat kidney tissues lacking beta-mannosidase activity, acquired from animals affected with beta-mannosidosis, do not contain detectable quantities of the 90- and 100-kDa peptides as judged by monoclonal antibody reactivity. We postulate that the 90- and 100-kDa peptides represent two related forms of beta-mannosidase.	MICHIGAN STATE UNIV,DEPT PATHOL,627 E FEE HALL,E LANSING,MI 48824	Michigan State University					NINDS NIH HHS [NS-16886] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016886] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBITT B, 1991, J AM VET MED ASSOC, V198, P109; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERNARD M, 1986, INT J BIOCHEM, V18, P1065, DOI 10.1016/0020-711X(86)90255-7; BOYER PJ, 1990, LAB INVEST, V63, P100; BRYAN L, 1990, BIOCHEM BIOPH RES CO, V173, P491, DOI 10.1016/S0006-291X(05)80060-9; CAMPBELL AM, 1984, MONOCLONAL ANTIBODY; CAVANAGH KT, 1985, ENZYME, V34, P75, DOI 10.1159/000469366; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOPER A, 1986, NEW ENGL J MED, V315, P1231; COOPER A, 1991, J INHERIT METAB DIS, V14, P18, DOI 10.1007/BF01804383; DAWSON G, 1982, J BIOL CHEM, V257, P3369; DORLAND L, 1988, J INHERIT METAB DIS, V11, P255, DOI 10.1007/BF01804251; FREI JI, 1988, BIOCHEM J, V249, P871, DOI 10.1042/bj2490871; HARLOW E, 1988, ANTIBODIES LABORATOR; HEALY PJ, 1981, AUST VET J, V57, P504, DOI 10.1111/j.1751-0813.1981.tb05782.x; IWASAKI Y, 1989, J BIOCHEM-TOKYO, V106, P331, DOI 10.1093/oxfordjournals.jbchem.a122853; JOLLY RD, 1991, J NZ VET ASS, V38, P102; JONES MZ, 1981, J BIOL CHEM, V256, P5185; JONES MZ, 1981, J BIOL CHEM, V256, P5181; JONES MZ, 1983, J NEUROPATH EXP NEUR, V42, P268, DOI 10.1097/00005072-198305000-00005; JONES MZ, 1992, J INHERIT METAB DIS, V15, P57, DOI 10.1007/BF01800344; JONES MZ, 1984, J INHERIT METAB DIS, V7, P80, DOI 10.1007/BF01805811; KENNETT RH, 1980, MONOCLONAL ANTIBODIE, P365; KLEIJER WJ, 1990, J INHERIT METAB DIS, V13, P867, DOI 10.1007/BF01800211; KYOSAKA S, 1985, CHEM PHARM BULL, V33, P256; LOVELL KL, 1987, INT J DEV NEUROSCI, V5, P243, DOI 10.1016/0736-5748(87)90035-9; MATSUURA F, 1983, BIOCHIM BIOPHYS ACTA, V759, P67, DOI 10.1016/0304-4165(83)90190-3; MATSUURA F, 1981, ARCH BIOCHEM BIOPHYS, V211, P485, DOI 10.1016/0003-9861(81)90481-1; MCCABE NR, 1991, BIOCHIM BIOPHYS ACTA, V1077, P133, DOI 10.1016/0167-4838(91)90049-6; MCCABE NR, 1990, ENZYME, V43, P137, DOI 10.1159/000468720; NOESKE C, 1983, H-S Z PHYSIOL CHEM, V364, P1645, DOI 10.1515/bchm2.1983.364.2.1645; PEARCE RD, 1987, BIOCHEM J, V243, P603, DOI 10.1042/bj2430603; POLAKIS PG, 1984, ARCH BIOCHEM BIOPHYS, V234, P341, DOI 10.1016/0003-9861(84)90279-0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOBER HA, 1968, CRC HDB BIOCHEMISTRY, pJ195; TJOA S, 1990, J INHERIT METAB DIS, V13, P187, DOI 10.1007/BF01799685; VANPELT J, 1990, CLIN CHIM ACTA, V187, P55, DOI 10.1016/0009-8981(90)90261-P; WENGER DA, 1986, NEW ENGL J MED, V315, P1201, DOI 10.1056/NEJM198611063151906	38	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6178	6182						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556126				2022-12-27	WOS:A1992HK31800070
J	FELLER, G; LONHIENNE, T; DEROANNE, C; LIBIOULLE, C; VANBEEUMEN, J; GERDAY, C				FELLER, G; LONHIENNE, T; DEROANNE, C; LIBIOULLE, C; VANBEEUMEN, J; GERDAY, C			PURIFICATION, CHARACTERIZATION, AND NUCLEOTIDE-SEQUENCE OF THE THERMOLABILE ALPHA-AMYLASE FROM THE ANTARCTIC PSYCHROTROPH ALTEROMONAS-HALOPLANCTIS A23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-STEAROTHERMOPHILUS; SIGNAL SEQUENCES; PROTEINS; BACTERIA; ENZYMES; RESOLUTION; SUBSTRATE; RESIDUES; CALCIUM	The alpha-amylase excreted by the antarctic bacterium Alteromonas haloplanctis was purified and the corresponding amy gene was cloned and sequenced. N- and C-terminal amino acid sequencing were used to establish the primary structure of the mature A. haloplanctis alpha-amylase which is composed of 453 amino acids with a predicted M(r) of 49,340 and a pI of 5.5. Three Ca2+ ions are bound per molecule and its activity is modulated by chloride ions. Within the four consensus sequences, Asp-174, Glu-200, and Asp-264 are the proposed catalytic residues. The psychrotrophic A. haloplanctis alpha-amylase is characterized by a high amylolytic activity at low temperatures, a reduced apparent optimal temperature, and typical thermodynamic activation parameters. A. haloplanctis alpha-amylase has also a low thermal stability as demonstrated by the temperature effect on both activity and secondary structure. It is suggested that structure flexibility and lower sensitivity of secondary structure to temperature variations in the low temperature range are the main structural adaptations of the psychrotrophic enzyme. The unusual stacking of small amino acids around the catalytic residues is proposed as a factor inducing active site flexibility and concomitant high activity of the enzyme at low temperatures.	STATE UNIV GHENT, MICROBIOL LAB, B-9000 GHENT, BELGIUM	Ghent University	FELLER, G (corresponding author), UNIV LIEGE, INST CHEM B6, BIOCHEM LAB, B-4000 LIEGE, BELGIUM.		Lonhienne, Thierry/A-5828-2011					BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BIELY P, 1988, ANAL BIOCHEM, V172, P176, DOI 10.1016/0003-2697(88)90428-9; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHUNG H, 1980, BIOCHEM J, V185, P387, DOI 10.1042/bj1850387; DAMBMANN C, 1981, PROTEINASES THEIR IN, P231; FELLER G, 1990, FEMS MICROBIOL LETT, V66, P239, DOI 10.1016/0378-1097(90)90290-7; FELLER G, 1991, GENE, V102, P111, DOI 10.1016/0378-1119(91)90548-P; FELLER G, 1991, DNA CELL BIOL, V10, P381, DOI 10.1089/dna.1991.10.381; HASEGAWA A, 1976, J BIOCHEM, V79, P35, DOI 10.1093/oxfordjournals.jbchem.a131055; Hochachka P. W., 1984, BIOCH ADAPTATION; JAENICKE R, 1990, PHILOS T R SOC B, V326, P535, DOI 10.1098/rstb.1990.0030; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KOBORI H, 1984, P NATL ACAD SCI-BIOL, V81, P6691, DOI 10.1073/pnas.81.21.6691; LOW PS, 1973, P NATL ACAD SCI USA, V70, P430, DOI 10.1073/pnas.70.2.430; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MORITA RY, 1975, BACTERIOL REV, V39, P144, DOI 10.1128/MMBR.39.2.144-167.1975; MOZHAEV VV, 1988, CRC CR REV BIOCH MOL, V23, P235, DOI 10.3109/10409238809088225; OGASAHARA K, 1970, J BIOCHEM, V67, P65, DOI 10.1093/oxfordjournals.jbchem.a129235; RAIMBAUD E, 1989, INT J BIOL MACROMOL, V11, P217, DOI 10.1016/0141-8130(89)90072-X; RAUSCHER E, 1985, CLIN CHEM, V31, P14; SOMERO GN, 1975, J EXP ZOOL, V194, P175, DOI 10.1002/jez.1401940111; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P505, DOI 10.1093/nar/12.1Part2.505; SVENSSON B, 1988, FEBS LETT, V230, P72, DOI 10.1016/0014-5793(88)80644-6; TAKAGI H, 1990, J BIOL CHEM, V265, P6874; TAKKINEN K, 1983, J BIOL CHEM, V258, P1007; VIHINEN M, 1990, J BIOCHEM-TOKYO, V107, P267, DOI 10.1093/oxfordjournals.jbchem.a123037; VIHINEN M, 1989, CRIT REV BIOCHEM MOL, V24, P329, DOI 10.3109/10409238909082556; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145	31	175	186	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5217	5221						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544904				2022-12-27	WOS:A1992HH74700036
J	LAETHEM, RM; LAETHEM, CL; KOOP, DR				LAETHEM, RM; LAETHEM, CL; KOOP, DR			PURIFICATION AND PROPERTIES OF A CYTOCHROME-P450 ARACHIDONIC-ACID EPOXYGENASE FROM RABBIT RENAL-CORTEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; LAURIC ACID; 14,15-EPOXYEICOSATRIENOIC ACID; TREATED RABBITS; EPOXYEICOSATRIENOIC ACIDS; DIFFERENTIAL INDUCTION; OMEGA-HYDROXYLATION; CONSTITUTIVE FORMS; HYPERTENSIVE RATS; MULTIPLE FORMS	A rabbit cytochrome P450 which catalyzes the epoxidation of arachidonic acid to two of the four possible regioisomeric epoxyeicosatrienoic acid metabolites was purified from renal cortex. A small amount of the unresolved omega/omega-1 hydroxylated eicosatetraenoic acid products were also produced. The enzyme had a specific content of 8.4 nmol of P450/mg of protein and exhibited a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis after silver staining. Sequencing revealed a single NH2-terminal amino acid sequence with the first 20 residues identical to rabbit cytochrome P450 2C2. We suggest this enzyme be termed P450 2CAA (for arachidonic acid) until the complete sequence and substrate selectivity are established. Purified P450 2CAA was in the low spin state as evidenced by an absorption maximum at 415 nm; the reduced-carbonyl complex exhibited a maximum at 451 nm. The specific activity for metabolism of 7-mu-M arachidonic acid was 1.1 nmol of product formed/min/nmol of P450. About 75% of the metabolites were two of the four possible epoxyeicosatrienoic acids identified as the 11,12- and 14,15-epoxyeicosatrienoic acids by coelution with synthetic and commercial standards on reversed and normal-phase high pressure liquid chromatographic separations. The ratio of the 11,12- to 14,15-epoxyeicosatrienoic acids was 1.5:1. The purified enzyme exhibited no significant activity toward 7-ethoxyresorufin or progesterone, but demethylated aminopyrine and benzphetamine. Other fatty acids were also substrates for the enzyme. Oleic, linoleic, and lauric acids, all at about 10-mu-M, were metabolized at rates of 0.32, 0.72, and 0.73 nmol/min/nmol of P450, respectively. Monoclonal antibody that cross-reacts with P450 2C2 inhibited 63% of the microsomal epoxidation activity from renal cortex microsomes from phenobarbital-treated rabbits. The production of the epoxide metabolites of arachidonic acid suggests that P450 2CAA may have a significant role in arachidonic acid-mediated intra- and intercellular signalling pathways.	CASE WESTERN RESERVE UNIV, DEPT ENVIRONM HLTH SCI, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT PHARMACOL, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041618] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL41618] Funding Source: Medline; NIADDK NIH HHS [T32 AM07139] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAINS SK, 1985, BIOCHEM PHARMACOL, V34, P3221, DOI 10.1016/0006-2952(85)90338-7; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BONVENTRE JV, 1991, KIDNEY INT, V39, P438, DOI 10.1038/ki.1991.55; BURKE MD, 1974, DRUG METAB DISPOS, V2, P583; CAPDEVILA J, 1983, ENDOCRINOLOGY, V113, P421; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CARROLL MA, 1986, J HYPERTENS, V4, pS33; CASHMAN JR, 1987, NEUROENDOCRINOLOGY, V46, P246, DOI 10.1159/000124827; CHAN G, 1990, BIOCHEMISTRY-US, V29, P3743, DOI 10.1021/bi00467a021; CHUNG SK, 1974, TETRAHEDRON LETT, P3023; CLARE RA, 1991, J CHROMATOGR-BIOMED, V562, P237, DOI 10.1016/0378-4347(91)80581-V; Coon M J, 1978, Methods Enzymol, V52, P109; COREY EJ, 1979, J AM CHEM SOC, V101, P1586, DOI 10.1021/ja00500a035; DUTTON DR, 1987, ARCH BIOCHEM BIOPHYS, V255, P316, DOI 10.1016/0003-9861(87)90399-7; ELLIS EF, 1990, AM J PHYSIOL, V259, pH1171, DOI 10.1152/ajpheart.1990.259.4.H1171; ESCALANTE B, 1988, BIOCHEM BIOPH RES CO, V152, P1269, DOI 10.1016/S0006-291X(88)80422-4; ESCALANTE B, 1991, SCIENCE, V251, P799, DOI 10.1126/science.1846705; ESCALANTE B, 1990, J CARDIOVASC PHARM, V16, P438, DOI 10.1097/00005344-199009000-00013; FALCK JR, 1983, BIOCHEM BIOPH RES CO, V114, P743, DOI 10.1016/0006-291X(83)90843-4; FALCK JR, 1990, J BIOL CHEM, V265, P10244; FINLAYSON MJ, 1986, BIOCHEM BIOPH RES CO, V141, P728, DOI 10.1016/S0006-291X(86)80233-9; FINLAYSON MJ, 1987, ARCH BIOCHEM BIOPHYS, V252, P113, DOI 10.1016/0003-9861(87)90014-2; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; FORCE T, 1991, J BIOL CHEM, V266, P4295; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; GIBSON GG, 1989, XENOBIOTICA, V19, P1123; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; HASSETT C, 1990, NUCLEIC ACIDS RES, V18, P1429, DOI 10.1093/nar/18.6.1429; HENRICH WL, 1990, AM J PHYSIOL, V258, pE269, DOI 10.1152/ajpendo.1990.258.2.E269; HIRT D, 1987, CLIN RES, V35, pA635; IMAI Y, 1988, J BIOCHEM-TOKYO, V103, P143, DOI 10.1093/oxfordjournals.jbchem.a122220; IMAI Y, 1988, BIOCHEMISTRY-US, V27, P80, DOI 10.1021/bi00401a014; IMAI Y, 1987, J BIOCHEM-TOKYO, V101, P1129, DOI 10.1093/oxfordjournals.jbchem.a121977; IMAOKA S, 1989, BIOCHEM INT, V18, P731; JACOBSON HR, 1984, PROSTAGLANDINS MEMBR, P311; JOHNSON EF, 1985, ARCH BIOCHEM BIOPHYS, V237, P55, DOI 10.1016/0003-9861(85)90253-X; JOHNSON EF, 1987, J BIOL CHEM, V262, P5918; JOHNSON EF, 1984, XENOBIOTICA, V14, P3, DOI 10.3109/00498258409151395; JOHNSON EF, 1990, BIOCHEMISTRY-US, V29, P873, DOI 10.1021/bi00456a004; KOOP DR, 1981, J BIOL CHEM, V256, P704; KOOP DR, 1984, MOL PHARMACOL, V25, P494; KOOP DR, 1982, J BIOL CHEM, V257, P8472; KRONBACH T, 1989, P NATL ACAD SCI USA, V86, P8262, DOI 10.1073/pnas.86.21.8262; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANIADOSCHWARTZMAN M, 1988, J BIOL CHEM, V263, P2536; LEIGHTON JK, 1984, J BIOL CHEM, V259, P1165; LEIGHTON JK, 1984, BIOCHEMISTRY-US, V23, P204, DOI 10.1021/bi00297a005; LIN WK, 1990, BIOCHEM BIOPH RES CO, V167, P977, DOI 10.1016/0006-291X(90)90619-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OGITA K, 1983, BIOCHEM INT, V6, P191; OLIW EH, 1982, J BIOL CHEM, V257, P3771; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; PRITCHARD KA, 1990, BIOCHEM BIOPH RES CO, V167, P137, DOI 10.1016/0006-291X(90)91741-A; PROCTOR KG, 1987, CIRC RES, V60, P50, DOI 10.1161/01.RES.60.1.50; REUBI I, 1984, J BIOL CHEM, V259, P5887; SACERDOTI D, 1988, BIOCHEM PHARMACOL, V37, P521, DOI 10.1016/0006-2952(88)90223-7; SCHWARTZMAN M, 1985, NATURE, V314, P620, DOI 10.1038/314620a0; SCHWARTZMAN ML, 1987, P NATL ACAD SCI USA, V84, P8125, DOI 10.1073/pnas.84.22.8125; SHARMA RK, 1989, EUR J BIOCHEM, V184, P69, DOI 10.1111/j.1432-1033.1989.tb14991.x; Strittmatter P, 1978, Methods Enzymol, V52, P97; TANAKA S, 1990, BIOCHIM BIOPHYS ACTA, V1043, P177, DOI 10.1016/0005-2760(90)90293-7; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	64	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5552	5559						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544930				2022-12-27	WOS:A1992HH74700083
J	PALLEROS, DR; REID, KL; MCCARTY, JS; WALKER, GC; FINK, AL				PALLEROS, DR; REID, KL; MCCARTY, JS; WALKER, GC; FINK, AL			DNAK, HSP73, AND THEIR MOLTEN GLOBULES - 2 DIFFERENT WAYS HEAT-SHOCK PROTEINS RESPOND TO HEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAK; BOVINE ALPHA-LACTALBUMIN; STRESS PROTEINS; UNCOATING ATPASE; LIGHT-SCATTERING; COATED VESICLES; BETA-LACTAMASE; COMPACT STATE; STABILITY; PURIFICATION	The thermal stability of bovine brain hsp73, Escherichia coli DnaK, and its mutant T199A was studied by a combination of spectroscopic and chromatographic methods. DnaK undergoes a temperature-induced conformational change that leads to the formation of a molten globule at physiologically relevant temperatures (midpoint of the transition, t(m), 41-degrees-C). Native DnaK binds to a denatured form of alpha-lactalbumin in a temperature-dependent manner with maximum rate at about 40-degrees-C. The molten globule of DnaK is unable to bind denatured alpha-lactalbumin but recovers native structure and activity upon cooling. The half-life of the refolding process is 10 min at 35-degrees-C. Mg/ATP and Mg/ADP increase the thermal stability of DnaK; in the presence of these nucleotides the t. is shifted to 59-degrees-C. Binding of Mg/ATP (but not Mg/ADP or Mg/adenosine 5'-[gamma-thio]triphosphate) causes a conformational change in DnaK as determined by the emission fluorescence spectrum. The DnaK mutant T199A which lacks the threonine residue that is essential for ATP hydrolysis and autophosphorylation activity (McCarty, J. S., and Walker, G. C. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 9513-9517) shows nearly identical properties to the wild type in the presence or absence of nucleotides. Hsp73 undergoes similar temperature-induced transitions as determined by spectroscopic methods (Palleros, D. R., Welch, W. J., and Fink, A. L. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 5719-5723); however, contrary to DnaK, the molten globule of hsp73 irreversibly aggregates at temperatures higher than its t(m) (42-degrees-C).	UNIV CALIF SANTA CRUZ,DEPT CHEM & BIOCHEM,SANTA CRUZ,CA 95064; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	University of California System; University of California Santa Cruz; Massachusetts Institute of Technology (MIT)				/0000-0001-7243-8261	NIGMS NIH HHS [GM45316] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CORBETT RJT, 1984, BIOCHEMISTRY-US, V23, P1888, DOI 10.1021/bi00303a047; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; DOLGIKH DA, 1985, EUR BIOPHYS J BIOPHY, V13, P109, DOI 10.1007/BF00256531; FINDLY RC, 1983, SCIENCE, V219, P1223, DOI 10.1126/science.6828852; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GAST K, 1986, INT J BIOL MACROMOL, V8, P231, DOI 10.1016/0141-8130(86)90032-2; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HASS IG, 1983, NATURE, V306, P387; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; IKEGUCHI M, 1989, INT J PEPT PROT RES, V33, P289; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1986, INT J PEPT PROT RES, V27, P18; LEUSTEK T, 1989, P NATL ACAD SCI USA, V86, P7805, DOI 10.1073/pnas.86.20.7805; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MITCHINSON C, 1985, J MOL BIOL, V184, P331, DOI 10.1016/0022-2836(85)90384-5; Nozaki Y, 1972, Methods Enzymol, V26, P43; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PELHAM HRB, 1990, STRESS PROTEINS BIOL, P287; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PRIVALOV PL, 1989, J MOL BIOL, V205, P737, DOI 10.1016/0022-2836(89)90318-5; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; PTITSYN OB, 1986, STUD BIOPHYS, V112, P207; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; SCHMID FX, 1989, PROTEIN STRUCTURE PR, P283; SEARS DW, 1975, PHYSICAL PRINCIPLES, P445; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; STURZBECHER HW, 1987, ONCOGENE, V1, P201; SUSSMAN MD, 1987, NUCLEIC ACIDS RES, V15, P3923, DOI 10.1093/nar/15.9.3923; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	55	101	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5279	5285						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544910				2022-12-27	WOS:A1992HH74700045
J	SHAW, GC; FULCO, AJ				SHAW, GC; FULCO, AJ			BARBITURATE-MEDIATED REGULATION OF EXPRESSION OF THE CYTOCHROME-P450BM-3 GENE OF BACILLUS-MEGATERIUM BY BM3R1 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID MONOOXYGENASE; BACTERIAL CYTOCHROME-P-450; NUCLEOTIDE-SEQUENCES; ESCHERICHIA-COLI; PLASMID DNA; INDUCTION; SUBTILIS; OMEGA-2; CLONING; INVITRO	In a previous publication (Wen, L.-P., Ruettinger, R. T., and Fulco, A. J. (1989) J. Biol. Chem. 264, 10996-11003), we reported that about 1 kilobase of 5' flanking sequence was required for barbiturate-inducible expression of the cytochrome P450BM-3 gene in Bacillus megaterium. We have now found, by analysis of various deletion and frameshift derivatives of this region, that an open reading frame immediately upstream of the B. megaterium cytochrome P450BM-3 structural gene encodes a protein, designated Bm3R1, which negatively controls the expression of the P450BM-3 gene at the transcriptional level. A helix-turn-helix DNA binding motif was found near the N-terminal portion of Bm3R1 protein. The 5' terminus of the bm3R1 transcript generated in vivo was determined by nuclease S1 mapping and primer extension analysis to be 44 base pairs upstream of the translation initiation sequence GTG of bm3R1. A putative promoter sequence with a high degree of similarity to the -35 and -10 consensus sequence recognized by the Bacillus subtilis sigma-43 factor was located at an appropriate distance from the transcription start site. A B. megaterium mutant which highly constitutively produced P450BM-3 protein was isolated and complementation of this cytochrome P450BM-3-constitutive mutant by a DNA fragment containing the wild-type bm3R1 gene indicated that the mutation in this locus was trans-dominant. Sequence analysis of the bm3R1 gene and its upstream region from this mutant, after amplification by the polymerase chain reaction, identified a single base change that resulted in a glycine to glutamate substitution in the beta-turn region of the DNA binding motif. By placing the bm3R1 gene under the control of a tac promoter and changing the translation initiation sequence from GTG to ATG, we succeeded in overproducing the Bm3R1 protein in Escherichia coli. A 20-bp perfect palindromic putative operator site, located between the presumed promoter sequences and the bm3R1 structural gene, was defined both by in vivo titration of Bm3R1 repressor and by gel mobility shift assays using the cell-free extracts containing the overproduced wild-type or mutant Bm3R1 protein. The barbiturate effect in mediating the induction of cytochrome P450BM-3 appears to be indirect but probably involves, in part, the release of inhibition by Bm3R1 repressor protein by interfering with its binding to the palindromic putative operator sequence and perhaps to other sites on the regulatory region of the gene encoding cytochrome P450BM-3.	UNIV CALIF LOS ANGELES,SCH MED,BIOMED & ENVIRONM SCI LAB,900 VET AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIGMS NIH HHS [GM23913] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023913] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMAN E, 1983, GENE, V25, P167; Battey, 1986, BASIC METHODS MOL BI; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CARLTON BC, 1981, MANUAL METHODS GENER, P228; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CLARK BFC, 1966, J MOL BIOL, V17, P394, DOI 10.1016/S0022-2836(66)80150-X; COOPER TG, 1977, TOOLS BIOCH, P51; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DODD IB, 1987, J MOL BIOL, V194, P557, DOI 10.1016/0022-2836(87)90681-4; DOI RH, 1986, MICROBIOL REV, V50, P227, DOI 10.1128/MMBR.50.3.227-243.1986; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; FULCO AJ, 1987, LIFE SCI, V40, P1769, DOI 10.1016/0024-3205(87)90087-7; GRYCZAN TJ, 1978, J BACTERIOL, V134, P318, DOI 10.1128/JB.134.1.318-329.1978; HE JS, 1991, J BIOL CHEM, V266, P7864; HO PP, 1976, BIOCHIM BIOPHYS ACTA, V431, P249, DOI 10.1016/0005-2760(76)90145-4; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; IMANAKA T, 1982, J BACTERIOL, V149, P824, DOI 10.1128/JB.149.3.824-830.1982; KIM BH, 1983, BIOCHEM BIOPH RES CO, V116, P843, DOI 10.1016/S0006-291X(83)80219-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HY, 1991, J BIOL CHEM, V266, P11909; MATSON RS, 1977, BIOCHIM BIOPHYS ACTA, V487, P487, DOI 10.1016/0005-2760(77)90218-1; MCLAUGHLIN JR, 1981, J BIOL CHEM, V256, P1283; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Miura K., 1967, METHODS ENZYMOLOGY A, V12, P543; MIURA Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P305, DOI 10.1016/0005-2760(75)90089-2; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAPOLI C, 1981, J MOL BIOL, V149, P433, DOI 10.1016/0022-2836(81)90480-0; NARHI LO, 1982, J BIOL CHEM, V257, P2147; NARHI LO, 1983, BIOCHEM BIOPH RES CO, V116, P851, DOI 10.1016/S0006-291X(83)80220-4; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NARHI LO, 1987, J BIOL CHEM, V262, P6683; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; RESH MD, 1982, J BIOL CHEM, V257, P6978; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.ge.19.120185.002035; RUETTINGER RT, 1984, BIOCHIM BIOPHYS ACTA, V801, P372, DOI 10.1016/0304-4165(84)90141-7; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; RUETTINGER RT, 1981, J BIOL CHEM, V256, P5728; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOWALTER RE, 1990, J BACTERIOL, V172, P2946, DOI 10.1128/jb.172.6.2946-2954.1990; STEVENSON PM, 1983, BIOCHEM BIOPH RES CO, V112, P927, DOI 10.1016/0006-291X(83)91706-0; VALENTINHANSEN P, 1986, NUCLEIC ACIDS RES, V14, P2215, DOI 10.1093/nar/14.5.2215; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WEN LP, 1989, J BIOL CHEM, V264, P10996; WEN LP, 1987, J BIOL CHEM, V262, P6676; WEN LP, 1985, MOL CELL BIOCHEM, V67, P77; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	50	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5515	5526						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544926				2022-12-27	WOS:A1992HH74700079
J	WEISS, RH; NUCCITELLI, R				WEISS, RH; NUCCITELLI, R			INHIBITION OF TYROSINE PHOSPHORYLATION PREVENTS THROMBIN-INDUCED MITOGENESIS, BUT NOT INTRACELLULAR FREE CALCIUM RELEASE, IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; FLUORESCENCE; ACTIVATION; PDGF	Alpha-thrombin, a G-protein-coupled receptor agonist, is mitogenic for neonatal vascular smooth muscle (VSM) cells, but it also causes secretion of the tyrosine kinase-coupled receptor agonist platelet-derived growth factor (PDGF). In order to determine the role of growth factors with tyrosine kinase-coupled receptors in thrombin's mitogenic signal transduction cascade, the synergistic effect of basic fibroblast growth factor (bFGF) in this system was examined. While bFGF itself is a growth factor for VSM cells, it causes a 1.7-fold synergistic effect when added together with thrombin. Herbimycin A, a specific tyrosine kinase inhibitor, both decreases thrombin-induced mitogenesis by > 90% and abolishes tyrosine phosphorylation of phospholipase C (PLC)-gamma-1. The magnitude and time course of the increase in intracellular free calcium concentration in response to thrombin is comparable in both the presence and absence of herbimycin A. These results provide evidence that herbimycin A specifically inhibits PLC-gamma-1 tyrosine phosphorylation without affecting VSM cell viability or calcium release. Furthermore, tyrosine phosphorylation is a necessary step in thrombin's mitogenic signal transduction cascade, but it is not essential for thrombin-induced release of calcium from intracellular stores. These data suggest that a tyrosine kinase, possibly supplied by the bFGF receptor, plays an essential role in thrombin-induced mitogenesis.	VET ADM MED CTR,MARTINEZ,CA 94553; UNIV CALIF DAVIS,DEPT ZOOL,DAVIS,CA 95616	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Davis	WEISS, RH (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT MED,DIV NEPHROL,4301 X ST,DAVIS,CA 95616, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019966] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 19966] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HUANG CL, 1989, J BIOL CHEM, V264, P4391; JONES PA, 1979, P NATL ACAD SCI USA, V76, P353, DOI 10.1073/pnas.76.1.353; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KIM JW, 1990, J BIOL CHEM, V265, P3940; LI W, 1991, J BIOL CHEM, V266, P6808; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; MORRISON RS, 1991, J BIOL CHEM, V266, P728; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKASHIMA S, 1991, MOL PHARMACOL, V39, P475; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PARIS S, 1988, J BIOL CHEM, V263, P12893; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; SATO Y, 1991, BIOCHEM BIOPH RES CO, V174, P1260, DOI 10.1016/0006-291X(91)91557-S; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SJOLUND M, 1988, J CELL BIOL, V106, P403, DOI 10.1083/jcb.106.2.403; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WEISS RH, 1991, BIOCHEM BIOPH RES CO, V181, P617, DOI 10.1016/0006-291X(91)91235-5; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	30	102	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5608	5613						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544934				2022-12-27	WOS:A1992HH74700090
J	BONAVENTURA, C; CASHON, R; COLACINO, JM; HILDERMAN, RH				BONAVENTURA, C; CASHON, R; COLACINO, JM; HILDERMAN, RH			ALTERATION OF HEMOGLOBIN-FUNCTION BY DIADENOSINE 5',5'''-P1,P4-TETRAPHOSPHATE AND OTHER ALARMONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2,3-DIPHOSPHOGLYCERATE BINDING-SITE; NICOTINAMIDE ADENINE DINUCLEOTIDES; STRESS; AP4A; CONSEQUENCES; DEFICIENCY; OXIDATION; SYSTEMS; APPPPA; CELLS	Heat-shocked organisms are known to produce not only "heat shock proteins" but also diadenosine tetraphosphate (Ap4A) and related compounds that may act as "alarmones" that alert the cell to the onset of metabolic stress. We found that Ap4A is synthesized in chicken erythrocytes and that the Ap4A level in the whole blood of heat-stressed birds increases about 10-fold. In searching for alarmone receptors, we found that the diadenosine polyphosphates bind preferentially with high affinity to the deoxy conformation of hemoglobin in a ratio of one/tetramer. The binding affinity of this new class of effectors of hemoglobin function is directly related to the number of phosphates which bridge the nucleotide moieties, with the most dramatic in vitro effect on oxygen affinity being shown by Ap6A. Decreasing effects are brought about by diadenosine penta-, tetra-, tri-, di-, and monophosphates. The association constant for Ap4A binding to deoxygenated human hemoglobin at pH 7.25 is 26-mu-M-1, close to that for 2,3-diphosphoglygerate. At 100-fold excess over heme, AP4A increases the P50 of stripped Hb A in 0.05 M HEPES buffer at pH 7.25, 20-degrees-C, from 0.85 to 6.03 mm Hg. The binding, which markedly enhances the Bohr effect, involves the beta-chain anion-binding site. The kinetics of both ligand binding and dissociation are affected, with a greater quantitative effect on the oxygen dissociation process. Although the low concentration of the diadenosine polyphosphates in red cells precludes a physiologically significant modulation of oxygen delivery, competition with the ATP- and NAD(P)H-binding sites on hemoglobin or regulatory enzymes may prove to be of adaptive significance.	CLEMSON UNIV,DEPT BIOL SCI,CLEMSON,SC 29631	Clemson University	BONAVENTURA, C (corresponding author), DUKE UNIV,CTR MARINE BIOMED,MARINE LAB,BEAUFORT,NC 28516, USA.				NHLBI NIH HHS [5T32HL07057] Funding Source: Medline; NIEHS NIH HHS [ESO1908, 5R01-ES-04287] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P50ES001908, P30ES001908, R01ES004287] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALPER MD, 1978, J BACTERIOL, V133, P149, DOI 10.1128/JB.133.1.149-157.1978; ANDERSSON M, 1989, INT J BIOCHEM, V21, P707, DOI 10.1016/0020-711X(89)90200-0; BOCHNER BR, 1984, CELL, V37, P225, DOI 10.1016/0092-8674(84)90318-0; BOCHNER BR, 1982, CELL, V29, P929, DOI 10.1016/0092-8674(82)90455-X; BONAVENTURA J, 1975, J BIOL CHEM, V250, P9250; BONAVENTURA J, 1976, J BIOL CHEM, V251, P7563; CASHON R, 1986, J BIOL CHEM, V261, P2700; CAYLEY PJ, 1982, EUR J BIOCHEM, V122, P601; FLODGAARD H, 1982, BIOCHEM J, V208, P737, DOI 10.1042/bj2080737; GALLANT JA, 1979, ANNU REV GENET, V13, P393, DOI 10.1146/annurev.ge.13.120179.002141; GRUMMT F, 1978, P NATL ACAD SCI USA, V75, P371, DOI 10.1073/pnas.75.1.371; HILDERMAN RH, 1983, BIOCHEMISTRY-US, V22, P4353, DOI 10.1021/bi00288a001; HILDERMAN RH, 1991, J BIOL CHEM, V266, P6915; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; LEE PC, 1983, P NATL ACAD SCI-BIOL, V80, P7496, DOI 10.1073/pnas.80.24.7496; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; MEYERS KM, 1979, AM J PHYSIOL, V236, pR239; OGO S, 1989, J BIOL CHEM, V264, P11302; RAPAPORT E, 1976, P NATL ACAD SCI USA, V73, P3984, DOI 10.1073/pnas.73.11.3984; RIGGS AF, 1956, J GEN PHYSIOL, V39, P585, DOI 10.1085/jgp.39.4.585; Schlesinger M. J., 1982, HEAT SHOCK BACTERIA; STEPHENS JC, 1975, P NATL ACAD SCI USA, V72, P4389, DOI 10.1073/pnas.72.11.4389; SZABO A, 1976, BIOCHEMISTRY-US, V15, P2869, DOI 10.1021/bi00658a026; VARSHAVSKY A, 1983, CELL, V34, P711, DOI 10.1016/0092-8674(83)90526-3; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; ZAMECNIK P, 1983, ANAL BIOCHEM, V134, P1, DOI 10.1016/0003-2697(83)90255-5; Zamecnik P. C., 1968, REGULATORY MECHANISM, P3; ZAMECNIK PC, 1969, A BENZON S, V1, P276	28	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4652	4657						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537848				2022-12-27	WOS:A1992HF64200058
J	DELAUNOIT, Y; ZHAO, HF; BELANGER, A; LABRIE, F; SIMARD, J				DELAUNOIT, Y; ZHAO, HF; BELANGER, A; LABRIE, F; SIMARD, J			EXPRESSION OF LIVER-SPECIFIC MEMBER OF THE 3-BETA-HYDROXYSTEROID DEHYDROGENASE FAMILY, AN ISOFORM POSSESSING AN ALMOST EXCLUSIVE 3-KETOSTEROID REDUCTASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID BIOSYNTHESIS; ISOMERASE; TRILOSTANE; INHIBITOR; CELLS; GENE	We have recently characterized two types of rat 3-beta-hydroxysteroid dehydrogenase/DELTA-5-DELTA-4 isomerase (3-beta-HSD) isoenzymes expressed in adrenals and gonads. In addition, we have cloned a third type of cDNA encoding a predicted type III 3-beta-HSD protein specifically expressed in the male rat liver which shares 80% similarity with the two other isoenzymes. Transient expression in human HeLa cells of the cDNAs reveals that the type III 3-beta-HSD protein does not display oxidative activity for the classical substrates of 3-beta-HSD, in contrast to the type I 3-beta-HSD isoenzyme. However, in the presence of NADH, type III isoenzyme, in common with the type I isoform, converts 5-alpha-androstane-3,17-dione (A-dione) and 5-alpha-dihydrotestosterone (DHT) to the corresponding 3-beta-hydroxysteroids. In fact, the type I and the type III isoenzymes have the same affinity for DHT with K(m) values of 5.05 and 6.16-mu-M, respectively. When NADPH is used as cofactor, the affinity for DHT of the type III isoform becomes higher than that of the type I isoform with K(m) values of 0.12 and 1.18-mu-M, respectively. The type III isoform is thus a 3-ketoreductase using NADPH as preferred cofactor which is responsible for the conversion of 3-keto-saturated steroids such as DHT and A-dione into less active steroids.	CHU LAVAL, RES CTR,MRC,MOLEC ENDOCRINOL GRP,2705 LAURIER BLVD, QUEBEC CITY G1V 4G2, QUEBEC, CANADA; UNIV LAVAL, QUEBEC CITY G1V 4G2, QUEBEC, CANADA	Laval University; Laval University				Simard, Jacques/0000-0001-6906-3390				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; KOMANICKY P, 1978, J CLIN ENDOCR METAB, V47, P1042, DOI 10.1210/jcem-47-5-1042; LABRIE F, 1991, MOL CELL ENDOCRINOL, V78, pC113, DOI 10.1016/0303-7207(91)90116-A; LACHANCE Y, 1990, J BIOL CHEM, V265, P20469; LAX ER, 1974, EUR J BIOCHEM, V42, P561, DOI 10.1111/j.1432-1033.1974.tb03371.x; LEATHERBARROW RJ, 1985, P NATL ACAD SCI USA, V82, P7840, DOI 10.1073/pnas.82.23.7840; LUUTHE V, 1991, BIOCHEMISTRY-US, V30, P8861; NETER J, 1974, APPLIED LINEAR STATI, P160; POTTS GO, 1978, STEROIDS, V32, P257, DOI 10.1016/0039-128X(78)90010-7; RHEAUME E, 1991, MOL ENDOCRINOL, V5, P1147, DOI 10.1210/mend-5-8-1147; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SIMARD J, 1991, J BIOL CHEM, V266, P14842; SIMARD J, 1991, MOL CELL ENDOCRINOL, V75, P101, DOI 10.1016/0303-7207(91)90224-G; SMIRNOV AN, 1990, J STEROID BIOCHEM, V36, P617, DOI 10.1016/0022-4731(90)90181-Q; THE VL, 1989, MOL ENDOCRINOL, V3, P1310, DOI 10.1210/mend-3-8-1310; TRANT JM, 1990, P NATL ACAD SCI USA, V87, P9756, DOI 10.1073/pnas.87.24.9756; ZHAO HF, 1991, J BIOL CHEM, V266, P583; ZHAO HF, 1990, ENDOCRINOLOGY, V127, P3237, DOI 10.1210/endo-127-6-3237; ZHAO HF, 1989, FEBS LETT, V259, P153, DOI 10.1016/0014-5793(89)81516-9	19	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4513	4517						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537836				2022-12-27	WOS:A1992HF64200038
J	DYMECKI, SM; ZWOLLO, P; ZELLER, K; KUHAJDA, FP; DESIDERIO, SV				DYMECKI, SM; ZWOLLO, P; ZELLER, K; KUHAJDA, FP; DESIDERIO, SV			STRUCTURE AND DEVELOPMENTAL REGULATION OF THE B-LYMPHOID TYROSINE KINASE GENE BLK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; CELL-SPECIFIC GENES; LYMPHOCYTES-PRE-B; HUMAN LCK GENE; PROTEIN-KINASE; HEMATOPOIETIC-CELLS; CYTOPLASMIC DOMAINS; CONSERVED SEQUENCE; ANTIGEN RECEPTOR; PROMOTER REGION	The murine blk gene, which encodes a B-lymphoid-specific tyrosine kinase of the Src family (p55blk), contains 13 exons that span more than 30 kilobases of DNA on chromosome 14. In the first three exons, which encode the 5'-untranslated region and N-terminal amino acid sequence unique to p55blk, the blk gene differs from other members of the src family; in the last 10 exons, the organization of the blk gene is similar to that of other src genes. By primer extension and S1 nuclease protection analyses, we show that blk transcripts initiate from four major sites at the 5'-flank of blk; two sites predominate. The resulting transcripts differ only in the lengths of their 5'-untranslated sequences and encode identical proteins. None of the transcriptional start sites are preceded by consensus TATA elements, AT-rich elements, or extensive GC-rich regions. Expression of blk is regulated during B-cell development: blk RNA is expressed in all pro-B-, pre-B-, and mature B-cell lines examined, but is absent from plasma cell lines. Immunolocalization of p55blk in normal mouse spleen supports these observations: staining is restricted to lymphocytes and is concentrated in regions rich in B-cells; plasma cells and stromal cells are not stained with anti-Blk antibodies. Assays for RNA synthesis in isolated nuclei indicate that the lineage and developmental stage specificities of blk expression are regulated at least in part by changes in its rate of transcription.	JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA	Johns Hopkins University	DYMECKI, SM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.				NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NCI NIH HHS [CA16519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ANDERSON SJ, 1988, P NATL ACAD SCI USA, V85, P3551, DOI 10.1073/pnas.85.10.3551; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK HC, 1974, MANUAL HISTOLOGICAL, P42; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER MD, 1989, IMMUNOGLOBULIN GENES, P1; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; Favaloro J, 1980, Methods Enzymol, V65, P718; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK CA, 1991, GENOMICS, V9, P762, DOI 10.1016/0888-7543(91)90372-L; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LANE PJL, 1990, J IMMUNOL, V144, P3684; LEVITT N, 1989, GENE DEV, V3, P1019, DOI 10.1101/gad.3.7.1019; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LOCK P, 1990, MOL CELL BIOL, V10, P4603, DOI 10.1128/MCB.10.9.4603; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; PABST R, 1988, MIGRATION HOMING LYM, P64; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PATEL M, 1990, ONCOGENE, V5, P201; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TSANG SY, 1988, P NATL ACAD SCI USA, V85, P8598, DOI 10.1073/pnas.85.22.8598; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YANG Z, 1990, P NATL ACAD SCI USA, V87, P9226, DOI 10.1073/pnas.87.23.9226; ZIEGLER SF, 1991, ONCOGENE, V6, P283; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	71	64	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4815	4823						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537861				2022-12-27	WOS:A1992HF64200080
J	TOBIN, JF; WIRTH, DF				TOBIN, JF; WIRTH, DF			A SEQUENCE INSERTION TARGETING VECTOR FOR LEISHMANIA-ENRIETTII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEOMYCIN PHOSPHOTRANSFERASE GENE; SPLICED LEADER SEQUENCE; TRYPANOSOMA-BRUCEI; MESSENGER-RNAS; TUBULIN GENE; DISCONTINUOUS TRANSCRIPTION; HOMOLOGOUS RECOMBINATION; STABLE TRANSFECTION; DNA AMPLIFICATION; EXPRESSION	We have demonstrated previously that Leishmania enriettii contains the enzymatic machinery to mediate efficient interplasmidic homologous recombination. In this report we show that a sequence insertion targeting vector, pALT-Neo-Tub, can be inserted into the genome of L. enriettii by homologous recombination between alpha-tubulin sequences found in the plasmid and their homologs in the genome. pALT-Neo-Tub, a pBluescript-derived vector containing the neo(r) gene flanked by the alpha-tubulin intergenic and alpha-tubulin coding sequences, was used to transfect cells to G418 resistance. Analysis of the DNA from the drug resistant clones indicates that all of the insertion events are restricted to the alpha-tubulin gene repeats. As little as 200 base pairs of sequence homology between the plasmid and the genome is required for integration. Nonhomologous recombination events are not detected. These results indicate that exogenous DNA sequences can be integrated into the L. enriettii genome provided that they are flanked by homologous DNA sequences.	HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health					NIAID NIH HHS [AI-21365] Funding Source: Medline; NIGMS NIH HHS [GM-13640] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013640] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BEVERLEY SM, 1984, CELL, V38, P431, DOI 10.1016/0092-8674(84)90498-7; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; COMEAU AM, 1986, MOL BIOCHEM PARASIT, V21, P161, DOI 10.1016/0166-6851(86)90019-8; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DETKE S, 1988, J BIOL CHEM, V263, P3418; EDELMAN GM, 1970, NEUROSCIENCES 2ND ST, P962; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; KAFATOS FC, 1985, TRENDS GENET, V1, P301, DOI 10.1016/0168-9525(85)90119-2; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; Kaur K, 1986, Adv Exp Med Biol, V195 Pt B, P553; KUCHERLAPATI RS, 1984, P NATL ACAD SCI-BIOL, V81, P3153, DOI 10.1073/pnas.81.10.3153; LABAN A, 1989, P NATL ACAD SCI USA, V86, P9119, DOI 10.1073/pnas.86.23.9119; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LANDFEAR SM, 1986, MOL BIOCHEM PARASIT, V21, P235, DOI 10.1016/0166-6851(86)90129-5; LANDFEAR SM, 1984, NATURE, V309, P716, DOI 10.1038/309716a0; LANDFEAR SM, 1983, MOL CELL BIOL, V3, P1070, DOI 10.1128/MCB.3.6.1070; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; Marsden P.D., 1985, HUMAN PARASITIC DISE, V1, P183; MILLER SI, 1986, NUCLEIC ACIDS RES, V14, P7341, DOI 10.1093/nar/14.18.7341; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; OUELLETTE M, 1991, EMBO J, V10, P1009, DOI 10.1002/j.1460-2075.1991.tb08035.x; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PARSONS M, 1984, CELL, V38, P309, DOI 10.1016/0092-8674(84)90552-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SCHIMKE RT, 1986, P NATL ACAD SCI USA, V83, P2157, DOI 10.1073/pnas.83.7.2157; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SMITH GP, 1973, COLD SPRING HARB SYM, V38, P507, DOI 10.1101/SQB.1974.038.01.055; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; SZOSTAK JW, 1979, PLASMID, V2, P536, DOI 10.1016/0147-619X(79)90053-2; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; TOBIN JF, 1991, P NATL ACAD SCI USA, V88, P864, DOI 10.1073/pnas.88.3.864; TSCHUDI C, 1985, P NATL ACAD SCI USA, V82, P3998, DOI 10.1073/pnas.82.12.3998; WIRTH DF, 1983, MOL BIOCHEM PARASIT, V9, P83, DOI 10.1016/0166-6851(83)90059-2	44	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4752	4758						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537857				2022-12-27	WOS:A1992HF64200071
J	TORRI, AF; ENGLUND, PT				TORRI, AF; ENGLUND, PT			PURIFICATION OF A MITOCHONDRIAL-DNA POLYMERASE FROM CRITHIDIA-FASCICULATA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETOPLAST DNA; REPLICATION; GAMMA; IDENTITY; SUBUNIT; ENZYME; NUCLEI	The mitochondrial DNA polymerase from Crithidia fasciculata has been purified to near homogeneity. SDS-PAGE analysis of the purified enzyme reveals a single polypeptide with a molecular weight of approximately 43,000. The protein is basic, with an isoelectric point between 7.6-8.0. Its Stokes radius of 22 angstrom and its sedimentation coefficient of 4.1 S suggest a native molecular weight of 38,000, indicating that the protein is a monomer under our experimental conditions. Western blots and immunoprecipitations of crude extracts reveal a cross-reacting protein of 48 kDa, suggesting that the purified enzyme may be an enzymatically active proteolytic product. The mitochondrial origin of the polymerase was confirmed by cell fractionation. Our results indicate that the C. fasciculata enzyme may be among the smallest known mitochondria polymerases.			TORRI, AF (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.				NIGMS NIH HHS [GM 27608, GM 13604-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027608, R01GM027608, F32GM013604] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERTAZZONI U, 1977, EUR J BIOCHEM, V81, P237, DOI 10.1111/j.1432-1033.1977.tb11945.x; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; CHANG LMS, 1980, SCIENCE, V208, P510, DOI 10.1126/science.7367875; DUBE DK, 1979, BIOCHIM BIOPHYS ACTA, V561, P10, DOI 10.1016/0005-2787(79)90485-4; Fansler B S, 1974, Methods Enzymol, V29, P53; FOURY F, 1989, J BIOL CHEM, V264, P20552; FRY M, 1985, ANIMAL CELL DNA POLY; HAJDUK SL, 1984, CELL, V36, P483, DOI 10.1016/0092-8674(84)90241-1; HOLMES AM, 1984, MOL BIOCHEM PARASIT, V10, P195, DOI 10.1016/0166-6851(84)90007-0; HUBSCHER U, 1977, EUR J BIOCHEM, V81, P249, DOI 10.1111/j.1432-1033.1977.tb11946.x; LOEB LA, 1974, ENZYMES, P174; Maniatis T., 1982, MOL CLONING; MATSUKAGE A, 1987, J BIOL CHEM, V262, P8960; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OSTERGAARD E, 1987, BIOCHIM BIOPHYS ACTA, V908, P150, DOI 10.1016/0167-4781(87)90054-6; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P339, DOI 10.1146/annurev.mi.42.100188.002011; SCOVASSI AI, 1980, TRENDS BIOCHEM SCI, V5, P335, DOI 10.1016/0968-0004(80)90145-0; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; STEIGER RF, 1977, J PROTOZOOL, V24, P437, DOI 10.1111/j.1550-7408.1977.tb04771.x; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WERNETTE CM, 1976, EUR J BIOCHEM, V264, P21491; WILSON S, 1988, BIOCHIM BIOPHYS ACTA, V949, P149, DOI 10.1016/0167-4781(88)90078-4; WINTERSBERGER U, 1976, EUR J BIOCHEM, V68, P199, DOI 10.1111/j.1432-1033.1976.tb10779.x; YAMAGUCHI M, 1980, J BIOL CHEM, V255, P7002	28	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4786	4792						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537858				2022-12-27	WOS:A1992HF64200076
J	DENZIN, LK; VOSS, EW				DENZIN, LK; VOSS, EW			CONSTRUCTION, CHARACTERIZATION, AND MUTAGENESIS OF AN ANTIFLUORESCEIN SINGLE CHAIN ANTIBODY IDIOTYPE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; IGG ANTIBODIES; AFFINITY; BINDING; LIGAND; EXPRESSION; PROTEINS; DNA	In addition to crystallographic studies that determined antigen contact residues for monoclonal antifluorescein (Fl) antibody 4-4-20 (K(a) = 2.5 x 10(10) M-1), primary structure comparisons revealed idiotypically cross-reactive monoclonal antibodies (mAbs) 9-40 (K(a) = 4.4 x 10(7) M-1), 12-40 (K(a) = 4.0 x 10(8) M-1), and 5-14 (K(a) = 2.4 x 10(8) M-1) possessed identical Fl contact residues, with the exception of L34His for L34Arg. Site-specific mutagenesis of single chain antibody (SCA) 4-4-20 in which L34Arg was changed to L34His resulted in approximately 1000- and 3-fold decreases in binding affinity and Q(max) (maximum quenching of bound Fl), respectively, which suggested that L34Arg was directly involved in increased binding affinity and fluorescence quenching. Therefore, substitution of Arg for His at residue L34 in mAbs 9-40, 12-40, and 5-14 should result in increased binding affinity and Q(max). To facilitate site-specific mutagenesis studies, single chain derivatives of mAbs 9-40, 12-40, and 5-14 were constructed. Following expression in Escherichia coli, characterization of the SCAs demonstrated that when compared with the respective parental mAb, the SCAs possessed identical binding affinities and similar Q(max) and lambda(max) (absorption profiles of bound Fl) values. These results validated SCA 9-40, 12-40, and 5-14 for use in site-directed mutagenesis studies. Results of mutagenesis studies indicated that substitution of L34Arg into the active sites of 9-40, 12-40, and 5-14 was not enough to produce 4-4-20-like binding characteristics. Therefore, the following single chain mutants were constructed: 9-40L34Arg/L46Val, 12-40L34Arg/L46Val and 5-14L34Arg/L46Val, 9-40L34Arg/L46Val/H101Asp and 4-4-20H101Ala. Results demonstrated that these mutations were not able to render the mutant SCAs with increased binding affinity and fluorescence quenching values. Collectively, these results suggest that the combining sites of mAb 9-40, 12-40, and 5-14 may possess different active site structures than mAb 4-4-20.			DENZIN, LK (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,407 S GOODWIN AVE,URBANA,IL 61801, USA.							BATES RM, 1985, MOL IMMUNOL, V22, P871, DOI 10.1016/0161-5890(85)90072-0; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BEDZYK WD, 1989, J BIOL CHEM, V264, P1565; BEDZYK WD, 1986, MOL IMMUNOL, V23, P1319, DOI 10.1016/0161-5890(86)90017-9; BEDZYK WD, 1990, J BIOL CHEM, V265, P133; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; BEDZYK WD, 1991, MOL IMMUNOL, V23, P27; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GIBSON AL, 1988, PROTEINS, V3, P155, DOI 10.1002/prot.340030304; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HERRON JN, 1984, FLUORESCEIN HAPTEN I, P49; KABAT EA, 1987, SEQUENCES PROTEINS I, P1; KAWASAKI E, 1989, AMPLIFICATIONS FORUM, V3, P4; KRANZ DM, 1983, MOL IMMUNOL, V20, P1313, DOI 10.1016/0161-5890(83)90162-1; KRANZ DM, 1982, J BIOL CHEM, V257, P6987; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; KRANZ DM, 1984, FLUORESCEIN HAPTEN I, P121; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; Miller J. H., 1972, EXPT MOL GENETICS, P433; MORAHAN G, 1983, NATURE, V301, P720, DOI 10.1038/301720a0; NISHINARITA S, 1985, J IMMUNOL, V134, P2544; REINITZ DM, 1984, MOL IMMUNOL, V21, P775, DOI 10.1016/0161-5890(84)90164-0; REINITZ DM, 1985, J IMMUNOL, V135, P3365; RINFRET A, 1985, J IMMUNOL, V135, P2574; SCANDELLA D, 1985, J CELL BIOCH B, V9, P203; SEN J, 1986, Proteins Structure Function and Genetics, V1, P256, DOI 10.1002/prot.340010308; SMITH RA, 1983, APPL ENVIRON MICROB, V45, P586, DOI 10.1128/AEM.45.2.586-590.1983; SWINDLEHURST CA, 1991, BIOPHYS J, V59, P619, DOI 10.1016/S0006-3495(91)82277-9; TEMPLETON EFG, 1985, MOL IMMUNOL, V22, P45, DOI 10.1016/0161-5890(85)90033-1; WATT RM, 1977, IMMUNOCHEMISTRY, V14, P533, DOI 10.1016/0019-2791(77)90308-1; WATT RM, 1978, IMMUNOCHEMISTRY, V15, P875, DOI 10.1016/0161-5890(78)90121-9	38	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8925	8931						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577730				2022-12-27	WOS:A1992HR85400036
J	MYLES, ME; RUSSELL, JD; TRUPIN, JS; SMITH, JC; RUSSELL, SB				MYLES, ME; RUSSELL, JD; TRUPIN, JS; SMITH, JC; RUSSELL, SB			KELOID FIBROBLASTS ARE REFRACTORY TO INHIBITION OF DNA-SYNTHESIS BY PHORBOL ESTERS - ALTERED RESPONSE IS ACCOMPANIED BY REDUCED SENSITIVITY TO PROSTAGLANDIN-E2 AND ALTERED DOWN-REGULATION OF PHORBOL ESTER BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; ARACHIDONIC-ACID RELEASE; TUMOR PROMOTERS; MESSENGER-RNA; CELL-LINES; STIMULATION; EXPRESSION; GENE; 12-O-TETRADECANOYLPHORBOL-13-ACETATE	To investigate abnormal growth regulation in keloid fibroblasts, responses to phorbol esters were examined. Treatment of quiescent cultures with phorbol 12-myristate 13-acetate (PMA) blocked a normally occurring (20-24 h) peak of serum-stimulated thymidine incorporation in normal and keloid cells. In keloid fibroblasts PMA induced a delayed peak of DNA synthesis. When indomethacin was added with PMA the delayed peak appeared in normal fibroblasts. The ED50 for inhibition of the 20-24-h peak was 1 nm, whereas the delayed peak required a 50-fold-higher PMA concentration. In both cell types PMA induced prostaglandin E2 (PGE2) synthesis, and exogenous PGE2 caused 50% inhibition of the 20-24-h peak. When PMA and indomethacin were added with PGE2 the delayed peak was inhibited 90% in normal fibroblasts, whereas inhibition of keloid cells was the same as with PGE2 alone. Normal and keloid fibroblasts had the same number of phorbol ester binding sites. However, in normal cells, phorbol 12,13-dibutyrate bound with greater affinity, and down-regulation of phorbol ester binding occurred to a greater extent. These findings suggest that altered expression of protein kinase C isozymes or another molecule that binds phorbol esters may play a role in abnormal growth regulation of keloid cells.	MEHARRY MED COLL,SCH GRAD STUDIES,DIV BIOMED SCI,NASHVILLE,TN 37208; MEHARRY MED COLL,SCH MED,DEPT MICROBIOL,NASHVILLE,TN 37208; MEHARRY MED COLL,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37208	Meharry Medical College; Meharry Medical College; Meharry Medical College					NATIONAL CANCER INSTITUTE [R01CA017229] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S06RR008037] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K14HL002332] Funding Source: NIH RePORTER; NCI NIH HHS [CA-17229] Funding Source: Medline; NCRR NIH HHS [RR-08037] Funding Source: Medline; NHLBI NIH HHS [HL-02332] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; ASE K, 1988, FEBS LETT, V236, P396, DOI 10.1016/0014-5793(88)80064-4; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BALLOU LR, 1990, J IMMUNOL, V145, P4245; BLUMBERG PM, 1988, CANCER RES, V48, P1; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BURCH RM, 1988, J BIOL CHEM, V263, P4764; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHABBOTT H, 1986, P NATL ACAD SCI USA, V83, P3126, DOI 10.1073/pnas.83.10.3126; CHIDA K, 1983, CANCER RES, V43, P3638; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DATUBOBROWN DD, 1990, BRIT J PLAST SURG, V43, P70, DOI 10.1016/0007-1226(90)90047-4; DECKER SJ, 1984, MOL CELL BIOL, V4, P1718, DOI 10.1128/MCB.4.9.1718; DIAMOND L, 1978, LIFE SCI, V23, P1979, DOI 10.1016/0024-3205(78)90229-1; DRIEDGER PE, 1980, P NATL ACAD SCI-BIOL, V77, P567, DOI 10.1073/pnas.77.1.567; FURSTENBERGER G, 1978, BIOCHEM BIOPH RES CO, V84, P1103, DOI 10.1016/0006-291X(78)91697-2; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HORI T, 1989, J CELL PHYSIOL, V141, P275, DOI 10.1002/jcp.1041410207; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HWONG CL, 1989, J BIOL CHEM, V264, P14923; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; KO SD, 1977, P NATL ACAD SCI USA, V74, P3429, DOI 10.1073/pnas.74.8.3429; KORN JH, 1980, J CLIN INVEST, V65, P543, DOI 10.1172/JCI109698; LECHNER JF, 1980, CELL BIOL INT REP, V4, P23, DOI 10.1016/0309-1651(80)90005-3; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; MARAGANORE JM, 1987, TRENDS BIOCHEM SCI, V12, P176, DOI 10.1016/0968-0004(87)90082-X; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MAUVIEL A, 1988, FEBS LETT, V231, P125, DOI 10.1016/0014-5793(88)80715-4; MUIR IFK, 1990, BRIT J PLAST SURG, V43, P61, DOI 10.1016/0007-1226(90)90046-3; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARKER J, 1987, J BIOL CHEM, V262, P5385; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; RECHLER MM, 1976, J SUPRAMOL STR CELL, V4, P199, DOI 10.1002/jss.400040207; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; RUSSEL SB, 1988, COLLAGEN REL RES, V8, P537; RUSSELL JD, 1978, J CELL PHYSIOL, V97, P221, DOI 10.1002/jcp.1040970211; RUSSELL JD, 1976, PLAST RECONSTR SURG, V57, P207, DOI 10.1097/00006534-197602000-00014; RUSSELL SB, 1989, J BIOL CHEM, V264, P13730; RUSSELL SB, 1988, P NATL ACAD SCI USA, V85, P587, DOI 10.1073/pnas.85.2.587; SOLANKI V, 1981, P NATL ACAD SCI-BIOL, V78, P1722, DOI 10.1073/pnas.78.3.1722; STABEL S, 1987, J CELL PHYSIOL, V130, P111, DOI 10.1002/jcp.1041300116; TAKASU N, 1987, BIOCHEM BIOPH RES CO, V143, P880, DOI 10.1016/0006-291X(87)90331-7; TAO W, 1989, BIOCHEM J, V257, P633, DOI 10.1042/bj2570633; TASHJIAN AH, 1978, PROSTAGLANDINS, V16, P221, DOI 10.1016/0090-6980(78)90023-0; TAYLOR L, 1977, FEBS LETT, V79, P69, DOI 10.1016/0014-5793(77)80352-9; TAYLOR L, 1981, PROSTAGLANDINS, V22, P723, DOI 10.1016/0090-6980(81)90211-2; TRUPIN JS, 1983, COLLAGEN REL RES, V3, P13; VELDHUIS JD, 1987, MOL CELL ENDOCRINOL, V49, P249, DOI 10.1016/0303-7207(87)90219-X; VERMA AK, 1980, CANCER RES, V40, P308; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; YAMAGUCHI DT, 1988, J BIOL CHEM, V263, P10745; YAMASHITA T, 1987, J BIOL CHEM, V262, P5536; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	55	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9014	9020						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577738				2022-12-27	WOS:A1992HR85400049
J	ORMO, M; DEMARE, F; REGNSTROM, K; ABERG, A; SAHLIN, M; LING, J; LOEHR, TM; SANDERSLOEHR, J; SJOBERG, BM				ORMO, M; DEMARE, F; REGNSTROM, K; ABERG, A; SAHLIN, M; LING, J; LOEHR, TM; SANDERSLOEHR, J; SJOBERG, BM			ENGINEERING OF THE IRON SITE IN RIBONUCLEOTIDE REDUCTASE TO A SELF-HYDROXYLATING MONOOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RESONANCE RAMAN-SPECTROSCOPY; METHANE MONOOXYGENASE; ESCHERICHIA-COLI; CYTOCHROME-P-450; IDENTIFICATION; ACTIVATION; SUBUNIT; PROTEIN	Protein R2 of ribonucleotide reductase contains a dinuclear ferric iron center adjacent to a tyrosyl radical in the interior of the protein matrix. A patch of hydrophobic residues surrounds the iron-radical cofactor. Its importance during the oxidative generation of the iron-radical cofactor was investigated by site-directed mutagenesis of Phe-208 to tyrosine. The mutant protein R2 F208Y has prominent absorption bands at 460 and 720 nm reminiscent of those in ferric-catecholate complexes. Resonance Raman spectroscopy shows that the iron center of R2 F208Y contains a bidentate catechol ligand. The mechanism for generation of this protein-derived dihydroxyphenylalanine may be similar to the catalytic cycle of methane monooxygenase.	UNIV STOCKHOLM, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN; OREGON GRAD INST SCI & TECHNOL, DEPT CHEM & BIOL SCI, BEAVERTON, OR 97006 USA	Stockholm University				Sjoberg, Britt-Marie/0000-0001-5953-3360	NIGMS NIH HHS [GM 18865] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018865] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON KK, 1988, J BIOL CHEM, V263, P18621; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BACKES G, 1989, BIOCHEMISTRY-US, V28, P1923, DOI 10.1021/bi00430a074; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; CARDY DLN, 1991, MOL MICROBIOL, V5, P335, DOI 10.1111/j.1365-2958.1991.tb02114.x; COX DD, 1988, J AM CHEM SOC, V110, P2026, DOI 10.1021/ja00215a002; DALTON H, 1990, FEMS MICROBIOL LETT, V87, P201, DOI 10.1016/0378-1097(90)90455-Y; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1990, BIOCHEM BIOPH RES CO, V168, P659, DOI 10.1016/0006-291X(90)92371-6; FONTECAVE M, 1992, ADV ENZYMOL, V65, P147; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; GROVES JT, 1985, J CHEM EDUC, V62, P928, DOI 10.1021/ed062p928; GUENGERICH FP, 1990, FASEB J, V4, P2453, DOI 10.1096/fasebj.4.8.2185971; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PAZ MA, 1991, J BIOL CHEM, V266, P689; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; PYRZ JW, 1985, J AM CHEM SOC, V107, P614, DOI 10.1021/ja00289a013; QUE L, 1991, SCIENCE, V253, P273, DOI 10.1126/science.1857963; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SANDERSLOEHR J, 1989, IRON CARRIERS IRON P, P373; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SJOBERG BM, 1987, BIOCHEMISTRY-US, V26, P4242; STAINTHORPE AC, 1990, GENE, V91, P27, DOI 10.1016/0378-1119(90)90158-N; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004	30	54	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8711	8714						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577712				2022-12-27	WOS:A1992HR85400003
J	KUJUBU, DA; HERSCHMAN, HR				KUJUBU, DA; HERSCHMAN, HR			DEXAMETHASONE INHIBITS MITOGEN INDUCTION OF THE TIS10 PROSTAGLANDIN SYNTHASE CYCLOOXYGENASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLUCOCORTICOID RECEPTOR; PERITONEAL-MACROPHAGES; ARACHIDONIC-ACID; MESSENGER-RNA; GROWTH-FACTOR; 3T3 CELLS; C-JUN; PROTEIN; TRANSCRIPTION; BIOSYNTHESIS	Glucocorticoids block the induced secretion of prostaglandins in a variety of biological contexts. We have identified a primary response gene, TIS10, which encodes a mitogen-inducible prostaglandin synthase/cyclooxygenase in Swiss 3T3 cells. TIS10 is distinct from prostaglandin synthase/cyclooxygenase (EC 1.14.99.1), previously cloned from mouse, man, and sheep. Dexamethasone blocks prostaglandin E2 synthesis by 3T3 cells in response to tetradecanoylphorbol acetate. Dexamethasone also blocks both phorbol ester- and forskolin-induced TIS10 mRNA accumulation. In contrast, phorbol esters, forskolin, and dexamethasone have little or no effect on the levels of prostaglandin synthase/cyclooxygenase mRNA in 3T3 cells. Moreover, dexamethasone does not inhibit induction of TIS8/egr-1, another primary response gene. Inhibition of the synthesis of TIS10 prostaglandin synthase/cyclooxygenase may be a principal mechanism by which glucocorticoids block prostaglandin synthesis and secretion.	UNIV CALIF LOS ANGELES,SCH MED,BIOMED & ENVIRONM SCI LAB,WARREN HALL,900 VET AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV NEPHROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					PHS HHS [M24797, 1K11 01815] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADEREM AA, 1986, J EXP MED, V164, P165, DOI 10.1084/jem.164.1.165; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; BOTTOMS GD, 1985, CIRC SHOCK, V15, P155; BRINCKERHOFF CE, 1986, BIOCHEMISTRY-US, V25, P6378, DOI 10.1021/bi00369a006; BUTLERGRALLA E, 1983, BIOCHEM BIOPH RES CO, V111, P194, DOI 10.1016/S0006-291X(83)80135-1; CHANDRABOSE KA, 1978, P NATL ACAD SCI USA, V75, P214, DOI 10.1073/pnas.75.1.214; CHARRON J, 1986, P NATL ACAD SCI USA, V83, P8903, DOI 10.1073/pnas.83.23.8903; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Curtis-Prior P. B., 1988, PROSTAGLANDINS BIOL; DOERFLER ME, 1989, J CLIN INVEST, V83, P970, DOI 10.1172/JCI113983; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; ERMAN A, 1986, J PHARMACOL EXP THER, V239, P296; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; FU JY, 1990, J BIOL CHEM, V265, P16737; FULLER RW, 1984, CLIN SCI, V67, P653, DOI 10.1042/cs0670653; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HONG SCL, 1976, J BIOL CHEM, V251, P776; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAWAHARA RS, 1991, J BIOL CHEM, V266, P13261; KUFUBU DA, 1991, J BIOL CHEM, V266, P12866; KURLAND JI, 1978, J EXP MED, V147, P952, DOI 10.1084/jem.147.3.952; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; LIM RW, 1989, MOL CELL BIOL, V9, P1790, DOI 10.1128/MCB.9.4.1790; LIN AH, 1989, J BIOL CHEM, V264, P17379; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MORDACQ JD, 1989, GENE DEV, V3, P790; NARAYFEJESTOTH A, 1984, J CLIN INVEST, V74, P120, DOI 10.1172/JCI111391; NASJLETTI A, 1984, ENDOCRINOLOGY, V114, P1033, DOI 10.1210/endo-114-3-1033; NICHOLS CF, 1987, BIOCHIM BIOPHYS ACTA, V927, P148; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10974; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; PASH JM, 1988, FASEB J, V2, P2613, DOI 10.1096/fasebj.2.10.2968288; PHILIPPE J, 1990, ENDOCRINOLOGY, V127, P1640, DOI 10.1210/endo-127-4-1640; POON M, 1991, J BIOL CHEM, V266, P22375; POTESTIO FA, 1988, J CLIN ENDOCR METAB, V67, P1205, DOI 10.1210/jcem-67-6-1205; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; WU KK, 1991, P NATL ACAD SCI USA, V88, P2384, DOI 10.1073/pnas.88.6.2384; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3	48	408	411	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					7991	7994						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569057				2022-12-27	WOS:A1992HQ18500009
J	MU, D; JANES, SM; SMITH, AJ; BROWN, DE; DOOLEY, DM; KLINMAN, JP				MU, D; JANES, SM; SMITH, AJ; BROWN, DE; DOOLEY, DM; KLINMAN, JP			TYROSINE CODON CORRESPONDS TO TOPA QUINONE AT THE ACTIVE-SITE OF COPPER AMINE OXIDASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HANSENULA-POLYMORPHA; METABOLISM; ENZYMES	The recently discovered organic cofactor of bovine serum amine oxidase, topa quinone, is an uncommon amino acid residue in the polypeptide backbone (Janes, S. M., Mu, D., Wemmer, D., Smith, A. J., Kaur, S., Maltby, D., Burlingame, A. L., and Klinman, J. P. (1990) Science 248, 981-987). The amine oxidase gene from the yeast Hansenula polymorpha has been cloned and sequenced (Bruinenberg, P. G., Evers, M., Waterham, H. R., Kuipers, J., Arnberg, A. C., and Geert, A. B. (1989) Biochim. Biophys. Acta 1008, 157-167). In order to understand the incorporation of topa quinone in eukaryotes, we have isolated yeast amine oxidase from H. polymorpha. Following protocols established with bovine serum amine oxidase, yeast amine oxidase was derivatized with [C-14]phenylhydrazine, followed by thermolytic digestion and isolation of a dominant radiolabeled peptide by high pressure liquid chromatography. Comparison of resonance Raman spectra for this peptide to spectra of a model compound demonstrates that topa quinone is the cofactor. By alignment of a DNA-derived yeast amine oxidase sequence with the topa quinone-containing peptide sequence, it is found that the tyrosine codon, UAC, corresponds to topa quinone in the mature protein. In a similar manner, alignment of a tryptic peptide from bovine serum amine oxidase implicates tyrosine as the precursor to topa quinone in mammals.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; STANFORD UNIV,BECKMAN CTR,STANFORD,CA 94305; AMHERST COLL,DEPT CHEM,AMHERST,MA 01002	University of California System; University of California Berkeley; Stanford University; Amherst College			Mu, David/E-8933-2011	Mu, David/0000-0002-7762-0182	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027659, R01GM039296] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 39296, GM 27659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DE, 1991, J BIOL CHEM, V266, P4049; BRUINENBERG PG, 1989, BIOCHIM BIOPHYS ACTA, V1008, P157, DOI 10.1016/0167-4781(80)90003-2; GREENAWAY FT, 1991, ARCH BIOCHEM BIOPHYS, V285, P291, DOI 10.1016/0003-9861(91)90362-M; HAMES BD, 1987, GEL ELECTROPHORESIS, P55; HAYWOOD GW, 1981, BIOCHEM J, V199, P187, DOI 10.1042/bj1990187; ITOH N, 1991, NATURE, V350, P87; JANES SM, 1991, BIOCHEMISTRY-US, V30, P4599, DOI 10.1021/bi00232a034; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; KLINMAN JP, 1984, J BIOL CHEM, V259, P3399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARUMO K, 1986, BIOCHIM BIOPHYS ACTA, V872, P98, DOI 10.1016/0167-4838(86)90152-4; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; NEUMANN R, 1975, J BIOL CHEM, V250, P6362; RECSEI PA, 1984, ANNU REV BIOCHEM, V53, P357, DOI 10.1146/annurev.bi.53.070184.002041; SHIMAN R, 1970, METHODS ENZYMOLOGY A, V17, P609; STANLEY BA, 1989, J BIOL CHEM, V264, P21073; VANDIJKEN JP, 1976, ARCH MICROBIOL, V111, P137; VISHNIAC W, 1957, BACTERIOL REV, V21, P195, DOI 10.1128/MMBR.21.3.195-213.1957; WILLIAMS TJ, 1986, J BIOL CHEM, V261, P5949; ZWART KB, 1983, J GEN MICROBIOL, V129, P3157	21	143	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					7979	7982						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569055				2022-12-27	WOS:A1992HQ18500006
J	WIEGAND, RC; CARR, C; MINNERLY, JC; PAULEY, AM; CARRON, CP; LANGNER, CA; DURONIO, RJ; GORDON, JI				WIEGAND, RC; CARR, C; MINNERLY, JC; PAULEY, AM; CARRON, CP; LANGNER, CA; DURONIO, RJ; GORDON, JI			THE CANDIDA-ALBICANS MYRISTOYL-COA-PROTEIN N-MYRISTOYLTRANSFERASE GENE - ISOLATION AND EXPRESSION IN SACCHAROMYCES-CEREVISIAE AND ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; ALPHA-SUBUNIT; ACID; DNA; DISRUPTION; ACYLATION; SEQUENCE; TRANSFERASE; BINDING; MUTANTS	Myristoyl-CoA:protein N-myristoyltransferase (NMT) has recently been identified as a target for antiviral and antifungal therapy. Candida albicans is a dimorphic, asexual yeast that is a major cause of systemic fungal infections in immunosuppressed humans. Metabolic labeling studies indicate that C. albicans synthesizes one principal 20-kDa N-myristoylprotein. The single copy C. albicans NMT gene (ca-NMT1) was isolated and encodes a 451-amino acid protein that has 55% identity with Saccharomyces cerevisiae NMT. C. albicans NMT1 is able to complement the lethal phenotype of S. cerevisiae nmt1 null mutants by directing efficient acylation of the approximately 12 endogenous N-myristoylproteins produced by S. cerevisiae. C. albicans NMT was produced in Escherichia coli, a prokaryote with no endogenous NMT activity. In vitro studies of purified E. coli-derived S. cerevisiae and C. albicans NMTs revealed species-specific differences in the kinetic properties of synthetic octapeptide substrates derived from known N-myristoylproteins. Together these data indicate that C. albicans and S. cerevisiae NMTs have similar yet distinct substrate specificities which may be of therapeutic significance.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)	WIEGAND, RC (corresponding author), MONSANTO CO,CORP RES,CHESTERFIELD,MO 63198, USA.			Duronio, Robert/0000-0001-6469-6965	NIAID NIH HHS [AI30188, AI27179] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, U01AI030188] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AWAYA J, 1975, BIOCHIM BIOPHYS ACTA, V409, P267, DOI 10.1016/0005-2760(75)90022-3; BLUMER KJ, 1991, ANNU REV PHYSIOL, V53, P37; BONNER TI, 1973, J MOL BIOL, V81, P123, DOI 10.1016/0022-2836(73)90184-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAJTBURG J, 1990, ANTIMICROB AGENTS CH, V34, P183, DOI 10.1128/AAC.34.2.183; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BRYANT ML, 1991, P NATL ACAD SCI USA, V88, P2055, DOI 10.1073/pnas.88.6.2055; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; CYERT MS, 1991, YEAST CELL BIOL, P224; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; GLEE PM, 1987, ANAL BIOCHEM, V164, P207, DOI 10.1016/0003-2697(87)90387-3; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GORDON JI, 1990, CLIN RES, V38, P517; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HEUCKEROTH RO, 1990, J LIPID RES, V31, P1121; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; IWAGUCHI S, 1990, J GEN MICROBIOL, V136, P2433, DOI 10.1099/00221287-136-12-2433; JAHNG KY, 1988, MOL CELL BIOL, V8, P2484, DOI 10.1128/MCB.8.6.2484; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JAMES G, 1989, J BIOL CHEM, V264, P20928; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P8511, DOI 10.1073/pnas.87.21.8511; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KELLY R, 1987, MOL CELL BIOL, V7, P199, DOI 10.1128/MCB.7.1.199; KELLY R, 1988, MOL GEN GENET, V214, P24, DOI 10.1007/BF00340174; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KOMSHIAN SV, 1989, REV INFECT DIS, V11, P379; KURTZ MB, 1989, MOL GEN GENET, V217, P47, DOI 10.1007/BF00330941; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKER BA, 1989, NUCLEIC ACIDS RES, V17, P3783, DOI 10.1093/nar/17.10.3783; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MEYER KH, 1974, J BACTERIOL, V117, P345, DOI 10.1128/JB.117.2.345-350.1974; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; ORME TW, 1972, EUR J BIOCHEM, V24, P407, DOI 10.1111/j.1432-1033.1972.tb19700.x; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RIGGSBY WS, 1982, MOL CELL BIOL, V2, P853, DOI 10.1128/MCB.2.7.853; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; RUSTCHENKOBULGAC EP, 1990, J BACTERIOL, V172, P1276, DOI 10.1128/jb.172.3.1276-1283.1990; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER S, 1990, MICROBIOL REV, V54, P226, DOI 10.1128/MMBR.54.3.226-241.1990; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; SIKORSKI RS, 1989, GENETICS, V122, P19; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; WEY SB, 1988, ARCH INTERN MED, V148, P2642, DOI 10.1001/archinte.148.12.2642; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978	71	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8591	8598						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569105				2022-12-27	WOS:A1992HQ18500095
J	KELLER, PM; SCHULTZ, LD; CONDRA, C; KARCZEWSKI, J; CONNOLLY, TM				KELLER, PM; SCHULTZ, LD; CONDRA, C; KARCZEWSKI, J; CONNOLLY, TM			AN INHIBITOR OF COLLAGEN-STIMULATED PLATELET ACTIVATION FROM THE SALIVARY-GLANDS OF THE HAEMENTERIA-OFFICINALIS LEECH .2. CLONING OF THE CDNA AND EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IV CD36; ADHESION; PROTEIN; IDENTIFICATION; RECEPTOR; COMPLEX; PEPTIDE; BLOOD	Salivary glands of the leech Haementeria officinalis contain a protein, leech antiplatelet protein (LAPP), that specifically blocks collagen-mediated platelet aggregation (Connolly, T. M., Jacobs, J. W., and Condra, C. (1992) J. Biol. Chem. 267, 6893-6898). Degenerate oligonucleotides whose sequences were derived from two short peptides from V8 digests of the native LAPP were used as primers to generate a polymerase chain reaction (PCR) product which contains the cDNA region coding for the sequence between these two peptides. Using this PCR product as a hybridization probe, phage containing cDNA clones were isolated containing the entire deduced amino acid sequence for LAPP. Computer analysis of the amino acid sequence predicts a peptidase cleavage site between a 21-residue prepeptide and a mature protein of 126 amino acids. A DNA insert to express the predicted mature LAPP protein was generated by PCR amplification using phage-derived cDNA clones as a substrate. This insert encoded a fusion protein with the leader sequence of the yeast alpha-mating factor and the mature LAPP cDNA. These PCR products were cloned into the yeast expression vector pKH4-alpha-2. A KEX 2 Lys-Arg endopeptidase cleavage site was placed NH2-terminal to the predicted mature protein. This vector transfected into the yeast Saccharomyces cerevisiae directs expression of a secreted mature protein at levels up to 200 mg of LAPP/liter of culture medium. The recombinant protein was comparable to native LAPP in its electrophoretic mobility, its reactivity with anti-LAPP antisera, and its biological activity including inhibition of collagen-stimulated platelet aggregation and the adhesion of platelets to collagen. Availability of significant quantities of recombinant LAPP opens the way to further biochemical structure/function studies and to studies on the effects of an inhibitor of collagen-stimulated platelet aggregation in vivo.	MERCK SHARP & DOHME LTD,DEPT BIOL CHEM,W POINT,PA 19486	Merck & Company	KELLER, PM (corresponding author), MERCK SHARP & DOHME LTD,DEPT CELLULAR & MOLEC BIOL,W POINT,PA 19486, USA.							BARNES MJ, 1988, COLLAGEN, V1, P275; BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P1; COLLER BS, 1989, BLOOD, V74, P182; CONNOLLY TM, 1992, J BIOL CHEM, V267, P6893; DAUGHERTY BL, 1990, DNA CELL BIOL, V9, P453, DOI 10.1089/dna.1990.9.453; DECKMYN H, 1986, 5 ZB K AT ART TROMB, P55; FOLZ RJ, 1987, BIOCHEM BIOPH RES CO, V146, P870, DOI 10.1016/0006-291X(87)90611-5; HAN JH, 1989, GENE, V75, P47, DOI 10.1016/0378-1119(89)90382-X; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; JACOBSON MA, 1989, GENE, V85, P511, DOI 10.1016/0378-1119(89)90445-9; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T., 1982, MOL CLONING; NEEPER MP, 1990, J BIOL CHEM, V265, P17746; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SAWYER RT, 1986, EECH BIOL BEHAVIOR F, V2; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TANDON NN, 1989, J BIOL CHEM, V264, P7576; White T. J., PCR PROTOCOLS GUIDE	23	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6899	6904						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551898				2022-12-27	WOS:A1992HM05300069
J	NISHIYAMA, K; MIZUSHIMA, S; TOKUDA, H				NISHIYAMA, K; MIZUSHIMA, S; TOKUDA, H			THE CARBOXYL-TERMINAL REGION OF SECE INTERACTS WITH SECY AND IS FUNCTIONAL IN THE RECONSTITUTION OF PROTEIN TRANSLOCATION ACTIVITY IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; CYTOPLASMIC MEMBRANE; EXPORT; GENE; MUTANT; MACHINERY; PRECURSOR; FUSION	Genes encoding the C- and N-terminal regions of SecE were constructed and placed under the control of the tac promoter on plasmids. The C-terminal region of SecE (SecE-C) was sufficient for suppression of the secEcs phenotype, confirming the results of Schatz et al. (Schatz, P. J., Bieker, K. L., Ottemann, K. M., Silhavy, T. J., and Beckwith, J. (1991) EMBO J. 10, 1749-1757). SecE-C allowed the overproduction of SecY, and its overproduction was achieved when the tac-secY gene, on a plasmid, was induced, indicating that the C-terminal region is the site of interaction of SecE with SecY and that the interaction makes the two Sec proteins stable. SecE-C was purified and used with SecY for the reconstitution of protein translocation activity. SecE-C was active in the functional reconstitution. The SecE-C/SecY-dependent protein translocation absolutely required SecA and ATP as the native translocation reaction did. Quantitative analysis revealed that SecE-C was 50% as active as intact SecE. The N-terminal region of SecE (SecE-N) also suppressed in vivo the defect caused by the secEcs mutation. SecE-N was, however, inactive in the overproduction of SecY. A possible oligomeric structure of SecE is discussed.	UNIV TOKYO, INST APPL MICROBIOL, 1-1-1 YAYOI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CERRETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599, DOI 10.1093/nar/11.9.2599; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; KUMAMOTO C, 1984, J BACTERIOL, V154, P253; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MIZUSHIMA S, 1991, METHOD CELL BIOL, V34, P107; NISHIYAMA K, 1991, BIOCHIM BIOPHYS ACTA, V1065, P89, DOI 10.1016/0005-2736(91)90015-Z; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; RIGGS PD, 1988, GENETICS, V118, P571; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; SHIBUI T, 1988, AGR BIOL CHEM TOKYO, V52, P983; SUGIMURA K, 1988, BIOCHEM BIOPH RES CO, V153, P753, DOI 10.1016/S0006-291X(88)81159-8; TANI K, 1989, J BIOL CHEM, V264, P18582; TOKUDA H, 1991, FEBS LETT, V279, P233, DOI 10.1016/0014-5793(91)80156-W; TOKUDA H, 1990, EUR J BIOCHEM, V192, P583, DOI 10.1111/j.1432-1033.1990.tb19264.x; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMANE K, 1987, J BIOL CHEM, V262, P2358	25	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7170	7176						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551922				2022-12-27	WOS:A1992HM05300109
J	TSAY, JT; OH, W; LARSON, TJ; JACKOWSKI, S; ROCK, CO				TSAY, JT; OH, W; LARSON, TJ; JACKOWSKI, S; ROCK, CO			ISOLATION AND CHARACTERIZATION OF THE BETA-KETOACYL-ACYL CARRIER PROTEIN SYNTHASE-III GENE (FABH) FROM ESCHERICHIA-COLI K-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; ACETYL COENZYME-A; NUCLEOTIDE-SEQUENCE; THERMAL REGULATION; ANTIBIOTIC CERULENIN; SYNTHETASE; PURIFICATION; MUTANTS; BINDING; CLONING	beta-Ketoacyl-acyl carrier protein (ACP) synthase III catalyzes the condensation of acetyl-CoA with malonyl-ACP in dissociated (Type II) fatty acid synthase systems. A synthase III mutant was used to localize the structural gene to the 24.5-min region of the Escherichia coli chromosome, and the defective synthase III allele was designated fabH1. The fabH gene was identified on a 1.3-kilobase NruI-HindIII chromosomal DNA fragment (plasmid pWO114) that complemented the enzymatic defect in fabH1 strains. The NruI-HindIII fragment was sequenced and contained a single open reading frame predicted to encode a 33,517-dalton protein with an isoelectric point of 4.85. The fabH sequence contained an Ala-Cys-Ala tripeptide characteristic of condensing enzyme active sites. A T7 expression system showed that the NruI-HindIII fragment directed the synthesis of a single 34,800-dalton protein. This protein was purified and the order of the amino-terminal 30 residues of the protein corresponded exactly to the amino acid structure predicted from the DNA sequence. The purified protein possessed both acetoacetyl-ACP synthase and acetyl-CoA:ACP transacylase activities, and cells harboring plasmid pWO114 overproduced the two activities, supporting the conclusion that a single protein carries out both reactions. Overproduction of synthase III resulted in a significant increase in shorter-chain fatty acids in the membrane phospholipids. These catalytic properties are consistent with the proposed role of synthase III in the initiation of fatty acid synthesis.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA; VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM & NUTR, BLACKSBURG, VA 24061 USA; UNIV TENNESSEE CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; Virginia Polytechnic Institute & State University; University of Tennessee System; University of Tennessee Health Science Center			Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AW, 1972, J BIOL CHEM, V247, P3190; ALBERTS AW, 1969, METHOD ENZYMOL, V14, P50; ALBERTS AW, 1972, ENZYMES, V6, P37; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG SI, 1988, BIOCHEMISTRY-US, V27, P4753, DOI 10.1021/bi00413a026; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; CLAVERIEMARTIN F, 1989, J BACTERIOL, V171, P5479, DOI 10.1128/jb.171.10.5479-5486.1989; COOPER CL, 1987, J BACTERIOL, V169, P605, DOI 10.1128/jb.169.2.605-611.1987; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1, P474; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; DAGNOLO G, 1975, J BIOL CHEM, V250, P5283; DAGNOLO G, 1975, J BIOL CHEM, V250, P5289; DEBELLE F, 1986, NUCLEIC ACIDS RES, V14, P7453, DOI 10.1093/nar/14.18.7453; DEMENDOZA D, 1983, TRENDS BIOCHEM SCI, V8, P49, DOI 10.1016/0968-0004(83)90388-2; DEMENDOZA D, 1983, J BIOL CHEM, V258, P2098; FISHER RF, 1987, GENETICS, V117, P191; GARWIN JL, 1980, J BIOL CHEM, V255, P3263; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; GELMANN EP, 1972, J BACTERIOL, V112, P381, DOI 10.1128/JB.112.1.381-387.1972; GREENSPAN MD, 1969, J BIOL CHEM, V244, P6477; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JACKSON MB, 1978, BIOCHIM BIOPHYS ACTA, V512, P472, DOI 10.1016/0005-2736(78)90157-8; JAWORSKI JG, 1989, PLANT PHYSIOL, V90, P41, DOI 10.1104/pp.90.1.41; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; KAWAGUCHI A, 1982, J BIOCHEM-TOKYO, V92, P7, DOI 10.1093/oxfordjournals.jbchem.a133933; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; KOES RE, 1986, NUCLEIC ACIDS RES, V14, P5229, DOI 10.1093/nar/14.13.5229; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LANZ T, 1991, J BIOL CHEM, V266, P9971; LARSON TJ, 1984, J BACTERIOL, V160, P711, DOI 10.1128/JB.160.2.711-717.1984; LENNARZ WJ, 1962, P NATL ACAD SCI USA, V48, P840, DOI 10.1073/pnas.48.5.840; Liss L, 1987, FOCUS, V9, P13; LOWE PN, 1988, BIOCHEM J, V250, P789, DOI 10.1042/bj2500789; Miller J. H, 1972, EXPT MOL GENETICS; MOHAMED AH, 1988, J BIOL CHEM, V263, P12315; Morelle G, 1989, FOCUS, V11, P7; NISHIDA I, 1986, J BIOCHEM-TOKYO, V99, P1447, DOI 10.1093/oxfordjournals.jbchem.a135614; NISHIMURA A, 1990, NUCLEIC ACIDS RES, V18, P6169, DOI 10.1093/nar/18.20.6169; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLAKIS SE, 1973, J BIOL CHEM, V248, P7957; PRESCOTT DJ, 1970, J BIOL CHEM, V245, P5484; ROCK CO, 1980, ANAL BIOCHEM, V102, P362, DOI 10.1016/0003-2697(80)90168-2; ROCK CO, 1985, BIOCH LIPIDS MEMBRAN, P73; ROSENFELD IS, 1973, J BIOL CHEM, V248, P2452; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEIZER M, 1989, NUCLEIC ACIDS RES, V17, P567, DOI 10.1093/nar/17.2.567; SHIMAKATA T, 1983, J BIOL CHEM, V258, P3592; TABOR S, 1990, CURRENT PROTOCOLS MO; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; WANNER BL, 1986, J MOL BIOL, V191, P39, DOI 10.1016/0022-2836(86)90421-3; WILLIAMS.IP, 1966, J BIOL CHEM, V241, P2326	59	246	266	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6807	6814						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551888				2022-12-27	WOS:A1992HM05300054
J	SAWAMURA, M; NARA, Y; YAMORI, Y				SAWAMURA, M; NARA, Y; YAMORI, Y			LIVER MEVALONATE 5-PYROPHOSPHATE DECARBOXYLASE IS RESPONSIBLE FOR REDUCED SERUM-CHOLESTEROL IN STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; REVERSIBLE PHOSPHORYLATION; RISK-FACTORS; ASSAY	Spontaneously hypertensive rat (stroke-prone) (SHRSP) has an interestingly low serum cholesterol level due to a reduced biosynthesis of cholesterol in the liver (Iritani, N., Fukuda, E., Nara, Y., and Yamori, Y. (1977) Atherosclerosis 28, 217-222). In this study, we examined the mechanism underlying the reduction of hepatic cholesterol biosynthesis in the rat. Our initial findings in SHRSP, as compared with normotensive Wistar Kyoto rat (WKY), showed that 1) the incorporation of [C-14]acetate into cholesterol in the liver slices was markedly less, 2) 3-hydroxyl-3-methylglutaryl (HMG) CoA reductase activity was not reduced, and 3) the incorporation of [H-3]mevalonic acid into both cholesterol and squalene was significantly less. The above initial findings suggested that the reduction in the hepatic cholesterol biosynthesis took place in one or more enzymatic processes starting with mevalonic acid and continuing to squalene. When the incorporation of [H-3]mevalonic acid into phosphomevalonate derivatives was studied using an ion exchange column, only the radioactivity incorporated into isopentenyl-pyrophosphate (isopentenyl-PP) was less in SHRSP. Furthermore, the specific activity of diphosphomevalonate (mevalonate-PP) decarboxylase in the liver-soluble fractions was reduced 50% in SHRSP as compared with WKY. Kinetic studies using liver crude extracts indicated a lower V(max) value in SHRSP (SHRSP, 0.47; WKY, 2.05 nmol/min/mg), and an unchanged K(m) value (SHRSP, 18.2; WKY, 19.6-mu-M). The activity of mevalonate-PP decarboxylase was also found to be reduced in other tissues, including the brain, testis, small intestine, and cultured vascular smooth muscle cells. From the above observations, we concluded that the lower activity of mevalonate-PP decarboxylase was responsible for the reduced cholesterol biosynthesis in the liver of SHRSP.			SAWAMURA, M (corresponding author), SHIMANE MED UNIV, DEPT PATHOL, IZUMO, SHIMANE 693, JAPAN.							BEG ZH, 1987, METABOLISM, V36, P900, DOI 10.1016/0026-0495(87)90101-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCH K, 1959, J BIOL CHEM, V234, P2595; BRUCKDORFER KR, 1969, BIOCHIM BIOPHYS ACTA, V183, P334, DOI 10.1016/0005-2736(69)90089-3; CARDEMIL E, 1985, METHOD ENZYMOL, V110, P86; CUTHBERT JA, 1990, J BIOL CHEM, V265, P18568; EASOM RA, 1984, BIOCHEM J, V220, P739, DOI 10.1042/bj2200739; EDWARDS PA, 1979, J LIPID RES, V20, P40; GIBSON DM, 1987, ENZYMES ENZYME CONTR, V18, P179; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HOLLOWAY PW, 1967, BIOCHEM J, V104, P57, DOI 10.1042/bj1040057; IRITANI N, 1977, ATHEROSCLEROSIS, V28, P217, DOI 10.1016/0021-9150(77)90171-X; IRITANI N, 1982, JPN CIRC J, V46, P151, DOI 10.1253/jcj.46.151; JABALQUINTO AM, 1980, LIPIDS, V15, P196, DOI 10.1007/BF02540970; KAGAN A, 1985, STROKE, V16, P390, DOI 10.1161/01.STR.16.3.390; KENNELLY PJ, 1985, J LIPID RES, V26, P903; NORDSTROM JL, 1977, J BIOL CHEM, V252, P8924; OKAMOTO K, 1974, CIRC RES, V34, pI143; POPJAK G, 1969, METHOD ENZYMOL, V15, P393; RAMACHANDRAN CK, 1976, BIOCHEM BIOPH RES CO, V69, P42, DOI 10.1016/S0006-291X(76)80269-0; SATTERWHITE DM, 1985, METHOD ENZYMOL, V110, P92; SHAPIRO DJ, 1974, BIOCHIM BIOPHYS ACTA, V370, P369, DOI 10.1016/0005-2744(74)90098-9; SNYDER F, 1961, J LIPID RES, V2, P195; Takayama Y, 1975, J JPN COLL ANGIOL, V15, P455; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; YAMORI Y, 1978, JPN HEART J, V19, P665; YAMORI Y, 1981, JPN CIRC J, V45, P1068, DOI 10.1253/jcj.45.1068; YAMORI Y, 1988, Heart and Vessels, V4, P94, DOI 10.1007/BF02058995; YAMORI Y, 1976, CLIN EXP PHARM PHY S, V3, P199; Yamori Y, 1977, GENE ENV INTERACTION, P141	30	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6051	6055						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556116				2022-12-27	WOS:A1992HK31800052
J	DEBER, CM; LI, ZM; JOENSSON, C; GLIBOWICKA, M; XU, GY				DEBER, CM; LI, ZM; JOENSSON, C; GLIBOWICKA, M; XU, GY			TRANSMEMBRANE REGION OF WILD-TYPE AND MUTANT M13 COAT PROTEINS - CONFORMATIONAL ROLE OF BETA-BRANCHED RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; MODEL MEMBRANE-PROTEIN; BACKBONE DYNAMICS; NMR-SPECTROSCOPY; BACTERIOPHAGE; SEQUENCE; C-13; MUTAGENESIS; PREDICTION; BILAYERS	Although transmembrane (TM) segments of integral membrane proteins are putatively alpha-helical in conformation, beta-sheet promoters (Val, Ile, Thr) often account for approximately 40% of TM residue composition. We are examining the conformational role(s) of these residues, using as a model system the major coat protein of the filamentous bacteriophage M13. This 50-residue protein, which is located at the Escherichia coli host membrane during phage reproduction, contains a prototypic 19-residue hydrophobic midregion (residues 21-39: YIGYAWAMVVVIVGATIGI). Using "Eckstein" site-directed mutagenesis, we have generated several viable M13 coat protein mutants with beta-branched amino acid substitutions within their TM region. Mutant coat proteins, including Ile32 --> Val (I32V) and Ala27 --> Thr (A27T), were obtained in milligram quantities by growing M13 mutant phages in liter preparations, confirming that these coat proteins are capable of assuming their normal biological function(s) in phage reproduction. Circular dichroism spectroscopy performed in the membrane-mimetic medium of deoxycholate micelles indicated comparable a-helical contents of mutants I32V and A27T to wild-type protein. C-13 nuclear magnetic resonance experiments with mutant A27T demonstrated that the combination of additional beta-branched content and introduction of an -OH substituent induced chemical shift and temperature-dependent changes and influenced the local protein environment at sites up to 12 residues remote from the mutation site. In contrast, mutant I32V (of which a salient feature is a mid-TM pentavaline segment) behaved very similarly to wild-type coat. These findings are interpreted in terms of the range of TM secondary structure and stability which can be accommodated by viable M13 coat protein mutants.	UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto	DEBER, CM (corresponding author), HOSP SICK CHILDREN,RES INST,DIV BIOCHEM,TORONTO M5G 1X8,ONTARIO,CANADA.							ARFMANN HA, 1977, BIOPOLYMERS, V16, P1815, DOI 10.1002/bip.1977.360160815; ASBECK F, 1969, H-S Z PHYSIOL CHEM, V350, P1047, DOI 10.1515/bchm2.1969.350.2.1047; BANNER DW, 1981, NATURE, V289, P814, DOI 10.1038/289814a0; BLOUT ER, 1960, J AM CHEM SOC, V82, P3787, DOI 10.1021/ja01499a080; BOGUSKY MJ, 1988, PROTEINS, V4, P123, DOI 10.1002/prot.340040205; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BRANDL CJ, 1988, BIOPOLYMERS, V27, P1171, DOI 10.1002/bip.360270710; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLNAGO LA, 1987, BIOCHEMISTRY-US, V26, P847, DOI 10.1021/bi00377a028; DEBER CM, 1986, ARCH BIOCHEM BIOPHYS, V251, P68, DOI 10.1016/0003-9861(86)90052-4; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; EPAND RF, 1968, BIOPOLYMERS, V6, P1551, DOI 10.1002/bip.1968.360061104; FASMAN GD, 1990, TRENDS BIOCHEM SCI, V15, P89, DOI 10.1016/0968-0004(90)90187-G; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; HENRY GD, 1987, BIOCHEMISTRY-US, V26, P3626, DOI 10.1021/bi00386a056; HENRY GD, 1986, BIOCHEMISTRY-US, V25, P590, DOI 10.1021/bi00351a012; HENRY GD, 1990, BIOCHEM CELL BIOL, V68, P318, DOI 10.1139/o90-044; HUBNER P, 1988, GENE, V73, P319, DOI 10.1016/0378-1119(88)90496-9; JAHNIG F, 1990, TRENDS BIOCHEM SCI, V15, P93, DOI 10.1016/0968-0004(90)90188-H; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KUHN A, 1987, EMBO J, V6, P501, DOI 10.1002/j.1460-2075.1987.tb04781.x; KUHN A, 1985, J BIOL CHEM, V260, P5907; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEO GC, 1987, BIOCHEMISTRY-US, V26, P854, DOI 10.1021/bi00377a029; LI Z, 1992, 12TH P AM PEPT S; LI Z, 1992, BIOCHEM BIOPH RES CO, V180, P687; MUTTER M, 1982, CHEM PEPTIDES PROTEI, V1, P217; NAKASHIMA Y, 1981, J BIOL CHEM, V256, P5792; NOZAKI Y, 1976, NATURE, V259, P335, DOI 10.1038/259335a0; OPELLA SJ, 1987, Q REV BIOPHYS, V19, P7, DOI 10.1017/S0033583500004017; PAWAGI AB, 1990, BIOCHEMISTRY-US, V29, P950, DOI 10.1021/bi00456a015; SHON KJ, 1991, SCIENCE, V252, P1303, DOI 10.1126/science.1925542; SPRUIJT RB, 1989, BIOCHEMISTRY-US, V28, P9158, DOI 10.1021/bi00449a030; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WICKNER W, 1988, BIOCHEMISTRY-US, V27, P1081, DOI 10.1021/bi00404a001	35	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5296	5300						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544912				2022-12-27	WOS:A1992HH74700047
J	HARRIS, RJ; LING, VT; SPELLMAN, MW				HARRIS, RJ; LING, VT; SPELLMAN, MW			O-LINKED FUCOSE IS PRESENT IN THE 1ST EPIDERMAL GROWTH-FACTOR DOMAIN OF FACTOR-XII BUT NOT PROTEIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HYDROXYASPARTIC ACID; COMPLETE CDNA SEQUENCE; K-DEPENDENT PROTEINS; HUMAN FACTOR-VII; HUMAN FACTOR-IX; BLOOD-COAGULATION; ESCHERICHIA-COLI; BINDING-SITE; PLASMINOGEN-ACTIVATOR; NUCLEOTIDE-SEQUENCE	Epidermal growth factor (EGF) domains are found in many proteins, particularly those of the coagulation/fibrinolytic system. We and others have demonstrated that tissue plasminogen activator (t-PA) and prourokinase are modified by the attachment of fucose to equivalent threonine residues within their EGF domains. Factor XII and protein C each contain two EGF domains; in both proteins, the EGF domain nearest the N terminus has a threonine residue in a position homologous to that which is fucosylated in t-PA. In protein C, this site is 3 residues from the position of another post-translational modification, beta-hydroxylation of Asp-71. We isolated peptides containing these sites to determine, primarily by mass spectrometric analysis, the presence of O-linked fucose and/or beta-hydroxyaspartate. We found that factor XII is fully fucosylated at Thr-90. Protein C is unmodified at the equivalent site (Thr-68) and is completely beta-hydroxylated at Asp-71. It has been recently reported that the first EGF domain of human factor VII has O-linked fucose at the equivalent position (Ser-60) (Bjoern, S., Foster, D. C., Thim, L., Wiberg, F. C., Christensen, M., Komiyama, Y., Pedersen, A. H., and Kisiel, W. (1991) J. Biol. Chem. 266, 11051-11057), while it is unmodified at Asp-63 despite having the consensus sequence for beta-hydroxylation at the latter site. These observations raise the possibility that O-linked fucosylation and beta-hydroxylation of EGF domains are mutually exclusive post-translational modifications.			HARRIS, RJ (corresponding author), GENENTECH INC,DEPT MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080, USA.							BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BJOERN S, 1991, J BIOL CHEM, V266, P11051; BOWEN BR, 1989, J CELL BIOL, V109, P421, DOI 10.1083/jcb.109.1.421; BUKO AM, 1991, P NATL ACAD SCI USA, V88, P3992, DOI 10.1073/pnas.88.9.3992; CHLOUPEK RC, 1989, J CHROMATOGR, V463, P375, DOI 10.1016/S0021-9673(01)84491-5; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DRAKENBERG T, 1983, P NATL ACAD SCI-BIOL, V80, P1802, DOI 10.1073/pnas.80.7.1802; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; FOSTER DC, 1985, P NATL ACAD SCI USA, V82, P4673, DOI 10.1073/pnas.82.14.4673; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; HASE S, 1988, J BIOCHEM-TOKYO, V104, P867, DOI 10.1093/oxfordjournals.jbchem.a122571; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1985, BIO-TECHNOL, V3, P923, DOI 10.1038/nbt1085-923; HOWARD OMZ, 1987, BIOCHEMISTRY-US, V26, P3565, DOI 10.1021/bi00386a047; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; KLINGER MM, 1981, J BIOL CHEM, V256, P7932; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P4855, DOI 10.1021/bi00365a020; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MCMULLEN BA, 1983, BIOCHEMISTRY-US, V22, P2875, DOI 10.1021/bi00281a016; MCMULLEN BA, 1983, BIOCHEM BIOPH RES CO, V115, P8, DOI 10.1016/0006-291X(83)90961-0; NISHIMURA H, 1989, J BIOL CHEM, V264, P20320; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; PENNICA D, 1987, SCIENCE, V236, P83, DOI 10.1126/science.3453112; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; RAO AG, 1987, BIOCHEMISTRY-US, V26, P3556, DOI 10.1021/bi00386a046; RYAN J, 1989, J BIOL CHEM, V264, P20283; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SAVAGE CR, 1973, J BIOL CHEM, V248, P7669; SEJIMA H, 1990, BIOCHEM BIOPH RES CO, V171, P661, DOI 10.1016/0006-291X(90)91197-Z; STANLEY KK, 1985, EMBO J, V4, P375, DOI 10.1002/j.1460-2075.1985.tb03639.x; STENFLO J, 1988, J BIOL CHEM, V263, P21; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; SUGO T, 1986, J BIOL CHEM, V261, P5116; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; TOSI M, 1987, BIOCHEMISTRY-US, V26, P8516, DOI 10.1021/bi00400a004; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	51	68	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5102	5107						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544894				2022-12-27	WOS:A1992HH74700018
J	OGASAHARA, K; HIRAGA, K; ITO, W; MILES, EW; YUTANI, K				OGASAHARA, K; HIRAGA, K; ITO, W; MILES, EW; YUTANI, K			ORIGIN OF THE MUTUAL ACTIVATION OF THE ALPHA-SUBUNIT AND BETA-2-SUBUNIT IN THE ALPHA-2-BETA-2-COMPLEX OF TRYPTOPHAN SYNTHASE - EFFECT OF ALANINE OR GLYCINE SUBSTITUTIONS AT PROLINE RESIDUES IN THE ALPHA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; BETA-SUBUNIT; PYRIDOXAL-PHOSPHATE; CATALYTIC RESIDUE; L-SERINE; MECHANISM; BINDING; COMPLEX; SYNTHETASE	To understand how the alpha and beta-2 subunits of tryptophan synthase from Escherichia coli interact to form an alpha-2-beta-2 complex and undergo mutual activation, we have investigated alpha-subunits with single amino acid replacements at conserved proline residues. Although the activities of alpha-2-beta-2 complexes that contain wild type alpha-subunit or alpha-subunits substituted at positions 28, 62, 96, and 207 are similar, the activities of alpha-2-beta-2 complexes that contain alpha-subunits substituted at positions 57 and 132 are remarkably altered. Whereas the latter enzymes have greatly reduced activities in the individual half-reactions, they have considerably higher activities in the overall reaction. These remarkable activity results are explained by a decrease in the affinity of these mutant alpha-subunits for the beta-2 subunit and by an increase in the affinity in the combined presence of ligands of both the alpha-subunit and the beta-2 subunit. Isothermal calorimetric titrations of wild type beta-2 subunit with wild type alpha-subunit and a mutant alpha-subunit containing a substitution of glycine for proline at position 132 show that both the affinity and the exothermic association enthalpy are greatly reduced in the mutant alpha-subunit although the stoichiometry of association is unchanged. The affinity of the mutant alpha-subunit for the beta-2 subunits is greatly increased in the presence of an alpha-subunit ligand, alpha-glycerol phosphate. We conclude that proline 132 plays a critical role in subunit interaction and in mutual subunit activation.	OSAKA UNIV, INST PROT RES, 3-2 YAMADAOKA, SUITA, OSAKA 565, JAPAN; NIH, BETHESDA, MD 20892 USA	Osaka University; National Institutes of Health (NIH) - USA				Ito, Wataru/0000-0002-5631-8267				ADACHI O, 1974, J BIOL CHEM, V249, P5430; ADACHI O, 1974, J BIOL CHEM, V249, P7756; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; CRAWFORD IP, 1987, PROTEINS, V2, P118, DOI 10.1002/prot.340020206; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; CREIGHTON TE, 1966, J BIOL CHEM, V241, P980; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; DUNN MF, 1991, 8TH P INT S VIT B6 C; HATHAWAY GM, 1970, BIOCHEMISTRY-US, V9, P1801, DOI 10.1021/bi00810a020; HIGGINS W, 1979, BIOCHEMISTRY-US, V18, P4827, DOI 10.1021/bi00589a010; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KAYASTHA AM, 1991, J BIOL CHEM, V266, P7618; KIRSCHNER K, 1975, EUR J BIOCHEM, V60, P513, DOI 10.1111/j.1432-1033.1975.tb21030.x; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1991, BIOCHEMISTRY-US, V30, P479, DOI 10.1021/bi00216a025; LANE AN, 1983, EUR J BIOCHEM, V133, P531, DOI 10.1111/j.1432-1033.1983.tb07496.x; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LANE AN, 1983, EUR J BIOCHEM, V129, P571; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1988, J BIOL CHEM, V263, P8611; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1970, J BIOL CHEM, V245, P6016; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1980, BIOCH MED ASPECTS TR, P137; NAGATA S, 1989, J BIOL CHEM, V264, P6288; OGASAHARA K, 1980, J BIOCHEM-TOKYO, V88, P1733, DOI 10.1093/oxfordjournals.jbchem.a133148; PHILLIPS RS, 1984, BIOCHEMISTRY-US, V23, P6228, DOI 10.1021/bi00320a052; SUGINO Y, 1980, J BIOCHEM-TOKYO, V87, P351, DOI 10.1093/oxfordjournals.jbchem.a132746; TSCHOPP J, 1980, BIOCHEMISTRY-US, V19, P4514, DOI 10.1021/bi00560a020; WEISCHET WO, 1976, EUR J BIOCHEM, V65, P365, DOI 10.1111/j.1432-1033.1976.tb10350.x; WIESINGER H, 1979, BIOCHEMISTRY-US, V18, P1979, DOI 10.1021/bi00577a020; WILHELM P, 1982, EUR J BIOCHEM, V129, P51, DOI 10.1111/j.1432-1033.1982.tb07019.x; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yanofsky C., 1972, ENZYMES, P1, DOI [10.1016/s1874-6047(08)60445-x, DOI 10.1016/S1874-6047(08)60445-X]; YUTANI K, 1987, J BIOL CHEM, V262, P13429; YUTANI K, 1991, PROTEINS, V9, P90, DOI 10.1002/prot.340090203	42	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5222	5228						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544905				2022-12-27	WOS:A1992HH74700037
J	SPADY, DK; CUTHBERT, JA				SPADY, DK; CUTHBERT, JA			REGULATION OF HEPATIC STEROL-METABOLISM IN THE RAT - PARALLEL REGULATION OF ACTIVITY AND MESSENGER-RNA FOR 7-ALPHA-HYDROXYLASE BUT NOT 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE OR LOW-DENSITY-LIPOPROTEIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID BIOSYNTHESIS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; SODIUM-TAUROCHENODEOXYCHOLATE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; SYNTHESIS INVIVO; GENE-EXPRESSION; LIVER; HAMSTER; HEPATOCYTES	In vivo regulation of hepatic sterol metabolism was examined in the rat. Sodium cholate markedly suppressed hepatic 7-alpha-hydroxylase mRNA levels and activity when fed to rats on a low cholesterol diet. Sterol balance was maintained solely by decreasing hepatic cholesterol synthesis. Compensatory mechanisms were inadequate when cholate was fed to rats on a high cholesterol diet and massive amounts of cholesterol accumulated in the liver and plasma. Suppression of bile salt synthesis was not responsible since cholate did not suppress 7-alpha-hydroxylase activity when fed to rats on a high cholesterol diet. Moreover, total hepatic low density lipoprotein receptor activity was not suppressed even though liver cholesteryl ester levels were increased more than 350-fold. Changes in 7-alpha-hydroxylase activity were always accompanied by parallel changes in mRNA, whereas mRNA levels for 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase were reduced by 50% or less, even when cholesterol synthesis was suppressed by 98%. HMG-CoA reductase and low density lipoprotein receptor activities were regulated independently although mRNA levels for these two proteins were coordinately regulated. These findings indicate that 7-alpha-hydroxylase is controlled by mRNA levels, whereas in vivo cholesterol synthesis is predominantly controlled by posttranscriptional regulation of HMG-CoA reductase activity.			SPADY, DK (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38409] Funding Source: Medline; NIAID NIH HHS [AI17653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSEN JM, 1978, J BIOL CHEM, V253, P9024; AREBALO RE, 1982, P NATL ACAD SCI-BIOL, V79, P51, DOI 10.1073/pnas.79.1.51; BROWN MS, 1979, J BIOL CHEM, V254, P5144; CLARKE CF, 1984, J BIOL CHEM, V259, P439; CLARKE CF, 1983, P NATL ACAD SCI-BIOL, V80, P3305, DOI 10.1073/pnas.80.11.3305; COHEN BI, 1977, J LIPID RES, V18, P223; CUTHBERT JA, 1990, J LIPID RES, V31, P2067; DANIELSSON H, 1967, EUR J BIOCHEM, V2, P44, DOI 10.1111/j.1432-1033.1967.tb00103.x; DAVIS RA, 1983, J BIOL CHEM, V258, P3661; EDGE SB, 1986, J BIOL CHEM, V261, P3800; GLASS CK, 1983, J BIOL CHEM, V258, P7161; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GORDON JI, 1983, J BIOL CHEM, V258, P3356; HEUMAN DM, 1989, J LIPID RES, V30, P1161; HYLEMON PB, 1989, ANAL BIOCHEM, V182, P212, DOI 10.1016/0003-2697(89)90581-2; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; JESKE DJ, 1980, J LIPID RES, V21, P364; KUBASKA WM, 1985, J BIOL CHEM, V260, P3459; LEE LY, 1989, NUCLEIC ACIDS RES, V17, P1259, DOI 10.1093/nar/17.3.1259; LI YC, 1990, J BIOL CHEM, V265, P12012; MAHLEY RW, 1980, P NATL ACAD SCI-BIOL, V77, P225, DOI 10.1073/pnas.77.1.225; MOLOWA DT, 1989, BIOCHEM J, V260, P731, DOI 10.1042/bj2600731; MYANT NB, 1977, J LIPID RES, V18, P135; NESS GC, 1991, J BIOL CHEM, V266, P14854; NOSHIRO M, 1989, FEBS LETT, V257, P97, DOI 10.1016/0014-5793(89)81795-8; NOSHIRO M, 1990, FEBS LETT, V268, P137, DOI 10.1016/0014-5793(90)80992-R; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; RAICHT RF, 1974, GASTROENTEROLOGY, V67, P1155; SALTER AM, 1987, BIOCHEM J, V247, P79, DOI 10.1042/bj2470079; SHEFER S, 1991, J BIOL CHEM, V266, P2693; SHEFFER S, 1970, J LIPID RES, V11, P404; SPADY DK, 1983, J LIPID RES, V24, P303; SPADY DK, 1986, J CLIN INVEST, V77, P1474, DOI 10.1172/JCI112460; SPADY DK, 1987, J LIPID RES, V28, P32; SPADY DK, 1988, J CLIN INVEST, V81, P300, DOI 10.1172/JCI113321; SPADY DK, 1989, J LIPID RES, V30, P559; SPADY DK, 1985, J LIPID RES, V26, P465; SPADY DK, 1983, P NATL ACAD SCI-BIOL, V80, P3499, DOI 10.1073/pnas.80.11.3499; STRAKA MS, 1990, J BIOL CHEM, V265, P7145; TAMAI T, 1988, ATHEROSCLEROSIS, V69, P29, DOI 10.1016/0021-9150(88)90286-9; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TURLEY SD, 1983, GASTROENTEROLOGY, V84, P253; TURLEY SD, 1988, LIVER BIOL PATHOBIOL, P617; WILLIAMS DL, 1986, METHOD ENZYMOL, V128, P671	46	121	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5584	5591						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544932				2022-12-27	WOS:A1992HH74700087
J	ANAFI, M; GAZIT, A; GILON, C; BEN-NERIAH, Y; LEVITZKI, A				ANAFI, M; GAZIT, A; GILON, C; BEN-NERIAH, Y; LEVITZKI, A			SELECTIVE INTERACTIONS OF TRANSFORMING AND NORMAL ABL PROTEINS WITH ATP, TYROSINE-COPOLYMER SUBSTRATES, AND TYRPHOSTINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; C-ABL; PHILADELPHIA-CHROMOSOME; KINASE-ACTIVITY; FUSED TRANSCRIPT; GENE-PRODUCT; BCR; ONCOGENE	The transforming abl proteins p160gag-abl, p185bcr-abl, and p210bcr-abl and the normal protein p140c-abl have identical catalytic sites, but differ in their N-terminal domains. Previous studies have indicated that the transforming abl proteins possess higher tyrosine kinase activity than the normal abl proto-oncogene product. In the present study, we demonstrate that two transforming abl proteins, p210bcr-abl and p160gag-abl, exhibit a higher affinity toward ATP and synthetic tyrosine containing substrates than p140c-abl. Furthermore, protein tyrosine kinase blockers from the tyrphostin family can discriminate between normal abl and transforming abl proteins of both human and mouse origin. These results suggest that the transforming potency of the abl proteins may result from their higher affinities toward intracellular signal transducers and demonstrate for the first time that oncogene products can differ from their homologous proto-oncogene product in substrate specificity. The ability of tyrphostins to discriminate between normal and transforming abl proteins suggests that it may be possible to design specific abl kinase inhibitors to combat abl-associated human leukemias.	HEBREW UNIV JERUSALEM, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, HADASSAH MED SCH, LAUTENBERG CTR IMMUNOL, IL-91010 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, DEPT ORGAN CHEM, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem			Ben-Neriah, Yinon/L-6285-2019					ABELSON HT, 1970, CANCER RES, V30, P2213; ARRUSHDI A, 1988, ONCOGENE, V2, P353; AW TY, 1985, AM J PHYSIOL, V249, pC385, DOI 10.1152/ajpcell.1985.249.5.C385; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BENNERIAH Y, 1986, ONCOGENES GROWTH CON, P106; BRAUN S, 1984, J BIOL CHEM, V259, P2051; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, IN PRESS ADV CANCER, V57; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HUNTER T, 1984, ADV CYCLIC NUCL PROT, V17, P443; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JONES DP, 1986, AM J PHYSIOL, V250, pC663, DOI 10.1152/ajpcell.1986.250.5.C663; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LEVITZKI A, 1990, BIOCHEM PHARMACOL, V40, P913, DOI 10.1016/0006-2952(90)90474-Y; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUBIN CM, 1988, P NATL ACAD SCI USA, V85, P2795, DOI 10.1073/pnas.85.8.2795; SCHECHTER Y, 1989, EMBO J, V8, P1671, DOI 10.1002/j.1460-2075.1989.tb03558.x; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SISK WP, 1986, GENE, V48, P183, DOI 10.1016/0378-1119(86)90076-4; STEINITZ M, 1980, NATURE, V287, P443, DOI 10.1038/287443a0; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WOOLSON RF, 1987, STATISTICAL METHODS, P163; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	43	91	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4518	4523						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537837				2022-12-27	WOS:A1992HF64200039
J	GONZALEZYANES, B; CICERO, JM; BROWN, RD; WEST, CM				GONZALEZYANES, B; CICERO, JM; BROWN, RD; WEST, CM			CHARACTERIZATION OF A CYTOSOLIC FUCOSYLATION PATHWAY IN DICTYOSTELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-BIOSYNTHESIS; DEVELOPMENTAL REGULATION; PLASMA-MEMBRANES; LINKED GLYCANS; DISCOIDIN-II; RAT-LIVER; PURIFICATION; GLYCOSYLATION; OLIGOSACCHARIDES; TRANSFERASE	FP21 is a 21-kDa fucoprotein which fractionates with the cytosol after high-speed centrifugation of gently lysed Dictyostelium cells. Less than 0.7% of FP21 is associated with vesicles. In proliferating cells, 4 x 10(5) fucosyl moieties/cell are associated with FP21 as anionic, possibly O-linked oligosaccharides equal in size to 4.8 glucose units. FP21 is underfucosylated in a mutant strain (HL250) that depends on extracellular fucose for synthesis of GDP-fucose. To determine the cellular site of FP21 fucosylation, cytosolic and vesicular preparations from strain HL250 were compared for their ability to transfer fucose from GDP-fucose to FP21. Cytosolic preparations fucosylate endogenous FP21 in a time-, concentration-, and divalent cation-dependent fashion, with a K(m) for GDP-fucose of 1.4-mu-M. Activity in normal cell cytosol is dependent on exogenous mutant FP21, demonstrating that FP21 is normally fully fucosylated. Both mutant and normal cytosols are also able to alpha-fucosylate a type 1 glycolipid substrate (8-methoxycarbonyloctyl-Gal-beta-1-3-beta-GlcNAc), but not related substrates, with K(m) values for the type 1 glycolipid of 0.99 mM and for GDP-fucose of 1.6-mu-M. Competitive inhibition between FP21 and the type 1 glycolipid shows that the same enzyme fucosylates both substrates. Intact and permeabilized vesicle preparations from wild-type cells are unable to fucosylate FP21 or the type 1 glycolipid by a divalent cation-dependent mechanism, and thus are devoid of FP-21-fucosyltransferase. Since control experiments showed that vesicle leakage is minimal during cytosol preparation, these results indicate that FP21 is synthesized and fucosylated in the cytosolic compartment, by an unusual soluble fucosyltransferase.	UNIV FLORIDA,COLL MED,DEPT ANAT & CELL BIOL,POB 100235,GAINESVILLE,FL 32610; UNIV FLORIDA,INST FOOD & AGR SCI,DEPT ENTOMOL,GAINESVILLE,FL 32610; UNIV FLORIDA,INST FOOD & AGR SCI,DEPT NEMATOL,GAINESVILLE,FL 32610; UNIV FLORIDA,INST FOOD & AGR SCI,DEPT FOOD SCI & NUTR,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida					NIGMS NIH HHS [GM-37539] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; BARONDES SH, 1983, J CELL BIOL, V96, P291, DOI 10.1083/jcb.96.1.291; BEYER TA, 1980, J BIOL CHEM, V255, P5364; DAS OP, 1983, BIOCHIM BIOPHYS ACTA, V736, P45; ERDOS GW, 1983, J CELL BIOL, V97, P993, DOI 10.1083/jcb.97.4.993; FOSTER CS, 1991, J BIOL CHEM, V266, P3526; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; FRAZIER WA, 1975, J BIOL CHEM, V250, P7714; FREEZE HH, 1983, J BIOL CHEM, V258, P4874; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GONZALEZYANES B, 1989, DEV BIOL, V133, P576, DOI 10.1016/0012-1606(89)90060-2; GOODLOEHOLLAND CM, 1987, METHOD CELL BIOL, V28, P103; GREGG JH, 1978, EXP CELL RES, V112, P31, DOI 10.1016/0014-4827(78)90522-0; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HENDERSON PJF, 1985, TECHNIQUES LIF B 2 S, V1, P1; IVATT RJ, 1981, J SUPRAMOL STR CELL, V17, P359, DOI 10.1002/jsscb.380170407; IVATT RL, 1984, CELL, V38, P561, DOI 10.1016/0092-8674(84)90510-5; KEAN EL, 1991, J BIOL CHEM, V266, P942; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KYPRIANOU P, 1990, GLYCOCONJUGATE J, V7, P573, DOI 10.1007/BF01189078; LAM TY, 1981, DEV BIOL, V83, P127, DOI 10.1016/S0012-1606(81)80015-2; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MATSUDAIRE P, 1987, J BIOL CHEM, V262, P10135; MCMAHON D, 1977, BIOCHIM BIOPHYS ACTA, V465, P224, DOI 10.1016/0005-2736(77)90076-1; MURAMATSU H, 1986, EUR J BIOCHEM, V157, P71, DOI 10.1111/j.1432-1033.1986.tb09639.x; Opheim D J, 1978, Methods Enzymol, V50, P505; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SATIR BH, 1990, J CELL BIOL, V111, P901, DOI 10.1083/jcb.111.3.901; SOMMERS LW, 1982, J BIOL CHEM, V257, P811; SPUDICH JA, 1987, METHOD CELL BIOL, V28, P3; STONE DB, 1987, METHOD CELL BIOL, V28, P215; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TSCHURSIN E, 1989, DIFFERENTIATION, V40, P1, DOI 10.1111/j.1432-0436.1989.tb00807.x; WEST CM, 1988, EXP CELL RES, V175, P26, DOI 10.1016/0014-4827(88)90252-2; WEST CM, 1988, CELL DIFFER DEV, V23, P1, DOI 10.1016/0045-6039(88)90032-2; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105; ZINN AB, 1978, J BIOL CHEM, V253, P6761	41	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9595	9605						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577798				2022-12-27	WOS:A1992HT96500025
J	HAREL, R; SHARMA, YD; AGUILERA, A; UEYAMA, N; WU, JJ; EYRE, DR; JURICIC, L; CHANDRASEKARAN, S; LI, M; NAH, HD; UPHOLT, WB; TANZER, ML				HAREL, R; SHARMA, YD; AGUILERA, A; UEYAMA, N; WU, JJ; EYRE, DR; JURICIC, L; CHANDRASEKARAN, S; LI, M; NAH, HD; UPHOLT, WB; TANZER, ML			CLONING AND DEVELOPMENTAL EXPRESSION OF THE ALPHA 3-CHAIN OF CHICKEN TYPE-IX COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; CDNA CLONING; II COLLAGEN; CARTILAGE; PROTEOGLYCAN; POLYPEPTIDE; SEQUENCES; CONTAINS; DOMAIN; GENES	Fibrous and nonfibrous collagens comprise two major groups within the collagen family and both groups are found in a diverse variety of tissue fabrics. Type IX collagen is in the nonfibrous group; three different subunits of type IX collagen have been identified and the alpha-1 and alpha-2 subunits have been cloned. Using molecular cloning methods we have isolated, from an embryonic chicken cartilage library, cDNA clones which code for the entire alpha-3 chain of chicken type IX collagen. The cDNA clones encompass 2416 base pairs which have a conceptual open reading frame for a protein containing 675 amino acids including 193 Gly-X-Y repeats. These collagen repeats are in three separate domains which are interspersed with four major noncollagen domains. The collagen repeats also have four minor interruptions. This chain organization directly aligns with both the alpha-1 and alpha-2 chains of chicken type IX collagen. Comparison of the deduced amino acid sequence with peptide sequences of type IX collagens shows identity with 95 of the 96 known residues of the chicken alpha-3 chain and 81 of the 98 known residues of the bovine alpha-3 chain. The identical residues match those in five peptide fragments, two from the bovine protein and three from the chicken protein. The chicken and bovine alpha-3 chains have conserved cross-linking sites, separated by 137 residues which span 40 nm, the length of the hole zone in a collagen fibril. The NC3 domain of the chicken alpha-3 chain contains a repeat Cys-Pro motif which is present in both vertebrate and invertebrate nonfibrillar collagens. Northern blot hybridization exhibits a major mRNA of about 3.3 kilobases; this transcript is found in cartilaginous tissues in the embryo, including the developing limb and is not detected in other tissues or in the precondensation stage of limb development. The composite data delineate the primary structure of the alpha-3 chain of chicken type IX collagen, show its close relationship to the alpha-1 and alpha-2 chains, demonstrate its mRNA transcript, and show the appearance of that transcript in tissues of the developing chick embryo.	UNIV CONNECTICUT,CTR HLTH,SCH MED,DEPT BIOSTRUCT & FUNCT,FARMINGTON,CT 06030; UNIV WASHINGTON,DEPT ORTHOPED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Connecticut; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NIAMS NIH HHS [R37 AR037318, R01 AR036794, AR-12683] Funding Source: Medline; NICHD NIH HHS [HD22896] Funding Source: Medline; NIDCR NIH HHS [DE 07131] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD022896, R01HD022896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR037318, R37AR012683, R01AR036794, R01AR012683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007131] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AYAD S, 1989, BIOCHEM J, V262, P753, DOI 10.1042/bj2620753; BHATNAGAR RS, 1976, BIOCH COLLAGEN, P481; BREWTON RG, 1991, J BIOL CHEM, V266, P4752; BURGESON RE, 1988, ANNU REV CELL BIOL, V4, P551, DOI 10.1146/annurev.cb.04.110188.003003; COX GN, 1989, GENE, V76, P331, DOI 10.1016/0378-1119(89)90173-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EYRE D R, 1991, British Journal of Rheumatology, V30, P10; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; EYRE DR, 1991, ARTICULAR CARTILAGE, P119; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IRWIN MH, 1985, J CELL BIOL, V101, P814, DOI 10.1083/jcb.101.3.814; KOSHER RA, 1986, DEV BIOL, V118, P112, DOI 10.1016/0012-1606(86)90078-3; KRAMER JM, 1982, CELL, V30, P599, DOI 10.1016/0092-8674(82)90256-2; KULYK WM, 1991, MATRIX, V11, P282, DOI 10.1016/S0934-8832(11)80236-2; MAYNE R, 1985, ANN NY ACAD SCI, V460, P38, DOI 10.1111/j.1749-6632.1985.tb51155.x; MCCORMICK D, 1987, P NATL ACAD SCI USA, V84, P4044, DOI 10.1073/pnas.84.12.4044; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; MURAGAKI Y, 1990, EUR J BIOCHEM, V192, P703, DOI 10.1111/j.1432-1033.1990.tb19279.x; NAH HD, 1991, J BIOL CHEM, V266, P23446; NINOMIYA Y, 1984, P NATL ACAD SCI-BIOL, V81, P3014, DOI 10.1073/pnas.81.10.3014; NINOMIYA Y, 1990, EXTRACELLULAR MATRIX, P79; NISHIMURA I, 1989, J BIOL CHEM, V264, P20023; NORO A, 1983, J BIOL CHEM, V258, P9323; SANDELL LJ, 1990, EXTRACELLULAR MATRIX, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOKOMAKI M, 1990, ANN NY ACAD SCI, V580, P1, DOI 10.1111/j.1749-6632.1990.tb17912.x; SVOBODA KK, 1988, P NATL ACAD SCI USA, V85, P7496, DOI 10.1073/pnas.85.20.7496; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VANDERREST M, 1985, J BIOL CHEM, V260, P220; VASIOS G, 1988, J BIOL CHEM, V263, P2324; VASIOS G, 1987, BIOL EXTRACELLULAR M, P283; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WU JJ, 1989, CONNECT TISSUE RES, V20, P241, DOI 10.3109/03008208909023893; WU JJ, 1984, BIOCHEM BIOPH RES CO, V123, P1033, DOI 10.1016/S0006-291X(84)80237-5; YADA T, 1990, J BIOL CHEM, V265, P6992; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	43	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10070	10076						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577778				2022-12-27	WOS:A1992HT96500094
J	LOESER, RF; WALLIN, R				LOESER, RF; WALLIN, R			CELL-ADHESION TO MATRIX GLA PROTEIN AND ITS INHIBITION BY AN ARG-GLY-ASP-CONTAINING PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAMMA-CARBOXYGLUTAMIC ACID; GLYCOPROTEIN-IIB-IIIA; BINDING-SITES; BONE; ATTACHMENT; INTEGRINS; CARBOXYLASE; FIBRINOGEN; MECHANISM; WARFARIN	Matrix Gla protein (MGP) is a 14-kDa protein found in bone and cartilage which contains the unusual amino acid gamma-carboxyglutamic acid (Gla). The biological function of this protein has not been elucidated. Here we have demonstrated the adherence of chondrocytes, fibroblasts, osteosarcoma cells, and kidney mesangial cells to MGP purified from bovine bone. Maximum adherence occurred at MGP concentrations of 0.5-1.0-mu-g/ml. Removal of the calcium-binding Gla residues by thermal decarboxylation of MGP destroyed the proteins' cell adherence properties. Cell adherence to MGP was not affected by the presence of antibodies directed against the C-terminal (non-Gla) portion of the protein or the presence of cycloheximide during the adherence assay. However, the Arg-Gly-Asp-containing synthetic peptide Gly-Arg-Gly-Asp-Ser-Pro significantly inhibited cell attachment to MGP, whereas the control peptide Gly-Arg-Gly-Glu-Ser-Pro had minimal effect. These data indicate that MGP may function in mediating cell attachment to the extracellular matrix via a receptor that requires intact Gla residues and that can be inhibited by Arg-Gly-Asp-containing peptides.			LOESER, RF (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,MED CTR BLVD,WINSTON SALEM,NC 27157, USA.				NHLBI NIH HHS [HL-32070] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032070] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; APPEL RG, 1990, AM J PHYSIOL, V259, pE312, DOI 10.1152/ajpendo.1990.259.3.E312; BARONE LM, 1991, J CELL BIOCHEM, V46, P351, DOI 10.1002/jcb.240460410; FETEIH R, 1990, J BONE MINER RES, V5, P885; FRASER JD, 1988, J BIOL CHEM, V263, P11033; HALE JE, 1991, J BIOL CHEM, V266, P21145; HALE JE, 1988, J BIOL CHEM, V263, P5820; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HEWITT AT, 1982, J BIOL CHEM, V257, P2330; KEY LL, 1988, BONE MINER, V3, P201; LAM SCT, 1987, J BIOL CHEM, V262, P947; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LOESER R, 1992, BIOCHEM J, V282, P1; LOESER RF, 1991, CONNECT TISSUE RES, V26, P135, DOI 10.3109/03008209109152432; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PRICE PA, 1982, P NATL ACAD SCI-BIOL, V79, P7734, DOI 10.1073/pnas.79.24.7734; PRICE PA, 1984, METHOD ENZYMOL, V107, P548; PRICE PA, 1985, J BIOL CHEM, V260, P4971; PRICE PA, 1983, BIOCHEM BIOPH RES CO, V117, P765, DOI 10.1016/0006-291X(83)91663-7; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SOMERMAN MJ, 1987, J BONE MINER RES, V2, P259; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; WONG HJ, 1985, BIOCHEM J, V232, P119, DOI 10.1042/bj2320119; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	27	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9459	9462						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577789				2022-12-27	WOS:A1992HT96500003
J	REXIN, M; BUSCH, W; SEGNITZ, B; GEHRING, U				REXIN, M; BUSCH, W; SEGNITZ, B; GEHRING, U			STRUCTURE OF THE GLUCOCORTICOID RECEPTOR IN INTACT-CELLS IN THE ABSENCE OF HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; CHEMICAL CROSS-LINKING; MONOCLONAL-ANTIBODIES; 59-KILODALTON PROTEIN; RAT-LIVER; HSP90	The nonactivated glucocorticoid receptor (M(r) approximately 330,000, Stokes radius = 82 angstrom) contained in cell extracts and complexed with a steroidal ligand was previously investigated by chemical cross-linking. It was identified as a heterotetramer composed of one receptor polypeptide, two molecules of the 90-kDa heat shock protein hsp90, and one 59-kDa protein subunit (Rexin, M., Busch, W., and Gehring, U. (1991) J. Biol. Chem. 266, 24601-24605). We now have used the cross-linking technique to investigate the receptor structure in intact WEHI-7 mouse lymphoma cells at 37-degrees-C and under steroid-free conditions. Using immunochemical methods we show that the receptor present in whole cells likewise exists as a high molecular weight structure of Stokes radius 82 angstrom. It has a subunit composition identical to that of the nonactivated receptor-steroid complex in cell extracts. This is the first account of a steroid hormone receptor in its native state as it is contained in target cells under physiological conditions and before a hormonal signal is received.	UNIV HEIDELBERG,INST BIOL CHEM,NEUENHEIMER FELD 501,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								DANIEL V, 1991, J BIOL CHEM, V266, P1320; Danielson M, 1991, NUCLEAR HORMONE RECE, P39; DENIS M, 1988, J STEROID BIOCHEM, V30, P271, DOI 10.1016/0022-4731(88)90105-7; DENIS M, 1989, CANCER RES, V49, pS2275; FULLER PJ, 1991, FASEB J, V5, P3092, DOI 10.1096/fasebj.5.15.1743440; GEHRING U, 1987, MOL CELL ENDOCRINOL, V53, P33, DOI 10.1016/0303-7207(87)90189-4; GEHRING U, 1985, FEBS LETT, V179, P138, DOI 10.1016/0014-5793(85)80208-8; HARRIS AW, 1973, J IMMUNOL, V110, P431; LEFEBVRE P, 1989, BIOCHEM BIOPH RES CO, V159, P677, DOI 10.1016/0006-291X(89)90048-X; MENDEL DB, 1988, J BIOL CHEM, V263, P6695; OKRET S, 1985, BIOCHEMISTRY-US, V24, P6581, DOI 10.1021/bi00344a041; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; REXIN M, 1988, BIOCHEMISTRY-US, V27, P5593, DOI 10.1021/bi00415a030; REXIN M, 1991, J BIOL CHEM, V266, P24601; REXIN M, 1988, FEBS LETT, V241, P234, DOI 10.1016/0014-5793(88)81068-8; REXIN M, 1991, J STEROID BIOCHEM, V40, P287, DOI 10.1016/0960-0760(91)90194-A; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SEGNITZ B, 1990, J BIOL CHEM, V265, P2789; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; WESTPHAL HM, 1982, EMBO J, V1, P1467, DOI 10.1002/j.1460-2075.1982.tb01339.x	23	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9619	9621						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577799				2022-12-27	WOS:A1992HT96500028
J	BROSSMER, R; WAGNER, M; FISCHER, E				BROSSMER, R; WAGNER, M; FISCHER, E			SPECIFICITY OF THE SIALIC ACID-BINDING LECTIN FROM THE SNAIL CEPAEA-HORTENSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM-AGGLUTININ; GROUP-B; PURIFICATION; MOLECULES; SEQUENCE; AFFINITY	The specificity of the sialic acid-binding lectin from the snail Cepaea hortensis, purified by affinity chromatography on fetuin-Sepharose, was studied by hemagglutination inhibition assay applying 32 sialic acid derivatives and 14 glycoproteins. 2-alpha-Methyl-9-O-acetyl-NeuAc was the most potent inhibitor, followed closely by 2-alpha-methyl-NeuAc and 2-alpha-benzyl-NeuAc. An axially orientated carboxyl group is a prerequisite for maximal lectin-sugar binding. Neither size nor polarity of the alpha-anomeric substituent significantly influenced inhibition potency. An intact sialic acid N-acetyl group is essential for optimal lectin-sugar interaction. The trihydroxypropyl side chain also is of great importance. However, a bulky hydrophobic substituent at the side chain like a 9-O-tosyl residue did not decrease binding to the lectin. The lectin did not distinguish between NeuAc-alpha-2 --> 3Gal-beta-1 --> 4Glc and NeuAc-alpha-2 --> 6Gal-beta-1 --> 4Glc. Among other sugars tested, only N-acetylglucosamine showed inhibition, although 50-fold less. The most potent glycoprotein inhibitors were those carrying O-chains only or preferentially, as ovine submaxillary mucin, bovine submaxillary mucin, and glycophorin A. Tamm-Horsfall protein was an exception being a strong inhibitor, although carrying only N-chains. Asialoglycoproteins were inactive. Glycoproteins containing the NeuAc-alpha-2 --> 3Gal sequence inhibited the lectin as well as those with NeuAc-alpha-2 --> 6GalNAc. From the results a model of the lectin's binding site for sialic acid is suggested.	INST MICROBIOL & EXPTL THERAPY,O-6900 JENA,GERMANY		BROSSMER, R (corresponding author), UNIV HEIDELBERG,INST BIOCHEM 2,NEUENHEIMER FELD 328,W-6900 HEIDELBERG,GERMANY.							AHMED H, 1989, J BIOL CHEM, V264, P18673; AKIYAMA K, 1984, J BIOL CHEM, V259, P7151; Barondes S H, 1978, Methods Enzymol, V50, P302; BASABE JV, 1984, 12TH INT CARB S, P21; BASABE JV, 1987, THESIS U HEIDELBERG; BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; BROSSMER R, 1974, FEBS LETT, V40, P250, DOI 10.1016/0014-5793(74)80237-1; BROSSMER R, 1971, H-S Z PHYSIOL CHEM, V352, P1715, DOI 10.1515/bchm2.1971.352.2.1715; BROSSMER R, 1969, FEBS LETT, V4, P335, DOI 10.1016/0014-5793(69)80269-3; COHEN E, 1984, RECOGNITION PROTEINS, P55; FISCHER E, 1990, BIOL CHEM H-S, V371, P783; FRANZEN LE, 1980, J BIOL CHEM, V255, P5090; FRIEBOLIN H, 1981, BIOCHEM INT, V3, P321; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; HAGEDORN HW, 1986, HELV CHIM ACTA, V69, P2127, DOI 10.1002/hlca.19860690837; HOLM SE, 1985, J MED MICROBIOL, V19, P317, DOI 10.1099/00222615-19-3-317; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; KUHN R, 1966, CHEM BER-RECL, V99, P611, DOI 10.1002/cber.19660990235; LINDAHL M, 1987, GLYCOCONJUGATE J, V4, P51, DOI 10.1007/BF01048444; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; MACK H, 1987, TETRAHEDRON LETT, V28, P191, DOI 10.1016/S0040-4039(00)95683-1; MAGETDANA R, 1981, EUR J BIOCHEM, V114, P11; MANDAL C, 1987, BIOCHEM BIOPH RES CO, V148, P795, DOI 10.1016/0006-291X(87)90946-6; MANDAL C, 1990, EXPERIENTIA, V46, P433, DOI 10.1007/BF01954221; MARCHALONIS JJ, 1968, J MOL BIOL, V32, P453, DOI 10.1016/0022-2836(68)90022-3; MEINDL P, 1965, MONATSH CHEM VERW TL, V96, P802, DOI 10.1007/BF00919154; MEINDL P, 1969, MONATSH CHEM, V100, P1295, DOI 10.1007/BF00903465; MILLER RL, 1982, J BIOL CHEM, V257, P7574; MOHAN S, 1982, BIOCHEM J, V203, P253, DOI 10.1042/bj2030253; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; MOTLOVA J, 1986, J MED MICROBIOL, V22, P101, DOI 10.1099/00222615-22-2-101; NAGATA Y, 1974, J BIOL CHEM, V249, P3116; NICOLSON GL, 1974, INT REV CYTOL, V39, P89, DOI 10.1016/S0074-7696(08)60939-0; OEHME P, 1968, Z IMMUNITATSFORSCH, V136, P421; RAVINDRANATH MH, 1985, J BIOL CHEM, V260, P8850; REUTTER W, 1982, SIALIC ACIDS CHEM ME, P263; ROCHE AC, 1979, BIOMEDICAL APPLICATI, P603; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; SHARON N, 1987, TRENDS BIOCHEM SCI, V12, P488, DOI 10.1016/0968-0004(87)90235-0; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; STEVENSON FK, 1971, BIOCHIM BIOPHYS ACTA, V236, P59, DOI 10.1016/0005-2795(71)90149-8; SUPP M, 1980, H-S Z PHYSIOL CHEM, V361, P338; TOMITA M, 1975, P NATL ACAD SCI USA, V72, P2964, DOI 10.1073/pnas.72.8.2964; WAGNER M, 1982, ACTA HISTOCHEM, V71, P35, DOI 10.1016/S0065-1281(82)80009-3; WAGNER M, 1990, LECTINS BIOL BIOCH C, V7, P83; WAGNER M, 1986, Z F SCHILLER U JENA, V35, P270; WAGNER M, 1990, ADV LECTIN RES, P36; WANG WC, 1988, J BIOL CHEM, V263, P4576; WATZLAWICK H, 1991, BIOCHEM J, V277, P753, DOI 10.1042/bj2770753; YOGEESWARAN G, 1981, SCIENCE, V212, P1514, DOI 10.1126/science.7233237	51	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8752	8756						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577718				2022-12-27	WOS:A1992HR85400010
J	HIRATA, K; KIKUCHI, A; SASAKI, T; KURODA, S; KAIBUCHI, K; MATSUURA, Y; SEKI, H; SAIDA, K; TAKAI, Y				HIRATA, K; KIKUCHI, A; SASAKI, T; KURODA, S; KAIBUCHI, K; MATSUURA, Y; SEKI, H; SAIDA, K; TAKAI, Y			INVOLVEMENT OF RHO P21 IN THE GTP-ENHANCED CALCIUM-ION SENSITIVITY OF SMOOTH-MUSCLE CONTRACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOTULINUM ADP-RIBOSYLTRANSFERASE; BOVINE BRAIN CYTOSOL; BINDING PROTEIN; GENE-PRODUCT; CLOSTRIDIUM-BOTULINUM; SIGNAL TRANSDUCTION; PURIFICATION; RAS; IDENTIFICATION; PHOSPHORYLATION	In the rabbit mesenteric arterial smooth muscle skinned by saponin, Ca2+ induced contraction in a concentration-dependent manner. Guanosine 5'-(3-O-thio)triphosphate (GTP-gamma-S), a non-hydrolyzable GTP analogue, lowered the Ca2+ concentrations required for this contraction and increased the Ca2+ sensitivity of the skinned smooth muscle contraction. GTP-gamma-S alone did not induce the contraction in the absence of Ca2+. This GTP-gamma-S-enhanced Ca2+ sensitivity was completely abolished by an exoenzyme of Staphylococcus aureus, named EDIN, and an exoenzyme of Clostridium botulinum, named C3, both of which are known to ADP-ribosylate the rho p21 family that belongs to the ras p21-like small GTP-binding protein superfamily. The GTP-gamma-S-bound form of rhoA p21 overcame the inhibitory action of EDIN. smg p21B, another small GTP-binding protein, was inactive. EDIN ADP-ribosylated a protein, which was most likely to be rho p21, in the skinned smooth muscle. The GTP-gamma-S-bound form of rhoA p21, but not the GDP-bound form, substituted for GTP-gamma-S and enhanced the Ca2+ sensitivity of the skinned smooth muscle contraction. smg p21B was inactive. These results indicate that rhoA p21 is involved in the GTP-gamma-S-enhanced Ca2+ sensitivity of the smooth muscle contraction.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; NATL INST HLTH,DEPT VET SCI,TOKYO 208,JAPAN; BAYER YAKUHIN LTD,INST PHARMACOL,NISHI KU,KOBE 65123,JAPAN	Kobe University; National Institute of Health Sciences - Japan; Bayer AG			KURODA, SHINYA/G-4961-2014					BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIALOJAN C, 1988, J PHYSIOL-LONDON, V398, P81, DOI 10.1113/jphysiol.1988.sp017030; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; FUJIWARA T, 1989, J PHYSIOL-LONDON, V408, P535, DOI 10.1113/jphysiol.1989.sp017474; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KAWAHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P673, DOI 10.1016/0006-291X(90)92144-O; KAWATA M, 1989, BIOCHEM BIOPH RES CO, V163, P1418, DOI 10.1016/0006-291X(89)91137-6; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MORII N, 1991, J BIOL CHEM, V266, P7646; MORIISHI K, 1990, J BIOL CHEM, V265, P16614; NISHIMURA J, 1988, BIOCHEM BIOPH RES CO, V157, P677, DOI 10.1016/S0006-291X(88)80303-6; OHMORI T, 1989, J BIOL CHEM, V264, P1877; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SAIDA K, 1978, J GEN PHYSIOL, V72, P1, DOI 10.1085/jgp.72.1.1; SAIDA K, 1992, IN PRESS J VASC MED; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SOMLYO AP, 1985, CIRC RES, V57, P497, DOI 10.1161/01.RES.57.4.497; SUGAI M, 1990, BIOCHEM BIOPH RES CO, V173, P92, DOI 10.1016/S0006-291X(05)81026-5; SUGAI M, 1992, J BIOL CHEM, V267, P2600; TAKAI Y, 1984, ADV CYCLIC NUCL PROT, V18, P119; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	36	401	408	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8719	8722						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577714				2022-12-27	WOS:A1992HR85400005
J	IKONEN, E; ULMANEN, I; PELTONEN, L				IKONEN, E; ULMANEN, I; PELTONEN, L			DELETION OF THE 3'-UNTRANSLATED REGION OF ASPARTYLGLUCOSAMINIDASE MESSENGER-RNA RESULTS IN A LYSOSOMAL ACCUMULATION DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POLYMERASE CHAIN-REACTION; DNA; HYBRIDIZATION; FRAGMENTS; PRODUCTS; PROTEINS; POLY(A); PROBES; GELS; TAIL	Aspartylglucosaminuria (AGU) is a lysosomal storage disease due to mutations in the aspartylglucosaminidase (AGA) gene. The deficient enzyme activity in patients' cells blocks one of the final steps in the degradation of N-linked glycoproteins. All the AGU mutations identified so far affect the coding region of the AGA gene. Here we report a homozygous 876-base pair deletion, which removes the 3'-noncoding area but leaves the coding region of the AGA mRNA intact. This deletion does not prevent transcription termination or polyadenylation of the patient's truncated mRNA, and the steady state level of the mRNA is comparable with the control. However, the quantity of AGA polypeptide chains in the patient's fibroblasts is negligible. This suggests that the deletion interferes with the translational efficiency in vivo and provides a unique model to pursue the biological significance of untranslated regions of human mRNAs.	ORION FARMOS PHARMACEUT,ORION RES CTR,SF-00380 HELSINKI,FINLAND		IKONEN, E (corresponding author), NATL PUBL HLTH INST,DEPT HUMAN MOLEC GENET,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND.							ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; AULA P, 1986, J MENT DEFIC RES, V30, P365; AULA P, 1989, PRENATAL DIAG, V9, P617, DOI 10.1002/pd.1970090904; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BENGTSTROM M, 1990, NUCLEOS NUCLEOT, V9, P123, DOI 10.1080/07328319008045115; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER KJ, 1991, J BIOL CHEM, V266, P12105; FISHER KJ, 1991, FEBS LETT, V288, P173, DOI 10.1016/0014-5793(91)81028-7; GRENS A, 1990, J BIOL CHEM, V265, P11810; HALILA R, 1991, BIOCHEM J, V276, P251, DOI 10.1042/bj2760251; IKONEN E, 1991, EMBO J, V10, P51, DOI 10.1002/j.1460-2075.1991.tb07920.x; IKONEN E, 1991, GENOMICS, V11, P206, DOI 10.1016/0888-7543(91)90120-4; IKONEN E, 1991, P NATL ACAD SCI USA, V88, P11222, DOI 10.1073/pnas.88.24.11222; ISENBERG JN, 1975, J PEDIATR-US, V86, P713, DOI 10.1016/S0022-3476(75)80355-6; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagerstrom M, 1991, PCR Methods Appl, V1, P111; MAKINO M, 1966, BIOCHEM BIOPH RES CO, V24, P961, DOI 10.1016/0006-291X(66)90344-5; MAKINO M, 1968, J BIOCHEM, V63, P186, DOI 10.1093/oxfordjournals.jbchem.a128760; Maniatis T, 1989, DECONTAMINATION DILU; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARK H, 1991, FEBS LETT, V288, P168, DOI 10.1016/0014-5793(91)81027-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SYVANEN AC, 1988, NUCLEIC ACIDS RES, V16, P11327, DOI 10.1093/nar/16.23.11327; SYVANEN AC, 1992, GENOMICS, V12, P590, DOI 10.1016/0888-7543(92)90452-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F	33	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8715	8718						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577713				2022-12-27	WOS:A1992HR85400004
J	PERRELLA, M; DAVIDS, N; ROSSIBERNARDI, L				PERRELLA, M; DAVIDS, N; ROSSIBERNARDI, L			THE ASSOCIATION REACTION BETWEEN HEMOGLOBIN AND CARBON-MONOXIDE AS STUDIED BY THE ISOLATION OF THE INTERMEDIATES - IMPLICATIONS ON THE MECHANISM OF COOPERATIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; CARBOXYHEMOGLOBIN; DISSOCIATION; EQUILIBRIUM; PROTEINS; KINETICS; STATES; MODEL; CO	The concentrations of the intermediates in the association reaction between human hemoglobin and CO at 20-degrees-C, pH 7, under conditions of negligible dissociation of the ligand, were measured by cryogenic techniques. The monoligated species were predominant at all values of overall ligand bound studied. The analysis of the experimental data assuming a scheme of four consecutive reactions indicated that the binding rates increased in a continuous fashion. A significant acceleration after the binding of the second molecule of ligand occurred in the presence of 0.1 M KCl, but not with the addition of an excess of inositol hexaphosphate, indicating that major functional, and possibly structural, transitions occur at the diligated state. Differences in the concentrations of the intermediates in the same state of ligation were observed under all conditions. The analyses of the data on the basis of schemes of multiple pathways of reaction indicated that the beta-subunits reacted about 1.5 times faster than the alpha-subunits in the first ligation reaction. After the addition of inositol hexaphosphate, the alpha-subunits reacted about 1.5 times faster than the beta-subunits in the first ligation step, but the overall rate of the first CO binding step was unchanged.	PENN STATE UNIV,UNIV PK,PA 16801	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	PERRELLA, M (corresponding author), DIPARTIMENTO SCI & TECNOL BIOMED,VIA CELORIA 2,I-20133 MILAN,ITALY.							ACKERS GK, 1981, J MOL BIOL, V147, P559, DOI 10.1016/0022-2836(81)90400-9; ACKERS GK, 1990, BIOPHYS CHEM, V37, P371, DOI 10.1016/0301-4622(90)88036-R; ACKERS GK, 1987, ANNU REV BIOPHYS BIO, V16, P583; BALDWIN JM, 1979, J MOL BIOL, V129, P183; BENESCH R, 1968, P NATL ACAD SCI USA, V61, P1102, DOI 10.1073/pnas.61.3.1102; BRUNORI M, 1970, J MOL BIOL, V49, P461, DOI 10.1016/0022-2836(70)90257-3; COLETTA M, 1991, EUR J BIOCHEM, V196, P569, DOI 10.1111/j.1432-1033.1991.tb15851.x; DAVIDS N, 1964, COMMUN ACM, V7, P547, DOI 10.1145/364847.364873; Douzou P., 1977, CRYOBIOCHEMISTRY INT; Evelyn KA, 1938, J BIOL CHEM, V126, P655; GIBSON QH, 1973, J BIOL CHEM, V248, P1281; GIBSON QH, 1959, PROG BIOPHYS MOL BIO, V9, P1; GIBSON QH, 1957, PROC R SOC SER B-BIO, V146, P206, DOI 10.1098/rspb.1957.0005; GILL SJ, 1985, BIOPHYS CHEM, V21, P1, DOI 10.1016/0301-4622(85)85001-8; GRAY RD, 1971, J BIOL CHEM, V246, P5176; GRAY RD, 1971, J BIOL CHEM, V246, P7168; HOPFIELD JJ, 1971, J MOL BIOL, V61, P425, DOI 10.1016/0022-2836(71)90391-3; JOHNSON ME, 1974, BIOCHEMISTRY-US, V13, P3653, DOI 10.1021/bi00715a005; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P364; LEE AWM, 1988, BIOCHEMISTRY-US, V27, P1285, DOI 10.1021/bi00404a031; LIDDINGTON R, 1988, NATURE, V331, P725, DOI 10.1038/331725a0; MIURA S, 1987, BIOCHEMISTRY-US, V26, P2149, DOI 10.1021/bi00382a013; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PERRELLA M, 1983, J BIOCHEM BIOPH METH, V7, P187, DOI 10.1016/0165-022X(83)90028-3; PERRELLA M, 1990, BIOPHYS CHEM, V37, P211, DOI 10.1016/0301-4622(90)88020-S; PERRELLA M, 1990, BIOPHYS CHEM, V35, P97, DOI 10.1016/0301-4622(90)80064-E; PERRELLA M, 1983, J BIOL CHEM, V258, P4511; PERRELLA M, 1981, J BIOL CHEM, V256, P1098; PERRELLA M, 1986, J BIOL CHEM, V261, P8391; PERRELLA M, 1988, S OXYGEN BINDING HEM; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; SAMAJA M, 1987, J BIOL CHEM, V262, P4528; SHARMA VS, 1988, J BIOL CHEM, V263, P2292; SHARMA VS, 1976, J BIOL CHEM, V251, P4267; SHARMA VS, 1989, J BIOL CHEM, V264, P10582; SMITH FR, 1985, P NATL ACAD SCI USA, V82, P5347, DOI 10.1073/pnas.82.16.5347; SMITH FR, 1987, P NATL ACAD SCI USA, V84, P7089, DOI 10.1073/pnas.84.20.7089; VIGGIANO G, 1979, P NATL ACAD SCI USA, V76, P3673, DOI 10.1073/pnas.76.8.3673	39	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8744	8751						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577717				2022-12-27	WOS:A1992HR85400009
J	HONORE, B; LEFFERS, H; MADSEN, P; RASMUSSEN, HH; VANDEKERCKHOVE, J; CELIS, JE				HONORE, B; LEFFERS, H; MADSEN, P; RASMUSSEN, HH; VANDEKERCKHOVE, J; CELIS, JE			MOLECULAR-CLONING AND EXPRESSION OF A TRANSFORMATION-SENSITIVE HUMAN PROTEIN CONTAINING THE TPR MOTIF AND SHARING IDENTITY TO THE STRESS-INDUCIBLE YEAST PROTEIN STI1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; AMINO-ACID-SEQUENCE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; SECONDARY-STRUCTURE; MRC-5 FIBROBLASTS; GENE; MITOCHONDRIA; IMPORT; CELLS	A transformation-sensitive human protein (IEF SSP 3521) that is 2-fold up-regulated in SV40-transformed MRC-5 fibroblasts has been purified by two-dimensional gel electrophoresis, microsequenced, and cDNA cloned using oligodeoxyribonucleotides. The 2.1-kilobase cDNA encodes a 543-amino acid protein with a calculated molecular mass of 62.6 kDa and a calculated pl of 6.77. Expression of the cDNA in AMA cells using the vaccinia virus expression system followed by two-dimensional gel electrophoresis showed that the protein comigrated with IEF SSP 3521. The protein contains the tetratricopeptide repeat found in families of fungal proteins required for mitosis and RNA synthesis. In particular, the protein has 42% amino acid sequence identity to STI1, a stress-inducible mediator of the heat shock response in Saccharomyces cerevisiae. Northern blot analysis indicated that the 3521 mRNA is up-regulated in several transformed cells. Immunofluorescence studies using a polyclonal antibody raised against the purified protein revealed that the antigen is present mainly in the nucleus of SV40 transformed MRC-5 fibroblasts, while it localizes to the Golgi apparatus and small vesicles in their normal counterparts. The possible physiological role of IEF SSP 3521 is discussed in the light of the structural relationship with STI1.	AARHUS UNIV, DANISH CTR HUMAN GENOME RES, DK-8000 AARHUS, DENMARK; STATE UNIV GHENT, FYSIOL CHEM LAB, B-9000 GHENT, BELGIUM	Aarhus University; Ghent University	HONORE, B (corresponding author), AARHUS UNIV, INST MED BIOCHEM, OLE WORMS ALLE, BLDG 170, DK-8000 AARHUS, DENMARK.		Honoré, Bent/ABF-3650-2021	Madsen, Peder Sondergaard/0000-0002-8845-4802; Honore, Bent/0000-0002-3459-7429				BAUW G, 1987, P NATL ACAD SCI USA, V84, P4806, DOI 10.1073/pnas.84.14.4806; BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; BOGUSKI MS, 1990, NATURE, V346, P114, DOI 10.1038/346114a0; BOGUSKI MS, 1986, J LIPID RES, V27, P1011; BOGUSKI MS, 1986, J BIOL CHEM, V261, P6398; BRAVO R, 1982, CLIN CHEM, V28, P949; BRAVO R, 1982, J MOL BIOL, V154, P121, DOI 10.1016/0022-2836(82)90421-1; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CELIS JE, 1990, ELECTROPHORESIS, V11, P1072, DOI 10.1002/elps.1150111203; CELIS JE, 1990, ELECTROPHORESIS, V11, P989, DOI 10.1002/elps.1150111202; CELIS JE, 1989, ELECTROPHORESIS, V10, P76, DOI 10.1002/elps.1150100204; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOI A, 1990, GENE, V91, P123, DOI 10.1016/0378-1119(90)90172-N; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GUBLER U, 1988, NUCLEIC ACIDS RES, V16, P2726, DOI 10.1093/nar/16.6.2726; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARTWELL LH, 1985, GENETICS, V110, P381; HASE T, 1983, EMBO J, V2, P2169, DOI 10.1002/j.1460-2075.1983.tb01718.x; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; ICHO T, 1987, NUCLEIC ACIDS RES, V15, P8439, DOI 10.1093/nar/15.20.8439; JACOBS KA, 1988, NUCLEIC ACIDS RES, V16, P4637, DOI 10.1093/nar/16.10.4637; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEFFERS H, 1989, J MOL BIOL, V206, P1, DOI 10.1016/0022-2836(89)90519-6; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MORRIS NR, 1975, GENET RES, V26, P237, DOI 10.1017/S0016672300016049; MURRAY AW, 1991, SCI AM, V264, P56, DOI 10.1038/scientificamerican0391-56; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ODONNELL KL, 1991, J CELL SCI, V99, P711; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OVCHINNIKOV YA, 1982, NUCLEIC ACIDS RES, V1, P97; RASMUSSEN HH, 1991, ELECTROPHORESIS, V12, P873, DOI 10.1002/elps.1150121107; RASMUSSEN HH, 1991, ADV LIF SCI, P103; RHEE SK, 1989, YEAST, V5, P149, DOI 10.1002/yea.320050304; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; THIRUP S, 1990, PROTEINS, V7, P291, DOI 10.1002/prot.340070310; TOHE A, 1980, P NATL ACAD SCI-BIOL, V77, P527, DOI 10.1073/pnas.77.1.527; TUNON P, 1984, J BIOCHEM BIOPH METH, V9, P171, DOI 10.1016/0165-022X(84)90008-3	52	153	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8485	8491						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569099				2022-12-27	WOS:A1992HQ18500082
J	SOPER, TS; LARIMER, FW; MURAL, RJ; LEE, EH; HARTMAN, FC				SOPER, TS; LARIMER, FW; MURAL, RJ; LEE, EH; HARTMAN, FC			ROLE OF ASPARAGINE-111 AT THE ACTIVE-SITE OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE FROM RHODOSPIRILLUM-RUBRUM AS EXPLORED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; RIBULOSEBISPHOSPHATE CARBOXYLASE; 1,5-BISPHOSPHATE CARBOXYLASE; SUBUNIT INTERACTIONS; MUTANTS; ENZYME; HYBRIDIZATION; RESOLUTION	Crystallographic studies of ribulose-1,5-bisphosphate carboxylase/oxygenase from Rhodospirillum rubrum suggest that active-site Asn111 interacts with Mg2+ and/or substrate (Lundqvist, T., and Schneider, G. (1991) J. Biol. Chem. 266, 12604-12611). To examine possible catalytic roles of Asn111, we have used site-directed mutagenesis to replace it with a glutaminyl, aspartyl, seryl, or lysyl residue. Although the mutant proteins are devoid of detectable carboxylase activity, their ability to form a quaternary complex comprised of CO2, Mg2+, and a reaction-intermediate analogue is indicative of competence in activation chemistry and substrate binding. The mutant proteins retain enolization activity, as measured by exchange of the C3 proton of ribulose bisphosphate with solvent, thereby demonstrating a preferential role of Asn111 in some later step of overall catalysis. The active sites of this homodimeric enzyme are formed by interactive domains from adjacent subunits (Larimer, F. W., Lee, E. H., Mural, R. J., Soper, T. S., and Hartman, F. C. (1987) J. Biol. Chem. 262, 15327-15329). Crystallography assigns Asn111 to the aminoterminal domain of the active site (Knight, S., Andersson, I., and Branden, C.-I. (1990) J. Mol. Biol. 215, 113-160). The observed formation of enzymatically active heterodimers by the in vivo hybridization of an inactive position-111 mutant with inactive carboxyl-terminal domain mutants is consistent with this assignment.			SOPER, TS (corresponding author), OAK RIDGE NATL LAB,DIV BIOL,PROT ENGN & MOLEC MUTAGENESIS PROGRAM,OAK RIDGE,TN 37831, USA.							ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; GUTTERIDGE S, 1988, PLANT PHYSIOL BIOCH, V26, P675; HARPEL MR, 1991, J BIOL CHEM, V266, P24734; HARTMAN FC, 1987, BIOCHEM BIOPH RES CO, V145, P1158, DOI 10.1016/0006-291X(87)91558-0; HARTMAN FC, 1985, J BIOL CHEM, V260, P3968; HARTMAN FC, 1987, J BIOL CHEM, V262, P3496; HARTMAN FC, 1989, J BIOL CHEM, V264, P11784; Horecker B. L., 1958, BIOCHEM PREP, V6, P83; JAWOROWSKI A, 1984, J BIOL CHEM, V259, P6783; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KULIOPULOS A, 1989, BIOCHEMISTRY-US, V28, P149, DOI 10.1021/bi00427a022; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDRO JA, 1991, BIOCHEMISTRY-US, V30, P9274, DOI 10.1021/bi00102a020; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LARIMER FW, 1990, PROTEIN ENG, V3, P227, DOI 10.1093/protein/3.3.227; LORIMER GH, 1977, ANAL BIOCHEM, V78, P66, DOI 10.1016/0003-2697(77)90009-4; LORIMER GH, 1988, J BIOL CHEM, V263, P6468; LUNDQVIST T, 1991, J BIOL CHEM, V266, P12604; LUNDQVIST T, 1991, BIOCHEMISTRY-US, V30, P904, DOI 10.1021/bi00218a004; MIZIORKO HM, 1980, BIOCHEMISTRY-US, V19, P1167, DOI 10.1021/bi00547a020; MURAL RJ, 1990, J BIOL CHEM, V265, P6501; NIYOGI SK, 1986, J BIOL CHEM, V261, P87; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; PIERCE J, 1986, BIOCHEMISTRY-US, V25, P1636, DOI 10.1021/bi00355a029; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5473; SCHLOSS JV, 1982, METHOD ENZYMOL, V90, P522; SCHLOSS JV, 1990, ENZYMATIC MODEL CARB, P321; SMITH HB, 1990, J BIOL CHEM, V265, P1243; SMITH HB, 1991, BIOCHEMISTRY-US, V30, P5172, DOI 10.1021/bi00235a009; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOPER TS, 1989, J PROTEIN CHEM, V8, P239, DOI 10.1007/BF01024947; SUE JM, 1982, BIOCHEMISTRY-US, V21, P5404, DOI 10.1021/bi00265a004; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; VANDYK DE, 1986, BIOCHEMISTRY-US, V25, P5145, DOI 10.1021/bi00366a024; VIERA J, 1987, METHOD ENZYMOL, V153, P3	37	14	14	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8452	8457						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569095				2022-12-27	WOS:A1992HQ18500076
J	WATANABE, M; SOFUNI, T; NOHMI, T				WATANABE, M; SOFUNI, T; NOHMI, T			INVOLVEMENT OF CYS(69) RESIDUE IN THE CATALYTIC MECHANISM OF N-HYDROXYARYLAMINE O-ACETYLTRANSFERASE OF SALMONELLA-TYPHIMURIUM - SEQUENCE SIMILARITY AT THE AMINO-ACID LEVEL SUGGESTS A COMMON CATALYTIC MECHANISM OF ACETYLTRANSFERASE FOR SALMONELLA-TYPHIMURIUM AND HIGHER ORGANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; COA DEPENDENT ENZYME; ACETYL-COA; NUCLEOTIDE-SEQUENCE; TESTER STRAINS; PHENOTYPIC SELECTION; SENSITIVE METHOD; CHICKEN LIVER; PIGEON LIVER; DNA-BINDING	Acetyl-coenzyme A:N-hydroxyarylamine O-acetyltransferase is ubiquitous in species ranging from bacteria to mammals and is involved in the metabolic activation of N-hydroxyarylamines derived from mutagenic and carcinogenic aromatic amines and nitroarenes. The nucleotide sequence of the gene that encodes O-acetyltransferase of Salmonella typhimurium was determined, and its deduced amino acid sequence was compared with those of arylamine N-acetyltransferases (EC 2.3.1.5) of higher organisms. The gene of S. typhimurium encoded a protein with a calculated molecular weight of 32,177. Chromosome DNA of S. typhimurium TA1538/1,8-DNP, an O-acetyltransferase-deficient strain, had a -1 frameshift mutation of CCC to CC at the coding region. To date, 11 genes encoding N-acetyltransferase have been cloned from human, rabbit, hamster, and chicken. The N-terminal region of O-acetyltransferase of S. typhimurium with about 170 amino acids showed 25-33% homology with the corresponding region of N-acetyltransferases of the higher organisms. Of the 5 cysteine residues of O-acetyltransferase of S. typhimurium, Cys69 was the only residue that was conserved in all N-acetyltransferases of the higher organisms. The amino acid sequence of Arg-Gly-Gly-X-Cys, including the Cys69, was highly conserved. The mutant O-acetyltransferase of S. typhimurium, which contained Ala69 instead of Cys69, no longer showed the activities of O- and N-acetyltransferase. These results suggest that the Cys69 of S. typhimurium and its corresponding cysteine residues of the higher organisms are essential for the enzyme activities as acetyl-coenzyme A-binding sites.	NATL INST HYG SCI,BIOL SAFETY RES CTR,DIV GENET & MUTAGENESIS,1-18-1 KAMIYOGA,SETAGAYA KU,TOKYO 158,JAPAN	National Institute of Health Sciences - Japan								ABUZEID M, 1991, MOL CARCINOGEN, V4, P81, DOI 10.1002/mc.2940040112; ANDRES HH, 1988, J BIOL CHEM, V263, P7521; ANDRES HH, 1983, BIOCHIM BIOPHYS ACTA, V746, P182, DOI 10.1016/0167-4838(83)90073-0; ANDRES HH, 1983, BIOCHIM BIOPHYS ACTA, V746, P193, DOI 10.1016/0167-4838(83)90074-2; BERANEK DT, 1982, P NATL ACAD SCI-BIOL, V79, P5175, DOI 10.1073/pnas.79.17.5175; BLUM M, 1990, NUCLEIC ACIDS RES, V18, P5295, DOI 10.1093/nar/18.17.5295; BLUM M, 1990, NUCLEIC ACIDS RES, V18, P5287, DOI 10.1093/nar/18.17.5287; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; BLUM M, 1990, DNA CELL BIOL, V9, P193, DOI 10.1089/dna.1990.9.193; BLUM M, 1989, NUCLEIC ACIDS RES, V17, P3589, DOI 10.1093/nar/17.9.3589; CHEON G, 1990, FASEB J, V4, pA610; DEGUCHI T, 1988, J BIOL CHEM, V263, P7528; DEGUCHI T, 1990, J BIOL CHEM, V265, P12757; EINISTO P, 1991, MUTAT RES, V259, P95, DOI 10.1016/0165-1218(91)90113-Z; EINISTO P, 1990, MUTAT RES, V245, P87, DOI 10.1016/0165-7992(90)90005-5; FLAMMANG TJ, 1985, CARCINOGENESIS, V6, P251, DOI 10.1093/carcin/6.2.251; FLAMMANG TJ, 1988, CARCINOGENIC MUTAGEN, P137; GRANT DM, 1989, NUCLEIC ACIDS RES, V17, P3978, DOI 10.1093/nar/17.10.3978; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HEIN DW, 1988, BIOESSAYS, V9, P200, DOI 10.1002/bies.950090605; HEIN DW, 1988, BIOCHIM BIOPHYS ACTA, V948, P37, DOI 10.1016/0304-419X(88)90004-2; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JOSEPHY PD, 1989, BIOESSAYS, V11, P108, DOI 10.1002/bies.950110408; JOSEPHY PD, 1989, CANCER RES, V49, P853; KATO R, 1986, CRIT REV TOXICOL, V16, P307, DOI 10.3109/10408448609037466; KATO R, 1988, CARCINOGENIC MUTAGEN, P125; KING CM, 1983, ENVIRON HEALTH PERSP, V49, P43, DOI 10.1289/ehp.834943; KIRLIN WG, 1989, CANCER RES, V49, P2448; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTANO SS, 1989, MOL PHARMACOL, V35, P599; MCCOY EC, 1983, MUTAT RES, V121, P17, DOI 10.1016/0165-7992(83)90081-7; MCCOY EC, 1981, ENVIRON MUTAGEN, V3, P421, DOI 10.1002/em.2860030403; MILLER JA, 1970, CANCER RES, V30, P559; OHASKO S, 1990, J BIOL CHEM, V265, P4630; OHSAKO S, 1988, J BIOL CHEM, V263, P7534; OHTOMI M, 1989, EUR J BIOCHEM, V185, P253, DOI 10.1111/j.1432-1033.1989.tb15110.x; ROSENKRANZ HS, 1983, MUTAT RES, V114, P217, DOI 10.1016/0165-1110(83)90034-9; SAITO K, 1983, BIOCHEM BIOPH RES CO, V116, P141, DOI 10.1016/0006-291X(83)90392-3; SAITO K, 1986, J BIOCHEM-TOKYO, V99, P1689, DOI 10.1093/oxfordjournals.jbchem.a135644; SAITO K, 1985, ARCH BIOCHEM BIOPHYS, V239, P286, DOI 10.1016/0003-9861(85)90838-0; SANCAR A, 1979, J BACTERIOL, V137, P692, DOI 10.1128/JB.137.1.692-693.1979; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI Y, 1991, J BIOL CHEM, V266, P13243; SHINOHARA A, 1985, CARCINOGENESIS, V6, P305, DOI 10.1093/carcin/6.2.305; TOKIWA H, 1986, CRIT REV TOXICOL, V17, P23, DOI 10.3109/10408448609037070; VATSIS KP, 1991, P NATL ACAD SCI USA, V88, P6333, DOI 10.1073/pnas.88.14.6333; WALSH C, 1979, ENZYMATIC REACTION M, P671; WATANABE M, 1987, BIOCHEM BIOPH RES CO, V147, P974, DOI 10.1016/S0006-291X(87)80165-1; WATANABE M, 1990, MUTAT RES, V234, P337, DOI 10.1016/0165-1161(90)90044-O; WATANABE M, 1989, MUTAT RES, V216, P211, DOI 10.1016/0165-1161(89)90007-1; Weber W W, 1981, Methods Enzymol, V77, P272; WEBER WW, 1985, PHARMACOL REV, V37, P25; WEBER WW, 1987, ACETYLATOR GENES DRU; Weisburger JH, 1988, CARCINOGENIC MUTAGEN, P3; YAMAZOE Y, 1982, BIOCHEM BIOPH RES CO, V107, P165, DOI 10.1016/0006-291X(82)91684-9	57	117	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8429	8436						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569093				2022-12-27	WOS:A1992HQ18500073
J	ZALVIDE, JB; CANCIO, E; ALVAREZ, CV; REGUEIRO, BJ; DOMINGUEZ, F				ZALVIDE, JB; CANCIO, E; ALVAREZ, CV; REGUEIRO, BJ; DOMINGUEZ, F			PROTHYMOSIN-ALPHA MESSENGER-RNA LEVELS ARE INVARIANT THROUGHOUT THE CELL-CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN; GENE-EXPRESSION; HISTONE GENE; PROLIFERATION; MOUSE; CDNA	Prothymosin-alpha (PT-alpha) mRNA levels were evaluated at different stages during the cell cycle. NIH 3T3 cells were synchronized: (a) by serum deprivation, (b) by mitotic shake off after nocodazole arrest, and (c) by double thymidine block. Cell synchronism was estimated by flow cytometry. In cells grown in serum-free medium, PT-alpha-mRNA levels were almost undetectable. 14 h after serum restoration PT-alpha-mRNA was induced as had been described by others (Eschendfeldt, W. H., and Berger, S. L. (1986) Proc. Natl. Acad. Sci. U.S. A. 83, 9403-9407). PT-alpha-mRNA induction seems to require the synthesis of proteic factor(s) since PT-alpha-mRNA response to serum restoration was abolished in the presence of cycloheximide. Interestingly, cycling cells that were synchronized at different stages of the cycle by means of mitotic shake off after nocodazole arrest or double thymidine block did not show variations in the levels of PT-alpha-mRNA when progressed synchronously through the cycle. On the contrary, histone H4 mRNA was expressed only during the S phase. These data indicate that PT-alpha-mRNA was present in roughly the same amount through all phases of the cell cycle, arguing against the concept that PT-alpha is a cell cycle-regulated gene.	FAC MED SANTIAGO DE COMPOSTELA,DEPT FISIOL,LAB NEUROCIENCIAS RAMON DOMINGUEZ,SANTIAGO,SPAIN; FAC MED SANTIAGO DE COMPOSTELA,DEPT MICROBIOL,SANTIAGO,SPAIN; FAC MED SANTIAGO DE COMPOSTELA,HOSP XERAL GALICIA,SANTIAGO,SPAIN	Complexo Hospitalario Universitario de Santiago de Compostela			Alvarez, Clara V/AAN-4173-2020; Zalvide, Juan/ABG-4050-2020; Regueiro, Benito/H-4264-2014	Zalvide, Juan/0000-0001-7645-156X; Alvarez, Clara V/0000-0003-1500-4058; Regueiro, Benito/0000-0002-4009-7922				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BUSTELO XR, 1991, J BIOL CHEM, V266, P1443; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTEAS CN, 1990, P NATL ACAD SCI USA, V87, P3269, DOI 10.1073/pnas.87.9.3269; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; FEDER JN, 1989, J BIOL CHEM, V264, P20583; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GOODALL GJ, 1986, P NATL ACAD SCI USA, V83, P8926, DOI 10.1073/pnas.83.23.8926; HARITOS A, 1983, P NATL ACAD SCI USA, V80, P1008; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KROCZEK RA, 1990, ANAL BIOCHEM, V184, P90, DOI 10.1016/0003-2697(90)90017-4; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; LEDER JN, 1990, J CELL BIOL, V111, P2693; MAKAROVA T, 1989, FEBS LETT, V257, P247, DOI 10.1016/0014-5793(89)81544-3; MANROW RE, 1991, J BIOL CHEM, V266, P3916; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; ROSON E, 1990, HISTOCHEMISTRY, V94, P597; ROSON E, 1990, J HISTOCHEM CYTOCHEM, V38, P1889, DOI 10.1177/38.12.2254650; SAMBROOK J, 1989, MOL CLONING LABORTOR; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; Stein Gary S., 1989, P133; SU YL, 1989, ANN NEUROL, V26, P277, DOI 10.1002/ana.410260216; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TSITSILONI OE, 1989, EXPERIENTIA, V45, P332, DOI 10.1007/BF01957467; Vindelov L, 1990, Methods Cell Biol, V33, P127; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WATTS JD, 1990, EUR J BIOCHEM, V192, P643, DOI 10.1111/j.1432-1033.1990.tb19271.x; WATTS JD, 1989, FEBS LETT, V245, P17, DOI 10.1016/0014-5793(89)80182-6	34	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8692	8695						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569109				2022-12-27	WOS:A1992HQ18500109
J	EAKIN, AE; MILLS, AA; HARTH, G; MCKERROW, JH; CRAIK, CS				EAKIN, AE; MILLS, AA; HARTH, G; MCKERROW, JH; CRAIK, CS			THE SEQUENCE, ORGANIZATION, AND EXPRESSION OF THE MAJOR CYSTEINE PROTEASE (CRUZAIN) FROM TRYPANOSOMA-CRUZI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; AMINO-ACID; ESCHERICHIA-COLI; PROTEINASE; EPIMASTIGOTES; CDNA; IDENTIFICATION; PURIFICATION; LOCALIZATION; CLEAVAGE	The complete sequence of the gene encoding the major cysteine protease from Trypanosoma cruzi is reported. The amino acid sequence predicted from the gene sequence aligns well with members of the papain family of cysteine proteases, suggesting the name cruzain. The sequence is most closely related to the cysteine protease of Trypanosoma brucei (59.3%) and the murine cathepsin L (42.2%). At least six copies of the gene are present in the genome and are organized in a tandem array of copies which are identical in all restriction endonuclease sites tested. The gene appears to be expressed in all developmental stages of T. cruzi with mRNA levels approximately 2-fold higher in the intracellular amastigote form. A copy of the T. cruzi gene was expressed in bacteria as an inactive, insoluble fusion polypeptide to approximately 5% of the total cell protein. The fusion protein was readily purified, solubilized in urea, and successfully refolded to produce a polyprotein which processed autocatalytically to yield approximately 1 mg of active protease per 3 g of wet cell paste. The processed form of the recombinant protease has an NH2-terminal sequence identical to that of the mature form of the protease purified from T. cruzi (Murta, A. C. M., Persechini, P. M., Souto-Padron, T., de Souza, W., Guimaraes, J. A., and Scharfstein, J. (1990) Mol. Biochem. Parasitol. 43, 27-38; Cazzulo, J. J., Couso, R., Raimondi, A., Wernstedt, C., and Hellman, U. (1989) Mol. Biochem. Parasitol 33, 33-42). This suggests that the recombinant protease possesses the requisite specificity and activity to correctly process the proform of the protease in vitro. Kinetic assays with peptide substrates demonstrate that the substrate specificity and kinetic parameters for the recombinant protease are consistent with those of the endogenous protease. The proteolytic activity of the recombinant protease is enhanced by dithiothreitol, inhibited by leupeptin, N(alpha)-p-tosyl-L-lysine chloromethyl ketone and trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane (E-64) but is unaffected by phenylmethylsulfonyl fluoride, pepstatin, and 1,10-phenanthroline. More specifically, the recombinant enzyme was inhibited by benzyloxycarbonyl-Phe-Arg-fluoromethyl ketone, which inhibits replication and differentiation of T. cruzi within mammalian cells in culture.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; PALO ALTO MED RES FDN,DEPT IMMUNOL & INFECT DIS,PALO ALTO,CA 94301; STANFORD UNIV,MED CTR,STANFORD,CA 94305	University of California System; University of California San Francisco; Palo Alto Medical Foundation Research Institute; Stanford University	EAKIN, AE (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143, USA.				NIGMS NIH HHS [GM07175] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASLUND L, 1991, MOL BIOCHEM PARASIT, V45, P345, DOI 10.1016/0166-6851(91)90103-D; BONALDO MC, 1991, EXP PARASITOL, V73, P44, DOI 10.1016/0014-4894(91)90006-I; BONTEMPI E, 1989, MOL BIOCHEM PARASIT, V33, P43, DOI 10.1016/0166-6851(89)90040-6; BONTEMPI E, 1984, COMP BIOCHEM PHYS B, V77, P599, DOI 10.1016/0305-0491(84)90282-7; CAMPETELLA O, 1990, FEMS MICROBIOL LETT, V67, P145, DOI 10.1111/j.1574-6968.1990.tb13852.x; CAZZULO JJ, 1990, BIOCHIM BIOPHYS ACTA, V1037, P186, DOI 10.1016/0167-4838(90)90166-D; CAZZULO JJ, 1990, MOL BIOCHEM PARASIT, V38, P41, DOI 10.1016/0166-6851(90)90203-X; CAZZULO JJ, 1989, MOL BIOCHEM PARASIT, V33, P33, DOI 10.1016/0166-6851(89)90039-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN LW, 1986, GENE, V48, P219, DOI 10.1016/0378-1119(86)90080-6; Drenth J, 1971, Adv Protein Chem, V25, P79, DOI 10.1016/S0065-3233(08)60279-X; EAKIN AE, 1990, MOL BIOCHEM PARASIT, V39, P1, DOI 10.1016/0166-6851(90)90002-4; ENGCHILD JJ, 1991, J BIOL CHEM, V266, P747; GAN ZR, 1989, GENE, V79, P159; GARCIAZAPATA MTA, 1991, HUNTERS TROPICAL MED, P628; HARTH G, 1987, P NATL ACAD SCI USA, V84, P8320, DOI 10.1073/pnas.84.23.8320; HELLMAN U, 1991, MOL BIOCHEM PARASIT, V44, P15, DOI 10.1016/0166-6851(91)90216-S; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSTON FAO, 1984, BIO-TECHNOL, V2, P800, DOI 10.1038/nbt0984-800; MCKERROW JH, 1989, EXP PARASITOL, V68, P111, DOI 10.1016/0014-4894(89)90016-7; MENDONCAPREVIATO L, 1983, BIOCHEMISTRY-US, V22, P4980, DOI 10.1021/bi00290a016; MOTTRAM JC, 1989, FEBS LETT, V258, P211, DOI 10.1016/0014-5793(89)81655-2; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; MURTA ACM, 1990, MOL BIOCHEM PARASIT, V43, P27, DOI 10.1016/0166-6851(90)90127-8; NORTH MJ, 1991, PARASITOL TODAY, V7, P249, DOI 10.1016/0169-4758(91)90239-K; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PAMER EG, 1990, NUCLEIC ACIDS RES, V18, P6141, DOI 10.1093/nar/18.20.6141; PAMER EG, 1991, INFECT IMMUN, V59, P1074, DOI 10.1128/IAI.59.3.1074-1078.1991; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; RANGEL HA, 1981, TROPENMED PARASITOL, V32, P87; RANGEL HA, 1981, EXP PARASITOL, V52, P199, DOI 10.1016/0014-4894(81)90075-8; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFFER MA, 1988, PLANT PHYSIOL, V87, P431, DOI 10.1104/pp.87.2.431; SCHARFSTEIN J, 1986, J IMMUNOL, V137, P1336; SIGAL E, 1990, J BIOL CHEM, V265, P5113; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTOPADRON T, 1990, J CELL SCI, V96, P485; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; SUTTON RE, 1988, MOL CELL BIOL, V8, P494, DOI 10.1128/MCB.8.1.494; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERPLOEG LHT, 1986, CELL, V47, P479, DOI 10.1016/0092-8674(86)90608-2; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YUEN SW, 1989, BIOTECHNIQUES, V7, P74	47	259	264	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7411	7420						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559982				2022-12-27	WOS:A1992HN48500033
J	BANDYOPADHYAY, SK; SEN, GC				BANDYOPADHYAY, SK; SEN, GC			ROLE OF PROTEIN-PHOSPHORYLATION IN ACTIVATION OF INTERFERON-STIMULATED GENE FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED NUCLEAR FACTORS; KINASE-C; TRANSCRIPTION INITIATION; RESPONSIVE SEQUENCES; PROMOTER ELEMENT; ALPHA-INTERFERON; GAMMA-INTERFERON; SYNTHETASE GENE; 2-5A SYNTHETASE; DOWN-REGULATION	Possible involvement of protein phosphorylation in interferon (IFN)-mediated activation of IFN-stimulated gene factor 3 (ISGF3) was investigated. For this purpose, in vivo experiments with specific inhibitors of protein kinases and in vitro experiments with protein phosphatases were carried out. In HeLaM cells, 2-aminopurine, an inhibitor of double-stranded RNA-dependent protein kinase, blocked the induction of ISGF3-gamma subunit but not the activation of ISGF3-alpha subunit. A series of experiments using combinations of protein and RNA synthesis inhibitors and 2-aminopurine indicated that the block elicited by 2-aminopurine was at the level of ISGF3-gamma mRNA synthesis. Activation of ISGF3-alpha, although insensitive to 2-aminopurine, was completely blocked by 10 nM staurosporine, an inhibitor of protein kinase C. On the other hand, even 500 nm staurosporine did not block the induction of ISGF3-gamma. Incubation of cytoplasmic or nuclear extracts of IFN-treated HeLaM cells in vitro with alkaline phosphatase completely eliminated their ability to form the ISGF3 complex but not the ISGF1 complex. Treatment with acid phosphatase, on the other hand, changed the electrophoretic mobility of the ISGF3 complex but did not obliterate it. Complementation experiments revealed that ISGF3-alpha was the alkaline phosphatase-sensitive component of the complex. These results suggest that a protein kinase C-mediated phosphorylation step is involved in ISGF3-alpha activation and a 2-aminopurine-sensitive component is involved in ISGF3-gamma mRNA induction.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,9500 EUCLID AVE,NC2105,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022510] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22510] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKAI H, 1989, J BIOL CHEM, V264, P3252; BANDYOPADHYAY SK, 1989, J BIOL CHEM, V264, P14216; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; COHEN B, 1989, NUCLEIC ACIDS RES, V17, P1679, DOI 10.1093/nar/17.4.1679; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERUSALIMSKY JD, 1989, P NATL ACAD SCI USA, V86, P1973, DOI 10.1073/pnas.86.6.1973; FALTYNEK CR, 1989, J BIOL CHEM, V264, P14305; FAN XD, 1988, P NATL ACAD SCI USA, V85, P5122, DOI 10.1073/pnas.85.14.5122; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GRIBAUDO G, 1987, J BIOL CHEM, V262, P11878; HUG H, 1988, MOL CELL BIOL, V8, P3065, DOI 10.1128/MCB.8.8.3065; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; KALVAKOLANU DVR, 1991, J BIOL CHEM, V266, P83; KORBER B, 1987, P NATL ACAD SCI USA, V84, P3380, DOI 10.1073/pnas.84.10.3380; KUSARI J, 1986, MOL CELL BIOL, V6, P2062, DOI 10.1128/MCB.6.6.2062; KUSARI J, 1987, MOL CELL BIOL, V7, P528, DOI 10.1128/MCB.7.1.528; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; RAJ NBK, 1989, J BIOL CHEM, V264, P16658; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SAMANTA H, 1986, J BIOL CHEM, V261, P1849; SEN GC, 1991, HORMONAL CONTROL GEN, P349; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; WATHELET MG, 1987, EUR J BIOCHEM, V169, P313, DOI 10.1111/j.1432-1033.1987.tb13614.x; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	41	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6389	6395						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556141				2022-12-27	WOS:A1992HK31800099
J	HEDBOM, E; ANTONSSON, P; HJERPE, A; AESCHLIMANN, D; PAULSSON, M; ROSAPIMENTEL, E; SOMMARIN, Y; WENDEL, M; OLDBERG, A; HEINEGARD, D				HEDBOM, E; ANTONSSON, P; HJERPE, A; AESCHLIMANN, D; PAULSSON, M; ROSAPIMENTEL, E; SOMMARIN, Y; WENDEL, M; OLDBERG, A; HEINEGARD, D			CARTILAGE MATRIX PROTEINS - AN ACIDIC OLIGOMERIC PROTEIN (COMP) DETECTED ONLY IN CARTILAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PROTEOGLYCANS; PURIFICATION; METHANOLYSIS; BONE	An M(r) = 524,000 oligomeric protein was isolated from bovine cartilage and designated COMP (Cartilage Oligomeric Matrix Protein). The protein is composed of disulfide-bonded subunits with an apparent M(r) of 100,000 each. It is markedly anionic, probably due to its high contents of aspartic acid and glutamic acid, as well as to its substitution with negatively charged carbohydrates. COMP was found in all cartilages analyzed, but could not be detected in other tissues by enzyme-linked immunosorbent assay of guanidine HCl extracts. Within a given cartilage, COMP shows a preferential localization to the territorial matrix surrounding the chondrocytes.	UNIV LUND,DEPT MED & PHYSIOL CHEM,POB 94,S-22100 LUND,SWEDEN; KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT PATHOL,S-14186 HUDDINGE,SWEDEN; UNIV BERN,ME MULLER INST BIOMECH,CH-3010 BERN,SWITZERLAND	Lund University; Karolinska Institutet; University of Bern				Aeschlimann, Daniel/0000-0003-0930-7706				CARLSON DM, 1968, J BIOL CHEM, V243, P616; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; FIFE RS, 1989, J CLIN INVEST, V84, P1432, DOI 10.1172/JCI114317; FIFE RS, 1984, BIOCHIM BIOPHYS ACTA, V802, P506, DOI 10.1016/0304-4165(84)90370-2; FRANZEN A, 1987, DIFFERENTIATION, V36, P199, DOI 10.1111/j.1432-0436.1987.tb00194.x; FRANZEN A, 1984, BIOCHEM J, V224, P47, DOI 10.1042/bj2240047; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HJERPE A, 1982, J CHROMATOGR, V235, P221, DOI 10.1016/S0021-9673(00)95803-5; HJERPE A, 1983, J CHROMATOGR, V259, P334, DOI 10.1016/S0021-9673(01)88014-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON T, 1991, J BIOL CHEM, V266, P20428; MILLER EJ, 1987, METHOD ENZYMOL, V144, P3; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; PAULSSON M, 1979, BIOCHEM J, V183, P539, DOI 10.1042/bj1830539; PAULSSON M, 1981, BIOCHEM J, V197, P367, DOI 10.1042/bj1970367; PAULSSON M, 1983, BIOCHEM J, V212, P659, DOI 10.1042/bj2120659; POOLE AR, 1982, J CELL BIOL, V92, P249, DOI 10.1083/jcb.92.2.249; REYNOLDS JA, 1970, P NATL ACAD SCI USA, V66, P1002, DOI 10.1073/pnas.66.3.1002; SAXNE T, 1992, IN PRESS J RHEUMATOL; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; SOMMARIN Y, 1989, EXP CELL RES, V184, P181, DOI 10.1016/0014-4827(89)90376-5; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	26	435	474	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6132	6136						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556121				2022-12-27	WOS:A1992HK31800063
J	MORGELIN, M; HEINEGARD, D; ENGEL, J; PAULSSON, M				MORGELIN, M; HEINEGARD, D; ENGEL, J; PAULSSON, M			ELECTRON-MICROSCOPY OF NATIVE CARTILAGE OLIGOMERIC MATRIX PROTEIN PURIFIED FROM THE SWARM RAT CHONDROSARCOMA REVEALS A 5-ARMED STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEO-ARTHRITIS; GLYCOPROTEIN; IDENTIFICATION; PROTEOGLYCANS; AGGREGATION; COMPLEMENT; BINDING	Cartilage oligomeric matrix protein was isolated in the native state from the Swarm rat chondrosarcoma. A crucial step was its selective extraction with EDTA-containing buffer. The purified protein was subjected to electron microscopy using rotary shadowing and negative stain. The images allowed the construction of a structural model. The bouquet-like protein consists of five 28-nm-long arms containing a peripheral globular domain, a flexible strand, and a central assembly domain, where the five arms meet in a cylindrical structure.	UNIV LUND,DEPT MED & PHYSIOL CHEM,S-22100 LUND,SWEDEN; UNIV BERN,ME MULLER INST BIOMECH,CH-3010 BERN,SWITZERLAND	Lund University; University of Bern	MORGELIN, M (corresponding author), UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,KLINGELBERSTR 70,CH-4056 BASEL,SWITZERLAND.							CHOI HU, 1971, P NATL ACAD SCI USA, V68, P877, DOI 10.1073/pnas.68.5.877; ENGEL J, 1987, METHOD ENZYMOL, V145, P1; FIFE RS, 1989, J CLIN INVEST, V84, P1432, DOI 10.1172/JCI114317; FIFE RS, 1985, J HISTOCHEM CYTOCHEM, V33, P127, DOI 10.1177/33.2.3881518; FIFE RS, 1984, BIOCHIM BIOPHYS ACTA, V802, P506, DOI 10.1016/0304-4165(84)90370-2; FIFE RS, 1986, ARTHRITIS RHEUM, V29, P1256, DOI 10.1002/art.1780291011; FIFE RS, 1988, ARTHRITIS RHEUM, V31, P553, DOI 10.1002/art.1780310414; FIFE RS, 1991, J LAB CLIN MED, V117, P332; FRANZEN A, 1987, DIFFERENTIATION, V36, P199, DOI 10.1111/j.1432-0436.1987.tb00194.x; GREGORY JD, 1973, BIOCHEM J, V133, P383, DOI 10.1042/bj1330383; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON T, 1991, J BIOL CHEM, V266, P20428; LAWLER J, 1987, SEMIN THROMB HEMOST, V13, P245, DOI 10.1055/s-2007-1003499; LU J, 1990, J IMMUNOL, V144, P2287; PAULSSON M, 1979, BIOCHEM J, V183, P539, DOI 10.1042/bj1830539; PAULSSON M, 1981, BIOCHEM J, V197, P367, DOI 10.1042/bj1970367; PAULSSON M, 1984, COLLAGEN REL RES, V4, P219; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSCHOPP J, 1980, EUR J IMMUNOL, V10, P529, DOI 10.1002/eji.1830100709	25	176	182	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6137	6141						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556122				2022-12-27	WOS:A1992HK31800064
J	DIEMER, V; HOYLE, M; BAGLIONI, C; MILLIS, AJT				DIEMER, V; HOYLE, M; BAGLIONI, C; MILLIS, AJT			EXPRESSION OF PORCINE COMPLEMENT CYTOLYSIS INHIBITOR MESSENGER-RNA IN CULTURED AORTIC SMOOTH-MUSCLE CELLS - CHANGES DURING DIFFERENTIATION INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CAROTID-ARTERY; RETE TESTIS FLUID; IMMUNOHISTOCHEMICAL LOCALIZATION; SULFATED GLYCOPROTEIN-2; MOLECULAR-CLONING; S-PROTEIN; PHENOTYPE; ATHEROSCLEROSIS; GROWTH; MODULATION	Porcine smooth muscle cells (SMC) grown to a high density monolayer culture undergo a morphological transition in which the cells draw away from the substrate and form multicellular nodules. The cells within the nodule resemble SMC in the aortic media and in some atherosclerotic plaques. The process of nodule formation is associated with the enhanced production of a secreted 38-kDa glycoprotein. To characterize the 38-kDa protein and its expression, a cDNA clone (pc38K) was isolated by immunological screening of an expression library. The 1646-base pair cDNA contains a single open reading frame encoding 446 amino acids. This sequence shows 72% homology with the human complement cytolysis inhibitor (CLI), also called serum protein-40,40, and 68% identity with rat sulfated glycoprotein-2. Based on this homology, we refer to the protein encoded by pc38K as CLI. This polypeptide includes a potential signal sequence, seven glycosylation sites and 10 cysteines in two clusters of five each. Southern blot analysis reveals that a single copy gene encoding CLI is present in mammals and chicken. In Northern blot analysis of SMC RNA, pc38K hybridizes to a mRNA of about 1.9 kilobases that is preferentially expressed in nodular SMC. The steady state level of this mRNA increases as the cultures begin to form multilayered regions. High levels of the mRNA persist after the cells are trypsin-dissociated. Culture medium conditioned by nodular SMC also induces an increase of CLI mRNA. Analysis of RNA extracted from porcine tissues show the highest levels of CLI mRNA in brain and liver; lower levels are detected in other tissues, including the aorta. Possible functions for the CLI are discussed.	SUNY ALBANY, DEPT BIOL SCI, CTR CELLULAR DIFFERENTIAT, ALBANY, NY 12222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany					NATIONAL CANCER INSTITUTE [R01CA029895] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040417] Funding Source: NIH RePORTER; NCI NIH HHS [CA29895] Funding Source: Medline; NHLBI NIH HHS [HL40417] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; BRENNAN MJ, 1983, DEV BIOL, V97, P391, DOI 10.1016/0012-1606(83)90095-7; BRENNAN MJ, 1982, J CELL PHYSIOL, V112, P284, DOI 10.1002/jcp.1041120219; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHAMLEYCAMPBELL JH, 1981, ATHEROSCLEROSIS, V40, P347, DOI 10.1016/0021-9150(81)90145-3; CHAMLEYCAMPBELL JH, 1981, J CELL BIOL, V89, P379, DOI 10.1083/jcb.89.2.379; CHENG CY, 1988, BIOCHEMISTRY-US, V27, P4079, DOI 10.1021/bi00411a026; CLOWES AW, 1983, LAB INVEST, V49, P327; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; DILLEY RJ, 1987, ATHEROSCLEROSIS, V63, P99, DOI 10.1016/0021-9150(87)90109-2; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; GIMBRONE MA, 1975, LAB INVEST, V33, P16; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; GUETTIER C, 1989, VIRCHOWS ARCH A, V414, P309, DOI 10.1007/BF00734084; HAFF LA, 1976, BIOCHEMISTRY-US, V15, P4110, DOI 10.1021/bi00663a030; HARTMANN K, 1991, J BIOL CHEM, V266, P9924; HEDIN U, 1987, DIFFERENTIATION, V33, P239, DOI 10.1111/j.1432-0436.1987.tb01563.x; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAY JF, 1975, VIRCHOWS ARCH B, V18, P205; MILLIS AJT, 1986, J CELL PHYSIOL, V127, P366, DOI 10.1002/jcp.1041270304; MILLIS AJT, 1985, J BIOL CHEM, V260, P3754; MILLIS AJT, 1988, J CELL PHYSIOL, V134, P200, DOI 10.1002/jcp.1041340205; Murphy B F, 1989, Int Immunol, V1, P551, DOI 10.1093/intimm/1.5.551; MURPHY BF, 1989, PATHOLOGY, V21, P275, DOI 10.3109/00313028909061073; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; PROTTER AA, 1982, NUCLEIC ACIDS RES, V10, P4935, DOI 10.1093/nar/10.16.4935; ROSS R, 1981, ARTERIOSCLEROSIS, V1, P293, DOI 10.1161/01.ATV.1.5.293; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1971, J CELL BIOL, V50, P159, DOI 10.1083/jcb.50.1.159; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SEIFERT PS, 1989, J CLIN INVEST, V84, P597, DOI 10.1172/JCI114204; SEIFERT PS, 1988, ATHEROSCLEROSIS, V73, P91, DOI 10.1016/0021-9150(88)90030-5; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; STROHMAN RC, 1977, CELL, V10, P265, DOI 10.1016/0092-8674(77)90220-3; THYBERG J, 1983, DIFFERENTIATION, V25, P156; VLAICU R, 1985, ATHEROSCLEROSIS, V57, P163, DOI 10.1016/0021-9150(85)90030-9	44	44	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5257	5264						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544909				2022-12-27	WOS:A1992HH74700042
J	MIYAZONO, K; THYBERG, J; HELDIN, CH				MIYAZONO, K; THYBERG, J; HELDIN, CH			RETENTION OF THE TRANSFORMING GROWTH FACTOR-BETA-1 PRECURSOR IN THE GOLGI-COMPLEX IN A LATENT ENDOGLYCOSIDASE H-SENSITIVE FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT COMPLEX; FACTOR-BETA; HUMAN-PLATELETS; ENDOPLASMIC-RETICULUM; RNA EXPRESSION; MANNOSIDASE-II; MESSENGER-RNA; A-CHAIN; B-CHAIN; PROTEIN	Transforming growth factor-beta-1 (TGF-beta-1) is synthesized as a latent high molecular weight complex in a human erythroleukemia cell line, HEL, treated with phorbol 12-myristate 13-acetate. The complex is comprised of three components: mature TGF-beta-1, the TGF-beta-1 latency-associated peptide (beta-1-LAP), and the latent TGF-beta-1-binding protein (LTBP). LTBP plays an important role in the assembly and secretion of the latent TGF-beta-1 complex; if the TGF-beta-1 precursor fails to bind to LTBP, much of it remains inside the cells and may contain anomalous disulfide bond(s) between beta-1-LAP and the mature TGF-beta-1 molecule (Miyazono, K., Olofsson, A., Colosetti, P., and Heldin, C.-H. (1991) EMBO J. 10, 1091-1101). In the present work, we have investigated the subcellular localization and properties of the TGF-beta-1 precursor retained intracellularly. When the HEL cells were metabolically labeled and chased for up to 72 h, a considerable part of the TGF-beta-1 precursor was still observed intracellularly in an unprocessed form. The secreted form of the TGF-beta-1 precursor was resistant to endoglycosidase H, whereas the intracellular form of the TGF-beta-1 precursor was sensitive to endoglycosidase H, regardless of the presence or absence of swainsonine, an inhibitor of mannosidase II. Indirect immunofluorescence microscopy revealed that the TGF-beta-1 precursor co-localized with mannosidase II, a marker for the Golgi complex, but not with protein disulfide isomerase, a marker for the endoplasmic reticulum. The intracellular TGF-beta-1 precursor was prepared from phorbol 12-myristate 13-acetate-treated HEL cells and tested for TGF-beta-1 bioactivity. Half-maximal inhibition of the DNA synthesis in mink lung epithelial cells, Mv1Lu, was observed at 80 pm of the acid-treated TGF-beta-1 precursor, whereas nontreated material showed minimal growth inhibitory activity. Taken together, these results indicate that the TGF-beta-1 precursor is retained inside the cells in the Golgi complex, mainly in a latent, immature form.	KAROLINSKA INST, DEPT MED CELL BIOL, S-10401 STOCKHOLM 60, SWEDEN	Karolinska Institutet	MIYAZONO, K (corresponding author), LUDWIG INST CANC RES, CTR BIOMED, BOX 595, S-75124 UPPSALA, SWEDEN.							BASCOM CC, 1989, MOL CELL BIOL, V9, P5508, DOI 10.1128/MCB.9.12.5508; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BODMER S, 1989, J IMMUNOL, V143, P3222; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; GATHERER D, 1990, DEVELOPMENT, V110, P445; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HEINE UI, 1991, CELL REGUL, V2, P467, DOI 10.1091/mbc.2.6.467; HUYLEBROECK D, 1990, MOL ENDOCRINOL, V4, P1153, DOI 10.1210/mend-4-8-1153; JAKOWLEW SB, 1991, DEV BIOL, V143, P135, DOI 10.1016/0012-1606(91)90061-7; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOREMEN KW, 1986, J BIOL CHEM, V261, P945; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NOVIKOFF PM, 1983, P NATL ACAD SCI-BIOL, V80, P4364, DOI 10.1073/pnas.80.14.4364; OKADA F, 1989, J BIOCHEM-TOKYO, V106, P304, DOI 10.1093/oxfordjournals.jbchem.a122849; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; PELTON RW, 1990, DEVELOPMENT, V110, P609; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; ROBERTS AB, 1991, CIBA F SYMP, V157, P7; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SHA X, 1989, MOL ENDOCRINOL, V3, P1090, DOI 10.1210/mend-3-7-1090; THYBERG J, 1990, J CELL SCI, V97, P219; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WAKEFIELD L, 1990, J CELL SCI, P139; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965	43	86	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5668	5675						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544940				2022-12-27	WOS:A1992HH74700100
J	CHIANG, PK; BURBELO, PD; BRUGH, SA; GORDON, RK; FUKUDA, K; YAMADA, Y				CHIANG, PK; BURBELO, PD; BRUGH, SA; GORDON, RK; FUKUDA, K; YAMADA, Y			ACTIVATION OF COLLAGEN-IV GENE-EXPRESSION IN F9 TERATOCARCINOMA CELLS BY 3-DEAZAADENOSINE ANALOGS - INDIRECT INHIBITORS OF METHYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLHOMOCYSTEINE HYDROLASE; DNA METHYLATION; DIFFERENTIATION; ALPHA-1(IV); PROMOTER; POTENT	3-Deazaadenosine analogs can function as inhibitors and also as alternative substrates of S-adenosylhomocysteine (AdoHcy) hydrolase. In cells treated with the analogs, AdoHcy invariably accumulates, leading to inhibition of cellular methylation. F9 teratocarcinoma cells, stably transfected with two collagen (IV) promoter-enhancer-CAT constructs and treated with 10-mu-M 3-deazaadenosine, 3-deaza-(+/-)-aristeromycin or 3-deazaneplanocin, showed a strong induction of CAT activities without affecting differentiation. In comparison, the same 3-deaza analogs did not affect the CAT activity in F9 cells transfected with the beta-actin promoter-CAT construct. Furthermore, Northern blot analysis of endogenous mRNA from wild-type F9 cells treated with the 3-deaza nucleosides all showed an induction of the collagen alpha-1(IV) chain mRNA. Thus, the 3-deaza analogs most likely affect DNA methylation because their results are consistent with the previous observation that the integrated collagen alpha-1(IV) promoter-enhancer constructs were activated with 5 azacytidine.	NIDA,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	CHIANG, PK (corresponding author), WALTER REED ARMY MED CTR,APPL BIOCHEM BRANCH,WASHINGTON,DC 20307, USA.		Burbelo, Peter D./B-1027-2009					AAARBAKKE J, 1986, CANCER RES, V46, P5469; Aarbaldce J., 1987, TUMOR CELL DIFFERENT, P231; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BURBELO PD, 1990, J BIOL CHEM, V265, P4839; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHIANG PK, 1981, SCIENCE, V211, P1164, DOI 10.1126/science.7466386; CHIANG PK, 1986, BIOL METHYLATION DRU, P239; CHIANG PK, 1985, METHOD PHARMACOL, V6, P127; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; GLAZER RI, 1986, BIOCHEM BIOPH RES CO, V135, P688, DOI 10.1016/0006-291X(86)90048-3; GREENBERG ML, 1989, J BIOL CHEM, V264, P795; HYMAN BT, 1982, BIOCHIM BIOPHYS ACTA, V713, P375, DOI 10.1016/0005-2760(82)90256-9; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; KILLEN PD, 1988, J BIOL CHEM, V263, P12310; KIM IK, 1983, ARCH BIOCHEM BIOPHYS, V226, P65, DOI 10.1016/0003-9861(83)90271-0; LAKSHMI TM, 1988, INDIAN J EXP BIOL, V26, P922; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MIURA GA, 1984, ANAL BIOCHEM, V141, P161, DOI 10.1016/0003-2697(84)90440-8; MONTGOMERY JA, 1982, J MED CHEM, V25, P626, DOI 10.1021/jm00348a004; RAZIN A, 1988, P NATL ACAD SCI USA, V85, P9003, DOI 10.1073/pnas.85.23.9003; RIGGS AD, 1983, ADV CANCER RES, V40, P1, DOI 10.1016/S0065-230X(08)60678-8; SHATTIL SJ, 1982, BLOOD, V59, P906; SMITH JD, 1990, BIOCHIM BIOPHYS ACTA, V1047, P290, DOI 10.1016/0005-2760(90)90528-6; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TSENG CKH, 1989, J MED CHEM, V32, P1442, DOI 10.1021/jm00127a007; WIESMANN WP, 1985, AM J PHYSIOL, V248, pF43, DOI 10.1152/ajprenal.1985.248.1.F43	29	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4988	4991						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537874				2022-12-27	WOS:A1992HF64200103
J	TORREBLANCO, A; ADACHI, E; ROMANIC, AM; PROCKOP, DJ				TORREBLANCO, A; ADACHI, E; ROMANIC, AM; PROCKOP, DJ			COPOLYMERIZATION OF NORMAL TYPE-I COLLAGEN WITH 3 MUTATED TYPE-I COLLAGENS CONTAINING SUBSTITUTIONS OF CYSTEINE AT DIFFERENT GLYCINE POSITIONS IN THE ALPHA-1(I) CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELICAL DOMAIN; CHICK-EMBRYO TENDONS; OSTEOGENESIS IMPERFECTA; FIBRILS INVITRO; N-PROTEINASE; PROCOLLAGEN; GENE; FORM; PURIFICATION; MUTATIONS	Previous observations with type I collagen from a proband with lethal osteogenesis imperfecta demonstrated that type I collagen containing a substitution of cysteine for glycine alpha-1-748 copolymerized with normal type I collagen (Kadler, K. E., Torre-Blanco, A., Adachi, E., Vogel, B. E., Hojima, Y., and Prockop, D. J. (1991) Biochemistry 30, 5081-5088). Here, three preparations containing normal type I procollagen and type I procollagen with a substitution of cysteine for glycine alpha-1-175, glycine alpha-1-691, or glycine alpha-1-988 were purified from cultured skin fibroblasts from probands with osteogenesis imperfecta. The procollagens were then used as substrates in a system for assaying the self-assembly of type I collagen into fibrils. The cysteine-substituted collagens in all three preparations were incorporated into fibrils. The cysteine alpha-1-175 and cysteine alpha-1-691 collagens were shown to increase the lag time and decrease the propagation rate constant for fibril assembly. All three preparations containing cysteine-substituted collagens formed fibrils with diameters that were two to four times the diameter of fibrils formed under the same conditions by normal type I collagen. Also, the three preparations containing cysteine-substituted collagens had higher solubilities than normal type I collagen. The results, therefore, demonstrated that the three cysteine-substituted collagens copolymerized with normal type I collagen. The effects of the mutated collagens on fibril assembly can be understood in terms of a recently proposed model of fibril growth from symmetrical tips by assuming that the mutated monomers partially inhibit tip growth but not lateral growth of the fibrils. Of special interest was the observation that the Cys alpha-1-175 collagen from a proband with a non-lethal variant of osteogenesis imperfecta had quantitatively less effect on several parameters of fibril assembly at 37-degrees-C than cysteine-substituted collagens from three probands with lethal variants of the disease.			TORREBLANCO, A (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038188] Funding Source: NIH RePORTER; NCRR NIH HHS [1 S10 RR01426] Funding Source: Medline; NIAMS NIH HHS [AR-38188] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BUTLER WT, 1966, J BIOL CHEM, V241, P3882; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; COHN DH, 1986, P NATL ACAD SCI USA, V83, P6045, DOI 10.1073/pnas.83.16.6045; DEVRIES WN, 1986, J BIOL CHEM, V261, P9056; FIEDLERNAGY C, 1982, J BIOL CHEM, V257, P9181; GELMAN RA, 1979, J BIOL CHEM, V254, P180; GRANT ME, 1968, BIOCHEM J, V108, P586; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; KADLER K, 1987, J BIOL CHEM, V262, P15796; KADLER KE, 1990, BIOCHEM J, V268, P339, DOI 10.1042/bj2680339; KADLER KE, 1991, BIOCHEMISTRY-US, V30, P5081, DOI 10.1021/bi00234a035; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; MIYAHARA M, 1982, J BIOL CHEM, V257, P8442; PRETORIUS PJ, 1990, MATRIX COLL REL RES, V10, pA245; PROCKOP DJ, 1990, J BIOL CHEM, V265, P15349; ROMANIC AM, 1991, J BIOL CHEM, V266, P12703; SPIRO RG, 1969, J BIOL CHEM, V244, P602; Steinmann B, 1988, Ann N Y Acad Sci, V543, P47, DOI 10.1111/j.1749-6632.1988.tb55315.x; STEINMANN B, 1984, J BIOL CHEM, V259, P1129; STEINMANN B, 1991, IN PRESS BIOCH J; TORREBLANCO A, 1992, J BIOL CHEM, V267, P2650; VOGEL BE, 1987, J BIOL CHEM, V262, P14737; VOGEL BE, 1988, J BIOL CHEM, V263, P19249; WESTERHAUSEN A, 1990, J BIOL CHEM, V265, P13995; WIRTZ MK, 1990, MATRIX COLL REL RES, V10, pA251; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0	27	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4968	4973						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537873				2022-12-27	WOS:A1992HF64200100
J	WAYS, DK; COOK, PP; WEBSTER, C; PARKER, PJ				WAYS, DK; COOK, PP; WEBSTER, C; PARKER, PJ			EFFECT OF PHORBOL ESTERS ON PROTEIN KINASE-C-ZETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR PROMOTERS; CELLS; DIFFERENTIATION; HETEROGENEITY; CULTURE; BRAIN	Protein kinase C-zeta (PKC-zeta) is a member of the protein kinase C gene family which using in vitro preparations has been described as being resistant to activation by phorbol esters. PKC-zeta was found to be expressed in several cell types as an 80-kDa protein. In vitro translation of a full-length PKC-zeta construct also yielded as a primary translation product an 80-kDa protein. In the U937 cell, PKC-zeta was slightly more abundant in the cytosol than in the particulate fraction. Acute exposure of U937 cells to tetradecanoyl-phorbol-13-acetate (TPA), phorbol dibutyrate, mezerin, or diacylglycerol derivatives did not induce translocation of this isoform to the particulate fraction. Chronic exposure to 1-mu-M TPA failed to translocate or down-regulate PKC-zeta in U937, HL-60, COS, or HeLa-fibroblast fusion cells. To examine whether PKC-zeta was activated by TPA, PKC activity was evaluated in COS cells transiently over-expressing this isoform. In non-transfected cells, two peaks of phospholipid- and TPA-dependent kinase activity were observed. Eluting at a lower salt concentration was a peak of activity associated with PKC-alpha. PKC-zeta eluted with the second peak of activity and at a higher salt concentration. In transfected cells which expressed PKC-zeta at 4-10-fold over endogenous levels, there was only a slight increase in activity associated with the second peak. The activity and quantity of PKC-zeta did not strictly correlate. Treatment with TPA under conditions that did not alter PKC-zeta content abolished detection of the second peak of PKC activity eluting from the Mono Q column. Thus, PKC-zeta does not translocate or down-regulate in response to phorbol esters or diacylglycerol derivatives. However, for reasons discussed these studies do not resolve the issue of whether this isoform is activated by TPA.	E CAROLINA UNIV,SCH MED,DEPT MICROBIOL IMMUNOL,GREENVILLE,NC 27858; IMPERIAL CANC RES FUND,PROT PHOSPHORYLAT LAB,LONDON WC2A 3PX,ENGLAND	University of North Carolina; East Carolina University; Cancer Research UK	WAYS, DK (corresponding author), E CAROLINA UNIV,SCH MED,DEPT MED,GREENVILLE,NC 27858, USA.		Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933	NCI NIH HHS [CA43023] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN R, 1977, NATURE, V266, P538, DOI 10.1038/266538a0; DIAMOND L, 1977, NATURE, V269, P247, DOI 10.1038/269247a0; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; DURONIO V, 1990, J CELL PHYSIOL, V145, P381, DOI 10.1002/jcp.1041450225; HUBERMAN E, 1979, CANCER RES, V39, P2618; ISHII P, 1970, SCIENCE, V200, P530; KILEY S, 1990, J BIOL CHEM, V265, P15704; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Lerner RA, 1981, P NATL ACAD SCI USA, V78, P3404; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MIAO RM, 1978, NATURE, V274, P271, DOI 10.1038/274271a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; ROVERA G, 1977, SCIENCE, V240, P868; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; STANBRIDGE E, 1981, SOMAT CELL GENET, V1, P699; STUART RK, 1980, SCIENCE, V208, P402, DOI 10.1126/science.6245446; TAKETANI Y, 1983, P NATL ACAD SCI-BIOL, V80, P1646, DOI 10.1073/pnas.80.6.1646; WAYS D, 1991, J BIOL CHEM, V266, P1258; WAYS DK, 1987, CANCER RES, V47, P3344; YAMASAKI H, 1977, P NATL ACAD SCI USA, V74, P3451, DOI 10.1073/pnas.74.8.3451	25	319	320	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4799	4805						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537859				2022-12-27	WOS:A1992HF64200078
J	MUNFORD, RS; HUNTER, JP				MUNFORD, RS; HUNTER, JP			ACYLOXYACYL HYDROLASE, A LEUKOCYTE ENZYME THAT DEACYLATES BACTERIAL LIPOPOLYSACCHARIDES, HAS PHOSPHOLIPASE, LYSOPHOSPHOLIPASE, DIACYLGLYCEROLLIPASE, AND ACYLTRANSFERASE ACTIVITIES INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-NEUTROPHILS; FATTY-ACIDS; SUBSTRATE-SPECIFICITY; PURIFICATION; METABOLISM; PROTEINS; CALCIUM; FUSION; LIPASE; CELLS	Human acyloxyacyl hydrolase (AOAH) is a leukocyte enzyme that hydrolyzes acyloxyacyl bonds in the lipid A region of bacterial lipopolysaccharide (LPS), thereby detoxifying the LPS. We report here that the enzyme also acts in vitro on glycerophospholipids, lysophospholipids, and diacylglycerol. While AOAH preferentially removes palmitate or stearate from the sn-1 position of phospholipid and diacylglycerol substrates that have unsaturated acyl chains in the sn-2 position, it is able to cleave both palmitates from sn-1,2-dipalmitoylphosphatidylcholine and sn-1,2-dipalmitoylglycerol. This apparent preference for removing saturated (or shorter) acyl chains from glycerolipids is consistent with its ability to cleave laurate more rapidly than palmitoleate from lipopolysaccharide (Erwin, A. L., and Munford, R. S. (1990) J. Biol. Chem. 265, 16444-16449). AOAH also catalyzes acyl transfer from LPS and phosphatidylethanolamine to acceptor lipids; approximately equal amounts of laurate and myristate are transferred from LPS to monooleoylglyceryl ether, forming acyloleoylglyceryl ether. The demonstration that AOAH has phospholipase, lysophospholipase, diacylglycerol lipase, and acyltransferase activities in vitro suggests that the enzyme may have roles in addition to LPS deacylation (detoxification) in phagocytic cells.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	MUNFORD, RS (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018188, R56AI018188, R37AI018188] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18188] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES GF, 1968, J BACTERIOL, V95, P833, DOI 10.1128/JB.95.3.833-843.1968; BALSINDE J, 1991, J BIOL CHEM, V266, P15638; BALSINDE J, 1988, J BIOL CHEM, V263, P1929; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; ELSBACH P, 1963, AM J PHYSIOL, V205, P1154, DOI 10.1152/ajplegacy.1963.205.6.1154; ERWIN AL, 1990, J BIOL CHEM, V265, P16444; FRANSON R, 1974, J LIPID RES, V15, P380; HAGEN FS, 1991, BIOCHEMISTRY-US, V30, P8415, DOI 10.1021/bi00098a020; HALL CL, 1983, P NATL ACAD SCI-BIOL, V80, P6671, DOI 10.1073/pnas.80.21.6671; HOSTETLER KY, 1986, BIOCHEMISTRY-US, V25, P6456, DOI 10.1021/bi00369a017; KENNERLY DA, 1979, J EXP MED, V150, P1039, DOI 10.1084/jem.150.4.1039; KUCERA GL, 1988, J BIOL CHEM, V263, P1920; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MUNFORD RS, 1990, MICROBIAL DETERMINANTS OF VIRULENCE AND HOST RESPONSE, P271; MUNFORD RS, 1985, INFECT IMMUN, V48, P464, DOI 10.1128/IAI.48.2.464-473.1985; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; MUNFORD RS, 1989, J BIOL CHEM, V264, P15613; MUNFORD RS, 1991, METHOD ENZYMOL, V209, P485; NACCACHE PH, 1984, J LEUKOCYTE BIOL, V36, P333, DOI 10.1002/jlb.36.3.333; PLUCKTHUN A, 1982, BIOCHEMISTRY-US, V21, P1743; RAO RH, 1981, EXP LUNG RES, V2, P9, DOI 10.3109/01902148109052298; SCHULTZ A, 1984, VIROLOGY, V133, P431, DOI 10.1016/0042-6822(84)90409-4; TANAKA T, 1988, J BIOL CHEM, V263, P13670; TRAYNOR JR, 1981, BIOCHIM BIOPHYS ACTA, V665, P571, DOI 10.1016/0005-2760(81)90272-1; VANDENBOSCH H, 1974, BIOCHIM BIOPHYS ACTA, V348, P197, DOI 10.1016/0005-2760(74)90231-8; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; WAITE M, 1985, J LIPID RES, V26, P1379; WAITE M, 1987, HDB LIPID RES, V5; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WRIGHT GW, 1990, J BIOL CHEM, V265, P6675; YAMAGUCHI T, 1986, BIOCHIM BIOPHYS ACTA, V861, P440, DOI 10.1016/0005-2736(86)90452-9	31	49	51	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10116	10121						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577781				2022-12-27	WOS:A1992HT96500100
J	TAKATA, Y; WEBSTER, NJG; OLEFSKY, JM				TAKATA, Y; WEBSTER, NJG; OLEFSKY, JM			INTRACELLULAR SIGNALING BY A MUTANT HUMAN INSULIN-RECEPTOR LACKING THE CARBOXYL-TERMINAL TYROSINE AUTOPHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; V-ROS; KINASE; ACTIVATION; PROTEIN; FIBROBLASTS; MULTIPLE; SERUM; S6	We have recently characterized a mutant insulin receptor (Y/F2) in which the two tyrosines in the carboxyl terminus (Tyr1316, Tyr1322) were mutated to phenylalanine. Compared with wild type receptors, the Y/F2 receptor exhibited markedly enhanced sensitivity to insulin-stimulated DNA synthesis with normal insulin-stimulated glucose uptake (Takata, Y., Webster, N. J. G., and Olefsky, J. M. (1991) J. Biol. Chem. 266, 9135-9139). In this paper, we present further evidence for the divergence of the metabolic and mitogenic signaling pathways utilized by the insulin receptor. The mutant receptor showed normal sensitivity and responsiveness for insulin-stimulated glucose incorporation into glycogen. The insulin sensitivity for phosphorylation of two substrates (pp180 and pp220) was the same in both Y/F2 cells and HIRc cells. Phosphotyrosine content, however, was greater in Y/F2 cells than in HIRc cells, especially in the basal state. Insulin stimulated S6 kinase activity 2-6-fold, with an ED50 of -10 nm in Rat 1 cells and 0.5 nm in HIRc cells. The sensitivity to insulin was enhanced in Y/F2 cells with an ED50 of 0.1 nm. These effects were insulin-specific, since insulin-like growth factor (IGF)-I-stimulated mitogenesis was normal. In summary: 1) Y/F2 receptors exhibit normal metabolic and enhanced mitogenic signaling; 2) the enhanced mitogenic signaling is specific for the insulin receptor in the Y/F2 cells, since IGF-I-stimulated mitogenesis is normal; 3) Y/F2 cells display increased endogenous substrate phosphorylation and augmented insulin-stimulated S6 kinase activity placing these responses among insulin's mitogenic effects; and 4) these results are consistent with the concept that the COOH-terminal tyrosine residues of the insulin receptor are normally inhibitory to mitogenic signaling.	VET ADM MED CTR,MED RES SERV,SAN DIEGO,CA 92161	US Department of Veterans Affairs; Veterans Health Administration (VHA)	TAKATA, Y (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093, USA.		Webster, Nick/AAI-8410-2021		NIDDK NIH HHS [DK 33651, DK 33649] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033649, R37DK033649, R01DK033651, R37DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDO A, 1991, FOLIA ENDOCRINOL JPN, V67, P910; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BOULTON TG, 1990, J BIOL CHEM, V265, P2713; CHIN JE, 1991, J BIOL CHEM, V266, P15587; CZECH MP, 1988, J BIOL CHEM, V263, P11017; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GORDEN HJ, 1987, BIOCHEMISTRY-US, V26, P2374; HEIDENREICH KA, 1989, ENDOCRINOLOGY, V125, P1458, DOI 10.1210/endo-125-3-1458; HOFMANN C, 1989, ENDOCRINOLOGY, V124, P257, DOI 10.1210/endo-124-1-257; KAMPS MP, 1988, ONCOGENE, V2, P305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE WL, 1990, ENDOCRINOLOGY, V127, P2854, DOI 10.1210/endo-127-6-2854; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MASSAGUE J, 1985, METHOD ENZYMOL, V109, P179; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DM, 1986, J BIOL CHEM, V263, P8904; MYERS MG, 1991, J BIOL CHEM, V266, P10616; Ogata K, 1979, Methods Enzymol, V59, P502; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; SAKATA S, 1988, IMMUNOL INVEST, V17, P237, DOI 10.3109/08820138809052963; SOOS MA, 1990, J BIOCHEM-TOKYO, V270, P382; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; THIES RS, 1989, J BIOL CHEM, V264, P12820; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P765	28	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9065	9070						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577744				2022-12-27	WOS:A1992HR85400057
J	WRIGHT, JF; PERNOLLET, M; REBOUL, A; AUDE, C; COLOMB, MG				WRIGHT, JF; PERNOLLET, M; REBOUL, A; AUDE, C; COLOMB, MG			IDENTIFICATION AND PARTIAL CHARACTERIZATION OF A LOW AFFINITY METAL-BINDING SITE IN THE LIGHT CHAIN OF TETANUS TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTOXIN TYPE-A; T-CELL EPITOPES; ESCHERICHIA-COLI; PROTEINS; SEQUENCE; OXIDATION	Tetanus toxin was shown to contain a metal-binding site for zinc and copper. Equilibrium dialysis binding experiments using Zn-65 indicated an association constant of 9-15-mu-M, with one zinc-binding site/toxin molecule. The zinc-binding site was localized to the toxin light chain as determined by binding of Zn-65 to the light chain but not to the heavy chain after separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transfer to Immobilon membranes. Copper was an efficient inhibitor of Zn-65 binding to tetanus toxin and caused two peptide bond cleavages in the toxin light chain in the presence of ascorbate. These metal-catalyzed oxidative cleavages were inhibited by the presence of zinc. Partial characterization of metal-catalyzed oxidative modifications of a peptide based on a putative metal-binding site (HELIH) in the toxin light chain was used to map the metal-binding site in the protein.	CEN, DEPT BIOL MOLEC & STRUCT,INSERM,U238, IMMUNOCHIM LAB,85X, F-38041 GRENOBLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)								AHNERTHILGER G, 1989, FEBS LETT, V242, P245, DOI 10.1016/0014-5793(89)80478-8; BINZ T, 1990, J BIOL CHEM, V265, P9153; CALABRESE L, 1989, J BIOL CHEM, V264, P6183; CORNETTE JL, 1989, METHOD ENZYMOL, V178, P611; DASGUPTA BR, 1984, ARCH BIOCHEM BIOPHYS, V232, P172, DOI 10.1016/0003-9861(84)90532-0; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; FAIRWEATHER NF, 1986, NUCLEIC ACIDS RES, V14, P7809, DOI 10.1093/nar/14.19.7809; FARBER JM, 1986, J BIOL CHEM, V261, P4574; JHON DY, 1991, BIOFACTORS, V3, P121; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KORBASHI P, 1989, J BIOL CHEM, V264, P8479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARX G, 1986, BIOCHEM J, V236, P397, DOI 10.1042/bj2360397; MASELLE SY, 1991, FEMS MICROBIOL IMMUN, V76, P171, DOI 10.1111/j.1574-6968.1991.tb04211.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAZEN A, 1988, ANAL BIOCHEM, V172, P39, DOI 10.1016/0003-2697(88)90408-3; MERRIFIELD RB, 1964, BIOCHEMISTRY-US, V3, P1385, DOI 10.1021/bi00897a032; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; MOCHIDA S, 1989, FEBS LETT, V253, P47, DOI 10.1016/0014-5793(89)80926-3; OZUTSUMI K, 1985, APPL ENVIRON MICROB, V49, P939, DOI 10.1128/AEM.49.4.939-943.1985; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT RA, 1988, BIOCHEMISTRY-US, V27, P5411, DOI 10.1021/bi00415a005; SIGMAN DS, 1990, BIOCHEMISTRY-US, V29, P9097, DOI 10.1021/bi00491a001; SKOTLAND T, 1983, EUR J BIOCHEM, V132, P171, DOI 10.1111/j.1432-1033.1983.tb07343.x; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; STILLE CJ, 1987, MOL IMMUNOL, V24, P1021, DOI 10.1016/0161-5890(87)90068-X; THIELENS NM, 1990, J BIOL CHEM, V265, P14469; UCHIDA K, 1990, ARCH BIOCHEM BIOPHYS, V283, P20, DOI 10.1016/0003-9861(90)90606-Y; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VIJAYARAGHAVAN J, 1990, J BIOL CHEM, V265, P14150; VILLIERS MB, 1991, SCAND J IMMUNOL, V34, P585, DOI 10.1111/j.1365-3083.1991.tb01582.x; YAMASHITA MM, 1990, P NATL ACAD SCI USA, V87, P5648, DOI 10.1073/pnas.87.15.5648	34	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9053	9058						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577743				2022-12-27	WOS:A1992HR85400055
J	ZHENG, J; SCHODEL, F; PETERSON, DL				ZHENG, J; SCHODEL, F; PETERSON, DL			THE STRUCTURE OF HEPADNAVIRAL CORE ANTIGENS - IDENTIFICATION OF FREE THIOLS AND DETERMINATION OF THE DISULFIDE BONDING PATTERN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-B VIRUS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; PROTEIN; ELECTROPHORESIS; PARTICLES; SERUM	A set of wild-type and mutant human, woodchuck, and duck hepatitis viral core proteins have been prepared and used to study the free thiol groups and the disulfide bonding pattern present within the core particle. Human (HBcAg) and woodchuck (WHcAg) core proteins contain 4 cysteine residues, whereas duck (DHcAg) core protein contains a single cysteine residue. Each of the cysteines of HBcAg has been eliminated, either singly or in combinations, by a two-step mutagenesis procedure. All of the proteins were shown to have very similar physical and immunochemical properties. All assemble into essentially identical core particle structures. Therefore disulfide bonds are not essential for core particle formation. No intra-chain disulfide bonds occur. Cys107 is a free thiol buried within the particle structure, whereas Cys48 is present partly as a free sulfhydryl which is exposed at the surface of the particle. Cys61 is always and Cys48 is partly involved in interchain disulfide bonds with the identical residues of another monomer, whereas Cys183 is always involved in a disulfide bond with the Cys183 of a different monomer. WHcAg has the same pattern of bonding, whereas DHcAg lacks any disulfide bonds, and the single free sulfhydryl, Cys153 which is equivalent to Cys107 of HBcAg, is buried.	VIRGINIA COMMONWEALTH UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,RICHMOND,VA 23298; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Virginia Commonwealth University; Max Planck Society					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015955] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15955] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGOS P, 1988, EMBO J, V7, P819, DOI 10.1002/j.1460-2075.1988.tb02880.x; BIRNBAUM F, 1990, J VIROL, V64, P3319, DOI 10.1128/JVI.64.7.3319-3330.1990; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FEITELSON MA, 1982, J VIROL, V43, P687, DOI 10.1128/JVI.43.2.687-696.1982; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GALLINA A, 1989, J VIROL, V63, P4645, DOI 10.1128/JVI.63.11.4645-4652.1989; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GIRONES R, 1989, P NATL ACAD SCI USA, V86, P1846, DOI 10.1073/pnas.86.6.1846; JENKINS WT, 1962, BIOCHEM PREP, V9, P83; KANEKO S, 1989, J CLIN MICROBIOL, V27, P1930, DOI 10.1128/JCM.27.9.1930-1933.1989; LAYNE E, 1957, METHOD ENZYMOL, V3, P4447; MARION PL, 1983, CURR TOP MICROBIOL, V105, P99; MCKAY P, 1981, J MED VIROL, V8, P237; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OU JH, 1986, P NATL ACAD SCI USA, V83, P1578, DOI 10.1073/pnas.83.6.1578; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; PUGH J, 1989, J VIROL, V63, P1371, DOI 10.1128/JVI.63.3.1371-1376.1989; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SCHJEIDE OA, 1969, ANAL BIOCHEM, V27, P473; SUMMERS J, 1981, HEPATOLOGY, V2, P179; TAKAHASHI K, 1983, J IMMUNOL, V130, P2903	24	83	97	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9422	9429						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577770				2022-12-27	WOS:A1992HR85400108
J	POLESKY, AH; DAHLBERG, ME; BENKOVIC, SJ; GRINDLEY, NDF; JOYCE, CM				POLESKY, AH; DAHLBERG, ME; BENKOVIC, SJ; GRINDLEY, NDF; JOYCE, CM			SIDE-CHAINS INVOLVED IN CATALYSIS OF THE POLYMERASE REACTION OF DNA-POLYMERASE-I FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; AMINO-ACID-SEQUENCE; KLENOW FRAGMENT; CRYSTAL-STRUCTURE; KINETIC MECHANISM; REACTION PATHWAY; POLA GENE; BINDING; PROTEIN; COMPLEX	To continue our mutagenesis study of the polymerase active site of the Klenow fragment of DNA polymerase I, we have characterized new mutants with substitutions at Asp705, Glu710, and Glu883, and have investigated further the mutations in residues Arg668, Gln849, and Asp882, which showed strong k(cat) effects in our previous study. To determine which step of the reaction is rate-limiting for each mutant protein, we measured the effect on the reaction rate of an alpha-thio-substituted dNTP. One group of mutants showed a substantial sulfur elemental effect, while a second group, like wild-type Klenow fragment, was unaffected by the phosphorothioate substitution. Consistent with earlier data, these results imply that, between formation of the enzyme-DNA-dNTP ternary complex and completion of phosphodiester bond formation, there are two kinetically distinct steps, only one of which is sensitive to sulfur substitution. The rather complex elemental effect data obtained with the mutant derivatives of Klenow fragment are more consistent with the elemental effect being the result of a steric clash in one of the transition states than with explanations based on electronegativity differences between sulfur and oxygen. The data suggest that the side chain of Asp882 is involved in the proposed steric clash, and that Gln849 and Glu883 participate in the sulfur-sensitive step of the reaction. Based on our results, and comparisons with other phosphoryl transfer enzymes, possible mechanisms for the polymerase reaction are discussed.	YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA; PENN STATE UNIV, DEPT CHEM, University Pk, PA 16802 USA	Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIGMS NIH HHS [GM-13306, GM-28550] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028550] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; ATKINSON MR, 1969, BIOCHEMISTRY-US, V8, P4897, DOI 10.1021/bi00840a037; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1989, NUCLEIC ACIDS MOL BI, V3, P28; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; BRESLOW R, 1968, J AM CHEM SOC, V90, P7376, DOI 10.1021/ja01028a054; BRODY RS, 1981, BIOCHEMISTRY-US, V20, P1245, DOI 10.1021/bi00508a030; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; CARROLL SS, 1990, CHEM REV, V90, P1291, DOI 10.1021/cr00105a011; CHEN JT, 1983, NUCLEIC ACIDS RES, V11, P3737, DOI 10.1093/nar/11.11.3737; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; COTTON FA, 1979, P NATL ACAD SCI USA, V76, P2551, DOI 10.1073/pnas.76.6.2551; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DANGE V, 1990, SCIENCE, V248, P585, DOI 10.1126/science.2185542; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; DORSKY DI, 1990, J VIROL, V64, P1394, DOI 10.1128/JVI.64.3.1394-1397.1990; ECKSTEIN F, 1975, ANGEW CHEM INT EDIT, V14, P160, DOI 10.1002/anie.197501601; ECKSTEIN F, 1968, Febs Letters, V2, P85, DOI 10.1016/0014-5793(68)80108-5; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; ENGLUND PT, 1969, J BIOL CHEM, V244, P3045; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FREEMONT P S, 1986, Proteins Structure Function and Genetics, V1, P66, DOI 10.1002/prot.340010111; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; GIBBS JS, 1988, P NATL ACAD SCI USA, V85, P6672, DOI 10.1073/pnas.85.18.6672; HE JJ, 1991, SCIENCE, V251, P1479, DOI 10.1126/science.1900953; HEATH DF, 1956, J CHEM SOC, P3804, DOI 10.1039/jr9560003804; HEATH DF, 1956, J CHEM SOC, P3796, DOI 10.1039/jr9560003796; HECHT MH, 1983, P NATL ACAD SCI-BIOL, V80, P2676, DOI 10.1073/pnas.80.9.2676; HELLINGA HW, 1987, NATURE, V327, P437, DOI 10.1038/327437a0; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; JENCKS WP, 1987, COLD SPRING HARB SYM, V52, P65, DOI 10.1101/SQB.1987.052.01.010; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; Joyce CM, 1991, CURR OPIN STRUC BIOL, V1, P123, DOI 10.1016/0959-440X(91)90020-T; JOYCE CM, 1985, J MOL BIOL, V186, P283, DOI 10.1016/0022-2836(85)90105-6; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; JOYCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P1830, DOI 10.1073/pnas.80.7.1830; JOYCE CM, 1982, J BIOL CHEM, V257, P1958; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KOMIVES EA, 1991, BIOCHEMISTRY-US, V30, P3011, DOI 10.1021/bi00226a005; KORNBERG A, 1969, SCIENCE, V163, P1410, DOI 10.1126/science.163.3874.1410; Kornberg A., 1980, DNA REPLICATION, P101; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; MCCLURE WR, 1975, J BIOL CHEM, V250, P4073; MCGRATH ME, 1989, BIOCHEMISTRY-US, V28, P9264, DOI 10.1021/bi00450a005; MILDVAN AS, 1979, CRC CR REV BIOCH MOL, V6, P219, DOI 10.3109/10409237909102564; MIZRAHI V, 1985, BIOCHEMISTRY-US, V24, P4010, DOI 10.1021/bi00336a031; MULLEN GP, 1989, J BIOL CHEM, V264, P19637; MULLEN GP, 1990, J BIOL CHEM, V265, P14327; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; PERREAULT JP, 1991, BIOCHEMISTRY-US, V30, P4020, DOI 10.1021/bi00230a029; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; RUSH J, 1990, J BIOL CHEM, V265, P4821; Sambrook J, 1989, MOL CLONING LABORATO; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SLOAN DL, 1975, J BIOL CHEM, V250, P8913; STEYAERT J, 1990, BIOCHEMISTRY-US, V29, P9064, DOI 10.1021/bi00490a025; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; WARWICKER J, 1985, J MOL BIOL, V186, P645, DOI 10.1016/0022-2836(85)90136-6; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816	77	187	196	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8417	8428						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569092				2022-12-27	WOS:A1992HQ18500072
J	SHERMAN, PM; LAWRENCE, DA; YANG, AY; VANDENBERG, ET; PAIELLI, D; OLSON, ST; SHORE, JD; GINSBURG, D				SHERMAN, PM; LAWRENCE, DA; YANG, AY; VANDENBERG, ET; PAIELLI, D; OLSON, ST; SHORE, JD; GINSBURG, D			SATURATION MUTAGENESIS OF THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 REACTIVE CENTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY ANGIONEUROTIC-EDEMA; SITE-DIRECTED MUTAGENESIS; AMINO-ACID SUBSTITUTIONS; ENDOTHELIAL-CELLS; ESCHERICHIA-COLI; ANTITHROMBIN-III; SERINE PROTEASES; C1 INHIBITOR; CLONING; ALPHA-1-ANTITRYPSIN	Plasminogen activator inhibitor-1 (PAI-1) is a specific inhibitor of the serine proteases tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). To systematically investigate the roles of the reactive center P1 and P1' residues in PAI-1 function, saturation mutagenesis was utilized to construct a library of PAI-1 variants. Examination of 177 unique recombinant proteins indicated that a basic residue was required at P1 for significant inhibitory activity toward uPA, whereas all substitutions except proline were tolerated at P1'. P1Lys variants exhibited lower inhibition rate constants and greater sensitivity to P1' substitutions than PArg variants. Alterations at either P1 or P1' generally had a larger effect on the inhibition of tPA. A number of variants that were relatively specific for either uPA or tPA were identified. P1Lys-P1' Ala reacted 40-fold more rapidly with uPA than tPA, whereas P1Lys-P1' Trp showed a 6.5-fold preference for tPA. P1-P1' variants containing additional mutations near the reactive center demonstrated only minor changes in activity, suggesting that specific amino acids in this region do not contribute significantly to PAI-1 function. These findings have important implications for the role of reactive center residues in determining serine protease inhibitor (serpin) function and target specificity.	UNIV MICHIGAN, SCH MED,HOWARD HUGHES MED INST,4520 MSRB I, 1150 W MED DR, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; HENRY FORD HOSP, DIV BIOCHEM RES, DETROIT, MI 48202 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Henry Ford Health System; Henry Ford Hospital				Lawrence, Daniel/0000-0003-3126-1935	NHLBI NIH HHS [R01-HL45930, R01-HL39137] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039137, R01HL045930] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERTY RA, 1979, PHYSICAL CHEM; AULAK KS, 1988, BIOCHEM J, V253, P615, DOI 10.1042/bj2530615; AUSTIN RC, 1991, BLOOD, V77, P2185; BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BAUER BF, 1989, NUCLEIC ACIDS RES, V17, P812, DOI 10.1093/nar/17.2.812; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CASO R, 1991, BRIT J HAEMATOL, V77, P87, DOI 10.1111/j.1365-2141.1991.tb07953.x; CUGNO M, 1990, J CLIN INVEST, V85, P1215, DOI 10.1172/JCI114555; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; DOOLITTLE RF, 1983, SCIENCE, V222, P417, DOI 10.1126/science.6604942; DUGGLEBY RG, 1981, ANAL BIOCHEM, V110, P9, DOI 10.1016/0003-2697(81)90104-4; EADIE JS, 1987, NUCLEIC ACIDS RES, V15, P8333, DOI 10.1093/nar/15.20.8333; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; ERDJUMENT H, 1988, J BIOL CHEM, V263, P5589; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HARLOW E, 1988, ANTIBODIES LABORATOR; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; HOLMES WE, 1987, SCIENCE, V238, P209, DOI 10.1126/science.2958938; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JALLAT S, 1986, PROTEIN ENG, V1, P29, DOI 10.1093/protein/1.1.29; KEIJER J, 1991, J BIOL CHEM, V266, P10700; KONKLE BA, 1988, J CLIN INVEST, V82, P579, DOI 10.1172/JCI113635; KOWALSKI D, 1976, BIOCHEMISTRY-US, V15, P1300, DOI 10.1021/bi00651a021; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEVIN EG, 1987, BLOOD, V70, P1090; LEVY NJ, 1990, P NATL ACAD SCI USA, V87, P265, DOI 10.1073/pnas.87.1.265; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MATHESON N, 1989, BIOCHEM BIOPH RES CO, V159, P271, DOI 10.1016/0006-291X(89)92433-9; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MCCLAIN WH, 1986, NUCLEIC ACIDS RES, V14, P6770, DOI 10.1093/nar/14.16.6770; MELHADO LL, 1982, J AM CHEM SOC, V104, P7299, DOI 10.1021/ja00389a065; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; ODANI S, 1978, J BIOCHEM-TOKYO, V84, P1; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PATSTON PA, 1990, J BIOL CHEM, V265, P10786; REILLY TM, 1990, J BIOL CHEM, V265, P9570; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SAKSELA O, 1985, BIOCHIM BIOPHYS ACTA, V823, P35, DOI 10.1016/0304-419X(85)90014-9; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHUBEITA HE, 1990, J BIOL CHEM, V265, P18379; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEPHENS AW, 1988, J BIOL CHEM, V263, P15849; STRANDBERG L, 1991, J BIOL CHEM, V266, P13852; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; YORK JD, 1991, J BIOL CHEM, V266, P8495	59	87	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7588	7595						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559996				2022-12-27	WOS:A1992HN48500057
J	WHEELER, L; WANG, Y; MATHEWS, CK				WHEELER, L; WANG, Y; MATHEWS, CK			SPECIFIC ASSOCIATIONS OF BACTERIOPHAGE-T4 PROTEINS WITH IMMOBILIZED DEOXYCYTIDYLATE HYDROXYMETHYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DCMP-HYDROXYMETHYLASE; PURIFICATION; COMPLEX; REPLICATION	Is the enzymatic machinery for DNA precursor biosynthesis linked to the DNA replication apparatus? To identify intermolecular associations among deoxyribonucleotide biosynthetic enzymes and to ask whether these enzymes are linked to replication proteins, we analyzed radiolabeled T4 bacteriophage proteins that bind specifically to a column of immobilized T4 deoxycytidylate hydroxymethylase. More than a dozen T4 proteins and a few Escherichia coli proteins are adsorbed specifically by this column. Several of the T4 proteins were identified by two-dimensional gel electrophoresis and radioautography. These include five enzymes involved in DNA precursor biosynthesis, dCMP hydroxymethylase, thymidylate synthase, dihydrofolate reductase, dCTPase-dUTPase, and ribonucleotide reductase large and small subunits, plus several proteins of DNA metabolism and replication. Analysis of extracts of cells infected with phage amber mutants defective in specific proteins suggested a specific association involving thymidylate synthase and the gene 32 single-strand DNA-binding protein.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331	Oregon State University					NIAID NIH HHS [AI-15145] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015145] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN JR, 1983, J BIOL CHEM, V258, P5746; BRUSH GS, 1990, J BACTERIOL, V172, P2935, DOI 10.1128/jb.172.6.2935-2939.1990; Burke R., 1983, BACTERIOPHAGE T4, P321; CHAO J, 1977, J VIROL, V24, P557, DOI 10.1128/JVI.24.2.557-563.1977; CHIU CS, 1982, J BIOL CHEM, V257, P5087; CHIU CS, 1973, J VIROL, V12, P199, DOI 10.1128/JVI.12.1.199-201.1973; COOK KS, 1982, J VIROL, V42, P767, DOI 10.1128/JVI.42.3.767-772.1982; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; JI JP, 1991, MOL GEN GENET, V226, P257, DOI 10.1007/BF00273611; KRAUSS SW, 1973, J VIROL, V11, P783, DOI 10.1128/JVI.11.5.783-791.1973; KUTTER EM, 1991, IN PRESS GENETICS; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMM N, 1988, EUR J BIOCHEM, V172, P553, DOI 10.1111/j.1432-1033.1988.tb13925.x; MANOIL C, 1977, J BIOL CHEM, V252, P2734; MATHEWS CK, 1988, TRENDS BIOCHEM SCI, V13, P394, DOI 10.1016/0968-0004(88)90182-X; MATHEWS CK, 1982, P NATL ACAD SCI-BIOL, V79, P302, DOI 10.1073/pnas.79.2.302; MILLER ES, 1985, J BIOL CHEM, V260, P3053; Moen L K, 1988, J Mol Recognit, V1, P48, DOI 10.1002/jmr.300010109; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PUROHIT S, 1984, J BIOL CHEM, V259, P6261; THYLEN C, 1989, J BIOL CHEM, V264, P15169; WANG Y, 1989, J VIROL, V11, P4736; WILLIAMS WE, 1977, GENETICS, V86, P501	23	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7664	7670						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560001				2022-12-27	WOS:A1992HN48500066
J	CHEN, ZP; CHEN, KY				CHEN, ZP; CHEN, KY			MECHANISM OF REGULATION OF ORNITHINE DECARBOXYLASE GENE-EXPRESSION BY ASPARAGINE IN A VARIANT MOUSE NEUROBLASTOMA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOMA-CELLS; MESSENGER-RNA; TRANSLATIONAL REGULATION; PROTO-ONCOGENE; INDUCTION; TRANSCRIPTION; DEGRADATION; FIBROBLASTS; POLYAMINES; ENZYME	We have developed a clonal variant, named DF-40, from the N2a mouse neuroblastoma cell line, which has the ornithine decarboxylase (L-ornithine carboxylyase, EC 4.1.1.17, ODC) gene amplified. When DF-40 cells were maintained in a simple salt glucose medium (e.g. Earle's balanced salt solution), L-asparagine alone was sufficient to induce a maximal increase in ODC activity. The increase in ODC activity correlated well with an increase in the amount of ODC protein. Northern blot analysis indicated that asparagine caused a 12-15-fold increase in ODC mRNA. The half-life of ODC mRNA induced by asparagine in DF-40 cells changed from more than 8 h to about 25 min upon removal of asparagine from the culture in the presence of actinomycin D. In contrast, asparagine had little or no effect on the rate of transcription of the ODC gene. Pulse labeling of cells for 15 min with [S-35]methionine showed a 90-140-fold increase in the synthesis of ODC protein after 4-8 h of incubation with asparagine. The removal of asparagine from the medium resulted in a rapid loss of ODC protein with a half-life as short as 12 min. The presence of asparagine increased the half-life of ODC protein by 3-5-fold when measured in the presence of cycloheximide. Taken together, our data show that asparagine induced ODC gene expression in DF-40 cells, primarily by post-transcriptional stabilization of ODC mRNA. In addition, asparagine specifically stimulated the synthesis and suppressed the degradation of ODC protein.	RUTGERS STATE UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08903	Rutgers State University New Brunswick				Chen, Kuang Yu/0000-0002-5629-7785	NCI NIH HHS [CA-49695] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049695] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; CHANG ZF, 1988, J BIOL CHEM, V263, P11431; CHEN KY, 1977, P NATL ACAD SCI USA, V74, P3791, DOI 10.1073/pnas.74.9.3791; CHEN KY, 1982, J CELL PHYSIOL, V110, P285, DOI 10.1002/jcp.1041100311; CHEN KY, 1980, FEBS LETT, V119, P307, DOI 10.1016/0014-5793(80)80278-X; CHEN KY, 1983, BIOCHIM BIOPHYS ACTA, V755, P244; CHEN KY, 1989, J CELL BIOL, V107, pA445; CHEN ZP, 1991, BIOCHIM BIOPHYS ACTA, V1133, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON DF, 1983, MOL CELL BIOL, V3, P1552, DOI 10.1128/MCB.3.9.1552; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; ERWIN BG, 1983, BIOCHEMISTRY-US, V22, P3027, DOI 10.1021/bi00281a037; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; GIBBS JB, 1980, P NATL ACAD SCI-BIOL, V77, P995, DOI 10.1073/pnas.77.2.995; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Hayashi S., 1989, ORNITHINE DECARBOXYL, P35; HOLTTA E, 1986, J BIOL CHEM, V261, P9502; HOVIS JG, 1986, J BIOL CHEM, V261, P380; HUDSON RL, 1988, P NATL ACAD SCI USA, V85, P279, DOI 10.1073/pnas.85.1.279; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KAHANA C, 1985, J BIOL CHEM, V260, P5390; KAMEJI T, 1982, BIOCHIM BIOPHYS ACTA, V717, P111, DOI 10.1016/0304-4165(82)90387-7; KANAMOTO R, 1987, J BIOL CHEM, V262, P14801; KONTULA KK, 1984, P NATL ACAD SCI-BIOL, V81, P731, DOI 10.1073/pnas.81.3.731; LAW CL, 1987, BIOCHEM INT, V14, P667; MCCONLOGUE L, 1983, J BIOL CHEM, V258, P2083; Pegg  A., 1981, POLYAMINES BIOL MED, P3; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1989, ORNITHINE DECARBOXYL, P21; PERSSON L, 1984, BIOCHEMISTRY-US, V23, P3777, DOI 10.1021/bi00311a033; PERSSON L, 1985, BIOCHEM BIOPH RES CO, V131, P239, DOI 10.1016/0006-291X(85)91794-2; POULIN R, 1990, J BIOL CHEM, V265, P4025; RINEHART CA, 1985, P NATL ACAD SCI USA, V82, P4365, DOI 10.1073/pnas.82.13.4365; ROSS E, 1973, ANAL BIOCHEM, V54, P394; SERTICH GJ, 1987, BIOCHEM BIOPH RES CO, V143, P424, DOI 10.1016/0006-291X(87)91371-4; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; VICEPSMADORE D, 1982, BIOCHIM BIOPHYS ACTA, V717, P305, DOI 10.1016/0304-4165(82)90184-2	41	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6946	6951						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551904				2022-12-27	WOS:A1992HM05300076
J	BALDARI, CT; MACCHIA, G; TELFORD, JL				BALDARI, CT; MACCHIA, G; TELFORD, JL			INTERLEUKIN-2 PROMOTER ACTIVATION IN T-CELLS EXPRESSING ACTIVATED HA-RAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN KINASE-C; SIGNAL TRANSDUCTION; PHORBOL ESTER; PC12 CELLS; STIMULATION; INDUCTION; ONCOGENE; COMPLEX; GENES	Antigen triggering of the T-cell receptor results in an accumulation of activated GTP-bound p21(ras) protein. To assess the role of ras protein in T-cell activation we have cotransfected the murine thymoma line EL4 with a construct capable of expressing a constitutively active, oncogenic form of Ha-ras and a reporter construct containing the human interleukin-2 promoter fused upstream of the bacterial gene for chloramphenicol acetyltransferase. We show that the ras oncoprotein contributes to interleukin-2 promoter activation. Its pattern of synergism with a calcium ionophore or the lymphokine interleukin-1 indicates that it replaces a signal mediated by protein kinase C. Interleukin-2 promoter activity in the presence of ras oncoprotein was inhibited by H7, a potent inhibitor of protein kinase C, but not by HA1004, an inhibitor of cyclic nucleotide-dependent kinase, suggesting that protein kinase C mediates the ras effect. In addition, we show that in these cells, expression of activated ras results in activation of a synthetic promoter containing several copies of an NF-kappa-B binding site.	SCLAVO RES CTR,VIA FIORENTINA 1,I-53100 SIENNA,ITALY; UNIV SIENA,DEPT EVOLUT BIOL,I-53100 SIENNA,ITALY	University of Siena			Telford, John Laird/ABG-8144-2020	Baldari, Cosima/0000-0002-4414-6744				ABRAHAM RT, 1987, J BIOL CHEM, V262, P2719; BALDARI CT, 1991, J BIOL CHEM, V266, P19103; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERRY N, 1990, P NATL ACAD SCI USA, V87, P2294, DOI 10.1073/pnas.87.6.2294; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ESPEL E, 1990, EMBO J, V9, P929, DOI 10.1002/j.1460-2075.1990.tb08191.x; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HALIOTIS T, 1990, INT J CANCER, V45, P1177, DOI 10.1002/ijc.2910450631; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; MACCHIA G, 1990, MOL CELL BIOL, V10, P2731, DOI 10.1128/MCB.10.6.2731; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SATOH T, 1988, FEBS LETT, V236, P185, DOI 10.1016/0014-5793(88)80311-9; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0	25	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4289	4291						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537820				2022-12-27	WOS:A1992HF64200004
J	PHIZICKY, EM; CONSAUL, SA; NEHRKE, KW; ABELSON, J				PHIZICKY, EM; CONSAUL, SA; NEHRKE, KW; ABELSON, J			YEAST TRANSFER-RNA LIGASE MUTANTS ARE NONVIABLE AND ACCUMULATE TRANSFER-RNA SPLICING INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE GENE; PRECURSOR TRANSFER-RNAS; CLONED DNA FRAGMENTS; WHEAT-GERM; SUBSTRATE RECOGNITION; INTERVENING SEQUENCES; TERTIARY STRUCTURES; ENDONUCLEASE; PURIFICATION; TRANSCRIPTION	We show here that yeast tRNA ligase protein is essential in the cell and participates in joining together tRNA half-molecules resulting from excision of the intron by the splicing endonuclease. A haploid yeast strain carrying a chromosomal deletion of the ligase gene is viable only if ligase protein can be supplied from a plasmid copy of the gene. When synthesis of the plasmid-borne ligase gene is repressed, cells eventually die and accumulate endonuclease cut but unligated half-molecules and intervening sequences. Half-molecules that accumulate appear to be fully end-processed. Two temperature-sensitive ligase mutant strains have been isolated; these strains accumulate a similar set of unligated half-molecules at the nonpermissive temperature.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology	PHIZICKY, EM (corresponding author), UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA.			Nehrke, Keith/0000-0001-9697-726X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038775] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38775] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APOSTOL BL, 1991, J BIOL CHEM, V266, P7445; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BUDD M, 1987, P NATL ACAD SCI USA, V84, P2838, DOI 10.1073/pnas.84.9.2838; BUSBY S, 1982, J MOL BIOL, V154, P197, DOI 10.1016/0022-2836(82)90060-2; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; CULBERTSON MR, 1989, YEAST, V5, P405, DOI 10.1002/yea.320050602; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; GANDINIATTARDI D, 1985, EMBO J, V4, P3289; GREER CL, 1986, MOL CELL BIOL, V6, P635, DOI 10.1128/MCB.6.2.635; GREER CL, 1987, MOL CELL BIOL, V7, P76, DOI 10.1128/MCB.7.1.76; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HO CK, 1990, EMBO J, V9, P1245, DOI 10.1002/j.1460-2075.1990.tb08232.x; HOPPER AK, 1978, CELL, V14, P211, DOI 10.1016/0092-8674(78)90108-3; HURT DJ, 1987, MOL CELL BIOL, V7, P1208, DOI 10.1128/MCB.7.3.1208; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; KONARSKA M, 1981, NATURE, V293, P112, DOI 10.1038/293112a0; LASKI FA, 1983, J BIOL CHEM, V258, P1974; LEE MC, 1985, J BIOL CHEM, V260, P3108; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; MCCRAITH SM, 1990, MOL CELL BIOL, V10, P1049, DOI 10.1128/MCB.10.3.1049; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; NISHIKURA K, 1981, J MOL BIOL, V145, P405, DOI 10.1016/0022-2836(81)90212-6; OCONNOR JP, 1991, MOL CELL BIOL, V11, P425, DOI 10.1128/MCB.11.1.425; OCONNOR JP, 1990, THESIS U PITTSBURGH; OGDEN RC, 1984, NUCLEIC ACIDS RES, V12, P9367, DOI 10.1093/nar/12.24.9367; OGDEN RC, 1979, CELL, V17, P399, DOI 10.1016/0092-8674(79)90166-1; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; PICK L, 1986, J BIOL CHEM, V261, P6684; PICK L, 1986, J BIOL CHEM, V261, P6694; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; STANGE N, 1988, EMBO J, V7, P3823, DOI 10.1002/j.1460-2075.1988.tb03267.x; STUCKA R, 1988, NUCLEIC ACIDS RES, V16, P3583, DOI 10.1093/nar/16.8.3583; SWERDLOW H, 1984, J BIOL CHEM, V259, P5197; SZEKELY E, 1988, J BIOL CHEM, V263, P13839; TANNER NK, 1988, BIOCHEMISTRY-US, V27, P8852, DOI 10.1021/bi00424a025; TRAGLIA HM, 1989, MOL CELL BIOL, V9, P2989, DOI 10.1128/MCB.9.7.2989; TYC K, 1983, EMBO J, V2, P605, DOI 10.1002/j.1460-2075.1983.tb01470.x; VANTOL H, 1988, NUCLEIC ACIDS RES, V16, P1951, DOI 10.1093/nar/16.5.1951; VANZYL WH, 1989, GENETICS, V123, P55; WANG SS, 1988, MOL CELL BIOL, V8, P5140, DOI 10.1128/MCB.8.12.5140; WESTAWAY SK, 1988, J BIOL CHEM, V263, P3171; WINEY M, 1988, GENETICS, V118, P609; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004; ZILLMANN M, 1991, MOL CELL BIOL, V11, P5410, DOI 10.1128/MCB.11.11.5410	49	63	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4577	4582						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537841				2022-12-27	WOS:A1992HF64200047
J	SCHILLINGBARTETZKO, S; FRANCESCHI, F; STERNBACH, H; NIERHAUS, KH				SCHILLINGBARTETZKO, S; FRANCESCHI, F; STERNBACH, H; NIERHAUS, KH			APPARENT ASSOCIATION CONSTANTS OF TRANSFER-RNAS FOR THE RIBOSOMAL A-SITE, P-SITE, AND E-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; CODON-ANTICODON INTERACTION; ALLOSTERIC 3-SITE MODEL; ELONGATION CYCLE; BINDING-SITES; MESSENGER-RNA; PROTEIN-BIOSYNTHESIS; SCATCHARD PLOTS; TRANSLOCATION; SUBUNITS	Association constants for tRNA binding to poly(U) programmed ribosomes were assessed under standardized conditions with a single preparation of ribosomes, tRNAs, and elongation factors, respectively, at 15 and 10 mM Mg2+. Association constants were determined by Scatchard plot analysis (the constants are given in units of [10(7)/M] measured at 15 mM Mg2+): the ternary complex Phe-tRNA.elongation factor EF-Tu.GTP (12 +/- 3), Phe-tRNA (1 +/- 0.4), AcPhe-tRNA (0.7 +/- 0.3), and deacylated tRNA(Phe) (0.4 +/- 0.15) bind with decreasing affinity to the A site of poly(U)-programmed ribosomes. tRNA(Phe) (7.2 +/- 0.8) binds to the P site with higher affinity than AcPhe-tRNA (3.7 +/- 1.3). The affinity of the E site for deacylated tRNA(Phe) (1 +/- 0.2) is about the same as that of the A site for AcPhe-tRNA (0.7 +/- 0.3). At lower Mg2+ concentrations the affinity of the E site ligand becomes stronger relative to the affinities of the A site ligands. Phe-tRNA and ternary complexes can occupy the A site at 0-degrees-C in the presence of poly(U) even if the P site is free, whereas, as already known, deacylated tRNA or AcPhe-tRNA bind first to the P site of programmed ribosomes. Hill plot analyses of the binding data confirm an allosteric linkage between A and E sites in the sense of a negative cooperativity.	MAX PLANCK INST MOLEC GENET, WITTMAN ABT, IHNESTR 73, W-1000 BERLIN 33, GERMANY; MAX PLANCK INST EXPTL MED, CHEM ABT, W-3400 GOTTINGEN, GERMANY	Max Planck Society; Max Planck Society			Franceschi, Francois/AAF-5860-2021					ADAM G, 1977, PHYSILKALISCHE CHEM, P399; BAGHURST PA, 1978, J THEOR BIOL, V74, P523, DOI 10.1016/0022-5193(78)90239-4; BARTETZKO A, 1988, METHOD ENZYMOL, V164, P650; BERGEMANN K, 1983, J BIOL CHEM, V258, P5105; CHANGEUX JP, 1968, BIOCHEMISTRY-US, V7, P553, DOI 10.1021/bi00842a601; DIX DB, 1986, J BIOL CHEM, V261, P112; FERSHT A, 1977, ENZYME STRUCTURE MEC, P217; GEIGENMULLER U, 1986, EUR J BIOCHEM, V161, P715, DOI 10.1111/j.1432-1033.1986.tb10498.x; GNIRKE A, 1989, J BIOL CHEM, V264, P7291; HOLSCHUH K, 1981, NATURE, V293, P675, DOI 10.1038/293675a0; KANG C, 1985, J MOL BIOL, V181, P241, DOI 10.1016/0022-2836(85)90088-9; KIRILLOV SV, 1980, FEBS LETT, V120, P221, DOI 10.1016/0014-5793(80)80302-4; KIRILLOV SV, 1986, J BIOMOL STRUCT DYN, V4, P263, DOI 10.1080/07391102.1986.10506345; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; LEBERMAN R, 1980, ANAL BIOCHEM, V104, P29, DOI 10.1016/0003-2697(80)90272-9; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; LILL R, 1987, J MOL BIOL, V196, P137, DOI 10.1016/0022-2836(87)90516-X; LILL R, 1984, BIOCHEMISTRY-US, V23, P6710, DOI 10.1021/bi00321a066; LUSK JE, 1968, J BIOL CHEM, V243, P2618; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; NIERHAUS KH, 1980, BIOL IMPLICATIONS PR, P121; PETERS M, 1979, J MOL BIOL, V134, P471, DOI 10.1016/0022-2836(79)90364-4; REMME J, 1989, EUR J BIOCHEM, V183, P281, DOI 10.1111/j.1432-1033.1989.tb14925.x; RHEINBERGER HJ, 1987, J BIOMOL STRUCT DYN, V5, P435, DOI 10.1080/07391102.1987.10506403; RHEINBERGER HJ, 1988, METHOD ENZYMOL, V164, P658; RHEINBERGER HJ, 1986, J BIOL CHEM, V261, P9133; RHEINBERGER HJ, 1983, P NATL ACAD SCI-BIOL, V80, P4213, DOI 10.1073/pnas.80.14.4213; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; RHEINBERGER HJ, 1983, EUR J BIOCHEM, V134, P421, DOI 10.1111/j.1432-1033.1983.tb07584.x; RICHEY B, 1987, J BIOL CHEM, V262, P7157; RODRIGUEZ A, 1980, J BIOL CHEM, V255, P8116; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4703; SCHMITT M, 1982, EUR J BIOCHEM, V127, P525; WATANABE S, 1973, BIOCHIM BIOPHYS ACTA, V319, P383, DOI 10.1016/0005-2787(73)90178-0; WELLS BD, 1980, NUCLEIC ACIDS RES, V8, P3229, DOI 10.1093/nar/8.14.3229; WINTERMEYER W, 1985, MECHANISMS PROTEIN S, P76; WURMBACH P, 1979, P NATL ACAD SCI USA, V76, P2143, DOI 10.1073/pnas.76.5.2143; ZIERLER K, 1989, TRENDS BIOCHEM SCI, V14, P314, DOI 10.1016/0968-0004(89)90157-6	41	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4693	4702						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537852				2022-12-27	WOS:A1992HF64200064
J	PERSAT, F; BOUHOURS, JF; MOJON, M; PETAVY, AF				PERSAT, F; BOUHOURS, JF; MOJON, M; PETAVY, AF			GLYCOSPHINGOLIPIDS WITH GAL-BETA-1-6GAL SEQUENCES IN METACESTODES OF THE PARASITE ECHINOCOCCUS-MULTILOCULARIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTAL-CHANGES; TRYPANOSOMA-CRUZI; RAT STOMACH; GLYCOLIPIDS; ANTIGENS; IDENTIFICATION; GANGLIOSIDES; BIOSYNTHESIS; INFECTION; GENETICS	Neutral glycosphingolipids of the metacestodes of Echinococcus multilocularis, an animal and human parasite, were resolved by high performance thin layer chromatography into 12 fractions. Nine of these fractions were permethylated, analyzed by electron impact-mass spectrometry, and submitted to methylation analysis by gas chromatography-mass spectrometry. Native fractions were analyzed by liquid secondary ion-mass spectrometry and degraded sequentially by exoglycosidases. In addition to a previously described galactosylceramide, a di-, a tri-, and a tetragalactosylceramide having Gal-beta-1-6Gal internal linkages were characterized. This type of carbohydrate chain has been described in glycolipids of a marine mollusk, Turbo cornutus (Matsubara, T., and Hayashi, A. (1981) J. Biochem. (Tokyo), 89,645-650). In addition two novel fucolipids were found with the following structures: Fuc-alpha-1-3Gal-beta-1-6Gal-Cer and Gal-beta-1-6(Fuc-alpha-1-3)Gal-beta-1-6Gal-Cer. Ceramides contained sphinganine and either nonhydroxy fatty acids with 16, 18, 26, and 28 carbon atoms, or hydroxy fatty acids, with 16 and 18 carbon atoms. Di-, tri-, and tetragalactosylceramides containing the Gal-beta-1-6Gal disaccharide were found to be immunogenic in humans.	INSERM,U76,F-75005 PARIS,FRANCE; GOTHENBURG UNIV,DEPT MED BIOCHEM,S-41124 GOTHENBURG,SWEDEN	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Gothenburg	PERSAT, F (corresponding author), UNIV CLAUDE BERNARD,DEPT PARASITOL & PATHOL EXOT,8 AVE ROCKEFELLER,F-69373 LYONS 08,FRANCE.		Persat, Florence/AAW-5561-2021	Persat, Florence/0000-0002-3421-8177				Aspinall G. O., 1970, POLYSACCHARIDES; AVILA JL, 1990, AM J TROP MED HYG, V43, P52, DOI 10.4269/ajtmh.1990.43.52; BARRETOBERGTER E, 1985, COMP BIOCHEM PHYS B, V80, P543, DOI 10.1016/0305-0491(85)90287-1; BARRETT J, 1983, BIOL EUCESTODA, V2, P392; BOUHOURS D, 1985, J BIOL CHEM, V260, P2172; BOUHOURS JF, 1987, J BIOL CHEM, V262, P16370; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DISSOUS C, 1986, NATURE, V323, P443, DOI 10.1038/323443a0; FERGUSON MAJ, 1988, PARASITE IMMUNOL, V10, P465, DOI 10.1111/j.1365-3024.1988.tb00236.x; GLAUDEMANS CPJ, 1987, MOL IMMUNOL, V24, P371, DOI 10.1016/0161-5890(87)90179-9; HAKOMORI SE, 1974, METHOD ENZYMOL, V23, P345; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HOUNSELL EF, 1987, CHEM SOC REV, V16, P161, DOI 10.1039/cs9871600161; KARLSSON KA, 1982, BIOL MEMBR, V4, P1; KARLSSON KA, 1974, J BIOL CHEM, V249, P4819; KISHIMOTO Y, 1986, CHEM PHYS LIPIDS, V42, P117, DOI 10.1016/0009-3084(86)90047-2; KROEZE WK, 1987, INT J PARASITOL, V17, P873, DOI 10.1016/0020-7519(87)90003-8; Kundu S K, 1981, Methods Enzymol, V72, P185, DOI 10.1016/S0076-6879(81)72012-3; KUNZ J, 1991, PARASITOL RES, V77, P443, DOI 10.1007/BF00931642; MARCUS DM, 1976, ADV IMMUNOL, V23, P203, DOI 10.1016/S0065-2776(08)60321-1; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; MATSUBARA T, 1981, J BIOCHEM-TOKYO, V89, P645, DOI 10.1093/oxfordjournals.jbchem.a133241; MERILL AH, 1986, J BIOL CHEM, V261, P3764; NAOI M, 1974, ANAL BIOCHEM, V58, P571, DOI 10.1016/0003-2697(74)90226-7; NISHIMURA K, 1991, GLYCOCONJUGATE J, V8, P242; PERSAT F, 1988, COMP BIOCHEM PHYS B, V91, P133, DOI 10.1016/0305-0491(88)90124-1; PERSAT F, 1990, MOL BIOCHEM PARASIT, V38, P97, DOI 10.1016/0166-6851(90)90209-5; PERSAT F, 1990, MOL BIOCHEM PARASIT, V41, P1, DOI 10.1016/0166-6851(90)90090-9; PERSAT F, 1991, PARASITE IMMUNOL, V13, P379, DOI 10.1111/j.1365-3024.1991.tb00291.x; PETRY K, 1988, MOL BIOCHEM PARASIT, V30, P113, DOI 10.1016/0166-6851(88)90104-1; PILLER F, 1984, J BIOL CHEM, V259, P3385; POTTER M, 1972, METHOD ENZYMOL, V28, P388; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RADIN NS, 1984, J LIPID RES, V25, P1536; SAITO T, 1971, J LIPID RES, V12, P257; SIDDIQUI B, 1971, J BIOL CHEM, V246, P5766; SINGH BN, 1987, J CELL BIOCHEM, V11, P493; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; UENO K, 1978, J LIPID RES, V19, P863; VIEIRA RP, 1988, J BIOL CHEM, V263, P18176; Watkins W M, 1980, Adv Hum Genet, V10, P1; WEISS JB, 1986, J IMMUNOL, V136, P4275; 1977, LIPIDS, V12, P455	43	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8764	8769						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577719				2022-12-27	WOS:A1992HR85400012
J	CONAWAY, RC; BRADSHER, JN; CONAWAY, JW				CONAWAY, RC; BRADSHER, JN; CONAWAY, JW			MECHANISM OF ASSEMBLY OF THE RNA POLYMERASE-II PREINITIATION COMPLEX - EVIDENCE FOR A FUNCTIONAL INTERACTION BETWEEN THE CARBOXYL-TERMINAL DOMAIN OF THE LARGEST SUBUNIT OF RNA POLYMERASE-II AND A HIGH MOLECULAR MASS FORM OF THE TATA FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED TRANSCRIPTION FACTORS; MAJOR LATE PROMOTER; MONOCLONAL-ANTIBODY; INITIAL COMPLEX; PURIFICATION; LIVER; INVITRO; REPEAT; ADENOVIRUS-2; INVIVO	Genetic evidence argues that the highly conserved carboxyl-terminal domain (CTD) of the largest subunit of RNA polymerase II functions directly in the regulation of transcription of many eukaryotic genes. The observation that partial deletion of the CTD of yeast RNA polymerase II reduces the ability of the enzyme to respond to signals from a variety of upstream activating sequences led to the proposal that the CTD plays a role in the dialogue between regulatory factors that bind upstream activating sequences and the "general" or "basal" transcription factors associated with RNA polymerase II at the promoter (Scafe, C., Chao, D., Lopes, J., Hirsch, J. P., Henry, S., and Young, R. A. (1990) Nature 347, 491-494). Biochemical evidence for an interaction of the CTD with specific components of the basal transcription apparatus, however, has been lacking. To identify target(s) for CTD action, we probed steps in assembly of the RNA polymerase II preinitiation complex with monoclonal antibodies specific for the CTD. Our findings reveal a novel interaction of the CTD with a high molecular mass form of the TATA factor. This interaction occurs during binding of RNA polymerase II to its promoter and requires the action of additional basal transcription factors; it is not observed when the single-subunit yeast transcription factor IID serves as the TATA factor.			CONAWAY, RC (corresponding author), OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.			Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; CONAWAY JW, 1990, J BIOL CHEM, V265, P7564; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY JW, 1991, SCIENCE, V88, P6205; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DAHMUS ME, 1983, J BIOL CHEM, V258, P2303; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FLORES O, 1990, J BIOL CHEM, V265, P5629; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIM WY, 1989, J BIOL CHEM, V264, P3169; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MOYLE M, 1989, MOL CELL BIOL, V9, P5750, DOI 10.1128/MCB.9.12.5750; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TIMMERS MHT, 1991, GENE DEV, V5, P1946; WHITE JH, 1991, P NATL ACAD SCI USA, V88, P7674, DOI 10.1073/pnas.88.17.7674; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	35	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8464	8467						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569096				2022-12-27	WOS:A1992HQ18500078
J	HIRONAKA, T; FURUKAWA, K; ESMON, PC; FOURNEL, MA; SAWADA, S; KATO, M; MINAGA, T; KOBATA, A				HIRONAKA, T; FURUKAWA, K; ESMON, PC; FOURNEL, MA; SAWADA, S; KATO, M; MINAGA, T; KOBATA, A			COMPARATIVE-STUDY OF THE SUGAR CHAINS OF FACTOR-VIII PURIFIED FROM HUMAN PLASMA AND FROM THE CULTURE MEDIA OF RECOMBINANT BABY HAMSTER-KIDNEY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; HEMOPHILIA-A; CARBOHYDRATE MOIETY; HUMAN-ERYTHROCYTES; MAMMALIAN-CELLS; OVARY CELLS; HUMAN-IGG; OLIGOSACCHARIDES; ANTIBODY; LECTIN	The asparagine-linked sugar chains of blood coagulation factor VIII preparations purified from human plasma of blood group A donors and from the culture media of recombinant BHK cells were released as oligosaccharides by hydrazinolysis. These sugar chains were converted to radioactive oligosaccharides by reduction with sodium borotritide and separated into neutral and acidic fractions by paper electrophoresis. Most of the acidic oligosaccharides were converted to neutral ones by sialidase digestion, indicating that they are sialyl derivatives. The neutral and sialidase-treated acidic oligosaccharides were fractionated by serial chromatography on immobilized lectin columns and Bio-Gel P-4 column. Structural study of each oligosaccharide by sequential exo- and endoglycosidase digestion and by methylation analysis revealed that both factor VIII preparations contain mainly high mannose-type and bi-, tri-, and tetra-antennary complex-type sugar chains. Some of the biantennary complex-type sugar chains from human plasma factor VIII contain blood group A and/or H determinant, while those from recombinant product do not. Some of the bi-, tri- and tetra-antennary complex-type sugar chains of the recombinant factor VIII contain the Gal-alpha 1 --> 3Gal group. A small number of the triantennary complex-type sugar chains from both preparations was found to contain the Gal-beta-1 --> 4(Fuc-alpha-1 --> 3)GlcNAc-beta-1 --> 4(Gal-beta-1 --> 4GlcNAc-beta-1 --> 2)Man group. Studies of pharmacokinetic parameters of the recombinant factor VIII infused into baboons revealed that its half-life in blood circulation is similar to that of plasma derived factor VIII, suggesting that the oligosaccharide structural differences between them do not affect the fate of factor VIII in vivo.	UNIV TOKYO,INST MED SCI,DEPT BIOCHEM,MINATO KU,TOKYO 108,JAPAN; BAYER YAKUHIN LTD,INST PHARMACOL,KOBE 65123,JAPAN; CUTTER BIOL MILES INC,BERKELEY,CA 94701; BAYER YAKUHIN LTD,DIV MED & DEV,CHUO KU,OSAKA 541,JAPAN	University of Tokyo; Bayer AG; Bayer AG								AMANO J, 1991, J BIOL CHEM, V266, P11461; ARONSON DL, 1990, TRANSFUSION, V30, P748, DOI 10.1046/j.1537-2995.1990.30891020338.x; AVILA JL, 1989, J IMMUNOL, V142, P2828; CUMMINGS RD, 1988, J BIOL CHEM, V263, P511; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EATON DL, 1987, J BIOL CHEM, V262, P3285; ELICES MJ, 1986, J BIOL CHEM, V261, P6064; ENDO T, 1990, BIOCHEMISTRY-US, V29, P9126, DOI 10.1021/bi00491a005; ESMON PC, 1990, BLOOD, V76, P1593; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FURUKAWA K, 1989, ARCH BIOCHEM BIOPHYS, V270, P302, DOI 10.1016/0003-9861(89)90032-5; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GALILI U, 1987, P NATL ACAD SCI USA, V84, P1369, DOI 10.1073/pnas.84.5.1369; GALILI U, 1988, INFECT IMMUN, V56, P1730, DOI 10.1128/IAI.56.7.1730-1737.1988; GILES AR, 1988, BLOOD, V72, P335; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; HANSEN L, 1988, J BIOL CHEM, V263, P15713; HELLSTERN P, 1986, THROMB HAEMOSTASIS, V56, P353; HINDSGAUL O, 1982, CARBOHYD RES, V109, P109, DOI 10.1016/0008-6215(82)84034-2; HOKKE CH, 1990, FEBS LETT, V275, P9, DOI 10.1016/0014-5793(90)81427-P; KAGAWA Y, 1988, J BIOL CHEM, V263, P17508; KANE WH, 1988, BLOOD, V71, P539; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KERNOFF PBA, 1984, BLOOD, V63, P31; KOBATA A, 1982, METHOD ENZYMOL, V83, P625; KOBATA A, 1987, METHOD ENZYMOL, V138, P779; Kobata A., 1984, BIOL CARBOHYDRATES, V2, P87; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LIANG CJ, 1980, J BIOCHEM-TOKYO, V88, P51; MALAISE MG, 1987, CLIN IMMUNOL IMMUNOP, V45, P1, DOI 10.1016/0090-1229(87)90106-1; OGATA S, 1975, J BIOCHEM, V78, P687, DOI 10.1093/oxfordjournals.jbchem.a130956; PFEIFFER G, 1989, EUR J BIOCHEM, V186, P273, DOI 10.1111/j.1432-1033.1989.tb15206.x; PIERCECRETEL A, 1989, EUR J BIOCHEM, V182, P247; SANTOSO S, 1991, THROMB HAEMOSTASIS, V65, P196; SCHWARTZ RS, 1990, NEW ENGL J MED, V323, P1800, DOI 10.1056/NEJM199012273232604; SLOMIANY A, 1984, J BIOL CHEM, V259, P4743; SPIK G, 1975, FEBS LETT, V50, P296, DOI 10.1016/0014-5793(75)90053-8; SPIRO RG, 1984, J BIOL CHEM, V259, P9858; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; TAKEUCHI M, 1989, P NATL ACAD SCI USA, V86, P7819, DOI 10.1073/pnas.86.20.7819; TANIGAWARA Y, 1990, CHEM PHARM BULL, V38, P517, DOI 10.1248/cpb.38.517; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJI J, 1990, CHEM PHARM BULL, V38, P765, DOI 10.1248/cpb.38.765; VANHALBEEK H, 1988, EUR J BIOCHEM, V177, P443; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; YAMASHITA K, 1985, J BIOL CHEM, V260, P4688; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105	52	112	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8012	8020						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569060				2022-12-27	WOS:A1992HQ18500012
J	WATANABE, T; NAKAGAWA, T; IKEMIZU, J; NAGAHAMA, M; MURAKAMI, K; NAKAYAMA, K				WATANABE, T; NAKAGAWA, T; IKEMIZU, J; NAGAHAMA, M; MURAKAMI, K; NAKAYAMA, K			SEQUENCE REQUIREMENTS FOR PRECURSOR CLEAVAGE WITHIN THE CONSTITUTIVE SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PITUITARY ATT-20 CELLS; HAMSTER OVARY CELLS; HUMAN RENIN; YEAST KEX2; PROCESSING ENDOPROTEASE; CONVERTING ENZYME; HUMAN PRORENIN; GENE-PRODUCT; ENDOPEPTIDASE	We have recently demonstrated that the Arg-X-Lys/Arg-Arg sequence is a signal for precursor cleavage catalyzed by furin, a mammalian homologue of the yeast precursor-processing endoprotease Kex2, within the constitutive secretory pathway. In this study, we further examined sequence requirements for the constitutive precursor cleavage by expression of various prorenin mutants with amino acid substitutions around the native Lys-Arg cleavage site in Chinese hamster ovary cells. The results delineate the following sequence rules that govern the constitutive precursor cleavage. (a) A basic residue (Lys or Arg) at the 4th (position -4) or 6th (position -6) residue upstream of the cleavage site besides basic residues at positions -1 and -2 is necessary. (b) At position -2, a Lys residue is more preferable than Arg. (c) At position -4, an Arg residue is more preferable than Lys. (d) At position 1, a hydrophobic aliphatic amino acid is not suitable.	UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,4 CTR GENE EXPT,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba; University of Tsukuba; University of Tsukuba			Nakayama, Kazuhisa/ABF-2924-2020	Nakayama, Kazuhisa/0000-0001-7701-7183				BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BRENNAN SO, 1990, J BIOL CHEM, V265, P21494; BRENNAN SO, 1988, FEBS LETT, V229, P167, DOI 10.1016/0014-5793(88)80819-6; BRENNAN SO, 1989, BIOCHIM BIOPHYS ACTA, V993, P48, DOI 10.1016/0304-4165(89)90141-4; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; EIPPER BA, 1987, PSYCHOPHARMACOLOGY 3, V4, P385; FRITZ LC, 1987, J BIOL CHEM, V262, P12409; FRITZ LC, 1986, P NATL ACAD SCI USA, V83, P4114, DOI 10.1073/pnas.83.12.4114; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HATSUZAWA K, 1990, J BIOCHEM-TOKYO, V107, P854, DOI 10.1093/oxfordjournals.jbchem.a123137; HATSUZAWA K, 1990, J BIOL CHEM, V265, P20075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Klenk H D, 1988, Adv Virus Res, V34, P247, DOI 10.1016/S0065-3527(08)60520-5; KORNER J, 1991, P NATL ACAD SCI USA, V88, P6834, DOI 10.1073/pnas.88.15.6834; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; MASUDA T, 1982, BIOMED RES-TOKYO, V3, P541, DOI 10.2220/biomedres.3.541; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MISUMI Y, 1990, NUCLEIC ACIDS RES, V18, P6719, DOI 10.1093/nar/18.22.6719; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V159, P305, DOI 10.1016/0006-291X(89)92438-8; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; NAGAHAMA M, 1989, FEBS LETT, V259, P202, DOI 10.1016/0014-5793(89)81528-5; NAGAHAMA M, 1991, EUR J BIOCHEM, V197, P135, DOI 10.1111/j.1432-1033.1991.tb15891.x; NAGAHAMA M, 1991, J BIOCHEM, V110, P806, DOI 10.1093/oxfordjournals.jbchem.a123664; NAKAYAMA K, 1990, J BIOL CHEM, V265, P21027; NAKAYAMA K, 1989, FEBS LETT, V257, P89, DOI 10.1016/0014-5793(89)81793-4; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; ODA K, 1991, BIOCHEM BIOPH RES CO, V175, P690, DOI 10.1016/0006-291X(91)91621-I; PRATT RE, 1988, J BIOL CHEM, V263, P3137; RHODES CJ, 1989, J BIOL CHEM, V264, P14240; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	47	110	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8270	8274						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569080				2022-12-27	WOS:A1992HQ18500048
J	BIZZOZERO, OA; LEYBA, J; NUNEZ, DJ				BIZZOZERO, OA; LEYBA, J; NUNEZ, DJ			CHARACTERIZATION OF PROTEOLIPID PROTEIN FATTY ACYLESTERASE FROM RAT-BRAIN MYELIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID ACYLATION; ACYL-COAS; IDENTIFICATION; SITE; SUBFRACTIONS; MUTATION; CYSTEINE; INVITRO; ENTRY; GENE	A protein fatty acylesterase activity that catalyzes the removal of fatty acid from exogenous proteolipid protein (PLP) has been demonstrated in isolated rat brain myelin. Optimum enzyme activity for the deacylation of PLP was obtained in 0.5% Triton X-100, 1 mm dithiothreitol at pH 7.0 and at 37-degrees-C. Other detergents (octyl beta-D-glucoside, Nonidet P-40, and Tween 20) have little or no effect, whereas deacylation was completely abolished by 0.1% sodium dodecyl sulfate or boiling the membrane fraction for 5 min prior to incubation. Under optimal conditions, the rate of deacylation was linear up to 20 min, and the apparent K(m) for bovine [H-3]palmitoyl-PLP was 18-mu-M. The myelin-associated PLP fatty acylesterase has no apparent requirements for divalent cations (Ca2+, Mg2+, Mn2+), and chelators such as EDTA, [ethylenebis(oxyethylenenitrilo)]tetraacetic acid, and 1,10-phenantroline have little or no effect on enzyme activity. Sulfhydryl and histidine residues are needed for full enzyme activity, whereas the active serine"-directed inhibitor phenylmethylsulfonyl fluoride has no effect. The myelin-associated protein fatty acylesterase was present throughout brain development and in all myelin subfractions, in agreement with the dynamic metabolism of PLP-bound fatty acids. Enzyme activity was also present in sciatic nerve, brain cortex, and heart whereas liver was devoid of activity. Several esterases, including phospholipase A2, glyoxalase II, and acetylcholinesterase, did not remove fatty acid from PLP. Myelin basic protein, palmitoyl-CoA hydrolase, and myelin-associated nonspecific esterase were also ruled out as the PLP fatty acylesterase. Thus, all data seem to indicate that this enzyme is different from esterases of the lipid metabolism. Finally, stimulation of protein phosphorylation with Ca2+, but not with cyclic-AMP, inhibited PLP deacylation, suggesting that the myelin-associated protein fatty acylesterase activity is regulated by endogenous Ca2+-dependent protein kinases.			BIZZOZERO, OA (corresponding author), UNIV NEW MEXICO, SCH MED, DEPT BIOCHEM, BASIC MED SCI BLDG, 914 CAMINO DE SALUD, ALBUQUERQUE, NM 87131 USA.				NINDS NIH HHS [NS-28129] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028129] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGRAWAL HC, 1982, J BIOL CHEM, V257, P4588; BALL JC, 1981, BIOCHEMISTRY-US, V20, P899, DOI 10.1021/bi00507a038; BANIK NL, 1985, J NEUROCHEM, V45, P581, DOI 10.1111/j.1471-4159.1985.tb04026.x; BASU A, 1988, ARCH BIOCHEM BIOPHYS, V261, P384, DOI 10.1016/0003-9861(88)90354-2; BENJAMINS JA, 1976, J NEUROCHEM, V27, P565, DOI 10.1111/j.1471-4159.1976.tb12283.x; Berge R K, 1981, Methods Enzymol, V71 Pt C, P234; BERGE RK, 1979, EUR J BIOCHEM, V95, P89, DOI 10.1111/j.1432-1033.1979.tb12942.x; BERGER M, 1986, J BIOL CHEM, V261, P4912; BIZZOZERO O, 1982, J CHROMATOGR, V227, P33, DOI 10.1016/S0378-4347(00)80353-9; BIZZOZERO OA, 1984, NEUROCHEM INT, V6, P659, DOI 10.1016/0197-0186(84)90047-0; BIZZOZERO OA, 1986, J NEUROCHEM, V47, P772; BIZZOZERO OA, 1986, BIOCHEMISTRY-US, V25, P6762, DOI 10.1021/bi00370a006; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; BIZZOZERO OA, 1990, J NEUROCHEM, V55, P1986, DOI 10.1111/j.1471-4159.1990.tb05786.x; BIZZOZERO OA, 1990, BIOCHEM BIOPH RES CO, V170, P375, DOI 10.1016/0006-291X(90)91284-Y; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P2138; BIZZOZERO OA, 1985, J NEUROSCI RES, V14, P197, DOI 10.1002/jnr.490140205; BIZZOZERO OA, 1983, NEUROCHEM INT, V5, P729, DOI 10.1016/0197-0186(83)90098-0; BIZZOZERO OA, 1986, J NEUROCHEM, V46, P630, DOI 10.1111/j.1471-4159.1986.tb13013.x; BIZZOZERO OA, 1991, J BIOL CHEM, V266, P17092; BIZZOZERO OA, 1985, J NEUROCHEM, V45, P1228, DOI 10.1111/j.1471-4159.1985.tb05547.x; BIZZOZERO OA, 1991, FAL ASBMB S BIOL SIG, P21; BIZZOZERO OA, 1991, T AM SOC NEUROCHEM, V22, P265; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; DESJARDINS KC, 1983, J CELL BIOL, V97, P438, DOI 10.1083/jcb.97.2.438; Dunkley P. R., 1974, RESEARCH METHODS NEU, V2, P219; ETO Y, 1972, J NEUROCHEM, V19, P117, DOI 10.1111/j.1471-4159.1972.tb01260.x; FOLCH J, 1951, J BIOL CHEM, V191, P807; Fredrikson G, 1981, Methods Enzymol, V71 Pt C, P636; FULGAR L, 1974, FEBS LETT, V47, P15; Gallo L L, 1981, Methods Enzymol, V71 Pt C, P664; GENCIC S, 1989, AM J HUM GENET, V45, P435; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HUTTUNEN JK, 1971, BIOCHIM BIOPHYS ACTA, V239, P411, DOI 10.1016/0005-2760(71)90034-8; JAMES G, 1989, J BIOL CHEM, V264, P20998; Kolattukudy P E, 1981, Methods Enzymol, V71 Pt C, P230; KONAT G, 1987, Journal of Neurochemistry, V48, pS139; LEE MB, 1984, MYELIN, P197; LEES M, 1989, Journal of Neurochemistry, V52, pS195; LEES MB, 1983, ARCH BIOCHEM BIOPHYS, V226, P643, DOI 10.1016/0003-9861(83)90334-X; LEES MB, 1983, HDB NEUROCHEMISTRY, V4, P435; LEES MB, 1988, NEURONAL GLIAL PROTE, P267; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACK D, 1988, BIOCHEM J, V256, P1021, DOI 10.1042/bj2561021; MORELL P, 1975, ANAL BIOCHEM, V68, P148, DOI 10.1016/0003-2697(75)90688-0; NAVE KA, 1987, J NEUROCHEM, V49, P1873, DOI 10.1111/j.1471-4159.1987.tb02449.x; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Norton WT., 1984, MYELIN, P147, DOI DOI 10.1007/978-1-4757-1830-0_5; RIENKKINEN PJ, 1969, BRAIN RES, V14, P772; SCHMIDT M, 1988, J BIOL CHEM, V263, P18635; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; STOFFYN P, 1971, BIOCHEM BIOPH RES CO, V44, P157, DOI 10.1016/S0006-291X(71)80172-9; TAYLOR DC, 1990, ANAL BIOCHEM, V184, P311, DOI 10.1016/0003-2697(90)90686-4; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TOWNSEND LE, 1982, J BIOL CHEM, V257, P9745; ZAND R, 1979, T AM SOC NEUROCHEM, V10, P218	57	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7886	7894						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560018				2022-12-27	WOS:A1992HN48500096
J	GARCIA, JC; STRUBE, M; LEINGANG, K; KELLER, K; MUECKLER, MM				GARCIA, JC; STRUBE, M; LEINGANG, K; KELLER, K; MUECKLER, MM			AMINO-ACID SUBSTITUTIONS AT TRYPTOPHAN-388 AND TRYPTOPHAN-412 OF THE HEPG2 (GLUT1) GLUCOSE TRANSPORTER INHIBIT TRANSPORT ACTIVITY AND TARGETING TO THE PLASMA-MEMBRANE IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE; CYTOCHALASIN-B; STRUCTURAL REQUIREMENTS; HEXOSE TRANSPORTER; CELL MEMBRANE; BINDING; PROTEIN; EXPRESSION; SYSTEM; LIGAND	All 6 tryptophan residues in the human HepG2-type glucose transporter (Glut1) were individually altered by site-directed mutagenesis to investigate the role of these residues in transport function. Tryptophan residues in positions 48, 65, 186, 363, 388, and 412 of Glut1 were changed to either a glycine or leucine residue. Mutant mRNAs were synthesized and injected into Xenopus laevis oocytes. Transporter function as assessed by uptake of 2-deoxy-D-[H-3]glucose or transport of 3-O-[H-3]methylglucose was decreased in the 388 and 412 mutants but was unaltered in all other mutants. The amount of the mutant transporters expressed in total membrane and plasma membrane fractions was measured using Glut1-specific antibodies. Calculation of the intrinsic transport activity of each of the mutants using these data demonstrated that the reduced transport activity of the 412 mutants was caused entirely by a dramatic decrease in the intrinsic activity of the mutant proteins whereas the reduced activity of the 388 mutants was a result of a decreased level of the protein in oocytes, decreased targeting to the plasma membrane, and a modest decrease in the intrinsic activity. Protease/glycosidase mapping of in vitro translation products indicated that the effects of the 388 and 412 point mutations could not be attributed to a disruption in the ability of the mutant proteins to insert properly into the membrane. The ID50 for cytochalasin B inhibition of 2-deoxyglucose uptake was increased from 5 x 10(-7) M for the wild-type Glut1 to 4 x 10(-6) M in the 388 mutants but was unaltered in the 412 mutants. These observations suggest that 1) Trp-412 may comprise part of a hexose binding site or is involved in maintaining a local tertiary structure critical for transport function; 2) Trp-388 is involved in stabilizing the equilibrium binding of cytochalasin B to the transporter. Trp-388 may therefore lie near a substrate binding site and also appears to participate in stabilization of local tertiary structure important for full catalytic activity and efficient targeting to the Xenopus plasma membrane.	WASHINGTON UNIV, SCH MED,DEPT CELL BIOL & PHYSIOL,BOX 8228, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, DIV RENAL, ST LOUIS, MO 63110 USA; FREE UNIV BERLIN, INST PHARMACOL, W-1000 BERLIN 33, GERMANY	Washington University (WUSTL); Washington University (WUSTL); Free University of Berlin			Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695, R01DK038495] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38495, DK43695] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ J, 1987, J BIOL CHEM, V262, P9347; BALDWIN SA, 1982, BIOCHEMISTRY-US, V21, P3836, DOI 10.1021/bi00259a018; BALDWIN SA, 1989, METHOD ENZYMOL, V174, P39; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; BARNETT JEG, 1975, BIOCHEM J, V145, P417, DOI 10.1042/bj1450417a; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; CAIRNS MT, 1984, BIOCHEM J, V221, P179, DOI 10.1042/bj2210179; CAIRNS MT, 1986, BIOCHEM SOC T, V14, P747, DOI 10.1042/bst0140747; CARTERSU C, 1982, J BIOL CHEM, V257, P5419; CELENZA JL, 1988, P NATL ACAD SCI USA, V85, P2130, DOI 10.1073/pnas.85.7.2130; CHIN JJ, 1987, P NATL ACAD SCI USA, V84, P4113, DOI 10.1073/pnas.84.12.4113; DEVES R, 1978, BIOCHIM BIOPHYS ACTA, V510, P339, DOI 10.1016/0005-2736(78)90034-2; DEZIEL M, 1984, BIOCHIM BIOPHYS ACTA, V772, P403, DOI 10.1016/0005-2736(84)90157-3; DEZIEL MR, 1984, BIOCHIM BIOPHYS ACTA, V776, P10, DOI 10.1016/0005-2736(84)90245-1; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; GRIFFIN JF, 1982, P NATL ACAD SCI-BIOL, V79, P3759, DOI 10.1073/pnas.79.12.3759; HOLMAN GD, 1986, BIOCHIM BIOPHYS ACTA, V855, P115, DOI 10.1016/0005-2736(86)90195-1; HOLMAN GD, 1987, BIOCHIM BIOPHYS ACTA, V897, P395, DOI 10.1016/0005-2736(87)90437-8; JUNG EKY, 1986, J BIOL CHEM, V261, P9155; KAHLENBERG A, 1972, CAN J BIOCHEM CELL B, V50, P638, DOI 10.1139/o72-088; KARIM AR, 1987, BIOCHIM BIOPHYS ACTA, V902, P402, DOI 10.1016/0005-2736(87)90208-2; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; KATAGIRI H, 1991, J BIOL CHEM, V266, P7769; KELLER K, 1989, J BIOL CHEM, V264, P18884; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS DA, 1991, MOL CELL BIOL, V11, P3804, DOI 10.1128/MCB.11.7.3804; LIENHARD GE, 1984, BIOCHIM BIOPHYS ACTA, V769, P404, DOI 10.1016/0005-2736(84)90324-9; LUNDAHL P, 1984, J CHROMATOGR, V297, P129, DOI 10.1016/S0021-9673(01)89036-1; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; MUECKLER M, 1990, DIABETES, V39, P1; MUECKLER M, 1989, RED BLOOD CELL MEMBR, P31; NEHLIN JO, 1989, GENE, V85, P313, DOI 10.1016/0378-1119(89)90423-X; PAWAGI AB, 1990, BIOCHEMISTRY-US, V29, P950, DOI 10.1021/bi00456a015; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHANAHAN MF, 1983, BIOCHEMISTRY-US, V22, P2750, DOI 10.1021/bi00280a024; SHANAHAN MF, 1982, J BIOL CHEM, V257, P7290; SZKUTNICKA K, 1989, J BACTERIOL, V171, P4486, DOI 10.1128/JB.171.8.4486-4493.1989; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; WALSMLEY AR, 1988, TRENDS BIOCHEM SCI, V13, P226; WHEELER TJ, 1985, ANNU REV PHYSIOL, V47, P503, DOI 10.1146/annurev.ph.47.030185.002443; WHEELER TJ, 1981, J BIOL CHEM, V256, P8907	53	167	167	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7770	7776						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560011				2022-12-27	WOS:A1992HN48500081
J	MCCARTHY, MP; MOORE, MA				MCCARTHY, MP; MOORE, MA			EFFECTS OF LIPIDS AND DETERGENTS ON THE CONFORMATION OF THE NICOTINIC ACETYLCHOLINE-RECEPTOR FROM TORPEDO-CALIFORNICA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID SURFACE-CHARGE; CARBENE-GENERATING REAGENT; INTEGRAL MEMBRANE-PROTEIN; ION PERMEABILITY CONTROL; RECONSTITUTED MEMBRANES; FUNCTIONAL-PROPERTIES; BINDING-PROPERTIES; CHAIN-LENGTH; K+ CHANNEL; RAT-BRAIN	The hydrophobic, photoreactive probe 3-(trifluoromethyl)-3-m-[I-125]iodophenyl)diazirine ([I-125]TID) was used to characterize the effects of lipids and detergents on acetylcholine receptor (AChR) conformation. Affinity purified AChR reconstituted into dioleoylphosphatidylcholine (DOPC), dioleoylphosphatidic acid (DOPA), and cholesterol showed the same pattern of [I-125]TID-labeling and demonstrated the same reduction in labeling of all four subunits upon desensitization by the agonist carbamylcholine, as partially purified AChR in native lipids. On the basis of the patterns of [I-125]TID incorporation, reconstitution into DOPC/DOPA also appeared to stabilize the resting (functional) conformation of the AChR, while reconstitution in DOPC/cholesterol or DOPC alone largely desensitized the AChR. The effects of lipids on the functional state of the AChR was determined independently by measuring the ability of AChR reconstituted into different lipid combinations to undergo the change in affinity for agonist diagnostic of desensitization. The dramatic reduction in the apparent levels of [I-125]TID associated with the subunits of the AChR observed upon agonist-induced desensitization was shown not to be due to a change in affinity for tightly bound lipid. Solubilization of affinity purified AChR reconstituted into DOPC/DOPA/cholesterol by the non-ionic detergents octyl glucoside, Triton X-100, and Tween 20 (final detergent concentration = 1%) was shown to produce the same pattern of [I-125]TID-labeling as desensitization by agonist, while solubilization in 1% sodium cholate appeared to stabilize a conformation of the AChR more similar to the resting state.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center	MCCARTHY, MP (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854, USA.							Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ANDREASEN TJ, 1980, BIOCHEMISTRY-US, V19, P4719, DOI 10.1021/bi00561a027; ANHOLT R, 1981, J BIOL CHEM, V256, P4377; BALDWIN PA, 1985, BIOCHEMISTRY-US, V24, P2633, DOI 10.1021/bi00332a007; BARRANTES FJ, 1989, CRIT REV BIOCHEM MOL, V24, P437, DOI 10.3109/10409238909086961; BELL JE, 1984, BIOPHYS J, V45, P279, DOI 10.1016/S0006-3495(84)84154-5; BHUSHAN A, 1990, BIOCHIM BIOPHYS ACTA, V1027, P93, DOI 10.1016/0005-2736(90)90053-Q; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRILEY MS, 1978, EUR J BIOCHEM, V84, P429, DOI 10.1111/j.1432-1033.1978.tb12184.x; BRUNNER J, 1985, BIOCHEMISTRY-US, V24, P5422, DOI 10.1021/bi00341a021; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; CHANGEUX JP, 1976, COLD SPRING  HARBOR, V30, P211; CRIADO M, 1982, BIOCHEMISTRY-US, V21, P3622, DOI 10.1021/bi00258a015; CRIADO M, 1984, J BIOL CHEM, V259, P9188; DALZIEL AW, 1980, FEBS LETT, V122, P193, DOI 10.1016/0014-5793(80)80435-2; DAMLE VN, 1978, BIOCHEM BIOPH RES CO, V84, P845, DOI 10.1016/0006-291X(78)91661-3; DUNBAR BS, 1988, 2 DIMENSIONAL ELECTR, P218; EARNEST JP, 1987, MEMBRANE PROTEINS, P117; ELLENA JF, 1983, BIOCHEMISTRY-US, V22, P5523, DOI 10.1021/bi00293a012; EPSTEIN M, 1978, J BIOL CHEM, V253, P6660; FELLER DJ, 1985, J BIOL CHEM, V260, P1542; FONG TM, 1987, BIOCHEMISTRY-US, V26, P3871, DOI 10.1021/bi00387a020; FONG TM, 1986, BIOCHEMISTRY-US, V25, P830, DOI 10.1021/bi00352a015; FRIELLE T, 1982, J BIOL CHEM, V257, P4979; GONZALEZROS JM, 1982, BIOCHEMISTRY-US, V21, P3467, DOI 10.1021/bi00257a033; GONZALEZROS JM, 1980, P NATL ACAD SCI-BIOL, V77, P1796, DOI 10.1073/pnas.77.4.1796; GOULD RJ, 1982, J BIOL CHEM, V257, P477; GUY HR, 1987, TRENDS NEUROSCI, V10, P318, DOI 10.1016/0166-2236(87)90087-7; HASEGAWA JI, 1987, J NEUROCHEM, V49, P1007, DOI 10.1111/j.1471-4159.1987.tb09987.x; HEIDMANN T, 1978, FEBS LETT, V94, P397, DOI 10.1016/0014-5793(78)80986-7; HOPPE J, 1984, BIOCHEMISTRY-US, V23, P5610, DOI 10.1021/bi00318a035; HUANG KS, 1981, J BIOL CHEM, V256, P3802; JONES OT, 1988, BIOCHEMISTRY-US, V27, P3733, DOI 10.1021/bi00410a032; JONES OT, 1988, BIOCHEMISTRY-US, V27, P2364, DOI 10.1021/bi00407a018; KILLIAN PL, 1980, BIOCHEM BIOPH RES CO, V93, P409; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARD J, 1990, J VIROL, V64, P3486, DOI 10.1128/JVI.64.7.3486-3491.1990; MCCARTHY MP, 1986, ANNU REV NEUROSCI, V9, P383; MCCARTHY MP, 1989, J BIOL CHEM, V264, P10911; MCCARTHY MP, 1989, BIOCHEMISTRY-US, V28, P40, DOI 10.1021/bi00427a007; MEISTER H, 1985, J BIOL CHEM, V260, P16321; MIELKE DL, 1988, J BIOL CHEM, V263, P3177; MOCZYDLOWSKI E, 1985, J MEMBRANE BIOL, V83, P273, DOI 10.1007/BF01868701; OCHOA ELM, 1983, BIOCHIM BIOPHYS ACTA, V727, P151, DOI 10.1016/0005-2736(83)90379-6; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; QUAST U, 1978, BIOCHEMISTRY-US, V17, P2405, DOI 10.1021/bi00605a024; ROTSTEIN NP, 1987, J NEUROCHEM, V49, P1333, DOI 10.1111/j.1471-4159.1987.tb00996.x; SCHMIDT J, 1973, ANAL BIOCHEM, V52, P349, DOI 10.1016/0003-2697(73)90036-5; SHOUFFANI A, 1990, J BIOL CHEM, V265, P6002; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; VEMURI R, 1989, J BIOL CHEM, V264, P8680; WALKER JW, 1981, BIOCHEMISTRY-US, V20, P2191, DOI 10.1021/bi00511a018; WEILAND G, 1977, J BIOL CHEM, V252, P7648; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009	54	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7655	7663						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560000				2022-12-27	WOS:A1992HN48500065
J	BIGGERSTAFF, M; WOOD, RD				BIGGERSTAFF, M; WOOD, RD			REQUIREMENT FOR ERCC-1 AND ERCC-3 GENE-PRODUCTS IN DNA EXCISION REPAIR INVITRO - COMPLEMENTATION USING RODENT AND HUMAN CELL-EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CDNA CLONING; MOLECULAR CHARACTERIZATION; CHO CELLS; GROUP-A; MUTANTS; UV; PROTEINS	Numerous rodent cell lines exist that have defects in nucleotide excision repair of DNA caused by alterations in genes that fall into 10 different complementation groups. The precise roles in the repair of these genes are unknown. We report here that extracts from Chinese hamster ovary cells of excision repair-defective complementation groups 1 and 3 are defective in DNA excision repair in a cell-free system. In vitro complementation can be achieved by mixing extracts from the two groups with one another. In addition, extracts from a human cell line representing xeroderma pigmentosum complementation group B could complement rodent complementation group 1 extracts, but not group 3 extracts. This is consistent with an identity of the ERCC-3 and xeroderma pigmentosum group B genes. Cellular evidence points toward a defect in the incision of damaged DNA in group 1 and 3 mutants. Since the ERCC-1 and ERCC-3 proteins are required for the in vitro reaction, it appears that both gene products are directly involved in the enzymatic incision of damaged DNA, or in preincision reactions. The experiments reported here provide the biochemical basis of an approach to analyze the function of these nucleotide excision repair proteins.			BIGGERSTAFF, M (corresponding author), IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND.		Wood, Richard/M-6319-2018	Wood, Richard/0000-0002-9495-6892				BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; BUSCH D, 1989, MUTAGENESIS, V4, P349, DOI 10.1093/mutage/4.5.349; BUSCH DB, 1980, SOMAT CELL GENET, V6, P407, DOI 10.1007/BF01542792; CHENG S, 1991, NUCLEIC ACIDS RES, V19, P657, DOI 10.1093/nar/19.3.657; CHENG WS, 1978, CANCER RES, V38, P1601; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; DEANDRADE HHR, 1989, MOL GEN GENET, V219, P75; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; FUCHS RPP, 1975, NATURE, V257, P151, DOI 10.1038/257151a0; GROSSMAN L, 1990, PHOTOCHEM PHOTOBIOL, V51, P749, DOI 10.1111/php.1990.51.6.749; HANAWALT PC, 1991, MUTAT RES, V247, P203, DOI 10.1016/0027-5107(91)90016-H; HANSSON J, 1990, NUCLEIC ACIDS RES, V18, P35, DOI 10.1093/nar/18.1.35; HANSSON J, 1989, NUCLEIC ACIDS RES, V17, P8073, DOI 10.1093/nar/17.20.8073; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HEFLICH RH, 1979, PHOTOCHEM PHOTOBIOL, V30, P247, DOI 10.1111/j.1751-1097.1979.tb07142.x; HEIGERBERNAYS WJ, 1990, BIOCHEMISTRY-US, V29, P8461, DOI 10.1021/bi00488a037; HOEIJMAKERS JHJ, 1990, CANCER CELL-MON REV, V2, P311; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; HOY CA, 1985, CANCER RES, V45, P1737; HUSAIN ISU, 1989, NUCLEIC ACIDS RES, V17, P4471; KOFFELSCHWARTZ N, 1987, J MOL BIOL, V193, P651, DOI 10.1016/0022-2836(87)90348-2; KRIEK E, 1967, BIOCHEMISTRY-US, V6, P177, DOI 10.1021/bi00853a029; LIN JJ, 1990, J BIOL CHEM, V265, P21337; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MITCHELL DL, 1985, MUTAT RES, V143, P109, DOI 10.1016/S0165-7992(85)80018-X; REARDON JT, 1991, NUCLEIC ACIDS RES, V19, P4623, DOI 10.1093/nar/19.17.4623; REYNOLDS P, 1985, EMBO J, V4, P3549, DOI 10.1002/j.1460-2075.1985.tb04115.x; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; RYDBERG B, 1990, J BIOL CHEM, V265, P9563; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232; SELBY CP, 1990, MUTAT RES, V236, P203, DOI 10.1016/0921-8777(90)90005-P; SIBGHATULLAH, 1990, BIOCHEMISTRY-US, V29, P5711, DOI 10.1021/bi00476a011; STEFANINI M, 1991, CANCER RES, V51, P3965; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; THOMPSON LH, 1991, MUTAT RES, V247, P213, DOI 10.1016/0027-5107(91)90017-I; THOMPSON LH, 1980, SOMAT CELL GENET, V6, P391, DOI 10.1007/BF01542791; THOMPSON LH, 1988, SOMAT CELL MOLEC GEN, V14, P605, DOI 10.1007/BF01535314; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANDUIN M, 1988, MUTAT RES, V193, P123, DOI 10.1016/0167-8817(88)90042-9; VANDUIN M, 1988, NUCLEIC ACIDS RES, V16, P5305, DOI 10.1093/nar/16.12.5305; VANDUIN M, 1989, MUTAT RES, V217, P83, DOI 10.1016/0921-8777(89)90059-1; VANHOUTEN B, 1986, P NATL ACAD SCI USA, V83, P8077; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; WANG ZG, 1991, J BIOL CHEM, V266, P22472; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, MOL CELL BIOL, V10, P2570, DOI 10.1128/MCB.10.6.2570; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WESTERVELD A, 1984, NATURE, V310, P425, DOI 10.1038/310425a0; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981; WOOD RD, 1991, NATURE, V350, P190, DOI 10.1038/350190a0; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WOOD RD, 1982, MUTAT RES, V95, P505, DOI 10.1016/0027-5107(82)90281-0; WOOD RD, 1982, PHOTOCHEM PHOTOBIOL, V36, P169, DOI 10.1111/j.1751-1097.1982.tb04359.x; ZDZIENICKA MZ, 1986, MUTAT RES, V166, P59, DOI 10.1016/0167-8817(86)90041-6; ZDZIENICKA MZ, 1991, MUTAGENESIS, V6, P179, DOI 10.1093/mutage/6.3.179	59	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6879	6885						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551896				2022-12-27	WOS:A1992HM05300066
J	HUANG, HB; BRESLOW, E				HUANG, HB; BRESLOW, E			IDENTIFICATION OF THE UNSTABLE NEUROPHYSIN DISULFIDE AND LOCALIZATION TO THE HORMONE-BINDING SITE - RELATIONSHIP TO FOLDING-UNFOLDING PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; VASOPRESSIN; PRECURSOR; OXYTOCIN	For unliganded neurophysin, the effects of reduction of a single disulfide and limited regeneration of activity following reduction have suggested metastable disulfide pairing relative to that of the neurophysin precursor. This metastability was confirmed in the present study by the demonstration of almost complete regeneration of activity from the reduced state in the presence of ligand peptides, conditions mimicking precursor folding. To assign the source of the metastability of the unliganded mature protein, the disulfide(s) most susceptible to reduction and the last to be reoxidized following complete reduction were identified. Partial reduction of the first disulfide followed by trapping of the generated thiols with [C-14]iodoacetate gave a distribution of label consistent with identification of the unstable disulfide as the 10-54 bridge and rapid interchange of the Cys-10 thiol with other disulfides in the amino-terminal disulfide domain. The same thiol distribution was seen at the terminal stage of reoxidation following complete reduction, providing evidence that unfolding and folding pathways are the same at this stage. The results indicate that, in the absence of bound peptide, the state with correct pairing of the 10-54 bridge has no significant thermodynamic advantage over interchanged states of the amino-terminal domain. However, since the 10-54 bridge is located at the peptide-binding site, the correct pairing is directly stabilized by ligand peptides. Moreover, since the other three bridges of the amino domain are homologous to bridges in the carboxyl-terminal domain that do not appear to be unstable, the results allow the possibility that the 10-54 bridge, which is unique to the amino domain, destabilizes other disulfides in that domain.	CORNELL UNIV, MED CTR, COLL MED, DEPT BIOCHEM, 1300 YORK AVE, NEW YORK, NY 10021 USA	Cornell University					NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005396] Funding Source: NIH RePORTER; NCRR NIH HHS [SO7 RR05396] Funding Source: Medline; NIGMS NIH HHS [GM-17528] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDO S, 1987, J BIOL CHEM, V262, P12962; BRESLOW E, 1973, BIOCHEMISTRY-US, V12, P4644, DOI 10.1021/bi00747a016; BRESLOW E, 1990, ADV ENZYMOL RAMB, V63, P1; BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132; BURMAN S, 1989, P NATL ACAD SCI USA, V86, P429, DOI 10.1073/pnas.86.2.429; CHAIKEN IM, 1975, ANN NY ACAD SCI, V248, P442, DOI 10.1111/j.1749-6632.1975.tb34204.x; CHEN LQ, 1991, P NATL ACAD SCI USA, V88, P4240, DOI 10.1073/pnas.88.10.4240; DONOVAN JW, 1969, PHYSICAL PRINCIPLE A, P101; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; KANMERA T, 1985, J BIOL CHEM, V260, P8474; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1982, NATURE, V295, P299, DOI 10.1038/295299a0; MENDENDEZBOTET CJ, 1975, BIOCHEMISTRY-US, V14, P3825; NICOLAS P, 1980, BIOCHEMISTRY-US, V19, P3565, DOI 10.1021/bi00556a023; RABBANI LD, 1982, BIOCHEMISTRY-US, V21, P817, DOI 10.1021/bi00534a001; SARDANA V, 1987, BIOCHEMISTRY-US, V26, P995, DOI 10.1021/bi00378a004; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; TANIYAMA Y, 1991, J BIOL CHEM, V266, P6456; VIRMANISARDANA V, 1983, INT J PEPT PROT RES, V21, P182; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303	23	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6750	6756						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551883				2022-12-27	WOS:A1992HM05300045
J	LIU, ES; OU, JH; LEE, AS				LIU, ES; OU, JH; LEE, AS			BREFELDIN-A AS A REGULATOR OF GRP78 GENE-EXPRESSION IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM IONOPHORE A23187; PROTEIN GRP78; GLUCOSE STARVATION; TRANSCRIPTIONAL REGULATION; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; 2 GENES; HAMSTER; BINDING	We report here that brefeldin A (BFA), which specifically blocks protein transport from the endoplasmic reticulum to the Golgi apparatus and causes resorption of Golgi membrane to the endoplasmic reticulum, specifically induced the endoplasmic reticulum-resident protein GRP78. Treatment of a human hepatoma cell line Alex-PC with BFA at a concentration of 5-mu-g/ml increased the grp78 transcript level by 12-fold. Analyses of the transcriptional rate of grp78 and the transfection with grp78 promoter suggested that this cell line utilized a posttranscriptional mechanism to increase the expression of grp78 in response to BFA. The induction process was partially dependent on de novo protein synthesis. Interestingly, in a hamster lung fibroblast cell line, K12, the induction of grp78 by BFA could be mediated by a transcriptional control mechanism. We further demonstrated that in K12 cells the region of the grp78 promoter responsive to BFA was within a 40-base pair region between -169 and -130, containing the conserved grp core and a 10-base pair region between -99 to -90 that contained a proximal CCAAT element. A model of how BFA regulates grp78 expression at both the transcriptional and posttranscriptional level is presented.	UNIV SO CALIF,SCH MED,DEPT BIOCHEM,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,NORRIS CANC RES INST,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033	University of Southern California; University of Southern California; University of Southern California				Lee, Amy/0000-0002-0378-5443	NATIONAL CANCER INSTITUTE [R37CA027607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026244] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA 27607] Funding Source: Medline; NIAID NIH HHS [AI26244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTISHEVSKY A, 1987, NATURE, V328, P823, DOI 10.1038/328823a0; ARTISHEVSKY A, 1984, MOL CELL BIOL, V4, P2364, DOI 10.1128/MCB.4.11.2364; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; DAY AR, 1989, DNA-J MOLEC CELL BIO, V8, P301, DOI 10.1089/dna.1.1989.8.301; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEE AS, 1983, J BIOL CHEM, V258, P597; LEE AS, 1981, J CELL PHYSIOL, V106, P119, DOI 10.1002/jcp.1041060113; LEE AS, 1986, J CELL PHYSIOL, V129, P277, DOI 10.1002/jcp.1041290302; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; LIN AY, 1984, P NATL ACAD SCI-BIOL, V81, P988, DOI 10.1073/pnas.81.4.988; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NAKAKI T, 1989, MOL CELL BIOL, V9, P2233, DOI 10.1128/MCB.9.5.2233; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; RESENDEZ E, 1986, J CELL BIOL, V103, P2145, DOI 10.1083/jcb.103.6.2145; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SHIU RPC, 1977, P NATL ACAD SCI USA, V74, P3840, DOI 10.1073/pnas.74.9.3840; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; WANG J, 1991, J VIROL, V65, P5080, DOI 10.1128/JVI.65.9.5080-5083.1991; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; YEH CT, 1991, J VIROL, V65, P2327, DOI 10.1128/JVI.65.5.2327-2331.1991	31	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7128	7133						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551919				2022-12-27	WOS:A1992HM05300103
J	SHIRAKAWA, H; YOSHIDA, M				SHIRAKAWA, H; YOSHIDA, M			STRUCTURE OF A GENE CODING FOR HUMAN HMG2 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILITY GROUP PROTEIN-1; HISTONE CHROMATIN PROTEINS; SINGLE-STRANDED-DNA; RNA POLYMERASE-II; FULL-LENGTH CDNA; RAT-LIVER HMG1; NUCLEOTIDE-SEQUENCE; UNIDIRECTIONAL DIGESTION; PREFERENTIAL AFFINITY; CHROMOSOMAL-PROTEINS	A human genomic library was screened with the pig thymus cDNA coding for chromosomal protein HMG2. A 4341-base pair fragment containing the entire gene encoding this protein was isolated and characterized. The HMG2 gene is 2665 base pairs long from the start site to the end of transcription and comprises 5 exons. The size of mRNA postulated from the exons is 1125 base pairs long, consistent with that obtained by Northern hybridization analysis. The canonical 5'-regulatory motifs, CCAAT, are present, while the TATA element is absent from the gene. Southern analysis suggested that HMG2 protein is encoded by a single or only a few genes of high homology. The primary structure of the human HMG2 protein consists of 208 amino acid residues, deduced from the coding region of the gene, is different from that of pig HMG2 in only two amino acids; one is exchanged and the other is missing. The amino acid sequences of two DNA binding domains, "HMG-box," also recently found in several transcription factors, are completely homologous in human and pig HMG2. The present study, which is the first one on the isolation and characterization of complete gene coding for HMG2 protein, may be useful for evolutional and genomic analysis of the proteins containing the HMG-box sequences for DNA binding.	SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN	Tokyo University of Science			Shirakawa, Hitoshi/D-1406-2009	SHIRAKAWA, HITOSHI/0000-0002-4828-5274				BEGUM N, 1990, J BIOL CHEM, V265, P11936; BIDNEY DL, 1978, BIOCHEM BIOPH RES CO, V85, P1211, DOI 10.1016/0006-291X(78)90671-X; BONNEANDREA C, 1984, EMBO J, V3, P1193, DOI 10.1002/j.1460-2075.1984.tb01950.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; HAMADA H, 1985, BIOCHEMISTRY-US, V24, P1428, DOI 10.1021/bi00327a022; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; ISACKSON PJ, 1979, J BIOL CHEM, V254, P5569; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; JAVAHERIAN K, 1979, NUCLEIC ACIDS RES, V6, P3569, DOI 10.1093/nar/6.11.3569; KAPLAN DJ, 1988, NUCLEIC ACIDS RES, V16, P10375, DOI 10.1093/nar/16.21.10375; LIM HM, 1988, GENE ANAL TECH, V5, P32, DOI 10.1016/0735-0651(88)90024-6; MAKIGUCHI K, 1984, J BIOCHEM-TOKYO, V95, P423, DOI 10.1093/oxfordjournals.jbchem.a134623; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PAONESSA G, 1987, NUCLEIC ACIDS RES, V15, P9077, DOI 10.1093/nar/15.21.9077; SAMBROOK J, 1989, MOL CLONING LAB MANU, P779; SHIRAKAWA H, 1990, BIOCHEMISTRY-US, V29, P4419, DOI 10.1021/bi00470a022; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; TREMETHICK DJ, 1988, NUCLEIC ACIDS RES, V16, P11107, DOI 10.1093/nar/16.23.11107; TSUDA K, 1988, BIOCHEMISTRY-US, V27, P6159, DOI 10.1021/bi00416a050; WAGA S, 1990, J BIOL CHEM, V265, P19424; WAGA S, 1989, BIOCHIM BIOPHYS ACTA, V1007, P209, DOI 10.1016/0167-4781(89)90041-9; WAGA S, 1988, BIOCHEM BIOPH RES CO, V153, P334, DOI 10.1016/S0006-291X(88)81227-0; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; YOSHIDA M, 1984, J BIOCHEM-TOKYO, V95, P117, DOI 10.1093/oxfordjournals.jbchem.a134573	30	37	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6641	6645						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551873				2022-12-27	WOS:A1992HM05300031
J	SCHNEIDER, E; FREUNDLIEB, S; TAPIO, S; BOOS, W				SCHNEIDER, E; FREUNDLIEB, S; TAPIO, S; BOOS, W			MOLECULAR CHARACTERIZATION OF THE MALT-DEPENDENT PERIPLASMIC ALPHA-AMYLASE OF ESCHERICHIA-COLI ENCODED BY MALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-LAMBDA RECEPTOR; BINDING-PROTEIN; NUCLEOTIDE-SEQUENCE; OUTER-MEMBRANE; BACILLUS-POLYMYXA; ACTIVE-TRANSPORT; STRUCTURAL GENE; BETA-AMYLASE; AVTA GENE; CLONING	malS, the gene encoding the periplasmic alpha-amylase, is under the regulatory control of the MalT protein, the gene activator of the Escherichia coli maltose system. We sequenced the DNA region encoding malS and its control elements. malS consists of an open reading frame of 2,028 base pairs encoding a protein of 676 amino acids with a deduced molecular weight of 75,664 including a typical amino-terminal signal sequence of 17 amino acids. The deduced amino acid sequence of malS was compared with that of other proteins. We found homologies to alpha-amylases and a cyclodextrin glucanotransferase but not to beta-amylases. In addition, MaIS showed significant homology to another maltodextrin-utilizing and MalT-dependent enzyme of E. coli, maltodextrin glucosidase (MalZ) but not to amylomaltase (MalQ), the major maltodextrin-degrading enzyme. Conserved regions that have been proposed to constitute enzymatically active sites in alpha-amylases are present in MalS. Two of these sequences can also be found in the amino terminus of the lambda-receptor, a maltodextrin-specific channel in the outer membrane. The nucleotide sequence of the control region of malS revealed MalT binding sites correctly spaced for the start of the malS transcript. At the position 219 base pairs upstream of malS, we found a divergently transcribed gene, bax, which has been recognized previously. Downstream of malS, after a 513-base pair intergenic region, lies the convergently transcribed gene avtA, which codes for the alanine/valine transaminase.	UNIV CONSTANCE,DEPT BIOL,POB 5560,W-7750 CONSTANCE,GERMANY	University of Konstanz			Tapio, Soile/CAJ-5871-2022; Tapio, Soile/M-7358-2014	Tapio, Soile/0000-0001-9860-3683				BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BELFORT M, 1985, CELL, V41, P375, DOI 10.1016/S0092-8674(85)80010-6; BENZ R, 1987, J MEMBRANE BIOL, V100, P21, DOI 10.1007/BF02209137; BINDER F, 1986, GENE, V47, P269, DOI 10.1016/0378-1119(86)90070-3; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRASS JM, 1983, J BACTERIOL, V155, P97, DOI 10.1128/JB.155.1.97-106.1983; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHAPON C, 1982, J BACTERIOL, V150, P722, DOI 10.1128/JB.150.2.722-729.1982; CHARBIT A, 1988, J MOL BIOL, V201, P487, DOI 10.1016/0022-2836(88)90630-4; CLEMENT JM, 1981, CELL, V27, P507, DOI 10.1016/0092-8674(81)90392-5; COLE ST, 1983, MOL GEN GENET, V189, P400, DOI 10.1007/BF00325901; COLE ST, 1986, GENE, V42, P201, DOI 10.1016/0378-1119(86)90297-0; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; DUPLAY P, 1984, J BIOL CHEM, V259, P606; FRANCOZ E, 1990, RES MICROBIOL, V141, P1039, DOI 10.1016/0923-2508(90)90078-5; FREUNDLIEB S, 1988, J BIOL CHEM, V263, P314; FREUNDLIEB S, 1986, J BIOL CHEM, V261, P2946; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FUCHS R, 1990, NUCLEIC ACIDS RES, V18, P4319, DOI 10.1093/nar/18.15.4319; FUJITA M, 1989, J BACTERIOL, V171, P1333, DOI 10.1128/jb.171.3.1333-1339.1989; HEINE HG, 1988, J BACTERIOL, V170, P1730, DOI 10.1128/jb.170.4.1730-1738.1988; HENGGE R, 1983, BIOCHIM BIOPHYS ACTA, V737, P443, DOI 10.1016/0304-4157(83)90009-6; KAWAZU T, 1987, J BACTERIOL, V169, P1564, DOI 10.1128/jb.169.4.1564-1570.1987; KELLERMANN O, 1974, EUR J BIOCHEM, V47, P139, DOI 10.1111/j.1432-1033.1974.tb03677.x; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LAWLIS VB, 1984, APPL ENVIRON MICROB, V47, P15, DOI 10.1128/AEM.47.1.15-21.1984; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LIU L, 1987, NUCLEIC ACIDS RES, V15, P9461, DOI 10.1093/nar/15.22.9461; Maniatis T., 1982, MOL CLONING; Miller J.H., 1972, EXPT MOL GENETICS; MONOD J, 1950, Ann Inst Pasteur (Paris), V78, P65; NAKAJIMA R, 1986, APPL MICROBIOL BIOT, V23, P335; NAKAKUKI T, 1982, J JPN SOC STARCH SCI, V29, P179; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PALM D, 1985, NATURE, V313, P500, DOI 10.1038/313500a0; PALMER TN, 1976, EUR J BIOCHEM, V69, P105, DOI 10.1111/j.1432-1033.1976.tb10863.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PUGSLEY AP, 1988, MOL MICROBIOL, V2, P473, DOI 10.1111/j.1365-2958.1988.tb00053.x; RAIBAUD O, 1989, J MOL BIOL, V205, P471, DOI 10.1016/0022-2836(89)90218-0; RAIBAUD O, 1987, J BACTERIOL, V169, P3059, DOI 10.1128/jb.169.7.3059-3061.1987; RANDALLH.L, 1973, J BACTERIOL, V116, P1436, DOI 10.1128/JB.116.3.1436-1446.1973; REYES M, 1986, J BACTERIOL, V165, P918, DOI 10.1128/jb.165.3.918-922.1986; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; RICHTERICH P, 1989, BIOTECHNIQUES, V7, P52; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ M, 1967, EUR J BIOCHEM, V2, P132, DOI 10.1111/j.1432-1033.1967.tb00117.x; Schwartz M, 1987, ESCHERICHIA COLI SAL, P1482; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SVENSSON B, 1988, FEBS LETT, V230, P72, DOI 10.1016/0014-5793(88)80644-6; SZMELCMAN S, 1975, J BACTERIOL, V124, P112, DOI 10.1128/JB.124.1.112-118.1975; SZMELCMAN S, 1976, EUR J BIOCHEM, V65, P13, DOI 10.1111/j.1432-1033.1976.tb10383.x; TAPIO S, 1991, J BIOL CHEM, V266, P19450; UOZUMI N, 1989, J BACTERIOL, V171, P375, DOI 10.1128/jb.171.1.375-382.1989; VIDALINGIGLIARDI D, 1991, P NATL ACAD SCI USA, V88, P229, DOI 10.1073/pnas.88.1.229; VIDALINGIGLIARDI D, 1991, J MOL BIOL, V218, P323, DOI 10.1016/0022-2836(91)90715-I; VIHINEN M, 1989, CRIT REV BIOCHEM MOL, V24, P329, DOI 10.3109/10409238909082556; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WANG MD, 1987, J BACTERIOL, V169, P4228, DOI 10.1128/jb.169.9.4228-4234.1987; WIESMEYER H, 1960, BIOCHIM BIOPHYS ACTA, V39, P427, DOI 10.1016/0006-3002(60)90195-5; WIRSEL S, 1989, MOL MICROBIOL, V3, P3, DOI 10.1111/j.1365-2958.1989.tb00097.x; [No title captured]	69	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5148	5154						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544897				2022-12-27	WOS:A1992HH74700025
J	KOJIMA, T; SHWORAK, NW; ROSENBERG, RD				KOJIMA, T; SHWORAK, NW; ROSENBERG, RD			MOLECULAR-CLONING AND EXPRESSION OF 2 DISTINCT CDNA-ENCODING HEPARAN-SULFATE PROTEOGLYCAN CORE PROTEINS FROM A RAT ENDOTHELIAL-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; SURFACE; MEMBRANES; SEQUENCE; FIBROBLASTS; GROWTH; DOMAIN; GENE	The cloned rat fat pad endothelial cell (RFP-EC) line synthesizes anticoagulantly active heparan sulfate proteoglycans (HSPG(act)) and anticoagulantly inactive heparan sulfate proteoglycans (HSPG(inact)), both of which exhibit 25-, 30-, and 50-kDa core proteins of extremely similar structure. The primary sequences of internal peptides obtained from HSPG(inact) core proteins and the NH2-terminal sequence analyses of the 25-kDa component from the HSPG(inact) core proteins demonstrate that the 30-kDa component is a previously unidentified species, designated as ryudocan, with the 25-kDa component representing a proteolytic degradation product, while the 50-kDa component is the rat homolog of syndecan (Saunders, S. Jalkanen, M., O'Farrell, S., and Bernfield, M. (1989) J. Cell Biol. 108, 1547-1556). Specific oligonucleotide probes were obtained for ryudocan and syndecan by polymerase chain reaction, and the corresponding cDNAs were isolated from a RFP-EC library. The cDNAs encode type I integral membrane proteins of 202 and 313 amino acids, respectively, which have homologous transmembrane and intracellular domains but very distinct extracellular regions. In particular, ryudocan exhibits only three potential glycosaminoglycan attachment sites within the extracellular region while syndecan has five glycosaminoglycan attachment sites within the same domain. Both species are expressed in RFP-EC lines, primary rat aortic smooth muscle cells and primary rat skin fibroblast cells. The levels of ryudocan and syndecan mRNA were measured by quantitative polymerase chain reaction in primary microvascular endothelial cells and closely associated non-endothelial cells isolated by cell sorting. Ryudocan and syndecan MRNAs were abundantly expressed in both populations representing about 0.1-0.5% of mRNA.	MIT,DEPT BIOL,E25-229,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Shworak, Nicholas/AAJ-6770-2020; Kojima, Tetsuhito/I-6271-2014	Shworak, Nicholas/0000-0001-7783-4634; Kojima, Tetsuhito/0000-0002-1905-1065	NHLBI NIH HHS [HL41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEBENEK K, 1989, J BIOL CHEM, V264, P16948; CASTELLOT JJ, 1982, J BIOL CHEM, V257, P1256; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; DOI T, 1987, MOL CELL BIOL, V7, P898, DOI 10.1128/MCB.7.2.898; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MADRI JA, 1983, J CELL BIOL, V97, P153, DOI 10.1083/jcb.97.1.153; Maniatis T., 1982, MOL CLONING; MARCUM JA, 1985, BIOCHEM BIOPH RES CO, V126, P365, DOI 10.1016/0006-291X(85)90615-1; MARCUM JA, 1986, EXP CELL RES, V166, P253, DOI 10.1016/0014-4827(86)90525-2; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOREMEN KW, 1989, P NATL ACAD SCI USA, V86, P5276, DOI 10.1073/pnas.86.14.5276; OETTINGER HF, 1991, GENOMICS, V11, P334, DOI 10.1016/0888-7543(91)90140-A; PARKS DR, 1984, METHOD ENZYMOL, V108, P197; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VOYTA JC, 1984, J CELL BIOL, V99, pA81; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WEITZHANDLER M, 1988, J BIOL CHEM, V263, P6949; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	31	181	185	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4870	4877						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537865				2022-12-27	WOS:A1992HF64200086
J	GUFFANTI, AA; KRULWICH, TA				GUFFANTI, AA; KRULWICH, TA			FEATURES OF APPARENT NONCHEMIOSMOTIC ENERGIZATION OF OXIDATIVE-PHOSPHORYLATION BY ALKALIPHILIC BACILLUS-FIRMUS OF4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACULTATIVELY ALKALOPHILIC STRAINS; PROTON MOTIVE FORCE; ESCHERICHIA-COLI; STREPTOCOCCUS-LACTIS; NA+/H+ ANTIPORTER; MEMBRANE-VESICLES; RESPIRATORY-CHAIN; ATP SYNTHESIS; HIGH PH; TRANSPORT	Oxidative phosphorylation by extremely alkaliphilic Bacillus species violates two major predictions of the chemiosmotic hypothesis: the magnitude of the chemiosmotic driving force, the DELTA-p (electrochemical proton gradient), is too low to account for the phosphorylation potentials observed during growth at pH 10.5 without using a much higher H+/ATP stoichiometry than used during growth at pH 7.5, and artificially imposed diffusion potentials fail to energize ATP synthesis above about pH 9.5 (Guffanti, A. A., and Krulwich, T. A. (1989) Annu. Rev. Microbiol. 43, 435-463). To further examine the latter observation, large valinomycin-mediated potassium diffusion potentials were imposed across starved cells of Bacillus firmus OF4 at various pH values from pH 7.5 to 10.5. As the external pH increased above pH 8, there was a sharp decrease in the rate of ATP synthesis in response to an imposed diffusion potential. The rate of ATP synthesis fell to zero by pH 9.2 and 9.4, respectively, in the presence and absence of a small inwardly directed Na+ gradient. Electrogenic Na+/H+ antiport and Na+/alpha-aminoisobutyric acid symport proceeded at substantial rates throughout. When synthesis was energized by an electron donor, cells under comparable conditions synthesized ATP at rapid rates up to pH 10.5. The proton transfers that occur during respiration-dependent oxidative phosphorylation at pH 10.5 may depend upon specific complexes. Cells grown at pH 7.5, which have one-third the levels of the caa3-type terminal oxidase, and slightly lower levels of certain other respiratory chain complexes than pH 10.5-grown cells, support only low rates of ATP synthesis at pH 10.5, although energy-dependent symport and antiport rates are comparable with those in pH 10.5-grown cells. A model is presented for oxidative phosphorylation by the alkaliphilic Bacillus that involves a nonchemiosmotic direct intramembrane transfer of protons from specific respiratory chain complexes to the F0 sector of the ATPase, whereas remaining respiratory chain complexes extrude protons into the bulk to generate the bulk potential required both for ATP synthesis and other bioenergetic work. A pK-regulated gate or a delocalized proton pathway that fails to work above pH 9.5 are suggested as possible features that account for the loss of efficacy of a bulk-imposed diffusion potential in energizing ATP synthesis above pH 9.4.	CUNY MT SINAI SCH MED, DEPT BIOCHEM, BOX 1020, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028454] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28454] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKKER EP, 1982, BIOCHIM BIOPHYS ACTA, V681, P474, DOI 10.1016/0005-2728(82)90190-6; BRISKIN DP, 1991, PLANT PHYSIOL, V95, P242, DOI 10.1104/pp.95.1.242; CLEJAN S, 1986, J BACTERIOL, V168, P334, DOI 10.1128/jb.168.1.334-340.1986; Cramer W.A., 1990, ENERGY TRANSDUCTION; DEVRIJ W, 1986, EUR J BIOCHEM, V156, P431; DILLEY RA, 1989, ANN NY ACAD SCI, V574, P246; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; DIMROTH P, 1991, BIOESSAYS, V13, P463, DOI 10.1002/bies.950130906; FERGUSON SJ, 1985, BIOCHIM BIOPHYS ACTA, V811, P47, DOI 10.1016/0304-4173(85)90005-9; GARCIA ML, 1983, J BACTERIOL, V156, P1151, DOI 10.1128/JB.156.3.1151-1157.1983; GUFFANTI AA, 1988, J BIOL CHEM, V263, P14748; GUFFANTI AA, 1986, J BACTERIOL, V167, P766, DOI 10.1128/jb.167.3.766-773.1986; GUFFANTI AA, 1978, J BIOL CHEM, V253, P708; GUFFANTI AA, 1984, J BIOL CHEM, V259, P2971; GUFFANTI AA, 1985, ARCH BIOCHEM BIOPHYS, V239, P327, DOI 10.1016/0003-9861(85)90695-2; GUFFANTI AA, 1987, J BACTERIOL, V169, P4469, DOI 10.1128/jb.169.10.4469-4478.1987; GUFFANTI AA, 1991, J GEN MICROBIOL, V137, P2375, DOI 10.1099/00221287-137-10-2375; GUPTE SS, 1991, BIOCHIM BIOPHYS ACTA, V1069, P131, DOI 10.1016/0005-2736(91)90114-N; HAINES TH, 1983, P NATL ACAD SCI-BIOL, V80, P160, DOI 10.1073/pnas.80.1.160; HICKS DB, 1991, J BACTERIOL, V173, P5010, DOI 10.1128/jb.173.16.5010-5016.1991; HICKS DB, 1990, J BIOL CHEM, V265, P20547; HICKS DB, 1986, J BIOL CHEM, V261, P2896; HIROTA N, 1983, J BIOL CHEM, V258, P577; HOFFMANN A, 1991, EUR J BIOCHEM, V196, P493, DOI 10.1111/j.1432-1033.1991.tb15841.x; HOFFMANN A, 1991, EUR J BIOCHEM, V201, P467, DOI 10.1111/j.1432-1033.1991.tb16304.x; HORNER RD, 1986, J BIOL CHEM, V261, P3408; IVEY DM, 1991, MOL GEN GENET, V229, P292, DOI 10.1007/BF00272169; IVEY DM, 1990, MOSBACH C, V41, P105; KASHKET ER, 1980, J BACTERIOL, V143, P128, DOI 10.1128/JB.143.1.128-134.1980; KITADA M, 1983, J BACTERIOL, V154, P330, DOI 10.1128/JB.154.1.330-335.1983; KITADA M, 1982, J BACTERIOL, V152, P1096; KRULWICH TA, 1989, J BIOENERG BIOMEMBR, V21, P663, DOI 10.1007/BF00762685; KRULWICH TA, 1989, ANNU REV MICROBIOL, V43, P435; KRULWICH TA, 1985, J BIOL CHEM, V260, P4055; KRULWICH TA, 1981, FEMS MICROBIOL LETT, V133, P299; LAUBINGER W, 1988, BIOCHEMISTRY-US, V27, P7531, DOI 10.1021/bi00419a053; LEWIS RJ, 1981, J BIOL CHEM, V256, P543; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1961, BIOL REV CAMB PHILOS, V41, P451; POOLMAN B, 1987, J BACTERIOL, V169, P2755, DOI 10.1128/jb.169.6.2755-2761.1987; QUIRK PG, 1991, BIOCHIM BIOPHYS ACTA, V1058, P131, DOI 10.1016/S0005-2728(05)80229-4; ROHDE M, 1989, BIOCHIM BIOPHYS ACTA, V985, P233, DOI 10.1016/0005-2736(89)90369-6; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1018, P1, DOI 10.1016/0005-2728(90)90103-B; ROTTENBERG H, 1985, MODERN CELL BIOL, V4, P47; ROTTENBERG H, 1984, J MEMBRANE BIOL, V81, P1127; SCHULDINER S, 1975, BIOCHEMISTRY-US, V14, P5451, DOI 10.1021/bi00696a011; SLATER EC, 1987, EUR J BIOCHEM, V166, P489, DOI 10.1111/j.1432-1033.1987.tb13542.x; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; TEISSIE J, 1990, BIOCHEMISTRY-US, V29, P59, DOI 10.1021/bi00453a008; WESTERHOFF HV, 1984, FEBS LETT, V165, P1, DOI 10.1016/0014-5793(84)80002-2; WILLIAMS RJP, 1961, J THEOR BIOL, V1, P1, DOI 10.1016/0022-5193(61)90023-6; ZARITSKY A, 1981, J MEMBRANE BIOL, V63, P215, DOI 10.1007/BF01870983; ZILBERSTEIN D, 1982, J BIOL CHEM, V257, P3687	54	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9580	9588						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577797				2022-12-27	WOS:A1992HT96500023
J	ISAAC, L; ISENMAN, DE				ISAAC, L; ISENMAN, DE			STRUCTURAL REQUIREMENTS FOR THIOESTER BOND FORMATION IN HUMAN-COMPLEMENT COMPONENT C3 - REASSESSMENT OF THE ROLE OF THIOESTER BOND INTEGRITY ON THE CONFORMATION OF C3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE CDNA SEQUENCE; AMINO-ACID SEQUENCE; 4TH COMPONENT; 3RD COMPONENT; NUCLEOTIDE-SEQUENCE; NUCLEOPHILIC MODIFICATION; MURINE COMPLEMENT; THIOLESTER BOND; ALPHA-CHAIN; ALPHA-2-MACROGLOBULIN	A unique thioester bond, formed between the side chains of neighboring C and Q residues, is present in complement components C3 and C4 and the protease inhibitor alpha-2-macroglobulin. This structure is essential for mediating covalent attachment to target acceptors and also for maintaining these proteins in their native conformation. An examination of the residues in the immediate vicinity of the C and Q reveals a very high degree of sequence similarity among the three proteins which crosses species barriers. The following is the sequence flanking the thioester residues in C3, the highly conserved amino acids being underlined and the the thioester-forming residues being indicated by italics: 1005V-T-P-S-G-C-G-E-Q-N-M-I-G-M-T-P-T1021. Through a site-directed mutagenesis and cDNA expression approach, we have examined the importance of the conserved amino acids in the formation, stability, and function of the thioester bond in C3. The behavior of the mutants fell into three categories. The potential loss in peptide backbone flexibility by the replacement of G1009 by A or S was permissive to thioester formation and function as was replacement of M1015 by the still fairly bulky residue F. In contrast, replacement of M1015 by A resulted in an alpha-chain which was highly unstable toward proteolytic degradation. The third category, which included mutant molecules P1007G, P1020G, E1012Q, and Q1013N, displayed an unusual phenotype in which both the autolytic fragmentation and the hemolytic activity characteristics of thioester-intact molecules were absent. However, like their wildtype counter-part, these molecules retained the ability to be cleaved by C3 convertase (C4b2a), a conformation-dependent property that is normally lost in the conversion of native C3 to thioester-hydrolyzed C3(H2O). Since an identical functional profile was obtained when the thioester was deliberately prevented from forming in the mutant C101OA, we conclude that if a stable thioester fails to form during biosynthesis, at least parts of the mature protein can adopt a more native-like conformation than is the case when the thioester is first formed and then hydrolyzed in the mature protein. In view of these new findings, the interpretation of the previously observed correlation between the loss of thioester integrity and the adoption of a C3b-like conformation must be reassessed.	UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto			Isaac, Lourdes/I-7186-2012	Isaac, Lourdes/0000-0002-7746-8942				AUERBACH HS, 1990, J CLIN INVEST, V86, P96, DOI 10.1172/JCI114721; BELT KT, 1984, CELL, V36, P907; BJORK I, 1982, BIOCHEM J, V207, P347; BOLOTIN C, 1977, BIOCHEMISTRY-US, V16, P2008, DOI 10.1021/bi00628a039; COLE FS, 1985, J IMMUNOL, V134, P2610; COOPER NR, 1970, J EXP MED, V132, P775, DOI 10.1084/jem.132.4.775; COOPER NR, 1968, IMMUNOCHEMISTRY, V5, P155, DOI 10.1016/0019-2791(68)90100-6; DAVIES SG, 1981, BIOSCIENCE REP, V1, P461, DOI 10.1007/BF01121579; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; ENGHILD JJ, 1990, BIOCHEMISTRY-US, V29, P10070, DOI 10.1021/bi00495a009; FOTHERGILL J, 1982, NATURE, V298, P705, DOI 10.1038/298705a0; FRITZINGER D C, 1991, Complement and Inflammation, V8, P152; GEHRING MR, 1987, J BIOL CHEM, V262, P446; GIGLI I, 1976, BIOCHEM J, V157, P541, DOI 10.1042/bj1570541; GONIAS SL, 1983, ANN NY ACAD SCI, V421, P457, DOI 10.1111/j.1749-6632.1983.tb18139.x; HALL M, 1989, FEBS LETT, V254, P111, DOI 10.1016/0014-5793(89)81019-1; HARLOW E, 1988, ANTIBODIES LAB MANUA, P586; HOWARD JB, 1981, P NATL ACAD SCI-BIOL, V78, P2235, DOI 10.1073/pnas.78.4.2235; HOWARD JB, 1983, ANN NY ACAD SCI, V421, P160, DOI 10.1111/j.1749-6632.1983.tb18106.x; INOUYE S, 1987, SYNTHESIS APPLICATIO, P181; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; ISENMAN DE, 1983, ANN NY ACAD SCI, V421, P277, DOI 10.1111/j.1749-6632.1983.tb18115.x; ISENMAN DE, 1982, BIOCHEMISTRY-US, V21, P1109, DOI 10.1021/bi00535a001; JANATOVA J, 1980, BIOCHEMISTRY-US, V19, P4479, DOI 10.1021/bi00560a015; JANATOVA J, 1981, BIOCHEMISTRY-US, V20, P2394, DOI 10.1021/bi00512a005; KAN CC, 1985, P NATL ACAD SCI USA, V82, P2282, DOI 10.1073/pnas.82.8.2282; KARP DR, 1983, J BIOL CHEM, V258, P4490; KUSANO M, 1986, IMMUNOL INVEST, V15, P365, DOI 10.3109/08820138609052955; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; MISUMI Y, 1990, NUCLEIC ACIDS RES, V18, P2178, DOI 10.1093/nar/18.8.2178; NAGASAWA S, 1977, P NATL ACAD SCI USA, V74, P2998, DOI 10.1073/pnas.74.7.2998; NODA LH, 1953, J AM CHEM SOC, V75, P913, DOI 10.1021/ja01100a041; NONAKA M, 1991, Complement and Inflammation, V8, P200; OGATA RT, 1985, J IMMUNOL, V135, P4239; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PANGBURN MK, 1983, ANN NY ACAD SCI, V421, P291, DOI 10.1111/j.1749-6632.1983.tb18116.x; POLLEY MJ, 1967, J EXP MED, V126, P1013, DOI 10.1084/jem.126.6.1013; RAPP HJ, 1963, J IMMUNOL, V91, P826; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEPICH DS, 1985, P NATL ACAD SCI USA, V82, P5895, DOI 10.1073/pnas.82.17.5895; SIM RB, 1981, BIOCHEM J, V193, P129, DOI 10.1042/bj1930129; SOTTRUPJENSEN L, 1985, P NATL ACAD SCI USA, V82, P9, DOI 10.1073/pnas.82.1.9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; SPYCHER SE, 1987, J BIOL CHEM, V262, P14606; STOOPS JK, 1991, COMPLEMENT INFLAMMAT, V8, P226; STRAIGHT DL, 1983, BIOCHEMISTRY-US, V21, P4550; SUGGS SV, 1981, DEV BIOL USING PURIF, P683; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; TACK BF, 1983, SPRINGER SEMIN IMMUN, V6, P259, DOI 10.1007/BF02116276; TANIGUCHISIDLE A, 1992, J BIOL CHEM, V267, P635; THOMAS ML, 1983, BIOCHEMISTRY-US, V22, P942, DOI 10.1021/bi00273a036; THOMAS ML, 1982, P NATL ACAD SCI-BIOL, V79, P1054, DOI 10.1073/pnas.79.4.1054; WETSEL RA, 1984, J BIOL CHEM, V259, P3857	54	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10062	10069						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577777				2022-12-27	WOS:A1992HT96500093
J	YOSHIZUMI, M; KOUREMBANAS, S; TEMIZER, DH; CAMBRIA, RP; QUERTERMOUS, T; LEE, ME				YOSHIZUMI, M; KOUREMBANAS, S; TEMIZER, DH; CAMBRIA, RP; QUERTERMOUS, T; LEE, ME			TUMOR-NECROSIS-FACTOR INCREASES TRANSCRIPTION OF THE HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH-FACTOR GENE IN VASCULAR ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXPRESSION; ATHEROSCLEROSIS; PATHOGENESIS; CHAIN; ACID	Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a recently identified, potent vascular smooth muscle cell (SMC) mitogen of macrophage origin. To determine whether this gene is transcribed and regulated in vascular endothelial cells, we measured HB-EGF mRNA levels in human umbilical vein endothelial cells (HUVEC) by RNA blot analysis with an HB-EGF cDNA probe. The base-line level of HB-EFG mRNA in HUVEC in culture was low. However, tumor necrosis factor-alpha (TNF-alpha) and interleukin-1-beta markedly increased HB-EGF mRNA levels in HUVEC by 12- and 7-fold, respectively, and induction of the gene by TNF-alpha was both dose- and time-dependent. In response to TNF-alpha, HB-EGF mRNA levels quickly increased and peaked at 1 h, indicating that HB-EGF belongs to the family of immediate early genes. In nuclear run-off experiments, TNF-alpha increased the rate of HB-EGF gene transcription by 3.2-fold. To our knowledge this is the first demonstration that the HB-EGF gene is transcribed in vascular endothelial cells. The inducible transcription of this potent SMC mitogen gene in endothelial cells suggests that HB-EGF may have an important role in the pathogenesis of atherosclerosis.	MASSACHUSETTS GEN HOSP,GEN MED SERV,CARDIAC UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,SURG SERV,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN; CHILDRENS HOSP MED CTR,JOINT PROGRAM NEONATOL,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Tokyo; Harvard University; Boston Children's Hospital				Quertermous, Thomas/0000-0002-7645-9067				BARATH P, 1990, AM J PATHOL, V137, P503; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; DICORLETO PE, 1988, ENDOTHELIAL CELLS, V2, P51; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LEE ME, 1990, J CLIN INVEST, V86, P141, DOI 10.1172/JCI114677; LEE ME, 1991, J BIOL CHEM, V266, P16188; LIBBY P, 1991, LAB INVEST, V64, P5; LYNCH DC, 1985, CELL, V41, P49, DOI 10.1016/0092-8674(85)90060-1; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; MOYER CF, 1991, AM J PATHOL, V138, P951; MUNRO JM, 1988, LAB INVEST, V58, P249; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; VILCEK J, 1991, J BIOL CHEM, V266, P7313; [No title captured]	26	143	146	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9467	9469						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577791				2022-12-27	WOS:A1992HT96500005
J	CHENG, HC; NISHIO, H; HATASE, O; RALPH, S; WANG, JH				CHENG, HC; NISHIO, H; HATASE, O; RALPH, S; WANG, JH			A SYNTHETIC PEPTIDE DERIVED FROM P34CDC2 IS A SPECIFIC AND EFFICIENT SUBSTRATE OF SRC-FAMILY TYROSINE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; PHOSPHORYLATION; EXPRESSION; MEMBRANES; PRODUCT; CELLS; GENE	A peptide derived from p34cdc2, cdc2(6-20)NH2 with the amino acid sequence of KVEKIGEGTYGVVYK-amide, was found to be a specific and efficient substrate for a pp60c-src-related protein tyrosine kinase from bovine spleen (STK). Glu-12 and Thr-14 were identified to be substrate specificity determinants in this peptide (Cheng, H.-C., Litwin, C. M. E., Hwang, D. M., and Wang, J. H. (1991) J. Biol. Chem. 266, 17919-17925). In this study, we demonstrated the presence of cdc2(6-20)NH2 peptide tyrosine kinase activity in the membrane fractions of bovine brain, spleen, thymus, lung, liver, and kidney. Hydroxylapatite column chromatography of thymus membrane extract revealed four protein tyrosine kinases, TK-I, TK-II, TK-III, and TK-IV, with different relative activities toward cdc2(6-20)NH2 and a general tyrosine kinase substrate, poly(Glu/Tyr). Only TK-1 and TK-II showed significant activity toward cdc2(6-20)NH2, they were suggested as belonging to the src-family by virtue of their cross-reactivity with an antibody against a synthetic peptide corresponding to a conserved sequence of src-family kinases. Further immunological characterization using antibodies specific to individual src-related protein tyrosine kinases suggested that TK-I, TK-II, and STK are bovine homologs of p56lck, p55fyn, and p56lyn, respectively. Substrate specificity and kinetic characterization of src-family tyrosine kinases including human platelet pp60c-src, bovine p56lyn, p56lck, and p55fyn, as well as several non-src-related tyrosine kinases including epidermal growth factor receptor, p43v-abl, TK-III, and TK-IV showed that all the src-family tyrosine kinases but none of the other kinases displayed efficient cdc2(6-20)NH2 phosphorylation. In all cases, the high efficiency of cdc2(6-20) NH2 peptide phosphorylation could be markedly attenuated when Glu-12 and Thr-14 of the peptide were substituted, respectively, by valine and serine.	UNIV CALGARY, FAC MED, DEPT MED BIOCHEM, MED RES COUNCIL GRP SIGNAL TRANSDUCT, CALGARY T2N 4N1, ALBERTA, CANADA; KAGAWA MED SCH, DEPT PHYSIOL, KITA 76107, KAGAWA, JAPAN; ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, PARKVILLE, VIC 3050, AUSTRALIA	University of Calgary; Kagawa University; Ludwig Institute for Cancer Research; Royal Melbourne Hospital			Ralph, Stephen J./AAE-4888-2019	Ralph, Stephen J./0000-0002-4335-092X; Cheng, Heung-Chin/0000-0002-4965-7148				ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN S, 1984, J BIOL CHEM, V259, P2051; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; CHENG HC, 1991, J BIOL CHEM, V266, P17919; Corbin J D, 1974, Methods Enzymol, V38, P287; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FEDER D, 1990, J BIOL CHEM, V265, P8205; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOUSE C, 1984, EUR J BIOCHEM, V140, P363, DOI 10.1111/j.1432-1033.1984.tb08109.x; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1986, ENZYMES, V17, P192; KASUGA M, 1983, J BIOL CHEM, V258, P973; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PETERS DJ, 1990, ONCOGENE, V5, P1313; PIKE LJ, 1982, P NATL ACAD SCI-BIOL, V79, P1443, DOI 10.1073/pnas.79.5.1443; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; WONG TW, 1983, J BIOL CHEM, V258, P1022	28	162	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9248	9256						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577758				2022-12-27	WOS:A1992HR85400083
J	LEE, CM; HAUN, RS; TSAI, SC; MOSS, J; VAUGHAN, M				LEE, CM; HAUN, RS; TSAI, SC; MOSS, J; VAUGHAN, M			CHARACTERIZATION OF THE HUMAN GENE ENCODING ADP-RIBOSYLATION FACTOR-I, A GUANINE NUCLEOTIDE-BINDING ACTIVATOR OF CHOLERA-TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TRANSCRIPTION FACTOR; PROTEIN; PROMOTER; SEQUENCE; ACID; MATURATION; POLY(A); SUBUNIT; SITE	Mammalian ADP-ribosylation factors (ARFs), approximately 20-kDa guanine nucleotide-binding proteins that stimulate cholera toxin ADP-ribosyltransferase activity, were grouped into three classes based on deduced amino acid sequence. Human ARF 1, a class I ARF, is identical with its bovine counterpart, has a distinctive pattern of tissue and developmental expression, and is encoded by a approximately 1.9-kilobase mRNA. ARF 1 cDNAs were isolated from a human fibroblast cDNA library; one arose via an alternative polyadenylation signal (AA-TACA) 84 nucleotides 5' to the polyadenylation signal (AATAAA) used in the 1815-base pair cDNA. The polyadenylation signals, their respective locations, and the surrounding nucleotide sequences are conserved in human and rat. The human ARF 1 gene, with four introns, spans approximately 16.5 kilobases. Exon 1 (46 base pairs) contains only untranslated sequence. Translation initiates in exon 2, which encodes the sequence GXXXXGK involved in phosphate binding (GTP hydrolysis). The sequence DVGG is encoded in exon 3, and NKQD, which is involved in the interaction with the guanine ring, is interrupted following the codon for Q by intron 4. The carboxyl-terminal 53 amino acids and > 1110 base pairs of 3'-untranslated region are encoded in exon 5. Primer extension and mung bean and S1 nuclease mapping indicated multiple transcription initiation sites and were consistent with Northern analyses. The 5'-flanking region has a high GC content but no TATA or CAAT box, as found in housekeeping genes. In addition, the two human class I ARF genes, ARF 1 and ARF 3, have similar exon/intron organizations and use GC-rich promoters.			LEE, CM (corresponding author), NHLBI, CELLULAR METAB LAB, RM 5N307, BLDG 10, BETHESDA, MD 20892 USA.		Lee, Chii-Ming/M-7799-2015	Lee, Chii-Ming/0000-0002-1075-5787				ATWATER JA, 1990, ANNU REV GENET, V24, P519; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, ADP RIBOSYLATING TOX, P439; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FROHMAN MA, 1990, AMPLIFICATIONS, V5, P11; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HEATH CV, 1990, J BIOL CHEM, V265, P9098; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; MURTAGH JJ, 1992, IN PRESS J BIOL CHEM, V266; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; ROSCHER AA, 1983, J CLIN INVEST, V72, P626, DOI 10.1172/JCI111012; SAMBROOK J, 1989, MOL CLONING LABORATO, pCH7; SANDBERG M, 1990, BIOCHEM BIOPH RES CO, V167, P323, DOI 10.1016/0006-291X(90)91768-N; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TSAI SC, 1991, J BIOL CHEM, V266, P23053; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSUCHIYA M, 1989, BIOCHEMISTRY-US, V28, P9668, DOI 10.1021/bi00451a019; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6	36	44	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9028	9034						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577740				2022-12-27	WOS:A1992HR85400051
J	DUFFY, EJ; LOLLAR, P				DUFFY, EJ; LOLLAR, P			INTRINSIC PATHWAY ACTIVATION OF FACTOR-X AND ITS ACTIVATION PEPTIDE-DEFICIENT DERIVATIVE, FACTOR XDES-143-191	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; BOVINE FACTOR-X; BLOOD-COAGULATION; HUMAN-LEUKOCYTE; PROTEINS; SPECIFICITY; THROMBIN; ELASTASE; CHROMATOGRAPHY; CATALYSIS	The role of the activation peptide in determining the substrate specificity of intrinsic pathway factor X (fX) activation was studied by using a novel derivative of fX in which 49 residues were removed enzymatically from the NH, terminus of the 52-residue activation peptide by an enzyme from the venom of the snake Agkistrodon rhodostoma. The modified protein, designated fX(des-143-191), is inactive but is activated to alpha-fXa by either the intrinsic fX activation complex (intrinsic fXase) composed of factor IXa-beta, thrombin-activated factor VIII (fVIIIa(IIa)), and phospholipid vesicles or by the fX coagulant protein from Russell's viper venom (RVV-XCP). Both the K(m) and k(cat) for the activation of fX by RVVXCP were greater than for fX(des-143-191), resulting in less than a 2-fold difference in the catalytic efficiency (k(cat)/K(m)) suggestive of nonproductive binding of fX(des-143-191) to RVV-XCP. The activation of each substrate by intrinsic fXase revealed that the k(cat) was 100-fold greater for fX than fX(des-143-191) (16 and 0.16 s-1, respectively), although there was no detectable difference in K(m) (60 and 80 nM, respectively). Activations by fIXa-beta/phospholipid in the absence of fVIIIa(IIa) also revealed a difference in k(cat) but not K(m), but the difference in k(cat) was smaller (k(cat) of 0.007 and 0.002 s-1 and K(m) of 220 and 170 nM for fX and fX(des-143-191), respectively). Analysis of product versus time curves demonstrated that fVIIIa(IIa) promotes formation of the acyl-enzyme intermediate during fX activation. We conclude that the activation peptide plays a critical role during acyl-enzyme formation that is most pronounced in the presence of fVIIIa(IIa). The absence of K(m) differences suggests that residues NH2-terminal to P3 do not contribute to the initial formation of the enzyme-substrate complex.	EMORY UNIV,DEPT MED,DIV HEMATOL ONCOL,DRAWER AJ,ATLANTA,GA 30322	Emory University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL035058, R01HL040921] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35058, HL-40921] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BEALS JM, 1989, ARCH BIOCHEM BIOPHYS, V268, P485, DOI 10.1016/0003-9861(89)90316-0; BENDER ML, 1967, J CHEM EDUC, V44, P84, DOI 10.1021/ed044p84; Bevington P.R., 1969, DATA REDUCTION ERROR; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; Cantor C. R, 1980, BIOPHYSICAL CHEM 2, P591; CASTILLO MJ, 1983, BIOCHEMISTRY-US, V22, P121; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DAVIE EW, 1987, HEMOSTASIS THROMBOSI, P242; FERSHT A, 1985, ENZYME STRUCTURE MEC, P121; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KOSOW DP, 1976, THROMB RES, V9, P565, DOI 10.1016/0049-3848(76)90104-3; KOSOW DP, 1974, THROMB RES, V4, P29; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1987, BIOCHEMISTRY-US, V26, P7627, DOI 10.1021/bi00398a015; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERTENS K, 1980, BIOCHEM J, V185, P647, DOI 10.1042/bj1850647; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; ROSING J, 1980, J BIOL CHEM, V255, P274; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STEIN RL, 1987, BIOCHEMISTRY-US, V26, P1301, DOI 10.1021/bi00379a015; STROUD RM, 1977, ANNU REV BIOPHYS BIO, V6, P177, DOI 10.1146/annurev.bb.06.060177.001141; THOMPSON RC, 1973, BIOCHEMISTRY-US, V12, P57, DOI 10.1021/bi00725a011; THOMPSON RC, 1974, BIOCHEMISTRY-US, V13, P5495, DOI 10.1021/bi00724a007; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VANIERSEL J, 1985, ANAL BIOCHEM, V151, P196, DOI 10.1016/0003-2697(85)90072-7	33	59	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7821	7827						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560014				2022-12-27	WOS:A1992HN48500087
J	HAGLER, J; SHUMAN, S				HAGLER, J; SHUMAN, S			STABILITY OF TERNARY TRANSCRIPTION COMPLEXES OF VACCINIA VIRUS-RNA POLYMERASE AT PROMOTER-PROXIMAL POSITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC UV5 PROMOTER; MESSENGER-RNA; II INVITRO; INITIATION; TERMINATION; PURIFICATION; ELONGATION; VIRIONS; RELEASE; ENZYME	We have used DNA templates containing a vaccinia early promoter fused to G-less cassettes of varying length to study the formation of ternary transcription complexes by vaccinia virus RNA polymerase. Elongating polymerases were induced to pause at discrete sites on the DNA template by omission of GTP from transcription reactions. For most of the templates examined, the predominant sites of pausing were at or near the downstream border of the G-less transcription unit, as revealed by the size distribution of labeled RNAs synthesized in pulse-labeling reactions. Stability of ternary complexes containing nascent RNAs of any given length was assessed by the ability of these RNAs to be elongated upon provision of GTP. This criterion of stability could be met by complexes containing nascent RNAs as short as seven, eight, or nine nucleotides. In the presence of 3'-OMeGTP, nearly homogeneous populations of 3'-coterminal elongation complexes were positioned at the first G residue of the template. 3'-OMeG-arrested polymerases resumed elongation upon addition of GTP, apparently via sequential pyrophosphorolysis and nucleotide exchange at the site of elongation block. The ability to fix the 3' end facilitated analysis of initiation site choice based on the sizes of short nascent transcripts. Site choice was flexible and depended on the concentration of both the potential initiating NTP and the donor NTP participating in first phosphodiester bond formation. RNA polymerase could initiate at multiple positions within a nine-nucleotide region of the template. The rate of chain elongation by vaccinia polymerase during a single synchronous round of RNA synthesis was found to be 20-50 nucleotides per second.			HAGLER, J (corresponding author), SLOAN KETTERING MEM CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM 42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; BROYLES SS, 1991, J BIOL CHEM, V266, P15539; BROYLES SS, 1991, J BIOL CHEM, V266, P15545; BROYLES SS, 1990, J VIROL, V64, P1523, DOI 10.1128/JVI.64.4.1523-1529.1990; CAI H, 1987, J BIOL CHEM, V262, P298; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; GERSHON PD, 1990, P NATL ACAD SCI USA, V87, P4401, DOI 10.1073/pnas.87.11.4401; HAGLER J, 1992, IN PRESS SCIENCE; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KRAKOW JS, 1976, RNA POLYMERASE, P127; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LUO Y, 1991, J BIOL CHEM, V266, P13303; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MOSS B, 1976, VIROLOGY, V72, P341, DOI 10.1016/0042-6822(76)90163-X; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782	29	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7644	7654						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559999				2022-12-27	WOS:A1992HN48500064
J	LUNDGREN, DW				LUNDGREN, DW			EFFECT OF HYPOTONIC STRESS ON ORNITHINE DECARBOXYLASE MESSENGER-RNA EXPRESSION IN CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; GROWTH; DNA	This report examines the effect of hypotonic stress on ornithine decarboxylase (ODC) activity and ODC mRNA concentrations in LLC-PK1 cells. Earle's balanced salts solution minus glucose (EBSS-G) with decreasing concentrations of NaCl was utilized as the ODC induction medium. Hypotonic EBSS-G increased both the concentration of ODC mRNA and the specific activity of ODC in LLC-PK1 cells. Actinomycin D and cycloheximide prevented the increase in enzyme activity resulting from hypotonic stress. Actinomycin D was also a potent inhibitor of ODC mRNA expression resulting from hypotonic stress. Cycloheximide had very little effect on the induction of ODC mRNA in cells incubated in hypotonic EBSS-G. The magnitude of the increase in both ODC mRNA concentrations and enzyme activity was dependent on the incubation time in hypotonic media. The increase in ODC mRNA concentrations preceded the elevation in enzyme activity. ODC mRNA concentrations and the specific activity of ODC increased as a function of decreasing media osmolarity. The addition of purtrescine, spermidine, and spermine to EBSS-G containing reduced NaCl suppressed the increase in LLC-PK1 ODC activity related to hypotonic stress. In contrast, these polyamines did not prevent the increase in ODC mRNA resulting from hypotonic shock. Furthermore, it was demonstrated that hypotonic stress increases ODC mRNA levels and enzyme activity in four additional cell lines from two different species. Based on these results it is suggested that one or more signal transducers associated with cell volume expansion enhance expression of the ODC gene.			LUNDGREN, DW (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,METROHLTH MED CTR,DEPT PEDIAT,RES BLDG,RM 346,3395 SCRANTON RD,CLEVELAND,OH 44109, USA.				NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [CA-43703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGER SL, 1987, GUIDE MOL CLONING TE, P49; BUTLER AP, 1991, EXP CELL RES, V194, P56, DOI 10.1016/0014-4827(91)90129-I; DAVIS LG, 1986, BASIC METHODS MOL BI, P84; FEINSTEIN SC, 1985, P NATL ACAD SCI USA, V82, P5761, DOI 10.1073/pnas.82.17.5761; FRIEDMAN Y, 1977, BIOCHEM BIOPH RES CO, V77, P57, DOI 10.1016/S0006-291X(77)80164-2; GINTY DD, 1990, AM J PHYSIOL, V258, pG454, DOI 10.1152/ajpgi.1990.258.3.G454; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P1; HICKOK NJ, 1987, DNA-J MOLEC CELL BIO, V6, P179, DOI 10.1089/dna.1987.6.179; KAHANA C, 1985, J BIOL CHEM, V260, P5390; KAPYAHO K, 1981, BIOCHIM BIOPHYS ACTA, V714, P93; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LUNDGREN DW, 1990, AM J PHYSIOL, V259, pC647, DOI 10.1152/ajpcell.1990.259.4.C647; MCCONLOGUE L, 1984, P NATL ACAD SCI-BIOL, V81, P540, DOI 10.1073/pnas.81.2.540; MITCHELL JLA, 1985, BIOCHEM J, V228, P297, DOI 10.1042/bj2280297; MUNRO GF, 1972, J BIOL CHEM, V247, P1272; MUNRO GF, 1975, BIOCHIM BIOPHYS ACTA, V411, P263, DOI 10.1016/0304-4165(75)90306-2; PERRY JW, 1980, BIOCHIM BIOPHYS ACTA, V629, P24, DOI 10.1016/0304-4165(80)90261-5; POULIN R, 1991, J BIOL CHEM, V266, P6142; POULIN R, 1990, J BIOL CHEM, V265, P4025; Rosen K., 1990, FOCUS, V12, P23; SCALABRINO G, 1991, MOL CELL ENDOCRINOL, V77, P1, DOI 10.1016/0303-7207(91)90056-X; SCALABRINO G, 1991, MOL CELL ENDOCRINOL, V77, P37, DOI 10.1016/0303-7207(91)90057-Y; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; VICEPSMADORE D, 1982, BIOCHIM BIOPHYS ACTA, V717, P305, DOI 10.1016/0304-4165(82)90184-2	25	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6841	6847						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551891				2022-12-27	WOS:A1992HM05300059
J	LARSON, TJ; CANTWELL, JS; VANLOOBHATTACHARYA, AT				LARSON, TJ; CANTWELL, JS; VANLOOBHATTACHARYA, AT			INTERACTION AT A DISTANCE BETWEEN MULTIPLE OPERATORS CONTROLS THE ADJACENT, DIVERGENTLY TRANSCRIBED GLPTQ-GLPACB OPERONS OF ESCHERICHIA-COLI K-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC SN-GLYCEROL-3-PHOSPHATE DEHYDROGENASE; MOLECULAR GENETIC-ANALYSIS; NUCLEOTIDE-SEQUENCE; DNA; CLONING; REGULON; IDENTIFICATION; PROMOTER; PROTEIN; EXPRESSION	The glp regulon of Escherichia coli encodes the proteins required for utilization of sn-glycerol 3-phosphate and its precursors. Transcription of the divergently transcribed glpTQ and glpACB operons is initiated at sites separated by 132 base pairs (bp) of DNA. These operons are controlled negatively by glp repressor and positively by the cAMP-cAMP receptor protein (CRP) complex. The locations of the binding sites for the glp repressor and for cAMP . CRP in the control regions of these operons were determined by DNase I footprinting. Binding of the glp repressor protected the region -32 to -51 (O(T)) in the glpTQ promoter, which was also the binding site for cAMP . CRP. Four repressor binding sites (-41 to -60 (O(A)1), -9 to -28 (O(A)2), +12 to -8 (O(A)3), and +52 to +33 (O(A)4)) and two cAMP . CRP binding sites (+11 to -11 and -30 to -51) were found in the glpACB promoter region. Comparison of the sequences of the repressor binding sites found in the glpTQ-glpACB control region with those operators previously described in the glpD operon allowed formulation of a consensus operator sequence which was the palindrome 5'-WATGTTCGWTAWCGAACATW-3' (W is A or T). The role of each operator was assessed by measuring repression in constructs where individual operators were altered by site-directed mutagenesis. Alteration Of OT did not significantly decrease repression of either operon. Each of the glpACB operators contributed to repression of both operons. These results suggest involvement of glpACB operator(s) in control of glpTQ expression perhaps via formation of a repression loop. Evidence supporting this hypothesis was obtained by measuring the degree of repression of the glpTQ promoter in constructs containing 6- or 10-bp insertions between the glpTQ and glpACB operators. A 6-bp insertion located within O(A)2 or between O(T) and O(A)1 eliminated repression of the glpTQ promoter, whereas significant repression was maintained in the case of a 10-bp insertion within O(A)2.			LARSON, TJ (corresponding author), VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM & NUTR,BLACKSBURG,VA 24061, USA.							ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; ADHYA S, 1982, CELL, V29, P939, DOI 10.1016/0092-8674(82)90456-1; AUSTIN D, 1991, J BACTERIOL, V173, P101, DOI 10.1128/jb.173.1.101-107.1991; BELL AI, 1990, MOL MICROBIOL, V4, P1753, DOI 10.1111/j.1365-2958.1990.tb00553.x; BLAZY B, 1986, J BIOL CHEM, V261, P1645; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLARK DJ, 1967, J MOL BIOL, V23, P99, DOI 10.1016/S0022-2836(67)80070-6; COLE ST, 1988, J BACTERIOL, V170, P2448, DOI 10.1128/jb.170.6.2448-2456.1988; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; DORMAN CJ, 1988, J BACTERIOL, V170, P2816, DOI 10.1128/jb.170.6.2816-2826.1988; EHRMANN M, 1987, J BACTERIOL, V169, P526, DOI 10.1128/jb.169.2.526-532.1987; EIGLMEIER K, 1987, MOL MICROBIOL, V1, P251, DOI 10.1111/j.1365-2958.1987.tb01931.x; EIGLMEIER K, 1989, MOL MICROBIOL, V3, P869, DOI 10.1111/j.1365-2958.1989.tb00236.x; FREEDBERG WB, 1973, J BACTERIOL, V115, P816, DOI 10.1128/JB.115.3.816-823.1973; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; GRALLA JD, 1989, CELL, V57, P193, DOI 10.1016/0092-8674(89)90955-0; GUSSIN GN, 1983, LAMBDA, V2, P93; HARMAN JG, 1986, J BIOL CHEM, V261, P6332; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; IUCHI S, 1990, J BACTERIOL, V172, P179, DOI 10.1128/JB.172.1.179-184.1990; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P368; KURITZKES DR, 1984, J BACTERIOL, V157, P591, DOI 10.1128/JB.157.2.591-598.1984; LARSON TJ, 1987, J BIOL CHEM, V262, P15869; LARSON TJ, 1982, J BACTERIOL, V152, P1008; LIN ECC, 1976, ANNU REV MICROBIOL, V30, P535, DOI 10.1146/annurev.mi.30.100176.002535; LIN ECC, 1987, ESCHERICHIA COLI SAL, V1, P244; Liss L, 1987, FOCUS, V9, P13; LUPSKI JR, 1990, J BACTERIOL, V172, P6129, DOI 10.1128/jb.172.10.6129-6134.1990; Miller J. H, 1972, EXPT MOL GENETICS; RODRIGUEZ RL, 1983, RECOMBINANT DNA TECH, P164; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER K, 1987, METHOD ENZYMOL, V153, P452; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHWEIZER H, 1987, J BACTERIOL, V169, P507, DOI 10.1128/jb.169.2.507-513.1987; SCHWEIZER H, 1986, MOL GEN GENET, V202, P488, DOI 10.1007/BF00333282; SCHWEIZER H, 1985, J BACTERIOL, V161, P563, DOI 10.1128/JB.161.2.563-566.1985; SWEET G, 1990, J BACTERIOL, V172, P424, DOI 10.1128/JB.172.1.424-430.1990; TOMMASSEN J, 1991, MOL GEN GENET, V226, P321, DOI 10.1007/BF00273621; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; WALKER MS, 1991, MOL MICROBIOL, V5, P353, DOI 10.1111/j.1365-2958.1991.tb02116.x; WEISSENBORN DL, 1992, J BIOL CHEM, V267, P6122; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YE SZ, 1988, J BACTERIOL, V170, P4209, DOI 10.1128/jb.170.9.4209-4215.1988; ZHANG XP, 1990, J BIOL CHEM, V265, P12400	47	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6114	6121						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556120				2022-12-27	WOS:A1992HK31800061
J	BIDANSET, DJ; GUIDRY, C; ROSENBERG, LC; CHOI, HU; TIMPL, R; HOOK, M				BIDANSET, DJ; GUIDRY, C; ROSENBERG, LC; CHOI, HU; TIMPL, R; HOOK, M			BINDING OF THE PROTEOGLYCAN DECORIN TO COLLAGEN TYPE-VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCAN; AMINO-ACID SEQUENCE; ALPHA-3 CHAIN; VONWILLEBRAND-FACTOR; GLYCOPROTEIN-IB; SACCHAROMYCES-CEREVISIAE; CONNECTIVE TISSUES; GLOBULAR DOMAINS; ADENYLYL CYCLASE; MOSAIC STRUCTURE	We have examined the interactions between the small dermatan sulfate proteoglycan decorin and collagen types I-VI using solid phase binding assays. The results of these studies showed that I-125-decorin bound most efficiently to collagen type VI in a time- and concentration-dependent manner. Furthermore, this interaction was specific and of moderately high affinity (K(d) approximately 3 x 10(-7) M). Binding of decorin to collagen type VI appears to involve the decorin core protein rather than the glycosaminoglycan side chains, since the isolated core protein as well as a recombinant fusion protein containing a major segment (65%) of the human decorin core protein inhibited binding of I-125-decorin to collagen type VI. Other related proteoglycans and their respective core proteins also inhibited the binding of I-125-decorin to collagen type VI, whereas unrelated proteins and isolated glycosaminoglycan chains were without effect. In addition to decorin, collagen type II was also shown to bind to immobilized collagen type VI. Both interactions were effectively inhibited by preincubation of the immobilized collagen VI with decorin or collagen type II. These results suggested that the collagen type VI molecule has binding sites for collagen type II and decorin which are located in close proximity on the collagen type VI molecule. Possible functional roles of these interactions are discussed.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; MONTEFIORE MED CTR,ORTHOPED RES LABS,BRONX,NY 10467; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	University of Alabama System; University of Alabama Birmingham; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Max Planck Society	BIDANSET, DJ (corresponding author), UNIV ALABAMA,DEPT BIOCHEM,1918 UNIV BLVD,BHSB 508,BIRMINGHAM,AL 35294, USA.				NIADDK NIH HHS [AM27807] Funding Source: Medline; NIAMS NIH HHS [AR34614, AR21498] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM027807] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR021498, R01AR034614] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; BONALDO P, 1989, J BIOL CHEM, V264, P20235; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; BRUNS RR, 1986, J CELL BIOL, V103, P393, DOI 10.1083/jcb.103.2.393; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1988, J BIOL CHEM, V263, P18601; CHU ML, 1987, EUR J BIOCHEM, V168, P309, DOI 10.1111/j.1432-1033.1987.tb13422.x; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; CHUNG E, 1976, BIOCHEM BIOPH RES CO, V71, P1167, DOI 10.1016/0006-291X(76)90776-2; COLICELLI J, 1990, MOL CELL BIOL, V10, P2539, DOI 10.1128/MCB.10.6.2539; COLOMBATTI A, 1987, J BIOL CHEM, V262, P14454; COLOMBATTI A, 1989, MATRIX, V9, P177, DOI 10.1016/S0934-8832(89)80048-4; DOLIANA R, 1990, J CELL BIOL, V111, P2197, DOI 10.1083/jcb.111.5.2197; ENGEL J, 1985, ANN NY ACAD SCI, V460, P25, DOI 10.1111/j.1749-6632.1985.tb51154.x; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; HAUSSER H, 1989, BIOCHEM J, V263, P137, DOI 10.1042/bj2630137; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; KATOAKA T, 1985, CELL, V43, P493; KOLLER E, 1989, EMBO J, V8, P1073, DOI 10.1002/j.1460-2075.1989.tb03475.x; LEE FS, 1990, P NATL ACAD SCI USA, V87, P1876; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; OBRINK B, 1973, EUR J BIOCHEM, V33, P387, DOI 10.1111/j.1432-1033.1973.tb02695.x; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; OIKE Y, 1982, J BIOL CHEM, V257, P9751; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; ORR GA, 1981, J BIOL CHEM, V256, P761; PARETI FI, 1987, J BIOL CHEM, V262, P13835; PLAAS AHK, 1989, J BIOL CHEM, V264, P14447; POOLE AR, 1986, J HISTOCHEM CYTOCHEM, V34, P619, DOI 10.1177/34.5.3701029; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1404; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; ROSENBERG LC, 1986, CIBA F SYMP, V124, P47; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCOTT JE, 1986, CIBA F SYMP, V124, P104; SCOTT JE, 1985, BIOSCIENCE REP, V5, P71, DOI 10.1007/BF01117443; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; SCOTT JE, 1985, BIOSCIENCE REP, V5, P765, DOI 10.1007/BF01119875; STALLCUP WB, 1990, J CELL BIOL, V111, P3177, DOI 10.1083/jcb.111.6.3177; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TRUEB B, 1986, EMBO J, V5, P2815, DOI 10.1002/j.1460-2075.1986.tb04573.x; ULDBJERG N, 1988, BIOCHEM J, V251, P643, DOI 10.1042/bj2510643; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YOUNG RD, 1985, J CELL SCI, V74, P95	55	311	314	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5250	5256						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544908				2022-12-27	WOS:A1992HH74700041
J	MEDIN, JA; COLEMAN, MS				MEDIN, JA; COLEMAN, MS			LACK OF FUNCTIONAL-SIGNIFICANCE OF CYS(227) AND CYS(234) IN TERMINAL DEOXYNUCLEOTIDYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERASE; EXPRESSION; GENE; DNA	Identification of the three functional regions (catalytic, nucleotide substrate-binding, DNA substrate-binding) of the monofunctional template independent DNA polymerase terminal deoxynucleotidyltransferase has not been completely established. The potential participation of 2 amino acid residues, Cys227 and Cys234, has been controversial, and conflicting data have been published. To investigate the role of Cys227, the human terminal transferase cDNA was modified by site-directed mutagenesis to introduce a glycine codon at this position. Mutant and control wild-type human terminal transferase cDNAs had to be inserted into baculovirus genomes by homologous recombination and overexpressed in Trichoplusia ni insect larvae because terminal transferase cDNAs have not been successfully expressed in bacterial systems. The Cys227 --> Gly mutant and wild-type enzymes displayed similar k(m) values for both the nucleotide (dGTP) and DNA initiator (dA50) substrates. The k(cat) for the mutant enzyme (0.56 s-1) was comparable to that of the native enzyme (0.58 s-1). Additionally, catalysis by both mutant and wild-type enzymes was stimulated by Zn2+. These results together with the observation that the amino acid residue at position 234 is not conserved across species indicated that neither Cys234 nor Cys227 is an essential residue in the active site of terminal transferase.			MEDIN, JA (corresponding author), UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.				NATIONAL CANCER INSTITUTE [R01CA026391] Funding Source: NIH RePORTER; NCI NIH HHS [CA26391] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; CHANG LMS, 1988, J BIOL CHEM, V263, P12509; CHANG LMS, 1990, J BIOL CHEM, V265, P17436; DEIBEL MR, 1980, J BIOL CHEM, V255, P4206; DEIBEL MR, 1980, ARCH BIOCHEM BIOPHYS, V202, P414, DOI 10.1016/0003-9861(80)90445-2; EVANS RK, 1989, BIOCHEMISTRY-US, V28, P707, DOI 10.1021/bi00428a044; EVANS RK, 1989, BIOCHEMISTRY-US, V28, P713, DOI 10.1021/bi00428a045; FARRAR YJK, 1991, BIOCHEMISTRY-US, V30, P3075, DOI 10.1021/bi00226a014; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KATO KI, 1967, J BIOL CHEM, V242, P2780; KOIWAI O, 1986, NUCLEIC ACIDS RES, V14, P5777, DOI 10.1093/nar/14.14.5777; MATSUKAGE A, 1987, J BIOL CHEM, V262, P8960; MEDIN JA, 1990, P NATL ACAD SCI USA, V87, P2760, DOI 10.1073/pnas.87.7.2760; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PANDEY V, 1988, J BIOL CHEM, V263, P3744; RILEY LK, 1988, P NATL ACAD SCI USA, V85, P2489, DOI 10.1073/pnas.85.8.2489; ROBBINS DJ, 1988, NUCLEIC ACIDS RES, V16, P2943, DOI 10.1093/nar/16.7.2943; VLADIMIROV YA, 1970, PHOTOCHEM PHOTOBIOL, V11, P227, DOI 10.1111/j.1751-1097.1970.tb05992.x	19	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5199	5201						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544903				2022-12-27	WOS:A1992HH74700033
J	KENNEDY, ICS; JUNE, CH; OSHEA, JJ				KENNEDY, ICS; JUNE, CH; OSHEA, JJ			EXPRESSION OF THE HUMAN EPIDERMAL GROWTH-FACTOR RECEPTOR IN A MURINE T-CELL HYBRIDOMA - A TRANSMEMBRANE PROTEIN TYROSINE KINASE CAN SYNERGIZE WITH THE T-CELL ANTIGEN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYMPHOCYTES-T; PHOSPHOLIPASE C-II; SIGNAL TRANSDUCTION; ONCOGENE PRODUCTS; CD4 RECEPTOR; SRC FAMILY; ZETA-CHAIN; PHOSPHORYLATION; ACTIVATION; STIMULATION	Although the T-cell receptor for antigen (TCR) lacks intrinsic kinase activity, stimulation of this receptor induces tyrosine phosphorylation of multiple substrates. In contrast, the epidermal growth factor receptor (EGFR) has intrinsic cytoplasmic tyrosine kinase catalytic activity that is activated upon EGF binding. To compare the functional effects of the TCR and a transmembrane protein tyrosine kinase (PTK), we used retrovirus-mediated gene transduction to express the human c-erbB proto-oncogene, encoding the EGFR, in a murine T-cell hybridoma. Tyrosine phosphorylation induced by the TCR and the EGFR occurred on substrates unique to each receptor as well as on several shared substrates, including the zeta-chain of the TCR. Stimulation of the EGFR induced calcium ion flux in these cells, suggesting that the heterologous tyrosine kinase can couple to the T-cell phospholipase signal transduction pathway, but this stimulus did not lead to interleukin 2 production. However, EGF stimulation of transduced cells significantly enhanced TCR signaling, as assessed by interleukin 2 production, indicating that cross talk can occur between the TCR and a transmembrane PTK.	USN,MED RES INST,IMMUNE CELL BIOL PROGRAM,BETHESDA,MD 20892	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy	KENNEDY, ICS (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,EXPTL IMMUNOL LAB,FREDERICK,MD 21702, USA.							ACRES RB, 1985, IMMUNOLOGY, V54, P9; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTRELL D, 1987, NATURE, V325, P540, DOI 10.1038/325540a0; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; COCHET C, 1988, J BIOL CHEM, V263, P3290; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CUTRY AF, 1989, J BIOL CHEM, V264, P19700; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; Goustin AS, 1990, GROWTH FACTORS, V2, P189, DOI 10.3109/08977199009071505; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HSI ED, 1989, P NATL ACAD SCI USA, V264, P10836; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JOHNSON HM, 1985, J IMMUNOL, V134, P2824; JUNE CH, 1990, J IMMUNOL, V144, P1591; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KOZAK RW, 1987, CELL IMMUNOL, V109, P318, DOI 10.1016/0008-8749(87)90315-7; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATIS LA, 1990, ANNU REV IMMUNOL, V8, P65; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MONOSTORI E, 1990, J IMMUNOL, V144, P1010; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P1741, DOI 10.1073/pnas.88.5.1741; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REYNOLDS FH, 1981, NATURE, V292, P259, DOI 10.1038/292259a0; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1987, J IMMUNOL, V139, P2708; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SAMELSON LE, 1986, NATURE, V338, P257; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHMITTVERHULST AM, 1987, NATURE, V325, P628, DOI 10.1038/325628a0; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SNOW EC, 1981, J IMMUNOL, V126, P161; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VIVIER E, 1991, J IMMUNOL, V146, P206; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640	60	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4924	4929						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537871				2022-12-27	WOS:A1992HF64200094
J	WANG, YH; BARKER, P; GRIFFITH, J				WANG, YH; BARKER, P; GRIFFITH, J			VISUALIZATION OF DIAGNOSTIC HETERODUPLEX DNAS FROM CYSTIC-FIBROSIS DELETION HETEROZYGOTES PROVIDES AN ESTIMATE OF THE KINKING OF DNA BY BULGED BASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING DEOXYTRIDECANUCLEOTIDE DUPLEXES; POLYMERASE CHAIN-REACTION; INSERTION MUTATION; IDENTIFICATION; TEMPERATURE; MISMATCHES; CARRIERS; STACKS; MODEL; GENE	Previous studies (Hsieh, C.-H., and Griffith, J. D. (1989) Proc. Natl. Acad. Sci. U.S.A. 86, 4833-4837) of DNAs containing extra or bulged bases on one of the two strands of a duplex showed that they exhibit slower electrophoretic mobility than non-bulged DNAs, indicating that bulges create stiff kinks in the DNA. Here we paired a 97-base single-stranded DNA from the intact cystic fibrosis (CF) gene with a complementary 94-base strand containing a central 3-base deletion (DELTA-F508), common to many CF patients. This produced a 94-base pair DNA with a central 3-base bulge. Visualization of these DNAs by electron microscopy showed that twice as many bulge-containing DNAs bad a central kink as compared with the nonbulged controls. Examination of the distribution of kinking angles showed that the bulged population contained 5-7-fold more molecules with a central kink of 80 +/- 10-degrees than did the control molecules. When the 3-base bulge was replaced by a 3-base gap, the resulting duplex DNA showed central kinks with a somewhat lower frequency but greater range of kinking angles.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV ALABAMA,DEPT BIOCHEM,MOLEC GENET LAB,BIRMINGHAM,AL 35294; UNIV ALABAMA,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,BIRMINGHAM,AL 35294	University of North Carolina; University of North Carolina Chapel Hill; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31819] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGLANI F, 1990, AM J HUM GENET, V47, P169; BARKER PE, 1990, GENOME MAPPING SEQUE, P23; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BHATTACHARYYA A, 1989, NUCLEIC ACIDS RES, V17, P6821, DOI 10.1093/nar/17.17.6821; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; GRIFFITH J, 1986, CELL, V46, P717, DOI 10.1016/0092-8674(86)90347-8; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HSIEH CH, 1989, P NATL ACAD SCI USA, V86, P4833, DOI 10.1073/pnas.86.13.4833; KALNIK MW, 1989, BIOCHEMISTRY-US, V28, P294, DOI 10.1021/bi00427a040; KALNIK MW, 1989, J BIOL CHEM, V264, P3702; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; LEBLANC DA, 1991, BIOCHEMISTRY-US, V30, P4042, DOI 10.1021/bi00230a031; RICE JA, 1989, BIOCHEMISTRY-US, V28, P4512, DOI 10.1021/bi00436a058; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS J, 1990, AM J HUM GENET, V46, P395; SHORE S, 1990, AM J HUM GENET, V47, P169; TRIGGSRAINE BL, 1990, AM J HUM GENET, V46, P183; VANDENHOOGEN YT, 1988, NUCLEIC ACIDS RES, V16, P2971, DOI 10.1093/nar/16.7.2971; WANG YH, 1991, BIOCHEMISTRY-US, V30, P5443, DOI 10.1021/bi00236a017; WANG YH, 1991, BIOCHEMISTRY-US, V30, P1358, DOI 10.1021/bi00219a028; WOODSON SA, 1988, BIOCHEMISTRY-US, V27, P3130, DOI 10.1021/bi00409a004	24	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4911	4915						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537869				2022-12-27	WOS:A1992HF64200092
J	YANAGISHITA, M; HASCALL, VC				YANAGISHITA, M; HASCALL, VC			CELL-SURFACE HEPARAN-SULFATE PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							OVARIAN GRANULOSA-CELLS; GROWTH-FACTOR-BETA; INTRACELLULAR DEGRADATION; TRANSPORT; CULTURE; NUCLEI; GLYCOSAMINOGLYCANS; ANTITHROMBIN; HEPATOCYTES; METABOLISM				YANAGISHITA, M (corresponding author), NIDR,BONE RES BRANCH,BETHESDA,MD 20892, USA.							ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BRAUKER JH, 1991, DEV BIOL, V147, P285, DOI 10.1016/0012-1606(91)90286-C; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; CARDIN AD, 1989, T ASSOC AM PHYSICIAN, V102, P101; CAREY DJ, 1990, J BIOL CHEM, V265, P20627; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; FEDARKO NS, 1989, J CELL PHYSIOL, V139, P287, DOI 10.1002/jcp.1041390210; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FRANSSON LA, 1989, HEPARIN, P115; FURUKAWA K, 1977, BIOCHIM BIOPHYS ACTA, V499, P278, DOI 10.1016/0304-4165(77)90010-1; GALLAGHER JT, 1988, BIOCHEM J, V250, P719, DOI 10.1042/bj2500719; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; Hopwood J. J., 1989, HEPARIN CHEM BIOL PR, P191; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; ISHIHARA M, 1987, J BIOL CHEM, V262, P4708; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JACOBSSON KG, 1986, BIOCHEM J, V240, P625, DOI 10.1042/bj2400625; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOJIMA K, 1992, J BIOL CHEM, V267, P4870; Lindahl, 1989, HEPARIN CHEM BIOL PR, P51; Lindahl U., 1989, HEPARIN, P159; LORIES V, 1992, J BIOL CHEM, V267, P1116; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; Nader H. B., 1989, HEPARIN CHEM BIOL PR, P81; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; PEJLER G, 1987, J BIOL CHEM, V262, P5036; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SALTIEL AR, 1986, SCIENCE, V233, P967, DOI 10.1126/science.3016898; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SUNDERS S, 1989, J CELL BIOL, V18, P1547; TAKEUCHI Y, 1990, J BIOL CHEM, V265, P13661; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; VAINIO S, 1991, DEV BIOL, V147, P322, DOI 10.1016/0012-1606(91)90290-J; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YANAGISHITA M, 1989, J BIOL CHEM, V264, P17551; YANAGISHITA M, 1985, J BIOL CHEM, V260, P1075; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9505; YANAGISHITA M, 1985, J BIOL CHEM, V260, P5445; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YANAGISHITA M, 1984, J BIOL CHEM, V259, P260; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	49	405	411	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9451	9454						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577788				2022-12-27	WOS:A1992HT96500001
J	KADIMA, W; ROY, M; LEE, RWK; KAARSHOLM, NC; DUNN, MF				KADIMA, W; ROY, M; LEE, RWK; KAARSHOLM, NC; DUNN, MF			STUDIES OF THE ASSOCIATION AND CONFORMATIONAL PROPERTIES OF METAL-FREE INSULIN IN ALKALINE SODIUM-CHLORIDE SOLUTIONS BY ONE-DIMENSIONAL AND 2-DIMENSIONAL H-1-NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; NATIVE HUMAN INSULIN; H-1-NMR ASSIGNMENTS; SELF-ASSOCIATION; BOVINE INSULIN; ZINC-BINDING; HEXAMER; PROINSULIN; SPECTROSCOPY; STABILIZES	One- and two-dimensional H-1 NMR spectroscopy have been employed to probe the association and subsequent conformational changes of metal-free insulin in sodium chloride solution at pH 9 and 9.4. These studies establish that the proton resonances of His(B5) and His(B10) are useful signatures of aggregation and conformation. Changes in chemical shifts and areas of resonances due to the C2 protons of His(B10) and His(B5) and transfer of magnetization experiments served to identify the association as the assembly of tetramer from dimers under our experimental conditions (pH 9.4, [insulin] > 1 mM, [NaCl] = 0.1 M). Sodium chloride also alters the equilibrium distribution of species in favor of a tetrameric species. The association equilibrium constant was estimated from area measurements to be approximately 5 x 10(3) M-1 at pH 9.4, 26 +/- 0.1-degrees-C, and 0.1 M sodium chloride. Under conditions of 0.1 M sodium chloride concentration, nuclear Overhauser effect experiments in the one- and two-dimensional modes revealed an operative nuclear Overhauser effect between the His(B5) C2 protons and the 2,6 ring protons of a Tyr residue provisionally assigned as Tyr(B16). We conclude that this interaction is a diagnostic signature of a conformational transition where-upon an extended chain from residues B1 to B9 (T-state) is transformed into an alpha-helix (R-state) thus bringing the rings of His(B5) and Tyr(B16) from adjacent subunits across the monomer-monomer interface into van der Waals contact. This conformational flexibility is an added consideration to the discussion of the relevant structure of insulin for receptor binding.	UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA; UNIV CALIF RIVERSIDE, DEPT CHEM, RIVERSIDE, CA 92521 USA; NOVO RES INST, DK-2880 BAGSVAERD, DENMARK	University of California System; University of California Riverside; University of California System; University of California Riverside; Novo Nordisk			Kadima, Webe/AAE-4924-2020					BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BAX A, 1983, J MAGN RESON, V53, P517, DOI 10.1016/0022-2364(83)90225-1; BOHIDAR HB, 1984, BIOPOLYMERS, V23, P2407; BRADBURY JH, 1977, EUR J BIOCHEM, V76, P573, DOI 10.1111/j.1432-1033.1977.tb11627.x; BRADBURY JH, 1981, J MOL BIOL, V150, P609, DOI 10.1016/0022-2836(81)90385-5; BRADBURY JH, 1985, BIOCHEM J, V229, P731, DOI 10.1042/bj2290731; BRADER ML, 1991, BIOCHEMISTRY-US, V30, P6636, DOI 10.1021/bi00241a002; BRADER ML, 1990, J BIOL CHEM, V265, P15666; BRADER ML, 1990, J AM CHEM SOC, V112, P4585, DOI 10.1021/ja00167a090; BRANGE J, 1988, NATURE, V333, P679, DOI 10.1038/333679a0; BRANGE J, 1983, ACTA MED SCAND, P135; COFFMAN FD, 1988, BIOCHEMISTRY-US, V27, P6179, DOI 10.1021/bi00416a053; DEGRAAFF RAG, 1981, STRUCTURAL STUDIES M, P547; DEMELO J, 1990, WORLD BANK ECON REV, V4, P209, DOI 10.1093/wber/4.2.209; DEREWENDA U, 1989, NATURE, V338, P594, DOI 10.1038/338594a0; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOTY P, 1952, J AM CHEM SOC, V74, P2065, DOI 10.1021/ja01128a063; DUNN MF, 1987, 5TH P INT S CALC BIN, P372; FREDERICQ E, 1956, ARCH BIOCHEM BIOPHYS, V65, P218, DOI 10.1016/0003-9861(56)90189-8; FREDERICQ E, 1954, J POLYM SCI, V12, P287, DOI 10.1002/pol.1954.120120123; GOLDMAN J, 1974, BIOCHEMISTRY-US, V13, P4566, DOI 10.1021/bi00719a015; HILL CP, 1991, BIOCHEMISTRY-US, V30, P917, DOI 10.1021/bi00218a006; HOFACKER GL, 1983, INTRAMOLECULAR INTER, P229; HOLLADAY LA, 1977, BIOCHIM BIOPHYS ACTA, V494, P245, DOI 10.1016/0005-2795(77)90152-0; HUA QX, 1991, BIOCHEMISTRY-US, V30, P5505, DOI 10.1021/bi00236a025; HUA QX, 1990, BIOCHEMISTRY-US, V29, P10545, DOI 10.1021/bi00498a018; JEFFREY PD, 1966, BIOCHEMISTRY-US, V5, P489, DOI 10.1021/bi00866a014; JEFFREY PD, 1965, BIOCHIM BIOPHYS ACTA, V109, P551, DOI 10.1016/0926-6585(65)90181-0; JEFFREY PD, 1976, BIOCHEMISTRY-US, V15, P4660, DOI 10.1021/bi00666a018; KAARSHOLM NC, 1990, ARCH BIOCHEM BIOPHYS, V283, P496, DOI 10.1016/0003-9861(90)90673-M; KAARSHOLM NC, 1989, BIOCHEMISTRY-US, V28, P4427, DOI 10.1021/bi00436a046; KAARSHOLM NC, 1987, BIOCHEMISTRY-US, V26, P883, DOI 10.1021/bi00377a032; KADIMA W, 1986, THESIS U ALBERTA EDM, P31; KLINE AD, 1990, BIOCHEMISTRY-US, V29, P2906, DOI 10.1021/bi00464a003; LORD RS, 1973, BIOCHEMISTRY-US, V12, P4385, DOI 10.1021/bi00746a014; MARK AE, 1987, BIOPHYS CHEM, V27, P103, DOI 10.1016/0301-4622(87)80051-0; MARTINDALE H, 1982, DIABETES, V31, P364, DOI 10.2337/diabetes.31.4.364; MERSH JD, 1982, PROG NMR SPECTROSCOP, V15, P353; MILTHORPE BK, 1977, BIOCHIM BIOPHYS ACTA, V495, P195, DOI 10.1016/0005-2795(77)90376-2; PALMIERI R, 1988, BIOCHEMISTRY-US, V27, P3387, DOI 10.1021/bi00409a040; PEKAR AH, 1972, BIOCHEMISTRY-US, V11, P4013, DOI 10.1021/bi00772a001; PERMUTT MA, 1981, ISLETS LANGERHANS BI, P75; POCKER Y, 1980, BIOCHEMISTRY-US, V19, P5043, DOI 10.1021/bi00563a017; POCKER Y, 1981, BIOCHEMISTRY-US, V20, P4354, DOI 10.1021/bi00518a019; PORTER RR, 1953, BIOCHEM J, V53, P320, DOI 10.1042/bj0530320; ROY M, 1989, J BIOL CHEM, V264, P19081; ROY M, 1990, BIOCHIM BIOPHYS ACTA, V1053, P63, DOI 10.1016/0167-4889(90)90027-B; ROY M, 1990, J BIOL CHEM, V265, P5448; SMITH GD, 1984, P NATL ACAD SCI-BIOL, V81, P7093, DOI 10.1073/pnas.81.22.7093; STEINER KF, 1975, COLD SPRING HARBOR C, V2, P531; STEINER RF, 1952, ARCH BIOCHEM BIOPHYS, V39, P333, DOI 10.1016/0003-9861(52)90344-5; STORM MC, 1985, BIOCHEMISTRY-US, V24, P1749, DOI 10.1021/bi00328a027; STRAZZA S, 1985, ARCH BIOCHEM BIOPHYS, V238, P30, DOI 10.1016/0003-9861(85)90137-7; SUDMEIER JL, 1981, SCIENCE, V212, P560, DOI 10.1126/science.7010607; WEISS MA, 1989, BIOCHEMISTRY-US, V28, P9855, DOI 10.1021/bi00451a046; WEISS MA, 1991, BIOCHEMISTRY-US, V30, P7373, DOI 10.1021/bi00244a004; WILLIAMSON KL, 1979, BIOCHEMISTRY-US, V18, P5966, DOI 10.1021/bi00593a032; WOLLMER A, 1987, BIOL CHEM H-S, V368, P903, DOI 10.1515/bchm3.1987.368.2.903; WOLLMER A, 1980, INSULIN CHEM STRUCTU, P27; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P17	60	30	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8963	8970						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577733				2022-12-27	WOS:A1992HR85400042
J	VOYIATZAKI, CS; SOTERIADOU, KP				VOYIATZAKI, CS; SOTERIADOU, KP			IDENTIFICATION AND ISOLATION OF THE LEISHMANIA TRANSFERRIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; CELL-SURFACE GLYCOPROTEIN; MEDIATED ENDOCYTOSIS; IRON TRANSPORT; PROTEINS; PROLIFERATION; ANTIBODIES; MEMBRANE; STORAGE	In a previous report, we have presented several lines of evidence, derived from widely different methodologies, suggesting that Leishmania has specific receptors for transferrin with a K(d) similar to the mammalian transferrin receptor. This paper describes the identification, purification, and biochemical characterization of Leishmania transferrin receptor. The Leishmania transferrin receptor, detected on intact parasites by immunoperoxidase staining, was first identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by Western blot analysis, using I-125-transferrin, as a 70-kDa protein. It has been isolated initially from Leishmania infantum promastigotes using affinity chromatography on a transferrin-Sepharose column and, subsequently, from Leishmania major promastigotes. The use of polyclonal antisera to the purified 70-kDa Leishmania transferrin receptor and to the purified rat transferrin receptor showed that the two receptors are antigenically distinct. The 70-kDa Leishmania transferrin receptor was subsequently characterized as an integral membrane glycoprotein. The monomeric state of the Leishmania transferrin receptor was demonstrated by gel filtration of purified receptor complexed with I-125-transferrin. Thus, the Leishmania transferrin receptor, unlike the mammalian receptor, is not a disulfide-linked dimer but a single 70-kDa polypeptide.	HELLEN INST PASTEUR,BIOCHEM LAB,127 VASSILISSIS SOFIAS AVE,GR-11521 ATHENS,GREECE									AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; ALVAREZ E, 1989, EMBO J, V8, P2231, DOI 10.1002/j.1460-2075.1989.tb08347.x; BARERJEEBHATNAG.N, 1990, INFECT IMMUN, V58, P2875; BORDIER C, 1987, PARASITOL TODAY, V3, P151, DOI 10.1016/0169-4758(87)90199-2; CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; CRICHTON RR, 1987, EUR J BIOCHEM, V164, P485, DOI 10.1111/j.1432-1033.1987.tb11155.x; DWYER DM, 1980, J PROTOZOOL, V27, P176, DOI 10.1111/j.1550-7408.1980.tb04676.x; FRAZIER JL, 1982, J CLIN INVEST, V69, P583; HALDAR K, 1986, P NATL ACAD SCI USA, V83, P8565, DOI 10.1073/pnas.83.22.8565; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KARIN M, 1981, J BIOL CHEM, V256, P3245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLEY JF, 1985, MOL CELL BIOL, V5, P1814, DOI 10.1128/MCB.5.8.1814; LIMA MF, 1990, MOL BIOCHEM PARASIT, V38, P245, DOI 10.1016/0166-6851(90)90027-J; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NEWMAN R, 1982, TRENDS BIOCHEM SCI, V7, P397, DOI 10.1016/0968-0004(82)90184-0; OMARY MB, 1981, J BIOL CHEM, V256, P2888; PEARSON RD, 1983, REV INFECT DIS, V5, P907; RODRIGUEZ MH, 1986, NATURE, V324, P388, DOI 10.1038/324388a0; RUSSELL DG, 1988, J IMMUNOL, V140, P1274; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SCHRYVERS AB, 1988, MOL MICROBIOL, V2, P281, DOI 10.1111/j.1365-2958.1988.tb00029.x; SELIGMAN PA, 1979, J BIOL CHEM, V254, P9943; SOTERIADOU KP, 1988, INFECT IMMUN, V56, P1180, DOI 10.1128/IAI.56.5.1180-1186.1988; STEARNE PA, 1985, J IMMUNOL, V134, P3474; SUTHERLAND R, 1981, P NATL ACAD SCI-BIOL, V78, P4515, DOI 10.1073/pnas.78.7.4515; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; TROWBRIDGE IS, 1982, J CELL PHYSIOL, V112, P403, DOI 10.1002/jcp.1041120314; TROWBRIDGE IS, 1988, MONOCLONAL ANTIBODY, V45, P121; TURCO SJ, 1988, PARASITOL TODAY, V4, P255, DOI 10.1016/0169-4758(88)90144-5; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P8318; TZINIA AK, 1991, MOL BIOCHEM PARASIT, V47, P83, DOI 10.1016/0166-6851(91)90150-5; VOYIATZAKI CS, 1990, J BIOL CHEM, V265, P22380	36	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9112	9117						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577747				2022-12-27	WOS:A1992HR85400064
J	DIRUSSO, CC; HEIMERT, TL; METZGER, AK				DIRUSSO, CC; HEIMERT, TL; METZGER, AK			CHARACTERIZATION OF FADR, A GLOBAL TRANSCRIPTIONAL REGULATOR OF FATTY-ACID METABOLISM IN ESCHERICHIA-COLI - INTERACTION WITH THE FADB PROMOTER IS PREVENTED BY LONG-CHAIN FATTY ACYL COENZYME-AS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; GENE FADR; MULTIENZYME COMPLEX; NUCLEOTIDE-SEQUENCE; GEL-ELECTROPHORESIS; OPERON FUSION; DEGRADATION; EXPRESSION; CLONING; PROTEINS	The Escherichia coli fadR gene product, FadR, is a multifunctional regulator of fatty acid metabolism. In this work we have purified FadR by a two-step procedure employing two ion-exchange columns. The amino-terminal sequence of the purified protein confirms the sequence of the protein derived from analysis of the DNA sequence (DiRusso, C. C. (1988) Nucleic Acids Res. 16, 7995-8009) and indicates that the initiating methionine is cleaved from the mature protein. Purified FadR binds to a 326-base pair HaeIII fragment of fadB DNA which carries the fadB promoter. DNase I footprinting localizes the operator to a sequence, 5' ATCTGGTACGACCAGAT3', at + 1 to + 17 nucleotides relative to the start of transcription. Using protein-DNA gel retention assays, we estimate the K(eq) of FadR binding to the fadB operator to be approximately 3 x 10(-10) M. Binding of FadR is specifically inhibited by long chain fatty acyl-CoA compounds. The apparent K(i) values for oleoyl-CoA, palmitoyl-CoA, and palmitoleoyl-CoA are each 5 nM while that of myristoyl-CoA is 250 nM. Decanoyl-CoA, crotonoyl-CoA, and free fatty acids inhibited binding only at concentrations above 1-mu-M.			DIRUSSO, CC (corresponding author), UNIV TENNESSEE CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA.				NIGMS NIH HHS [GM38104] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038104] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK PN, 1991, J BACTERIOL, V173, P435, DOI 10.1128/jb.173.2.435-442.1991; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNE C, 1988, NUCLEIC ACIDS RES, V16, P10924, DOI 10.1093/nar/16.22.10924; CLARK D, 1981, J BACTERIOL, V148, P521, DOI 10.1128/JB.148.2.521-526.1981; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; CONSTANTINIDES PP, 1985, J BIOL CHEM, V260, P7573; CRONAN JE, 1988, J BIOL CHEM, V263, P4641; DIRUSSO CC, 1988, NUCLEIC ACIDS RES, V16, P7995, DOI 10.1093/nar/16.16.7995; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; DIRUSSO CC, 1985, J BACTERIOL, V161, P583, DOI 10.1128/JB.161.2.583-588.1985; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HAYDON DJ, 1991, FEMS MICROBIOL LETT, V79, P291, DOI 10.1016/0378-1097(91)90101-F; HENRY MF, 1989, J BACTERIOL, V171, P5254, DOI 10.1128/jb.171.10.5254-5261.1989; JO YL, 1986, J BIOL CHEM, V261, P5252; KAMEDA K, 1981, J BIOL CHEM, V256, P5702; KLEIN K, 1971, EUR J BIOCHEM, V19, P442, DOI 10.1111/j.1432-1033.1971.tb01334.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Maxam A M, 1980, Methods Enzymol, V65, P499; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NUNN WD, 1986, MICROBIOL REV, V50, P179, DOI 10.1128/MMBR.50.2.179-192.1986; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; PRAMANIK A, 1979, J BACTERIOL, V137, P469, DOI 10.1128/JB.137.1.469-473.1979; SALLUS L, 1983, J BACTERIOL, V155, P1450, DOI 10.1128/JB.155.3.1450-1454.1983; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONS RW, 1980, J BACTERIOL, V142, P621, DOI 10.1128/JB.142.2.621-632.1980; SIMONS RW, 1980, J BACTERIOL, V143, P726, DOI 10.1128/JB.143.2.726-730.1980; SPRATT SK, 1984, J BACTERIOL, V158, P535, DOI 10.1128/JB.158.2.535-542.1984; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TIPPETT PS, 1982, J BIOL CHEM, V257, P2839; VERSHON AK, 1987, J MOL BIOL, V195, P311, DOI 10.1016/0022-2836(87)90652-8	34	160	165	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8685	8691						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569108				2022-12-27	WOS:A1992HQ18500108
J	VALENZUELA, CF; KERR, JA; JOHNSON, DA				VALENZUELA, CF; KERR, JA; JOHNSON, DA			QUINACRINE BINDS TO THE LIPID-PROTEIN INTERFACE OF THE TORPEDO ACETYLCHOLINE-RECEPTOR - A FLUORESCENCE STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBRA ALPHA-TOXIN; NONCOMPETITIVE BLOCKERS; H-3 CHLORPROMAZINE; ION CHANNEL; CHOLINERGIC RECEPTOR; ENERGY-TRANSFER; AMINO-ACIDS; MEMBRANES; SITE; ORIENTATION	It has been argued both that there is a high affinity noncompetitive inhibitor binding site in the lumen of the acetylcholine receptor and that this lumen exists on the central axis of the receptor. Such a site would be expected to be 20-40 angstrom from the membrane lipids. We tested whether, in fact, quinacrine, a potent fluorescent noncompetitive inhibitor, binds to such a site. We measured quenching of receptor-bound quinacrine fluorescence by fluorescence dipolar energy transfer to lipid probes, 5-(N-dodecanoylamino)eosin and N-(3-sulfopropyl)-4-)p-didecylaminostyryl)pyridinium, or by collision with paramagnetic lipid probes 2,2,6,6-tetramethylpiperidine-1-oxyl and 3-doxyl-17-beta-hydroxy-5-alpha-androstane (spin-labeled androstane). Initial control experiments established that in the presence of carbamylcholine, quinacrine binds to a phencyclidine-sensitive site on the Torpedo receptor with a K(d) equal to 0.14-mu-M and with a quantum yield of 0.18. Fluorescence energy transfer from receptor-bound quinacrine had a magnitude consistent with quinacrine being < 10 angstrom from the lipid fluorescent probes. 2,2,6,6-Tetramethylpiperidine-1-oxyl and spin-labeled androstane were two to five times more effective at quenching receptor-bound quinacrine fluorescence than the fluorescence from membrane-partitioned 5-(dodecanoylamino) fluorescein. These results suggest that the quinacrine binding site is too close to the lipid domain to be in the lumen of the receptor, and therefore it is probably located on the outer surface of the membrane-spanning domain of the acetylcholine receptor.	UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside								ADAMS PR, 1980, J PHYSIOL-LONDON, V306, P261, DOI 10.1113/jphysiol.1980.sp013396; ADAMS PR, 1981, J MEMBRANE BIOL, V58, P161, DOI 10.1007/BF01870902; ADAMS PR, 1980, J PHYSIOL-LONDON, V306, P283, DOI 10.1113/jphysiol.1980.sp013397; [Anonymous], 1959, CHEM ENG PROG; BOYD ND, 1984, BIOCHEMISTRY-US, V23, P4023, DOI 10.1021/bi00313a003; CHANGEUX JP, 1990, TRENDS PHARMACOL SCI, V11, P485, DOI 10.1016/0165-6147(90)90049-E; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; CHEN RF, 1965, SCIENCE, V150, P1593, DOI 10.1126/science.150.3703.1593; COX RN, 1985, J BIOL CHEM, V260, P7186; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; DIPAOLA M, 1990, J BIOL CHEM, V265, P11017; DONNELLYROBERTS DL, 1991, BIOCHEMISTRY-US, V30, P7484, DOI 10.1021/bi00244a017; DREYER EB, 1986, J BIOL CHEM, V261, P3727; ELLENA JF, 1983, BIOCHEMISTRY-US, V22, P5523, DOI 10.1021/bi00293a012; Forster T., 1959, DISCUSS FARADAY SOC, V27, P7, DOI DOI 10.1039/DF9592700007; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GRUNHAGEN HH, 1976, J MOL BIOL, V106, P517, DOI 10.1016/0022-2836(76)90250-3; HEIDMANN T, 1983, BIOCHEMISTRY-US, V22, P3112, DOI 10.1021/bi00282a014; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3466, DOI 10.1021/bi00283a025; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JOHNSON DA, 1985, BIOPHYS J, V48, P949, DOI 10.1016/S0006-3495(85)83858-3; JOHNSON DA, 1990, J BIOL CHEM, V265, P7360; JONES OT, 1988, BIOCHEMISTRY-US, V27, P2364, DOI 10.1021/bi00407a018; KARLIN A, 1991, HARVEY LECT, V85, P71; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LONDON E, 1982, MOL CELL BIOCHEM, V45, P181; MARSH D, 1978, P NATL ACAD SCI USA, V75, P4329, DOI 10.1073/pnas.75.9.4329; MCCARTHY MP, 1989, BIOCHEMISTRY-US, V28, P40, DOI 10.1021/bi00427a007; MERKLE H, 1987, BIOCHIM BIOPHYS ACTA, V897, P238, DOI 10.1016/0005-2736(87)90420-2; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; OIKI S, 1988, P NATL ACAD SCI USA, V85, P8703, DOI 10.1073/pnas.85.22.8703; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; PEDERSEN SE, 1990, BIOPHYS J, V57, pA126; REED K, 1975, ARCH BIOCHEM BIOPHYS, V167, P138, DOI 10.1016/0003-9861(75)90449-X; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; SCHREIERMUCCILLO S, 1976, ARCH BIOCHEM BIOPHYS, V172, P1, DOI 10.1016/0003-9861(76)90041-2; SHAKLAI N, 1977, BIOCHEMISTRY-US, V16, P5585, DOI 10.1021/bi00644a031; STRYER L, 1982, METHOD ENZYMOL, V81, P668; TAYLOR P, 1991, ANN NY ACAD SCI, V625, P568, DOI 10.1111/j.1749-6632.1991.tb33893.x; TSAI MC, 1979, MOL PHARMACOL, V16, P382; VALENZUELA CF, 1992, IN PRESS MOL PHARM	45	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8238	8244						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569077				2022-12-27	WOS:A1992HQ18500044
J	BINDER, S; MARCHFELDER, A; BRENNICKE, A; WISSINGER, B				BINDER, S; MARCHFELDER, A; BRENNICKE, A; WISSINGER, B			RNA EDITING IN TRANSSPLICING INTRON SEQUENCES OF NAD2 MESSENGER-RNAS IN OENOTHERA MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDASE SUBUNIT-II; PLANT-MITOCHONDRIA; GENE ORGANIZATION; RIBOSOMAL PROTEIN-S12; NUCLEOTIDE-SEQUENCE; DNA; CHLOROPLAST; TRANSCRIPTS; EXPRESSION; DEHYDROGENASE	The complete open reading frame of subunit 2 of the NADH dehydrogenase in Oenothera mitochondria is split into five exons. The first two and the last three exons are encoded in distant genomic locations and are transcribed separately. Three tRNA genes coding for tRNA(Cys), tRNA(Asn), and tRNA(Tyr) are located upstream of the terminal three exons c, d, and e. The genomic distance, the interspersed tRNA genes, and the group II intron sequences flanking the two separated exons suggest trans-splicing to be required to connect exons b and c. Maturation of the mRNA includes RNA editing at 36 sites in the open reading frame. Three RNA editing events are observed in the split group II intron sequences. Two of these events allow after editing additional base pairings in the secondary structure, one in the stem of domain I, the other in the putative trans-pairing region of domain IV. These RNA editings may thus be involved in the trans-splicing reaction.			BINDER, S (corresponding author), INST GENBIOL FORSCH,IHNESTR 63,W-1000 BERLIN 33,GERMANY.			Marchfelder, Anita/0000-0002-1382-1794				BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BINDER S, 1990, CURR GENET, V17, P353, DOI 10.1007/BF00314884; CHAPDELAINE Y, 1991, CELL, V65, P465, DOI 10.1016/0092-8674(91)90464-A; CHOQUET Y, 1988, CELL, V52, P903, DOI 10.1016/0092-8674(88)90432-1; CLARY DO, 1985, J MOL EVOL, V22, P252, DOI 10.1007/BF02099755; CONKLIN PL, 1991, GENE DEV, V5, P1407, DOI 10.1101/gad.5.8.1407; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; DEBRUIJN MHL, 1983, NATURE, V304, P234, DOI 10.1038/304234a0; DEVRIES H, 1986, EMBO J, V5, P779, DOI 10.1002/j.1460-2075.1986.tb04281.x; DUJON B, 1983, MITOCHONDRIA 1983, P1; FOX TD, 1981, CELL, V26, P315, DOI 10.1016/0092-8674(81)90200-2; FUKUZAWA H, 1986, FEBS LETT, V198, P11, DOI 10.1016/0014-5793(86)81174-7; GOLDSCHMIDTCLERMONT M, 1991, CELL, V65, P135, DOI 10.1016/0092-8674(91)90415-U; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HIESEL R, 1983, EMBO J, V2, P2173, DOI 10.1002/j.1460-2075.1983.tb01719.x; HIESEL R, 1990, CURR GENET, V18, P371, DOI 10.1007/BF00318219; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; KNOOP V, 1991, EMBO J, V10, P3483, DOI 10.1002/j.1460-2075.1991.tb04912.x; KUCK U, 1987, EMBO J, V6, P2185, DOI 10.1002/j.1460-2075.1987.tb02489.x; LAMATTINA L, 1991, NUCLEIC ACIDS RES, V19, P3275, DOI 10.1093/nar/19.12.3275; LEAVER CJ, 1982, ANNU REV PLANT PHYS, V33, P373, DOI 10.1146/annurev.pp.33.060182.002105; LEVINGS CS, 1989, CELL, V56, P171, DOI 10.1016/0092-8674(89)90890-8; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHUSTER W, 1990, EMBO J, V9, P263, DOI 10.1002/j.1460-2075.1990.tb08104.x; SCHUSTER W, 1990, FEBS LETT, V268, P252, DOI 10.1016/0014-5793(90)81021-F; SCHUSTER W, 1988, PLANT MOL BIOL PRACT, P79; SEDEROFF RR, 1984, ADV GENET, V22, P1, DOI 10.1016/S0065-2660(08)60038-3; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; WAHLEITHNER JA, 1990, P NATL ACAD SCI USA, V87, P548, DOI 10.1073/pnas.87.2.548; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; WISSINGER B, 1990, MOL GEN GENET, V224, P389, DOI 10.1007/BF00262433; WISSINGER B, 1991, CELL, V65, P473, DOI 10.1016/0092-8674(91)90465-B; XUE YB, 1990, MOL GEN GENET, V221, P195, DOI 10.1007/BF00261720; ZAITA N, 1987, FEBS LETT, V210, P153, DOI 10.1016/0014-5793(87)81326-1	37	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7615	7623						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559998				2022-12-27	WOS:A1992HN48500060
J	BLOCK, JA; INEROT, SE; KIMURA, JH				BLOCK, JA; INEROT, SE; KIMURA, JH			HETEROGENEITY OF KERATAN SULFATE SUBSTITUTED ON HUMAN CHONDROCYTIC LARGE PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGE-RELATED-CHANGES; CARTILAGE PROTEOGLYCANS; OLIGOSACCHARIDES; FIBROMODULIN	Newly synthesized S-35-labeled chondrocytic keratan sulfate chains were generated by chondrocytes of human chondrosarcoma cell line 105KC and were analyzed for heterogeneity of regional substitution, hydrodynamic size, and charge density. After isolation of the high density large chondrocytic proteoglycans and sequential digestions with chondroitinase ABC, L-1-to-sylamido-2-phenylethyl chloromethyl ketone-treated trypsin, and alpha-chymotrypsin, followed by Superose 6 chromatography, two populations of keratan sulfate-containing proteoglycan fragments were identified and pooled separately. Keratan sulfate chains from each of the regions were compared after release by Pronase digestion, and differences in substitution patterns were observed; keratan sulfate chains of greater polydispersity, as well as a population of larger hydrodynamic size, were present in only one of the two regions. Alkaline/borohydride treatment confirmed both the existence of a population of uniquely large keratan sulfate chains and its restriction to a single region of proteoglycan fragments. In addition to heterogeneity of hydrodynamic size, the keratan sulfate chains exhibited regional heterogeneity of charge density and hence, of sulfation patterns. Analysis by Mono Q chromatography identified distinct groups of keratan sulfate that segregated by charge density and whose proportionate composition differed between the proteoglycan regions. Furthermore, the most highly charged species were unique to a single region and encompassed the chains of larger hydrodynamic size. This suggests that there may be regional heterogeneity of keratan sulfate chains substituted along a single class of proteoglycans and identifies a novel population of large, highly sulfated chondrocytic keratan sulfate chains.	RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT BIOCHEM,CHICAGO,IL 60612; GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT ORTHOPED,S-41345 GOTHENBURG,SWEDEN; HENRY FORD HOSP,CTR BONE & JOINT,BIOCHEM SECT,DETROIT,MI 48202	Rush University; Sahlgrenska University Hospital; University of Gothenburg; Henry Ford Health System; Henry Ford Hospital	BLOCK, JA (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT MED RHEUMATOL,1653 W CONGRESS PKWY,CHICAGO,IL 60612, USA.			Block, Joel/0000-0002-0330-7353	NIAMS NIH HHS [AR36850] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; BAKER JR, 1969, BIOCHEM J, V115, pP11; BAYLISS MT, 1978, BIOCHEM J, V176, P683, DOI 10.1042/bj1760683; BLOCK JA, 1991, J BONE JOINT SURG AM, V73A, P647, DOI 10.2106/00004623-199173050-00002; BLOCK JA, 1991, CONNECT TISSUE RES, V26, P295, DOI 10.3109/03008209109152446; BRAY BA, 1967, J BIOL CHEM, V242, P3373; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CARNEY SL, 1988, PHYSIOL REV, V68, P858, DOI 10.1152/physrev.1988.68.3.858; CHOI HU, 1971, P NATL ACAD SCI USA, V68, P877, DOI 10.1073/pnas.68.5.877; DELUCA S, 1980, J BIOL CHEM, V255, P6077; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FUNDERBURGH JL, 1987, J BIOL CHEM, V262, P11634; HASCALL VC, 1982, METHOD ENZYMOL, V82, P769; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; HEINEGARD D, 1972, BIOCHIM BIOPHYS ACTA, V285, P181, DOI 10.1016/0005-2795(72)90190-0; HEINEGARD D, 1977, J BIOL CHEM, V252, P1971; LINDAHL U, 1973, J BIOL CHEM, V248, P7234; MEYER K, 1953, J BIOL CHEM, V205, P611; Nakazawa K., 1989, KERATAN SULPHATE CHE, P99; NIEDUSZYNSKI IA, 1990, BIOCHEM J, V271, P243, DOI 10.1042/bj2710243; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PLAAS AHK, 1989, J BIOL CHEM, V264, P14447; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; ROBINSON HC, 1973, BIOCHEM J, V133, P457, DOI 10.1042/bj1330457; SCOTT JE, 1988, J ANAT, V158, P95; SENO N, 1965, J BIOL CHEM, V240, P1005; SWEET MBE, 1979, ARCH BIOCHEM BIOPHYS, V198, P439, DOI 10.1016/0003-9861(79)90518-6; TANG PW, 1986, EUR J BIOCHEM, V160, P537, DOI 10.1111/j.1432-1033.1986.tb10072.x; THONAR EJMA, 1979, ARCH BIOCHEM BIOPHYS, V194, P179, DOI 10.1016/0003-9861(79)90608-8	29	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7245	7252						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559968				2022-12-27	WOS:A1992HN48500011
J	MARTELL, RE; STRAHLER, JR; SIMPSON, RU				MARTELL, RE; STRAHLER, JR; SIMPSON, RU			IDENTIFICATION OF LAMIN-B AND HISTONES AS 1,25-DIHYDROXYVITAMIN-D3-REGULATED NUCLEAR PHOSPHOPROTEINS IN HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; PREMATURE CHROMOSOME CONDENSATION; PHORBOL ESTER; INDUCED DIFFERENTIATION; GEL-ELECTROPHORESIS; MYC PROTOONCOGENE; TOPOISOMERASE-II; NIH-3T3 CELLS; LINE HL-60; PHOSPHORYLATION	1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3)-induced differentiation of HL-60 leukemia cells is accompanied by a number of cellular changes including regulation of oncogene expression and induction of terminal differentiation. We investigated the mechanism by which 1,25-(OH)2D3 induces these changes. We detected 10 nuclear phosphoproteins, designated p66, p45, p36, p33, p32, p27, p22, P19, p18 and p17, that show alterations in phosphorylation within 6-40 h of 1,25-(OH)2D3 treatment. When phosphorylation reactions were performed with isolated nuclei (in vitro), three of these proteins were phosphorylated in a calcium and phospholipid dependent manner: p66, p36, and p19 P66 was phosphorylated in response to 1,25-(OH)2D3 and purified in a manner similar to that used for nuclear lamins. Western blot analysis of 2-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels confirmed its identity as lamin B. Phosphorylation of p17 and p18 decreased following 1,25-(OH)2D3 treatment. We separated p17 and p18 by SDS-PAGE and obtained N-terminal amino acid sequence to identify these phosphoproteins as histones H2b and H3, respectively. P19 and p22 were both DNA-cellulose binding proteins whose phosphorylation was altered by 1,25-(OH)2D3 treatment. Increased phosphorylation of p27 was detected using 2-dimensional SDS-PAGE. Phosphorylation of nuclear proteins in the intact cell (in vivo), revealed increases in p66, p45, p36, and p33 phosphorylation and a decrease in p17 phosphorylation following 1,25-(OH)2D3 treatment. We detected an increase in phosphorylation of p32, which was extracted with salt from nuclei and migrated on SDS-PAGE similar to histone H1. Thus, we have identified 1,25-(OH)2D3-sensitive nuclear phosphoproteins, including lamin B and several histones. We have also detected and characterized several less abundant nuclear DNA binding phosphoproteins whose phosphorylation was affected by 1,25-(OH)2D3.	UNIV MICHIGAN,MED CTR,CTR MOLEC GENET,DEPT PHARMACOL,M6322 MED SCI BLDG 1,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PEDIAT & COMMUN DIS,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA043859] Funding Source: NIH RePORTER; NCI NIH HHS [CA-43859] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJIRO K, 1985, J BIOL CHEM, V260, P5379; AJIRO K, 1983, J BIOL CHEM, V258, P4534; AJIRO K, 1990, J BIOL CHEM, V265, P6494; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; BENAVENTE R, 1986, J CELL BIOL, V103, P1847, DOI 10.1083/jcb.103.5.1847; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRESNICK EH, 1986, CANCER RES, V46, P4979; BUSS JE, 1983, METHOD ENZYMOL, V99, P7; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHOU RH, 1986, BIOCHEM BIOPH RES CO, V141, P213, DOI 10.1016/S0006-291X(86)80356-4; CHOU RH, 1990, CANCER RES, V50, P3199; CIVITELLI R, 1990, ENDOCRINOLOGY, V127, P2253, DOI 10.1210/endo-127-5-2253; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEBORD GD, 1988, CANCER LETT, V41, P69; EVANS SW, 1986, BLOOD, V68, P906; FAILLE A, 1986, ANTICANCER RES, V6, P1053; FAN XD, 1988, P NATL ACAD SCI USA, V85, P5122, DOI 10.1073/pnas.85.14.5122; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; FEUERSTEIN N, 1984, J BIOL CHEM, V259, P2782; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GIRARD PR, 1987, CANCER RES, V47, P2892; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; HILL LC, 1991, EMBO J, V10, P1939; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HORNBECK P, 1988, P NATL ACAD SCI USA, V85, P2279, DOI 10.1073/pnas.85.7.2279; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; KAUFMANN SH, 1989, J BIOL CHEM, V264, P13946; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KISS Z, 1988, FEBS LETT, V231, P41, DOI 10.1016/0014-5793(88)80698-7; KRAUSS SW, 1987, J BIOL CHEM, V262, P3432; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; MACFARLANE DE, 1986, J BIOL CHEM, V261, P6947; MANGELSDORF DJ, 1984, J CELL BIOL, V98, P391, DOI 10.1083/jcb.98.2.391; MARTELL RE, 1987, J BIOL CHEM, V262, P5570; MARTELL RE, 1988, BIOCHEM PHARMACOL, V37, P635, DOI 10.1016/0006-2952(88)90136-0; MATSUI T, 1986, CANCER RES, V46, P583; MAZEN A, 1987, J MOL BIOL, V194, P741, DOI 10.1016/0022-2836(87)90251-8; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MICHISHITA M, 1991, BIOCHEM BIOPH RES CO, V176, P979, DOI 10.1016/0006-291X(91)90378-K; NISHIKAWA M, 1986, LIFE SCI, V39, P1101, DOI 10.1016/0024-3205(86)90202-X; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; POMMIER Y, 1990, J BIOL CHEM, V265, P9418; RIGBY WFC, 1985, J IMMUNOL, V135, P2279; ROBERGE M, 1990, J CELL BIOL, V111, P1753, DOI 10.1083/jcb.111.5.1753; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; SIMPSON RU, 1986, BIOESSAYS, V4, P65, DOI 10.1002/bies.950040206; SOLOMON DH, 1991, CELL GROWTH DIFFER, V2, P187; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STERNER R, 1987, NUCLEIC ACIDS RES, V15, P4375, DOI 10.1093/nar/15.11.4375; STRAHLER JR, 1989, PROTEIN STRUCTURE PR, P65; SZOPA J, 1980, BIOCHEMISTRY-US, V19, P990; TAOKA T, 1989, BIOCHEM INT, V18, P1193; TAPLEY PM, 1985, EUR J BIOCHEM, V151, P419, DOI 10.1111/j.1432-1033.1985.tb09118.x; THOMAS TP, 1988, CANCER RES, V48, P1910; WALI RK, 1990, J CLIN INVEST, V85, P1296, DOI 10.1172/JCI114567; WENDT MD, 1990, FED PROC, V49, P435; WOOD AW, 1983, BIOCHEM BIOPH RES CO, V116, P605, DOI 10.1016/0006-291X(83)90567-3; WOODFORD TA, 1986, J BIOL CHEM, V261, P4669; YADA Y, 1989, BIOCHEM BIOPH RES CO, V163, P1517, DOI 10.1016/0006-291X(89)91152-2; YONEDA T, 1991, ENDOCRINOLOGY, V129, P683, DOI 10.1210/endo-129-2-683; ZYLBERKATZ E, 1985, CANCER RES, V45, P5159	68	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7511	7519						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559989				2022-12-27	WOS:A1992HN48500047
J	NEYLON, CB; NICKASHIN, A; LITTLE, PJ; TKACHUK, VA; BOBIK, A				NEYLON, CB; NICKASHIN, A; LITTLE, PJ; TKACHUK, VA; BOBIK, A			THROMBIN-INDUCED CA2+ MOBILIZATION IN VASCULAR SMOOTH-MUSCLE UTILIZES A SLOWLY RIBOSYLATING PERTUSSIS TOXIN-SENSITIVE G-PROTEIN - EVIDENCE FOR THE INVOLVEMENT OF A G-PROTEIN IN INOSITOL TRISPHOSPHATE-DEPENDENT CA2+ RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEIN; KINASE-C ACTIVATION; ANGIOTENSIN-II; INTRACELLULAR CALCIUM; ENDOPLASMIC-RETICULUM; ENDOTHELIAL-CELLS; GENE-EXPRESSION; CA-2+ RELEASE; MYOSIN PHOSPHORYLATION; SARCOPLASMIC-RETICULUM	The role of pertussis toxin (PT)-sensitive and -insensitive guanine nucleotide-binding proteins (G proteins) in the stimulation of Ca2+ mobilization by thrombin was investigated in cultured rat aortic smooth muscle cells. Characterization using immunoblotting with specific antisera indicated the presence in isolated membranes of the G-alpha(i2), G-alpha(i3), G-alpha(s), G-beta-35, and G-beta-36 protein subunits as well as a lower molecular weight species of unknown identity. To assess the importance of G proteins in the coupling of thrombin receptors to Ca2+ mobilization, we investigated the effect of PT on Ca2+ responses using fluorescence spectroscopy and the Ca2+ indicator dye Fura-2. Pretreatment of cells for 2 h with PT (1-mu-g/ml), which produced 91.3% ADP-ribosylation of PT-sensitive G proteins, did not affect the magnitude of thrombin-induced release of Ca2+ from internal stores, suggesting that the residual 8.7% of PT-sensitive G proteins, or PT-insensitive mechanisms, was responsible for Ca2+ release. However, after an 18-h pretreatment with PT, which produced ADP-ribosylation of the total complement of PT-sensitive G proteins, the thrombin-induced peak Ca2+ response was inhibited by approximately 72%, suggesting that the major fraction of the Ca2+ response was mediated by a slowly ribosylating component. The delayed effect of the toxin was not caused by down-regulation of the beta-subunit of G proteins because quantitative immunoblots showed that levels of the beta-subunit remained constant throughout the period of PT pretreatment. It was also not caused by a reduction in the size of the thrombin-releasable Ca2+ pool because Ca2+ release induced by agents that release Ca2+ directly from internal stores, 2,5-di-tert-butylhydroquinone or thapsigargin, was not affected. In addition, the delayed effect of PT could not be explained in terms of differences in thrombin-induced [H-3]inositol trisphosphate (IP3) formation because the level of inhibition of IP3 formation after a 2-h PT treatment was similar to that present after an 18-h pretreatment. The results indicate that a slowly ribosylating PT-sensitive species is the major G protein pathway that couples thrombin-receptor activation to Ca2+ mobilization. This G protein appears to be involved not in the mechanisms that generate IP3 but rather possibly in coupling at the level of the intracellular Ca2+ store.	CARDIOL RES CTR, INST EXPTL CARDIOL, MOLEC ENDOCRINOL LAB, MOSCOW 121552, USSR	National Medical Research Center of Cardiology	NEYLON, CB (corresponding author), ALFRED HOSP, BAKER MED RES INST, COMMERCIAL RD, PRAHRAN, VIC 3181, AUSTRALIA.		Tkachuk, Vsevolod A/J-9357-2012; Little, Peter J./F-9865-2015; Tkachuk, Vsevolod/AAE-1136-2022	Little, Peter J./0000-0002-0335-3835; Tkachuk, Vsevolod/0000-0002-7492-747X				AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERK BC, 1988, CIRCULATION, V78, P921; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; BROCK TA, 1988, J CELL PHYSIOL, V136, P54, DOI 10.1002/jcp.1041360107; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; BRUNS C, 1987, FEBS LETT, V212, P40, DOI 10.1016/0014-5793(87)81552-1; CASTELLOT JJ, 1987, VASCULAR SMOOTH MUSC, V1, P93; CHUEH SH, 1987, J BIOL CHEM, V262, P13857; CODINA J, 1988, BIOCHEM BIOPH RES CO, V150, P848, DOI 10.1016/0006-291X(88)90469-X; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DAWSON AP, 1989, CELL CALCIUM, V10, P343, DOI 10.1016/0143-4160(89)90060-2; DAWSON AP, 1985, FEBS LETT, V185, P147, DOI 10.1016/0014-5793(85)80759-6; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GAO B, 1987, J BIOL CHEM, V262, P17254; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GILL DL, 1989, NATURE, V342, P16, DOI 10.1038/342016a0; GILL DL, 1986, NATURE, V320, P461, DOI 10.1038/320461a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUANG CL, 1987, J BIOL CHEM, V262, P14134; HUANG CL, 1987, NATURE, V329, P849, DOI 10.1038/329849a0; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; KANAIDE H, 1986, BIOCHEM BIOPH RES CO, V140, P195, DOI 10.1016/0006-291X(86)91076-4; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KAWAHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P673, DOI 10.1016/0006-291X(90)92144-O; KAWAHARA Y, 1988, BIOCHEM BIOPH RES CO, V150, P52, DOI 10.1016/0006-291X(88)90485-8; KIKUCHI A, 1986, J BIOL CHEM, V261, P1558; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOBAYASHI S, 1988, J PHYSIOL-LONDON, V403, P601, DOI 10.1113/jphysiol.1988.sp017267; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; LITTLE PJ, 1986, AM J PHYSIOL, V251, pC707, DOI 10.1152/ajpcell.1986.251.5.C707; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; NEYLON CB, 1990, AM J PHYSIOL, V259, pC675, DOI 10.1152/ajpcell.1990.259.4.C675; NEYLON CB, 1991, J BIOL CHEM, V266, P4251; OHYA Y, 1991, CIRC RES, V68, P763, DOI 10.1161/01.RES.68.3.763; POBINER BF, 1985, J BIOL CHEM, V260, P6200; REMBOLD CM, 1990, J PHYSIOL-LONDON, V429, P77, DOI 10.1113/jphysiol.1990.sp018245; REMBOLD CM, 1988, CIRC RES, V63, P593, DOI 10.1161/01.RES.63.3.593; REYNOLDS EE, 1989, BIOCHEM BIOPH RES CO, V160, P868, DOI 10.1016/0006-291X(89)92515-1; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SAIDA K, 1987, BIOCHEM BIOPH RES CO, V144, P1313, DOI 10.1016/0006-291X(87)91453-7; SAIDA K, 1988, J CARDIOVASC PHARM, V12, pS47; SASAGURI T, 1985, BIOCHEM J, V231, P497, DOI 10.1042/bj2310497; SASAGURI T, 1986, BIOCHEM J, V239, P567, DOI 10.1042/bj2390567; SATOH S, 1987, PFLUG ARCH EUR J PHY, V410, P132, DOI 10.1007/BF00581905; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TAWADA Y, 1987, J BIOCHEM-TOKYO, V102, P1499, DOI 10.1093/oxfordjournals.jbchem.a122197; TAYLOR CW, 1990, BIOCHEM J, V272, P1; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREJO J, 1991, J BIOL CHEM, V266, P7876; UDRISAR D, 1990, P NATL ACAD SCI USA, V87, P6321, DOI 10.1073/pnas.87.16.6321; UEDA T, 1986, J BIOL CHEM, V261, P3184; VANHOUTTE PM, 1986, ANNU REV PHYSIOL, V48, P307; VOYNOYASENETSKAYA TA, 1989, FASEB J, V3, P44, DOI 10.1096/fasebj.3.1.2535990; WALZ DA, 1985, P SOC EXP BIOL MED, V180, P518; WATKINS DC, 1989, J BIOL CHEM, V264, P4186; WEST RE, 1985, J BIOL CHEM, V260, P4428	71	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7295	7302						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559973				2022-12-27	WOS:A1992HN48500018
J	YEE, J; DENNIS, PP				YEE, J; DENNIS, PP			ISOLATION AND CHARACTERIZATION OF A NADP-DEPENDENT GLUTAMATE-DEHYDROGENASE GENE FROM THE PRIMITIVE EUKARYOTE GIARDIA-LAMBLIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; ASPERGILLUS-NIDULANS; TRYPANOSOMA-CRUZI; NEUROSPORA-CRASSA; PROTEIN; EXPRESSION; METABOLISM; RNA; LOCALIZATION	Giardia lamblia is believed to be the earliest branching derivative from the eucaryotic lineage. Genomic and cDNA clones encoding the giardia NADP-dependent glutamate dehydrogenase have been isolated and characterized. Southern hydridization using genomic DNA indicates that the gene encoding this activity is unique and single copy. Primer extension, S1 nuclease protection, and genomic and cDNA sequence analysis demonstrate that gene transcripts are initiated within a conserved AT-rich sequence element immediately preceding the ATG translation initiation codon and the short 5' untranslated region is not extended by transsplicing. The open reading frame is 1350 nucleotides in length and encodes a protein of 449 amino acids. The reading frame is not interrupted by introns and the primary transcript is probably not subjected to RNA editing. In the strictly anaerobic metabolism of giardia, NADP-dependent glutamate dehydrogenase activity participates along with alanine aminotransferase, in the cyclic dissipation of reducing equivalents (NADPH) through the conversion of pyruvate to alanine. The deduced amino acid sequence of the giardia protein exhibits substantial homology to numerous fungal and eubacterial NADP-dependent glutamate dehydrogenases. Comparisons of alignment gap positions and amino acid identities indicate that the giardia sequence is at least as similar or more similar to the eubacterial sequence than it is to the fungal sequence. This supports the hypothesis that giardia diverged very early from the eucaryotic lineage.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia	YEE, J (corresponding author), CANADIAN INST ADV RES,PROGRAM EVOLUT BIOL,VANCOUVER V6T 1Z3,BC,CANADA.							ADAM RD, 1988, J EXP MED, V167, P109, DOI 10.1084/jem.167.1.109; ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; AGGARWAL A, 1990, NUCLEIC ACIDS RES, V18, P3409, DOI 10.1093/nar/18.11.3409; BAKER DA, 1988, NUCLEIC ACIDS RES, V16, P7177, DOI 10.1093/nar/16.14.7177; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAZZULO JJ, 1984, COMP BIOCHEM PHYS B, V79, P309, DOI 10.1016/0305-0491(84)90381-X; CAZZULO JJ, 1988, FEMS MICROBIOL LETT, V56, P215, DOI 10.1111/j.1574-6968.1988.tb03180.x; DOWNING WL, 1987, J MOL BIOL, V194, P609, DOI 10.1016/0022-2836(87)90238-5; Favaloro J, 1980, Methods Enzymol, V65, P718; FEINBERG A, 1982, ANAL BIOCHEM, V132, P6; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILLIN FD, 1990, P NATL ACAD SCI USA, V87, P4463, DOI 10.1073/pnas.87.12.4463; HAWKINS AR, 1989, MOL GEN GENET, V218, P105, DOI 10.1007/BF00330572; HOLBERTON D, 1988, J MOL BIOL, V204, P789, DOI 10.1016/0022-2836(88)90370-1; JARROLL EL, 1989, J PROTOZOOL, V36, P190, DOI 10.1111/j.1550-7408.1989.tb01073.x; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; KINNAIRD JH, 1983, GENE, V26, P253, DOI 10.1016/0378-1119(83)90195-6; KIRKMASON KE, 1989, MOL BIOCHEM PARASIT, V36, P87, DOI 10.1016/0166-6851(89)90204-1; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LINDMARK DG, 1980, MOL BIOCHEM PARASIT, V1, P1, DOI 10.1016/0166-6851(80)90037-7; MATTAJ IW, 1982, FEBS LETT, V147, P21, DOI 10.1016/0014-5793(82)81003-X; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER SM, 1990, J BACTERIOL, V172, P4927, DOI 10.1128/jb.172.9.4927-4935.1990; MOWATT M, 1992, MOL BIOCHEM PARASIT, V49, P215; MOYE WS, 1985, J BIOL CHEM, V260, P8502; NAGASU T, 1985, GENE, V37, P247, DOI 10.1016/0378-1119(85)90279-3; NEWMAN A, 1987, EMBO J, V6, P3833, DOI 10.1002/j.1460-2075.1987.tb02720.x; NEWTON CH, 1990, J BACTERIOL, V172, P579, DOI 10.1128/jb.172.2.579-588.1990; PAGET TA, 1992, IN PRESS MOL BIOCH P; PEATTIE DA, 1989, J CELL BIOL, V109, P2323, DOI 10.1083/jcb.109.5.2323; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; STEVENS L, 1989, FEMS MICROBIOL LETT, V57, P173; VIERULA PJ, 1989, J BIOL CHEM, V264, P1108	35	63	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7539	7544						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559991				2022-12-27	WOS:A1992HN48500050
J	FAZIO, S; YAO, ZM; MCCARTHY, BJ; RALL, SC				FAZIO, S; YAO, ZM; MCCARTHY, BJ; RALL, SC			SYNTHESIS AND SECRETION OF APOLIPOPROTEIN-E OCCUR INDEPENDENTLY OF SYNTHESIS AND SECRETION OF APOLIPOPROTEIN-B-CONTAINING LIPOPROTEINS IN HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; CULTURED RAT HEPATOCYTES; MESSENGER-RNA; HEP-G2; LIVER; LINE; ACID	The synthesis and secretion of apolipoprotein (apo) E, a major protein component of very low density lipoproteins, were examined in the human hepatoma cell line HepG2 under metabolic conditions known to stimulate lipogenesis and the production of apoB-containing lipoproteins. When HepG2 cells were incubated in the presence of fetal bovine serum (5 or 10%) or canine chylomicron remnants (5 or 10-mu-g of protein), the secretion of triglycerides and cholesteryl esters of lipoproteins of d < 1.063 g/ml increased, as determined by the incorporation of [C-14]acetate. Determination of the distribution of apoE among media lipoproteins by agarose column chromatography showed that the majority of secreted apoE was associated with large lipoproteins when cells were incubated with fetal bovine serum. However, immunoblot analysis of total media apoE revealed that incubating cells with or without the lipogenic factors had no effect on the amount of apoE secreted. Pulse-chase and continuous labeling experiments demonstrated that the synthesis and secretion of apoE did not vary under the different metabolic conditions, even though there was a 5-fold increase in apoB secretion in response to increased lipogenesis. Neither apoE nor apoB mRNA levels responded to the lipogenic stimuli. We conclude that the synthesis and secretion of apoE are independent of the production of apoB-containing lipoproteins in HepG2 cells.			FAZIO, S (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,GLADSTONE INST CARDIOVAS DIS,SAN FRANCISCO,CA 94140, USA.				NHLBI NIH HHS [HL41633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSTROM K, 1988, J BIOL CHEM, V263, P4434; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG WY, 1988, J BIOL CHEM, V263, P13880; DASHTI N, 1989, J LIPID RES, V30, P1365; DAVIS RA, 1980, J BIOL CHEM, V255, P2039; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; DAVIS RA, 1985, J BIOL CHEM, V260, P4137; DAVIS RA, 1989, J BIOL CHEM, V264, P8970; ELLSWORTH JL, 1986, J LIPID RES, V27, P858; GIBBONS GF, 1990, BIOCHEM J, V268, P1; HAMILTON RL, 1991, J LIPID RES, V32, P529; HORIE Y, 1992, J BIOL CHEM, V267, P1962; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; THRIFT RN, 1986, J LIPID RES, V27, P236; VANCE JE, 1990, ANNU REV NUTR, V10, P337, DOI 10.1146/annurev.nu.10.070190.002005; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WONG L, 1989, J CELL PHYSIOL, V141, P441, DOI 10.1002/jcp.1041410227; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	23	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6941	6945						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551903				2022-12-27	WOS:A1992HM05300075
J	LEBONNIEC, BF; GUINTO, ER; ESMON, CT				LEBONNIEC, BF; GUINTO, ER; ESMON, CT			THE ROLE OF CALCIUM-IONS IN FACTOR-X ACTIVATION BY THROMBIN-E192Q	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-X; GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION FACTOR-X; PROTEIN-C; BLOOD-COAGULATION; HUMAN THROMBOMODULIN; CA-2+ BINDING; FACTOR-V; SPECIFICITY; REGION	Despite considerable sequence similarities, blood coagulation serine proteases exhibit remarkable specificity with respect to which zymogen they activate. The basis for this specificity presumably involves recognition of a short sequence within the extended binding pocket of the enzyme, other interactions remote from the catalytic groove, and modulation by a definite protein cofactor. In addition, Ca2+ plays a major role in most activation processes, but, because both the enzyme and its substrate interact with Ca2+, whether Ca2+ influences the substrate, the enzyme, or both remains an open question. Thrombin is not a factor X-activating enzyme, but when Glu192, 3 residues remote from the active Ser195, is replaced with glutamine, the resultant serine protease (E192Q) becomes a bovine, but not human, factor X activator. Kinetic experiments with peptides corresponding to human and bovine factor X activating sites reveal that threonine at position P2 in human (versus a valine in bovine) accounts for the species specificity. Substitution of the threonine in P2 of the human sequence with valine allows E192Q to cleave the human peptide whereas substitution of the valine in P2 of the bovine sequence with threonine hinders E192Q catalysis. Thrombin has no high affinity Ca2+ binding sites, and E192Q proteolysis of these peptides is not altered by Ca2+. The influence of Ca2+ in E192Q-mediated factor X activation provides therefore new insights into the role of the different Ca2+ binding sites in factor X. With factor X as substrate, the addition of Ca2+ enhances K(cat) 4-fold but increases K(m) 10-fold. When the vitamin K-dependent gamma-carboxyglutamic acid domain of factor X is removed, the K(m) remains high with or without Ca2+ whereas K(cat) still increases upon addition of the metal ion. These results suggest that factor X undergoes two metal-dependent transitions that influence the presentation of the activation site to activators.	OKLAHOMA MED RES FDN, HOWARD HUGHES MED INST, 825 NE 13, OKLAHOMA CITY, OK 73104 USA; OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT PATHOL, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM, OKLAHOMA CITY, OK 73190 USA	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center			Le Bonniec, Bernard/S-5756-2016; Le Bonniec, Bernard/ABA-1366-2020	Le Bonniec, Bernard/0000-0002-8432-7363; Le Bonniec, Bernard/0000-0002-8432-7363	NHLBI NIH HHS [R01-HL29807, R37-HL30340] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029807, R37HL030340] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMPHLETT GW, 1982, BIOCHEMISTRY-US, V21, P125, DOI 10.1021/bi00530a022; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; BLOMBACK B, 1986, ANN NY ACAD SCI, V485, P120, DOI 10.1111/j.1749-6632.1986.tb34573.x; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; CHANG JY, 1985, EUR J BIOCHEM, V151, P225, DOI 10.1111/j.1432-1033.1985.tb09092.x; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; CHASE T, 1970, METHOD ENZYMOL, V19, P21; Esmon C T, 1987, Dev Biol Stand, V67, P51; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON CT, 1973, THESIS WASH U, P135; ESMON NL, 1983, J BIOL CHEM, V258, P2238; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FERSHT A, 1987, ENZYME STRUCTURE MEC, P109; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P4882, DOI 10.1021/bi00776a002; FUNG MR, 1985, P NATL ACAD SCI USA, V82, P3591, DOI 10.1073/pnas.82.11.3591; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1976, J BIOL CHEM, V251, P6807; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; HOFMANN H, 1987, BIOCHEMISTRY-US, V26, P780, DOI 10.1021/bi00377a019; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HUANG LH, 1991, BIOCHEMISTRY-US, V30, P7402, DOI 10.1021/bi00244a006; JACKSON CM, 1972, BIOCHEMISTRY-US, V11, P4873, DOI 10.1021/bi00776a001; JACKSON CM, 1984, PROG HEMOST THROMB, V7, P55; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; Jesty J, 1976, Methods Enzymol, V45, P95; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MCRAE BJ, 1981, BIOCHEMISTRY-US, V20, P7196, DOI 10.1021/bi00528a022; MITSUI Y, 1979, NATURE, V277, P447, DOI 10.1038/277447a0; MORITA T, 1979, VITAMIN K METABOLISM, P124; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OWEN WG, 1974, J BIOL CHEM, V249, P594; PERSSON E, 1991, J BIOL CHEM, V266, P2444; POZSGAY M, 1981, EUR J BIOCHEM, V115, P491; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SESHADRI TP, 1991, J MOL BIOL, V220, P481, DOI 10.1016/0022-2836(91)90025-2; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; SUGO T, 1984, J BIOL CHEM, V259, P5705; TENG CM, 1981, THROMB RES, V22, P213, DOI 10.1016/0049-3848(81)90323-6; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; [No title captured]	52	44	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6970	6976						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551906				2022-12-27	WOS:A1992HM05300079
J	TRAXLER, B; LEE, C; BOYD, D; BECKWITH, J				TRAXLER, B; LEE, C; BOYD, D; BECKWITH, J			THE DYNAMICS OF ASSEMBLY OF A CYTOPLASMIC MEMBRANE-PROTEIN IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE; GENETIC-ANALYSIS; TOPOLOGY; DETERMINANTS; INSERTION; SEQUENCE; FUSIONS; MALF	The topology of integral cytoplasmic membrane proteins can be analyzed using alkaline phosphatase fusions by determining which constructs have low and which have high specific activity. We show that in all cases the enzymatic activity is due to the fraction of the alkaline phosphatase moiety of the fusion protein localized to the periplasm. We present evidence that these fusions can also be used to analyze the process of assembly of cytoplasmic proteins into the membrane. The rate of acquisition of protease resistance of the alkaline phosphatase moiety of such hybrid proteins is compared for fusions to periplasmic and cytoplasmic domains. We show that this process, which is assumed to be representative of export of alkaline phosphatase, is significantly slower for fusions to cytoplasmic and certain periplasmic domains than for most periplasmic domains. These results are discussed in the context of the normal assembly of integral membrane proteins.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School								BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BOYD D, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P314; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRICKMAN ER, 1974, J MOL BIOL, V96, P307; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; FROSHAUER S, 1984, J BIOL CHEM, V259, P896; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; KUHN A, 1986, NATURE, V322, P335, DOI 10.1038/322335a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MANOIL C, 1988, TRENDS GENET, V4, P223, DOI 10.1016/0168-9525(88)90154-0; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; MICHAELIS S, 1986, J BACTERIOL, V167, P160, DOI 10.1128/jb.167.1.160-167.1986; Miller J.H., 1972, EXPT MOL GENETICS; ROBERTS CH, 1984, J BIOL CHEM, V259, P729; SANMILLAN JL, 1989, J BACTERIOL, V171, P5536, DOI 10.1128/jb.171.10.5536-5541.1989; SCHLESINGER MJ, 1965, J BIOL CHEM, V240, P4293; Shaw W V, 1975, Methods Enzymol, V43, P737; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671	22	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5339	5345						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544915				2022-12-27	WOS:A1992HH74700053
J	KUBOTA, S; TASHIRO, K; YAMADA, Y				KUBOTA, S; TASHIRO, K; YAMADA, Y			SIGNALING SITE OF LAMININ WITH MITOGENIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BASEMENT-MEMBRANE COMPONENTS; GROWTH-FACTOR; SYNTHETIC PEPTIDE; CELL ATTACHMENT; PROTO-ONCOGENE; FOS PROTEINS; C-FOS; BINDING; JUN; RECEPTOR	Laminin, a basement membrane glycoprotein, has diverse biological activities including cell adhesion, growth, and differentiation. However, little is known concerning the signal transduction and active site involved in cell growth. In this study, we have shown that laminin and a 19-mer peptide (PA22-2) from the carboxyl-terminal end of the long arm of the laminin A chain, which was previously shown to promote cell adhesion and neurite outgrowth, stimulate thymidine incorporation and cell growth of PC12 cells. Laminin and PA22-2 (PA) were also found to induce a rapid and transient mRNA expression of c-fos and c-jun protooncogenes in PC12 cells. Further, both laminin and PA stimulated the DNA binding activity of c-Fos and c-Jun protein complex to the AP-1 site. We have also found that there is a correlation between cell growth, c-fos expression, and the ability of cell attachment to laminin or to PA in different cell types. These results suggest that the PA sequence is a potent site in laminin for both signal transduction and cell growth.	NIDR,DEV BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CARPENTER G, 1976, J CELL PHYSIOL, V88, P227, DOI 10.1002/jcp.1040880212; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; CLEMENT B, 1990, J CELL BIOL, V110, P185, DOI 10.1083/jcb.110.1.185; COUCHMAN JR, 1983, J CELL BIOL, V96, P177, DOI 10.1083/jcb.96.1.177; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; DAVIS LG, 1988, BASIC METHODS MOL BI, P130; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; FARMER SR, 1989, CELL SHAPE DETERMINA, P173; GEHLSEN KR, 1988, SCIENCE, V241, P1228, DOI 10.1126/science.2970671; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MCGARVEY ML, 1984, DEV BIOL, V105, P18, DOI 10.1016/0012-1606(84)90257-4; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OCALAN M, 1988, DEV BIOL, V125, P158, DOI 10.1016/0012-1606(88)90068-1; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SITU R, 1984, J CELL SCI, V70, P167; TASHIRO K, 1991, J CELL PHYSIOL, V146, P451, DOI 10.1002/jcp.1041460316; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; VONDERMARK K, 1985, BIOCHIM BIOPHYS ACTA, V823, P147; VUKICEVIC S, 1990, CELL, V63, P437, DOI 10.1016/0092-8674(90)90176-F; WEEKS BS, 1990, J NEUROSCI RES, V27, P418, DOI 10.1002/jnr.490270321; WU BY, 1989, J BIOL CHEM, V264, P9000	34	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4285	4288						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537819				2022-12-27	WOS:A1992HF64200003
J	SELSTED, ME; NOVOTNY, MJ; MORRIS, WL; TANG, YQ; SMITH, W; CULLOR, JS				SELSTED, ME; NOVOTNY, MJ; MORRIS, WL; TANG, YQ; SMITH, W; CULLOR, JS			INDOLICIDIN, A NOVEL BACTERICIDAL TRIDECAPEPTIDE AMIDE FROM NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE NEUTROPHILS; ANTIMICROBIAL PEPTIDES; LARGE GRANULES; BACTENECINS; ANTIBACTERIAL; POLYPEPTIDES; PROTEINS; PURIFICATION	A potent and structurally novel antimicrobial peptide was purified from the cytoplasmic granules of bovine neutrophils. Suspensions of Staphylococcus aureus and Escherichia coli were virtually sterilized by the peptide at a concentration of 10-mu-g/ml. The peptide was found to be comprised of 13 amino acids, 5 of which were tryptophan residues, and the carboxyl-terminal arginine was carboxamidated. The primary structure of the peptide, which we have named indolicidin, is H-Ile-Leu-Pro-Trp-Lys-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg-NH2. The mole percent of tryptophan in indolicidin is the highest observed among known protein sequences. The multiple tryptophan residues presumably play an important role in the function of this unique antibiotic peptide.	UNIV CALIF IRVINE,COLL MED,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF DAVIS,SCH VET MED,DEPT PATHOL,DAVIS,CA 95616	University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Davis	SELSTED, ME (corresponding author), UNIV CALIF IRVINE,COLL MED,DEPT PATHOL,IRVINE,CA 92717, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022931, R01AI022931] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22931] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMREIN PC, 1980, BLOOD, V56, P442; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; CARLSON GP, 1973, P SOC EXP BIOL MED, V142, P853, DOI 10.3181/00379727-142-37131; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FRANK RW, 1990, J BIOL CHEM, V265, P18871; GENNARO R, 1983, INFECT IMMUN, V40, P684, DOI 10.1128/IAI.40.2.684-690.1983; GENNARO R, 1989, INFECT IMMUN, V57, P3142, DOI 10.1128/IAI.57.10.3142-3146.1989; LEHRER RI, 1990, BLOOD, V76, P2169; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; MARZARI R, 1988, INFECT IMMUN, V56, P2193, DOI 10.1128/IAI.56.8.2193-2197.1988; ROMEO D, 1988, J BIOL CHEM, V263, P9573; SAVOINI A, 1984, ANTIMICROB AGENTS CH, V26, P405, DOI 10.1128/AAC.26.3.405; SELSTED ME, 1986, ANAL BIOCHEM, V155, P270, DOI 10.1016/0003-2697(86)90436-7; SELSTED ME, 1984, INFECT IMMUN, V45, P150, DOI 10.1128/IAI.45.1.150-154.1984; SELSTED ME, 1992, 12TH P AM PEPT S; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; SPITZNAGEL JK, 1990, J CLIN INVEST, V86, P1381, DOI 10.1172/JCI114851; ZANETTI M, 1990, J CELL BIOL, V111, P1363, DOI 10.1083/jcb.111.4.1363	23	447	472	0	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4292	4295						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537821				2022-12-27	WOS:A1992HF64200005
J	MURTAGH, JJ; MOWATT, MR; LEE, CM; LEE, FJS; MISHIMA, K; NASH, TE; MOSS, J; VAUGHAN, M				MURTAGH, JJ; MOWATT, MR; LEE, CM; LEE, FJS; MISHIMA, K; NASH, TE; MOSS, J; VAUGHAN, M			GUANINE NUCLEOTIDE-BINDING PROTEINS IN THE INTESTINAL PARASITE GIARDIA-LAMBLIA - ISOLATION OF A GENE ENCODING AN SIMILAR-TO-20-KDA ADP-RIBOSYLATION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; CHOLERA-TOXIN; MESSENGER-RNA; ALPHA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; GTP; DNA; YEAST; SEQUENCES	Giardia lamblia is a protozoan intestinal parasite that has characteristics of both eukaryotes and prokaryotes. To determine whether genes for guanine nucleotide-binding proteins are present in Giardia, genomic DNA and cDNA libraries were screened by polymerase chain reaction and by hybridization with mixed oligonucleotide probes complementary to sequences encoding conserved GTP-binding domains. A gene with a high degree of sequence identity with mammalian ADP-ribosylation factors (ARFs), believed to be important in vesicular transport, was identified. The Giardia ARF gene had a 573-base open reading frame encoding 191 amino acids which are 63-70% identical with known mammalian and yeast ARFs. Sequence conservation among ARFs was greatest in putative GTP-binding domains. A single ARF mRNA species of approximately 750 bases was found in two different Giardia isolates. Primer extension and RNA sequencing of the Giardia ARF transcript revealed a short (6-base) 5'-untranslated region similar in size to those found in other Giardia transcripts. Giardia extracts contained ARF activity, as shown by stimulation of cholera toxin-catalyzed ADP-ribosylation and a Giardia ARF expressed in Escherichia coli as a fusion protein likewise exhibited biochemical activity. Its presence in Giardia is consistent with the view that ARF emerged before the divergence of this protozoan from other eukaryotes (approximately 1.5 billion years ago), and that an ARF-like protein may have been the ancestor of several other classes of signal-transducing guanine nucleotide-binding proteins, including the a subunits of the heterotrimeric G proteins.	NHLBI,CELLULAR METAB LAB,BLDG 10-5N307,BETHESDA,MD 20892; NIAID,PARASIT DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Lee, Chii-Ming/M-7799-2015	Lee, Chii-Ming/0000-0002-1075-5787; LEE, FANG-JEN/0000-0002-2167-2426				AGGARWAL A, 1990, NUCLEIC ACIDS RES, V18, P3409, DOI 10.1093/nar/18.11.3409; AGGARWAL A, 1989, MOL BIOCHEM PARASIT, V32, P39, DOI 10.1016/0166-6851(89)90127-8; AGGARWAL A, 1987, EXP PARAISITOL, V64, P335; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIRNBAUMER L, 1990, FASEB J, V4, P3178, DOI 10.1096/fasebj.4.14.2172060; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOTSTEIN D, 1988, COLD SPRING HARB SYM, V53, P629, DOI 10.1101/SQB.1988.053.01.072; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS ML, 1985, ANAL BIOCHEM, V151, P211, DOI 10.1016/0003-2697(85)90168-X; ESCHENFELDT WH, 1987, METHOD ENZYMOL, V152, P337; GELIEBTER J, 1986, P NATL ACAD SCI USA, V83, P3371, DOI 10.1073/pnas.83.10.3371; GILLIN FD, 1990, P NATL ACAD SCI USA, V87, P4463, DOI 10.1073/pnas.87.12.4463; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAUN RS, 1992, IN PRESS GENE AMST; HULTMAN T, 1991, BIOTECHNIQUES, V10, P84; HURLEY JB, 1990, SOC GEN PHY, V45, P157; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KIMURA M, 1989, GENOME, V31, P24, DOI 10.1139/g89-009; KIRKMASON KE, 1989, MOL BIOCHEM PARASIT, V36, P87, DOI 10.1016/0166-6851(89)90204-1; KNOTH K, 1988, NUCLEIC ACIDS RES, V16, P10932, DOI 10.1093/nar/16.22.10932; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; MA H, 1990, P NATL ACAD SCI USA, V87, P3821, DOI 10.1073/pnas.87.10.3821; MITCHELL LG, 1989, ANAL BIOCHEM, V178, P239, DOI 10.1016/0003-2697(89)90631-3; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MOWATT MR, 1991, MOL BIOCHEM PARASIT, V49, P215, DOI 10.1016/0166-6851(91)90065-E; MURTAGH JJ, 1991, MOL CELL BIOL, V11, P1146, DOI 10.1128/MCB.11.2.1146; NAKAFUKU M, 1987, P NATL ACAD SCI USA, V84, P2140, DOI 10.1073/pnas.84.8.2140; NASAH TE, 1991, IN PRESS MOL BIOCH P; NASH TE, 1985, J INFECT DIS, V152, P64, DOI 10.1093/infdis/152.1.64; NASH TE, 1986, J IMMUNOL, V136, P2628; NASH TE, 1988, J IMMUNOL, V141, P636; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; QUAN F, 1989, P NATL ACAD SCI USA, V86, P4321, DOI 10.1073/pnas.86.11.4321; REINER DS, 1990, EUR J CELL BIOL, V53, P142; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSUCHIYA M, 1989, BIOCHEMISTRY-US, V28, P9668, DOI 10.1021/bi00451a019; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; UHLEN M, 1989, NATURE, V340, P733, DOI 10.1038/340733a0; UPCROFT P, 1991, EXPER SUPPL, V58, P70; VANDERVOORN L, 1990, J MOL BIOL, V213, P17, DOI 10.1016/S0022-2836(05)80118-4; WENHSIUNG L, 1991, FUNDAMENTALS MOL EVO, P67; YAFFE D, 1985, NUCLEIC ACIDS RES, V13, P3723, DOI 10.1093/nar/13.10.3723	62	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9654	9662						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577802				2022-12-27	WOS:A1992HT96500033
J	SHI, YQ; RANDO, RR				SHI, YQ; RANDO, RR			KINETIC MECHANISM OF ISOPRENYLATED PROTEIN METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SUBUNITS CONTAIN; CYSTEINE METHYL-ESTER; GTP-BINDING PROTEINS; POSTTRANSLATIONAL MODIFICATION; CARBOXYL TERMINI; FARNESYL; P21RAS; IDENTIFICATION; TRANSFERASE; TRANSDUCIN	The kinetic mechanism of the rod outer segment (ROS) isoprenylated protein methyltransferase was investigated. This S-adenosyl-L-methionine (AdoMet)-linked enzyme transfers methyl groups to carboxyl-terminal isoprenylated cysteine residues of proteins, generating methyl esters. The enzyme also processes simple substrates such as N-acetyl-S-farnesyl-L-CySteine (L-AFC). Initial studies showed that a ping-pong Bi Bi mechanism could be eliminated. In a ping-pong Bi Bi mechanism plots of 1/v versus 1/[substrate A] at different fixed substrate B concentrations are expected to yield a family of parallel lines whose slopes equal K(m)/V(max). In fact, converging curves were found, which suggested a sequential mechanism. Dead-end inhibitors were used in order to further investigate the kinetic mechanism. S-Farnesylthioacetic acid is shown to be a dead-end competitive inhibitor with respect to the prenylated substrate L-AFC. On the other hand, S-farnesylthioacetic acid proved to be uncompetitive with respect to AdoMet, suggesting an ordered mechanism with AdoMet binding first. Further evidence for this mechanism came from product inhibition studies using the methyl ester of L-AFC (L-AFCMe) and S-adenosyl-L-homocysteine (AdoHcy). Since AdoMet binds first to the enzyme, one of the products (L-AFCMe or AdoHcy) should be a competitive inhibitor with respect to it. It could be shown that AdoHcy is a competitive inhibitor with respect to AdoMet, but L-AFCMe is a mixed-type inhibitor both with respect to AdoMet and to L-AFC. Therefore, AdoHcy combines with the same enzyme form as does AdoMet, and must be released from the enzyme last. Moreover, L-AFC and L-AFCMe must bind to different forms of the enzyme.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,250 LONGWOOD AVE,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL EYE INSTITUTE [R01EY003624] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034346] Funding Source: NIH RePORTER; NEI NIH HHS [EY-03624] Funding Source: Medline; NHLBI NIH HHS [HL-34346] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; CAAMANO CA, 1989, J NEUROCHEM, V53, P1883, DOI 10.1111/j.1471-4159.1989.tb09257.x; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GUNTHERT U, 1981, J BIOL CHEM, V256, P9346; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HINCHIGERI SB, 1982, PHOTOSYNTHETICA, V16, P554; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; OTA IM, 1989, J BIOL CHEM, V264, P12879; PEREZSALA D, 1991, P NATL ACAD SCI USA, V88, P3043, DOI 10.1073/pnas.88.8.3043; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SEGEL IH, 1975, ENZYME KINETICS, P606; SEGEL IH, 1975, ENZYME KINETICS, P777; SHAFER WR, 1989, SCIENCE, V245, P379; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; STRYER L, 1988, COLD SPRING HARB SYM, V53, P283, DOI 10.1101/SQB.1988.053.01.035; SWANSON RJ, 1983, J BIOL CHEM, V258, P599; TAN EW, 1991, J BIOL CHEM, V266, P10719; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WU JC, 1987, J BIOL CHEM, V262, P4778; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286	34	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9547	9551						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577795				2022-12-27	WOS:A1992HT96500018
J	BARABAS, K; SIZENSKY, JA; FAULK, WP				BARABAS, K; SIZENSKY, JA; FAULK, WP			TRANSFERRIN CONJUGATES OF ADRIAMYCIN ARE CYTOTOXIC WITHOUT INTERCALATING NUCLEAR-DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG RESISTANCE; CYTO-TOXICITY; CELL-GROWTH; BINDING; RECEPTORS; MEMBRANE; DERIVATIVES; DAUNOMYCIN; ANTIBODIES; EXPRESSION	Studies of the biological chemistry of most anticancer drugs have revealed their cytotoxicity is expressed after the drugs have entered cells. It is thought that anthracycline antitumor drugs exert their cytotoxicity by entering cells, diffusing into nuclei, and inhibiting topoisomerase II and/or intercalating DNA base pairs. In order to deliver anthracyclines to transferrin (TRF) receptors on the plasma membranes of human tumor cells, we have prepared conjugates of adriamycin (ADR) with human TRF. These TRF-ADR conjugates were found to be stable at low pH and to exert more efficient cytotoxicity than free drug. By using spectro-fluorometry, we found that the fluorescence of ADR within the conjugate was quenched by native DNA, demonstrating the presence of conformationally available drug to intercalate with nuclear DNA. However, fluorescence was not quenched when conjugate was reacted with viable cells, indicating that ADR did not reach the nucleus. Results of fluorescence microscopy experiments confirmed that free but not conjugated ADR reached the nuclei of viable cells, and TRF-ADR conjugates labeled with fluorescein isothiocyanate were found to initiate lateral diffusion as determined by patch and cap reactions. The involvement of TRF receptors was shown by flow cytometry experiments in which native TRF inhibited binding of fluorescein-labeled TRF-ADR conjugates. These data suggest that TRF-ADR conjugates mediate cytotoxicity by a mechanism other than intercalation with nuclear DNA. This mechanism, revealed by conjugating ADR to a TRF carrier, may not initiate complications such as cardiotoxicity and drug resistance.	PURDUE UNIV,DEPT MED CHEM,W LAFAYETTE,IN 47907; HUNGARIAN ACAD SCI,BIOL RES CTR,INST BIOPHYS,H-6701 SZEGED,HUNGARY	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Hungarian Academy of Sciences; Hungarian Biological Research Center	BARABAS, K (corresponding author), METHODIST HOSP INDIANA,CTR REPROD & TRANSPLANTAT IMMUNOL,INDIANAPOLIS,IN 46202, USA.							ARCAMONE F, 1981, DOXORUBICIN ANTICANC, P93; BARABAS K, 1991, AM J REPROD IMMUNOL, V25, P120, DOI 10.1111/j.1600-0897.1991.tb01078.x; BODLEY A, 1989, CANCER RES, V49, P5969; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BURKE TG, 1985, BIOCHEMISTRY-US, V24, P5972, DOI 10.1021/bi00342a043; CRANE FL, 1990, GROWTH FACTORS GENES, P228; DIMARCO A, 1971, BIOCHEM PHARMACOL, V20, P1323, DOI 10.1016/0006-2952(71)90365-0; DUPONT B, 1972, TISSUE ANTIGENS, V2, P141; EDELMAN GM, 1976, SCIENCE, V192, P218, DOI 10.1126/science.769162; EDIDIN M, 1987, CURR TOP MEMBR TRANS, V29, P91; FAULK W P, 1990, Molecular Biotherapy, V2, P57; Faulk W.P., 1990, OXIDOREDUCTION PLASM, V1, P205; FAULK WP, 1980, LANCET, V2, P390; FAULK WP, 1972, PROG ALLERGY, V16, P9; FAULK WP, 1979, PROC R SOC SER B-BIO, V204, P83, DOI 10.1098/rspb.1979.0014; FAULK WP, 1991, BIOCHEM INT, V25, P815; FAULK WP, 1975, NATURE, V256, P123, DOI 10.1038/256123a0; FAULK WP, 1990, AM J REPROD IMMUNOL, V21, P151; FAULK WP, 1988, PLASMA MEMBRANE OXID, P173; GALBRAITH GMP, 1980, CELL IMMUNOL, V49, P215, DOI 10.1016/0008-8749(80)90072-6; GALBRAITH RM, 1981, IMMUNOLOGY, V44, P703; GOLDMAN R, 1978, BIOCHIM BIOPHYS ACTA, V512, P254, DOI 10.1016/0005-2736(78)90251-1; GOORMAGHTIGH E, 1980, BIOCHIM BIOPHYS ACTA, V597, P1, DOI 10.1016/0005-2736(80)90145-5; GOORMAGHTIGH E, 1983, BIOCHEM PHARMACOL, V32, P889, DOI 10.1016/0006-2952(83)90593-2; GOORMAGHTIGH E, 1980, BIOCHEM PHARMACOL, V29, P3003, DOI 10.1016/0006-2952(80)90050-7; HAMILTON TC, 1984, CANCER RES, V44, P5286; HENRY N, 1985, BIOCHEMISTRY-US, V24, P7085, DOI 10.1021/bi00346a010; HURWITZ E, 1975, CANCER RES, V35, P1175; JEANNESSON P, 1990, CANCER RES, V50, P1231; KESSEL D, 1970, CANCER RES, V30, P2695; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; LESLEY J, 1984, CELL IMMUNOL, V83, P14, DOI 10.1016/0008-8749(84)90220-X; LESLEY JF, 1985, MOL CELL BIOL, V5, P1814, DOI 10.1128/MCB.5.8.1814; MAY PM, 1980, INORG CHIM A-BIOINOR, V46, P221, DOI 10.1016/S0020-1693(00)84195-X; MCCORMICK JN, 1971, J EXP MED, V133, P1, DOI 10.1084/jem.133.1.1; MINOW RA, 1975, CANCER CHEMOTH REP 3, V6, P195; MYERS C, 1986, FASEB J, V45, P2792; NECKERS LM, 1983, P NATL ACAD SCI-BIOL, V80, P3494, DOI 10.1073/pnas.80.11.3494; NEIDLE S, 1987, BIOCHEM J, V243, P1; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; POMMIER Y, 1986, CANCER RES, V46, P611; POTMESIL M, 1988, ANTHRACYCLINE ANTHRA, P447; RAMU A, 1989, RESISTANCE ANTINEOPL, P63; ROGERS KE, 1984, BIOCHEM PHARMACOL, V33, P605, DOI 10.1016/0006-2952(84)90315-0; ROGERS KE, 1983, CANCER RES, V43, P2741; SIZENSKY J, 1991, IN PRESS AM J REPROD; SUN IL, 1987, BIOCHEM INT, V14, P119; SUN IL, 1990, OXIDOREDUCTION PLASM, V1, P257; SUN IL, 1992, IN PRESS BIOCH BIOPH; TARASIUK J, 1989, BIOCHIM BIOPHYS ACTA, V1013, P109, DOI 10.1016/0167-4889(89)90038-4; TOKES ZA, 1982, P NATL ACAD SCI-BIOL, V79, P2026, DOI 10.1073/pnas.79.6.2026; TOKOYAMA M, 1990, CANCER RES, V50, P1693; TOOLESIMMS W, 1991, BIOCHEM BIOPH RES CO, V176, P1437, DOI 10.1016/0006-291X(91)90447-F; TRITTON TR, 1982, SCIENCE, V217, P248, DOI 10.1126/science.7089561; VAICKUS L, 1985, J IMMUNOL, V135, P1987; VANBOCKXMEER FM, 1978, EUR J BIOCHEM, V92, P147; WANG AL, 1985, CANCER TREAT REP, V69, P677; Yeh C. J. G., 1984, PROTIDES BIOL FLUIDS, V32, P441; YEH CJG, 1982, EXP CELL RES, V138, P429, DOI 10.1016/0014-4827(82)90192-6; YEH CJG, 1984, VOX SANG, V46, P217, DOI 10.1111/j.1423-0410.1984.tb00078.x; YEH CJG, 1984, CLIN IMMUNOL IMMUNOP, V52, P1; ZWEIER JL, 1984, J BIOL CHEM, V259, P6056	63	70	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9437	9442						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577771				2022-12-27	WOS:A1992HR85400110
J	BONEWALD, LF; KESTER, MB; SCHWARTZ, Z; SWAIN, LD; KHARE, A; JOHNSON, TL; LEACH, RJ; BOYAN, BD				BONEWALD, LF; KESTER, MB; SCHWARTZ, Z; SWAIN, LD; KHARE, A; JOHNSON, TL; LEACH, RJ; BOYAN, BD			EFFECTS OF COMBINING TRANSFORMING GROWTH-FACTOR-BETA AND 1,25-DIHYDROXYVITAMIN-D3 ON DIFFERENTIATION OF A HUMAN OSTEOSARCOMA (MG-63)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEO-SARCOMA CELLS; ALKALINE-PHOSPHATASE; TRANSCRIPTIONAL REGULATION; CHONDROCYTE CULTURES; PHOSPHOLIPASE-C; MESSENGER-RNA; RETINOIC ACID; RESTING ZONE; BONE; PROTEIN	Transforming growth factor-beta (TGF-beta) and 1,25-dihydroxyvitamin D3 (1,25D3), when added simultaneously to a human osteosarcoma cell line, MG-63, induce alkaline phosphatase activity 40-70-fold over basal levels, 6-7-fold over 1,25D3 treatment alone, and 15-20-fold over TGF-beta treatment alone. TGF-beta and 1,25D3 synergistically increased alkaline phosphatase specific activity in both matrix vesicles and plasma membrane isolated from the cultures, but the specific activity was greater in and targeted to the matrix vesicle fraction. Inhibitor and cleavage studies proved that the enzymatic activity was liver/bone/kidney alkaline phosphatase. Preincubation of MG-63 cells with TGF-beta for 30 min before addition of 1,25D3 was sufficient for maximal induction of enzyme activity. Messenger RNA for liver/bone/kidney alkaline phosphatase was increased 2.1-fold with TGF-beta, 1.7-fold with 1,25D3, and 4.8-fold with the combination at 72 h. Human alkaline phosphatase protein as detected by radioimmunoassay was stimulated only 6.3-fold over control levels with the combination. This combination of factors was tested for their effect on production of three other osteoblast cell proteins: collagen type I, osteocalcin, and fibronectin. TGF-beta inhibited 1,25D3-induced osteocalcin production, whereas both factors were additive for fibronectin and collagen type I production. TGF-beta appears to modulate the differentiation effects of 1,25D3 on this human osteoblast-like cell and thereby retain the cell in a non-fully differentiated state.	UNIV TEXAS, HLTH SCI CTR, DEPT ORTHOPAED, SAN ANTONIO, TX 78284 USA; UNIV TEXAS, HLTH SCI CTR, DEPT CELLULAR & STRUCT BIOL, SAN ANTONIO, TX 78284 USA; HEBREW UNIV JERUSALEM, HADASSAH FAC DENT MED, JERUSALEM, ISRAEL	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Hebrew University of Jerusalem	BONEWALD, LF (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT MED, DIV ENDOCRINOL & METAB, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.		Bonewald, Lynda/Q-3638-2019	Leach, Robin/0000-0002-3201-5579	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005937] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39357] Funding Source: Medline; NIDCR NIH HHS [DE08563, DE05937] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BERESFORD JN, 1984, METAB BONE DIS RELAT, V5, P299; BONEWALD LF, 1990, J CELL PHYSIOL, V145, P200, DOI 10.1002/jcp.1041450203; BONEWALD LF, 1990, CLIN ORTHOP RELAT R, P261; BONEWALD LF, 1989, CONNECT TISSUE RES, V23, P201, DOI 10.3109/03008208909002418; BONEWALD LF, 1987, J BONE MINER RES  S1, V2, P23; BORGERS M, 1973, J HISTOCHEM CYTOCHEM, V21, P812, DOI 10.1177/21.9.812; BOYAN BD, 1988, BONE, V9, P185, DOI 10.1016/8756-3282(88)90008-7; BOYAN BD, 1989, J BIOL CHEM, V264, P11879; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRABB ID, 1990, J BONE MINER RES, V5, P1105; DOTY SB, 1980, J HISTOCHEM CYTOCHEM, V28, P66, DOI 10.1177/28.1.6153197; DWORETZKY SI, 1990, P NATL ACAD SCI USA, V87, P4605, DOI 10.1073/pnas.87.12.4605; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINKELMAN RD, 1985, J DENT RES, V64, P1008, DOI 10.1177/00220345850640070301; FITZPATRICK DF, 1969, J BIOL CHEM, V244, P3561; FRANCESCHI RT, 1985, J CELL PHYSIOL, V123, P401, DOI 10.1002/jcp.1041230316; FRANCESCHI RT, 1987, J BIOL CHEM, V262, P4165; FRANCESCHI RT, 1990, J BONE MINER RES, V5, P1157; FRANCESCHI RT, 1988, J BONE MINER RES  S1, V3, P57; GARBA MT, 1986, CALCIFIED TISSUE INT, V38, P296, DOI 10.1007/BF02556610; GESTENFELD LC, 1987, DEV BIOL, V122, P49; GUNDBERG CM, 1984, METHOD ENZYMOL, V107, P516; HEBDA PA, 1988, J INVEST DERMATOL, V91, P440, DOI 10.1111/1523-1747.ep12476480; HEINO J, 1989, J BIOL CHEM, V264, P21806; HILL CS, 1990, J BONE MINER RES S2, V5, P646; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; IWAMOTO M, 1989, BIOCHEM BIOPH RES CO, V159, P1006, DOI 10.1016/0006-291X(89)92208-0; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; KATO Y, 1988, P NATL ACAD SCI USA, V85, P9552, DOI 10.1073/pnas.85.24.9552; LAJEUNESSE D, 1990, J BONE MINER RES, V5, P915, DOI 10.1002/jbmr.5650050904; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIAN JB, 1985, J BIOL CHEM, V260, P8706; LOW MG, 1977, BIOCHEM J, V167, P281, DOI 10.1042/bj1670281; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCELLI C, 1990, J BONE MINER RES, V5, P1087; MASSAGUE J, 1987, J CELL PHYSIOL, P43; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; MULIVOR RA, 1978, ANN HUM GENET, V42, P1, DOI 10.1111/j.1469-1809.1978.tb00927.x; NAKAMURA T, 1988, ARCH BIOCHEM BIOPHYS, V265, P190, DOI 10.1016/0003-9861(88)90384-0; NG KW, 1989, J MOL ENDOCRINOL, V3, P57, DOI 10.1677/jme.0.0030057; NODA M, 1989, ENDOCRINOLOGY, V124, P612, DOI 10.1210/endo-124-2-612; NODA M, 1988, J BIOL CHEM, V263, P13916; NODA M, 1987, J CELL PHYSIOL, V133, P426, DOI 10.1002/jcp.1041330303; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PFEILSCHIFTER J, 1987, ENDOCRINOLOGY, V121, P212, DOI 10.1210/endo-121-1-212; POSER JW, 1980, J BIOL CHEM, V255, P8685; Price P.A., 1987, CALCIUM REGULATION B, V9, P419; PRICE PA, 1980, J BIOL CHEM, V255, P1660; RIZZINO A, 1988, DEV BIOL, V130, P411, DOI 10.1016/0012-1606(88)90337-5; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SCHWARTZ Z, 1990, BIOCHIM BIOPHYS ACTA, V1027, P278, DOI 10.1016/0005-2736(90)90319-J; SEYEDIN SM, 1986, J BIOL CHEM, V261, P5693; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; TONG PS, 1990, J INVEST DERMATOL, V94, P126, DOI 10.1111/1523-1747.ep12873985; VANBELLE H, 1972, BIOCHIM BIOPHYS ACTA, V289, P158, DOI 10.1016/0005-2744(72)90118-0; WEISS MJ, 1986, P NATL ACAD SCI USA, V83, P7182, DOI 10.1073/pnas.83.19.7182; WERGEDAL JE, 1992, METABOLISM, V41, P42, DOI 10.1016/0026-0495(92)90189-H; WERGEDAL JE, 1990, J BONE MINER RES S2, V5, P238; WHYTE MP, 1986, J PEDIATR-US, V108, P82, DOI 10.1016/S0022-3476(86)80773-9; WUTHIER RE, 1977, CALC TISS RES, V24, P163, DOI 10.1007/BF02223311; [No title captured]	66	181	183	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8943	8949						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577731				2022-12-27	WOS:A1992HR85400039
J	KRIKORIAN, JG; BLOCH, RJ				KRIKORIAN, JG; BLOCH, RJ			TREATMENTS THAT EXTRACT THE 43K-PROTEIN FROM ACETYLCHOLINE-RECEPTOR CLUSTERS MODIFY THE CONFORMATION OF CYTOPLASMIC DOMAINS OF ALL SUBUNITS OF THE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO POSTSYNAPTIC MEMBRANES; MARMORATA ELECTRIC ORGAN; CELL-SUBSTRATE CONTACT; CULTURED RAT MYOTUBES; MONOCLONAL-ANTIBODIES; RICH MEMBRANES; ALPHA-SUBUNIT; NEUROMUSCULAR-JUNCTION; SKELETAL-MUSCLE; TRANSMEMBRANE TOPOGRAPHY	The nicotinic acetylcholine receptor (AChR) of Torpedo electric organ and vertebrate skeletal muscle is closely associated with a M(r) 43,000 protein (43K). In this study, we have examined the effects on the AChR of treatments which remove the 43K protein. We used semiquantitative fluorescence techniques to measure the binding of antibodies to clustered AChR in cultured rat myotubes. We found that labeling by antibodies to the cytoplasmic portions of each of the four receptor polypeptides increased significantly upon extraction of the 43K protein. Labeling by an antibody to an extracellular epitope of the alpha-subunits was not affected by removal of the 43K Protein, suggesting that changes were restricted to the cytoplasmic domains of the AChR. Increases in labeling by antibodies were more limited following protease treatment, which removes most cytoskeletal structures but leaves the 43K protein bound to the membrane. Competition between an antibody to the beta-subunit and an antibody to the gamma and delta-subunits suggests that the cytoplasmic portion of the AChR still retains a degree of native structure in the absence of the 43K protein. Our results suggest that, although some of these changes may be due to simply exposing additional epitopes on the AChR, the cytoplasmic portions of all the subunits of the AChR undergo significant conformational changes upon extraction of the 43K protein.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,660 W REDWOOD ST,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017282] Funding Source: NIH RePORTER; NINDS NIH HHS [NS17282] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAETSCHER M, 1986, J CELL BIOL, V103, P369, DOI 10.1083/jcb.103.2.369; BARRANTES FJ, 1980, FEBS LETT, V112, P73, DOI 10.1016/0014-5793(80)80131-1; BLOCH RJ, 1984, J CELL BIOL, V99, P984, DOI 10.1083/jcb.99.3.984; BLOCH RJ, 1987, J CELL BIOL, V104, P645, DOI 10.1083/jcb.104.3.645; BLOCH RJ, 1991, J CELL BIOL, V115, P435, DOI 10.1083/jcb.115.2.435; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; BLOCH RJ, 1986, J CELL BIOL, V102, P1447, DOI 10.1083/jcb.102.4.1447; BLOCH RJ, 1983, J CELL BIOL, V97, P217, DOI 10.1083/jcb.97.1.217; BLOCH RJ, 1989, EXP CELL RES, V182, P583, DOI 10.1016/0014-4827(89)90261-9; BLOCH RJ, 1980, CELL, V21, P25, DOI 10.1016/0092-8674(80)90111-7; BLOCH RJ, 1988, AM J PHYSIOL, V254, pC345, DOI 10.1152/ajpcell.1988.254.3.C345; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BRIDGMAN PC, 1987, J CELL BIOL, V105, P1829, DOI 10.1083/jcb.105.4.1829; BURDEN SJ, 1983, CELL, V35, P687, DOI 10.1016/0092-8674(83)90101-0; BURDEN SJ, 1985, P NATL ACAD SCI USA, V82, P8270, DOI 10.1073/pnas.82.23.8270; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; CARTAUD J, 1981, J CELL BIOL, V90, P418, DOI 10.1083/jcb.90.2.418; CHANG HW, 1977, BIOCHEMISTRY-US, V16, P4513, DOI 10.1021/bi00639a028; DANIELS MP, 1990, J CELL SCI, V97, P615; DANIELS MP, 1990, EXP CELL RES, V186, P99, DOI 10.1016/0014-4827(90)90215-V; DEROMANELLI ICB, 1987, BIOCHEM J, V105, P111; ELLIOTT J, 1980, BIOCHEM J, V185, P667, DOI 10.1042/bj1850667; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; FROEHNER SC, 1984, J CELL BIOL, V99, P88, DOI 10.1083/jcb.99.1.88; FROEHNER SC, 1983, J BIOL CHEM, V258, P7112; GENTRY LE, 1983, J BIOL CHEM, V258, P1219; GUY HR, 1987, TRENDS NEUROSCI, V10, P318, DOI 10.1016/0166-2236(87)90087-7; GYSIN R, 1981, J BIOL CHEM, V256, P1373; HALL ZW, 1981, J CELL BIOL, V90, P789, DOI 10.1083/jcb.90.3.789; HAMILTON SL, 1977, BIOCHEM BIOPH RES CO, V79, P692, DOI 10.1016/0006-291X(77)91167-6; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; LAROCHELLE WJ, 1986, J BIOL CHEM, V261, P5270; LO MMS, 1980, FEBS LETT, V111, P407, DOI 10.1016/0014-5793(80)80838-6; MCCREA PD, 1987, EMBO J, V6, P3619, DOI 10.1002/j.1460-2075.1987.tb02693.x; MITRA AK, 1989, J CELL BIOL, V109, P755, DOI 10.1083/jcb.109.2.755; NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690; NGHIEM HO, 1983, P NATL ACAD SCI-BIOL, V80, P6403, DOI 10.1073/pnas.80.20.6403; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; PEDERSEN SE, 1990, J BIOL CHEM, V265, P569; PENG HB, 1985, J CELL BIOL, V100, P1698, DOI 10.1083/jcb.100.5.1698; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; PORTER S, 1983, J BIOL CHEM, V258, P34; PUMPLIN DW, 1989, J CELL BIOL, V109, P739, DOI 10.1083/jcb.109.2.739; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2621, DOI 10.1021/bi00357a051; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2633, DOI 10.1021/bi00357a052; RAVDIN P, 1977, ANAL BIOCHEM, V80, P585, DOI 10.1016/0003-2697(77)90682-0; RAVDIN P, ANAL BIOCHEM, V83, P336; ROUSSELET A, 1982, EMBO J, V1, P439, DOI 10.1002/j.1460-2075.1982.tb01188.x; SALPETER MM, 1985, PROG NEUROBIOL, V25, P297, DOI 10.1016/0301-0082(85)90018-8; SARGENT PB, 1984, J CELL BIOL, V98, P609, DOI 10.1083/jcb.98.2.609; SCHUETZE SM, 1987, ANNU REV NEUROSCI, V10, P403, DOI 10.1146/annurev.ne.10.030187.002155; SEALOCK R, 1982, J NEUROSCI, V2, P918; SEALOCK R, 1984, J CELL BIOL, V98, P2239, DOI 10.1083/jcb.98.6.2239; SEALOCK R, 1986, EXP CELL RES, V163, P143, DOI 10.1016/0014-4827(86)90566-5; SOBEL A, 1978, P NATL ACAD SCI USA, V75, P510, DOI 10.1073/pnas.75.1.510; STEINBACH JH, 1986, RECEPTORS CELLULAR R, P183; STRADER CD, 1980, BIOCHEM BIOPH RES CO, V92, P365, DOI 10.1016/0006-291X(80)90342-3; STROUD RM, 1985, ANNU REV CELL BIOL, V1, P317, DOI 10.1146/annurev.cellbio.1.1.317; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; TOYOSHIMA C, 1988, NATURE, V336, P247, DOI 10.1038/336247a0; TZARTOS S, 1986, J NEUROIMMUNOL, V10, P235, DOI 10.1016/0165-5728(86)90105-0; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; TZARTOS SJ, 1988, P NATL ACAD SCI USA, V85, P2899, DOI 10.1073/pnas.85.9.2899; WENNOGLE LP, 1980, EUR J BIOCHEM, V106, P381, DOI 10.1111/j.1432-1033.1980.tb04584.x; WOODRUFF ML, 1987, J CELL BIOL, V104, P939, DOI 10.1083/jcb.104.4.939	70	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9118	9128						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577748				2022-12-27	WOS:A1992HR85400065
J	SUGUMARAN, G; KATSMAN, M; SILBERT, JE				SUGUMARAN, G; KATSMAN, M; SILBERT, JE			EFFECTS OF BREFELDIN-A ON THE LOCALIZATION OF CHONDROITIN SULFATE-SYNTHESIZING ENZYMES - ACTIVITIES IN SUBFRACTIONS OF THE GOLGI FROM CHICK-EMBRYO EPIPHYSEAL CARTILAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR-TRANSPORT; RAT HEPATOCYTES; BIOSYNTHESIS; PROTEINS; PROTEOCHONDROITIN; OLIGOSACCHARIDES; CELLS; SITE; ER	Membranes from brefeldin A-treated and untreated chick embryo epiphyseal cartilage were fractionated separately by equilibrium sucrose density gradient centrifugation. Fractions were assayed for Gal I transferase, Gal II transferase, Gal ovalbumin transferase, chondroitin polymerization on endogenous acceptors, GalNAc transfer to exogenous chondroitin hexasaccharide, and sulfate transfer to exogenous chondroitin. Gal I transferase and Gal II transferase activities were found in heavier cis- and medial-Golgi fractions, but with distributions different from each other. Brefeldin A had no effect on either their distribution or their total activity. Gal ovalbumin transferase activity in fractions from untreated cartilage was found as a dual peak in medial- and trans-Golgi areas. The latter peak was diminished in the fractions from the brefeldin A-treated cartilage, whereas the former peak was correspondingly increased. A similar dual medial- and trans-Golgi distribution for chondroitin polymerization on endogenous acceptors was seen with fractions from untreated cartilage. This was modified in fractions from brefeldin A-treated cartilage with a complete loss of synthesis in the trans-Golgi peak and a slight increase in synthesis in the medial-Golgi peak. However, the distribution of GalNAc transferase activity using exogenous chondroitin hexasaccharide indicated that considerable chondroitin-synthesizing activity still remained in these trans-Golgi fractions. This demonstrated that brefeldin A had caused a block in movement of endogenous proteochondroitin acceptors to the trans-Golgi site of synthesis. Sulfotransferase activity was also found in a dual distribution similar to that of the chondroitin polymerization and GalNAc transferase, with a small reduction in activity in the trans-Golgi fractions of brefeldin A-treated cartilage. Thus, treatment of cartilage with brefeldin A resulted in the loss of considerable trans-Golgi chondroitin sulfate-synthesizing enzyme activity and a block in the transport of one form of proteochondroitin precursor to the trans-Golgi membranes.	DEPT VET AFFAIRS, OUTPATIENT CLIN, CONNECT TISSUE RES LAB, BOSTON, MA 01730 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School								DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V109, P61; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FALTYNEK CR, 1981, J BIOL CHEM, V256, P7202; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; HELTING T, 1969, J BIOL CHEM, V244, P2790; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1991, CELL, V64, P1183; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; ROBINSON JA, 1981, BIOCHEM J, V194, P839, DOI 10.1042/bj1940839; RODEN L, 1972, METHODS ENZYMOLOGY B, V28, P638; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SILBERT JE, 1976, J BIOL CHEM, V251, P3942; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; SUGUMARAN G, 1986, CARBOHYD RES, V151, P185, DOI 10.1016/S0008-6215(00)90339-2; SUGUMARAN G, 1989, METHOD ENZYMOL, V179, P422; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; SUGUMARAN G, 1990, J BIOL CHEM, V265, P18284; SUGUMARAN G, 1991, BIOCHEM J, V277, P787, DOI 10.1042/bj2770787; ULMER JB, 1991, EUR J CELL BIOL, V54, P38; VELASCO A, 1988, EUR J CELL BIOL, V47, P241; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	27	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8802	8806						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577720				2022-12-27	WOS:A1992HR85400018
J	CHAN, LNL; GERHARDT, EM				CHAN, LNL; GERHARDT, EM			TRANSFERRIN RECEPTOR GENE IS HYPEREXPRESSED AND TRANSCRIPTIONALLY REGULATED IN DIFFERENTIATING ERYTHROID-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; RIBOSOMAL-RNA; IRON; EXPRESSION; REGION; SEQUENCES; PROTEIN	We have analyzed the developmental pattern of expression of the chicken transferrin receptor (CTR) gene in various chick embryonic tissues. Northern analyses of RNA from embryonic tissues at different stages of development and cultured chick embryonic fibroblasts (CEFs) show that CTR is hyperexpressed in differentiating erythroid cells such that the steady-state level of CTR mRNA in these cells could be 200 or more times higher than in nonerythroid cells. In vitro nuclear transcription assays using nuclei from embryonic erythroid and brain cells, as well as CEFs, demonstrate that the vast differences in CTR mRNA levels in there cells are reflected in their respective CTR gene transcriptional activities. During development, the steady-state level of CTR mRNA declines in all tissues and, in erythroid cells, this pattern is accompanied by a similar decline in beta-globin mRNA levels. These changes are concurrent with the decreases in CTR and beta-globin mRNA transcriptional activities during erythroid maturation. Taken together, our results indicate that the hyperexpression of the CTR gene in differentiating erythroid cells is regulated to a significant degree at the transcriptional level. We also demonstrate that, in erythroid cells, neither CTR gene transcription nor CTR mRNA stability is regulated by intracellular iron levels.			CHAN, LNL (corresponding author), UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77550, USA.							Ausubel FM, 1988, MOL REPROD DEV; BATTISTINI A, 1991, BLOOD, V78, P2098, DOI 10.1182/blood.V78.8.2098.bloodjournal7882098; BATTISTINI A, 1991, J BIOL CHEM, V266, P528; BOWMAN LH, 1981, NUCLEIC ACIDS RES, V9, P4951, DOI 10.1093/nar/9.19.4951; BRIDGES KR, 1984, J BIOL CHEM, V259, P2970; BRUNS GAP, 1973, PHILOS T ROY SOC B, V266, P225, DOI 10.1098/rstb.1973.0050; CARNEY DH, 1978, J CELL PHYSIOL, V95, P13, DOI 10.1002/jcp.1040950103; CASEY JL, 1988, NUCLEIC ACIDS RES, V16, P629, DOI 10.1093/nar/16.2.629; CASEY JL, 1988, P NATL ACAD SCI USA, V85, P1787, DOI 10.1073/pnas.85.6.1787; CHAN LN, 1978, MEMBRANE BIOCHEM, V2, P47, DOI 10.3109/09687687809063857; CHAN LNL, 1989, NUCLEIC ACIDS RES, V17, P3763, DOI 10.1093/nar/17.10.3763; CHAN R, 1989, J CELL BIOCH S13C, V24, P24; DOLAN M, 1983, J BIOL CHEM, V258, P3983; GERHARDT EM, 1991, GENE, V102, P249, DOI 10.1016/0378-1119(91)90085-P; GOKAL PK, 1986, J BIOL CHEM, V261, P2536; HARFORD JB, 1991, INTRACELLULAR TRAFFI, P302; HORTON MA, 1983, EXP CELL RES, V144, P361, DOI 10.1016/0014-4827(83)90415-9; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; IACOPETTA BJ, 1982, BIOCHIM BIOPHYS ACTA, V687, P204, DOI 10.1016/0005-2736(82)90547-8; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; MAHAJAN PB, 1987, J BIOL CHEM, V262, P16150; MATTIA E, 1984, J BIOL CHEM, V259, P2689; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NUNEZ MT, 1977, BRIT J HAEMATOL, V36, P519, DOI 10.1111/j.1365-2141.1977.tb00992.x; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PELICCI PG, 1982, FEBS LETT, V145, P350, DOI 10.1016/0014-5793(82)80198-1; RAO K, 1986, MOL CELL BIOL, V6, P236, DOI 10.1128/MCB.6.1.236; RAO KK, 1985, MOL CELL BIOL, V5, P595, DOI 10.1128/MCB.5.4.595; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; Sambrook J, 1989, MOL CLONING LABORATO; Testa U, 1985, Curr Top Hematol, V5, P127; WARD JH, 1982, J BIOL CHEM, V257, P317; WARD JH, 1984, J BIOL CHEM, V259, P3235	33	57	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8254	8259						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569079				2022-12-27	WOS:A1992HQ18500046
J	SHECHTER, I; KLINGER, E; RUCKER, ML; ENGSTROM, RG; SPIRITO, JA; ISLAM, MA; BOETTCHER, BR; WEINSTEIN, DB				SHECHTER, I; KLINGER, E; RUCKER, ML; ENGSTROM, RG; SPIRITO, JA; ISLAM, MA; BOETTCHER, BR; WEINSTEIN, DB			SOLUBILIZATION, PURIFICATION, AND CHARACTERIZATION OF A TRUNCATED FORM OF RAT HEPATIC SQUALENE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; CHOLESTEROL BIOSYNTHETIC-PATHWAY; MEVALONATE-DERIVED PRODUCT; ENDOPLASMIC-RETICULUM; DEGRADATION; PROTEINS; ENZYME; PYROPHOSPHATE; GLYCOPROTEIN; DOMAIN	Rat hepatic microsomal squalene synthetase (EC 2.5.1.21) was induced 2 5-fold by feeding rats with diet containing the hydroxymethylglutaryl-coenzyme A reductase inhibitor, fluvastatin, and cholestyramine, a bile acid sequestrant. A soluble squalene synthetase protein with an estimated mass of 32-35 kDa, as determined by gel filtration chromatography on Sephacryl S-200 column, was solubilized out of the microsomes by controlled proteolysis with trypsin. Approximately 25% of the activity was recovered in a soluble form. The enzyme was purified to homogeneity utilizing a series of column chromatography purification steps on DEAE-cellulose, hydroxylapatite, and phenyl-Sepharose sequentially. The purified enzyme showed a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Initial kinetic analysis indicated an S0.5 values for trans-farnesyl diphosphate of 1.0-mu-M and for NADPH of 40-mu-M. The V(max) with respect to trans-farnesyl diphosphate was calculated at 1.2-mu-mol/min/mg. NADH also serves as substrate for the reaction with S0.5 value of 800-mu-M. Western blot analysis utilizing rabbit antisera raised against the purified, trypsin-truncated enzyme showed a single band for the isolated solubilized enzyme at 32-33 kDa and a band for the intact microsomal enzyme at about 45-47 kDa.	TEL AVIV UNIV,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL; SANDOZ INC,RES INST,E HANOVER,NJ 07936	Tel Aviv University; Novartis; Sandoz	SHECHTER, I (corresponding author), ELEANOR ROOSEVELT INST,DENVER,CO 80206, USA.							AGNEW WS, 1978, J BIOL CHEM, V253, P4574; COHEN LH, 1986, BIOCHEM BIOPH RES CO, V138, P335, DOI 10.1016/0006-291X(86)90285-8; DOTAN I, 1982, BIOCHIM BIOPHYS ACTA, V713, P427, DOI 10.1016/0005-2760(82)90262-4; DOUGLAS TJ, 1972, PLANT PHYSIOL, V49, P417, DOI 10.1104/pp.49.3.417; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; EDWARDS PA, 1980, J BIOL CHEM, V255, P3715; EILENBERG H, 1989, J LIPID RES, V30, P1127; FAUST JR, 1979, P NATL ACAD SCI USA, V76, P5018, DOI 10.1073/pnas.76.10.5018; GAFNI Y, 1979, ANAL BIOCHEM, V92, P248, DOI 10.1016/0003-2697(79)90653-5; GILL G, 1985, CELL, V41, P249; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HANDLER B, 1991, PAP AM CHEM SOC, V201, P1; HELLER RA, 1973, BIOCHEM BIOPH RES CO, V50, P859, DOI 10.1016/0006-291X(73)91324-7; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; KAMIYA Y, 1979, AGR BIOL CHEM TOKYO, V43, P363, DOI 10.1080/00021369.1979.10863433; KUSWIKRABIEGA G, 1987, J BIOL CHEM, V262, P1505; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; LISCUM L, 1985, J BIOL CHEM, V260, P522; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NESS GC, 1981, BIOCHEM BIOPH RES CO, V102, P81, DOI 10.1016/0006-291X(81)91491-1; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; POPJAK G, 1969, METHOD ENZYMOL, V15, P394; POULTER CD, 1981, BIOSYNTHESIS ISOPREN, P413; RILLING HC, 1969, J AM CHEM SOC, V19, P1041; SASIAK K, 1988, ARCH BIOCHEM BIOPHYS, V260, P622, DOI 10.1016/0003-9861(88)90490-0; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SHECHTER I, 1971, J BIOL CHEM, V246, P7690; SHECHTER I, 1980, J LIPID RES, V21, P277; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836	33	85	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8628	8635						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569107				2022-12-27	WOS:A1992HQ18500100
J	TREMBLAY, GB; MEJIA, NR; MACKENZIE, RE				TREMBLAY, GB; MEJIA, NR; MACKENZIE, RE			THE NADP-DEPENDENT METHYLENETETRAHYDROFOLATE DEHYDROGENASE-METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE-FORMYLTETRAHYDROFOLATE SYNTHETASE IS NOT EXPRESSED IN SPODOPTERA-FRUGIPERDA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL SERINE HYDROXYMETHYLTRANSFERASE; ASCITES TUMOR-CELLS; SACCHAROMYCES-CEREVISIAE; PURIFICATION; ENZYMES; MUTANTS; PATHWAY	The insect cell line derived from Spodoptera frugiperda (Sf9) does not, express the activities of the trifunctional NADP-dependent methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase-formyltetrahydrofolate synthetase. The lack of synthetase activity was confirmed by the inability to incorporate radiolabeled formate into nucleotides. The cells express, instead, a Mg2+ and NAD-dependent bifunctional methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase with properties similar to the enzyme found in the mitochondria of transformed mammalian cells. In contrast, the enzyme in Sf9 cells is localized in the cytoplasm. Nutritional studies in defined medium with dialyzed serum demonstrated that the Sf9 cell does not require added purines or pyrimidines for growth. It is auxotrophic for cysteine and glycine; this latter requirement is probably due to the absence of mitochondrial serine hydroxymethyltransferase. Incorporation of labeled glycine and serine into DNA indicates that only serine is a source of one-carbon units. These results suggest that the mitochondria in Sf9 cells do not play a major role in folate-mediated metabolism.	MCGILL UNIV,DEPT BIOCHEM,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA	McGill University								APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BARLOWE C K, 1988, Biofactors, V1, P171; BARLOWE CK, 1990, BIOCHEMISTRY-US, V29, P7089, DOI 10.1021/bi00482a020; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHASIN LA, 1974, P NATL ACAD SCI USA, V71, P718, DOI 10.1073/pnas.71.3.718; COOPER AJL, 1983, ANNU REV BIOCHEM, V52, P187, DOI 10.1146/annurev.bi.52.070183.001155; DRURY EJ, 1975, ARCH BIOCHEM BIOPHYS, V169, P662, DOI 10.1016/0003-9861(75)90210-6; FREEMAN KB, 1965, BIOCHEM J, V94, P494, DOI 10.1042/bj0940494; FUJIOKA M, 1969, BIOCHIM BIOPHYS ACTA, V185, P338, DOI 10.1016/0005-2744(69)90427-6; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GRZELAKOWSKASZTABERT B, 1976, INSECT BIOCHEM, V6, P227, DOI 10.1016/0020-1790(76)90087-1; HENIKOFF S, 1986, P NATL ACAD SCI USA, V83, P720, DOI 10.1073/pnas.83.3.720; Hink W.F., 1976, P319; JAFFE JJ, 1979, J PARASITOL, V65, P226, DOI 10.2307/3280151; JAFFE JJ, 1980, COMP BIOCHEM PHYS B, V66, P597, DOI 10.1016/0305-0491(80)90257-6; JONES EW, 1972, GENETICS, V70, P233; KAO F, 1969, GENETICS, V64, P1284; KIKUCHI G, 1973, MOL CELL BIOCHEM, V1, P169, DOI 10.1007/BF01659328; LJUNGDAHL LG, 1984, FOLATES PTERINS, V1, P571; MacKenzie R E, 1980, Methods Enzymol, V66, P609; MacKenzie R E, 1984, FOLATES PTERINS CHEM, V1, P255; MALKIN LI, 1964, BIOCHIM BIOPHYS ACTA, V85, P117, DOI 10.1016/0926-6569(64)90172-5; MASCISCH A, 1991, SOMAT CELL MOLEC GEN, V17, P391, DOI 10.1007/BF01233064; MATTHEWS RG, 1984, FOLATES PTERINS, V1, P497; MCDANIEL H, 1986, J BIOL CHEM, V261, P884; MEJIA NR, 1988, BIOCHEM BIOPH RES CO, V155, P1, DOI 10.1016/S0006-291X(88)81040-4; MEJIA NR, 1986, J BIOL CHEM, V261, P9509; MEJIA NR, 1985, J BIOL CHEM, V260, P4616; NOUR JM, 1991, J BIOL CHEM, V266, P18363; PASZEWSKI A, 1975, J BACTERIOL, V124, P893, DOI 10.1128/JB.124.2.893-904.1975; RAGSDALE SW, 1984, J BIOL CHEM, V259, P3499; RIOSORLANDI EM, 1988, J BIOL CHEM, V263, P4662; Sambrook J, 1989, MOL CLONING LABORATO; Sassa S., 1981, ADV HUM GENET, P121; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SCRIMGEOUR KG, 1960, BIOCHEM BIOPH RES CO, V2, P230, DOI 10.1016/0006-291X(60)90019-X; SHANNON KW, 1986, J BIOL CHEM, V261, P2266; SHANNON KW, 1988, J BIOL CHEM, V263, P7717; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; TAYLOR RT, 1977, ARCH BIOCHEM BIOPHYS, V181, P331, DOI 10.1016/0003-9861(77)90512-4; TAYLOR RT, 1982, ARCH BIOCHEM BIOPHYS, V217, P609, DOI 10.1016/0003-9861(82)90543-4; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; WYATT GR, 1951, BIOCHEM J, V48, P584, DOI 10.1042/bj0480584; ZELIKSON R, 1977, EUR J BIOCHEM, V79, P285, DOI 10.1111/j.1432-1033.1977.tb11808.x	44	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8281	8285						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569082				2022-12-27	WOS:A1992HQ18500050
J	CHEATHAM, B; KAHN, CR				CHEATHAM, B; KAHN, CR			CYSTEINE-647 IN THE INSULIN-RECEPTOR IS REQUIRED FOR NORMAL COVALENT INTERACTION BETWEEN ALPHA-SUBUNIT AND BETA-SUBUNIT AND SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GEL-ELECTROPHORESIS; LIVER PLASMA-MEMBRANES; RAT HEPATOMA-CELLS; TYROSINE KINASE; DISULFIDE BONDS; PHOSPHORYLATION; DITHIOTHREITOL; REDUCTION; AFFINITY; PROTEIN	We have investigated the structural and functional properties of two mutant insulin receptors in which Cys647 and Cys682,683,685 have been replaced with Ser (IR(S647) and IR(S682,683,685), respectively). Compared with the wild-type receptor (IR(WT)), both mutant receptors displayed altered sensitivities to dithiothreitol with respect to insulin binding and reduction of oligomeric forms. Subunit composition of the oligomeric forms of the receptors as determined by two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis of I-125-labeled receptors indicated that Cys682,683,685 are required for normal heterotetrameric structure and that Cys647 plays a major role in the normal covalent association of the alpha- and beta-subunits. Under nonreducing conditions, the affinity-labeled IR(S647) migrated, almost exclusively, as a 230-kDa species which appeared to represent an alpha(2) form of the receptor. Furthermore, Chinese hamster ovary cells expressing IR(S647) did not exhibit basal or insulin-stimulated autophosphorylation, suggesting that Cys647 is also required for signal transduction.	BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,DEPT MED,RES DIV,1 JOSLIN PL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031036, P30DK036836, R01DK031036] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-31036, DK-36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1989, J BIOL CHEM, V264, P1694; BOYLE TR, 1985, J BIOL CHEM, V260, P8593; CARK S, 1991, BIOCHEM J, V276, P27; CRETTAZ M, 1984, J BIOL CHEM, V259, P1543; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; FINN FM, 1990, P NATL ACAD SCI USA, V87, P419, DOI 10.1073/pnas.87.1.419; FRIAS I, 1989, DIABETES, V38, pA60; GHERZI R, 1989, J BIOL CHEM, V264, P8627; GRUNFELD C, 1985, BIOCHEM BIOPH RES CO, V133, P389, DOI 10.1016/0006-291X(85)90918-0; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; HEDO JA, 1987, J BIOL CHEM, V262, P954; HEDO JA, 1981, P NATL ACAD SCI-BIOL, V78, P4791, DOI 10.1073/pnas.78.8.4791; HSUAN JJ, 1989, BIOCHEM J, V259, P519, DOI 10.1042/bj2590519; JACOBS S, 1980, J CLIN INVEST, V66, P1424, DOI 10.1172/JCI109996; JACOBS S, 1979, P NATL ACAD SCI USA, V76, P4918, DOI 10.1073/pnas.76.10.4918; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KASUGA M, 1982, J BIOL CHEM, V257, P9891; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEF JW, 1987, J BIOL CHEM, V262, P14837; MARON R, 1984, DIABETOLOGIA, V27, P118, DOI 10.1007/BF00275665; MASSAGUE J, 1982, J BIOL CHEM, V257, P6729; MASSAGUE J, 1980, P NATL ACAD SCI-BIOL, V77, P7137, DOI 10.1073/pnas.77.12.7137; ORCHINNIKOV YA, 1988, FEBS LETT, V230, P1; PERUMAL NB, 1984, J BIOL CHEM, V259, P5357; PILCH PF, 1980, J BIOL CHEM, V255, P1722; SCHWEITZER JB, 1980, P NATL ACAD SCI-BIOL, V77, P4692, DOI 10.1073/pnas.77.8.4692; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; SWEET LJ, 1987, J BIOL CHEM, V262, P16730; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WILDEN PA, 1989, BIOCHEMISTRY-US, V28, P785, DOI 10.1021/bi00428a056; WILDEN PA, 1986, BIOCHEMISTRY-US, V25, P4381, DOI 10.1021/bi00363a031; XU QY, 1990, J BIOL CHEM, V265, P18673; YIP CC, 1978, J BIOL CHEM, V253, P1743	37	36	37	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7108	7115						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551916				2022-12-27	WOS:A1992HM05300100
J	ELDERING, E; HUIJBREGTS, CCM; LUBBERS, YTP; LONGSTAFF, C; HACK, CE				ELDERING, E; HUIJBREGTS, CCM; LUBBERS, YTP; LONGSTAFF, C; HACK, CE			CHARACTERIZATION OF RECOMBINANT C1-INHIBITOR P1-VARIANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY ANGIONEUROTIC-EDEMA; HUMAN-PLASMA KALLIKREIN; HUMAN C1BAR INHIBITOR; REACTIVE SITE; C1 INHIBITOR; FACTOR-XII; ALPHA-1-PROTEINASE INHIBITOR; PROTEINASE-INHIBITORS; PROTEASE INHIBITORS; HUMAN-COMPLEMENT	Twelve human C1 inhibitor P1 variants were constructed by site-directed mutagenesis of the codon for arginine 444 and were expressed in COS-1 cells to analyze the functional properties. The ability to bind to target proteases, as well as potential substrate-like behavior, was investigated with radioimmunoassays. The P1-Lys variant retained binding capacity toward C1s, plasmin, and kallikrein. In addition, complex formation with C1s was detected for P1-Asn and P1-His. All other P1 substitutions resulted in C1 inhibitor variants that neither complexed with nor were inactivated by C1s, kallikrein, beta-factor XIIa, or plasmin. Electrophoretic studies confirmed that P1-Lys and P1-His can form sodium dodecyl sulfate-resistant complexes with C1s. In contrast, the C1s-P1-Asn complex dissociated upon addition of sodium dodecyl sulfate. Kinetic experiments by the method of progress curves generated association rate constants (k(on)) with C1s of 4.2 x 10(4) M-1 s-1 for recombinant wild-type C1 inhibitor and 1.7 x 10(4) M-1 s-1 for P1-Lys. For P1-Asn and P1-His, k(on) was decreased approximately 100-fold. The results from inhibition experiments were compatible with a model of reversible inhibition, although the observed dissociation rate for wild-type C1 inhibitor is too low (1-2 x 10(-6) s-1) to be physiologically relevant. The overall inhibition constant (K(i)) was estimated to be 0.03 nM. With P1-Asn, reversible inhibition could be demonstrated directly upon dilution of preformed complexes; the observed dissociation rate constant was 3.2 x 10(-4) s-1; and K(i) increased to approximately 380 nM. These findings are discussed in relation to inhibitor specificity and inhibition mechanism.	UNIV AMSTERDAM, EXPTL & CLIN IMMUNOL LAB, 1066 CX AMSTERDAM, NETHERLANDS; NATL INST BIOL STANDARDS & CONTROL, S MIMMS ENG 3QG, HERTS, ENGLAND	University of Amsterdam; National Institute for Biological Standards & Control	ELDERING, E (corresponding author), NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, PLESMANLAAN 125, 1066 CX AMSTERDAM, NETHERLANDS.		Levi, Marcel/AAZ-8559-2020; Longstaff, Colin/D-2413-2013	Longstaff, Colin/0000-0001-7608-208X				AULAK KS, 1988, BIOCHEM J, V253, P615, DOI 10.1042/bj2530615; AULAK KS, 1990, BIOCHEM J, V271, P565, DOI 10.1042/bj2710565; BEATTY K, 1982, BIOCHIM BIOPHYS ACTA, V704, P221, DOI 10.1016/0167-4838(82)90149-2; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; Carrell R. W., 1987, THROMB DIATH HAEMO, P1; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1989, MOL BIOL MED, V6, P35; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; DEAGOSTINI A, 1984, J CLIN INVEST, V73, P1542, DOI 10.1172/JCI111360; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1985, J CLIN INVEST, V75, P124, DOI 10.1172/JCI111664; DONALDSON VH, 1987, BLOOD, V69, P1096; ELDERING E, 1988, J BIOL CHEM, V263, P11776; ERDJUMENT H, 1988, J BIOL CHEM, V263, P5589; HARPEL PC, 1975, J CLIN INVEST, V55, P593, DOI 10.1172/JCI107967; HARRISON RA, 1983, BIOCHEMISTRY-US, V22, P5001, DOI 10.1021/bi00290a019; HIEMSTRA PS, 1987, SCAND J IMMUNOL, V26, P111, DOI 10.1111/j.1365-3083.1987.tb02243.x; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1989, J BIOL CHEM, V264, P10200; LENNICK M, 1986, BIOCHEMISTRY-US, V25, P3890, DOI 10.1021/bi00361a023; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; Maniatis T., 1982, MOL CLONING; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MEIJERS JCM, 1988, BIOCHEMISTRY-US, V27, P959, DOI 10.1021/bi00403a018; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORTON PA, 1989, J BIOL CHEM, V264, P7228; NAGASE H, 1981, BIOCHEM J, V193, P187, DOI 10.1042/bj1930187; NILSSON T, 1982, FEBS LETT, V142, P111, DOI 10.1016/0014-5793(82)80230-5; NUIJENS JH, 1989, J CLIN INVEST, V84, P443, DOI 10.1172/JCI114185; NUIJENS JH, 1988, BLOOD, V72, P1841; NUIJENS JH, 1989, J BIOL CHEM, V264, P12941; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PERKINS SJ, 1990, J MOL BIOL, V214, P751, DOI 10.1016/0022-2836(90)90290-3; PILATTE Y, 1989, J IMMUNOL METHODS, V120, P37, DOI 10.1016/0022-1759(89)90286-X; PROGRAIS LJ, 1987, J IMMUNOL METHODS, V99, P113, DOI 10.1016/0022-1759(87)90039-1; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SALVESEN GS, 1985, J BIOL CHEM, V260, P2432; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAPIRA M, 1981, BIOCHEMISTRY-US, V20, P2738, DOI 10.1021/bi00513a006; SCOTT CF, 1986, J CLIN INVEST, V77, P631, DOI 10.1172/JCI112346; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SHIEH BH, 1987, J BIOL CHEM, V262, P6055; SIM RB, 1979, FEBS LETT, V97, P111, DOI 10.1016/0014-5793(79)80063-0; SKRIVER K, 1989, J BIOL CHEM, V264, P3066; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; TOSI M, 1987, BIOCHEMISTRY-US, V26, P8516, DOI 10.1021/bi00400a004; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VANDERGRAAF F, 1983, BIOCHEMISTRY-US, V22, P4860, DOI 10.1021/bi00289a037	60	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7013	7020						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551909				2022-12-27	WOS:A1992HM05300085
J	HARRIS, CA; HUNTE, B; KRAUSS, MR; TAYLOR, A; EPSTEIN, LB				HARRIS, CA; HUNTE, B; KRAUSS, MR; TAYLOR, A; EPSTEIN, LB			INDUCTION OF LEUCINE AMINOPEPTIDASE BY INTERFERON-GAMMA - IDENTIFICATION BY PROTEIN MICROSEQUENCING AFTER PURIFICATION BY PREPARATIVE 2-DIMENSIONAL GEL-ELECTROPHORESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; IMMUNE INTERFERON; HUMAN-FIBROBLASTS; ALPHA-INTERFERON; MESSENGER-RNAS; CELL-LINES; BETA-ACTIN; POLYPEPTIDES; LYMPHOKINE; MACROPHAGE	The protein previously called "M(r) approximately 50/pI approximately 6.9," which we observed to be induced by the immunoregulatory cytokine interferon (IFN)-gamma in human fibroblasts, was purified from a total cell lysate by preparative two-dimensional gel electrophoresis and identified by partial amino-terminal sequencing as leucine aminopeptidase (LAP), a 53-kDa cytosolic exopeptidase. Induction of LAP protein by IFN-gamma, confirmed by immunoblotting with an antiserum raised against bovine lens LAP, is a consequence of induction of LAP mRNA and occurs in all four human cell lines examined: HS153 fibroblasts, ACHN renal carcinoma, A549 lung carcinoma, and A375 melanoma. Induction of LAP mRNA is a secondary response to IFN-gamma, blocked by inhibition of protein synthesis with cycloheximide.	UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; PROT DATABASES INC,HUNTINGTON STN,NY 11746; TUFTS UNIV,USDA,HUMAN NUTR RES CTR AGING,BOSTON,MA 02111	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Tufts University; United States Department of Agriculture (USDA)					NCI NIH HHS [CA-44446, CA-27903] Funding Source: Medline; NEI NIH HHS [EY08566] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027903, R37CA027903, R01CA044446] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY008566] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; BERESINI MH, 1990, ELECTROPHORESIS, V11, P232, DOI 10.1002/elps.1150110307; BERESINI MH, 1988, J IMMUNOL, V140, P485; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; BROWN JL, 1976, J BIOL CHEM, V251, P1009; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; Carbone F. R., 1989, Fundamental immunology., P541; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CUYPERS HT, 1982, J BIOL CHEM, V257, P7077; EPSTEIN LB, 1984, INTERFERON, V2, P185; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GARRELS JI, 1980, TRENDS BIOCHEM SCI, V8, P281; GEPPERT TD, 1985, J IMMUNOL, V135, P3750; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALL SC, 1991, P AM SOC MASS SPECTR, P473; HANSON H, 1976, METHODS ENZYMOLOGY B, V45, P504; HARRIS CA, 1991, J IMMUNOL, V147, P149; IJZERMANS JNM, 1989, IMMUNOBIOLOGY, V179, P456, DOI 10.1016/S0171-2985(89)80049-X; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KRETSCHM.K, 1965, H-S Z PHYSIOL CHEM, V340, P126, DOI 10.1515/bchm2.1965.340.1-2.126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; SEELIG AO, 1991, NATURE, V353, P662; SMITH DM, 1992, TUMOR NECROSIS FACTOR : STRUCTURE-FUNCTION RELATIONSHIP AND CLINICAL APPLICATION, P173; SMITH DM, 1991, 2D PAGE 91, P145; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; STEEG PS, 1982, J EXP MED, V156, P1780, DOI 10.1084/jem.156.6.1780; TAYLOR A, 1982, CURR EYE RES, V2, P47, DOI 10.3109/02713688208998379; TAYLOR A, 1991, J CELL BIOCH SG, V15, P137; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; ULKER N, 1987, J BIOL CHEM, V262, P16798; WALLACH D, 1982, NATURE, V299, P833, DOI 10.1038/299833a0; WEIL J, 1983, NATURE, V301, P437, DOI 10.1038/301437a0; WEIL J, 1980, J INTERFERON RES, V1, P111, DOI 10.1089/jir.1980.1.111; WONG GHW, 1983, J IMMUNOL, V131, P788; ZLOTNIK A, 1983, J IMMUNOL, V131, P2814	46	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6865	6869						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551894				2022-12-27	WOS:A1992HM05300063
J	STILES, GL				STILES, GL			ADENOSINE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ADENYLATE CYCLASE SYSTEM; CHRONIC CAFFEINE INGESTION; RAT CEREBRAL-CORTEX; BINDING SUBUNIT; PHOTOAFFINITY CROSSLINKING; A1; PURIFICATION; DESENSITIZATION; IDENTIFICATION; A1-ADENOSINE		DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University	STILES, GL (corresponding author), DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA.				NHLBI NIH HHS [P50HL17670, R01-HL35134] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035134, P50HL017670] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRINGTON WW, 1989, J BIOL CHEM, V264, P13157; BARRINGTON WW, 1990, MOL PHARMACOL, V38, P177; BARRINGTON WW, 1989, P NATL ACAD SCI USA, V86, P6572, DOI 10.1073/pnas.86.17.6572; BERNE RM, 1963, AM J PHYSIOL, V204, P317, DOI 10.1152/ajplegacy.1963.204.2.317; BERNE RM, 1980, CIRC RES, V47, P807, DOI 10.1161/01.RES.47.6.807; BILARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; CUSACK NJ, 1990, ANN NY ACAD SCI, V603, P172; DALY JW, 1985, ADV CYCLIC NUCL PROT, V19, P29; Drury AN, 1929, J PHYSIOL-LONDON, V68, P213, DOI 10.1113/jphysiol.1929.sp002608; FREDHOLM BB, 1982, ACTA PHYSIOL SCAND, V115, P283, DOI 10.1111/j.1748-1716.1982.tb07078.x; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; GERWINS P, 1991, MOL PHARMACOL, V40, P149; GREEN RM, 1986, J CLIN INVEST, V77, P222, DOI 10.1172/JCI112280; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; JACOBSON KA, 1988, BIOCHEM PHARMACOL, V37, P3653, DOI 10.1016/0006-2952(88)90398-X; KURTZ A, 1987, J BIOL CHEM, V262, P6296; KWONG FYP, 1988, BIOCHEM J, V255, P243; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LONGABAUGH JP, 1989, MOL PHARMACOL, V36, P681; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; NAKATA H, 1989, J BIOL CHEM, V264, P16545; NEWBY AC, 1984, TRENDS BIOCHEM SCI, V9, P42, DOI 10.1016/0968-0004(84)90176-2; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; OLAH ME, 1990, ARCH BIOCHEM BIOPHYS, V283, P440, DOI 10.1016/0003-9861(90)90665-L; OLAH ME, 1992, IN PRESS J BIOL CHEM; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; PARSONS WJ, 1987, J BIOL CHEM, V262, P841; RAMKUMAR V, 1991, MOL PHARMACOL, V40, P639; RAMKUMAR V, 1988, J CLIN INVEST, V82, P242, DOI 10.1172/JCI113577; Ramkumar V, 1988, Prog Drug Res, V32, P195; RAPIEJKO PJ, 1987, BIOCHEM J, V241, P761; REPPERT SM, 1991, MOL ENDOCRINOL, V5, P1037, DOI 10.1210/mend-5-8-1037; STILES GL, 1986, J BIOL CHEM, V261, P839; STILES GL, 1985, J BIOL CHEM, V260, P806; STILES GL, 1991, NEWS PHYSIOL SCI, V6, P161; STILES GL, 1987, MOL PHARMACOL, V32, P184; VONCALKER D, 1979, J NEUROCHEM, V33, P999; WHITE BC, 1980, SCIENCE, V209, P1547, DOI 10.1126/science.7433978	40	281	294	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6451	6454						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551861				2022-12-27	WOS:A1992HM05300001
J	VISSE, R; DERUIJTER, M; MOOLENAAR, GF; VANDEPUTTE, P				VISSE, R; DERUIJTER, M; MOOLENAAR, GF; VANDEPUTTE, P			ANALYSIS OF UVRABC ENDONUCLEASE REACTION INTERMEDIATES ON CISPLATIN-DAMAGED DNA USING MOBILITY SHIFT GEL-ELECTROPHORESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ENZYMATIC-PROPERTIES; (A)BC EXCINUCLEASE; EXCISION NUCLEASE; ABC EXCINUCLEASE; POLYMERASE-I; HELICASE-II; REPAIR; PROTEIN; INCISION	One of the last understood steps in the UvrABC mediated excision repair process is the recognition of lesions in the DNA. The isolation of different reaction intermediates is of vital importance for the unraveling of the mechanism. A mobility shift gel electrophoresis assay is described which visualizes such intermediates. After incubation of a DNA substrate containing a specific cisplatin adduct with UvrA alone or with UvrA and UvrB, UvrA.DNA, UvrAB.DNA and UvrB.DNA complexes were observed which could be identified using specific antibodies. At low UvrA concentrations using specific antibodies. At low UvrA concentrations in the presence of UvrB only the UvrB.DNA complex is observed. Bands corresponding to the UvrAB.DNA complex and also other nonspecific bands are found at relatively high UvrA concentrations. The DNase-I footprint for the UvrAB.- and UvrB.DNA complex are very similar and protect about 20 bases. Both complexes are incised in the presence of UvrC with comparable efficiency. The UvrAB.- and the UvrB.DNA complex were both incised at the 8th phosphodiester bond 5' to a specific cisplatin adduct. In addition the UvrAB.DNA complex could also be incised at the 15th phosphodiesterbond 5' to the damaged site. The results suggest that the UvrB.DNA complex is the natural substrate for UvrC-induced incision.			VISSE, R (corresponding author), LEIDEN UNIV,GORLAEUS LABS,DEPT BIOCHEM,MOLEC GENET LAB,POB 9502,2300 RA LEIDEN,NETHERLANDS.							BACKENDORF C, 1989, NUCLEIC ACIDS RES, V17, P10337, DOI 10.1093/nar/17.24.10337; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; KRISTIE TM, 1986, P NATL ACAD SCI USA, V83, P3218, DOI 10.1073/pnas.83.10.3218; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; ORREN DK, 1988, UCLA S MOL CELL BIOL, V83, P87; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SEEBERG E, 1976, NATURE, V263, P524, DOI 10.1038/263524a0; SELBY CP, 1990, MUTAT RES, V236, P203, DOI 10.1016/0921-8777(90)90005-P; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1991, J BIOL CHEM, V266, P7609; VOIGT JM, 1989, J BIOL CHEM, V264, P5172; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157; ZWETSLOOT JCM, 1985, MUTAT RES, V166, P89	26	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6736	6742						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551881				2022-12-27	WOS:A1992HM05300043
J	LIGTENBERG, MJL; KRUIJSHAAR, L; BUIJS, F; VANMEIJER, M; LITVINOV, SV; HILKENS, J				LIGTENBERG, MJL; KRUIJSHAAR, L; BUIJS, F; VANMEIJER, M; LITVINOV, SV; HILKENS, J			CELL-ASSOCIATED EPISIALIN IS A COMPLEX CONTAINING 2 PROTEINS DERIVED FROM A COMMON PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA-ASSOCIATED MUCIN; RECEPTOR PRECURSORS; 3T3-L1 ADIPOCYTES; BIOSYNTHESIS; INSULIN; GLYCOSYLATION; EXPRESSION; SIALOMUCIN; CLEAVAGE; CLONING	cDNA for the epithelial sialomucin episialin encodes a transmembrane molecule with a large extracellular domain, which mainly consists of repeats of 20 amino acids. Here we confirm the existence of a previously proposed proteolytic cleavage of episialin that occurs in the endoplasmic reticulum (Hilkens, J., and Buijs, F. (1988) J. Biol. Chem. 263, 4215-4222) and show that a similar cleavage takes place in in vitro translation systems. Using in vitro translation of truncated mRNAs, we map the cleavage site to a region located between 71 and 53 amino acids upstream of the transmembrane domain. Analysis of a mutant, in which this region has been deleted, indicates that the cleavage sites used in vitro and in vivo are identical or in close proximity. Both cleavage products remain associated although they are not linked through disulfide bonds. Therefore, the subunit derived from the N terminus, which represents the actual mucin-like domain, remains indirectly anchored to the cell membrane as a result of its interaction with the C-terminal subunit.	NETHERLANDS CANC INST,ANTONI VAN LEEUWENHOEKHUIS,DIV TUMOR BIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute			Ligtenberg, Marjolijn/N-9666-2013	Ligtenberg, Marjolijn/0000-0003-1290-1474; Hilkens, John/0000-0002-0932-7793				ABE M, 1989, CANCER RES, V49, P2834; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; DEUTSCH PJ, 1983, P NATL ACAD SCI-BIOL, V80, P133, DOI 10.1073/pnas.80.1.133; FIEDLER F, 1987, EUR J BIOCHEM, V163, P303, DOI 10.1111/j.1432-1033.1987.tb10801.x; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; HEDO JA, 1983, J BIOL CHEM, V258, P20; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HILKENS J, 1988, J BIOL CHEM, V263, P4215; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; HILKENS J, 1986, CANCER RES, V46, P2582; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P1228, DOI 10.1073/pnas.80.5.1228; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN MS, 1990, J BIOL CHEM, V265, P15294; LIGTENBERG MJL, 1991, NUCLEIC ACIDS RES, V19, P297, DOI 10.1093/nar/19.2.297; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LIGTENBERG MJL, 1992, IN PRESS CANCER RES; LINSLEY PS, 1988, J BIOL CHEM, V263, P8390; LOPEZOTIN C, 1989, J BIOL CHEM, V264, P9107; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; WHANG Y, 1987, J VIROL, V61, P1796, DOI 10.1128/JVI.61.6.1796-1807.1987; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x	25	251	265	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6171	6177						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556125				2022-12-27	WOS:A1992HK31800069
J	DONOHUE, SJ; ROSEBOOM, PH; KLEIN, DC				DONOHUE, SJ; ROSEBOOM, PH; KLEIN, DC			BOVINE HYDROXYINDOLE-O-METHYLTRANSFERASE - SIGNIFICANT SEQUENCE REVISION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Hydroxyindole-O-methyltransferase (HIOMT) catalyzes the final step in melatonin synthesis. The nucleotide and deduced amino acid sequences of bovine HIOMT have been reported. Our laboratory recently isolated a cDNA clone encoding human HIOMT. Comparison of the human and bovine nucleotide sequences revealed several discrepancies which prevented perfect alignment and produced defined regions of virtually no homology in the deduced amino acid sequence. Consequently, we repeated sequence analysis of the original bovine HIOMT cDNA clone, the results of which are reported here. The revised nucleotide sequence includes 23 differences from the published sequence. This completely changes the deduced amino acid sequence in two regions, encompassing a total of 96 residues, or 28% of the protein. The revised deduced amino acid sequence predicts different post-translational modifications as compared to that of the original deduced sequence. This information will make it possible in future investigations of HIOMT to design improved polymerase chain reaction primers, peptides for the generation of antisera, and probes for various types of analysis and screening of libraries.	NICHHD,NEUROENDOCRINOL SECT,DEV NEUROBIOL LAB,BLDG 36,ROOM 4A07,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Klein, David/0000-0002-1792-5806				DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ISHIDA I, 1987, J BIOL CHEM, V262, P2895; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463	3	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5184	5185						2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544900				2022-12-27	WOS:A1992HH74700030
J	FEARON, K; MASON, TL				FEARON, K; MASON, TL			STRUCTURE AND FUNCTION OF MRP20 AND MRP49, THE NUCLEAR GENES FOR 2 PROTEINS OF THE 54-S-SUBUNIT OF THE YEAST MITOCHONDRIAL RIBOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; SACCHAROMYCES-CEREVISIAE; LARGE SUBUNIT; TRANSLATIONAL ACTIVATOR; RNA; CLONING; BIOGENESIS; BINDING; L25; RECONSTITUTION	MRP20 and MRP49 are proteins of the large subunit of the mitochondrial ribosome in Saccharomyces cerevisiae. Their genes were identified through immunological screening of a genomic library in the expression vector lambda-gt11. Nucleotide sequencing revealed that MRP49 is tightly linked to TPK3 and encodes a 16-kDa, basic protein with no significant relatedness to any other known protein. MRP20 specifies a 263-amino-acid polypeptide with sequence similarity to members of the L23 family of ribosomal proteins. The levels of the mRNAs and proteins for both MRP20 and MRP49 were regulated in response to carbon source. In [rho0] strains lacking mitochondrial rRNA, the levels of the two proteins were reduced severalfold, presumably because the unassembled proteins are unstable. Null mutants of MRP20 converted to [rho-] or [rho0], a characteristic phenotype of mutations in essential genes for mitochondrial translation. Inactivation of MRP49 caused a cold-sensitive respiration-deficient phenotype, indicating that MRP49 is not an essential ribosomal protein. The mrp49 mutants were defective in the assembly of stable 54 S ribosomal subunits at the nonpermissive temperature. With the results presented here, there are now published sequences for 14 yeast mitochondrial ribosomal proteins, only five of which bear discernable relationships to eubacterial ribosomal proteins.	UNIV MASSACHUSETTS, DEPT BIOCHEM, AMHERST, MA 01003 USA; UNIV MASSACHUSETTS, PROGRAM MOLEC & CELLULAR BIOL, AMHERST, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst								ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BARONASLOWELL DM, 1990, MOL CELL BIOL, V10, P5235, DOI 10.1128/MCB.10.10.5235; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; DABBS ER, 1983, MOL GEN GENET, V192, P301, DOI 10.1007/BF00392166; Dabbs ER, 1986, STRUCTURE FUNCTION G, P733; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; DANG H, 1990, J BIOL CHEM, V265, P7449; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Douglas M, 1979, Methods Enzymol, V56, P58; ELBARADI TTAL, 1985, EMBO J, V4, P2101, DOI 10.1002/j.1460-2075.1985.tb03898.x; ELBARADI TTAL, 1987, J MOL BIOL, V195, P909, DOI 10.1016/0022-2836(87)90494-3; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FAYE G, 1976, FEBS LETT, V69, P167, DOI 10.1016/0014-5793(76)80678-3; FEARON K, 1988, MOL CELL BIOL, V8, P3636, DOI 10.1128/MCB.8.9.3636; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; GRIVELL LA, 1989, EUR J BIOCHEM, V182, P477, DOI 10.1111/j.1432-1033.1989.tb14854.x; GROHMANN L, 1989, EUR J BIOCHEM, V183, P155, DOI 10.1111/j.1432-1033.1989.tb14907.x; GUTELL RR, 1988, NUCLEIC ACIDS RES, V16, pR175, DOI 10.1093/nar/16.suppl.r175; GUTHRIE C, 1969, P NATL ACAD SCI USA, V63, P384, DOI 10.1073/pnas.63.2.384; HAFFTER P, 1990, GENETICS, V125, P495; HEROLD M, 1987, J BIOL CHEM, V262, P8826; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANG W, 1991, J BACTERIOL, V173, P4013, DOI 10.1128/jb.173.13.4013-4020.1991; KANG W, 1991, MOL GEN GENET, V225, P474, DOI 10.1007/BF00261690; KITAKAWA M, 1990, NUCLEIC ACIDS RES, V18, P1521, DOI 10.1093/nar/18.6.1521; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUSHITA Y, 1989, MOL GEN GENET, V219, P119, DOI 10.1007/BF00261166; MCMULLIN TW, 1990, MOL CELL BIOL, V10, P4590, DOI 10.1128/MCB.10.9.4590; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; MYERS AM, 1987, J BIOL CHEM, V262, P3388; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; PARTALEDIS JA, 1988, MOL CELL BIOL, V8, P3647, DOI 10.1128/MCB.8.9.3647; RAUE HA, 1989, J MOL EVOL, V28, P418, DOI 10.1007/BF02603077; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUTGERS CA, 1990, BIOCHIM BIOPHYS ACTA, V1050, P74, DOI 10.1016/0167-4781(90)90144-Q; RUTGERS CA, 1991, J MOL BIOL, V218, P375, DOI 10.1016/0022-2836(91)90719-M; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZE H, 1982, EMBO J, V1, P609, DOI 10.1002/j.1460-2075.1982.tb01216.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TERPSTRA P, 1979, J BIOL CHEM, V254, P2662; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; WALLECZEK J, 1989, J BIOL CHEM, V264, P4231; WALLECZEK J, 1988, EMBO J, V7, P3571, DOI 10.1002/j.1460-2075.1988.tb03234.x; WANG SS, 1987, MOL CELL BIOL, V7, P4431, DOI 10.1128/MCB.7.12.4431; WEITZMANN C, 1985, BIOCHEMISTRY-US, V24, P2268, DOI 10.1021/bi00330a022; WEITZMANN CJ, 1990, BIOCHEMISTRY-US, V29, P3458, DOI 10.1021/bi00466a006; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; YOKOI F, 1991, FEBS LETT, V281, P64, DOI 10.1016/0014-5793(91)80359-B; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	58	53	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5162	5170						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544898				2022-12-27	WOS:A1992HH74700027
J	XU, ZS; LIU, WS; WILLARD, MB				XU, ZS; LIU, WS; WILLARD, MB			IDENTIFICATION OF 6 PHOSPHORYLATION SITES IN THE COOH-TERMINAL TAIL REGION OF THE RAT NEUROFILAMENT PROTEIN-M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES DISTINGUISH; NF-M; MAMMALIAN NEUROFILAMENTS; INTERMEDIATE FILAMENTS; HEAD DOMAIN; SEQUENCE; SUBUNIT; INVITRO; POLYPEPTIDES; KINASE	The COOH-terminal tail domain of the neurofilament polypeptide M from rat nervous tissue contains approximately six molecules of phosphate. We report here that protein kinases in a crude cytoskeleton preparation of rat nervous tissue phosphorylated a set of tryptic peptides of M similar (but not identical) to those phosphorylated by living dorsal root ganglion cells in culture. Using these phosphopeptides as markers, we purified these same peptides from rat spinal cord and identified six specific phosphorylation sites in M by enzymatic and chemical criteria. These sites, serines 502, 506, 536, 606, 608, and 666, are all located in the COOH-terminal tail domain. Four are embedded in the repeated motif KSP whereas two are within variants of this motif, KSD and ESP. All of the sites that were preceded by lysine were resistant to alkaline phosphatase prior to modification of the lysine with citraconic anhydride. The identification of these sites should aid in investigations of the function of the phosphorylation of this protein and provides criteria for identifying the relevant kinases.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,660 S EUCLID AVE,ST S EUCLID AVE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL EYE INSTITUTE [R37EY002682, R01EY002682] Funding Source: NIH RePORTER; NEI NIH HHS [EYO 2682] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; EYER J, 1988, BIOCHEM J, V252, P655, DOI 10.1042/bj2520655; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GEISLER N, 1983, EMBO J, V2, P1295, DOI 10.1002/j.1460-2075.1983.tb01584.x; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; GEISLER N, 1987, FEBS LETT, V221, P403, DOI 10.1016/0014-5793(87)80964-X; GEORGES E, 1986, J NEUROCHEM, V47, P477; GLICKSMAN MA, 1987, J NEUROBIOL, V18, P167, DOI 10.1002/neu.480180205; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; JONES SM, 1982, J BIOL CHEM, V257, P9902; JULIEN JP, 1981, J NEUROCHEM, V37, P1579, DOI 10.1111/j.1471-4159.1981.tb06330.x; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; Klapper M H, 1972, Methods Enzymol, V25, P531, DOI 10.1016/S0076-6879(72)25050-9; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LEFEBVRE S, 1987, BIOCHEM BIOPH RES CO, V145, P1006, DOI 10.1016/0006-291X(87)91535-X; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; MATUS A, 1988, TRENDS NEUROSCI, V11, P291, DOI 10.1016/0166-2236(88)90086-0; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MOON HM, 1981, J CELL BIOL, V89, P560, DOI 10.1083/jcb.89.3.560; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1986, J BIOL CHEM, V261, P6298; NIXON RA, 1986, J CELL BIOL, V102, P647, DOI 10.1083/jcb.102.2.647; SHAW G, 1989, BIOCHEM BIOPH RES CO, V162, P294, DOI 10.1016/0006-291X(89)91995-5; SHECKET G, 1982, J BIOL CHEM, V257, P4788; SIHAG RK, 1988, FEBS LETT, V233, P181, DOI 10.1016/0014-5793(88)81380-2; SIHAG RK, 1989, J BIOL CHEM, V264, P457; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TORADELBAUFFE D, 1986, BIOCHEMISTRY-US, V25, P283; VALLANO ML, 1985, BIOCHEM BIOPH RES CO, V130, P957, DOI 10.1016/0006-291X(85)91708-5; WIBLE BA, 1989, P NATL ACAD SCI USA, V86, P720, DOI 10.1073/pnas.86.2.720; WONG J, 1984, J BIOL CHEM, V259, P867; XU ZS, 1990, J NEUROSCI, V10, P1838; ZOPF D, 1990, NUCLEIC ACIDS RES, V18, P521, DOI 10.1093/nar/18.3.521	42	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4467	4471						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537832				2022-12-27	WOS:A1992HF64200031
J	CHANG, YH; TEICHERT, U; SMITH, JA				CHANG, YH; TEICHERT, U; SMITH, JA			MOLECULAR-CLONING, SEQUENCING, DELETION, AND OVEREXPRESSION OF A METHIONINE AMINOPEPTIDASE GENE FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; BINDING DOMAINS; ZINC-FINGER; PROTEINS; YEAST; ACETYLTRANSFERASE; SPECIFICITIES; PURIFICATION; INVIVO	A yeast gene for a methionine aminopeptidase, one of the central enzymes in protein synthesis, was cloned and sequenced. The DNA sequence encodes a precursor protein containing 387 amino acid residues. The mature protein, whose NH2-terminal sequence, was confirmed by Edman degradation, consists of 377 amino acids. The function of the 10-residue sequence at the NH2 terminus, containing 1 serine and 6 threonine residues, remains to be established. In contrast to the structure of the prokaryotic enzyme, the yeast methionine aminopeptidase consists of two functional domains: a unique NH2-terminal domain containing two motifs resembling zine fingers, which may allow the protein to interact with ribosomes, and a catalytic COOH-terminal domain resembling other prokaryotic methionine aminopeptidases. Furthermore, unlike the case for the prokaryotic gene, the deletion of the yeast MAP1 gene is not lethal, suggesting for the first time that alternative NH2-terminal processing pathway(s) exist for cleaving methionine from nascent polypeptide chains in eukaryotic cells.	MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	CHANG, YH (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG SYP, 1989, J BACTERIOL, V171, P4071, DOI 10.1128/jb.171.7.4071-4072.1989; CHANG YH, 1990, J BIOL CHEM, V265, P19892; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; LEE FJS, 1989, J BIOL CHEM, V264, P12339; MANIATIS T, 1982, MOL CLONING LABORATO, P320; MILLER CG, 1989, J BACTERIOL, V171, P5215, DOI 10.1128/jb.171.9.5215-5217.1989; MILLER CG, 1987, P NATL ACAD SCI USA, V84, P2718, DOI 10.1073/pnas.84.9.2718; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; NAKAMURA K, 1990, J BIOCHEM-TOKYO, V107, P603; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHERMAN F, 1986, METHODS YEAST GENETI, P79; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WHITEHEAD AS, 1983, P NATL ACAD SCI USA, V80, P31; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978	33	103	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8007	8011						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569059				2022-12-27	WOS:A1992HQ18500011
J	HACKNEY, DD; LEVITT, JD; SUHAN, J				HACKNEY, DD; LEVITT, JD; SUHAN, J			KINESIN UNDERGOES A 9-S TO 6-S CONFORMATIONAL TRANSITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; HEAVY-CHAIN; ELECTRON-MICROSCOPY; ATPASE ACTIVITY; MYOSIN; MOTILITY; MUSCLE; IDENTIFICATION; SUBFRAGMENTS; NUCLEOTIDE	Addition of NaCl or KCl in the presence of 50 nM ATP induces a shift in the sedimentation coefficient (apparent s20,w) of kinesin from 9.4 S at low ionic strength to 6.5 S at high ionic strength. The midpoint for the transition occurs at ionic strength values of 0.39,0.25, and 0.18 for pH values of 6.3,6.9, and 8.3, respectively. Gel filtration experiments indicate that the transition to the 6.5 S species is accompanied by a decrease in the diffusion coefficient. Under all conditions which were tested, the 64-kDa beta-subunits comigrate with the 120-kDa alpha-subunits without any evidence for dissociation of the alpha-2-beta-2 complex. These results are consistent with the change in sedimentation coefficient being due a conformational transition between a folded form at low ionic strength and an extended form at high ionic strength. This conformational transition is not significantly affected by the nature of the nucleotide bound at the active site since similar results are obtained both in the presence of excess EDTA, which removes the bound ADP, and after replacement of the bound ADP with adenosine 5'-(beta-gamma-imino)triphosphate. The alpha-2 form of kinesin, which lacks the beta-subunits, undergoes a similar transition between a 6.7 S form at low ionic strength and a 5.1 S form at high ionic strength with a midpoint for the transition at an ionic strength of 0.5 at pH 6.9. Electron microscopic observation also indicates a transition between a folded conformation at low ionic strength and an extended conformation at high ionic strength for both the alpha-2-beta-2 and alpha-2 species.	CARNEGIE MELLON UNIV, BIOPHYS & BIOCHEM PROGRAM, PITTSBURGH, PA 15213 USA	Carnegie Mellon University	HACKNEY, DD (corresponding author), CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR025980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028562] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR25980] Funding Source: Medline; NINDS NIH HHS [NS28562] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERS GK, 1967, J BIOL CHEM, V242, P3237; AMOS LA, 1987, J CELL SCI, V87, P105; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; COHN SA, 1989, J BIOL CHEM, V264, P4290; CROSS RA, 1988, J MOL BIOL, V203, P173, DOI 10.1016/0022-2836(88)90100-3; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HACKNEY DD, 1989, J BIOL CHEM, V264, P15943; HACKNEY DD, 1991, METHOD ENZYMOL, V196, P175; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4589; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWEY S, 1969, J MOL BIOL, V42, P1, DOI 10.1016/0022-2836(69)90483-5; MARGOSSIAN SS, 1981, BIOCHEMISTRY-US, V20, P2151, DOI 10.1021/bi00511a012; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MCINTOSH JR, 1989, J BIOL CHEM, V264, P6001; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SOBER HA, 1968, HDB BIOCH, pC3; SUZUKI H, 1985, J BIOL CHEM, V260, P4810; SUZUKI H, 1982, J BIOCHEM-TOKYO, V91, P1699, DOI 10.1093/oxfordjournals.jbchem.a133861; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	30	149	151	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8696	8701						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569110				2022-12-27	WOS:A1992HQ18500110
J	TSENG, H; BERK, BC				TSENG, H; BERK, BC			THE NA/K/2CL COTRANSPORTER IS INCREASED IN HYPERTROPHIED VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/K+/CL COTRANSPORT; INTRACELLULAR PH; NA+/H+ ANTIPORT; CYTOPLASMIC PH; FISSION YEAST; ANIMAL-CELLS; PROTEIN; FIBROBLASTS; TRANSPORT; K+	Hypertrophy of vascular smooth muscle cells (VSMC) is a pathogenic feature of hypertension which may contribute to abnormal vessel tone and function. As a consequence of the increase in cell size associated with hypertrophy, it is likely that alterations in the mechanisms that regulate VSMC intracellular volume occur. Because the Na+/H+ exchanger plays an important role in volume regulation and because we previously observed long term alterations in Na+/H+ exchange and pH(i) in response to angiotensin-II-induced (ang II) hypertrophy, we studied cell-acidifying mechanisms. To do this, we measured alkaline recovery from NH4Cl-mediated alkalinization, using the fluorescent dye, 2',7'-bis-(2-carboxyethyl)-5(6)-carboxyfluorescein. VSMC were growth-arrested (0.4% calf serum for 24 h) or hypertrophied (100 nM ang II in 0.4% calf serum for 24 h). Ang II-treated cells exhibited a 107% increase in alkaline recovery over control cells (13.86 +/- 1.87 versus 6.68 +/- 1.01 mmol H+/min/liter cells). The increase in alkaline recovery was not a result of increased Cl-/HCO3- exchange because it was not HCO3- dependent nor inhibited by 4,4'-diisothiocyano-2,2'-stilbenedisulfonic acid. Studies with bumetanide and the sterically inhibited substrate N(CH3)4+ showed that the alkaline recovery was mediated by NH4+ transport via the Na/K/2Cl cotransporter. Ang II-treated cells exhibited a 334% increase in bumetanide-sensitive alkaline recovery over control cells (9.16 +/- 1.90 versus 2.11 +/- 1.46 mmol H+/min/liter cells). Ang II-treated cells also exhibited a 90% increase in bumetanide-sensitive Rb-86 uptake over control cells. These findings demonstrate that Na/K/2Cl cotransport activity is specifically induced in ang II-hypertrophied VSMC and establish this transporter as a component of the hypertrophic growth response.	EMORY UNIV, SCH MED, DEPT PHYSIOL, ATLANTA, GA 30322 USA	Emory University	TSENG, H (corresponding author), EMORY UNIV, SCH MED, DEPT MED, DIV CARDIOL, ATLANTA, GA 30322 USA.			Berk, Bradford/0000-0002-2767-4115				AALKJAER C, 1991, J PHYSIOL-LONDON, V436, P57, DOI 10.1113/jphysiol.1991.sp018539; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1987, J BIOL CHEM, V262, P5057; BOBIK A, 1991, AM J PHYSIOL, V260, pC581, DOI 10.1152/ajpcell.1991.260.3.C581; DETH RC, 1987, BLOOD VESSELS, V24, P321; DUHM J, 1987, J MEMBRANE BIOL, V98, P15, DOI 10.1007/BF01871042; EVELOFF JL, 1987, AM J PHYSIOL, V252, pF1, DOI 10.1152/ajprenal.1987.252.1.F1; FANTES P, 1979, NATURE, V279, P428, DOI 10.1038/279428a0; FRANKLIN CC, 1989, J BIOL CHEM, V264, P6667; GECK P, 1985, ANN NY ACAD SCI, V456, P166, DOI 10.1111/j.1749-6632.1985.tb14862.x; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GERSTHEIMER FP, 1987, PFLUG ARCH EUR J PHY, V409, P60, DOI 10.1007/BF00584750; GRIFFIN SA, 1991, HYPERTENSION, V17, P626, DOI 10.1161/01.HYP.17.5.626; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; HOMMA T, 1990, J BIOL CHEM, V265, P17613; HOMMA T, 1991, J BIOL CHEM, V266, P13553; KAHN AM, 1991, AM J PHYSIOL, V261, pC837, DOI 10.1152/ajpcell.1991.261.5.C837; KINNE R, 1986, J MEMBRANE BIOL, V94, P279, DOI 10.1007/BF01869723; KORBMACHER C, 1988, PFLUG ARCH EUR J PHY, V412, P29, DOI 10.1007/BF00583728; KRUG LM, 1990, CLIN RES, V38, pA26; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ODONNELL ME, 1980, AM J PHYSIOL, V255, P8534; OWENS GK, 1987, HYPERTENSION, V9, P178, DOI 10.1161/01.HYP.9.2.178; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; PANET R, 1991, J CELL BIOL, V114, P337, DOI 10.1083/jcb.114.2.337; PARIS S, 1986, J BIOL CHEM, V261, P6177; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SAIER MH, 1984, MOL CELL BIOCHEM, V59, P11; SHIELDS R, 1978, CELL, V15, P469, DOI 10.1016/0092-8674(78)90016-8; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TOWLE DW, 1987, AM J PHYSIOL, V252, pR479, DOI 10.1152/ajpregu.1987.252.3.R479; VIGNE P, 1988, J BIOL CHEM, V263, P18023; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2	38	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8161	8167						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569072				2022-12-27	WOS:A1992HQ18500032
J	ZOELLER, RA; RANGASWAMY, S; HERSCOVITZ, H; RIZZO, WB; HAJRA, AK; DAS, AK; MOSER, HW; MOSER, A; LAZAROW, PB; SANTOS, MJ				ZOELLER, RA; RANGASWAMY, S; HERSCOVITZ, H; RIZZO, WB; HAJRA, AK; DAS, AK; MOSER, HW; MOSER, A; LAZAROW, PB; SANTOS, MJ			MUTANTS IN A MACROPHAGE-LIKE CELL-LINE ARE DEFECTIVE IN PLASMALOGEN BIOSYNTHESIS, BUT CONTAIN FUNCTIONAL PEROXISOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY RECOGNIZED GROUP; ZELLWEGER SYNDROME; GENETIC-DISEASES; FATTY-ACIDS; DISORDERS; NEUTROPHILS; BIOGENESIS; PRECURSORS	We have used a fluorescence-activated cytotoxicity protocol, 9-(1'-pyrene)nonanol (P9OH)/UV selection (Morand, O. H., Allen, L.-A. H., Zoeller, R. A., and Raetz, C. R. H. (1990) Biochim. Biophys. Acta 1034, 132-141), to isolate a series of plasmalogen-deficient mutants in a murine, macrophage-like cell line, RAW 264.7. Three of these mutants, RAW.7, RAW.12, and RAW.108, displayed varying degrees of plasmalogen deficiency (48, 17, and 14% of wild-type levels, respectively), and all three mutants were deficient in peroxisomal dihydroxyacetone phosphate (DHAP) acyltransferase activity (5% of wild-type). Unlike previously described Chinese hamster ovary (CHO) cell mutants, the RAW mutants contained intact, functional, peroxisomes and normal levels of alkyl-DHAP synthase activity, a peroxisomal, membrane-bound enzyme. In RAW.7 and RAW.108 cells, the loss of peroxisomal DHAP acyltransferase is the primary lesion. RAW.12 displayed not only a deficiency in the DHAP acyltransferase activity, but also displayed a second lesion in the biosynthetic pathway, a deficiency in DELTA-1'-desaturase activity (plasmanylethanolamine desaturase, EC 1.14.99.19), the final step in plasmenylethanolamine biosynthesis. The deficiencies expressed in the mutants represent unique lesions in plasmalogen biosynthesis. Since the RAW cell line is a macrophage-like responsive cell line, these mutants can be used to examine the role of plasmalogens in cellular functions such as arachidonic acid metabolism, prostaglandin synthesis, protein secretion, and signal transduction.	KENNEDY INST HANDICAPPED CHILDREN,BALTIMORE,MD 21205; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PEDIAT & HUMAN GENET,RICHMOND,VA 23298; UNIV MICHIGAN,SCH MED,DEPT BIOCHEM,ANN ARBOR,MI 48109; CUNY MT SINAI SCH MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10029	Virginia Commonwealth University; University of Michigan System; University of Michigan; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	ZOELLER, RA (corresponding author), BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02118, USA.			Herscovitz, Haya/0000-0001-8067-6091; Das, Arun/0000-0002-0883-1816; Zoeller, Raphael/0000-0002-6560-0993	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040192] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40192-04] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER RC, 1990, J PHARMACOL EXP THER, V252, P1028; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, VVolume 1, P481; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BLANK ML, 1986, ARCH BIOCHEM BIOPHYS, V251, P55, DOI 10.1016/0003-9861(86)90050-0; BLANK ML, 1983, ANAL BIOCHEM, V133, P430, DOI 10.1016/0003-2697(83)90105-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DAVIS PA, 1981, ARCH BIOCHEM BIOPHYS, V211, P20, DOI 10.1016/0003-9861(81)90424-0; Hajra A. K., 1983, ETHER LIPIDS, P85; HAJRA AK, 1968, BIOCHEM BIOPH RES CO, V33, P929, DOI 10.1016/0006-291X(68)90401-4; HAJRA AK, 1983, CHEM PHYS LIPIDS, V33, P179, DOI 10.1016/0009-3084(83)90020-8; Horrocks L A, 1978, Adv Exp Med Biol, V101, P397; Horrocks L. A., 1982, PHOSPHOLIPIDS, P51; JONES CL, 1980, J BIOL CHEM, V255, P8289; JOSHI VC, 1979, J BIOL CHEM, V254, P1779; LABELLE EF, 1974, J BIOL CHEM, V249, P6936; LOHNER K, 1991, BIOCHIM BIOPHYS ACTA, V1061, P132, DOI 10.1016/0005-2736(91)90277-F; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; MORAND OH, 1990, BIOCHIM BIOPHYS ACTA, V1034, P132, DOI 10.1016/0304-4165(90)90066-6; MORAND OH, 1988, J BIOL CHEM, V263, P11597; MOSER AE, 1984, NEW ENGL J MED, V310, P1141, DOI 10.1056/NEJM198405033101802; MOSER HW, 1980, ANN NEUROL, V7, P542, DOI 10.1002/ana.410070607; MUELLER HW, 1984, J LIPID RES, V25, P383; OWENS K, 1966, BIOCHEM J, V100, P354, DOI 10.1042/bj1000354; PALTAUF F, 1974, J BIOL CHEM, V249, P2661; PATTON S, 1966, J LIPID RES, V7, P452; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; RIZZO WB, 1986, NEUROLOGY, V36, P357, DOI 10.1212/WNL.36.3.357; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SCHRAKAMP G, 1988, J LIPID RES, V29, P325; SCHUTGENS RBH, 1986, EUR J PEDIATR, V144, P430, DOI 10.1007/BF00441734; STVENS VL, 1990, J BIOL CHEM, V265, P15653; Sugiura T., 1987, PLATELET ACTIVATING, P55; TENCE M, 1985, THROMB RES, V38, P207, DOI 10.1016/0049-3848(85)90148-3; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; WANDERS RJA, 1984, BIOCHEM BIOPH RES CO, V123, P1054, DOI 10.1016/S0006-291X(84)80240-5; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872; ZOELLER RA, 1987, J BIOL CHEM, V262, P17212	41	37	37	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8299	8306						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569085				2022-12-27	WOS:A1992HQ18500053
J	FERREIRA, RMB; TEIXEIRA, ARN				FERREIRA, RMB; TEIXEIRA, ARN			SULFUR STARVATION IN LEMNA LEADS TO DEGRADATION OF RIBULOSE-BISPHOSPHATE CARBOXYLASE WITHOUT PLANT DEATH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; PROTEIN-DEGRADATION; BARLEY LEAVES; MINOR FRONDS; WHEAT LEAVES; TURNOVER	Little is known about the degradation of the most abundant protein in nature, ribulose-bisphosphate carboxylase (RuBP carboxylase, EC 4.1.1.39), probably reflecting the fact that no stress situation has been identified capable of causing extensive RuBP carboxylase degradation without causing the death of the plant. We have subjected plants of Lemna minor L. to a variety of stress situations, nutritive deficiencies in particular, and have found a single condition-sulfur starvation-that caused almost complete degradation of RuBP carboxylase without causing plant death. Moreover, the enzyme was preferentially degraded under these conditions. However, when the plants were deprived of calcium, no RuBP carboxylase degradation was observed. Instead, the enzyme was oxidized and polymerized into high molecular mass aggregates. On the other hand, RuBP carboxylase shows an extreme stability when Lemna is deprived of some macronutrients (e.g. nitrogen, phosphorus, potassium, and magnesium) probably reflecting that this plant had to evolve in a way to cope with frequent shortages of such elements. The implications of these data for the role of RuBP carboxylase as a leaf storage protein are discussed.	CTR TECNOL QUIM & BIOL, P-2780 OEIRAS, PORTUGAL		FERREIRA, RMB (corresponding author), INST SUPER AGRON, DEPT BOT & ENGN BIOL, P-1399 LISBON, PORTUGAL.		Ferreira, Ricardo M S Boavida/B-9502-2011	Ferreira, Ricardo Boavida/0000-0002-5027-7564				ARIAS IM, 1969, J BIOL CHEM, V244, P3303; ASHTON AR, 1982, FEBS LETT, V145, P1, DOI 10.1016/0014-5793(82)81194-0; DAVIES DD, 1978, PLANT PHYSIOL, V61, P54, DOI 10.1104/pp.61.1.54; DICE JF, 1978, P NATL ACAD SCI USA, V75, P2093, DOI 10.1073/pnas.75.5.2093; DICE JF, 1973, J BIOL CHEM, V248, P4220; ELLIS RJ, 1979, TRENDS BIOCHEM SCI, V4, P241, DOI 10.1016/0968-0004(79)90212-3; FERREIRA RB, 1987, PLANT PHYSIOL, V83, P869, DOI 10.1104/pp.83.4.869; FERREIRA RB, 1987, PLANT PHYSIOL, V83, P878, DOI 10.1104/pp.83.4.878; FERREIRA RB, 1989, PLANTA, V179, P448, DOI 10.1007/BF00397584; FERREIRA RB, 1989, PLANTA, V179, P456, DOI 10.1007/BF00397585; FRIEDRICH JW, 1980, PLANT PHYSIOL, V65, P1103, DOI 10.1104/pp.65.6.1103; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; Huffaker R C, 1978, Basic Life Sci, V11, P139; KAWASHIMA N, 1970, ANN REV PLANT PHYSIO, V21, P325, DOI 10.1146/annurev.pp.21.060170.001545; KLEINKOPF GE, 1970, PLANT PHYSIOL, V46, P416, DOI 10.1104/pp.46.3.416; KUNG SD, 1976, SCIENCE, V191, P429; Levitt J., 1980, RESPONSES PLANTS ENV, V1, DOI [10.1006/anbo.2000.1352, DOI 10.1006/ANBO.2000.1352]; LONG EC, 1976, 1042NUC7655T BECKM B; MIYADAI K, 1990, PLANT PHYSIOL, V92, P1215, DOI 10.1104/pp.92.4.1215; PETERSON LW, 1973, PLANT PHYSIOL, V51, P1042, DOI 10.1104/pp.51.6.1042; PIERCE J, 1988, PHYSIOL PLANTARUM, V72, P690, DOI 10.1111/j.1399-3054.1988.tb09183.x; SICHER RC, 1979, PLANT PHYSIOL, V64, P880, DOI 10.1104/pp.64.5.880; TINGEY SV, 1986, J EXP BOT, V37, P625, DOI 10.1093/jxb/37.5.625; WITTENBACH VA, 1979, PLANT PHYSIOL, V64, P884, DOI 10.1104/pp.64.5.884; ZAK R, 1977, J BIOL CHEM, V252, P3430	25	73	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7253	7257						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559969				2022-12-27	WOS:A1992HN48500012
J	LI, ZP; SMITH, CD; SMOLLEY, JR; BRIDGE, JHB; FRANK, JS; PHILIPSON, KD				LI, ZP; SMITH, CD; SMOLLEY, JR; BRIDGE, JHB; FRANK, JS; PHILIPSON, KD			EXPRESSION OF THE CARDIAC NA+-CA2+ EXCHANGER IN INSECT CELLS USING A BACULOVIRUS VECTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; VESICLES; CA	We constructed a recombinant baculovirus containing cardiac Na+-Ca2+ exchanger cDNA under control of the polyhedrin promoter. When either Sf9 or Sf21 insect cells are infected with the recombinant baculovirus, both Na+-Ca2+ exchanger protein and Na+-Ca2+ exchange activity are expressed at high level. The exchanger protein can be detected either by immunoblot or, by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of whole cell lysate. At maximal expression, the exchanger protein comprises about 3-5% of total cell protein. The Na+-Ca2+ exchanger can be purified by alkaline extraction of infected cells followed by elution from a Bio-Rad Prep Cell. The expressed exchanger, in contrast to the native sarcolemmal exchanger, is not glycosylated. Sf9 cells expressing the exchanger are intensely stained by anti-exchanger antibodies as observed by immunofluorescence. The expressed exchanger is predominately in the cell plasma membrane since it is susceptible to extracellular trypsin. In Ca-45(2+) flux experiments, the expressed Na+-Ca2+ exchange activity is about 4-fold higher than that in cultured neonatal rat heart cells. The expressed exchanger was also analyzed electrophysiologically using whole cell patch clamp techniques. The characteristics of inward exchange currents in infected Sf21 cells are very similar to those of ventricular myocytes, although of a larger magnitude.	UNIV CALIF LOS ANGELES,SCH MED,CARDIOVASC RES LAB,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; UNIV UTAH,DEPT MED,SALT LAKE CITY,UT 84112; UNIV UTAH,NORA ECCLES HARRISON CARDIOVASC RES & TRAINING INST,SALT LAKE CITY,UT 84112	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NHLBI NIH HHS [HL28791, HL27821, HL42357] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042357, R01HL028791, R01HL027821] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CHEON J, 1988, J BIOL CHEM, V263, P2309; DURKIN JT, 1991, IN PRESS ARCH BIOCH; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KLAIBER K, 1990, NEURON, V5, P221, DOI 10.1016/0896-6273(90)90311-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MIURA Y, 1989, J GEN PHYSIOL, V93, P1129, DOI 10.1085/jgp.93.6.1129; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NICOLL DA, 1991, IN PRESS ANN NY ACAD; PHILIPSON KD, 1987, BIOCHIM BIOPHYS ACTA, V899, P59, DOI 10.1016/0005-2736(87)90239-2; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PHILIPSON KD, 1990, CALCIUM HEART, P85; Sambrook J, 1989, MOL CLONING LABORATO; SMITH CD, 1992, IN PRESS BIOCH BIOPH; SPITZER KW, 1989, AM J PHYSIOL, V256, pC441, DOI 10.1152/ajpcell.1989.256.2.C441; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; VEMURI R, 1989, AM J PHYSIOL, V256, pC1273, DOI 10.1152/ajpcell.1989.256.6.C1273	19	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7828	7833						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560015				2022-12-27	WOS:A1992HN48500088
J	ZHOU, G; BROYLES, SS; DIXON, JE; ZALKIN, H				ZHOU, G; BROYLES, SS; DIXON, JE; ZALKIN, H			AVIAN GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE PROPEPTIDE PROCESSING AND ACTIVITY ARE DEPENDENT UPON ESSENTIAL CYSTEINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI-PURF; AMINO-ACID-SEQUENCE; IRON-SULFUR PROTEIN; BACILLUS-SUBTILIS; NUCLEOTIDE-SEQUENCE; INDEPENDENT TRANSLATION; EXPRESSION SYSTEM; VACCINIA VIRUS; UTILIZING SITE	Avian glutamine phosphoribosylpyrophosphate amidotransferase contains an NH2-terminal propeptide-like sequence. NH2-terminal sequence analysis of immunoaffinity purified enzyme from chicken liver indicates that the propeptide is processed and the mature enzyme starts with Cys1. Propeptide processing was investigated by site-directed mutagenesis using a system for expression in HeLa cells. Glutamine-dependent activity and processing were abolished by replacement of the conserved cysteine at position 1, whereas NH3-dependent activity was retained. Cys1 is thus inferred to have a role in glutamine-dependent activity and in propeptide processing. Inactive, insoluble enzymes in which the propeptide was not processed were obtained as a result of replacements of cysteines 415 and 488. Cysteine residues at positions 415 and 488 are inferred to be ligands to an Fe-S cluster on the basis of sequence similarity to the enzyme from Bacillus subtilis. Mutation of Cys269 and Cys295 led to loss of enzyme activity and propeptide processing, although solubility was unchanged. The results suggest that incorporation of an Fe-S cluster is needed for native structure, resultant propeptide processing, and glutamine-dependent activity.			ZHOU, G (corresponding author), PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907, USA.				NIGMS NIH HHS [GM25658] Funding Source: Medline; PHS HHS [18849, 28432] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BADET B, 1987, BIOCHEMISTRY-US, V26, P1940, DOI 10.1021/bi00381a023; BECKER MA, 1987, J BIOL CHEM, V262, P14531; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRANDONI JA, 1989, J BIOL CHEM, V264, P6058; HAROLOW E, 1988, ANTIBODIES LABORATOR; HARTMAN SC, 1963, J BIOL CHEM, V238, P3024; HOLMES EW, 1973, J BIOL CHEM, V248, P144; ITAKURA M, 1979, J BIOL CHEM, V254, P333; LEFF RL, 1984, ADV ENZYME REGUL, V22, P403, DOI 10.1016/0065-2571(84)90022-0; LINN T, 1990, J BACTERIOL, V172, P1077, DOI 10.1128/jb.172.2.1077-1084.1990; MAKAROFF CA, 1983, J BIOL CHEM, V258, P586; MAKAROFF CA, 1986, J BIOL CHEM, V261, P1416; MANTSALA P, 1984, J BIOL CHEM, V259, P8478; MANTSALA P, 1984, J BIOL CHEM, V259, P4230; MESSENGER LJ, 1979, J BIOL CHEM, V254, P3382; MEYER E, 1979, J BIOL CHEM, V254, P5397; Miller JH, 1972, EXPT MOL GENETICS, P403; RECSEI PA, 1983, P NATL ACAD SCI-BIOL, V80, P973, DOI 10.1073/pnas.80.4.973; ROWE PB, 1968, J BIOL CHEM, V243, P6373; SCHENDEL FJ, 1988, BIOCHEMISTRY-US, V27, P214; SHEN Y, 1990, BIOCHEMISTRY-US, V29, P218, DOI 10.1021/bi00453a030; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOUCIET JL, 1988, J BIOL CHEM, V263, P3323; SWITZER R L, 1989, Biofactors, V2, P77; SWITZER RL, 1989, ALLOSTERIC ENZYMES, P129; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSO JY, 1982, J BIOL CHEM, V257, P3525; TSO JY, 1982, J BIOL CHEM, V257, P3532; VANHEEKE G, 1989, J BIOL CHEM, V264, P19475; VOLLMER SJ, 1983, J BIOL CHEM, V258, P582; WONG JY, 1977, J BIOL CHEM, V252, P7424; ZHOU GC, 1990, J BIOL CHEM, V265, P21152	35	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7936	7942						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560022				2022-12-27	WOS:A1992HN48500102
J	BLACK, ME; HRUBY, DE				BLACK, ME; HRUBY, DE			SITE-DIRECTED MUTAGENESIS OF A CONSERVED DOMAIN IN VACCINIA VIRUS THYMIDINE KINASE - EVIDENCE FOR A POTENTIAL ROLE IN MAGNESIUM BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ADENYLATE KINASE; ATP; SEQUENCE; F1-ATPASE	Alignment of prokaryotic and vertebrate type II thymidine kinases (TK) (EC 2.7.1.21), such as that encoded by vaccinia virus (VVTK), reveals three conserved regions: designated domains I, III, and VII. Domains I and III of VVTK contain residues which closely resemble segments A (ATP) and B (Mg2+), respectively, of a Mg.ATP binding descriptor proposed previously (Walker, J.E., Saraster, M., Runswick, M-J., and Gay, N. J. (1982) EMBO J. 1, 945-951). In support of this hypothesis, domain I of the VVTK enzyme has previously been identified as the ATP binding site (Black and Hruby, 1990b). With regard to Mg2+ binding, several features of the VVTK domain III suggest that it may be responsible for this activity: 1) sequence similarity to a magnesium binding motif proposed previously (Walker, J. E., Saraster, M., Runswick, M-J., and Gay, N. J. (1982) EMBO J. 1, 945-951);2) alignment of the predicted secondary structure of type II TK enzymes with other magnesium-binding enzymes such as adenylate kinase, EF-TU, and p21 reveals a conserved aspartic acid residue preceded by several hydrophobic residues within domain III; and 3) the conserved VVTK domain III aspartic acid residue (D82) aligns with D93 residue of adenylate kinase which is has been shown by NMR to participate in Mg2+ binding (Yan, H., and Tsai, M.-D., Biochemistry, in press). To directly examine the potential contribution of the conserved domain III D82 residue of VVTK in magnesium binding, site-directed mutagenesis was performed on positions D82 and G84 to generate four mutants, N82, L82, I82, and V84. Each mutant was analyzed for enzyme activity, divalent cation requirements, tetramer formation, and ATP binding ability. The results obtained were consistent with D82 playing a direct role in Mg2+ binding and suggest that while the aspartic acid does not appear to participate directly with ATP binding it may instead act to facilitate ATP hydrolysis by binding Mg2+ which aids to correctly position ATP for nucleophilic attack.			BLACK, ME (corresponding author), OREGON STATE UNIV,CTR GENE RES & BIOTECHNOL,DEPT MICROBIOL,CORVALLIS,OR 97331, USA.				NIAID NIH HHS [AI-20563] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLACK ME, 1990, J BIOL CHEM, V265, P17584; BLACK ME, 1990, BIOCHEM BIOPH RES CO, V169, P1080, DOI 10.1016/0006-291X(90)92005-K; BLACK ME, 1991, MOL MICROBIOL, V5, P373, DOI 10.1111/j.1365-2958.1991.tb02119.x; BRADLEY MK, 1987, P NATL ACAD SCI USA, V84, P4026, DOI 10.1073/pnas.84.12.4026; CHIN DT, 1988, J BIOL CHEM, V263, P11718; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18802; FOLKERS G, 1989, ARCH PHARM, V322, P409, DOI 10.1002/ardp.19893220706; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; HRUBY DE, 1985, VIRUS RES, V2, P151, DOI 10.1016/0168-1702(85)90245-X; HRUBY DE, 1981, VIROLOGY, V113, P594, DOI 10.1016/0042-6822(81)90187-2; JAMES P, 1990, FEBS LETT, V272, P139; KIM HJ, 1990, BIOCHEMISTRY-US, V29, P1107, DOI 10.1021/bi00457a002; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LIU QY, 1988, VIROLOGY, V163, P638, DOI 10.1016/0042-6822(88)90308-X; MOELLER W, 1985, FEBS LETT, V186, P1; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINOHARA Y, 1990, BIOPHYS CHEM, V36, P201, DOI 10.1016/0301-4622(90)80025-3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILLIAMS RJP, 1970, Q REV CHEM SOC, V24, P313; WILSON EM, 1989, GENE, V77, P69, DOI 10.1016/0378-1119(89)90360-0; YAN H, 1992, IN PRESS BIOCHEMISTR	25	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6801	6806						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551887				2022-12-27	WOS:A1992HM05300053
J	CONNOLLY, TM; JACOBS, JW; CONDRA, C				CONNOLLY, TM; JACOBS, JW; CONDRA, C			AN INHIBITOR OF COLLAGEN-STIMULATED PLATELET ACTIVATION FROM THE SALIVARY-GLANDS OF THE HAEMENTERIA-OFFICINALIS LEECH .1. IDENTIFICATION, ISOLATION, AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IV CD36; INDUCED AGGREGATION; DEPENDENT ADHESION; HIRUDO-MEDICINALIS; POTENT INHIBITOR; FACTOR XA; IA; GHILIANII; SUBENDOTHELIUM; COAGULATION	A protein that blocks collagen-stimulated platelet aggregation has been identified and isolated from the soluble fraction of salivary glands from Haementeria officinalis leeches. We have named this protein leech antiplatelet protein (LAPP). LAPP was isolated from soluble crude salivary gland extract by heparin-agarose, size exclusion, and C18 reverse phase high-performance chromatography. Its molecular weight is approximately 16,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis under both reduced and nonreduced conditions. The sequences of peptides generated by V8 digestion of LAPP as well as its amino acid composition suggested no homology to other known proteins. The IC50 for LAPP to inhibit platelet aggregation was approximately 60 nM. This inhibitory activity is specific for collagen-induced aggregation. Platelet aggregation in response to ADP, arachidonic acid, U46619, thrombin, and ionophore A23187 was not inhibited by LAPP at a concentration that blocked platelet aggregation to collagen by 100%. In contrast, crude salivary gland-soluble extract contained activity(ies) which inhibited aggregation to all these agonists except thrombin at 1 unit/ml and 2-mu-M A23187. Thus, the H. officinalis leech has evolved multiple mechanisms to prevent hemostasis, including an inhibitor of collagen-stimulated platelet aggregation. The identification and isolation of LAPP demonstrates the existence of a new type of platelet inhibitor that should be useful to better understand the mechanism of collagen stimulation of platelets.			CONNOLLY, TM (corresponding author), MERCK SHARP & DOHME LTD,DEPT BIOL CHEM,W POINT,PA 19486, USA.							BARNES MJ, 1988, COLLAGEN, V1, P275; BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P1; BUDZYNSKI AZ, 1981, P SOC EXP BIOL MED, V168, P259; COLLER BS, 1989, BLOOD, V74, P182; CONDRA C, 1989, THROMB HAEMOSTASIS, V61, P437; DECKMYN H, 1990, THROMB HAEMOSTASIS, V64, P74; DECKMYN H, 1986, ZBORNIK K O ATEROSKL, P55; GASIC GJ, 1983, CANCER RES, V43, P1633; KEHREL B, 1988, BLOOD, V71, P1074; KELLER PM, 1992, J BIOL CHEM, V267, P6899; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; MARKWARDT F, 1970, METHOD ENZYMOL, V19, P925; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MUNRO R, 1989, THROMB HAEMOSTASIS, V61, P366; NIEUWENHUIS HK, 1986, BLOOD, V68, P692; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NUTT E, 1988, J BIOL CHEM, V263, P10162; RIGBI M, 1987, COMP BIOCHEM PHYS C, V88, P95, DOI 10.1016/0742-8413(87)90052-1; RIGBI M, 1987, COMP BIOCHEM PHYS B, V87, P567, DOI 10.1016/0305-0491(87)90053-8; Santoro S A, 1988, Prog Clin Biol Res, V283, P291; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SAWYER RT, 1988, HEMOSTASIS ANIMAL VE, P271; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SUGIYAMA T, 1987, BLOOD, V69, P1712; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718	29	68	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6893	6898						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551897				2022-12-27	WOS:A1992HM05300068
J	MIYATA, Y; YAHARA, I				MIYATA, Y; YAHARA, I			THE 90-KDA HEAT-SHOCK PROTEIN, HSP90, BINDS AND PROTECTS CASEIN KINASE-II FROM SELF-AGGREGATION AND ENHANCES ITS KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; CELL GLUCOCORTICOID RECEPTOR; REGULATED EIF-2-ALPHA KINASE; EPIDERMAL GROWTH-FACTOR; TRANSFORMING PROTEIN; STEROID-RECEPTORS; PHOSPHORYLATION; PURIFICATION; ASSOCIATION; COMMON	We found that a preparation of the 90-kDa heat shock protein, HSP90, purified to apparent homogeneity, contains a serine/threonine kinase which phosphorylates HSP90. The protein kinase was identified as casein kinase II (CKII) according to its properties. The protein kinase was separable from HSP90 by adsorption to heparin-Sepharose or phosphocellulose. CKII was coimmunoprecipitated with HSP90 by anti-HSP90 antibodies from cell extracts. Sucrose density gradient centrifugation analysis revealed that an addition of anti-HSP90 antibodies to cell extracts induces a shift of the sedimentation peak of CKII toward the bottom of a centrifuge tube. These results suggest that CKII is associated with HSP90 in cell lysates at low salt conditions. Furthermore, the CKII.HSP90 complex was reconstituted from purified HSP90-free CKII and CKII-free HSP90. In a buffer at low ionic strength, CKII forms large aggregates, but HSP90 dissociates the aggregates. Finally, we found that HSP90 activates CKII; an addition of HSP90 to CKII dramatically increased phosphorylation of exogenous substrates as well as the CKII-beta subunit. Taken altogether, these observations suggest that CKII is structurally and functionally active when it forms a complex with HSP90.	TOKYO METROPOLITAN INST MED SCI, DEPT CELL BIOL, 3-18-22 HON KOMAGOME, BUNKYO KU, TOKYO 113, JAPAN	Tokyo Metropolitan Institute of Medical Science			Miyata, Y/X-7111-2019					ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DENIS M, 1989, CANCER RES, V49, pS2275; DOUGHERTY JJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P74, DOI 10.1016/0167-4889(87)90067-X; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; GLOVER CVC, 1986, J BIOL CHEM, V261, P14349; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HOWARD KJ, 1988, J BIOL CHEM, V263, P3474; INANO K, 1990, FEBS LETT, V267, P157, DOI 10.1016/0014-5793(90)80313-8; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1985, BIOCHIM BIOPHYS ACTA, V846, P248, DOI 10.1016/0167-4889(85)90072-2; MIYATA Y, 1991, J BIOL CHEM, V266, P8779; MULNERLORILLON O, 1988, EUR J BIOCHEM, V171, P107, DOI 10.1111/j.1432-1033.1988.tb13765.x; NISHIDA E, 1986, J BIOL CHEM, V261, P6033; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRATT WB, 1989, CANCER RES, V49, pS2222; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SZYSZKA R, 1989, BIOCHEMISTRY-US, V28, P1435, DOI 10.1021/bi00430a001; TUAZON PT, 1991, ADV 2ND MESSENGER PH, V23, P123; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; YONEZAWA N, 1988, EUR J BIOCHEM, V177, P1, DOI 10.1111/j.1432-1033.1988.tb14337.x	50	291	296	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7042	7047						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551911				2022-12-27	WOS:A1992HM05300089
J	BEDOYAN, J; GUPTA, R; THOMA, F; SMERDON, MJ				BEDOYAN, J; GUPTA, R; THOMA, F; SMERDON, MJ			TRANSCRIPTION, NUCLEOSOME STABILITY, AND DNA-REPAIR IN A YEAST MINICHROMOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRRADIATED PLASMID DNA; SACCHAROMYCES-CEREVISIAE; EXCISION-REPAIR; MESSENGER-RNA; DIFFERENTIAL REPAIR; PYRIMIDINE DIMERS; ESCHERICHIA-COLI; GENE; CHROMATIN; SEQUENCES	The template strand of the URA3 gene in the minichromosome YRpTRURAP is repaired of UV-induced cyclobutyl pyrimidine dimers (PD) much more efficiently than the nontemplate strand in growth-arrested Saccharomyces cerevisiae cells (Smerdon, M. J., and Thoma, F. (1990) Cell 61, 675). However, other regions of the plasmid are also efficiently repaired. We have examined the transcription and chromatin structure of these regions in growth-arrested cells to allow a more detailed comparison of transcription, nucleosome stability, and excision repair efficiency. Northern analysis, using strand-specific probes, indicates that four different transcripts are made from YRpTRURAP in addition to the URA3 mRNA in both growing and growth-arrested cells. The templates for these transcripts encompass all of the efficiently repaired regions outside of the URA3 gene. Nucleosome mapping indicates that the structure of the minichromosome in growth-arrested cells is indistinguishable from that of growing cells except for two nucleosomes in the region 500-800 base pairs 5' of the URA3 gene which become much less stable in growth-arrested cells. Comparison of the distribution of YRpTRURAP topoisomers in the two states, however, indicates that these nucleosomes are not lost from the majority of plasmid molecules. One of the four transcripts initiates in this region and increases by more than 5-fold in growth-arrested cells. Another transcript extends into a "slowly repaired" region which contains a very stable nucleosome. By determining the stability and relative amounts (at equilibrium) of the RNAs made from YRpTRURAP, transcription rates were determined and compared with the average PD repair rate for the different template regions. The results indicate that: 1) the rate of excision repair increases once a low, basal rate of transcription is achieved; 2) beyond this rate of transcription there is no simple correlation between the rates of transcription and PD repair; 3) nucleosome stability may "override" the coupling between transcription and repair if the transcription rate is low; and 4) at higher transcription rates, repair may be insensitive to nucleosome stability.	WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA; SWISS FED INST TECHNOL, INST ZELLBIOL, CH-8093 ZURICH, SWITZERLAND	Washington State University; ETH Zurich					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002614, R37ES002614, R01ES004106] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES02614, ES04106] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BACH ML, 1979, P NATL ACAD SCI USA, V76, P386, DOI 10.1073/pnas.76.1.386; BAJWA W, 1988, MOL CELL BIOL, V8, P3439, DOI 10.1128/MCB.8.8.3439; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; CHEN W, 1985, EMBO J, V4, P3273, DOI 10.1002/j.1460-2075.1985.tb04077.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOPER AJ, 1987, ENZYME INDUCTION MUT, P73; DOBSON MJ, 1983, NUCLEIC ACIDS RES, V11, P2287, DOI 10.1093/nar/11.8.2287; DOMINSKI Z, 1984, MOL GEN GENET, V193, P167, DOI 10.1007/BF00327432; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; ELORZA MV, 1976, BIOCHIM BIOPHYS ACTA, V454, P263, DOI 10.1016/0005-2787(76)90229-X; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; GANNON F, 1979, NATURE, V278, P428, DOI 10.1038/278428a0; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; IKAI K, 1985, PHOTOCHEM PHOTOBIOL, V42, P179, DOI 10.1111/j.1751-1097.1985.tb01557.x; JOHNSTON GC, 1978, CELL, V14, P951, DOI 10.1016/0092-8674(78)90349-5; LAN SY, 1985, BIOCHEMISTRY-US, V24, P7771, DOI 10.1021/bi00347a041; LEADON SA, 1986, NUCLEIC ACIDS RES, V14, P8979, DOI 10.1093/nar/14.22.8979; LEADON SA, 1988, MOL CELL BIOL, V8, P5331, DOI 10.1128/MCB.8.12.5331; Maniatis T., 1982, MOL CLONING; MCCREADY SJ, 1980, CURR GENET, V2, P207, DOI 10.1007/BF00435687; MCCREADY SJ, 1987, J CELL SCI, P25; MORSE RH, 1988, CELL, V54, P285, DOI 10.1016/0092-8674(88)90190-0; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; OKUMOTO DS, 1987, NUCLEIC ACIDS RES, V15, P10021, DOI 10.1093/nar/15.23.10021; PIPER PW, 1987, ENZYME INDUCTION MUT, P41; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SANTIAGO TC, 1986, NUCLEIC ACIDS RES, V14, P8347, DOI 10.1093/nar/14.21.8347; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SMERDON MJ, 1990, NUCLEIC ACIDS RES, V18, P2045, DOI 10.1093/nar/18.8.2045; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; THOMA F, 1985, NATURE, V315, P250, DOI 10.1038/315250a0; THOMA F, 1986, J MOL BIOL, V190, P177, DOI 10.1016/0022-2836(86)90291-3; WHITE CI, 1987, MUTAT RES, V183, P161, DOI 10.1016/0167-8817(87)90058-7; WHITE CI, 1987, CURR GENET, V11, P321, DOI 10.1007/BF00355407; WHITE CI, 1985, MOL GEN GENET, V201, P99, DOI 10.1007/BF00397993; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; YARGER JG, 1986, MOL CELL BIOL, V6, P1095, DOI 10.1128/MCB.6.4.1095; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	49	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5996	6005						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556111				2022-12-27	WOS:A1992HK31800045
J	LIU, M; KRUL, ES; SUBBAIAH, PV				LIU, M; KRUL, ES; SUBBAIAH, PV			EFFECT OF APOPROTEIN-B CONFORMATION ON THE ACTIVATION OF LYSOLECITHIN ACYLTRANSFERASE AND LECITHIN-CHOLESTEROL ACYLTRANSFERASE - STUDIES WITH SUBFRACTIONS OF LOW-DENSITY LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER TRANSFER PROTEIN; APOLIPOPROTEIN-A-I; PLASMA-LIPOPROTEINS; SUBSTRATE-SPECIFICITY; TRIGLYCERIDE CONTENT; CELL-SURFACE; EXPRESSION; EPITOPES; BINDING; ESTERIFICATION	In order to determine the role of apoprotein (apo) B conformation in the activation of the lysolecithin acyltransferase reaction, we studied the activation of purified enzyme by various subfractions of low density lipoprotein (LDL), isolated by density gradient centrifugation. The activation of LAT correlated positively with the density of LDL and negatively with cholesterol/protein and triglyceride (TG)/protein ratios. The enzyme activation was also positively correlated with the number of trinitrobenzenesulfonic acid-reactive lysine amino groups, which increased with increasing density of LDL. The immunoaffinity of the LDL subfractions for B1B6, a monoclonal antibody directed to the receptor-binding region of apoB, increased with increasing density, while the affinity toward C1.4, a monoclonal antibody directed to the amino-terminal region of apoB, was not altered. Enrichment of normal whole LDL with TG resulted in a 45% reduction in enzyme activation, a 27% decrease in the number of trinitrobenzenesulfonic acid-reactive lysine groups, and a marked reduction in the immunoaffinity for B1B6. All these parameters reversed to normal when the TG-enriched LDL was treated with milk lipoprotein lipase, which specifically reduced the TG content of LDL. The LDL subfractions also supported cholesterol esterification by the purified enzyme, in parallel with lysolecithin esterification, indicating that apoB can also serve as an activator of the lecithin-cholesterol acyltransferase reaction. These results strongly suggest that the localized conformational change of apoB which occurs during the TG depletion of the precursor particle is critical for its activation of acyltransferase reactions, in a manner analogous to its interaction with the cellular receptors.	RUSH MED COLL,DEPT MED,ENDOCRINOL SECT,1653 W CONGRESS PKWY,CHICAGO,IL 60612; RUSH MED COLL,DEPT BIOCHEM,CHICAGO,IL 60612; WASHINGTON UNIV,LIPID RES CTR,ST LOUIS,MO 63110	Rush University; Rush University; Washington University (WUSTL)			Subbaiah, Papasani/U-1104-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039194, R01HL036073] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-39194, HL-36073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIRAM M, 1988, J BIOL CHEM, V263, P16842; BARTER PJ, 1985, ATHEROSCLEROSIS, V58, P97, DOI 10.1016/0021-9150(85)90058-9; BARTER PJ, 1983, BIOCHIM BIOPHYS ACTA, V751, P261, DOI 10.1016/0005-2760(83)90283-7; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADLEY WA, 1984, J BIOL CHEM, V259, P4728; CHAIT A, 1984, BIOCHIM BIOPHYS ACTA, V795, P314, DOI 10.1016/0005-2760(84)90081-X; CHECOVICH WJ, 1991, ARTERIOSCLER THROMB, V11, P351, DOI 10.1161/01.ATV.11.2.351; CHEN CH, 1982, BIOCHEM BIOPH RES CO, V107, P1091, DOI 10.1016/0006-291X(82)90633-7; CHEN CH, 1982, J LIPID RES, V23, P680; CHEN GC, 1989, J BIOL CHEM, V264, P14369; CHUNG J, 1982, ATHEROSCLEROSIS, V45, P33, DOI 10.1016/0021-9150(82)90169-1; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DOLPHIN PJ, 1987, ATHEROMA LISBON, V13, P16; Eisenberg S, 1975, Adv Lipid Res, V13, P1; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GAMBERT P, 1990, J LIPID RES, V31, P1199; GRIFFIN BA, 1990, ATHEROSCLEROSIS, V83, P59, DOI 10.1016/0021-9150(90)90131-2; KINOSHITA M, 1990, J LIPID RES, V31, P701; KNIPPING G, 1986, BIOCHEMISTRY-US, V25, P5242, DOI 10.1021/bi00366a039; KRUL ES, 1988, J LIPID RES, V29, P937; KUKSIS A, 1982, ATHEROSCLEROSIS, V41, P221, DOI 10.1016/0021-9150(82)90187-3; KUNITAKE ST, 1990, J BIOL CHEM, V265, P20739; LEE DM, 1982, J LIPID RES, V23, P14; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; MARCEL YL, 1983, NIH831266 PUBL, P414; MARINETTI GV, 1962, J LIPID RES, V3, P1; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; PORTMAN OW, 1973, BIOCHIM BIOPHYS ACTA, V326, P34, DOI 10.1016/0005-2760(73)90025-8; RUDEL LL, 1986, J LIPID RES, V27, P465; SESTAK TL, 1989, THESIS RUSH U CHICAG; SHEN MMS, 1981, J LIPID RES, V22, P236; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; STOKKE KT, 1971, SCAND J CLIN LAB INV, V27, P21, DOI 10.3109/00365517109080184; SUBBAIAH PV, 1985, ATHEROSCLEROSIS, V54, P99, DOI 10.1016/0021-9150(85)90157-1; SUBBAIAH PV, 1991, J LIPID RES, V32, P1601; SUBBAIAH PV, 1985, J BIOL CHEM, V260, P5308; SUBBAIAH PV, 1980, J BIOL CHEM, V255, P9275; SUBBAIAH PV, 1979, BIOCHIM BIOPHYS ACTA, V573, P212, DOI 10.1016/0005-2760(79)90189-9; SUBBAIAH PV, 1982, METABOLISM, V294, P298; SUBBAIAH PV, 1989, CIRCULATION, V80, P355; TENG B, 1985, J BIOL CHEM, V260, P5067; TIKKANEN MJ, 1984, ARTERIOSCLEROSIS, V4, P138, DOI 10.1161/01.ATV.4.2.138; TSAO BP, 1982, J BIOL CHEM, V257, P5222; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; YOKOYAMA S, 1980, J BIOL CHEM, V255, P7333	47	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5139	5147						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544896				2022-12-27	WOS:A1992HH74700024
J	BROWN, KE; KINDY, MS; SONENSHEIN, GE				BROWN, KE; KINDY, MS; SONENSHEIN, GE			EXPRESSION OF THE C-MYB PROTOONCOGENE IN BOVINE VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; V-MYB; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; TRANS-ACTIVATION; GENE-EXPRESSION; CDNA CLONES; PROTOONCOGENE; DNA; DIFFERENTIATION	Previously we have shown that bovine vascular smooth muscle cells (SMCs) express c-myb mRNA (Reilly, C. F., Kindy, M. S., Brown, K. E., Rosenberg, R. D., and Sonenshein, G. E. (1989) J. Biol. Chem. 264, 6990-6995). Here we have characterized changes in the low level of c-myb mRNA expressed in quiescent serum-deprived subconfluent SMCs upon entry into the cell cycle. After serum stimulation, levels of c-myb mRNA increased 3-4-fold during late G1 and remained at this level during S phase. A 1.5-kilobase partial c-myb cDNA clone, isolated from a bovine SMC library, was partially sequenced and found to be 89 and 85% homologous to the human and murine c-myb genes, respectively. Using bovine and murine c-myb clones, no change in the rate of c-myb gene transcription or mRNA stability was detected during the cell cycle. Thus, the regulation of changes in c-myb mRNA levels in SMCs appears distinct from mechanisms seen in hematopoietic or fibroblastic cells. Vectors containing myb binding sites linked to the thymidine kinase promoter and the chloramphenicol acetyltransferase reporter gene were transiently transfected into SMC cultures. KHK-CAT-dAX, which contains nine concatenated myb binding sites, exhibited 7-fold more activity than the parental dAX-TK-CAT vector in exponentially growing SMCs. The levels of chloramphenicol acetyltransferase activity in exponentially growing cells were approximately 2-fold higher than in cells that had been serum deprived for 24 h and were entering quiescence. Thus SMCs produce a functional c-myb protein that can activate transcription from a heterologous promoter. Furthermore, introduction of antisense c-myb oligonucleotides to quiescent serum-deprived SMC cultures severely inhibited entry of cells into S phase upon serum addition. Thus, expression of the c-myb oncogene plays an important role in cell cycle progression of SMCs.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,80 E CONCORD ST,BOSTON,MA 02118; UNIV KENTUCKY,DEPT BIOCHEM,LEXINGTON,KY 40536	Boston University; University of Kentucky					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007429, P01HL013262] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL 07429, HL13262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTERMAN RBM, 1984, MOL CELL BIOL, V4, P123, DOI 10.1128/MCB.4.1.123; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOND JF, 1983, MOL CELL BIOL, V3, P1333, DOI 10.1128/MCB.3.8.1333; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P21, DOI 10.1002/jcp.1041240105; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEAN M, 1983, NATURE, V305, P443, DOI 10.1038/305443a0; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; FEINBERG A, 1982, ANAL BIOCHEM, V132, P6; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KINDY MS, 1986, J BIOL CHEM, V261, P2865; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MANIATIS T, 1982, MOL CLONING LABORATO, P326; MUSCOVICI C, 1975, CURR TOP MICROBIOL I, V71, P79; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; REILLY CF, 1989, J BIOL CHEM, V264, P6990; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; STEPP MA, 1986, J BIOL CHEM, V261, P6542; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	43	80	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4625	4630						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537845				2022-12-27	WOS:A1992HF64200054
J	HOE, MH; HUNT, RC				HOE, MH; HUNT, RC			LOSS OF ONE ASPARAGINE-LINKED OLIGOSACCHARIDE FROM HUMAN TRANSFERRIN RECEPTORS RESULTS IN SPECIFIC CLEAVAGE AND ASSOCIATION WITH THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS; CELL-SURFACE RECEPTOR; CHAIN BINDING-PROTEIN; SIGNAL SEQUENCE; BIOSYNTHESIS; EXPRESSION; IDENTIFICATION; TRANSFECTION; ACQUISITION; DEGRADATION	The coding sequence for the human transferrin receptor gene has been mutated in order to abolish the attachment of the oligosaccharide closest to the transmembrane sequence. Expression of the mutant receptor in Chinese hamster ovary cells resulted, after analysis under nonreducing conditions, in an 85- and a 73-kDa receptor species. After reduction, the 85-kDa receptors were mostly converted to 73 kDa, although with short labeling periods some 85-kDa receptor remained suggesting that the mutated gene was capable of coding for the entire polypeptide which was then proteolytically processed. This was supported by in vitro translation of mRNA from either wild type or mutant cells which in both cases yielded an 80-kDa protein, the full size of the nonglycosylated protein. The solubility characteristics of the mutant receptor suggest that it contains the COOH-terminal extracellular domain but not the transmembrane sequence. This is supported by the endoglycosidase H sensitivity of the 73-kDa protein which is compatible with the retention of two of the original three high mannose oligosaccharides. The receptor that lacks one oligosaccharide is unable to form intermonomer disulfide bridges or to migrate to the cell surface and is located in the endoplasmic reticulum where it is further degraded after a lag period of about 30 min.	UNIV S CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,COLUMBIA,SC 29208	University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NATIONAL CANCER INSTITUTE [R01CA041050] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41050] Funding Source: Medline; NEI NIH HHS [EY 06162] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BOLE DG, 1989, J HISTOCHEM CYTOCHEM, V37, P1817, DOI 10.1177/37.12.2685110; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DAVIS RJ, 1987, J BIOL CHEM, V262, P16041; DO SI, 1990, J BIOL CHEM, V265, P114; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; FREEZE HH, 1986, J BIOL CHEM, V261, P127; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; Hanover JA, 1985, ENDOCYTOSIS, P131; HUNT RC, 1989, J BIOL CHEM, V264, P9643; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; KUHN LC, 1984, CELL, V37, P95, DOI 10.1016/0092-8674(84)90304-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MORRISON M, 1970, BIOCHEMISTRY-US, V9, P2995, DOI 10.1021/bi00817a010; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OLSON TS, 1987, J BIOL CHEM, V262, P6816; OMARY MB, 1981, J BIOL CHEM, V256, P2888; RECKHOW CL, 1988, J BIOL CHEM, V263, P7297; ROSNER MR, 1982, METHOD ENZYMOL, V83, P399; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SCHNEIDER C, 1983, FEBS LETT, V158, P259, DOI 10.1016/0014-5793(83)80591-2; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; SLIEKER LJ, 1986, J BIOL CHEM, V261, P5233; Tarentino A L, 1978, Methods Enzymol, V50, P574; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P8318; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; ZERIAL M, 1986, EMBO J, V5, P1543, DOI 10.1002/j.1460-2075.1986.tb04395.x; [No title captured]	46	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4916	4923						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537870				2022-12-27	WOS:A1992HF64200093
J	CONAWAY, JW; BRADSHER, JN; CONAWAY, RC				CONAWAY, JW; BRADSHER, JN; CONAWAY, RC			MECHANISM OF ASSEMBLY OF THE RNA POLYMERASE-II PREINITIATION COMPLEX - TRANSCRIPTION FACTOR-DELTA AND FACTOR-EPSILON PROMOTE STABLE BINDING OF THE TRANSCRIPTION APPARATUS TO THE INITIATOR ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA BOX-BINDING; ACCURATE TRANSCRIPTION; SEQUENCES DOWNSTREAM; FUNCTIONAL-ANALYSIS; PROTEIN; PURIFICATION; GENE; LIVER; DNA; IDENTIFICATION	Assembly of RNA polymerase II with the core region of TATA box-containing promoters requires the action of the TATA factor and four transcription factors designated alpha, beta-gamma, delta, and epsilon, which have each been purified to near homogeneity from rat liver. Evidence from previous studies argues that alpha and beta-gamma play a crucial role in delivering RNA polymerase II to the promoter (Conaway, R. C., Garrett, K. P., Hanley, J. P., and Conaway, J. W. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 6205-6209). Here we describe the interaction of transcription factor-delta with preinitiation intermediates assembled in the presence of either recombinant yeast TFIID or the high molecular mass, endogenous TATA factor-tau from rat liver (Conaway, J. W., Hanley, J. P., Garrett, K. P., and Conaway, R. C. (1991) J. Biol. Chem. 266, 7804-7811). Results of template challenge experiments argue that delta-enters the preinitiation complex through interactions with multiple components of the transcription apparatus. We observe that, in the presence of recombinant TFIID, delta-interacts stably with the preinitiation complex only in the presence of RNA polymerase II, alpha, and beta-gamma, whereas, in the presence of tau, delta is capable of interacting stably with the Initial Complex independently of RNA polymerase II. Results of restriction site protection experiments reveal that delta and epsilon-promote binding of the transcription apparatus to the Initiator element and support the model that RNA polymerase II assembles at the core promoter in at least two discrete steps, first "touching down" near the TATA element and finally extending its interaction downstream to encompass the cap site.			CONAWAY, JW (corresponding author), OKLAHOMA CHILDRENS MEM HOSP,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104, USA.			Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CONAWAY JW, 1990, J BIOL CHEM, V265, P7564; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLORES O, 1990, J BIOL CHEM, V265, P5629; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KADESCH TR, 1982, J MOL BIOL, V155, P1, DOI 10.1016/0022-2836(82)90489-2; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; WHITE JH, 1991, P NATL ACAD SCI USA, V88, P7674, DOI 10.1073/pnas.88.17.7674	52	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10142	10148						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577784				2022-12-27	WOS:A1992HT96500104
J	GOPALAN, V; VANDERJAGT, DJ; LIBELL, DP; GLEW, RH				GOPALAN, V; VANDERJAGT, DJ; LIBELL, DP; GLEW, RH			TRANSGLUCOSYLATION AS A PROBE OF THE MECHANISM OF ACTION OF MAMMALIAN CYTOSOLIC BETA-GLUCOSIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOLS; LIVER; REACTIVITY; HYDROLYSIS	This study establishes that guinea pig liver cytosolic beta-glucosidase generates a common glucosyl-enzyme intermediate from a variety of aryl beta-D-glucoside substrates and that the intermediate can react with various acceptors to form distinct products at rates which are dependent on the structure, nucleophilicity, and concentration of the acceptor. Specifically, we demonstrate that water and linear alkanols will react with the glucosyl-enzyme intermediate to form D-glucose and alkyl-beta-D-glucoside (e.g. octyl-beta-D-glucoside), respectively. The rate of alcoholysis is 24-fold greater than the rate of hydrolysis of the glucosyl-enzyme intermediate and accounts for the increase in steady-state rate of substrate disappearance in the presence of alcohols. In addition, the substrate molecule itself (e.g. p-nitrophenyl-beta-D-galactoside (pNP-Gal)) can serve as an acceptor in the transglycosylation reaction, thereby enabling the enzyme to synthesize disaccharide glycosides (e.g. pNP-beta-Gal(6 --> 1)beta-Gal). The transglycosylation data point to the presence of two hydrophobic subsites in the active site of the cytosolic beta-glucosidase. These data support a model in which the cytosolic beta-glucosidase binds an acceptor and a glycosyl donor simultaneously within its catalytic center and efficiently catalyzes the transfer of a sugar residue from the donor to the acceptor.	UNIV NEW MEXICO,SCH MED,DEPT BIOCHEM,ALBUQUERQUE,NM 87131	University of New Mexico					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM031357] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 31357] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENDER ML, 1964, J AM CHEM SOC, V86, P3697, DOI 10.1021/ja01072a019; BERGEL A, 1989, ANAL BIOCHEM, V179, P382, DOI 10.1016/0003-2697(89)90149-8; BIELY P, 1991, EUR J BIOCHEM, V200, P157, DOI 10.1111/j.1432-1033.1991.tb21062.x; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTE GL, 1990, GLYCOCONJUGATE J, V7, P145, DOI 10.1007/BF01050377; DALE MP, 1986, BIOCHEMISTRY-US, V25, P2522, DOI 10.1021/bi00357a036; DISTLER JJ, 1977, ARCH BIOCHEM BIOPHYS, V178, P631, DOI 10.1016/0003-9861(77)90235-1; FASTREZ J, 1973, BIOCHEMISTRY-US, V12, P2025, DOI 10.1021/bi00735a001; FERSHT A, 1985, ENZYME STRUCTURE MEC, P193; GOPALAN V, 1989, BIOCHEM J, V262, P541, DOI 10.1042/bj2620541; GOPALAN V, 1989, J BIOL CHEM, V264, P15418; GREENZAI.P, 1971, BIOCHEMISTRY-US, V10, P1210; GUSAKOV AV, 1991, BIOCHIM BIOPHYS ACTA, V1073, P481, DOI 10.1016/0304-4165(91)90219-7; HUBER RE, 1984, ARCH BIOCHEM BIOPHYS, V234, P151, DOI 10.1016/0003-9861(84)90336-9; INWARD PW, 1965, J BIOL CHEM, V240, P1986; LALEGERIE P, 1982, BIOCHIMIE, V64, P977, DOI 10.1016/S0300-9084(82)80379-9; LAMARCO KL, 1986, BIOCHEM J, V237, P469, DOI 10.1042/bj2370469; LEGLER G, 1988, ARCH BIOCHEM BIOPHYS, V260, P437, DOI 10.1016/0003-9861(88)90467-5; LI YT, 1991, J BIOL CHEM, V266, P10723; OVEREND WG, 1962, J CHEM SOC, V4, P3429; PETERS SP, 1975, CLIN CHIM ACTA, V60, P391, DOI 10.1016/0009-8981(75)90083-2; SCHUSTER SM, 1979, BIOCHEMISTRY-US, V18, P1162, DOI 10.1021/bi00574a007; SEGEL JH, 1975, ENZYME KINETICS, P227; STOKES TM, 1972, BIOCHEMISTRY-US, V11, P1061, DOI 10.1021/bi00756a018; UMEZURIKE GM, 1971, BIOCHIM BIOPHYS ACTA, V250, P182, DOI 10.1016/0005-2744(71)90132-X; VANDERGR.G, 1973, EUR J BIOCHEM, V38, P122; VIRATELLE O, 1969, BIOCHEM BIOPH RES CO, V37, P1036, DOI 10.1016/0006-291X(69)90236-8	28	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9629	9638						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577800				2022-12-27	WOS:A1992HT96500030
J	HUTH, JR; MOUNTJOY, K; PERINI, F; RUDDON, RW				HUTH, JR; MOUNTJOY, K; PERINI, F; RUDDON, RW			INTRACELLULAR FOLDING PATHWAY OF HUMAN CHORIONIC GONADOTROPIN-BETA SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; CHORIOCARCINOMA CELLS; PROTEIN; ALPHA; SECRETION; CHAINS; BIOSYNTHESIS; ASSOCIATION; ISOMERASE; CULTURES	Few experimental models have been used to investigate how proteins fold inside a cell. Using the formation of disulfide bonds as an index of conformational changes during protein folding, we have developed a unique system to determine the intracellular folding pathway of the beta-subunit of human chorionic gonadotropin (hCG). Three folding intermediates of the beta-subunit were purified from [S-35]cysteine-labeled JAR choriocarcinoma cells by immunoprecipitation and by reverse-phase high performance liquid chromatography (HPLC). To identify unformed disulfide bonds, nonreduced folding intermediates were treated with trypsin to liberate non-disulfide-bound, [S-35]cysteine-containing peptides from the disulfide-linked peptides. Released peptides were purified by HPLC and identified by amino acid sequencing. The amount of a peptide that was released indicated the extent of disulfide bond formation involving the cysteine in that peptide. Of the six disulfide bonds in hCG-beta, bonds 34-88 and 38-57 form first. The rate-limiting event of folding involves the formation of the S-S bonds between cysteines 23 and 72 and cysteines 9 and 90. Disulfide bond 93-100, the formation of which appears to be necessary for assembly with the alpha-subunit of the hCG heterodimer, forms next. Finally, disulfide bond 26-110 forms after assembly with the alpha-subunit, suggesting that completion of folding of the COOH terminus in the beta-subunit occurs after assembly with the a subunit.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,600 S 42ND ST,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198; UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA032949] Funding Source: NIH RePORTER; NCI NIH HHS [CA32949] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEEBE JS, 1990, ENDOCRINOLOGY, V126, P384, DOI 10.1210/endo-126-1-384; BEEBE JS, 1990, J BIOL CHEM, V265, P312; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHEN F, 1991, J BIOL CHEM, V266, P6904; COLE LA, 1983, ENDOCRINOLOGY, V113, P1176, DOI 10.1210/endo-113-3-1176; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DORNMAIR K, 1990, P NATL ACAD SCI USA, V87, P4134, DOI 10.1073/pnas.87.11.4134; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FINKELSTEIN AV, 1991, NATURE, V351, P497, DOI 10.1038/351497a0; FUNAKOSHI S, 1991, P NATL ACAD SCI USA, V88, P6981, DOI 10.1073/pnas.88.16.6981; GARNIER J, 1974, FEBS LETT, V45, P166, DOI 10.1016/0014-5793(74)80837-9; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GURD FRN, 1967, METHOD ENZYMOL, V11, P532; HENSCHEN A, 1986, ADV METH PROTEIN MIC, P248; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; Matthews CR, 1991, CURR OPIN STRUC BIOL, V1, P28; MINDROIU T, 1986, J BIOL CHEM, V261, P7407; MISE T, 1981, J BIOL CHEM, V256, P6587; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; NALL BT, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P198; PETERS BP, 1984, J BIOL CHEM, V259, P5123; PETERS T, 1982, J BIOL CHEM, V257, P8847; POLLAK S, 1990, ENDOCRINOLOGY, V126, P199, DOI 10.1210/endo-126-1-199; RUDDON RW, 1979, P NATL ACAD SCI USA, V76, P5143, DOI 10.1073/pnas.76.10.5143; RUDDON RW, 1987, J BIOL CHEM, V262, P12533; RUDDON RW, 1981, J BIOL CHEM, V256, P1389; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SPACKMAN DH, 1960, J BIOL CHEM, V235, P648; STRICKLAND TW, 1982, J BIOL CHEM, V257, P2954; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TANIYAMA Y, 1990, J BIOL CHEM, V265, P7570; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	39	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8870	8879						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577725				2022-12-27	WOS:A1992HR85400029
J	LI, XY; VANHUIJSDUIJNEN, RH; MANTOVANI, R; BENOIST, C; MATHIS, D				LI, XY; VANHUIJSDUIJNEN, RH; MANTOVANI, R; BENOIST, C; MATHIS, D			INTRON-EXON ORGANIZATION OF THE NF-Y GENES - TISSUE-SPECIFIC SPLICING MODIFIES AN ACTIVATION DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT-BINDING-FACTOR; DNA-BINDING; HETEROLOGOUS SUBUNITS; HELA-CELLS; YEAST HAP2; TRANSCRIPTION; PROTEINS; PROMOTER; ENHANCER; RECOGNITION	NF-Y is a highly conserved transcription factor which recognizes CCAAT motifs in a variety of genes. We report here the genomic organization of the genes encoding both subunits, which gives interesting clues about the functional organization of the proteins. We also report the existence of isoforms of NF-YA which result from differential splicing. These alternative splicing events map within a glutamine-rich activation domain and show a marked cell- and tissue-specific bias.			LI, XY (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE.		van Huijsduijnen, Rob A.M. Hooft/B-3653-2009	van Huijsduijnen, Rob A.M. Hooft/0000-0002-2261-9424				BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; BUSTURIA A, 1990, EMBO J, V9, P3551, DOI 10.1002/j.1460-2075.1990.tb07565.x; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DORN A, 1989, MOL CELL BIOL, V9, P312, DOI 10.1128/MCB.9.1.312; DUTTA A, 1990, GENE DEV, V4, P243, DOI 10.1101/gad.4.2.243; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; HAHN S, 1988, SCIENCE, V240, P317, DOI 10.1126/science.2832951; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kingston RE, 1989, CURR OPIN CELL BIOL, V1, P1081, DOI 10.1016/S0955-0674(89)80054-7; KNIGHT GB, 1987, P NATL ACAD SCI USA, V84, P8350, DOI 10.1073/pnas.84.23.8350; KOCH W, 1989, MOL CELL BIOL, V9, P303, DOI 10.1128/MCB.9.1.303; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VANWIJNEN AJ, 1988, BIOCHEMISTRY-US, V27, P6534, DOI 10.1021/bi00417a051; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; WUARIN J, 1990, J MOL BIOL, V214, P865, DOI 10.1016/0022-2836(90)90341-I	35	134	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8984	8990						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577736				2022-12-27	WOS:A1992HR85400045
J	LUNDSTROM, J; KRAUSE, G; HOLMGREN, A				LUNDSTROM, J; KRAUSE, G; HOLMGREN, A			A PRO TO HIS MUTATION IN ACTIVE-SITE OF THIOREDOXIN INCREASES ITS DISULFIDE-ISOMERASE ACTIVITY 10-FOLD - NEW REFOLDING SYSTEMS FOR REDUCED OR RANDOMLY OXIDIZED RIBONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEINS; INTERCHANGE; REDUCTION; REACTIVITY; INSULIN; FORM	Thioredoxin (Trx) from Escherichia coli was compared with bovine protein disulfide-isomerase (PDI) for its ability to catalyze native disulfide formation in either reduced or randomly oxidized (scrambled) ribonuclease A (RNase). On a molar basis, a 100-fold higher concentration of Trx than of PDI was required to give the same rate of native disulfide formation measured as recovery of RNase activity. A Pro-34 to His (P34H Trx) mutation in the active site of E. coli Trx (WCGPC), mimicking the two suggested active sites in PDI (WCGHC), increased the catalytic activity in disulfide formation about 10-fold. The mutant P34H Trx displayed a 35-mV higher redox potential (E0') of the active site disulfide/dithiol relative to wild type Trx, making it more similar to the redox potential observed for PDI. This higher redox potential correlates well with the enhanced activity and suggests a role for the histidine side chain. Enzymatic isomerization of disulfides in scrambled, oxidized RNase requires the presence of a catalytic thiol such as GSH to initiate the thiol-disulfide interchange. Bovine thioredoxin reductase, together with NADPH, could replace GSH. For oxidative folding of reduced RNase in air with Trx, P34H Trx, or PDI, catalytic amounts of sodium selenite (1-mu-M) resulted in rapid disulfide formation and high yields of ribonuclease activity equivalent to previously known redox buffers of GSH and GSSG. These results demonstrate no obligatory role for glutathione in disulfide formation. A possible mechanism for the unknown thiol oxidative process accompanying folding and protein disulfide formation in vivo is discussed.			LUNDSTROM, J (corresponding author), KAROLINSKA HOSP, DEPT BIOCHEM 1, BOX 60400, S-10401 STOCKHOLM 60, SWEDEN.		Krause, Günter/A-1858-2012	Krause, Günter/0000-0003-3905-0921				Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; CREIGHTON TE, 1988, BIOPHYS CHEM, V31, P155, DOI 10.1016/0301-4622(88)80021-8; CREIGHTON TE, 1980, J MOL BIOL, V74, P234; CROOK EM, 1960, BIOCHEM J, V74, P234, DOI 10.1042/bj0740234; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GANTHER HE, 1969, BIOCHEMISTRY-US, V8, P2557, DOI 10.1021/bi00834a044; GILBERT HF, 1989, BIOCHEMISTRY-US, V28, P7298, DOI 10.1021/bi00444a023; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GIVOL D, 1964, J BIOL CHEM, V239, P3114; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOLMGREN A, 1989, 4TH P INT S SEL BIOL, P58; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; PIGIET VP, 1986, P NATL ACAD SCI USA, V83, P7643, DOI 10.1073/pnas.83.20.7643; SHAKED Z, 1980, BIOCHEMISTRY-US, V19, P4156, DOI 10.1021/bi00559a004; SINGH R, 1990, J AM CHEM SOC, V112, P1190, DOI 10.1021/ja00159a046; SINGH R, 1990, J AM CHEM SOC, V112, P6304, DOI 10.1021/ja00173a018; Stadtman T C, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P1; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	37	101	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9047	9052						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577742				2022-12-27	WOS:A1992HR85400054
J	KILLE, P; LEES, WE; DARKE, BM; WINGE, DR; DAMERON, CT; STEPHENS, PE; KAY, J				KILLE, P; LEES, WE; DARKE, BM; WINGE, DR; DAMERON, CT; STEPHENS, PE; KAY, J			SEQUESTRATION OF CADMIUM AND COPPER BY RECOMBINANT RAINBOW-TROUT AND HUMAN METALLOTHIONEINS AND BY CHIMERIC (MERMAID AND FISHMAN) PROTEINS WITH INTERCHANGED DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; MOLECULAR-CLONING; THIOLATE CLUSTER; METAL-BINDING; EXPRESSION; CDNA; GENE	A family of synthetic genes was constructed encoding a rainbow trout metallothionein (MT), a human MT, and two chimeric molecules which contained respectively (i) the N-terminal (or head) domain of human MT followed by the C-terminal (or tail) domain of a fish MT (termed mermaid MT) and (ii) the head domain of fish MT fused with the tail domain of human MT (denoted fishman MT). These were expressed in Escherichia coli and the four recombinant proteins were purified to homogeneity therefrom. All four were found to bind 7 g atoms of Cd(II) per mol; at pH 7.0, but not at pH 8.6, four Cd(II) ions were sequestered preferentially in the tail (or alpha) domain. Reciprocally, copper was found to bind preferentially in the head (or beta) domain. The human and fishman MTs displayed a stoichiometry of 12 g atoms of Cu(I) per mol, while rainbow trout and mermaid MTs bound only 10. The significance of these findings is discussed in relation to the different positional organization of cysteine residues close to the N and C termini of mammalian and piscine metallothioneins.	UNIV WALES COLL CARDIFF,DEPT BIOCHEM,POB 903,CARDIFF CF1 1ST,WALES; CELLTECH LTD,SLOUGH SL1 4EN,ENGLAND; UNIV UTAH,SCH MED,DEPT MED,SALT LAKE CITY,UT 84132; UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	Cardiff University; Celltech Group Ltd; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah			Kille, Peter/A-4337-2010	Kille, Peter/0000-0001-6023-5221	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES-03817] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BONHAM K, 1987, DNA-J MOLEC CELL BIO, V6, P519, DOI 10.1089/dna.1987.6.519; BYRD J, 1988, J BIOL CHEM, V263, P6688; CHAN KM, 1989, CAN J ZOOL, V67, P2520, DOI 10.1139/z89-356; CHATTERJEE A, 1990, MOL CELL BIOCHEM, V94, P175, DOI 10.1007/BF00214124; CHERNAIK ML, 1991, P NATL ACAD SCI USA, V88, P3024, DOI 10.1073/pnas.88.8.3024; CISMOWSKI MJ, 1991, BIOCHEMISTRY-US, V30, P6626, DOI 10.1021/bi00240a036; DAMERON CT, 1991, P NATL ACAD SCI USA, V88, P6127, DOI 10.1073/pnas.88.14.6127; FERNANDO LP, 1989, GENE, V81, P177, DOI 10.1016/0378-1119(89)90349-1; GOOD M, 1988, BIOCHEMISTRY-US, V27, P7163, DOI 10.1021/bi00418a074; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KAY J, 1986, BIOCHEM SOC T, V15, P453; KAY J, 1990, INT J BIOCHEM, V23, P1; KIKUCHI Y, 1988, MOL IMMUNOL, V25, P1033; KILLE P, 1991, BIOCHIM BIOPHYS ACTA, V1089, P407, DOI 10.1016/0167-4781(91)90187-Q; KILLE P, 1989, BIOCHIM BIOPHYS ACTA, V1048, P178; LYTLE FE, 1970, APPL SPECTROSC, V24, P319, DOI 10.1366/000370270774371651; MESSERLE BA, 1990, J MOL BIOL, V214, P765, DOI 10.1016/0022-2836(90)90291-S; NIELSON KB, 1985, J BIOL CHEM, V260, P5342; NIELSON KB, 1984, J BIOL CHEM, V259, P4941; NIELSON KB, 1983, J BIOL CHEM, V258, P3063; NOREY CG, 1990, COMP BIOCHEM PHYS B, V95, P597, DOI 10.1016/0305-0491(90)90027-Q; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; ROESIJADI G, 1991, BIOCHIM BIOPHYS ACTA, V1074, P230, DOI 10.1016/0304-4165(91)90157-C; VASAK M, 1980, BIOCHEMISTRY-US, V19, P416, DOI 10.1021/bi00544a003; WINGE DR, 1983, P NATL ACAD SCI-BIOL, V80, P2472, DOI 10.1073/pnas.80.9.2472; WINGE DR, 1982, J BIOL CHEM, V257, P3471	27	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8042	8049						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569063				2022-12-27	WOS:A1992HQ18500016
J	LEE, WJ; MA, H; TAKANO, E; YANG, HQ; HATANAKA, M; MAKI, M				LEE, WJ; MA, H; TAKANO, E; YANG, HQ; HATANAKA, M; MAKI, M			MOLECULAR DIVERSITY IN AMINO-TERMINAL DOMAINS OF HUMAN CALPASTATIN BY EXON SKIPPING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; GENE-EXPRESSION; MESSENGER-RNA; BIOLOGIC MEMBRANES; CALPAIN-II; INHIBITOR; SEQUENCES; BINDING; PEPTIDE; TISSUES	Calpastatin, a specific inhibitor of calpain, consists of a unique N-terminal domain (domain L) and four repetitive calpain-inhibition domains (domains 1-4). Calpastatin cDNA of human was reported to have two deletions in domains L and 1, as compared with that of pig and rabbit. We isolated human calpastatin genomic DNA clones, and the sequence analysis revealed seven exons for domain L and five exons for domain 1. Those deletions in the human cDNA were retained in its genomic DNA as exons 3 and 11. By the reverse transcription polymerase chain reaction method, three calpastatin cDNAs, full-length domains L and 1, and two natural mutants with deletions in either exon 3 or in both exons 3 and 5, were cloned from human fibroblast WI-38 cell line mRNA. Domain L was found to be rich in basic amino acid residues, especially for exon 3, and its N-terminal half was highly conserved among species. The isoelectric points (pI) of domain L and domains 1-4 were calculated to be 10.27 and 4.26-4.90, respectively. Moreover, human tissues and cell lines displayed different patterns of reverse transcription polymerase chain reaction products in agarose gel electrophoresis. Therefore, alternative splicing is most likely the cause for the molecular diversity, and the multiple isoforms are implicated for specific physiological roles.	KYOTO UNIV,FAC MED,INST VIRUS RES,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT CLIN SCI & LAB MED,KYOTO 606,JAPAN	Kyoto University; Kyoto University			Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491				ADACHI Y, 1991, J BIOL CHEM, V266, P3968; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMARA SG, 1984, MOL CELL BIOL, V4, P2151, DOI 10.1128/MCB.4.10.2151; Asada K, 1989, J Enzyme Inhib, V3, P49, DOI 10.3109/14756368909030363; BELLES B, 1988, PFLUG ARCH EUR J PHY, V412, P554, DOI 10.1007/BF00582548; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DANG CV, 1989, J BIOL CHEM, V264, P18019; EMORI Y, 1987, P NATL ACAD SCI USA, V84, P3590, DOI 10.1073/pnas.84.11.3590; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; IMAJOH S, 1987, BIOCHEM BIOPH RES CO, V146, P630, DOI 10.1016/0006-291X(87)90575-4; INAZAWA J, 1990, CYTOGENET CELL GENET, V54, P156, DOI 10.1159/000132982; ISHIDA S, 1991, BIOCHIM BIOPHYS ACTA, V1088, P436; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAMEYAMA A, 1991, 64TH ANN M JAP BIOCH, P1009; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; KORNBLIHTT AR, 1984, NUCLEIC ACIDS RES, V12, P5853, DOI 10.1093/nar/12.14.5853; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEE WJ, 1990, BIOCHEM INT, V22, P163; LEE WJ, 1992, BIOCHIM BIOPHYS ACTA, V1129, P251, DOI 10.1016/0167-4781(92)90500-Y; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LIANG Y, 1991, J BIOL CHEM, V266, P6999; MABROUK K, 1991, FEBS LETT, V289, P13, DOI 10.1016/0014-5793(91)80898-D; MAGENDZO K, 1991, J BIOL CHEM, V266, P3228; MAGNUSON VL, 1991, J BIOL CHEM, V266, P14654; MAKI M, 1987, FEBS LETT, V223, P174, DOI 10.1016/0014-5793(87)80531-8; MAKI M, 1989, J BIOL CHEM, V264, P18866; Maki M., 1990, INTRACELLULAR CALCIU, P37; MELLGREN RL, 1989, BIOCHIM BIOPHYS ACTA, V999, P71, DOI 10.1016/0167-4838(89)90032-0; MELLGREN RL, 1988, BIOCHEM BIOPH RES CO, V150, P170, DOI 10.1016/0006-291X(88)90501-3; MELLGREN RL, 1990, INTRACELLULAR CALCIU, P115; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURACHI T, 1989, BIOCHEM INT, V18, P263; MURACHI T, 1983, TRENDS BIOCHEM SCI, V8, P167, DOI 10.1016/0968-0004(83)90165-2; NAKAMURA M, 1991, 64TH ANN M JAP BIOCH, P915; PARKES C, 1986, PROTEINASE INHIBITOR, P571; ROMANIN C, 1991, EUR J PHYSL, V418, P86; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SKOOG B, 1991, TRENDS ANAL CHEM, V266, P3968; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; TAKANO E, 1991, BIOMED BIOCHIM ACTA, V50, P517; YOKOTA H, 1991, MOL CELL PROBE, V5, P261, DOI 10.1016/0890-8508(91)90047-N	47	110	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8437	8442						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569094				2022-12-27	WOS:A1992HQ18500074
J	PAN, YT; KAUSHAL, GP; PAPANDREOU, G; GANEM, B; ELBEIN, AD				PAN, YT; KAUSHAL, GP; PAPANDREOU, G; GANEM, B; ELBEIN, AD			D-MANNONOLACTAM AMIDRAZONE - A NEW MANNOSIDASE INHIBITOR THAT ALSO INHIBITS THE ENDOPLASMIC-RETICULUM OR CYTOPLASMIC ALPHA-MANNOSIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUNG BEAN SEEDLINGS; ASPARAGINE-LINKED OLIGOSACCHARIDES; LIVER GOLGI MEMBRANES; GLUCOSIDASE-II; PURIFICATION; CELLS; BIOSYNTHESIS; HOMOGENEITY; IA	The amidrazone of D-mannonolactam (see compound 5, Fig. 1) was synthesized chemically as a mimic of the mannopyranosyl cation and tested as a potential inhibitor of mannosidases. In this study compound 5 is shown to be a more general mannosidase inhibitor than other currently known compounds and exhibits properties not previously observed with any other mannosidase inhibitors. Thus D-mannonolactam amidrazone not only inhibits the Golgi mannosidase I (IC50 = 4-mu-M) and mannosidase II (IC50 = 90-100 nM), but it is the first inhibitor that has been shown to be a potent inhibitor of the soluble or endoplasmic reticulum alpha-mannosidase (IC50 = 1-mu-M). This compound also inhibited the aryl-mannosidases regardless of anomeric configuration although it was much more effective on enzymes recognizing alpha-linked mannose, i. e. jack bean and mung bean alpha-mannosidases (IC50 = 400 nM) as compared with fungal beta-mannosidase (IC50 = 150-mu-M). Mannonoamidrazone was tested in animal cell cultures using influenza virus-infected Madin-Darby canine kidney cells as a model system, and was found to prevent almost completely the formation of complex types of N-linked oligosaccharides with the formation of about equal amounts of Man9(GlcNAc)2 and Man8(GlcNAc)2 structures. Thus D-mannonolactam amidrazone is a potent but broad spectrum mannosidase inhibitor whose structure and properties should provide valuable insight into the design of other useful glycosidase inhibitors.	CORNELL UNIV,DEPT CHEM,BAKER LAB,ITHACA,NY 14853	Cornell University	PAN, YT (corresponding author), UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205, USA.				NHLBI NIH HHS [HL-17783] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017783] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BISCHOFF J, 1986, J BIOL CHEM, V261, P4766; BISCHOFF J, 1986, J BIOL CHEM, V261, P4758; BONAY P, 1991, EUR J BIOCHEM, V197, P229, DOI 10.1111/j.1432-1033.1991.tb15903.x; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; DORLING PR, 1980, BIOCHEM J, V191, P649, DOI 10.1042/bj1910649; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; ELBEIN AD, 1977, J BIOL CHEM, V252, P2026; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FORSEE WT, 1989, J BIOL CHEM, V264, P3869; FUHRMANN U, 1985, BIOCHIM BIOPHYS ACTA, V825, P95, DOI 10.1016/0167-4781(85)90095-8; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KAUSHAL GP, 1990, BIOCHEMISTRY-US, V29, P2168, DOI 10.1021/bi00460a030; KAUSHAL GP, 1990, J BIOL CHEM, V265, P16271; PAN YT, 1987, BIOCHEM CELL BIOL, V65, P345, DOI 10.1139/o87-044; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; PAPANDREOU G, 1991, IN PRESS J AM CHEM S; PASTUSZAK I, 1990, Glycobiology, V1, P71, DOI 10.1093/glycob/1.1.71; ROTH J, 1990, EUR J CELL BIOL, V53, P131; SCHWEDEN J, 1986, ARCH BIOCHEM BIOPHYS, V248, P335, DOI 10.1016/0003-9861(86)90429-7; SZUMILO T, 1986, BIOCHEM BIOPH RES CO, V134, P1395, DOI 10.1016/0006-291X(86)90404-3; SZUMILO T, 1986, ARCH BIOCHEM BIOPHYS, V247, P261, DOI 10.1016/0003-9861(86)90583-7; SZUMILO T, 1986, PLANT PHYSIOL, V81, P383, DOI 10.1104/pp.81.2.383; TABAS I, 1979, J BIOL CHEM, V254, P1655; TROPEA JE, 1990, BIOCHEMISTRY-US, V29, P10062, DOI 10.1021/bi00495a008; TULSIANI DRP, 1988, J BIOL CHEM, V263, P5408; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; TULSIANI DRP, 1985, J BIOL CHEM, V260, P3081; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; WINKLER DA, 1989, J MED CHEM, V32, P2084, DOI 10.1021/jm00129a011	29	33	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8313	8318						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569086				2022-12-27	WOS:A1992HQ18500055
J	AHMAD, S; GLAVAS, NA; BRAGG, PD				AHMAD, S; GLAVAS, NA; BRAGG, PD			SUBUNIT INTERACTIONS INVOLVED IN THE ASSEMBLY OF PYRIDINE-NUCLEOTIDE TRANSHYDROGENASE IN THE MEMBRANES OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL SIGNAL SEQUENCE; AMINO-ACID RESIDUES; LEADER PEPTIDASE; PROTEIN TRANSLOCATION; CYTOPLASMIC MEMBRANE; TRUNCATED FORMS; DETERMINANTS; LOCALIZATION; ORIENTATION; BINDING	The pyridine nucleotide transhydrogenase (PNT) of Escherichia coli consists of two different subunits (alpha and beta) and assembles as a tetramer (alpha(2)beta(2)) in the inner membrane. The pnt genes from E. coli have been cloned on a multicopy plasmid resulting in high level expression of the enzyme activity. We have studied the influence of the different segments of the polypeptide chains of the alpha and beta subunits on the assembly and function of the enzyme by constructing a series of deletion mutants for both of the subunits. Our results show that the assembly of the beta subunit is contingent upon the insertion of the alpha subunit into the membrane, while the alpha subunit can assemble independently of the beta subunit. All deletions constructed for the cytosolic portion of the alpha subunit gave no incorporation of the alpha subunit and, as a consequence, of the beta subunit, also. Of the four membrane-spanning regions of the alpha subunit, the last two were indispensable, while the deletion of the first two still allowed the association of alpha as well as of the beta subunit with the membrane. However, the enzyme was not functional. The two subunits were also loosely associated as mild detergent treatment released them from the membrane in contrast with the wild-type enzyme. Deletions within the beta subunit had little effect on the assembly of the alpha subunit, although less was incorporated. All deletions involving the cytosolic portion of the beta subunit resulted in loss of incorporation into the membrane. Of the eight membrane-spanning regions of the beta subunit, the deletion of regions 2-3, 2-4, 2-6, and 2-7 yielded significant association of both the subunits with the membrane. However, none of these mutants assembled a functional enzyme, and again the two subunits were loosely associated with the membrane. Based on the stringent requirement of the cytosolic portions of alpha and beta subunits for assembly, a model is proposed that suggests interactions between these two regions must occur prior to assembly.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM,2146 HLTH SCI MALL,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia			Ahmad, Suhail/AAJ-5456-2021					BOS TJ, 1984, P NATL ACAD SCI-BIOL, V81, P2327, DOI 10.1073/pnas.81.8.2327; BOSCH D, 1986, J MOL BIOL, V189, P449, DOI 10.1016/0022-2836(86)90316-5; BOSCH D, 1988, J BIOL CHEM, V263, P9952; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; DALBEY RE, 1987, J BIOL CHEM, V262, P13241; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Heijne G., 1988, EUR J BIOCHEM, V174, P671; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWS JK, 1989, EMBO J, V8, P2095, DOI 10.1002/j.1460-2075.1989.tb03618.x; Maniatis T., 1982, MOL CLONING; RYDSTROM J, 1987, COENZYMES COFACTOR B, V2, P433; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STOCHAJ U, 1988, J BACTERIOL, V170, P2639, DOI 10.1128/jb.170.6.2639-2645.1988; VONHEIJNE G, 1988, P NATL ACAD SCI USA, V85, P3363; WAKABAYASHI S, 1987, BIOCHEM INT, V15, P915; YAMAGUCHI M, 1988, J BIOL CHEM, V263, P2761; YAMANE K, 1988, J BIOL CHEM, V263, P19690; YAMANE K, 1990, J BIOL CHEM, V265, P21166; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZERIAL M, 1987, CELL, V48, P147, DOI 10.1016/0092-8674(87)90365-5	27	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7007	7012						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551908				2022-12-27	WOS:A1992HM05300084
J	TATE, CG; MUIRY, JAR; HENDERSON, PJF				TATE, CG; MUIRY, JAR; HENDERSON, PJF			MAPPING, CLONING, EXPRESSION, AND SEQUENCING OF THE RHAT GENE, WHICH ENCODES A NOVEL L-RHAMNOSE-H+ TRANSPORT PROTEIN IN SALMONELLA-TYPHIMURIUM AND ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA FRAGMENTS; TRANSCRIPTION TERMINATION; PLASMID VECTORS; LINKAGE MAP; BACTERIOPHAGE; PURIFICATION; GALACTOSE; PRODUCTS; PROMOTER; AGAROSE	A L-rhamnose transport-negative strain of Escherichia coli was generated by Mu d(Ap(R),lac)I mutagenesis. This strain was used to isolate a clone of Salmonella typhimurium DNA that encoded L-rhamnose-H+ transport activity, the gene for which, rhaT, was sequenced. The rhaT gene was mapped on the E. coli chromosome between rhaR and sodA at 87.9 min, initially by Southern blot analysis and then by the isolation, expression, and sequencing of the rhaT gene. Both rhaT genes encoded a hydrophobic protein of 344 amino acids (91% identical) that contained 10 putative transmembrane regions. The RhaT protein represents a novel class of sugar transport protein.			TATE, CG (corresponding author), UNIV CAMBRIDGE, DEPT BIOCHEM, TENNIS COURT RD, CAMBRIDGE CB2 1QW, ENGLAND.		Henderson, Peter JF/Q-1907-2018	Henderson, Peter/0000-0002-9187-0938; Tate, Christopher/0000-0002-2008-9183	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALZARBAN S, 1984, J BACTERIOL, V158, P603, DOI 10.1128/JB.158.2.603-608.1984; BACHMANN BJ, 1983, MICROBIOL REV, V47, P180, DOI 10.1128/MMBR.47.2.180-230.1983; BADIA J, 1989, FEMS MICROBIOL LETT, V65, P253, DOI 10.1016/0378-1097(89)90226-7; BADIA J, 1991, J BACTERIOL, V173, P5144, DOI 10.1128/jb.173.16.5144-5150.1991; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CHEN YM, 1987, J BACTERIOL, V169, P3712, DOI 10.1128/jb.169.8.3712-3719.1987; Cheshire MN., 1979, NATURE ORIGIN CARBOH; CHIU TH, 1964, BIOCHIM BIOPHYS ACTA, V92, P489, DOI 10.1016/0926-6569(64)90009-4; CHIU TH, 1965, BIOCHEM BIOPH RES CO, V19, P511, DOI 10.1016/0006-291X(65)90155-5; DAVIS EO, 1984, J BIOL CHEM, V259, P1520; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HENDERSON PJF, 1977, BIOCHEM J, V162, P309, DOI 10.1042/bj1620309; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HENDERSON PJF, 1986, METHOD ENZYMOL, V125, P387; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; IKEMURA T, 1981, J MOL BIOL, V151, P389, DOI 10.1016/0022-2836(81)90003-6; JOHNSON KR, 1990, ANAL BIOCHEM, V190, P170, DOI 10.1016/0003-2697(90)90176-A; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T., 1982, MOL CLONING; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; MUIRY JAR, 1989, THESIS U CAMBRIDGE U; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; POWER J, 1967, GENETICS, V55, P557; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SAWADA H, 1964, BIOCHIM BIOPHYS ACTA, V92, P26, DOI 10.1016/0926-6569(64)90265-2; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEINMAN HM, 1978, J BIOL CHEM, V253, P8708; TAKAGI Y, 1964, BIOCHIM BIOPHYS ACTA, V92, P18, DOI 10.1016/0926-6569(64)90264-0; TAKAGI Y, 1964, BIOCHIM BIOPHYS ACTA, V92, P10, DOI 10.1016/0926-6569(64)90263-9; TAKAGI Y, 1986, NUCLEIC ACIDS RES, V14, P4577; Thein SI., 1986, HUMAN GENETIC DIS PR, P33; TOBIN JF, 1987, J MOL BIOL, V196, P789, DOI 10.1016/0022-2836(87)90405-0; TOBIN JF, 1990, J MOL BIOL, V211, P75, DOI 10.1016/0022-2836(90)90012-B; TOBIN JF, 1990, J MOL BIOL, V211, P1, DOI 10.1016/0022-2836(90)90003-5; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WILSON DM, 1957, J BACTERIOL, V73, P415, DOI 10.1128/JB.73.3.415-420.1957; WILSON DM, 1957, J BACTERIOL, V73, P410, DOI 10.1128/JB.73.3.410-414.1957; [No title captured]	46	38	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6923	6932						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551902				2022-12-27	WOS:A1992HM05300073
J	GRAY, H; WONG, TW				GRAY, H; WONG, TW			PURIFICATION AND IDENTIFICATION OF SUBUNIT STRUCTURE OF THE HUMAN MITOCHONDRIAL-DNA POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'->5' EXONUCLEASE; CATALYTIC SUBUNIT; XENOPUS-LAEVIS; GAMMA; REPLICATION; EMBRYOS; ENZYME	The mitochondrial DNA polymerase of HeLa cells was purified 18,000-fold to near homogeneity. The purified polymerase cofractionated with two polypeptides that had molecular mass of 140 and 54 kDa. The 140-kDa subunit was specifically radiolabeled in a photoaffinity cross-linking assay and is most likely the catalytic subunit of the mitochondrial DNA polymerase. The purified enzyme exhibited properties that have been attributed to DNA polymerase-gamma and shows a preference for replicating primed poly(pyrimidine) DNA templates in the presence of 0.5 mM MgCl2. As in the case of mitochondrial DNA polymerases from other animal cells, human DNA polymerase-gamma cofractionated with a 3' --> 5' exonuclease activity. However, it has not been possible to determine if the two enzymatic activities reside in the same polypeptide. The exonuclease activity preferentially removes mismatched nucleotides from the 3' end of a duplex DNA and is not active toward DNA with matched 3' ends. These properties are consistent with the notion that the exonuclease activity plays a proofreading function in the replication of the organelle genome.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,675 HOES LANE,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NIGMS NIH HHS [GM39250] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039250] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CHENG YC, 1987, J BIOL CHEM, V262, P2187; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; FOURY F, 1989, J BIOL CHEM, V264, P20552; FRIEDLENDER B, 1972, P NATL ACAD SCI USA, V69, P452; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; JUI HY, 1991, NUCLEIC ACIDS RES, V19, P905, DOI 10.1093/nar/19.4.905; KAGUNI LS, 1989, P NATL ACAD SCI USA, V86, P6469, DOI 10.1073/pnas.86.17.6469; KNOPF KW, 1976, BIOCHEMISTRY-US, V15, P4540, DOI 10.1021/bi00665a032; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOSBAUGH DW, 1988, NUCLEIC ACIDS RES, V16, P5645, DOI 10.1093/nar/16.12.5645; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WONG TW, 1985, J BIOL CHEM, V260, P1530; WONG TW, 1985, CELL, V42, P951, DOI 10.1016/0092-8674(85)90291-0; YAMAGUCHI M, 1980, J BIOL CHEM, V255, P7002	21	110	112	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5835	5841						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556099				2022-12-27	WOS:A1992HK31800021
J	SCHEWE, M; MULLER, P; KORTE, T; HERRMANN, A				SCHEWE, M; MULLER, P; KORTE, T; HERRMANN, A			THE ROLE OF PHOSPHOLIPID ASYMMETRY IN CALCIUM-PHOSPHATE-INDUCED FUSION OF HUMAN ERYTHROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; MEMBRANE-FUSION; AMINOPHOSPHOLIPID TRANSLOCASE; DIVALENT-CATIONS; LIPID ASYMMETRY; SPIN-LABEL; GHOSTS; CELLS; PHOSPHATIDYLSERINE; FLUORESCENCE	To elucidate the role of phospholipid asymmetry in calcium-phosphate-induced fusion of human erythrocytes, we examined the interaction of erythrocyte membranes with asymmetric and symmetric bilayer distributions of phospholipids. Fusion of human erythrocytes was monitored by light microscopy as well as spectrophotometrically by the octadecylrhodamine dequenching assay. Phospholipid translocation and distribution between the inner and the outer leaflet of intact red blood cells were determined with spin-labeled phosphatidylserine (PS), phosphatidylethanolamine (PE), and phosphatidylcholine (PC). Significant fusion of lipid-asymmetric red blood cells where PS and PE are predominantly oriented to the inner leaflet was only observed at Ca2+ concentrations greater-than-or-equal-to 10 mM (in the presence of 10 mM phosphate buffer) while fusion of lipid-symmetric erythrocyte membranes was established at greater-than-or-equal-to 1.5 mM Ca2+. The Ca2+ threshold of fusion of lipid-asymmetric red blood cells was significantly reduced (i) after exposure of PS to the outer layer but not after redistribution of PE alone, and (ii) upon incorporation of spin-labeled PS into the outer leaflet of red blood cells. Spin-labeled PE or PC did not affect fusion, suggesting that the serine headgroup is an important factor in calcium-phosphate-induced fusion.	HUMBOLDT UNIV,FACHBEREICH BIOL,INST BIOPHYS,INVALIDENSTR 42,O-1040 BERLIN,GERMANY	Humboldt University of Berlin								BAKER RF, 1979, BIORHEOLOGY, V16, P285; BAKER RF, 1979, BIOCHEM BIOPH RES CO, V86, P920, DOI 10.1016/0006-291X(79)91800-X; BALDWIN JM, 1990, BIOCHIM BIOPHYS ACTA, V1028, P14, DOI 10.1016/0005-2736(90)90259-Q; BITBOL M, 1987, BIOCHIM BIOPHYS ACTA, V904, P268, DOI 10.1016/0005-2736(87)90376-2; BLUMENTHAL R, 1987, J BIOL CHEM, V262, P13614; BLUMENTHAL R, 1987, CURR TOP MEMBR TRANS, V29, P203; BROWN AM, 1983, J PHYSIOL-LONDON, V343, P455, DOI 10.1113/jphysiol.1983.sp014904; CALVEZ JY, 1988, BIOCHEMISTRY-US, V27, P5666, DOI 10.1021/bi00415a041; CLAGUE MJ, 1990, BIOCHEMISTRY-US, V29, P1303, DOI 10.1021/bi00457a028; COLLEAU M, 1991, CHEM PHYS LIPIDS, V57, P29, DOI 10.1016/0009-3084(91)90046-E; CONNOR J, 1990, BIOCHIM BIOPHYS ACTA, V1025, P82, DOI 10.1016/0005-2736(90)90193-R; CUMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; FAROOQUI SM, 1987, BIOCHIM BIOPHYS ACTA, V904, P239, DOI 10.1016/0005-2736(87)90373-7; FASSEL TA, 1988, BIOCHIM BIOPHYS ACTA, V943, P267, DOI 10.1016/0005-2736(88)90558-5; FRALEY R, 1980, BIOCHEMISTRY-US, V19, P6021, DOI 10.1021/bi00567a012; HENSELEIT U, 1990, BIOCHIM BIOPHYS ACTA, V1029, P127, DOI 10.1016/0005-2736(90)90445-T; HERRMANN A, 1988, BIOCHIM BIOPHYS ACTA, V943, P411, DOI 10.1016/0005-2736(88)90372-0; HERRMANN A, 1991, CELL AND MODEL MEMBRANE INTERACTIONS, P89; HERRMANN A, 1991, BIOMED BIOCHIM ACTA, V50, P251; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P4054, DOI 10.1021/bi00469a005; HERRMANN A, 1990, BIOCHIM BIOPHYS ACTA, V1027, P41, DOI 10.1016/0005-2736(90)90045-P; HERRMANN A, 1986, BIOSCIENCE REP, V6, P185, DOI 10.1007/BF01115005; HERRMANN A, 1990, SPRINGER SERIES BIOP, P3; HOEKSTRA D, 1985, EUR J BIOCHEM, V146, P131, DOI 10.1111/j.1432-1033.1985.tb08629.x; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HULLIN F, 1991, BIOCHIM BIOPHYS ACTA, V1061, P15, DOI 10.1016/0005-2736(91)90263-8; MORROT G, 1989, BIOCHEMISTRY-US, V28, P3456, DOI 10.1021/bi00434a046; OHKI S, 1988, MOL MECHANISMS MEMBR, P123; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; PAPAHADJOPOULOS D, 1990, J BIOENERG BIOMEMBR, V22, P157, DOI 10.1007/BF00762944; PERETZ H, 1974, J CELL BIOL, V63, P1, DOI 10.1083/jcb.63.1.1; SCHLEGEL RA, 1988, MOL MECHANISMS MEMBR, P289; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SEIGNEURET M, 1984, BIOCHEMISTRY-US, V23, P4271, DOI 10.1021/bi00314a002; SHIGA T, 1979, BIOCHIM BIOPHYS ACTA, V553, P84, DOI 10.1016/0005-2736(79)90032-4; TANAKA KI, 1976, BIOCHIM BIOPHYS ACTA, V426, P218, DOI 10.1016/0005-2736(76)90333-3; TAYLOR D, 1977, BIOCHEM BIOPH RES CO, V76, P205, DOI 10.1016/0006-291X(77)90712-4; TULLIUS EK, 1989, BIOSCIENCE REP, V9, P623, DOI 10.1007/BF01119806; WILLIAMS JH, 1966, LIPIDS, V1, P391, DOI 10.1007/BF02532542; WILLIAMSON P, 1985, J CELL PHYSIOL, V123, P209, DOI 10.1002/jcp.1041230209; WYKLE RL, 1980, ARCH BIOCHEM BIOPHYS, V199, P526, DOI 10.1016/0003-9861(80)90310-0; ZACHOWSKI A, 1990, EXPERIENTIA, V46, P645	43	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5910	5915						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556105				2022-12-27	WOS:A1992HK31800032
J	KOJIMA, T; LEONE, CW; MARCHILDON, GA; MARCUM, JA; ROSENBERG, RD				KOJIMA, T; LEONE, CW; MARCHILDON, GA; MARCUM, JA; ROSENBERG, RD			ISOLATION AND CHARACTERIZATION OF HEPARAN-SULFATE PROTEOGLYCANS PRODUCED BY CLONED RAT MICROVASCULAR ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-ANTITHROMBIN COMPLEX; ANTICOAGULANT ACTIVITY; HEPARINLIKE MOLECULES; BINDING SEQUENCE; HIGH-AFFINITY; FACTOR-XA; IDENTIFICATION; RESIDUES; PROTEINS	We have isolated heparan sulfate proteoglycans (HSPGs) from cloned rat microvascular endothelial cells using a combination of ion-exchange chromatography, affinity fractionation with antithrombin III (AT III), and gel filtration in denaturing solvents. The anticoagulantly active heparan sulfate proteoglycans (HSPG(act)) which bind tightly to AT III bear mainly anticoagulantly active heparan sulfate (HS(act)) whereas the anticoagulantly inactive heparan sulfate proteoglycans (HSPG(inact)) possess mainly anticoagulantly inactive heparan sulfate (HS(inact)). HS(inact) and HS(inact) were also isolated by a combination of ion-exchange chromatography, treatment with protease and chondroitin ABC lyase, and affinity fractionation with AT III. HS(act) and HS(inact) have molecular sizes of about 25-30 kDa with the same overall composition of monosaccharides except that HS(act) exhibits about nine glucuronsyl 3-O-sulfated glucosamines/chain whereas HS(inact) possesses about three glucuronsyl 3-O-sulfated glucosamines/chain. Direct isolation of the AT III-binding site of HS(act) exposing carbohydrate chains to Flavobacterium heparitinase in the presence of protease inhibitor revealed only a single interaction site which contained two to three glucuronsyl 3-O-sulfated glucosamine residues. The core proteins of HSPG(act) and HSPG(inact) were isolated by treatment with Flavobacterium heparitinase and purification by ion-exchange chromatography. The molecular sizes of the core proteins were established by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and their primary structures were examined by cleavage with trypsin or endopeptidase Glu-C as well as separation of peptides by reverse-phase high performance liquid chromatography. The results showed that both sets of core proteins exhibited three major components with molecular sizes of 50, 30, and 25 kDa, respectively. The 25-kDa species appears to be a proteolytic degradation product of the 30-kDa species. The peptide mapping revealed that HSPG(act) and HSPG(inact) possess extremely similar core proteins.	MIT,DEPT BIOL,E25-229,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139; UNIV FLORIDA,COLL DENT,DEPT PERIODONT,GAINESVILLE,FL 32610; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02215	Massachusetts Institute of Technology (MIT); State University System of Florida; University of Florida; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Kojima, Tetsuhito/I-6271-2014	Kojima, Tetsuhito/0000-0002-1905-1065	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484, P01HL033014] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41484, HL33014] Funding Source: Medline; NIDCR NIH HHS [DE07010] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DEAGOSTINI A, 1991, THROMB HAEMOSTASIS, V65, P875; HOPWOOD J, 1976, FEBS LETT, V69, P51, DOI 10.1016/0014-5793(76)80651-5; JACOBSSON I, 1979, BIOCHEM J, V179, P77, DOI 10.1042/bj1790077; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU HK, 1980, J BIOL CHEM, V255, P5885; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; Linker A., 1972, METHODS ENZYMOL, P902; MARCUM JA, 1985, BIOCHEM BIOPH RES CO, V126, P365, DOI 10.1016/0006-291X(85)90615-1; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1984, BIOCHEMISTRY-US, V23, P1730, DOI 10.1021/bi00303a023; MARCUM JA, 1986, AM J PHYSIOL, V250, pH879, DOI 10.1152/ajpheart.1986.250.5.H879; MARCUM JA, 1983, AM J PHYSIOL, V245, pH725, DOI 10.1152/ajpheart.1983.245.5.H725; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; ROSENBERG JS, 1975, J BIOL CHEM, V250, P1607; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; ROSENBERG RD, 1978, P NATL ACAD SCI USA, V75, P3065, DOI 10.1073/pnas.75.7.3065; ROSENBERG RD, 1985, REV HEMATOLOGY, P351; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; STONE K, 1988, PROTEIN SEQUENCE MIC; SWANN DA, 1966, BIOCHIM BIOPHYS ACTA, V130, P112, DOI 10.1016/0304-4165(66)90014-6	31	140	140	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4859	4869						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537864				2022-12-27	WOS:A1992HF64200085
J	DANIEL, H; MORSE, EL; ADIBI, SA				DANIEL, H; MORSE, EL; ADIBI, SA			DETERMINANTS OF SUBSTRATE AFFINITY FOR THE OLIGOPEPTIDE/H+ SYMPORTER IN THE RENAL BRUSH-BORDER MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDE TRANSPORT-SYSTEM; SMALL-INTESTINE; PEPTIDE-TRANSPORT; HUMAN JEJUNUM; AMINO-ACIDS; RAT; VESICLES; RABBIT; GLYCYLSARCOSINE; ABSORPTION	We and others have shown previously the existence of high and low affinity systems for oligopeptide transport in kidney brush border membrane vesicles (BBMV). In the present study we investigated the relationship between the structure of substrates and their affinity for interaction with the high-affinity oligopeptide/H+ transporter in kidney BBMV. Based on competition experiments using [H-3]Gly-Gln as a probe we determined the K(i) values for more than 60 selected peptides. For a high-affinity interaction with the carrier site the following structural features of substrates are required: (a) both a free amino and carboxyl terminus; (b) the amino group and peptide bond nitrogen located in the alpha-position; (c) a trans peptide bond rather than the cis configuration; (d) L-alpha-amino acid isomers in both COOH and NH2 termini, although D-isomers of hydrophobic amino acids are acceptable in the NH2 terminus; and (e) a backbone of < 3 amino acid residues. A striking finding of the present study is that, for peptides satisfying these minimal structural requirements, the primary determinant of affinity is hydrophobicity. The fact that there is a highly significant (p < 0.001) correlation between K(i) and hydrophobicity allows the prediction of the affinity for any di- or tripeptide composed of alpha-amino acids in the L-form.	UNIV PITTSBURGH, SCH MED, CLIN NUTR RES UNIT, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, SCH MED, DEPT MED, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Daniel, Hannelore/B-8982-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015861] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-15861] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE M, 1987, J PHYSIOL-LONDON, V394, P481, DOI 10.1113/jphysiol.1987.sp016882; ABUMRAD NN, 1989, AM J PHYSIOL, V257, pE228, DOI 10.1152/ajpendo.1989.257.2.E228; ADDISON JM, 1975, CLIN SCI MOL MED, V49, P305, DOI 10.1042/cs0490305; ADIBI SA, 1977, J CLIN INVEST, V60, P1008, DOI 10.1172/JCI108851; ADIBI SA, 1974, J CLIN INVEST, V53, P1368, DOI 10.1172/JCI107685; ASATOOR AM, 1973, CLIN SCI MOL MED, V45, P199, DOI 10.1042/cs0450199; BOYD CAR, 1982, J PHYSIOL-LONDON, V324, P411, DOI 10.1113/jphysiol.1982.sp014121; BURSTON D, 1990, CLIN SCI, V79, P267, DOI 10.1042/cs0790267; BURSTON D, 1979, BIOCHIM BIOPHYS ACTA, V553, P175, DOI 10.1016/0005-2736(79)90039-7; BURSTON D, 1972, CLIN SCI, V43, P823, DOI 10.1042/cs0430823; CHRISTENSEN HN, 1975, BIOL TRANSPORT; DANIEL H, 1991, J BIOL CHEM, V266, P19917; Delange R. J., 1971, ENZYMES, VIII, P81; GANAPATHY V, 1984, J BIOL CHEM, V259, P8954; GANAPATHY V, 1982, BIOCHIM BIOPHYS ACTA, V691, P362, DOI 10.1016/0005-2736(82)90427-8; GANAPATHY V, 1985, BIOCHIM BIOPHYS ACTA, V816, P234, DOI 10.1016/0005-2736(85)90490-0; GANAPATHY V, 1981, J BIOL CHEM, V256, P118; HANSCH C, 1973, J MED CHEM, V16, P1207, DOI 10.1021/jm00269a003; INUI KI, 1984, BIOCHIM BIOPHYS ACTA, V769, P449, DOI 10.1016/0005-2736(84)90329-8; JAKUBKE HD, 1982, AMINOSAUREN PEPTIDE; KIM YS, 1974, BIOCHIM BIOPHYS ACTA, V370, P283, DOI 10.1016/0005-2744(74)90053-9; KRAMER W, 1988, BIOCHIM BIOPHYS ACTA, V939, P167, DOI 10.1016/0005-2736(88)90059-4; MIYAMOTO Y, 1988, BIOCHEM J, V249, P247, DOI 10.1042/bj2490247; Neame K. D., 1972, ELEMENTARY KINETICS; SILBERNAGL S, 1987, AM J PHYSIOL, V253, pF448, DOI 10.1152/ajprenal.1987.253.3.F448; SKOPICKI HA, 1991, AM J PHYSIOL, V261, pF670, DOI 10.1152/ajprenal.1991.261.4.F670; SMITHSON KW, 1977, J CLIN INVEST, V60, P665, DOI 10.1172/JCI108818; TIRUPPATHI C, 1990, J BIOL CHEM, V265, P14870; TIRUPPATHI C, 1990, BIOCHEM J, V268, P27, DOI 10.1042/bj2680027; TIRUPPATHI C, 1987, PEDIATR RES, V22, P641; WILSON D, 1989, BIOCHIM BIOPHYS ACTA, V986, P123, DOI 10.1016/0005-2736(89)90280-0; [No title captured]	32	95	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9565	9573						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577796				2022-12-27	WOS:A1992HT96500021
J	PANGBURN, MK				PANGBURN, MK			SPONTANEOUS REFORMATION OF THE INTRAMOLECULAR THIOESTER IN COMPLEMENT PROTEIN C3 AND LOW-TEMPERATURE CAPTURE OF A CONFORMATIONAL INTERMEDIATE CAPABLE OF REFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD COMPONENT; PUTATIVE THIOESTER; COVALENT-BINDING; SENSITIVE SITE; 4TH COMPONENT; NATIVE C-3; PATHWAY; ALPHA-2-MACROGLOBULIN; BOND; METHYLAMINE	Three human plasma proteins contain intramolecular thioester bonds: complement components C3 and C4 and alpha-2-macroglobulin. Their thioesters form when glutamine and cysteine residues react in the newly translated proteins and ammonia is released. We have reversed this reaction by treating C3 with ammonia to cleave the thioester and reform the original Gln and Cys. Thioester scission initiates a multistep conformational transition. One intermediate was sufficiently stable to be isolated by high performance liquid chromatography. It lacked native C3 functions and was shown to contain one free sulfhydryl group. Incubation of this ammonia-inactivated C3 intermediate in the absence of ammonia resulted in refolding to a native C3 conformation and recovery of thioester-dependent functions, as evidenced by: 1) return of hemolytic function, 2) return of autolytic cleavage of the alpha-chain, and 3) return of the ability to attach to surfaces during complement activation. Refolding and thioester reformation were dependent on a free SH group and were inhibited by HgCl2 and other thiol-specific reagents. Incubation of ammonia-inactivated C3 at 25-degrees-C at pH 7.4 resulted in recovery of 70% of the original C3 function. Refolding and thioester reformation exhibited a Gibbs free energy of +5.2 kcal/mol and were favored over unfolding to the final inactive form. During reformation of native C3 from (CH3NH2)-C-14-treated C3, return of the native conformation was accompanied by release of radiolabel from the protein and return of hemolytic complement function. These results suggest that folding of C3 provides both the energy and environment necessary to react the Gln and Cys residues, release ammonia, and form the thioester bond.			PANGBURN, MK (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,TYLER,TX 75710, USA.				NIDDK NIH HHS [DK-35081] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035081, R01DK035081] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHRISTOPHERSON RI, 1983, METHOD ENZYMOL, V91, P278; FEINMAN RD, 1983, ANN NY ACAD SCI, V421, P1; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GEE AP, 1983, METHOD ENZYMOL, V93, P339; Gordon J, 1926, BIOCHEM J, V20, P1028, DOI 10.1042/bj0201028; GORSKI JP, 1980, J BIOL CHEM, V255, P25; GOTZE O, 1971, J EXP MED, V134, pS90; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; HOWARD JB, 1980, J BIOL CHEM, V255, P7082; HOWARD JB, 1980, J BIOL CHEM, V255, P3820; IIJIMA M, 1984, J BIOCHEM-TOKYO, V96, P1539, DOI 10.1093/oxfordjournals.jbchem.a134983; ISAAC L, 1991, Complement and Inflammation, V8, P166; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; ISENMAN DE, 1984, J IMMUNOL, V132, P3019; ISENMAN DE, 1980, J IMMUNOL, V125, P1798; JANATOVA J, 1980, BIOCHEMISTRY-US, V19, P4471; JANATOVA J, 1981, BIOCHEMISTRY-US, V20, P2394, DOI 10.1021/bi00512a005; KHAN SA, 1982, J BIOL CHEM, V257, P1864; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW S K A, 1991, Complement and Inflammation, V8, P181; LAW SK, 1980, P NATL ACAD SCI-BIOL, V77, P7194, DOI 10.1073/pnas.77.12.7194; LAW SK, 1979, J IMMUNOL, V123, P1388; LAW SKA, 1981, BIOCHEMISTRY-US, V20, P7457, DOI 10.1021/bi00529a020; LAW SKA, 1990, BIOCHEM SOC T, V18, P1155; LEVINE RP, 1989, CURR TOP MICROBIOL I, V153, P73; OSTERBERG R, 1989, EUR J BIOCHEM, V183, P507, DOI 10.1111/j.1432-1033.1989.tb21078.x; PANGBURN MK, 1980, J EXP MED, V152, P1102, DOI 10.1084/jem.152.4.1102; PANGBURN MK, 1987, J IMMUNOL METHODS, V102, P7, DOI 10.1016/S0022-1759(87)80003-0; PANGBURN MK, 1983, BIOCHEMISTRY-US, V22, P178, DOI 10.1021/bi00270a026; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; PANGBURN MK, 1983, J IMMUNOL, V131, P1930; PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856; Pillemer L, 1941, J IMMUNOL, V40, P89; REILLY B D, 1991, Complement and Inflammation, V8, P215; SIM RB, 1981, BIOCHEM J, V193, P115, DOI 10.1042/bj1930115; SJOBERG M, 1991, EUR J BIOCHEM, V197, P61, DOI 10.1111/j.1432-1033.1991.tb15882.x; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STOOPS JK, 1991, COMPLEMENT INFLAMMAT, V8, P226; SWENSON RP, 1979, P NATL ACAD SCI USA, V76, P4313, DOI 10.1073/pnas.76.9.4313; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764	41	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8584	8590						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569104				2022-12-27	WOS:A1992HQ18500094
J	SPORMANN, DO; HEIM, J; WOLF, DH				SPORMANN, DO; HEIM, J; WOLF, DH			BIOGENESIS OF THE YEAST VACUOLE (LYSOSOME) - THE PRECURSOR FORMS OF THE SOLUBLE HYDROLASE CARBOXYPEPTIDASE-YSCS ARE ASSOCIATED WITH THE VACUOLAR MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DICTYOSTELIUM-DISCOIDEUM; ENDOPLASMIC-RETICULUM; ALKALINE-PHOSPHATASE; PROTEIN-DEGRADATION; SOLE COMPARTMENTS; SECRETORY PATHWAY; ACID-PHOSPHATASE; ESCHERICHIA-COLI; PEP4 GENE	We have studied the structure, biosynthesis, intracellular routing, and vacuolar localization of carboxypeptidase yscS in the yeast Saccharomyces cerevisiae. Nondenaturing polyacrylamide gel electrophoresis revealed two forms of carboxypeptidase yscS with different electrophoretic mobility. Antibodies specific for carboxypeptidase yscS recognized two glycoproteins of 77- and 74-kDa apparent molecular mass which differ by one N-linked carbohydrate residue. Both observations suggest that carboxypeptidase yscS exists in two catalytically active forms. The enzyme was found to be synthesized as two active high molecular mass precursor forms which are converted to the mature forms with a half-time of 20 min. The mature forms of carboxypeptidase yscS appeared soluble in the vacuolar lumen, while the precursor proteins accumulated tightly associated with the vacuolar membrane. The single hydrophobic domain present at the N terminus is believed to be responsible for the membrane association of the precursor molecules. Double mutants defective in proteinase yscA and proteinase yscB synthesize solely the carboxypeptidase yscS precursor forms. Correct proteolytic cleavage of the precursor forms was performed using purified proteinase yscB in vitro. Sec61, sec18, and sec7 mutants, conditionally defective in the secretory pathway, accumulate carboxypeptidase yscS precursor protein. Thus the carboxypeptidase yscS precursor molecules are delivered to the vacuole in a membrane bound form via the secretory pathway. After assembly into the vacuolar membrane, proteinase yscB presumably cleaves the precursor molecules to release soluble carboxypeptidase yscS forms into the lumen of the vacuole. The proposed mechanism is different from the delivery mechanism found for the other soluble vacuolar hydrolases in yeast.	UNIV STUTTGART,INST BIOCHEM,PFAFFENWALDRING 55,W-7000 STUTTGART 80,GERMANY; CIBA GEIGY AG,BIOTECHNOL ABT,CH-4002 BASEL,SWITZERLAND	University of Stuttgart; Novartis								Achstetter T, 1985, Yeast, V1, P139, DOI 10.1002/yea.320010203; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BERNSTEIN M, 1989, MOL CELL BIOL, V9, P1191, DOI 10.1128/MCB.9.3.1191; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLACHLYDYSON E, 1987, J CELL BIOL, V104, P1183, DOI 10.1083/jcb.104.5.1183; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BORDALLO J, 1991, FEBS LETT, V283, P27, DOI 10.1016/0014-5793(91)80546-F; BUELL G, 1985, NUCLEIC ACIDS RES, V13, P1923, DOI 10.1093/nar/13.6.1923; CARDELLI JA, 1986, J CELL BIOL, V102, P1264, DOI 10.1083/jcb.102.4.1264; CARDELLI JA, 1987, METHOD CELL BIOL, V28, P139; CHANG YH, 1989, J BIOL CHEM, V264, P6979; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; EBERT DL, 1989, J CELL BIOL, V109, P1445, DOI 10.1083/jcb.109.4.1445; EMTER O, 1984, FEBS LETT, V166, P321, DOI 10.1016/0014-5793(84)80104-0; FERRONOVICK S, 1984, J CELL BIOL, V98, P35, DOI 10.1083/jcb.98.1.35; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647; HASILIK A, 1978, EUR J BIOCHEM, V85, P599, DOI 10.1111/j.1432-1033.1978.tb12275.x; Hayashi R, 1976, Methods Enzymol, V45, P568; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; HERRERO E, 1988, Microbiologia (Madrid), V4, P73; HIRSCH HH, 1992, EUR J BIOCHEM, V203, P641, DOI 10.1111/j.1432-1033.1992.tb16594.x; Hirsch HH., 1989, MOL CELL BIOL YEASTS, P134; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONES EW, 1989, UCLA S CELLULAR PROT, P141; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOMINAMI E, 1981, BIOCHIM BIOPHYS ACTA, V661, P124, DOI 10.1016/0005-2744(81)90091-7; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; MATILE P, 1967, ARCH MIKROBIOL, V56, P148, DOI 10.1007/BF00408765; MECHLER B, 1988, EMBO J, V7, P1705, DOI 10.1002/j.1460-2075.1988.tb02999.x; MECHLER B, 1982, J BIOL CHEM, V257, P1203; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; MIERENDORF RC, 1985, J CELL BIOL, V100, P1777, DOI 10.1083/jcb.100.5.1777; MOEHLE CM, 1989, J CELL BIOL, V108, P309, DOI 10.1083/jcb.108.2.309; MOEHLE CM, 1987, GENETICS, V115, P255; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PLANKERT U, 1991, EUR J BIOCHEM, V196, P191, DOI 10.1111/j.1432-1033.1991.tb15803.x; POHLMANN R, 1988, EMBO J, V7, P2343, DOI 10.1002/j.1460-2075.1988.tb03078.x; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUPP S, 1991, FEBS LETT, V293, P62, DOI 10.1016/0014-5793(91)81153-Y; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIFFER H H, 1990, Yeast, V6, pS479; SPORMANN DO, 1991, EUR J BIOCHEM, V197, P399, DOI 10.1111/j.1432-1033.1991.tb15924.x; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUMBLY RJ, 1983, J BACTERIOL, V156, P36, DOI 10.1128/JB.156.1.36-48.1983; VANDERWILDEN W, 1973, Z NATURFORSCH C, VC 28, P416; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WIEMKEN A, 1979, ARCH MICROBIOL, V123, P23, DOI 10.1007/BF00403499; WOLF DH, 1981, J BACTERIOL, V147, P418, DOI 10.1128/JB.147.2.418-426.1981; WOLF DH, 1977, EUR J BIOCHEM, V73, P553, DOI 10.1111/j.1432-1033.1977.tb11350.x; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIHISA T, 1990, J BIOL CHEM, V265, P22418; ZUBENKO GS, 1983, P NATL ACAD SCI-BIOL, V80, P510, DOI 10.1073/pnas.80.2.510	64	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8021	8029						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569061				2022-12-27	WOS:A1992HQ18500013
J	LINN, SC; KUDRYCKI, KE; SHULL, GE				LINN, SC; KUDRYCKI, KE; SHULL, GE			THE PREDICTED TRANSLATION PRODUCT OF A CARDIAC AE3 MESSENGER-RNA CONTAINS AN N-TERMINUS DISTINCT FROM THAT OF THE BRAIN AE3 CL-/HCO3- EXCHANGER - CLONING OF A CARDIAC AE3 CDNA, ORGANIZATION OF THE AE3 GENE, AND IDENTIFICATION OF AN ALTERNATIVE TRANSCRIPTION INITIATION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE TRANSPORT; ANION-EXCHANGER; BAND-3 GENE; SEQUENCES; PROMOTER; EXPRESSION; PROTEINS; KIDNEY; EFFICIENT; REGION	We have isolated cDNAs encoding a cardiac variant of the AE3 Cl-/HCO3- exchanger from a rat heart library. The predicted cardiac AE3 polypeptide is 1030 amino acids in length, while the AE3 variant expressed in brain consists of 1227 amino acids. The C-terminal 957 amino acids of both polypeptides are identical, but the cardiac protein contains a unique N-terminal sequence of 73 amino acids which replaces the first 270 amino acids of the brain form. To determine the genetic basis for the differences between the cardiac and brain AE3 variants, we isolated and characterized the rat gene. Exons 1-6 contain the 5'-untranslated sequence and the first 270 codons of the brain mRNA, while exons 7-23 contain the coding and 3'-untranslated sequences which are common to the brain and cardiac mRNAs. The 5'-untranslated and unique N-terminal coding sequences of the cardiac mRNA are contained within a single exon, termed C1, which forms part of the intron between exons 6 and 7 of the brain transcription unit. Primer extension and S1 nuclease protection assays demonstrate that transcription of the cardiac AE3 mRNA precursor is initiated within this intron. Therefore, alternative promoter and exon usage are involved in generation of the two AE3 mRNAs.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University of Cincinnati					NHLBI NIH HHS [HL41496] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; COX JV, 1988, MOL CELL BIOL, V8, P1327, DOI 10.1128/MCB.8.3.1327; DEMUTH DR, 1986, EMBO J, V5, P1205, DOI 10.1002/j.1460-2075.1986.tb04348.x; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; FUNDER J, 1976, J PHYSIOL-LONDON, V262, P679, DOI 10.1113/jphysiol.1976.sp011615; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUNN RB, 1973, J GEN PHYSIOL, V61, P185, DOI 10.1085/jgp.61.2.185; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KIM HRC, 1988, MOL CELL BIOL, V8, P4416, DOI 10.1128/MCB.8.10.4416; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; LEE BS, 1991, J BIOL CHEM, V266, P11448; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LOW PS, 1989, ANION TRANSPORT PROT, P103; Maniatis T., 1982, MOL CLONING; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NEWMAN PR, 1990, DNA CELL BIOL, V9, P749, DOI 10.1089/dna.1990.9.749; NIKOVITS W, 1986, NUCLEIC ACIDS RES, V14, P3377, DOI 10.1093/nar/14.8.3377; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VAUGHANJONES RD, 1982, INTRACELLULAR PH ITS, P239; WERNKE GR, 1988, BIOPHYS J, V55, P390	41	95	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7927	7935						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560021				2022-12-27	WOS:A1992HN48500101
J	QUINN, MT; MULLEN, ML; JESAITIS, AJ				QUINN, MT; MULLEN, ML; JESAITIS, AJ			HUMAN NEUTROPHIL CYTOCHROME-B CONTAINS MULTIPLE HEMES - EVIDENCE FOR HEME ASSOCIATED WITH BOTH SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; PLASMA-MEMBRANE; HUMAN-GRANULOCYTES; CHLOROPLAST CYTOCHROME-B-559; RADIATION INACTIVATION; CHROMOSOMAL LOCATION; LIGHT CHAIN; SUPEROXIDE; GENE	Human phagocyte cytochrome b is the terminal component of the microbicidal superoxide generating system. Although the primary structure of this protein has been determined, little is known about the placement of the heme prosthetic groups in this heterodimeric integral membrane protein. Analysis of the cytochrome using lithium dodecyl sulfate-polyacrylamide gel electrophoresis at 0-degrees-C followed by tetramethylbenzidine heme staining demonstrated the presence of heme in both the 91- and 22-kDa subunits identified by Western blot analysis using peptide specific antisera. Exposure of cytochrome b (purified or in isolated neutrophil plasma membranes) to Staphylococcal protease V8 or trypsin did not affect absorbance spectra. However, such treatment resulted in degradation of both subunits to smaller fragments, including characteristic immunoreactive 20-kDa fragments of both the large and small subunits of the cytochrome that retained one or both of the hemes. The spectral stability to proteolysis and size of the proteolytic heme-containing fragments generated explains previous reports which suggested that the heme resided in the small subunit. Our current results indicate that human neutrophil cytochrome b is a bi-heme or possibly tri-heme molecule with at least one heme residing in the large subunit and one shared between both subunits and that the heme-containing regions of the cytochrome probably lie within the membrane lipid bilayer. Such a multi-heme structure would be consistent with an electron transfer function for this cytochrome by providing an efficient mechanism for transferring electrons across the plasma membrane to the extracellular surface where oxygen could be reduced to create superoxide.			QUINN, MT (corresponding author), MONTANA STATE UNIV, DEPT CHEM & BIOCHEM, BOZEMAN, MT 59717 USA.			Jesaitis, Algirdas/0000-0001-9001-5617	PHS HHS [5R0126711] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BABCOCK GT, 1985, BIOCHEMISTRY-US, V24, P3638, DOI 10.1021/bi00335a036; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BABIOR BM, 1987, TRENDS BIOCHEM SCI, V12, P241, DOI 10.1016/0968-0004(87)90118-6; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BEAUREGARD G, 1987, METHOD BIOCHEM ANAL, V32, P313; BELLAVITE P, 1988, FREE RADICAL BIO MED, V4, P225, DOI 10.1016/0891-5849(88)90044-5; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; BERATAN DN, 1991, MOL BASIS OXIDATIVE; BORREGAARD N, 1988, RESPIRATORY BURST IT, P1; BRAIN RD, 1977, PLANT PHYSIOL, V59, P948, DOI 10.1104/pp.59.5.948; CAUBERGS R, 1988, PLASMA MEMBRANE OXID, P273; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRANE FL, 1988, PLASMA MEMBRANE OXID, P1; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; CROSS AR, 1985, BIOCHEM J, V226, P881, DOI 10.1042/bj2260881; DELEPELAIRE P, 1979, P NATL ACAD SCI USA, V76, P111, DOI 10.1073/pnas.76.1.111; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; ESPOSTI MD, 1989, BIOCHIM BIOPHYS ACTA, V977, P249, DOI 10.1016/S0005-2728(89)80079-9; ESPOSTI MD, 1991, BIOCHIM BIOPHYS ACTA, V1056, P243; FUJII H, 1990, J BIOCHEM-TOKYO, V108, P292, DOI 10.1093/oxfordjournals.jbchem.a123196; GUIKEMA JA, 1981, BIOCHIM BIOPHYS ACTA, V637, P189, DOI 10.1016/0005-2728(81)90157-2; HERRMANN RG, 1984, FEBS LETT, V176, P239, DOI 10.1016/0014-5793(84)80949-7; HURST JK, 1991, J BIOL CHEM, V266, P1627; IIZUKA T, 1985, J BIOL CHEM, V260, P2049; JESAITIS AJ, 1977, PLANT PHYSIOL, V59, P941, DOI 10.1104/pp.59.5.941; JESAITIS AJ, 1990, J CLIN INVEST, V85, P821, DOI 10.1172/JCI114509; KEMPNER ES, 1989, METHOD ENZYMOL, V172, P410; KEMPNER ES, 1988, ADV ENZYMOL RAMB, V61, P107; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; LOW H, 1985, BIOCHIM BIOPHYS ACTA, V844, P142, DOI 10.1016/0167-4889(85)90084-9; LUTTER R, 1985, J BIOL CHEM, V260, P2237; MALECH HL, 1987, NEW ENGL J MED, V317, P687, DOI 10.1056/NEJM198709103171107; MAYO SL, 1986, SCIENCE, V233, P948, DOI 10.1126/science.3016897; MORRE DJ, 1986, PROTOPLASMA, V133, P195, DOI 10.1007/BF01304635; Morre DJ, 1988, PLASMA MEMBRANE OXID, P45; NUGENT JHA, 1989, BIOCHEM J, V264, P921, DOI 10.1042/bj2640921; PARKOS CA, 1985, J BIOL CHEM, V260, P6541; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, BIOCHIM BIOPHYS ACTA, V932, P71, DOI 10.1016/0005-2728(88)90140-5; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PEMBER SO, 1984, J BIOL CHEM, V259, P590; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1978, NATURE, V276, P515, DOI 10.1038/276515a0; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; TAE GS, 1988, BIOCHEMISTRY-US, V27, P9075, DOI 10.1021/bi00426a002; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; UENO I, 1991, FEBS LETT, V281, P130, DOI 10.1016/0014-5793(91)80375-D; WIDGER WR, 1985, FEBS LETT, V191, P186, DOI 10.1016/0014-5793(85)80005-3; WIDGER WR, 1984, J BIOL CHEM, V259, P3870; YAMAGUCHI T, 1989, J BIOL CHEM, V264, P112	56	95	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7303	7309						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559974				2022-12-27	WOS:A1992HN48500019
J	CHAO, W; LIU, HL; HANAHAN, DJ; OLSON, MS				CHAO, W; LIU, HL; HANAHAN, DJ; OLSON, MS			PLATELET-ACTIVATING FACTOR-STIMULATED PROTEIN TYROSINE PHOSPHORYLATION AND EICOSANOID SYNTHESIS IN RAT KUPFFER CELLS - EVIDENCE FOR CALCIUM-DEPENDENT AND PROTEIN-KINASE C-DEPENDENT AND C-INDEPENDENT PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; HUMAN-NEUTROPHILS; PHOSPHATIDIC-ACID; RABBIT PLATELETS; HORSE PLATELETS; FACTOR RECEPTOR; GROWTH-FACTOR; BINDING; CA-2+; MECHANISM	The lipid mediator platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, AGEPC) has been shown to elicit several important biochemical signaling responses in mammalian cells, including polyphosphoinositide hydrolysis, arachidonic acid release/eicosanoid production, and protein tyrosine phosphorylation. In the present study, the roles of Ca2+ and protein kinase C (PKC), two signaling components of the phospholipase C pathway, in AGEPC-stimulated eicosanoid production and protein tyrosine phosphorylation, were investigated in cultured rat Kupffer cells. AGEPC at nanomolar concentrations induced an increase in intracellular calcium concentration ([Ca2+]i), stimulated membrane PKC activity, and resulted in protein tyrosine phosphorylation. The maximal increase in [Ca2+]i and membrane PKC activity in response to AGEPC were observed within 30-50 s, whereas the AGEPC-induced protein tyrosine phosphorylation reached maximal levels within 2-5 min. [Ethylenebis(oxyethylenenitrilo)]tetraacetic acid (EGTA) but not 8-(N,N-diethylamino)-octyl-3,4,5-trimethoxybenzoate hydrochloride (TMB-8), an inhibitor of calcium release from intracellular compartments, nearly abolished the AGEPC-induced increase in [Ca2+]i suggesting involvement of extracellular calcium influx in this event. Both EGTA and TMB-8 abolished or inhibited AGEPC-stimulated protein tyrosine phosphorylation and eicosanoid formation, respectively. The calcium ionophore A23187 alone stimulated eicosanoid production and protein tyrosine phosphorylation with an identical pattern to that of AGEPC. Phorbol myristate acetate (PMA), an activator of PKC, which did not affect [Ca2+]i, mimicked the actions of AGEPC, stimulating eicosanoid production and promoting tyrosine phosphorylation of a set of proteins similar to those phosphorylated following AGEPC stimulation. AGEPC-enhanced tyrosine phosphorylation of some of the protein substrates and eicosanoid production were inhibited in cells "down-regulated" for PKC. Furthermore, both PMA- and AGEPC-stimulated eicosanoid production and protein tyrosine phosphorylation were attenuated or abolished by at least one of the PKC inhibitors, staurosporine, and calphostin C. Taken together, these results are consistent with the conclusions that: (a) AGEPC stimulates the phospholipase-mediated arachidonic acid release/eicosanoid synthesis cascade and protein tyrosine phosphorylation through extracellular Ca2+-dependent and PKC-dependent and -independent mechanisms(s) and (b) the Ca2+-PKC interaction determines the efficacy of the AGEPC-stimulated cellular events.			CHAO, W (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284, USA.			Chao, Wei/0000-0002-2505-1360	NIDDK NIH HHS [DK-33538] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033538] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL RM, 1991, J BIOL CHEM, V266, P4661; BERKOW RL, 1990, BLOOD, V75, P2445; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BILLAH MM, 1983, P NATL ACAD SCI-BIOL, V80, P965, DOI 10.1073/pnas.80.4.965; BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P1194, DOI 10.1016/0006-291X(79)91163-X; BOUNVENTRE JV, 1988, J CLIN INVEST, V82, P168; BRAQUET P, 1987, PHARMACOL REV, V39, P97; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHAO W, 1989, J BIOL CHEM, V264, P13591; CHAO W, 1990, ARCH BIOCHEM BIOPHYS, V282, P188, DOI 10.1016/0003-9861(90)90103-6; CHAO W, 1989, J BIOL CHEM, V264, P20448; CHIOU CY, 1975, BRIT J PHARMACOL, V53, P279, DOI 10.1111/j.1476-5381.1975.tb07359.x; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DHAR A, 1990, MOL PHARMACOL, V37, P519; DOMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FISHER RA, 1989, FEBS LETT, V251, P22, DOI 10.1016/0014-5793(89)81421-8; FORCE T, 1991, J BIOL CHEM, V266, P6650; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GRIESS G, 1990, 1ST P INT C EL TEAN, P86; GROSS JL, 1990, BIOCHEM PHARMACOL, V40, P343, DOI 10.1016/0006-2952(90)90697-J; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GRYNKIEWICZ G, 1990, J BIOL CHEM, V265, P18234; HANAHAN DJ, 1980, J BIOL CHEM, V255, P5514; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HOUSLAY MD, 1986, BIOCHEM J, V234, P737, DOI 10.1042/bj2340737; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HWANG SB, 1990, J LIPID MEDIATOR, V2, P123; HWANG SB, 1986, J BIOL CHEM, V261, P532; JIANG W, 1990, J CELL BIOL, V110, P1049, DOI 10.1083/jcb.110.4.1049; KADIRI C, 1990, MOL PHARMACOL, V38, P418; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KNOOK DL, 1976, EXP CELL RES, V99, P444, DOI 10.1016/0014-4827(76)90605-4; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1982, J BIOL CHEM, V257, P7314; LEEBLUNDBERG FLM, 1991, J BIOL CHEM, V266, P7746; NAKASHIMA S, 1989, J IMMUNOL, V143, P1295; NISHIZUKA Y, 1989, ANNU REV BIOCHEM, V58, P31; OFLAHERTY JT, 1990, J BIOL CHEM, V265, P21619; OFLAHERTY JT, 1989, J BIOL CHEM, V264, P6836; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SHUKLA SD, 1982, BIOCHEM BIOPH RES CO, V106, P697, DOI 10.1016/0006-291X(82)91767-3; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; TAO W, 1989, BIOCHEM J, V257, P633, DOI 10.1042/bj2570633; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRILIVAS I, 1989, J BIOL CHEM, V264, P3102; WEISS BA, 1991, J BIOL CHEM, V266, P2126; WHATLEY RE, 1989, J BIOL CHEM, V264, P6326; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0; YAMAZAKI M, 1989, P NATL ACAD SCI USA, V86, P5791, DOI 10.1073/pnas.86.15.5791	55	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6725	6735						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551880				2022-12-27	WOS:A1992HM05300042
J	NESBITT, JE; FULLER, GM				NESBITT, JE; FULLER, GM			DYNAMICS OF INTERLEUKIN-6 INTERNALIZATION AND DEGRADATION IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							STIMULATORY FACTOR-II; GROWTH-FACTOR; CELLS; RECEPTORS; PROTEIN	We have investigated the dissociation, internalization, and degradation of I-125-interleukin-6 (I-125-IL-6) by primary rat hepatocytes. Temperature shift experiments following saturation binding of I-125-IL-6 to cell surface receptors in hepatocytes showed a rapid loss of surface-bound I-125-IL-6 (t1/2 = 15 min), concomitant with a rapid rise in internalized radiolabeled ligand. After reaching a maximum by 30 min at 37-degrees-C, the level of internalized I-125-IL-6 decreased with time and appeared in the culture media in a non-trichloroacetic acid-precipitable (degraded) state. The addition of the lysosomotropic agent chloroquine inhibited this receptor-mediated degradation of IL-6 without affecting ligand internalization. Polyacrylamide gel electrophoresis analysis of internalized I-125-IL-6 confirms these results. Additionally, we show that the IL-6-IL-6 receptor complex is stable, and dissociation of these two molecular species occurs at a pH below 5.0. In contrast to published results, data presented in this study clearly indicate that IL-6 is rapidly internalized and degraded within hepatocytes by a receptor-mediated mechanism.	UNIV ALABAMA, DEPT CELL BIOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043155] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43155] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CASTELL J, 1990, EUR J BIOCHEM, V189, P113, DOI 10.1111/j.1432-1033.1990.tb15466.x; CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; FULLER GM, 1988, METHOD ENZYMOL, V163, P474; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GRENETT HE, 1991, GENE, V101, P267, DOI 10.1016/0378-1119(91)90422-8; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NESBITT JE, 1992, MOL BIOL CELL, V3, P103, DOI 10.1091/mbc.3.1.103; ROSEJOHN S, 1991, J BIOL CHEM, V266, P3841; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SNYERS L, 1989, ANN NY ACAD SCI, V557, P388; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; VANSNICK J, 1987, J EXP MED, V165, P641, DOI 10.1084/jem.165.3.641; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253	25	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5739	5742						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556093				2022-12-27	WOS:A1992HK31800005
J	RODNICK, KJ; SLOT, JW; STUDELSKA, DR; HANPETER, DE; ROBINSON, LJ; GEUZE, HJ; JAMES, DE				RODNICK, KJ; SLOT, JW; STUDELSKA, DR; HANPETER, DE; ROBINSON, LJ; GEUZE, HJ; JAMES, DE			IMMUNOCYTOCHEMICAL AND BIOCHEMICAL-STUDIES OF GLUT4 IN RAT SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATABLE GLUCOSE TRANSPORTER; PLASMA-MEMBRANE; INSULIN ACTION; TRANSVERSE TUBULES; VESICLES; PROTEINS; TRANSLOCATION; ADIPOCYTES; CELLS; IDENTIFICATION	In muscle and adipocytes, glucose transport is regulated by the translocation of insulin regulatable glucose transporters (GLUT4) between an intracellular compartment and the cell surface. In these studies we have characterized the cellular compartments containing GLUT4 in rat skeletal muscle. Immunocytochemical studies showed that in unstimulated muscle, GLUT4 was not present in surface membranes. Tubulo-vesicular structures clustered in the trans Golgi reticulum were enriched in GLUT4. GLUT4 underwent translocation to the sarcolemma in response to combined stimulation with insulin and exercise. Using immunoisolation, the intracellular GLUT4 vesicles (IRGTV) were purified 300-fold over the cell homogenate. IRGTV from unstimulated muscle were not enriched in markers specific for the sarcolemma, transverse tubules, sarcoplasmic reticulum or mitochondria; this was confirmed using gel filtration chromatography. Insulin resulted in a 40% decrease in GLUT4 levels in IRGTV confirming that this represents the intracellular compartment of GLUT4. GLUT4 is a major component of the IRGTV, constituting at least 5% of total vesicle protein. A subset of polypeptides are also markedly enriched in the muscle IRGTV. In conclusion, these data suggest that translocation of GLUT4 from intracellular tubulo-vesicular structures is the major mechanism by which insulin and exercise regulate muscle glucose transport.	WASHINGTON UNIV,SCH MED,DEPT PHYSIOL & CELL BIOL,BOX 8228,660 S EUCLID AVE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63110; UNIV UTRECHT,SCH MED,DEPT CELL BIOL,3584 CX UTRECHT,NETHERLANDS	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Utrecht University				James, David/0000-0001-5946-5257	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042503, R01DK018986] Funding Source: NIH RePORTER; NIA NIH HHS [AG-00078] Funding Source: Medline; NIDDK NIH HHS [DK-42503, DK-18986] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERS GK, 1967, J BIOL CHEM, V242, P3237; BALDINI G, 1991, J BIOL CHEM, V266, P4037; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CURTISPR.PB, 1969, DIABETOLOGIA, V5, P384, DOI 10.1007/BF00427976; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DECURTIS I, 1989, CELL, V58, P719, DOI 10.1016/0092-8674(89)90106-2; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; FRIEDMAN JE, 1991, DIABETES, V40, P150, DOI 10.2337/diabetes.40.1.150; GERHART DZ, 1989, J NEUROSCI RES, V22, P464, DOI 10.1002/jnr.490220413; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; Hales C N, 1980, Methods Enzymol, V70, P334; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HOLLOSZY JO, 1965, J BIOL CHEM, V240, P3493; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, BIOCHEM J, V256, P725, DOI 10.1042/bj2560725; JAMES DE, 1985, AM J PHYSIOL, V248, pE567, DOI 10.1152/ajpendo.1985.248.5.E567; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1987, J BIOL CHEM, V262, P11817; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JORGENSEN AO, 1990, J CELL BIOL, V110, P1173, DOI 10.1083/jcb.110.4.1173; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; KONO T, 1961, ARCH BIOCHEM BIOPHYS, V93, P520, DOI 10.1016/S0003-9861(61)80046-5; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; NARAHARA HT, 1979, BIOCHIM BIOPHYS ACTA, V552, P247, DOI 10.1016/0005-2736(79)90281-5; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; REYNOLDS JA, 1983, ANAL BIOCHEM, V130, P471, DOI 10.1016/0003-2697(83)90618-8; SLOT JW, 1990, NATURE, V346, P369, DOI 10.1038/346369a0; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STERNLICHT E, 1988, AM J PHYSIOL, V254, pE633, DOI 10.1152/ajpendo.1988.254.5.E633; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	38	176	177	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6278	6285						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556135				2022-12-27	WOS:A1992HK31800084
J	CHEETHAM, JA; LARDY, HA				CHEETHAM, JA; LARDY, HA			BOVINE SPERMATOZOA INCORPORATE P-32(I) INTO ADP BY AN UNKNOWN PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYE-BINDING; NUCLEOTIDES; METABOLISM; MITOCHONDRIA; QUANTITATION; SEPARATION; THIOKINASE; SUCCINATE; PYRUVATE; MUSCLE	Intact ejaculated bovine sperm incorporate P-32(i) into ADP to a specific activity two to three times higher than into ATP. This contrasts with other cell types where ATP specific activity is higher than that of ADP. Predominant labeling of ADP may be partially due to compartmentation of ATP, but removal of cytosolic ATP does not change the relative labeling of ADP and ATP. Dilution of extracellular P-32(i) following labeling resulted in loss of 70% of label from ADP but only 50% loss from gamma-ATP at 26 min. ADP was labeled in the absence of detectable ATP in the presence of rotenone plus antimycin. Fractionation of ejaculated sperm yielded midpieces that are depleted of adenylate kinase and have coupled respiration. ATP was labeled with P-32(i), but ADP was not in midpieces. Evidence for mitochondrial substrate level phosphorylation-supported incorporation of P-32(i) into nucleotides was observed for intact sperm incubated with pyruvate and inhibitors of oxidative phosphorylation, but this activity did not occur in midpieces and does not appear to explain disproportionate labeling of ADP. We conclude that labeling of ADP in intact and permeabilized cells occurs by two pathways; one involves adenylate kinase, and the other is an unknown pathway which may be independent of ATP.	UNIV WISCONSIN,INST ENZYME RES,MADISON,WI 53705; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIADDK NIH HHS [AM10334] Funding Source: Medline; NIGMS NIH HHS [GM07215-12] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM010334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DA, 1986, FEBS LETT, V194, P171, DOI 10.1016/0014-5793(86)80071-0; BABCOCK DF, 1975, J BIOL CHEM, V250, P6488; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYGRAVE FL, 1967, P NATL ACAD SCI USA, V57, P1409, DOI 10.1073/pnas.57.5.1409; HAGIHARA B, 1960, J BIOL CHEM, V235, P889; HALANGK W, 1987, BIOCHIM BIOPHYS ACTA, V893, P100, DOI 10.1016/0005-2728(87)90153-8; HELDT HW, 1967, EUR J BIOCHEM, V1, P199, DOI 10.1111/j.1432-1033.1967.tb00064.x; HUTSON SM, 1977, J BIOL CHEM, V252, P1309; KHYM JX, 1975, CLIN CHEM, V21, P1245; LEVINSON C, 1971, J CELL PHYSIOL, V78, P257, DOI 10.1002/jcp.1040780213; LINDBERG O, 1950, EXP CELL RES, V1, P105, DOI 10.1016/0014-4827(50)90051-6; MORTON BE, 1967, BIOCHEMISTRY-US, V6, P57, DOI 10.1021/bi00853a011; OTTAWAY JH, 1981, INT J BIOCHEM, V13, P401, DOI 10.1016/0020-711X(81)90111-7; PAINTER GR, 1989, P NATL ACAD SCI USA, V86, P2239, DOI 10.1073/pnas.86.7.2239; PAYNE SM, 1982, ANAL BIOCHEM, V123, P151, DOI 10.1016/0003-2697(82)90636-4; REICH JG, 1968, EUR J BIOCHEM, V6, P384, DOI 10.1111/j.1432-1033.1968.tb00459.x; REIMANN EM, 1978, BIOCHIM BIOPHYS ACTA, V523, P516, DOI 10.1016/0005-2744(78)90054-2; ROSSI A, 1975, J MOL CELL CARDIOL, V7, P891, DOI 10.1016/0022-2828(75)90150-9; RUFFO A, 1962, BIOCHEM J, V85, P588, DOI 10.1042/bj0850588; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SCHOFF P K, 1987, Journal of Cell Biology, V105, p124A; SCHOFF PK, 1989, J BIOL CHEM, V264, P6086; SMITH CM, 1974, J BIOL CHEM, V249, P1497; SMITH MB, 1985, BIOL REPROD, V33, P1029, DOI 10.1095/biolreprod33.5.1029; TILL U, 1973, EUR J BIOCHEM, V35, P167, DOI 10.1111/j.1432-1033.1973.tb02822.x; TOKUMITSU Y, 1973, BIOCHIM BIOPHYS ACTA, V292, P325, DOI 10.1016/0005-2728(73)90039-X; VANDOP C, 1977, J BIOL CHEM, V252, P1303; VINCENT R, 1983, ANAL BIOCHEM, V135, P355, DOI 10.1016/0003-2697(83)90696-6; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300	29	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5186	5192						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544901				2022-12-27	WOS:A1992HH74700031
J	CHAO, FF; BLANCHETTEMACKIE, EJ; TERTOV, VV; SKARLATOS, SI; CHEN, YJ; KRUTH, HS				CHAO, FF; BLANCHETTEMACKIE, EJ; TERTOV, VV; SKARLATOS, SI; CHEN, YJ; KRUTH, HS			HYDROLYSIS OF CHOLESTERYL ESTER IN LOW-DENSITY-LIPOPROTEIN CONVERTS THIS LIPOPROTEIN TO A LIPOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; RICH LIPID PARTICLES; HUMAN AORTIC INTIMA; UNESTERIFIED CHOLESTEROL; DIFFERENT MECHANISMS; PLASMA-LIPOPROTEINS; CA++ ANTAGONISTS; PURIFICATION; HYDROLASE; LOCALIZATION	Previously, we isolated and characterized unique liposomal-like, cholesterol-rich lipid particles that accumulate in human atherosclerotic lesions. Human plasma low density lipoprotein (LDL) has a molar ratio of total cholesterol to phospholipid (3:1) similar to that of this lesion cholesterol-rich lipid particle. However, LDL is enriched in cholesteryl ester while the lesion lipid particle is enriched in unesterified cholesterol. To examine a possible precursor-product relationship between LDL and the lesion lipid particle, we hydrolyzed the cholesteryl ester core of LDL with cholesterol esterase. Cholesteryl ester hydrolysis occurred only after LDL was treated with trypsin. Trypsin pretreatment was not required for cholesteryl ester hydrolysis of LDL oxidized with copper, a treatment that also degrades apolipoprotein B, the major protein moiety in LDL. In contrast to greater than 90% hydrolysis of cholesteryl ester in trypsin-cholesterol esterase-treated or copper-oxidized LDL, there was only 18% hydrolysis of cholesteryl ester in similarly treated high density lipoprotein. With a limited 10-min hydrolysis of LDL cholesteryl ester, LDL-sized particles and newly formed larger flattened films or discs were present. With complete hydrolysis of LDL cholesteryl ester, LDL particles converted to complex multilamellar, liposomal-like, structures with sizes approximately five times larger than native LDL. These liposomal-like particles derived from LDL were chemically and structurally similar to unesterified cholesterol-rich lipid particles that accumulate in atherosclerotic lesions.	NHLBI,MOLEC DIS BRANCH,EXPTL ATHEROSCLEROSIS SECT,BLDG 10,RM 5N-113,BETHESDA,MD 20892; NIADDKD,CELLULAR & DEV BIOL LAB,BETHESDA,MD 20892; USSR CARDIOL RES CTR,INST EXPTL CARDIOL,MOSCOW,USSR	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Medical Research Center of Cardiology								ALAUPOVIC P, 1980, HDB ELECTROPHORESIS, V1, P27; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BOTCHER CJF, 1962, FED P S11, V21, P15; BUCK RC, 1951, AMA ARCH PATHOL, V51, P224; CARDIN AD, 1986, BIOCHEMISTRY-US, V25, P5258, DOI 10.1021/bi00366a041; CHAO FF, 1988, AM J PATHOL, V131, P73; CHAO FF, 1990, AM J PATHOL, V136, P169; CHAPMAN MJ, 1978, EUR J BIOCHEM, V87, P475, DOI 10.1111/j.1432-1033.1978.tb12398.x; Fiske CH, 1925, J BIOL CHEM, V66, P375; FOLCH J, 1957, J BIOL CHEM, V226, P497; FONG LG, 1987, J LIPID RES, V28, P1466; Fredrickson DS, 1972, METABOLIC BASIS INHE, P493; GAMBLE W, 1978, J LIPID RES, V19, P1068; GUYTON JR, 1989, AM J PATHOL, V134, P705; HATCH FT, 1968, PRACTICAL METHODS PL, P47; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Helwig J.T., 1979, SAS USERS GUIDE; HOFF HF, 1974, BIOCHIM BIOPHYS ACTA, V351, P407, DOI 10.1016/0005-2795(74)90205-0; HOFF HF, 1982, ATHEROSCLEROSIS, V42, P273, DOI 10.1016/0021-9150(82)90157-5; INSULL W, 1966, J CLIN INVEST, V45, P513, DOI 10.1172/JCI105365; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KATZ SS, 1980, J BIOL CHEM, V255, P9753; KHOO JC, 1979, J BIOL CHEM, V254, P1785; KOTHARI HV, 1975, LIPIDS, V10, P322, DOI 10.1007/BF02532453; KOTHARI HV, 1970, BIOCHIM BIOPHYS ACTA, V202, P325, DOI 10.1016/0005-2760(70)90194-3; KOTHARI HV, 1973, BIOCHIM BIOPHYS ACTA, V296, P446, DOI 10.1016/0005-2760(73)90102-1; KRUTH HS, 1984, AM J PATHOL, V114, P201; KRUTH HS, 1985, ATHEROSCLEROSIS, V57, P337, DOI 10.1016/0021-9150(85)90045-0; KRUTH HS, 1983, LAB INVEST, V50, P87; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NOBLE RP, 1968, J LIPID RES, V9, P693; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; ROBENEK H, 1988, ARTERIOSCLEROSIS, V8, P57, DOI 10.1161/01.ATV.8.1.57; RUDEL LL, 1986, J LIPID RES, V27, P465; SAKURADA T, 1976, BIOCHIM BIOPHYS ACTA, V424, P204; SCHMITZ G, 1988, ARTERIOSCLEROSIS, V8, P46, DOI 10.1161/01.ATV.8.1.46; SIMIONESCU N, 1986, AM J PATHOL, V123, P109; SMITH EB, 1972, LANCET, V1, P463; SMITH EB, 1970, ATHEROSCLEROSIS, V11, P417, DOI 10.1016/0021-9150(70)90021-3; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; WOLF AV, 1979, HDB CHEM PHYSICS, P227; 1984, JAMA-J AM MED ASSOC, V251, P365	43	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4992	4998						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537875				2022-12-27	WOS:A1992HF64200104
J	SIMMONS, WH; ORAWSKI, AT				SIMMONS, WH; ORAWSKI, AT			MEMBRANE-BOUND AMINOPEPTIDASE-P FROM BOVINE LUNG - ITS PURIFICATION, PROPERTIES, AND DEGRADATION OF BRADYKININ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY MICROVILLAR MEMBRANE; ECTO-ENZYMES; HUMAN-SERUM; PEPTIDASE; CLEAVAGE; SOLUBILIZATION; ASSAY; BOND	The membrane-bound form of aminopeptidase P (aminoacylprolyl-peptide hydrolase) (EC 3.4.11.9) was purified to apparent homogeneity from bovine lung microsomes. The enzyme was solubilized using phosphatidylinositol-specific phospholipase C (Bacillus thuringiensis), indicating that bovine lung aminopeptidase P is attached to membranes via a glycosylphosphatidylinositol anchor. The enzyme was purified 1900-fold with a yield of 25% by chromatography on decyl-agarose, omega-aminodecyl-agarose, a second decylagarose column, DEAE-Sephacel, and an ultrafiltration step. Native gradient polyacrylamide gel electrophoresis revealed a single stained protein band whose position in the gel corresponded to cleavage of the Arg1-Pro2 bond of bradykinin. The M(r) was 360,000 by gel permeation chromatography and 95,000 by reducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The substrate specificity of aminopeptidase P was determined using approximately 50 peptides with proline in the second position. The enzyme could hydrolyze lower NH2-terminal homologs of bradykinin, including Arg-Pro-Pro, which was used as the routine substrate in a rapid fluorescence assay performed in the absence of added Mn2+. Some peptides having NH2-terminal amino acids other than arginine were also cleaved. Aminopeptidase P appeared to favor peptides that had 2 proline residues or proline analogs in positions 2 and 3 of the substrate. In general, tripeptides having a single proline residue in position 2 were poor substrates. Aminopeptidase P was inhibited by a series of peptides, 3-8 residues long, having an NH2-terminal Pro-Pro sequence. The enzyme was also inhibited by metal-chelating agents, 2-mercaptoethanol (4 mM), p-chloromercuribenzenesulfonic acid, and NaCl at concentrations greater-than-or-equal-to 0.25 M. The purified enzyme had a pH optimum of 6.5-7.0 and was most stable in the basic pH range. A role for membrane-bound aminopeptidase P in the pulmonary inactivation of circulating bradykinin is proposed.	LOYOLA UNIV,STRITCH SCH MED,DEPT MOLEC & CELLULAR BIOCHEM,MAYWOOD,IL 60153	Loyola University Chicago								BAKER CRF, 1991, CIRC SHOCK, V33, P37; DEHM P, 1970, FEBS LETT, V9, P225, DOI 10.1016/0014-5793(70)80361-1; DEHM P, 1970, EUR J BIOCHEM, V17, P364, DOI 10.1111/j.1432-1033.1970.tb01174.x; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; FERREIRA SH, 1977, METABOLIC FUNCTIONS, P33; FLEMINGER G, 1982, EUR J BIOCHEM, V125, P609, DOI 10.1111/j.1432-1033.1982.tb06726.x; HARBECK HT, 1991, EUR J BIOCHEM, V198, P451, DOI 10.1111/j.1432-1033.1991.tb16035.x; HENDRIKS D, 1991, CLIN CHIM ACTA, V196, P87, DOI 10.1016/0009-8981(91)90061-G; HOLTZMAN EJ, 1987, ANAL BIOCHEM, V162, P476, DOI 10.1016/0003-2697(87)90423-4; HOOPER NM, 1990, BIOCHEM J, V267, P509, DOI 10.1042/bj2670509; HOOPER NM, 1988, FEBS LETT, V229, P340, DOI 10.1016/0014-5793(88)81152-9; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; LASCH J, 1988, FEBS LETT, V227, P171, DOI 10.1016/0014-5793(88)80891-3; LASCH J, 1986, BIOMED BIOCHIM ACTA, V45, P833; LIN LN, 1979, BIOCHEMISTRY-US, V18, P5037, DOI 10.1021/bi00590a002; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Orawski A T, 1989, Adv Exp Med Biol, V247B, P355; ORAWSKI AT, 1989, PEPTIDES, V10, P1063, DOI 10.1016/0196-9781(89)90191-5; ORAWSKI AT, 1987, MOL CELL BIOCHEM, V75, P123; ORAWSKI AT, 1983, FED PROC, V42, P257; REVANN TR, 1991, FASEB J, V5, pA1579; ROTH M, 1971, ANAL CHEM, V43, P880, DOI 10.1021/ac60302a020; RYAN J W, 1990, FASEB Journal, V4, pA999; RYAN JW, 1989, AM J PHYSIOL, V257, pL53, DOI 10.1152/ajplung.1989.257.2.L53; RYAN JW, 1991, FASEB J, V5, pA1579; RYAN JW, 1989, FASEB J, V3, pA1026; RYAN JW, 1970, ADV EXP MED BIOL, V8, P263; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SIDOROWICZ W, 1984, AM J HEMATOL, V17, P383, DOI 10.1002/ajh.2830170408; SIDOROWICZ W, 1984, P SOC EXP BIOL MED, V175, P503; SZECHINSKI J, 1983, ENZYME, V29, P21, DOI 10.1159/000469600; TAYLOR S, 1973, ANAL BIOCHEM, V56, P140, DOI 10.1016/0003-2697(73)90178-4; YOSHIMOTO T, 1988, AGR BIOL CHEM TOKYO, V52, P1957	33	86	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4897	4903						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537867				2022-12-27	WOS:A1992HF64200090
J	TAMURA, TA; MAKINO, Y; MIKOSHIBA, K; MURAMATSU, M				TAMURA, TA; MAKINO, Y; MIKOSHIBA, K; MURAMATSU, M			DEMONSTRATION OF A TESTIS-SPECIFIC TRANS-ACTING FACTOR TET-1 INVITRO THAT BINDS TO THE PROMOTER OF THE MOUSE PROTAMINE-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BASIC-PROTEIN GENE; TRANSCRIPTION FACTOR; TRANSLATIONAL CONTROL; SPERMATOGENIC CELLS; NUCLEOTIDE-SEQUENCE; GROWTH-HORMONE; MESSENGER-RNA; EXPRESSION; CDNA	We have established testis-specific in vitro transcription of the mouse protamine 1 (MP1) gene using rat testis nuclear extracts. Addition of testis nuclear extracts to brain extracts enhanced transcription from the MP1 upstream sequence-carrying adenovirus major late promoter. Moreover, the MP1 upstream region from positions -92 to -41 alone exhibited transcriptional activation in a tissue-specific manner. DNase I footprinting demonstrated the presence of a DNA-binding factor around position -60 (Tet-1) in testis nuclear extracts, but not in other tissues. Gel shift analysis also revealed the presence of testis-specific Tet-1. Since mutational analysis in transcriptional and binding assays demonstrates that the Tet-1 site is responsible for transcriptional activation, we suggest that Tet-1 is a novel tissue-specific trans-acting factor. The Tet-1-recognizing sequence was delineated to the 11-mer TGACTTCATAA at position -64. Although the first 8-mer in the Tet-1 11-mer shares homology with the cyclic AMP-responsive element, Tet-1 is demonstrated to be distinct from known cAMP-responsive element-binding factors.	UNIV TOKYO,INST MED SCI,DEPT BIOCHEM,MINATO KU,TOKYO 108,JAPAN; OSAKA UNIV,INST PROT RES,DIV MACROMOLEC FUNCT,SUITA,OSAKA 565,JAPAN; UNIV TOKYO,FAC MED,DEPT BIOCHEM,TOKYO 113,JAPAN	University of Tokyo; Osaka University; University of Tokyo	TAMURA, TA (corresponding author), SAITAMA MED SCH,DEPT BIOCHEM,MOROYAMA MACHI,MOROYAMA,SAITAMA 35004,JAPAN.		Mikoshiba, Katsuhiko/N-7943-2015					ALLEN RL, 1988, MOL CELL BIOL, V8, P3260, DOI 10.1128/MCB.8.8.3260; AOYAMA A, 1990, BIOCHEM BIOPH RES CO, V167, P648, DOI 10.1016/0006-291X(90)92074-A; BALHORN R, 1984, EXP CELL RES, V150, P298, DOI 10.1016/0014-4827(84)90572-X; BEDFORD JM, 1974, J EXP ZOOL, V188, P137, DOI 10.1002/jez.1401880203; BEHRINGER RR, 1988, P NATL ACAD SCI USA, V85, P2648, DOI 10.1073/pnas.85.8.2648; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BELLVE AR, 1977, J HISTOCHEM CYTOCHEM, V25, P480, DOI 10.1177/25.7.893996; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; BUNICK D, 1990, P NATL ACAD SCI USA, V87, P891, DOI 10.1073/pnas.87.3.891; BUNICK D, 1990, EXP CELL RES, V188, P147, DOI 10.1016/0014-4827(90)90290-Q; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GOLD B, 1983, DEV BIOL, V98, P392, DOI 10.1016/0012-1606(83)90368-8; GOTO M, 1990, EXP CELL RES, V186, P273, DOI 10.1016/0014-4827(90)90306-U; HATZOPOULOS AK, 1988, TRANSCRIPTION SPLICI, P43; HECHT NB, 1986, EXP CELL RES, V164, P183, DOI 10.1016/0014-4827(86)90465-9; Hecht NB., 1986, EXPT APPROACHES MAMM, P151; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JANKOWSKI JM, 1984, CAN J BIOCHEM CELL B, V62, P291, DOI 10.1139/o84-041; JANKOWSKI JM, 1987, BIOSCIENCE REP, V7, P955, DOI 10.1007/BF01122129; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; KESHET E, 1990, MOL CELL BIOL, V10, P5021, DOI 10.1128/MCB.10.9.5021; KLEENE KC, 1985, BIOCHEMISTRY-US, V24, P719, DOI 10.1021/bi00324a027; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; KLEENE KC, 1983, DEV BIOL, V98, P455, DOI 10.1016/0012-1606(83)90375-5; KOLK AHJ, 1975, BIOCHIM BIOPHYS ACTA, V393, P307, DOI 10.1016/0005-2795(75)90057-4; KRAWETZ SA, 1988, J MOL EVOL, V27, P291, DOI 10.1007/BF02101190; KRAWETZ SA, 1987, DNA-J MOLEC CELL BIO, V6, P47, DOI 10.1089/dna.1987.6.47; LEE CH, 1987, BIOL CHEM H-S, V368, P131, DOI 10.1515/bchm3.1987.368.1.131; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MCKAY DJ, 1985, BIOSCIENCE REP, V5, P383, DOI 10.1007/BF01116555; Meistrich M L, 1977, Methods Cell Biol, V15, P15, DOI 10.1016/S0091-679X(08)60207-1; MICHIELS F, 1989, EMBO J, V8, P1559, DOI 10.1002/j.1460-2075.1989.tb03540.x; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; SAUTIERE P, 1984, EUR J BIOCHEM, V144, P121, DOI 10.1111/j.1432-1033.1984.tb08439.x; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; TAMURA T, 1989, TECHNIQUE, V1, P33; TAMURA TA, 1989, MOL CELL BIOL, V9, P3122, DOI 10.1128/MCB.9.7.3122; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TOBITA T, 1983, BIOCHIM BIOPHYS ACTA, V744, P141, DOI 10.1016/0167-4838(83)90083-3; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YELICK PC, 1987, MOL CELL BIOL, V7, P2173, DOI 10.1128/MCB.7.6.2173	47	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4327	4332						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537824				2022-12-27	WOS:A1992HF64200013
J	MESSINA, JL; STANDAERT, ML; ISHIZUKA, T; WEINSTOCK, RS; FARESE, RV				MESSINA, JL; STANDAERT, ML; ISHIZUKA, T; WEINSTOCK, RS; FARESE, RV			ROLE OF PROTEIN-KINASE-C IN INSULINS REGULATION OF C-FOS TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOMA-CELLS; MESSENGER RIBONUCLEIC-ACID; PYRUVATE-DEHYDROGENASE ACTIVITY; BC3H-1 CULTURED MYOCYTES; GROWTH-FACTOR; ORNITHINE DECARBOXYLASE; GENE-EXPRESSION; GLUCOSE-TRANSPORT; DNA-SYNTHESIS; 3T3 CELLS	One of insulin's actions is the induction of DNA synthesis and cell division, but little is known about the molecular mechanisms involved. Previous studies indicate that insulin stimulates cell division and regulates the expression of several genes in rat H4IIE (H4) hepatoma cells. One of these genes is the proto-oncogene c-fos, a cellular gene whose deregulation has been implicated in the process of cellular differentiation and division. We have shown that insulin induces transcription of the c-fos gene in H4 cells. In the present study, the phorbol ester, phorbol 12-myristate 13-acetate (PMA), stimulated c-fos transcription in a rapid and dose-dependent manner with an 800% increase in transcription following 15-30 min of addition. This increase in c-fos transcription was transitory, returning towards baseline transcription rates within 120 min. PMA stimulated the translocation of protein kinase C (PKC) from the cytoplasm to the membrane in H4 hepatoma cells, as evidenced by a 77% decrease in cytosolic PKC and a 29% increase in membrane PKC activity following 10 min of treatment. Insulin addition to H4 cells for 10 min also resulted in a 31% decrease in cytosolic PKC activity, suggesting a translocation response. When H4 cells were pretreated with PMA for 24 h, there was a decrease of 20-45% in both cytosolic and membrane PKC activity and a complete loss of PMA's induction of c-fos transcription. Thus, the cells were functionally desensitized to further PMA addition. When cells were pretreated with PMA for 24 h, the insulin-induced increase in transcription of c-fos was reduced by 50%. Western blot analysis indicated that the PKC-beta isozyme followed a translocation pattern almost identical with that of total PKC activity. These results suggest that a PMA-sensitive form of PKC is preferentially lost upon PMA pretreatment and that this PKC subtype may be necessary for insulin to fully induce c-fos gene expression.	JAMES A HALEY VET HOSP,TAMPA,FL 33612; VET ADM MED CTR,SYRACUSE,NY 13210; SUNY HLTH SCI CTR,DEPT MED,SYRACUSE,NY 13210; UNIV S FLORIDA,COLL MED,DEPT INTERNAL MED,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT BIOCHEM,TAMPA,FL 33612	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	MESSINA, JL (corresponding author), SUNY HLTH SCI CTR,DEPT PHYSIOL,SYRACUSE,NY 13210, USA.		Farese, Robert/B-3605-2015		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040456] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40456] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSEN MS, 1990, MOL CELL BIOL, V10, P5525, DOI 10.1128/MCB.10.10.5525; ACEVEDODUNCAN M, 1989, FEBS LETT, V244, P174, DOI 10.1016/0014-5793(89)81186-X; BLACKSHEAR PJ, 1987, MOL ENDOCRINOL, V1, P44, DOI 10.1210/mend-1-1-44; BUTLER AP, 1991, EXP CELL RES, V194, P56, DOI 10.1016/0014-4827(91)90129-I; BUTLER AP, 1991, J CELL PHYSIOL, V147, P256, DOI 10.1002/jcp.1041470210; CAVALIERI F, 1987, MOL CELL BIOL, V7, P3554, DOI 10.1128/MCB.7.10.3554; CHU DTW, 1987, MOL ENDOCRINOL, V1, P53, DOI 10.1210/mend-1-1-53; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COOPER DR, 1989, BIOCHEM BIOPH RES CO, V161, P327, DOI 10.1016/0006-291X(89)91600-8; COOPER DR, 1987, J BIOL CHEM, V262, P3633; COOPER DR, 1990, BIOCHIM BIOPHYS ACTA, V1054, P95, DOI 10.1016/0167-4889(90)90210-5; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAO ML, 1985, J IMMUNOL METHODS, V82, P225; DEASUA LJ, 1973, P NATL ACAD SCI USA, V70, P1388, DOI 10.1073/pnas.70.5.1388; DEASUA LJ, 1977, NATURE, V265, P450, DOI 10.1038/265450a0; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; EGAN JJ, 1990, P NATL ACAD SCI USA, V87, P1052, DOI 10.1073/pnas.87.3.1052; FABBRO D, 1988, J CARDIOVASC PHARM, V12, pS73; FARESE RV, 1988, AM J MED, V85, P36, DOI 10.1016/0002-9343(88)90396-8; FARESE RV, 1985, ENDOCRINOLOGY, V116, P2650, DOI 10.1210/endo-116-6-2650; FARESE RV, 1991, ANTISENSE RES DEV, V1, P35, DOI 10.1089/ard.1991.1.35; FARESE RV, 1984, J BIOL CHEM, V259, P7094; GOODMAN SA, 1988, ARCH BIOCHEM BIOPHYS, V266, P343, DOI 10.1016/0003-9861(88)90266-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIMALDI P, 1983, MOL CELL ENDOCRINOL, V29, P271, DOI 10.1016/0303-7207(83)90017-5; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HOLLENBERG MD, 1975, J BIOL CHEM, V250, P3845; INOUE M, 1977, J BIOL CHEM, V252, P7610; ISHIZUKA T, 1990, DIABETES, V39, P181, DOI 10.2337/diabetes.39.2.181; ISHIZUKA T, 1989, FEBS LETT, V257, P337, DOI 10.1016/0014-5793(89)81565-0; ISHIZUKA T, 1990, BIOCHEM BIOPH RES CO, V169, P966, DOI 10.1016/0006-291X(90)91988-5; KASIK JW, 1987, MOL CELL BIOL, V7, P3349, DOI 10.1128/MCB.7.9.3349; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KOONTZ JW, 1984, MOL CELL BIOCHEM, V58, P139, DOI 10.1007/BF00240613; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; LANGENBACH R, 1975, J NATL CANCER I, V55, P801, DOI 10.1093/jnci/55.4.801; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEFFERT HL, 1974, J CELL BIOL, V62, P792, DOI 10.1083/jcb.62.3.792; MCCAFFREY P, 1987, J BIOL CHEM, V262, P1442; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MESSINA JL, 1990, BIOCHEM BIOPH RES CO, V172, P759, DOI 10.1016/0006-291X(90)90739-A; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MESSINA JL, 1989, ENDOCRINOLOGY, V124, P754, DOI 10.1210/endo-124-2-754; MESSINA JL, 1985, J BIOL CHEM, V260, P6418; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; ONG J, 1987, ENDOCRINOLOGY, V120, P353, DOI 10.1210/endo-120-1-353; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; STANDAERT ML, 1987, ENDOCRINOLOGY, V121, P941, DOI 10.1210/endo-121-3-941; VILA MD, 1989, FEBS LETT, V244, P177, DOI 10.1016/0014-5793(89)81187-1; WAYS K, 1991, J BIOL CHEM, V266, P1258; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINSTOCK RS, 1988, ENDOCRINOLOGY, V123, P366, DOI 10.1210/endo-123-1-366; YAMAMOTO T, 1988, J BIOCHEM-TOKYO, V104, P53, DOI 10.1093/oxfordjournals.jbchem.a122422; YAMASAKI H, 1977, P NATL ACAD SCI USA, V74, P3451, DOI 10.1073/pnas.74.8.3451; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	56	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9223	9228						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577756				2022-12-27	WOS:A1992HR85400079
J	WALMSLEY, AR; SHAW, JG; KELLY, DJ				WALMSLEY, AR; SHAW, JG; KELLY, DJ			THE MECHANISM OF LIGAND-BINDING TO THE PERIPLASMIC C4-DICARBOXYLATE BINDING-PROTEIN (DCTP) FROM RHODOBACTER-CAPSULATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSPORT-SYSTEMS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; RHODOPSEUDOMONAS-CAPSULATA; MEMBRANE-VESICLES; CRYSTALLIZATION; RECONSTITUTION; CLONING; COMPLEX; ATP	The kinetics of ligand binding to the periplasmic C4-dicarboxylate binding protein (DctP) from Rhodobacter capsulatus were investigated by exploiting the changes in the intrinsic fluorescence of the protein upon binding ligands. Steady state measurements have shown that L-malate, succinate, and fumarate are all bound with sub-micromolar K(d) values, whereas D-malate is bound 2 orders of magnitude more weakly. Stopped-flow studies have revealed that the binding process involves at least three steps. In the absence of ligand, the protein is in equilibrium between an essentially nonbinding form, BP1, and the binding form, BP2. Ligands bind to the BP2 form, shifting the equilibrium toward the BP2-L conformation, and also inducing a further isomerization of the protein, to the BP3-L form. The kinetic properties of the four different conformational states of the DctP protein identified in this study would be consistent with their identification as the closed-conformation, the open-conformation, an open-liganded conformation, and a closed-liganded conformation. The latter three states have been identified by x-ray crystallographic studies of binding proteins, but no kinetic or structural data have been presented previously to support the possibility of a closed but unliganded conformation.			WALMSLEY, AR (corresponding author), UNIV SHEFFIELD,KREBS & ROBERT HILL INST,DEPT MOLEC BIOL & BIOTECHNOL,POB 594,5TH COURT,SHEFFIELD S10 2UH,ENGLAND.							AMES GF, 1989, J BIOL CHEM, V264, P3998; AMES GF, 1988, J BIOENERG BIOMEMBR, V20, P1, DOI 10.1007/BF00762135; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; HAMBLIN MJ, 1990, MOL MICROBIOL, V4, P1567, DOI 10.1111/j.1365-2958.1990.tb02068.x; HIGGINS CF, 1990, PHILOS T R SOC B, V326, P353, DOI 10.1098/rstb.1990.0017; HILLMER P, 1977, J BACTERIOL, V129, P724, DOI 10.1128/JB.129.2.724-731.1977; Lehrer S S, 1978, Methods Enzymol, V49, P222; LO TCY, 1975, J BIOL CHEM, V250, P1600; MAO B, 1982, J BIOL CHEM, V257, P1131; MILLER DM, 1983, J BIOL CHEM, V258, P3665; MILLER DM, 1980, J BIOL CHEM, V254, P2465; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; PARSONS RG, 1974, J BIOL CHEM, V249, P3602; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SACK JS, 1989, J MOL BIOL, V206, P192; SHAW JG, 1991, ARCH MICROBIOL, V155, P466, DOI 10.1007/BF00244963; SHAW JG, 1991, MOL MICROBIOL, V5, P3055, DOI 10.1111/j.1365-2958.1991.tb01865.x; SWEET GD, 1984, J BIOL CHEM, V259, P1586; WALMSLEY AR, 1989, ANAL BIOCHEM, V176, P313, DOI 10.1016/0003-2697(89)90315-1; WEAVER PF, 1975, ARCH MICROBIOL, V105, P207, DOI 10.1007/BF00447139; WIDENHORN KA, 1988, J BACTERIOL, V170, P883, DOI 10.1128/jb.170.2.883-888.1988; WILLIS RC, 1974, ARCH BIOCHEM BIOPHYS, V161, P64, DOI 10.1016/0003-9861(74)90235-5	24	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8064	8072						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569065				2022-12-27	WOS:A1992HQ18500019
J	ANDREWS, DW; YOUNG, JC; MIRELS, LF; CZARNOTA, GJ				ANDREWS, DW; YOUNG, JC; MIRELS, LF; CZARNOTA, GJ			THE ROLE OF THE N-REGION IN SIGNAL SEQUENCE AND SIGNAL-ANCHOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVELY CHARGED RESIDUES; IMMUNOGLOBULIN-GAMMA-CHAINS; ENDOPLASMIC-RETICULUM; PROTEIN TRANSLOCATION; MICROSOMAL-MEMBRANES; STOP TRANSFER; RECOGNITION PARTICLE; HEAVY-CHAIN; PEPTIDE; HYDROPHOBICITY	To determine the role of sequences other than the hydrophobic core in mediating signal sequence function, we examined the behavior of fusion proteins and deletion mutants in cell-free systems. We demonstrate that neither the N nor the C region of the preprolactin signal sequence is necessary for translocation. However, insertion of sequences with either a net charge of +2.5 or -6.0 between the N region and the hydrophobic core of the signal converted it into a signal-anchor. The topologies adopted (types I and II, respectively) were opposite those predicted from the distribution of charges surrounding the hydrophobic core of the signals. When these mutant signals were located in the interior of an otherwise secreted protein, both sequences functioned as stop-transfer sequences. Related mutations were assayed in fusion proteins in which the IgM transmembrane domain functioned as an amino-terminal signal-anchor. For these molecules, the distribution of charged residues surrounding the hydrophobic core had no influence on the topology adopted. Our results suggest that features other than simple charge distribution play an important role in determining membrane topology in vitro.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	ANDREWS, DW (corresponding author), MCMASTER UNIV,DEPT BIOCHEM,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA.			Andrews, David/0000-0002-9266-7157				ANDREWS D, 1989, BIOTECHNIQUES, V7, P960; ANDREWS DW, 1988, J BIOL CHEM, V263, P15791; ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BIRD P, 1990, J BIOL CHEM, V265, P8420; BONATTI S, 1979, J BIOL CHEM, V254, P2261; CHENG HL, 1982, NATURE, V296, P410, DOI 10.1038/296410a0; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CIOFFI JA, 1989, J BIOL CHEM, V264, P15052; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; GREEN R, 1989, J BIOL CHEM, V264, P2963; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; IBRAHIMI I, 1987, J BIOL CHEM, V262, P10189; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KENDALL DA, 1990, BIOPOLYMERS, V29, P139, DOI 10.1002/bip.360290119; KOHARA A, 1991, J BIOL CHEM, V266, P20363; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LINGAPPA VR, 1984, P NATL ACAD SCI-BIOL, V81, P456, DOI 10.1073/pnas.81.2.456; LINGAPPA VR, 1979, NATURE, V281, P711; LIPP J, 1988, J CELL BIOL, V106, P1813, DOI 10.1083/jcb.106.6.1813; MIZE NK, 1986, CELL, V47, P711, DOI 10.1016/0092-8674(86)90514-3; PARKS GD, 1989, J CELL BIOL, V109, P2023, DOI 10.1083/jcb.109.5.2023; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PERARA E, 1985, J CELL BIOL, V101, P2292, DOI 10.1083/jcb.101.6.2292; PILLAI S, 1987, P NATL ACAD SCI USA, V84, P7654, DOI 10.1073/pnas.84.21.7654; PRABHAKARAN M, 1990, BIOCHEM J, V269, P691, DOI 10.1042/bj2690691; ROGERS J, 1981, CELL, V26, P19, DOI 10.1016/0092-8674(81)90029-5; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEELE G, 1983, METHOD ENZYMOL, V96, P94; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SHINDE UP, 1989, BIOSCIENCE REP, V9, P737, DOI 10.1007/BF01114812; STIRZAKER SC, 1987, J CELL BIOL, V105, P2897, DOI 10.1083/jcb.105.6.2897; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; SZCZESNASKORUPA E, 1987, J BIOL CHEM, V262, P8896; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; TUCKER PW, 1979, SCIENCE, V206, P1303, DOI 10.1126/science.117549; TYLER BM, 1982, P NATL ACAD SCI-BIOL, V79, P2008, DOI 10.1073/pnas.79.6.2008; von Heijne G, 1987, Protein Seq Data Anal, V1, P41; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YAMAWAKIKATAOKA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2623, DOI 10.1073/pnas.79.8.2623; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0	52	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7761	7769						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560010				2022-12-27	WOS:A1992HN48500080
J	HEINEMANN, U; HAHN, M				HEINEMANN, U; HAHN, M			C-C-A-G-G-C-M5C-T-G-G - HELICAL FINE-STRUCTURE, HYDRATION, AND COMPARISON WITH C-C-A-G-G-C-C-T-G-G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-DNA DODECAMER; CRYSTAL-STRUCTURE; BASE SEQUENCE; CONFORMATION; RESOLUTION; REFINEMENT; GEOMETRY; TRACT	The self-complementary DNA duplex C-C-A-G-G-C-m5C-T-G-G has been refined against 1.75-angstrom x-ray diffraction data to an R value of 17.4%. In the crystal of space group P6, 10-base pair DNA fragments with characteristic sequence-related fine structure stack end to end to form long antiparallel B-type double helices. As shown by a structure analysis at lower resolution (Heinemann, U., and Alings, C. (1991) EMBO J. 10, 35-43), the overall geometry of C-C-A-G-G-C-m5C-T-G-G is similar to that of the unmethylated analog C-C-A-G-G-C-C-T-G-G despite a different crystal environment. The present high resolution structure analysis permits a detailed comparison of the two duplexes and their hydration spheres. Helical parameters are significantly correlated between both molecules, with the exception of the base pair propeller. Sugar pucker and backbone torsion angles-alpha, gamma, delta, and chi show similar mean values, but their individual values deviate significantly between duplexes. In contrast, torsion angles-beta, epsilon, and zeta change along the strands of both duplexes in much the same way. The effect of single-site methylation on DNA conformation appears to be small and limited to the base pairs directly involved. Methylation tends to push base pairs toward the minor groove of the helix. A regular minor groove hydration pattern involves dual hydrogen bonding of water molecules to O-4' and base atoms of C-C-A-G-G-C-m5C-T-G-G.			HEINEMANN, U (corresponding author), FREE UNIV BERLIN,INST KRISTALLOG,TAKUSTR 6,W-1000 BERLIN 33,GERMANY.		Heinemann, Udo/S-3379-2016; Heinemann, Udo/AAH-4766-2019	Heinemann, Udo/0000-0002-8191-3850; Heinemann, Udo/0000-0002-8191-3850				ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; Berman HM, 1991, CURR OPIN STRUC BIOL, V1, P423, DOI 10.1016/0959-440X(91)90042-R; CALLADINE CR, 1982, J MOL BIOL, V161, P343, DOI 10.1016/0022-2836(82)90157-7; Chandrasekaran R., 1989, LANDOLTBORNSTEIN B, V1/II, P31; CHUPRINA VP, 1991, P NATL ACAD SCI USA, V88, P593, DOI 10.1073/pnas.88.2.593; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; CRUSE WBT, 1986, J MOL BIOL, V192, P891, DOI 10.1016/0022-2836(86)90035-5; DICKERSON RE, 1983, J MOL BIOL, V166, P419, DOI 10.1016/S0022-2836(83)80093-X; DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0; Dickerson RE, 1989, EMBO J, V8, P1; DICKERSON RE, 1985, BIOL MACROMOL, V2, P471; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; FREDERICK CA, 1988, J BIOL CHEM, V263, P17872; GRZESKOWIAK K, 1991, J BIOL CHEM, V266, P8861; HEINEMANN U, 1991, J BIOMOL STRUCT DYN, V8, P801, DOI 10.1080/07391102.1991.10507846; HEINEMANN U, 1989, J MOL BIOL, V210, P369, DOI 10.1016/0022-2836(89)90337-9; HEINEMANN U, 1991, EMBO J, V10, P35, DOI 10.1002/j.1460-2075.1991.tb07918.x; HEINEMANN U, 1991, NUCLEIC ACIDS RES, V19, P427, DOI 10.1093/nar/19.3.427; HEINEMANN U, 1987, NUCLEIC ACIDS RES, V15, P9531, DOI 10.1093/nar/15.22.9531; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; JAIN S, 1989, BIOCHEMISTRY-US, V28, P2360, DOI 10.1021/bi00432a002; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MALIN R, 1991, J BIOL CHEM, V266, P4848; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NORTH ACT, 1968, ACTA CRYSTALL A-CRYS, VA 24, P351, DOI 10.1107/S0567739468000707; PRIVE GG, 1987, SCIENCE, V238, P498, DOI 10.1126/science.3310237; PRIVE GG, 1991, J MOL BIOL, V217, P177, DOI 10.1016/0022-2836(91)90619-H; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; SHAKKED Z, 1989, NATURE, V342, P456, DOI 10.1038/342456a0; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; YANAGI K, 1991, J MOL BIOL, V217, P201, DOI 10.1016/0022-2836(91)90620-L; YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332; 1983, EUR J BIOCHEM, V131, P9	33	95	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7332	7341						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559976				2022-12-27	WOS:A1992HN48500022
J	SHADEL, GS; BALDWIN, TO				SHADEL, GS; BALDWIN, TO			IDENTIFICATION OF A DISTANTLY LOCATED REGULATORY ELEMENT IN THE LUXD GENE REQUIRED FOR NEGATIVE AUTOREGULATION OF THE VIBRIO-FISCHERI LUXR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; BACTERIAL BIOLUMINESCENCE; CYCLIC-AMP; OPERON; REPRESSION; AUTOINDUCER; OPERATOR; REGULON	Expression of bioluminescence in the marine bacterium Vibrio fischeri is controlled by a unique cell density-dependent regulatory mechanism called autoinduction. The genes required for bioluminescence (the lux genes) are organized in two divergently transcribed operons (luxR-luxICDABEG). One operon (luxICDABEG) contains the genes required for light production (luxCDABE) and the synthesis of a diffusible signal molecule called autoinducer (luxI). The other operon contains the luxR gene which encodes a transcriptional regulatory protein that activates transcription of both lux operons in the presence of autoinducer. This bidirectional stimulatory mechanism leads to a Positive feedback circuit that results in a rapid increase in light production at a Particular culture cell density which is characteristic of autoinduction. Transcriptional Positive feedback is apparently limited by a negative autoregulatory circuit through which LuxR acts to inhibit its own synthesis. Transcriptional negative autoregulation requires autoinducer, the lux operator located in the control region (which is the binding site for LuxR), and negative acting DNA sequences in the luxICDABEG operon. Deletion analysis of the luxICDABEG operon demonstrated that a negative acting element is located in the luxD gene at a position 2.0 kilobases from the lux operator. The nucleotide sequence of this luxD element is similar to the lux operator (11 of 20 base pairs identical) and can function as a LuxR-binding site when it replaces the lux operator in the control region. These results suggest that the luxD element functions as a low affinity binding site for LuxR and that occupancy of this site is required to achieve transcriptional negative autoregulation of luxR.	TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843; TEXAS A&M UNIV SYST,CTR MACROMOLEC DESIGN,INST BIOSCI & TECHNOL,COLLEGE STN,TX 77843; TEXAS A&M UNIV SYST,DEPT CHEM,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042428] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42428] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOUYAL M, 1989, CELL, V58, P545, DOI 10.1016/0092-8674(89)90435-2; BALDWIN TO, 1989, J BIOLUM CHEMILUM, V4, P326, DOI 10.1002/bio.1170040145; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; DANDANELL G, 1987, NATURE, V325, P823, DOI 10.1038/325823a0; DEVINE JH, 1988, BIOCHEMISTRY-US, V27, P837, DOI 10.1021/bi00402a052; DEVINE JH, 1989, P NATL ACAD SCI USA, V86, P5688, DOI 10.1073/pnas.86.15.5688; DUNLAP PV, 1988, J BACTERIOL, V170, P4040, DOI 10.1128/jb.170.9.4040-4046.1988; DUNLAP PV, 1985, J BACTERIOL, V164, P45, DOI 10.1128/JB.164.1.45-50.1985; DUNLAP PV, 1989, J BACTERIOL, V171, P3549, DOI 10.1128/jb.171.6.3549-3552.1989; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; EBERHARD A, 1972, J BACTERIOL, V109, P1101, DOI 10.1128/JB.109.3.1101-1105.1972; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; EISMANN E, 1987, J MOL BIOL, V195, P946; ENGEBRECHT J, 1987, NUCLEIC ACIDS RES, V15, P10455, DOI 10.1093/nar/15.24.10455; ENGEBRECHT J, 1983, CELL, V32, P773, DOI 10.1016/0092-8674(83)90063-6; Engebrecht J, 1986, GENET ENG, V8, P31; FLASHNER Y, 1988, P NATL ACAD SCI USA, V85, P8968, DOI 10.1073/pnas.85.23.8968; FRIEDRICH WF, 1983, ARCH MICROBIOL, V134, P87, DOI 10.1007/BF00407937; GRALLA JD, 1989, CELL, V57, P193, DOI 10.1016/0092-8674(89)90955-0; HASTINGS JW, 1963, J OPT SOC AM, V53, P1410, DOI 10.1364/JOSA.53.001410; HUO L, 1988, P NATL ACAD SCI USA, V85, P5444, DOI 10.1073/pnas.85.15.5444; IRANI MH, 1983, CELL, V32, P783, DOI 10.1016/0092-8674(83)90064-8; KAPLAN HB, 1985, J BACTERIOL, V163, P1210, DOI 10.1128/JB.163.3.1210-1214.1985; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P1367; MAJUMDAR A, 1984, P NATL ACAD SCI-BIOL, V81, P6100, DOI 10.1073/pnas.81.19.6100; MANDAL N, 1990, GENE DEV, V4, P410, DOI 10.1101/gad.4.3.410; MOSSING MC, 1986, SCIENCE, V233, P889, DOI 10.1126/science.3090685; NEALSON KH, 1970, J BACTERIOL, V104, P313, DOI 10.1128/JB.104.1.313-322.1970; SHADEL GS, 1991, J BACTERIOL, V173, P568, DOI 10.1128/jb.173.2.568-574.1991; SHADEL GS, 1990, J BIOLUM CHEMILUM, V5, P99, DOI 10.1002/bio.1170050205; SHADEL GS, 1990, J BACTERIOL, V172, P3980, DOI 10.1128/jb.172.7.3980-3987.1990; SWARTZMAN E, 1990, J BACTERIOL, V172, P6797, DOI 10.1128/jb.172.12.6797-6802.1990; TUGGLE CK, 1990, J BACTERIOL, V172, P1711, DOI 10.1128/jb.172.4.1711-1718.1990	33	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7690	7695						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1560004				2022-12-27	WOS:A1992HN48500070
J	ANTONNY, B; CHABRE, M				ANTONNY, B; CHABRE, M			CHARACTERIZATION OF THE ALUMINUM AND BERYLLIUM FLUORIDE SPECIES WHICH ACTIVATE TRANSDUCIN - ANALYSIS OF THE BINDING AND DISSOCIATION KINETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-PHOSPHATE; INTRINSIC FLUORESCENCE; STRUCTURAL ANALOGS; F-ACTIN; COMPLEXES; NUCLEOTIDE; INHIBITION; PROTEINS; SITE; GTP	Aluminofluoride and beryllofluoride complexes can activate the heterotrimeric G-proteins by binding next to GDP in the nucleotide site of their G-alpha subunit and acting as analogs of the gamma-phosphate of a GTP. However, the exact structures of the activatory complexes in solution as well as those of the bound complexes in the nucleotide site are still disputed. We have studied, by monitoring the activation-dependent tryptophan fluorescence of transducin T-alpha subunit, the pF (-log[F-]) and pH dependencies of the kinetics of activation and deactivation of T-alpha-GDP in the presence of NaF and aluminum or beryllium salts. Comparisons were made with the calculated pF and pH dependencies of the distribution of the metallofluoride complexes, in order to identify the activating species. We observed that the contribution of a magnesium-dependent mechanism of activation by fluoride (Antonny, B., Bigay, J., and Chabre, M. (1990) FEBS Lett. 268, 277-280) and effects due to slow equilibration kinetics between various aluminofluoride complexes could give rise to puzzling kinetics that had caused misinterpretations of previous results. Once corrected for theses effects, our results suggest that with aluminum AlF3(OH)- is, rather than AlF4-, the main activating species and that the bound form of the complex is tetracoordinated GDP-AlF3. Deactivation kinetics depend on the free fluoride concentration in the medium, suggesting that the simple bimolecular scheme: T-alpha-GDP-AlF3 if and only if T-alpha-GDP + AlF3(OH) does not fully describe the interaction. Fluorides in the bound complexes can also exchange with free F- ions in solution. With beryllium, two complexes are activatory: BeF3-.H2O and BeF2(OH)-.H2O. In the nucleotide site these give two tetracoordinated complexes, GDP.BeF3 and GDP.BeF2(OH), as shown by their different dissociation rates.	CNRS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Antonny, Bruno/ABH-7434-2020	Antonny, Bruno/0000-0002-9166-8668				ANTONNY B, 1990, FEBS LETT, V268, P277, DOI 10.1016/0014-5793(90)81027-L; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; CARLIER MF, 1988, BIOCHEMISTRY-US, V27, P3555, DOI 10.1021/bi00410a005; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COMBEAU C, 1989, J BIOL CHEM, V264, P19017; DETERRE P, 1984, FEBS LETT, V178, P228, DOI 10.1016/0014-5793(84)80606-7; DUPUIS A, 1989, FEBS LETT, V255, P47, DOI 10.1016/0014-5793(89)81058-0; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; MARTIN RB, 1986, CLIN CHEM, V32, P1797; MARTIN RB, 1988, BIOCHEM BIOPH RES CO, V155, P1194; MISSIAEN L, 1989, BIOCHEM J, V261, P655, DOI 10.1042/bj2610655; PARIS S, 1987, J BIOL CHEM, V262, P1970; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888	19	87	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6710	6718						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551879				2022-12-27	WOS:A1992HM05300040
J	PATRICK, DR; ZHANG, K; DEFEOJONES, D; VUOCOLO, GR; MAIGETTER, RZ; SARDANA, MK; OLIFF, A; HEIMBROOK, DC				PATRICK, DR; ZHANG, K; DEFEOJONES, D; VUOCOLO, GR; MAIGETTER, RZ; SARDANA, MK; OLIFF, A; HEIMBROOK, DC			CHARACTERIZATION OF FUNCTIONAL HPV-16 E7 PROTEIN PRODUCED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; GENE ENCODES TRANSACTIVATION; ABSORPTION FINE-STRUCTURE; MUTATIONAL ANALYSIS; TRANSFORMATION; BINDING; ADENOVIRUS-E1A; IDENTIFICATION; PEPTIDES; DOMAINS	Human papillomaviruses (HPVs) are the etiologic agents responsible for genital warts and are contributing factors in the pathogenesis of human cervical cancer. The HPV E7 gene is transcriptionally active in these diseases and has been shown to transform mammalian cells in vitro. We have expressed and purified the HPV-16 E7 gene product in Escherichia coli. The isolated E7 protein contains zinc in a 1:1 molar ratio. X-ray absorption fine structure studies demonstrated that the zinc is coordinated by 4 sulfur ligands. We sequentially derivatized the E7 cysteines to differentiate between solvent-exposed, metal-bound, and disulfide-associated cysteines. Our results demonstrate that Cys24 and Cys68 are accessible to solvent, while cysteines in the two conserved Cys-X-X-Cys motifs are likely involved in binding zinc. We observed no evidence for the existence of disulfide bonds in recombinant E7 protein under the conditions tested.	MERCK SHARP & DOHME LTD, DEPT CANC RES, West Point, PA 19486 USA; MERCK SHARP & DOHME LTD, DEPT BIOL CHEM, West Point, PA 19486 USA; BIOSTRUCTURES INST, UNIV CITY SCI CTR, PHILADELPHIA, PA 19104 USA; MERCK SHARP & DOHME LTD, DEPT CELLULAR & MOLEC BIOL, West Point, PA 19486 USA	Merck & Company; Merck & Company; Merck & Company								BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BERG JM, 1989, PROG INORG CHEM, V37, P143; BOULDIN C, 1984, THESIS U WASHINGTON, P63; CREIGHTON TE, 1983, FUNCTIONS GLUTATHION, P205; CROSIER E, 1987, XRAY ABSORPTION PRIN, P443; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; JONES RE, 1990, J BIOL CHEM, V265, P12782; KELLARIS KV, 1989, BIOCHEMISTRY-US, V28, P3469, DOI 10.1021/bi00434a048; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PA, 1981, REV MOD PHYS, V53, P769, DOI 10.1103/RevModPhys.53.769; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LINEMEYER DL, 1987, BIO-TECHNOL, V5, P960, DOI 10.1038/nbt0987-960; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RAWLS JA, 1990, J VIROL, V64, P6121, DOI 10.1128/JVI.64.12.6121-6129.1990; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; STERN EA, 1986, HDB SYNCHROTRON RAD, P955; STOREY A, 1990, J GEN VIROL, V71, P965, DOI 10.1099/0022-1317-71-4-965; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WEBSTER LC, 1991, P NATL ACAD SCI USA, V88, P9989, DOI 10.1073/pnas.88.22.9989; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; ZHANG K, 1988, BIOCHEMISTRY-US, V27, P7470, DOI 10.1021/bi00419a045	32	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6910	6915						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551900				2022-12-27	WOS:A1992HM05300071
J	WOLFF, EC; KINZY, TG; MERRICK, WC; PARK, MH				WOLFF, EC; KINZY, TG; MERRICK, WC; PARK, MH			2 ISOFORMS OF EIF-5A IN CHICK-EMBRYO - ISOLATION, ACTIVITY, AND COMPARISON OF SEQUENCES OF THE HYPUSINE-CONTAINING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION FACTOR-4D; HAMSTER OVARY CELLS; SACCHAROMYCES-CEREVISIAE; RABBIT RETICULOCYTES; AMINO-ACID; FACTOR 4D; IDENTIFICATION; PURIFICATION; PRECURSOR; SPERMIDINE	Eukaryotic translation initiation factor 5A (eIF-5A) (older terminology, eIF-4D) is unique in that it contains the unusual amino acid hypusine (N(epsilon)-(4-amino-2-hydroxybutyl)lysine). Hypusine is formed by a posttranslational event in which a specific lysine residue is modified by a structural contribution from spermidine. Metabolic labeling of chick embryo fibroblasts with [H-3]spermidine or [H-3]lysine gives rise to two distinct proteins, designated I (approximately 20 kDa and pI 5.6) and II (approximately 18 kDa and pI 5.35), that contain [H-3]hypusine. Upon incubation with [H-3]lysine the labeling of the two proteins followed a similar time course and showed approximately the same ratio over the 6-h incubation period. [H-3]Hypusine-containing proteins from cells which had been cultured with [H-3]spermidine were employed as tracers for isolation of hypusine-containing proteins from whole chick embryos. Four such proteins were obtained. Two of these proteins, I and II, correspond to the two native proteins synthesized in chick embryo fibroblasts; the other two forms, Ia and IIa, displayed properties suggesting that they were derived from the native proteins, I and II, respectively, during purification. The amino acid compositions and the tryptic peptide maps of the 20-kDa protein (I) and the 18-kDa protein (II) suggest that they are closely related but distinct proteins. In fact, amino acid sequence analysis of the two major proteins revealed differences in the polypeptide backbone of the two proteins. In spite of structural differences, the two native forms (I and II), as well as the two altered forms (Ia and IIa), were effective in stimulating methionyl-puromycin synthesis, providing evidence that they are indeed functional isoforms of eIF-5A.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University	WOLFF, EC (corresponding author), NIDR,CELLULAR DEV & ONCOL LAB,BLDG 30,RM 211,BETHESDA,MD 20892, USA.			Kinzy, Terri/0000-0003-1394-9226	NIADDK NIH HHS [AM-07319] Funding Source: Medline; NIGMS NIH HHS [GM-26796] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; BENNE R, 1978, J BIOL CHEM, V253, P3078; BENNE R, 1978, J BIOL CHEM, V253, P3070; CHEN KY, 1983, BIOCHIM BIOPHYS ACTA, V756, P395, DOI 10.1016/0304-4165(83)90350-1; CHEN KY, 1987, FASEB J, V46, P2090; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; COOPER HL, 1982, CELL, V29, P791, DOI 10.1016/0092-8674(82)90441-X; DOU QP, 1989, J CHIN CHEM SOC-TAIP, V36, P443, DOI 10.1002/jccs.198900061; DUNCAN RF, 1986, J BIOL CHEM, V261, P2903; ELDER JH, 1977, J BIOL CHEM, V252, P6510; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GORDON ED, 1987, J BIOL CHEM, V262, P16585; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Hirs CHW, 1967, METHOD ENZYMOL, P59, DOI [10.1016/S0076-6879(67)11008-2, DOI 10.1016/S0076-6879(67)11008-2]; HUNTER E, 1979, METHOD ENZYMOL, V58, P381; KEMPER WM, 1976, J BIOL CHEM, V251, P5551; LOWRY CV, 1986, MOL CELL BIOL, V6, P4145, DOI 10.1128/MCB.6.12.4145; MEHTA KD, 1990, J BIOL CHEM, V265, P8802; MEHTA KD, 1989, J BIOL CHEM, V264, P8670; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MERRICK WC, 1990, BIOCHIM BIOPHYS ACTA, V1050, P235, DOI 10.1016/0167-4781(90)90173-Y; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; PARK MH, 1988, J BIOL CHEM, V263, P7447; PARK MH, 1986, J BIOL CHEM, V261, P4515; PARK MH, 1982, J BIOL CHEM, V257, P7217; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1991, J BIOL CHEM, V266, P7988; PARK MH, 1981, P NATL ACAD SCI-BIOL, V78, P2869, DOI 10.1073/pnas.78.5.2869; PARK MH, 1984, J BIOL CHEM, V259, P4563; PARK MH, 1987, J BIOL CHEM, V262, P12730; RISS B, 1990, TRENDS BIOCHEM SCI, V15, P421; SANDHOLZER U, 1989, FEBS LETT, V246, P94, DOI 10.1016/0014-5793(89)80260-1; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P1578; Voorma H O, 1979, Methods Enzymol, V60, P124, DOI 10.1016/S0076-6879(79)60012-5; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; YANG YC, 1990, BIOCHIM BIOPHYS ACTA, V1033, P133; 1989, EUR J BIOCHEM, V1, P1	40	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					6107	6113						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556119				2022-12-27	WOS:A1992HK31800060
J	SAITOH, O; WANG, WC; LOTAN, R; FUKUDA, M				SAITOH, O; WANG, WC; LOTAN, R; FUKUDA, M			DIFFERENTIAL GLYCOSYLATION AND CELL-SURFACE EXPRESSION OF LYSOSOMAL MEMBRANE-GLYCOPROTEINS IN SUBLINES OF A HUMAN COLON CANCER EXHIBITING DISTINCT METASTATIC POTENTIALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASN-LINKED OLIGOSACCHARIDES; POLY-N-ACETYLLACTOSAMINE; HAMSTER-KIDNEY CELLS; FUCOSYL-TRANSFERASE; CARBOHYDRATE STRUCTURES; HUMAN-GRANULOCYTES; PLASMA-MEMBRANE; MELANOMA-CELLS; TUMOR-CELLS; SIALYL-LEX	Changes in the glycosylation of asparagine-linked oligosaccharides have been shown in various tumor cells, including human colon cancer. Attempts were made to elucidate the difference in Asn-linked oligosaccharides attached to lysosomal membrane glycoproteins isolated from sublines of human colon carcinoma exhibiting high and low metastatic potentials in nude mice. Lysosomal membrane glycoproteins (lamp) 1 and 2 were immunoprecipitated from the cells after labeling with radioactive sugars, and the glycopeptides prepared were fractionated by serial lectin affinity chromatography employing immobilized concanavalin A, Datura stramonium agglutinin, and tomato lectin. Comparison of Asn-linked oligosaccharides from the different colonic carcinoma cells revealed the following features. First, the highly metastatic carcinoma cells express more poly-N-acetyllactosaminyl side chains with branched galactose residues than cells with low metastatic potential. Second, sialylation is more significant in the highly metastatic carcinoma cells than in the poorly metastatic ones. Conversely, N-acetyllactosamine units are less fucosylated in the highly metastatic cells than in poorly metastatic cells. These structural changes were apparently caused by the increase in sialyltransferase and the decrease in alpha-1 --> 3 fucosyltransferase in the highly metastatic cells. The results also suggest that highly metastatic carcinoma cells express more sialyl Le(X) structures at the termini of poly-N-acetyllactosaminyl side chains than poorly metastatic carcinoma cells. Further, highly metastatic cells were found to express more lamp-1 and lamp-2 on the cell surface. These results were found to be correlated to the increased expression of sialyl Le(X) structures with high affinity binding of anti-sialyl Le(X) antibody on highly metastatic cells. Increased expression of sialyl Le(X) in the poly-N-acetyllactosamines of the cell surface may contribute to the metastatic behavior of the cells, assuming that this structure can serve as a better ligand for selectins present on endothelial cells and platelets.	LA JOLLA CANC RES FDN,CANC RES CTR,10901 N TORREY PINES RD,LA JOLLA,CA 92037; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77030	Sanford Burnham Prebys Medical Discovery Institute; Bristol-Myers Squibb; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [R01 CA48737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMOS B, 1990, J BIOL CHEM, V265, P19192; BERG EL, 1991, J BIOL CHEM, V266, P14869; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CHEN JW, 1988, J BIOL CHEM, V263, P8754; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; DENNIS JW, 1986, CANCER RES, V46, P5131; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FINNE J, 1982, J CELL BIOL, V92, P277, DOI 10.1083/jcb.92.2.277; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1984, BIOL GLYCOPROTEINS, P183; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HANSSON GC, 1985, J BIOL CHEM, V260, P9388; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; HO MK, 1983, J BIOL CHEM, V258, P636; HOFF SD, 1989, CANCER RES, V49, P6883; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; HUBBARD SC, 1987, J BIOL CHEM, V262, P16403; HUMPHRIES MJ, 1986, CANCER RES, V46, P5215; HUMPHRIES MJ, 1986, P NATL ACAD SCI USA, V83, P1752, DOI 10.1073/pnas.83.6.1752; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFERTE S, 1989, BIOCHEM J, V259, P569, DOI 10.1042/bj2590569; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LEE N, 1990, J BIOL CHEM, V265, P20476; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; MORIKAWA K, 1988, CANCER RES, V48, P1943; MORIKAWA K, 1988, CANCER RES, V48, P6863; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; PALCIC MM, 1990, J BIOL CHEM, V265, P6759; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PIERCE M, 1986, J BIOL CHEM, V261, P772; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SAITOH O, 1991, CANCER RES, V51, P2854; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VIITALA J, 1988, P NATL ACAD SCI USA, V85, P3743, DOI 10.1073/pnas.85.11.3743; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098; YAMASHITA K, 1989, J BIOL CHEM, V264, P17873; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YOUAKIM A, 1989, CANCER RES, V49, P6889; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	61	284	315	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5700	5711						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544942				2022-12-27	WOS:A1992HH74700105
J	LIU, SX; ZHANG, PH; JI, XH; JOHNSON, WW; GILLILAND, GL; ARMSTRONG, RN				LIU, SX; ZHANG, PH; JI, XH; JOHNSON, WW; GILLILAND, GL; ARMSTRONG, RN			CONTRIBUTION OF TYROSINE-6 TO THE CATALYTIC MECHANISM OF ISOENZYME-3-3 OF GLUTATHIONE-S-TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACTIVE-SITE; RAT-LIVER; ANION	The role of the hydroxyl group of tyrosine 6 in the catalytic mechanism of isoenzyme 3-3 of rat glutathione S-transferase has been examined by x-ray crystallography and site-specific replacement of the residue with phenylalanine and evaluation of the catalytic properties of the mutant enzyme. This particular tyrosine residue is conserved in the sequences of all of the cytosolic enzymes and is found, in crystal structures of both isoenzyme 3-3 from the mu-gene class and an isoenzyme from the pi-gene class, to be proximal to the sulfur of glutathione (GSH) or glutathione sulfonate bound at the active site. The 2.2-angstrom structure of the binary complex of isoenzyme 3-3 and GSH indicates that the hydroxyl group of Tyr6 is located 3.2-3.5 angstrom from the sulfur of GSH, well within hydrogen bonding distance. Removal of the hydroxyl group of Tyr6 has essentially no effect on the dissociation constant (22 +/- 3-mu-M) for GSH. Nevertheless the Y6F mutant exhibits a turnover number which is only about 1% that of the native enzyme when assayed at pH 6.5 with either 1-chloro-2,4-dinitrobenzene (CDNB) or 4-phenyl-3-buten-2-one. UV difference spectra of the binary enzyme-GSH complexes suggest that the predominant ionization state of GSH in the active site of the Y6F mutant is the neutral thiol (eg. E(Y6F).GSH) which is in contrast to the native enzyme in which the thiol is substantially deprotonated (e.g. E.GS-). Spectrophotometric titration suggests that the pK(a) of the thiol is 6.9 +/- 0.3 in the E.GSH complex and greater-than-or-equal-to 8 in the E(Y6F).GSH binary complex. In addition, the pH dependence of k(cat)/K(m)CDNB reveals that the reactions catalyzed by the native enzyme and the Y6F mutant are dependent on a single ionization in the E.GSH and E(Y6F).GSH complexes with pK(a) = 6.2 +/- 0.1 and 7.8 +/- 0.3, respectively. The results suggest that the hydrogen bond between Tyr6 and the enzyme-bound nucleophile helps to lower the pK(a) of GSH in the binary enzyme-substrate complex.	UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLLEGE PK,MD 20742; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,SHADY GROVE,MD; NATL INST STAND & TECHNOL,ROCKVILLE,MD 20852	University System of Maryland; University of Maryland College Park; National Institute of Standards & Technology (NIST) - USA			Ji, Xinhua/C-9664-2012	Ji, Xinhua/0000-0001-6942-1514	NIGMS NIH HHS [GM 30910] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030910] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; CHEN WJ, 1988, BIOCHEMISTRY-US, V27, P647, DOI 10.1021/bi00402a023; Cleland W W, 1979, Methods Enzymol, V63, P103; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; DEMCHENKO AP, 1986, ULTRAVIOLET SPECTROS, P222; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P6252, DOI 10.1021/bi00441a017; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; GREGORET LM, 1991, PROTEINS, V9, P99, DOI 10.1002/prot.340090204; HOESCH RM, 1989, J BIOL CHEM, V264, P17712; HSIEH JC, 1991, BIOCHEM J, V278, P293, DOI 10.1042/bj2780293; JAKOBSON I, 1977, EUR J BIOCHEM, V77, P253, DOI 10.1111/j.1432-1033.1977.tb11664.x; JAKOBY WB, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P87; KATUSZ RM, 1991, BIOCHEMISTRY-US, V30, P11230, DOI 10.1021/bi00111a006; KUBO Y, 1989, CHEM RES TOXICOL, V2, P144, DOI 10.1021/tx00009a003; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RICCI G, 1991, J BIOL CHEM, V266, P21409; SESAY MA, 1987, J MOL BIOL, V197, P377, DOI 10.1016/0022-2836(87)90133-1; STENBERG G, 1991, BIOCHEM J, V274, P549, DOI 10.1042/bj2740549; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; VANOMMEN B, 1988, J BIOL CHEM, V263, P12939; VANOMMEN B, 1991, BIOCHEM J, V276, P661, DOI 10.1042/bj2760661; WANG RW, 1991, ARCH BIOCHEM BIOPHYS, V286, P574, DOI 10.1016/0003-9861(91)90082-T; ZHANG PH, 1991, J BIOL CHEM, V266, P19475; ZHANG PH, 1990, BIOPOLYMERS, V29, P159, DOI 10.1002/bip.360290121	28	193	194	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4296	4299						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537822				2022-12-27	WOS:A1992HF64200006
J	FABRY, M; SCHAEFER, E; ELLIS, L; KOJRO, E; FAHRENHOLZ, F; BRANDENBURG, D				FABRY, M; SCHAEFER, E; ELLIS, L; KOJRO, E; FAHRENHOLZ, F; BRANDENBURG, D			DETECTION OF A NEW HORMONE CONTACT SITE WITHIN THE INSULIN-RECEPTOR ECTODOMAIN BY THE USE OF A NOVEL PHOTOREACTIVE INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; GROWTH-FACTOR; CYTOPLASMIC DOMAIN; BACULOVIRUS VECTOR; SHORTENED INSULIN; INVITRO POTENCY; INSECT CELLS; BINDING-SITE; REGION; KINASE	We have used a preparation of soluble human insulin receptor ectodomain and a novel photoreactive, biotinylated derivative of insulin (4-azidosalicyloyl(B1-biocytinyl-B2-lysine)-insulin) to identify a new hormone contact site within the extracellular domain of the insulin receptor. The ectodomain was photoaffinity-labeled and digested to completion with trypsin, and the resulting tryptic fragment was purified by either HPLC or by streptavidin-affinity chromatography. The amino terminus of the fragment was identified as Gly390 within the alpha-subunit. These results suggest that residues that are carboxyl-terminal to the cysteine-rich domain, in addition to previously identified regions within the amino terminus of the alpha-subunit, contribute to the insulin binding site. The implications of these results for the de novo folding of the insulin receptor to constitute the hormone binding site are discussed.	RHEIN WESTFAL TH AACHEN,DEUTSCH WOLLFORSCHUNGSINST,VELTMANPL 8,W-5100 AACHEN,GERMANY; TEXAS A&M UNIV SYST,INST BIOSCI & TECHNOL,HOUSTON,TX 77030; MAX PLANCK INST BIOPHYS,W-6000 FRANKFURT,GERMANY	RWTH Aachen University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Max Planck Society								BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BAYER EA, 1990, METHOD ENZYMOL, V184, P415; Blundell T., 1972, ADV PROTEIN CHEM, V26, P279; BRANDENBURG D, 1990, MODERN METHODS PROTE, P305; Carne A F, 1988, Methods Mol Biol, V3, P89, DOI 10.1385/0-89603-126-8:89; CASARETTO M, 1987, BIOL CHEM H-S, V368, P709, DOI 10.1515/bchm3.1987.368.1.709; CHRISTIANSEN K, 1991, P NATL ACAD SCI USA, V88, P249, DOI 10.1073/pnas.88.1.249; CLARK S, 1991, BIOCHEM J, V276, P27, DOI 10.1042/bj2760027; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P318, DOI 10.1073/pnas.69.2.318; CUATRECASAS P, 1990, HDB EXPT PHARM, V92; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; DEMEYTS P, 1976, METHODS RECEPTOR RES, V1, P301; DONNER DB, 1983, J BIOL CHEM, V258, P9413; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; Ellis L, 1988, J Mol Recognit, V1, P25, DOI 10.1002/jmr.300010106; ELLIS L, 1988, J VIROL, V62, P1634, DOI 10.1128/JVI.62.5.1634-1639.1988; FABRY M, 1992, BIOL CHEM H-S, V373, P143, DOI 10.1515/bchm3.1992.373.1.143; FABRY M, 1992, PEPTIDES CHEM BIOL, P72; FISCHER WH, 1986, BIOL CHEM H-S, V367, P999, DOI 10.1515/bchm3.1986.367.2.999; FISCHER WH, 1985, BIOL CHEM H-S, V366, P521, DOI 10.1515/bchm3.1985.366.1.521; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HEFFETZ D, 1986, J BIOL CHEM, V261, P889; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HSUAN JJ, 1989, BIOCHEM J, V259, P519, DOI 10.1042/bj2590519; JOHNSON JD, 1988, P NATL ACAD SCI USA, V85, P7516, DOI 10.1073/pnas.85.20.7516; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KOWIT JD, 1982, ANAL BIOCHEM, V123, P86, DOI 10.1016/0003-2697(82)90627-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; MORRISON BD, 1988, J BIOL CHEM, V263, P7806; MOSTHAF L, 1990, EMBO J, V9, P2408; NAKAGAWA SH, 1986, J BIOL CHEM, V261, P7332; PILCH PF, 1980, SCIENCE, V210, P1152, DOI 10.1126/science.7003712; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SISSOM J, 1989, BIOCHEM J, V261, P119, DOI 10.1042/bj2610119; SISSOM JF, 1991, BIOCHEM BIOPH RES CO, V177, P764, DOI 10.1016/0006-291X(91)91854-6; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P2722, DOI 10.1021/bi00432a053; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WHITTAKER J, 1988, J BIOL CHEM, V263, P3063; XU QY, 1990, J BIOL CHEM, V265, P18673; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; YIP CC, 1991, BIOCHEMISTRY-US, V30, P695, DOI 10.1021/bi00217a016; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	50	85	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8950	8956						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577732				2022-12-27	WOS:A1992HR85400040
J	WATSON, RB; WALLIS, GA; HOLMES, DF; VILJOEN, D; BYERS, PH; KADLER, KE				WATSON, RB; WALLIS, GA; HOLMES, DF; VILJOEN, D; BYERS, PH; KADLER, KE			EHLERS-DANLOS SYNDROME TYPE-VIIB - INCOMPLETE CLEAVAGE OF ABNORMAL TYPE-I PROCOLLAGEN BY N-PROTEINASE INVITRO RESULTS IN THE FORMATION OF COPOLYMERS OF COLLAGEN AND PARTIALLY CLEAVED PNCOLLAGEN THAT ARE NEAR CIRCULAR IN CROSS-SECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSION ELECTRON-MICROSCOPY; CHICK-EMBRYO TENDONS; CONNECTIVE-TISSUE; FIBRILS DENOVO; PC-COLLAGEN; POLYMERIZATION; IDENTIFICATION; PURIFICATION; MUTATION; VARIANT	We have shown that a child with Ehlers Danlos syndrome (EDS) type VII has a G to A transition at the first nucleotide of intron 6 in one of her COL1A2 alleles. Half of the cDNA clones prepared from the proband's pro-alpha-2(I) mRNA lacked exon 6. The type I procollagen secreted by the proband's dermal fibroblasts in culture was purified, and collagen fibrils were generated in vitro by cleavage of the procollagen with the procollagen N- and C-proteinases. Incubation of the procollagen with N-proteinase resulted in a 1:1 mixture of pCcollagen and uncleaved procollagen. Incubation of this mixture with C-proteinase generated collagen and abnormal pNcollagen (pNcollagen-ex6) that readily copolymerized into fibrils. By electron microscopy these fibrils resembled the hieroglyphic fibrils seen in the N-proteinase-deficient skin of dermatosparactic animals and humans and were distinct from the near circular cross-section fibrils seen in the tissues of individuals with EDS type VII. Further incubation of the hieroglyphic fibrils with N-proteinase resulted in partial cleavage of the pNcollagen-ex6 in which the abnormal pN-alpha-2(I) chains remained intact. These fibrils were not hieroglyphic but were near circular in cross-section. Fibrils formed from collagen and pNcollagen-ex6 that had been partially cleaved with elevated amounts of N-proteinase prior to fibril formation were also near circular in cross-section. The results are consistent with a model of collagen fibril formation in which the intact N-propeptides are located exclusively at the surface of the hieroglyphic fibrils. Partial cleavage of the pNcollagen-ex6 by N-proteinase allows the N-propeptides to be incorporated within the body of the fibrils. The model provides an explanation for the morphology and molecular composition of collagen fibrils in the tissues of patients with EDS type VII.	UNIV MANCHESTER,SCH BIOL SCI,DEPT MED BIOPHYS,MANCHESTER M13 9PT,LANCS,ENGLAND; UNIV CAPE TOWN,DEPT HUMAN GENET,CAPE TOWN 7945,SOUTH AFRICA; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of Manchester; University of Cape Town; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	WATSON, RB (corresponding author), UNIV MANCHESTER,SCH BIOL SCI,DEPT BIOCHEM & MOLEC BIOL,OXFORD RD,MANCHESTER M13 9PT,LANCS,ENGLAND.		KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683; Byers, Peter H./0000-0001-7786-7030	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR021557] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR21557] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; BERGER J, 1985, BIOCHEMISTRY-US, V25, P600; BIRK DE, 1989, P NATL ACAD SCI USA, V86, P4549, DOI 10.1073/pnas.86.12.4549; BYERS PH, 1989, METABOLIC BASIS INHE, P2805; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P1367, DOI 10.1002/bip.360280803; CHAPMAN JA, BIOPOLYMERS, V28, P2201; Chromczynski P, 1987, ANAL BIOCHEM, V162, P156; COHN DH, 1990, CLIN PERINATOL, V17, P793, DOI 10.1016/S0095-5108(18)30546-3; COUNTS DF, 1980, J INVEST DERMATOL, V74, P96, DOI 10.1111/1523-1747.ep12519991; DOMBROWSKI KE, 1988, J BIOL CHEM, V263, P16545; ENGEL A, 1982, MICRON, V13, P425, DOI 10.1016/0047-7206(82)90094-2; ENGEL A, 1978, ULTRAMICROSCOPY, V3, P273, DOI 10.1016/S0304-3991(78)80037-0; ENGEL A, 1981, ULTRAMICROSCOPY, V7, P45, DOI 10.1016/0304-3991(81)90022-X; ENGEL A, 1984, J ULTRA MOL STRUCT R, V88, P105, DOI 10.1016/S0022-5320(84)80003-9; EYRE DR, 1985, J BIOL CHEM, V260, P1322; FIEDLERNAGY C, 1981, ARCH BIOCHEM BIOPHYS, V212, P668, DOI 10.1016/0003-9861(81)90411-2; FJOLSTAD M, 1974, J PATHOL, V112, P183, DOI 10.1002/path.1711120309; FREEMAN R, 1981, J MICROSC-OXFORD, V122, P275, DOI 10.1111/j.1365-2818.1981.tb01267.x; FRIEDEN C, 1983, BIOCHEMISTRY-US, V22, P5836, DOI 10.1021/bi00294a023; FRIEDEN C, 1989, TRENDS BIOCHEM SCI, V14, P283, DOI 10.1016/0968-0004(89)90065-0; GREENBERG ME, 1987, CURRENT PROTOCOLS MO, V1, P2; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOLBROOK KA, 1980, J INVEST DERMATOL, V74, P100, DOI 10.1111/1523-1747.ep12520000; HOLMES DF, 1991, J MOL BIOL, V220, P111, DOI 10.1016/0022-2836(91)90385-J; KADLER KE, 1988, J BIOL CHEM, V263, P10517; KADLER KE, 1990, ANN NY ACAD SCI, V580, P214, DOI 10.1111/j.1749-6632.1990.tb17930.x; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KADLER KE, 1990, BIOCHEM J, V268, P339, DOI 10.1042/bj2680339; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUFFER MA, 1975, ENTROPY DRIVEN PROCE, V20; LENAERS A, 1971, EUR J BIOCHEM, V23, P533, DOI 10.1111/j.1432-1033.1971.tb01651.x; LICHTENSTEIN JR, 1973, SCIENCE, V182, P298, DOI 10.1126/science.182.4109.298; MANIATIS T, 1982, MOL CLONING, P213; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; NA GC, 1989, BIOCHEMISTRY-US, V28, P7153, DOI 10.1021/bi00444a004; NICHOLLS AC, 1991, HUM GENET, V87, P193, DOI 10.1007/BF00204180; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; OOSAWA F, 1975, THERMODYNAMICS POLYM, P109; PELTONEN L, 1980, P NATL ACAD SCI USA, V71, P6179; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANZAWA K, 1985, J BIOL CHEM, V260, P1120; TIMASHEFF SN, 1980, ANNU REV BIOCHEM, V49, P565, DOI 10.1146/annurev.bi.49.070180.003025; VASAN NS, 1991, AM J HUM GENET, V48, P305; VILJOEN D, 1987, CLIN GENET, V32, P196; WEIL D, 1990, J BIOL CHEM, V265, P16007; WEIL D, 1989, EMBO J, V8, P1705, DOI 10.1002/j.1460-2075.1989.tb03562.x; WEIL D, 1988, J BIOL CHEM, V263, P8561; WILLING MC, 1990, J CLIN INVEST, V85, P285; WIRTZ MK, 1990, J BIOL CHEM, V265, P6312; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0	54	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9093	9100						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1577745				2022-12-27	WOS:A1992HR85400061
J	GILDERSLEEVE, RF; CROSS, AR; CULLEN, KE; FAGEN, AP; WILLIAMS, RC				GILDERSLEEVE, RF; CROSS, AR; CULLEN, KE; FAGEN, AP; WILLIAMS, RC			MICROTUBULES GROW AND SHORTEN AT INTRINSICALLY VARIABLE RATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIDEO LIGHT-MICROSCOPY; DYNAMIC INSTABILITY; INDIVIDUAL MICROTUBULES; GTP HYDROLYSIS; BRAIN TUBULIN; ELECTRON-MICROSCOPY; SURFACE LATTICE; LENGTH CHANGES; LIVING CELLS; POLYMERIZATION	Microtubules were assembled from pure tubulin with axonemal pieces serving as nuclei. They were observed by video-enhanced differential-interference-contrast light microscopy. Their lengths were measured from videotaped images at frequent intervals (0.13-5 s). Error analysis indicated that the uncertainty in measuring a single length was quite small; the 95% confidence limit approximated the microscope's limit of resolution. Rates of growth and shortening of the dynamically unstable microtubules, obtained from the length-versus-time data, were found to be highly variable. The variability was far too large to be attributed to known random error of measurement and must be a property of the microtubules. Further experiments were aimed at finding its structural cause. The variability of rates exhibited by a single microtubule was as great as that of the whole population. The locations at which a growing microtubule changed its rate of growth were not related to the locations at which rates changed during its subsequent shortening. The cause of the variability must therefore be both small relative to the size of a microtubule and transient relative to its lifetime. Fluctuations in configuration of the microtubule's cap appear to be the likeliest source.	VANDERBILT UNIV, DEPT MOLEC BIOL, NASHVILLE, TN 37232 USA	Vanderbilt University				Fagen, Adam/0000-0002-7545-8484	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025638] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25638] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN C, 1974, J MOL BIOL, V90, P381, DOI 10.1016/0022-2836(74)90381-7; BANERJEE A, 1990, J BIOL CHEM, V265, P1794; BANERJEE A, 1991, J BIOL CHEM, V266, P1689; BAYLEY PM, 1990, J CELL SCI, V95, P33; BELL CW, 1982, METHOD CELL BIOL, V24, P373; BERG HC, 1984, J GEN MICROBIOL, V130, P2915; BINDER LI, 1975, P NATL ACAD SCI USA, V72, P1122, DOI 10.1073/pnas.72.3.1122; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON PR, 1978, J CELL BIOL, V77, P120, DOI 10.1083/jcb.77.1.120; CAPLOW M, 1988, J BIOL CHEM, V263, P10344; CAPLOW M, 1989, BIOCHEMISTRY-US, V28, P8136, DOI 10.1021/bi00446a026; CARLIER MF, 1989, INT REV CYTOL, V115, P139; CARLIER MF, 1989, BIOCHEMISTRY-US, V28, P1783, DOI 10.1021/bi00430a054; CARLIER MF, 1988, BIOCHEMISTRY-US, V27, P3555, DOI 10.1021/bi00410a005; CARLIER MF, 1981, BIOCHEMISTRY-US, V20, P1918, DOI 10.1021/bi00510a030; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; CHEN YD, 1985, P NATL ACAD SCI USA, V82, P1131, DOI 10.1073/pnas.82.4.1131; CHEN YT, 1990, CELL MOTIL CYTOSKEL, V17, P214, DOI 10.1002/cm.970170308; CLEVELAND DW, 1987, J CELL BIOL, V104, P381, DOI 10.1083/jcb.104.3.381; CORREIA JJ, 1987, J BIOL CHEM, V262, P17278; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; CROSS AR, 1991, CELL MOTIL CYTOSKEL, V20, P272, DOI 10.1002/cm.970200403; DETRICH HW, 1985, J BIOL CHEM, V260, P9479; DYE RB, 1992, IN PRESS CELL MOTIL; ENGELBORGHS Y, 1989, MICROTUBULE PROTEINS, P1; EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; FARRELL KW, 1987, J CELL BIOL, V104, P1035, DOI 10.1083/jcb.104.4.1035; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GEORGE HJ, 1981, BIOCHEMISTRY-US, V20, P2402, DOI 10.1021/bi00512a006; HILL TL, 1981, BIOPHYS J, V33, P353, DOI 10.1016/S0006-3495(81)84900-4; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P4803, DOI 10.1073/pnas.77.8.4803; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; JOSHI HC, 1990, CELL MOTIL CYTOSKEL, V16, P159, DOI 10.1002/cm.970160302; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; MANDELKOW EM, 1986, J CELL BIOL, V102, P1067, DOI 10.1083/jcb.102.3.1067; MANDELKOW EM, 1985, J MOL BIOL, V181, P123, DOI 10.1016/0022-2836(85)90330-4; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MARGOLIS RL, 1990, EMBO J, V9, P4095, DOI 10.1002/j.1460-2075.1990.tb07631.x; MCEWEN B, 1980, J MOL BIOL, V139, P123, DOI 10.1016/0022-2836(80)90300-9; MELKI R, 1990, BIOCHEMISTRY-US, V29, P8921, DOI 10.1021/bi00490a007; MELKI R, 1989, BIOCHEMISTRY-US, V28, P9143, DOI 10.1021/bi00449a028; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; OBRIEN ET, 1990, BIOCHEMISTRY-US, V29, P6648, DOI 10.1021/bi00480a014; OBRIEN ET, 1987, BIOCHEMISTRY-US, V26, P4148, DOI 10.1021/bi00387a061; PIERSON GB, 1978, J CELL BIOL, V76, P223, DOI 10.1083/jcb.76.1.223; ROARK DE, 1969, ANN NY ACAD SCI, V164, P245, DOI 10.1111/j.1749-6632.1969.tb14043.x; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SCHEELE RB, 1982, J MOL BIOL, V154, P485, DOI 10.1016/S0022-2836(82)80008-9; SCHNAPP BJ, 1986, METHOD ENZYMOL, V134, P561; SCHULZE E, 1988, NATURE, V334, P356, DOI 10.1038/334356a0; SIMON JR, 1990, J CELL SCI, V96, P571; STEWART RJ, 1990, BIOCHEMISTRY-US, V29, P6489, DOI 10.1021/bi00479a022; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; SUPRENANT KA, 1991, CELL MOTIL CYTOSKEL, V19, P207, DOI 10.1002/cm.970190308; VOTER WA, 1991, CELL MOTIL CYTOSKEL, V18, P55, DOI 10.1002/cm.970180106; VOTER WA, 1984, J BIOL CHEM, V259, P430; WADE RH, 1990, J MOL BIOL, V212, P775, DOI 10.1016/0022-2836(90)90236-F; WALKER RA, 1991, J CELL BIOL, V114, P73, DOI 10.1083/jcb.114.1.73; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WEISENBERG RC, 1976, BIOCHEMISTRY-US, V15, P4248, DOI 10.1021/bi00664a018; WILLIAMS R C JR, 1992, P151; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	64	111	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					7995	8006						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569058				2022-12-27	WOS:A1992HQ18500010
J	KOCHHAR, S; HUNZIKER, PE; LEONGMORGENTHALER, P; HOTTINGER, H				KOCHHAR, S; HUNZIKER, PE; LEONGMORGENTHALER, P; HOTTINGER, H			PRIMARY STRUCTURE, PHYSICOCHEMICAL PROPERTIES, AND CHEMICAL MODIFICATION OF NAD+-DEPENDENT D-LACTATE DEHYDROGENASE - EVIDENCE FOR THE PRESENCE OF ARG-235, HIS-303, TYR-101, AND TRP-19 AT OR NEAR THE ACTIVE-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; AFFINITY CHROMATOGRAPHY; MALATE-DEHYDROGENASE; LACTOBACILLUS-CASEI; N-BROMOSUCCINIMIDE; PROTEINS; BINDING; PURIFICATION; RESOLUTION; RESIDUE	The NAD+-dependent D-lactate dehydrogenase was purified to apparent homogeneity from Lactobacillus bulgaricus and its complete amino acid sequence determined. Two gaps in the polypeptide chain (10 residues) were filled by the deduced amino acid sequence of the polymerase chain reaction amplified D-lactate dehydrogenase gene sequence. The enzyme is a dimer of identical subunits (specific activity 2800 +/- 100 units/min at 25-degrees-C). Each subunit contains 332 amino acid residues; the calculated subunit M(r) being 36,831. Isoelectric focusing showed at least four protein bands between pH 4.0 and 4.7; the subunit M(r) of each subform is 36,000. The pH dependence of the kinetic parameters, K(m), V(m), and k(cat)/K(m), suggested an enzymic residue with a pK(a) value of about 7 to be involved in substrate binding as well as in the catalytic mechanism. Treatment of the enzyme with group-specific reagents 2,3-butanedione, diethylpyrocarbonate, tetranitromethane, or N-bromosuccinimide resulted in complete loss of enzyme activity. In each case, inactivation followed pseudo first-order kinetics. Inclusion of pyruvate and/or NADH reduced the inactivation rates manyfold, indicating the presence of arginine, histidine, tyrosine, and tryptophan residues at or near the active site. Spectral properties of chemically modified enzymes and analysis of kinetics of inactivation showed that the loss of enzyme activity was due to modification of a single arginine, histidine, tryptophan, or tyrosine residue. Peptide mapping in conjunction with peptide purification and amino acid sequence determination showed that Arg-235, His-303, Tyr-101, and Trp-19 were the sites of chemical modification. Arg-235 and His-303 are involved in the binding of 2-oxo acid substrate whereas other residues are involved in binding of the cofactor.	UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND	University of Zurich	KOCHHAR, S (corresponding author), NESTLE RES CTR,VERS CHEZ LES BLANC,POB 44,CH-1000 LAUSANNE 26,SWITZERLAND.							ABADZAPATERO C, 1987, J MOL BIOL, V198, P445, DOI 10.1016/0022-2836(87)90293-2; BERGHAUSER J, 1971, H-S Z PHYSIOL CHEM, V352, P52, DOI 10.1515/bchm2.1971.352.1.52; BIRKTOFT JJ, 1983, J BIOL CHEM, V258, P472; BOHME HJ, 1972, J CHROMATOGR, V69, P209, DOI 10.1016/S0021-9673(00)83103-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODELIUS P, 1973, FEBS LETT, V35, P223, DOI 10.1016/0014-5793(73)80290-X; BUEHNER M, 1984, 13TH INT C CRYST HAM; CAMPESE D, 1984, BIOCHIM BIOPHYS ACTA, V784, P147, DOI 10.1016/0167-4838(84)90121-3; CHRISTEN P, 1968, BIOCHEMISTRY-US, V7, P1531, DOI 10.1021/bi00844a041; CLARKE AR, 1989, TRENDS BIOCHEM SCI, V14, P101, DOI 10.1016/0968-0004(89)90131-X; CUATRECASAS P, 1968, J BIOL CHEM, V243, P4787; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DENICOLASEOANE A, 1990, J BIOL CHEM, V265, P3691; DENNIS D, 1960, J BIOL CHEM, V235, P810; EVENTOFF W, 1974, BIOCHIM BIOPHYS ACTA, V341, P327, DOI 10.1016/0005-2744(74)90225-3; FESTE A, 1981, J BIOL CHEM, V256, P6374; Fontana A, 1972, Methods Enzymol, V25, P419, DOI 10.1016/S0076-6879(72)25037-6; GARLAND RC, 1973, ARCH BIOCHEM BIOPHYS, V157, P36, DOI 10.1016/0003-9861(73)90386-X; GARVIE EI, 1980, MICROBIOL REV, V44, P106, DOI 10.1128/MMBR.44.1.106-139.1980; GASSER F, 1970, J GEN MICROBIOL, V62, P241, DOI 10.1099/00221287-62-2-241; Grafin DE, 1990, METHOD ENZYMOL, V182, P425; GRAU UM, 1981, J MOL BIOL, V151, P289, DOI 10.1016/0022-2836(81)90516-7; GREENLER JM, 1989, PLANT MOL BIOL, V13, P139, DOI 10.1007/BF00016133; Gros E., 1967, METHOD ENZYMOL, V11, P238; HANCOCK WS, 1975, J AM CHEM SOC, V97, P7488, DOI 10.1021/ja00859a018; HART KW, 1987, BIOCHEM BIOPH RES CO, V146, P346, DOI 10.1016/0006-291X(87)90731-5; HART KW, 1987, BIOCHIM BIOPHYS ACTA, V914, P294, DOI 10.1016/0167-4838(87)90289-5; Hayashi R, 1977, Methods Enzymol, V47, P84; HOGREFE HH, 1987, J BIOL CHEM, V262, P13155; HOLBROOK JJ, 1973, BIOCHEM J, V131, P729, DOI 10.1042/bj1310729; Holbrook JJ., 1975, ENZYMES, P191; HOTTINGER H, 1987, GENE, V60, P75, DOI 10.1016/0378-1119(87)90215-0; HUNZIKER PE, 1980, BIOCHEM J, V187, P515, DOI 10.1042/bj1870515; IWATA S, 1989, J BIOCHEM-TOKYO, V106, P558, DOI 10.1093/oxfordjournals.jbchem.a122894; JECKEL D, 1971, H-S Z PHYSIOL CHEM, V352, P769, DOI 10.1515/bchm2.1971.352.1.769; KAIDE S, 1991, J BIOCHEM-TOKYO, V109, P6; Kandler O., 1986, BERGEYS MANUAL SYSTE, P1208; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEJOHN HB, 1971, J BIOL CHEM, V246, P2116; LERCH HP, 1989, GENE, V78, P47, DOI 10.1016/0378-1119(89)90313-2; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LIU WH, 1968, BIOCHEMISTRY-US, V7, P2886, DOI 10.1021/bi00848a027; LONG GL, 1973, ARCH BIOCHEM BIOPHYS, V154, P711, DOI 10.1016/0003-9861(73)90026-X; LONG GL, 1968, SCIENCE, V162, P685, DOI 10.1126/science.162.3854.685; LONG GL, 1973, ARCH BIOCHEM BIOPHYS, V154, P696, DOI 10.1016/0003-9861(73)90025-8; Lundblad R.L, 1984, CHEM REAGENTS PROTEI, VI; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V2; MAYR U, 1982, EUR J BIOCHEM, V126, P549, DOI 10.1111/j.1432-1033.1982.tb06816.x; Miles E W, 1977, Methods Enzymol, V47, P431; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OCARRA P, 1972, FEBS LETT, V21, P281, DOI 10.1016/0014-5793(72)80183-2; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHNISHI M, 1983, BIOCHIM BIOPHYS ACTA, V744, P64, DOI 10.1016/0167-4838(83)90341-2; PARKER DM, 1982, BIOCHEM J, V201, P465, DOI 10.1042/bj2010465; PFLEIDERER G, 1967, EUR J BIOCHEM, V2, P171, DOI 10.1111/j.1432-1033.1967.tb00122.x; PIONTEK K, 1990, PROTEINS, V7, P74, DOI 10.1002/prot.340070108; RAETZ CRH, 1975, P NATL ACAD SCI USA, V72, P2274, DOI 10.1073/pnas.72.6.2274; RIORDAN JF, 1968, BIOCHEMISTRY-US, V7, P1525, DOI 10.1021/bi00844a040; RULE GS, 1985, J BACTERIOL, V161, P1059, DOI 10.1128/JB.161.3.1059-1068.1985; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENLEIN PV, 1989, J BACTERIOL, V171, P6084, DOI 10.1128/jb.171.11.6084-6092.1989; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; SONDEREGGER P, 1985, EMBO J, V4, P1395, DOI 10.1002/j.1460-2075.1985.tb03792.x; Spande T.F., 1967, DETERMINATION TRYPTO, P498; TAGUCHI H, 1991, J BIOL CHEM, V266, P12588; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; WILKS HM, 1990, BIOCHEMISTRY-US, V29, P8587, DOI 10.1021/bi00489a013; YANG PC, 1972, BIOCHEMISTRY-US, V11, P2218, DOI 10.1021/bi00762a002; YANKEELOV JA, 1970, BIOCHEMISTRY-US, V9, P2433, DOI 10.1021/bi00814a007	72	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8499	8513						15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1569100				2022-12-27	WOS:A1992HQ18500084
J	LEVY, FO; GUDERMANN, T; PEREZREYES, E; BIRNBAUMER, M; KAUMANN, AJ; BIRNBAUMER, L				LEVY, FO; GUDERMANN, T; PEREZREYES, E; BIRNBAUMER, M; KAUMANN, AJ; BIRNBAUMER, L			MOLECULAR-CLONING OF A HUMAN SEROTONIN RECEPTOR (S12) WITH A PHARMACOLOGICAL PROFILE RESEMBLING THAT OF THE 5-HT1D SUBTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; GTP-BINDING-PROTEIN; ADENYLATE-CYCLASE; 5-HYDROXYTRYPTAMINE RECEPTOR; GUANINE-NUCLEOTIDE; COMPLEMENTARY-DNA; BRAIN MEMBRANES; FAMILY; EXPRESSION; SEQUENCE	We report the molecular cloning of a fragment of human genomic DNA called S12, containing an open reading frame of 1170 nucleotides, which encodes a receptor for serotonin of 390 amino acids. The receptor function of the S12 protein was demonstrated by functional expression in mouse LS12 cells obtained by stable transfection of Ltk- cells, and LM5S12 cells, derived from LM5 cells (Ltk- cells previously transfected with the M5 muscarinic acetylcholine receptor). Adenylyl cyclase studies showed that the S12 receptor is able to mediate inhibition of adenylyl cyclase in response to serotonin in both types of cells. As studied in LM5S12 cells, the S12 receptor did not promote Ca2+ mobilization from internal stores, nor did it significantly modulate the sustained increase in [Ca2+]i elicited by stimulation of the phospholipase C stimulating M5 acetylcholine receptor. The pharmacologic profile of S12 as seen in adenylyl cyclase assays is as follows: (EC50 in nM): serotonin, full agonist (37 nM), 5-carboxamidotryptamine, full agonist (10 nM), sumatriptan, full agonist (50 nM), metergoline, partial agonist (10 nM), methysergide, partial agonist (40 nM), yohimbine, partial agonist (150 nM), metitepin, antagonist (K(B) = 0.7 to 1.2 nM). We propose that the human S12 serotonin receptor is a receptor of the 5-hydroxytryptamine1D subtype.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,CLIN PHARMACOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND; SMITHKLINE BEECHAM PHARMACEUT,WELWYN GARDEN CIT AL6 9AR,HERTS,ENGLAND; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030; BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; GlaxoSmithKline; Baylor College of Medicine; Baylor College of Medicine	LEVY, FO (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019318] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD-09581, R01-HD-5198] Funding Source: Medline; NIDDK NIH HHS [R37-DK-19318] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOWITZ J, 1982, ENDOCRINOLOGY, V110, P336, DOI 10.1210/endo-110-2-336; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BIRNBAUMER L, 1976, ENDOCRINOLOGY, V99, P163, DOI 10.1210/endo-99-1-163; BIRNBAUMER M, 1990, MOL ENDOCRINOL, V4, P245, DOI 10.1210/mend-4-2-245; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; BRADLEY PB, 1986, NEUROPHARMACOLOGY, V25, P563, DOI 10.1016/0028-3908(86)90207-8; BRANCHEK TA, 1988, J NEUROSCI, V8, P2582; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUMUIS A, 1988, MOL PHARMACOL, V34, P880; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; FARGIN A, 1989, J BIOL CHEM, V264, P14848; FOZARD J, 1989, PERIPHERAL ACTIONS 5; FRAZER A, 1990, ANNU REV PHARMACOL, V30, P307; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GUDERMANN T, 1992, J BIOL CHEM, V267, P4429; HAMBLIN MW, 1991, MOL PHARMACOL, V40, P143; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HERRICKDAVIS K, 1988, J NEUROCHEM, V51, P1906, DOI 10.1111/j.1471-4159.1988.tb01176.x; HEURING RE, 1987, J NEUROSCI, V7, P894; HOYER D, 1991, J RECEPTOR RES, V11, P197, DOI 10.3109/10799899109066399; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; JULIUS D, 1990, P NATL ACAD SCI USA, V87, P928, DOI 10.1073/pnas.87.3.928; KAUMANN AJ, 1990, BRIT J PHARMACOL, V100, P879, DOI 10.1111/j.1476-5381.1990.tb14108.x; KAUMANN AJ, 1990, N-S ARCH PHARMACOL, V342, P619; KIT S, 1963, EXP CELL RES, V31, P297, DOI 10.1016/0014-4827(63)90007-7; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEONHARDT S, 1989, J NEUROCHEM, V53, P465, DOI 10.1111/j.1471-4159.1989.tb07357.x; LEVY FO, 1992, FEBS LETT, V296, P201, DOI 10.1016/0014-5793(92)80379-U; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LIAO CF, 1990, J BIOL CHEM, V265, P11273; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MATTERA R, 1986, FEBS LETT, V206, P36, DOI 10.1016/0014-5793(86)81336-9; MOLDERINGS GJ, 1990, N-S ARCH PHARMACOL, V342, P371; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRITCHETT DB, 1988, EMBO J, V7, P4135, DOI 10.1002/j.1460-2075.1988.tb03308.x; RAYMOND JR, 1991, J BIOL CHEM, V266, P372; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLICKER E, 1989, N-S ARCH PHARMACOL, V340, P45; SCHOEFFTER P, 1988, N-S ARCH PHARMACOL, V337, P602; SCHOEFFTER P, 1989, N-S ARCH PHARMACOL, V340, P285; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUMNER MJ, 1989, BRIT J PHARMACOL, V97, P292, DOI 10.1111/j.1476-5381.1989.tb11953.x; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WAEBER C, 1990, NEUROCHEM RES, V15, P567, DOI 10.1007/BF00973745; WAEBER C, 1989, SYNAPSE, V4, P168, DOI 10.1002/syn.890040212; WAEBER C, 1988, N-S ARCH PHARMACOL, V337, P595; WANG Y, 1988, BIOTECHNIQUES, V6, P843; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	60	79	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7553	7562						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559993				2022-12-27	WOS:A1992HN48500052
J	PORTER, DJT				PORTER, DJT			PURINE NUCLEOSIDE PHOSPHORYLASE - KINETIC MECHANISM OF THE ENZYME FROM CALF SPLEEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; INHIBITION; PURIFICATION; TOXICITY	Ribose 1-phosphate, phosphate, and acyclovir diphosphate quenched the fluorescence of purine nucleoside phosphorylase at pH 7.1 and 25-degrees-C. The fluorescence of enzyme-bound guanine was similar to that of anionic guanine in ethanol. Guanine and ribose 1-phosphate bound to free enzyme, whereas inosine and guanosine were not bound to free enzyme in the absence of phosphate. Thus, synthesis proceeded by a random mechanism, and phosphorolysis proceeded by an ordered mechanism. Steady-state kinetic data for the phosphorolysis of 100-mu-M guanosine were fitted to a bifunctional kinetic model with catalytic rate constants of 22 and 1.3 s-1. The dissociation rate constants for guanine from the enzyme-guanine complex at high and low phosphate concentrations were similar to the catalytic rate constants. Fluorescence changes of the enzyme during phosphorolysis suggested that ribose 1-phosphate dissociated from the enzyme ribose 1-phosphate-guanine complex rapidly and that guanine dissociated from the enzyme-guanine complex slowly. The association and dissociation rate constants for acyclovir diphosphate, a potent inhibitor of the enzyme (Tuttle, J. V., and Krenitsky, T. A. (1984) J. Biol. Chem. 259, 4065-4069), were also dependent on phosphate concentration. The effects of phosphate are discussed in terms of a dual functional binding site for phosphate.			PORTER, DJT (corresponding author), WELLCOME RES LABS,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709, USA.							AGARWAL RP, 1969, J BIOL CHEM, V244, P644; ASSENZA SP, 1984, J CHROMATOGR, V289, P355, DOI 10.1016/S0021-9673(00)95101-X; Bevington P.R., 1969, DATA REDUCTION ERROR; BZOWSKA A, 1991, BIOCHEM PHARMACOL, V41, P1791, DOI 10.1016/0006-2952(91)90117-N; CARLSON JD, 1979, BIOCHIM BIOPHYS ACTA, V571, P21, DOI 10.1016/0005-2744(79)90221-3; CARLSON JD, 1979, BIOCHIM BIOPHYS ACTA, V566, P259, DOI 10.1016/0005-2744(79)90029-9; DADDONA PE, 1986, J BIOL CHEM, V261, P1667; DEMPCY RO, 1991, BIOCHEMISTRY-US, V30, P8480, DOI 10.1021/bi00098a028; EALICK SE, 1990, J BIOL CHEM, V265, P1812; FRIEDKIN M, 1950, J BIOL CHEM, V184, P449; HEMMINKI K, 1980, ACTA CHEM SCAND B, V34, P603, DOI 10.3891/acta.chem.scand.34b-0603; KALCKAR HM, 1947, J BIOL CHEM, V167, P429; KAZMERS IS, 1981, SCIENCE, V214, P1137, DOI 10.1126/science.6795718; KIM BK, 1968, J BIOL CHEM, V243, P1771; KIM BK, 1968, J BIOL CHEM, V243, P1763; KRENITSKY TA, 1967, MOL PHARMACOL, V3, P526; KRENITSKY TA, 1990, J BIOL CHEM, V265, P3066; LEWIS AS, 1976, BIOCHEMISTRY-US, V15, P4451, DOI 10.1021/bi00665a018; LEWIS AS, 1979, J BIOL CHEM, V254, P9927; MOYER TP, 1976, ARCH BIOCHEM BIOPHYS, V174, P622, DOI 10.1016/0003-9861(76)90391-X; NAKAMURA CE, 1986, BIOCHEM PHARMACOL, V35, P133, DOI 10.1016/0006-2952(86)90504-6; PARKS RE, 1972, ENZYMES, V7, P483; ROPP PA, 1991, J BIOL CHEM, V266, P7682; SALAMONE SJ, 1982, BIOCHEMISTRY-US, V21, P6383, DOI 10.1021/bi00268a010; SHEWACH DS, 1986, CANCER RES, V46, P519; SICAR JC, 1988, DRUGS FUTURE, V13, P653; SICAR JC, 1986, J MED CHEM, V29, P1804; STEIN JM, 1987, BIOCHEM PHARMACOL, V36, P1237, DOI 10.1016/0006-2952(87)90076-1; STOECKLER JD, 1982, BIOCHEM PHARMACOL, V31, P163, DOI 10.1016/0006-2952(82)90206-4; STOECKLER JD, 1986, CANCER RES, V46, P1774; STOECKLER JD, 1986, FASEB J, V45, P2773; TUTTLE JV, 1984, J BIOL CHEM, V259, P4065; UDENFRIEND S, 1962, ANAL BIOCHEM, V3, P49, DOI 10.1016/0003-2697(62)90043-X; UMEMURA S, 1982, J BIOL CHEM, V257, P13374	34	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7342	7351						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1559977				2022-12-27	WOS:A1992HN48500023
J	CMARIK, JL; HUMPHREYS, WG; BRUNER, KL; LLOYD, RS; TIBBETTS, C; GUENGERICH, FP				CMARIK, JL; HUMPHREYS, WG; BRUNER, KL; LLOYD, RS; TIBBETTS, C; GUENGERICH, FP			MUTATION SPECTRUM AND SEQUENCE ALKYLATION SELECTIVITY RESULTING FROM MODIFICATION OF BACTERIOPHAGE M13MP18 DNA WITH S-(2-CHLOROETHYL)GLUTATHIONE - EVIDENCE FOR A ROLE OF S-(2-(N7-GUANYL)ETHYL)GLUTATHIONE AS A MUTAGENIC LESION FORMED FROM ETHYLENE DIBROMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACTERIAL-CELLS; 1,2-DIBROMOETHANE; SPECIFICITY; GLUTATHIONE; POLYMERASE; ADDUCTS; ACTIVATION; BINDING; GUANINE	The major DNA adduct (> 95% total) resulting from the bioactivation of ethylene dibromide by conjugation with GSH is S-(2-(N7-guanyl)ethyl)GSH. The mutagenic potential of this adduct has been uncertain, however, because the observed mutagenicity might be caused by other adducts present at much lower levels, e.g. S-(2-(N1-adenyl)ethyl)GSH. To assess the formation of other potential adducts, S-(2-(N3-deoxycytidyl)ethyl)GSH, S-(2-(O6-deoxyguanosyl)ethyl)GSH, and S-(2-(N2-deoxyguanosyl)ethyl)GSH were prepared and used as standards in the analysis of calf thymus DNA modified by treatment with [1,2-C-14]ethylene dibromide and GSH in the prsence of rat liver cytosol; only minor amounts (< 0.2%) were found. A forward mutation assay in (repair-deficient) Salmonella typhimurium TA100 and sequence analysis were utilized to determine the type, site, and frequency of mutations in a portion of the lacZ gene resulting from in vitro modification of bacteriophage M13mp 18 DNA with S-(2-chloroethyl)GSH, an analog of the ethylene dibromide-GSH conjugate. An adduct level of approximately 8 nmol (mg DNA)-1 resulted in a 10-fold increase in mutation frequency relative to the spontaneous level. The spectrum of spontaneous mutations was quite varied, but the spectrum of S-(2-chloroethyl)GSH-induced mutations consisted primarily of base substitutions, of which G:C to A:T transitions accounted for 75% (70% of the total mutations). All available evidence implicates S-(2-(N7-guanyl)ethyl)GSH as the cause of these mutations inasmuch as the levels of the minor adducts are not consistent with the mutation frequency observed in this system. The sequence selectivity of alkylation was determined by treatment of end-labeled lac DNA fragments with S-(2-chloroethyl)GSH, cleavage of the DNA at adduct sites, and electrophoretic analysis. Comparison of the sequence selectivity with the mutation spectrum revealed no obligate relationship between the extent of adduct formation and the number of mutations which resulted at different sites. We suggest that the mechanism of mutagenesis involves DNA sequence-dependent alterations in the interaction of the polymerase with the (modified) template and incoming nucleotide.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT MICROBIOL,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University				Lloyd, R. Stephen/0000-0001-7273-372X	NCI NIH HHS [CA 44353] Funding Source: Medline; NIEHS NIH HHS [ES 01590, ES 00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES001590, P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BASU AK, 1988, CHEM RES TOXICOL, V1, P1, DOI 10.1021/tx00001a001; BOWLING JM, 1991, NUCLEIC ACIDS RES, V19, P3089, DOI 10.1093/nar/19.11.3089; BRASH DE, 1987, P NATL ACAD SCI USA, V84, P3782, DOI 10.1073/pnas.84.11.3782; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CMARIK JL, 1990, CANCER RES, V50, P2747; CMARIK JL, 1991, THESIS VANDERBILT U; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P4120, DOI 10.1073/pnas.75.9.4120; EISENSTADT E, 1987, ESCHERICHIA COLI SAL, V2, P1016; FOSTER PL, 1988, MUTAT RES, V194, P171, DOI 10.1016/0167-8817(88)90019-3; GAFFNEY BL, 1989, BIOCHEMISTRY-US, V28, P5881, DOI 10.1021/bi00440a026; GREVATT PC, 1991, J BIOL CHEM, V266, P1269; GROOPMAN JD, 1981, P NATL ACAD SCI-BIOL, V78, P5445, DOI 10.1073/pnas.78.9.5445; GUENGERICH FP, 1977, BIOCHEM PHARMACOL, V26, P1909, DOI 10.1016/0006-2952(77)90165-4; GUPTA PK, 1991, CARCINOGENESIS, V12, P819, DOI 10.1093/carcin/12.5.819; HORSFALL MJ, 1990, ENVIRON MOL MUTAGEN, V15, P107, DOI 10.1002/em.2850150208; HUMPHREYS WG, 1990, BIOCHEMISTRY-US, V29, P10342, DOI 10.1021/bi00497a008; HUMPHREYS WG, 1991, CHEM RES TOXICOL, V4, P632, DOI 10.1021/tx00024a005; KERKLAAN PRM, 1985, BIOCHEM PHARMACOL, V34, P2151, DOI 10.1016/0006-2952(85)90410-1; KIM DH, 1989, CANCER RES, V49, P5843; KIM DH, 1990, CHEM RES TOXICOL, V3, P587, DOI 10.1021/tx00018a015; KOEHLER DR, 1991, J BIOL CHEM, V266, P11766; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; KOGA N, 1986, BIOCHEMISTRY-US, V25, P2192, DOI 10.1021/bi00356a051; KRUMMEL B, 1990, PCR PROTOCOLS GUIDE, P184; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; LASKO DD, 1988, J BIOL CHEM, V263, P15429; LAWLEY PD, 1962, NATURE, V192, P1091; LECLERC JE, 1984, J MOL BIOL, V180, P217, DOI 10.1016/S0022-2836(84)80001-7; MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9; Maxam A M, 1980, Methods Enzymol, V65, P499; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MILLER EC, 1981, CANCER-AM CANCER SOC, V47, P2327, DOI 10.1002/1097-0142(19810515)47:10<2327::AID-CNCR2820471003>3.0.CO;2-Z; OIDA T, 1991, BIOCHEMISTRY-US, V30, P10513, DOI 10.1021/bi00107a021; OZAWA N, 1983, P NATL ACAD SCI-BIOL, V80, P5266, DOI 10.1073/pnas.80.17.5266; PETERSON LA, 1988, J AM CHEM SOC, V110, P3284, DOI 10.1021/ja00218a045; RABKIN SD, 1984, J MOL BIOL, V178, P569, DOI 10.1016/0022-2836(84)90239-0; RANNUG U, 1980, MUTAT RES, V76, P269, DOI 10.1016/0165-1110(80)90020-2; RICHARDSON FC, 1990, MUTAT RES, V233, P127, DOI 10.1016/0027-5107(90)90157-Y; ROSS J, 1988, MUTAT RES, V201, P203, DOI 10.1016/0027-5107(88)90127-3; SAHASRABUDHE S, 1989, MOL GEN GENET, V217, P20, DOI 10.1007/BF00330937; SAHASRABUDHE SR, 1990, BIOCHEMISTRY-US, V29, P10899, DOI 10.1021/bi00501a006; SAHM J, 1989, BIOCHEMISTRY-US, V28, P2836, DOI 10.1021/bi00433a014; SAMBAMURTI K, 1988, GENETICS, V120, P863; SAMBROOK J, 1989, MOL CLONING LABORATO, P429; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; SINGER B, 1989, BIOCHEMISTRY-US, V28, P1478, DOI 10.1021/bi00430a008; SUN M, 1984, SCIENCE, V223, P464, DOI 10.1126/science.6362008; SWANN PF, 1990, MUTAT RES, V233, P81, DOI 10.1016/0027-5107(90)90153-U; YANG JL, 1988, MOL CELL BIOL, V8, P3364, DOI 10.1128/MCB.8.8.3364; ZABIN I, 1982, MOL CELL BIOCHEM, V49, P87	50	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6672	6679						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551876				2022-12-27	WOS:A1992HM05300035
J	NAGALLA, SR; GIBSON, BW; TANG, DZ; REEVE, JR; SPINDEL, ER				NAGALLA, SR; GIBSON, BW; TANG, DZ; REEVE, JR; SPINDEL, ER			GASTRIN-RELEASING PEPTIDE (GRP) IS NOT MAMMALIAN BOMBESIN - IDENTIFICATION AND MOLECULAR-CLONING OF A TRUE AMPHIBIAN GRP DISTINCT FROM AMPHIBIAN BOMBESIN IN BOMBINA-ORIENTALIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; MESSENGER-RNAS; RAT-BRAIN; SEQUENCE-ANALYSIS; NEUROMEDIN-C; LOCALIZATION; IONIZATION; INTESTINE; ALYTESIN; TISSUE	On the basis of structural homology and similar biological activity, gastrin-releasing peptide (GRP) has been considered the mammalian equivalent of amphibian bombesin. In this paper we now show this to be incorrect. Chromatography of frog (Bombina orientalis) gut extracts demonstrated two peaks of bombesin-like immunoreactivity (BLI), one similar in size to GRP and one similar in size to amphibian bombesin. These peaks were purified by high pressure liquid chromatography then subjected to mass spectrometric analyses to determine molecular weights and amino acid sequence. Based on the amino acid sequence of the lower molecular weight BLI species, a mixed oligonucleotide probe was prepared and used to screen a B. orientalis stomach cDNA library. Sequence analysis showed that all hybridizing clones encoded a 155-amino acid protein homologous to the mammalian GRP precursor. The mass spectra of the high and low molecular weight peaks of frog gut BLI were consistent with their origin from the processing of the frog GRP (fGRP) precursor into GRP-29 and GRP-10, just like the processing of the rat GRP precursor. Sequence homology showed that the fGRP precursor is more closely related to the mammalian GRP precursors than to either the frog bombesin or frog ranatensin precursors. Northern blot analysis showed that fGRP is encoded by a mRNA of 980 bases, clearly different from the 750-base mRNA which encodes frog bombesin. Northern blot analysis and in situ hybridization showed fGRP mRNA in frog brain and stomach and bombesin mRNA in frog skin, brain, and stomach. That frogs have independent genes for both GRP and bombesin raises the possibility that mammals have an as yet uncharacterized gene encoding a true mammalian bombesin.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; VET ADM WADSWORTH MED CTR,CTR ULCER RES & EDUC,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024	University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	NAGALLA, SR (corresponding author), OREGON REG PRIMATE RES CTR,DIV NEUROSCI,505 NW 185TH AVE,BEAVERTON,OR 97006, USA.		Reeve, James/GYI-8415-2022		NCI NIH HHS [CA39237] Funding Source: Medline; NCRR NIH HHS [RR00163, RR01614] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA039237, R01CA039237] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163, P41RR001614] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANASTASI A, 1971, EXPERIENTIA, V27, P166, DOI 10.1007/BF02145873; AUSUBEL FM, 1987, CURRENT PRTOCOLS MOL; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; BOLAFFI JL, 1979, CELL TISSUE RES, V202, P505; BROWN M, 1978, LIFE SCI, V23, P2721, DOI 10.1016/0024-3205(78)90652-5; CANLON JM, 1991, BIOCHEM BIOPH RES CO, V178, P526; CONLON JM, 1987, GEN COMP ENDOCR, V68, P415, DOI 10.1016/0016-6480(87)90080-3; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FALICK AM, 1986, ANAL CHEM, V58, P1308, DOI 10.1021/ac00298a009; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; HINES WM, 1992, IN PRESS J AM SOC MA; LEBACQVERHEYDEN AM, 1988, MOL ENDOCRINOL, V2, P556, DOI 10.1210/mend-2-6-556; LECHAGO J, 1981, GEN COMP ENDOCR, V45, P1, DOI 10.1016/0016-6480(81)90160-X; LECHAGO J, 1978, GEN COMP ENDOCR, V36, P553, DOI 10.1016/0016-6480(78)90095-3; LEMAIRE S, 1989, PEPTIDES, V10, P355, DOI 10.1016/0196-9781(89)90043-0; MCDONALD TJ, 1980, FEBS LETT, V122, P45, DOI 10.1016/0014-5793(80)80398-X; MCDONALD TJ, 1979, BIOCHEM BIOPH RES CO, V90, P227, DOI 10.1016/0006-291X(79)91614-0; MINAMINO N, 1984, BIOCHEM BIOPH RES CO, V124, P925, DOI 10.1016/0006-291X(84)91046-5; MOODY TW, 1979, BIOCHEM BIOPH RES CO, V90, P7, DOI 10.1016/0006-291X(79)91582-1; ORLOFF MS, 1984, PEPTIDES, V5, P865, DOI 10.1016/0196-9781(84)90108-6; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; RANE IM, 1988, J BIOL CHEM, V263, P13317; REEVE JR, 1983, J BIOL CHEM, V258, P5582; SAUSVILLE EA, 1986, J BIOL CHEM, V261, P2451; SCHULTZBERG M, 1983, BRAIN RES, V269, P190, DOI 10.1016/0006-8993(83)90981-2; SHAW C, 1987, J NEUROCHEM, V49, P1348, DOI 10.1111/j.1471-4159.1987.tb00998.x; SIMERLY RB, 1991, MOL ENDOCRINOL, V5, P424, DOI 10.1210/mend-5-3-424; SPINDEL E, 1986, TRENDS NEUROSCI, V9, P130, DOI 10.1016/0166-2236(86)90042-1; SPINDEL ER, 1987, GEN COMP ENDOCR, V67, P67, DOI 10.1016/0016-6480(87)90206-1; SPINDEL ER, 1990, P NATL ACAD SCI USA, V87, P9813, DOI 10.1073/pnas.87.24.9813; SPINDEL ER, 1984, P NATL ACAD SCI-BIOL, V81, P5699, DOI 10.1073/pnas.81.18.5699; SPINDEL ER, 1986, P NATL ACAD SCI USA, V83, P19, DOI 10.1073/pnas.83.1.19; TACHE Y, 1982, TRENDS NEUROSCI, V5, P431, DOI 10.1016/0166-2236(82)90234-X; WAGNER RM, 1987, BIOMED ENVIRON MASS, V14, P69, DOI 10.1002/bms.1200140204; WALLS FC, 1990, BIOLOGICAL MASS SPECTROMETRY /, P197; WALSH JH, 1979, FED PROC, V38, P2315; WALSH JH, 1982, REGUL PEPTIDES, V3, P1, DOI 10.1016/0167-0115(82)90002-7; WHARTON J, 1978, NATURE, V273, P769, DOI 10.1038/273769a0; YOSHIE S, 1985, CELL TISSUE RES, V239, P25, DOI 10.1007/BF00214898; ZOELLER RT, 1989, PEPTIDES, V10, P415	41	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6916	6922						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1551901				2022-12-27	WOS:A1992HM05300072
J	LOWENSON, JD; CLARKE, S				LOWENSON, JD; CLARKE, S			RECOGNITION OF D-ASPARTYL RESIDUES IN POLYPEPTIDES BY THE ERYTHROCYTE L-ISOASPARTYL/D-ASPARTYL PROTEIN METHYLTRANSFERASE - IMPLICATIONS FOR THE REPAIR HYPOTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTACT HUMAN-ERYTHROCYTES; MYELIN BASIC-PROTEIN; CARBOXYL METHYLTRANSFERASE; MEMBRANE-PROTEINS; SUBSTRATE-SPECIFICITY; ENZYMATIC METHYLATION; SEMINAL RIBONUCLEASE; CARBOXYPEPTIDASE-Y; HUMAN LENSES; DEAMIDATION	We provide here the first direct evidence that D-aspartyl residues in peptides are substrates for the L-isoaspartyl/D-aspartyl protein carboxyl methyltransferase (EC 2.1.1.77). We do this by showing that D-aspartic acid beta-methyl ester can be isolated from carboxypeptidase Y digests of enzymatically methylated D-aspartyl-containing synthetic peptides. The specificity of this reaction is supported by the lack of methylation of L-aspartyl-containing peptides under similar conditions. Methylation of D-aspartyl residues in synthetic peptides was not observed previously because with K(m) values ranging from 2.5 to 4.8 mM, these peptides are recognized by the methyltransferase with 700-10,000-fold lower affinity than are their L-isoaspartyl-containing counterparts. The physiological significance of D-aspartyl methylation was investigated in two ways. First, analysis of in situ methylated human erythrocyte proteins showed that at least 22% of the methyl groups associated with the proteins ankyrin and band 4.1 are on D-aspartyl residues, suggesting that D-aspartyl methylation is an important function of the methyltransferase in vivo. Second, mathematical modeling of the protein aging and methylation reactions occurring in intact erythrocytes indicated that the accumulation of D-aspartyl residues can be reduced as much as 2-5-fold by the methyltransferase activity. Although this reduction is much less than that predicted for L-isoaspartyl residues, it may be significant in maintaining functional proteins throughout the 120-day life span of these cells.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	LOWENSON, JD (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024, USA.		Lowenson, Jonathan/AAN-6768-2020		NIGMS NIH HHS [GM 07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTIGUES A, 1990, J BIOL CHEM, V265, P4853; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; ASWAD DW, 1984, J BIOL CHEM, V259, P714; ASWAD DW, 1984, ANAL BIOCHEM, V137, P405, DOI 10.1016/0003-2697(84)90106-4; BADA JL, 1984, METHOD ENZYMOL, V106, P98; BARBER JR, 1984, J BIOL CHEM, V259, P7115; BARBER JR, 1983, J BIOL CHEM, V258, P1189; BARTEN DM, 1990, LIFE SCI, V47, P181, DOI 10.1016/0024-3205(90)90319-M; BENNETT V, 1985, ANNU REV BIOCHEM, V54, P273, DOI 10.1146/annurev.biochem.54.1.273; BRUNAUER LS, 1986, J BIOL CHEM, V261, P2538; CHAZIN WJ, 1989, BIOCHEMISTRY-US, V28, P8646, DOI 10.1021/bi00447a055; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; CLARKE S, 1984, METHOD ENZYMOL, V106, P330; CLARKE S, 1986, BIOL METHYLATION DRU, P3; DIDONATO A, 1986, BIOCHEMISTRY-US, V25, P8361, DOI 10.1021/bi00374a005; FISHER GH, 1986, BIOCHEM BIOPH RES CO, V135, P683, DOI 10.1016/0006-291X(86)90047-1; FREITAG C, 1981, J BIOL CHEM, V256, P6102; FRIEDMAN AR, 1991, INT J PEPT PROT RES, V37, P14; FU JC, 1991, J BIOL CHEM, V266, P14562; GALLETTI P, 1988, EUR J BIOCHEM, V177, P233, DOI 10.1111/j.1432-1033.1988.tb14367.x; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GEIGER T, 1987, J BIOL CHEM, V262, P785; GEORGENASCIMENT.C, 1990, BIOCHEMISTRY-US, V29, P9586; GILBERT JM, 1988, BIOCHEMISTRY-US, V27, P5227, DOI 10.1021/bi00414a042; GROENEN PJTA, 1990, FEBS LETT, V269, P109, DOI 10.1016/0014-5793(90)81131-7; HAYASHI R, 1975, J BIOCHEM-TOKYO, V77, P69; HELFMAN PM, 1977, GERONTOLOGY, V23, P419, DOI 10.1159/000212218; HENZEL WJ, 1989, J BIOL CHEM, V264, P15905; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; JANSON CA, 1980, J BIOL CHEM, V255, P1640; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1990, BIOCHEMISTRY-US, V29, P4373, DOI 10.1021/bi00470a017; JONES BN, 1986, METHODS PROTEIN MICR, P338; KONOPINSKA D, 1967, ANGEW CHEM INT EDIT, V6, P248, DOI 10.1002/anie.196702481; LADINO CA, 1990, MECH AGEING DEV, V55, P123, DOI 10.1016/0047-6374(90)90020-G; LING E, 1988, J BIOL CHEM, V263, P2209; LOU LL, 1987, BIOCHEMISTRY-US, V26, P52, DOI 10.1021/bi00375a008; LOWENSON J, 1987, FASEB J, V46, P2090; LOWENSON JD, 1991, GERONTOLOGY, V37, P128; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; LURA R, 1988, BIOCHEMISTRY-US, V27, P7671, DOI 10.1021/bi00420a015; MACFARLANE DE, 1984, J BIOL CHEM, V259, P1357; MANNING MC, 1989, PHARM RES-DORDR, V6, P903, DOI 10.1023/A:1015929109894; MASTERS PM, 1978, P NATL ACAD SCI USA, V75, P1204, DOI 10.1073/pnas.75.3.1204; MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; MCFADDEN PN, 1986, J BIOL CHEM, V261, P1503; MEINWALD YC, 1986, INT J PEPT PROT RES, V28, P79; MOR A, 1991, J BIOL CHEM, V266, P6264; MURAOKA S, 1991, BIOMED RES-TOKYO, V12, P61, DOI 10.2220/biomedres.12.61; MURRAY ED, 1984, J BIOL CHEM, V259, P722; OCONNOR CM, 1984, P NATL ACAD SCI-BIOL, V81, P7757, DOI 10.1073/pnas.81.24.7757; OCONNOR CM, 1983, J BIOL CHEM, V258, P8485; OCONNOR CM, 1984, J BIOL CHEM, V259, P2570; OCONNOR CM, 1988, J BIOL CHEM, V263, P1386; OTA IM, 1988, BIOCHEM BIOPH RES CO, V151, P1136, DOI 10.1016/S0006-291X(88)80484-4; SAMANEN J, 1988, J MED CHEM, V31, P510, DOI 10.1021/jm00398a005; SCARBOROUGH RM, 1988, J BIOL CHEM, V263, P16818; SCHUBERT D, 1973, H-S Z PHYSIOL CHEM, V354, P781, DOI 10.1515/bchm2.1973.354.2.781; SHAPIRA R, 1988, J NEUROCHEM, V50, P649, DOI 10.1111/j.1471-4159.1988.tb02960.x; SOONG CJ, 1987, ARCH BIOCHEM BIOPHYS, V254, P509, DOI 10.1016/0003-9861(87)90131-7; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; TERWILLIGER TC, 1981, J BIOL CHEM, V256, P3067; VANDENOETELAAR PJM, 1989, EXP EYE RES, V48, P209, DOI 10.1016/S0014-4835(89)80070-3; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; YAMADA H, 1985, BIOCHEMISTRY-US, V24, P7953, DOI 10.1021/bi00348a017	67	116	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5985	5995						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1556110				2022-12-27	WOS:A1992HK31800044
J	PARK, DH; PLAPP, BV				PARK, DH; PLAPP, BV			INTERCONVERSION OF E-ISOENZYME AND S-ISOENZYME OF HORSE LIVER ALCOHOL-DEHYDROGENASE - SEVERAL RESIDUES CONTRIBUTE INDIRECTLY TO CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS; NICOTINAMIDE ADENINE-DINUCLEOTIDE; TERNARY COMPLEX; BINDING; SUBSTRATE	The E and S isoenzymes of horse liver alcohol dehydrogenase differ by 10 amino acid residues, but only the S isoenzyme is active on 3-beta-hydroxysteroids. This functional difference was correlated to the differences in structures of the isoenzymes by characterizing a series of chimeric enzymes, which could represent intermediates in the evolution of catalytic activity. Deletion of Asp-115 from the E isoenzyme created the E/D115-DELTA enzyme that is active on steroids. The deletion alters the substrate binding pocket by moving Leu-116, which sterically hinders binding of steroids in the E isoenzyme. A chimeric enzyme (ESE) that has four changes in or near the substrate binding pocket (T94I/R101S/F110L/D115-DELTA) was 15-30-fold more catalytically efficient (V/K(m)) on uncharged steroids than was the E/D115-DELTA enzyme. Molecular modeling suggests that the substitutions at residues 94 and 110 indirectly affect the activity on steroids. ESE enzyme was 6-fold more active than the S isoenzyme on neutral steroids, due to substitutions not in the substrate binding pocket. The K366E and the Q17E/A43T/A59T substitutions in the S isoenzyme gave 2-fold increases in V/K(m) on steroids, which together can account for the changes observed with the ESE enzyme. The enzymes that are active on steroids did not bind 2,2,2-trifluoroethanol as tightly and were catalytically less efficient than the E isoenzyme with small alcohols. However, these enzymes were two to three and four to five orders of magnitude more efficient with 1-hexanol and 5-beta-androstane-3-beta,17-beta-diol, respectively, than with ethanol. These results demonstrate that several residues not directly participating in substrate binding or chemical catalysis contribute to catalytic efficiency.			PARK, DH (corresponding author), UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242, USA.		Plapp, Bryce V/F-6353-2010		NIAAA NIH HHS [AA06223] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006223] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Branden C.-I., 1975, ENZYMES, V11, P103; Cleland W W, 1979, Methods Enzymol, V63, P103; CRONHOLM T, 1975, ACTA CHEM SCAND B, V29, P571, DOI 10.3891/acta.chem.scand.29b-0571; DWORSCHACK RT, 1977, BIOCHEMISTRY-US, V16, P111, DOI 10.1021/bi00620a018; EKLUND H, 1982, J BIOL CHEM, V257, P4349; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; GANZHORN AJ, 1987, J BIOL CHEM, V262, P3754; GOULD RM, 1990, BIOCHEMISTRY-US, V29, P5463, DOI 10.1021/bi00475a009; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; JONES TA, 1985, METHOD ENZYMOL, V115, P157; LIVELY CR, 1987, BIOCHEMISTRY-US, V26, P5719, DOI 10.1021/bi00392a021; Maniatis T., 1982, MOL CLONING; MCEVILY AJ, 1988, BIOCHEMISTRY-US, V27, P4284, DOI 10.1021/bi00412a013; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; PARK DH, 1991, J BIOL CHEM, V266, P13296; PIETRUSZKO R, 1969, ARCH BIOCHEM BIOPHYS, V131, P288, DOI 10.1016/0003-9861(69)90133-7; PLAPP BV, 1970, J BIOL CHEM, V245, P1727; REYNIER M, 1969, ACTA CHEM SCAND, V23, P1130, DOI 10.3891/acta.chem.scand.23-1130; RYZEWSKI CN, 1980, BIOCHEMISTRY-US, V21, P4843; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SEKHAR VC, 1988, BIOCHEMISTRY-US, V27, P5082, DOI 10.1021/bi00414a020; Sund H., 1963, ENZYMES, V7, P25; THEORELL H, 1970, ARCH BIOCHEM BIOPHYS, V139, P241, DOI 10.1016/0003-9861(70)90067-6; THEORELL H, 1963, BIOCHEM Z, V338, P537; WALLER G, 1965, ARCH BIOCHEM BIOPHYS, V111, P671, DOI 10.1016/0003-9861(65)90249-3	26	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5527	5533						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544927				2022-12-27	WOS:A1992HH74700080
J	TUCK, SF; PETERSON, JA; DEMONTELLANO, PRO				TUCK, SF; PETERSON, JA; DEMONTELLANO, PRO			ACTIVE-SITE TOPOLOGIES OF BACTERIAL CYTOCHROME-P450101 (P450CAM), CYTOCHROME-P450108 (P450TERP), AND CYTOCHROME-P450102 (P450BM-3) - INSITU REARRANGEMENT OF THEIR PHENYL-IRON COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-MEGATERIUM; AMINO-ACID; SECONDARY STRUCTURE; MEMBRANE TOPOLOGY; CRYSTAL-STRUCTURE; SEQUENCE; PROTEINS; CYTOCHROMES-P450; HYDROXYLATION; NUCLEOTIDE	The reactions of cytochromes P450101 (P450cam), P450108 (P450terp), and P450102 (P450BM-3) with phenyldiazene result in the formation of phenyl-iron complexes with absorption maxima at 474-478 nm. Treatment of the cytochrome P450 complexes with K3Fe(CN)e decreases the 474-478 nm absorbance and shifts the phenyl group from the iron to the porphyrin nitrogens. Acidification and extraction of the prosthetic group from each of the ferricyanide-treated enzymes yields a different mixture of the four possible N-phenylprotoporphyrin IX regioisomers. The ratios of the regioisomers with the phenyl ring on pyrrole rings B, A, C, and D (in order of elution from the high performance liquid chromatography column) are, respectively: cytochrome P450cam, 0:0:1:4; P450terp, 0:0:0:1; and P450BM-3, 2:10:2:1. The isomer ratio for recombinant cytochrome P450BM-3 without the cytochrome P450 reductase domain (2:9:2:1) shows that the reductase domain does not detectably perturb the active site topology of cytochrome P450BM-3. Potassium ions modulate the intensity of the spectrum of the phenyl-iron complex of cytochrome P450cam, but do not alter the N-phenyl isomer ratio. Computer graphics analysis of the crystal structure of the cytochrome P450cam phenyl-iron complex indicates that the active site of cytochrome P450cam is open above pyrrole ring D and, to a small extent, pyrrole ring C, in complete agreement with the observed N-phenylprotoporphyrin IX regioisomer pattern. The regioisomer ratios indicate that the active site of cytochrome P450terp is only open above pyrrole ring D, whereas that of cytochrome P450BM-3 is open to some extent above all the pyrrole rings but particularly above pyrrole ring A. The bacterial enzymes thus have topologies distinct from each other and from those of the mammalian enzymes so far investigated, which have active sites that are open to a comparable extent above pyrrole rings A and D.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [5 P30 DK26743] Funding Source: Medline; NIGMS NIH HHS [GM25515, GM43479] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025515, R01GM025515, R01GM043479] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DIPRIMO C, 1990, J BIOL CHEM, V265, P5361; EDWARDS RJ, 1989, BIOCHEMISTRY-US, V28, P3762, DOI 10.1021/bi00435a021; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HANIU M, 1982, J BIOL CHEM, V257, P2664; HO PP, 1976, BIOCHIM BIOPHYS ACTA, V431, P249, DOI 10.1016/0005-2760(76)90145-4; HOA GHB, 1982, EUR J BIOCHEM, V124, P311; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; LANGE R, 1979, EUR J BIOCHEM, V94, P491, DOI 10.1111/j.1432-1033.1979.tb12917.x; LU JY, 1990, FASEB J, V4, pA2243; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MIURA Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P305, DOI 10.1016/0005-2760(75)90089-2; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; O'Keeffe D H, 1978, Methods Enzymol, V52, P151; OMURA T, 1964, J BIOL CHEM, V239, P2370; PETERSON JA, 1971, ARCH BIOCHEM BIOPHYS, V144, P678, DOI 10.1016/0003-9861(71)90375-4; PETERSON JA, 1990, J BIOL CHEM, V265, P6066; PETERSON JA, 1977, J BIOL CHEM, V252, P4431; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; Sambrook J, 1989, MOL CLONING LABORATO; SLIGAR SG, 1986, CYTOCHROME P450 STRU, P429; Sokatch JR, 1986, BACTERIA, V10, P557; SWANSON BA, 1991, J AM CHEM SOC, V113, P8146, DOI 10.1021/ja00021a046; SWANSON BA, 1992, ARCH BIOCHEM BIOPHYS, V292, P42, DOI 10.1016/0003-9861(92)90048-2; SWANSON BA, 1991, J BIOL CHEM, V266, P19258; TRETIAKOV VE, 1989, ARCH BIOCHEM BIOPHYS, V275, P429, DOI 10.1016/0003-9861(89)90389-5; UNGER BP, 1986, J BIOL CHEM, V261, P1158; ZVELEBIL MJJM, 1991, PROTEIN ENG, V4, P271, DOI 10.1093/protein/4.3.271	35	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5614	5620						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1544935				2022-12-27	WOS:A1992HH74700091
J	SCHRAG, JD; WINKLER, FK; CYGLER, M				SCHRAG, JD; WINKLER, FK; CYGLER, M			PANCREATIC LIPASES - EVOLUTIONARY INTERMEDIATES IN A POSITIONAL CHANGE OF CATALYTIC CARBOXYLATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LIPOPROTEIN-LIPASE; DIENELACTONE HYDROLASE; SEQUENCE; CLONING; ACETYLCHOLINESTERASE; PROTEINS; GENE	Comparison of the fold of lipases from Geotrichum candidum and from human pancreas identified a high degree of similarity which was not expected on the basis of their amino acid sequences. Although both enzymes utilize a serine protease-like catalytic triad, they differ in the topological position of the acid. We speculate that these proteins are evolutionarily related and that the pancreatic lipase is an evolutionary intermediate in the pathway of migration of the catalytic acid to a new position within the fold.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MONTREAL H4P 2R2,QUEBEC,CANADA; F HOFFMANN LA ROCHE & CO LTD,PHARMA DIV RES TECHNOL,CH-4002 BASEL,SWITZERLAND	National Research Council Canada; Roche Holding								BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BOWNES M, 1988, P NATL ACAD SCI USA, V85, P1554, DOI 10.1073/pnas.85.5.1554; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; DATTA S, 1988, J BIOL CHEM, V263, P1107; DECARO J, 1981, BIOCHIM BIOPHYS ACTA, V671, P129, DOI 10.1016/0005-2795(81)90126-4; ENERBACK S, 1987, GENE, V58, P1, DOI 10.1016/0378-1119(87)90023-0; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; GRUSBY MJ, 1990, CELL, V60, P451, DOI 10.1016/0092-8674(90)90596-7; GUBERNATOR K, 1991, GBF MONOGRAPHS, V16, P9; LIAO DI, 1990, J BIOL CHEM, V265, P6528; MICKEL FS, 1989, J BIOL CHEM, V264, P12895; PATHAK D, 1988, J MOL BIOL, V204, P435, DOI 10.1016/0022-2836(88)90587-6; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; PERSSON B, 1989, EUR J BIOCHEM, V179, P39, DOI 10.1111/j.1432-1033.1989.tb14518.x; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SHIMADA Y, 1990, J BIOCHEM-TOKYO, V107, P703, DOI 10.1093/oxfordjournals.jbchem.a123112; SIKORAV JL, 1987, EMBO J, V6, P1865, DOI 10.1002/j.1460-2075.1987.tb02445.x; SLABAS AR, 1990, BIOCHEM J, V269, P279, DOI 10.1042/bj2690279; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; SWILLENS S, 1986, BIOCHEM BIOPH RES CO, V137, P142, DOI 10.1016/0006-291X(86)91187-3; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907	23	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4300	4303						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1537823				2022-12-27	WOS:A1992HF64200007
